fluorouracil has been researched along with Metastase in 2898 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of lapatinib for the treatment of advanced or metastatic HER2-overexpressing breast cancer based upon a review of the manufacturer's submission to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal (STA) process." | 10.24 | Lapatinib for the treatment of HER2-overexpressing breast cancer. ( Clegg, A; Jones, J; Picot, J; Takeda, A; von Keyserlingk, C, 2009) |
| "The purpose of this study was to examine the efficacy of a combination treatment of sequential irinotecan and doxifluridine, an intermediate of capecitabine, evaluated by the response rate and safety in patients with metastatic colorectal cancer." | 10.23 | A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer. ( Amano, M; Fukunaga, M; Ikeda, K; Ikeda, M; Ikenaga, M; Ishida, H; Kato, T; Mishima, H; Monden, M; Murata, K; Ohnishi, T; Ota, H; Sakamoto, J; Sekimoto, M; Tominaga, S, 2008) |
| "When administered as a single agent in pretreated patients with advanced breast cancer, paclitaxel (Taxol) exhibits remarkable antitumor activity." | 10.18 | Paclitaxel as first-line treatment for metastatic breast cancer. The Taxol Investigational Trials Group, Australia and New Zealand. ( Ackland, S; Bishop, JF; Dewar, J; Goldstein, D; Gurney, H; Kennedy, I; Levi, J; Olver, IN; Stephenson, J; Tattersall, MH; Toner, GC; Walpole, E, 1997) |
| "The XELAVIRI trial compared sequential (fluoropyrimidine and bevacizumab; irinotecan (Iri) at progression) versus initial combination therapy (fluoropyrimidine, bevacizumab, Iri) of treatment-naïve metastatic colorectal cancer (mCRC)." | 9.41 | Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial). ( Decker, T; Denzlinger, C; Fischer von Weikersthal, L; Gießen-Jung, C; Graeven, U; Heinemann, V; Heinrich, K; Held, S; Jung, A; Kaiser, F; Kirchner, T; Kumbrink, J; Kurreck, A; Modest, DP; Neumann, J; Schenk, M; Schuster, V; Schwaner, I; Stahler, A; Stintzing, S, 2021) |
| "To evaluate pharmacokinetics, efficacy and safety of fixed-dose combination (FDC) of oral capecitabine + cyclophosphamide in metastatic breast cancer (MBC) patients progressing after anthracycline and/or taxane chemotherapy." | 9.41 | Fixed dose combination of capecitabine and cyclophosphamide in metastatic breast cancer: Results from THE ENCLOSE phase 2/3 randomized multicenter study. ( Babu, S; Bajaj, V; Bhat, G; Biswas, G; Bondarde, SA; Boya, RR; Choudhury, K; Gupta, S; Joshi, N; Khan, MA; Lakshmaiah, KC; Maksud, TM; Mamillapalli, G; Neve, RS; Patel, AA; Patel, JG; Patel, P; Patil, P; Raja, G, 2021) |
| "In locally advanced or metastatic biliary tract cancer (BTC), second-line chemotherapy is challenging after progression from first-line gemcitabine/cisplatin." | 9.41 | A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy. ( Choi, IS; Kim, JH; Kim, JS; Kim, JW; Kim, KH; Kim, YJ; Lee, JH; Park, JH; Suh, KJ, 2021) |
| "The TRICOLORE trial previously demonstrated that S-1 and irinotecan plus bevacizumab was non-inferior, based on progression-free survival (PFS), to 5-fluorouracil, leucovorin and oxaliplatin (mFOLFOX6)/capecitabine and oxaliplatin (CapeOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer (mCRC)." | 9.41 | Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III ( Baba, H; Denda, T; Gamoh, M; Ishioka, C; Iwanaga, I; Kobayashi, Y; Komatsu, Y; Kotake, M; Morita, S; Nakamura, M; Ohori, H; Sakashita, A; Sato, A; Shimada, K; Takahashi, M; Takahashi, S; Takashima, A; Tsuda, M; Yamada, Y; Yamaguchi, T; Yuki, S, 2021) |
| " Eligible patients aged ≥70 with unresectable metastatic, untreated, RAS/BRAF wildtype metastatic colorectal cancer will be randomised 1:1 to receive panitumumab alone or panitumumab plus infusional 5-fluorouracil." | 9.41 | MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG). ( Bailey, L; Briscoe, K; Burge, M; Caird, S; Chantrill, L; Cuff, J; Espinoza, D; Francesconi, A; Karapetis, C; Ladwa, R; Pavlakis, N; Price, T; Segelov, E; Shannon, J; Siu, HWD; Sjoquist, K; Srivastav, R; Steer, C; Tebbutt, N; Thavaneswaran, S; Tie, J; Wilson, K; Wuttke, M; Yip, S, 2021) |
| "The global, randomized NAPOLI-1 phase 3 trial reported a survival benefit with liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (nal-IRI+5-FU/LV) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) after previous gemcitabine-based therapy." | 9.34 | Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study. ( Bang, YJ; Belanger, B; Chen, JS; Chen, LT; Chiu, CF; Choi, HJ; Kim, JS; Lee, KH; Li, CP; Oh, DY; Park, JO; Rau, KM; Shan, YS; Shim, HJ, 2020) |
| " 130 male and 63 female eligible patients with metastatic colorectal cancer were randomized to receive chronomodulated Irinotecan with peak delivery rate at 1 of 6 clock hours staggered by 4 hours on day 1, then fixed-time chronomodulated Fluorouracil-Leucovorin-Oxaliplatin for 4 days, q3 weeks." | 9.34 | Sex-dependent least toxic timing of irinotecan combined with chronomodulated chemotherapy for metastatic colorectal cancer: Randomized multicenter EORTC 05011 trial. ( Adam, R; Ballesta, A; Bouchahda, M; Chollet, P; Focan, C; Garufi, C; Giacchetti, S; Huang, Q; Innominato, PF; Karaboué, A; Lévi, FA, 2020) |
| "To evaluate the safety and tolerability of escalating doses of selinexor plus 5-fluorouracil, leucovorin and oxaliplatin (mFOLFOX6) in metastatic colorectal cancer (mCRC) patients." | 9.34 | Selinexor (KPT-330), an Oral Selective Inhibitor of Nuclear Export (SINE) Compound, in Combination with FOLFOX in Patients with Metastatic Colorectal Cancer (mCRC) - Final Results of the Phase I Trial SENTINEL. ( Amberg, S; Bokemeyer, C; Kranich, AL; Mann, J; Nilsson, S; Papadimitriou, K; Rolfo, C; Stein, A; Theile, S, 2020) |
| "Curcumin is a safe and tolerable adjunct to FOLFOX chemotherapy in patients with metastatic colorectal cancer." | 9.30 | Curcumin Combined with FOLFOX Chemotherapy Is Safe and Tolerable in Patients with Metastatic Colorectal Cancer in a Randomized Phase IIa Trial. ( Barber, S; Brown, K; Foreman, N; Gescher, A; Griffin-Teall, N; Howells, LM; Irving, GRB; Iwuji, COO; Morgan, B; Patel, SR; Sidat, Z; Singh, R; Steward, WP; Thomas, AL; Walter, H, 2019) |
| "This randomized phase III trial compared hepatic arterial infusion (HAI) chemotherapy with 5-fluorouracil (5-FU) followed by uracil/tegafur (UFT) and leucovorin (LV) versus UFT/LV alone for patients with curatively resected liver metastases from colorectal cancer (CRC)." | 9.27 | A randomized phase III study of hepatic arterial infusion chemotherapy with 5-fluorouracil and subsequent systemic chemotherapy versus systemic chemotherapy alone for colorectal cancer patients with curatively resected liver metastases (Japanese Foundatio ( Aoyama, T; Asahara, T; Hirata, K; Kusano, M; Nakamori, S; Oba, K; Ohashi, Y; Okabayashi, K; Saji, S; Sakamoto, J; Tsuji, Y; Yoshikawa, T, 2018) |
| "Fluorouracil and folinic acid with irinotecan (FOLFIRI) plus bevacizumab (BV) is widely used as second-line chemotherapy for patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidines, oxaliplatin, and BV." | 9.24 | Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab. ( Ando, M; Araida, T; Hamano, M; Hayashi, K; Hirai, E; Itabashi, M; Kameoka, S; Kawakami, K; Kuramochi, H; Nakajima, G; Okuyama, R; Yokomizo, H; Yoshimatsu, K, 2017) |
| "The study was designed to compare an anthracycline-containing regimen to a regimen combining both anthracycline and paclitaxel as adjuvant therapy for high-risk breast cancer patients." | 9.22 | 5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial. ( Accortanzo, V; Adami, F; Bighin, C; Bruzzi, P; Castiglione, F; Cavazzini, G; Conte, P; Danese, S; Del Mastro, L; Durando, A; Garrone, O; Landucci, E; Levaggi, A; Michelotti, A; Miglietta, L; Pastorino, S; Piras, M; Pronzato, P; Scotto, T, 2016) |
| "A multicenter, open-label, noncomparative, randomized phase II study (PEPCOL) was conducted to evaluate the efficacy and safety of the irinotecan or PEP02 (MM-398, nanoliposomal irinotecan) with leucovorin (LV)/5-fluorouracil (5-FU) combination as second-line treatment in patients with metastatic colorectal cancer (mCRC)." | 9.22 | PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer. ( André, T; Arbaud, C; Bachet, JB; Bennamoun, M; Bonnetain, F; Brusquant, D; Chibaudel, B; de Gramont, A; Dupuis, O; Garcia, ML; Hammel, P; Khalil, A; Larsen, AK; Louvet, C; Maindrault-Gœbel, F; Tournigand, C; Wang, YW; Yeh, CG, 2016) |
| "The aim of this study was to evaluate safety and toxicity of chronomodulated capecitabine administered in the morning and at noon according to a specific time schedule (Brunch Regimen: Breakfast and Lunch) as a part of first-line XELOX chemotherapy in patients with metastatic colorectal cancer." | 9.22 | Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study. ( Ciftci, R; Iner-Koksal, U; Kaytan-Saglam, E; Namal, E; Okyar, A; Ordu, C; Pala-Kara, Z; Pilancı, KN; Saglam, S; Yucel, S, 2016) |
| " This randomized phase II study evaluated the antitumor activity and safety of icrucumab and ramucirumab each in combination with mFOLFOX-6 in patients with metastatic colorectal cancer after disease progression on first-line therapy with a fluoropyrimidine and irinotecan." | 9.22 | Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy. ( Alcindor, T; Asmis, T; Bendell, J; Berry, S; Binder, P; Burkes, R; Chan, E; Chan, T; Gao, L; Gill, S; Jeyakumar, A; Kambhampati, SR; Kauh, J; Kudrik, F; Moore, M; Nasroulah, F; Ramdas, N; Rao, S; Rothenstein, J; Spratlin, J; Strevel, E; Tang, PA; Tang, S; Yang, L; Zbuk, K, 2016) |
| "The aim of this study was to determine the recommended dose (RD) of a triweekly capecitabine, oxaliplatin, irinotecan, and bevacizumab (XELOXIRI/bevacizumab) regimen that was easier to administer than FOLFOXIRI/bevacizumab, using capecitabine instead of 5-fuorouracil (5-FU), in patients with metastatic colorectal cancer (mCRC)." | 9.20 | A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer. ( Furuhata, T; Hayashi, T; Hirakawa, M; Hirata, K; Iyama, S; Kato, J; Kawano, Y; Kobune, M; Miyanishi, K; Mizuguchi, T; Murase, K; Ohnuma, H; Okagawa, Y; Okita, K; Osuga, T; Sato, T; Sato, Y; Takada, K; Takahashi, M; Takimoto, R, 2015) |
| "This study was conducted to evaluate the efficacy and safety of the combination of capecitabine and oral leucovorin (LV) as a third-line chemotherapy for patients with metastatic colorectal cancer (CRC) showing resistance to irinotecan- and oxaliplatin-containing regimens." | 9.20 | A phase II study of capecitabine and oral leucovorin as a third-line chemotherapy in patients with metastatic colorectal cancer. ( Choi, DR; Choi, YK; Han, B; Kim, BC; Kim, HS; Kim, JB; Kim, JH; Kim, KY; Song, HH; Yoon, SN; Zang, DY, 2015) |
| "We conducted a phase II trial of 5-fluorouracil and oxaliplatin combination chemotherapy as a second-line treatment in unresectable/metastatic biliary tract cancer patients who had failed gemcitabine-based chemotherapy." | 9.20 | Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer. ( Chi, KC; Hwang, IG; Jang, JS; Jun, HJ; Lee, HR; Lee, S; Nam, EM; Oh, SY; Park, JO; Park, YS; Rho, MH, 2015) |
| "The oral multikinase inhibitor regorafenib improves overall survival (OS) in patients with metastatic colorectal cancer (CRC) for which all standard treatments have failed." | 9.20 | Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial. ( Argilés, G; Benson, A; Cascinu, S; Ciardiello, F; Grunert, J; Guillén Ponce, C; Köhne, CH; Luigi Garosi, V; Macpherson, IR; Rivera, F; Saunders, MP; Sobrero, A; Strumberg, D; Tabernero, J; Van Cutsem, E; Wagner, A; Zalcberg, J, 2015) |
| " We included patients older than 18 years with previously untreated metastatic colorectal cancer, with stable disease or better after induction treatment with six 3-weekly cycles of capecitabine, oxaliplatin, and bevacizumab (CAPOX-B), WHO performance status of 0 or 1, and adequate bone marrow, liver, and renal function." | 9.20 | Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. ( Braun, HJ; Cats, A; Creemers, GJ; de Jongh, FE; Derleyn, VA; Erdkamp, FL; Erjavec, Z; Haasjes, JG; Honkoop, AH; Jansen, RL; Koopman, M; Loosveld, OJ; May, A; Mol, L; Nieboer, P; Punt, CJ; Simkens, LH; ten Tije, AJ; Tol, J; van der Hoeven, JJ; van der Torren, AM; van Tinteren, H; Wals, J, 2015) |
| "Anthracycline and taxane are classes of drugs that are frequently used in the adjuvant and palliative settings of metastatic breast cancer (MBC); however, treatment failure occurs in most cases." | 9.20 | Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: an open-label, multi-center, non-comparative phase II study. ( Chang, HK; Chen, JS; Chen, YY; Lee, KD; Lin, YC; Rau, KM; Wang, CH, 2015) |
| "S-1, a novel oral prodrug of 5-fluorouracil (5-FU), and irinotecan with or without bevacizumab is known to be effective in metastatic colorectal cancer (mCRC)." | 9.20 | S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies. ( Goto, A; Ichikawa, Y; Iwasa, S; Kato, K; Matsumoto, H; Nagashima, K; Okita, NT; Shimada, Y; Yamada, Y; Yamaguchi, T; Yasui, H, 2015) |
| "This randomised, open-label, phase I/II study evaluated the efficacy and safety of nintedanib, an oral, triple angiokinase inhibitor, combined with chemotherapy, relative to bevacizumab plus chemotherapy as first-line therapy in patients with metastatic colorectal cancer (mCRC)." | 9.20 | A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients. ( Bennouna, J; Bouché, O; Capdevila, J; Carrato, A; D'Haens, G; Dressler, H; Ducreux, M; Latini, L; Oum'Hamed, Z; Prenen, H; Sobrero, A; Staines, H; Studeny, M; Van Cutsem, E, 2015) |
| "The purpose of this randomised phase III trial was to evaluate whether the addition of simvastatin, a synthetic 3-hydroxy-3methyglutaryl coenzyme A reductase inhibitor, to XELIRI/FOLFIRI chemotherapy regimens confers a clinical benefit to patients with previously treated metastatic colorectal cancer." | 9.20 | A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer. ( Han, SW; Hong, YS; Hwang, IG; Jung, SH; Kang, HJ; Kang, WK; Kim, HS; Kim, ST; Kim, TW; Lee, J; Lee, JY; Lee, KH; Lim, HY; Lim, SH; Park, JO; Park, SH; Park, YS, 2015) |
| "The antiangiogenic agent aflibercept (ziv-aflibercept in the United States) in combination with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) significantly improved survival in a phase III study of patients with metastatic colorectal cancer (mCRC) previously treated with an oxaliplatin-based regimen." | 9.19 | Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. ( Allegra, CJ; Chevalier, S; Ferry, DR; Lakomý, R; McKendrick, JJ; Moiseyenko, VM; Prausová, J; Ruff, P; Soussan-Lazard, K; Tabernero, J; Van Cutsem, E; van Hazel, GA, 2014) |
| "Lapatinib is approved in combination with capecitabine for treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) who have progressed on prior trastuzumab in the metastatic setting." | 9.19 | A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer. ( Brain, E; Briggs, K; Caglevic, C; Desilvio, M; Janni, W; Karaszewska, B; Marini, L; Papadimitriou, C; Pikiel, J; Potemski, P; Salat, C; Sarosiek, T; Staroslawska, E, 2014) |
| "We investigated the efficacy and safety of capecitabine and gemcitabin (GemCap) in heavily pre-treated, therapy-resistant metastatic colorectal cancer (mCRC) patients and the clinical importance of cell-free DNA (cfDNA) measurement." | 9.19 | Gemcitabine and capecitabine for heavily pre-treated metastatic colorectal cancer patients--a phase II and translational research study. ( Andersen, RF; Jakobsen, A; Pallisgaard, N; Ploen, J; Spindler, KL, 2014) |
| " This phase I study used radiolabeled huA33 in combination with capecitabine to target chemoradiation to metastatic colorectal cancer." | 9.19 | Targeted chemoradiation in metastatic colorectal cancer: a phase I trial of 131I-huA33 with concurrent capecitabine. ( Cavicchiolo, T; Chappell, B; Gill, S; Herbertson, RA; Hopkins, W; Lee, FT; Lee, ST; Murphy, R; O'Keefe, GJ; Poon, A; Saunder, T; Scott, AM; Scott, FE; Tebbutt, NC, 2014) |
| "Irinotecan, leucovorin, and bolus and continuous-infusion 5-fluorouracil administered every two weeks (FOLFIRI regimen) is active in patients with metastatic colorectal cancer." | 9.19 | Phase I study of combination therapy with irinotecan, leucovorin, and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for advanced colorectal cancer in Japanese patients. ( Arai, T; Goto, A; Hamaguchi, T; Muro, K; Sasaki, Y; Shimada, Y; Shirao, K; Ura, T; Yamada, Y, 2014) |
| " A phase II study was conducted to determine the feasibility of a dose-intense two weekly schedule of capecitabine, oxaliplatin, and bevacizumab in metastatic colorectal cancer (mCRC)." | 9.19 | Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study. ( Adams, J; Deva, S; Findlay, MP; Hinder, VA; Isaacs, R; Jackson, CG; O'Donnell, A; Perez, DJ; Robinson, BA; Sharples, K; Thompson, PI, 2014) |
| "Neratinib in combination with capecitabine had a manageable toxicity profile and showed promising antitumor activity in patients with HER2-positive metastatic breast cancer pretreated with trastuzumab and lapatinib." | 9.19 | Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. ( Baselga, J; Cortés, J; Garcia-Saenz, JA; Germa, C; Harb, W; Kiger, C; Kim, SB; Martin, M; Moroose, R; Pluard, T; Saura, C; Wang, K; Xu, B, 2014) |
| "We report updated progression-free survival (PFS) and overall survival (OS) data from a trial that compared capecitabine plus oxaliplatin (CapeOX) versus S-1 plus oxaliplatin (SOX) for the first-line treatment of metastatic colorectal cancer." | 9.19 | S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial. ( Baek, JY; Cho, SH; Chung, IJ; Hong, YS; Jo, SJ; Kang, HJ; Kim, JH; Kim, KP; Kim, ST; Kim, SY; Kim, TW; Lee, J; Lee, JW; Lee, KH; Lee, KW; Lim, HY; Park, YS; Shin, DB; Shin, SJ, 2014) |
| "The purpose of this phase II study was to evaluate the safety and efficacy of weekly irinotecan and capecitabine (wXELIRI) treatment in patients with metastatic colorectal cancer, specifically the rate of severe diarrhea." | 9.19 | Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients. ( Chen, Z; Guo, W; Li, J; Li, W; Liu, T; Shen, L; Xu, J; Zhang, W; Zhu, X, 2014) |
| "Combinations of trastuzumab with paclitaxel or capecitabine are effective therapies in human epidermal growth factor 2 (HER2)-positive metastatic breast cancer (MBC)." | 9.17 | Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer. ( Benekli, M; Berk, V; Buyukberber, S; Coskun, U; Demirci, U; Ozkan, M; Sevinc, A; Tonyali, O; Ucgul, E; Uncu, D; Yildiz, R, 2013) |
| "The pro-drug capecitabine is approved for treatment of anthracycline- and paclitaxel-resistant metastatic breast cancer." | 9.17 | Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer. ( Armstrong, DK; Connolly, RM; Davidson, NE; Fetting, JH; Garrett-Mayer, E; Hoskins, JM; Jeter, SC; McLeod, HL; Rudek, MA; Stearns, V; Watkins, SP; Wolff, AC; Wright, LA; Zhao, M, 2013) |
| " In this study, we determined the dose, efficacy, and tolerability of irinotecan according to UGT1A1 genotypes when combined with capecitabine in patients with metastatic colorectal cancer." | 9.17 | A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer. ( Bae, KS; Chang, HM; Hong, YS; Kang, YK; Kim, HS; Kim, KP; Kim, TW; Lee, JL; Lee, JS; Shin, JG; Sym, SJ, 2013) |
| "Palliative chemotherapy with cisplatin/5-fluorouracil (5FU) is the commonest regimen employed for metastatic and recurrent head and neck squamous cell carcinoma (SCCHN) and nasopharyngeal carcinoma (NPC)." | 9.17 | Carboplatin/5-fluorouracil as an alternative to cisplatin/5- fluorouracil for metastatic and recurrent head and neck squamous cell carcinoma and nasopharyngeal carcinoma. ( Aslan, NM; Chee Ee Phua, V; Ismail, F; Kua, VF, 2013) |
| "To investigate the safety and efficacy of pemetrexed combined with chemotherapy as second or third line in patients with stage IV colorectal cancer (CRC)." | 9.17 | Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer. ( Cao, J; Huang, XE; Liu, J; Lu, YY; Wu, XY; You, SX, 2013) |
| "The aim of this study was to evaluate 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) PET for early prediction of the standard anatomic response and survival outcomes in patients with metastatic colorectal cancer (mCRC) receiving leucovorin, 5-fluorouracil (5-FU), and oxaliplatin (FOLFOX)." | 9.17 | 3'-Deoxy-3'-18F-fluorothymidine PET for the early prediction of response to leucovorin, 5-fluorouracil, and oxaliplatin therapy in patients with metastatic colorectal cancer. ( Hong, YS; Kim, HJ; Kim, HO; Kim, JS; Kim, KP; Kim, TW; Lee, JL; Lee, SJ; Moon, DH; Oh, SJ; Ryu, JS, 2013) |
| "This study evaluated the activity of 2 schedules of erlotinib in combination with chemotherapy, and the prognostic significance of serum amphiregulin (AREG) and transforming growth factor alpha (TGFa) in metastatic colorectal cancer." | 9.17 | Intermittent versus continuous erlotinib with concomitant modified "XELOX" (q3W) in first-line treatment of metastatic colorectal cancer: correlation with serum amphiregulin and transforming growth factor alpha. ( Ahuja, A; Chan, AT; Chan, C; Chan, SL; Dattatray, RD; Ho, WM; Hui, EP; King, AD; Lau, W; Ma, BB; Mo, F; Poon, A; To, KF; Wong, SC, 2013) |
| " This randomized, multicenter, parallel-group, open-label phase II trial compared axitinib with bevacizumab each in combination with 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX) or 5-fluorouracil/leucovorin/irinotecan (FOLFIRI) for second-line treatment of metastatic colorectal cancer." | 9.17 | Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study. ( Barone, C; Bendell, JC; Bloom, J; Kim, JG; Kim, S; Pastorelli, D; Pericay, C; Ricart, AD; Rosbrook, B; Sobrero, AF; Swieboda-Sadlej, A; Tarazi, J; Tournigand, C; Wainberg, ZA, 2013) |
| "Bi-weekly dosing of paclitaxel and capecitabine seems to yield promising responses in advanced breast cancer, with an acceptable adverse-event profile." | 9.17 | Bi-weekly paclitaxel and capecitabine as a second- or third-line treatment for advanced breast cancer: a pilot study. ( Kautio, AL; Kellokumpu-Lehtinen, PL; Lehtinen, I; Tanner, M; Tuunanen, T, 2013) |
| "It was the aim of this study to evaluate maintenance therapy with bevacizumab + capecitabine following induction with bevacizumab + capecitabine + oxaliplatin (XELOX) versus bevacizumab + XELOX until progression as first-line therapy in metastatic colorectal cancer (mCRC)." | 9.17 | Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III 'Stop and Go' study results--a Turkish Oncology Group Trial. ( Buyukberber, S; Buyukunal, E; Camci, C; Cevik, D; Dane, F; Kilickap, S; Ozdener, F; Sencan, O; Uslu, R; Yalcin, S; Yilmaz, U; Zengin, N, 2013) |
| "This phase II trial investigated the efficacy of an induction regimen of bevacizumab, capecitabine plus oxaliplatin (XELOX) followed by maintenance therapy with bevacizumab plus erlotinib as first-line therapy in patients with metastatic colorectal cancer." | 9.17 | Phase II study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer. ( Alonso, V; Bustos, IA; Cirera, L; Dueñas, R; Falcó, E; García-Girón, C; Muñoz, A; Pericay, C; Rivera, F; Salud, A, 2013) |
| " The purpose of this study is to explore the interaction between vinorelbine (N) and capecitabine (X) in breast cancer cells and to compare the simultaneous or sequential administration of the two drugs in patients with metastatic breast cancer (MBC) as first-line treatment." | 9.17 | Vinorelbine and capecitabine in anthracycline- and/or taxane-pretreated metastatic breast cancer: sequential or combinational? ( Gan, Y; Gu, SY; Guo, HY; Hu, XC; Wang, BY; Wang, JL; Wang, LP; Wang, ZH; Zhang, J; Zhao, XM, 2013) |
| "We aimed to investigate the efficacy and tolerability of sorafenib combined with cisplatin and 5-fluorouracil (5-FU) in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC)." | 9.17 | Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma. ( Hu, ZH; Huang, PY; Huang, Y; Lin, SJ; Liu, JL; Liu, LZ; Ma, YX; Pan, JJ; Song, XQ; Wu, JX; Wu, X; Xu, F; Xue, C; Yu, QT; Zhang, J; Zhang, JW; Zhang, L; Zhao, HY; Zhao, LP; Zhao, YY, 2013) |
| "Randomised phase 3 trials in metastatic breast cancer have shown that combining bevacizumab with either paclitaxel or capecitabine significantly improves progression-free survival and response rate compared with chemotherapy alone but the relative efficacy of bevacizumab plus paclitaxel versus bevacizumab plus capecitabine has not been investigated." | 9.17 | Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. ( Beslija, S; Brodowicz, T; Greil, R; Kahan, Z; Kaufman, B; Lang, I; Melichar, B; Messinger, D; Pienkowski, T; Ryvo, L; Sirbu, D; Steger, GG; Stemmer, SM; Zielinski, C; Zvirbule, Z, 2013) |
| "To evaluate the efficacy and safety of an all-oral vinorelbine and capecitabine combination therapy in anthracycline- ± taxane-pretreated HER2/Neu-negative metastatic breast cancer (MBC)." | 9.17 | All-oral combination of vinorelbine and capecitabine as first-line treatment in HER2/Neu-negative metastatic breast cancer. ( Elghazaly, H; Rostom, Y; Tawfik, H, 2013) |
| "The combination of bevacizumab and bolus 5-fluorouracil, leucovorin and irinotecan is highly effective in patients with metastatic colorectal cancer (mCRC)." | 9.17 | Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizu ( Adenis, A; Boucher, E; Chauffert, B; Conroy, T; Ducreux, M; François, E; Ichanté, JL; Montoto-Grillot, C; Pierga, JY; Pignon, JP; Ychou, M, 2013) |
| "This double-blind, phase III study aimed to demonstrate that sunitinib plus FOLFIRI (fluorouracil, leucovorin, and irinotecan) was superior to placebo plus FOLFIRI in previously untreated metastatic colorectal cancer (mCRC)." | 9.17 | Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial. ( Bondarenko, I; Carrato, A; Christensen, JG; De la Cruz, JA; Jonker, DJ; Korytowsky, B; Lechuga, MJ; Lim, R; Lin, X; Roman, L; Shparyk, Y; Staszewska-Skurczynska, M; Sun, Y; Swieboda-Sadlej, A; Tursi, JM; Van Cutsem, E; Williams, JA, 2013) |
| " We aimed at identifying novel genetic markers that would improve prediction of irinotecan toxicity and response in advanced colorectal cancer patients treated with folic acid (leucovorin), fluorouracil (5-FU), and irinotecan (camptosar)-based regimens." | 9.17 | Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens. ( Bélanger, AS; Cecchin, E; Couture, F; Guillemette, C; Harvey, M; Innocenti, F; Jonker, D; Lévesque, E; Toffoli, G, 2013) |
| " The primary objectives of this study were to determine the maximum tolerated dose of vandetanib with capecitabine and oxaliplatin, without and with bevacizumab, for the first line treatment of metastatic colorectal cancer (mCRC), and to define the dose limiting toxicities." | 9.16 | A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer. ( Cabebe, EC; Fisher, GA; Sikic, BI, 2012) |
| "To determine the dose-limiting toxicities (DLTs) and the maximum tolerated doses (MTD) of oral metronomic vinorelbine with capecitabine in patients with metastatic breast cancer (MBC)." | 9.16 | A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer. ( Androulakis, N; Ardavanis, A; Georgoulias, V; Kalbakis, K; Kourakos, P; Malamos, N; Mavroudis, D; Polyzos, A; Saridaki, Z; Vamvakas, L, 2012) |
| "Combination therapy with ixabepilone and capecitabine (cape) is approved for use in patients with locally advanced/metastatic breast cancer that is resistant to treatment with anthracyclines or taxanes." | 9.16 | Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer. ( Bell, JA; Conte, P; Corey-Lisle, PK; Hortobagyi, G; Mukhopadhyay, P; Orsini, L; Peck, R; Revicki, DA; Roche, H; Safikhani, S, 2012) |
| "PEFG regimen (P:cisplatin, E:epirubicin, F:5-fluorouracil, G:gemcitabine) significantly prolonged progression-free (PFS) and overall survival (OS) of patients with advanced pancreatic adenocarcinoma (PA) with respect to standard gemcitabine." | 9.16 | A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen). ( Balzano, G; Belli, C; Cappio, S; Cereda, S; Doglioni, C; Fugazza, C; Ghidini, M; Longoni, S; Nicoletti, R; Passoni, P; Reni, M; Rezzonico, S; Rognone, A; Slim, N; Villa, E, 2012) |
| "The lesions of 5 patients with multiple cutaneous metastases were treated topically, 5 days per week, with 5-fluorouracil in the morning and imiquimod at night." | 9.16 | Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil. ( Desmedt, E; Florin, V; Mortier, L; Vercambre-Darras, S, 2012) |
| "Registered dose capecitabine monotherapy is active against metastatic breast cancer (MBC), but retrospective analyses indicate that lower doses may be as effective and better tolerated." | 9.16 | Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer. ( Calvani, N; Cinefra, M; Cinieri, S; Fedele, P; Marino, A; Mazzoni, E; Nacci, A; Orlando, L; Rizzo, P; Schiavone, P; Sponziello, F, 2012) |
| "This study was intended to ascertain the feasibility of a combination therapy with irinotecan by 24-h intravenous infusion (24-h CPT-11) and 5-fluorouracil (5-FU) for patients with metastatic colorectal cancer, to estimate the dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD), to determine the recommended dose (RD) for the Phase II study, and to evaluate the efficacy of the combination therapy." | 9.16 | Phase I study of irinotecan by 24-h intravenous infusion in combination with 5-fluorouracil in metastatic colorectal cancer. ( Gamo, M; Kambe, M; Kanamaru, R; Kikuchi, H; Ohashi, Y; Yoshioka, T, 2012) |
| "Oral administration of cyclophosphamide (CTX) and capecitabine may have a greater potential for treatment of metastatic breast cancer (MBC) due to anti-angiogenesis resulting from the metronomic dosage and upregulation of thymidine phosphorylase by CTX." | 9.16 | An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study. ( Hong, X; Hu, X; Leaw, S; Lu, J; Shao, Z; Wang, J; Wang, Z, 2012) |
| "The Breast Cancer Study Group of the Hellenic Oncology Research Group conducted a phase III trial of single-agent capecitabine versus the vinorelbine/gemcitabine doublet in patients with metastatic breast cancer (MBC) pretreated with anthracyclines and taxanes." | 9.16 | A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer. ( Ardavanis, A; Boukovinas, I; Georgoulias, V; Malamos, N; Mavroudis, D; Pallis, AG; Varthalitis, I, 2012) |
| "To determine whether capecitabine schedule adaptation improves the tolerability of capecitabine-paclitaxel combination therapy for metastatic breast cancer (MBC), patients with anthracycline-pretreated HER2-negative MBC were randomized to either arm A (21-day cycles: capecitabine 1,000 mg/m(2) twice daily, days 1-14; paclitaxel 60 mg/m(2), days 1, 8, and 15) or arm B (28-day cycles: capecitabine 1,000 mg/m(2) twice daily, days 1-5, 8-12, and 15-19; paclitaxel 80 mg/m(2), days 1, 8, and 15)." | 9.16 | A GINECO randomized phase II trial of two capecitabine and weekly paclitaxel schedules in metastatic breast cancer. ( Alexandre, J; Bachelot, T; Bourgeois, H; de Rauglaudre, G; Hardy-Bessard, AC; Jaubert, D; Largillier, R; Lortholary, A; Paraiso, D, 2012) |
| "A phase I study was performed to determine the maximal tolerated dose (MTD), recommended dose (RD), safety and efficacy of vinflunine when combined with capecitabine in patients with metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes, with pharmacokinetic blood sampling to test potential drug-drug interactions." | 9.16 | A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes. ( Bonneterre, J; Bourbouloux, E; Campone, M; Fumoleau, P; Isambert, N; Milano, G; Roché, H, 2012) |
| " This phase 2 study assessed enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab as maintenance therapy for metastatic colorectal cancer (MCRC)." | 9.16 | A double-blind, randomized, placebo-controlled, phase 2 study of maintenance enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line therapy for metastatic colorectal cancer. ( Di Bartolomeo, M; Fuchs, M; Heinemann, V; Hossain, AM; Nicol, S; Stoffregen, C; Wolff, RA, 2012) |
| "This phase II trial was conducted to determine the activity and safety of the combination of fixed-dose rate (FDR) gemcitabine and capecitabine in metastatic biliary tract cancer (BTC) patients." | 9.16 | A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients. ( Bronte, G; Catalano, V; Falcone, A; Graziano, F; Masi, G; Russo, A; Santini, D; Tonini, G; Vasile, E; Vincenzi, B; Virzi, V, 2012) |
| "Previous phase III studies raised concern about the safety of the combination of capecitabine and irinotecan in patients with metastatic colorectal cancer (mCRC)." | 9.16 | A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer. ( Chen, E; Feld, R; Knox, J; Krzyzanowska, MK; Liu, G; MacKay, H; Moore, MJ; Petronis, J; Renouf, DJ; Wang, L; Welch, S, 2012) |
| "Using the recommended doses obtained from our previous phase 1 trial of a modified Saltz chemotherapy regimen for metastatic colorectal cancer (weekly irinotecan and bolus 5-fluorouracil/l-leucovorin for 3 weeks every 28 days), we performed the present phase 2 trial to evaluate efficacy and toxicity." | 9.16 | Phase 2 study of modified irinotecan and bolus 5-fluorouracil/l-leucovorin in Japanese metastatic colorectal cancer patients. ( Akashi, K; Baba, E; Esaki, T; Fujishima, H; Kusaba, H; Makiyama, A; Mitsugi, K; Nakano, S; Tanaka, R; Uchino, K, 2012) |
| " This study aimed to determine the efficacy and tolerability of a paclitaxel and capecitabine combination in Thai patients with metastatic breast cancer (MBC) not previously treated for metastatic disease." | 9.16 | Capecitabine and weekly paclitaxel as first-line therapy in Thai patients with metastatic breast cancer. ( Chitapanarux, I; Kamnerdsupaphon, P; Lorvidhaya, V; Somwangprasert, A; Srisukho, S; Sukthomya, V; Tharavichitkul, E; Trakultivakorn, H; Watcharachan, K, 2012) |
| "We conducted a multiinstitutional phase II study of capecitabine in combination with vinorelbine and trastuzumab in patients eligible to receive first- or second-line treatment for human epidermal growth factor receptor type 2 (HER2)-positive (HER2(+)) metastatic breast cancer (MBC)." | 9.16 | Phase II interventional study (N0337) of capecitabine in combination with vinorelbine and trastuzumab for first- or second-line treatment of HER2-positive metastatic breast cancer: a north central cancer treatment group trial. ( Allred, JB; Bernath, AM; Fishkin, PA; Fitch, TR; Flynn, P; Perez, EA; Salim, M; Stella, PJ; Tan, WW; Wiesenfeld, M, 2012) |
| "We report the first results from a phase II, open-label study designed to evaluate the efficacy and safety of bevacizumab in combination with trastuzumab and capecitabine as first-line therapy for human epidermal growth factor receptor (HER)-2-positive locally recurrent (LR) or metastatic breast cancer (MBC)." | 9.16 | Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer. ( Gligorov, J; Lichinitser, M; Lluch, A; Makhson, A; Martín, M; Mitchell, L; Scotto, N; Semiglazov, V; Tjulandin, S, 2012) |
| "005) evaluating first-line bevacizumab plus paclitaxel or capecitabine for locally recurrent or metastatic breast cancer." | 9.16 | Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer. ( Beslija, S; Brodowicz, T; Greil, R; Inbar, MJ; Kahán, Z; Kaufman, B; Lang, I; Messinger, D; Steger, GG; Stemmer, SM; Zielinski, C; Zvirbule, Z, 2012) |
| "To evaluate the maximum tolerated dose (MTD) and pharmacokinetic profile of a chronomodulated, dose-intensified regimen of capecitabine in combination with oxaliplatin (XELOX) in metastatic colorectal cancer (mCRC)." | 9.16 | Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer. ( Chen, X; Choo, SP; Chowbay, B; Farid, M; Koo, WH; Ong, SY; Ramasamy, S; Tan, SH; Toh, HC, 2012) |
| "This retrospective analysis aimed to determine whether early dose reduction impacts the efficacy of ixabepilone plus capecitabine in women with metastatic breast cancer (MBC)." | 9.16 | Maintenance of clinical efficacy after dose reduction of ixabepilone plus capecitabine in patients with anthracycline- and taxane-resistant metastatic breast cancer: a retrospective analysis of pooled data from 2 phase III randomized clinical trials. ( Bosserman, L; Gómez, H; Li, RK; Manikhas, A; Medina, C; Mukhopadhyay, P; Opatt, D; Ro, J; Sparano, JA; Thomas, E; Vahdat, L; Valero, V; Vrdoljak, E; Xu, B, 2012) |
| "To evaluate the efficacy and safety of docetaxel plus capecitabine (DC) combination as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer (MBC)." | 9.16 | A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer. ( Bozionelou, V; Georgoulias, V; Kalykaki, A; Karachaliou, N; Kontopodis, E; Mavroudis, D; Papadimitraki, E; Syrigos, K; Tryfonidis, K; Ziras, N, 2012) |
| "We performed an analysis of the efficacy of capecitabine monotherapy as maintenance treatment for metastatic breast cancer (MBC) after response to capecitabine-based chemotherapy [capecitabine plus docetaxel (XT) or vinorelbine (XN)] as a first-line or a second-line treatment." | 9.16 | Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer. ( Bian, L; Cao, Y; Huang, H; Jiang, Z; Song, S; Wang, T; Wu, S; Zhang, S, 2012) |
| "Lapatinib plus capecitabine is an effective treatment option for trastuzumab-refractory HER2-positive metastatic breast cancer." | 9.16 | Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer. ( Bang, YJ; Bates, M; Cha, Y; Haddad, M; Han, SW; Huang, W; Im, SA; Kim, TY; Lee, KS; Lie, Y; Oh, DY; Paquet, A; Park, IH; Ro, J; Sherwood, T; Weidler, J, 2012) |
| "Hand-foot syndrome (HFS) is a limiting toxicity of capecitabine, which is not life-threatening but could compromise capecitabine efficacy." | 9.16 | Incidence of hand-foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen. ( Aparicio, J; Dueñas, R; Falcó, E; Gómez-Martin, C; Irigoyen, A; Lacasta, A; Llorente, B; López, RL; Muñoz, ML; Pérez, B; Reboredo, M; Regueiro, P; Safont, MJ; Sánchez, A; Sanchez-Viñes, E; Serrano, R, 2012) |
| " HORIZON II [Cediranib (AZD2171, RECENTIN) in Addition to Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer] assessed infusional fluorouracil, leucovorin, and oxaliplatin/capecitabine and oxaliplatin (FOLFOX/CAPOX) with or without cediranib in patients with previously untreated metastatic colorectal cancer (mCRC)." | 9.16 | Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II). ( Cheng, Y; Fielding, A; Hochhaus, A; Hoff, PM; Kim, TW; Koynov, KD; Kurteva, G; Li, J; Pestalozzi, BC; Pike, L; Pintér, T; Robertson, JD; Saunders, MP; Tebbutt, NC; van Eyll, B, 2012) |
| "A regimen consisting of 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) is widely used in France in the first-line treatment of metastatic colorectal cancer (MCRC)." | 9.15 | Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. ( Adenis, A; Bennouna, J; Bergougnoux, L; Conroy, T; Douillard, JY; Ducreux, M; Faroux, R; Hebbar, M; Kockler, L; Lledo, G; Rebischung, C; Ychou, M, 2011) |
| "To evaluate the efficacy, safety and quality of life of a short course of oxaliplatin plus capecitabine (XELOX) followed by single-agent capecitabine in patients with previously untreated, inoperable, metastatic colorectal cancer." | 9.15 | Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study. ( Allen, J; Bentley, D; Gollins, S; Lloyd, A; Morris, J; Saunders, MP; Soe, W; Swindell, R; Taylor, MB; Valle, J; Waddell, T, 2011) |
| "Safety and efficacy of gemcitabine plus docetaxel (GD) and capecitabine plus docetaxel (CD) were compared in patients with metastatic breast cancer, where the alternate crossover monotherapy (GD→C or CD→G) was predetermined." | 9.15 | Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer. ( Ansari, RH; Brufsky, A; Cavalheiro, J; Chen, SC; De La Cruz Vargas, JA; Fein, LE; Gill, JF; Hart, LL; Kim, SB; Obasaju, CK; Orlando, M; Russell, CA; Schwartzberg, LS; Seidman, AD; Stein, RS; Stewart, JF; Tai, DF; Zhao, L, 2011) |
| "Previously untreated patients with metastatic gastroesophageal adenocarcinoma received bevacizumab 10 mg/kg, docetaxel 40 mg/m², fluorouracil 400 mg/m², leucovorin 400 mg/m² on day 1, fluorouracil 1,000 mg/m²/d × 2 days intravenous continuous infusion beginning on day 1, and cisplatin 40 mg/m² on day 3." | 9.15 | Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. ( Capanu, M; Ilson, DH; Jhawer, M; Kelsen, DP; Lefkowitz, RA; Robinson, E; Shah, MA, 2011) |
| "This study was designed to determine the efficacy and tolerability of capecitabine, oxaliplatin and bevacizumab in combination with cetuximab as first-line therapy for advanced colorectal cancer." | 9.15 | A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer. ( Aklilu, M; Ashton, J; Bendell, JC; Blobe, GC; Cushman, S; Fernando, NH; Hurwitz, HI; Morse, MA; Nixon, AB; Pang, H; Wong, NS, 2011) |
| "To evaluate the efficacy and safety of docetaxel plus thiotepa(TXT/TSPA) and docetaxel plus capecitabine(TXT/CAPE) in patients with metastatic breast cancer." | 9.15 | [Randomized clinical case-control trial for the comparison of docetaxel plus thiotepa versus docetaxel plus capecitabine in patients with metastatic breast cancer]. ( Che, L; DI, Lj; Jia, J; Jiang, Hf; Liang, X; Ren, J; Song, Gh; Wang, Xl; Yang, Hb; Yu, J; Zhang, J; Zhou, Xn; Zhu, Yl, 2011) |
| "Capecitabine has antitumor activity in metastatic breast cancer (MBC); however, its optimal dose and schedule remain unclear." | 9.15 | Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer. ( Feigin, K; Gajria, D; Geneus, S; Hudis, CA; Norton, L; Patil, S; Tan, LK; Theodoulou, M; Traina, TA, 2011) |
| "The addition of cetuximab to irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer (mCRC) was shown to reduce the risk of disease progression and increase the chance of response in patients with KRAS wild-type disease." | 9.15 | Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. ( Cascinu, S; Celik, I; Ciardiello, F; Cunningham, D; Folprecht, G; Köhne, CH; Láng, I; Maurel, J; Nowacki, MP; Rougier, P; Schlichting, M; Shchepotin, I; Tejpar, S; Van Cutsem, E; Zubel, A, 2011) |
| "Patients with gallbladder cancer or cholangiocarcinoma were treated with the combination of gemcitabine 1,000 mg/m(2) IV over 100 min on days 1 and 8 and capecitabine 650 mg/m(2) BID PO on days 1-14, administered every 21 days." | 9.15 | A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202. ( Ahmad, SA; Blanke, CD; El-Khoueiry, AB; Gold, PJ; Holcombe, RF; Iqbal, S; Lenz, HJ; Messino, MJ; Rankin, C, 2011) |
| "To assess the efficacy of capecitabine plus docetaxel (XT) versus epirubicin plus docetaxel (ET) as first-line therapy for metastatic breast cancer (MBC)." | 9.15 | Final results of ERASME-4: a randomized trial of first-line docetaxel plus either capecitabine or epirubicin for metastatic breast cancer. ( Agostini, C; Bachelot, T; Bajard, A; Boisseau, M; Coeffic, D; Dramais, D; Ferri-Dessens, RM; Guastalla, JP; Kaphan, R; Oprea, C; Perol, D; Provencal, J; Ray-Coquard, I, 2011) |
| "The AIO KRK-0104 randomised phase II trial investigated the efficacy and safety of two capecitabine-based regimens: combination of capecitabine and irinotecan (CAPIRI) plus cetuximab (CAPIRI-C) and combination of capecitabine with oxaliplatin (CAPOX) plus cetuximab (CAPOX-C) in the first-line treatment of metastatic colorectal cancer (mCRC)." | 9.15 | Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial. ( Abenhardt, W; Decker, T; Dietzfelbinger, H; Fischer von Weikersthal, L; Giessen, C; Haberl, C; Hass, HG; Heinemann, V; Kappauf, H; Klein, S; Mittermüller, J; Moosmann, N; Oruzio, D; Puchtler, G; Schulze, M; Stauch, M; Stintzing, S; Vehling-Kaiser, U; Zellmann, K, 2011) |
| " However, circadian chronomodulated chemotherapy with 5-fluorouracil, leucovorin, and oxaliplatin (chronoFLO4) offered no survival benefit as compared with the non-time-stipulated FOLFOX2, in an international randomized trial involving patients with previously untreated metastatic colorectal cancer (EORTC 05963)." | 9.15 | Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-Fluorouracil-leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963). ( Bjarnason, GA; Carvalho, C; Focan, C; Garufi, C; Giacchetti, S; Iacobelli, S; Innominato, PF; Karaboué, A; Lévi, F; Moreau, T; Smaaland, R; Tampellini, M; Tumolo, S, 2011) |
| "The present study was done to establish a prognostic model for patients and trials using an oxaliplatin-based or irinotecan-based first-line chemotherapy in metastatic colorectal cancer." | 9.15 | Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study. ( André, T; Artru, P; Bengrine-Lefevre, L; Bonnetain, F; Chibaudel, B; de Gramont, A; Desramé, J; Larsen, AK; Louvet, C; Teixeira, L; Tournigand, C, 2011) |
| "The AIO KRK 0110/ML22011 trial is a two-arm, multicenter, open-label randomized phase III trial comparing the efficacy and safety of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in the first-line treatment of metastatic colorectal cancer." | 9.15 | A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial. ( Aubele, P; Bangerter, M; Denzlinger, C; Freiberg-Richter, J; Giessen, C; Heinemann, V; Hinke, A; Kullmann, F; Mayerle, J; Modest, DP; Moosmann, N; Schulz, C; Sieber, M; Stintzing, S; Teschendorf, C; Vehling-Kaiser, U; von Weikersthal, LF, 2011) |
| "In a multicenter, double-blind phase II trial, we compared the efficacy and safety of perifosine plus capecitabine (P-CAP) with placebo plus capecitabine (CAP) in patients with metastatic colorectal cancer (mCRC) who had progressed after as many as two prior therapies." | 9.15 | Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer. ( Bendell, JC; Campos, LT; Gardner, L; Hagenstad, C; Hermann, RC; Nemunaitis, J; Richards, DA; Sportelli, P; Vukelja, SJ, 2011) |
| "Irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI) is accepted as a reference treatment for the first-line treatment of patients with metastatic colorectal cancer (MCRC)." | 9.14 | Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the ( Aranda, E; Benavides, M; Cámara, JC; Carrato, A; Constenla, M; Díaz-Rubio, E; Dueñas, R; Gomez, A; Marcuello, E; Martinez-Villacampa, M; Massutti, B; Navarro, M; Reboredo, M; Valladares, M, 2009) |
| "Oxaliplatin, 5-fluorouracil (5-FU), and leucovorin (LV) are standard first-line treatments for patients with metastatic colorectal cancer (mCRC)." | 9.14 | Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. ( Bridgewater, J; Cassidy, J; Chan, RT; Clingan, P; Cunningham, D; Glynne-Jones, R; Koralewski, P; Mainwaring, P; Pluzanska, A; Sirohi, B; Szczylik, C; Tabah-Fisch, I; Utracka-Hutka, B; Wang, JY; Wasan, H; Zaluski, J, 2009) |
| "This study evaluated the maximum tolerated dose (MTD) and the dose limiting toxicity (DLT) of erlotinib when combined to irinotecan and capecitabine in pre-treated metastatic colorectal cancer patients." | 9.14 | Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients. ( Bajetta, E; Bajetta, R; Buzzoni, R; Di Bartolomeo, M; Dotti, KF; Ferrario, E; Galassi, M; Gevorgyan, A; Mariani, L; Venturino, P, 2009) |
| "5-Fluorouracil refractory metastatic colorectal cancer patients were intravenously treated with HA-Irinotecan (300 mg/m(2) irinotecan with 1,000 mg/m(2) HA) on day 1 of a 21-day cycle." | 9.14 | A pilot human evaluation of a formulation of irinotecan and hyaluronic acid in 5-fluorouracil-refractory metastatic colorectal cancer patients. ( Brown, TJ; Cinc, E; Fox, RM; Gibbs, P; Jennens, R; Michael, M; Ng, R; Pho, M, 2009) |
| "This phase II study was conducted to determine the efficacy and safety of capecitabine and bevacizumab in untreated elderly metastatic colorectal cancer patients." | 9.14 | A phase II study of first-line biweekly capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer. ( Fakih, MG; Khushalani, N; Mashtare, T; Puthillath, A; Romano, K; Ross, ME; Steinbrenner, L; Wilding, G; Wisniewski, M, 2009) |
| "This randomized study assessed whether the best overall response rate (ORR) of cetuximab combined with oxaliplatin, leucovorin, and fluorouracil (FOLFOX-4) was superior to that of FOLFOX-4 alone as first-line treatment for metastatic colorectal cancer." | 9.14 | Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. ( Aparicio, J; Bokemeyer, C; Bondarenko, I; de Braud, F; Donea, S; Hartmann, JT; Koralewski, P; Loos, AH; Ludwig, H; Makhson, A; Schuch, G; Stroh, C; Zubel, A, 2009) |
| ") vinorelbine and capecitabine was shown to be feasible and effective in metastatic breast cancer (MBC)." | 9.14 | Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer. ( Brandely, M; Crivellari, D; Foa, P; Fougeray, R; Goldhirsch, A; Mattioli, R; Nolè, F; Pinotti, G; Verri, E, 2009) |
| " In this study the efficacy and safety of the fully oral combination of oral vinorelbine (Navelbine Oral) plus capecitabine (Xeloda) in metastatic breast cancer (MBC) patients pretreated with anthracycline, was evaluated." | 9.14 | A phase II trial of oral vinorelbine and capecitabine in anthracycline pretreated patients with metastatic breast cancer. ( Filip, S; Finek, J; Holubec, L; Kormunda, S; Kozevnikova, R; Pavlikova, I; Sediva, M; Sefrhansova, L; Svoboda, T; Votavova, M, 2009) |
| "Using data from a recent randomized trial, we evaluated the cost effectiveness of ixabepilone plus capecitabine versus capecitabine alone in patients with predominantly metastatic breast cancer considered to be taxane-resistant and previously treated with or resistant to an anthracycline." | 9.14 | Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. ( Anstrom, KJ; Li, Y; Reed, SD; Schulman, KA, 2009) |
| "This study was designed to investigate the efficacy and safety of the epidermal growth factor receptor (EGFR) inhibitor cetuximab combined with irinotecan, folinic acid (FA) and two different doses of infusional 5-fluorouracil (5-FU) in the first-line treatment of EGFR-detectable metastatic colorectal cancer." | 9.14 | Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. ( Brezault, C; Cals, L; Husseini, F; Loos, AH; Nippgen, J; Peeters, M; Raoul, JL; Rougier, P; Van Laethem, JL, 2009) |
| "Irinotecan-based chemotherapy regimens are 1 option for treatment of metastatic colorectal cancer (mCRC)." | 9.14 | Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study. ( Barrueco, J; Jackson, NA; Marshall, J; Meyerhardt, J; Mitchell, E; Soufi-Mahjoubi, R; Zhang, X, 2009) |
| "This multicentre, international phase II trial evaluated the efficacy and safety profile of a first-line combination of oral vinorelbine plus capecitabine for women with metastatic breast cancer (MBC)." | 9.14 | All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial. ( Becquart, D; Bougnoux, P; Chan, A; Conte, PF; Espie, M; Majois, F; Morand, M; Tubiana-Mathieu, N; Vaissiere, N; Villanova, G, 2009) |
| "To evaluate the efficacy of bevacizumab in combination of irinotecan,fluorouracil and leucovorin for metastatic colorectal cancer treated by failed prior oxaliplatin -based regiment." | 9.14 | [Clinical research of bevacizumab in combination with irinotecan, fluorouracil and leucovorin for advanced metastatic colorectal cancer]. ( Chen, B; Chen, JZ; Cui, F; Luo, RC; Wan, C; Zheng, H, 2009) |
| "To evaluate the efficacy and safety of irinotecan combined with xeloda (CAPIRI regimen) in patients with metastatic colorectal cancer after failure of chemotherapy with oxaliplatin." | 9.14 | [Efficacy and safety of combination of irinotecan and capecitabine in patients with metastatic colorectal cancer after failure of chemotherapy with oxaliplatin]. ( Bai, CM; Chen, SC; Cheng, YJ; Jia, N; Shao, YJ; Zhou, JF, 2009) |
| "Bevacizumab (Avastin) significantly improves overall survival (OS) and progression-free survival (PFS) when combined with first-line irinotecan (IFL) plus bolus 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic colorectal cancer (CRC)." | 9.14 | Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. ( Ackland, S; Chiara, S; Clarke, S; Gapski, J; Langer, B; Mainwaring, P; Perez-Carrión, R; Sobrero, A; Young, S, 2009) |
| "A multicenter, phase II study was conducted to evaluate the efficacy and safety of the Japanese intermittent 4-week regimen of capecitabine in patients with advanced/metastatic breast cancer." | 9.14 | Phase II study of 4-weekly capecitabine monotherapy in advanced/metastatic breast cancer. ( Aogi, K; Horikoshi, N; Kimura, M; Kusama, M; Miura, S; Noguchi, S; Nomizu, T; Shin, E; Tabei, T; Toyama, K; Yoshimoto, M; Yoshimura, N, 2010) |
| "This phase II study was designed in order to evaluate efficacy and safety of the combination of vinorelbine (VNB), fluorouracil (FU) and leucovorin (LV) in patients with metastatic breast carcinoma (MBC) previously treated with anthracyclines and taxanes." | 9.14 | Vinorelbine and fluorouracil plus leucovorin combination (ViFL) in patients with anthracycline and taxane-pretreated metastatic breast cancer: a phase II study. ( Bergnolo, P; Bianco, L; Boglione, A; Comandone, A; Cutin, SC; Dal Canton, O; Garetto, F; Inguì, M; Oliva, C; Pochettino, P, 2010) |
| "Docetaxel (T; Taxotere) with capecitabine (X) is active against metastatic breast cancer (MBC); bevacizumab (BV) has demonstrated efficacy with taxanes in the first-line setting." | 9.14 | North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer. ( Dentchev, T; Dueck, AC; Fitch, TR; Geeraerts, LH; Graham, DL; Gross, HM; Hillman, DW; Kahanic, SP; Le-Lindqwister, NA; Liu, H; Palmieri, FM; Patel, TA; Perez, EA, 2010) |
| "On the basis of clinical activity of capecitabine and gemcitabine for metastatic breast cancer, we carried out a multicenter phase II clinical trial on the combination of these two agents in advanced anthracycline-pretreated breast cancer patients." | 9.14 | Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial). ( Andrés, R; Baselga, J; Bermejo, B; Ciruelos, EM; Cortés, J; Cortés-Funes, H; García, E; Gómez, P; Lluch, A; Manso, L; Mayordomo, JI; Mendiola, C; Muñoz, M; Ojeda, B; Rodríguez, CA; Saura, C, 2010) |
| "The primary objective of this study was to determine the activity and safety profile of biweekly oxaliplatin combined with continuous oral capecitabine in the first-line treatment of metastatic colorectal cancer." | 9.14 | Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin. ( Bargagli, G; Bellan, C; Conca, R; Fiaschi, AI; Francini, E; Francini, G; Lazzi, S; Lorenzi, B; Martellucci, I; Pascucci, A; Petrioli, R, 2010) |
| "We examined the toxicity/efficacy of capecitabine with thalidomide, administered over 21-day cycles, in 24 previously treated metastatic breast cancer (MBC) patients." | 9.14 | Phase II study of capecitabine in combination with thalidomide in patients with metastatic breast cancer. ( Barton, JH; Burris, HA; Greco, FA; Hainsworth, JD; Jones, SF; Meluch, AA; Shipley, D; Yardley, DA, 2010) |
| "A dose-finding study was performed to evaluate the dose-limiting toxicity (DLT), maximum-tolerated dose (MTD) and the recommended dose (RD) of escalating the doses of capecitabine and fixed doses of irinotecan and oxaliplatin on a biweekly schedule for metastatic colorectal cancer patients (mCRC)." | 9.14 | Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis. ( Bandres, E; Bitarte, N; Chopitea, A; Gacía-Foncillas, J; Patiño-Garcia, A; Ponz-Sarvise, M; Ramirez, N; Rodríguez, J; Viudez, A; Zarate, R, 2010) |
| "Combined therapy with irinotecan/fluorouracil/levoleucovorin (calcium levofolinate) [IFL] has lost its position as the standard regimen for metastatic colorectal cancer because its toxicity and effectiveness have become controversial." | 9.14 | Modified-irinotecan/fluorouracil/levoleucovorin therapy as ambulatory treatment for metastatic colorectal cancer: results of phase I and II studies. ( Asaka, M; Fuse, N; Kato, T; Komatsu, Y; Kudo, M; Kunieda, Y; Miyagishima, T; Sakata, Y; Tateyama, M; Wakahama, O; Watanabe, M; Yuuki, S, 2010) |
| "Capecitabine is an established therapy for metastatic breast cancer." | 9.14 | Study of low-dose capecitabine monotherapy for metastatic breast cancer. ( Abe, C; Akagi, K; Masuda, N; Nakayama, T; Nishida, Y; Noguchi, S; Ogino, N; Sakamoto, J; Taguchi, T; Yoshidome, K; Yoshikawa, Y, 2010) |
| "Ixabepilone plus capecitabine demonstrated a clear activity and an acceptable safety profile in Chinese patients with anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer, and the majority of patients completed 6 cycles of the therapy with manageable neuropathy toxicities." | 9.14 | Ixabepilone plus capecitabine for Chinese patients with metastatic breast cancer progressing after anthracycline and taxane treatment. ( Fan, Y; Wang, J; Xu, B, 2010) |
| "To determine whether adding bevacizumab, with or without mitomycin, to capecitabine monotherapy improves progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) in an open-label, three-arm randomized trial." | 9.14 | Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. ( Ackland, SP; Broad, A; Chua, Y; Cummins, MM; Cunningham, D; Forgeson, G; Ganju, V; Gebski, VJ; Price, TJ; Robinson, B; Saunders, MP; Simes, RJ; Stockler, MR; Tebbutt, NC; van Hazel, GA; Wilson, K; Zalcberg, JR; Zannino, D, 2010) |
| "A phase I multicentre trial was conducted to define the recommended dose of capecitabine in combination with oxaliplatin and irinotecan (OCX) in metastatic colorectal cancer." | 9.14 | Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced/metastatic colorectal cancer: a phase I trial (SAKK 41/03). ( Cathomas, R; Köberle, D; Lanz, D; Popescu, R; Roth, A; Ruhstaller, T; Simcock, M; Uhlmann, C; von Moos, R; Widmer, L, 2010) |
| "We sought to determine whether the combination of ixabepilone plus capecitabine improved overall survival (OS) compared with capecitabine alone in patients with metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes." | 9.14 | Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. ( Conte, P; Da Costa, SC; Manikhas, A; Medina, C; Peck, R; Perez Manga, G; Poulart, V; Rixe, O; Ro, J; Rondinon, M; Rubio, G; Sparano, JA; Vrdoljak, E; Xu, B, 2010) |
| "Patients with histologically confirmed metastatic or locally advanced adenocarcinoma of the stomach or gastroesophageal junction received docetaxel 25 mg/m2 and oxaliplatin 50 mg/m2 on days 1 and 8 with capecitabine 625 mg/m2 twice daily from day 1-14, in 21-day cycles." | 9.14 | Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma. ( Aggarwal, S; Goel, G; Jauhri, M; Negi, A, 2010) |
| "To determine the recommended doses of oral vinorelbine (VN) and capecitabine (C) in metastatic breast cancer." | 9.14 | Phase I study of oral vinorelbine and capecitabine in patients with metastatic breast cancer. ( Anton, A; Bermejo, B; Casado, A; Gayo, J; Lao, J; Lluch, A; Martin, M; Muñoz, M; Paules, AB; Provencio, M, 2010) |
| "These data confirm that the combination of trastuzumab plus capecitabine and docetaxel is highly active in patients with HER-2-overexpressing anthracycline-pretreated breast cancer, offering a significant survival benefit and is well tolerated." | 9.14 | Trastuzumab plus capecitabine and docetaxel as first-line therapy for HER2-positive metastatic breast cancer: phase II results. ( Fotiou, S; Gennatas, C; Gennatas, S; Michalaki, V, 2010) |
| "This phase II study prospectively evaluated the feasibility of vinorelbine in combination with capecitabine in Chinese patients with metastatic breast cancer (MBC) pretreated with anthracyclines and taxanes." | 9.14 | Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes. ( Cai, R; Fan, Y; Li, Q; Ma, F; Wang, J; Xu, B; Yuan, P; Zhang, P, 2010) |
| "To determine activity and safety of capecitabine at a moderate dose of 2000 mg/m(2) as first-line therapy for metastatic breast cancer." | 9.14 | First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: results of the MONICA trial. ( Bauer, W; Costa, SD; Distelrath, A; Gerber, B; Hagen, V; Kaufmann, M; Kleine-Tebbe, A; Loibl, S; Maass, N; Mehta, K; Ruckhaeberle, E; Schneeweiss, A; Schrader, I; Sütterlin, MW; Tomé, O; von Minckwitz, G; Wiest, W, 2010) |
| "Vinorelbine and capecitabine are both active in breast cancer with moderate toxicity." | 9.14 | Combination of oral vinorelbine and capecitabine in the treatment of metastatic breast cancer patients previously exposed to anthracyclines: a pilot study. ( Hassan, M; Osman, MM, 2010) |
| "To demonstrate the noninferiority of capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid and oxaliplatin (FOLFOX-4) as second-line therapy in patients with metastatic colorectal cancer after prior irinotecan-based chemotherapy." | 9.13 | Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. ( Bang, YJ; Butts, C; Cox, JV; Cunningham, D; Goel, R; Gollins, S; Laguerre, S; Navarro, M; Rothenberg, ML; Siu, LL, 2008) |
| "The aim of the study was to investigate the associations between UGT1A1(*)28 genotype and (1) response rates, (2) febrile neutropenia and (3) dose intensity in patients with metastatic colorectal cancer treated with irinotecan." | 9.13 | UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study. ( Antonini, NF; Gelderblom, H; Guchelaar, HJ; Kweekel, DM; Punt, CJ; Van der Straaten, T, 2008) |
| "The aim of this study was to evaluate the efficacy and safety of capecitabine in combination with vinorelbine in patients with metastatic breast cancer (MBC) pretreated with anthracyclines and taxanes." | 9.13 | A Phase II study of capecitabine and vinorelbine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes. ( Batista, N; Cruz, J; Dómine, M; Estévez, LG; León, A; Provencio, M; Rodríguez, M; Sánchez-Rovira, P; Velasco, A, 2008) |
| "To describe the considerations leading to marketing approval of ixabepilone in combination with capecitabine and as monotherapy for the treatment of advanced breast cancer that is refractory to other chemotherapies." | 9.13 | Ixabepilone in combination with capecitabine and as monotherapy for treatment of advanced breast cancer refractory to previous chemotherapies. ( Aziz, R; Booth, B; Bullock, J; Dagher, R; Harapanhalli, R; Jiang, X; Justice, R; Kaminskas, E; Kasliwal, R; Lechleider, RJ; Leighton, J; Pazdur, R; Pope, S; Sridhara, R, 2008) |
| "The aim of this study was to determine the safety, maximum tolerated dose (MTD), recommended phase II dose, and efficacy of the epothilone B analogue ixabepilone plus capecitabine in anthracycline-pretreated/ resistant and taxane-resistant metastatic breast cancer (MBC)." | 9.13 | Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer. ( Bunnell, C; Gralow, J; Klimovsky, J; Peck, R; Poulart, V; Schwartzberg, L; Thomas, E; Vahdat, L, 2008) |
| "Patients with measurable, metastatic adenocarcinoma of the stomach or esophagogastric junction and no prior chemotherapy received oxaliplatin 85 mg/m(2), leucovorin 200 mg/m(2), and fluorouracil 2600 mg/m(2) as a 24-h infusion in combination with docetaxel 50 mg/m(2) (FLOT) on day 1 every 2 weeks." | 9.13 | Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. ( Al-Batran, SE; Atmaca, A; Clemens, MR; Fritz, M; Hartmann, JT; Hofheinz, R; Homann, N; Jäger, E; Mahlberg, R; Pauligk, C; Probst, S; Rethwisch, V; Seipelt, G; Sievert, M; Stoehlmacher, J, 2008) |
| "The addition of lapatinib (Tykerb/Tyverb) to capecitabine (Xeloda) delays disease progression more effectively than capecitabine monotherapy in women with previously treated HER2+ metastatic breast cancer (MBC)." | 9.13 | Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer. ( Amonkar, MM; Cameron, D; Geyer, C; Sherrill, B; Stein, S; Walker, M, 2008) |
| "We report severe skin toxicity observed in anthracycline-pretreated metastatic breast cancer patients receiving the combination of capecitabine and weekly paclitaxel." | 9.13 | Severe skin toxicity observed with the combination of capecitabine and weekly paclitaxel in metastatic breast cancer patients. ( Bosnjak, SM; Radulovic, S; Susnjar, S, 2008) |
| "To compare the time to deterioration in health-related quality of life (HRQoL) in patients with previously untreated metastatic colorectal cancer receiving a 5-fluorouracil (5-FU)-based chemotherapy regimen with or without the addition of bevacizumab (BV) in two randomized, placebo-controlled studies." | 9.13 | Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer. ( Cella, D; Holmgren, E; Hurwitz, HI; Kabbinavar, FF; Wallace, JF; Yi, J; Yost, KJ, 2008) |
| " Food and Drug Administration approved lapatinib (Tykerb tablets; GlaxoSmithKline, Philadelphia), an oral, small molecule, dual tyrosine kinase inhibitor of ErbB-2 and ErbB-1, for use in combination with capecitabine for the treatment of patients with human epidermal growth factor receptor (HER)-2-overexpressing metastatic breast cancer who had received prior therapy including an anthracycline, a taxane, and trastuzumab." | 9.13 | FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. ( Cohen, MH; Ibrahim, A; Johnson, J; Justice, R; Ko, CW; Pazdur, R; Ryan, Q; Sridhara, R, 2008) |
| "We investigated the gefitinib, 5-fluorouracil (5-FU), leucovorin and oxaliplatin (IFOX) regimen as first-line therapy in patients with metastatic colorectal cancer." | 9.13 | A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer. ( Cho, CD; Fisher, GA; Halsey, J; Kuo, T; Ramsey, M; Rouse, RV; Schwartz, E; Sikic, BI, 2008) |
| " Effects of the ABCC2 genotype on the pharmacokinetics (PK) of irinotecan and the metabolites were examined in Japanese patients with metastatic colorectal cancer receiving irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI)." | 9.13 | Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI). ( Akiyama, Y; Ando, Y; Araki, K; Endo, H; Fujita, K; Ichikawa, W; Ishida, H; Kawara, K; Matsunaga, M; Miya, T; Mizuno, K; Nagashima, F; Narabayashi, M; Sasaki, Y; Sunakawa, Y; Tanaka, R; Yamamoto, W; Yamashita, K, 2008) |
| "Since the combination of capecitabine and irinotecan has successfully been used as a first-line treatment in metastatic colorectal cancer (MCRC), we expected promising results when given as a second-line treatment to metastatic colorectal patients who had been pretreated with 5-Fluorouracil and Oxaliplatin." | 9.13 | The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer. ( Ahn, JB; Cho, BC; Choi, HJ; Chung, HC; Jeung, HC; Rha, SY; Roh, JK; Shin, SJ, 2008) |
| "To evaluate the efficacy and toxicity of a combination of intravenous vinorelbine and 5-fluorouracil (5-FU) given by continuous infusion in the treatment of metastatic breast cancer previously treated with anthracyclines and taxanes." | 9.13 | Vinorelbine and infusional 5-fluorouracil in anthracycline and taxane pre-treated metastatic breast cancer. ( Bishop, JL; Joffe, JK; Johnston, SR; McIllmurray, MB; Neave, F; O'Reilly, SM; Price, CG; Stuart, NS; Whipp, EC, 2008) |
| " Initial results of a phase III trial demonstrated that lapatinib plus capecitabine is superior to capecitabine alone in women with HER2-positive advanced breast cancer that progressed following prior therapy including trastuzumab." | 9.13 | A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. ( Cameron, D; Campone, M; Casey, M; Chan, A; Chan, S; Crown, J; Davidson, N; Geyer, CE; Gorbounova, V; Jagiello-Gruszfeld, A; Kaufman, B; Lindquist, D; Newstat, B; Oliva, C; Paoletti, P; Pienkowski, T; Press, M; Raats, JI; Romieu, CG; Roychowdhury, D; Rubin, S; Skarlos, D; Stein, S; Viens, P, 2008) |
| "Capecitabine added to docetaxel extends survival in metastatic breast cancer (MBC) and shows additive efficacy with erlotinib in pre-clinical studies." | 9.13 | Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study. ( Baselga, J; De Rosa, F; Fettner, S; Jones, R; Rakhit, A; Trigo, JM; Twelves, C; Wright, T, 2008) |
| "We evaluated the outcome of 140 patients aged > or = 70 years of age who received first-line treatment for metastatic colorectal cancer within the German phase III trial of FUFOX (5-fluorouracil/leucovorin/oxaliplatin) versus CAPOX (capecitabine/oxaliplatin)." | 9.13 | Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer. ( Arkenau, HT; Englisch-Fritz, C; Freier, W; Graeven, U; Greil, R; Grothey, A; Hinke, A; Kretzschmar, A; Kubicka, S; Porschen, R; Schmiegel, W; Schmoll, HJ; Seufferlein, T, 2008) |
| "A phase I study was performed to determine the maximal tolerated dose, recommended doses (RDs), safety and efficacy of oral vinorelbine when combined with capecitabine in an all-oral chemotherapy regimen in patients with metastatic breast cancer (MBC), with pharmacokinetic blood sampling to investigate potential drug-drug interactions." | 9.12 | Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer. ( Adamoli, L; Blanchot, G; Catania, C; Goldhirsch, A; Imadalou, K; Longerey, B; Munzone, E; Nolè, F; Sanna, G, 2006) |
| "Irinotecan or oxaliplatin combined with 5-fluorouracil (5-FU) +/- folinic acid (FA) has changed the treatment standards for metastatic colorectal cancer (CRC)." | 9.12 | Irinotecan, oxaliplatin plus bolus 5-fluorouracil and low dose folinic acid every 2 weeks: a feasibility study in metastatic colorectal cancer patients. ( Bas, C; Bella, S; Chacon, M; Coppola, F; Escobar, E; Hidalgo, J; Korbenfeld, E; Martin, C; Martinez, J; Reale, M; Richardet, E; Senna, S; Smilovich, AM; Wasserman, E, 2006) |
| "We conducted a phase II study to determine the activity and tolerability of weekly paclitaxel, 5-fluorouracil (5-FU) and folinic acid plus granulocyte colony-stimulating factor (G-CSF) support in anthracycline-pre-treated or -resistant metastatic breast cancer patients." | 9.12 | Weekly paclitaxel, 5-fluorouracil and folinic acid with granulocyte colony-stimulating factor support in metastatic breast cancer patients: a phase II study. ( Agostara, B; Barni, S; Bria, E; Colella, E; Cuppone, F; D'Ottavio, AM; Frontini, L; Izzo, F; Nistico, C; Sperduti, I; Terzoli, E; Valenza, R, 2006) |
| "The purpose of this study was to evaluate the safety and activity of fixed-dose capecitabine in patients with advanced colorectal cancer and to correlate pretreatment plasma concentrations of homocysteine and serum and red cell folate with toxicity." | 9.12 | A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer. ( Beale, P; Clarke, SJ; Horvath, L; Ong, S; Rivory, L; Sharma, R, 2006) |
| "Determine the toxicity, tolerability, and pharmacokinetics of SU5416, a vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, coadministered with bolus 5-fluorouracil (5-FU), leucovorin, and irinotecan (IFL) in untreated patients with metastatic colorectal cancer." | 9.12 | Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer. ( Berlin, JD; Cropp, GF; Donnelly, E; Fleischer, AC; Hande, KR; Hannah, AL; Lockhart, AC; Rothenberg, ML; Schaaf, LJ; Schumaker, RD, 2006) |
| "To investigate the combination of erlotinib, capecitabine, and oxaliplatin in patients who were previously treated for metastatic colorectal cancer." | 9.12 | Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. ( Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; Meyerhardt, JA; Michelini, A; Ryan, DP; Sheehan, S; Vincitore, M; Zhu, AX, 2006) |
| "To evaluate the efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer." | 9.12 | [Efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer]. ( Chen, JZ; Liao, WJ; Luo, RC; Zheng, H, 2006) |
| "We conducted two phase II trials evaluating the combination of 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) as first-line treatment in 74 metastatic colorectal cancer patients." | 9.12 | First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer. ( Allegrini, G; Andreuccetti, M; Barbara, C; Brunetti, IM; Bursi, S; Cerri, E; Cupini, S; Falcone, A; Loupakis, F; Marcucci, L; Masi, G; Murr, R; Ricci, S, 2006) |
| "This phase II study evaluated the safety and efficacy of weekly docetaxel and capecitabine in patients with metastatic breast cancer." | 9.12 | Phase II study of weekly docetaxel and capecitabine in patients with metastatic breast cancer. ( Allen, J; Hauger, M; Kendra, K; Merriman, N; Moore, T; Mrozek, E; Nadella, P; Ramaswamy, B; Rhoades, CA; Shapiro, CL; Villalona-Calero, M; Watson, H; Young, D, 2006) |
| "In a prospective study, 250 metastatic colorectal cancer patients were treated with irinotecan, fluorouracil, and leucovorin as first-line treatment." | 9.12 | The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. ( Biason, P; Boccalon, M; Bonura, S; Buonadonna, A; Cecchin, E; Corona, G; D'Andrea, M; De Pangher, V; Errante, D; Frustaci, S; Gaion, F; Galligioni, E; Giusto, M; Medici, M; Pasetto, LM; Pessa, S; Russo, A; Sandri, P; Toffoli, G, 2006) |
| "Currently, there is no standard treatment for patients with anthracycline and taxane-refractory metastatic breast cancer (MBC)." | 9.12 | Sequential therapy with capecitabine followed by vinorelbine/cisplatin in patients with anthracycline/taxane-refractory metastatic breast cancer. ( Chao, TC; Chen, PM; Hsiao, LT; Lin, PC; Wang, WS; Yang, MH; Yen, CC, 2006) |
| "Oxaliplatin (OXA) and irinotecan (IRI) are active drugs for metastatic colorectal cancer, their toxicity profiles are not overlapping, and both drugs have shown at least additivity with folinic acid-modulated 5-fluorouracil (5FU)." | 9.12 | Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer. ( Casaretti, R; Comella, P; De Rosa, V; Fiore, F; Izzo, F; Massidda, B; Palmeri, S; Putzu, C; Sandomenico, C, 2006) |
| "The aim of this phase II study was to evaluate safety and efficacy of an oxaliplatin/vinorelbine/5-fluorouracil (FON) combination in anthracycline and taxane-pretreated metastatic breast cancer patients." | 9.12 | A phase II study of an oxaliplatin/vinorelbine/5-fluorouracil combination in patients with anthracycline-pretreated and taxane-pretreated metastatic breast cancer. ( Brienza, S; Chollet, P; Coeffic, D; Cvitkovic, E; Delozier, T; Delva, R; Guastalla, JP; Levy, C; Mousseau, M; Vannetzel, JM; Yovine, A; Zazzi, ES, 2006) |
| "Capecitabine is a fluoropyrimidine carbamate that acts as a prodrug, mimics continuous infusion of 5-fluorouracil (5-FU), and has encouraging antitumor activity in women with metastatic breast cancer." | 9.12 | Capecitabine/Cyclophosphamide/Methotrexate for patients with metastatic breast cancer: a dose-finding, feasibility, and efficacy study. ( Fasolo, A; Gianni, L; Marchiano, A; Mariani, G; Moliterni, A; Petrelli, F; Valagussa, P; Zambetti, M, 2006) |
| "Irinotecan at 180 mg/m2 combined with an infusional 5-fluorouracil/leucovorin (5-FU/LV) regimen (FOLFIRI) is a standard first line therapy for metastatic colorectal cancer (mCRC)." | 9.12 | Multicentre phase II study using increasing doses of irinotecan combined with a simplified LV5FU2 regimen in metastatic colorectal cancer. ( Bressole, F; Chalbos, P; Debrigode, C; Desseigne, F; Duffour, J; Gourgou, S; Mineur, L; Pinguet, F; Poujol, S; Ychou, M, 2007) |
| "The combination chemotherapy of capecitabine and cisplatin demonstrated a promising antitumor activity with mild toxicity profile in patients with advanced biliary tract cancer." | 9.12 | Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer. ( Choi, SH; Heo, JS; Hong, YS; Hwang, IG; Kang, WK; Lee, J; Lee, SC; Lim, HY; Park, JO; Park, YS, 2007) |
| "To determine the maximum tolerated doses (MTD), toxicities, efficacy, and pharmacokinetics (PK) of gefitinib combined with irinotecan, 5-fluorouracil (5-FU) and leucovorin (IFL) in patients with previously untreated advanced colorectal cancer." | 9.12 | Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. ( Clark, JW; D'Amato, F; Dancey, J; Earle, CC; Eder, JP; Enzinger, PC; Fuchs, CS; Kinsella, K; Mayer, RJ; Meyerhardt, JA; Michelini, A; Ogino, S; Ryan, DP; Stewart, CF; Supko, JG; Zhu, AX, 2007) |
| "A phase II study was conducted to evaluate the toxicity and efficacy of irinotecan/5-fluorouracil/leucovorin (CPT-11/5-FU/LV (AIO schedule)) as salvage treatment in patients with metastatic colorectal cancer." | 9.12 | Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: a phase II trial. ( Agelaki, S; Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kourousis, C; Mavroudis, D; Pallis, A; Souglakos, J; Vardakis, N, 2007) |
| "To compare the use of capecitabine plus oxaliplatin (CAPOX) with infusional fluorouracil (FU)/folinic acid plus oxaliplatin (FUFOX) as first-line therapy for patients with metastatic colorectal cancer (MCRC)." | 9.12 | Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. ( Arkenau, HT; Freier, W; Graeven, U; Greil, R; Grothey, A; Hinke, A; Kretzschmar, A; Kubicka, S; Porschen, R; Schmiegel, W; Schmoll, HJ; Seufferlein, T, 2007) |
| "The aim of this phase III trial was to compare the efficacy and safety of capecitabine plus oxaliplatin (XELOX) versus Spanish-based continuous-infusion high-dose fluorouracil (FU) plus oxaliplatin (FUOX) regimens as first-line therapy for metastatic colorectal cancer (MCRC)." | 9.12 | Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Tri ( Abad, A; Aparicio, J; Aranda, E; Carrato, A; Chaves, M; Díaz-Rubio, E; Gómez-España, A; González-Flores, E; Losa, F; Massutí, B; Maurel, J; Queralt, B; Reina, JJ; Rivera, F; Sastre, J; Tabernero, J, 2007) |
| "To evaluate the efficacy and safety of ixabepilone in patients with metastatic breast cancer (MBC) resistant to anthracycline, taxane, and capecitabine, in this multicenter, phase II study." | 9.12 | Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. ( Bosserman, L; Cai, C; Hortobagyi, GN; Lerzo, G; Mullaney, B; Peck, R; Perez, EA; Pivot, X; Thomas, E; Vahdat, L; Viens, P, 2007) |
| "To assess activity and safety of an experimental combination of irinotecan and oxaliplatin (IRINOX) as first-line treatment in advanced colorectal cancer." | 9.12 | A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5 FU2 + irinotecan or LV5 FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study ( Adenis, A; Bécouarn, Y; Boucher, E; Cany, L; Cvitkovic, F; Jacob, JH; Montoto-Grillot, C; Senesse, P; Thézenas, S; Ychou, M, 2007) |
| "Ixabepilone plus capecitabine demonstrates superior efficacy to capecitabine alone in patients with metastatic breast cancer pretreated or resistant to anthracyclines and resistant to taxanes." | 9.12 | Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. ( Campone, M; Chan, VF; Chung, HC; de Mendoza, FH; Fein, LE; Gomez, HL; Jassem, J; Klimovsky, JV; Lerzo, GL; Li, RK; Mukhopadhyay, P; Peck, RA; Pivot, XB; Roché, HH; Thomas, ES; Vahdat, LT; Xu, B, 2007) |
| "This phase II study investigated the efficacy and safety of cetuximab combined with standard oxaliplatin-based chemotherapy (infusional fluorouracil, leucovorin, and oxaliplatin [FOLFOX-4]) in the first-line treatment of epidermal growth factor receptor-expressing metastatic colorectal cancer (mCRC)." | 9.12 | Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. ( André, T; Casado, E; Cervantes, A; Ciardiello, F; de Gramont, A; Díaz-Rubio, E; Humblet, Y; Kisker, O; Soulié, P; Tabernero, J; Tortora, G; Valera, JS; Van Cutsem, E; Van Laethem, JL; Verslype, C, 2007) |
| "The aim of the current randomized Phase II study was to investigate the efficacy and safety of capecitabine combined with irinotecan as first-line treatment in metastatic colorectal carcinoma (CRC)." | 9.11 | Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. ( Artale, S; Bajetta, E; Beretta, E; Biasco, G; Bonaglia, L; Bonetti, A; Buzzoni, R; Carreca, I; Cassata, A; Cortinovis, D; Di Bartolomeo, M; Ferrario, E; Frustaci, S; Iannelli, A; Lambiase, A; Mariani, L; Marini, G; Pinotti, G, 2004) |
| "Treating patients with anthracycline- and taxane-pretreated metastatic breast cancer (MBC) represents a significant challenge to oncologists." | 9.11 | Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. ( Audhuy, B; Clippe, C; Culine, S; Curé, H; Dièras, V; Fumoleau, P; Largillier, R; Lesimple, T; Montestruc, F; Morère, JF; Mouri, Z; Namer, M; Orfeuvre, H; Serin, D; Vuillemin, E, 2004) |
| "The purpose is to determine the plasma pharmacokinetics, the maximum-tolerable dose and to preliminary evaluate the antitumor activity of irinotecan administered as a 7-day continuous infusion every 21 days in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed." | 9.11 | A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed. ( Allegrini, G; Barbara, C; Cupini, S; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Masi, G, 2004) |
| "The objective of the trial is to evaluate the efficacy of capecitabine in patients with metastatic hormone-resistant prostate carcinoma (HRPC), in terms of prostate-specific antigen (PSA) response and clinical benefit (decrease of pain or analgesic score) and its safety profile." | 9.11 | Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial. ( Bauer, J; Bernhard, J; Bonomo, M; Borner, M; Cerny, T; Dietrich, D; Gillessen, S; Gschwend, A; Hanselmann, S; Hering, F; Morant, R; Rochlitz, C; Schmid, HP; Wernli, M, 2004) |
| "5-Fluorouracil (5-FU) and Vinorelbine (Vin) are active in the second line therapy of metastatic breast cancer (MBC)." | 9.11 | Second line chemotherapy with 5 fluorouracil and vinorelbine in anthracycline and taxane pretreated patients with metastatic breast cancer. ( Aravantinos, G; Bakoyiannis, C; Christodoulou, C; Fountzilas, G; Janinis, J; Kosmidis, P; Razis, E; Timotheadou, H, 2004) |
| "An open-label, non-randomized, compassionate-use study was carried out to investigate the effects of oral capecitabine at a dose of 1 250 mg/m2 twice daily on days 1 to 14 every 21 days in anthracycline- and taxane-pretreated advanced/metastatic breast cancer patients." | 9.11 | Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer. ( Bremnes, Y; Mjaaland, I; Ostenstad, B; Risberg, T; Sommer, HH; Wist, EA, 2004) |
| "Of 813 patients with previously untreated metastatic colorectal cancer, we randomly assigned 402 to receive irinotecan, bolus fluorouracil, and leucovorin (IFL) plus bevacizumab (5 mg per kilogram of body weight every two weeks) and 411 to receive IFL plus placebo." | 9.11 | Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. ( Baron, A; Berlin, J; Cartwright, T; Fehrenbacher, L; Ferrara, N; Fyfe, G; Griffing, S; Hainsworth, J; Heim, W; Holmgren, E; Hurwitz, H; Kabbinavar, F; Novotny, W; Rogers, B; Ross, R, 2004) |
| "FOLFOX, a bimonthly combination of leucovorin, 5-fluorouracil and oxaliplatin, is active in metastatic colorectal cancer, but sometimes causes cumulative sensory neurotoxicity." | 9.11 | Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. ( André, T; Artru, P; Carola, E; de Gramont, A; Louvet, C; Mabro, M; Maindrault-Goebel, F; Tournigand, C, 2004) |
| "A dose-finding study was undertaken to determine the maximum-tolerated dose, and the recommended dose of docetaxel in combination with 12-h timed (22:00-10:00) flat infusion of 5-fluorouracil (5-FU) in metastatic breast cancer patients." | 9.11 | Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study. ( Baldi, PL; Calista, F; Cannita, K; Cianci, G; DE Galitiis, F; DI Rocco, ZC; Ficorella, C; Marchetti, P; Morelli, MF; Natoli, C; Porzio, G; Ricevuto, E; Tinari, N, 2004) |
| "We have evaluated the efficacy and safety of the combination of capecitabine and vinorelbine in metastatic breast cancer (MBC) patients previously treated with anthracycline-and taxane-containing regimens." | 9.11 | Capecitabine and vinorelbine in patients with metastatic breast cancer previously treated with anthracycline and taxane. ( Ahn, JH; Ahn, SH; Kang, YK; Kim, SB; Kim, SM; Kim, TW; Kim, WK; Lee, JS; Park, JM, 2004) |
| "The effectiveness of capecitabine, an oral fluoropyrimidine carbamate, is well documented in previously untreated metastatic colorectal cancer patients (overall response rate: 25%)." | 9.11 | Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy. ( Bang, YJ; Heo, DS; Joh, YH; Kim, DW; Kim, NK; Kim, TM; Kim, TY; Kwon, JH; Lee, JJ; Oh, DY; Yu, SJ, 2004) |
| "The addition of capecitabine to docetaxel on a 3-week schedule resulted in superior response rate, increased time to progression (TTP), and improved overall survival in patients with anthracycline-pretreated metastatic breast cancer (MBC)." | 9.11 | Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer. ( Au, HJ; Bodnar, DM; Joy, AA; Koski, SL; Mackey, JR; Scarfe, AG; Smith, SW; Smylie, MG; Soulieres, D; Tonkin, KS, 2004) |
| "A combination of irinotecan 125 mg/m2, 5-fluorouracil (5-FU) 500 mg/m2, and leucovorin (LV) 20 mg/m2 (Saltz regimen; treatment on days 1, 8, 15, and 22 every 6 weeks) is widely used for the treatment of metastatic colorectal cancer." | 9.11 | Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer. ( Arai, T; Goto, A; Hamaguchi, T; Hosokawa, A; Muro, K; Shimada, Y; Shirao, K; Ura, T; Yamada, Y, 2004) |
| "Thirty-six patients with advanced breast cancer were stratified for the presence of bone and non-bone involvement and treated at four dose levels from capecitabine 800 mg/m2 orally days 1-14 and vinorelbine 20 mg/m2 intravenously days 1 and 8, to capecitabine 1250 mg/m2 orally days 1-14 and vinorelbine 25 mg/m2 intravenously days 1 and 8, for a maximum of six cycles." | 9.11 | Capecitabine and vinorelbine in elderly patients (> or =65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99). ( Aebi, S; Ballabeni, P; Castiglione-Gertsch, M; Goldhirsch, A; Hess, D; Pagani, O; Rauch, D; Rufener, B; Thürlimann, B, 2004) |
| "In a previous phase I-II study we demonstrated that the FOLFOXIRI regimen [irinotecan 125-175 mg/m2 day 1, oxaliplatin 100 mg/m2 day 1, l-leucovorin (l-LV) 200 mg/m2 day 1, 5-fluorouracil (5-FU) 3800 mg/m2 as a 48-h chronomodulated continuous infusion starting on day 1, repeated every 2 weeks] has promising activity and efficacy in metastatic colorectal cancer." | 9.11 | First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule. ( Allegrini, G; Andreuccetti, M; Brunetti, I; Cerri, E; Cupini, S; Falcone, A; Fontana, E; Marcucci, L; Masi, G; Ricci, S, 2004) |
| "To define the maximum-tolerated dose (MTD) and to evaluate the dose-limiting toxicities (DLT) of the combination of capecitabine and vinorelbine in patients with metastatic breast cancer who relapse after adjuvant and/or first-line treatment." | 9.11 | Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer. ( Borquez, D; Harstrick, A; Kaufmann, M; Loibl, S; Oberhoff, C; Schleucher, R; Seeber, S; Vanhoefer, U; von Minckwitz, G; Welt, A, 2005) |
| "Since the need for nonanthracycline-containing chemotherapy regimens increases with the increased use of anthracyclines in earlier stages of breast cancer, we investigated the feasibility of the combination of docetaxel and 5-fluorouracil (5-FU) with folinic acid (FA)." | 9.11 | A phase I dose-escalating study of docetaxel plus folinic acid and 5-fluorouracil in anthracycline-pretreated patients with metastatic breast cancer. ( Nortier, JW; Rodenburg, CJ; Slee, PH; van Bochove, A, 2004) |
| "The aim of the current study was to evaluate the antitumor activity and toxicity of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin (FMP therapy) in chemotherapy-naive patients with metastatic hepatocellular carcinoma (HCC)." | 9.11 | A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma. ( Ikeda, M; Morizane, C; Okusaka, T; Takezako, Y; Ueno, H, 2005) |
| "This randomized phase III trial compared the efficacy and safety of capecitabine with or without bevacizumab, a monoclonal antibody to vascular endothelial growth factor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane." | 9.11 | Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. ( Chap, LI; Cobleigh, MA; Dickler, M; Fehrenbacher, L; Holmes, FA; Langmuir, V; Marcom, PK; Miller, KD; Overmoyer, BA; Reimann, JD; Rugo, HS; Sing, AP, 2005) |
| "Capecitabine and irinotecan are commonly used in the treatment of metastatic colorectal cancer (CRC)." | 9.11 | UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. ( Andria, ML; Bever, J; Blanchard, RL; Carlini, LE; Gold, P; Hill, T; Meropol, NJ; Rogatko, A; Wang, H, 2005) |
| "Although irinotecan 350 mg m(-2) is a standard option for relapsed/refractory advanced colorectal cancer, there is some evidence that suggests that a higher dose may be more effective, with acceptable tolerability, following 5-fluorouracil (5-FU)." | 9.11 | Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study. ( Bleiberg, H; Borner, M; Dirix, L; Gonzalez Baron, M; Gruia, G; Joosens, E; Morant, R; Roth, A; Sibaud, D; Van Belle, S; Van Cutsem, E; Van Laethem, JL, 2005) |
| "A phase I-II multicenter trial was conducted to define the maximal tolerated dose and describe the activity of an OCFL combination using oxaliplatin (OHP), irinotecan (CPT-11) and 5-fluorouracil (FU)/leucovorin (LV) in metastatic colorectal cancer (CRC)." | 9.11 | Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study. ( Allal, A; Bauer, J; Gervaz, P; Mentha, G; Morant, R; Philippe, M; Roth, AD; Ruhstaller, T; Seium, Y; Stupp, R; Trembleau, C, 2005) |
| "In a phase III trial, combining bevacizumab (BV)--a recombinant, humanized, monoclonal antibody targeting vascular endothelial growth factor--with irinotecan, bolus fluorouracil (FU), and leucovorin (LV; IFL) increased survival compared with IFL alone in first-line treatment of patients with metastatic colorectal cancer (CRC)." | 9.11 | Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. ( Berlin, J; Fehrenbacher, L; Hainsworth, JD; Hambleton, J; Heim, W; Holmgren, E; Hurwitz, HI; Kabbinavar, F; Novotny, WF, 2005) |
| "Irinotecan combined with continuous-infusion 5-fluorouracil (5FU) has been shown to be an effective and tolerable regimen in the treatment of metastatic colorectal cancer (MCRC)." | 9.11 | Phase II study of irinotecan, leucovorin, 5-fluorouracil and tegafur/uracil for metastatic colorectal cancer. ( Asama, T; Ashida, T; Ayabe, T; Chisato, N; Ebisawa, Y; Kamiya, K; Kasai, S; Kohgo, Y; Kono, T; Tomita, I, 2005) |
| "Seventy-two patients suffering from a metastatic colorectal cancer received, as first line treatment, a combination chronotherapy with 5-FU and folinic acid (infused from 10 pm to 10 am with a peak at 4 am, respectively at doses of 700 and 300 mg/m2 per day) and carboplatin (infused at the dose of 40 mg/m2 per day from 10 am to 10 pm with a peak at 4 pm)." | 9.11 | [Chronotherapy combining 5-fluorouracil, folinic acid and carboplatin as first line treatment in metastatic colorectal cancer. A phase 2 study]. ( Biquet, JF; David, A; Delforge, M; Focan, C; Focan-Henrard, D; Graas, MP; Kreutz, F; Longrée, L; Materne, R; Moeneclaey, N; Weerts, J, 2005) |
| "To compare the efficacy and safety of doxorubicin and docetaxel (AT) with fluorouracil, doxorubicin, and cyclophosphamide (FAC) as first-line chemotherapy for metastatic breast cancer (MBC)." | 9.11 | Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of ( Bokma, HJ; Bontenbal, M; Braun, HJ; Creemers, GJ; de Boer, AC; Goey, SH; Janssen, JT; Kerkhofs, LG; Leys, RB; Ruit, JB; Schmitz, PI; Schothorst, KL; Seynaeve, C; van der Velden, PC; Verweij, J, 2005) |
| "A biweekly regimen of irinotecan 200 mg/m2 on day 1 and levo-leucovorin (LV) 250 mg/m2 plus 5-fluorouracil (5-FU) 850 mg/m2 via intravenous bolus on day 2 was assessed in 2 consecutive randomized trials in metastatic colorectal cancer (CRC)." | 9.11 | Safety and efficacy of irinotecan plus high-dose leucovorin and intravenous bolus 5-fluorouracil for metastatic colorectal cancer: pooled analysis of two consecutive southern Italy cooperative oncology group trials. ( Buzzi, F; Comella, P; De Cataldis, G; De Lucia, L; Farris, A; Filippelli, G; Leo, S; Lorusso, V; Maiorino, L; Mancarella, S; Massidda, B; Natale, D; Palmeri, S; Roselli, M; Tafuto, S, 2005) |
| "com) and infusional 5-fluorouracil (5-FU) as second-line therapy in metastatic colorectal cancer (MCRC)." | 9.11 | Combined therapy with weekly irinotecan, infusional 5-fluorouracil and the selective COX-2 inhibitor rofecoxib is a safe and effective second-line treatment in metastatic colorectal cancer. ( Gamucci, T; Gasparini, G; Gattuso, D; Longo, R; Mariani, L; Morabito, A; Sarmiento, R; Torino, F; Vitale, S, 2005) |
| "To evaluate the efficacy and tolerance of irinotecan (CPT-11) in combination with bolus and continuous infusion of 5-fluorouracil (5-FU) and leucovorin (LV) (FOLFIRI regimen) as first-line treatment of elderly patients with metastatic colorectal cancer (MCC)." | 9.11 | Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial. ( Agelaki, S; Androulakis, N; Georgoulias, V; Kakolyris, S; Kouroussis, C; Mavroudis, D; Milaki, G; Pallis, A; Souglakos, J; Xenidis, N, 2005) |
| "We studied the activity of combined oxaliplatin and fluorouracil-leucovorin in 16 consecutive patients with advanced biliary tract adenocarcinomas." | 9.10 | Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial. ( Arkenau, HT; Gregor, M; Greschniok, A; Hass, HG; Klump, B; Nehls, O; Porschen, R, 2002) |
| "To determine the feasibility, recommended doses, plasma pharmacokinetics, and antitumor activity of a biweekly chemotherapy regimen with oxaliplatin (L-OHP), irinotecan (CPT-11), infusional fluorouracil (5-FU), and leucovorin (LV) in metastatic colorectal cancer patients." | 9.10 | Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. ( Allegrini, G; Brunetti, IM; Conte, P; Cupini, S; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Masi, G; Pfanner, E, 2002) |
| "To assess the activity and safety of combined folinic acid (FA), 5-fluorouracil (5-FU) and mitomycin C (MMC) in metastatic breast cancer patients previously treated with at least two chemotherapy regimens." | 9.10 | Folinic acid, 5-fluorouracil and mitomycin C in metastatic breast cancer patients previously treated with at least two chemotherapy regimens. ( Correale, P; Fiaschi, AI; Francini, G; Marsili, S; Messinese, S; Petrioli, R; Pozzessere, D; Sabatino, M, 2002) |
| "Overall results of this study indicate that the administration of clinically relevant single-agent doses of both capecitabine and oxaliplatin is feasible and seems to result in promising therapeutic activity in patients with advanced colorectal cancer." | 9.10 | Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer. ( Huber, H; Kornek, GV; Längle, F; Raderer, M; Scheithauer, W; Schmid, K; Schüll, B, 2002) |
| "Irinotecan (CPT-11) has been shown to prolong survival and improve quality of life in comparison to best supportive care in colorectal cancer patients with pretreatment of bolus 5-fluorouracil (5-FU)." | 9.10 | Adding weekly irinotecan to high-dose 5-fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer--a phase II study. ( Emig, M; Hartung, G; Hehlmann, R; Hochhaus, A; Hofheinz, R; Pilz, L; Queisser, W; Samel, S; Willeke, F, 2002) |
| "This multicentre, randomised phase III study compared docetaxel with 5-fluorouracil+vinorelbine in patients with metastatic breast cancer after failure of neo/adjuvant or one line of palliative anthracycline-based chemotherapy." | 9.10 | Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. ( Assadourian, S; Bonneterre, J; Fargeot, P; Guastalla, JP; Monnier, A; Namer, M; Roché, H, 2002) |
| "We investigated the activity of irinotecan given with a more convenient modified bimonthly de Gramont regimen of bolus and infusional 5-fluorouracil [IrMdG] in advanced or metastatic colorectal cancer in the first and second line setting." | 9.10 | Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer. ( Hochhauser, D; James, R; Ledermann, JA; Leonard, P; Seymour, MT, 2002) |
| "Most patients with colorectal cancer (CRC) who have failed initial 5-fluorouracil (5-FU) chemotherapy have worsening of disease-related symptoms (DRS) and quality of life (QOL)." | 9.10 | The palliative benefit of irinotecan in 5-fluorouracil-refractory colorectal cancer: its prospective evaluation by a Multicenter Canadian Trial. ( Feld, R; Fields, A; Goel, R; Hedley, D; Jolivet, J; Lee, IM; Maroun, J; Michael, M; Moore, MJ; Oza, A; Pintilie, M, 2002) |
| "This phase II study was designed to evaluate the efficacy and toxicities of oral doxifluridine plus leucovorin as a randomized trial with those of intravenous 5-fluorouracil (5-FU) plus leucovorin in previously untreated metastatic colorectal cancer (CRC)." | 9.10 | Oral doxifluridine plus leucovorin in metastatic colorectal cancer: randomized phase II trial with intravenous 5-fluorouracil plus leucovorin. ( Ahn, JH; Kang, YK; Kim, JC; Kim, JG; Kim, TW; Kim, WK; Lee, JH; Lee, JS; Min, YJ; Yu, CS, 2003) |
| "This phase II multicenter trial evaluated the efficacy and toxicity of weekly paclitaxel, 5-fluorouracil, and leucovorin administered as first-line therapy for metastatic breast cancer." | 9.10 | A phase II trial of weekly paclitaxel, 5-fluorouracil, and leucovorin as first-line treatment for metastatic breast cancer. ( Asmar, L; Canfield, VA; Ellis, PG; Ferri, WA; Hynes, HE; Loesch, DM; Parker, GA; Robert, NJ, 2003) |
| "To determine whether biochemical modulation with LV (leucovorin) enhances the efficacy of CAF (cyclophosphamide, doxorubicin, and fluorouracil) against metastatic breast cancer." | 9.10 | Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140. ( Abrams, J; Aisner, J; Allen, SL; Berry, DA; Chuang, E; Cirrincione, C; Cooper, MR; Duggan, DB; Henderson, IC; Norton, L; Parnes, HL; Perry, MC; Szatrowski, TP, 2003) |
| " In preclinical models, there appears to be additive or synergistic effects when combining 5-Fluorouracil (5-FU) with nonsteroidal anti-inflammatory agents (NSAIDs) for the treatment of colorectal neoplasms." | 9.10 | Increased toxicity and lack of efficacy of Rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: A phase II study. ( Ashfaq, R; Becerra, CR; Frenkel, EP; Gaynor, RB, 2003) |
| "To model the cost-effectiveness of adopting capecitabine/docetaxel combination therapy in place of single-agent taxane therapy for women in the province of Ontario, Canada, receiving treatment for anthracycline-pretreated metastatic breast cancer." | 9.10 | Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer. ( Ilersich, AL; Verma, S, 2003) |
| "In North America, no effective therapy has been available for patients with progressive metastatic colorectal cancer after front-line treatment with irinotecan, bolus fluorouracil (FU), and leucovorin (IFL)." | 9.10 | Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. ( Berlin, JD; Bigelow, RH; Burger, BG; Garay, CA; Gupta, S; Haller, DG; Hart, LL; Le Bail, N; Marshall, JL; Oza, AM; Ramanathan, RK; Rothenberg, ML, 2003) |
| "Irinotecan has shown activity in advanced colorectal cancer resistant to leucovorin and fluorouracil." | 9.10 | Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer. ( André, T; Artru, P; Carola, E; de Gramont, A; Gilles-Amar, V; Krulik, M; Louvet, C; Mabro, M, 2003) |
| "In this multicenter phase II study the efficacy and safety of the alternating schedule of irinotecan (CPT-11) with bolus 5-fluorouracil (5-FU) and leucovorin (LV) were assessed as first-line chemotherapy in patients with metastatic colorectal cancer (CRC)." | 9.10 | A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer. ( Aparicio, J; Borrega, P; de la Puente, CG; Lorenzo, A; Moreno-Nogueira, JA; Pica, JM; Reina, JJ; Rueda, A; Salvador, J, 2003) |
| "To determine the activity of biweekly oxaliplatin, combined with weekly bolus fluorouracil (FU) and low-dose leucovorin (LV) chemotherapy (bFOL), as first-line therapy for patients with metastatic colorectal cancer." | 9.10 | Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer. ( Chachoua, A; Escalon, J; Hochster, H; Muggia, F; Speyer, J; Zeleniuch-Jacquotte, A, 2003) |
| "Capecitabine is a rationally designed oral, tumor-activated fluoropyrimidine carbamate with high activity in metastatic breast cancer." | 9.10 | Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. ( Jänicke, F; Jonat, W; Kaufmann, M; Kieback, DG; Kölbl, H; Kuhn, W; Lück, HJ; Mohrmann, S; Reichardt, P; Schindler, AE; Thuss-Patience, PC; Von Minckwitz, G, 2003) |
| "A phase II study was conducted to assess the toxicity and response rate of vinorelbine (NavelbineR) combined with epirubicin and fluorouracil (NEF) in metastatic breast cancer." | 9.10 | Vinorelbine, epirubicin and fluorouracil as first-line therapy in metastatic breast cancer--a phase II trial. ( Blomqvist, C; Elomaa, I; Joensuu, H, 2003) |
| "We studied the safety and clinical activity of exisulind in combination with capecitabine in 35 patients with metastatic breast cancer (MBC)." | 9.10 | Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer. ( Arun, B; Booser, D; Esteva, FJ; Gibbs, A; Hortobagyi, GN; Murray, JL; Nealy, KM; Pusztai, L; Rivera, E; Smith, TL; Symmans, WF; Thompson, WJ; Valero, V; Whitehead, C; Zhen, JH, 2003) |
| "Phase II studies have suggested an improved response rate and acceptable toxicity profile associated with gemcitabine combinations compared to gemcitabine alone for treatment of metastatic adenocarcinoma of the pancreas." | 9.10 | Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas. ( Araneo, M; Bruckner, HW; DeGregorio, P; Firoozi, K; Frager, D; Grossbard, ML; Homel, P; Jindal, K; Kozuch, P; Marino, J; Mortazabi, F, 2003) |
| "To evaluate the toxicity and efficacy of a modified deGramont regimen of 5-fluorouracil (5-FU), leucovorin, and oxaliplatin in patients with advanced colorectal cancer who have progressed on at least one but not more than two prior chemotherapy regimens." | 9.10 | A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer. ( Catarius, KJ; Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; Mayer, RJ; Ryan, DP; Stuart, K; Winkelmann, J, 2003) |
| "The tolerance and efficacy of oxaliplatin and irinotecan for metastatic colorectal cancer are unknown in elderly patients." | 9.10 | Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly. ( Aparicio, T; Artru, P; Belloc, J; Desramé, J; Dominguez, S; Etienney, I; Ezenfis, J; Lecomte, T; Locher, C; Mabro, M; Mitry, E; Montembault, S; Vayre, L, 2003) |
| " once every 3 weeks was assessed in 60 patients with advanced colorectal cancer (CRC) showing failure to 5-fluorouracil (5-FU) treatment." | 9.10 | Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study. ( Abad, A; Antón, A; Aranda, E; Balcells, M; Carrato, A; Cervantes, A; Díaz-Rubio, E; Fenández-Martos, C; Gallén, M; Huarte, L; Marcuello, E; Massutti, B; Sastre, J, 2003) |
| "This multicenter, open-label, phase II study was performed to assess the efficacy and toxicity of irinotecan 350 mg/m2 intravenously every 3 weeks in patients with advanced colorectal cancer (CRC) previously treated with 5-fluorouracil (5-FU)." | 9.10 | A multicenter phase II study of irinotecan in patients with advanced colorectal cancer previously treated with 5-fluorouracil. ( Arizcun, A; Cruz, JJ; de la Torre, A; Diz, P; Duarte, I; España, P; García López, MJ; García-Girón, C; Martínez del Prado, P; Méndez, M; Navalon, M; Pujol, E; Salut, A, 2003) |
| "This study combined oxaliplatin with the Nordic bolus schedule of 5-fluorouracil (5-FU) and folinic acid (FA) as first-line treatment in metastatic colorectal cancer." | 9.10 | Nordic 5-fluorouracil/leucovorin bolus schedule combined with oxaliplatin (Nordic FLOX) as first-line treatment of metastatic colorectal cancer. ( Dahl, O; Sørbye, H, 2003) |
| "To define the cyclophosphamide (CTX) maximal tolerated dose when combined with fixed doses of gemcitabine, fluorouracil (5-FU) and folinic acid (leucovorin, LFA) in metastatic breast cancer patients pretreated with anthracyclines and taxanes." | 9.10 | A phase I-II study on a gemcitabine-cyclophosphamide-fluorouracil/folinic acid triplet combination in anthracycline- and taxane-refractory breast cancer patients. ( Botti, G; Capasso, I; Comella, G; Comella, P; Cortino, GR; D'Aiuto, G; Di Bonito, M; Frasci, G; Rubulotta, R; Thomas, R; Vallone, P, 2002) |
| "The combination of CPT-11 with 5-fluorouracil (5-FU) in advanced colorectal cancer (ACC) represents an attractive approach." | 9.10 | Irinotecan (CPT-11) in combination with infusional 5-fluorouracil and leucovorin (de Gramont regimen) as first-line treatment in patients with advanced colorectal cancer: a multicenter phase II study. ( Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kandilis, K; Kouroussis, C; Mavroudis, D; Sarra, E; Souglakos, J; Vamvakas, L; Ziras, N, 2002) |
| "To study tolerability and efficacy of an intensified chronomodulated schedule of fluorouracil (5-FU) and l-folinic acid (l-FA) as first-line treatment of metastatic colorectal cancer, 5-FU was given near individually determined dose-limiting toxicity in a multicenter phase II trial." | 9.10 | Phase II trial of chronomodulated infusion of high-dose fluorouracil and l-folinic acid in previously untreated patients with metastatic colorectal cancer. ( Adenis, A; Chevalier, V; Chipponi, J; Chollet, P; Coudert, B; Curé, H; Focan, C; Kwiatkowski, F; Lévi, F; Niezgodzki, G; Perpoint, B; Pezet, D; Tubiana-Mathieu, N, 2002) |
| "Cimetidine has been shown to have beneficial effects in colorectal cancer patients." | 9.10 | Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis-X and sialyl Lewis-A epitope expression on tumour cells. ( Imaeda, Y; Kobayashi, K; Matsumoto, S; Okamoto, T; Suzuki, H; Umemoto, S, 2002) |
| "To compare the efficacy and tolerability of eniluracil (EU)/fluorouracil (5-FU) with that of 5-FU/leucovorin (LV) as first-line therapy for patients with metastatic/advanced colorectal cancer." | 9.10 | Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer. ( Ansari, RH; Bell, WN; Colwell, B; Levin, J; McGuirt, PV; Pazdur, R; Schilsky, RL; Thirlwell, MP; West, WH; White, RL; Wong, A; Yates, BB, 2002) |
| "This phase II study was designed to evaluate the efficacy and toxicity of 3-h interval sequential methotrexate (MTX) and 5-fluorouracil (5-FU) with leucovorin (LV) rescue in the treatment of patients with metastatic colorectal cancer." | 9.10 | Effect of a 3-hour interval between methotrexate and 5-fluorouracil in the treatment of metastatic colorectal cancer. ( Hamaguchi, T; Haruyama, K; Matsumura, Y; Muro, K; Shimada, Y; Shirao, K; Sugano, K; Yamada, Y, 2002) |
| "The aim of this study was to determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and potential activity of combined gemcitabine and continuous infusion 5-fluorouracil (5-FU) in metastatic breast cancer (MBC) patients that are resistant to anthracyclines or have been pretreated with both anthracyclines and taxanes." | 9.10 | An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes. ( Awada, A; Batter, V; Beex, L; Biganzoli, L; Cufer, T; Hamilton, A; Lohrisch, C; Nooij, M; Piccart, M, 2002) |
| "Twenty-one patients with recurrent or metastatic breast cancer were treated with paclitaxel (Taxol) as a 1-hour infusion on day 1 only of a 14-day cycle." | 9.10 | Phase II study of low-dose infusional 5-fluorouracil and paclitaxel (Taxol) given every 2 weeks in metastatic breast cancer. ( Amamoo, MA; Collichio, FA; Fogleman, J; Graham, M; Griggs, J, 2002) |
| "To evaluate the response rate and adverse reactions of xeloda, an analogue of 5-fluorouracil, in the treatment of relapsed and metastatic breast cancer." | 9.10 | [Capecitabine (xeloda) in the treatment of relapsed and metastatic breast cancer]. ( Duan, Y; Guan, Z; Liu, X; Song, S; Wu, S; Yang, L; Yu, J, 2002) |
| " This randomised, phase II trial evaluated the efficacy and safety of capecitabine or paclitaxel in patients with anthracycline-pretreated metastatic breast cancer." | 9.10 | Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. ( Ackland, S; Alba Conejo, E; Burger, HU; Eisenberg, P; Laws, S; Melnychuk, D; Moiseyenko, V; O'Reilly, SM; Osterwalder, B; Pienkowski, T; Talbot, DC; Van Belle, S, 2002) |
| "To evaluate the efficacy and tolerance of irinotecan (CPT-11) in combination with oxaliplatin (L-OHP) plus fluorouracil (5-FU)/leucovorin (LV) (de Gramont regimen) as first-line treatment of metastatic colorectal cancer (MCC)." | 9.10 | Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial. ( Agelaki, S; Androulakis, N; Athanasiadis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kourousis, Ch; Mavroudis, D; Samonis, G; Souglakos, J; Tsetis, D; Vardakis, N, 2002) |
| "Docetaxel and capecitabine, a tumor-activated oral fluoropyrimidine, show high single-agent efficacy in metastatic breast cancer (MBC) and synergy in preclinical studies." | 9.10 | Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. ( Ayoub, JP; Cervantes, G; Fumoleau, P; Jones, S; Leonard, R; Lui, WY; Mauriac, L; Miles, D; Moiseyenko, V; O'Shaughnessy, J; Twelves, C; Van Hazel, G; Verma, S; Vukelja, S, 2002) |
| "To determine the maximum-tolerated dose (MTD) of a weekly schedule of irinotecan (CPT-11), leucovorin (LV), and a 24-hour infusion of fluorouracil (5-FU24h) as first-line chemotherapy in advanced colorectal cancer and to assess preliminary data on the antitumor activity." | 9.09 | Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer. ( Achterrath, W; Harstrick, A; Köhne, CH; Rustum, YM; Seeber, S; Vanhoefer, U; Wilke, H, 1999) |
| "The efficacy of combination therapy with vinorelbine, cyclophosphamide, and 5-fluorouracil was assessed in women who had received no prior therapy for locally advanced or metastatic breast cancer." | 9.09 | Treatment with a nonanthracycline regimen in advanced breast cancer: vinorelbine, cyclophosphamide, and 5-fluorouracil with folinic acid. ( Biville, F; Closon, MH; Delgado, FM; Fernandez, R; Gruia, G; Llombart, A; Lluch, A; Turpin, F, 1999) |
| "In a prospective multicenter trial, 279 patients with metastatic colorectal cancer who had failed 5-fluorouracil therapy were randomized 2:1 to receive either best supportive care (BSC) plus treatment with the topoisomerase I inhibitor, irinotecan (CPT-11; Rhône-Poulenc Rorer, Antony, France), at a dose of 350 mg/m2 every 3 weeks or BSC alone." | 9.09 | A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group. ( Cunningham, D; Glimelius, B, 1999) |
| "In a multicenter phase III trial, 267 patients with nonbulky metastatic colorectal cancer who had failed first-line 5-fluorouracil (5-FU) therapy were randomized to receive second-line treatment with either the new topoisomerase agent, irinotecan (Rhône-Poulenc Rorer, Antony, France), or a high-dose infusional 5-FU regimen." | 9.09 | Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group. ( Blijham, GH; Van Cutsem, E, 1999) |
| "In a prospective randomized trial, 40 stage IV breast cancer patients undergoing intermediate high-dose chemotherapy (cyclophosphamide, 5-fluorouracil plus epirubicin or methotrexate), received either recombinant human G-CSF (rhG-CSF, group I) or ciprofloxacin and amphotericin B (CAB, group II) for prevention of febrile leucopenia (FL)." | 9.09 | Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B. ( de Vries, EG; Hospers, GA; Mulder, NH; Schröder, CP; Sleijfer, DT; van der Graaf, WT; Willemse, PH, 1999) |
| "To determine whether immunohistochemical thymidylate synthase (TS) quantitation predicts for clinical outcome in patients with advanced colorectal cancer treated by fluorouracil (FUra)-based chemotherapy." | 9.09 | Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. ( Antonelli, G; Aschele, C; Baldo, C; Casazza, S; Debernardis, D; Lionetto, R; Maley, F; Sobrero, A; Tunesi, G, 1999) |
| "The present study was conducted to investigate the efficacy and toxicity of a cisplatin and 5-fluorouracil (5-FU) combination in previously treated advanced breast cancer." | 9.09 | Phase II study of cisplatin and 5-fluorouracil in previously treated metastatic breast cancer: an Eastern Cooperative Oncology Group study (PA 185). ( Abeloff, MD; Hochster, H; Kucuk, O; Pandya, KJ; Skeel, RT, 1999) |
| "Twelve women with metastatic breast cancer were treated with continuous infusion high dose leucovorin, 5-fluorouracil and cisplatin." | 9.09 | Continuous-infusion high-dose leucovorin with 5-fluorouracil and cisplatin for relapsed metastatic breast cancer: a phase II study. ( Booser, DJ; Holmes, FA; Hortobagyi, GN; Walters, RS, 2000) |
| "Oral idarubicin (IDA) is an active drug in metastatic breast cancer, but its role in the management of this tumor is yet not established completely." | 9.09 | Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients. ( Aita, P; Bearz, A; Boiocchi, M; Colussi, AM; Corona, G; Crivellari, D; Robieux, I; Sorio, R; Stocco, F; Toffoli, G, 2000) |
| "We evaluated economic implications of treatment with irinotecan, following a RCT which demonstrated significantly increased survival at 1 year with irinotecan (45%) compared to infusional 5-fluorouracil (5-FU) (32%) in patients with metastatic colorectal cancer." | 9.09 | Medical care consumption in a phase III trial comparing irinotecan with infusional 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer after 5-FU failure. ( Blijham, G; Jolain, B; Rougier, P; Schmitt, C; Van Cutsem, E, 1999) |
| "To determine the efficacy of fluorouracil (5-FU) plus eniluracil when administered to patients with previously untreated metastatic colorectal cancer." | 9.09 | Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer. ( Beck, T; Bell, WN; Chevlen, EM; Hochster, H; Hohneker, J; Levin, J; Lokich, J; Mani, S; McGuirt, C; O'Rourke, MA; Schilsky, RL; Weaver, CH; White, R, 2000) |
| "To determine whether the duration and the dose of epirubicin modify the long-term outcome of patients with metastatic breast cancer (MBC)." | 9.09 | Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment. ( , 2000) |
| "This phase I study evaluated the maximum tolerated dose, dose-limiting toxicity and recommended dose of docetaxel in combination with 5-fluorouracil (5-FU) in patients with metastatic breast cancer previously treated with anthracycline-based chemotherapy." | 9.09 | Docetaxel in combination with 5-fluorouracil in patients with metastatic breast cancer previously treated with anthracycline-based chemotherapy: a phase I, dose-finding study. ( Besenval, M; Boisdron-Celle, M; Delva, R; Gamelin, E; Lortholary, A; Maillard, P; Perard, D; Vernillet, L, 2000) |
| "A randomized study of the effectiveness of treatment with capecitabine (Xeloda) (22) and paclitaxel (taxol) (19) was carried out in breast cancer patients resistant to anthracycline antibiotic drugs." | 9.09 | [A comparative randomized phase-II study of Xeloda (capecitabine) and paclitaxel in patients with breast cancer progressing after anthracycline antibiotics]. ( Dalbot, DC; Gordon, RJ; Griffin, T; Moiseenko, VM; O'Reilly, SM; Osterwalder, B; Van Belle, S, 2000) |
| "The combination of fluorouracil and leucovorin has until recently been standard therapy for metastatic colorectal cancer." | 9.09 | Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. ( Ackland, SP; Blanke, C; Cox, JV; Elfring, GL; Fehrenbacher, L; Locker, PK; Maroun, JA; Miller, LL; Moore, MJ; Pirotta, N; Rosen, LS; Saltz, LB, 2000) |
| "To evaluate the feasibility and activity of vinorelbine in association with protracted infusional fluorouracil in patients with advanced breast cancer who were previously treated with anthracycline-containing regimens." | 9.09 | Phase II study of vinorelbine with protracted fluorouracil infusion as a second- or third-line approach for advanced breast cancer patients previously treated with anthracyclines. ( Alquati, P; Berruti, A; Botta, M; Bottini, A; Brunelli, A; De Lena, M; Dogliotti, L; Donadio, M; Gorzegno, G; Lorusso, V; Mancarella, S; Sperone, P; Tampellini, M, 2000) |
| "The continuous infusion of fluorouracil presents a superior pharmacological profile than its bolus administration, while vinorelbine is a new drug associated with good clinical activity in pretreated metastatic breast cancer." | 9.09 | Five-day infusion fluorouracil plus vinorelbine in women with breast cancer previously treated with anthracyclines and paclitaxel. ( Demicheli, R; Garbagnati, F; Mariani, G; Potepan, P; Verderio, P; Zambetti, M, 2000) |
| "The purpose of this study was to determine the efficacy of twice weekly hypo-fractionated radiation therapy (RT) plus continuous infusion 5-fluorouracil for unresectable or locally advanced colorectal cancer with synchronous metastases." | 9.09 | Avoidance of colostomy placement in advanced colorectal cancer with twice weekly hypofractionated radiation plus continuous infusion 5-fluorouracil. ( Breslin, T; Janjan, NA; Lenzi, R; Rich, TA; Skibber, J, 2000) |
| "A phase II study was carried out to evaluate the efficacy and toxicity of a double biochemical modulation of 5-fluorouracil (5-FU) by methotrexate (MTX) and leucovorin (LV) in patients with advanced unresectable colorectal cancer." | 9.09 | Double modulation of 5-fluorouracil by leucovorin and low-dose methotrexate in advanced colorectal cancer. ( Cizej, TE; Markovic, A; Plesnicar, A; Stabuc, B, 2000) |
| "Studies of bimonthly 48-hour regimens of high-dose leucovorin (LV) (FOLinic acid), 5-fluorouracil (5-FU) by continuous infusion combined with OXaliplatin (FOLFOX) in pretreated patients with metastatic colorectal cancer suggest that oxaliplatin dose intensity is an important prognostic factor for response rate and progression-free survival (PFS)." | 9.09 | Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). ( André, T; Artru, P; Carola, E; de Gramont, A; Gilles, V; Izrael, V; Krulik, M; Lotz, JP; Louvet, C; Mabro, M; Maindrault-Goebel, F; Molitor, JL; Tournigand, C, 2000) |
| "Irinotecan is a topoisomerase I inhibitor that prolongs survival in patients with colorectal cancer refractory to fluorouracil (5-FU) and leucovorin (LV)." | 9.09 | Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard. ( Alakl, M; Awad, L; Douillard, JY; Elfring, GL; Gruia, G; Locker, PK; Miller, LL; Pirotta, N; Saltz, LB, 2001) |
| "To determine the relative efficacy of a cyclophosphamide epirubicin and fluorouracil (CEF) regimen compared with an intravenous (IV) cyclophosphamide, methotrexate, and fluorouracil (CMF) combination in metastatic breast cancer." | 9.09 | Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study. ( Ackland, SP; Anton, A; Breitbach, GP; Colajori, E; Delfino, C; Efremidis, A; Ezzat, A; Fittipaldo, A; Kolaric, K; Lopez, M; Tursi, JM; Viaro, D, 2001) |
| "This phase III trial compared the efficacy and safety of doxorubicin and paclitaxel (AT) to 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) as first-line therapy for women with metastatic breast cancer." | 9.09 | Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. ( Berzins, J; Gorbunova, V; Jassem, J; Jelic, S; Mrsic-Krmpotic, Z; Munier, S; Nagykalnai, T; Pieńkowski, T; Płuzańska, A; Renard, J; Weil, C; Wigler, N, 2001) |
| "To evaluate whether an accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) chemotherapy regimen with the support of granulocyte colony-stimulating factor (G-CSF) induces a higher activity and efficacy compared with standard CEF in metastatic breast cancer patients." | 9.09 | Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter G ( Bergaglio, M; Carnino, F; Comis, S; Contu, A; Del Mastro, L; Gallo, L; Guarneri, D; Lionetto, R; Pronzato, P; Rosso, R; Venturini, M; Vesentini, L, 2001) |
| "To evaluate the efficacy and toxicity of a cisplatin, epirubicin, gemcitabine, and fluorouracil (PEF-G) schedule on stage IV pancreatic adenocarcinoma." | 9.09 | Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma. ( Balzano, G; Di Carlo, V; Galli, L; Nicoletti, R; Panucci, MG; Passoni, P; Reni, M; Villa, E; Zerbi, A, 2001) |
| "To identify the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of oxaliplatin (L-OHP) given on a weekly schedule including fixed doses of leucovorin (LV) and infusional 5-fluorouracil (5-FU), to define the toxicity profile of this regimen and to find preliminary evidence of its activity in pretreated patients with metastatic colorectal cancer (MCRC)." | 9.09 | Phase I study of a weekly schedule of oxaliplatin, high-dose leucovorin, and infusional fluorouracil in pretreated patients with advanced colorectal cancer. ( Manzione, L; Pizza, C; Rosati, G; Rossi, A; Tucci, A, 2001) |
| "Thirty-three metastatic colorectal cancer patients were randomized to receive a 60-minute infusion of irinotecan before or after a 48-hour infusion of 5-FU modulated by LV." | 9.09 | Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients. ( Allegrini, G; Comis, S; Conte, P; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Lencioni, M; Masi, G; Pfanner, E, 2001) |
| "We sought to define the recommended dose of cyclophosphamide (CTX) for subsequent phase II assessment when combined with fixed doses of gemcitabine (Gemzar; Eli Lilly and Company, Indianapolis, IN) and 5-fluorouracil/folinic acid in metastatic breast cancer patients previously treated with anthracyclines and taxanes." | 9.09 | Gemcitabine/cyclophosphamide/5-fluorouracil/folinic acid triplet combination in anthracycline- and taxane-refractory breast cancer patients: a Southern Italy Cooperative Oncology Group phase I/II study. ( Botti, G; Capasso, I; Comella, G; Comella, P; Cortino, GR; D'Aiuto, G; De Rosa, V; Frasci, G; Thomas, R, 2001) |
| "The purpose of this study was to evaluate the activity and tolerance of high-dose leucovorin (LV) and infusional 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) as salvage chemotherapy in patients with metastatic breast cancer (MBC) pretreated with anthracyclines and taxanes." | 9.09 | Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracyclin ( Agelaki, S; Christodoulakis, M; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Mavroudis, D; Souglakos, J; Stylianou, K; Vamvakas, L, 2001) |
| "Oral capecitabine was evaluated in terms of overall response rate, safety, and tolerability as first-line therapy in women aged > or = 55 years with advanced/metastatic breast cancer." | 9.09 | Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. ( Bell, D; Blum, J; Burger, HU; Jones, SE; Laws, S; Mauriac, L; Miles, D; Moiseyenko, V; Oshaughnessy, JA; Osterwalder, B; Rosso, R, 2001) |
| "A total of 35 women with advanced, metastatic breast cancer were treated with combination chemotherapy consisting of folinic acid 500 mg/m2 over 2 hours administered with 600 mg/m2 of 5FU at the midpoint of the folinic acid infusion weekly for 6 weeks, plus 60 mg/m2 of thiotepa on day 1 and day 28." | 9.08 | Phase II trial of 5-fluorouracil, folinic acid, and N,N1,N11-triethylenethiophosphoramide (thiotepa) in patients with advanced breast cancer. ( Blumenreich, M; Hadley, T; Hamm, J; Hendler, F; Joseph, G; Morris, K; Seeger, J; Woodcock, T, 1995) |
| "Sixty-one patients with primary node positive stage III breast cancers were randomized to receive postoperative radiotherapy and doxorubicin-based chemotherapy (eight cycles of CAFt: cyclophosphamide, adriamycin, oral ftorafur) with or without tamoxifen as adjuvant treatment." | 9.08 | The prognosis of stage III breast cancer treated with postoperative radiotherapy and adriamycin-based chemotherapy with and without tamoxifen. Eight year follow-up results of a randomized trial. ( Blomqvist, C; Elomaa, I; Gröhn, P; Rissanen, P; Saarto, T; Tiusanen, K, 1995) |
| "These results indicate that suramin is inactive in patients with metastatic colorectal cancer pretreated with fluoropyrimidines." | 9.08 | Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine-based chemotherapy. A phase II study. ( Brunetti, I; Cianci, C; Conte, PF; Danesi, R; Del Tacca, M; Falcone, A; Pfanner, E, 1995) |
| "Phase II study results demonstrating high efficacy and low toxicity for a weekly schedule of high-dose 5-fluorouracil/folinic acid (5-FU/FA) in intensively pretreated metastatic breast cancer patients prompted the addition of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) to this regimen in a phase I/II trial in outpatients: high-dose 5-FU (24-hour infusion)/FA (2-hour infusion preceding 5-FU) is given for 6 weeks (days 1, 8, 15, 22, 29, and 36), with paclitaxel (3-hour infusion) administered on days 1 and 22; 2 weeks' rest follows." | 9.08 | Phase I/II study with paclitaxel in combination with weekly high-dose 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer: an interim analysis. ( Becher, R; Diergarten, K; Eberhardt, W; Harstrick, A; Klaassen, U; Pari, CP; Seeber, S; Strumberg, D; Wilke, H, 1995) |
| "We undertook a multicenter phase II trial of 5-fluorouracil (5FU) + 1-leucovorin (1-LV) in previously untreated patients with metastatic colorectal cancer to determine the response rate, response duration, time to progression, survival, and toxicity." | 9.08 | A phase II trial of 5-fluorouracil and 1-leucovorin in patients with metastatic colorectal cancer. ( Erlichman, C; Fine, S; Gorg, C; Gustavsson, B; Hoffmann, W; Kerr, I; Preusser, P; Schmoll, HJ; Thuerlimann, B, 1996) |
| "Infusional 5-fluorouracil (F) with cisplatin (C) and epirubicin (E), so-called infusional ECF, is a highly active new schedule against locally advanced or metastatic breast cancer." | 9.08 | Phase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infusional ECarboF): a very active and well-tolerated outpatient regimen. ( Allum, WH; Baum, M; Bonnefoi, H; Ebbs, S; O'Brien, ME; Powles, TJ; Seymour, MT; Smith, IE, 1996) |
| "Fourteen evaluable patients with metastatic bladder cancer were treated with 5-fluorouracil at 300 mg/m2 and folinic acid at 200 mg/m2 daily for five days." | 9.08 | A phase II study of 5-fluorouracil and high dose folinic acid in cisplatin-refractory metastatic bladder cancer. ( Aitken, SE; Huan, SD; Stewart, DJ, 1995) |
| "Methotrexate (MTX) has been described to modulate the activity of fluorouracil (5-FU) in patients with metastatic colorectal cancer." | 9.08 | Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: final results of a randomized European Organization for Research and Treatment of Cancer Study. ( Bleiberg, H; Blijham, G; Buset, M; Collette, L; Dalmark, M; de Greve, J; Lacave, A; Sahmoud, T; Selleslag, J; Wagener, T; Wils, J, 1996) |
| "From January 1992 to July 1993, 28 patients with metastatic breast cancer were entered in a phase II trial to assess the activity and toxicity of the combination of mitoxantrone, 5-fluoruracil, and leucovorin." | 9.08 | Salvage chemotherapy in metastatic breast cancer: an experience with the combination of mitoxantrone, 5-fluorouracil, and L-leucovorin. ( Anastasi, P; Basurto, C; Colozza, M; De Angelis, V; Giansanti, M; Gori, S; Ludovini, V; Mosconi, AM; Tonato, M, 1996) |
| "A phase II study was performed to evaluate the clinical and immunological effects of a regimen of fluorouracil (5-FU) and folinic acid (FA) combined with thymopentin (TP-5) and interleukin-2 (IL-2) in the treatment of patients with metastatic colorectal cancer." | 9.08 | Sequential biochemotherapy for metastatic colorectal cancer using fluorouracil, folinic acid, thymopentin and interleukin-2: clinical and immunological effects. ( Ameglio, F; Di Lauro, L; Frasca, AM; Gandolfo, GM; Garaci, E; Lopez, M; Paoletti, G; Rasi, G; Santini, S; Vitelli, G, 1995) |
| "Our phase II study results demonstrating high efficacy and low toxicity for a weekly schedule of high-dose 5-fluorouracil (5-FU)/folinic acid (FA) in intensively pretreated metastatic breast cancer patients prompted the addition of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) to this regimen in a phase I/ II outpatient study." | 9.08 | Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer. ( Klaassen, U; Seeber, S; Wilke, H, 1996) |
| "5-Fluorouracil (5-FU) remains the most active therapeutic agent in advanced colorectal cancer." | 9.08 | 5-Fluorouracil continuous infusion in metastatic colorectal cancer. ( Ang, PT; Tan, EH, 1996) |
| "To assess the antitumor efficacy and safety profile of the combination of Fluorouracil (5FU) and vinorelbine given as first-line therapy to patients with advanced breast cancer." | 9.08 | Efficacy and tolerance of vinorelbine and fluorouracil combination as first-line chemotherapy of advanced breast cancer: results of a phase II study using a sequential group method. ( Bellissant, E; Dieras, V; Espie, M; Extra, JM; Marty, M; Mignot, L; Morvan, F; Pierga, JY; Tresca, P, 1996) |
| "A comparative, randomized trial was conducted to determine the efficacy of oral UFT (Tegafur and Uracil) versus 5-fluorouracil (5-FU) in combination with cyclophosphamide and doxorubicin in patients with metastatic breast cancer." | 9.08 | A comparative, randomized trial of UFT and 5-fluorouracil in combination with cyclophosphamide and doxorubicin in the treatment of advanced breast cancer patients at The Philippines General Hospital. ( De Guzman, LM; Fernando, GY; Guancia, AA; Romana, IB; Samson, MC; Villalon, AH, 1997) |
| "5-Fluorouracil plus folinic acid and paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) are effective salvage therapies for metastatic breast cancer patients." | 9.08 | Paclitaxel, 5-fluorouracil, and folinic acid in metastatic breast cancer: BRE-26, a phase II trial. ( Hande, KR; Johnson, DH; Paul, D, 1997) |
| "Fifty-five women with metastatic breast cancer were treated with a regimen consisting of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) 175 mg/m2 administered intravenously over 3 hours on day 1 only plus leucovorin given intravenously over 30 to 60 minutes followed by 5-fluorouracil 350 mg/m2 via intravenous push on days 1 to 3 every 28 days for six cycles." | 9.08 | Paclitaxel/5-fluorouracil/leucovorin in metastatic breast cancer: a Vanderbilt Cancer Center phase II trial. ( Garrett, M; Hande, KR; Johnson, DH; Nicholson, B; Paul, D; Shyr, Y, 1997) |
| "Forty-five patients with advanced or metastatic breast cancer were enrolled in this phase I-II study and treated with 5-fluorouracil (350 mg/m2 i." | 9.08 | Phase I-II study of vinorelbine in combination with 5-fluorouracil and folinic acid as first-line chemotherapy in metastatic breast cancer: a regimen with a low subjective toxic burden. ( Aapro, M; Andreoni, G; de Braud, F; De Pas, TM; Goldhirsch, A; Minchella, I; Monti, S; Nolè, F; Zampino, MG, 1997) |
| "When administered as a single agent to previously treated patients with advanced breast cancer, paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has good activity." | 9.08 | A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5-fluorouracil/prednisone in previously untreated patients with advanced breast cancer: preliminary results. Taxol Investigational Trials Group, Australia/New Zealand. ( Ackland, S; Bishop, JF; Dewar, J; Goldstein, D; Gurney, H; Kennedy, I; Levi, J; Olver, I; Stephenson, J; Tattersall, MH; Toner, G; Walpole, E, 1997) |
| "Our phase II study results demonstrating high efficacy and low toxicity for a weekly schedule of high-dose, 24-hour infusional 5-fluorouracil (5-FU)/leucovorin (LV) in intensively pretreated patients with metastatic breast cancer prompted the addition of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) to the regimen for a phase I/II study of outpatient second-line treatment of metastatic breast cancer." | 9.08 | Infusional 5-fluorouracil/leucovorin plus paclitaxel and cisplatin in the first-line treatment of metastatic breast cancer: results of a phase II study. ( Borquez, D; Harstrick, A; Klaassen, U; Müller, C; Seeber, S; Wilke, H, 1997) |
| "Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) is a highly active single agent in the treatment of breast cancer." | 9.08 | Paclitaxel with mitoxantrone with or without 5-fluorouracil and high-dose leucovorin in the treatment of metastatic breast cancer. ( Greco, FA; Hainsworth, JD, 1997) |
| "In this phase II trial we have evaluated the activity and toxicity of a combination regimen containing mitoxantrone, L-leucovorin, and fluorouracil in patients with advanced breast cancer pretreated with anthracyclines." | 9.08 | Mitoxantrone, fluorouracil, and L-folinic acid in anthracycline-pretreated metastatic breast cancer patients. ( Acito, L; Bascioni, R; De Signoribus, G; Giorgi, F; Giuliodori, L; Giustini, L; Silva, RR; Testa, E, 1997) |
| "From February 1995 through October 1996, 25 patients with metastatic colorectal cancer showing a clinical resistance to 5-fluorouracil (5-FU) entered this study." | 9.08 | Synergistic activity of oxaliplatin and 5-fluorouracil in patients with metastatic colorectal cancer with progressive disease while on or after 5-fluorouracil. ( Aapro, MS; Biffi, R; Brienza, S; De Pas, T; deBraud, F; Munzone, E; Nolè, F, 1998) |
| "Bolus 5-fluorouracil (5-FU) is a phase-specific drug with a short plasma half-life that is used in combination with bolus cyclophosphamide and methotrexate in the treatment of breast cancer." | 9.08 | Cyclophosphamide, methotrexate and infusional 5-fluorouracil (infusional CMF) in metastatic breast cancer. ( Ganesan, TS; Harris, AL; Isaacs, R; Koukourakis, MI; O'Byrne, KJ; Salisbury, AJ; Saunders, MP; Talbot, DC; Taylor, M; Varcoe, S, 1998) |
| "A phase II trial was performed to investigate the efficacy and tolerance of vinorelbine (VNB), 5-fluorouracil (5-FU), l-leucovorin (LLV) and recombinant human granulocyte colony-stimulating factor (G-CSF) in advanced breast cancer." | 9.08 | Effective treatment of advanced breast cancer with vinorelbine, 5-fluorouracil and l-leucovorin plus human granulocyte colony-stimulating factor. ( Depisch, D; Haider, K; Hejna, M; Kornek, GV; Krauss, G; Kwasny, W; Lang, F; Raderer, M; Scheithauer, W; Weinländer, G, 1998) |
| "Patients with proven metastatic colorectal cancer, which had progressed within 6 months of treatment with fluorouracil, were randomly assigned either 300-350 mg/m2 irinotecan every 3 weeks with supportive care or supportive care alone, in a 2:1 ratio." | 9.08 | Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. ( Awad, L; Cunningham, D; Heikkila, R; Herait, P; Hickish, TF; Jacques, C; James, RD; Johannesen, TB; Punt, CJ; Pyrhönen, S; Starkhammar, H; Topham, CA, 1998) |
| "Data from 12 metastatic colorectal cancer patients who were submitted to a pilot study with a multistep subcutaneous (sc) low dose recombinant interleukin-2 (rIL-2), 5-fluorouracil (5-FU) and leucovorin (LV) administration were compared with those from 13 historical controls who were comparable for the major prognostic indices." | 9.08 | A multistep therapy with subcutaneous low dose recombinant interleukin-2, 5-fluorouracil and leucovorin prolongs the response of metastatic colorectal cancer patients: a pilot study. ( Anselmi, L; Carpi, A; Ferrari, P; Nicolini, A; Sagripanti, A, 1998) |
| " We conducted a Phase II trial of an anthracycline analogue, pirarubicin, administered in combination with 5-fluorouracil and cyclophosphamide every 3 weeks, as front-line chemotherapy in women with metastatic breast cancer." | 9.08 | Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer. ( Buzdar, A; Dhingra, K; Fraschini, G; Frye, D; Hortobagyi, GN; Newman, RA; Smith, T; Theriault, R; Walters, R, 1995) |
| "This multicenter phase II study was designed to assess the efficacy of the alternating schedule of irinotecan (CPT-11) with bolus 5-fluorouracil (5-FU) and leucovorin (LV) in first-line chemotherapy for metastatic colorectal cancer (CRC)." | 9.08 | A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer. ( Barone, C; Cognetti, F; Cote, C; Dirix, L; Filez, L; Garufi, C; Gruia, G; Humblet, Y; Pozzo, C; Starkhammar, H; Terzoli, E; Van Cutsem, E, 1998) |
| "Thirty-seven consecutive patients with advanced and/or metastatic gastric adenocarcinoma received a combination of 5-fluorouracil 600 mg/m2 on days 1, 8, 29, 36; epidoxorubicin 75 mg/m2 i." | 9.07 | Combination chemotherapy of 5-fluorouracil, epidoxorubicin and mitomycin C in the palliative treatment of locally advanced and/or metastatic adenocarcinoma of the stomach. ( Bajardi, G; Cannata, G; Cipolla, C; Curto, G; Gebbia, V; Latteri, M; Mastrandrea, G; Pischedda, G; Testa, A; Valenza, R, 1994) |
| "In a phase II study, we treated 35 women with metastatic breast cancer with the following regimen: mitoxantrone 12 mg/m2 i." | 9.07 | The use of mitoxantrone, 5-fluorouracil and high-dose leucovorin in the treatment of advanced breast cancer. ( Hainsworth, JD, 1993) |
| "Based upon the hypothesis that dipyridamole would potentiate the cytotoxicity of mitoxantrone and the combination of 5-fluorouracil (5-FU) and leukovorin, we performed a phase I/II trial of the combination of dipyridamole, 5-FU, leukovorin, and mitoxantrone in patients with metastatic breast cancer." | 9.07 | Phase I/II trial of dipyridamole, 5-fluorouracil, leukovorin, and mitoxantrone in metastatic breast cancer. ( Budd, GT; Bukowski, RM; Herzog, P, 1994) |
| "A phase II study to test the toxicity and the efficacy of a weekly combination of Mitoxantrone, 5-Fluorouracil and L-Leucovorin (MFL) was carried out in 43 patients with metastatic breast cancer." | 9.07 | Phase II study of weekly mitoxantrone, 5-fluorouracil, and leucovorin in metastatic breast cancer. ( Campora, E; Gardin, G; Giudici, S; Lanfranco, C; Merlini, L; Miglietta, L; Naso, C; Repetto, L; Testore, F; Venturino, A, 1994) |
| "To investigate the efficacy and toxicity of continuous infusion fluorouracil (5-FU) with every-3-weeks epirubicin and cisplatin (ECF) in advanced breast cancer in a phase II study." | 9.07 | Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: an active new regimen. ( Ashley, S; Jones, AL; O'Brien, ME; Ramage, F; Robertshaw, H; Smith, IE; Talbot, D; Walsh, G, 1994) |
| "60 patients with metastatic breast cancer were entered in a phase II study using folinic acid, 5-fluorouracil bolus and infusion and mitoxantrone with or without cyclophosphamide." | 9.07 | Folinic acid, 5-fluorouracil bolus and infusion and mitoxantrone with or without cyclophosphamide in metastatic breast cancer. ( Beerblock, K; de Gramont, A; Demuynck, B; Guillot, T; Krulik, M; Louvet, C; Marpeau, L; Pigné, A; Soubrane, D; Varette, C, 1993) |
| "In a Phase I-II clinical trial, 19 ambulatory women with metastatic breast cancer were treated with a combination of mitoxantrone, 5-fluorouracil, and leucovorin (MFL)." | 9.07 | A phase I clinical trial of a combination of mitoxantrone, 5-fluorouracil, and high-dose leucovorin given on a day 1 and day 8 schedule to patients with metastatic breast cancer. ( Gomez, EG; Vogel, CL, 1994) |
| "To compare the effect on toxicity and efficacy of the fluorouracil 500 mg/m2, epirubicin 60 mg/m2, and cyclophosphamide 500 mg/m2 (FEC) regimen divided into 4 weekly doses with conventional every-4-week administration in metastatic breast cancer." | 9.07 | Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin, and fluorouracil in metastatic breast cancer: a randomized trial comparing weekly and every-4-week administration. ( Blomqvist, C; Elomaa, I; Helle, L; Hietanen, P; Nevasaari, K; Rissanen, P, 1993) |
| "A phase II study was undertaken to assess the effect of CAF plus depo-buserelin, as first-line treatment, in premenopausal women with breast cancer." | 9.07 | Cyclophosphamide, doxorubicin and fluorouracil (CAF) plus depo-buserelin in the treatment of premenopausal women with metastatic breast cancer. ( Falkson, CI; Falkson, G; Falkson, HC, 1992) |
| "From January 31, 1986 to January 31, 1989, 184 eligible patients were enrolled in a randomized study of either infusional or bolus 5-fluorouracil (5-FU) for the treatment of metastatic measurable colorectal cancer." | 9.07 | Systemic infusion versus bolus chemotherapy with 5-fluorouracil in measurable metastatic colorectal cancer. ( Bogues, W; Cripps, IC; Fields, A; Maroun, J; McCormick, R; Pater, J; Shah, A; Temple, W; Weinerman, B; Wilson, K, 1992) |
| "Fifty-five women with metastatic breast cancer were treated with carboplatin (CBDCA), 55 mg/m2 i." | 9.07 | Carboplatin (CBDCA), 5-fluorouracil (5-FU) and mitoxantrone (DHAD): an effective and well tolerated regimen for metastatic breast cancer. ( Gonzalez, FG; Herranz, P; Hidalgo, OF; Rebollo, J; Tangco, E; Vieitez, JM, 1992) |
| "Sixty-seven patients with advanced breast cancer were prospectively entered into a Phase II trial of cyclophosphamide 100 mg/m2 orally on days 1-14, methotrexate 40 mg/m2 intravenously (i." | 9.07 | A phase II trial of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisolone rapidly alternating with doxorubicin and vincristine (CMFP/AV) in advanced breast cancer. ( Bishop, JF; Dipell, JF; Jeal, P; Laidlaw, CR; Olver, IN; Rischin, D; Zimet, A, 1992) |
| "In a randomised study 142 patients with advanced oestrogen-receptor-negative breast cancer in the tumour tissue received chemotherapy alone or chemotherapy combined with high doses (1000 mg daily) of oral medroxyprogesterone acetate (HD-MPA)." | 9.07 | Chemotherapy with or without high-dose medroxyprogesterone acetate in oestrogen-receptor-negative advanced breast cancer. Norwegian Breast Cancer Group. ( Gundersen, S; Hannisdal, E; Høst, H; Klepp, O; Kvinnsland, S; Lund, E, 1992) |
| "A high rate of response to 5-fluorouracil (5FU) and alpha-interferon (alpha IFN) combination therapy has been reported in metastatic colorectal cancer patients." | 9.07 | Alpha-interferon in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer: a phase I study. ( Burghouts, JT; de Mulder, PH; Punt, CJ; Wagener, DJ, 1992) |
| "Several reports on fluorouracil (5-FU) and alfa interferon (IFN-alpha) combination therapy in patients with advanced colorectal cancer have been published." | 9.07 | Fluorouracil continuous infusion plus alfa interferon plus oral folinic acid in advanced colorectal cancer. ( Burghouts, JT; de Mulder, PH; Punt, CJ; Wagener, DJ, 1992) |
| "In a clinical phase II study, 23 patients with progressive metastatic colorectal cancer and failure after first-line chemotherapy with fluorouracil (5-FU) and folinic acid (FA) were treated with a 5-day continuous infusion of recombinant interleukin-2 (IL-2), 3 x 10(6) cetus U/m2/d, followed after a rest period of 2 days by 5-FU, 600 mg/m2/d, and FA, 300 mg/m2/d over an additional 3 days." | 9.07 | Interleukin-2 followed by fluorouracil and folinic acid in refractory colorectal cancer--results of a clinical phase II study. ( Hiddemann, W; Koch, O; Musch, E; Ottensmeier, C; Rückle, H; Ruelfs, C; van de Loo, J, 1992) |
| "5-Fluorouracil (5-FU) remains the most effective chemotherapeutic agent in the management of patients with metastatic colorectal cancer." | 9.07 | Treatment of advanced colorectal cancer by 5-fluorouracil-leucovorin combination with or without allopurinol: a prospective randomized study. ( Chaitchik, S; Inbar, M; Merimsky, O, 1991) |
| "A new combination of mitoxantrone, folinic acid (leucovorin), and infusional fluorouracil (5-FU) was administered to 57 previously treated patients with metastatic breast cancer to evaluate the response rate, response duration, and toxicity of this regimen." | 9.07 | Phase II study of mitoxantrone, leucovorin, and infusional fluorouracil for treatment of metastatic breast cancer. ( Allison, MA; Brooks, B; Jones, SE; Mennel, RG; Paulson, RS; Rea, B; Tilmann, K; Westrick, MA, 1991) |
| "Between September 1988 and August 1990, we treated 35 women with metastatic breast cancer with a novel regimen containing mitoxantrone, fluorouracil (5-FU), and high-dose leucovorin." | 9.07 | Mitoxantrone, fluorouracil, and high-dose leucovorin: an effective, well-tolerated regimen for metastatic breast cancer. ( Andrews, MB; Greco, FA; Hainsworth, JD; Johnson, DH, 1991) |
| "A phase I study of 5-fluorouracil 600 mg/m2/week and folinic acid 500 mg/m2/week on day 1 and cisplatin administered weekly on day 2 was carried out on 30 patients with metastatic colorectal carcinoma of which 20 patients were pretreated with 5-fluorouracil." | 9.07 | A phase I study of cisplatinum plus 5-fluorouracil in modulation with citrovorum factor in metastatic colorectal carcinoma. ( Creaven, P; Gebbia, N; Gebbia, V; Palmeri, S; Petrelli, N; Rausa, L; Russo, A; Rustum, Y, 1991) |
| "Thirty patients with advanced breast cancer, previously treated with anthracycline and 5 fluorouracil in bolus administration, were evaluated with a chemotherapy regimen generally used in head and neck cancer." | 9.06 | [Phase II trial as 2nd line chemotherapy with 5 fluorouracil and cisplatin (5FU-CDDP) for advanced breast cancer]. ( Bastit, P; Bugat, R; Cappelaere, P; Chauvergne, J; Fumoleau, P; Horner, D; Metz, R, 1990) |
| "Ninety-one patients with metastatic colorectal cancer were treated with continuous ambulatory 5-fluorouracil (5FU) infusion 250-300 mg/m2/day through a chronic indwelling central venous catheter." | 9.06 | Continuous systemic 5-fluorouracil infusion in advanced colorectal cancer: results in 91 patients. ( Anderson, T; Ausman, R; Beatty, P; Frick, J; Haas, C; Hansen, R; Quebbeman, E; Ritch, P; Schulte, W, 1989) |
| "The efficacy and toxicity of leucovorin 500 mg/m2 administered intravenously (IV) over 30 minutes daily for five days followed in one hour by fluorouracil (5-FU) 375 mg/m2 administered IV daily for five days, each given every 3 weeks, was assessed in 54 previously treated patients with metastatic breast cancer." | 9.06 | Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. ( Allegra, CJ; Drake, JC; Egan, EF; Lippman, ME; Steinberg, SM; Swain, SM, 1989) |
| "Seventy-seven patients with previously untreated, measurable, histologically confirmed, metastatic adenocarcinoma of the rectum or sigmoid were randomized to receive either epirubicin 90 mg/m2 (75 mg/m2 if prior radiotherapy) i." | 9.06 | A phase III randomized trial of epirubicin versus 5-fluorouracil in metastatic rectal/sigmoid adenocarcinoma. ( Blum, RH; Lafleur, F; Molinaro, P, 1989) |
| "94 evaluable patients with metastatic breast cancer were randomly assigned to 5-fluorouracil, adriamycin, and cyclophosphamide (FAC) or 5-fluorouracil, epirubicin, and cyclophosphamide (FEC), with cycles repeated every 3 weeks." | 9.06 | 5-Fluorouracil, adriamycin, cyclophosphamide (FAC) vs. 5-fluorouracil, epirubicin, cyclophosphamide (FEC) in metastatic breast cancer. ( Carpano, S; Conti, EM; Di Lauro, L; Lopez, M; Papaldo, P; Vici, P, 1989) |
| "In a randomized crossover study, 181 patients over the age of 65 with recurrent breast cancer received either tamoxifen or cyclophosphamide, methotrexate, and fluorouracil (CMF)." | 9.06 | Combination chemotherapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women. ( Cummings, FJ; Falkson, G; Gelman, RS; Taylor, SG, 1986) |
| "Fifty consecutive patients with recurrent and metastatic endometrial carcinoma were treated with melphalan, 5-fluorouracil, and medroxyprogesterone acetate with or without tamoxifen as first-line chemotherapy." | 9.06 | Melphalan, 5-fluorouracil, and medroxyprogesterone acetate in metastatic endometrial carcinoma. ( Emrich, LJ; Lele, SB; Patsner, B; Piver, MS, 1986) |
| "Seventy-six patients with metastatic breast cancer were treated with fluorouracil, adriamycin (doxorubicin) and cyclophosphamide (FAC) plus high-dose medroxyprogesterone acetate (HD-MPA)." | 9.05 | 5-Fluorouracil, adriamycin and cyclophosphamide combined with high-dose medroxyprogesterone acetate in advanced breast cancer. ( Barduagni, A; Barduagni, M; Di Lauro, L; Lopez, M; Papaldo, P; Perno, CF, 1983) |
| "The prospective controlled phase III clinical trial compared the therapeutic value of the cis-platinum - adriamycin - cyclophosphamide combination (CAP) and that of the combination of cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisolone (CMFVP) in untreated metastatic breast cancer." | 9.05 | CAP (cyclophosphamide, adriamycin, platinum) vs CMFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisolone) combination chemotherapy in untreated metastatic breast cancer. A preliminary report of a controlled clinical study. ( Cervek, J; Kolarić, K; Roth, A; Vukas, D, 1984) |
| "Fifty-five patients with newly diagnosed, estrogen receptor negative, metastatic breast cancer were entered in a trial of mitoxantrone, 10 mg/m2 intravenous (IV), cyclophosphamide, 500 mg/m2 IV, and 5-fluorouracil, 1000 mg/m2 IV, which were given on day 1 of a 21-day treatment interval." | 9.05 | Mitoxantrone, cyclophosphamide, and 5-fluorouracil in the treatment of hormonally unresponsive metastatic breast cancer. ( Blumenschein, GR; Buzdar, AU; Esparza, L; Holmes, FA; Hortobagyi, GN; Yap, HY, 1984) |
| "Twenty-nine patients with advanced adenocarcinoma of the pancreas were treated with a combination of mitomycin-C, 5-fluorouracil, and adriamycin (MIFA III)." | 9.05 | MIFA III (mitomycin-C, 5-fluorouracil, and adriamycin) chemotherapy for advanced adenocarcinoma of the pancreas. ( Cheng, EW; Magill, GB; Sordillo, PP; Sternberg, CN, 1984) |
| "Data on 162 women (90 premenopausal and 72 postmenopausal) with metastatic breast cancer randomized to receive cyclophosphamide, Adriamycin (doxorubicin) and 5-fluorouracil (CAF) on two Eastern Cooperative Oncology Group (ECOG) protocols were analyzed." | 9.05 | The Eastern Cooperative Oncology Group experience with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer. ( Carbone, PP; Cummings, FJ; Falkson, G; Falkson, HC; Gelman, RS; Tormey, DC, 1985) |
| "Thirty-eight patients with advanced breast cancer were treated with the 'VEMFAH' multiple-drug combination chemotherapy, consisting of vincristine (V), cyclophosphamide (Endoxan; E), methotrexate (M), 5-fluorouracil (F), adriamycin (A), and prednisolone (H)." | 9.05 | The effects of multiple combination chemotherapy with vincristine, cyclophosphamide (Endoxan), methotrexate, 5-fluorouracil, adriamycin and prednisolone (VEMFAH) for advanced breast cancer. ( Hoshino, A; Ito, Y; Kamiya, O; Kinoshita, T; Kojima, T; Nagata, K; Ohara, K; Sato, H; Sugiura, I; Yamada, M, 1985) |
| "In a prospective study eleven patients with metastasizing breast cancer were treated with 5-fluorouracil, adriamycin, and cyclophosphamide )FAC)." | 9.04 | [Adriamycin, cyclophosphamide, and 5-fluorouracil in the treatment of metastasizing breast cancer (author's transl)]. ( Boecker, WR; Höffken, K; Schmidt, CG; Seeber, S, 1976) |
| "Sixty patients with metastatic or primary inoperable breast cancer not suitable for hormone alteration therapy were blindly randomized between weekly 5-fluorouracil, intravenously, and daily physiologic doses of conjugated estrogens by mouth against weekly 5-fluorouracil, intravenously, and placebo." | 9.04 | Clinical studies of 5-fluorouracil + premarin in the treatment of breast cancer. ( Colsky, J; Hall, TC; Pocock, SJ; Shnider, BI; Taylor, SG, 1975) |
| "Seventy-eight advanced breast cancer patients with hormone-resistant disease or visceral metastases were randomized to receive either of two low dose regimens consisting of cyclophosphamide (C), methotrexate (M), 5-fluorouracil (F), and Adriamycin (A) as their initial chemotherapy." | 9.04 | Low dose chemotherapy of metastatic breast cancer with cyclophosphamide, adriamycin, methotrexate, 5-fluorouracil (CAMF) versus sequential cyclophosphamide, methotrexate, 5-fluorouracil (CMF) and adriamycin. ( Catalano, RB; Creech, RH; Engstrom, PF; Grotzinger, PJ; Harris, DT, 1979) |
| "The addition of levamisole, administered in adjunctive manner between the cycles of conventional high dose chemotherapy in patients with hormone resistant end state breast cancer substantially improved the survival of treated patients." | 9.04 | Levamisole: as adjuvant to cyclic chemotherapy in breast cancer. ( Mason, B; Stephens, EJ; Wood, HF, 1978) |
| "One hundred and fourteen evaluable patients with measurable metastatic breast cancer were treated with a combination chemoimmunotherapy program (5-fluorouracil, adriamycin, and cyclophosphamide [FAC-levamisole [LSM])." | 9.04 | Response of disseminated breast cancer to combined modality treatment with chemotherapy and levamisole with or without Bacillus Calmette-Guérin. ( Blumenschein, GR; Buzdar, AU; Gutterman, JU; Hersh, EM; Hortobagyi, GN; Tashima, CK; Yap, HY, 1978) |
| "We performed the present systematic review and meta-analysis to evaluate the efficacy and safety for S-1-based regimens comparing to intravenous fluorouracil-based ones in Asian patients with metastatic colorectal carcinoma (mCRC)." | 9.01 | Efficacy and safety assessment of S-1-based regimens comparing to intravenous fluorouracil-based ones in Asian patients with metastatic colorectal carcinoma: A system review and meta-analysis. ( Chen, J; Wang, J, 2019) |
| "The relative efficacy and safety of first-line metastatic colorectal cancer (mCRC) treatment regimens, capecitabine with irinotecan (CAPIRI) and 5-fluorouracil/leucovorin plus irinotecan (FOLFIRI), are not well defined." | 8.91 | Meta-analysis comparing the safety and efficacy of metastatic colorectal cancer treatment regimens, capecitabine plus irinotecan (CAPIRI) and 5-fluorouracil/leucovorin plus irinotecan (FOLFIRI). ( Cao, J; Ding, HH; Ji, ZY; Jiang, T; Jin, JH; Song, WF; Wang, JJ; Wang, LW; Wu, WD, 2015) |
| "The National Institute for Health and Care Excellence (NICE) invited the manufacturer of aflibercept (Sanofi) to submit clinical and cost-effectiveness evidence for aflibercept in combination with irinotecan and fluorouracil-based therapy [irinotecan/5-fluorouracil/folinic acid (FOLFIRI)] for the treatment of metastatic colorectal cancer which has progressed following prior oxaliplatin-based chemotherapy, as part of the Institute's Single Technology Appraisal process." | 8.91 | The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of ( Duarte, A; Duffy, S; Rodriguez-Lopez, R; Simmonds, M; Spackman, E; Wade, R; Woolacott, N, 2015) |
| "To determine if a low fixed dosing strategy of capecitabine would produce comparable clinical activity with less adverse toxicities compared to published data with higher doses in the setting of metastatic breast cancer (mBC)." | 8.90 | A retrospective study evaluating a fixed low dose capecitabine monotherapy in women with HER-2 negative metastatic breast cancer. ( Ahn, E; Ambros, T; Aruna, M; Kronish, L; Mahtani, RL; Montero, AJ; Vogel, CL; Zaravinos, J; Zeichner, SB, 2014) |
| "Capecitabine has proven effective as a chemotherapy for metastatic breast cancer." | 8.89 | Clinical efficacy of including capecitabine in neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis of randomized controlled trials. ( Jiang, Y; Li, Q; Liu, J; Wei, W; Yang, H, 2013) |
| "Both capecitabine and bevacizumab are established agents in the treatment of metastatic breast cancer, but until recently clinical data supporting their use in combination were limited." | 8.88 | Combining capecitabine and bevacizumab in metastatic breast cancer: a comprehensive review. ( Martin, M; Miles, D; Robert, N; Vrdoljak, E; Zielinski, C, 2012) |
| "The present study suggests that capecitabine-based chemotherapy is as effective as capecitabine-free chemotherapy in patients with metastatic and/or advanced breast cancer with different toxicity profiles." | 8.88 | Efficacy and toxicity of capecitabine-based chemotherapy in patients with metastatic or advanced breast cancer: results from ten randomized trials. ( Meng, L; Wang, Y; Wei, JF; Yang, H, 2012) |
| "We performed a computerized search using combinations of the following keywords: "metastatic colorectal cancer," "Xeloda," "chemotherapy," "capecitabine," or "5-fluorouracil." | 8.87 | Capecitabine-based chemotherapy for metastatic colorectal cancer. ( Fan, J; Ling, W; Ma, Y; Wang, H, 2011) |
| "Capecitabine monotherapy is considered standard treatment in anthracycline- and taxane-pretreated metastatic breast cancer and has proven efficacy in this setting." | 8.87 | Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer. ( Blum, JL; Hennessy, BT; Leonard, R; O'Shaughnessy, J, 2011) |
| "A 61-year-old woman with metastatic breast cancer who was undergoing treatment with capecitabine developed erythema, fissuring, and erosions over both hands and feet, consistent with HFS." | 8.87 | Capecitabine-induced hand-foot syndrome complicated by pseudomonal superinfection resulting in bacterial sepsis and death: case report and review of the literature. ( Baker, SG; Cotliar, JA; Gunawardane, ND; Hoesly, FJ, 2011) |
| "Capecitabine, an oral prodrug of 5-fluorouracil, is indicated for adjuvant treatment in patients with Dukes' C colon cancer and for subsequent lines in metastatic colorectal cancer." | 8.86 | Economic evaluation of capecitabine as adjuvant or metastatic therapy in colorectal cancer. ( Best, JH; Garrison, LP, 2010) |
| "In both studies, women with locally advanced breast cancer or MBC pretreated with, or resistant to, taxanes or anthracyclines were randomly assigned to ixabepilone plus capecitabine, or capecitabine alone, until disease progression or unacceptable toxicity occurred." | 8.86 | Ixabepilone plus capecitabine for breast cancer patients with an early metastatic relapse after adjuvant chemotherapy: two clinical trials. ( Fornier, M, 2010) |
| "Capecitabine is an oral fluoropyrimidine that is shown to have similar efficacy to 5-fluorouracil (5-FU) when used both alone and in combination with oxaliplatin in the treatment of colorectal cancer (CRC)." | 8.86 | Differences in efficacy and safety between capecitabine and infusional 5-fluorouracil when combined with irinotecan for the treatment of metastatic colorectal cancer. ( Aliberti, C; Chiriatti, A; Fiorentini, G; Licitra, S; Montagnani, F, 2010) |
| "This article reviews the preclinical and clinical data on ixabepilone in patients with locally advanced and metastatic breast cancer (MBC) and provides guidance for pharmacists on its optimal use." | 8.85 | The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer. ( Boehnke Michaud, L, 2009) |
| "Capecitabine (N -pentyloxycarbonyl-5-deoxy-5-fluorocytidine), an oral prodrug of 5-fluorouracil, has provided compelling efficacy data for the treatment of metastatic breast cancer and stage III or IV colorectal cancer, both as monotherapy and in combination regimens." | 8.85 | Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer. ( Aprile, G; Mazzer, M; Moroso, S; Puglisi, F, 2009) |
| "Continuous-infusion 5-fluorouracil (5-FU)/leucovorin (LV) and oxaliplatin is a frequently used regimen in metastatic colorectal cancer." | 8.84 | Is XELOX equivalent to FOLFOX or other continuous-infusion 5-fluorouracil chemotherapy in metastatic colorectal cancer? ( Bennouna, J; Douillard, JY; Senellart, H, 2008) |
| "To evaluate the clinical and cost-effectiveness of capecitabine and tegafur with uracil (UFT/LV) as first-line treatments for patients with metastatic colorectal cancer, as compared with 5-fluorouracil/folinic acid (5-FU/FA) regimens." | 8.82 | Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation. ( Brewer, N; Cowan, J; Kaltenthaler, E; Ward, S, 2003) |
| "To examine the clinical effectiveness and cost-effectiveness of oral capecitabine for locally advanced and metastatic breast cancer in relation to its licensed indications." | 8.82 | Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda) for locally advanced and/or metastatic breast cancer. ( Hawkins, N; Jones, L; Richardson, G; Riemsma, R; Westwood, M; Wright, K, 2004) |
| "Irinotecan is a cornerstone drug in the management of metastatic colorectal cancer, as demonstrated by several randomized studies proving a survival benefit for the first time." | 8.82 | Irinotecan-based regimens in the adjuvant therapy of colorectal cancer. ( Douillard, JY, 2005) |
| "Gemcitabine has demonstrated single-agent efficacy in the treatment of advanced breast cancer, with response rates of up to 42%." | 8.81 | Gemcitabine/anthracycline combinations in metastatic breast cancer. ( Zielinski, CC, 2002) |
| "Oxaliplatin was first introduced to the clinical setting as a combination therapy with 5-fluorouracil/folinic acid (5-FU/FA) in an attempt to improve the response rate obtained with 5-FU/FA against colorectal cancer." | 8.80 | Oxaliplatin plus 5-fluorouracil: clinical experience in patients with advanced colorectal cancer. ( Bleiberg, H; de Gramont, A, 1998) |
| "Two randomized phase III trials with irinotecan as second-line treatment of metastatic colorectal cancer have shown that irinotecan (CPT-11, Camptosar) significantly improves survival when compared with best supportive care or continuous infusion of fluorouracil (5-FU) after failure of 5-FU." | 8.80 | Irinotecan and high-dose fluorouracil/leucovorin for metastatic colorectal cancer. ( Douillard, JY, 2000) |
| "To compare the efficacy and safety of folinic acid, fluorouracil and irinotecan (FOLFIRI) plus bevacizumab or aflibercept in metastatic colorectal cancer (mCRC) patients pretreated with oxaliplatin-based chemotherapy." | 8.12 | A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer. ( Hong, JY; Jo, H; Kang, WK; Kim, H; Kim, ST; Lee, J; Lee, MS; Lee, YP; Lim, HY; Park, JO; Park, SH; Park, YS, 2022) |
| "BACKGROUND The impact of therapeutic drug management (TDM) on reducing toxicity and improving efficacy in colorectal cancer (CRC) patients receiving fluorouracil-based chemotherapy is still unclear." | 8.02 | Clinical Benefit of Therapeutic Drug Monitoring in Colorectal Cancer Patients Who Received Fluorouracil-Based Chemotherapy. ( Chang, R; Chang, Y; Han, J; Qian, J; Shen, C; Zhao, H; Zhou, X, 2021) |
| "The standard first- and second- line chemotherapy backbone regimens for metastatic colorectal cancer (mCRC) are 5-fluorouracil (5-FU)/capecitabine-based with addition of irinotecan or oxaliplatin." | 7.96 | Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme. ( Carter, AM; Iveson, T; Mullamitha, S; Shiu, KK; Spooner, C; Stevens, D, 2020) |
| "5-Fluorouracil (5-FU) is one of the most effective drugs for the treatment of colorectal cancer (CRC)." | 7.96 | Enalapril overcomes chemoresistance and potentiates antitumor efficacy of 5-FU in colorectal cancer by suppressing proliferation, angiogenesis, and NF-κB/STAT3-regulated proteins. ( Cai, J; Li, W; Liu, Y; Ma, L; Xu, Y; Yang, Y; Zhang, Y, 2020) |
| "Metastatic breast cancer (mBC) patients with DPYD genetic variants linked to loss of dihydropyrimidine dehydrogenase (DPD) activity are at risk of severe capecitabine-associated toxicities." | 7.91 | Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients. ( Charlton, P; DeSouza, K; Kapiris, M; Karapanagiotou, E; Mansi, J; Marinaki, A; Okonta, L; Papadatos-Pastos, D; Pouptsis, A; Stavraka, C, 2019) |
| "Compared with conventional fluorouracil plus cisplatin (FP) regimen, gemcitabine plus cisplatin (GP) can prolong survival in patients with recurrent or metastatic nasopharyngeal carcinoma, but the economic impact of this practice remains unknown." | 7.91 | Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma. ( Chen, X; Jiang, J; Liang, W; Wan, N; Yang, Y; Zhang, L; Zhang, T, 2019) |
| " Median time from initial diagnosis of metastases to the start of regorafenib and treatment duration was 13." | 7.88 | Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial). ( Aranda, E; Benavides, M; Durán, G; Falcó, E; García-Alfonso, P; Gómez, A; López, R; López-Ladrón, A; Montagut, C; Muñoz, A; Rivera, F; Ruiz de Mena, I; Salgado, M; Sastre, J, 2018) |
| "We analyzed the results of previously treated patients with metastatic colorectal cancer (mCRC) who received regorafenib plus FOLFIRI with the irinotecan dose escalation on the basis of uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping." | 7.85 | Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated According to Uridine Diphosphate Glucuronosyltransferase 1A1 Genotyping in Patients With Metastatic Colorectal Cancer. ( Cheng, TL; Hu, HM; Huang, CW; Ma, CJ; Tsai, HL; Wang, JY; Wu, IC; Yeh, YS, 2017) |
| "To evaluate the efficiency and safety of hepatic artery infusion chemotherapy (HAIC) using raltitrexed or 5-fluorouracil for colorectal cancer (CRC) liver metastasis (CRCLM)." | 7.85 | Hepatic artery infusion with raltitrexed or 5-fluorouracil for colorectal cancer liver metastasis. ( Chen, H; Gao, S; Guo, JH; Li, XT; Wang, XD; Zhang, HY; Zhang, PJ; Zhu, X, 2017) |
| "To evaluate the safety and efficacy of the combination therapy of fluorouracil, leucovorin and irinotecan (FOLFIRI) and aflibercept in Asian patients with metastatic colorectal cancer (mCRC), who had progressed after oxaliplatin-based chemotherapy." | 7.83 | Safety and efficacy of aflibercept in combination with fluorouracil, leucovorin and irinotecan in the treatment of Asian patients with metastatic colorectal cancer. ( Chong, DQ; Choo, SP; Chua, C; Imperial, M; Manalo, M; Ng, M; Tan, IB; Teo, P; Yong, G, 2016) |
| "Thymidylate synthase (TYMS) is an important enzyme for 5-fluorouracil (5-FU) metabolism in metastatic colorectal cancer (mCRC) patients." | 7.81 | Thymidylate synthase expression in circulating tumor cells: a new tool to predict 5-fluorouracil resistance in metastatic colorectal cancer patients. ( Abdallah, EA; Alves, VS; Araújo, DV; Buim, ME; Chinen, LT; Dettino, AL; Fanelli, MF; Gasparini Junior, JL; Machado Netto, MC; Mingues, NB; Ocea, LM; Rocha, BM; Romero, JV; Souza E Silva, V, 2015) |
| "The primary objective of this study was to determine the activity and safety of 3-weekly oxaliplatin combined with gemcitabine and oral capecitabine in the first-line treatment of advanced biliary tract cancer." | 7.81 | Three-weekly oxaliplatin combined with gemcitabine and capecitabine in the first-line treatment of patients with advanced biliary tract cancer. ( Fiaschi, AI; Francini, E; Laera, L; Marrelli, D; Petrioli, R; Roviello, F; Roviello, G, 2015) |
| "500 mg/m(2) uracil was administered orally to 12 subjects with stages II-III colorectal cancer (CRC) who were treated in the adjuvant setting and to 12 subjects with stage IV metastasized CRC, all treated with CAP containing therapy." | 7.81 | Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients. ( Gelderblom, H; Guchelaar, HJ; Maring, JG; Opdam, F; van Kuilenburg, AB; van Staveren, MC, 2015) |
| "Capecitabine is an oral fluoropyrimidine derivative which is frequently used alone or in combination regimens for the treatment of metastatic breast cancer." | 7.80 | Lack of prognostic value of mean corpuscular volume with capecitabine therapy in metastatic breast cancer. ( Berk, V; Bozkurt, O; Cetin, B; Duran, AO; Inanc, M; Kaplan, MA; Karaca, H; Ozaslan, E; Ozkan, M, 2014) |
| "To report on the efficacy and safety of mitomycin-C-capecitabine (MIXE) regimen as salvage chemotherapy regimen for patients with refractory metastatic colorectal cancer." | 7.79 | Mitomycin-C and capecitabine (MIXE) as salvage treatment in patients with refractory metastatic colorectal cancer: a retrospective study. ( Brennan, M; Garcon, MC; Kaley, K; Rodriguez, G; Saif, MW, 2013) |
| "To report a retrospective data on the efficacy and safety of capecitabine and temozolomide (CAPTEM regimen) in patients with metastatic pancreatic neuroendocrine tumors (pNETs) who have failed prior therapies." | 7.79 | A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy. ( Brennan, M; Garcon, MC; Kaley, K; Rodriguez, G; Rodriguez, T; Saif, MW, 2013) |
| "The aim of this study was to evaluate the efficacy and tolerability of a gemcitabine, 5-fluorouracil and leucovorin (GEMFUFOL) chemotherapy regimen as first line treatment of metastatic biliary tract cancer." | 7.79 | Two-week combination chemotherapy with gemcitabine, high-dose folinic acid and 5 fluorouracil (GEMFUFOL) as first-line treatment of metastatic biliary tract cancers. ( Oztop, I; Unal, OU; Unek, IT; Yilmaz, AU, 2013) |
| "We analyzed the clinical efficacy and safety of capecitabine plus oxaliplatin( XELOX) and bevacizumab( BV) as neoadjuvant chemotherapy, administered for the treatment of patients with resectable metastatic colorectal cancer between October 2009 and December 2012." | 7.79 | [Neoadjuvant chemotherapy with capecitabine plus oxaliplatin and bevacizumab for the treatment of patients with resectable metastatic colorectal cancer]. ( Egawa, T; Ito, Y; Kemmochi, T; Makino, H; Mihara, K; Mori, T; Nagashima, A; Ohkubo, Y; Yamamuro, W, 2013) |
| "The goal of the present study was to compare the efficacy of the combination of cetuximab and irinotecan to the combination of oxaliplatin and fluoropyrimidines as second-line chemotherapy in patients with irinotecan-refractory and oxaliplatin-naïve metastatic colorectal cancer (mCRC) harboring wild-type KRAS." | 7.79 | Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRAS. ( Baek, JY; Hong, YS; Kim, HJ; Kim, JC; Kim, JH; Kim, KP; Kim, SY; Kim, TW; Lee, JL; Lim, SB; Park, JH; Park, SJ; Yu, CS, 2013) |
| "Lapatinib plus capecitabine emerged as an efficacious therapy in metastatic breast cancer (mBC)." | 7.78 | The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer. ( Benhaim, L; Bohanes, PO; El-Khoueiry, A; El-Khoueiry, R; Gerger, A; Labonte, MJ; Ladner, RD; Lenz, HJ; Ning, Y; Wilson, PM; Yang, D; Zhang, W, 2012) |
| "The efficacy of bevacizumab combined with infusional 5-fluorouracil/leucovorin (5-FU/LV) plus irinotecan (FOLFIRI) as the second-line treatment for metastatic colorectal cancer (mCRC) has not been fully clarified, although bevacizumab combined with infusional 5-FU/LV plus oxaliplatin (FOLFOX) in the second-line setting has demonstrated a survival benefit." | 7.78 | Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV stud ( Baba, E; Bando, H; Boku, N; Esaki, T; Fukunaga, M; Hyodo, I; Kato, S; Katsumata, K; Miyake, Y; Moriwaki, T; Ozeki, M; Satoh, T; Takashima, A; Yamashita, K; Yamazaki, K; Yoshida, S, 2012) |
| "Docetaxel plus capecitabine, a commonly used chemotherapeutic regimen for metastatic breast cancer (MBC), is highly variable in its effectiveness." | 7.78 | Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine. ( Che, L; Di, L; Dong, N; Jia, J; Jiang, H; Ren, J; Song, G; Wang, C; Wang, X; Wang, Z; Yu, J; Zheng, X; Zhou, X; Zhu, B, 2012) |
| "Capecitabine is often offered as a first-line chemotherapy option for metastatic breast cancer (MBC)." | 7.78 | Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer. ( Anderson, R; Balkrishnan, R; Camacho, F; Kamal, AH; Kimmick, G; Wei, W, 2012) |
| "The aim of the present study was to investigate the gene expression of biomarkers associated with the sensitivity to fluoropyrimidine and taxanes in recurrent/advanced breast cancer patients treated with first-line capecitabine chemotherapy." | 7.78 | Evaluations of biomarkers associated with sensitivity to 5-fluorouracil and taxanes for recurrent/advanced breast cancer patients treated with capecitabine-based first-line chemotherapy. ( Hu, ZH; Huang, H; Huang, Y; Lin, SX; Lin, TY; Tian, Y; Zhao, HY, 2012) |
| "We retrospectively investigated the efficacy and toxicity of lapatinib plus capecitabine in 45 HER2-positive breast cancer patients." | 7.78 | [Efficacy and toxicity of lapatinib plus capecitabine therapy in HER2-positive metastatic breast cancer]. ( Chiba, A; Inaba, M; Inari, H; Ino, H; Kojima, I; Kuroda, K; Matsuo, A; Matsuura, H; Mukaibashi, T; Shimizu, S; Suganuma, N; Yamanaka, T; Yoshida, A, 2012) |
| "To evaluate effects of UDP-glucuronosyltransferase1A1 (UGT1A1) and thymidylate synthetase (TS) gene polymorphisms on irinotecan in metastatic colorectal cancer (mCRC)." | 7.78 | UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil. ( Jiao, SC; Liu, ZY; Shen, L; Wang, JW; Wang, Y; Xu, JM; Xu, N, 2012) |
| "There has been no report on sorafenib therapy in patients with metastatic hepatocellular carcinoma (HCC) who had been treated with systemic chemotherapy." | 7.77 | Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy. ( Bang, YJ; Han, SW; Im, SA; Kim, JW; Kim, TY; Lee, JO; Oh, DY, 2011) |
| "We sought to determine if an association exists between age and capecitabine efficacy among patients with metastatic breast cancer (MBC)." | 7.77 | Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials. ( Blum, JL; Glück, S; Hu, S; Kaye, JA; Kohles, J; McKenna, E; Odom, D; Scotto, N, 2011) |
| "The primary purpose of this study was to evaluate the role of thymidylate synthase (TS) and thymidine phosphorylase (TP) as biomarkers to predict clinical outcomes of capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer (MBC)." | 7.77 | Thymidylate synthase and thymidine phosphorylase as predictive markers of capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. ( Ahn, JS; Cho, EY; Choi, YL; Im, YH; Kim, ST; Lee, SJ; Park, YH, 2011) |
| "A total of 152 patients with metastatic colorectal cancer who were treated with oxaliplatin and continuous infusion 5-fluorouracil were genotyped for 21 polymorphisms in 13 cancer-related genes by PCR." | 7.77 | Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin. ( El-Khouiery, A; Gordon, MA; Iqbal, S; Labonte, M; Ladner, RD; Lenz, HJ; Lurje, G; Nagashima, F; Sherrod, A; Wilson, P; Yang, D; Zhang, W, 2011) |
| " We aimed to evaluate the effect of pretreatment serum metabolic profiles generated by (1)H NMR spectroscopy on toxicity in patients with inoperable colorectal cancer receiving single agent capecitabine." | 7.77 | Pharmacometabonomic profiling as a predictor of toxicity in patients with inoperable colorectal cancer treated with capecitabine. ( Backshall, A; Clarke, SJ; Keun, HC; Sharma, R, 2011) |
| " Based on clinical data and using modeling techniques, the work analyzes the pharmacodynamic interaction between capecitabine and docetaxel used in combination in metastatic breast cancer." | 7.77 | Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancer. ( Bruno, R; Claret, L; Frances, N; Iliadis, A, 2011) |
| "Capecitabine is a widely accepted option in pre-treated metastatic breast cancer (MBC) patients." | 7.77 | Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors. ( Bertucci, F; Esterni, B; Extra, JM; Gilabert, M; Gonçalves, A; Jacquemier, J; Madroszyk, A; Tarpin, C; Viens, P, 2011) |
| "Combined low-dose therapy of oral capecitabine (Xeloda) and cyclophosphamide (XC) has been demonstrated to be useful for long-term control of lesions in patients with metastatic breast cancer (MBC) and is aimed at symptomatic alleviation and prolongation of survival." | 7.77 | Clinical efficacy of capecitabine and cyclophosphamide (XC) in patients with metastatic breast cancer. ( Doihara, H; Ikeda, H; Masuda, H; Nishiyama, K; Nogami, T; Shien, T; Taira, N, 2011) |
| "Prophylactic pyridoxine was given to 38 patients receiving capecitabine (alone or in combination with cyclophosphamide) for metastatic breast cancer and compared with historical data from 40 patients receiving capecitabine without pyridoxine in our clinic." | 7.76 | Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer. ( Fujita, T; Hayashi, H; Iwata, H; Kimura, M; Kondo, N; Toyama, T; Tsunoda, N; Tsuzuki, N; Yamashita, H; Yamashita, T; Yoshimoto, N, 2010) |
| "We investigated the efficacy of intra-arterial 5-fluorouracil (5-FU) and systemic interferon (IFN)-alpha (5-FU-IFN) in the treatment of hepatocellular carcinoma (HCC) with portal vein tumor thrombosis in the first branch or trunk (Vp3/4) and extrahepatic metastases." | 7.76 | Intra-arterial 5-fluorouracil/interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases. ( Aikata, H; Chayama, K; Hieda, M; Hiramatsu, A; Ishikawa, M; Kakizawa, H; Katamura, Y; Kawakami, Y; Kawaoka, T; Kimura, Y; Takahashi, S; Takaki, S; Waki, K, 2010) |
| "Single agent capecitabine is effective and well tolerated in metastatic breast cancer (MBC)." | 7.76 | Moderate dose capecitabine in older patients with metastatic breast cancer: a standard option for first line treatment? ( Ashley, S; Johnston, S; Kotsori, AA; Noble, JL; Smith, IE, 2010) |
| "We investigated 30 patients with advanced and metastatic breast cancer who underwent capecitabine therapy in our department from July, 2004 to April, 2009." | 7.76 | [More effective positioning of capecitabine for advanced and metastatic breast cancer]. ( Kawaguchisakita, N; Kohno, Y; Tsubota, Y; Tsuyuki, S; Ukikusa, M, 2010) |
| "The aim was to evaluate the cost of capecitabine vs conventional combination chemotherapics such as 5-fluorouracil (5-FU) for the treatment of metastatic colorectal cancer (mCRC) in Italy." | 7.76 | Cost analysis of capecitabine vs 5-fluorouracil-based treatment for metastatic colorectal cancer patients. ( Bianchessi, C; Bollina, R; Carteni, G; Cozzi, C; De Portu, S; Grimaldi, AM; Mantovani, LG; Ravaioli, A; Tamburini, E; Testa, TE, 2010) |
| "Patients with locally advanced and metastatic colorectal cancer treated with capecitabine or 5-fluorouracil/leucovorin (5-FU/LV) as monotherapy or combination therapy with oxaliplatin from 2003-2006 were identified in the Thomson Reuters MarketScan® databases." | 7.76 | Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison. ( Cartwright, T; Chu, E; McKenna, EF; Schulman, KL, 2010) |
| "The aim of this study was to retrospectively analyze the efficacy and safety of the combination of 5-fluorouracil (5-FU), dacarbazine, and epirubicin (FDE) in 39 patients with advanced, well-differentiated neuroendocrine tumors (NETs)." | 7.76 | Evaluation of the combination 5-fluorouracil, dacarbazine, and epirubicin in patients with advanced well-differentiated neuroendocrine tumors. ( Bruneton, D; Cassier, PA; Chayvialle, JA; Hervieu, V; Lombard-Bohas, C; Pilleul, F; Scoazec, JY; Walter, T, 2010) |
| "Combination of capecitabine and irinotecan (XELIRI regimen) is an active and well tolerated treatment for metastatic colorectal cancer (mCRC)." | 7.76 | Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer. ( Alvarez-Suarez, S; García-Alfonso, P; Jerez-Gilarranz, Y; Khosravi, P; Martin, M; Muñoz-Martin, AJ; Riesco-Martinez, M, 2010) |
| "002], presence of visceral metastases at the beginning of capecitabine treatment (HR = 2." | 7.75 | Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer. ( Andreetta, C; Damante, G; Di Loreto, C; Fasola, G; Minisini, A; Pandolfi, M; Pegolo, E; Piga, A; Pizzolitto, S; Puglisi, F; Puppin, C; Valent, F, 2009) |
| "A recent clinical trial demonstrated that the addition of lapatinib to capecitabine in the treatment of HER-2-positive advanced breast cancer (ABC) significantly increases median time to progression." | 7.75 | Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer. ( Hay, JW; Le, QA, 2009) |
| " single-agent capecitabine for first- or second-line treatment of metastatic breast cancer (MBC) METHODS: Data from the medical charts of 61 patients who received single-agent capecitabine, docetaxel, or paclitaxel therapy were supplemented with data from the 38-item Patient Care Monitor (PCM) survey of symptom burden and quality of life, prospectively collected during chemotherapy." | 7.75 | Patient and practice impact of capecitabine compared to taxanes in first-/second-line chemotherapy for metastatic breast cancer. ( Cobb, P; Houts, AC; Schwartzberg, LS; Stepanski, EJ; Walker, MS, 2009) |
| "A total of 76 patients with recurrent or metastatic colorectal cancer treated with capecitabine and oxaliplatin (XELOX) combination chemotherapy were enrolled in the present study." | 7.75 | Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin. ( Bae, SH; Chae, YS; Choi, GS; Jeon, SW; Jun, SH; Kang, BM; Kim, JG; Kum, Y; Lim, KH; Moon, JH; Park, IJ; Ryoo, HM; Sohn, SK, 2009) |
| " Here, we prospectively studied patients with metastatic breast cancer receiving capecitabine treatment in order to determine if sarcopenia was associated with a higher incidence of toxicity and a shorter time to tumor progression (TTP)." | 7.75 | Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. ( Baracos, VE; Koski, S; Mackey, JR; McCargar, LJ; Mourtzakis, M; Pituskin, E; Prado, CM; Reiman, T; Sawyer, MB; Tonkin, K, 2009) |
| "We examined 51 patients treated with Capecitabine for metastatic breast cancer." | 7.75 | [Palliative chemotherapy for metastatic breast cancer with capecitabine]. ( Inaba, T; Kashiwaba, M; Komatsu, H; Takeda, Y; Takiyama, I; Tomisawa, Y; Wakabayashi, G, 2009) |
| "We evaluated the efficacy and toxicity of combination chemotherapy with capecitabine and cisplatin (XP) in patients with metastatic hepatocellular carcinoma (HCC)." | 7.75 | Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma. ( Bang, YJ; Im, SA; Kim, JH; Kim, TY; Lee, JO; Lee, KW; Oh, DY, 2009) |
| "We designed a study protocol in 2005 and 16 patients with metastatic colorectal cancer were treated accordingly in the first line setting with XELIRI regimen (capecitabin, irinotecan) + bevacizumab." | 7.75 | [Bevacizumab in combination with capecitabine and irinotecan (XELIRI) in treatment of metastatic colorectal cancer]. ( Kocák, I; Kocáková, I; Nemecek, R; Rehák, Z; Standara, M; Svoboda, M, 2009) |
| "A case of gastric endocrine cell carcinoma successfully treated by FU (5-FU/UFT) +irinotecan (CPT-11) adjuvant therapy against recurrent metastases is reported with some discussion." | 7.75 | [A Case of gastric endocrine cell carcinoma successfully treated by FU plus irinotecan(CPT-11)adjuvant therapy against recurrent metastases]. ( Hara, T; Hiramatsu, K; Hosoya, J; Kato, K; Kimura, A; Kojima, T; Machiki, Y; Otsuji, H; Sakuragawa, T; Tanaka, H; Tsuchiya, T; Yoshida, K, 2009) |
| "In this study, we investigated the efficacy and toxicity of fluorouracil(FU)+Leucovorin(LV)with oxaliplatin (FOLFOX)and irinotecan(FOLFIRI)for patients with advanced or metastatic colorectal cancer." | 7.74 | Efficacy and toxicity of fluorouracil, leucovorin plus oxaliplatin (FOLFOX4 and modified FOLFOX6) followed by fluorouracil, leucovorin plus irinotecan(FOLFIRI)for advanced or metastatic colorectal cancer--case studies. ( Adachi, K; Arimoto, Y; Kanamiya, Y; Nakamura, R; Nishio, K; Oba, H; Ohtani, H; Shintani, M; Yui, S, 2008) |
| "Capecitabine exerts considerable therapeutic efficacy in metastatic breast cancer (MBC) patients previously treated with anthracyclines and taxanes." | 7.74 | Efficacy of lower dose capecitabine in patients with metastatic breast cancer and factors influencing therapeutic response and outcome. ( Evrensel, T; Goker, E; Kurt, E; Manavoglu, O; Ozdemir, N; Sezgin, C, 2007) |
| "The oxaliplatin/fluorouracil/leucovorin (FOL-FOX regimen) is an effective and generally well-tolerated regimen in Western clinical studies of advanced colorectal cancer." | 7.74 | Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience. ( Fukuoka, M; Nakagawa, K; Okamoto, I; Ozaki, T; Satoh, T; Shimizu, T; Tamura, K, 2007) |
| "The objectives of the present study were to evaluate the efficacy and safety of an outpatient-basis chemotherapy of oxaliplatin, 5-fluorouracil, and leucovorin as the first-line treatment for patients with advanced colorectal cancer." | 7.74 | Outpatient-basis chemotherapy of oxaliplatin, 5-fluorouracil, and leucovorin as first-line treatment for patients with metastatic or recurrent colorectal cancer. ( Ahn, BM; Baek, JH; Chae, YS; Cho, YY; Choi, GS; Jun, SH; Kim, JG; Kim, SN; Lee, IT; Lee, SJ; Moon, JH; Sohn, SK, 2007) |
| "Capecitabine is a fluoropyrimidine-based drug that offers physicians a more convenient treatment for advanced colorectal cancer (CRC), with manageable toxicity and antitumor activity comparable to that of continuous-infusion therapies with 5-fluorouracil (5-FU)." | 7.74 | DPD is a molecular determinant of capecitabine efficacy in colorectal cancer. ( Danenberg, KD; Danenberg, PV; Jakobsen, A; Kuramochi, H; Lindebjerg, J; Nielsen, JN; Shimizu, D; Vallböhmer, D; Yang, DY, 2007) |
| "Taxanes (TX) were administered to 246 of 292 patients with recurrent/metastatic breast cancer (MBC) who were treated in Hiei Hospital between January 2001 and May 2006." | 7.74 | [Evaluation of therapeutic regimens for taxane-resistant recurrent/metastatic breast cancer]. ( Iguchi, C; Kan, N; Kodama, H; Nio, Y; Yoshikawa, K, 2007) |
| "A combination of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) is one of the standard regimens for palliative and adjuvant chemotherapy for colorectal cancer." | 7.74 | Feasibility of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) for Japanese patients with unresectable metastatic colorectal cancer. ( Asaka, M; Doi, T; Fuse, N; Kojima, T; Muto, M; Ohtsu, A; Tahara, M; Takeuchi, S; Taku, K; Yoshida, S, 2007) |
| "We retrospectively evaluated the efficacy and safety of combination therapy of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer (MBC)." | 7.74 | Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer. ( Hatake, K; Ito, Y; Iwase, T; Osako, T; Takahashi, S; Tokudome, N, 2008) |
| "We report a case of elderly metastatic breast cancer with a complete response to the treatment with XC (X: capecitabine and C: cyclophosphamide)." | 7.74 | [A case of elderly metastatic breast cancer with a complete response to treatment with capecitabine and cyclophosphamide]. ( Furukawa, K; Iida, S; Iwasaki, R; Naito, Z; Noguchi, T; Sugisaki, Y; Tajiri, T; Tsuchiya, S; Yanagihara, K; Yokoyama, T, 2007) |
| "The clinical efficacy and safety of irinotecan plus infusional fluorouracil/l-leucovorin (FOLFIRI) in patients with fluoropyrimidine-resistant metastatic colorectal cancer were studied retrospectively." | 7.74 | [Clinical study of irinotecan plus infusional fluorouracil/l-leucovorin (FOLFIRI) in patients with fluoropyrimidine-resistant metastatic colorectal cancer]. ( Hori, S; Hyodo, I; Iguchi, H; Imamine, S; Kajiwara, T; Kataoka, J; Moriwaki, T; Nasu, J; Nishina, T, 2007) |
| "The efficacy and tolerability of therapy with gemcitabine plus cisplatin were evaluated in 49 patients with disseminated breast cancer refractory to anthracyclines, docetaxel and capecitabine." | 7.73 | [Gemcitabine plus cisplatin therapy in breast cancer refractory to anthracyclines, docetaxel and capecitabine]. ( Filatova, LV; Gershanovich, ML; Semiglazova, TIu, 2005) |
| "To examine the prevalence of anemia and its impact of hemoglobin (Hgb) levels in predicting outcomes of 5-fluorouracil (FU)-based first-line chemotherapy for patients with advanced gastric cancer (AGC)." | 7.73 | Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer. ( Bang, SM; Cho, EK; Jung, CW; Kang, WK; Kim, K; Kim, S; Kim, WS; Lee, J; Lee, JH; Lee, SH; Park, JO; Park, K; Park, SH; Park, YS; Shin, DB, 2006) |
| "The present study aimed to prospectively investigate the influence of thymidylate synthase (TS) polymorphisms (5'-TSER, 3'-TSUTR) on the disease-free survival (DFS) and overall survival (OS) of patients with colorectal cancer (CRC) who were treated with adjuvant 5-fluorouracil (5-FU) therapy." | 7.73 | Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil. ( Adleff, V; Budai, B; Czeglédi, F; Gyergyay, F; Hitre, E; Horváth, Z; Kásler, M; Kovács, T; Kralovánszky, J; Láng, I; Lövey, J; Orosz, Z, 2005) |
| "Fifty-seven patients with metastatic breast cancer have been treated with reduced dose capecitabine 1g/m2 twice daily for 14 days repeated every 3 weeks after failure of a number of chemotherapy regimens or hormonal treatment." | 7.73 | Reduced dose capecitabine is an effective and well-tolerated treatment in patients with metastatic breast cancer. ( Coleman, RE; El-Helw, L, 2005) |
| "Irinotecan, in combination with 5-fluorouracil (5-FU) and a high dose of leucovorin (LV), known as FOLFIRI regimen, has shown activity in recurrent or metastatic colorectal cancer." | 7.73 | Irinotecan, continuous 5-fluorouracil, and low dose of leucovorin (modified FOLFIRI) as first line of therapy in recurrent or metastatic colorectal cancer. ( Byun, JH; Chang, SK; Choi, MG; Choi, SI; Hong, YS; Kang, JH; Lee, DS; Lee, KS; Lee, MA; Oh, ST; Shim, BY; Woo, IS, 2005) |
| "A considerable proportion of estrogen receptor (ER)-positive breast cancer recurs despite tamoxifen treatment, which is a serious problem commonly encountered in clinical practice." | 7.73 | Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer. ( Bae, JY; Bae, YJ; Han, MR; Han, W; Hwang, KT; Hwang, SE; Kang, JJ; Kim, SW; Lee, JE; Lee, JH; Noh, DY; Shin, HJ, 2006) |
| "We investigated 29 patients with advanced and recurrent breast cancers who underwent capecitabine therapy in the department." | 7.73 | [Therapeutic efficacy of capecitabine on advanced and recurrent breast cancer with special reference to time to progression]. ( Hironou, M; Ikeda, M; Kurebayashi, J; Nakashima, K; Nomura, T; Ookubo, S; Seki, M; Shiiki, S; Sonoo, H; Tanaka, K; Udagawa, K; Yamamoto, Y, 2006) |
| " In this study, digital karyotyping was used to search for genomic alterations in liver metastases that were clinically resistant to 5-fluorouracil (5-FU)." | 7.72 | Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. ( Bardelli, A; Choti, M; Diaz, LA; Donehower, R; Galizia, G; Iacobuzio-Donahue, C; Kinzler, KW; Lengauer, C; Parmigiani, G; Romans, K; Saha, S; Shih, IeM; Velculescu, VE; Vogelstein, B; Wang, TL, 2004) |
| "Preclinical in vitro and in vivo studies have demonstrated synergistic interactions between 5-fluorouracil (5-FU) and type I and II IFNs against human colorectal cancer cells." | 7.72 | Combined 5-fluorouracil/systemic interferon-beta gene therapy results in long-term survival in mice with established colorectal liver metastases. ( Barsoum, J; Choi, EA; Fraker, DL; Lei, H; Maron, DJ; Mick, R; Spitz, FR; Wilson, JM; Yu, QC, 2004) |
| "Capecitabine is a novel oral chemotherapy agent designed to generate 5-fluorouracil (5-FU) preferentially in tumor tissue, and is the most effective therapy for anthracycline and taxane-resistant breast cancer." | 7.72 | Effect of capecitabine on mean corpuscular volume in patients with metastatic breast cancer. ( Hamilton, M; Karvellas, CJ; Mackey, JR; Sawyer, M, 2004) |
| "To determine whether deleted in colon cancer (DCC) protein expression in colorectal cancer (CRC) metastases could predict outcome to palliative fluorouracil (FU)-based chemotherapy and to assess whether it is similar to that observed in the corresponding primary tumors." | 7.72 | Deleted in colon cancer protein expression in colorectal cancer metastases: a major predictor of survival in patients with unresectable metastatic disease receiving palliative fluorouracil-based chemotherapy. ( Aschele, C; Bandelloni, R; Casazza, S; Debernardis, D; Gallo, L; Lonardi, S; Monfardini, S, 2004) |
| "The efficacy of a concomitant oxaliplatin/bolus 5-fluorouracil/leucovorin regimen in 123 heavily pretreated patients with advanced colorectal cancer was evaluated." | 7.72 | Compassionate-use oxaliplatin with bolus 5-fluorouracil/leucovorin in heavily pretreated patients with advanced colorectal cancer. ( Amin-Zimmerman, F; Glisson, SD; Hargis, JB; Hicks, RM; Kosfeld, RE; LaRocca, RV; Leaton, KE, 2004) |
| "This study was conducted to evaluate the prognostic significance of thymidylate synthase (TS) expression in the tumor tissue of patients with metastatic colorectal cancer (CRC) who received protracted venous infusions of 5-fluorouracil (5-FU)." | 7.72 | Prognostic significance of thymidylate synthase in patients with metastatic colorectal cancer who receive protracted venous infusions of 5-fluorouracil. ( Araake, M; Hamaguchi, T; Hosokawa, A; Morita, H; Muro, K; Orita, H; Shimada, Y; Shirao, K; Yamada, Y, 2004) |
| "The 5 fluorouracil hepato-arterial infusion (5-FU HAI) therapy has a good effect on the liver metastases of colorectal cancer." | 7.72 | [The 5-fluorouracil hepato-arterial infusion with oral UFT therapy for the hepatic and extra hepatic metastases of colorectal cancer]. ( Ebuchi, M; Hasegawa, K; Kato, K; Koide, A; Maruyama, M; Maruyama, S; Ohbu, M; Takashima, I, 2004) |
| "Following the encouraging results achieved with the oral fluoropyrimidine capecitabine in clinical trials, a named patient programme was initiated in the UK, through which patients with advanced breast cancer were prescribed capecitabine monotherapy." | 7.71 | Capecitabine named-patient programme for patients with advanced breast cancer. the UK experience. ( Breddy, J; Cameron, D; Chaturvedi, A; Hutcheon, A; Leonard, RC; Salazar, R; Twelves, C, 2002) |
| "TS levels were measured immunohistochemically on archival specimens of colorectal cancer metastases from 124 patients homogeneously treated in a series of clinical trials at our institutions with: (A) leucovorin (LV)-modulated infusional 5-FU (n = 48); (B) LV-modulated bolus 5-FU (n = 41); (C) methotrexate (MTX)-modulated bolus 5-FU (n = 35)." | 7.71 | Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil. ( Aschele, C; Bandelloni, R; Barni, S; Cascinu, S; Catalano, V; Debernardis, D; Drudi, G; Gallo, L; Giordani, P; Lonardi, S; Maley, F; Monfardini, S; Turci, D, 2002) |
| "Irinotecan (CPT-11), oxaliplatin (OXA) and different folinic acid(FA) modulated 5-fluorouracil (5-FU) regimens are active as first-and second-line chemotherapy of metastatic colorectal cancer." | 7.71 | Weekly oxaliplatin, high-dose folinic acid and 24h-5-fluorouracil (FUFOX) as salvage therapy in metastatic colorectal cancer patients pretreated with irinotecan and folinic acid/5-fluorouracil regimens. ( Galle, PR; Heike, M; Hildner, K; Hoffmann, T; Moehler, M; Siebler, J, 2002) |
| "Results from two phase II studies in metastatic breast cancer have shown that the novel, tumour-selective fluoropyrimidine capecitabine provides an effective and well tolerated therapy in patients with metastatic breast cancer failing or resistant to anthracycline and taxane therapy." | 7.71 | Clinical experience of capecitabine in metastatic breast cancer. ( O'Shaughnessy, J, 2002) |
| "Capecitabine could potentially be used for secondline treatment in patients with progressive metastatic cholangiocarcinoma." | 7.71 | Capecitabine as second-line treatment for metastatic cholangiocarcinoma: a report of two cases. ( Heinemann, V; Schalhorn, A; Stemmler, J, 2002) |
| "The comparative saliva/plasma pharmacokinetics of 5-fluorouracil (5-FU) were investigated in 21 patients with metastatic colorectal cancer receiving high-dose folinic acid (LV (leucovorin) 200 mg/m2) followed by 5-FU bolus (400 mg/m2) and continuous infusion (600, 750, 900 or 1200 mg/m2) on days 1 and 2." | 7.70 | Plasma and salivary pharmacokinetics of 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer receiving 5-FU bolus plus continuous infusion with high-dose folinic acid. ( Astre, C; Bressolle, F; Duffour, J; Joulia, JM; Pinguet, F; Ychou, M, 1999) |
| "In a recent multicentre, randomised, controlled, open-label study (Rougier and colleagues, Lancet 1998, 352, 1407-1412), irinotecan significantly increased survival without any deterioration in quality of life compared with best-estimated infusional 5-fluorouracil (5-FU) therapy in the setting of second-line treatment for metastatic colorectal cancer." | 7.70 | Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU. ( Hickish, T; Iveson, TJ; Schmitt, C; Van Cutsem, E, 1999) |
| "The authors describe the retrospective analysis of treatment by 5-fluorouracil and interferon-a aof 34 patients with advanced colorectal cancer." | 7.70 | Retrospective evaluation of 5-fluorouracil-interferon-a aTreatment of advanced colorectal cancer patients. ( András, C; Antal, L; Csiki, Z; Gál, I; Szegedi, G; Takács, I, 2000) |
| "Thymidylate synthase (TS) expression in colorectal cancer metastases has been shown to predict for the clinical response to 5-fluorouracil." | 7.70 | Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. ( Aschele, C; Debernardis, D; Maley, F; Sobrero, A; Tunesi, G, 2000) |
| "Nineteen patients with metastatic breast cancer who had failed prior first line FEC chemotherapy (fluorouracil 500 mg/m2, epirubicin 50 mg/m2 cyclophosphamide 500 mg/m2, every 4 weeks) were treated with a combination of fluorouracil 500 mg/m2, doxorubicin 50 mg/m2 and cyclophosphamide 500 mg/m2 every 4 weeks (FAC)." | 7.69 | FAC (fluorouracil, doxorubicin, cyclophosphamide) as second line chemotherapy in patients with metastatic breast cancer progressing under FEC (fluorouracil, epirubicin, cyclophosphamide) chemotherapy. ( Biron, P; Catimel, G; Chauvin, F; Clável, M; Guastalla, JP; Rebattu, P, 1994) |
| "Previous phase II studies of continuous infusion Fluorouracil (5-FU) (CI 5-FU) in refractory metastatic breast cancer have shown modest activity with low toxicity." | 7.69 | Continuous infusion 5-fluorouracil as first-line therapy for metastatic breast cancer. ( Chu, L; Havlin, KA; Peterson, BL; Sutton, LM; Winer, EP, 1996) |
| "We treated 39 women with newly diagnosed stage IV breast cancer with a new regimen of mitoxantrone 18 mg/m2 on days 1, 29, 57, vincristine 1." | 7.68 | Mitoxantrone, vincristine, and 5-fluorouracil with leucovorin modulation as induction chemotherapy prior to high-dose intensification in metastatic breast cancer. ( Bitran, JD; Huffman, S; Mick, R; Myers, SE; Williams, SF, 1993) |
| "Since there is no effective second line chemotherapy in colorectal cancer resistant to fluorouracil, this study was carried out to evaluate the therapeutic activity of the pineal hormone melatonin, which has appeared to have antineoplastic activity in some experimental conditions, in patients with metastatic colorectal carcinoma who did not respond to fluorouracil." | 7.68 | A study of the pineal hormone melatonin as a second line therapy in metastatic colorectal cancer resistant to fluorouracil plus folates. ( Archili, C; Barni, S; Crispino, S; Lissoni, P; Paolorossi, F; Tancini, G, 1990) |
| "Methotrexate and 5-FU were given sequentially with a 7-hour interval to 43 evaluable patients with heavily pretreated metastatic breast cancer." | 7.67 | Sequential methotrexate and 5-FU in breast cancer resistant to the conventional application of these drugs. ( Bartsch, H; Fritze, D; Herrmann, R; Jungi, F; Manegold, C; Schroeder, M; Tigges, FJ, 1984) |
| "Thirty-eight evaluable patients with metastatic breast cancer refractory to hormonal therapy and multiple chemotherapy regimens were treated with mitolactol at a dose of 130 mg/m2/day orally for 10 days every 6 weeks." | 7.67 | Phase II study of mitolactol in chemotherapy-refractory metastatic breast cancer. ( Catalano, RB; Creech, RH; Dierks, KM; Shah, MK, 1984) |
| "Based on in vitro studies that have demonstrated synergy between recombinant alfa-2a-interferon (rIFN alpha-2a) and the fluoropyrimidine, fluorouracil (5FU), against two human colon cancer cell lines, a pilot clinical trial was initiated to determine the effects of the combination of 5FU and rIFN alpha-2a in patients with advanced, unresectable colorectal carcinoma." | 7.67 | Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. ( Goldman, M; Itri, L; Lyver, A; Rader, M; Schwartz, EL; Wadler, S; Weinberg, V; Wiernik, PH; Zimmerman, M, 1989) |
| "Sixty women with metastatic breast cancer refractory to at least one chemotherapeutic regimen were treated with fluorouracil (FUra) and high-dose continuous infusion folinic acid (leucovorin calcium)." | 7.67 | Refractory metastatic breast cancer: salvage therapy with fluorouracil and high-dose continuous infusion leucovorin calcium. ( Akman, S; Bertrand, M; Carr, B; Doroshow, JH; Flanagan, B; Goldberg, D; Leong, L; Margolin, K; Newman, E; Odujinrin, O, 1989) |
| "Thirty-six patients with metastatic breast cancer, 23 with documented progression of the disease after first-line chemotherapy (CAF or CMF) and 13 without prior chemotherapy, were treated with a simultaneous 120-h infusion of cisplatin (CDDP) and 5-fluorouracil (5-FU)." | 7.67 | 120 hours simultaneous infusion of cisplatin and fluorouracil in metastatic breast cancer. ( Barrajón, E; Campbell, W; Fernández Hidalgo, O; Gil, A; González, F; Lacave, AJ, 1989) |
| "In an attempt to increase the clinical activity of 5-fluorouracil (5-FU) by blocking the thymidine salvage pathway, 15 patients with refractory metastatic breast cancer (MBC) were treated with oral dipyridamole (D): 75 mg p." | 7.67 | 5-Fluorouracil and dipyridamole in metastatic breast cancer: a pilot study. ( Marini, G; Marpicati, P; Montini, E; Palazzi, M; Pipino, G; Simoncini, E; Zaniboni, A, 1989) |
| "Twenty-six patients (25 evaluable for response) with previously treated metastatic breast cancer were treated with intermediate-dose methotrexate (300 mg/m2) followed by 5-fluorouracil (600 mg/m2) and folinic acid-SF (Leucovorin) rescue (10 mg/m2 q 6 h X 6 doses) with or without tamoxifen (20 mg) and conjugated estrogen (Premarin) (." | 7.67 | Salvage treatment with intermediate-dose methotrexate and 5-fluorouracil in metastatic breast cancer. ( Lippman, M; Steinberg, S; Swain, SM, 1988) |
| "Fifty-two patients with hormonally unresponsive or estrogen receptor negative metastatic breast cancer who had not received prior chemotherapy received mitoxantrone 10 mg/m2, cyclophosphamide 500 mg/m2, and 5-fluorouracil 1000 mg/m2 (MCF) by short intravenous infusion every 21 days." | 7.67 | Mitoxantrone, cyclophosphamide, and fluorouracil in metastatic breast cancer unresponsive to hormonal therapy. ( Blumenschein, GR; Buzdar, AU; Esparza, L; Holmes, FA; Hortobagyi, GN; Hug, V; Yap, HY, 1987) |
| "Three first-line combination chemotherapy regimens which included mitoxantrone were studied for the treatment of advanced breast cancer." | 7.67 | Use of mitoxantrone-based combination chemotherapy regimens as first-line treatment for advanced breast cancer. ( Bezwoda, WR; Dansey, RD; Hesdorffer, CS, 1987) |
| "Thirty-six patients with advanced breast cancer were treated with the regimen of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF)." | 7.66 | Correlation of estrogen receptors and response to chemotherapy of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in advanced breast cancer. ( Chang, JC; Wergowske, G, 1981) |
| "One hundred and fourteen evaluable patients with metastatic breast cancer were treated with a program consisting of 5-FU, Adriamycin, cyclophosphamide (FAC) and nonspecific immunotherapy with Levamisole." | 7.66 | Combined chemoimmunotherapy for advanced breast cancer: a comparison of BCG and levamisole. ( Blumenschein, GR; Burgess, MA; Buzdar, AU; Gutterman, JU; Hersh, EM; Hortobagyi, GN; Tashima, CK; Yap, HY, 1979) |
| "A heparinized catheter was used for the regional infusion of 5-fluorouracil in seven patients with liver metastases." | 7.66 | Heparinized catheters for long-term intraarterial infusion of 5-fluorouracil in liver metastases. ( Forsberg, L; Owman, T; Tylén, U, 1979) |
| "One hundred and five patients with metastatic breast cancer were treated with 5-fluorouracil, Adriamycin, cyclophosphamide and BCG (FAC-BCG)." | 7.66 | Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG. ( Blumenschein, GR; Burgess, MA; Buzdar, AU; Einhorn, L; Gutterman, JU; Hersh, EM; Hortobagyi, GN; Richman, SP; Tashima, CK, 1979) |
| "Metastasizing mammary adenocarcinoma 13762 in female Fischer rats has been used as a model for studying postoperative adjuvant chemotherapy, using methotrexate (Mtx) and 5-fluouracil (5FU) either singly or in combinations." | 7.65 | Adjuvant postoperative chemotherapy with 5-fluorouracil and methotrexate: effect of schedule of administration on metastasis of 13762 mammary adenocarcinoma. ( Khwaja, TA; Lee, YT, 1977) |
| "Seven patients with advanced endometrial adenocarcinoma achieved objective tumor regression following chemotherapy with cyclophosphamide, Adriamycin, 5-fluorouracil, and medroxyprogesterone acetate." | 7.65 | Combination chemotherapy of advanced endometrial adenocarcinoma with adriamycin, cyclophosphamide, 5-fluorouracil, and medroxyprogesterone acetate. ( Bruckner, HW; Deppe, G, 1977) |
| "Three patients with biopsy-proven lentigo maligna were treated with topical 5-fluorouracil." | 7.65 | Topical chemotherapy of lentigo maligna with 5-fluorouracil. ( Krementz, ET; Litwin, MS; Mansell, PW; Reed, RJ, 1975) |
| "Metastatic colorectal cancer (mCRC) has low survival rates." | 6.90 | A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer. ( Beck, JT; Berlin, JD; Cubillo Gracian, A; Deming, DA; Elez Fernandez, E; Garcia-Alfonso, P; Gorbunova, V; Hofheinz, RD; Luo, Y; Mangel, L; Nechaeva, M; Ramanathan, RK; Sullivan, D; Torres, AH, 2019) |
| "Eniluracil/5-FU/Lv might enable these patients to continue with oral 5-FU rather than switching to the generally less well tolerated intravenous microtubule-interfering agents." | 6.79 | Eniluracil plus 5-fluorouracil and leucovorin: treatment for metastatic breast cancer patients in whom capecitabine treatment rapidly failed. ( Burdaeva, O; Chang, JC; Kirby, MG; Rivera, E; Semiglazov, V; Spector, T, 2014) |
| "Metastatic breast cancer (MBC) remains an incurable illness in the majority of cases, despite major therapeutic advances." | 6.78 | Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. ( Bachelot, T; Blasinska-Morawiec, M; Capitain, O; Cognetti, F; Crown, JP; Davidson, N; Diéras, V; Fasching, PA; Fountzilas, G; Greil, R; Huang, X; Kern, KA; Kreienberg, R; Liedtke, C; Miller, WH; Paolini, J; Ramos, M; Romieu, G; Staroslawska, E; Tassell, V; Wildiers, H; Yardley, DA, 2013) |
| "The aims of this study were to establish the maximum tolerated dose (MTD) of oxaliplatin in combination with fixed doses of gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in solid tumors, including advanced pancreatic cancer, and to evaluate the toxicity of the regimen." | 6.78 | Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas. ( Chalasani, SB; Chung, MS; Grossbard, ML; Kozuch, PS; Malamud, S; Mirzoyev, T; Olszewski, AJ, 2013) |
| "XELOX is a promising regimen for anthracycline-pretreated metastatic breast cancer although careful patient selection is indicated and alternate dosing schedules should be explored to minimize neurologic morbidity." | 6.78 | Capecitabine and oxaliplatin in combination as first- or second-line therapy for metastatic breast cancer: a Wisconsin Oncology Network trial. ( Champeny, TL; Chang, JE; Hansen, RM; Kim, K; Meadows, S; Njiaju, UO; Powers, K; Stewart, JA; Tevaarwerk, AJ; Traynor, AM; Van Ummersen, L, 2013) |
| "Cediranib is a highly potent inhibitor of vascular endothelial growth factor (VEGF) signalling with activity against all three VEGF receptors." | 6.78 | Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer. ( Cunningham, D; D'Haens, G; Douillard, JY; Robertson, J; Stone, AM; Van Cutsem, E; Wong, RP, 2013) |
| "Cediranib is an oral, highly potent VEGF signaling inhibitor of all three VEGF receptors." | 6.77 | Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer. ( Boku, N; Mishima, H; Okamoto, W; Satoh, T; Shi, X; Shimamura, T; Yamaguchi, K; Yamazaki, K, 2012) |
| "Patients with advanced breast cancer were randomized to first-line chemotherapy with a combination of epirubicin (Farmorubicin(®)) and paclitaxel (Taxol(®)) alone (ET) or in combination with capecitabine (Xeloda(®), TEX)." | 6.77 | Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial. ( Aström, G; Bergh, J; Brandberg, Y; Carlsson, L; Carstensen, J; Einbeigi, Z; Fernö, M; Hatschek, T; Hellström, M; Lidbrink, E; Linderholm, B; Lindh, B; Loman, N; Malmberg, M; Rotstein, S; Söderberg, M; Sundquist, M; Svensson, H; Walz, TM, 2012) |
| "Leucovorin Sodium (LV/Na) has a high solubility, and is stable when given with continuous infusion of 5-FU." | 6.77 | A phase II randomized study of combined infusional leucovorin sodium and 5- FU versus the leucovorin calcium followed by 5-FU both in combination with irinotecan or oxaliplatin in patients with metastatic colorectal cancer. ( Bleiberg, H; D'Haens, G; Deleu, I; Efira, A; Humblet, Y; Paesmans, M; Peeters, M; Rezaei Kalantari, H; Vandebroek, A; Vergauwe, P, 2012) |
| "Patients with metastatic colorectal cancer (mCRC) were randomized to XELOX plus bevacizumab using a standard triweekly cycle (Q3W) or a dose-dense biweekly cycle (Q2W) schedule." | 6.77 | A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard). ( Cartwright, T; Hu, S; Hurwitz, H; Kwok, A; McKenna, E; Mitchell, EP; Patt, YZ, 2012) |
| "Cabazitaxel (XRP6258) is a new taxoid that is active in chemotherapy-resistant tumour cell lines." | 6.76 | A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study. ( Awada, A; Besse, T; Campone, M; Dubin, F; Machiels, JP; Magherini, E; Pivot, X; Semiond, D; Villanueva, C, 2011) |
| " Although skin toxicities are the most common adverse events associated with EGFR inhibitors, the differences in efficacy and safety between pre-emptive and reactive skin treatment according to KRAS tumor status has not been reported." | 6.76 | The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status. ( Iannotti, N; Lacouture, ME; Mitchell, EP; Pillai, MV; Piperdi, B; Shearer, H; Xu, F; Yassine, M, 2011) |
| "Survival time for metastatic breast cancer (MBC) can be substantially improved by combination chemotherapy in the adjuvant setting." | 6.75 | A Phase II trial of the combination of vinorelbine and capecitabine as second-line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines. ( Alexopoulos, A; Ardavanis, A; Ioannidis, G; Kandylis, C; Malliou, S; Orphanos, G; Rigatos, G; Stavrakakis, J, 2010) |
| "As a project of the Kanagawa Colorectal Cancer Study Group, we performed this study to analyze the efficacy and the safety of modified FOLFIRI (irinotecan: 150 mg/m2) therapy for Japanese patients with metastatic colorectal cancer." | 6.75 | [Modified FOLFIRI (l-LV, 5-fluorouracil and irinotecan) therapy for Japanese patients with metastatic colorectal cancer]. ( Akaike, M; Imada, T; Masuda, M; Matsukawa, H; Ozawa, Y; Rino, Y; Shiozawa, M; Shiraishi, R; Suzuki, H; Takahashi, M; Tamura, I; Yamamoto, N; Yamamoto, Y; Yukawa, N, 2010) |
| " This study aims to achieve an improved disease free survival for patients after resection or resection combined with RFA of colorectal liver metastases by adding the angiogenesis inhibitor bevacizumab to an adjuvant regimen of CAPOX." | 6.75 | A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment. ( Bergman, AM; Dalesio, O; Rinkes, IH; Schouten, SB; Snoeren, N; Tollenaar, RA; van der Sijp, JR; van Hillegersberg, R; Verheul, HM; Voest, EE, 2010) |
| "Liver metastasectomies were performed in 26% of all pts and in 39% of pts with LM." | 6.75 | "Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study. ( Antonucci, A; Baldi, PL; Bruera, G; Cannita, K; De Galitiis, F; Ficorella, C; Mancini, M; Marchetti, P; Ricevuto, E; Santomaggio, A; Tudini, M, 2010) |
| "Tetrathiomolybdate (TM) is an oral copper chelator under development as an anti-angiogenic agent." | 6.74 | A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer. ( Brewer, GJ; Gartner, EM; Griffith, KA; Henja, GF; Merajver, SD; Pan, Q; Zalupski, MM, 2009) |
| "The quality of life (QL) of advanced gastric cancer patients receiving irinotecan, folinic acid and 5-fluorouracil (5-FU) (IF arm) or cisplatin with 5-FU (CF arm) is presented." | 6.74 | Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial. ( Barone, C; Bugat, R; Curran, D; Dank, M; Goker, E; Peschel, C; Pozzo, C; Valvere, V; Wenczl, M; Yalcin, S; Zaluski, J, 2009) |
| " Ninety metastatic breast cancer patients were randomized to receive vinorelbine at one of the eight possible dosing times." | 6.73 | A randomized multicenter study of optimal circadian time of vinorelbine combined with chronomodulated 5-fluorouracil in pretreated metastatic breast cancer patients: EORTC trial 05971. ( Amoroso, D; Baron, B; Biville, F; Chollet, P; Coudert, B; Cvickovic, F; Fillet, G; Focan, C; Genet, D; Giacchetti, S; Gorlia, T; Lentz, MA; Lévi, F; Marreaud, S; Van Der Auwera, J; Zambelli, A, 2008) |
| "Treatment of HER-2-negative metastatic breast cancer (MBC) patients after anthracycline exposure is controversial." | 6.73 | A multicentre phase II study to evaluate sequential docetaxel followed by capecitabine treatment in anthracycline-pretreated HER-2-negative patients with metastatic breast cancer. ( Bayo, J; Bernabé, R; Fernández, A; Fernández-Freire, A; Fuentes, J; Lomas, M; Moreno, A; Rodríguez, A; Ruiz, M; Salvador, J, 2008) |
| "The R0 secondary resection rate of metastases was greater in the FOLFOXIRI arm (6% v 15%; P = ." | 6.73 | Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor ( Allegrini, G; Andreuccetti, M; Barbara, C; Benedetti, G; Brunetti, I; Chiara, S; Cortesi, E; Crinò, L; Evangelista, W; Falcone, A; Fanchini, L; Fioretto, L; Granetto, C; Masi, G; Orlandini, C; Pfanner, E; Picone, V; Porcile, G; Ricci, S; Vitello, S, 2007) |
| "The management of metastatic breast cancer becomes increasingly intricate, requiring new drugs and combinations." | 6.73 | Results of a phase I trial of intravenous vinorelbine plus oral capecitabine as first-line chemotherapy of metastatic breast cancer. ( Biville, F; Chauffert, B; Coudert, B; Favier, L; Ferrant, E; Fumoleau, P; Garnier, J; Isambert, N; Mayer, F; Zanetta, S, 2008) |
| "Individual FU dose adjustment based on pharmacokinetic monitoring resulted in significantly improved objective response rate, a trend to higher survival rate, and fewer grade 3/4 toxicities." | 6.73 | Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. ( Boisdron-Celle, M; Delva, R; Dorval, E; Gamelin, E; Jacob, J; Merrouche, Y; Morel, A; Pezet, D; Piot, G; Raoul, JL, 2008) |
| "Thalidomide was escalated individually to 600 mg po QD as tolerated." | 6.72 | The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer. ( Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; McCollum, AD; Michelini, A; Ryan, DP; Wu, B, 2006) |
| "Patients with untreated advanced colorectal cancer were enrolled to this single arm phase II multi-center cooperative group trial of bevacizumab combined with IFL." | 6.72 | A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. ( Benson, AB; Catalano, PJ; Giantonio, BJ; Levy, DE; Meropol, NJ; O'dwyer, PJ, 2006) |
| "Overall, 77." | 6.72 | Capecitabine and mitomycin C is an effective combination for anthracycline- and taxane-resistant metastatic breast cancer. ( Burattini, L; La Cesa, A; Marcucci, F; Massacesi, C; Pilone, A; Rocchi, MB; Santini, D; Tonini, G; Zepponi, L, 2006) |
| "Capecitabine was administered to single-patient cohorts at escalating doses of 1500, 2000, and 2500 mg/m2/day in two equally divided doses for 14 of 21 days, beginning on day 1." | 6.71 | A pilot study of edrecolomab (Panorex, 17-1A antibody) and capecitabine in patients with advanced or metastatic adenocarcinoma. ( Fehn, K; Landau, L; Makower, D; Mani, S; Sparano, JA; Versola, M; Wadler, S; Wissel, P, 2003) |
| "The pharmacokinetics of ftorafur, 5-fluorouracil (5FU) and uracil were investigated in order to built a population pharmacokinetic model for the anticancer drug UFT, administered with leucovorin and vinorelbine." | 6.71 | Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancer. ( Bonneterre, J; Campone, M; Deporte-Fety, R; Fargeot, P; Fumoleau, P; Kerbrat, P; Urien, S, 2003) |
| " The purpose of the current study was to determine whether dose intensification of parenteral hydroxyurea in combination with fluorouracil could enhance the response rates of the combination against refractory upper gastrointestinal malignancies." | 6.71 | Phase II clinical trial of parenteral hydroxyurea in combination with fluorouracil, interferon and filgrastim in the treatment of advanced pancreatic, gastric and neuroendocrine tumors. ( Haynes, H; Kaleya, R; Kaubisch, A; Rozenblit, A; Wadler, S, 2004) |
| "The purpose of our study was to determine the maximum-tolerated dose, dose-limiting toxicity, safety profile, and pharmacokinetics of the polyamine synthesis inhibitor SAM486A given in combination with 5-fluorouracil/leucovorin (5-FU/LV) in cancer patients." | 6.71 | Phase I and pharmacokinetic study of the polyamine synthesis inhibitor SAM486A in combination with 5-fluorouracil/leucovorin in metastatic colorectal cancer. ( Bootle, D; Bridgewater, J; Choi, L; de Bruijn, P; Eskens, FA; Ledermann, JA; Mueller, C; Planting, AS; Sklenar, I; Sparreboom, A; van Zuylen, L; Verweij, J, 2004) |
| "This study was originally designed as a phase I/II study, with a dose escalation of docetaxel in combination with epirubicin 50 mg m(-2) and 5-fluorouracil (5-FU) 200 mg m(-2) day(-1)." | 6.71 | Phase II study of docetaxel in combination with epirubicin and protracted venous infusion 5-fluorouracil (ETF) in patients with recurrent or metastatic breast cancer. A Yorkshire breast cancer research group study. ( Bradley, C; Crawford, SM; Dent, J; Dodwell, D; Humphreys, AC; Joffe, JK; Perren, TJ; Rodwell, S, 2004) |
| " Studies of bimonthly regimens of high-dose leucovorin (LV) and 5-fluorouracil (5-FU) by continuous infusion combined with oxaliplatin (L-OHP) have shown encouraging response rates in patients not responding to a bimonthly LV/5-FU regimen." | 6.70 | Whole-body hyperthermia (41.8 degrees C) combined with bimonthly oxaliplatin, high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer: a phase II study. ( Atanackovic, D; Corovic, A; Gruber, Y; Hegewisch-Becker, S; Hossfeld, DK; Nierhaus, A; Pichlmeier, U, 2002) |
| "Furthermore, presence of lung metastases, a primary rectal cancer and presence of lymph node metastases all predicted a better outcome in the multivariate setting." | 6.70 | Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. ( Aranda, E; Baron, B; Blijham, G; Cunningham, D; Di Costanzo, F; Glimelius, B; Hecker, H; Köhne, CH; Micheel, S; Palmer, M; Pignatti, F; Rougier, P; Scheithauer, W; Schöffski, P; Wils, J, 2002) |
| " Studies to assess the generation of progenitor cells in long-term bone marrow cultures were performed immediately preceding chemotherapy and at the end of six dosing cycles in 18 patients." | 6.69 | A randomized phase-II study of BB-10010 (macrophage inflammatory protein- 1alpha) in patients with advanced breast cancer receiving 5-fluorouracil, adriamycin, and cyclophosphamide chemotherapy. ( Clemons, MJ; Czaplewski, LG; DeTakats, P; Dexter, TM; Dougal, M; Dürig, J; Earl, H; Griffiths, A; Howell, A; Hunter, MG; Kiernan, J; Lord, BI; Marshall, E; Miles, D; Millar, A; Testa, NG; Towlson, K; Watanabe, K; Wood, LM, 1998) |
| "Metastatic breast cancer is commonly thought to be incurable." | 6.69 | The addition of paclitaxel to continuous infusion 5-fluorouracil is an active regimen for metastatic breast cancer. ( Coniglio, D; Elkordy, M; Fishman, R; Gilbert, C; Hussein, A; Matters, L; Peters, WP; Petros, W; Ross, M; Rubin, P; Vredenburgh, J, 1998) |
| "Advanced breast cancer remains a major clinical problem." | 6.68 | A phase II trial of mitoxantrone plus cyclophosphamide and 5-fluorouracil in modulation with levo-folinate for advanced breast cancer patients. ( Leonardi, V; Meli, M; Palmeri, S; Peralta, S; Rausa, L; Rini, GB; Russo, A, 1995) |
| "Site of metastases included liver (n = 16), lung (n = 7), abdomen (n = 2), pelvic recurrences (n = 2), cutaneous (n = 1)." | 6.68 | Cytarabine and cisplatin as salvage therapy in patients with metastatic colorectal cancer who failed 5-fluorouracil + folinic acid regimen. French Northern Oncology Group. ( Adenis, A; Bonneterre, J; Carlier, D; Darloy, F; Demaille, A; Pion, JM, 1995) |
| "Thirty-five patients with metastatic colorectal cancer were treated; 15 (41%) had received previous therapy, 22 (63%) had W." | 6.68 | A phase I-II trial of five-day continuous intravenous infusion of 5-fluorouracil delivered at circadian rhythm modulated rate in patients with metastatic colorectal cancer. ( Adam, R; Bismuth, H; Caussanel, JP; Jasmin, C; Lévi, F; Metzger, G; Misset, JL; Smolensky, M; Soussan, A, 1995) |
| "To determine the most effective dose of leucovorin (folinic acid [FA]) within a weekly bolus fluorouracil (FU) schedule, we conducted a randomized multicenter trial to compare therapeutic effects and toxicity of high-dose FA versus low-dose FA combined with FU at equal doses in both treatment groups." | 6.68 | Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. ( Bernhard, G; Bernhard, H; Heike, M; Jäger, E; Klein, O; Knuth, A; Lautz, D; Meyer zum Büschenfelde, KH; Michaelis, J, 1996) |
| "24 patients with advanced breast cancer entered the study: 16 aged 65-70 yrs, 4 patients 70-75 yrs, and 4 > 75 yrs." | 6.68 | Phase II study of mitoxantrone, 5-fluorouracil, and levo-leucovorin (MLF) in elderly advanced breast cancer patients. ( Caroti, C; Gallo, L; Mammoliti, S; Merlini, L, 1996) |
| "Residual metastases were surgically removed in 13 patients (26%)." | 6.68 | Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. ( Adam, R; Bertheault-Cvitkovic, F; Bismuth, H; Brienza, S; Brummer, PD; Ithzaki, M; Jami, A; Kunstlinger, F; Lévi, F; Misset, JL, 1996) |
| "5-Fluorouracil was given at an initial daily dose of 250 mg/m2 administered continuously with the aid of an elastomer, non-electronic pump through a permanent central venous line for 21 days followed by a 7-day rest." | 6.68 | Low-dose continuous intravenous infusion of 5-fluorouracil for metastatic breast cancer. ( Cavalli, F; Goldhirsch, A; Marini, G; Pesce, G; Regazzoni, S, 1996) |
| "In metastatic breast cancer patients who have had prior exposure to anthracyclines, single agents induce less than 15% and combination chemotherapy less than 20%-30% of objective responses." | 6.68 | Phase I/II study with a weekly 24-hour infusion of 5-fluorouracil plus high-dose folinic acid (HD-FU/FA) in intensively pretreated patients with metastatic breast cancer. ( Achterrath, W; Becher, R; Eberhardt, W; Harstrick, A; Hayungs, J; Klaassen, U; Losch, M; Seeber, S; Stahl, M; Vanhoefer, U; Wilke, H, 1996) |
| "These studies demonstrate that the present dose and schedule of AZT in combination with 5-FU + LV has significant activity in metastatic colorectal cancer and that the combination of 5-FU + LV with AZT increases the amount of DNA damage." | 6.68 | Maximum tolerable doses of intravenous zidovudine in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer patients. Clinical evidence of significant antitumor activity and enhancement of zidovudine-induced DNA single strand break ( Allegrini, G; Andreuccetti, M; Antonuzzo, A; Brunetti, I; Conte, PF; Danesi, R; Del Tacca, M; Falcone, A; Lencioni, M; Malvaldi, G; Pfanner, E, 1997) |
| "Amonafide is a new imide derivative of naphthalic acid." | 6.68 | Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642). ( Berkowitz, I; Berry, D; Costanza, ME; Duggan, D; Henderson, IC; Kalra, J; Lyss, AP; Ratain, MJ; Shapiro, C; Wu, K, 1995) |
| "The purpose of this study was to determine the maximal tolerable dose (MTD) of epirubicin and ADR-529 given in combination with cyclophosphamide, 5-fluorouracil, and tamoxifen." | 6.67 | The cardioprotector ADR-529 and high-dose epirubicin given in combination with cyclophosphamide, 5-fluorouracil, and tamoxifen: a phase I study in metastatic breast cancer. ( Bastholt, L; Gjedde, SB; Jakobsen, P; Mirza, MR; Mouridsen, HT; Rose, C; Sørensen, B, 1994) |
| "The fraction of breast cancer cells undergoing DNA synthesis at any one time is relatively low, which is problematic because most chemotherapeutic agents are most effective against dividing cells." | 6.67 | Randomized trial of cyclophosphamide, methotrexate, and 5-fluorouracil with or without estrogenic recruitment in women with metastatic breast cancer. ( Foley, JF; Gesme, DH; Goldberg, RM; Hartmann, LC; Hatfield, AK; Ingle, JN; Jung, SH; Krook, JE; Mailliard, JA; Veeder, MH, 1994) |
| "Sixteen patients with metastatic colorectal cancer have been treated with a regimen involving an 120 h continuous infusion of rIL-2, 18 x 10(6) iu m-2 day followed by three injections of 5FU 600 mg m-2 at weekly intervals." | 6.67 | A phase-III study of recombinant interleukin 2 and 5-fluorouracil chemotherapy in patients with metastatic colorectal cancer. ( Franks, CR; Hamblin, TJ; Oskam, R; Palmer, P; Sadullah, S; Stevenson, J; Williamson, P, 1993) |
| "Concerning bone metastases there was no difference between the two schedules in response rate, nor in the median remission duration (CAP 11, FAC 10 months)." | 6.66 | Combination of cyclophosphamide, adriamycin and platinum (CAP) versus 5-fluorouracil, adriamycin and cyclophosphamide (FAC) as primary treatment in metastatic breast cancer: results of a prospective randomized study. ( Kolarić, K; Potrebica, V; Vukas, D, 1989) |
| "Thirty-six patients with metastatic breast cancer were admitted into the study." | 6.66 | Sequential administration of cyclophosphamide, methotrexate, 5-fluorouracil, and folinic acid as salvage treatment in metastatic breast cancer. ( Amoroso, D; Ardizzoni, A; Bertelli, G; Canobbio, L; Conte, PF; Cusimano, MP; Fusco, V; Gulisano, M; Lionetto, R; Pronzato, P, 1987) |
| " The risk of mortality, therapeutic efficacy, and adverse effect were meta-analyzed." | 6.53 | Efficacy and safety of addition of bevacizumab to FOLFIRI or irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer: A meta-analysis. ( Chen, K; Gong, Y; Shen, Y; Zhang, Q; Zhou, T, 2016) |
| " Herein, we critically discuss the current data on the efficacy and safety profile of bevacizumab in combination with fluoropyrimidine-based chemotherapy for first-line and maintenance treatment of metastatic CRC and briefly comment on existing controversies and future perspectives." | 6.52 | Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer. ( Grapsa, D; Saif, MW; Syrigos, K, 2015) |
| "Capecitabine has become a standard treatment option for metastatic breast cancer, as a single agent or in combination." | 6.50 | Breast cancer, DPYD mutations and capecitabine-related ileitis: description of two cases and a review of the literature. ( Aftimos, PG; Errihani, H; Mokrim, M; Piccart-Gebhart, M, 2014) |
| "Capecitabine has previously been compared to 5-fluorouracil-either as a monotherapy or in combination with oxaliplatin, irinotecan, or biological drugs-and has been found to have comparable efficacy and safety profiles." | 6.50 | Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer? ( Aguado, C; Díaz-Rubio, E; García-Paredes, B; Sastre, J; Sotelo, MJ, 2014) |
| "Capecitabine has substantial antitumor activity in the first-line treatment of patients with MBC in prospective, randomized, phase II/III clinical trials as monotherapy and in combination with biologic and novel agents." | 6.48 | Capecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancer. ( Dalivoust, P; Debled, M; Harbeck, N; Kaufmann, M; O'Shaughnessy, JA; Robert, NJ; Siedentopf, F, 2012) |
| "Patients with breast cancer that becomes resistant to taxanes and anthracyclines experience considerable morbidity and mortality." | 6.47 | Ixabepilone for the treatment of breast cancer. ( Alvarez, RH; Hortobagyi, GN; Valero, V, 2011) |
| "Lapatinib is an oral, small-molecule, dual kinase inhibitor that targets both HER2 and the EGF receptor." | 6.45 | Lapatinib in metastatic breast cancer. ( Berton-Rigaud, D; Bourbouloux, E; Campone, M; Frenel, JS; Sadot-Lebouvier, S; Zanetti, A, 2009) |
| "Around 16% to 20% of women with breast cancer have advanced, metastasized breast cancer." | 6.45 | Lapatinib for treatment of advanced or metastasized breast cancer: systematic review. ( Ferraz, MB; Puga, ME; Riera, R; Soárez, PC, 2009) |
| " Following a pivotal trial demonstrating that capecitabine confers increased survival when used in combination with docetaxel, it is being investigated intensively in combined regimens using other standard chemotherapeutic agents, as well as with novel molecularly targeted therapies." | 6.44 | Capecitabine in combination with novel targeted agents in the management of metastatic breast cancer: underlying rationale and results of clinical trials. ( Tripathy, D, 2007) |
| " In addition, studies show that dosing flexibility with capecitabine/docetaxel allows management of side effects without compromising efficacy." | 6.42 | Optimizing the management of HER2-negative metastatic breast cancer with capecitabine (Xeloda). ( Leonard, R; Miles, D; Reichardt, P; Twelves, C, 2004) |
| "Gemcitabine has demonstrated a good efficacy in number of tumor types." | 6.41 | [Gemcitabine and breast cancer]. ( Besse, B; Spano, JP, 2002) |
| "Capecitabine is an orally administered fluoropyrimidine which is selectively activated in tumour tissue to the active moiety fluorouracil and is cytotoxic through inhibition of DNA synthesis." | 6.41 | Capecitabine: a review of its use in the treatment of advanced or metastatic colorectal cancer. ( Goa, KL; McGavin, JK, 2001) |
| "Irinotecan or CPT11 is a topoisomerase 1 inhibitor." | 6.40 | [Irinotecan monotherapy in the treatment of colorectal cancers: results of phase II trials]. ( Peeters, M; Van Cutsem, E, 1998) |
| "Irinotecan treated patients lived for significantly longer than those on 5FU: median time of survival was 10." | 6.40 | [Second-line irinotecan chemotherapy in the treatment of metastatic colorectal cancers: phase III trials]. ( Ducreux, M; Mitry, E; Rougier, P, 1998) |
| "Doxorubicin, the most active agent for breast cancer, was studied first." | 6.39 | Paclitaxel combination therapy in the treatment of metastatic breast cancer. ( Holmes, FA, 1996) |
| "This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of lapatinib for the treatment of advanced or metastatic HER2-overexpressing breast cancer based upon a review of the manufacturer's submission to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal (STA) process." | 6.24 | Lapatinib for the treatment of HER2-overexpressing breast cancer. ( Clegg, A; Jones, J; Picot, J; Takeda, A; von Keyserlingk, C, 2009) |
| "The purpose of this study was to examine the efficacy of a combination treatment of sequential irinotecan and doxifluridine, an intermediate of capecitabine, evaluated by the response rate and safety in patients with metastatic colorectal cancer." | 6.23 | A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer. ( Amano, M; Fukunaga, M; Ikeda, K; Ikeda, M; Ikenaga, M; Ishida, H; Kato, T; Mishima, H; Monden, M; Murata, K; Ohnishi, T; Ota, H; Sakamoto, J; Sekimoto, M; Tominaga, S, 2008) |
| "This study was conducted before the approval of oxaliplatin, cetuximab, and bevacizumab and was designed to evaluate a novel microtubule targeting agent, T138067, in patients with metastatic colorectal cancer (CRC) previously treated with irinotecan and 5-fluorouracil." | 6.23 | Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma. ( Bergsland, E; Berlin, JD; Lockhart, AC; Rosen, L; Rothenberg, M; Venook, A, 2008) |
| "When administered as a single agent in pretreated patients with advanced breast cancer, paclitaxel (Taxol) exhibits remarkable antitumor activity." | 6.18 | Paclitaxel as first-line treatment for metastatic breast cancer. The Taxol Investigational Trials Group, Australia and New Zealand. ( Ackland, S; Bishop, JF; Dewar, J; Goldstein, D; Gurney, H; Kennedy, I; Levi, J; Olver, IN; Stephenson, J; Tattersall, MH; Toner, GC; Walpole, E, 1997) |
| "17 patients with metastasizing colorectal cancer were treated in a phase II-study with systemic intravenous chemotherapy (Petrelli N, Proc ASCO 286, 1987) consisting of leucovorin 500 mg/m2 in a 2 hr infusion and 5-fluorouracil (5-FU) 600 mg/m2 bolus one hour after the commencement of the leucovorin infusion." | 6.16 | [5-Fluorouracil (5-FU)/leucovorin in comparison to other current chemotherapy protocols in metastasizing colorectal carcinoma]. ( Baur, M; Dittrich, C; Havelec, L; Mader, R; Marosi, C; Scheithauer, W; Schlappack, O, 1991) |
| "Cetuximab in combination with chemotherapy is a standard first-line treatment regimen for patients with metastatic colorectal cancer (mCRC) RAS wild-type (wt); however, the efficacy of cetuximab plus leucovorin, fluorouracil and oxaliplatin (FOLFOX) had never been demonstrated in a prospective, randomized, controlled phase III study." | 5.51 | [The TAILOR study establishes, in patients mCRC wt, the first line use of FOLFOX in combination with cetuximab]. ( Colombo, A; Porretto, CM; Rosati, G, 2022) |
| "Irinotecan (CPT-11) is a drug used against a wide range of tumor types." | 5.51 | Population pharmacokinetic model of irinotecan and its metabolites in patients with metastatic colorectal cancer. ( Aldaz, A; Insausti, A; Oyaga-Iriarte, E; Sayar, O, 2019) |
| " Through univariate and multivariate logistic regression analyses, factors predicting the development of serious adverse events, fatal adverse events, and toxicity-related hospitalizations were determined." | 5.51 | Predictors of toxicity-related hospitalization in four randomized studies of 5-fluorouracil-based chemotherapy in metastatic colorectal cancer. ( Abdel-Rahman, O; Ahmed, O, 2019) |
| "Adjuvant chemotherapy is used for human breast cancer patients, even after curative surgery of primary tumor, to prevent tumor recurrence primarily as a form of metastasis." | 5.48 | Involvement of Prokineticin 2-expressing Neutrophil Infiltration in 5-Fluorouracil-induced Aggravation of Breast Cancer Metastasis to Lung. ( Baba, T; Matsugo, S; Mukaida, N; Muranaka, H; Sasaki, S; Takahashi, C; Tanabe, Y, 2018) |
| "Right-sided colorectal cancer (RSCRC) were associated with reduced overall response rate (ORR) (4." | 5.46 | The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab. ( Antoniotti, C; Cascinu, S; Cremolini, C; Demurtas, L; Falcone, A; Gelsomino, F; Giampieri, R; Loretelli, C; Mandolesi, A; Masi, G; Meriggi, F; Pusceddu, V; Puzzoni, M; Scartozzi, M; Zaniboni, A; Ziranu, P, 2017) |
| "Distant metastases was the predominant site of failure, seen in 5 patients (20%)." | 5.46 | Induction Methotrexate, Cisplatin, and 5-Fluorouracil Versus Cisplatin and 5-Fluorouracil Followed by Radiotherapy in Pediatric Nasopharyngeal Carcinoma: A Retrospective Analysis in a Tertiary Cancer Center. ( Abu-Hijlih, R; Al Mousa, A; Ismael, T; Mohamad, I; Mula-Hussain, L; Salem, A; Sultan, I, 2017) |
| "Currently, metastatic colorectal cancer is treated as a homogeneous disease and only RAS mutational status has been approved as a negative predictive factor in patients treated with cetuximab." | 5.46 | Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies. ( Bibeau, F; Del Rio, M; Emile, JF; Gongora, C; Martineau, P; Mollevi, C; Robert, J; Roger, P; Selves, J; Tubiana-Mathieu, N; Vie, N; Ychou, M, 2017) |
| "Treatment with lenalidomide reduced tumor vessel density (p = 0." | 5.43 | Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity. ( Aglietta, M; Bertotti, A; Bussolino, F; Gammaitoni, L; Giraudo, E; Giraudo, L; Grignani, G; Leone, F; Leuci, V; Luraghi, P; Maione, F; Mesiano, G; Migliardi, G; Rotolo, R; Sangiolo, D; Sassi, F; Todorovic, M; Trusolino, L, 2016) |
| "We present 2 patients with metastatic colorectal cancer who had progressed despite treatment with first-line FOLFOX and second-line FOLFIRI combination chemotherapy regimens." | 5.42 | Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy. ( El-Deiry, WS; Marks, EI; Scicchitano, A; Tan, C; Yang, Z; Zhang, J; Zhou, L, 2015) |
| "The XELAVIRI trial compared sequential (fluoropyrimidine and bevacizumab; irinotecan (Iri) at progression) versus initial combination therapy (fluoropyrimidine, bevacizumab, Iri) of treatment-naïve metastatic colorectal cancer (mCRC)." | 5.41 | Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial). ( Decker, T; Denzlinger, C; Fischer von Weikersthal, L; Gießen-Jung, C; Graeven, U; Heinemann, V; Heinrich, K; Held, S; Jung, A; Kaiser, F; Kirchner, T; Kumbrink, J; Kurreck, A; Modest, DP; Neumann, J; Schenk, M; Schuster, V; Schwaner, I; Stahler, A; Stintzing, S, 2021) |
| "To evaluate pharmacokinetics, efficacy and safety of fixed-dose combination (FDC) of oral capecitabine + cyclophosphamide in metastatic breast cancer (MBC) patients progressing after anthracycline and/or taxane chemotherapy." | 5.41 | Fixed dose combination of capecitabine and cyclophosphamide in metastatic breast cancer: Results from THE ENCLOSE phase 2/3 randomized multicenter study. ( Babu, S; Bajaj, V; Bhat, G; Biswas, G; Bondarde, SA; Boya, RR; Choudhury, K; Gupta, S; Joshi, N; Khan, MA; Lakshmaiah, KC; Maksud, TM; Mamillapalli, G; Neve, RS; Patel, AA; Patel, JG; Patel, P; Patil, P; Raja, G, 2021) |
| "In locally advanced or metastatic biliary tract cancer (BTC), second-line chemotherapy is challenging after progression from first-line gemcitabine/cisplatin." | 5.41 | A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy. ( Choi, IS; Kim, JH; Kim, JS; Kim, JW; Kim, KH; Kim, YJ; Lee, JH; Park, JH; Suh, KJ, 2021) |
| "The TRICOLORE trial previously demonstrated that S-1 and irinotecan plus bevacizumab was non-inferior, based on progression-free survival (PFS), to 5-fluorouracil, leucovorin and oxaliplatin (mFOLFOX6)/capecitabine and oxaliplatin (CapeOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer (mCRC)." | 5.41 | Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III ( Baba, H; Denda, T; Gamoh, M; Ishioka, C; Iwanaga, I; Kobayashi, Y; Komatsu, Y; Kotake, M; Morita, S; Nakamura, M; Ohori, H; Sakashita, A; Sato, A; Shimada, K; Takahashi, M; Takahashi, S; Takashima, A; Tsuda, M; Yamada, Y; Yamaguchi, T; Yuki, S, 2021) |
| " Eligible patients aged ≥70 with unresectable metastatic, untreated, RAS/BRAF wildtype metastatic colorectal cancer will be randomised 1:1 to receive panitumumab alone or panitumumab plus infusional 5-fluorouracil." | 5.41 | MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG). ( Bailey, L; Briscoe, K; Burge, M; Caird, S; Chantrill, L; Cuff, J; Espinoza, D; Francesconi, A; Karapetis, C; Ladwa, R; Pavlakis, N; Price, T; Segelov, E; Shannon, J; Siu, HWD; Sjoquist, K; Srivastav, R; Steer, C; Tebbutt, N; Thavaneswaran, S; Tie, J; Wilson, K; Wuttke, M; Yip, S, 2021) |
| "Lapatinib was dissolved in water, and cholestyramine was continuously given twice a day." | 5.40 | Optimal tolerability and high efficacy of a modified schedule of lapatinib-capecitabine in advanced breast cancer patients. ( Gamucci, T; Mauri, M; Mentuccia, L; Moscetti, L; Pavese, I; Pizzuti, L; Sperduti, I; Vaccaro, A; Vici, P; Zampa, G, 2014) |
| "Cholangiocarcinoma is categorized into intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC)." | 5.40 | Efficacy of hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic pegylated interferon α-2b for advanced intrahepatic cholangiocarcinoma. ( Kasai, K; Kasai, Y; Kooka, Y; Miyamoto, Y; Oikawa, K; Oikawa, T; Sawara, K; Suzuki, A; Suzuki, Y; Takikawa, Y; Ushio, A, 2014) |
| "Colorectal cancer metastasis is a major cause of mortality worldwide, which may only be controlled with novel methods limiting tumor dissemination and chemoresistance." | 5.40 | Unbiased proteomic and transcript analyses reveal that stathmin-1 silencing inhibits colorectal cancer metastasis and sensitizes to 5-fluorouracil treatment. ( Chung, MC; Lim, TK; Tan, HT; Tan, XF; Wu, W, 2014) |
| "Prognosis of metastatic breast cancer is poor with a 5-year survival rate of 21%." | 5.40 | Simultaneous 24 h-infusion of high-dose 5-fluorouracil and sodium-folinate as alternative to capecitabine in advanced breast cancer. ( Friedrich, M; Kummer, S; Terjung, A, 2014) |
| " All patients were genotyped for MTHFR 1298A>C and 677C>T polymorphisms and analysed in both cohorts separately for the association between the MTHFR genotype and incidence of grade 3-4 overall toxicity and specific adverse events, as well as efficacy parameters." | 5.39 | MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer. ( Gelderblom, H; Guchelaar, HJ; Punt, CJ; van Huis-Tanja, LH, 2013) |
| "Chemoresistance of breast cancer is a worldwide problem for breast cancer and the resistance to chemotherapeutic agents frequently led to the subsequent recurrence and metastasis." | 5.39 | 53BP1 sensitizes breast cancer cells to 5-fluorouracil. ( Kong, X; Li, X; Wang, Y; Yan, S; Yang, Q, 2013) |
| "Elderly patients with metastatic colorectal cancer (mCRC) differ from the general population and are underrepresented in clinical trials." | 5.39 | Oxaliplapin and capecitabine (XELOX) based chemotherapy in the treatment of metastatic colorectal cancer: the right choice in elderly patients. ( Aprile, G; Bearz, A; Berretta, M; Borsatti, E; Canzonieri, V; Ferrari, L; Fiorica, F; Fisichella, R; Foltran, L; Lestuzzi, C; Lleshi, A; Lutrino, S; Nasti, G; Talamini, R; Tirelli, U; Urbani, M, 2013) |
| ", Salt Lake City, UT) that measures plasma 5-FU concentration and reports an AUC in mg · h/L has been developed to optimize therapy using pharmacokinetic (PK) dosing." | 5.38 | Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6. ( Grier, CE; Hamilton, SA; Haregewoin, A; Kaldate, RR; McLeod, HL, 2012) |
| " We also observed bioavailability of ursolic acid in the serum and tissue of animals." | 5.38 | Ursolic acid inhibits growth and metastasis of human colorectal cancer in an orthotopic nude mouse model by targeting multiple cell signaling pathways: chemosensitization with capecitabine. ( Aggarwal, BB; Baladandayuthapani, V; Deorukhkar, A; Diagaradjane, P; Guha, S; Kannappan, R; Krishnan, S; Prasad, S; Reuter, S; Sung, B; Wei, C; Yadav, VR, 2012) |
| " Recently, fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) demonstrated their superiority in first-line therapy." | 5.38 | Influcence of localization of primary tumor on effectiveness of 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: a retrospective study. ( Chauffert, B; Gentil, J; Ghiringhelli, F; Lorgis, V, 2012) |
| "Squamous cell cancer of the anal canal (anal cancer) is a rare disease but with worldwide increasing incidence." | 5.37 | Single-agent paclitaxel in advanced anal cancer after failure of cisplatin and 5-fluorouracil chemotherapy. ( Abbas, A; Fakih, M; Nehme, E, 2011) |
| "Abdominal CT revealed metastases to para-aortic lymph node, so our diagnosis was unresectable sigmoid colon cancer." | 5.35 | [A case of sigmoid colon cancer with metastases of para-aortic lymph nodes treated with curative resection after irinotecan plus 5-fluorouracil and l-leucovorin combination chemotherapy]. ( Fukazawa, A; Hayashi, T; Konno, H; Kurachi, K; Nakajima, A; Nakamura, K; Nakamura, T; Suzuki, S, 2008) |
| " Grade 3 or 4 hematological toxicities were leukocytopenia in four patients, and neutropenia in 12 patients, while non-hematological toxicities such as nausea, anorexia and sensory neuropathy occurred in only one patient each adverse event." | 5.35 | The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer. ( Hattori, M; Honda, I; Kato, N; Kobayashi, D; Matsushita, H; Okochi, O; Tsuboi, K, 2009) |
| "The global, randomized NAPOLI-1 phase 3 trial reported a survival benefit with liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (nal-IRI+5-FU/LV) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) after previous gemcitabine-based therapy." | 5.34 | Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study. ( Bang, YJ; Belanger, B; Chen, JS; Chen, LT; Chiu, CF; Choi, HJ; Kim, JS; Lee, KH; Li, CP; Oh, DY; Park, JO; Rau, KM; Shan, YS; Shim, HJ, 2020) |
| " 130 male and 63 female eligible patients with metastatic colorectal cancer were randomized to receive chronomodulated Irinotecan with peak delivery rate at 1 of 6 clock hours staggered by 4 hours on day 1, then fixed-time chronomodulated Fluorouracil-Leucovorin-Oxaliplatin for 4 days, q3 weeks." | 5.34 | Sex-dependent least toxic timing of irinotecan combined with chronomodulated chemotherapy for metastatic colorectal cancer: Randomized multicenter EORTC 05011 trial. ( Adam, R; Ballesta, A; Bouchahda, M; Chollet, P; Focan, C; Garufi, C; Giacchetti, S; Huang, Q; Innominato, PF; Karaboué, A; Lévi, FA, 2020) |
| "To evaluate the safety and tolerability of escalating doses of selinexor plus 5-fluorouracil, leucovorin and oxaliplatin (mFOLFOX6) in metastatic colorectal cancer (mCRC) patients." | 5.34 | Selinexor (KPT-330), an Oral Selective Inhibitor of Nuclear Export (SINE) Compound, in Combination with FOLFOX in Patients with Metastatic Colorectal Cancer (mCRC) - Final Results of the Phase I Trial SENTINEL. ( Amberg, S; Bokemeyer, C; Kranich, AL; Mann, J; Nilsson, S; Papadimitriou, K; Rolfo, C; Stein, A; Theile, S, 2020) |
| "The phase III West Japan Oncology Group (WJOG) 4407G study showed noninferiority of folinic acid, bolus/continuous fluorouracil, and irinotecan plus bevacizumab to modified folinic acid, bolus/continuous fluorouracil, and oxaliplatin 6 plus bevacizumab in progression-free survival (PFS) as first-line chemotherapy for patients with metastatic colorectal cancer." | 5.34 | Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases: A post hoc analysis of the WJOG4407G phase III study. ( Hironaka, S; Hosokawa, A; Kusaba, H; Matsuda, C; Morita, S; Muro, K; Okamura, S; Shinozaki, K; Shirakawa, T; Tamura, T; Tsuda, M; Tsuda, T; Tsushima, T; Ueda, S; Yamashita, H; Yamazaki, K, 2020) |
| "Microsatellite instability is a recognised pathway of colorectal carcinogenesis responsible for about 15% of all sporadic colorectal cancers." | 5.33 | 5-fluorouracil (5FU) treatment does not influence invasion and metastasis in microsatellite unstable (MSI-H) colorectal cancer. ( Kaufman, A; Ramanathan, P; Robinson, BG; Schnitzler, M; Warusavitarne, J, 2006) |
| "Under the diagnosis of multiple lung metastases, the patient was hospitalized and received intensive chemotherapy with docetaxel 40 mg/week (day 1), 5-fluorouracil 500 mg/day (days 1-5), cisplatin 10 mg/day (days 1-5)." | 5.33 | A case of early relapsed multiple lung metastases after esophagectomy successfully treated with S-1/cisplatin therapy after docetaxel/5-fluorouracil/cisplatin therapy. ( Honda, J; Miyoshi, T; Seike, J; Tangoku, A; Umemoto, A; Yoshida, T, 2006) |
| "Fluorouracil (5-FU), leucovorin (LV) and oxaliplatin (FOLFOX) plus panitumumab therapy is a commonly used first-line chemotherapy for metastatic colorectal cancer (mCRC)." | 5.30 | SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer. ( Fukunaga, M; Kato, T; Kotaka, M; Kuramochi, H; Kuroda, H; Kurosawa, S; Minagawa, N; Mishima, H; Miura, T; Miwa, K; Munemoto, Y; Nagata, N; Nakamura, M; Noura, S; Oba, K; Sakamoto, J; Satake, H; Takahashi, M; Takahashi, T; Touyama, T, 2019) |
| " The main eligibility criterion was disease progression after bevacizumab plus fluorouracil with irinotecan or oxaliplatin in patients with wild-type KRAS exon 2 metastatic colorectal cancer." | 5.30 | Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial. ( Adenis, A; Artru, P; Bennouna, J; Bertaut, A; Borel, C; Borg, C; Bouché, O; Conroy, T; Denis, MG; Deplanque, G; des Guetz, G; François, E; Ghiringhelli, F; Hebbar, M; Hiret, S; Seitz, JF; Stanbury, T, 2019) |
| "A phase II trial (planned n=58) using second-line therapy for metastatic colorectal cancer with either oxaliplatin-based (mFOLFOX6) or irinotecan-based (FOLFIRI) combination chemotherapy and 100 mg erlotinib daily on days 3-8 after each infusion (days 1 and 2) every 14 days." | 5.30 | A Phase II Study Alternating Erlotinib With Second-line mFOLFOX6 or FOLFIRI for Metastatic Colorectal Cancer. ( Burt, A; Chen, EY; Donovan, J; Kampa-Schittenhelm, KM; Kearney, MR; Lopez, CD; Strother, J; Todd, K; Vaccaro, GM, 2019) |
| "Aflibercept in combination with 5‑fluorouracil (5‑FU)/irinotecan improves overall survival in the second‑line therapy of patients with metastatic colorectal cancer (mCRC)." | 5.30 | Efficacy of aflibercept with FOLFOX and maintenance with fluoropyrimidine as first‑line therapy for metastatic colorectal cancer: GERCOR VELVET phase II study. ( André, T; Auby, D; Bachet, JB; Bonnetain, F; Chibaudel, B; Dauba, J; De Gramont, A; Deplanque, G; Desramé, J; Dubreuil, O; Garcia, ML; Hamed, NB; Larsen, AK; Lebrun-Ly, V; Lecaille, C; Lledo, G; Louvet, C; Meurisse, A; Tijeras-Raballand, A; Tournigand, C, 2019) |
| "Curcumin is a safe and tolerable adjunct to FOLFOX chemotherapy in patients with metastatic colorectal cancer." | 5.30 | Curcumin Combined with FOLFOX Chemotherapy Is Safe and Tolerable in Patients with Metastatic Colorectal Cancer in a Randomized Phase IIa Trial. ( Barber, S; Brown, K; Foreman, N; Gescher, A; Griffin-Teall, N; Howells, LM; Irving, GRB; Iwuji, COO; Morgan, B; Patel, SR; Sidat, Z; Singh, R; Steward, WP; Thomas, AL; Walter, H, 2019) |
| "Capecitabine (Xeloda) is a rationally designed oral, tumor-selective fluoropyrimidine carbamate aimed at preferential conversion to 5-fluorouracil (5-FU) within the tumor." | 5.30 | Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. ( Banken, L; Cassidy, J; Glynne-Jones, R; Goggin, T; Reigner, B; Roos, B; Schüller, J; Twelves, C; Utoh, M; Weidekamm, E, 1999) |
| "The benefits from medical treatment in colorectal cancer are limited." | 5.28 | Reversal of resistance to doxifluridine and fluorouracil in metastatic colorectal cancer: the role of high-dose folinic acid. ( Bajetta, E; Colleoni, M; de Braud, F; Nelli, P; Nolè, F; Zilembo, N, 1992) |
| "Those with metastases in the liver or a lymphangitic pattern on chest x-ray were allowed either a single prior regimen for advanced disease or no therapy for metastatic disease if less than 1 year had elapsed since the completion of adjuvant chemotherapy." | 5.28 | Effective initial therapy of advanced breast cancer with fluorouracil and high-dose, continuous infusion calcium leucovorin. ( Akman, SA; Blevins, C; Doroshow, JH; Leong, LA; Margolin, KA; Morgan, RJ; Raschko, JW; Somlo, G, 1992) |
| "Twenty-five patients with pretreated advanced colorectal carcinoma were subjected to second-line chemotherapy with sequential high-dose methotrexate and 5-fluorouracil." | 5.28 | Second-line chemotherapy of advanced colorectal cancer with sequential high-dose methotrexate and 5-fluorouracil. ( Airoma, G; Bianco, AR; Caponigro, F; Gridelli, C; Incoronato, P; Palmieri, G; Pepe, R, 1991) |
| "Aflibercept (ziv-aflibercept) significantly improves progression-free (PFS) and overall survival (OS) when added to 5-fluorouracil, leucovorin and irinotecan (FOLFIRI), compared with FOLFIRI alone, in patients with metastatic colorectal cancer previously treated with oxaliplatin-based therapy." | 5.27 | Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial. ( Dochy, E; Lakomy, R; Macarulla, T; Magherini, E; Moiseyenko, VM; Papamichael, D; Prausova, J; Ruff, P; Soussan-Lazard, K; Van Cutsem, E; van Hazel, GA, 2018) |
| "The authors hypothesized that patients with metastatic colorectal cancer (mCRC) who had tumors with low thymidylate synthase (TS-L) expression would have a higher response rate to combined 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) plus bevacizumab (FOLFOX/Bev) than those with high TS (TS-H) expression and that combined irinotecan and oxaliplatin (IROX) plus bevacizumab (IROX/Bev) would be more effective than FOLFOX/Bev in those with TS-H tumors." | 5.27 | Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG-ACRIN Cancer Research Group (E4203). ( Benson, AB; Catalano, PJ; Cheema, PS; Chiorean, EG; Feng, Y; George, TJ; Grem, JL; Hall, MJ; Kauh, JS; Meropol, NJ; Mulcahy, MF; O'Dwyer, PJ; Saltzman, JN; Zangmeister, J, 2018) |
| "This analysis investigated the cost-effectiveness of panitumumab plus mFOLFOX6 (oxaliplatin, 5-fluorouracil, and leucovorin) compared with bevacizumab plus mFOLFOX6 in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer (mCRC)." | 5.27 | A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US. ( Christodoulopoulou, A; Garawin, T; Graham, CN; Hechmati, G; Knox, HN; Sabatelli, L; Strickler, JH, 2018) |
| "This randomized phase III trial compared hepatic arterial infusion (HAI) chemotherapy with 5-fluorouracil (5-FU) followed by uracil/tegafur (UFT) and leucovorin (LV) versus UFT/LV alone for patients with curatively resected liver metastases from colorectal cancer (CRC)." | 5.27 | A randomized phase III study of hepatic arterial infusion chemotherapy with 5-fluorouracil and subsequent systemic chemotherapy versus systemic chemotherapy alone for colorectal cancer patients with curatively resected liver metastases (Japanese Foundatio ( Aoyama, T; Asahara, T; Hirata, K; Kusano, M; Nakamori, S; Oba, K; Ohashi, Y; Okabayashi, K; Saji, S; Sakamoto, J; Tsuji, Y; Yoshikawa, T, 2018) |
| "Patients with metastatic adenocarcinoma of the pancreas or biliary tract, previously untreated or having received 1 cytotoxic regimen for advanced disease, were treated with gemcitabine 1000 mg/m intravenously (IV) over 100 minutes, cisplatin 35 mg/m IV over 30 minutes, and 5-FU 2400 mg/m IV over 48 hours on day 1 of a 14-day cycle." | 5.27 | A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers. ( Davis, EJ; Griffith, KA; Kim, EJ; McDonnell, KJ; Ruch, JM; Zalupski, MM, 2018) |
| "Mitomycin C was given to 9 patients as a third-line regimen with resulting 5 NC for 2-4 months." | 5.27 | [Sequential treatment of progressive metastatic colorectal cancer with 5-fluorouracil/folinic acid, dipyramidole and mitomycin C]. ( Farroukh, R; Gerlach, D; Hoffmann, W; Kress, M; Migeod, F; Seeber, S, 1988) |
| "Patients with hepatic metastases have 5-FU TBCs about half that of those found in patients without hepatic involvement." | 5.26 | Clearance of continuously infused 5-fluorouracil in adults having lung or gastrointestinal carcinoma with or without hepatic metastases. ( Byfield, JE; Floyd, RA; Frankel, SS; Griffiths, JC; Hornbeck, CL, 1982) |
| "Of the 14 evaluable patients (11 with breast carcinoma and three with sarcoma), one patient with breast carcinoma achieved a partial remission and a second patient with breast carcinoma remained stable." | 5.26 | Amphotericin B and combination chemotherapy in the treatment of refractory metastatic breast carcinoma and sarcoma. ( Blumenschein, GR; Buzdar, AU; Krutchik, AN; Sinkovics, JG, 1978) |
| "In evaluating response by sites of metastases, lymph nodes (30%), lung nodules (22%), and subcutaneous deposits (2/3) had the highest incidence of C." | 5.25 | An effective low-dose intermittent cyclophosphamide, methotrexate, and 5-fluorouracil treatment regimen for metastatic breast cancer. ( Catalano, RB; Creech, RH; Engstrom, PF; Mastrangelo, MJ, 1975) |
| "Fluorouracil and folinic acid with irinotecan (FOLFIRI) plus bevacizumab (BV) is widely used as second-line chemotherapy for patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidines, oxaliplatin, and BV." | 5.24 | Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab. ( Ando, M; Araida, T; Hamano, M; Hayashi, K; Hirai, E; Itabashi, M; Kameoka, S; Kawakami, K; Kuramochi, H; Nakajima, G; Okuyama, R; Yokomizo, H; Yoshimatsu, K, 2017) |
| "In Japan, oxaliplatin (OXA)/5-fluorouracil (5-FU)/leucovorin (LV)-the mFOLFOX6 regimen-is the most frequently used first-line chemotherapy backbone for metastatic colorectal cancer." | 5.24 | mFOLFOX6 Plus Panitumumab Versus 5-FU/LV Plus Panitumumab After Six Cycles of Frontline mFOLFOX6 Plus Panitumumab: A Randomized Phase II Study of Patients With Unresectable or Advanced/Recurrent, RAS Wild-type Colorectal Carcinoma (SAPPHIRE)-Study Design ( Kurosawa, S; Mishima, H; Nagata, N; Oba, K; Sakamoto, J, 2017) |
| "The aim of this multicenter, open-label, randomized phase II trial was to evaluate the efficacy of a dose-dense capecitabine and oxaliplatin (XELOX) regimen in patients with metastatic colorectal cancer (mCRC) for whom reintroduction of oxaliplatin had been planned as a third- or later-line regimen." | 5.22 | Multicenter randomized phase II clinical trial of oxaliplatin reintroduction as a third- or later-line therapy for metastatic colorectal cancer-biweekly versus standard triweekly XELOX (The ORION Study). ( Bando, H; Fujii, A; Fukunaga, M; Hata, T; Honda, M; Ishibashi, K; Kobayashi, M; Matsuda, C; Mishima, H; Munemoto, Y; Nagata, N; Oba, K; Oshiro, M; Tanaka, C; Tokunaga, Y, 2016) |
| "The study was designed to compare an anthracycline-containing regimen to a regimen combining both anthracycline and paclitaxel as adjuvant therapy for high-risk breast cancer patients." | 5.22 | 5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial. ( Accortanzo, V; Adami, F; Bighin, C; Bruzzi, P; Castiglione, F; Cavazzini, G; Conte, P; Danese, S; Del Mastro, L; Durando, A; Garrone, O; Landucci, E; Levaggi, A; Michelotti, A; Miglietta, L; Pastorino, S; Piras, M; Pronzato, P; Scotto, T, 2016) |
| "A multicenter, open-label, noncomparative, randomized phase II study (PEPCOL) was conducted to evaluate the efficacy and safety of the irinotecan or PEP02 (MM-398, nanoliposomal irinotecan) with leucovorin (LV)/5-fluorouracil (5-FU) combination as second-line treatment in patients with metastatic colorectal cancer (mCRC)." | 5.22 | PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer. ( André, T; Arbaud, C; Bachet, JB; Bennamoun, M; Bonnetain, F; Brusquant, D; Chibaudel, B; de Gramont, A; Dupuis, O; Garcia, ML; Hammel, P; Khalil, A; Larsen, AK; Louvet, C; Maindrault-Gœbel, F; Tournigand, C; Wang, YW; Yeh, CG, 2016) |
| "SIRFLOX was a randomized, multicenter trial designed to assess the efficacy and safety of adding selective internal radiation therapy (SIRT) using yttrium-90 resin microspheres to standard fluorouracil, leucovorin, and oxaliplatin (FOLFOX)-based chemotherapy in patients with previously untreated metastatic colorectal cancer." | 5.22 | SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer. ( Boucher, E; Bower, G; Cade, DN; Eliadis, P; Ferguson, T; Findlay, MP; Ganju, V; Gebski, V; Gibbs, P; Heinemann, V; Isaacs, R; Kröning, H; Moeslein, F; Peeters, M; Perez, D; Powell, A; Price, D; Ricke, J; Robinson, BA; Rodríguez, J; Shacham-Shmueli, E; Sharma, NK; Strickland, AH; Taieb, J; Thurston, K; Tichler, T; Van Buskirk, M; van Hazel, GA; Walpole, E; Wolf, I, 2016) |
| "The aim of this study was to evaluate safety and toxicity of chronomodulated capecitabine administered in the morning and at noon according to a specific time schedule (Brunch Regimen: Breakfast and Lunch) as a part of first-line XELOX chemotherapy in patients with metastatic colorectal cancer." | 5.22 | Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study. ( Ciftci, R; Iner-Koksal, U; Kaytan-Saglam, E; Namal, E; Okyar, A; Ordu, C; Pala-Kara, Z; Pilancı, KN; Saglam, S; Yucel, S, 2016) |
| "We previously showed that a sequential chemotherapy with dose-dense oxaliplatin (FOLFOX7) and irinotecan (FOLFIRI; irinotecan plus 5-fluorouracil/leucovorin) is not superior to FOLFOX4 in patients at advanced stage of colorectal cancer with liver metastases." | 5.22 | Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III Trial. ( André, T; Bonnetain, F; Brusquant, D; Chibaudel, B; de Gramont, A; Garcia-Larnicol, ML; Hamidou, Z; Hebbar, M; Hug de Larauze, M; Louvet, C, 2016) |
| "It is now widely accepted that therapeutic antibodies targeting epidermal growth factor receptor (EGFR) can have efficacy in KRAS wild-type advanced colorectal cancer (CRC) patients." | 5.22 | TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer. ( Brünner, N; Christensen, IJ; Glimelius, B; Guren, TK; Ikdahl, T; Kure, EH; Moreira, JM; Nielsen, HJ; Noer, J; Nordgaard, C; Pfeiffer, P; Sorbye, H; Tarpgaard, LS; Tveit, KM; Ørum-Madsen, MS, 2016) |
| "FIRE-3 compared first-line 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus cetuximab with FOLFIRI plus bevacizumab in patients with KRAS exon 2 wild-type metastatic colorectal cancer." | 5.22 | FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. ( Al-Batran, SE; Decker, T; Giessen-Jung, C; Heinemann, V; Heintges, T; Held, S; Jagenburg, A; Jung, A; Kahl, C; Kiani, A; Kirchner, T; Kullmann, F; Lerch, MM; Lerchenmüller, C; Modest, DP; Moehler, M; Rossius, L; Scheithauer, W; Seipelt, G; Stauch, M; Stintzing, S; Vehling-Kaiser, U; von Weikersthal, LF, 2016) |
| "This randomized phase II trial compared panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) with bevacizumab plus FOLFIRI as second-line chemotherapy for wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) and to explore the values of oncogenes in circulating tumor DNA (ctDNA) and serum proteins as predictive biomarkers." | 5.22 | Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G. ( Boku, N; Denda, T; Hyodo, I; Moriwaki, T; Muro, K; Nishina, T; Nishio, K; Okuda, H; Sakai, K; Shitara, K; Takano, T; Tokunaga, S; Tsuda, M; Yamanaka, T; Yamazaki, K; Yonesaka, K, 2016) |
| " This randomized phase II study evaluated the antitumor activity and safety of icrucumab and ramucirumab each in combination with mFOLFOX-6 in patients with metastatic colorectal cancer after disease progression on first-line therapy with a fluoropyrimidine and irinotecan." | 5.22 | Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy. ( Alcindor, T; Asmis, T; Bendell, J; Berry, S; Binder, P; Burkes, R; Chan, E; Chan, T; Gao, L; Gill, S; Jeyakumar, A; Kambhampati, SR; Kauh, J; Kudrik, F; Moore, M; Nasroulah, F; Ramdas, N; Rao, S; Rothenstein, J; Spratlin, J; Strevel, E; Tang, PA; Tang, S; Yang, L; Zbuk, K, 2016) |
| "The results for efficacy and safety over the time course of the VEGF Trap (aflibercept) with irinotecan in colorectal cancer after failure of oxaliplatin regimen trial were analysed based on data from 1226 patients randomised to receive FOLFIRI plus either aflibercept (n=612) or placebo (n=614)." | 5.20 | Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy. ( Arnold, D; Bhargava, P; Chevalier, S; Cunningham, D; Ferry, DR; Hoff, PM; Lakomỳ, R; Macarulla, T; McKendrick, JJ; Moiseyenko, VM; Prausová, J; Ruff, P; Schmoll, HJ; Ten Tije, AJ; Van Cutsem, E; Van Hazel, GA; Vishwanath, RL, 2015) |
| "The aim of this study was to determine the recommended dose (RD) of a triweekly capecitabine, oxaliplatin, irinotecan, and bevacizumab (XELOXIRI/bevacizumab) regimen that was easier to administer than FOLFOXIRI/bevacizumab, using capecitabine instead of 5-fuorouracil (5-FU), in patients with metastatic colorectal cancer (mCRC)." | 5.20 | A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer. ( Furuhata, T; Hayashi, T; Hirakawa, M; Hirata, K; Iyama, S; Kato, J; Kawano, Y; Kobune, M; Miyanishi, K; Mizuguchi, T; Murase, K; Ohnuma, H; Okagawa, Y; Okita, K; Osuga, T; Sato, T; Sato, Y; Takada, K; Takahashi, M; Takimoto, R, 2015) |
| "This study was conducted to evaluate the efficacy and safety of the combination of capecitabine and oral leucovorin (LV) as a third-line chemotherapy for patients with metastatic colorectal cancer (CRC) showing resistance to irinotecan- and oxaliplatin-containing regimens." | 5.20 | A phase II study of capecitabine and oral leucovorin as a third-line chemotherapy in patients with metastatic colorectal cancer. ( Choi, DR; Choi, YK; Han, B; Kim, BC; Kim, HS; Kim, JB; Kim, JH; Kim, KY; Song, HH; Yoon, SN; Zang, DY, 2015) |
| "We conducted a phase II trial of 5-fluorouracil and oxaliplatin combination chemotherapy as a second-line treatment in unresectable/metastatic biliary tract cancer patients who had failed gemcitabine-based chemotherapy." | 5.20 | Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer. ( Chi, KC; Hwang, IG; Jang, JS; Jun, HJ; Lee, HR; Lee, S; Nam, EM; Oh, SY; Park, JO; Park, YS; Rho, MH, 2015) |
| "The oral multikinase inhibitor regorafenib improves overall survival (OS) in patients with metastatic colorectal cancer (CRC) for which all standard treatments have failed." | 5.20 | Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial. ( Argilés, G; Benson, A; Cascinu, S; Ciardiello, F; Grunert, J; Guillén Ponce, C; Köhne, CH; Luigi Garosi, V; Macpherson, IR; Rivera, F; Saunders, MP; Sobrero, A; Strumberg, D; Tabernero, J; Van Cutsem, E; Wagner, A; Zalcberg, J, 2015) |
| " We included patients older than 18 years with previously untreated metastatic colorectal cancer, with stable disease or better after induction treatment with six 3-weekly cycles of capecitabine, oxaliplatin, and bevacizumab (CAPOX-B), WHO performance status of 0 or 1, and adequate bone marrow, liver, and renal function." | 5.20 | Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. ( Braun, HJ; Cats, A; Creemers, GJ; de Jongh, FE; Derleyn, VA; Erdkamp, FL; Erjavec, Z; Haasjes, JG; Honkoop, AH; Jansen, RL; Koopman, M; Loosveld, OJ; May, A; Mol, L; Nieboer, P; Punt, CJ; Simkens, LH; ten Tije, AJ; Tol, J; van der Hoeven, JJ; van der Torren, AM; van Tinteren, H; Wals, J, 2015) |
| " We assessed the efficacy and safety of ramucirumab versus placebo in combination with second-line FOLFIRI (leucovorin, fluorouracil, and irinotecan) for metastatic colorectal cancer in patients with disease progression during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine." | 5.20 | Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin ( Bodoky, G; Chang, SC; Ciuleanu, TE; Clingan, PR; Cohn, AL; Garcia-Alfonso, P; Garcia-Carbonero, R; Grothey, A; Kim, TW; Lonardi, S; Nasroulah, F; Obermannova, R; Portnoy, DC; Prausová, J; Simms, L; Tabernero, J; Van Cutsem, E; Yamazaki, K; Yoshino, T, 2015) |
| "Anthracycline and taxane are classes of drugs that are frequently used in the adjuvant and palliative settings of metastatic breast cancer (MBC); however, treatment failure occurs in most cases." | 5.20 | Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: an open-label, multi-center, non-comparative phase II study. ( Chang, HK; Chen, JS; Chen, YY; Lee, KD; Lin, YC; Rau, KM; Wang, CH, 2015) |
| "S-1, a novel oral prodrug of 5-fluorouracil (5-FU), and irinotecan with or without bevacizumab is known to be effective in metastatic colorectal cancer (mCRC)." | 5.20 | S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies. ( Goto, A; Ichikawa, Y; Iwasa, S; Kato, K; Matsumoto, H; Nagashima, K; Okita, NT; Shimada, Y; Yamada, Y; Yamaguchi, T; Yasui, H, 2015) |
| "This randomised, open-label, phase I/II study evaluated the efficacy and safety of nintedanib, an oral, triple angiokinase inhibitor, combined with chemotherapy, relative to bevacizumab plus chemotherapy as first-line therapy in patients with metastatic colorectal cancer (mCRC)." | 5.20 | A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients. ( Bennouna, J; Bouché, O; Capdevila, J; Carrato, A; D'Haens, G; Dressler, H; Ducreux, M; Latini, L; Oum'Hamed, Z; Prenen, H; Sobrero, A; Staines, H; Studeny, M; Van Cutsem, E, 2015) |
| "In the TRIBE study, FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab significantly improved progression-free survival of patients with metastatic colorectal cancer compared with FOLFIRI (fluorouracil, leucovorin, and irinotecan) plus bevacizumab." | 5.20 | FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. ( Allegrini, G; Antoniotti, C; Boni, L; Carlomagno, C; Cazzaniga, M; Chiara, S; Cremolini, C; D'Amico, M; Falcone, A; Fontanini, G; Granetto, C; Lonardi, S; Loupakis, F; Lupi, C; Mezi, S; Ronzoni, M; Sensi, E; Tomasello, G; Tonini, G; Zaniboni, A, 2015) |
| "We evaluated the influence of RAS mutation status on the treatment effect of panitumumab in a prospective-retrospective analysis of a randomized, multicenter phase III study of panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) versus FOLFIRI alone as second-line therapy in patients with metastatic colorectal cancer (mCRC; ClinicalTrials." | 5.20 | Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer. ( André, T; Cervantes, A; Chan, E; Ciuleanu, TE; Ducreux, M; He, P; Hotko, Y; Jung, AS; Koukakis, R; Lordick, F; Oliner, KS; Patterson, SD; Peeters, M; Price, TJ; Punt, CJ; Roman, L; Sidhu, R; Sobrero, AF; Strickland, AH; Terwey, JH; Van Cutsem, E; Wilson, G; Yu, H, 2015) |
| "The purpose of this randomised phase III trial was to evaluate whether the addition of simvastatin, a synthetic 3-hydroxy-3methyglutaryl coenzyme A reductase inhibitor, to XELIRI/FOLFIRI chemotherapy regimens confers a clinical benefit to patients with previously treated metastatic colorectal cancer." | 5.20 | A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer. ( Han, SW; Hong, YS; Hwang, IG; Jung, SH; Kang, HJ; Kang, WK; Kim, HS; Kim, ST; Kim, TW; Lee, J; Lee, JY; Lee, KH; Lim, HY; Lim, SH; Park, JO; Park, SH; Park, YS, 2015) |
| "The conventional first-line chemotherapy for metastatic colorectal cancer (mCRC) consists of fluorouracil (5-FU) in combination with either oxaliplatin or irinotecan." | 5.19 | Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment. ( Guren, T; Ikdahl, T; Kjersem, JB; Kure, EH; Lingjaerde, OC; Tveit, KM, 2014) |
| "The antiangiogenic agent aflibercept (ziv-aflibercept in the United States) in combination with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) significantly improved survival in a phase III study of patients with metastatic colorectal cancer (mCRC) previously treated with an oxaliplatin-based regimen." | 5.19 | Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. ( Allegra, CJ; Chevalier, S; Ferry, DR; Lakomý, R; McKendrick, JJ; Moiseyenko, VM; Prausová, J; Ruff, P; Soussan-Lazard, K; Tabernero, J; Van Cutsem, E; van Hazel, GA, 2014) |
| "Lapatinib is approved in combination with capecitabine for treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) who have progressed on prior trastuzumab in the metastatic setting." | 5.19 | A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer. ( Brain, E; Briggs, K; Caglevic, C; Desilvio, M; Janni, W; Karaszewska, B; Marini, L; Papadimitriou, C; Pikiel, J; Potemski, P; Salat, C; Sarosiek, T; Staroslawska, E, 2014) |
| "Exposure-response (E-R) analyses for ado-trastuzumab emtansine (T-DM1, Kadcyla) were performed using data from a randomized, active control (lapatinib plus capecitabine) trial in patients with human epidermal growth factor 2-positive metastatic breast cancer." | 5.19 | Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer. ( Amiri Kordestani, L; Blumenthal, G; Booth, B; Cortazar, P; Ibrahim, A; Justice, R; Liu, Q; Mehrotra, N; Rahman, A; Schrieber, S; Song, P; Tang, S; Wang, J; Wang, Y; Xu, Q, 2014) |
| "We investigated the efficacy and safety of capecitabine and gemcitabin (GemCap) in heavily pre-treated, therapy-resistant metastatic colorectal cancer (mCRC) patients and the clinical importance of cell-free DNA (cfDNA) measurement." | 5.19 | Gemcitabine and capecitabine for heavily pre-treated metastatic colorectal cancer patients--a phase II and translational research study. ( Andersen, RF; Jakobsen, A; Pallisgaard, N; Ploen, J; Spindler, KL, 2014) |
| " This phase I study used radiolabeled huA33 in combination with capecitabine to target chemoradiation to metastatic colorectal cancer." | 5.19 | Targeted chemoradiation in metastatic colorectal cancer: a phase I trial of 131I-huA33 with concurrent capecitabine. ( Cavicchiolo, T; Chappell, B; Gill, S; Herbertson, RA; Hopkins, W; Lee, FT; Lee, ST; Murphy, R; O'Keefe, GJ; Poon, A; Saunder, T; Scott, AM; Scott, FE; Tebbutt, NC, 2014) |
| "The MTD of (90)Y delivered in conjunction with capecitabine in the setting of intrahepatic cholangiocarcinoma or metastatic disease confined to the liver exceeds 170 Gy." | 5.19 | Chemoradiation of hepatic malignancies: prospective, phase 1 study of full-dose capecitabine with escalating doses of yttrium-90 radioembolization. ( Benson, AB; Gates, VL; Habib, A; Hickey, R; Kircher, S; Lewandowski, RJ; Mulcahy, MF; Newman, S; Nimeiri, H; Salem, R; Vouche, M, 2014) |
| "Irinotecan, leucovorin, and bolus and continuous-infusion 5-fluorouracil administered every two weeks (FOLFIRI regimen) is active in patients with metastatic colorectal cancer." | 5.19 | Phase I study of combination therapy with irinotecan, leucovorin, and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for advanced colorectal cancer in Japanese patients. ( Arai, T; Goto, A; Hamaguchi, T; Muro, K; Sasaki, Y; Shimada, Y; Shirao, K; Ura, T; Yamada, Y, 2014) |
| " Three of six patients in cohort 2B-1 experienced grade 3 mucositis, and further study of the combination of everolimus, mFOLFOX6 and panitumumab was aborted." | 5.19 | A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors. ( Bernard, S; Davies, JM; Dees, EC; Goldberg, RM; Ivanova, A; Keller, K; McRee, AJ; O'Neil, BH; Sanoff, HG, 2014) |
| " From August 2012 to August 2013, 34 patients with pathologically documented advanced colorectal cancer (T3/T4 with metastases or nodal status up to N3) and measurable metastatic disease, who required palliative chemotherapy based on the combination of 5-fluorouracil, oxaliplatin and irinotecan, were prospectively recruited in this study." | 5.19 | Association between chemotherapy and plasma adipokines in patients with colorectal cancer. ( Kasperczyk, S; Malinowska-Borowska, J; Nowak, P; Rogalska, A; Świętochowska, E; Słomian, G, 2014) |
| " A phase II study was conducted to determine the feasibility of a dose-intense two weekly schedule of capecitabine, oxaliplatin, and bevacizumab in metastatic colorectal cancer (mCRC)." | 5.19 | Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study. ( Adams, J; Deva, S; Findlay, MP; Hinder, VA; Isaacs, R; Jackson, CG; O'Donnell, A; Perez, DJ; Robinson, BA; Sharples, K; Thompson, PI, 2014) |
| "Neratinib in combination with capecitabine had a manageable toxicity profile and showed promising antitumor activity in patients with HER2-positive metastatic breast cancer pretreated with trastuzumab and lapatinib." | 5.19 | Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. ( Baselga, J; Cortés, J; Garcia-Saenz, JA; Germa, C; Harb, W; Kiger, C; Kim, SB; Martin, M; Moroose, R; Pluard, T; Saura, C; Wang, K; Xu, B, 2014) |
| "This phase II study aims to evaluate the efficacy and safety of biweekly cetuximab in combination with oxaliplatin, leucovorin, and fluorouracil (FOLFOX-4) as first-line treatment of metastatic wild-type KRAS colorectal cancer." | 5.19 | Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study). ( Alonso, V; Cirera, L; Fernandez-Plana, J; Mendez, M; Pericay, C; Quintero, G; Saigi, E; Salgado, M; Salud, A, 2014) |
| "We report updated progression-free survival (PFS) and overall survival (OS) data from a trial that compared capecitabine plus oxaliplatin (CapeOX) versus S-1 plus oxaliplatin (SOX) for the first-line treatment of metastatic colorectal cancer." | 5.19 | S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial. ( Baek, JY; Cho, SH; Chung, IJ; Hong, YS; Jo, SJ; Kang, HJ; Kim, JH; Kim, KP; Kim, ST; Kim, SY; Kim, TW; Lee, J; Lee, JW; Lee, KH; Lee, KW; Lim, HY; Park, YS; Shin, DB; Shin, SJ, 2014) |
| "The purpose of this phase II study was to evaluate the safety and efficacy of weekly irinotecan and capecitabine (wXELIRI) treatment in patients with metastatic colorectal cancer, specifically the rate of severe diarrhea." | 5.19 | Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients. ( Chen, Z; Guo, W; Li, J; Li, W; Liu, T; Shen, L; Xu, J; Zhang, W; Zhu, X, 2014) |
| "Elderly patients with previously untreated metastatic colorectal cancer (mCRC) were randomly assigned to receive fluorouracil (FU) -based chemotherapy either alone or in combination with irinotecan (IRI) in the Fédération Francophone de Cancérologie Digestive (FFCD) 2001-02 study." | 5.17 | Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients. ( Aparicio, T; Bouché, O; Breysacher, G; Charneau, J; Cretin, J; Gargot, D; Gasmi, M; Jouve, JL; Le Brun-Ly, V; Lecomte, T; Locher, C; Mitry, E; Ramdani, M; Seitz, JF; Stefani, L; Subtil, F; Teillet, L, 2013) |
| "Combinations of trastuzumab with paclitaxel or capecitabine are effective therapies in human epidermal growth factor 2 (HER2)-positive metastatic breast cancer (MBC)." | 5.17 | Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer. ( Benekli, M; Berk, V; Buyukberber, S; Coskun, U; Demirci, U; Ozkan, M; Sevinc, A; Tonyali, O; Ucgul, E; Uncu, D; Yildiz, R, 2013) |
| "The pro-drug capecitabine is approved for treatment of anthracycline- and paclitaxel-resistant metastatic breast cancer." | 5.17 | Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer. ( Armstrong, DK; Connolly, RM; Davidson, NE; Fetting, JH; Garrett-Mayer, E; Hoskins, JM; Jeter, SC; McLeod, HL; Rudek, MA; Stearns, V; Watkins, SP; Wolff, AC; Wright, LA; Zhao, M, 2013) |
| " In this study, we determined the dose, efficacy, and tolerability of irinotecan according to UGT1A1 genotypes when combined with capecitabine in patients with metastatic colorectal cancer." | 5.17 | A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer. ( Bae, KS; Chang, HM; Hong, YS; Kang, YK; Kim, HS; Kim, KP; Kim, TW; Lee, JL; Lee, JS; Shin, JG; Sym, SJ, 2013) |
| "Palliative chemotherapy with cisplatin/5-fluorouracil (5FU) is the commonest regimen employed for metastatic and recurrent head and neck squamous cell carcinoma (SCCHN) and nasopharyngeal carcinoma (NPC)." | 5.17 | Carboplatin/5-fluorouracil as an alternative to cisplatin/5- fluorouracil for metastatic and recurrent head and neck squamous cell carcinoma and nasopharyngeal carcinoma. ( Aslan, NM; Chee Ee Phua, V; Ismail, F; Kua, VF, 2013) |
| "To investigate the safety and efficacy of pemetrexed combined with chemotherapy as second or third line in patients with stage IV colorectal cancer (CRC)." | 5.17 | Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer. ( Cao, J; Huang, XE; Liu, J; Lu, YY; Wu, XY; You, SX, 2013) |
| "The aim of this study was to evaluate 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) PET for early prediction of the standard anatomic response and survival outcomes in patients with metastatic colorectal cancer (mCRC) receiving leucovorin, 5-fluorouracil (5-FU), and oxaliplatin (FOLFOX)." | 5.17 | 3'-Deoxy-3'-18F-fluorothymidine PET for the early prediction of response to leucovorin, 5-fluorouracil, and oxaliplatin therapy in patients with metastatic colorectal cancer. ( Hong, YS; Kim, HJ; Kim, HO; Kim, JS; Kim, KP; Kim, TW; Lee, JL; Lee, SJ; Moon, DH; Oh, SJ; Ryu, JS, 2013) |
| "This study evaluated the activity of 2 schedules of erlotinib in combination with chemotherapy, and the prognostic significance of serum amphiregulin (AREG) and transforming growth factor alpha (TGFa) in metastatic colorectal cancer." | 5.17 | Intermittent versus continuous erlotinib with concomitant modified "XELOX" (q3W) in first-line treatment of metastatic colorectal cancer: correlation with serum amphiregulin and transforming growth factor alpha. ( Ahuja, A; Chan, AT; Chan, C; Chan, SL; Dattatray, RD; Ho, WM; Hui, EP; King, AD; Lau, W; Ma, BB; Mo, F; Poon, A; To, KF; Wong, SC, 2013) |
| " This randomized, multicenter, parallel-group, open-label phase II trial compared axitinib with bevacizumab each in combination with 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX) or 5-fluorouracil/leucovorin/irinotecan (FOLFIRI) for second-line treatment of metastatic colorectal cancer." | 5.17 | Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study. ( Barone, C; Bendell, JC; Bloom, J; Kim, JG; Kim, S; Pastorelli, D; Pericay, C; Ricart, AD; Rosbrook, B; Sobrero, AF; Swieboda-Sadlej, A; Tarazi, J; Tournigand, C; Wainberg, ZA, 2013) |
| "Bi-weekly dosing of paclitaxel and capecitabine seems to yield promising responses in advanced breast cancer, with an acceptable adverse-event profile." | 5.17 | Bi-weekly paclitaxel and capecitabine as a second- or third-line treatment for advanced breast cancer: a pilot study. ( Kautio, AL; Kellokumpu-Lehtinen, PL; Lehtinen, I; Tanner, M; Tuunanen, T, 2013) |
| "It was the aim of this study to evaluate maintenance therapy with bevacizumab + capecitabine following induction with bevacizumab + capecitabine + oxaliplatin (XELOX) versus bevacizumab + XELOX until progression as first-line therapy in metastatic colorectal cancer (mCRC)." | 5.17 | Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III 'Stop and Go' study results--a Turkish Oncology Group Trial. ( Buyukberber, S; Buyukunal, E; Camci, C; Cevik, D; Dane, F; Kilickap, S; Ozdener, F; Sencan, O; Uslu, R; Yalcin, S; Yilmaz, U; Zengin, N, 2013) |
| "This phase II trial investigated the efficacy of an induction regimen of bevacizumab, capecitabine plus oxaliplatin (XELOX) followed by maintenance therapy with bevacizumab plus erlotinib as first-line therapy in patients with metastatic colorectal cancer." | 5.17 | Phase II study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer. ( Alonso, V; Bustos, IA; Cirera, L; Dueñas, R; Falcó, E; García-Girón, C; Muñoz, A; Pericay, C; Rivera, F; Salud, A, 2013) |
| " The purpose of this study is to explore the interaction between vinorelbine (N) and capecitabine (X) in breast cancer cells and to compare the simultaneous or sequential administration of the two drugs in patients with metastatic breast cancer (MBC) as first-line treatment." | 5.17 | Vinorelbine and capecitabine in anthracycline- and/or taxane-pretreated metastatic breast cancer: sequential or combinational? ( Gan, Y; Gu, SY; Guo, HY; Hu, XC; Wang, BY; Wang, JL; Wang, LP; Wang, ZH; Zhang, J; Zhao, XM, 2013) |
| "We aimed to investigate the efficacy and tolerability of sorafenib combined with cisplatin and 5-fluorouracil (5-FU) in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC)." | 5.17 | Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma. ( Hu, ZH; Huang, PY; Huang, Y; Lin, SJ; Liu, JL; Liu, LZ; Ma, YX; Pan, JJ; Song, XQ; Wu, JX; Wu, X; Xu, F; Xue, C; Yu, QT; Zhang, J; Zhang, JW; Zhang, L; Zhao, HY; Zhao, LP; Zhao, YY, 2013) |
| " The present study was an open-label, sequential-cohort, dose-escalation trial of intravenous aflibercept administered every 2 weeks in combination with 5-fluorouracil, levofolinate, and irinotecan (FOLFIRI) in patients with previously treated metastatic colorectal cancer (mCRC)." | 5.17 | A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer. ( Asayama, M; Boku, N; Doi, T; Fujino, T; Machida, N; Ohtsu, A; Onozawa, Y; Yamaguchi, K; Yamazaki, K; Yoshino, T, 2013) |
| "The objective of this economic evaluation, which was based on patients from two randomized controlled clinical trials (NO16966 and NO16967), was to compare direct medical costs to the Australian health-care system of capecitabine plus oxaliplatin (XELOX) and bolus and/or infusional 5-fluorouracil (5-FU) plus folinic acid combined with oxaliplatin (modified [m] FOLFOX-6) in first-line and second-line treatment of advanced or metastatic colorectal cancer (mCRC)." | 5.17 | Pharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX-6 regimens: implications for health-care utilization in Australia. ( Gibbs, P; Hack, SP; Kerr, A; Price, T; Stokes, L; Todd, C; Tran, G, 2013) |
| "Randomised phase 3 trials in metastatic breast cancer have shown that combining bevacizumab with either paclitaxel or capecitabine significantly improves progression-free survival and response rate compared with chemotherapy alone but the relative efficacy of bevacizumab plus paclitaxel versus bevacizumab plus capecitabine has not been investigated." | 5.17 | Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. ( Beslija, S; Brodowicz, T; Greil, R; Kahan, Z; Kaufman, B; Lang, I; Melichar, B; Messinger, D; Pienkowski, T; Ryvo, L; Sirbu, D; Steger, GG; Stemmer, SM; Zielinski, C; Zvirbule, Z, 2013) |
| "To evaluate the efficacy and safety of an all-oral vinorelbine and capecitabine combination therapy in anthracycline- ± taxane-pretreated HER2/Neu-negative metastatic breast cancer (MBC)." | 5.17 | All-oral combination of vinorelbine and capecitabine as first-line treatment in HER2/Neu-negative metastatic breast cancer. ( Elghazaly, H; Rostom, Y; Tawfik, H, 2013) |
| "The combination of bevacizumab and bolus 5-fluorouracil, leucovorin and irinotecan is highly effective in patients with metastatic colorectal cancer (mCRC)." | 5.17 | Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizu ( Adenis, A; Boucher, E; Chauffert, B; Conroy, T; Ducreux, M; François, E; Ichanté, JL; Montoto-Grillot, C; Pierga, JY; Pignon, JP; Ychou, M, 2013) |
| "This double-blind, phase III study aimed to demonstrate that sunitinib plus FOLFIRI (fluorouracil, leucovorin, and irinotecan) was superior to placebo plus FOLFIRI in previously untreated metastatic colorectal cancer (mCRC)." | 5.17 | Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial. ( Bondarenko, I; Carrato, A; Christensen, JG; De la Cruz, JA; Jonker, DJ; Korytowsky, B; Lechuga, MJ; Lim, R; Lin, X; Roman, L; Shparyk, Y; Staszewska-Skurczynska, M; Sun, Y; Swieboda-Sadlej, A; Tursi, JM; Van Cutsem, E; Williams, JA, 2013) |
| " We aimed at identifying novel genetic markers that would improve prediction of irinotecan toxicity and response in advanced colorectal cancer patients treated with folic acid (leucovorin), fluorouracil (5-FU), and irinotecan (camptosar)-based regimens." | 5.17 | Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens. ( Bélanger, AS; Cecchin, E; Couture, F; Guillemette, C; Harvey, M; Innocenti, F; Jonker, D; Lévesque, E; Toffoli, G, 2013) |
| "In this study we evaluated the clinical efficacy and tolerability of low dose, capecitabine (500mg twice daily) together with oral cyclophosphamide (CTX) (a dose of 50mg once daily) in patients with metastatic breast cancer." | 5.16 | Metronomic chemotherapy in metastatic breast cancer: impact on VEGF. ( El Mahdy, MM; El-Arab, LR; Swellam, M, 2012) |
| " In the TEX trial, 287 patients with locally advanced or distant metastatic breast cancer were randomized to either epirubicin and paclitaxel (ET) or epirubicin, paclitaxel, and capecitabine (TEX)." | 5.16 | Health-related quality of life as prognostic factor for response, progression-free survival, and survival in women with metastatic breast cancer. ( Brandberg, Y; Einbeigi, Z; Hatschek, T; Johansson, H; Svensson, H, 2012) |
| " The primary objectives of this study were to determine the maximum tolerated dose of vandetanib with capecitabine and oxaliplatin, without and with bevacizumab, for the first line treatment of metastatic colorectal cancer (mCRC), and to define the dose limiting toxicities." | 5.16 | A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer. ( Cabebe, EC; Fisher, GA; Sikic, BI, 2012) |
| "To determine the dose-limiting toxicities (DLTs) and the maximum tolerated doses (MTD) of oral metronomic vinorelbine with capecitabine in patients with metastatic breast cancer (MBC)." | 5.16 | A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer. ( Androulakis, N; Ardavanis, A; Georgoulias, V; Kalbakis, K; Kourakos, P; Malamos, N; Mavroudis, D; Polyzos, A; Saridaki, Z; Vamvakas, L, 2012) |
| "Combination therapy with ixabepilone and capecitabine (cape) is approved for use in patients with locally advanced/metastatic breast cancer that is resistant to treatment with anthracyclines or taxanes." | 5.16 | Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer. ( Bell, JA; Conte, P; Corey-Lisle, PK; Hortobagyi, G; Mukhopadhyay, P; Orsini, L; Peck, R; Revicki, DA; Roche, H; Safikhani, S, 2012) |
| "PEFG regimen (P:cisplatin, E:epirubicin, F:5-fluorouracil, G:gemcitabine) significantly prolonged progression-free (PFS) and overall survival (OS) of patients with advanced pancreatic adenocarcinoma (PA) with respect to standard gemcitabine." | 5.16 | A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen). ( Balzano, G; Belli, C; Cappio, S; Cereda, S; Doglioni, C; Fugazza, C; Ghidini, M; Longoni, S; Nicoletti, R; Passoni, P; Reni, M; Rezzonico, S; Rognone, A; Slim, N; Villa, E, 2012) |
| "The lesions of 5 patients with multiple cutaneous metastases were treated topically, 5 days per week, with 5-fluorouracil in the morning and imiquimod at night." | 5.16 | Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil. ( Desmedt, E; Florin, V; Mortier, L; Vercambre-Darras, S, 2012) |
| "Registered dose capecitabine monotherapy is active against metastatic breast cancer (MBC), but retrospective analyses indicate that lower doses may be as effective and better tolerated." | 5.16 | Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer. ( Calvani, N; Cinefra, M; Cinieri, S; Fedele, P; Marino, A; Mazzoni, E; Nacci, A; Orlando, L; Rizzo, P; Schiavone, P; Sponziello, F, 2012) |
| "This study was intended to ascertain the feasibility of a combination therapy with irinotecan by 24-h intravenous infusion (24-h CPT-11) and 5-fluorouracil (5-FU) for patients with metastatic colorectal cancer, to estimate the dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD), to determine the recommended dose (RD) for the Phase II study, and to evaluate the efficacy of the combination therapy." | 5.16 | Phase I study of irinotecan by 24-h intravenous infusion in combination with 5-fluorouracil in metastatic colorectal cancer. ( Gamo, M; Kambe, M; Kanamaru, R; Kikuchi, H; Ohashi, Y; Yoshioka, T, 2012) |
| "Oral administration of cyclophosphamide (CTX) and capecitabine may have a greater potential for treatment of metastatic breast cancer (MBC) due to anti-angiogenesis resulting from the metronomic dosage and upregulation of thymidine phosphorylase by CTX." | 5.16 | An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study. ( Hong, X; Hu, X; Leaw, S; Lu, J; Shao, Z; Wang, J; Wang, Z, 2012) |
| "The Breast Cancer Study Group of the Hellenic Oncology Research Group conducted a phase III trial of single-agent capecitabine versus the vinorelbine/gemcitabine doublet in patients with metastatic breast cancer (MBC) pretreated with anthracyclines and taxanes." | 5.16 | A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer. ( Ardavanis, A; Boukovinas, I; Georgoulias, V; Malamos, N; Mavroudis, D; Pallis, AG; Varthalitis, I, 2012) |
| "To determine whether capecitabine schedule adaptation improves the tolerability of capecitabine-paclitaxel combination therapy for metastatic breast cancer (MBC), patients with anthracycline-pretreated HER2-negative MBC were randomized to either arm A (21-day cycles: capecitabine 1,000 mg/m(2) twice daily, days 1-14; paclitaxel 60 mg/m(2), days 1, 8, and 15) or arm B (28-day cycles: capecitabine 1,000 mg/m(2) twice daily, days 1-5, 8-12, and 15-19; paclitaxel 80 mg/m(2), days 1, 8, and 15)." | 5.16 | A GINECO randomized phase II trial of two capecitabine and weekly paclitaxel schedules in metastatic breast cancer. ( Alexandre, J; Bachelot, T; Bourgeois, H; de Rauglaudre, G; Hardy-Bessard, AC; Jaubert, D; Largillier, R; Lortholary, A; Paraiso, D, 2012) |
| "A phase I study was performed to determine the maximal tolerated dose (MTD), recommended dose (RD), safety and efficacy of vinflunine when combined with capecitabine in patients with metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes, with pharmacokinetic blood sampling to test potential drug-drug interactions." | 5.16 | A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes. ( Bonneterre, J; Bourbouloux, E; Campone, M; Fumoleau, P; Isambert, N; Milano, G; Roché, H, 2012) |
| "Molecular markers to predict response to 5-fluorouracil (FU)-based treatment of recurrent or metastasised colorectal cancer (mCRC) are not established." | 5.16 | Response prediction in metastasised colorectal cancer using intratumoural thymidylate synthase: results of a randomised multicentre trial. ( Danenberg, K; Danenberg, P; Goeb, R; Hebart, H; Henne-Bruns, D; Kornmann, M; Kron, M; Link, KH; Staib, L, 2012) |
| " This phase 2 study assessed enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab as maintenance therapy for metastatic colorectal cancer (MCRC)." | 5.16 | A double-blind, randomized, placebo-controlled, phase 2 study of maintenance enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line therapy for metastatic colorectal cancer. ( Di Bartolomeo, M; Fuchs, M; Heinemann, V; Hossain, AM; Nicol, S; Stoffregen, C; Wolff, RA, 2012) |
| "The aim of this phase III trial was to compare the efficacy and safety of bevacizumab alone with those of bevacizumab and capecitabine plus oxaliplatin (XELOX) as maintenance treatment following induction chemotherapy with XELOX plus bevacizumab in the first-line treatment of patients with metastatic colorectal cancer (mCRC)." | 5.16 | First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. ( Abad, A; Antón, A; Aranda, E; Arrivi, A; Benavides, M; Cervantes, A; Díaz-Rubio, E; Dueñas, R; Escudero, P; Fernández-Martos, C; Gallén, M; Gómez-España, A; González, E; Lacasta, A; Llanos, M; López-Ladrón, A; Losa, F; Marcuello, E; Martínez de Prado, P; Massutí, B; Rivera, F; Safont, MJ; Sastre, J; Tabernero, JM; Valladares, M, 2012) |
| "This phase II trial was conducted to determine the activity and safety of the combination of fixed-dose rate (FDR) gemcitabine and capecitabine in metastatic biliary tract cancer (BTC) patients." | 5.16 | A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients. ( Bronte, G; Catalano, V; Falcone, A; Graziano, F; Masi, G; Russo, A; Santini, D; Tonini, G; Vasile, E; Vincenzi, B; Virzi, V, 2012) |
| "Previous phase III studies raised concern about the safety of the combination of capecitabine and irinotecan in patients with metastatic colorectal cancer (mCRC)." | 5.16 | A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer. ( Chen, E; Feld, R; Knox, J; Krzyzanowska, MK; Liu, G; MacKay, H; Moore, MJ; Petronis, J; Renouf, DJ; Wang, L; Welch, S, 2012) |
| "Using the recommended doses obtained from our previous phase 1 trial of a modified Saltz chemotherapy regimen for metastatic colorectal cancer (weekly irinotecan and bolus 5-fluorouracil/l-leucovorin for 3 weeks every 28 days), we performed the present phase 2 trial to evaluate efficacy and toxicity." | 5.16 | Phase 2 study of modified irinotecan and bolus 5-fluorouracil/l-leucovorin in Japanese metastatic colorectal cancer patients. ( Akashi, K; Baba, E; Esaki, T; Fujishima, H; Kusaba, H; Makiyama, A; Mitsugi, K; Nakano, S; Tanaka, R; Uchino, K, 2012) |
| " This study aimed to determine the efficacy and tolerability of a paclitaxel and capecitabine combination in Thai patients with metastatic breast cancer (MBC) not previously treated for metastatic disease." | 5.16 | Capecitabine and weekly paclitaxel as first-line therapy in Thai patients with metastatic breast cancer. ( Chitapanarux, I; Kamnerdsupaphon, P; Lorvidhaya, V; Somwangprasert, A; Srisukho, S; Sukthomya, V; Tharavichitkul, E; Trakultivakorn, H; Watcharachan, K, 2012) |
| "The addition of irinotecan to infusional 5 fluorouracil and leucovorin significantly improves the response rate and survival compared with 5 fluorouracil/leucovorin alone in metastatic colorectal cancer." | 5.16 | First-line treatment with capecitabine combined with irinotecan in patients with advanced colorectal carcinoma: a phase II study. ( Assy, N; Basher, W; Chetver, L; Shnaider, J; Zidan, J, 2012) |
| "We conducted a multiinstitutional phase II study of capecitabine in combination with vinorelbine and trastuzumab in patients eligible to receive first- or second-line treatment for human epidermal growth factor receptor type 2 (HER2)-positive (HER2(+)) metastatic breast cancer (MBC)." | 5.16 | Phase II interventional study (N0337) of capecitabine in combination with vinorelbine and trastuzumab for first- or second-line treatment of HER2-positive metastatic breast cancer: a north central cancer treatment group trial. ( Allred, JB; Bernath, AM; Fishkin, PA; Fitch, TR; Flynn, P; Perez, EA; Salim, M; Stella, PJ; Tan, WW; Wiesenfeld, M, 2012) |
| "We report the first results from a phase II, open-label study designed to evaluate the efficacy and safety of bevacizumab in combination with trastuzumab and capecitabine as first-line therapy for human epidermal growth factor receptor (HER)-2-positive locally recurrent (LR) or metastatic breast cancer (MBC)." | 5.16 | Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer. ( Gligorov, J; Lichinitser, M; Lluch, A; Makhson, A; Martín, M; Mitchell, L; Scotto, N; Semiglazov, V; Tjulandin, S, 2012) |
| "This study aimed at assessing the efficacy and safety of biweekly oxaliplatin in combination with continuous infusional 5-fluorouracil and leucovorin (modified FOLFOX regimen) in patients with advanced small bowel adenocarcinoma (SBA)." | 5.16 | A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma. ( Feng, M; Liu, YW; Qiu, F; Xiang, XJ; Xiong, JP; Yan, J; Yu, F; Zhan, ZY; Zhang, L; Zhao, JG, 2012) |
| "005) evaluating first-line bevacizumab plus paclitaxel or capecitabine for locally recurrent or metastatic breast cancer." | 5.16 | Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer. ( Beslija, S; Brodowicz, T; Greil, R; Inbar, MJ; Kahán, Z; Kaufman, B; Lang, I; Messinger, D; Steger, GG; Stemmer, SM; Zielinski, C; Zvirbule, Z, 2012) |
| "To evaluate the maximum tolerated dose (MTD) and pharmacokinetic profile of a chronomodulated, dose-intensified regimen of capecitabine in combination with oxaliplatin (XELOX) in metastatic colorectal cancer (mCRC)." | 5.16 | Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer. ( Chen, X; Choo, SP; Chowbay, B; Farid, M; Koo, WH; Ong, SY; Ramasamy, S; Tan, SH; Toh, HC, 2012) |
| "This retrospective analysis aimed to determine whether early dose reduction impacts the efficacy of ixabepilone plus capecitabine in women with metastatic breast cancer (MBC)." | 5.16 | Maintenance of clinical efficacy after dose reduction of ixabepilone plus capecitabine in patients with anthracycline- and taxane-resistant metastatic breast cancer: a retrospective analysis of pooled data from 2 phase III randomized clinical trials. ( Bosserman, L; Gómez, H; Li, RK; Manikhas, A; Medina, C; Mukhopadhyay, P; Opatt, D; Ro, J; Sparano, JA; Thomas, E; Vahdat, L; Valero, V; Vrdoljak, E; Xu, B, 2012) |
| "To evaluate the efficacy and safety of docetaxel plus capecitabine (DC) combination as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer (MBC)." | 5.16 | A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer. ( Bozionelou, V; Georgoulias, V; Kalykaki, A; Karachaliou, N; Kontopodis, E; Mavroudis, D; Papadimitraki, E; Syrigos, K; Tryfonidis, K; Ziras, N, 2012) |
| "We performed an analysis of the efficacy of capecitabine monotherapy as maintenance treatment for metastatic breast cancer (MBC) after response to capecitabine-based chemotherapy [capecitabine plus docetaxel (XT) or vinorelbine (XN)] as a first-line or a second-line treatment." | 5.16 | Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer. ( Bian, L; Cao, Y; Huang, H; Jiang, Z; Song, S; Wang, T; Wu, S; Zhang, S, 2012) |
| "Lapatinib plus capecitabine is an effective treatment option for trastuzumab-refractory HER2-positive metastatic breast cancer." | 5.16 | Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer. ( Bang, YJ; Bates, M; Cha, Y; Haddad, M; Han, SW; Huang, W; Im, SA; Kim, TY; Lee, KS; Lie, Y; Oh, DY; Paquet, A; Park, IH; Ro, J; Sherwood, T; Weidler, J, 2012) |
| "Hand-foot syndrome (HFS) is a limiting toxicity of capecitabine, which is not life-threatening but could compromise capecitabine efficacy." | 5.16 | Incidence of hand-foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen. ( Aparicio, J; Dueñas, R; Falcó, E; Gómez-Martin, C; Irigoyen, A; Lacasta, A; Llorente, B; López, RL; Muñoz, ML; Pérez, B; Reboredo, M; Regueiro, P; Safont, MJ; Sánchez, A; Sanchez-Viñes, E; Serrano, R, 2012) |
| " HORIZON II [Cediranib (AZD2171, RECENTIN) in Addition to Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer] assessed infusional fluorouracil, leucovorin, and oxaliplatin/capecitabine and oxaliplatin (FOLFOX/CAPOX) with or without cediranib in patients with previously untreated metastatic colorectal cancer (mCRC)." | 5.16 | Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II). ( Cheng, Y; Fielding, A; Hochhaus, A; Hoff, PM; Kim, TW; Koynov, KD; Kurteva, G; Li, J; Pestalozzi, BC; Pike, L; Pintér, T; Robertson, JD; Saunders, MP; Tebbutt, NC; van Eyll, B, 2012) |
| "We randomly assigned patients with HER2-positive advanced breast cancer, who had previously been treated with trastuzumab and a taxane, to T-DM1 or lapatinib plus capecitabine." | 5.16 | Trastuzumab emtansine for HER2-positive advanced breast cancer. ( Baselga, J; Blackwell, K; Diéras, V; Fang, L; Gianni, L; Guardino, E; Krop, IE; Lu, MW; Miles, D; Oh, DY; Olsen, S; Pegram, M; Verma, S; Welslau, M, 2012) |
| "In the MACRO study, patients with metastatic colorectal cancer (mCRC) were randomised to first-line treatment with 6 cycles of capecitabine and oxaliplatin (XELOX) plus bevacizumab followed by either single-agent bevacizumab or XELOX plus bevacizumab until disease progression." | 5.16 | Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative study. ( Aranda, E; Arrivi, A; Bando, I; Benavides, M; Cervantes, A; Díaz-Rubio, E; Fernández-Martos, C; Gómez-España, A; González, E; Manzano, JL; Marcuello, E; Martínez de Prado, P; Massutí, B; Montagut, C; Reboredo, M; Rivera, F; Safont, MJ; Sastre, J, 2012) |
| "A regimen consisting of 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) is widely used in France in the first-line treatment of metastatic colorectal cancer (MCRC)." | 5.15 | Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. ( Adenis, A; Bennouna, J; Bergougnoux, L; Conroy, T; Douillard, JY; Ducreux, M; Faroux, R; Hebbar, M; Kockler, L; Lledo, G; Rebischung, C; Ychou, M, 2011) |
| "To evaluate the efficacy, safety and quality of life of a short course of oxaliplatin plus capecitabine (XELOX) followed by single-agent capecitabine in patients with previously untreated, inoperable, metastatic colorectal cancer." | 5.15 | Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study. ( Allen, J; Bentley, D; Gollins, S; Lloyd, A; Morris, J; Saunders, MP; Soe, W; Swindell, R; Taylor, MB; Valle, J; Waddell, T, 2011) |
| "Safety and efficacy of gemcitabine plus docetaxel (GD) and capecitabine plus docetaxel (CD) were compared in patients with metastatic breast cancer, where the alternate crossover monotherapy (GD→C or CD→G) was predetermined." | 5.15 | Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer. ( Ansari, RH; Brufsky, A; Cavalheiro, J; Chen, SC; De La Cruz Vargas, JA; Fein, LE; Gill, JF; Hart, LL; Kim, SB; Obasaju, CK; Orlando, M; Russell, CA; Schwartzberg, LS; Seidman, AD; Stein, RS; Stewart, JF; Tai, DF; Zhao, L, 2011) |
| "Previously untreated patients with metastatic gastroesophageal adenocarcinoma received bevacizumab 10 mg/kg, docetaxel 40 mg/m², fluorouracil 400 mg/m², leucovorin 400 mg/m² on day 1, fluorouracil 1,000 mg/m²/d × 2 days intravenous continuous infusion beginning on day 1, and cisplatin 40 mg/m² on day 3." | 5.15 | Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. ( Capanu, M; Ilson, DH; Jhawer, M; Kelsen, DP; Lefkowitz, RA; Robinson, E; Shah, MA, 2011) |
| "This study was designed to determine the efficacy and tolerability of capecitabine, oxaliplatin and bevacizumab in combination with cetuximab as first-line therapy for advanced colorectal cancer." | 5.15 | A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer. ( Aklilu, M; Ashton, J; Bendell, JC; Blobe, GC; Cushman, S; Fernando, NH; Hurwitz, HI; Morse, MA; Nixon, AB; Pang, H; Wong, NS, 2011) |
| "To evaluate the efficacy and safety of docetaxel plus thiotepa(TXT/TSPA) and docetaxel plus capecitabine(TXT/CAPE) in patients with metastatic breast cancer." | 5.15 | [Randomized clinical case-control trial for the comparison of docetaxel plus thiotepa versus docetaxel plus capecitabine in patients with metastatic breast cancer]. ( Che, L; DI, Lj; Jia, J; Jiang, Hf; Liang, X; Ren, J; Song, Gh; Wang, Xl; Yang, Hb; Yu, J; Zhang, J; Zhou, Xn; Zhu, Yl, 2011) |
| "Capecitabine has antitumor activity in metastatic breast cancer (MBC); however, its optimal dose and schedule remain unclear." | 5.15 | Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer. ( Feigin, K; Gajria, D; Geneus, S; Hudis, CA; Norton, L; Patil, S; Tan, LK; Theodoulou, M; Traina, TA, 2011) |
| "0 mg/kg q2w, concomitantly with a combination of capecitabine and oxaliplatin (XELOX) and FOLFOX-4 (oxaliplatin in combination with infusional 5-FU/LV), respectively, in patients with metastatic colorectal cancer (mCRC)." | 5.15 | A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer. ( Abt, M; Burns, I; Chen, E; Goldstein, D; Major, P; McKendrick, J; Rittweger, K; Robinson, B; Zhi, J, 2011) |
| "A combination of fluorouracil and leucovorin (5-FU/LV) with oxaliplatin (FOLFOX) is an established first-line therapy for metastatic colorectal cancer (mCRC)." | 5.15 | Modified FOLFOX6 with oxaliplatin stop-and-go strategy and oral S-1 maintenance therapy in advanced colorectal cancer: CCOG-0704 study. ( Fujiwara, M; Iwata, N; Kodera, Y; Koike, M; Nakao, A; Nakayama, G; Ohashi, N; Okuda, N; Tanaka, C; Watanabe, T; Yokoyama, H, 2011) |
| "The addition of cetuximab to irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer (mCRC) was shown to reduce the risk of disease progression and increase the chance of response in patients with KRAS wild-type disease." | 5.15 | Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. ( Cascinu, S; Celik, I; Ciardiello, F; Cunningham, D; Folprecht, G; Köhne, CH; Láng, I; Maurel, J; Nowacki, MP; Rougier, P; Schlichting, M; Shchepotin, I; Tejpar, S; Van Cutsem, E; Zubel, A, 2011) |
| "Patients with gallbladder cancer or cholangiocarcinoma were treated with the combination of gemcitabine 1,000 mg/m(2) IV over 100 min on days 1 and 8 and capecitabine 650 mg/m(2) BID PO on days 1-14, administered every 21 days." | 5.15 | A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202. ( Ahmad, SA; Blanke, CD; El-Khoueiry, AB; Gold, PJ; Holcombe, RF; Iqbal, S; Lenz, HJ; Messino, MJ; Rankin, C, 2011) |
| "To assess the efficacy of capecitabine plus docetaxel (XT) versus epirubicin plus docetaxel (ET) as first-line therapy for metastatic breast cancer (MBC)." | 5.15 | Final results of ERASME-4: a randomized trial of first-line docetaxel plus either capecitabine or epirubicin for metastatic breast cancer. ( Agostini, C; Bachelot, T; Bajard, A; Boisseau, M; Coeffic, D; Dramais, D; Ferri-Dessens, RM; Guastalla, JP; Kaphan, R; Oprea, C; Perol, D; Provencal, J; Ray-Coquard, I, 2011) |
| "The AIO KRK-0104 randomised phase II trial investigated the efficacy and safety of two capecitabine-based regimens: combination of capecitabine and irinotecan (CAPIRI) plus cetuximab (CAPIRI-C) and combination of capecitabine with oxaliplatin (CAPOX) plus cetuximab (CAPOX-C) in the first-line treatment of metastatic colorectal cancer (mCRC)." | 5.15 | Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial. ( Abenhardt, W; Decker, T; Dietzfelbinger, H; Fischer von Weikersthal, L; Giessen, C; Haberl, C; Hass, HG; Heinemann, V; Kappauf, H; Klein, S; Mittermüller, J; Moosmann, N; Oruzio, D; Puchtler, G; Schulze, M; Stauch, M; Stintzing, S; Vehling-Kaiser, U; Zellmann, K, 2011) |
| " However, circadian chronomodulated chemotherapy with 5-fluorouracil, leucovorin, and oxaliplatin (chronoFLO4) offered no survival benefit as compared with the non-time-stipulated FOLFOX2, in an international randomized trial involving patients with previously untreated metastatic colorectal cancer (EORTC 05963)." | 5.15 | Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-Fluorouracil-leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963). ( Bjarnason, GA; Carvalho, C; Focan, C; Garufi, C; Giacchetti, S; Iacobelli, S; Innominato, PF; Karaboué, A; Lévi, F; Moreau, T; Smaaland, R; Tampellini, M; Tumolo, S, 2011) |
| "The present study was done to establish a prognostic model for patients and trials using an oxaliplatin-based or irinotecan-based first-line chemotherapy in metastatic colorectal cancer." | 5.15 | Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study. ( André, T; Artru, P; Bengrine-Lefevre, L; Bonnetain, F; Chibaudel, B; de Gramont, A; Desramé, J; Larsen, AK; Louvet, C; Teixeira, L; Tournigand, C, 2011) |
| "The AIO KRK 0110/ML22011 trial is a two-arm, multicenter, open-label randomized phase III trial comparing the efficacy and safety of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in the first-line treatment of metastatic colorectal cancer." | 5.15 | A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial. ( Aubele, P; Bangerter, M; Denzlinger, C; Freiberg-Richter, J; Giessen, C; Heinemann, V; Hinke, A; Kullmann, F; Mayerle, J; Modest, DP; Moosmann, N; Schulz, C; Sieber, M; Stintzing, S; Teschendorf, C; Vehling-Kaiser, U; von Weikersthal, LF, 2011) |
| "An ancillary phase II study was conducted to study interindividual variability in cetuximab pharmacokinetics and its influence on progression-free survival (PFS) in metastatic colorectal cancer patients cotreated with irinotecan and 5-fluorouracil." | 5.15 | Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. ( Azzopardi, N; Boisdron-Celle, M; Gamelin, E; Gouilleux-Gruart, V; Lecomte, T; Morel, A; Paintaud, G; Piller, F; Ternant, D; Vignault-Desvignes, C; Watier, H, 2011) |
| "The efficacy and safety of bevacizumab with modified irinotecan, leucovorin bolus, and 5-fluorouracil intravenous infusion (mIFL) in the first-line treatment of metastatic colorectal cancer (mCRC) has not been well evaluated in randomized clinical trials in Chinese patients." | 5.15 | Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial. ( Ba, Y; Feng, FY; Guan, ZZ; He, J; Liang, J; Luo, RC; Qi, C; Qin, SK; Shen, L; Wang, D; Wang, JJ; Wang, LW; Xu, JM; Xu, RH; Yu, SY, 2011) |
| "In a multicenter, double-blind phase II trial, we compared the efficacy and safety of perifosine plus capecitabine (P-CAP) with placebo plus capecitabine (CAP) in patients with metastatic colorectal cancer (mCRC) who had progressed after as many as two prior therapies." | 5.15 | Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer. ( Bendell, JC; Campos, LT; Gardner, L; Hagenstad, C; Hermann, RC; Nemunaitis, J; Richards, DA; Sportelli, P; Vukelja, SJ, 2011) |
| " We evaluated the efficacy and safety of cetuximab plus 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX), the ERBIRINOX regimen, as first-line treatment in patients with unresectable metastatic colorectal cancer (mCRC)." | 5.15 | Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial. ( Assenat, E; Bibeau, F; Bleuse, JP; Crapez-Lopez, E; Desseigne, F; Kramar, A; Mineur, L; Portales, F; Samalin, E; Thezenas, S; Viret, F; Ychou, M, 2011) |
| "Irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI) is accepted as a reference treatment for the first-line treatment of patients with metastatic colorectal cancer (MCRC)." | 5.14 | Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the ( Aranda, E; Benavides, M; Cámara, JC; Carrato, A; Constenla, M; Díaz-Rubio, E; Dueñas, R; Gomez, A; Marcuello, E; Martinez-Villacampa, M; Massutti, B; Navarro, M; Reboredo, M; Valladares, M, 2009) |
| "Oxaliplatin, 5-fluorouracil (5-FU), and leucovorin (LV) are standard first-line treatments for patients with metastatic colorectal cancer (mCRC)." | 5.14 | Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. ( Bridgewater, J; Cassidy, J; Chan, RT; Clingan, P; Cunningham, D; Glynne-Jones, R; Koralewski, P; Mainwaring, P; Pluzanska, A; Sirohi, B; Szczylik, C; Tabah-Fisch, I; Utracka-Hutka, B; Wang, JY; Wasan, H; Zaluski, J, 2009) |
| "This study evaluated the maximum tolerated dose (MTD) and the dose limiting toxicity (DLT) of erlotinib when combined to irinotecan and capecitabine in pre-treated metastatic colorectal cancer patients." | 5.14 | Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients. ( Bajetta, E; Bajetta, R; Buzzoni, R; Di Bartolomeo, M; Dotti, KF; Ferrario, E; Galassi, M; Gevorgyan, A; Mariani, L; Venturino, P, 2009) |
| "5-Fluorouracil refractory metastatic colorectal cancer patients were intravenously treated with HA-Irinotecan (300 mg/m(2) irinotecan with 1,000 mg/m(2) HA) on day 1 of a 21-day cycle." | 5.14 | A pilot human evaluation of a formulation of irinotecan and hyaluronic acid in 5-fluorouracil-refractory metastatic colorectal cancer patients. ( Brown, TJ; Cinc, E; Fox, RM; Gibbs, P; Jennens, R; Michael, M; Ng, R; Pho, M, 2009) |
| "This phase II study was conducted to determine the efficacy and safety of capecitabine and bevacizumab in untreated elderly metastatic colorectal cancer patients." | 5.14 | A phase II study of first-line biweekly capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer. ( Fakih, MG; Khushalani, N; Mashtare, T; Puthillath, A; Romano, K; Ross, ME; Steinbrenner, L; Wilding, G; Wisniewski, M, 2009) |
| "This randomized study assessed whether the best overall response rate (ORR) of cetuximab combined with oxaliplatin, leucovorin, and fluorouracil (FOLFOX-4) was superior to that of FOLFOX-4 alone as first-line treatment for metastatic colorectal cancer." | 5.14 | Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. ( Aparicio, J; Bokemeyer, C; Bondarenko, I; de Braud, F; Donea, S; Hartmann, JT; Koralewski, P; Loos, AH; Ludwig, H; Makhson, A; Schuch, G; Stroh, C; Zubel, A, 2009) |
| " Capecitabine (CAP) and oxaliplatin (OX) are synergistic with radiotherapy (RT) and active in colorectal neoplasms." | 5.14 | Neo-adjuvant treatment of rectal cancer with capecitabine and oxaliplatin in combination with radiotherapy: a phase II study. ( Bucci, L; Cannella, L; Carlomagno, C; D'Armiento, FP; D'Armiento, MR; De Placido, S; De Stefano, A; Farella, A; Pacelli, R; Pepe, S; Pesce, G; Solla, R, 2009) |
| ") vinorelbine and capecitabine was shown to be feasible and effective in metastatic breast cancer (MBC)." | 5.14 | Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer. ( Brandely, M; Crivellari, D; Foa, P; Fougeray, R; Goldhirsch, A; Mattioli, R; Nolè, F; Pinotti, G; Verri, E, 2009) |
| "We randomly assigned 755 patients with previously untreated metastatic colorectal cancer to capecitabine, oxaliplatin, and bevacizumab (CB regimen, 378 patients) or the same regimen plus weekly cetuximab (CBC regimen, 377 patients)." | 5.14 | Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. ( Antonini, NF; Cats, A; Creemers, GJ; Dalesio, O; Dijkstra, JR; Erdkamp, FL; Koopman, M; Mol, L; Punt, CJ; Richel, DJ; Rodenburg, CJ; Schrama, JG; Sinnige, HA; Tol, J; van Groeningen, CJ; van Krieken, JH; Vink-Börger, ME; Voest, EE; Vos, AH, 2009) |
| " In this study the efficacy and safety of the fully oral combination of oral vinorelbine (Navelbine Oral) plus capecitabine (Xeloda) in metastatic breast cancer (MBC) patients pretreated with anthracycline, was evaluated." | 5.14 | A phase II trial of oral vinorelbine and capecitabine in anthracycline pretreated patients with metastatic breast cancer. ( Filip, S; Finek, J; Holubec, L; Kormunda, S; Kozevnikova, R; Pavlikova, I; Sediva, M; Sefrhansova, L; Svoboda, T; Votavova, M, 2009) |
| "Using data from a recent randomized trial, we evaluated the cost effectiveness of ixabepilone plus capecitabine versus capecitabine alone in patients with predominantly metastatic breast cancer considered to be taxane-resistant and previously treated with or resistant to an anthracycline." | 5.14 | Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. ( Anstrom, KJ; Li, Y; Reed, SD; Schulman, KA, 2009) |
| "We investigated the efficacy of cetuximab plus irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer and sought associations between the mutation status of the KRAS gene in tumors and clinical response to cetuximab." | 5.14 | Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. ( Bodoky, G; Chang Chien, CR; D'Haens, G; Folprecht, G; Hitre, E; Köhne, CH; Lim, R; Makhson, A; Nippgen, J; Pintér, T; Roh, JK; Rougier, P; Ruff, P; Schlichting, M; Stroh, C; Tejpar, S; Van Cutsem, E; Zaluski, J, 2009) |
| "This study was designed to investigate the efficacy and safety of the epidermal growth factor receptor (EGFR) inhibitor cetuximab combined with irinotecan, folinic acid (FA) and two different doses of infusional 5-fluorouracil (5-FU) in the first-line treatment of EGFR-detectable metastatic colorectal cancer." | 5.14 | Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. ( Brezault, C; Cals, L; Husseini, F; Loos, AH; Nippgen, J; Peeters, M; Raoul, JL; Rougier, P; Van Laethem, JL, 2009) |
| "Irinotecan-based chemotherapy regimens are 1 option for treatment of metastatic colorectal cancer (mCRC)." | 5.14 | Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study. ( Barrueco, J; Jackson, NA; Marshall, J; Meyerhardt, J; Mitchell, E; Soufi-Mahjoubi, R; Zhang, X, 2009) |
| "We randomly assigned patients with stage I, II, IIIA, or IIIB breast cancer to standard chemotherapy (either cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide plus doxorubicin) or capecitabine." | 5.14 | Adjuvant chemotherapy in older women with early-stage breast cancer. ( Becker, HP; Berry, DA; Burstein, HJ; Cirrincione, CT; Cohen, HJ; Dressler, LG; Gralow, JR; Grenier, D; Hart, RD; Hudis, CA; Kartcheske, PA; Kornblith, AB; Magrinat, G; Mahmood, AA; Mauer, AM; Muss, HB; Norton, L; Parker, BA; Partridge, AH; Perez, EA; Theodoulou, M; Wheeler, JD; Winer, EP; Wolff, AC, 2009) |
| "The purpose of the study was to evaluate the cost-effectiveness of capecitabine plus oxaliplatin (XELOX) compared with 5-fluorouracil/folinic acid and oxaliplatin (FOLFOX4) as first-line or second-line chemotherapy in patients with metastatic colorectal cancer." | 5.14 | Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials. ( Fukuda, T; Shiroiwa, T; Tsutani, K, 2009) |
| "This multicentre, international phase II trial evaluated the efficacy and safety profile of a first-line combination of oral vinorelbine plus capecitabine for women with metastatic breast cancer (MBC)." | 5.14 | All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial. ( Becquart, D; Bougnoux, P; Chan, A; Conte, PF; Espie, M; Majois, F; Morand, M; Tubiana-Mathieu, N; Vaissiere, N; Villanova, G, 2009) |
| "To evaluate the efficacy of bevacizumab in combination of irinotecan,fluorouracil and leucovorin for metastatic colorectal cancer treated by failed prior oxaliplatin -based regiment." | 5.14 | [Clinical research of bevacizumab in combination with irinotecan, fluorouracil and leucovorin for advanced metastatic colorectal cancer]. ( Chen, B; Chen, JZ; Cui, F; Luo, RC; Wan, C; Zheng, H, 2009) |
| "To evaluate the efficacy and safety of irinotecan combined with xeloda (CAPIRI regimen) in patients with metastatic colorectal cancer after failure of chemotherapy with oxaliplatin." | 5.14 | [Efficacy and safety of combination of irinotecan and capecitabine in patients with metastatic colorectal cancer after failure of chemotherapy with oxaliplatin]. ( Bai, CM; Chen, SC; Cheng, YJ; Jia, N; Shao, YJ; Zhou, JF, 2009) |
| "Bevacizumab (Avastin) significantly improves overall survival (OS) and progression-free survival (PFS) when combined with first-line irinotecan (IFL) plus bolus 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic colorectal cancer (CRC)." | 5.14 | Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. ( Ackland, S; Chiara, S; Clarke, S; Gapski, J; Langer, B; Mainwaring, P; Perez-Carrión, R; Sobrero, A; Young, S, 2009) |
| "A multicenter, phase II study was conducted to evaluate the efficacy and safety of the Japanese intermittent 4-week regimen of capecitabine in patients with advanced/metastatic breast cancer." | 5.14 | Phase II study of 4-weekly capecitabine monotherapy in advanced/metastatic breast cancer. ( Aogi, K; Horikoshi, N; Kimura, M; Kusama, M; Miura, S; Noguchi, S; Nomizu, T; Shin, E; Tabei, T; Toyama, K; Yoshimoto, M; Yoshimura, N, 2010) |
| "This phase II study was designed in order to evaluate efficacy and safety of the combination of vinorelbine (VNB), fluorouracil (FU) and leucovorin (LV) in patients with metastatic breast carcinoma (MBC) previously treated with anthracyclines and taxanes." | 5.14 | Vinorelbine and fluorouracil plus leucovorin combination (ViFL) in patients with anthracycline and taxane-pretreated metastatic breast cancer: a phase II study. ( Bergnolo, P; Bianco, L; Boglione, A; Comandone, A; Cutin, SC; Dal Canton, O; Garetto, F; Inguì, M; Oliva, C; Pochettino, P, 2010) |
| "Docetaxel (T; Taxotere) with capecitabine (X) is active against metastatic breast cancer (MBC); bevacizumab (BV) has demonstrated efficacy with taxanes in the first-line setting." | 5.14 | North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer. ( Dentchev, T; Dueck, AC; Fitch, TR; Geeraerts, LH; Graham, DL; Gross, HM; Hillman, DW; Kahanic, SP; Le-Lindqwister, NA; Liu, H; Palmieri, FM; Patel, TA; Perez, EA, 2010) |
| "On the basis of clinical activity of capecitabine and gemcitabine for metastatic breast cancer, we carried out a multicenter phase II clinical trial on the combination of these two agents in advanced anthracycline-pretreated breast cancer patients." | 5.14 | Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial). ( Andrés, R; Baselga, J; Bermejo, B; Ciruelos, EM; Cortés, J; Cortés-Funes, H; García, E; Gómez, P; Lluch, A; Manso, L; Mayordomo, JI; Mendiola, C; Muñoz, M; Ojeda, B; Rodríguez, CA; Saura, C, 2010) |
| "The primary objective of this study was to determine the activity and safety profile of biweekly oxaliplatin combined with continuous oral capecitabine in the first-line treatment of metastatic colorectal cancer." | 5.14 | Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin. ( Bargagli, G; Bellan, C; Conca, R; Fiaschi, AI; Francini, E; Francini, G; Lazzi, S; Lorenzi, B; Martellucci, I; Pascucci, A; Petrioli, R, 2010) |
| "We examined the toxicity/efficacy of capecitabine with thalidomide, administered over 21-day cycles, in 24 previously treated metastatic breast cancer (MBC) patients." | 5.14 | Phase II study of capecitabine in combination with thalidomide in patients with metastatic breast cancer. ( Barton, JH; Burris, HA; Greco, FA; Hainsworth, JD; Jones, SF; Meluch, AA; Shipley, D; Yardley, DA, 2010) |
| "A dose-finding study was performed to evaluate the dose-limiting toxicity (DLT), maximum-tolerated dose (MTD) and the recommended dose (RD) of escalating the doses of capecitabine and fixed doses of irinotecan and oxaliplatin on a biweekly schedule for metastatic colorectal cancer patients (mCRC)." | 5.14 | Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis. ( Bandres, E; Bitarte, N; Chopitea, A; Gacía-Foncillas, J; Patiño-Garcia, A; Ponz-Sarvise, M; Ramirez, N; Rodríguez, J; Viudez, A; Zarate, R, 2010) |
| "Combined therapy with irinotecan/fluorouracil/levoleucovorin (calcium levofolinate) [IFL] has lost its position as the standard regimen for metastatic colorectal cancer because its toxicity and effectiveness have become controversial." | 5.14 | Modified-irinotecan/fluorouracil/levoleucovorin therapy as ambulatory treatment for metastatic colorectal cancer: results of phase I and II studies. ( Asaka, M; Fuse, N; Kato, T; Komatsu, Y; Kudo, M; Kunieda, Y; Miyagishima, T; Sakata, Y; Tateyama, M; Wakahama, O; Watanabe, M; Yuuki, S, 2010) |
| "Capecitabine is an established therapy for metastatic breast cancer." | 5.14 | Study of low-dose capecitabine monotherapy for metastatic breast cancer. ( Abe, C; Akagi, K; Masuda, N; Nakayama, T; Nishida, Y; Noguchi, S; Ogino, N; Sakamoto, J; Taguchi, T; Yoshidome, K; Yoshikawa, Y, 2010) |
| "Ixabepilone plus capecitabine demonstrated a clear activity and an acceptable safety profile in Chinese patients with anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer, and the majority of patients completed 6 cycles of the therapy with manageable neuropathy toxicities." | 5.14 | Ixabepilone plus capecitabine for Chinese patients with metastatic breast cancer progressing after anthracycline and taxane treatment. ( Fan, Y; Wang, J; Xu, B, 2010) |
| "To determine whether adding bevacizumab, with or without mitomycin, to capecitabine monotherapy improves progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) in an open-label, three-arm randomized trial." | 5.14 | Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. ( Ackland, SP; Broad, A; Chua, Y; Cummins, MM; Cunningham, D; Forgeson, G; Ganju, V; Gebski, VJ; Price, TJ; Robinson, B; Saunders, MP; Simes, RJ; Stockler, MR; Tebbutt, NC; van Hazel, GA; Wilson, K; Zalcberg, JR; Zannino, D, 2010) |
| "A phase I multicentre trial was conducted to define the recommended dose of capecitabine in combination with oxaliplatin and irinotecan (OCX) in metastatic colorectal cancer." | 5.14 | Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced/metastatic colorectal cancer: a phase I trial (SAKK 41/03). ( Cathomas, R; Köberle, D; Lanz, D; Popescu, R; Roth, A; Ruhstaller, T; Simcock, M; Uhlmann, C; von Moos, R; Widmer, L, 2010) |
| "We sought to determine whether the combination of ixabepilone plus capecitabine improved overall survival (OS) compared with capecitabine alone in patients with metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes." | 5.14 | Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. ( Conte, P; Da Costa, SC; Manikhas, A; Medina, C; Peck, R; Perez Manga, G; Poulart, V; Rixe, O; Ro, J; Rondinon, M; Rubio, G; Sparano, JA; Vrdoljak, E; Xu, B, 2010) |
| "Patients with histologically confirmed metastatic or locally advanced adenocarcinoma of the stomach or gastroesophageal junction received docetaxel 25 mg/m2 and oxaliplatin 50 mg/m2 on days 1 and 8 with capecitabine 625 mg/m2 twice daily from day 1-14, in 21-day cycles." | 5.14 | Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma. ( Aggarwal, S; Goel, G; Jauhri, M; Negi, A, 2010) |
| "To determine the recommended doses of oral vinorelbine (VN) and capecitabine (C) in metastatic breast cancer." | 5.14 | Phase I study of oral vinorelbine and capecitabine in patients with metastatic breast cancer. ( Anton, A; Bermejo, B; Casado, A; Gayo, J; Lao, J; Lluch, A; Martin, M; Muñoz, M; Paules, AB; Provencio, M, 2010) |
| "These data confirm that the combination of trastuzumab plus capecitabine and docetaxel is highly active in patients with HER-2-overexpressing anthracycline-pretreated breast cancer, offering a significant survival benefit and is well tolerated." | 5.14 | Trastuzumab plus capecitabine and docetaxel as first-line therapy for HER2-positive metastatic breast cancer: phase II results. ( Fotiou, S; Gennatas, C; Gennatas, S; Michalaki, V, 2010) |
| "This phase II study prospectively evaluated the feasibility of vinorelbine in combination with capecitabine in Chinese patients with metastatic breast cancer (MBC) pretreated with anthracyclines and taxanes." | 5.14 | Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes. ( Cai, R; Fan, Y; Li, Q; Ma, F; Wang, J; Xu, B; Yuan, P; Zhang, P, 2010) |
| "To determine activity and safety of capecitabine at a moderate dose of 2000 mg/m(2) as first-line therapy for metastatic breast cancer." | 5.14 | First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: results of the MONICA trial. ( Bauer, W; Costa, SD; Distelrath, A; Gerber, B; Hagen, V; Kaufmann, M; Kleine-Tebbe, A; Loibl, S; Maass, N; Mehta, K; Ruckhaeberle, E; Schneeweiss, A; Schrader, I; Sütterlin, MW; Tomé, O; von Minckwitz, G; Wiest, W, 2010) |
| "Vinorelbine and capecitabine are both active in breast cancer with moderate toxicity." | 5.14 | Combination of oral vinorelbine and capecitabine in the treatment of metastatic breast cancer patients previously exposed to anthracyclines: a pilot study. ( Hassan, M; Osman, MM, 2010) |
| "To demonstrate the noninferiority of capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid and oxaliplatin (FOLFOX-4) as second-line therapy in patients with metastatic colorectal cancer after prior irinotecan-based chemotherapy." | 5.13 | Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. ( Bang, YJ; Butts, C; Cox, JV; Cunningham, D; Goel, R; Gollins, S; Laguerre, S; Navarro, M; Rothenberg, ML; Siu, LL, 2008) |
| "The aim of the study was to investigate the associations between UGT1A1(*)28 genotype and (1) response rates, (2) febrile neutropenia and (3) dose intensity in patients with metastatic colorectal cancer treated with irinotecan." | 5.13 | UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study. ( Antonini, NF; Gelderblom, H; Guchelaar, HJ; Kweekel, DM; Punt, CJ; Van der Straaten, T, 2008) |
| "The aim of this study was to evaluate the efficacy and safety of capecitabine in combination with vinorelbine in patients with metastatic breast cancer (MBC) pretreated with anthracyclines and taxanes." | 5.13 | A Phase II study of capecitabine and vinorelbine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes. ( Batista, N; Cruz, J; Dómine, M; Estévez, LG; León, A; Provencio, M; Rodríguez, M; Sánchez-Rovira, P; Velasco, A, 2008) |
| "To describe the considerations leading to marketing approval of ixabepilone in combination with capecitabine and as monotherapy for the treatment of advanced breast cancer that is refractory to other chemotherapies." | 5.13 | Ixabepilone in combination with capecitabine and as monotherapy for treatment of advanced breast cancer refractory to previous chemotherapies. ( Aziz, R; Booth, B; Bullock, J; Dagher, R; Harapanhalli, R; Jiang, X; Justice, R; Kaminskas, E; Kasliwal, R; Lechleider, RJ; Leighton, J; Pazdur, R; Pope, S; Sridhara, R, 2008) |
| "The aim of this study was to determine the safety, maximum tolerated dose (MTD), recommended phase II dose, and efficacy of the epothilone B analogue ixabepilone plus capecitabine in anthracycline-pretreated/ resistant and taxane-resistant metastatic breast cancer (MBC)." | 5.13 | Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer. ( Bunnell, C; Gralow, J; Klimovsky, J; Peck, R; Poulart, V; Schwartzberg, L; Thomas, E; Vahdat, L, 2008) |
| "Patients with measurable, metastatic adenocarcinoma of the stomach or esophagogastric junction and no prior chemotherapy received oxaliplatin 85 mg/m(2), leucovorin 200 mg/m(2), and fluorouracil 2600 mg/m(2) as a 24-h infusion in combination with docetaxel 50 mg/m(2) (FLOT) on day 1 every 2 weeks." | 5.13 | Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. ( Al-Batran, SE; Atmaca, A; Clemens, MR; Fritz, M; Hartmann, JT; Hofheinz, R; Homann, N; Jäger, E; Mahlberg, R; Pauligk, C; Probst, S; Rethwisch, V; Seipelt, G; Sievert, M; Stoehlmacher, J, 2008) |
| "Patients with metastatic colorectal cancer were treated with fluorouracil, leucovorin, and irinotecan and were also given ALVAC-CEA/B7." | 5.13 | Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer. ( Benson, AB; Berinstein, NL; Caterini, J; Conry, RM; Cripps, C; Dalfen, R; Debenedette, M; Elias, I; Garett, C; Heim, WJ; Kaufman, HL; Kim-Schulze, S; Lenz, HJ; Marshall, J; Moore, M; Salha, D; Singh, D; Urba, WJ; Vogel, T; von Mehren, M; Yu, M, 2008) |
| "Our aim was to evaluate the activity and toxicity of capecitabine and cisplatin (CapCisp) combination in anthracycline- and taxane-pretreated metastatic breast cancer patients." | 5.13 | Capecitabine and cisplatin combination is an active and well-tolerated doublet in the treatment of metastatic breast carcinoma patients pretreated with anthracycline and taxanes. ( Abali, H; Budakoglu, B; Hayran, M; Oksuzoglu, B; Yildirim, N; Zengin, N, 2008) |
| "The addition of lapatinib (Tykerb/Tyverb) to capecitabine (Xeloda) delays disease progression more effectively than capecitabine monotherapy in women with previously treated HER2+ metastatic breast cancer (MBC)." | 5.13 | Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer. ( Amonkar, MM; Cameron, D; Geyer, C; Sherrill, B; Stein, S; Walker, M, 2008) |
| "We report severe skin toxicity observed in anthracycline-pretreated metastatic breast cancer patients receiving the combination of capecitabine and weekly paclitaxel." | 5.13 | Severe skin toxicity observed with the combination of capecitabine and weekly paclitaxel in metastatic breast cancer patients. ( Bosnjak, SM; Radulovic, S; Susnjar, S, 2008) |
| "To compare the time to deterioration in health-related quality of life (HRQoL) in patients with previously untreated metastatic colorectal cancer receiving a 5-fluorouracil (5-FU)-based chemotherapy regimen with or without the addition of bevacizumab (BV) in two randomized, placebo-controlled studies." | 5.13 | Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer. ( Cella, D; Holmgren, E; Hurwitz, HI; Kabbinavar, FF; Wallace, JF; Yi, J; Yost, KJ, 2008) |
| " Food and Drug Administration approved lapatinib (Tykerb tablets; GlaxoSmithKline, Philadelphia), an oral, small molecule, dual tyrosine kinase inhibitor of ErbB-2 and ErbB-1, for use in combination with capecitabine for the treatment of patients with human epidermal growth factor receptor (HER)-2-overexpressing metastatic breast cancer who had received prior therapy including an anthracycline, a taxane, and trastuzumab." | 5.13 | FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. ( Cohen, MH; Ibrahim, A; Johnson, J; Justice, R; Ko, CW; Pazdur, R; Ryan, Q; Sridhara, R, 2008) |
| "We investigated the gefitinib, 5-fluorouracil (5-FU), leucovorin and oxaliplatin (IFOX) regimen as first-line therapy in patients with metastatic colorectal cancer." | 5.13 | A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer. ( Cho, CD; Fisher, GA; Halsey, J; Kuo, T; Ramsey, M; Rouse, RV; Schwartz, E; Sikic, BI, 2008) |
| " Effects of the ABCC2 genotype on the pharmacokinetics (PK) of irinotecan and the metabolites were examined in Japanese patients with metastatic colorectal cancer receiving irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI)." | 5.13 | Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI). ( Akiyama, Y; Ando, Y; Araki, K; Endo, H; Fujita, K; Ichikawa, W; Ishida, H; Kawara, K; Matsunaga, M; Miya, T; Mizuno, K; Nagashima, F; Narabayashi, M; Sasaki, Y; Sunakawa, Y; Tanaka, R; Yamamoto, W; Yamashita, K, 2008) |
| "Since the combination of capecitabine and irinotecan has successfully been used as a first-line treatment in metastatic colorectal cancer (MCRC), we expected promising results when given as a second-line treatment to metastatic colorectal patients who had been pretreated with 5-Fluorouracil and Oxaliplatin." | 5.13 | The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer. ( Ahn, JB; Cho, BC; Choi, HJ; Chung, HC; Jeung, HC; Rha, SY; Roh, JK; Shin, SJ, 2008) |
| "To evaluate the efficacy and toxicity of a combination of intravenous vinorelbine and 5-fluorouracil (5-FU) given by continuous infusion in the treatment of metastatic breast cancer previously treated with anthracyclines and taxanes." | 5.13 | Vinorelbine and infusional 5-fluorouracil in anthracycline and taxane pre-treated metastatic breast cancer. ( Bishop, JL; Joffe, JK; Johnston, SR; McIllmurray, MB; Neave, F; O'Reilly, SM; Price, CG; Stuart, NS; Whipp, EC, 2008) |
| "A phase II trial was initiated to evaluate the efficacy and toxicity of combination chemotherapy with irinotecan (CPT-11) plus capecitabine in patients with metastatic colorectal cancer." | 5.13 | Efficacy of combination chemotherapy with irinotecan (CPT-11) plus capecitabine in patients with metastatic or advanced colorectal carcinoma--a dual-centre phase II study: the MAC-6. ( Au, GK; Chan, RT; Choi, CK; Ho, JW; Law, WL; Lui, L; Siu, S; Tung, SY, 2008) |
| " Initial results of a phase III trial demonstrated that lapatinib plus capecitabine is superior to capecitabine alone in women with HER2-positive advanced breast cancer that progressed following prior therapy including trastuzumab." | 5.13 | A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. ( Cameron, D; Campone, M; Casey, M; Chan, A; Chan, S; Crown, J; Davidson, N; Geyer, CE; Gorbounova, V; Jagiello-Gruszfeld, A; Kaufman, B; Lindquist, D; Newstat, B; Oliva, C; Paoletti, P; Pienkowski, T; Press, M; Raats, JI; Romieu, CG; Roychowdhury, D; Rubin, S; Skarlos, D; Stein, S; Viens, P, 2008) |
| "Capecitabine added to docetaxel extends survival in metastatic breast cancer (MBC) and shows additive efficacy with erlotinib in pre-clinical studies." | 5.13 | Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study. ( Baselga, J; De Rosa, F; Fettner, S; Jones, R; Rakhit, A; Trigo, JM; Twelves, C; Wright, T, 2008) |
| "We evaluated the outcome of 140 patients aged > or = 70 years of age who received first-line treatment for metastatic colorectal cancer within the German phase III trial of FUFOX (5-fluorouracil/leucovorin/oxaliplatin) versus CAPOX (capecitabine/oxaliplatin)." | 5.13 | Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer. ( Arkenau, HT; Englisch-Fritz, C; Freier, W; Graeven, U; Greil, R; Grothey, A; Hinke, A; Kretzschmar, A; Kubicka, S; Porschen, R; Schmiegel, W; Schmoll, HJ; Seufferlein, T, 2008) |
| "To evaluate the efficacy and safety of bevacizumab when added to first-line oxaliplatin-based chemotherapy (either capecitabine plus oxaliplatin [XELOX] or fluorouracil/folinic acid plus oxaliplatin [FOLFOX-4]) in patients with metastatic colorectal cancer (MCRC)." | 5.13 | Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. ( Cassidy, J; Clarke, S; Couture, F; Díaz-Rubio, E; Figer, A; Koski, S; Lichinitser, M; Rivera, F; Saltz, LB; Scheithauer, W; Sirzén, F; Wong, R; Yang, TS, 2008) |
| "To investigate the safety/tolerability of the EGFR-antibody cetuximab when added to irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) for first-line treatment in patients with metastatic colorectal cancer (mCRC)." | 5.12 | Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. ( Folprecht, G; Köhne, CH; Lutz, MP; Nolting, A; Pollert, P; Schöffski, P; Seufferlein, T, 2006) |
| "A phase I study was performed to determine the maximal tolerated dose, recommended doses (RDs), safety and efficacy of oral vinorelbine when combined with capecitabine in an all-oral chemotherapy regimen in patients with metastatic breast cancer (MBC), with pharmacokinetic blood sampling to investigate potential drug-drug interactions." | 5.12 | Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer. ( Adamoli, L; Blanchot, G; Catania, C; Goldhirsch, A; Imadalou, K; Longerey, B; Munzone, E; Nolè, F; Sanna, G, 2006) |
| "Irinotecan or oxaliplatin combined with 5-fluorouracil (5-FU) +/- folinic acid (FA) has changed the treatment standards for metastatic colorectal cancer (CRC)." | 5.12 | Irinotecan, oxaliplatin plus bolus 5-fluorouracil and low dose folinic acid every 2 weeks: a feasibility study in metastatic colorectal cancer patients. ( Bas, C; Bella, S; Chacon, M; Coppola, F; Escobar, E; Hidalgo, J; Korbenfeld, E; Martin, C; Martinez, J; Reale, M; Richardet, E; Senna, S; Smilovich, AM; Wasserman, E, 2006) |
| "We conducted a phase II study to determine the activity and tolerability of weekly paclitaxel, 5-fluorouracil (5-FU) and folinic acid plus granulocyte colony-stimulating factor (G-CSF) support in anthracycline-pre-treated or -resistant metastatic breast cancer patients." | 5.12 | Weekly paclitaxel, 5-fluorouracil and folinic acid with granulocyte colony-stimulating factor support in metastatic breast cancer patients: a phase II study. ( Agostara, B; Barni, S; Bria, E; Colella, E; Cuppone, F; D'Ottavio, AM; Frontini, L; Izzo, F; Nistico, C; Sperduti, I; Terzoli, E; Valenza, R, 2006) |
| "The purpose of this study was to evaluate the safety and activity of fixed-dose capecitabine in patients with advanced colorectal cancer and to correlate pretreatment plasma concentrations of homocysteine and serum and red cell folate with toxicity." | 5.12 | A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer. ( Beale, P; Clarke, SJ; Horvath, L; Ong, S; Rivory, L; Sharma, R, 2006) |
| "Determine the toxicity, tolerability, and pharmacokinetics of SU5416, a vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, coadministered with bolus 5-fluorouracil (5-FU), leucovorin, and irinotecan (IFL) in untreated patients with metastatic colorectal cancer." | 5.12 | Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer. ( Berlin, JD; Cropp, GF; Donnelly, E; Fleischer, AC; Hande, KR; Hannah, AL; Lockhart, AC; Rothenberg, ML; Schaaf, LJ; Schumaker, RD, 2006) |
| "To investigate the combination of erlotinib, capecitabine, and oxaliplatin in patients who were previously treated for metastatic colorectal cancer." | 5.12 | Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. ( Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; Meyerhardt, JA; Michelini, A; Ryan, DP; Sheehan, S; Vincitore, M; Zhu, AX, 2006) |
| "The aim of the study was to evaluate the safety and efficacy of the raltitrexed/5-fluorouracil/levofolinic acid combination regimen as first-line chemotherapy for elderly patients with advanced/metastatic colorectal cancer." | 5.12 | Raltitrexed plus levofolinic acid and bolus/continuous infusion 5-fluorouracil on a biweekly schedule for elderly patients with advanced colorectal carcinomas. ( Bordonaro, R; Borsellino, N; Callari, A; Caruso, M; Cicero, G; Ferraù, F; Gebbia, V; Tirrito, ML; Tralongo, P; Valenza, R; Verderame, F, 2006) |
| "To evaluate the efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer." | 5.12 | [Efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer]. ( Chen, JZ; Liao, WJ; Luo, RC; Zheng, H, 2006) |
| "We conducted two phase II trials evaluating the combination of 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) as first-line treatment in 74 metastatic colorectal cancer patients." | 5.12 | First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer. ( Allegrini, G; Andreuccetti, M; Barbara, C; Brunetti, IM; Bursi, S; Cerri, E; Cupini, S; Falcone, A; Loupakis, F; Marcucci, L; Masi, G; Murr, R; Ricci, S, 2006) |
| "This phase II study evaluated the safety and efficacy of weekly docetaxel and capecitabine in patients with metastatic breast cancer." | 5.12 | Phase II study of weekly docetaxel and capecitabine in patients with metastatic breast cancer. ( Allen, J; Hauger, M; Kendra, K; Merriman, N; Moore, T; Mrozek, E; Nadella, P; Ramaswamy, B; Rhoades, CA; Shapiro, CL; Villalona-Calero, M; Watson, H; Young, D, 2006) |
| "In a prospective study, 250 metastatic colorectal cancer patients were treated with irinotecan, fluorouracil, and leucovorin as first-line treatment." | 5.12 | The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. ( Biason, P; Boccalon, M; Bonura, S; Buonadonna, A; Cecchin, E; Corona, G; D'Andrea, M; De Pangher, V; Errante, D; Frustaci, S; Gaion, F; Galligioni, E; Giusto, M; Medici, M; Pasetto, LM; Pessa, S; Russo, A; Sandri, P; Toffoli, G, 2006) |
| "Currently, there is no standard treatment for patients with anthracycline and taxane-refractory metastatic breast cancer (MBC)." | 5.12 | Sequential therapy with capecitabine followed by vinorelbine/cisplatin in patients with anthracycline/taxane-refractory metastatic breast cancer. ( Chao, TC; Chen, PM; Hsiao, LT; Lin, PC; Wang, WS; Yang, MH; Yen, CC, 2006) |
| "Oxaliplatin (OXA) and irinotecan (IRI) are active drugs for metastatic colorectal cancer, their toxicity profiles are not overlapping, and both drugs have shown at least additivity with folinic acid-modulated 5-fluorouracil (5FU)." | 5.12 | Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer. ( Casaretti, R; Comella, P; De Rosa, V; Fiore, F; Izzo, F; Massidda, B; Palmeri, S; Putzu, C; Sandomenico, C, 2006) |
| "The aim of this phase II study was to evaluate safety and efficacy of an oxaliplatin/vinorelbine/5-fluorouracil (FON) combination in anthracycline and taxane-pretreated metastatic breast cancer patients." | 5.12 | A phase II study of an oxaliplatin/vinorelbine/5-fluorouracil combination in patients with anthracycline-pretreated and taxane-pretreated metastatic breast cancer. ( Brienza, S; Chollet, P; Coeffic, D; Cvitkovic, E; Delozier, T; Delva, R; Guastalla, JP; Levy, C; Mousseau, M; Vannetzel, JM; Yovine, A; Zazzi, ES, 2006) |
| "Capecitabine is a fluoropyrimidine carbamate that acts as a prodrug, mimics continuous infusion of 5-fluorouracil (5-FU), and has encouraging antitumor activity in women with metastatic breast cancer." | 5.12 | Capecitabine/Cyclophosphamide/Methotrexate for patients with metastatic breast cancer: a dose-finding, feasibility, and efficacy study. ( Fasolo, A; Gianni, L; Marchiano, A; Mariani, G; Moliterni, A; Petrelli, F; Valagussa, P; Zambetti, M, 2006) |
| "Irinotecan at 180 mg/m2 combined with an infusional 5-fluorouracil/leucovorin (5-FU/LV) regimen (FOLFIRI) is a standard first line therapy for metastatic colorectal cancer (mCRC)." | 5.12 | Multicentre phase II study using increasing doses of irinotecan combined with a simplified LV5FU2 regimen in metastatic colorectal cancer. ( Bressole, F; Chalbos, P; Debrigode, C; Desseigne, F; Duffour, J; Gourgou, S; Mineur, L; Pinguet, F; Poujol, S; Ychou, M, 2007) |
| "The combination chemotherapy of capecitabine and cisplatin demonstrated a promising antitumor activity with mild toxicity profile in patients with advanced biliary tract cancer." | 5.12 | Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer. ( Choi, SH; Heo, JS; Hong, YS; Hwang, IG; Kang, WK; Lee, J; Lee, SC; Lim, HY; Park, JO; Park, YS, 2007) |
| "To determine the maximum tolerated doses (MTD), toxicities, efficacy, and pharmacokinetics (PK) of gefitinib combined with irinotecan, 5-fluorouracil (5-FU) and leucovorin (IFL) in patients with previously untreated advanced colorectal cancer." | 5.12 | Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. ( Clark, JW; D'Amato, F; Dancey, J; Earle, CC; Eder, JP; Enzinger, PC; Fuchs, CS; Kinsella, K; Mayer, RJ; Meyerhardt, JA; Michelini, A; Ogino, S; Ryan, DP; Stewart, CF; Supko, JG; Zhu, AX, 2007) |
| "A phase II study was conducted to evaluate the toxicity and efficacy of irinotecan/5-fluorouracil/leucovorin (CPT-11/5-FU/LV (AIO schedule)) as salvage treatment in patients with metastatic colorectal cancer." | 5.12 | Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: a phase II trial. ( Agelaki, S; Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kourousis, C; Mavroudis, D; Pallis, A; Souglakos, J; Vardakis, N, 2007) |
| "We conducted a randomised phase II study to compare irinotecan monotherapy with irinotecan in combination with infusional 5-fluorouracil/folinic acid (5-FU/FA) regarding efficacy and safety of these regimens in second-line therapy after failed fluoropyrimidine therapy in patients with metastatic colorectal cancer (mCRC)." | 5.12 | A randomised phase II study of irinotecan in combination with 5-FU/FA compared with irinotecan alone as second-line treatment of patients with metastatic colorectal carcinoma. ( Arnold, D; Graeven, U; Heuer, T; Nusch, A; Porschen, R; Reinacher-Schick, A; Schmiegel, W, 2007) |
| "The objective of this multicenter phase III trial was to study the impact on time to treatment failure (TTF) and survival of cyclophosphamide, Adriamycin, and 5-fluorouracil (CAF) versus CAF/thiotepa, Adriamycin, vinblastine, and Halotestin (TsAVbH), a partially noncross-resistant regimen used in a rotating schedule in the treatment of hormone insensitive metastatic breast cancer in accordance with the Goldie and Coldman hypothesis." | 5.12 | Phase III study of standard combination versus rotating regimen of induction chemotherapy in patients with hormone insensitive metastatic breast cancer: an Eastern Cooperative Oncology Group Intergroup Study (E3185). ( Falkson, G; Hu, P; Osborne, CK; Pandya, KJ; Tormey, DC, 2007) |
| "To compare the use of capecitabine plus oxaliplatin (CAPOX) with infusional fluorouracil (FU)/folinic acid plus oxaliplatin (FUFOX) as first-line therapy for patients with metastatic colorectal cancer (MCRC)." | 5.12 | Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. ( Arkenau, HT; Freier, W; Graeven, U; Greil, R; Grothey, A; Hinke, A; Kretzschmar, A; Kubicka, S; Porschen, R; Schmiegel, W; Schmoll, HJ; Seufferlein, T, 2007) |
| "The aim of this phase III trial was to compare the efficacy and safety of capecitabine plus oxaliplatin (XELOX) versus Spanish-based continuous-infusion high-dose fluorouracil (FU) plus oxaliplatin (FUOX) regimens as first-line therapy for metastatic colorectal cancer (MCRC)." | 5.12 | Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Tri ( Abad, A; Aparicio, J; Aranda, E; Carrato, A; Chaves, M; Díaz-Rubio, E; Gómez-España, A; González-Flores, E; Losa, F; Massutí, B; Maurel, J; Queralt, B; Reina, JJ; Rivera, F; Sastre, J; Tabernero, J, 2007) |
| "Gefitinib, an orally active inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, combined with chemotherapy, has shown efficacy as second-line treatment for advanced colorectal cancer (CRC)." | 5.12 | First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer. ( Boselli, S; de Braud, F; Lorizzo, K; Magni, E; Martignetti, A; Massacesi, C; Santoro, L; Zampino, MG; Zaniboni, A; Zorzino, L, 2007) |
| "To evaluate the efficacy and safety of ixabepilone in patients with metastatic breast cancer (MBC) resistant to anthracycline, taxane, and capecitabine, in this multicenter, phase II study." | 5.12 | Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. ( Bosserman, L; Cai, C; Hortobagyi, GN; Lerzo, G; Mullaney, B; Peck, R; Perez, EA; Pivot, X; Thomas, E; Vahdat, L; Viens, P, 2007) |
| "In the OPTIMOX1 trial, previously untreated patients with advanced colorectal cancer were randomly assigned to two different schedules of leucovorin, fluorouracil, and oxaliplatin that were administered until progression in the control arm or in a stop-and-go fashion in the experimental arm." | 5.12 | Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. ( Abrahantes, JC; André, T; Burzykowski, T; Buyse, M; Carola, E; Cervantes, A; Chirivella, I; de Gramont, A; Etienne, PL; Figer, A; Flesch, M; Lledo, G; Louvet, C; Mineur, L; Perez-Staub, N; Quinaux, E; Rivera, F; Tabah-Fisch, I; Tournigand, C, 2007) |
| "The objective was to evaluate the efficacy and toxicity of leucovorin plus 5-fluorouracil combined with oxaliplatin (modified FOLFOX regimen) every 2 weeks on previously untreated advanced colorectal cancer patients in the Chinese population." | 5.12 | A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer. ( Qiu, F; Tang, XM; Tao, QS; Xiang, XJ; Xiong, JP; Xu, J; Yu, F; Zhang, L; Zhong, LX, 2007) |
| "An economic evaluation of the irinotecan, leucovorin, 5-fluorouracil (FOLFIRI) combination versus the irinotecan, oxaliplatin, leucovorin, 5-fluorouracil (FOLFOXIRI) regimen in patients with metastatic colorectal cancer was performed in the context of a randomised phase III study." | 5.12 | Economic analysis of a multicentre, randomised, phase III trial comparing FOLFOXIRI with FOLFIRI in patients with metastatic colorectal cancer in Greece. ( Fragoulakis, V; Georgoulias, V; Maniadakis, N; Pallis, A; Prezerakos, P, 2007) |
| "To assess activity and safety of an experimental combination of irinotecan and oxaliplatin (IRINOX) as first-line treatment in advanced colorectal cancer." | 5.12 | A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5 FU2 + irinotecan or LV5 FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study ( Adenis, A; Bécouarn, Y; Boucher, E; Cany, L; Cvitkovic, F; Jacob, JH; Montoto-Grillot, C; Senesse, P; Thézenas, S; Ychou, M, 2007) |
| "Two consecutive studies have evaluated the efficacy of oxaliplatin combined with the Nordic bolus schedule of 5-fluorouracil and folinic acid as first-line treatment in metastatic non-resectable colorectal cancer." | 5.12 | Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer. ( Berglund, A; Dahl, O; Glimelius, B; Ogreid, D; Sørbye, H; Tveit, KM; Wanderås, EH; Wentzel-Larsen, T, 2007) |
| "Tegafur is an oral fluorouracil prodrug used in the treatment of colorectal cancer." | 5.12 | A clinical pharmacokinetic analysis of tegafur-uracil (UFT) plus leucovorin given in a new twice-daily oral administration schedule. ( Bennouna, J; Cardot, JM; Château, Y; Douillard, JY; Etienne-Grimaldi, MC; François, E; Gamelin, E; Milano, G; Renée, N, 2007) |
| "Ixabepilone plus capecitabine demonstrates superior efficacy to capecitabine alone in patients with metastatic breast cancer pretreated or resistant to anthracyclines and resistant to taxanes." | 5.12 | Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. ( Campone, M; Chan, VF; Chung, HC; de Mendoza, FH; Fein, LE; Gomez, HL; Jassem, J; Klimovsky, JV; Lerzo, GL; Li, RK; Mukhopadhyay, P; Peck, RA; Pivot, XB; Roché, HH; Thomas, ES; Vahdat, LT; Xu, B, 2007) |
| "This phase II study investigated the efficacy and safety of cetuximab combined with standard oxaliplatin-based chemotherapy (infusional fluorouracil, leucovorin, and oxaliplatin [FOLFOX-4]) in the first-line treatment of epidermal growth factor receptor-expressing metastatic colorectal cancer (mCRC)." | 5.12 | Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. ( André, T; Casado, E; Cervantes, A; Ciardiello, F; de Gramont, A; Díaz-Rubio, E; Humblet, Y; Kisker, O; Soulié, P; Tabernero, J; Tortora, G; Valera, JS; Van Cutsem, E; Van Laethem, JL; Verslype, C, 2007) |
| "1) To confirm the efficacy of irinotecan plus folinic acid/continuous 5-fluorouracil as bimonthly FOLFIRI regimen in metastatic colorectal cancer patients." | 5.12 | FOLFIRI chemotherapy for metastatic colorectal cancer patients. ( Chitapanarux, I; Kamnerdsupaphon, P; Lorvidhaya, V; Sukthomya, V; Tonusin, A, 2007) |
| "The aim of the current randomized Phase II study was to investigate the efficacy and safety of capecitabine combined with irinotecan as first-line treatment in metastatic colorectal carcinoma (CRC)." | 5.11 | Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. ( Artale, S; Bajetta, E; Beretta, E; Biasco, G; Bonaglia, L; Bonetti, A; Buzzoni, R; Carreca, I; Cassata, A; Cortinovis, D; Di Bartolomeo, M; Ferrario, E; Frustaci, S; Iannelli, A; Lambiase, A; Mariani, L; Marini, G; Pinotti, G, 2004) |
| "Treating patients with anthracycline- and taxane-pretreated metastatic breast cancer (MBC) represents a significant challenge to oncologists." | 5.11 | Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. ( Audhuy, B; Clippe, C; Culine, S; Curé, H; Dièras, V; Fumoleau, P; Largillier, R; Lesimple, T; Montestruc, F; Morère, JF; Mouri, Z; Namer, M; Orfeuvre, H; Serin, D; Vuillemin, E, 2004) |
| "The purpose is to determine the plasma pharmacokinetics, the maximum-tolerable dose and to preliminary evaluate the antitumor activity of irinotecan administered as a 7-day continuous infusion every 21 days in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed." | 5.11 | A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed. ( Allegrini, G; Barbara, C; Cupini, S; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Masi, G, 2004) |
| "This study evaluates the efficacy of capecitabine using data from a large, well-characterised population of patients with metastatic colorectal cancer (mCRC) treated in two identically designed phase III studies." | 5.11 | Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. ( Bukowski, RM; Cunningham, D; Dufour, P; Graeven, U; Harper, P; Hoff, PM; Lokich, J; Madajewicz, S; Maroun, JA; Marshall, JL; Mitchell, EP; Perez-Manga, G; Rougier, P; Schilsky, RL; Schmiegel, W; Schoelmerich, J; Sobrero, A; Van Cutsem, E, 2004) |
| "The objective of the trial is to evaluate the efficacy of capecitabine in patients with metastatic hormone-resistant prostate carcinoma (HRPC), in terms of prostate-specific antigen (PSA) response and clinical benefit (decrease of pain or analgesic score) and its safety profile." | 5.11 | Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial. ( Bauer, J; Bernhard, J; Bonomo, M; Borner, M; Cerny, T; Dietrich, D; Gillessen, S; Gschwend, A; Hanselmann, S; Hering, F; Morant, R; Rochlitz, C; Schmid, HP; Wernli, M, 2004) |
| "The purpose of this report is to evaluate the efficacy and toxicity (Tx) of a double modulation of 5-fluorouracil (5-FU) by trimetrexate (TMTX) and leucovorin (LV) in patients with advanced recurrent (inoperable) or metastatic colorectal cancer (ACC)." | 5.11 | Double modulation of 5-fluorouracil by trimetrexate and leucovorin in patients with advanced colorectal carcinoma. ( Bologna, F; Dominguez, ME; Lacava, JA; Leone, BA; Machiavelli, MR; Ortiz, EH; Pérez, JE; Romero, AO; Salum, G; Vallejo, CT, 2004) |
| "5-Fluorouracil (5-FU) and Vinorelbine (Vin) are active in the second line therapy of metastatic breast cancer (MBC)." | 5.11 | Second line chemotherapy with 5 fluorouracil and vinorelbine in anthracycline and taxane pretreated patients with metastatic breast cancer. ( Aravantinos, G; Bakoyiannis, C; Christodoulou, C; Fountzilas, G; Janinis, J; Kosmidis, P; Razis, E; Timotheadou, H, 2004) |
| "Irinotecan (CPT-11) and bolus 5-fluorouracil (5-FU)/leucovorin (LV) administered weekly for 4 weeks every 42 days (Saltz regimen) is active but substantially toxic in patients with metastatic colorectal cancer (CRC)." | 5.11 | Phase I study of CPT-11 and bolus 5-FU/ l-leucovorin in patients with metastatic colorectal cancer. ( Baba, E; Fujishima, H; Harada, M; Kikuchi, I; Mitsugi, K; Miyanaga, O; Nakano, S; Ueda, A, 2004) |
| "An open-label, non-randomized, compassionate-use study was carried out to investigate the effects of oral capecitabine at a dose of 1 250 mg/m2 twice daily on days 1 to 14 every 21 days in anthracycline- and taxane-pretreated advanced/metastatic breast cancer patients." | 5.11 | Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer. ( Bremnes, Y; Mjaaland, I; Ostenstad, B; Risberg, T; Sommer, HH; Wist, EA, 2004) |
| "Oxaliplatin (L-OHP), irinotecan (CPT-11) and 5-fluorouracil (5-FU) have shown their efficacy in metastatic colorectal cancer." | 5.11 | Phase I study of the combination of oxaliplatin, irinotecan and continuous infusion 5-fluorouracil in digestive tumors. ( Abad, A; Antón, A; Carrato, A; Diaz-Rubio, E; Gallego, J; Manzano, JL; Marfa, X; Massutí, B; Yuste, AL, 2004) |
| "Of 813 patients with previously untreated metastatic colorectal cancer, we randomly assigned 402 to receive irinotecan, bolus fluorouracil, and leucovorin (IFL) plus bevacizumab (5 mg per kilogram of body weight every two weeks) and 411 to receive IFL plus placebo." | 5.11 | Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. ( Baron, A; Berlin, J; Cartwright, T; Fehrenbacher, L; Ferrara, N; Fyfe, G; Griffing, S; Hainsworth, J; Heim, W; Holmgren, E; Hurwitz, H; Kabbinavar, F; Novotny, W; Rogers, B; Ross, R, 2004) |
| "FOLFOX, a bimonthly combination of leucovorin, 5-fluorouracil and oxaliplatin, is active in metastatic colorectal cancer, but sometimes causes cumulative sensory neurotoxicity." | 5.11 | Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. ( André, T; Artru, P; Carola, E; de Gramont, A; Louvet, C; Mabro, M; Maindrault-Goebel, F; Tournigand, C, 2004) |
| "A dose-finding study was undertaken to determine the maximum-tolerated dose, and the recommended dose of docetaxel in combination with 12-h timed (22:00-10:00) flat infusion of 5-fluorouracil (5-FU) in metastatic breast cancer patients." | 5.11 | Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study. ( Baldi, PL; Calista, F; Cannita, K; Cianci, G; DE Galitiis, F; DI Rocco, ZC; Ficorella, C; Marchetti, P; Morelli, MF; Natoli, C; Porzio, G; Ricevuto, E; Tinari, N, 2004) |
| "We have evaluated the efficacy and safety of the combination of capecitabine and vinorelbine in metastatic breast cancer (MBC) patients previously treated with anthracycline-and taxane-containing regimens." | 5.11 | Capecitabine and vinorelbine in patients with metastatic breast cancer previously treated with anthracycline and taxane. ( Ahn, JH; Ahn, SH; Kang, YK; Kim, SB; Kim, SM; Kim, TW; Kim, WK; Lee, JS; Park, JM, 2004) |
| "The effectiveness of capecitabine, an oral fluoropyrimidine carbamate, is well documented in previously untreated metastatic colorectal cancer patients (overall response rate: 25%)." | 5.11 | Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy. ( Bang, YJ; Heo, DS; Joh, YH; Kim, DW; Kim, NK; Kim, TM; Kim, TY; Kwon, JH; Lee, JJ; Oh, DY; Yu, SJ, 2004) |
| "A phase II trial was designed to determine whether mistletoe extract can induce objective tumor response in patients with metastatic colorectal cancer resistant to 5-fluorouracil and leucovorin (5FU/LCV)-based chemotherapy." | 5.11 | Abnoba-viscum (mistletoe extract) in metastatic colorectal carcinoma resistant to 5-fluorouracil and leucovorin-based chemotherapy. ( Bar-Sela, G; Haim, N, 2004) |
| "The addition of capecitabine to docetaxel on a 3-week schedule resulted in superior response rate, increased time to progression (TTP), and improved overall survival in patients with anthracycline-pretreated metastatic breast cancer (MBC)." | 5.11 | Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer. ( Au, HJ; Bodnar, DM; Joy, AA; Koski, SL; Mackey, JR; Scarfe, AG; Smith, SW; Smylie, MG; Soulieres, D; Tonkin, KS, 2004) |
| "A combination of irinotecan 125 mg/m2, 5-fluorouracil (5-FU) 500 mg/m2, and leucovorin (LV) 20 mg/m2 (Saltz regimen; treatment on days 1, 8, 15, and 22 every 6 weeks) is widely used for the treatment of metastatic colorectal cancer." | 5.11 | Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer. ( Arai, T; Goto, A; Hamaguchi, T; Hosokawa, A; Muro, K; Shimada, Y; Shirao, K; Ura, T; Yamada, Y, 2004) |
| "Thirty-six patients with advanced breast cancer were stratified for the presence of bone and non-bone involvement and treated at four dose levels from capecitabine 800 mg/m2 orally days 1-14 and vinorelbine 20 mg/m2 intravenously days 1 and 8, to capecitabine 1250 mg/m2 orally days 1-14 and vinorelbine 25 mg/m2 intravenously days 1 and 8, for a maximum of six cycles." | 5.11 | Capecitabine and vinorelbine in elderly patients (> or =65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99). ( Aebi, S; Ballabeni, P; Castiglione-Gertsch, M; Goldhirsch, A; Hess, D; Pagani, O; Rauch, D; Rufener, B; Thürlimann, B, 2004) |
| "In a previous phase I-II study we demonstrated that the FOLFOXIRI regimen [irinotecan 125-175 mg/m2 day 1, oxaliplatin 100 mg/m2 day 1, l-leucovorin (l-LV) 200 mg/m2 day 1, 5-fluorouracil (5-FU) 3800 mg/m2 as a 48-h chronomodulated continuous infusion starting on day 1, repeated every 2 weeks] has promising activity and efficacy in metastatic colorectal cancer." | 5.11 | First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule. ( Allegrini, G; Andreuccetti, M; Brunetti, I; Cerri, E; Cupini, S; Falcone, A; Fontana, E; Marcucci, L; Masi, G; Ricci, S, 2004) |
| "To define the maximum-tolerated dose (MTD) and to evaluate the dose-limiting toxicities (DLT) of the combination of capecitabine and vinorelbine in patients with metastatic breast cancer who relapse after adjuvant and/or first-line treatment." | 5.11 | Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer. ( Borquez, D; Harstrick, A; Kaufmann, M; Loibl, S; Oberhoff, C; Schleucher, R; Seeber, S; Vanhoefer, U; von Minckwitz, G; Welt, A, 2005) |
| "Since the need for nonanthracycline-containing chemotherapy regimens increases with the increased use of anthracyclines in earlier stages of breast cancer, we investigated the feasibility of the combination of docetaxel and 5-fluorouracil (5-FU) with folinic acid (FA)." | 5.11 | A phase I dose-escalating study of docetaxel plus folinic acid and 5-fluorouracil in anthracycline-pretreated patients with metastatic breast cancer. ( Nortier, JW; Rodenburg, CJ; Slee, PH; van Bochove, A, 2004) |
| "The aim of the current study was to evaluate the antitumor activity and toxicity of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin (FMP therapy) in chemotherapy-naive patients with metastatic hepatocellular carcinoma (HCC)." | 5.11 | A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma. ( Ikeda, M; Morizane, C; Okusaka, T; Takezako, Y; Ueno, H, 2005) |
| "This randomized phase III trial compared the efficacy and safety of capecitabine with or without bevacizumab, a monoclonal antibody to vascular endothelial growth factor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane." | 5.11 | Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. ( Chap, LI; Cobleigh, MA; Dickler, M; Fehrenbacher, L; Holmes, FA; Langmuir, V; Marcom, PK; Miller, KD; Overmoyer, BA; Reimann, JD; Rugo, HS; Sing, AP, 2005) |
| "Capecitabine and irinotecan are commonly used in the treatment of metastatic colorectal cancer (CRC)." | 5.11 | UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. ( Andria, ML; Bever, J; Blanchard, RL; Carlini, LE; Gold, P; Hill, T; Meropol, NJ; Rogatko, A; Wang, H, 2005) |
| "Although irinotecan 350 mg m(-2) is a standard option for relapsed/refractory advanced colorectal cancer, there is some evidence that suggests that a higher dose may be more effective, with acceptable tolerability, following 5-fluorouracil (5-FU)." | 5.11 | Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study. ( Bleiberg, H; Borner, M; Dirix, L; Gonzalez Baron, M; Gruia, G; Joosens, E; Morant, R; Roth, A; Sibaud, D; Van Belle, S; Van Cutsem, E; Van Laethem, JL, 2005) |
| "A phase I-II multicenter trial was conducted to define the maximal tolerated dose and describe the activity of an OCFL combination using oxaliplatin (OHP), irinotecan (CPT-11) and 5-fluorouracil (FU)/leucovorin (LV) in metastatic colorectal cancer (CRC)." | 5.11 | Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study. ( Allal, A; Bauer, J; Gervaz, P; Mentha, G; Morant, R; Philippe, M; Roth, AD; Ruhstaller, T; Seium, Y; Stupp, R; Trembleau, C, 2005) |
| "In a phase III trial, combining bevacizumab (BV)--a recombinant, humanized, monoclonal antibody targeting vascular endothelial growth factor--with irinotecan, bolus fluorouracil (FU), and leucovorin (LV; IFL) increased survival compared with IFL alone in first-line treatment of patients with metastatic colorectal cancer (CRC)." | 5.11 | Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. ( Berlin, J; Fehrenbacher, L; Hainsworth, JD; Hambleton, J; Heim, W; Holmgren, E; Hurwitz, HI; Kabbinavar, F; Novotny, WF, 2005) |
| "Irinotecan combined with continuous-infusion 5-fluorouracil (5FU) has been shown to be an effective and tolerable regimen in the treatment of metastatic colorectal cancer (MCRC)." | 5.11 | Phase II study of irinotecan, leucovorin, 5-fluorouracil and tegafur/uracil for metastatic colorectal cancer. ( Asama, T; Ashida, T; Ayabe, T; Chisato, N; Ebisawa, Y; Kamiya, K; Kasai, S; Kohgo, Y; Kono, T; Tomita, I, 2005) |
| "We conducted a phase II study to assess the efficacy and tolerability of irinotecan and cisplatin as salvage chemotherapy in patients with advanced gastric adenocarcinoma, progressing after both 5-fluorouracil (5-FU)- and taxane-containing regimen." | 5.11 | Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes. ( Bang, SM; Cho, EK; Choi, EY; Chung, M; Ki Lee, W; Lee, JH; Park, SH; Shin, DB, 2005) |
| "Seventy-two patients suffering from a metastatic colorectal cancer received, as first line treatment, a combination chronotherapy with 5-FU and folinic acid (infused from 10 pm to 10 am with a peak at 4 am, respectively at doses of 700 and 300 mg/m2 per day) and carboplatin (infused at the dose of 40 mg/m2 per day from 10 am to 10 pm with a peak at 4 pm)." | 5.11 | [Chronotherapy combining 5-fluorouracil, folinic acid and carboplatin as first line treatment in metastatic colorectal cancer. A phase 2 study]. ( Biquet, JF; David, A; Delforge, M; Focan, C; Focan-Henrard, D; Graas, MP; Kreutz, F; Longrée, L; Materne, R; Moeneclaey, N; Weerts, J, 2005) |
| "The aim of this study was to better understand human breast cancer biology by studying how the timing of metastasis following primary resection is affected by adjuvant CMF (cyclophoshamide, methotrexate, 5-fluorouracil) chemotherapy." | 5.11 | Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process. ( Bonadonna, G; Demicheli, R; Hrushesky, WJ; Miceli, R; Moliterni, A; Retsky, MW; Valagussa, P; Zambetti, M, 2005) |
| "Building on results from Southwest Oncology Group trial 8905, this trial was designed to compare low-dose continuous infusion (LDCI) of 5-fluorouracil (5-FU) versus intermittent high-dose infusion (HDI) of 5-FU in disseminated colorectal cancer (CRC) for evidence of survival advantage based on dose intensity." | 5.11 | Assessment of infusional 5-fluorouracil schedule and dose intensity: a Southwest Oncology Group and Eastern Cooperative Oncology Group study. ( Bearden Iii, JD; Benedetti, JK; Hochster, H; Leichman, CG; Lenz, HJ; Macdonald, JS; Shields, AF; Wade Iii, JL; Zalupski, MM, 2005) |
| "A detailed questionnaire was completed after each chemotherapy cycle for patients with metastatic colorectal cancer enrolled in a phase I trial of oxaliplatin and capecitabine." | 5.11 | Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. ( Fioravanti, S; Grem, JL; Harold, N; Leonard, GD; Quinn, MG; Schuler, B; Thomas, RR; Wright, MA, 2005) |
| "To compare the efficacy and safety of doxorubicin and docetaxel (AT) with fluorouracil, doxorubicin, and cyclophosphamide (FAC) as first-line chemotherapy for metastatic breast cancer (MBC)." | 5.11 | Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of ( Bokma, HJ; Bontenbal, M; Braun, HJ; Creemers, GJ; de Boer, AC; Goey, SH; Janssen, JT; Kerkhofs, LG; Leys, RB; Ruit, JB; Schmitz, PI; Schothorst, KL; Seynaeve, C; van der Velden, PC; Verweij, J, 2005) |
| "A biweekly regimen of irinotecan 200 mg/m2 on day 1 and levo-leucovorin (LV) 250 mg/m2 plus 5-fluorouracil (5-FU) 850 mg/m2 via intravenous bolus on day 2 was assessed in 2 consecutive randomized trials in metastatic colorectal cancer (CRC)." | 5.11 | Safety and efficacy of irinotecan plus high-dose leucovorin and intravenous bolus 5-fluorouracil for metastatic colorectal cancer: pooled analysis of two consecutive southern Italy cooperative oncology group trials. ( Buzzi, F; Comella, P; De Cataldis, G; De Lucia, L; Farris, A; Filippelli, G; Leo, S; Lorusso, V; Maiorino, L; Mancarella, S; Massidda, B; Natale, D; Palmeri, S; Roselli, M; Tafuto, S, 2005) |
| "com) and infusional 5-fluorouracil (5-FU) as second-line therapy in metastatic colorectal cancer (MCRC)." | 5.11 | Combined therapy with weekly irinotecan, infusional 5-fluorouracil and the selective COX-2 inhibitor rofecoxib is a safe and effective second-line treatment in metastatic colorectal cancer. ( Gamucci, T; Gasparini, G; Gattuso, D; Longo, R; Mariani, L; Morabito, A; Sarmiento, R; Torino, F; Vitale, S, 2005) |
| "To evaluate the efficacy and tolerance of irinotecan (CPT-11) in combination with bolus and continuous infusion of 5-fluorouracil (5-FU) and leucovorin (LV) (FOLFIRI regimen) as first-line treatment of elderly patients with metastatic colorectal cancer (MCC)." | 5.11 | Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial. ( Agelaki, S; Androulakis, N; Georgoulias, V; Kakolyris, S; Kouroussis, C; Mavroudis, D; Milaki, G; Pallis, A; Souglakos, J; Xenidis, N, 2005) |
| "5-fluorouracil (5-FU), irinotecan, and oxaliplatin are the most active drugs in advanced colorectal cancer (CRC), and survival is improved with patient exposure to all of them." | 5.11 | FOLFOX alternated with FOLFIRI as first-line chemotherapy for metastatic colorectal cancer. ( Aparicio, J; Balcells, M; Busquier, I; Campos, JM; Fernandez-Martos, C; Llorca, C; Maestu, I; Perez-Enguix, D; Vincent, JM, 2005) |
| "Raltitrexed (Tomudex) is proven effective in metastatic colorectal cancer." | 5.10 | Ralitrexed (Tomudex) or Nordic-FLv regimen in metastatic colorectal cancer: a randomized phase II study focusing on quality of life, patients' preferences and health economics. ( Balteskard, L; Edna, TH; Laino, R; Norum, J; Rønning, G; Wählby, L, 2002) |
| "To estimate the disease-response rate, proportion of patients whose tumors can be made resectable, event-free survival (EFS), and toxicity in children with unresectable or metastatic hepatoblastoma (HB) after sequential treatment with the following: (1) carboplatin (CARBO); (2) CARBO, vincristine, and fluorouracil (CARBO-VCR-5-FU); and (3) high-dose cisplatin and etoposide (HDDP-ETOP)." | 5.10 | Treatment of unresectable and metastatic hepatoblastoma: a pediatric oncology group phase II study. ( Bowman, LC; Douglass, EC; Finegold, MJ; Katzenstein, HM; London, WB; Plaschkes, J; Reynolds, M, 2002) |
| "We studied the activity of combined oxaliplatin and fluorouracil-leucovorin in 16 consecutive patients with advanced biliary tract adenocarcinomas." | 5.10 | Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial. ( Arkenau, HT; Gregor, M; Greschniok, A; Hass, HG; Klump, B; Nehls, O; Porschen, R, 2002) |
| "To determine the feasibility, recommended doses, plasma pharmacokinetics, and antitumor activity of a biweekly chemotherapy regimen with oxaliplatin (L-OHP), irinotecan (CPT-11), infusional fluorouracil (5-FU), and leucovorin (LV) in metastatic colorectal cancer patients." | 5.10 | Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. ( Allegrini, G; Brunetti, IM; Conte, P; Cupini, S; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Masi, G; Pfanner, E, 2002) |
| "To assess the activity and safety of combined folinic acid (FA), 5-fluorouracil (5-FU) and mitomycin C (MMC) in metastatic breast cancer patients previously treated with at least two chemotherapy regimens." | 5.10 | Folinic acid, 5-fluorouracil and mitomycin C in metastatic breast cancer patients previously treated with at least two chemotherapy regimens. ( Correale, P; Fiaschi, AI; Francini, G; Marsili, S; Messinese, S; Petrioli, R; Pozzessere, D; Sabatino, M, 2002) |
| "We have investigated the efficacy, safety and quality of life profiles of three therapeutic combinations [irinotecan + leucovorin (LV)/5-fluorouracil (5-FU), oxaliplatin + LV/5-FU and irinotecan +oxaliplatin] in patients with metastatic colorectal cancer after failure of a 5-FU-based regimen, or whose disease had progressed within 6 months of the end of treatment." | 5.10 | Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study. ( Bennouna, J; Ducreux, M; Hua, A; Lepille, D; Marre, A; Méry-Mignard, D; Mignot, L; Rougier, P, 2002) |
| "Overall results of this study indicate that the administration of clinically relevant single-agent doses of both capecitabine and oxaliplatin is feasible and seems to result in promising therapeutic activity in patients with advanced colorectal cancer." | 5.10 | Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer. ( Huber, H; Kornek, GV; Längle, F; Raderer, M; Scheithauer, W; Schmid, K; Schüll, B, 2002) |
| "Irinotecan (CPT-11) has been shown to prolong survival and improve quality of life in comparison to best supportive care in colorectal cancer patients with pretreatment of bolus 5-fluorouracil (5-FU)." | 5.10 | Adding weekly irinotecan to high-dose 5-fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer--a phase II study. ( Emig, M; Hartung, G; Hehlmann, R; Hochhaus, A; Hofheinz, R; Pilz, L; Queisser, W; Samel, S; Willeke, F, 2002) |
| "This multicentre, randomised phase III study compared docetaxel with 5-fluorouracil+vinorelbine in patients with metastatic breast cancer after failure of neo/adjuvant or one line of palliative anthracycline-based chemotherapy." | 5.10 | Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. ( Assadourian, S; Bonneterre, J; Fargeot, P; Guastalla, JP; Monnier, A; Namer, M; Roché, H, 2002) |
| "We investigated the activity of irinotecan given with a more convenient modified bimonthly de Gramont regimen of bolus and infusional 5-fluorouracil [IrMdG] in advanced or metastatic colorectal cancer in the first and second line setting." | 5.10 | Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer. ( Hochhauser, D; James, R; Ledermann, JA; Leonard, P; Seymour, MT, 2002) |
| "Most patients with colorectal cancer (CRC) who have failed initial 5-fluorouracil (5-FU) chemotherapy have worsening of disease-related symptoms (DRS) and quality of life (QOL)." | 5.10 | The palliative benefit of irinotecan in 5-fluorouracil-refractory colorectal cancer: its prospective evaluation by a Multicenter Canadian Trial. ( Feld, R; Fields, A; Goel, R; Hedley, D; Jolivet, J; Lee, IM; Maroun, J; Michael, M; Moore, MJ; Oza, A; Pintilie, M, 2002) |
| "The purpose of this study was to evaluate the efficacy and tolerance of a combination of irinotecan, oxaliplatin, and 5-fluorouracil (5-FU)/leucovorin in advanced colorectal cancer (ACC)." | 5.10 | Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study. ( Brugarolas, A; Calvo, E; Cortés, J; de Irala, J; Fernández-Hidalgo, O; García-Foncillas, J; Martín-Algarra, S; Martínez-Monge, R; Rebollo, J; Rodríguez, J, 2002) |
| "This phase II study was designed to evaluate the efficacy and toxicities of oral doxifluridine plus leucovorin as a randomized trial with those of intravenous 5-fluorouracil (5-FU) plus leucovorin in previously untreated metastatic colorectal cancer (CRC)." | 5.10 | Oral doxifluridine plus leucovorin in metastatic colorectal cancer: randomized phase II trial with intravenous 5-fluorouracil plus leucovorin. ( Ahn, JH; Kang, YK; Kim, JC; Kim, JG; Kim, TW; Kim, WK; Lee, JH; Lee, JS; Min, YJ; Yu, CS, 2003) |
| "This phase II multicenter trial evaluated the efficacy and toxicity of weekly paclitaxel, 5-fluorouracil, and leucovorin administered as first-line therapy for metastatic breast cancer." | 5.10 | A phase II trial of weekly paclitaxel, 5-fluorouracil, and leucovorin as first-line treatment for metastatic breast cancer. ( Asmar, L; Canfield, VA; Ellis, PG; Ferri, WA; Hynes, HE; Loesch, DM; Parker, GA; Robert, NJ, 2003) |
| "To determine whether biochemical modulation with LV (leucovorin) enhances the efficacy of CAF (cyclophosphamide, doxorubicin, and fluorouracil) against metastatic breast cancer." | 5.10 | Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140. ( Abrams, J; Aisner, J; Allen, SL; Berry, DA; Chuang, E; Cirrincione, C; Cooper, MR; Duggan, DB; Henderson, IC; Norton, L; Parnes, HL; Perry, MC; Szatrowski, TP, 2003) |
| " In preclinical models, there appears to be additive or synergistic effects when combining 5-Fluorouracil (5-FU) with nonsteroidal anti-inflammatory agents (NSAIDs) for the treatment of colorectal neoplasms." | 5.10 | Increased toxicity and lack of efficacy of Rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: A phase II study. ( Ashfaq, R; Becerra, CR; Frenkel, EP; Gaynor, RB, 2003) |
| "To model the cost-effectiveness of adopting capecitabine/docetaxel combination therapy in place of single-agent taxane therapy for women in the province of Ontario, Canada, receiving treatment for anthracycline-pretreated metastatic breast cancer." | 5.10 | Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer. ( Ilersich, AL; Verma, S, 2003) |
| "In North America, no effective therapy has been available for patients with progressive metastatic colorectal cancer after front-line treatment with irinotecan, bolus fluorouracil (FU), and leucovorin (IFL)." | 5.10 | Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. ( Berlin, JD; Bigelow, RH; Burger, BG; Garay, CA; Gupta, S; Haller, DG; Hart, LL; Le Bail, N; Marshall, JL; Oza, AM; Ramanathan, RK; Rothenberg, ML, 2003) |
| "Irinotecan has shown activity in advanced colorectal cancer resistant to leucovorin and fluorouracil." | 5.10 | Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer. ( André, T; Artru, P; Carola, E; de Gramont, A; Gilles-Amar, V; Krulik, M; Louvet, C; Mabro, M, 2003) |
| "In this multicenter phase II study the efficacy and safety of the alternating schedule of irinotecan (CPT-11) with bolus 5-fluorouracil (5-FU) and leucovorin (LV) were assessed as first-line chemotherapy in patients with metastatic colorectal cancer (CRC)." | 5.10 | A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer. ( Aparicio, J; Borrega, P; de la Puente, CG; Lorenzo, A; Moreno-Nogueira, JA; Pica, JM; Reina, JJ; Rueda, A; Salvador, J, 2003) |
| "To determine the activity of biweekly oxaliplatin, combined with weekly bolus fluorouracil (FU) and low-dose leucovorin (LV) chemotherapy (bFOL), as first-line therapy for patients with metastatic colorectal cancer." | 5.10 | Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer. ( Chachoua, A; Escalon, J; Hochster, H; Muggia, F; Speyer, J; Zeleniuch-Jacquotte, A, 2003) |
| "Capecitabine is a rationally designed oral, tumor-activated fluoropyrimidine carbamate with high activity in metastatic breast cancer." | 5.10 | Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. ( Jänicke, F; Jonat, W; Kaufmann, M; Kieback, DG; Kölbl, H; Kuhn, W; Lück, HJ; Mohrmann, S; Reichardt, P; Schindler, AE; Thuss-Patience, PC; Von Minckwitz, G, 2003) |
| "A phase II study was conducted to assess the toxicity and response rate of vinorelbine (NavelbineR) combined with epirubicin and fluorouracil (NEF) in metastatic breast cancer." | 5.10 | Vinorelbine, epirubicin and fluorouracil as first-line therapy in metastatic breast cancer--a phase II trial. ( Blomqvist, C; Elomaa, I; Joensuu, H, 2003) |
| "We studied the safety and clinical activity of exisulind in combination with capecitabine in 35 patients with metastatic breast cancer (MBC)." | 5.10 | Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer. ( Arun, B; Booser, D; Esteva, FJ; Gibbs, A; Hortobagyi, GN; Murray, JL; Nealy, KM; Pusztai, L; Rivera, E; Smith, TL; Symmans, WF; Thompson, WJ; Valero, V; Whitehead, C; Zhen, JH, 2003) |
| "To evaluate the efficacy and safety of irinotecan as second-line treatment in patients with advanced colorectal cancer (ACC) failing or relapsing after 5-fluorouracil (5-FU) plus leucovorin (LV) standard chemotherapy." | 5.10 | Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study. ( Dimitrakopoulos, A; Giannakakis, T; Gouveris, P; Karadima, D; Kosmas, C; Margaris, H; Papalambros, E; Papastratis, G; Polyzos, A; Rokana, S; Tsavaris, N; Tsipras, H; Vadiaka, M; Ziras, N, 2003) |
| "Phase II studies have suggested an improved response rate and acceptable toxicity profile associated with gemcitabine combinations compared to gemcitabine alone for treatment of metastatic adenocarcinoma of the pancreas." | 5.10 | Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas. ( Araneo, M; Bruckner, HW; DeGregorio, P; Firoozi, K; Frager, D; Grossbard, ML; Homel, P; Jindal, K; Kozuch, P; Marino, J; Mortazabi, F, 2003) |
| "To evaluate the toxicity and efficacy of a modified deGramont regimen of 5-fluorouracil (5-FU), leucovorin, and oxaliplatin in patients with advanced colorectal cancer who have progressed on at least one but not more than two prior chemotherapy regimens." | 5.10 | A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer. ( Catarius, KJ; Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; Mayer, RJ; Ryan, DP; Stuart, K; Winkelmann, J, 2003) |
| "The tolerance and efficacy of oxaliplatin and irinotecan for metastatic colorectal cancer are unknown in elderly patients." | 5.10 | Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly. ( Aparicio, T; Artru, P; Belloc, J; Desramé, J; Dominguez, S; Etienney, I; Ezenfis, J; Lecomte, T; Locher, C; Mabro, M; Mitry, E; Montembault, S; Vayre, L, 2003) |
| " once every 3 weeks was assessed in 60 patients with advanced colorectal cancer (CRC) showing failure to 5-fluorouracil (5-FU) treatment." | 5.10 | Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study. ( Abad, A; Antón, A; Aranda, E; Balcells, M; Carrato, A; Cervantes, A; Díaz-Rubio, E; Fenández-Martos, C; Gallén, M; Huarte, L; Marcuello, E; Massutti, B; Sastre, J, 2003) |
| "This multicenter, open-label, phase II study was performed to assess the efficacy and toxicity of irinotecan 350 mg/m2 intravenously every 3 weeks in patients with advanced colorectal cancer (CRC) previously treated with 5-fluorouracil (5-FU)." | 5.10 | A multicenter phase II study of irinotecan in patients with advanced colorectal cancer previously treated with 5-fluorouracil. ( Arizcun, A; Cruz, JJ; de la Torre, A; Diz, P; Duarte, I; España, P; García López, MJ; García-Girón, C; Martínez del Prado, P; Méndez, M; Navalon, M; Pujol, E; Salut, A, 2003) |
| "This study combined oxaliplatin with the Nordic bolus schedule of 5-fluorouracil (5-FU) and folinic acid (FA) as first-line treatment in metastatic colorectal cancer." | 5.10 | Nordic 5-fluorouracil/leucovorin bolus schedule combined with oxaliplatin (Nordic FLOX) as first-line treatment of metastatic colorectal cancer. ( Dahl, O; Sørbye, H, 2003) |
| "To define the cyclophosphamide (CTX) maximal tolerated dose when combined with fixed doses of gemcitabine, fluorouracil (5-FU) and folinic acid (leucovorin, LFA) in metastatic breast cancer patients pretreated with anthracyclines and taxanes." | 5.10 | A phase I-II study on a gemcitabine-cyclophosphamide-fluorouracil/folinic acid triplet combination in anthracycline- and taxane-refractory breast cancer patients. ( Botti, G; Capasso, I; Comella, G; Comella, P; Cortino, GR; D'Aiuto, G; Di Bonito, M; Frasci, G; Rubulotta, R; Thomas, R; Vallone, P, 2002) |
| "The combination of CPT-11 with 5-fluorouracil (5-FU) in advanced colorectal cancer (ACC) represents an attractive approach." | 5.10 | Irinotecan (CPT-11) in combination with infusional 5-fluorouracil and leucovorin (de Gramont regimen) as first-line treatment in patients with advanced colorectal cancer: a multicenter phase II study. ( Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kandilis, K; Kouroussis, C; Mavroudis, D; Sarra, E; Souglakos, J; Vamvakas, L; Ziras, N, 2002) |
| "To study tolerability and efficacy of an intensified chronomodulated schedule of fluorouracil (5-FU) and l-folinic acid (l-FA) as first-line treatment of metastatic colorectal cancer, 5-FU was given near individually determined dose-limiting toxicity in a multicenter phase II trial." | 5.10 | Phase II trial of chronomodulated infusion of high-dose fluorouracil and l-folinic acid in previously untreated patients with metastatic colorectal cancer. ( Adenis, A; Chevalier, V; Chipponi, J; Chollet, P; Coudert, B; Curé, H; Focan, C; Kwiatkowski, F; Lévi, F; Niezgodzki, G; Perpoint, B; Pezet, D; Tubiana-Mathieu, N, 2002) |
| "Cimetidine has been shown to have beneficial effects in colorectal cancer patients." | 5.10 | Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis-X and sialyl Lewis-A epitope expression on tumour cells. ( Imaeda, Y; Kobayashi, K; Matsumoto, S; Okamoto, T; Suzuki, H; Umemoto, S, 2002) |
| "The aim of this study, using a Fleming single-stage design, was to explore the efficacy and safety of Taxotere 100 x mg x m(-2) docetaxel and FEC 75 cyclophosphamide 500 mg x m(-2), fluorouracil 500 x mg x m(-2) and epirubicin 75 mg x m(-2), in alternating and sequential schedules for the first-line treatment of metastatic breast cancer." | 5.10 | Sequential or alternating administration of docetaxel (Taxotere) combined with FEC in metastatic breast cancer: a randomised phase II trial. ( Bougnoux, Ph; Eymard, JC; Lotz, V; Mansouri, H; Namer, M; Spielmann, M; Tubiana-Hulin, M; Tubiana-Mathieu, N, 2002) |
| "To compare the efficacy and tolerability of eniluracil (EU)/fluorouracil (5-FU) with that of 5-FU/leucovorin (LV) as first-line therapy for patients with metastatic/advanced colorectal cancer." | 5.10 | Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer. ( Ansari, RH; Bell, WN; Colwell, B; Levin, J; McGuirt, PV; Pazdur, R; Schilsky, RL; Thirlwell, MP; West, WH; White, RL; Wong, A; Yates, BB, 2002) |
| "This phase II study was designed to evaluate the efficacy and toxicity of 3-h interval sequential methotrexate (MTX) and 5-fluorouracil (5-FU) with leucovorin (LV) rescue in the treatment of patients with metastatic colorectal cancer." | 5.10 | Effect of a 3-hour interval between methotrexate and 5-fluorouracil in the treatment of metastatic colorectal cancer. ( Hamaguchi, T; Haruyama, K; Matsumura, Y; Muro, K; Shimada, Y; Shirao, K; Sugano, K; Yamada, Y, 2002) |
| "The aim of this study was to determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and potential activity of combined gemcitabine and continuous infusion 5-fluorouracil (5-FU) in metastatic breast cancer (MBC) patients that are resistant to anthracyclines or have been pretreated with both anthracyclines and taxanes." | 5.10 | An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes. ( Awada, A; Batter, V; Beex, L; Biganzoli, L; Cufer, T; Hamilton, A; Lohrisch, C; Nooij, M; Piccart, M, 2002) |
| "Twenty-one patients with recurrent or metastatic breast cancer were treated with paclitaxel (Taxol) as a 1-hour infusion on day 1 only of a 14-day cycle." | 5.10 | Phase II study of low-dose infusional 5-fluorouracil and paclitaxel (Taxol) given every 2 weeks in metastatic breast cancer. ( Amamoo, MA; Collichio, FA; Fogleman, J; Graham, M; Griggs, J, 2002) |
| "To evaluate the response rate and adverse reactions of xeloda, an analogue of 5-fluorouracil, in the treatment of relapsed and metastatic breast cancer." | 5.10 | [Capecitabine (xeloda) in the treatment of relapsed and metastatic breast cancer]. ( Duan, Y; Guan, Z; Liu, X; Song, S; Wu, S; Yang, L; Yu, J, 2002) |
| " This randomised, phase II trial evaluated the efficacy and safety of capecitabine or paclitaxel in patients with anthracycline-pretreated metastatic breast cancer." | 5.10 | Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. ( Ackland, S; Alba Conejo, E; Burger, HU; Eisenberg, P; Laws, S; Melnychuk, D; Moiseyenko, V; O'Reilly, SM; Osterwalder, B; Pienkowski, T; Talbot, DC; Van Belle, S, 2002) |
| "To evaluate the efficacy and tolerance of irinotecan (CPT-11) in combination with oxaliplatin (L-OHP) plus fluorouracil (5-FU)/leucovorin (LV) (de Gramont regimen) as first-line treatment of metastatic colorectal cancer (MCC)." | 5.10 | Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial. ( Agelaki, S; Androulakis, N; Athanasiadis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kourousis, Ch; Mavroudis, D; Samonis, G; Souglakos, J; Tsetis, D; Vardakis, N, 2002) |
| "Docetaxel and capecitabine, a tumor-activated oral fluoropyrimidine, show high single-agent efficacy in metastatic breast cancer (MBC) and synergy in preclinical studies." | 5.10 | Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. ( Ayoub, JP; Cervantes, G; Fumoleau, P; Jones, S; Leonard, R; Lui, WY; Mauriac, L; Miles, D; Moiseyenko, V; O'Shaughnessy, J; Twelves, C; Van Hazel, G; Verma, S; Vukelja, S, 2002) |
| "To determine the maximum-tolerated dose (MTD) of a weekly schedule of irinotecan (CPT-11), leucovorin (LV), and a 24-hour infusion of fluorouracil (5-FU24h) as first-line chemotherapy in advanced colorectal cancer and to assess preliminary data on the antitumor activity." | 5.09 | Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer. ( Achterrath, W; Harstrick, A; Köhne, CH; Rustum, YM; Seeber, S; Vanhoefer, U; Wilke, H, 1999) |
| "The efficacy of combination therapy with vinorelbine, cyclophosphamide, and 5-fluorouracil was assessed in women who had received no prior therapy for locally advanced or metastatic breast cancer." | 5.09 | Treatment with a nonanthracycline regimen in advanced breast cancer: vinorelbine, cyclophosphamide, and 5-fluorouracil with folinic acid. ( Biville, F; Closon, MH; Delgado, FM; Fernandez, R; Gruia, G; Llombart, A; Lluch, A; Turpin, F, 1999) |
| "In a prospective multicenter trial, 279 patients with metastatic colorectal cancer who had failed 5-fluorouracil therapy were randomized 2:1 to receive either best supportive care (BSC) plus treatment with the topoisomerase I inhibitor, irinotecan (CPT-11; Rhône-Poulenc Rorer, Antony, France), at a dose of 350 mg/m2 every 3 weeks or BSC alone." | 5.09 | A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group. ( Cunningham, D; Glimelius, B, 1999) |
| "In a multicenter phase III trial, 267 patients with nonbulky metastatic colorectal cancer who had failed first-line 5-fluorouracil (5-FU) therapy were randomized to receive second-line treatment with either the new topoisomerase agent, irinotecan (Rhône-Poulenc Rorer, Antony, France), or a high-dose infusional 5-FU regimen." | 5.09 | Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group. ( Blijham, GH; Van Cutsem, E, 1999) |
| "In a prospective randomized trial, 40 stage IV breast cancer patients undergoing intermediate high-dose chemotherapy (cyclophosphamide, 5-fluorouracil plus epirubicin or methotrexate), received either recombinant human G-CSF (rhG-CSF, group I) or ciprofloxacin and amphotericin B (CAB, group II) for prevention of febrile leucopenia (FL)." | 5.09 | Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B. ( de Vries, EG; Hospers, GA; Mulder, NH; Schröder, CP; Sleijfer, DT; van der Graaf, WT; Willemse, PH, 1999) |
| "To determine whether immunohistochemical thymidylate synthase (TS) quantitation predicts for clinical outcome in patients with advanced colorectal cancer treated by fluorouracil (FUra)-based chemotherapy." | 5.09 | Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. ( Antonelli, G; Aschele, C; Baldo, C; Casazza, S; Debernardis, D; Lionetto, R; Maley, F; Sobrero, A; Tunesi, G, 1999) |
| "The efficacy of a new chemotherapeutic combination consisting of Cis-diammineglycolatoplatinum (Nedaplatin), a derivative of cisplatin (CDDP), and 5-fluorouracil (5FU) was evaluated in patients with advanced esophageal carcinomas." | 5.09 | A new combination chemotherapy with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for advanced esophageal cancers. ( Gamoh, M; Ishibashi, S; Ishioka, C; Kanamaru, R; Kato, S; Murakawa, Y; Shibata, H; Shimodaira, H; Shineha, R; Suzuki, T; Yoshioka, T, 1999) |
| "The present study was conducted to investigate the efficacy and toxicity of a cisplatin and 5-fluorouracil (5-FU) combination in previously treated advanced breast cancer." | 5.09 | Phase II study of cisplatin and 5-fluorouracil in previously treated metastatic breast cancer: an Eastern Cooperative Oncology Group study (PA 185). ( Abeloff, MD; Hochster, H; Kucuk, O; Pandya, KJ; Skeel, RT, 1999) |
| "Between January 1988 and December 1992, 231 patients with estrogen receptor (ER)-positive or ER-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, doxorubicin, and fluorouracil ¿CAF) or chemohormonal therapy (CAF plus tamoxifen and Halotestin ¿fluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI ¿CAFTH) as front-line therapy for metastatic breast cancer." | 5.09 | Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study. ( Abeloff, M; Falkson, G; Hu, P; Sledge, GW; Tormey, D, 2000) |
| "Twelve women with metastatic breast cancer were treated with continuous infusion high dose leucovorin, 5-fluorouracil and cisplatin." | 5.09 | Continuous-infusion high-dose leucovorin with 5-fluorouracil and cisplatin for relapsed metastatic breast cancer: a phase II study. ( Booser, DJ; Holmes, FA; Hortobagyi, GN; Walters, RS, 2000) |
| "Oral idarubicin (IDA) is an active drug in metastatic breast cancer, but its role in the management of this tumor is yet not established completely." | 5.09 | Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients. ( Aita, P; Bearz, A; Boiocchi, M; Colussi, AM; Corona, G; Crivellari, D; Robieux, I; Sorio, R; Stocco, F; Toffoli, G, 2000) |
| "We evaluated economic implications of treatment with irinotecan, following a RCT which demonstrated significantly increased survival at 1 year with irinotecan (45%) compared to infusional 5-fluorouracil (5-FU) (32%) in patients with metastatic colorectal cancer." | 5.09 | Medical care consumption in a phase III trial comparing irinotecan with infusional 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer after 5-FU failure. ( Blijham, G; Jolain, B; Rougier, P; Schmitt, C; Van Cutsem, E, 1999) |
| "To determine the efficacy of fluorouracil (5-FU) plus eniluracil when administered to patients with previously untreated metastatic colorectal cancer." | 5.09 | Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer. ( Beck, T; Bell, WN; Chevlen, EM; Hochster, H; Hohneker, J; Levin, J; Lokich, J; Mani, S; McGuirt, C; O'Rourke, MA; Schilsky, RL; Weaver, CH; White, R, 2000) |
| "To determine whether the duration and the dose of epirubicin modify the long-term outcome of patients with metastatic breast cancer (MBC)." | 5.09 | Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment. ( , 2000) |
| "This phase I study evaluated the maximum tolerated dose, dose-limiting toxicity and recommended dose of docetaxel in combination with 5-fluorouracil (5-FU) in patients with metastatic breast cancer previously treated with anthracycline-based chemotherapy." | 5.09 | Docetaxel in combination with 5-fluorouracil in patients with metastatic breast cancer previously treated with anthracycline-based chemotherapy: a phase I, dose-finding study. ( Besenval, M; Boisdron-Celle, M; Delva, R; Gamelin, E; Lortholary, A; Maillard, P; Perard, D; Vernillet, L, 2000) |
| "A randomized study of the effectiveness of treatment with capecitabine (Xeloda) (22) and paclitaxel (taxol) (19) was carried out in breast cancer patients resistant to anthracycline antibiotic drugs." | 5.09 | [A comparative randomized phase-II study of Xeloda (capecitabine) and paclitaxel in patients with breast cancer progressing after anthracycline antibiotics]. ( Dalbot, DC; Gordon, RJ; Griffin, T; Moiseenko, VM; O'Reilly, SM; Osterwalder, B; Van Belle, S, 2000) |
| "The combination of fluorouracil and leucovorin has until recently been standard therapy for metastatic colorectal cancer." | 5.09 | Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. ( Ackland, SP; Blanke, C; Cox, JV; Elfring, GL; Fehrenbacher, L; Locker, PK; Maroun, JA; Miller, LL; Moore, MJ; Pirotta, N; Rosen, LS; Saltz, LB, 2000) |
| "To evaluate the feasibility and activity of vinorelbine in association with protracted infusional fluorouracil in patients with advanced breast cancer who were previously treated with anthracycline-containing regimens." | 5.09 | Phase II study of vinorelbine with protracted fluorouracil infusion as a second- or third-line approach for advanced breast cancer patients previously treated with anthracyclines. ( Alquati, P; Berruti, A; Botta, M; Bottini, A; Brunelli, A; De Lena, M; Dogliotti, L; Donadio, M; Gorzegno, G; Lorusso, V; Mancarella, S; Sperone, P; Tampellini, M, 2000) |
| "The continuous infusion of fluorouracil presents a superior pharmacological profile than its bolus administration, while vinorelbine is a new drug associated with good clinical activity in pretreated metastatic breast cancer." | 5.09 | Five-day infusion fluorouracil plus vinorelbine in women with breast cancer previously treated with anthracyclines and paclitaxel. ( Demicheli, R; Garbagnati, F; Mariani, G; Potepan, P; Verderio, P; Zambetti, M, 2000) |
| "The purpose of this study was to determine the efficacy of twice weekly hypo-fractionated radiation therapy (RT) plus continuous infusion 5-fluorouracil for unresectable or locally advanced colorectal cancer with synchronous metastases." | 5.09 | Avoidance of colostomy placement in advanced colorectal cancer with twice weekly hypofractionated radiation plus continuous infusion 5-fluorouracil. ( Breslin, T; Janjan, NA; Lenzi, R; Rich, TA; Skibber, J, 2000) |
| "In a randomized trial, the authors evaluated the possible adjuvant activity of intraportal chemotherapy (with 5-fluorouracil 500 mg/m2/day in continuous infusion for 7 days and mitomycin C 10 mg/m2 at day 7) administered after surgery to half of the patients who underwent a full resection for Dukes B2 or C colorectal cancer." | 5.09 | Adjuvant intraportal chemotherapy for Dukes B2 and C colorectal cancer also receiving systemic treatment: results of a multicenter randomized trial. Groupe Régional d'Etude du Cancer Colo-Rectal (Belgium). ( Beauduin, M; Brohée, D; Bury, J; Focan, C; Herman, ML; Lecomte, M; Vindevoghel, A, 2000) |
| "A phase II study was carried out to evaluate the efficacy and toxicity of a double biochemical modulation of 5-fluorouracil (5-FU) by methotrexate (MTX) and leucovorin (LV) in patients with advanced unresectable colorectal cancer." | 5.09 | Double modulation of 5-fluorouracil by leucovorin and low-dose methotrexate in advanced colorectal cancer. ( Cizej, TE; Markovic, A; Plesnicar, A; Stabuc, B, 2000) |
| "Studies of bimonthly 48-hour regimens of high-dose leucovorin (LV) (FOLinic acid), 5-fluorouracil (5-FU) by continuous infusion combined with OXaliplatin (FOLFOX) in pretreated patients with metastatic colorectal cancer suggest that oxaliplatin dose intensity is an important prognostic factor for response rate and progression-free survival (PFS)." | 5.09 | Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). ( André, T; Artru, P; Carola, E; de Gramont, A; Gilles, V; Izrael, V; Krulik, M; Lotz, JP; Louvet, C; Mabro, M; Maindrault-Goebel, F; Molitor, JL; Tournigand, C, 2000) |
| "Irinotecan is a topoisomerase I inhibitor that prolongs survival in patients with colorectal cancer refractory to fluorouracil (5-FU) and leucovorin (LV)." | 5.09 | Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard. ( Alakl, M; Awad, L; Douillard, JY; Elfring, GL; Gruia, G; Locker, PK; Miller, LL; Pirotta, N; Saltz, LB, 2001) |
| "To determine the relative efficacy of a cyclophosphamide epirubicin and fluorouracil (CEF) regimen compared with an intravenous (IV) cyclophosphamide, methotrexate, and fluorouracil (CMF) combination in metastatic breast cancer." | 5.09 | Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study. ( Ackland, SP; Anton, A; Breitbach, GP; Colajori, E; Delfino, C; Efremidis, A; Ezzat, A; Fittipaldo, A; Kolaric, K; Lopez, M; Tursi, JM; Viaro, D, 2001) |
| "This phase III trial compared the efficacy and safety of doxorubicin and paclitaxel (AT) to 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) as first-line therapy for women with metastatic breast cancer." | 5.09 | Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. ( Berzins, J; Gorbunova, V; Jassem, J; Jelic, S; Mrsic-Krmpotic, Z; Munier, S; Nagykalnai, T; Pieńkowski, T; Płuzańska, A; Renard, J; Weil, C; Wigler, N, 2001) |
| "To evaluate whether an accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) chemotherapy regimen with the support of granulocyte colony-stimulating factor (G-CSF) induces a higher activity and efficacy compared with standard CEF in metastatic breast cancer patients." | 5.09 | Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter G ( Bergaglio, M; Carnino, F; Comis, S; Contu, A; Del Mastro, L; Gallo, L; Guarneri, D; Lionetto, R; Pronzato, P; Rosso, R; Venturini, M; Vesentini, L, 2001) |
| "To evaluate the efficacy and toxicity of a cisplatin, epirubicin, gemcitabine, and fluorouracil (PEF-G) schedule on stage IV pancreatic adenocarcinoma." | 5.09 | Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma. ( Balzano, G; Di Carlo, V; Galli, L; Nicoletti, R; Panucci, MG; Passoni, P; Reni, M; Villa, E; Zerbi, A, 2001) |
| "To identify the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of oxaliplatin (L-OHP) given on a weekly schedule including fixed doses of leucovorin (LV) and infusional 5-fluorouracil (5-FU), to define the toxicity profile of this regimen and to find preliminary evidence of its activity in pretreated patients with metastatic colorectal cancer (MCRC)." | 5.09 | Phase I study of a weekly schedule of oxaliplatin, high-dose leucovorin, and infusional fluorouracil in pretreated patients with advanced colorectal cancer. ( Manzione, L; Pizza, C; Rosati, G; Rossi, A; Tucci, A, 2001) |
| "Thirty-three metastatic colorectal cancer patients were randomized to receive a 60-minute infusion of irinotecan before or after a 48-hour infusion of 5-FU modulated by LV." | 5.09 | Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients. ( Allegrini, G; Comis, S; Conte, P; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Lencioni, M; Masi, G; Pfanner, E, 2001) |
| "We sought to define the recommended dose of cyclophosphamide (CTX) for subsequent phase II assessment when combined with fixed doses of gemcitabine (Gemzar; Eli Lilly and Company, Indianapolis, IN) and 5-fluorouracil/folinic acid in metastatic breast cancer patients previously treated with anthracyclines and taxanes." | 5.09 | Gemcitabine/cyclophosphamide/5-fluorouracil/folinic acid triplet combination in anthracycline- and taxane-refractory breast cancer patients: a Southern Italy Cooperative Oncology Group phase I/II study. ( Botti, G; Capasso, I; Comella, G; Comella, P; Cortino, GR; D'Aiuto, G; De Rosa, V; Frasci, G; Thomas, R, 2001) |
| "The purpose of this study was to evaluate the activity and tolerance of high-dose leucovorin (LV) and infusional 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) as salvage chemotherapy in patients with metastatic breast cancer (MBC) pretreated with anthracyclines and taxanes." | 5.09 | Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracyclin ( Agelaki, S; Christodoulakis, M; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Mavroudis, D; Souglakos, J; Stylianou, K; Vamvakas, L, 2001) |
| "Oral capecitabine was evaluated in terms of overall response rate, safety, and tolerability as first-line therapy in women aged > or = 55 years with advanced/metastatic breast cancer." | 5.09 | Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. ( Bell, D; Blum, J; Burger, HU; Jones, SE; Laws, S; Mauriac, L; Miles, D; Moiseyenko, V; Oshaughnessy, JA; Osterwalder, B; Rosso, R, 2001) |
| "A total of 35 women with advanced, metastatic breast cancer were treated with combination chemotherapy consisting of folinic acid 500 mg/m2 over 2 hours administered with 600 mg/m2 of 5FU at the midpoint of the folinic acid infusion weekly for 6 weeks, plus 60 mg/m2 of thiotepa on day 1 and day 28." | 5.08 | Phase II trial of 5-fluorouracil, folinic acid, and N,N1,N11-triethylenethiophosphoramide (thiotepa) in patients with advanced breast cancer. ( Blumenreich, M; Hadley, T; Hamm, J; Hendler, F; Joseph, G; Morris, K; Seeger, J; Woodcock, T, 1995) |
| "Sixty-four consecutive patients with locally advanced (n = 7) or metastatic breast cancer (n = 57), were treated with a combination of laevofolinic acid 100 mg m-2 plus 5-fluorouracil 340 mg m-2 i." | 5.08 | Laevofolinic acid, 5-fluorouracil, cyclophosphamide and escalating doses of epirubicin with granulocyte colony-stimulating factor support in locally advanced and/or metastatic breast carcinoma: a phase I-II study of the Southern Italy Oncology Group (GOIM ( Agostara, B; Cariello, S; Colucci, G; Durini, E; Gebbia, V; Giotta, F; Pacilio, G; Pezzella, G; Romito, S; Testa, A, 1995) |
| "Seventy-six patients with bladder cancer Stage T1G3 through T4 N0 M0 were entered in the same chemotherapy regimen (Cisplatin 20 mg/mq and 5-Fluorouracil 200 mg/mq daily for 5 days) alternated with different radiotherapy scheduling, the first 18 patients received two cycles of 20 Gy/10 fractions/12 days each; the second group of 58 patients received two cycles of 25 Gy/10 fractions/12 days each (the last 21 patients received Methotrexate 40 mg/mq instead of 5-Fluorouracil)." | 5.08 | Alternating chemo-radiotherapy in bladder cancer: a conservative approach. ( Boccardo, F; Canobbio, L; Curotto, A; Franzone, P; Giudici, S; Guarneri, D; Martorana, G; Orsatti, M; Scarpati, D; Venturini, M, 1995) |
| "135 patients with locally advanced or metastatic colorectal cancer were entered into a phase III trial evaluating the efficacy of chemoimmunotherapy [recombinant interleukin 2 (rIL2)/5-fluorouracil (5-FU) and leucovorin (LV)] versus chemotherapy alone (5-FU/LV)." | 5.08 | A phase III study of recombinant interleukin-2, 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in patients with unresectable or metastatic colorectal carcinoma. ( de Peuter, RA; Eremin, O; Franks, CR; Heys, SD; Oskam, R; Palmer, PA; Pein, F; Rainer, H; Ruggeri, EM, 1995) |
| "Sixty-one patients with primary node positive stage III breast cancers were randomized to receive postoperative radiotherapy and doxorubicin-based chemotherapy (eight cycles of CAFt: cyclophosphamide, adriamycin, oral ftorafur) with or without tamoxifen as adjuvant treatment." | 5.08 | The prognosis of stage III breast cancer treated with postoperative radiotherapy and adriamycin-based chemotherapy with and without tamoxifen. Eight year follow-up results of a randomized trial. ( Blomqvist, C; Elomaa, I; Gröhn, P; Rissanen, P; Saarto, T; Tiusanen, K, 1995) |
| "These results indicate that suramin is inactive in patients with metastatic colorectal cancer pretreated with fluoropyrimidines." | 5.08 | Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine-based chemotherapy. A phase II study. ( Brunetti, I; Cianci, C; Conte, PF; Danesi, R; Del Tacca, M; Falcone, A; Pfanner, E, 1995) |
| "Phase II study results demonstrating high efficacy and low toxicity for a weekly schedule of high-dose 5-fluorouracil/folinic acid (5-FU/FA) in intensively pretreated metastatic breast cancer patients prompted the addition of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) to this regimen in a phase I/II trial in outpatients: high-dose 5-FU (24-hour infusion)/FA (2-hour infusion preceding 5-FU) is given for 6 weeks (days 1, 8, 15, 22, 29, and 36), with paclitaxel (3-hour infusion) administered on days 1 and 22; 2 weeks' rest follows." | 5.08 | Phase I/II study with paclitaxel in combination with weekly high-dose 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer: an interim analysis. ( Becher, R; Diergarten, K; Eberhardt, W; Harstrick, A; Klaassen, U; Pari, CP; Seeber, S; Strumberg, D; Wilke, H, 1995) |
| "We undertook a multicenter phase II trial of 5-fluorouracil (5FU) + 1-leucovorin (1-LV) in previously untreated patients with metastatic colorectal cancer to determine the response rate, response duration, time to progression, survival, and toxicity." | 5.08 | A phase II trial of 5-fluorouracil and 1-leucovorin in patients with metastatic colorectal cancer. ( Erlichman, C; Fine, S; Gorg, C; Gustavsson, B; Hoffmann, W; Kerr, I; Preusser, P; Schmoll, HJ; Thuerlimann, B, 1996) |
| "Infusional 5-fluorouracil (F) with cisplatin (C) and epirubicin (E), so-called infusional ECF, is a highly active new schedule against locally advanced or metastatic breast cancer." | 5.08 | Phase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infusional ECarboF): a very active and well-tolerated outpatient regimen. ( Allum, WH; Baum, M; Bonnefoi, H; Ebbs, S; O'Brien, ME; Powles, TJ; Seymour, MT; Smith, IE, 1996) |
| "Fourteen evaluable patients with metastatic bladder cancer were treated with 5-fluorouracil at 300 mg/m2 and folinic acid at 200 mg/m2 daily for five days." | 5.08 | A phase II study of 5-fluorouracil and high dose folinic acid in cisplatin-refractory metastatic bladder cancer. ( Aitken, SE; Huan, SD; Stewart, DJ, 1995) |
| "Methotrexate (MTX) has been described to modulate the activity of fluorouracil (5-FU) in patients with metastatic colorectal cancer." | 5.08 | Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: final results of a randomized European Organization for Research and Treatment of Cancer Study. ( Bleiberg, H; Blijham, G; Buset, M; Collette, L; Dalmark, M; de Greve, J; Lacave, A; Sahmoud, T; Selleslag, J; Wagener, T; Wils, J, 1996) |
| "From January 1992 to July 1993, 28 patients with metastatic breast cancer were entered in a phase II trial to assess the activity and toxicity of the combination of mitoxantrone, 5-fluoruracil, and leucovorin." | 5.08 | Salvage chemotherapy in metastatic breast cancer: an experience with the combination of mitoxantrone, 5-fluorouracil, and L-leucovorin. ( Anastasi, P; Basurto, C; Colozza, M; De Angelis, V; Giansanti, M; Gori, S; Ludovini, V; Mosconi, AM; Tonato, M, 1996) |
| "A phase II study was performed to evaluate the clinical and immunological effects of a regimen of fluorouracil (5-FU) and folinic acid (FA) combined with thymopentin (TP-5) and interleukin-2 (IL-2) in the treatment of patients with metastatic colorectal cancer." | 5.08 | Sequential biochemotherapy for metastatic colorectal cancer using fluorouracil, folinic acid, thymopentin and interleukin-2: clinical and immunological effects. ( Ameglio, F; Di Lauro, L; Frasca, AM; Gandolfo, GM; Garaci, E; Lopez, M; Paoletti, G; Rasi, G; Santini, S; Vitelli, G, 1995) |
| "Our phase II study results demonstrating high efficacy and low toxicity for a weekly schedule of high-dose 5-fluorouracil (5-FU)/folinic acid (FA) in intensively pretreated metastatic breast cancer patients prompted the addition of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) to this regimen in a phase I/ II outpatient study." | 5.08 | Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer. ( Klaassen, U; Seeber, S; Wilke, H, 1996) |
| "5-Fluorouracil (5-FU) remains the most active therapeutic agent in advanced colorectal cancer." | 5.08 | 5-Fluorouracil continuous infusion in metastatic colorectal cancer. ( Ang, PT; Tan, EH, 1996) |
| "To assess the antitumor efficacy and safety profile of the combination of Fluorouracil (5FU) and vinorelbine given as first-line therapy to patients with advanced breast cancer." | 5.08 | Efficacy and tolerance of vinorelbine and fluorouracil combination as first-line chemotherapy of advanced breast cancer: results of a phase II study using a sequential group method. ( Bellissant, E; Dieras, V; Espie, M; Extra, JM; Marty, M; Mignot, L; Morvan, F; Pierga, JY; Tresca, P, 1996) |
| "A comparative, randomized trial was conducted to determine the efficacy of oral UFT (Tegafur and Uracil) versus 5-fluorouracil (5-FU) in combination with cyclophosphamide and doxorubicin in patients with metastatic breast cancer." | 5.08 | A comparative, randomized trial of UFT and 5-fluorouracil in combination with cyclophosphamide and doxorubicin in the treatment of advanced breast cancer patients at The Philippines General Hospital. ( De Guzman, LM; Fernando, GY; Guancia, AA; Romana, IB; Samson, MC; Villalon, AH, 1997) |
| "5-Fluorouracil plus folinic acid and paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) are effective salvage therapies for metastatic breast cancer patients." | 5.08 | Paclitaxel, 5-fluorouracil, and folinic acid in metastatic breast cancer: BRE-26, a phase II trial. ( Hande, KR; Johnson, DH; Paul, D, 1997) |
| "Fifty-five women with metastatic breast cancer were treated with a regimen consisting of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) 175 mg/m2 administered intravenously over 3 hours on day 1 only plus leucovorin given intravenously over 30 to 60 minutes followed by 5-fluorouracil 350 mg/m2 via intravenous push on days 1 to 3 every 28 days for six cycles." | 5.08 | Paclitaxel/5-fluorouracil/leucovorin in metastatic breast cancer: a Vanderbilt Cancer Center phase II trial. ( Garrett, M; Hande, KR; Johnson, DH; Nicholson, B; Paul, D; Shyr, Y, 1997) |
| "Forty-five patients with advanced or metastatic breast cancer were enrolled in this phase I-II study and treated with 5-fluorouracil (350 mg/m2 i." | 5.08 | Phase I-II study of vinorelbine in combination with 5-fluorouracil and folinic acid as first-line chemotherapy in metastatic breast cancer: a regimen with a low subjective toxic burden. ( Aapro, M; Andreoni, G; de Braud, F; De Pas, TM; Goldhirsch, A; Minchella, I; Monti, S; Nolè, F; Zampino, MG, 1997) |
| "When administered as a single agent to previously treated patients with advanced breast cancer, paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has good activity." | 5.08 | A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5-fluorouracil/prednisone in previously untreated patients with advanced breast cancer: preliminary results. Taxol Investigational Trials Group, Australia/New Zealand. ( Ackland, S; Bishop, JF; Dewar, J; Goldstein, D; Gurney, H; Kennedy, I; Levi, J; Olver, I; Stephenson, J; Tattersall, MH; Toner, G; Walpole, E, 1997) |
| "Our phase II study results demonstrating high efficacy and low toxicity for a weekly schedule of high-dose, 24-hour infusional 5-fluorouracil (5-FU)/leucovorin (LV) in intensively pretreated patients with metastatic breast cancer prompted the addition of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) to the regimen for a phase I/II study of outpatient second-line treatment of metastatic breast cancer." | 5.08 | Infusional 5-fluorouracil/leucovorin plus paclitaxel and cisplatin in the first-line treatment of metastatic breast cancer: results of a phase II study. ( Borquez, D; Harstrick, A; Klaassen, U; Müller, C; Seeber, S; Wilke, H, 1997) |
| "Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) is a highly active single agent in the treatment of breast cancer." | 5.08 | Paclitaxel with mitoxantrone with or without 5-fluorouracil and high-dose leucovorin in the treatment of metastatic breast cancer. ( Greco, FA; Hainsworth, JD, 1997) |
| "In this phase II trial we have evaluated the activity and toxicity of a combination regimen containing mitoxantrone, L-leucovorin, and fluorouracil in patients with advanced breast cancer pretreated with anthracyclines." | 5.08 | Mitoxantrone, fluorouracil, and L-folinic acid in anthracycline-pretreated metastatic breast cancer patients. ( Acito, L; Bascioni, R; De Signoribus, G; Giorgi, F; Giuliodori, L; Giustini, L; Silva, RR; Testa, E, 1997) |
| "Sixty metastatic and recurrent breast cancer patients who had been given cyclophosphamide, methotrexate and fluorouracil (CMF) therapy previously and were treated at the Oncology Departments of Cukurova and Ege University Medical Schools between March 1992-94, were randomized into 2 groups for the chemotherapy program." | 5.08 | Refractory breast cancer: a comparison of two different chemotherapy regimens. ( Bilkay, BC; Burgut, R; Erkisi, M; Hazar, B; Seyrek, E, 1997) |
| "One hundred ninety-five women (141 eligible) whose disease was in CR or in CR except for bone metastases following six cycles (6 months) of doxorubicin-containing induction treatment were randomized to receive cyclophosphamide, methotrexate, fluorouracil, prednisone, tamoxifen, and halotestin [CMF(P)TH] or observation." | 5.08 | Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. ( Abeloff, MD; Cummings, FJ; Falkson, G; Gelman, RS; Osborne, CK; Pandya, KJ; Sledge, GW; Tormey, D, 1998) |
| "From February 1995 through October 1996, 25 patients with metastatic colorectal cancer showing a clinical resistance to 5-fluorouracil (5-FU) entered this study." | 5.08 | Synergistic activity of oxaliplatin and 5-fluorouracil in patients with metastatic colorectal cancer with progressive disease while on or after 5-fluorouracil. ( Aapro, MS; Biffi, R; Brienza, S; De Pas, T; deBraud, F; Munzone, E; Nolè, F, 1998) |
| "Bolus 5-fluorouracil (5-FU) is a phase-specific drug with a short plasma half-life that is used in combination with bolus cyclophosphamide and methotrexate in the treatment of breast cancer." | 5.08 | Cyclophosphamide, methotrexate and infusional 5-fluorouracil (infusional CMF) in metastatic breast cancer. ( Ganesan, TS; Harris, AL; Isaacs, R; Koukourakis, MI; O'Byrne, KJ; Salisbury, AJ; Saunders, MP; Talbot, DC; Taylor, M; Varcoe, S, 1998) |
| "A phase II trial was performed to investigate the efficacy and tolerance of vinorelbine (VNB), 5-fluorouracil (5-FU), l-leucovorin (LLV) and recombinant human granulocyte colony-stimulating factor (G-CSF) in advanced breast cancer." | 5.08 | Effective treatment of advanced breast cancer with vinorelbine, 5-fluorouracil and l-leucovorin plus human granulocyte colony-stimulating factor. ( Depisch, D; Haider, K; Hejna, M; Kornek, GV; Krauss, G; Kwasny, W; Lang, F; Raderer, M; Scheithauer, W; Weinländer, G, 1998) |
| "Patients with proven metastatic colorectal cancer, which had progressed within 6 months of treatment with fluorouracil, were randomly assigned either 300-350 mg/m2 irinotecan every 3 weeks with supportive care or supportive care alone, in a 2:1 ratio." | 5.08 | Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. ( Awad, L; Cunningham, D; Heikkila, R; Herait, P; Hickish, TF; Jacques, C; James, RD; Johannesen, TB; Punt, CJ; Pyrhönen, S; Starkhammar, H; Topham, CA, 1998) |
| "Data from 12 metastatic colorectal cancer patients who were submitted to a pilot study with a multistep subcutaneous (sc) low dose recombinant interleukin-2 (rIL-2), 5-fluorouracil (5-FU) and leucovorin (LV) administration were compared with those from 13 historical controls who were comparable for the major prognostic indices." | 5.08 | A multistep therapy with subcutaneous low dose recombinant interleukin-2, 5-fluorouracil and leucovorin prolongs the response of metastatic colorectal cancer patients: a pilot study. ( Anselmi, L; Carpi, A; Ferrari, P; Nicolini, A; Sagripanti, A, 1998) |
| " We conducted a Phase II trial of an anthracycline analogue, pirarubicin, administered in combination with 5-fluorouracil and cyclophosphamide every 3 weeks, as front-line chemotherapy in women with metastatic breast cancer." | 5.08 | Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer. ( Buzdar, A; Dhingra, K; Fraschini, G; Frye, D; Hortobagyi, GN; Newman, RA; Smith, T; Theriault, R; Walters, R, 1995) |
| "This multicenter phase II study was designed to assess the efficacy of the alternating schedule of irinotecan (CPT-11) with bolus 5-fluorouracil (5-FU) and leucovorin (LV) in first-line chemotherapy for metastatic colorectal cancer (CRC)." | 5.08 | A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer. ( Barone, C; Cognetti, F; Cote, C; Dirix, L; Filez, L; Garufi, C; Gruia, G; Humblet, Y; Pozzo, C; Starkhammar, H; Terzoli, E; Van Cutsem, E, 1998) |
| "The combination bendamustine/methotrexate/fluorouracil (BMF) was proven versus cyclophosphomide/methotrexate/fluorouracil (CMF) in a stratified randomized pilot study as primary chemotherapy in 61 patients with metastatic breast cancer." | 5.08 | [Primary chemotherapy of metastatic breast carcinoma with bendamustine hydrochloride, methotrexate and fluorouracil versus cyclophosphamide, methotrexate and fluorouracil]. ( Ruffert, K, 1998) |
| "Thirty-seven consecutive patients with advanced and/or metastatic gastric adenocarcinoma received a combination of 5-fluorouracil 600 mg/m2 on days 1, 8, 29, 36; epidoxorubicin 75 mg/m2 i." | 5.07 | Combination chemotherapy of 5-fluorouracil, epidoxorubicin and mitomycin C in the palliative treatment of locally advanced and/or metastatic adenocarcinoma of the stomach. ( Bajardi, G; Cannata, G; Cipolla, C; Curto, G; Gebbia, V; Latteri, M; Mastrandrea, G; Pischedda, G; Testa, A; Valenza, R, 1994) |
| "In a phase II study, we treated 35 women with metastatic breast cancer with the following regimen: mitoxantrone 12 mg/m2 i." | 5.07 | The use of mitoxantrone, 5-fluorouracil and high-dose leucovorin in the treatment of advanced breast cancer. ( Hainsworth, JD, 1993) |
| "Based upon the hypothesis that dipyridamole would potentiate the cytotoxicity of mitoxantrone and the combination of 5-fluorouracil (5-FU) and leukovorin, we performed a phase I/II trial of the combination of dipyridamole, 5-FU, leukovorin, and mitoxantrone in patients with metastatic breast cancer." | 5.07 | Phase I/II trial of dipyridamole, 5-fluorouracil, leukovorin, and mitoxantrone in metastatic breast cancer. ( Budd, GT; Bukowski, RM; Herzog, P, 1994) |
| "A phase II study to test the toxicity and the efficacy of a weekly combination of Mitoxantrone, 5-Fluorouracil and L-Leucovorin (MFL) was carried out in 43 patients with metastatic breast cancer." | 5.07 | Phase II study of weekly mitoxantrone, 5-fluorouracil, and leucovorin in metastatic breast cancer. ( Campora, E; Gardin, G; Giudici, S; Lanfranco, C; Merlini, L; Miglietta, L; Naso, C; Repetto, L; Testore, F; Venturino, A, 1994) |
| " administration of different doses of ADR-529 (600-1000 mg/m2) together with different doses of epirubicin (E, 60-100 mg/m2), fixed-dose cyclophosphamide (C, 600 mg/m2), fixed-dose 5-fluorouracil (F, 600 mg/m2), and daily administration of tamoxifen (T, 30 mg; CEF-T) in the treatment of patients with metastatic breast cancer." | 5.07 | The pharmacokinetics of high-dose epirubicin and of the cardioprotector ADR-529 given together with cyclophosphamide, 5-fluorouracil, and tamoxifen in metastatic breast-cancer patients. ( Bastholt, L; Gjedde, SB; Jakobsen, P; Mirza, MR; Mouridsen, HT; Rose, C; Sørensen, B, 1994) |
| " 414 premenopausal patients with T2-T3 N0-N1 M0 breast cancer were randomised to receive either four cycles of neoadjuvant chemotherapy (cyclophosphamide, doxorubicin, 5-fluorouracil), followed by local-regional treatment (group I) or four cycles of adjuvant chemotherapy after primary irradiation +/- surgery (group II)." | 5.07 | Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. ( Asselain, B; Beuzeboc, P; Dorval, T; Durand, JC; Fourquet, A; Jouve, M; Palangié, T; Pierga, JY; Scholl, SM; Vilcoq, JR, 1994) |
| "To investigate the efficacy and toxicity of continuous infusion fluorouracil (5-FU) with every-3-weeks epirubicin and cisplatin (ECF) in advanced breast cancer in a phase II study." | 5.07 | Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: an active new regimen. ( Ashley, S; Jones, AL; O'Brien, ME; Ramage, F; Robertshaw, H; Smith, IE; Talbot, D; Walsh, G, 1994) |
| "60 patients with metastatic breast cancer were entered in a phase II study using folinic acid, 5-fluorouracil bolus and infusion and mitoxantrone with or without cyclophosphamide." | 5.07 | Folinic acid, 5-fluorouracil bolus and infusion and mitoxantrone with or without cyclophosphamide in metastatic breast cancer. ( Beerblock, K; de Gramont, A; Demuynck, B; Guillot, T; Krulik, M; Louvet, C; Marpeau, L; Pigné, A; Soubrane, D; Varette, C, 1993) |
| "In a Phase I-II clinical trial, 19 ambulatory women with metastatic breast cancer were treated with a combination of mitoxantrone, 5-fluorouracil, and leucovorin (MFL)." | 5.07 | A phase I clinical trial of a combination of mitoxantrone, 5-fluorouracil, and high-dose leucovorin given on a day 1 and day 8 schedule to patients with metastatic breast cancer. ( Gomez, EG; Vogel, CL, 1994) |
| "To compare the effect on toxicity and efficacy of the fluorouracil 500 mg/m2, epirubicin 60 mg/m2, and cyclophosphamide 500 mg/m2 (FEC) regimen divided into 4 weekly doses with conventional every-4-week administration in metastatic breast cancer." | 5.07 | Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin, and fluorouracil in metastatic breast cancer: a randomized trial comparing weekly and every-4-week administration. ( Blomqvist, C; Elomaa, I; Helle, L; Hietanen, P; Nevasaari, K; Rissanen, P, 1993) |
| "A phase II study was undertaken to assess the effect of CAF plus depo-buserelin, as first-line treatment, in premenopausal women with breast cancer." | 5.07 | Cyclophosphamide, doxorubicin and fluorouracil (CAF) plus depo-buserelin in the treatment of premenopausal women with metastatic breast cancer. ( Falkson, CI; Falkson, G; Falkson, HC, 1992) |
| "From January 31, 1986 to January 31, 1989, 184 eligible patients were enrolled in a randomized study of either infusional or bolus 5-fluorouracil (5-FU) for the treatment of metastatic measurable colorectal cancer." | 5.07 | Systemic infusion versus bolus chemotherapy with 5-fluorouracil in measurable metastatic colorectal cancer. ( Bogues, W; Cripps, IC; Fields, A; Maroun, J; McCormick, R; Pater, J; Shah, A; Temple, W; Weinerman, B; Wilson, K, 1992) |
| "Fifty-five women with metastatic breast cancer were treated with carboplatin (CBDCA), 55 mg/m2 i." | 5.07 | Carboplatin (CBDCA), 5-fluorouracil (5-FU) and mitoxantrone (DHAD): an effective and well tolerated regimen for metastatic breast cancer. ( Gonzalez, FG; Herranz, P; Hidalgo, OF; Rebollo, J; Tangco, E; Vieitez, JM, 1992) |
| "Sixty-seven patients with advanced breast cancer were prospectively entered into a Phase II trial of cyclophosphamide 100 mg/m2 orally on days 1-14, methotrexate 40 mg/m2 intravenously (i." | 5.07 | A phase II trial of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisolone rapidly alternating with doxorubicin and vincristine (CMFP/AV) in advanced breast cancer. ( Bishop, JF; Dipell, JF; Jeal, P; Laidlaw, CR; Olver, IN; Rischin, D; Zimet, A, 1992) |
| "In a randomised study 142 patients with advanced oestrogen-receptor-negative breast cancer in the tumour tissue received chemotherapy alone or chemotherapy combined with high doses (1000 mg daily) of oral medroxyprogesterone acetate (HD-MPA)." | 5.07 | Chemotherapy with or without high-dose medroxyprogesterone acetate in oestrogen-receptor-negative advanced breast cancer. Norwegian Breast Cancer Group. ( Gundersen, S; Hannisdal, E; Høst, H; Klepp, O; Kvinnsland, S; Lund, E, 1992) |
| "A high rate of response to 5-fluorouracil (5FU) and alpha-interferon (alpha IFN) combination therapy has been reported in metastatic colorectal cancer patients." | 5.07 | Alpha-interferon in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer: a phase I study. ( Burghouts, JT; de Mulder, PH; Punt, CJ; Wagener, DJ, 1992) |
| "Several reports on fluorouracil (5-FU) and alfa interferon (IFN-alpha) combination therapy in patients with advanced colorectal cancer have been published." | 5.07 | Fluorouracil continuous infusion plus alfa interferon plus oral folinic acid in advanced colorectal cancer. ( Burghouts, JT; de Mulder, PH; Punt, CJ; Wagener, DJ, 1992) |
| "In a clinical phase II study, 23 patients with progressive metastatic colorectal cancer and failure after first-line chemotherapy with fluorouracil (5-FU) and folinic acid (FA) were treated with a 5-day continuous infusion of recombinant interleukin-2 (IL-2), 3 x 10(6) cetus U/m2/d, followed after a rest period of 2 days by 5-FU, 600 mg/m2/d, and FA, 300 mg/m2/d over an additional 3 days." | 5.07 | Interleukin-2 followed by fluorouracil and folinic acid in refractory colorectal cancer--results of a clinical phase II study. ( Hiddemann, W; Koch, O; Musch, E; Ottensmeier, C; Rückle, H; Ruelfs, C; van de Loo, J, 1992) |
| "The mechanisms of biochemical modulation of 5-fluorouracil (5-FU) cytotoxicity by folinic acid (FA) have been elucidated, and the clinical use of this combination has improved response rates and survival in patients with metastatic colorectal cancer." | 5.07 | A phase I trial of 5-fluorouracil, folinic acid, and alpha-2a-interferon in patients with metastatic colorectal carcinoma. ( Bauer, L; Budd, GT; Bukowski, RM; Gibson, V; Inoshita, G; Murthy, S; Prestifilippo, J; Sergi, JS; Yalavarthi, P, 1992) |
| "5-Fluorouracil (5-FU) remains the most effective chemotherapeutic agent in the management of patients with metastatic colorectal cancer." | 5.07 | Treatment of advanced colorectal cancer by 5-fluorouracil-leucovorin combination with or without allopurinol: a prospective randomized study. ( Chaitchik, S; Inbar, M; Merimsky, O, 1991) |
| "A new combination of mitoxantrone, folinic acid (leucovorin), and infusional fluorouracil (5-FU) was administered to 57 previously treated patients with metastatic breast cancer to evaluate the response rate, response duration, and toxicity of this regimen." | 5.07 | Phase II study of mitoxantrone, leucovorin, and infusional fluorouracil for treatment of metastatic breast cancer. ( Allison, MA; Brooks, B; Jones, SE; Mennel, RG; Paulson, RS; Rea, B; Tilmann, K; Westrick, MA, 1991) |
| "Between September 1988 and August 1990, we treated 35 women with metastatic breast cancer with a novel regimen containing mitoxantrone, fluorouracil (5-FU), and high-dose leucovorin." | 5.07 | Mitoxantrone, fluorouracil, and high-dose leucovorin: an effective, well-tolerated regimen for metastatic breast cancer. ( Andrews, MB; Greco, FA; Hainsworth, JD; Johnson, DH, 1991) |
| "A phase I study of 5-fluorouracil 600 mg/m2/week and folinic acid 500 mg/m2/week on day 1 and cisplatin administered weekly on day 2 was carried out on 30 patients with metastatic colorectal carcinoma of which 20 patients were pretreated with 5-fluorouracil." | 5.07 | A phase I study of cisplatinum plus 5-fluorouracil in modulation with citrovorum factor in metastatic colorectal carcinoma. ( Creaven, P; Gebbia, N; Gebbia, V; Palmeri, S; Petrelli, N; Rausa, L; Russo, A; Rustum, Y, 1991) |
| "We treated 250 women with metastatic breast cancer with six courses of cyclophosphamide, doxorubicin, and fluorouracil given every three weeks." | 5.07 | Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. ( Capizzi, RL; Case, LD; Cooper, MR; Cruz, JM; Muss, HB; Powell, BL; Richards, F; Spurr, CL; White, DR, 1991) |
| "Forty four patients who had documented progression of metastatic colorectal cancer while receiving 5-fluorouracil (5-FU) monotherapy were treated with continuous infusion 5-FU, 300 mg/mg2/day, plus weekly low-dose cisplatin, 20 mg/m2." | 5.07 | Protracted infusion of 5-FU with weekly low-dose cisplatin as second-line therapy in patients with metastatic colorectal cancer who have failed 5-FU monotherapy. ( Ahlgren, JD; Goldberg, R; Gullo, JJ; Muir, WA; Schacter, L; Sisk, R; Trocki, O, 1991) |
| "Thirty patients with advanced breast cancer, previously treated with anthracycline and 5 fluorouracil in bolus administration, were evaluated with a chemotherapy regimen generally used in head and neck cancer." | 5.06 | [Phase II trial as 2nd line chemotherapy with 5 fluorouracil and cisplatin (5FU-CDDP) for advanced breast cancer]. ( Bastit, P; Bugat, R; Cappelaere, P; Chauvergne, J; Fumoleau, P; Horner, D; Metz, R, 1990) |
| " Our earlier study in breast cancer showed that second-line CAP (cyclophosphamide, adriamycin, cis-platinum) treatment was not cross-resistant to the CMFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisolone) regimen and produced a 51% response rate." | 5.06 | cis-platinum-based alternating non-cross-resistant chemotherapy as a first-line treatment in metastatic breast cancer. A phase II study. ( Kolarić, K; Tomek, R, 1990) |
| "Ninety-one patients with metastatic colorectal cancer were treated with continuous ambulatory 5-fluorouracil (5FU) infusion 250-300 mg/m2/day through a chronic indwelling central venous catheter." | 5.06 | Continuous systemic 5-fluorouracil infusion in advanced colorectal cancer: results in 91 patients. ( Anderson, T; Ausman, R; Beatty, P; Frick, J; Haas, C; Hansen, R; Quebbeman, E; Ritch, P; Schulte, W, 1989) |
| "A randomized trial was performed to determine relative efficacy and toxicity of two first-line combination chemotherapy regimens in women with metastatic breast cancer: CFP (cyclophosphamide, 5-fluorouracil, prednisone) and CMFP (cyclophosphamide, 5-fluorouracil, methotrexate, prednisone)." | 5.06 | Randomized clinical trial of CFP versus CMFP in women with metastatic breast cancer. ( Cullinan, SA; Ebbert, LP; Ingle, JN; Krook, JE; Mailliard, JA; Marschke, RF; Pfeifle, DM; Schaid, DJ; Votava, HJ; Windschitl, HE, 1989) |
| "The efficacy and toxicity of leucovorin 500 mg/m2 administered intravenously (IV) over 30 minutes daily for five days followed in one hour by fluorouracil (5-FU) 375 mg/m2 administered IV daily for five days, each given every 3 weeks, was assessed in 54 previously treated patients with metastatic breast cancer." | 5.06 | Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. ( Allegra, CJ; Drake, JC; Egan, EF; Lippman, ME; Steinberg, SM; Swain, SM, 1989) |
| "Seventy-seven patients with previously untreated, measurable, histologically confirmed, metastatic adenocarcinoma of the rectum or sigmoid were randomized to receive either epirubicin 90 mg/m2 (75 mg/m2 if prior radiotherapy) i." | 5.06 | A phase III randomized trial of epirubicin versus 5-fluorouracil in metastatic rectal/sigmoid adenocarcinoma. ( Blum, RH; Lafleur, F; Molinaro, P, 1989) |
| "Fifty patients with locally far progressed or metastasizing gastric carcinoma were treated with 5-fluorouracil, adriamycin and methotrexate using a slight modification of the FAMeth schema." | 5.06 | [The results of a modified FAMeth chemotherapy protocol in metastatic stomach carcinoma]. ( Crone-Münzebrock, W; Garbrecht, M; Henne-Bruns, D; Hossfeld, DK; Kremer, B; Platz, D; Weh, HJ, 1989) |
| "Two hundred sixty-three patients with advanced breast cancer were randomized to two treatment regimens consisting of fluorouracil, 500 mg/m2; cyclophosphamide, 500 mg/m2; and either epirubicin (Farmorubicin, Farmitalia Carlo Erba SpA, Italy), 50 mg/m2 (FEC); or doxorubicin (Adriamycin, Adria Laboratories, Columbus, OH), 50 mg/m2 (FAC), administered intravenously (IV) every 3 weeks." | 5.06 | A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group. ( , 1988) |
| "94 evaluable patients with metastatic breast cancer were randomly assigned to 5-fluorouracil, adriamycin, and cyclophosphamide (FAC) or 5-fluorouracil, epirubicin, and cyclophosphamide (FEC), with cycles repeated every 3 weeks." | 5.06 | 5-Fluorouracil, adriamycin, cyclophosphamide (FAC) vs. 5-fluorouracil, epirubicin, cyclophosphamide (FEC) in metastatic breast cancer. ( Carpano, S; Conti, EM; Di Lauro, L; Lopez, M; Papaldo, P; Vici, P, 1989) |
| " Patients were stratified by the presence or absence of hepatic metastases and by performance status, and were subsequently randomized to receive fluorouracil (5-FU) (15 mg/kg/wk) alone or the same dose of 5-FU plus cisplatin (60 mg/m2 every 3 weeks)." | 5.06 | A prospective randomized trial of fluorouracil versus fluorouracil plus cisplatin in the treatment of metastatic colorectal cancer: a Hoosier Oncology Group trial. ( Ansari, R; Correa, J; Hui, S; Kubilis, P; Loehrer, PJ; Meyer, S; Stephens, D; Turner, S; Woodburn, R, 1988) |
| "One hundred thirty-three consecutive, previously untreated patients who had metastatic breast cancer were treated with a combination of 5-fluorouracil, doxorubicin (Adriamycin), and cyclophosphamide (FAC)." | 5.06 | Combined antiestrogen and cytotoxic therapy with pseudomonas vaccine immunotherapy for metastatic breast cancer. A prospective, randomized trial. ( Ames, FC; Buzdar, AU; Fraschini, G; Frye, D; Gutterman, JU; Hortobagyi, GN; Hug, V; Martin, RG; Montague, E, 1987) |
| "Ninety-seven eligible and evaluable women with metastatic breast cancer were placed on a prospective clinical protocol to evaluate the use of continuous cyclic therapy with dibromodulcitol, doxorubicin, vincristine, tamoxifen, and fluoxymesterone (DAVTH) v DAVTH alternating with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP); and the use of pretreatment and serial carcinoembryonic antigen (CEA) levels in these patients." | 5.06 | Prospective evaluation of carcinoembryonic antigen levels and alternating chemotherapeutic regimens in metastatic breast cancer. ( Chang, AY; Davis, TE; Falkson, G; Falkson, HC; Loprinzi, CL; Rasmussen, P; Tormey, DC, 1986) |
| "In a randomized crossover study, 181 patients over the age of 65 with recurrent breast cancer received either tamoxifen or cyclophosphamide, methotrexate, and fluorouracil (CMF)." | 5.06 | Combination chemotherapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women. ( Cummings, FJ; Falkson, G; Gelman, RS; Taylor, SG, 1986) |
| "A total of 97 women with good-risk metastatic breast cancer received therapy with cyclophosphamide, doxorubicin, and 5-FU; half of these patients were randomly allocated to receive levamisole, 2." | 5.06 | Ineffectiveness of levamisole in prolonging remission or survival of women treated with cyclophosphamide, doxorubicin, and 5-fluorouracil for good-risk metastatic breast carcinoma: a Southeastern Cancer Study Group Trial. ( Carpenter, JT; Raney, M; Smalley, RV; Vogel, CL; Weiner, RS, 1986) |
| "Diethylstilbestrol (DES) can induce a recruitment into the proliferative pool of previously resting breast cancer cells in vivo." | 5.06 | Conventional versus cytokinetic polychemotherapy with estrogenic recruitment in metastatic breast cancer: results of a randomized cooperative trial. ( Alama, A; Amadori, D; Conte, PF; Demicheli, R; Gardin, G; Gentilini, P; Jacomuzzi, A; Lionetto, R; Pronzato, P; Rubagotti, A, 1987) |
| "Fifty-nine evaluable patients under 65 years of age with measurable metastatic breast cancer and without prior chemotherapy were randomly assigned to treatment with fluorouracil, Adriamycin (Adria Laboratories, Columbus, OH), and cyclophosphamide (FAC) at standard or high doses (100% to 260% higher than standard FAC) following a dose escalation schedule." | 5.06 | Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study. ( Blumenschein, GR; Bodey, GP; Buzdar, AU; Frye, D; Hortobagyi, GN; Legha, SS; Malik, R; Rodriguez, V; Smith, TL; Yap, HY, 1987) |
| "Fifty consecutive patients with recurrent and metastatic endometrial carcinoma were treated with melphalan, 5-fluorouracil, and medroxyprogesterone acetate with or without tamoxifen as first-line chemotherapy." | 5.06 | Melphalan, 5-fluorouracil, and medroxyprogesterone acetate in metastatic endometrial carcinoma. ( Emrich, LJ; Lele, SB; Patsner, B; Piver, MS, 1986) |
| "Seventy-six patients with metastatic breast cancer were treated with fluorouracil, adriamycin (doxorubicin) and cyclophosphamide (FAC) plus high-dose medroxyprogesterone acetate (HD-MPA)." | 5.05 | 5-Fluorouracil, adriamycin and cyclophosphamide combined with high-dose medroxyprogesterone acetate in advanced breast cancer. ( Barduagni, A; Barduagni, M; Di Lauro, L; Lopez, M; Papaldo, P; Perno, CF, 1983) |
| "One hundred-forty-five postmenopausal women with metastatic breast cancer entered a prospective randomized trial comparing treatment A (cyclophosphamide, methotrexate, and 5-fluorouracil; CMF) with treatment B (the same chemotherapy plus tamoxifen; CMF plus T)." | 5.05 | Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer. A prospective randomized study. ( Amadori, D; Boni, C; Cocconi, G; De Lisi, V; Giovanelli, E; Malacarne, P; Mori, P, 1983) |
| "One hundred thirty-six patients with isolated recurrence of breast cancer received regional therapy (surgery and/or irradiation) followed by combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide (FAC)." | 5.05 | Combined modality approach in breast cancer with isolated or multiple metastases. ( Blumenschein, GR; Buzdar, AU; Hortobagyi, GN; Marcus, CE; Montague, ED; Pinnamaneni, K; Smith, TL; Yap, HY, 1984) |
| "The prospective controlled phase III clinical trial compared the therapeutic value of the cis-platinum - adriamycin - cyclophosphamide combination (CAP) and that of the combination of cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisolone (CMFVP) in untreated metastatic breast cancer." | 5.05 | CAP (cyclophosphamide, adriamycin, platinum) vs CMFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisolone) combination chemotherapy in untreated metastatic breast cancer. A preliminary report of a controlled clinical study. ( Cervek, J; Kolarić, K; Roth, A; Vukas, D, 1984) |
| "Fifty-five patients with newly diagnosed, estrogen receptor negative, metastatic breast cancer were entered in a trial of mitoxantrone, 10 mg/m2 intravenous (IV), cyclophosphamide, 500 mg/m2 IV, and 5-fluorouracil, 1000 mg/m2 IV, which were given on day 1 of a 21-day treatment interval." | 5.05 | Mitoxantrone, cyclophosphamide, and 5-fluorouracil in the treatment of hormonally unresponsive metastatic breast cancer. ( Blumenschein, GR; Buzdar, AU; Esparza, L; Holmes, FA; Hortobagyi, GN; Yap, HY, 1984) |
| "Twenty-nine patients with advanced adenocarcinoma of the pancreas were treated with a combination of mitomycin-C, 5-fluorouracil, and adriamycin (MIFA III)." | 5.05 | MIFA III (mitomycin-C, 5-fluorouracil, and adriamycin) chemotherapy for advanced adenocarcinoma of the pancreas. ( Cheng, EW; Magill, GB; Sordillo, PP; Sternberg, CN, 1984) |
| "104 nonrandomized patients suffering from metastatic breast cancer were treated with monthly cycles of cyclophosphamide, methotrexate and 5-fluorouracil (CMF)." | 5.05 | Cyclic combination chemotherapy for metastatic breast cancer: comparison of two CMF schedules. ( Biran, S; Brufman, G, 1981) |
| "In 1977 we reported our results of an ongoing randomized clinical trial evaluating early or delayed adjuvant chemotherapy utilizing 5-flourouracil, cytoxan and prednisone in premenopausal patients with recurrent or advanced breast cancer." | 5.05 | An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advances breast cancer undergoing oophorectomy: a later analysis. ( Ahmann, DL; Bisel, HF; Edmonson, JH; Green, SJ; Hahn, RG; Ingle, JN; Lee, RA, 1982) |
| "To assess the effects of postoperative radiation therapy and chemotherapy on tumor recurrence and patient survival, 227 patients (data on 202 of whom were analyzed) who had undergone "curative" surgical resection for rectal adenocarcinoma were prospectively and randomly assigned to one of four treatments: no adjuvant therapy (concurrent controls, 58 patients), postoperative radiotherapy with 4000 or 4800 rad (50 patients), postoperative chemotherapy (fluorouracil and semustine [methyl-CCNU], 48 patients), or a combination of radiation therapy and chemotherapy (46 patients)." | 5.05 | Prolongation of the disease-free interval in surgically treated rectal carcinoma. ( , 1985) |
| "Data on 162 women (90 premenopausal and 72 postmenopausal) with metastatic breast cancer randomized to receive cyclophosphamide, Adriamycin (doxorubicin) and 5-fluorouracil (CAF) on two Eastern Cooperative Oncology Group (ECOG) protocols were analyzed." | 5.05 | The Eastern Cooperative Oncology Group experience with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer. ( Carbone, PP; Cummings, FJ; Falkson, G; Falkson, HC; Gelman, RS; Tormey, DC, 1985) |
| "One hundred fifty-five eligible women with metastatic breast cancer were randomly allocated to receive monthly cycles of either CMFP (cyclophosphamide, methotrexate, 5-fluorouracil, prednisone) or CAF (cyclophosphamide, doxorubicin, 5-fluorouracil), and 12 patients were studied to evaluate the effects of additional Corynebacterium parvum immunotherapy." | 5.05 | Comparison of CAF versus CMFP in metastatic breast cancer: analysis of prognostic factors. ( Cummings, FJ; Gelman, R; Horton, J, 1985) |
| "Thirty-eight patients with advanced breast cancer were treated with the 'VEMFAH' multiple-drug combination chemotherapy, consisting of vincristine (V), cyclophosphamide (Endoxan; E), methotrexate (M), 5-fluorouracil (F), adriamycin (A), and prednisolone (H)." | 5.05 | The effects of multiple combination chemotherapy with vincristine, cyclophosphamide (Endoxan), methotrexate, 5-fluorouracil, adriamycin and prednisolone (VEMFAH) for advanced breast cancer. ( Hoshino, A; Ito, Y; Kamiya, O; Kinoshita, T; Kojima, T; Nagata, K; Ohara, K; Sato, H; Sugiura, I; Yamada, M, 1985) |
| "Thirty-one patients with carcinoma of the breast with metastases were treated by adrenalectomy-oophorectomy and randomized either for combined chemotherapy, vincristine, fluorouracil, methotrexate and thiotepa, beginning within one week after operation and continuing for three months or no chemotherapy." | 5.04 | Adrenalectomy-oophorectomy and combined chemotherapy for carcinoma of the breast with metastases. ( Cady, B; Oberfield, RA; Pazianos, AG; Salzman, FA, 1979) |
| "In a prospective study eleven patients with metastasizing breast cancer were treated with 5-fluorouracil, adriamycin, and cyclophosphamide )FAC)." | 5.04 | [Adriamycin, cyclophosphamide, and 5-fluorouracil in the treatment of metastasizing breast cancer (author's transl)]. ( Boecker, WR; Höffken, K; Schmidt, CG; Seeber, S, 1976) |
| "Sixty patients with metastatic or primary inoperable breast cancer not suitable for hormone alteration therapy were blindly randomized between weekly 5-fluorouracil, intravenously, and daily physiologic doses of conjugated estrogens by mouth against weekly 5-fluorouracil, intravenously, and placebo." | 5.04 | Clinical studies of 5-fluorouracil + premarin in the treatment of breast cancer. ( Colsky, J; Hall, TC; Pocock, SJ; Shnider, BI; Taylor, SG, 1975) |
| "The results obtained in 14 patients suffering from hormone-resistant metastatic breast cancer treated with the following association: methotrexate (5-fluorouracyl in case of methotrexate intolerance), cyclophosphamide, vinblastin administered i." | 5.04 | [Combination antimetabolite-alkylating agent-vinblastine in the treatment of advanced breast cancer]. ( Germiniani, R; Lavorato, F; Pipino, G, 1977) |
| "Thirty-four patients with metastatic breast cancer and no prior chemotherapy were treated with an induction regimen of four courses of adriamycin-cyclophosphamide followed by a fixed sequence of three courses of methotrexate-5-fluorouracil alternating with each course of adriamycin-cyclophosphamide." | 5.04 | Treatment of metastatic breast cancer with adriamycin-cyclophosphamide induction followed by alternating combination therapy. ( Abeloff, MD; Ettinger, DS, 1977) |
| "One hundred and thirty-two previously untreated patients with metastatic adenocarcinoma of the gastrointestinal (GI) tract were randomized to receive either a 120-hr infusion of 5-fluorouracil (5FU) with mitomycin-C or mitomycin-C alone." | 5.04 | Mitomycin-C alone and in combination with infused 5-fluorouracil to the treatment of disseminated gastrointestinal carcinomas. ( Baker, LH; Buroker, TR; Kim, PN; Ratanatharathron, V; Vaitkevicius, VK; Wojtaszak, B, 1978) |
| "A prospective randomized trial was conducted comparing the clinical response of 78 previously untreated patients with advanced metastatic breast cancer to a combination of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) or to a combination of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF)." | 5.04 | A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. ( Blom, J; Bull, JM; Carbone, PP; Falkson, G; Li, SH; Perlin, E; Simon, R; Tormey, DC, 1978) |
| "In a randomized multi-institutional trial of the Eastern Cooperative Oncology Group, 316 patients with advanced measurable colorectal adenocarcinoma were treated with a weekly schedule of 5-fluorouracil given orally and intravenously with oral-5-fluorouracil in combination with cyclophosphamide or 6-thioguanine, or with oral Methyl CCNU administered once every eight weeks." | 5.04 | Chemotherapy of advanced measurable colon and rectal carcinoma with oral 5-fluorouracil, alone or in combination with cyclophosphamide or 6-thioguanine, with intravenous 5-fluorouracil or beta-2'-deoxythioguanosine or with oral 3(4-methyl-cyclohexyl)-1(2- ( Carbone, P; Conroy, JF; Douglass, HO; Lavin, PT; Woll, J, 1978) |
| "Twenty-seven patients with a diagnosis of metastatic adenocarcinoma of the prostate were treated in a randomized, prospective trial with either Cyclophosphamide or a combination of Adriamycin, 5-Fluorouracil, and Cyclophosphamide." | 5.04 | Cyclophosphamide (NSC 26271) versus the combination of adriamycin (NSC 123127), 5-fluorouracil (NSC 19893), and cyclophosphamide in the treatment of metastatic prostatic cancer: a randomized trial. ( Bateman, JR; Chlebowski, RT; Hestorff, R; Sardoff, L; Weiner, J, 1978) |
| "Seventy-eight advanced breast cancer patients with hormone-resistant disease or visceral metastases were randomized to receive either of two low dose regimens consisting of cyclophosphamide (C), methotrexate (M), 5-fluorouracil (F), and Adriamycin (A) as their initial chemotherapy." | 5.04 | Low dose chemotherapy of metastatic breast cancer with cyclophosphamide, adriamycin, methotrexate, 5-fluorouracil (CAMF) versus sequential cyclophosphamide, methotrexate, 5-fluorouracil (CMF) and adriamycin. ( Catalano, RB; Creech, RH; Engstrom, PF; Grotzinger, PJ; Harris, DT, 1979) |
| "The addition of levamisole, administered in adjunctive manner between the cycles of conventional high dose chemotherapy in patients with hormone resistant end state breast cancer substantially improved the survival of treated patients." | 5.04 | Levamisole: as adjuvant to cyclic chemotherapy in breast cancer. ( Mason, B; Stephens, EJ; Wood, HF, 1978) |
| "One hundred and fourteen evaluable patients with measurable metastatic breast cancer were treated with a combination chemoimmunotherapy program (5-fluorouracil, adriamycin, and cyclophosphamide [FAC-levamisole [LSM])." | 5.04 | Response of disseminated breast cancer to combined modality treatment with chemotherapy and levamisole with or without Bacillus Calmette-Guérin. ( Blumenschein, GR; Buzdar, AU; Gutterman, JU; Hersh, EM; Hortobagyi, GN; Tashima, CK; Yap, HY, 1978) |
| "Forty-five patients with disseminated breast cancer were given a trial of combination chemotherapy consisting of fluorouracil, adriamycin, and cyclophosphamide (FAC) and immunotherapy with BCG given by scarification." | 5.04 | Chemoimmunotherapy of advanced breast cancer: prolongation of remission and survival with BCG. ( Blumenschein, GR; Burgess, MA; Cardenas, JO; Freireich, EJ; Gottlieb, JA; Gutterman, JU; Hersh, EM; Hortobagyi, G; Livingston, RB; Mavligit, GM, 1976) |
| "We treated randomly 75 premenopausal patients with advanced breast cancer with combination chemotherapy (5-fluorouracil, cyclophosphamide and prednisone), either as an early adjunct to oophorectomy or as a delayed treatment upon appearance of progressive metastatic disease after operation." | 5.04 | An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advanced breast cancer undergoing oophorectomy. ( Ahmann, DL; Bisel, HF; Edmonson, JH; Hahn, RG; Lee, RA; O'Connell, MJ, 1977) |
| "A prospective study with two cytotoxic combinations (cyclophosphamide, methotrexate, and fluorouracil (CMF), and adriamycin plus vincristine (AV)) was carried out in 110 patients with advanced breast cancer." | 5.04 | Response and survival in advanced breast cancer after two non-cross-resistant combinations. ( Bonadonna, G; Brambilla, C; De Lena, M; Rossi, A; Valagussa, P, 1976) |
| "We performed the present systematic review and meta-analysis to evaluate the efficacy and safety for S-1-based regimens comparing to intravenous fluorouracil-based ones in Asian patients with metastatic colorectal carcinoma (mCRC)." | 5.01 | Efficacy and safety assessment of S-1-based regimens comparing to intravenous fluorouracil-based ones in Asian patients with metastatic colorectal carcinoma: A system review and meta-analysis. ( Chen, J; Wang, J, 2019) |
| "This meta-analysis aims to evaluate chemotherapy with XELOX (capecitabine plus oxaliplatin) versus FOLFOX (fluorouracil plus oxaliplatin) as a treatment for metastatic colorectal cancer (mCRC) in terms of efficacy and safety." | 4.93 | XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis. ( Cheng, Y; Guo, Y; Ma, L; Xiong, BH; Zhang, T, 2016) |
| "To compare the incidence of toxicity of 8 different chemotherapy regimens, including doxorubicin + paclitaxel, doxorubicin, capecitabine, CMF (cyclophosphamide + methotrexate + 5-fluorouracil), FAC (fluorouracil + doxorubicin + cyclophosphamide), doxorubicin + docetaxel, doxorubicin + cyclophosphamide and paclitaxel in the treatment of metastatic/advanced breast cancer." | 4.93 | A network meta-analysis for toxicity of eight chemotherapy regimens in the treatment of metastatic/advanced breast cancer. ( Gao, B; Guo, LJ; Hao, S; Jiang, Y; Luo, DL; Tian, WG; Zhang, S; Zhang, XH, 2016) |
| "The relative efficacy and safety of first-line metastatic colorectal cancer (mCRC) treatment regimens, capecitabine with irinotecan (CAPIRI) and 5-fluorouracil/leucovorin plus irinotecan (FOLFIRI), are not well defined." | 4.91 | Meta-analysis comparing the safety and efficacy of metastatic colorectal cancer treatment regimens, capecitabine plus irinotecan (CAPIRI) and 5-fluorouracil/leucovorin plus irinotecan (FOLFIRI). ( Cao, J; Ding, HH; Ji, ZY; Jiang, T; Jin, JH; Song, WF; Wang, JJ; Wang, LW; Wu, WD, 2015) |
| "The National Institute for Health and Care Excellence (NICE) invited the manufacturer of aflibercept (Sanofi) to submit clinical and cost-effectiveness evidence for aflibercept in combination with irinotecan and fluorouracil-based therapy [irinotecan/5-fluorouracil/folinic acid (FOLFIRI)] for the treatment of metastatic colorectal cancer which has progressed following prior oxaliplatin-based chemotherapy, as part of the Institute's Single Technology Appraisal process." | 4.91 | The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of ( Duarte, A; Duffy, S; Rodriguez-Lopez, R; Simmonds, M; Spackman, E; Wade, R; Woolacott, N, 2015) |
| "To determine if a low fixed dosing strategy of capecitabine would produce comparable clinical activity with less adverse toxicities compared to published data with higher doses in the setting of metastatic breast cancer (mBC)." | 4.90 | A retrospective study evaluating a fixed low dose capecitabine monotherapy in women with HER-2 negative metastatic breast cancer. ( Ahn, E; Ambros, T; Aruna, M; Kronish, L; Mahtani, RL; Montero, AJ; Vogel, CL; Zaravinos, J; Zeichner, SB, 2014) |
| "Capecitabine has proven effective as a chemotherapy for metastatic breast cancer." | 4.89 | Clinical efficacy of including capecitabine in neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis of randomized controlled trials. ( Jiang, Y; Li, Q; Liu, J; Wei, W; Yang, H, 2013) |
| "Both capecitabine and bevacizumab are established agents in the treatment of metastatic breast cancer, but until recently clinical data supporting their use in combination were limited." | 4.88 | Combining capecitabine and bevacizumab in metastatic breast cancer: a comprehensive review. ( Martin, M; Miles, D; Robert, N; Vrdoljak, E; Zielinski, C, 2012) |
| " In the USA, the approval of cetuximab has been recently expanded to include the first-line treatment of patients with KRAS mutation-negative (wild-type), EGFR-expressing, metastatic colorectal cancer (mCRC) when used in combination with FOLFIRI (irinotecan, fluorouracil, leucovorin [folinic acid])." | 4.88 | Cetuximab: a guide to its use in combination with FOLFIRI in the first-line treatment of metastatic colorectal cancer in the USA. ( Lyseng-Williamson, KA, 2012) |
| "The present study suggests that capecitabine-based chemotherapy is as effective as capecitabine-free chemotherapy in patients with metastatic and/or advanced breast cancer with different toxicity profiles." | 4.88 | Efficacy and toxicity of capecitabine-based chemotherapy in patients with metastatic or advanced breast cancer: results from ten randomized trials. ( Meng, L; Wang, Y; Wei, JF; Yang, H, 2012) |
| "The simultaneous administration of irinotecan, 5-fluorouracil, folinic acid and oxaliplatin (FOLFOXIRI) has been compared with standard 5-fluorouracil, folinic acid and irinotecan (FOLFIRI) in randomized trials in metastatic colorectal cancer patients." | 4.87 | A systematic review of FOLFOXIRI chemotherapy for the first-line treatment of metastatic colorectal cancer: improved efficacy at the cost of increased toxicity. ( Chiriatti, A; Fiorentini, G; Francini, G; Montagnani, F; Turrisi, G, 2011) |
| "We performed a computerized search using combinations of the following keywords: "metastatic colorectal cancer," "Xeloda," "chemotherapy," "capecitabine," or "5-fluorouracil." | 4.87 | Capecitabine-based chemotherapy for metastatic colorectal cancer. ( Fan, J; Ling, W; Ma, Y; Wang, H, 2011) |
| "Metastatic pancreatic ductal adenocarcinoma has a grim prognosis and gemcitabine has been the reference treatment for 15 years." | 4.87 | Metastatic pancreatic cancer: old drugs, new paradigms. ( Adenis, A; Conroy, T; Gavoille, C, 2011) |
| "Capecitabine monotherapy is considered standard treatment in anthracycline- and taxane-pretreated metastatic breast cancer and has proven efficacy in this setting." | 4.87 | Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer. ( Blum, JL; Hennessy, BT; Leonard, R; O'Shaughnessy, J, 2011) |
| "A 61-year-old woman with metastatic breast cancer who was undergoing treatment with capecitabine developed erythema, fissuring, and erosions over both hands and feet, consistent with HFS." | 4.87 | Capecitabine-induced hand-foot syndrome complicated by pseudomonal superinfection resulting in bacterial sepsis and death: case report and review of the literature. ( Baker, SG; Cotliar, JA; Gunawardane, ND; Hoesly, FJ, 2011) |
| "This meta-analysis was performed to evaluate the efficacy and safety of capecitabine plus oxaliplatin vs fluorouracil (FU) plus oxaliplatin as first line treatment for metastatic or advanced colorectal cancer." | 4.86 | Capecitabine plus oxaliplatin vs fluorouracil plus oxaliplatin as first line treatment for metastatic colorectal caner - meta-analysis of six randomized trials. ( Cao, Y; Gao, F; Liao, C; Liu, L; Mo, Z; Tan, A, 2010) |
| "Capecitabine, an oral prodrug of 5-fluorouracil, is indicated for adjuvant treatment in patients with Dukes' C colon cancer and for subsequent lines in metastatic colorectal cancer." | 4.86 | Economic evaluation of capecitabine as adjuvant or metastatic therapy in colorectal cancer. ( Best, JH; Garrison, LP, 2010) |
| "In both studies, women with locally advanced breast cancer or MBC pretreated with, or resistant to, taxanes or anthracyclines were randomly assigned to ixabepilone plus capecitabine, or capecitabine alone, until disease progression or unacceptable toxicity occurred." | 4.86 | Ixabepilone plus capecitabine for breast cancer patients with an early metastatic relapse after adjuvant chemotherapy: two clinical trials. ( Fornier, M, 2010) |
| "Capecitabine is an oral fluoropyrimidine that is shown to have similar efficacy to 5-fluorouracil (5-FU) when used both alone and in combination with oxaliplatin in the treatment of colorectal cancer (CRC)." | 4.86 | Differences in efficacy and safety between capecitabine and infusional 5-fluorouracil when combined with irinotecan for the treatment of metastatic colorectal cancer. ( Aliberti, C; Chiriatti, A; Fiorentini, G; Licitra, S; Montagnani, F, 2010) |
| " For colorectal liver metastases (mCRC), in a salvage setting, response was 79% for (90)Y-RE combined with 5-fluorouracil/leucovorin (5-FU/LV), and 79% when combined with 5-FU/LV/oxaliplatin or 5-FU/LV/irinotecan, and in a first-line setting 91% and 91%, respectively." | 4.85 | Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. ( Lam, MG; Nijsen, JF; van den Bosch, MA; van der Tweel, I; van Het Schip, AD; Vente, MA; Wondergem, M; Zonnenberg, BA, 2009) |
| "This article reviews the preclinical and clinical data on ixabepilone in patients with locally advanced and metastatic breast cancer (MBC) and provides guidance for pharmacists on its optimal use." | 4.85 | The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer. ( Boehnke Michaud, L, 2009) |
| "Capecitabine (N -pentyloxycarbonyl-5-deoxy-5-fluorocytidine), an oral prodrug of 5-fluorouracil, has provided compelling efficacy data for the treatment of metastatic breast cancer and stage III or IV colorectal cancer, both as monotherapy and in combination regimens." | 4.85 | Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer. ( Aprile, G; Mazzer, M; Moroso, S; Puglisi, F, 2009) |
| "Continuous-infusion 5-fluorouracil (5-FU)/leucovorin (LV) and oxaliplatin is a frequently used regimen in metastatic colorectal cancer." | 4.84 | Is XELOX equivalent to FOLFOX or other continuous-infusion 5-fluorouracil chemotherapy in metastatic colorectal cancer? ( Bennouna, J; Douillard, JY; Senellart, H, 2008) |
| "Multiple phase II trials evaluating ixabepilone in different populations of patients with metastatic breast cancer as well as a phase III trial in combination with capecitabine have recently been published." | 4.84 | Application of epothilones in breast cancer therapy. ( Cianfrocca, M, 2008) |
| "Bevacizumab, a monoclonal antibody to vascular endothelial growth factor, was approved in 2004 for use in combination with intravenous 5-fluorouracil-based chemotherapy for the treatment of metastatic colorectal cancer." | 4.83 | Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer. ( Hochster, HS, 2006) |
| "To evaluate the clinical and cost-effectiveness of capecitabine and tegafur with uracil (UFT/LV) as first-line treatments for patients with metastatic colorectal cancer, as compared with 5-fluorouracil/folinic acid (5-FU/FA) regimens." | 4.82 | Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation. ( Brewer, N; Cowan, J; Kaltenthaler, E; Ward, S, 2003) |
| " Oral prodrugs of 5-FU, such as capecitabine and uracil, have been developed in order to mimic the protracted infusion schedule of 5-FU, and these drugs may change the daily practice of palliative chemotherapy for colorectal cancer in the coming years." | 4.82 | New developments in systemic chemotherapy in advanced colorectal cancer. ( Cats, A, 2003) |
| "To examine the clinical effectiveness and cost-effectiveness of oral capecitabine for locally advanced and metastatic breast cancer in relation to its licensed indications." | 4.82 | Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda) for locally advanced and/or metastatic breast cancer. ( Hawkins, N; Jones, L; Richardson, G; Riemsma, R; Westwood, M; Wright, K, 2004) |
| " Although fluorouracil (5-FU) has been used for over 40 years, only in the last decade has its value been recognized in the treatment of advanced colorectal cancer." | 4.82 | Evidence-based update of chemotherapy options for metastatic colorectal cancer. ( Damjanovic, D; Findlay, MP; Thompson, P, 2004) |
| "Fluorouracil (FU) has been the mainstay of treatment for metastatic colorectal cancer (mCRC) for many years." | 4.82 | Critical evaluation of current treatments in metastatic colorectal cancer. ( Venook, A, 2005) |
| "Since the introduction of combined systemic chemotherapy with 5-folinic-acid (FA) and/or oxaliplatin or irinotecan, the median survival in patients with advanced colorectal cancer has increased to more than 20 months." | 4.82 | Indications and effect on survival of standard chemotherapy in advanced colorectal cancer. ( Kallinowski, B, 2005) |
| "Irinotecan is a cornerstone drug in the management of metastatic colorectal cancer, as demonstrated by several randomized studies proving a survival benefit for the first time." | 4.82 | Irinotecan-based regimens in the adjuvant therapy of colorectal cancer. ( Douillard, JY, 2005) |
| "In the last 50 years, 5-fluorouracil-based therapy has been the mainstay of adjuvant and palliative treatment for colorectal cancer but response rates and median survival have been dismal despite the introduction of thymidylate synthase modulators such as leucovorin." | 4.81 | The role of oxaliplatin in the treatment of advanced metastatic colorectal cancer: prospects and future directions. ( Schmoll, HJ, 2002) |
| " Two further trials are proposed: 3-weekly Herceptin as first-line monotherapy of metastatic breast cancer; and 3-weekly Herceptin with the oral 5-fluorouracil derivative, Xeloda (capecitabine)." | 4.81 | Dose scheduling--Herceptin. ( Leyland-Jones, B, 2001) |
| "Gemcitabine has demonstrated single-agent efficacy in the treatment of advanced breast cancer, with response rates of up to 42%." | 4.81 | Gemcitabine/anthracycline combinations in metastatic breast cancer. ( Zielinski, CC, 2002) |
| "Oxaliplatin was first introduced to the clinical setting as a combination therapy with 5-fluorouracil/folinic acid (5-FU/FA) in an attempt to improve the response rate obtained with 5-FU/FA against colorectal cancer." | 4.80 | Oxaliplatin plus 5-fluorouracil: clinical experience in patients with advanced colorectal cancer. ( Bleiberg, H; de Gramont, A, 1998) |
| " Synergistic effects with traditional therapy 5-fluorouracil/folinic acid have increased response rates significantly, improved time-sensitive response parameters, and facilitated the removal of previously unresectable hepatic metastases, thus changing the natural history of the disease." | 4.80 | Oxaliplatin for the treatment of advanced colorectal cancer: future directions. ( Bekradda, M; Cvitkovic, E; Ducreux, M; Louvet, C, 1998) |
| " Chemotherapy with fluorouracil (5FU) plus leucovorin remains a standard in the treatment of patients with metastatic colorectal cancer." | 4.80 | [Irinotecan in combination for colon cancer]. ( André, T; de Gramond, A; Ducreux, M; Gil-Delgado, M; Khayat, D; Ychou, M, 1998) |
| "The evolution of and rationale for fluorouracil-based strategies in the treatment of metastatic colorectal cancer are discussed, and the role of the new oral fluoropyrimidines is described." | 4.80 | Novel oral fluoropyrimidines in the treatment of metastatic colorectal cancer. ( Ignoffo, RJ, 1999) |
| " Phase II studies have shown that this agent has significant single-agent activity against both chemotherapy-naive and fluorouracil (5-FU)-refractory colorectal cancer." | 4.80 | Irinotecan-based combinations for the adjuvant treatment of stage III colon cancer. ( Saltz, L, 2000) |
| "Two randomized phase III trials with irinotecan as second-line treatment of metastatic colorectal cancer have shown that irinotecan (CPT-11, Camptosar) significantly improves survival when compared with best supportive care or continuous infusion of fluorouracil (5-FU) after failure of 5-FU." | 4.80 | Irinotecan and high-dose fluorouracil/leucovorin for metastatic colorectal cancer. ( Douillard, JY, 2000) |
| " This demonstration was achieved using a 5-day infusion of 5-fluorouracil, leucovorin, and oxaliplatin in patients with colorectal cancer metastases." | 4.79 | Chronotherapy for gastrointestinal cancers. ( Lévi, F, 1996) |
| "This retrospective study included 289 patients with metastatic colorectal cancer treated with second-line folinic acid, 5-fluorouracil, irinotecan, and vascular endothelial growth factor inhibitors." | 4.31 | Single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors. ( Chin, K; Fukuda, K; Fukuoka, S; Nakayama, I; Ogura, M; Ooki, A; Osumi, H; Shinozaki, E; Takahari, D; Wakatsuki, T; Yamaguchi, K; Yoshino, K, 2023) |
| "To compare the efficacy and safety of folinic acid, fluorouracil and irinotecan (FOLFIRI) plus bevacizumab or aflibercept in metastatic colorectal cancer (mCRC) patients pretreated with oxaliplatin-based chemotherapy." | 4.12 | A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer. ( Hong, JY; Jo, H; Kang, WK; Kim, H; Kim, ST; Lee, J; Lee, MS; Lee, YP; Lim, HY; Park, JO; Park, SH; Park, YS, 2022) |
| " p130Cas was inducible by 5-fluorouracil (5-FU) and FOLFIRI (folinic acid, 5-FU, irinotecan), and p130Cas and EREG were upregulated in distant metastases (GSE121418)." | 4.02 | p130Cas Is Correlated with EREG Expression and a Prognostic Factor Depending on Colorectal Cancer Stage and Localization Reducing FOLFIRI Efficacy. ( Jung, A; Kirchner, T; Klauschen, F; Kumbrink, J; Li, P; Pók-Udvari, A, 2021) |
| "FOLFOX is a combinational regimen of folinic acid (FnA, FOL), fluorouracil (5-Fu, F) and oxaliplatin (OxP, OX), and has been long considered as the standard treatment of colorectal cancer (CRC) and hepatocellular carcinoma (HCC)." | 4.02 | Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma. ( Guo, J; Huang, L; Liu, Y; Sun, D; Yu, Z; Zou, Y, 2021) |
| "To create a cost-effectiveness model to compare doublet therapy (encorafenib plus cetuximab) with standard chemotherapy (cetuximab plus irinotecan or cetuximab plus folinic acid, fluorouracil, and irinotecan) in treating patients with metastatic BRAF variant colorectal cancer." | 4.02 | Evaluation of the Cost-effectiveness of Doublet Therapy in Metastatic BRAF Variant Colorectal Cancer. ( Huntington, SF; Lacy, J; O'Hara, M; Patel, KK; Stein, S, 2021) |
| "5-Fluorouracil (5-FU) is an essential drug in systemic chemotherapy treatments for colorectal cancer (CRC)." | 4.02 | GABA-producing Lactobacillus plantarum inhibits metastatic properties and induces apoptosis of 5-FU-resistant colorectal cancer cells via GABA ( An, J; Ha, EM; Seok, H, 2021) |
| " The present study investigated the mechanisms underlying the response and resistance to 5‑fluorouracil (5‑FU) in colorectal cancer (CRC) cell lines." | 4.02 | Inhibition of chaperone‑mediated autophagy reduces tumor growth and metastasis and promotes drug sensitivity in colorectal cancer. ( Xiang, L; Xiao, X; Xuan, Y; Zhao, S; Zheng, HC, 2021) |
| " Eligible patients included those diagnosed with colorectal cancer with liver metastases that were planned to receive first line oxaliplatin plus 5-fluorouracil or capecitabine." | 4.02 | Effect of oxaliplatin plus 5-fluorouracil or capecitabine on circulating and imaging biomarkers in patients with metastatic colorectal cancer: a prospective biomarker study. ( Backen, A; Cheung, S; Descamps, T; Dive, C; Jackson, A; Jayson, GC; Little, RA; Mahmood, RD; Mescallado, N; Morgan, RD; Morris, K; Mullamitha, S; O'Connor, JPB; Parker, GJM; Saunders, M; Shaw, D; Watson, Y; Zhou, C, 2021) |
| "FOLFOX (5-Fluorouracile and oxaliplatin) exhibits promising activity in advanced well-differentiated neuroendocrine tumors (NETs)." | 4.02 | Efficacy of FOLFOX Chemotherapy in Metastatic Enteropancreatic Neuroendocrine Tumors. ( Cavaglione, G; Charrier, N; Mineur, L; Niccoli, P; Oziel-Taieb, S; Piana, G; Poizat, F; Raoul, JL; Zemmour, C, 2021) |
| "The efficacy of folinic acid, fluorouracil, and irinotecan (FOLFIRI) plus ramucirumab (F-RAM) or aflibercept (F-AFL) as a second-line treatment in metastatic colorectal cancer (mCRC) is established." | 4.02 | Risk-benefit Analysis of FOLFIRI Plus Ramucirumab/Aflibercept as a Third-line Treatment in Metastatic Colorectal Cancer. ( Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2021) |
| "BACKGROUND The impact of therapeutic drug management (TDM) on reducing toxicity and improving efficacy in colorectal cancer (CRC) patients receiving fluorouracil-based chemotherapy is still unclear." | 4.02 | Clinical Benefit of Therapeutic Drug Monitoring in Colorectal Cancer Patients Who Received Fluorouracil-Based Chemotherapy. ( Chang, R; Chang, Y; Han, J; Qian, J; Shen, C; Zhao, H; Zhou, X, 2021) |
| "The use of FOLFIRINOX (a combination of oxaliplatin, irinotecan, fluorouracil, and leucovorin) is one of the therapeutic standards in pancreatic adenocarcinoma." | 4.02 | Survival and Predictive Factors of Chemotherapy With FOLFIRINOX as First-Line Therapy in Metastatic Pancreatic Cancer: A Retrospective Multicentric Analysis. ( Ben Abdelghani, M; Caron, B; Duclos, B; Kurtz, JE; Nguimpi-Tambou, M; Noirclerc, M; Reimund, JM; Sondag, D, 2021) |
| "The NCT00339183 trial demonstrated that adding panitumumab to fluorouracil, leucovorin and irinotecan (FOLFIRI) as a second-line therapy of wild-type RAS metastatic colorectal cancer (mCRC) increases the median progression-free survival (PFS)." | 3.96 | Model-Based Cost-Effectiveness Analysis of Panitumumab Plus FOLFIRI for the Second-Line Treatment of Patients with Wild-Type Ras Metastatic Colorectal Cancer. ( Li, J; Peng, L; Shi, Y; Tan, C; Wan, X, 2020) |
| "The standard first- and second- line chemotherapy backbone regimens for metastatic colorectal cancer (mCRC) are 5-fluorouracil (5-FU)/capecitabine-based with addition of irinotecan or oxaliplatin." | 3.96 | Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme. ( Carter, AM; Iveson, T; Mullamitha, S; Shiu, KK; Spooner, C; Stevens, D, 2020) |
| "The authors sought to forecast survival and enhance treatment decisions for patients with liver metastatic colorectal cancer by using on-treatment radiomics signature to predict tumor sensitiveness to irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) alone (F) or in combination with cetuximab (FC)." | 3.96 | Radiomics Response Signature for Identification of Metastatic Colorectal Cancer Sensitive to Therapies Targeting EGFR Pathway. ( Dercle, L; Eggleton, P; Lu, L; Piessevaux, H; Qian, M; Schwartz, LH; Tejpar, S; Zhao, B, 2020) |
| "Cetuximab plus FOLFIRI (leucovorin, fluorouracil, and irinotecan) is the preferred first-line therapy for RAS and BRAF wild-type (RBWT) metastatic colorectal cancer (mCRC)." | 3.96 | Cetuximab Maintenance Therapy in Patients with Unresectable Wild-Type RAS and BRAF Metastatic Colorectal Cancer: A Single-Institute Prospective Study. ( Chen, H; Du, B; Hou, P; Jiang, T; Lai, J; Lin, M; Lin, X; Liu, Q; Wang, H; Wang, X; Yang, B; Zheng, J; Zhong, D, 2020) |
| "5-Fluorouracil (5-FU) is one of the most effective drugs for the treatment of colorectal cancer (CRC)." | 3.96 | Enalapril overcomes chemoresistance and potentiates antitumor efficacy of 5-FU in colorectal cancer by suppressing proliferation, angiogenesis, and NF-κB/STAT3-regulated proteins. ( Cai, J; Li, W; Liu, Y; Ma, L; Xu, Y; Yang, Y; Zhang, Y, 2020) |
| "In the treatment of metastatic colorectal cancer (mCRC), exposure to all three active cytotoxic agents, 5-fluorouracil/capecitabine, irinotecan and oxaliplatin, improves overall survival." | 3.96 | Utilisation of systemic therapy options in routine treatment of metastatic colorectal cancer in Australia. ( Ananda, S; Cooray, P; Delahunty, R; Desai, J; Gibbs, P; Johns, J; Kosmider, S; Lee, B; Lee, M; Mckendrick, J; Tie, J; Tran, B; Wong, HL; Wong, R, 2020) |
| "This study investigated the potential of single nucleotide polymorphisms as predictors of survival in two cohorts comprising 417 metastatic colorectal cancer (mCRC) patients treated with the FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) regimen." | 3.91 | Germline variability and tumor expression level of ribosomal protein gene RPL28 are associated with survival of metastatic colorectal cancer patients. ( Allain, EP; Buonadonna, A; Cecchin, E; Couture, F; D'Andrea, M; De Mattia, E; Guillemette, C; Jonker, D; Labriet, A; Lévesque, É; Rouleau, M; Simonyan, D; Toffoli, G; Villeneuve, L, 2019) |
| " The studies observed patients with wild-type [Kirsten] rat sarcoma viral oncogene homolog ([K]RAS/RAS) metastatic colorectal cancer (mCRC), who had been treated with panitumumab in combination with fluorouracil, leucovorin, and oxaliplatin (FOLFOX) in the first line or with panitumumab combined with fluorouracil, leucovorin, and irinotecan (FOLFIRI) in the second line following fluoropyrimidine-based chemotherapy." | 3.91 | Prospective Observational Cohort Study to Describe the Use of Panitumumab in Combination with Chemotherapy in Real-World Clinical Practice for Patients with Wild-Type RAS mCRC. ( Bjorklof, K; Buchler, T; Csoszi, T; Demonty, G; Hebart, H; Kafatos, G; Kiehl, M; Koukakis, R; Kuhn, A; Tomasek, J, 2019) |
| "Metastatic breast cancer (mBC) patients with DPYD genetic variants linked to loss of dihydropyrimidine dehydrogenase (DPD) activity are at risk of severe capecitabine-associated toxicities." | 3.91 | Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients. ( Charlton, P; DeSouza, K; Kapiris, M; Karapanagiotou, E; Mansi, J; Marinaki, A; Okonta, L; Papadatos-Pastos, D; Pouptsis, A; Stavraka, C, 2019) |
| "Compared with conventional fluorouracil plus cisplatin (FP) regimen, gemcitabine plus cisplatin (GP) can prolong survival in patients with recurrent or metastatic nasopharyngeal carcinoma, but the economic impact of this practice remains unknown." | 3.91 | Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma. ( Chen, X; Jiang, J; Liang, W; Wan, N; Yang, Y; Zhang, L; Zhang, T, 2019) |
| "The aim of this study was to investigate the efficacy and safety of first-line panitumumab plus folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in patients with wild-type KRAS and wild-type NRAS metastatic colorectal cancer (mCRC)." | 3.88 | FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer. ( Geredeli, C; Yasar, N, 2018) |
| " Median time from initial diagnosis of metastases to the start of regorafenib and treatment duration was 13." | 3.88 | Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial). ( Aranda, E; Benavides, M; Durán, G; Falcó, E; García-Alfonso, P; Gómez, A; López, R; López-Ladrón, A; Montagut, C; Muñoz, A; Rivera, F; Ruiz de Mena, I; Salgado, M; Sastre, J, 2018) |
| "The benefit of IFL (irinotecan, fluorouracil and leucovorin) regimen for metastatic colorectal cancer patients (mCRCs) with high levels of microsatellite instability (MSI-H) or loss of mismatch repair (dMMR) protein expression, is uncertain." | 3.88 | Patients with hMLH1 or/and hMSH2-deficient Metastatic Colorectal Cancer Are Associated with Reduced Levels of Vascular Endothelial Growth Factor-1 Expression and Higher Response Rate to Irinotecan-based Regimen. ( Bendardaf, R; Pyrhönen, S; Sharif-Askari, FS; Sharif-Askari, NS; Syrjänen, K, 2018) |
| "We analyzed the results of previously treated patients with metastatic colorectal cancer (mCRC) who received regorafenib plus FOLFIRI with the irinotecan dose escalation on the basis of uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping." | 3.85 | Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated According to Uridine Diphosphate Glucuronosyltransferase 1A1 Genotyping in Patients With Metastatic Colorectal Cancer. ( Cheng, TL; Hu, HM; Huang, CW; Ma, CJ; Tsai, HL; Wang, JY; Wu, IC; Yeh, YS, 2017) |
| "To investigate the possibility of enhancing an anti-metastatic effect of 5-fluorouracil (5-FU) on colorectal cancer (CRC) cells by combining it with continuous calcium supplementation." | 3.85 | Synergistically Anti-metastatic Effect of 5-Flourouracil on Colorectal Cancer Cells via Calcium-mediated Focal Adhesion Kinase Proteolysis. ( Jeong, KY; Kim, HM; Park, M; Sim, JJ; Sundaramoorthy, P, 2017) |
| "Adding cetuximab to FOLFIRI (5-fluorouracil, leucovorin, irinotecan) significantly improved progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) in patients with KRAS or RAS (KRAS/NRAS, exons 2-4) wild-type (wt) metastatic colorectal cancer (mCRC) in the first-line CRYSTAL study." | 3.85 | Quality of Life Analysis in Patients With RAS Wild-Type Metastatic Colorectal Cancer Treated With First-Line Cetuximab Plus Chemotherapy. ( Ando, M; Beier, F; Guenther, S; Ooki, A; Van Cutsem, E; von Hohnhorst, P; Yamaguchi, K, 2017) |
| "To evaluate the efficiency and safety of hepatic artery infusion chemotherapy (HAIC) using raltitrexed or 5-fluorouracil for colorectal cancer (CRC) liver metastasis (CRCLM)." | 3.85 | Hepatic artery infusion with raltitrexed or 5-fluorouracil for colorectal cancer liver metastasis. ( Chen, H; Gao, S; Guo, JH; Li, XT; Wang, XD; Zhang, HY; Zhang, PJ; Zhu, X, 2017) |
| "To evaluate the safety and efficacy of the combination therapy of fluorouracil, leucovorin and irinotecan (FOLFIRI) and aflibercept in Asian patients with metastatic colorectal cancer (mCRC), who had progressed after oxaliplatin-based chemotherapy." | 3.83 | Safety and efficacy of aflibercept in combination with fluorouracil, leucovorin and irinotecan in the treatment of Asian patients with metastatic colorectal cancer. ( Chong, DQ; Choo, SP; Chua, C; Imperial, M; Manalo, M; Ng, M; Tan, IB; Teo, P; Yong, G, 2016) |
| " The combination of epidermal growth factor receptor inhibitor with fluorouracil, leucovorin, and irinotecan was originally designed for the treatment of metastatic colorectal cancer." | 3.83 | Epidermal growth factor receptor inhibitor with fluorouracil, leucovorin, and irinotecan as an alternative treatment for advanced upper tract urothelial carcinoma: a case report. ( Chai, CY; Chien, TM; Huang, CN; Lin, CH; Lu, YM, 2016) |
| "5-fluorouracil (5-Fu) is still recognized as the mainstay in colorectal cancer chemotherapy, but the response rate of 5-Fu in colorectal cancer is less than 50%." | 3.83 | B7-H3 upregulates BRCC3 expression, antagonizing DNA damage caused by 5-Fu. ( Hua, D; Jiang, B; Liu, F; Ning, K; Sun, ZZ; Tang, SC; Zhang, T; Zhu, R, 2016) |
| "Patients with advanced gastric cancer with malignant ascites were treated with 60mg/m2 paclitaxel, followed by 500 mg/m2 5-FU and 250 mg/m2 l-LV on days 1, 8, and 15." | 3.83 | [Analysis of 5-Fluorouracil and Leucovorin Combined with Weekly Paclitaxel in Advanced Gastric Cancer]. ( Hoshino, H; Hosoda, Y; Kawada, J; Kim, Y; Nagai, K; Nishino, M; Okano, M; Okuyama, M; Tsujinaka, T, 2016) |
| " We simulated phase II trials by resampling patients from N9741, a randomized phase III trial of chemotherapy regimens for metastatic colorectal cancer, and compared the power of various end points to detect the superior therapy (FOLFOX [infusional fluorouracil, leucovorin, and oxaliplatin] had longer overall survival than both IROX [irinotecan plus oxaliplatin] and IFL [irinotecan and bolus fluorouracil plus leucovorin])." | 3.81 | Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials. ( Goldberg, RM; Gray, E; Karrison, TG; Sargent, DJ; Sharma, MR, 2015) |
| "The addition of bevacizumab to fluorouracil-based chemotherapy is a standard of care for previously untreated metastatic colorectal cancer." | 3.81 | First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis. ( Ayer, T; Chen, Q; El-Rayes, BF; Flowers, CR; Goldstein, DA; Howard, DH; Lipscomb, J, 2015) |
| " This study evaluates the influence of common genetic variations within the VEGF pathway in the clinical outcomes of 172 metastatic colorectal cancer (mCRC) patients treated with first-line oxaliplatin/5-fluorouracil chemotherapy." | 3.81 | Genetic variations in the VEGF pathway as prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy. ( Baiget, M; Barnadas, A; Berenguer-Llergo, A; Páez, D; Paré-Brunet, L; Río, E; Salazar, J; Sebio, A, 2015) |
| "Thymidylate synthase (TYMS) is an important enzyme for 5-fluorouracil (5-FU) metabolism in metastatic colorectal cancer (mCRC) patients." | 3.81 | Thymidylate synthase expression in circulating tumor cells: a new tool to predict 5-fluorouracil resistance in metastatic colorectal cancer patients. ( Abdallah, EA; Alves, VS; Araújo, DV; Buim, ME; Chinen, LT; Dettino, AL; Fanelli, MF; Gasparini Junior, JL; Machado Netto, MC; Mingues, NB; Ocea, LM; Rocha, BM; Romero, JV; Souza E Silva, V, 2015) |
| "The primary objective of this study was to determine the activity and safety of 3-weekly oxaliplatin combined with gemcitabine and oral capecitabine in the first-line treatment of advanced biliary tract cancer." | 3.81 | Three-weekly oxaliplatin combined with gemcitabine and capecitabine in the first-line treatment of patients with advanced biliary tract cancer. ( Fiaschi, AI; Francini, E; Laera, L; Marrelli, D; Petrioli, R; Roviello, F; Roviello, G, 2015) |
| "500 mg/m(2) uracil was administered orally to 12 subjects with stages II-III colorectal cancer (CRC) who were treated in the adjuvant setting and to 12 subjects with stage IV metastasized CRC, all treated with CAP containing therapy." | 3.81 | Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients. ( Gelderblom, H; Guchelaar, HJ; Maring, JG; Opdam, F; van Kuilenburg, AB; van Staveren, MC, 2015) |
| "12 patients with unresectable liver metastases from colorectal cancer were enrolled and received neoadjuvant FOLFIRI (5-fluorouracil, leucovorin, irinotecan) plus bevacizumab therapy." | 3.81 | Early Assessment of Colorectal Cancer Patients with Liver Metastases Treated with Antiangiogenic Drugs: The Role of Intravoxel Incoherent Motion in Diffusion-Weighted Imaging. ( Amato, DM; Avallone, A; Catalano, O; Filice, S; Fusco, R; Granata, V; Izzo, F; Nasti, G; Petrillo, A, 2015) |
| "Past reports have suggested that the addition of bevacizumab (BV) to oxaliplatin combined with 5-fluorouracil (5-FU) and folinic acid (leucovorin) (FOLFOX4) provides a limited survival benefit in metastatic colorectal cancer (mCRC)." | 3.80 | Retrospective analysis on the efficacy of bevacizumab with FOLFOX as a first-line treatment in Japanese patients with metastatic colorectal cancer. ( Matsusaka, S; Mizunuma, N; Shinozaki, E; Suenaga, M; Ueno, M; Yamaguchi, T, 2014) |
| "To explore genes of the killer-cell immunoglobulin-like receptor (KIR) and of the HLA ligand and their relationship with the outcome of metastatic colorectal cancer (mCRC) patients treated with first-line 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI)." | 3.80 | Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapy. ( Buonadonna, A; Caggiari, L; Cecchin, E; D' Andrea, M; De Re, V; De Zorzi, M; Innocenti, F; Racanelli, V; Talamini, R; Toffoli, G; Zagonel, V, 2014) |
| "Capecitabine is an oral fluoropyrimidine derivative which is frequently used alone or in combination regimens for the treatment of metastatic breast cancer." | 3.80 | Lack of prognostic value of mean corpuscular volume with capecitabine therapy in metastatic breast cancer. ( Berk, V; Bozkurt, O; Cetin, B; Duran, AO; Inanc, M; Kaplan, MA; Karaca, H; Ozaslan, E; Ozkan, M, 2014) |
| "To investigate the cost-effectiveness of panitumumab plus mFOLFOX6 (oxaliplatin, 5-fluorouracil and leucovorin) compared with bevacizumab plus mFOLFOX6 in first-line treatment of patients with wild-type RAS metastatic colorectal cancer (mCRC)." | 3.80 | Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. ( Barber, B; de Liège, F; Graham, CN; Hechmati, G; Hjelmgren, J; Knox, H; Lanier, J, 2014) |
| "5-Fluorouracil (5-FU) and its pro-drug Capecitabine have been widely used in treating colorectal cancer." | 3.80 | Potentially functional SNPs (pfSNPs) as novel genomic predictors of 5-FU response in metastatic colorectal cancer patients. ( Chong, SS; Choo, SP; Lee, CG; Ong, SJ; Ong, SY; Teo, YY; Wang, J; Wang, X; Zhao, M, 2014) |
| "Trastuzumab was registered in 2000 for the treatment of metastatic breast cancer, both as monotherapy and combination therapy with paclitaxel." | 3.80 | Trastuzumab in advanced breast cancer--a decade of experience in Germany. ( Eustermann, H; Harich, HD; Hinke, A; Jackisch, C; Reichert, D; Schoenegg, W; Selbach, J; Tesch, H; Welslau, M; Wohlfarth, T, 2014) |
| " Food and Drug Administration in combination with 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) for the treatment of patients with metastatic colorectal cancer who have previously received an oxaliplatin-containing chemotherapy regimen." | 3.79 | Aflibercept. ( Berlin, J; Chan, E; Ciombor, KK, 2013) |
| "To identify changes in peripheral immune responses in patients with metastatic colorectal cancer (mCRC) treated with irinotecan/5-fluorouracil/leucovorin (IFL) alone or in combination with cetuximab (C-IFL)." | 3.79 | Chemotherapy ± cetuximab modulates peripheral immune responses in metastatic colorectal cancer. ( Amptoulach, S; Gritzapis, AD; Karadima, ML; Kosmas, C; Skopelitis, E; Tsavaris, N; Voutsas, IF; Xynos, ID, 2013) |
| "We retrospectively analyzed ABCG2 expression levels in patients with metastatic colorectal cancer (CRC) to investigate the interaction between ABCG2 expression and the tumor response to oxaliplatin and 5-fluorouracil (FOLFOX)." | 3.79 | Expression of ABCG2 associated with tumor response in metastatic colorectal cancer patients receiving first-line FOLFOX therapy--preliminary evidence. ( Chang, SC; Chen, WS; Li, AF; Lin, CC; Lin, HH; Lin, JK; Lin, PC; Yang, SH, 2013) |
| "To report on the efficacy and safety of mitomycin-C-capecitabine (MIXE) regimen as salvage chemotherapy regimen for patients with refractory metastatic colorectal cancer." | 3.79 | Mitomycin-C and capecitabine (MIXE) as salvage treatment in patients with refractory metastatic colorectal cancer: a retrospective study. ( Brennan, M; Garcon, MC; Kaley, K; Rodriguez, G; Saif, MW, 2013) |
| "The efficacy and safety of bevacizumab(BV), combined with infusional 5-fluorouracil/leucovorin(5-FU/LV)plus irinotecan(FOLFIRI)as the second-line treatment for metastatic colorectal cancer(mCRC)after resection of the primary lesion, have not been fully clarified." | 3.79 | [Second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer after resection of the primary lesion]. ( Abe, H; Abe, M; Hirata, T; Mafune, K; Minamimura, K; Umemura, A, 2013) |
| "To report a retrospective data on the efficacy and safety of capecitabine and temozolomide (CAPTEM regimen) in patients with metastatic pancreatic neuroendocrine tumors (pNETs) who have failed prior therapies." | 3.79 | A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy. ( Brennan, M; Garcon, MC; Kaley, K; Rodriguez, G; Rodriguez, T; Saif, MW, 2013) |
| "The aim of this study was to evaluate the efficacy and tolerability of a gemcitabine, 5-fluorouracil and leucovorin (GEMFUFOL) chemotherapy regimen as first line treatment of metastatic biliary tract cancer." | 3.79 | Two-week combination chemotherapy with gemcitabine, high-dose folinic acid and 5 fluorouracil (GEMFUFOL) as first-line treatment of metastatic biliary tract cancers. ( Oztop, I; Unal, OU; Unek, IT; Yilmaz, AU, 2013) |
| "We analyzed the clinical efficacy and safety of capecitabine plus oxaliplatin( XELOX) and bevacizumab( BV) as neoadjuvant chemotherapy, administered for the treatment of patients with resectable metastatic colorectal cancer between October 2009 and December 2012." | 3.79 | [Neoadjuvant chemotherapy with capecitabine plus oxaliplatin and bevacizumab for the treatment of patients with resectable metastatic colorectal cancer]. ( Egawa, T; Ito, Y; Kemmochi, T; Makino, H; Mihara, K; Mori, T; Nagashima, A; Ohkubo, Y; Yamamuro, W, 2013) |
| "Preliminary results showed that there is a significant MCV increase in patients receiving capecitabine for metastatic colon and breast cancer after 12 weeks of treatment." | 3.79 | Increased mean corpuscular volume of red blood cells in patients treated with capecitabine for advanced breast and colon cancer. ( Gervasi, E; Giovanardi, F; Pezzuolo, D; Prati, G; Scaltriti, L; Scarabelli, L, 2013) |
| " We hypothesized that gene expression levels and germline variations in CD133 will predict clinical outcome in patients with metastatic colorectal cancer (mCRC), treated in first-line setting with 5-fluorouracil, oxaliplatin and bevacizumab (BV), and we investigated whether there is a correlation with gene expression levels of CD133, vascular endothelial growth factor (VEGF) and its receptors." | 3.79 | Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy. ( Danenberg, KD; El-Khoueiry, A; Hu-Lieskoven, S; Iqbal, S; Kahn, M; Lenz, HJ; Lurje, G; Ning, Y; Pohl, A; Shriki, J; Stebbing, J; Teo, JL; Winder, T; Yang, D; Zhang, W, 2013) |
| "Two anti-cancer drugs are currently approved for the treatment of HER2-positive metastatic breast cancer (MBC): trastuzumab-based therapy (TBT) administered intravenously as first line therapy until disease progression and lapatinib, an oral self-administered dual therapy with capecitabine (L+C) as second intention for patients who continue to progress despite TBT." | 3.79 | Budget impact analysis of the use of oral and intravenous anti-cancer drugs for the treatment of HER2-positive metastatic breast cancer. ( Benjamin, L; Buthion, V; Farah, B; Iskedjian, M; Rioufol, C; Vidal-Trécan, G, 2013) |
| "Clinical records of patients with pretreated advanced breast cancer and who were treated with the Metronomic-Cooper-type regimen consisting of weekly fixed doses of NPLD (30 mg IV) plus 5-Fluorouracil (5-FU) (500 mg IV) plus vincristine (0." | 3.79 | Safety and efficacy of metronomic non-pegylated liposomal encapsulated doxorubicin in heavily pretreated advanced breast cancer patients. ( Ciruelos, E; Cortés-Funes, H; Dorta, M; Ghanem, I; Manneh, R; Manso, L; Mendiola, C; Sepúlveda, J; Valdiviezo, N; Vega, E, 2013) |
| "The goal of the present study was to compare the efficacy of the combination of cetuximab and irinotecan to the combination of oxaliplatin and fluoropyrimidines as second-line chemotherapy in patients with irinotecan-refractory and oxaliplatin-naïve metastatic colorectal cancer (mCRC) harboring wild-type KRAS." | 3.79 | Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRAS. ( Baek, JY; Hong, YS; Kim, HJ; Kim, JC; Kim, JH; Kim, KP; Kim, SY; Kim, TW; Lee, JL; Lim, SB; Park, JH; Park, SJ; Yu, CS, 2013) |
| "The aim of this study was to determine the pathological complete remission (pCR) rate, and its relationship to clinical outcome, in patients with adenocarcinoma of the stomach or oesophagogastric junction receiving preoperative 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) every 2 weeks." | 3.78 | Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel. ( Al-Batran, SE; Altmannsberger, HM; Atmaca, A; Bruch, HP; Homann, N; Jäger, E; Luley, K; Noack, F; Pauligk, C; Werner Kraus, T, 2012) |
| "Studies treating adenocarcinoma of the pancreas with gemcitabine alone or in combination with a doublet have demonstrated modest improvements in survival." | 3.78 | A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma. ( Blackford, A; Chung, K; Cosgrove, D; De Jesus-Acosta, A; Diaz, LA; Donehower, RC; Flores, EI; Kinsman, K; Laheru, D; Le, DT; Oliver, GR; Wilfong, LS; Zheng, L, 2012) |
| "Lapatinib plus capecitabine emerged as an efficacious therapy in metastatic breast cancer (mBC)." | 3.78 | The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer. ( Benhaim, L; Bohanes, PO; El-Khoueiry, A; El-Khoueiry, R; Gerger, A; Labonte, MJ; Ladner, RD; Lenz, HJ; Ning, Y; Wilson, PM; Yang, D; Zhang, W, 2012) |
| "The efficacy of bevacizumab combined with infusional 5-fluorouracil/leucovorin (5-FU/LV) plus irinotecan (FOLFIRI) as the second-line treatment for metastatic colorectal cancer (mCRC) has not been fully clarified, although bevacizumab combined with infusional 5-FU/LV plus oxaliplatin (FOLFOX) in the second-line setting has demonstrated a survival benefit." | 3.78 | Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV stud ( Baba, E; Bando, H; Boku, N; Esaki, T; Fukunaga, M; Hyodo, I; Kato, S; Katsumata, K; Miyake, Y; Moriwaki, T; Ozeki, M; Satoh, T; Takashima, A; Yamashita, K; Yamazaki, K; Yoshida, S, 2012) |
| "Macrocytosis inversely related to risk of disease progression in patients treated with metronomic capecitabine plus cyclophosphamide and bevacizumab for metastatic breast cancer." | 3.78 | Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab. ( Bagnardi, V; Balduzzi, A; Bertolini, F; Cancello, G; Colleoni, M; Dellapasqua, S; Goldhirsch, A; Luini, A; Mancuso, P; Montagna, E; Pastrello, D; Sandri, MT, 2012) |
| "Docetaxel plus capecitabine, a commonly used chemotherapeutic regimen for metastatic breast cancer (MBC), is highly variable in its effectiveness." | 3.78 | Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine. ( Che, L; Di, L; Dong, N; Jia, J; Jiang, H; Ren, J; Song, G; Wang, C; Wang, X; Wang, Z; Yu, J; Zheng, X; Zhou, X; Zhu, B, 2012) |
| "Capecitabine is often offered as a first-line chemotherapy option for metastatic breast cancer (MBC)." | 3.78 | Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer. ( Anderson, R; Balkrishnan, R; Camacho, F; Kamal, AH; Kimmick, G; Wei, W, 2012) |
| "The aim of the present study was to investigate the gene expression of biomarkers associated with the sensitivity to fluoropyrimidine and taxanes in recurrent/advanced breast cancer patients treated with first-line capecitabine chemotherapy." | 3.78 | Evaluations of biomarkers associated with sensitivity to 5-fluorouracil and taxanes for recurrent/advanced breast cancer patients treated with capecitabine-based first-line chemotherapy. ( Hu, ZH; Huang, H; Huang, Y; Lin, SX; Lin, TY; Tian, Y; Zhao, HY, 2012) |
| "A combination of 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX) is a standard regimen for the chemotherapy of metastatic colorectal cancer." | 3.78 | Preventive effect of traditional Japanese medicine on neurotoxicity of FOLFOX for metastatic colorectal cancer: a multicenter retrospective study. ( Ando, T; Fukuoka, J; Horikawa, N; Hosokawa, A; Kajiura, S; Kobayashi, Y; Ogawa, K; Sugiyama, T; Suzuki, N; Tsukioka, Y; Ueda, A; Yabushita, K, 2012) |
| "To evaluate the effect of anthracycline pirarubicin-based regimen in association with different ways of fluorouracil (5-Fu) as neoadjuvant and adjuvant chemotherapy for primary breast cancer." | 3.78 | [Efficacy analysis of THP-containing regimens as neoadjuvant and adjuvant chemotherapy for primary breast cancer]. ( Fan, T; Fan, ZQ; Li, JF; Lin, BY; Ouyang, T; Wang, LZ; Wang, TF; Xie, YT, 2012) |
| "We retrospectively investigated the efficacy and toxicity of lapatinib plus capecitabine in 45 HER2-positive breast cancer patients." | 3.78 | [Efficacy and toxicity of lapatinib plus capecitabine therapy in HER2-positive metastatic breast cancer]. ( Chiba, A; Inaba, M; Inari, H; Ino, H; Kojima, I; Kuroda, K; Matsuo, A; Matsuura, H; Mukaibashi, T; Shimizu, S; Suganuma, N; Yamanaka, T; Yoshida, A, 2012) |
| "To evaluate effects of UDP-glucuronosyltransferase1A1 (UGT1A1) and thymidylate synthetase (TS) gene polymorphisms on irinotecan in metastatic colorectal cancer (mCRC)." | 3.78 | UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil. ( Jiao, SC; Liu, ZY; Shen, L; Wang, JW; Wang, Y; Xu, JM; Xu, N, 2012) |
| " The aim of this study was to investigate the possible predictive value of the VEGF-A SNPs, in patients with metastatic colorectal cancer (mCRC) treated with first-line capecitabine and oxaliplatin (XELOX)." | 3.77 | The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer. ( Andersen, RF; Brandslund, I; Garm Spindler, KL; Hansen, TF; Jakobsen, A; Lindebjerg, J, 2011) |
| "There has been no report on sorafenib therapy in patients with metastatic hepatocellular carcinoma (HCC) who had been treated with systemic chemotherapy." | 3.77 | Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy. ( Bang, YJ; Han, SW; Im, SA; Kim, JW; Kim, TY; Lee, JO; Oh, DY, 2011) |
| " We investigated associations between polymorphisms in both miRNA-containing genomic regions (primary and precursor miRNA) and in genes related to miRNA biogenesis with clinical outcome in metastatic colorectal cancer (mCRC) patients treated with 5-fluorouracil and irinotecan (CPT-11)." | 3.77 | Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan. ( Aranda, E; Bandrés, E; Boni, V; Garcia-Foncillas, J; Gomez, MA; Maiello, E; Villa, JC; Zarate, R, 2011) |
| "The aim was to evaluate the association between plasma tissue inhibitor of metalloproteinase-1 (TIMP-1) and serum carcinoembryonic antigen (CEA) levels and outcome in patients with metastatic colorectal cancer (mCRC) receiving XELOX (combination chemotherapy with capecitabine and oxaliplatin) as first-line treatment." | 3.77 | Plasma TIMP-1 levels and treatment outcome in patients treated with XELOX for metastatic colorectal cancer. ( Berglund, A; Brünner, N; Christensen, IJ; Frederiksen, C; Glimelius, B; Jensen, BV; Keldsen, N; Nielsen, HJ; Nielsen, SE; Pfeiffer, P; Qvortrup, C, 2011) |
| "We sought to determine if an association exists between age and capecitabine efficacy among patients with metastatic breast cancer (MBC)." | 3.77 | Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials. ( Blum, JL; Glück, S; Hu, S; Kaye, JA; Kohles, J; McKenna, E; Odom, D; Scotto, N, 2011) |
| "Several long-standing chemotherapy regimens are available to treat metastatic colorectal cancer (mCRC) including: oxaliplatin plus 5-fluorouracil (5-FU) and leucovorin (FOLFOX); and irinotecan plus 5-FU and leucovorin (FOLFIRI)." | 3.77 | Treatment patterns and metastasectomy among mCRC patients receiving chemotherapy and biologics. ( Barber, B; Gregory, C; Long, SR; Song, X; Wang, PF; Zhao, Z, 2011) |
| "The primary purpose of this study was to evaluate the role of thymidylate synthase (TS) and thymidine phosphorylase (TP) as biomarkers to predict clinical outcomes of capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer (MBC)." | 3.77 | Thymidylate synthase and thymidine phosphorylase as predictive markers of capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. ( Ahn, JS; Cho, EY; Choi, YL; Im, YH; Kim, ST; Lee, SJ; Park, YH, 2011) |
| "A total of 152 patients with metastatic colorectal cancer who were treated with oxaliplatin and continuous infusion 5-fluorouracil were genotyped for 21 polymorphisms in 13 cancer-related genes by PCR." | 3.77 | Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin. ( El-Khouiery, A; Gordon, MA; Iqbal, S; Labonte, M; Ladner, RD; Lenz, HJ; Lurje, G; Nagashima, F; Sherrod, A; Wilson, P; Yang, D; Zhang, W, 2011) |
| " We aimed to evaluate the effect of pretreatment serum metabolic profiles generated by (1)H NMR spectroscopy on toxicity in patients with inoperable colorectal cancer receiving single agent capecitabine." | 3.77 | Pharmacometabonomic profiling as a predictor of toxicity in patients with inoperable colorectal cancer treated with capecitabine. ( Backshall, A; Clarke, SJ; Keun, HC; Sharma, R, 2011) |
| " Based on clinical data and using modeling techniques, the work analyzes the pharmacodynamic interaction between capecitabine and docetaxel used in combination in metastatic breast cancer." | 3.77 | Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancer. ( Bruno, R; Claret, L; Frances, N; Iliadis, A, 2011) |
| "Capecitabine is a widely accepted option in pre-treated metastatic breast cancer (MBC) patients." | 3.77 | Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors. ( Bertucci, F; Esterni, B; Extra, JM; Gilabert, M; Gonçalves, A; Jacquemier, J; Madroszyk, A; Tarpin, C; Viens, P, 2011) |
| "After resection of CRC and synchronous metastases, 53 (84%) out of 63 patients without chemotherapy, and 38 (83%) out of 46 that received 5-fluorouracil (5-FU) alone or with leucovorin (LV) developed recurrent tumors." | 3.77 | FOLFOX as adjuvant chemotherapy after curative resection of distant metastases in patients with colorectal cancer. ( Kanazawa, T; Kawai, K; Kazama, S; Kitayama, J; Mori, K; Nagawa, H; Nozawa, H; Saito, S; Sunami, E; Yazawa, K, 2011) |
| "Regimens containing bevacizumab and 5-fluorouracil have achieved substantial progress in the treatment of colorectal cancer." | 3.77 | Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients. ( Iinuma, H; Ikeuchi, H; Ishihara, S; Kobunai, T; Matsuda, K; Nozawa, K; Watanabe, T; Yamamoto, Y, 2011) |
| "Palliative chemoradiotherapy using 5-fluorouracil plus cisplatin combined with concurrent 40 Gy irradiation effectively improved the symptom of dysphagia in Stage IVB esophageal cancer with acceptable toxicity and favorable survival." | 3.77 | Efficacy of concurrent chemoradiotherapy as a palliative treatment in stage IVB esophageal cancer patients with dysphagia. ( Doi, T; Fuse, N; Ikeda, E; Kaneko, K; Kojima, T; Minashi, K; Nihei, K; Ohtsu, A; Onozawa, M; Tahara, M; Yano, T; Yoshino, T, 2011) |
| "Combined low-dose therapy of oral capecitabine (Xeloda) and cyclophosphamide (XC) has been demonstrated to be useful for long-term control of lesions in patients with metastatic breast cancer (MBC) and is aimed at symptomatic alleviation and prolongation of survival." | 3.77 | Clinical efficacy of capecitabine and cyclophosphamide (XC) in patients with metastatic breast cancer. ( Doihara, H; Ikeda, H; Masuda, H; Nishiyama, K; Nogami, T; Shien, T; Taira, N, 2011) |
| "Oxaliplatin-associated neuropathy remains a dose-limiting toxicity of the standard chemotherapy regimen of oxaliplatin and capecitabine for metastatic colorectal cancer." | 3.76 | Heated (37 degrees C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy? ( Cathomas, R; Köberle, D; Mayer, G; Mey, U; Räss, A; Ruhstaller, T; von Moos, R, 2010) |
| "Prophylactic pyridoxine was given to 38 patients receiving capecitabine (alone or in combination with cyclophosphamide) for metastatic breast cancer and compared with historical data from 40 patients receiving capecitabine without pyridoxine in our clinic." | 3.76 | Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer. ( Fujita, T; Hayashi, H; Iwata, H; Kimura, M; Kondo, N; Toyama, T; Tsunoda, N; Tsuzuki, N; Yamashita, H; Yamashita, T; Yoshimoto, N, 2010) |
| "We investigated the efficacy of intra-arterial 5-fluorouracil (5-FU) and systemic interferon (IFN)-alpha (5-FU-IFN) in the treatment of hepatocellular carcinoma (HCC) with portal vein tumor thrombosis in the first branch or trunk (Vp3/4) and extrahepatic metastases." | 3.76 | Intra-arterial 5-fluorouracil/interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases. ( Aikata, H; Chayama, K; Hieda, M; Hiramatsu, A; Ishikawa, M; Kakizawa, H; Katamura, Y; Kawakami, Y; Kawaoka, T; Kimura, Y; Takahashi, S; Takaki, S; Waki, K, 2010) |
| "Single agent capecitabine is effective and well tolerated in metastatic breast cancer (MBC)." | 3.76 | Moderate dose capecitabine in older patients with metastatic breast cancer: a standard option for first line treatment? ( Ashley, S; Johnston, S; Kotsori, AA; Noble, JL; Smith, IE, 2010) |
| "We investigated 30 patients with advanced and metastatic breast cancer who underwent capecitabine therapy in our department from July, 2004 to April, 2009." | 3.76 | [More effective positioning of capecitabine for advanced and metastatic breast cancer]. ( Kawaguchisakita, N; Kohno, Y; Tsubota, Y; Tsuyuki, S; Ukikusa, M, 2010) |
| "The aim was to evaluate the cost of capecitabine vs conventional combination chemotherapics such as 5-fluorouracil (5-FU) for the treatment of metastatic colorectal cancer (mCRC) in Italy." | 3.76 | Cost analysis of capecitabine vs 5-fluorouracil-based treatment for metastatic colorectal cancer patients. ( Bianchessi, C; Bollina, R; Carteni, G; Cozzi, C; De Portu, S; Grimaldi, AM; Mantovani, LG; Ravaioli, A; Tamburini, E; Testa, TE, 2010) |
| "Between January 2006 and November 2009, 17 patients (median age of 61 years) with advanced pancreatic adenocarcinoma, after receiving gemcitabine-containing chemotherapy as first-line median ECOG performance status 1 and with adequate organ function, were treated with either weekly docetaxel at 25 mg/m(2) or 3-weekly docetaxel regimen (docetaxel at 75 mg/m(2) or docetaxel-gemcitabine-capecitabine or docetaxel-gemcitabine) until progressive disease." | 3.76 | Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study. ( Kaley, K; Penney, R; Saif, MW; Syrigos, K, 2010) |
| "Patients with locally advanced and metastatic colorectal cancer treated with capecitabine or 5-fluorouracil/leucovorin (5-FU/LV) as monotherapy or combination therapy with oxaliplatin from 2003-2006 were identified in the Thomson Reuters MarketScan® databases." | 3.76 | Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison. ( Cartwright, T; Chu, E; McKenna, EF; Schulman, KL, 2010) |
| "The aim of this study was to retrospectively analyze the efficacy and safety of the combination of 5-fluorouracil (5-FU), dacarbazine, and epirubicin (FDE) in 39 patients with advanced, well-differentiated neuroendocrine tumors (NETs)." | 3.76 | Evaluation of the combination 5-fluorouracil, dacarbazine, and epirubicin in patients with advanced well-differentiated neuroendocrine tumors. ( Bruneton, D; Cassier, PA; Chayvialle, JA; Hervieu, V; Lombard-Bohas, C; Pilleul, F; Scoazec, JY; Walter, T, 2010) |
| "Combination of capecitabine and irinotecan (XELIRI regimen) is an active and well tolerated treatment for metastatic colorectal cancer (mCRC)." | 3.76 | Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer. ( Alvarez-Suarez, S; García-Alfonso, P; Jerez-Gilarranz, Y; Khosravi, P; Martin, M; Muñoz-Martin, AJ; Riesco-Martinez, M, 2010) |
| "002], presence of visceral metastases at the beginning of capecitabine treatment (HR = 2." | 3.75 | Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer. ( Andreetta, C; Damante, G; Di Loreto, C; Fasola, G; Minisini, A; Pandolfi, M; Pegolo, E; Piga, A; Pizzolitto, S; Puglisi, F; Puppin, C; Valent, F, 2009) |
| "A recent clinical trial demonstrated that the addition of lapatinib to capecitabine in the treatment of HER-2-positive advanced breast cancer (ABC) significantly increases median time to progression." | 3.75 | Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer. ( Hay, JW; Le, QA, 2009) |
| " single-agent capecitabine for first- or second-line treatment of metastatic breast cancer (MBC) METHODS: Data from the medical charts of 61 patients who received single-agent capecitabine, docetaxel, or paclitaxel therapy were supplemented with data from the 38-item Patient Care Monitor (PCM) survey of symptom burden and quality of life, prospectively collected during chemotherapy." | 3.75 | Patient and practice impact of capecitabine compared to taxanes in first-/second-line chemotherapy for metastatic breast cancer. ( Cobb, P; Houts, AC; Schwartzberg, LS; Stepanski, EJ; Walker, MS, 2009) |
| "A total of 76 patients with recurrent or metastatic colorectal cancer treated with capecitabine and oxaliplatin (XELOX) combination chemotherapy were enrolled in the present study." | 3.75 | Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin. ( Bae, SH; Chae, YS; Choi, GS; Jeon, SW; Jun, SH; Kang, BM; Kim, JG; Kum, Y; Lim, KH; Moon, JH; Park, IJ; Ryoo, HM; Sohn, SK, 2009) |
| " She underwent recent chemotherapy with fluorouracil for metastatic colorectal cancer." | 3.75 | 5 flourouracil-induced apical ballooning syndrome: a case report. ( Dentali, F; Gianni, M; Lonn, E, 2009) |
| " Here, we prospectively studied patients with metastatic breast cancer receiving capecitabine treatment in order to determine if sarcopenia was associated with a higher incidence of toxicity and a shorter time to tumor progression (TTP)." | 3.75 | Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. ( Baracos, VE; Koski, S; Mackey, JR; McCargar, LJ; Mourtzakis, M; Pituskin, E; Prado, CM; Reiman, T; Sawyer, MB; Tonkin, K, 2009) |
| "We examined 51 patients treated with Capecitabine for metastatic breast cancer." | 3.75 | [Palliative chemotherapy for metastatic breast cancer with capecitabine]. ( Inaba, T; Kashiwaba, M; Komatsu, H; Takeda, Y; Takiyama, I; Tomisawa, Y; Wakabayashi, G, 2009) |
| "We evaluated the efficacy and toxicity of combination chemotherapy with capecitabine and cisplatin (XP) in patients with metastatic hepatocellular carcinoma (HCC)." | 3.75 | Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma. ( Bang, YJ; Im, SA; Kim, JH; Kim, TY; Lee, JO; Lee, KW; Oh, DY, 2009) |
| "We designed a study protocol in 2005 and 16 patients with metastatic colorectal cancer were treated accordingly in the first line setting with XELIRI regimen (capecitabin, irinotecan) + bevacizumab." | 3.75 | [Bevacizumab in combination with capecitabine and irinotecan (XELIRI) in treatment of metastatic colorectal cancer]. ( Kocák, I; Kocáková, I; Nemecek, R; Rehák, Z; Standara, M; Svoboda, M, 2009) |
| "A case of gastric endocrine cell carcinoma successfully treated by FU (5-FU/UFT) +irinotecan (CPT-11) adjuvant therapy against recurrent metastases is reported with some discussion." | 3.75 | [A Case of gastric endocrine cell carcinoma successfully treated by FU plus irinotecan(CPT-11)adjuvant therapy against recurrent metastases]. ( Hara, T; Hiramatsu, K; Hosoya, J; Kato, K; Kimura, A; Kojima, T; Machiki, Y; Otsuji, H; Sakuragawa, T; Tanaka, H; Tsuchiya, T; Yoshida, K, 2009) |
| "Thus, in women with advanced breast cancer excessive tumor cell burden and permanent drug resistance remain the major obstacles to obtaining complete remission and long-term disease free survival." | 3.75 | Chemotherapy of breast cancer: current views and results. ( Bonadonna, G; Valagussa, P, 1983) |
| "Although a variety of FOLFOX regimens (5-fluorouracil and L-leucovorin combined with oxaliplatin) are widely used for the treatment of advanced colorectal cancer, the neurotoxicity caused by oxaliplatin is often problematic." | 3.74 | Safety and efficacy of modified FOLFOX6 for treatment of metastatic or locally advanced colorectal cancer. A single-institution outcome study. ( Chiba, T; Fukushima, M; Ishiguro, H; Kanai, M; Kawamura, J; Kitano, T; Matsumoto, S; Miyamoto, S; Mori, Y; Nagayama, S; Nishimura, T; Nomura, A; Sakai, Y; Teramukai, S; Yanagihara, K, 2008) |
| "In this study, we investigated the efficacy and toxicity of fluorouracil(FU)+Leucovorin(LV)with oxaliplatin (FOLFOX)and irinotecan(FOLFIRI)for patients with advanced or metastatic colorectal cancer." | 3.74 | Efficacy and toxicity of fluorouracil, leucovorin plus oxaliplatin (FOLFOX4 and modified FOLFOX6) followed by fluorouracil, leucovorin plus irinotecan(FOLFIRI)for advanced or metastatic colorectal cancer--case studies. ( Adachi, K; Arimoto, Y; Kanamiya, Y; Nakamura, R; Nishio, K; Oba, H; Ohtani, H; Shintani, M; Yui, S, 2008) |
| "Capecitabine exerts considerable therapeutic efficacy in metastatic breast cancer (MBC) patients previously treated with anthracyclines and taxanes." | 3.74 | Efficacy of lower dose capecitabine in patients with metastatic breast cancer and factors influencing therapeutic response and outcome. ( Evrensel, T; Goker, E; Kurt, E; Manavoglu, O; Ozdemir, N; Sezgin, C, 2007) |
| "Seventeen discrete lesions in 13 patients with stage II-IV breast cancer were scanned prior to and at 1 week after treatment with combination 5-fluorouracil, epirubicin and cyclophosphamide (FEC) chemotherapy." | 3.74 | Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography. ( Aboagye, EO; Al-Nahhas, A; Coombes, RC; Kenny, L; Shousha, S; Vigushin, DM, 2007) |
| "Docetaxel, capecitabine and 5-fluorouracil have been shown to be active in the treatment of metastatic gastric adenocarcinoma." | 3.74 | Chemoimmunotherapy in the treatment of metastatic gastric cancer. ( Amiconi, G; Blasio, AD; Candeloro, G; Cesta, A; Necozione, S; Rea, S; Recchia, F; Saggio, G, 2007) |
| "Over the past decade, new cytotoxic and biologic therapies beyond the old standard-of-care, biomodulated fluorouracil (5-FU), have become available for the treatment of metastatic colorectal cancer (mCRC)." | 3.74 | Optimizing palliative treatment of metastatic colorectal cancer in the era of biologic therapy. ( Grothey, A; Marshall, JL, 2007) |
| "The oxaliplatin/fluorouracil/leucovorin (FOL-FOX regimen) is an effective and generally well-tolerated regimen in Western clinical studies of advanced colorectal cancer." | 3.74 | Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience. ( Fukuoka, M; Nakagawa, K; Okamoto, I; Ozaki, T; Satoh, T; Shimizu, T; Tamura, K, 2007) |
| "The objectives of the present study were to evaluate the efficacy and safety of an outpatient-basis chemotherapy of oxaliplatin, 5-fluorouracil, and leucovorin as the first-line treatment for patients with advanced colorectal cancer." | 3.74 | Outpatient-basis chemotherapy of oxaliplatin, 5-fluorouracil, and leucovorin as first-line treatment for patients with metastatic or recurrent colorectal cancer. ( Ahn, BM; Baek, JH; Chae, YS; Cho, YY; Choi, GS; Jun, SH; Kim, JG; Kim, SN; Lee, IT; Lee, SJ; Moon, JH; Sohn, SK, 2007) |
| "Capecitabine is a fluoropyrimidine-based drug that offers physicians a more convenient treatment for advanced colorectal cancer (CRC), with manageable toxicity and antitumor activity comparable to that of continuous-infusion therapies with 5-fluorouracil (5-FU)." | 3.74 | DPD is a molecular determinant of capecitabine efficacy in colorectal cancer. ( Danenberg, KD; Danenberg, PV; Jakobsen, A; Kuramochi, H; Lindebjerg, J; Nielsen, JN; Shimizu, D; Vallböhmer, D; Yang, DY, 2007) |
| "Taxanes (TX) were administered to 246 of 292 patients with recurrent/metastatic breast cancer (MBC) who were treated in Hiei Hospital between January 2001 and May 2006." | 3.74 | [Evaluation of therapeutic regimens for taxane-resistant recurrent/metastatic breast cancer]. ( Iguchi, C; Kan, N; Kodama, H; Nio, Y; Yoshikawa, K, 2007) |
| "A combination of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) is one of the standard regimens for palliative and adjuvant chemotherapy for colorectal cancer." | 3.74 | Feasibility of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) for Japanese patients with unresectable metastatic colorectal cancer. ( Asaka, M; Doi, T; Fuse, N; Kojima, T; Muto, M; Ohtsu, A; Tahara, M; Takeuchi, S; Taku, K; Yoshida, S, 2007) |
| "FOLFOX-4 (folinic acid/5-fluorouracil/oxaliplatin) chemotherapy is used to treat patients with colorectal liver metastases." | 3.74 | The pathological response to neoadjuvant chemotherapy with FOLFOX-4 for colorectal liver metastases: a comparative study. ( Aithal, GP; Aloysius, MM; Beckingham, IJ; Bessell, EM; Lobo, DN; Neal, KR; Zaitoun, AM, 2007) |
| "We retrospectively evaluated the efficacy and safety of combination therapy of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer (MBC)." | 3.74 | Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer. ( Hatake, K; Ito, Y; Iwase, T; Osako, T; Takahashi, S; Tokudome, N, 2008) |
| "We report a case of elderly metastatic breast cancer with a complete response to the treatment with XC (X: capecitabine and C: cyclophosphamide)." | 3.74 | [A case of elderly metastatic breast cancer with a complete response to treatment with capecitabine and cyclophosphamide]. ( Furukawa, K; Iida, S; Iwasaki, R; Naito, Z; Noguchi, T; Sugisaki, Y; Tajiri, T; Tsuchiya, S; Yanagihara, K; Yokoyama, T, 2007) |
| "The clinical efficacy and safety of irinotecan plus infusional fluorouracil/l-leucovorin (FOLFIRI) in patients with fluoropyrimidine-resistant metastatic colorectal cancer were studied retrospectively." | 3.74 | [Clinical study of irinotecan plus infusional fluorouracil/l-leucovorin (FOLFIRI) in patients with fluoropyrimidine-resistant metastatic colorectal cancer]. ( Hori, S; Hyodo, I; Iguchi, H; Imamine, S; Kajiwara, T; Kataoka, J; Moriwaki, T; Nasu, J; Nishina, T, 2007) |
| "Treatment-related safety data from three phase III clinical studies were analyzed by multivariate analysis: two comparing capecitabine with bolus FU/LV in metastatic colorectal cancer (MCRC) and one comparing capecitabine plus oxaliplatin (XELOX) with bolus FU/LV as adjuvant treatment for colon cancer." | 3.74 | Potential regional differences for the tolerability profiles of fluoropyrimidines. ( Allegra, C; Bertino, JR; Cassidy, J; Clarke, SJ; Cunningham, D; Douillard, JY; Gilberg, F; Gustavsson, BG; Haller, DG; Hoff, PM; Milano, G; O'Connell, M; Rothenberg, ML; Rustum, Y; Saltz, LB; Schmoll, HJ; Sirzén, F; Tabernero, J; Twelves, C; Van Cutsem, E, 2008) |
| "Capecitabine has demonstrated high efficacy as first-line treatment for metastatic colorectal cancer (mCRC)." | 3.74 | XELOX followed by XELIRI or the reverse sequence in advanced colorectal cancer. ( Argon, A; Aykan, NF; Basaran, M; Gumus, M; Guney, N; Saglam, S; Sakar, B; Tenekeci, AN; Ustaoglu, MA; Ustuner, Z, 2007) |
| "The efficacy and tolerability of therapy with gemcitabine plus cisplatin were evaluated in 49 patients with disseminated breast cancer refractory to anthracyclines, docetaxel and capecitabine." | 3.73 | [Gemcitabine plus cisplatin therapy in breast cancer refractory to anthracyclines, docetaxel and capecitabine]. ( Filatova, LV; Gershanovich, ML; Semiglazova, TIu, 2005) |
| "To examine the prevalence of anemia and its impact of hemoglobin (Hgb) levels in predicting outcomes of 5-fluorouracil (FU)-based first-line chemotherapy for patients with advanced gastric cancer (AGC)." | 3.73 | Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer. ( Bang, SM; Cho, EK; Jung, CW; Kang, WK; Kim, K; Kim, S; Kim, WS; Lee, J; Lee, JH; Lee, SH; Park, JO; Park, K; Park, SH; Park, YS; Shin, DB, 2006) |
| "The present study aimed to prospectively investigate the influence of thymidylate synthase (TS) polymorphisms (5'-TSER, 3'-TSUTR) on the disease-free survival (DFS) and overall survival (OS) of patients with colorectal cancer (CRC) who were treated with adjuvant 5-fluorouracil (5-FU) therapy." | 3.73 | Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil. ( Adleff, V; Budai, B; Czeglédi, F; Gyergyay, F; Hitre, E; Horváth, Z; Kásler, M; Kovács, T; Kralovánszky, J; Láng, I; Lövey, J; Orosz, Z, 2005) |
| "Fifty-seven patients with metastatic breast cancer have been treated with reduced dose capecitabine 1g/m2 twice daily for 14 days repeated every 3 weeks after failure of a number of chemotherapy regimens or hormonal treatment." | 3.73 | Reduced dose capecitabine is an effective and well-tolerated treatment in patients with metastatic breast cancer. ( Coleman, RE; El-Helw, L, 2005) |
| "Irinotecan, in combination with 5-fluorouracil (5-FU) and a high dose of leucovorin (LV), known as FOLFIRI regimen, has shown activity in recurrent or metastatic colorectal cancer." | 3.73 | Irinotecan, continuous 5-fluorouracil, and low dose of leucovorin (modified FOLFIRI) as first line of therapy in recurrent or metastatic colorectal cancer. ( Byun, JH; Chang, SK; Choi, MG; Choi, SI; Hong, YS; Kang, JH; Lee, DS; Lee, KS; Lee, MA; Oh, ST; Shim, BY; Woo, IS, 2005) |
| "(1) In patients with metastatic colorectal cancer initially treated with irinotecan combination therapy, second-line therapy with a combination of fluorouracil, folinic acid and oxaliplatin resulted in a median survival time of 21 months after the start of first-line chemotherapy, in one clinical trial." | 3.73 | Cetuximab: new drug. Metastatic colorectal cancer: an inappropriate evaluation. ( , 2005) |
| "The cost of chemotherapy has dramatically increased in advanced colorectal cancer patients, and the schedule of fluorouracil administration appears to be a determining factor." | 3.73 | Economic impact of simplified de Gramont regimen in first-line therapy in metastatic colorectal cancer. ( Bracco-Nolin, CH; Chaigneau, L; Huchet, B; Legat-Fagnoni, C; Limat, S; Pivot, X; Stein, U; Woronoff-Lemsi, MC, 2006) |
| "A considerable proportion of estrogen receptor (ER)-positive breast cancer recurs despite tamoxifen treatment, which is a serious problem commonly encountered in clinical practice." | 3.73 | Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer. ( Bae, JY; Bae, YJ; Han, MR; Han, W; Hwang, KT; Hwang, SE; Kang, JJ; Kim, SW; Lee, JE; Lee, JH; Noh, DY; Shin, HJ, 2006) |
| "We investigated 29 patients with advanced and recurrent breast cancers who underwent capecitabine therapy in the department." | 3.73 | [Therapeutic efficacy of capecitabine on advanced and recurrent breast cancer with special reference to time to progression]. ( Hironou, M; Ikeda, M; Kurebayashi, J; Nakashima, K; Nomura, T; Ookubo, S; Seki, M; Shiiki, S; Sonoo, H; Tanaka, K; Udagawa, K; Yamamoto, Y, 2006) |
| "The regional administration of 5-fluorouracil (5-FU) has been the fundamental therapy against liver metastases for the improvement of patient prognosis; however, there have been few reports about the immunological effects of this agent." | 3.72 | Antitumor effect of a splenic injection of 5-fluorouracil on metastatic liver cancer in mice. ( Asao, T; Kanoh, K; Kuwano, H; Nomoto, K; Shimura, T; Suzuki, H, 2004) |
| "This study was to investigate the effect of capecitabine on recurrent tumor and metastasis after curative resection of liver cancer, xenograft of a highly metastatic human hepatocellular carcinoma (HCC) tumor (LCI-D20), with special reference to the expression of platelet-derived endothelial cell growth factor (PD-ECGF)." | 3.72 | Capecitabine inhibits postoperative recurrence and metastasis after liver cancer resection in nude mice with relation to the expression of platelet-derived endothelial cell growth factor. ( Fan, J; Ji, Y; Li, XM; Liu, YK; Shi, YH; Sun, QM; Tang, ZY; Wu, ZQ; Xiao, YS; Ye, SL; Zhou, J, 2003) |
| "In order to treat a patient with extramammary Paget's disease who had multiple metastases, 500 mg/day of 5-fluorouracil (7 days per week) and 5 mg/day of cisplatin (5 days per week) were administrated intravenously for 24 hours and 1 hour, respectively." | 3.72 | Trial of low-dose 5-fluorouracil/cisplatin therapy for advanced extramammary Paget's disease. ( Kariya, K; Schwartz, RA; Tsuji, T, 2004) |
| " In this study, digital karyotyping was used to search for genomic alterations in liver metastases that were clinically resistant to 5-fluorouracil (5-FU)." | 3.72 | Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. ( Bardelli, A; Choti, M; Diaz, LA; Donehower, R; Galizia, G; Iacobuzio-Donahue, C; Kinzler, KW; Lengauer, C; Parmigiani, G; Romans, K; Saha, S; Shih, IeM; Velculescu, VE; Vogelstein, B; Wang, TL, 2004) |
| "Preclinical in vitro and in vivo studies have demonstrated synergistic interactions between 5-fluorouracil (5-FU) and type I and II IFNs against human colorectal cancer cells." | 3.72 | Combined 5-fluorouracil/systemic interferon-beta gene therapy results in long-term survival in mice with established colorectal liver metastases. ( Barsoum, J; Choi, EA; Fraker, DL; Lei, H; Maron, DJ; Mick, R; Spitz, FR; Wilson, JM; Yu, QC, 2004) |
| "Capecitabine is a novel oral chemotherapy agent designed to generate 5-fluorouracil (5-FU) preferentially in tumor tissue, and is the most effective therapy for anthracycline and taxane-resistant breast cancer." | 3.72 | Effect of capecitabine on mean corpuscular volume in patients with metastatic breast cancer. ( Hamilton, M; Karvellas, CJ; Mackey, JR; Sawyer, M, 2004) |
| "Seventy-five patients with advanced colorectal cancer and treated with CPT-11 and 5-fluorouracil, entered the study." | 3.72 | Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. ( Boisdron-Celle, M; Dumont, A; Gamelin, E; Guérin, O; Morel, A; Rouits, E, 2004) |
| "To determine whether deleted in colon cancer (DCC) protein expression in colorectal cancer (CRC) metastases could predict outcome to palliative fluorouracil (FU)-based chemotherapy and to assess whether it is similar to that observed in the corresponding primary tumors." | 3.72 | Deleted in colon cancer protein expression in colorectal cancer metastases: a major predictor of survival in patients with unresectable metastatic disease receiving palliative fluorouracil-based chemotherapy. ( Aschele, C; Bandelloni, R; Casazza, S; Debernardis, D; Gallo, L; Lonardi, S; Monfardini, S, 2004) |
| "The efficacy of a concomitant oxaliplatin/bolus 5-fluorouracil/leucovorin regimen in 123 heavily pretreated patients with advanced colorectal cancer was evaluated." | 3.72 | Compassionate-use oxaliplatin with bolus 5-fluorouracil/leucovorin in heavily pretreated patients with advanced colorectal cancer. ( Amin-Zimmerman, F; Glisson, SD; Hargis, JB; Hicks, RM; Kosfeld, RE; LaRocca, RV; Leaton, KE, 2004) |
| "This study was conducted to evaluate the prognostic significance of thymidylate synthase (TS) expression in the tumor tissue of patients with metastatic colorectal cancer (CRC) who received protracted venous infusions of 5-fluorouracil (5-FU)." | 3.72 | Prognostic significance of thymidylate synthase in patients with metastatic colorectal cancer who receive protracted venous infusions of 5-fluorouracil. ( Araake, M; Hamaguchi, T; Hosokawa, A; Morita, H; Muro, K; Orita, H; Shimada, Y; Shirao, K; Yamada, Y, 2004) |
| "The 5 fluorouracil hepato-arterial infusion (5-FU HAI) therapy has a good effect on the liver metastases of colorectal cancer." | 3.72 | [The 5-fluorouracil hepato-arterial infusion with oral UFT therapy for the hepatic and extra hepatic metastases of colorectal cancer]. ( Ebuchi, M; Hasegawa, K; Kato, K; Koide, A; Maruyama, M; Maruyama, S; Ohbu, M; Takashima, I, 2004) |
| "Following the encouraging results achieved with the oral fluoropyrimidine capecitabine in clinical trials, a named patient programme was initiated in the UK, through which patients with advanced breast cancer were prescribed capecitabine monotherapy." | 3.71 | Capecitabine named-patient programme for patients with advanced breast cancer. the UK experience. ( Breddy, J; Cameron, D; Chaturvedi, A; Hutcheon, A; Leonard, RC; Salazar, R; Twelves, C, 2002) |
| "TS levels were measured immunohistochemically on archival specimens of colorectal cancer metastases from 124 patients homogeneously treated in a series of clinical trials at our institutions with: (A) leucovorin (LV)-modulated infusional 5-FU (n = 48); (B) LV-modulated bolus 5-FU (n = 41); (C) methotrexate (MTX)-modulated bolus 5-FU (n = 35)." | 3.71 | Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil. ( Aschele, C; Bandelloni, R; Barni, S; Cascinu, S; Catalano, V; Debernardis, D; Drudi, G; Gallo, L; Giordani, P; Lonardi, S; Maley, F; Monfardini, S; Turci, D, 2002) |
| "Irinotecan (CPT-11), oxaliplatin (OXA) and different folinic acid(FA) modulated 5-fluorouracil (5-FU) regimens are active as first-and second-line chemotherapy of metastatic colorectal cancer." | 3.71 | Weekly oxaliplatin, high-dose folinic acid and 24h-5-fluorouracil (FUFOX) as salvage therapy in metastatic colorectal cancer patients pretreated with irinotecan and folinic acid/5-fluorouracil regimens. ( Galle, PR; Heike, M; Hildner, K; Hoffmann, T; Moehler, M; Siebler, J, 2002) |
| "The clinical relevance of bax and bcl-2 protein expression has been investigated in 84 patients with recurrent or metastatic colorectal cancer submitted to a chemotherapy regimen including methotrexate and fluorouracil/leucovorin." | 3.71 | Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer. ( Costa, A; Daidone, MG; Dellapasqua, S; Lacava, J; Lena, MD; Leone, B; Paradiso, A; Simone, G; Vallejo, C, 2001) |
| "Results from two phase II studies in metastatic breast cancer have shown that the novel, tumour-selective fluoropyrimidine capecitabine provides an effective and well tolerated therapy in patients with metastatic breast cancer failing or resistant to anthracycline and taxane therapy." | 3.71 | Clinical experience of capecitabine in metastatic breast cancer. ( O'Shaughnessy, J, 2002) |
| "Capecitabine could potentially be used for secondline treatment in patients with progressive metastatic cholangiocarcinoma." | 3.71 | Capecitabine as second-line treatment for metastatic cholangiocarcinoma: a report of two cases. ( Heinemann, V; Schalhorn, A; Stemmler, J, 2002) |
| "The comparative saliva/plasma pharmacokinetics of 5-fluorouracil (5-FU) were investigated in 21 patients with metastatic colorectal cancer receiving high-dose folinic acid (LV (leucovorin) 200 mg/m2) followed by 5-FU bolus (400 mg/m2) and continuous infusion (600, 750, 900 or 1200 mg/m2) on days 1 and 2." | 3.70 | Plasma and salivary pharmacokinetics of 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer receiving 5-FU bolus plus continuous infusion with high-dose folinic acid. ( Astre, C; Bressolle, F; Duffour, J; Joulia, JM; Pinguet, F; Ychou, M, 1999) |
| "In a recent multicentre, randomised, controlled, open-label study (Rougier and colleagues, Lancet 1998, 352, 1407-1412), irinotecan significantly increased survival without any deterioration in quality of life compared with best-estimated infusional 5-fluorouracil (5-FU) therapy in the setting of second-line treatment for metastatic colorectal cancer." | 3.70 | Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU. ( Hickish, T; Iveson, TJ; Schmitt, C; Van Cutsem, E, 1999) |
| "The authors describe the retrospective analysis of treatment by 5-fluorouracil and interferon-a aof 34 patients with advanced colorectal cancer." | 3.70 | Retrospective evaluation of 5-fluorouracil-interferon-a aTreatment of advanced colorectal cancer patients. ( András, C; Antal, L; Csiki, Z; Gál, I; Szegedi, G; Takács, I, 2000) |
| "Thymidylate synthase (TS) expression in colorectal cancer metastases has been shown to predict for the clinical response to 5-fluorouracil." | 3.70 | Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. ( Aschele, C; Debernardis, D; Maley, F; Sobrero, A; Tunesi, G, 2000) |
| "Twenty-four patients with metastatic colorectal cancer were treated with recombinant IL-2 (rIL-2) by continuous intravenous infusion for 5 days (18 x 10(6) U/m2 per 24 h), followed by three injections of 5-fluorouracil (600 mg/m2) and folinic acid (25 mg/m2) at weekly intervals." | 3.69 | Acute phase proteins and recombinant IL-2 therapy: prediction of response and survival in patients with colorectal cancer. ( Broom, J; Eremin, O; Heys, SD; Simpson, WG; Whiting, PH, 1995) |
| "Nineteen patients with metastatic breast cancer who had failed prior first line FEC chemotherapy (fluorouracil 500 mg/m2, epirubicin 50 mg/m2 cyclophosphamide 500 mg/m2, every 4 weeks) were treated with a combination of fluorouracil 500 mg/m2, doxorubicin 50 mg/m2 and cyclophosphamide 500 mg/m2 every 4 weeks (FAC)." | 3.69 | FAC (fluorouracil, doxorubicin, cyclophosphamide) as second line chemotherapy in patients with metastatic breast cancer progressing under FEC (fluorouracil, epirubicin, cyclophosphamide) chemotherapy. ( Biron, P; Catimel, G; Chauvin, F; Clável, M; Guastalla, JP; Rebattu, P, 1994) |
| "Although intrahepatic infusion therapy with 5-fluorouracil for unresectable colorectal liver metastases may lead to improved overall survival for some patients, it is not clear why a response is not observed in others." | 3.69 | p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. ( Benhattar, J; Cerottini, JP; Givel, JC; Metthez, G; Saraga, E, 1996) |
| " The objective of this study was to test the effect of tamoxifen and tamoxifen in combination with other agents [5-fluorouracil (5-FU) and interferon (IFN)] against experimental liver metastases of human colorectal tumor cells xenografted into nude mice." | 3.69 | Inhibition of experimental liver metastasis by combined treatment with tamoxifen and interferon. ( Bender, E; Katoh, A; Mahaffey, W; Marrangoni, A; McKeating, J; Werner, A, 1996) |
| "Previous phase II studies of continuous infusion Fluorouracil (5-FU) (CI 5-FU) in refractory metastatic breast cancer have shown modest activity with low toxicity." | 3.69 | Continuous infusion 5-fluorouracil as first-line therapy for metastatic breast cancer. ( Chu, L; Havlin, KA; Peterson, BL; Sutton, LM; Winer, EP, 1996) |
| "Based upon prior data suggesting that alpha-interferon possesses chemomodulatory activity, the Southwest Oncology Group conducted a study in which patients with hormone refractory, metastatic (stage D2) adenocarcinoma of the prostate were treated with 5-fluorouracil (5-FU) and Roferon-A." | 3.69 | Treatment of stage D2 hormone refractory carcinoma of the prostate with 5-fluorouracil and Roferon-A: a Southwest Oncology Group study. ( Barnett, TC; Crawford, ED; Marshall, ME; O'Rourke, M; Wolf, M, 1996) |
| "We treated 39 women with newly diagnosed stage IV breast cancer with a new regimen of mitoxantrone 18 mg/m2 on days 1, 29, 57, vincristine 1." | 3.68 | Mitoxantrone, vincristine, and 5-fluorouracil with leucovorin modulation as induction chemotherapy prior to high-dose intensification in metastatic breast cancer. ( Bitran, JD; Huffman, S; Mick, R; Myers, SE; Williams, SF, 1993) |
| " Sixteen patients with metastatic breast cancer were treated with four cycles of doxorubicin, 5-fluorouracil, and methotrexate (AFM induction)." | 3.68 | Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. ( Anderson, KC; Ayash, L; Elias, AD; Hunt, M; Lynch, C; Mazanet, R; Pap, S; Schwartz, G; Tepler, I; Wheeler, C, 1992) |
| "Forty-five consecutive patients with advanced colorectal cancer were treated with 5-fluorouracil and high dose folinic acid." | 3.68 | [Fluorouracil and high-dose folinic acid in the treatment of advanced colorectal carcinoma]. ( Angelini, F; Carassai, A; Carpano, S; D'Aprile, M; Leggio, M; Lopez, M; Natali, M; Tonini, G; Vici, P, 1990) |
| "Since there is no effective second line chemotherapy in colorectal cancer resistant to fluorouracil, this study was carried out to evaluate the therapeutic activity of the pineal hormone melatonin, which has appeared to have antineoplastic activity in some experimental conditions, in patients with metastatic colorectal carcinoma who did not respond to fluorouracil." | 3.68 | A study of the pineal hormone melatonin as a second line therapy in metastatic colorectal cancer resistant to fluorouracil plus folates. ( Archili, C; Barni, S; Crispino, S; Lissoni, P; Paolorossi, F; Tancini, G, 1990) |
| "Methotrexate and 5-FU were given sequentially with a 7-hour interval to 43 evaluable patients with heavily pretreated metastatic breast cancer." | 3.67 | Sequential methotrexate and 5-FU in breast cancer resistant to the conventional application of these drugs. ( Bartsch, H; Fritze, D; Herrmann, R; Jungi, F; Manegold, C; Schroeder, M; Tigges, FJ, 1984) |
| "Thirty-eight evaluable patients with metastatic breast cancer refractory to hormonal therapy and multiple chemotherapy regimens were treated with mitolactol at a dose of 130 mg/m2/day orally for 10 days every 6 weeks." | 3.67 | Phase II study of mitolactol in chemotherapy-refractory metastatic breast cancer. ( Catalano, RB; Creech, RH; Dierks, KM; Shah, MK, 1984) |
| "Hexamethylmelamine, mitomycin C and 5-fluorouracil infusion (HexMF) achieved a median survival of 9 months for the 45 patients with either metastatic stage III or unresectable stage II carcinoma of the pancreas." | 3.67 | Primary treatment of regional and disseminated pancreatic cancer with hexamethylmelamine, mitomycin C and 5-fluorouracil infusion. ( Bruckner, HW; Butwell, N; Gorbaty, MI; Kalman, J; McKenna, A; Spigelman, M; Storch, J, 1989) |
| "Based on in vitro studies that have demonstrated synergy between recombinant alfa-2a-interferon (rIFN alpha-2a) and the fluoropyrimidine, fluorouracil (5FU), against two human colon cancer cell lines, a pilot clinical trial was initiated to determine the effects of the combination of 5FU and rIFN alpha-2a in patients with advanced, unresectable colorectal carcinoma." | 3.67 | Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. ( Goldman, M; Itri, L; Lyver, A; Rader, M; Schwartz, EL; Wadler, S; Weinberg, V; Wiernik, PH; Zimmerman, M, 1989) |
| "Sixty women with metastatic breast cancer refractory to at least one chemotherapeutic regimen were treated with fluorouracil (FUra) and high-dose continuous infusion folinic acid (leucovorin calcium)." | 3.67 | Refractory metastatic breast cancer: salvage therapy with fluorouracil and high-dose continuous infusion leucovorin calcium. ( Akman, S; Bertrand, M; Carr, B; Doroshow, JH; Flanagan, B; Goldberg, D; Leong, L; Margolin, K; Newman, E; Odujinrin, O, 1989) |
| "Thirty-six patients with metastatic breast cancer, 23 with documented progression of the disease after first-line chemotherapy (CAF or CMF) and 13 without prior chemotherapy, were treated with a simultaneous 120-h infusion of cisplatin (CDDP) and 5-fluorouracil (5-FU)." | 3.67 | 120 hours simultaneous infusion of cisplatin and fluorouracil in metastatic breast cancer. ( Barrajón, E; Campbell, W; Fernández Hidalgo, O; Gil, A; González, F; Lacave, AJ, 1989) |
| "In an attempt to increase the clinical activity of 5-fluorouracil (5-FU) by blocking the thymidine salvage pathway, 15 patients with refractory metastatic breast cancer (MBC) were treated with oral dipyridamole (D): 75 mg p." | 3.67 | 5-Fluorouracil and dipyridamole in metastatic breast cancer: a pilot study. ( Marini, G; Marpicati, P; Montini, E; Palazzi, M; Pipino, G; Simoncini, E; Zaniboni, A, 1989) |
| "The influence of several variables on the effectiveness of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy given to 87 patients with stage II breast cancer was retrospectively analyzed." | 3.67 | Adjuvant chemotherapy with and without radiotherapy in stage II breast cancer. ( Biran, S; Brufman, G; Sulkes, A, 1988) |
| "Twenty-six patients (25 evaluable for response) with previously treated metastatic breast cancer were treated with intermediate-dose methotrexate (300 mg/m2) followed by 5-fluorouracil (600 mg/m2) and folinic acid-SF (Leucovorin) rescue (10 mg/m2 q 6 h X 6 doses) with or without tamoxifen (20 mg) and conjugated estrogen (Premarin) (." | 3.67 | Salvage treatment with intermediate-dose methotrexate and 5-fluorouracil in metastatic breast cancer. ( Lippman, M; Steinberg, S; Swain, SM, 1988) |
| "Fifty-two patients with hormonally unresponsive or estrogen receptor negative metastatic breast cancer who had not received prior chemotherapy received mitoxantrone 10 mg/m2, cyclophosphamide 500 mg/m2, and 5-fluorouracil 1000 mg/m2 (MCF) by short intravenous infusion every 21 days." | 3.67 | Mitoxantrone, cyclophosphamide, and fluorouracil in metastatic breast cancer unresponsive to hormonal therapy. ( Blumenschein, GR; Buzdar, AU; Esparza, L; Holmes, FA; Hortobagyi, GN; Hug, V; Yap, HY, 1987) |
| "Three first-line combination chemotherapy regimens which included mitoxantrone were studied for the treatment of advanced breast cancer." | 3.67 | Use of mitoxantrone-based combination chemotherapy regimens as first-line treatment for advanced breast cancer. ( Bezwoda, WR; Dansey, RD; Hesdorffer, CS, 1987) |
| "In order to test the possible cardiac-sparing effect of doxorubicin administered by six-hour intravenous infusion and to prospectively evaluate the role of resting left ventricular ejection fraction in monitoring these patients, 33 women with advanced breast cancer were treated with combination chemotherapy containing 5-fluorouracil, cyclophosphamide, and doxorubicin." | 3.67 | Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breast. ( Blum, RH; Dubin, N; Green, MD; Muggia, FM; Roses, D; Sanger, J; Speyer, JL; Wernz, JC, 1985) |
| "Twenty-two patients with advanced breast cancer have been treated with sequential chemo-hormonotherapy consisting of tamoxifen 20 mg/day orally for 14 consecutive days, followed by no therapy for ten days, then estrogen 0." | 3.67 | Modulated chemo-hormonotherapy in advanced breast cancer. A pilot study. ( Cruciani, G; Fiorentini, GM; Marangolo, M; Rosti, G; Tienghi, A; Turci, D, 1986) |
| "Seventeen patients with stage T3 bladder cancer were treated in a pilot study of initial chemotherapy (four courses of cyclophosphamide, methotrexate and 5-fluorouracil) followed by megavoltage radiotherapy 6000 cGy) to the bladder." | 3.67 | Chemotherapy before radiotherapy for T3 bladder cancer. A pilot study. ( Hart, AJ; Kaye, SB; MacFarlane, JR; McHattie, I, 1985) |
| "One hundred and ten patients with stage IV breast cancer were treated with five-drug chemotherapy consisting of prednisone, cyclophosphamide, 5-fluorouracil, methotrexate, and vincristine." | 3.66 | Sequential use of endocrine therapy and chemotherapy for metastatic breast cancer: effects on survival. ( Manni, A; Pearson, OH; Trujillo, JE, 1980) |
| "Adriamycin, bleomycin, 5-fluorouracil and methotrexate have been used in combination in a Phase II study and as adjuvant chemotherapy for patients with locally advanced bladder cancer." | 3.66 | Combination chemotherapy for advanced bladder cancer. ( Evans, RG; Hall, RR; Price, DA; Pritchett, CJ, 1982) |
| " A complete regression of pleural, pulmonary parenchymal, cutaneous, and bone metastases was seen following therapy with 5-fluorouracil, Adriamycin, and mitomycin C." | 3.66 | Adenoid cystic carcinoma of the salivary gland. Sustained complete response to chemotherapy. ( Budd, GT; Groppe, CW, 1983) |
| "The action of floxuridine depends greatly on its concentration for treatment of liver metastases of colorectal carcinomas and other tumors." | 3.66 | [Completely implantable infusion pump. A new therapeutic possibility for selected patients with liver tumors]. ( Balch, CM; Urist, MM, 1983) |
| "Logothetis and von Eschenbach first 1981 reported encouraging preliminary results of the DMF regimen (Doxorubicine = Adriamycin, Mitomycin, 5 Fluorouracil) in hormone refractory adenocarcinoma of the prostate." | 3.66 | [Treatment of metastasizing prostatic carcinoma with DMF. Presentation of a prospective study]. ( Burk, K; Gropp, C; Rodeck, G, 1983) |
| "A course of combined therapy (adriablastin, cyclophosphan, vincristine and, in some cases, 5-fluorouracil) was given to 50 breast cancer patients with metastases of different localization." | 3.66 | [Combination chemotherapy including anablastine in disseminated breast cancer]. ( Ass, NIa; Dement'eva, IP; Lipovich, MM, 1981) |
| "Serial plasma carcinoembryonic antigen (CEA) levels were measured in 167 patients with metastatic breast cancer treated with fluorouracil, doxorubicin hydrochloride, and cyclophosphamide (FAC)." | 3.66 | Serial plasma carcinoembryonic antigen measurements during treatment of metastatic breast cancer. ( Blumenschein, GR; Buzdar, AU; Fritsche, HA; Hortobagyi, GN; Mughal, AW; Yap, HY, 1983) |
| "Six patients with metastatic urothelial carcinoma--4 transitional cell carcinomas and 2 adenocarcinomas--were treated with cis-platinum (CDDP), adriamycin (ADM) and 5-fluorouracil (5-FU)." | 3.66 | [Chemotherapy of metastatic urothelial carcinoma]. ( Kawai, T; Kihara, K; Ogawa, M; Sakuramoto, T; Washizuka, M, 1982) |
| "The five-drug combination of fluorouracil imidazole carboxamide dimethyl triazeno, vincristine, bis-chloroethyl nitrosourea, and prednisone (FIVB + P) was given to 120 women with metastatic breast cancer." | 3.66 | A five-drug combination in the treatment of metastatic breast cancer. ( Falkson, G; Falkson, HC, 1981) |
| "Thirty-six patients with advanced breast cancer were treated with the regimen of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF)." | 3.66 | Correlation of estrogen receptors and response to chemotherapy of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in advanced breast cancer. ( Chang, JC; Wergowske, G, 1981) |
| "We retrospectively analyzed the role of the dose level of CMF (cyclophosphamide, methotrexate, and fluorouracil) in postoperative adjuvant chemotherapy for breast cancer and in chemotherapy for metastatic breast cancer." | 3.66 | Dose-response effect of adjuvant chemotherapy in breast cancer. ( Bonadonna, G; Valagussa, P, 1981) |
| "One hundred and fourteen evaluable patients with metastatic breast cancer were treated with a program consisting of 5-FU, Adriamycin, cyclophosphamide (FAC) and nonspecific immunotherapy with Levamisole." | 3.66 | Combined chemoimmunotherapy for advanced breast cancer: a comparison of BCG and levamisole. ( Blumenschein, GR; Burgess, MA; Buzdar, AU; Gutterman, JU; Hersh, EM; Hortobagyi, GN; Tashima, CK; Yap, HY, 1979) |
| "Six hundred nineteen patients with metastatic breast cancer, treated with a combination of 5-fluorouracil, Adriamycin, and cyclophosphamide, or close variations of this program, with or without immunotherapy were analyzed retrospectively to identify those host, tumor, or treatment characteristics that might be of prognostic importance in predicting response to chemotherapy and survival from onset of the 5-fluorouracil-Adriamycin-cyclophosphamide treatments." | 3.66 | Prognostic factors in metastatic breast cancer treated with combination chemotherapy. ( Blumenschein, GR; Gehan, EA; Gutterman, JU; Hortobagyi, GN; Legha, SS; Smith, T; Swenerton, KD; Yap, HY, 1979) |
| "A heparinized catheter was used for the regional infusion of 5-fluorouracil in seven patients with liver metastases." | 3.66 | Heparinized catheters for long-term intraarterial infusion of 5-fluorouracil in liver metastases. ( Forsberg, L; Owman, T; Tylén, U, 1979) |
| "One hundred and five patients with metastatic breast cancer were treated with 5-fluorouracil, Adriamycin, cyclophosphamide and BCG (FAC-BCG)." | 3.66 | Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG. ( Blumenschein, GR; Burgess, MA; Buzdar, AU; Einhorn, L; Gutterman, JU; Hersh, EM; Hortobagyi, GN; Richman, SP; Tashima, CK, 1979) |
| "Two hundred twenty-two patients with stage II or III breast cancer following regional therapy were treated with a combination of fluorouracil, doxorubicin hydrochloride (Adrimycin), cyclophosphamide, and BCG vaccine." | 3.66 | Postoperative adjuvant chemotherapy with fluorouracil, doxorubicin, cyclophosphamide, and BCG vaccine. A follow-up report. ( Blumenschein, GR; Buzdar, AU; Campos, LT; Freireich, EJ; Gehan, EA; Gutterman, JU; Hersh, EM; Hortobagyi, GN; Smith, TL; Tashima, CK; Wheeler, WL, 1979) |
| "Patients with advanced breast cancer who had not previously received chemotherapy were treated on a three-arm prospective study: adriamycin day 1 plus 5-FU on day 1 and 8 (AF), adriamycin day 1, plus 5-FU day 1 and 8, and cyclophosphamide day 1 (AFC), and adriamycin day 1 plus 5-FU day 1 and 8, cyclophosphamide day 1 and methotrexate day 1 (AFCM)." | 3.66 | Adriamycin in combination for the treatment of breast cancer: a Southwest Oncology Group study. ( Costanzi, J; Hoogstraten, B; Kennedy, A; Maloney, TR; Palmer, RL; Rivkin, S; Samal, B; Smith, F; Thigpen, T; Tranum, B; Tucker, WG; Vaughn, CB; Wilson, H, 1978) |
| "Three distinct subpopulations of tumor cells derived from a single parent strain BALB/cfC3H mammary adenocarcinoma were tested in vivo for sensitivity to cyclophosphamide, methotrexate, and 5-fluorouracil." | 3.66 | Heterogeneity in drug sensitivity among tumor cell subpopulations of a single mammary tumor. ( Calabresi, P; DeNucci, T; Dexter, DL; Heppner, GH; Miller, FR, 1978) |
| "Nine patients with extensive bilateral hepatic metastases of colorectal cancer were treated with hepatic artery ligation and continuous infusion of 5-fluorouracil (5-FU)." | 3.65 | Hepatic artery ligation and 5-fluorouracil infusion for metastatic colon carcinoma and primary hepatoma. ( Eilber, FR; Holmes, EC; Morton, DL; Ramming, KP; Sparks, FC, 1976) |
| "Cyclophosphamide, 5-fluorouracil, methotrexate, and prednisone were administered for 165, 28-day cycles to 33 patients with metastatic breast cancer." | 3.65 | Leucovorin in combination chemotherapy of breast cancer. ( Corder, MP; Flannery, EP; Herbst, KD; Justice, GR; Sheets, RF; Stone, WH, 1977) |
| "Metastasizing mammary adenocarcinoma 13762 in female Fischer rats has been used as a model for studying postoperative adjuvant chemotherapy, using methotrexate (Mtx) and 5-fluouracil (5FU) either singly or in combinations." | 3.65 | Adjuvant postoperative chemotherapy with 5-fluorouracil and methotrexate: effect of schedule of administration on metastasis of 13762 mammary adenocarcinoma. ( Khwaja, TA; Lee, YT, 1977) |
| " Following surgical removal of spontaneous mammary adenocarcinomas, phenylalanine mustard, adriamycin, and 5-fluorouracil (PAF) were administered at 4, 2, and 50 mg/kg, respectively, once a week for six injections." | 3.65 | Comparison of adjuvant chemotherapeutic activity against primary and metastatic spontaneous murine tumors. ( Anderson, JC; Fugmann, RA; Martin, DS; Stolfi, RL, 1977) |
| "Seven patients with advanced endometrial adenocarcinoma achieved objective tumor regression following chemotherapy with cyclophosphamide, Adriamycin, 5-fluorouracil, and medroxyprogesterone acetate." | 3.65 | Combination chemotherapy of advanced endometrial adenocarcinoma with adriamycin, cyclophosphamide, 5-fluorouracil, and medroxyprogesterone acetate. ( Bruckner, HW; Deppe, G, 1977) |
| "Forty-four patients with metastatic breast cancer were treated with monthly courses of cyclophosphamide, methotrexate and 5-fluorouracil." | 3.65 | Cyclic combination chemotherapy for metastatic breast cancer. ( Biran, S; Brufman, G; Hochman, A; Krasnokuki, D, 1977) |
| "Cesium-131 was administered intravenously to 39 patients with superficial metastases of mammary carcinoma and the concentration in tumor was compared with that in normal tissue by application of a detector in vivo, before and after 1 to 5 days of chemotherapy with cyclophosphamide (CP), 5-fluorouracil (FU), or diethylstilbestrol." | 3.65 | Selection of chemotherapy for metastatic mammary cancer by effect on cesium-131 uptake. ( Ferguson, DJ; Harper, PV, 1977) |
| "Three patients with biopsy-proven lentigo maligna were treated with topical 5-fluorouracil." | 3.65 | Topical chemotherapy of lentigo maligna with 5-fluorouracil. ( Krementz, ET; Litwin, MS; Mansell, PW; Reed, RJ, 1975) |
| "In 1966, we published the case report of a patient with adrenal carcinoma and wide spread metatasis who, after treatment with mitotane (o,p-DDD) and fluorouracil, developed Addison disease accompanied by a clinical remission." | 3.65 | Metastatic adrenal cortical carcinoma. Documented cure with combined chemotherapy. ( Ostuni, JA; Roginsky, MS, 1975) |
| "Thirty patients with an advanced bronchogenic carcinoma were treated with a combination of adriamycin and 5-fluorouracil; in eight the size of the tumour or its metastases was reduced by over 50%, and eight further patients experienced useful relief of symptoms." | 3.65 | Treatment of advanced bronchogenic carcinoma with adriamycin and 5-fluorouracil. ( Anderson, G; Bugaighis, A; Rees, GJ, 1975) |
| "Prolonged cyclic combination chemotherapy with cyclophosphamide, methotrexate and fluorouracil was evaluated as adjuvant treatment to radical mastectomy in primary breast cancer with positive axillary lymph nodes." | 3.65 | Combination chemotherapy as an adjuvant treatment in operable breast cancer. ( Bajetta, E; Bonadonna, G; Brambilla, C; Brugnatelli, L; Brusamolino, E; De Lena, M; Musumeci, R; Rossi, A; Tancini, G; Valagussa, P; Veronesi, U, 1976) |
| "Forty patients with metastatic breast cancer who had received no previous cytotoxic therapy were treated with a combination chemotherapy program CMF (P), which included methotrexate, 60 mg/m2, and 5-fluorouracil, 700 mg/m2 intravenously on the first and eighth days, in addition to cyclophosphamide, 100 mg/m2, and prednisone, 40 mg/m2, by mouth daily from the first to the fourteenth day of a 28-day cycle." | 3.65 | Combination chemotherapy for advanced breast cancer: response and effect on survival. ( Canellos, GP; Chabner, BA; DeVita, VT; Gold, GL; Schein, PS; Young, RC, 1976) |
| "Twenty-five patients with advanced metastatic breast cancer were treated with the combination of methotrexate 60 mg/M(2) and 5-fluorouracil 700 mg/M(2) intravenously on the first and eighth days, and cyclophosphamide 100 mg/M(2) and prednisone 40 mg/M(2) by mouth daily for the first 14 days of a 28-day cycle." | 3.65 | Cyclical combination chemotherapy for advanced breast carcinoma. ( Canellos, GP; Chabner, BA; Devita, VT; Gold, GL; Schein, PS; Young, RC, 1974) |
| "Thirty patients with advanced metastatic breast cancer were treated with 5-fluorouracil." | 3.64 | 5-Fluorouracil in metastatic mammary cancer. ( DEMAREE, EW; MOORMAN, HD, 1962) |
| " 5-Fluorouracil (5 FU) is the first chemotherapeutic agent found to have a significant effect on gastrointestinal adenocarcinoma." | 3.64 | PALLIATIVE MANAGEMENT OF GASTROINTESTINAL CANCER. ( HART, GD, 1964) |
| " Dose reduction was defined as any decrease from initial dose; dose delay was any dosing delay >3 days from target date." | 3.01 | Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1. ( Bekaii-Saab, T; Belanger, B; Blanc, JF; Chen, LT; de Jong, FA; Macarulla, T; Mirakhur, B; Siveke, JT, 2021) |
| "Metastatic pancreatic cancer (mPC) still harbors a dismal prognosis." | 3.01 | Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial. ( Aparicio, T; Bachet, JB; Bignon, AL; Bouché, O; Dahan, L; Desrame, J; François, E; Le Malicot, K; Lecaille, C; Lepage, C; Malka, D; Petorin, C; Phelip, JM; Rebischung, C; Rinaldi, Y; Seitz, JF; Turpin, A; Williet, N, 2021) |
| " No significant differences in acute hematological or gastrointestinal toxic effects were observed between the treatment arms." | 2.94 | Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial. ( Cao, JY; Chen, MY; Chen, QY; Chen, Y; Chua, MLK; Duan, CY; Guo, L; He, YX; Hua, YJ; Huang, PY; Jiang, R; Li, JB; Lin, M; Ling, L; Liu, Q; Liu, YP; Mai, HQ; Mo, HY; Shen, GP; Sun, R; Tan, SH; Tang, LQ; Wang, ZQ; Wu, YS; Xie, YL; Yang, Q; You, R; Zhang, HD; Zhang, MX; Zhang, YN; Zhuang, AH; Zou, X, 2020) |
| "gov, NCT01506167) that recruited patients with metastatic colorectal cancer scheduled to receive bevacizumab in combination with first-line chemotherapy as part of routine clinical practice." | 2.90 | ACORN: Observational Study of Bevacizumab in Combination With First-Line Chemotherapy for Treatment of Metastatic Colorectal Cancer in the UK. ( Baijal, S; Chau, I; Cunningham, D; Ellis, R; Harrison, M; Khakoo, S; Ograbek, A; Pedley, I; Raouf, S; Ross, P; Steward, W; Tahir, S, 2019) |
| " The studies demonstrated a significant benefit from the triplet at the price of an increased incidence of chemotherapy-related adverse events (AEs)." | 2.90 | Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies. ( Allegrini, G; Aprile, G; Bergamo, F; Boccaccino, A; Boni, L; Borelli, B; Buonadonna, A; Cordio, S; Cremolini, C; Dell'Aquila, E; Falcone, A; Latiano, TP; Libertini, M; Lonardi, S; Marmorino, F; Masi, G; Moretto, R; Passardi, A; Pella, N; Randon, G; Ratti, M; Ricci, V; Ronzoni, M; Rossini, D; Tamburini, E; Urbano, F; Zucchelli, G, 2019) |
| "Metastatic colorectal cancer (mCRC) has low survival rates." | 2.90 | A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer. ( Beck, JT; Berlin, JD; Cubillo Gracian, A; Deming, DA; Elez Fernandez, E; Garcia-Alfonso, P; Gorbunova, V; Hofheinz, RD; Luo, Y; Mangel, L; Nechaeva, M; Ramanathan, RK; Sullivan, D; Torres, AH, 2019) |
| "Metastatic colorectal cancer frequently occurs in elderly patients." | 2.87 | Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results. ( Aparicio, T; Baconnier, M; Bedenne, L; Bouché, O; El Hajbi, F; Etienne, PL; Faroux, R; François, E; Genet, D; Khemissa Akouz, F; Kirscher, S; Lavau-Denes, S; Lecomte, T; Locher, C; Maillard, E; Oden-Gangloff, A; Paillaud, E; Retornaz, F; Rinaldi, Y; Taieb, J, 2018) |
| "The actual resection rate of metastases was significantly associated with treatment setting (P = 0." | 2.87 | Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3. ( Becker, T; Bemelmans, M; Bruns, CJ; Denecke, T; Folprecht, G; Gebauer, B; Heinemann, V; Held, S; Lang, H; Modest, DP; Modest, HI; Neumann, UP; Pratschke, J; Rentsch, M; Ricard, I; Seehofer, D, 2018) |
| "Acne-like skin rash is a frequently occurring adverse event associated with drugs against the epidermal growth factor receptor." | 2.87 | EVITA-a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity. ( Al-Batran, SE; Ettrich, TJ; Feustel, HP; Heeger, S; Hofheinz, RD; Homann, N; Kripp, M; Lorenzen, S; Merx, K; Ocvirk, J; Schatz, M; Schulte, N; Schulz, H; Tetyusheva, M; Trojan, J; Vlassak, S, 2018) |
| "The primary end point was the 10-month progression-free rate (PFR); secondary end points included progression-free and overall survival, response rate, rate of metastases resection, and adverse events." | 2.87 | Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. ( Antoniotti, C; Aprile, G; Bergamo, F; Boni, L; Cardellino, GG; Coltelli, L; Corsi, DC; Cremolini, C; Dell'Aquila, E; Di Fabio, F; Falcone, A; Fontanini, G; Gemma, D; Grande, R; Lonardi, S; Lupi, C; Mancini, ML; Marcucci, L; Marmorino, F; Masi, G; Mescoli, C; Ronzoni, M; Salvatore, L; Tonini, G; Zagonel, V, 2018) |
| " Patients were randomly assigned (1:1) to either BEVZ92 or reference bevacizumab (5 mg/kg on day 1 of each cycle every 2 weeks) in combination with fluorouracil, leucovorin, and oxaliplatin (FOLFOX) or fluorouracil, leucovorin, and irinotecan (FOLFIRI)." | 2.87 | Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial. ( Abdalla, KC; Bondarenko, I; Del Campo García, A; Franke, F; Huerga, C; Melo Cruz, F; Mendonça Bariani, G; Millán, S; Ostwal, V; Paravisini, A; Peredpaya, S; Rahuman, SA; Ramesh, A; Roca, E; Romera, A; Shah, P; Shparyk, Y, 2018) |
| "Cardiotoxicity is a side effect of trastuzumab." | 2.84 | Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II ( Aalders, K; Bartlett, JMS; Biganzoli, L; Bogaerts, J; Cameron, D; De Valk, B; Khaled, H; Marreaud, S; Tryfonidis, K; Vermorken, J; Welnicka-Jaskiewicz, M, 2017) |
| "Data of 179 patients with N3 HNSCC from two GORTEC randomized trials (96-01 and 99-02) were pooled." | 2.84 | Very accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: Pooled analysis of two GORTEC randomized trials. ( Alfonsi, M; Aupérin, A; Bardet, E; Bourhis, J; Calais, G; Deprez, P; Geoffrois, L; Gery, B; Graff, P; Grégoire, V; Lapeyre, M; Maingon, P; Martin, L; Pignon, T; Rives, M; Sire, C; Tao, Y; Verrelle, P, 2017) |
| "Several predictors of metastatic colorectal cancer (mCRC) outcomes have been described." | 2.84 | Geriatric factors analyses from FFCD 2001-02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patients. ( Aparicio, T; Auby, D; Bachet, JB; Bouché, O; Boulat, O; Breysacher, G; Cretin, J; Faroux, R; Gargot, D; Gasmi, M; Genet, D; Jouve, JL; Khemissa, F; Lecomte, T; Lepère, C; Locher, C; Maillard, E; Mitry, E; Ramdani, M; Seitz, JF; Sobhani, I; Stefani, L; Teillet, L, 2017) |
| "Metastatic gastric cancer patients with stable disease or a better response after the completion of first-line chemotherapy were randomized to oral UFT (360mg/m2 × 2 weeks) every 3 weeks until disease progression/intolerable toxicity or to observation (OBS)." | 2.84 | Maintenance treatment of Uracil and Tegafur (UFT) in responders following first-line fluorouracil-based chemotherapy in metastatic gastric cancer: a randomized phase II study. ( Chen, Z; Guo, W; Huang, M; Li, J; Li, W; Liu, X; Qiu, L; Wang, H; Zhang, W; Zhao, X; Zhu, X, 2017) |
| " However, the safety and efficacy of nimotuzumab combined with chemotherapy in locally advanced or metastatic esophageal cancer patients remain unclear." | 2.84 | Nimotuzumab Combined with Chemotherapy is a Promising Treatment for Locally Advanced and Metastatic Esophageal Cancer. ( Han, X; Lu, N; Pan, Y; Xu, J, 2017) |
| "Cetuximab-induced skin rash Gd3+ occurs in ≥16% patients (pts) (Heinemann et al." | 2.84 | Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care. ( Boller, E; Dingeldein, G; Ehscheidt, P; Flohr, T; Galle, PR; Geer, T; Göhler, T; Hebart, H; Heike, M; Indorf, M; Josten, KM; Karthaus, M; Lang, C; Moehler, M; Neise, M; Rudi, J; Schimanski, CC; Schmittel, A; Staib, F; Wierecky, J; Wörns, MA, 2017) |
| "One-hundred twenty-seven patients were randomly assigned to parsatuzumab, 400 mg, or placebo, in combination with mFOLFOX6 plus bevacizumab, 5 mg/kg." | 2.84 | Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer. ( Anderson, M; Argiles, G; Braiteh, F; Chang, I; Chen, D; Funke, R; García-Carbonero, R; Gore, I; Hegde, P; Hurwitz, H; Jassem, J; McCall, B; Rhee, I; Rivera, F; Stroh, M; Tebbutt, N; van Cutsem, E; Wainberg, ZA; Wakshull, E; Ye, W, 2017) |
| "Doublet or triplet chemotherapy regimens in combination with anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodies (mAb), such as cetuximab or panitumumab, or the anti-vascular endothelial growth factor mAb bevacizumab, are the current recommended standard of care therapies for unresectable metastatic colorectal cancer (mCRC)." | 2.82 | Triplet chemotherapy in combination with anti-EGFR agents for the treatment of metastatic colorectal cancer: Current evidence, advances, and future perspectives. ( Cremolini, C; Esser, R; Falcone, A; Folprecht, G; Martinelli, E; Mazard, T; Modest, DP; Tsuji, A, 2022) |
| "Bevacizumab combined with modified FOLFOX6 is a standard regimen for colorectal cancer." | 2.80 | Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial. ( Cao, J; Hu, X; Li, T; Lv, F; Ni, C; Ragaz, J; Sun, S; Wang, B; Wang, L; Wang, Z; Wu, Z; Xie, J; Zhang, J; Zhang, S, 2015) |
| " Despite heterogeneity in response to aflibercept, no biomarkers for efficacy or adverse effects have been identified." | 2.80 | Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting. ( Chiron, M; Folprecht, G; Lambrechts, D; Margherini, E; Moisse, M; Pericay, C; Peuteman, G; Sagaert, X; Thienpont, B; Thuillier, V; Van Cutsem, E; Zalcberg, J; Zilocchi, C, 2015) |
| "Eniluracil/5-FU/Lv might enable these patients to continue with oral 5-FU rather than switching to the generally less well tolerated intravenous microtubule-interfering agents." | 2.79 | Eniluracil plus 5-fluorouracil and leucovorin: treatment for metastatic breast cancer patients in whom capecitabine treatment rapidly failed. ( Burdaeva, O; Chang, JC; Kirby, MG; Rivera, E; Semiglazov, V; Spector, T, 2014) |
| "We evaluated the safety and efficacy of biweekly capecitabine in combination with oxaliplatin in previously untreated patients with locally advanced or metastatic gastric cancer." | 2.79 | A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer. ( Bai, LY; Chao, Y; Chen, JS; Hsieh, JS; Li, CP; Su, WC; Su, YC; Tai, CJ; Wu, CC; Yeh, HT; Yeh, KH, 2014) |
| "In advanced gastric cancer (AGC), no globally accepted prognostic scoring system has been developed." | 2.79 | Determination of prognostic factors in Japanese patients with advanced gastric cancer using the data from a randomized controlled trial, Japan clinical oncology group 9912. ( Boku, N; Fukase, K; Goto, M; Koizumi, W; Mizusawa, J; Nishina, T; Ohtsu, A; Takahari, D; Takashima, A; Tamura, T; Tsuji, A; Yamada, Y; Yamaguchi, K; Yamazaki, K; Yoshino, T, 2014) |
| " The most frequent grade 3-4 adverse events included neutropenia (grade 3: 33." | 2.79 | An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer. ( Asmis, TR; Ayoub, JP; Ballal, S; Cervantes, A; Garcia-Carbonero, R; Maurel, J; Moore, MJ; Nasroulah, F; Rivera, F; Schwartz, JD; Tabernero, J, 2014) |
| "Surgery for colorectal liver metastases results in an overall survival of about 40% at 5 years." | 2.79 | Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. ( Bowers, M; Bridgewater, J; Butler, R; Cunningham, D; Dixon, E; Falk, S; Finch-Jones, M; Garden, OJ; Hickish, T; Hornbuckle, J; Iveson, T; Little, L; Maughan, T; O'Reilly, D; Peterson, M; Primrose, J; Pugh, S; Rees, M; Siriwardena, A; Stanton, L; Valle, J, 2014) |
| "Fluorouracil dose was reduced to 2400 mg/m² after two of the first three patients reported grade 3-4 diarrhoea (in one case with febrile neutropenia)." | 2.78 | FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). ( Aprile, G; Bergamo, F; Bracarda, S; Cremolini, C; Falcone, A; Fontanini, G; Fornaro, L; Lonardi, S; Loupakis, F; Lupi, C; Masi, G; Morvillo, M; Salvatore, L; Schirripa, M; Sensi, E; Vivaldi, C; Zagonel, V; Zaniboni, A, 2013) |
| "Metastatic breast cancer (MBC) remains an incurable illness in the majority of cases, despite major therapeutic advances." | 2.78 | Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. ( Bachelot, T; Blasinska-Morawiec, M; Capitain, O; Cognetti, F; Crown, JP; Davidson, N; Diéras, V; Fasching, PA; Fountzilas, G; Greil, R; Huang, X; Kern, KA; Kreienberg, R; Liedtke, C; Miller, WH; Paolini, J; Ramos, M; Romieu, G; Staroslawska, E; Tassell, V; Wildiers, H; Yardley, DA, 2013) |
| "In stage IV rectal cancer, palliative surgery is often carried out upfront." | 2.78 | Palliative radiotherapy and chemotherapy instead of surgery in symptomatic rectal cancer with synchronous unresectable metastases: a phase II study. ( Bujko, K; Kepka, L; Michalski, W; Olszyna-Serementa, M; Palucki, J; Pietrzak, L; Rutkowski, A; Tyc-Szczepaniak, D; Wyrwicz, L, 2013) |
| "Patients with metastatic colorectal cancer that harbors KRAS mutations in exon 2 do not benefit from anti-epidermal growth factor receptor (EGFR) therapy." | 2.78 | Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. ( Barugel, M; Bodoky, G; Burkes, R; Błasińska-Morawiec, M; Canon, JL; Cunningham, D; Douillard, JY; Humblet, Y; Jassem, J; Kocákova, I; Oliner, KS; Patterson, SD; Rivera, F; Rong, A; Rother, M; Ruff, P; Sidhu, R; Siena, S; Šmakal, M; Tabernero, J; Wiezorek, J; Williams, R, 2013) |
| "The study objectives were to evaluate the safety, tolerability, and preliminary efficacy of multiple doses of dulanermin in combination with modified FOLFOX6 and bevacizumab in previously untreated patients with locally advanced, recurrent, or metastatic colorectal cancer." | 2.78 | A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer. ( Ashkenazi, A; Kapp, AV; Kozloff, MF; Messersmith, WA; Peddi, PF; Portera, CC; Royer-Joo, S; Wainberg, ZA, 2013) |
| "Penis cancer is rare and clinical trial evidence on which to base treatment decisions is limited." | 2.78 | Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001). ( Bahl, A; Barber, J; Burnett, S; Carrington, B; Chester, JD; Cruickshank, C; Elliott, T; Hall, E; Harland, SJ; Nicholson, S; Pickering, L; Thomson, A; Waters, R, 2013) |
| "This prospective observational study assessed the efficacy of bevacizumab in combination with chemotherapy as preoperative treatment to downsize tumours for radical resection in patients with unresectable metastatic colorectal cancer (mCRC)." | 2.78 | Preoperative treatment with bevacizumab in combination with chemotherapy in patients with unresectable metastatic colorectal carcinoma. ( Albiol, M; Alsina, M; Codina-Barreras, A; Figueras, J; Guardeño, R; Hernandez-Yagüe, X; Lopez-Ben, S; Queralt, B; Soriano, J, 2013) |
| "The aims of this study were to establish the maximum tolerated dose (MTD) of oxaliplatin in combination with fixed doses of gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in solid tumors, including advanced pancreatic cancer, and to evaluate the toxicity of the regimen." | 2.78 | Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas. ( Chalasani, SB; Chung, MS; Grossbard, ML; Kozuch, PS; Malamud, S; Mirzoyev, T; Olszewski, AJ, 2013) |
| "XELOX is a promising regimen for anthracycline-pretreated metastatic breast cancer although careful patient selection is indicated and alternate dosing schedules should be explored to minimize neurologic morbidity." | 2.78 | Capecitabine and oxaliplatin in combination as first- or second-line therapy for metastatic breast cancer: a Wisconsin Oncology Network trial. ( Champeny, TL; Chang, JE; Hansen, RM; Kim, K; Meadows, S; Njiaju, UO; Powers, K; Stewart, JA; Tevaarwerk, AJ; Traynor, AM; Van Ummersen, L, 2013) |
| "Cediranib is a highly potent inhibitor of vascular endothelial growth factor (VEGF) signalling with activity against all three VEGF receptors." | 2.78 | Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer. ( Cunningham, D; D'Haens, G; Douillard, JY; Robertson, J; Stone, AM; Van Cutsem, E; Wong, RP, 2013) |
| "Squamous cell carcinoma is the main histological subtype of esophageal cancer in the east Asia." | 2.78 | A phase II study of oxaliplatin in combination with leucovorin and fluorouracil as first-line chemotherapy in patients with metastatic squamous cell carcinoma of esophagus. ( Chang, J; Ji, D; Li, W; Peng, W; Wang, H; Wang, J; Wu, X; Yu, H, 2013) |
| "This Phase Ib trial assessed the maximum tolerated dose (MTD) and safety of the Toll-like receptor 9 agonist IMO-2055 combined with 5-fluorouracil, cisplatin, and cetuximab (PFE) as first-line palliative treatment in patients with relapsed and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)." | 2.78 | Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck. ( Brümmendorf, TH; Delord, JP; Forssmann, U; Goddemeier, T; Kaminsky, MC; Keller, U; Machiels, JP, 2013) |
| "Capecitabine has clinical activity in MRCC patients who have non-clear cell histology and a good or intermediate prognosis." | 2.77 | Phase II, multicenter, uncontrolled trial of single-agent capecitabine in patients with non-clear cell metastatic renal cell carcinoma. ( Demidov, L; Galchenko, V; Kharkevich, G; Naidzionak, U; Petenko, N; Sinelnikov, I; Tsimafeyeu, I, 2012) |
| "To confirm the efficacy and toxicity of Erlotinib in combination with Gemcitabine and Capecitabine when used as a first-line therapy in metastatic/recurrent pancreatic cancer (PC)." | 2.77 | A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research. ( Bang, YJ; Kang, HJ; Kim, BS; Kim, JS; Lee, KH; Lee, KW; Oh, DY; Park, YS; Ryoo, HM; Sohn, CH; Song, HS; Zang, DY, 2012) |
| "This study evaluated the maximum tolerated dose (MTD) of sunitinib, a multitargeted tyrosine kinase inhibitor, combined with FOLFIRI (irinotecan 180 mg/m2 given over 90 min i." | 2.77 | A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. ( Aranda, E; Carrato, A; Chau, I; Countouriotis, AM; Cunningham, D; Guillen-Ponce, C; Iveson, TJ; Ramos, FJ; Ruiz-Garcia, A; Saunders, MP; Starling, N; Tabernero, J; Tursi, JM; Vázquez-Mazón, F; Wei, G, 2012) |
| "We enrolled 45 patients with metastatic renal cell carcinoma (RCC) at a progressive disease between March 2003 and April 2008 to assess the impact of an anti-inflammatory treatment regime in combination with metronomic low-dose chemotherapy." | 2.77 | Pioglitazone, etoricoxib, interferon-α, and metronomic capecitabine for metastatic renal cell carcinoma: final results of a prospective phase II trial. ( Andreesen, R; Berand, A; Bross, K; Grassinger, J; Reichle, A; Rogenhofer, S; Schrettenbrunner, I; Suedhoff, T; Vogelhuber, M; Walter, B; Wieland, WF; Wilke, J, 2012) |
| "Cediranib is an oral, highly potent VEGF signaling inhibitor of all three VEGF receptors." | 2.77 | Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer. ( Boku, N; Mishima, H; Okamoto, W; Satoh, T; Shi, X; Shimamura, T; Yamaguchi, K; Yamazaki, K, 2012) |
| "Capecitabine is an oral fluoropyrimidine with single-agent activity in metastatic nasopharyngeal carcinoma (NPC)." | 2.77 | Phase II trial of capecitabine plus cisplatin as first-line therapy in patients with metastatic nasopharyngeal cancer. ( Chua, DT; Hong, RL; Krishnan, G; Kurnianda, J; Ng, AW; Ng, WT; Seetalarom, K; Shotelersuk, K; Sze, WK; Wang, CH; Yang, MH; Yiu, HH, 2012) |
| "Patients with advanced breast cancer were randomized to first-line chemotherapy with a combination of epirubicin (Farmorubicin(®)) and paclitaxel (Taxol(®)) alone (ET) or in combination with capecitabine (Xeloda(®), TEX)." | 2.77 | Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial. ( Aström, G; Bergh, J; Brandberg, Y; Carlsson, L; Carstensen, J; Einbeigi, Z; Fernö, M; Hatschek, T; Hellström, M; Lidbrink, E; Linderholm, B; Lindh, B; Loman, N; Malmberg, M; Rotstein, S; Söderberg, M; Sundquist, M; Svensson, H; Walz, TM, 2012) |
| "The aim of this study was to determine the safety and efficacy of metronomic chemotherapy combined with targeted drugs in patients with metastatic breast cancer (MBC)." | 2.77 | Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity. ( Bagnardi, V; Bertolini, F; Calleri, A; Cancello, G; Colleoni, M; Dellapasqua, S; Goldhirsch, A; Intra, M; Luini, A; Montagna, E; Pastrello, D; Perri, G; Rampinelli, C; Veronesi, P; Viale, G, 2012) |
| "Leucovorin Sodium (LV/Na) has a high solubility, and is stable when given with continuous infusion of 5-FU." | 2.77 | A phase II randomized study of combined infusional leucovorin sodium and 5- FU versus the leucovorin calcium followed by 5-FU both in combination with irinotecan or oxaliplatin in patients with metastatic colorectal cancer. ( Bleiberg, H; D'Haens, G; Deleu, I; Efira, A; Humblet, Y; Paesmans, M; Peeters, M; Rezaei Kalantari, H; Vandebroek, A; Vergauwe, P, 2012) |
| "Patients with metastatic colorectal cancer (mCRC) were randomized to XELOX plus bevacizumab using a standard triweekly cycle (Q3W) or a dose-dense biweekly cycle (Q2W) schedule." | 2.77 | A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard). ( Cartwright, T; Hu, S; Hurwitz, H; Kwok, A; McKenna, E; Mitchell, EP; Patt, YZ, 2012) |
| "The Maintenance in Colorectal Cancer trial was a phase III study to assess maintenance therapy with single-agent bevacizumab versus bevacizumab plus chemotherapy in patients with metastatic colorectal cancer." | 2.77 | Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. ( Abad, A; Aranda, E; Arrivi, A; Benavides, M; Díaz-Rubio, E; Fernández-Martos, C; Gallén, M; Gómez-España, A; González, E; Maestro, ML; Marcuello, E; Massuti, B; Rivera, F; Sastre, J; Tabernero, JM; Valladares, M; Vidaurreta, M, 2012) |
| " This prospective phase II study evaluated the activity and toxicity of a modified regimen with lower doses of docetaxel and cisplatin combined with oral capecitabine instead of fluorouracil for patients with advanced gastric cancer." | 2.77 | Modified docetaxel-cisplatin in combination with capecitabine as first-line treatment in metastatic gastric cancer. a phase II study. ( Dimitroulis, D; Felekouras, E; Griniatsos, J; Karatzas, T; Karavokyros, J; Kontzoglou, K; Mantas, D; Nikiteas, N; Polyzos, A; Polyzos, K; Syrigos, K; Tsavaris, N; Vafiadis, I, 2012) |
| "IGF-1 was associated with the number of metastases (p = 0." | 2.77 | Prognostic significance of serum levels of vascular endothelial growth factor and insulin-like growth factor-1 in advanced gastric cancer patients treated with FOLFOX chemotherapy. ( Camphausen, K; Graves, CA; Kim, HJ; Kim, SH; Kwon, HC; Lee, JH; Lee, S; Oh, SY, 2012) |
| "We evaluated the efficacy and safety of cetuximab in combination with XELOX [XELoda® (capecitabine) and OXaliplatin] in advanced gastric cancer (AGC) patients." | 2.76 | A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer. ( Chang, HM; Kang, HJ; Kang, YK; Kim, C; Kim, TW; Lee, JL; Lim, HY; Park, YS; Ryoo, BY; Ryu, MH, 2011) |
| "Chemo-naïve patients with metastatic gastric cancer were enrolled to receive 4 cycles of TCF-dd (docetaxel initially 85 mg/m(2) and cisplatin initially 75 mg/m(2) on day 1 [later modified due to toxicity: 70 and 60 mg/m(2) respectively], l-folinic acid 100 mg/m(2) on days 1 and 2, 5-fluorouracil 400 mg/m(2) bolus and then 600 mg/m(2) as a 22 h continuous infusion on day 1 and 2, every 14 days)." | 2.76 | Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II trial. ( Brighenti, M; Buti, S; Dalla Chiesa, M; Donati, G; Lazzarelli, S; Passalacqua, R; Rovere, RK; Tomasello, G, 2011) |
| "Following significant hematotoxicity, dosing was modified to gemcitabine 1000 mg/m (Days 1, 8), capecitabine 1000 mg twice daily (Days 1-14), and bevacizumab 15 mg/kg (Day 1) on a 21-day cycle with evaluation every 3 cycles." | 2.76 | A phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinoma. ( Chung, EK; Hahn, OM; Karrison, T; Kasza, K; Manchen, E; Posadas, EM; Stadler, WM, 2011) |
| "The addition of cetuximab to chronotherapy allowed safe and effective therapeutic control of metastases, including their complete resection, despite previous failure of several treatment regimens." | 2.76 | Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability. ( Adam, R; Bouchahda, M; Giacchetti, S; Gorden, L; Guettier, C; Hauteville, D; Innominato, PF; Karaboué, A; Lévi, F; Saffroy, R, 2011) |
| "Response to anticancer therapy is believed to be directly related to the concentration of the anticancer drug in the tumor itself." | 2.76 | Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis study. ( de Bruijn, P; Ghobadi Moghaddam-Helmantel, IM; Konings, IR; Loos, WJ; Mathijssen, RH; Sleijfer, S; van Dam, LM; Verweij, J; Wiemer, EA, 2011) |
| "This study was conducted to determine the optimal dosage of the docetaxel-capecitabine-cisplatin (DXP) regimen and to evaluate its efficacy and safety in patients with advanced gastric cancer." | 2.76 | Phase I/II study of a combination of docetaxel, capecitabine, and cisplatin (DXP) as first-line chemotherapy in patients with advanced gastric cancer. ( Chang, HM; Kang, YK; Kim, BS; Kim, TW; Oh, ST; Ryu, MH; Yoo, C; Yook, JH, 2011) |
| "Cabazitaxel (XRP6258) is a new taxoid that is active in chemotherapy-resistant tumour cell lines." | 2.76 | A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study. ( Awada, A; Besse, T; Campone, M; Dubin, F; Machiels, JP; Magherini, E; Pivot, X; Semiond, D; Villanueva, C, 2011) |
| "Oral capecitabine was administered on days 1-14 of 3-week cycles." | 2.76 | Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours. ( Davies, JM; Farrugia, D; Hayward, N; Kirichek, O; Medley, L; Morel, AN; Reed, N; Talbot, DC; Thakker, RV, 2011) |
| "To evaluate the efficacy and safety of yiqi zhuyu decoction (YZD) combined with oxaliplatin plus 5-flurouracil/leucovorin (FOLFOX-4) in the patients with metastatic colorectal cancer (MCRC)." | 2.76 | Yiqi zhuyu decoction combined with FOLFOX-4 as first-line therapy in metastatic colorectal cancer. ( Cao, B; Deng, WL; Li, ST; Li, Z, 2011) |
| " Although skin toxicities are the most common adverse events associated with EGFR inhibitors, the differences in efficacy and safety between pre-emptive and reactive skin treatment according to KRAS tumor status has not been reported." | 2.76 | The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status. ( Iannotti, N; Lacouture, ME; Mitchell, EP; Pillai, MV; Piperdi, B; Shearer, H; Xu, F; Yassine, M, 2011) |
| "We evaluated the efficacy and safety of bolus 5-fluorouracil (5-FU) and leucovorin combined with weekly paclitaxel (FLTAX) in advanced gastric cancer (GC) patients." | 2.76 | Phase II study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel as first-line therapy for advanced gastric cancer. ( Hamaguchi, T; Iwasa, S; Kato, K; Kobayashi, K; Matsubara, J; Nagai, Y; Nakajima, TE; Nakayama, N; Shimada, Y; Takagi, S; Tsuji, A; Yamada, Y; Yoshioka, A, 2011) |
| "To evaluate the efficacy of late accelerated hyperfractionated conformal radiotherapy (LACF) combined with capecitabine on esophageal carcinoma." | 2.76 | [Efficacy of late accelerated hyperfractionated conformal radiotherapy combined with capecitabine for esophageal carcinoma]. ( Feng, XZ; Han, JQ; Sheng, W, 2011) |
| "Survival time for metastatic breast cancer (MBC) can be substantially improved by combination chemotherapy in the adjuvant setting." | 2.75 | A Phase II trial of the combination of vinorelbine and capecitabine as second-line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines. ( Alexopoulos, A; Ardavanis, A; Ioannidis, G; Kandylis, C; Malliou, S; Orphanos, G; Rigatos, G; Stavrakakis, J, 2010) |
| "Capecitabine was administered 2,000 mg/m(2) daily for 14 days followed by 1 week rest." | 2.75 | A phase-II study of combination of pegylated interferon alfa-2a and capecitabine in locally advanced or metastatic renal cell cancer. ( Kellokumpu-Lehtinen, PL; Koskinen, S; Sunela, KL, 2010) |
| "In metastatic renal cell carcinoma combinations of interferon alfa-2a, interleukin-2, and fluorouracil produce higher response rates and longer progression-free survival than do single agents." | 2.75 | Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. ( Aitchison, M; Gore, ME; Griffin, CL; Hancock, B; Hussain, T; James, N; Mardiak, J; Mulders, PF; Oliver, RT; Parmar, MK; Patel, PM; Pyle, L; Royston, P; Sylvester, R, 2010) |
| "Capecitabine seems to be an active, feasible and well-tolerated mode of palliative treatment for advanced HNC patients who have previously received PBT schedules." | 2.75 | Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment. ( Adansa, JC; Cruz, JJ; Gil-Arnaiz, I; Hitt, R; Irigoyen, A; Isla, D; Lambea, J; Lecumberri, MJ; Martinez-Trufero, J, 2010) |
| "Edotecarin (J-107088), a novel inhibitor of topoisomerase I has an additive effect on colon cell lines (HCT-116) when combined with 5-fluorouracil (5-FU)." | 2.75 | A phase I dose-escalation study of edotecarin (J-107088) combined with infusional 5-fluorouracil and leucovorin in patients with advanced/metastatic solid tumors. ( Diasio, RB; Douillard, JY; Saif, MW; Sellers, S, 2010) |
| "Forty patients with metastatic colorectal cancer were enrolled." | 2.75 | Molecular markers in circulating tumour cells from metastatic colorectal cancer patients. ( Cortesi, E; Gazzaniga, P; Gradilone, A; Iacovelli, R; Naso, G; Nicolazzo, C; Petracca, A; Raimondi, C, 2010) |
| "As a project of the Kanagawa Colorectal Cancer Study Group, we performed this study to analyze the efficacy and the safety of modified FOLFIRI (irinotecan: 150 mg/m2) therapy for Japanese patients with metastatic colorectal cancer." | 2.75 | [Modified FOLFIRI (l-LV, 5-fluorouracil and irinotecan) therapy for Japanese patients with metastatic colorectal cancer]. ( Akaike, M; Imada, T; Masuda, M; Matsukawa, H; Ozawa, Y; Rino, Y; Shiozawa, M; Shiraishi, R; Suzuki, H; Takahashi, M; Tamura, I; Yamamoto, N; Yamamoto, Y; Yukawa, N, 2010) |
| " This study aims to achieve an improved disease free survival for patients after resection or resection combined with RFA of colorectal liver metastases by adding the angiogenesis inhibitor bevacizumab to an adjuvant regimen of CAPOX." | 2.75 | A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment. ( Bergman, AM; Dalesio, O; Rinkes, IH; Schouten, SB; Snoeren, N; Tollenaar, RA; van der Sijp, JR; van Hillegersberg, R; Verheul, HM; Voest, EE, 2010) |
| "Liver metastasectomies were performed in 26% of all pts and in 39% of pts with LM." | 2.75 | "Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study. ( Antonucci, A; Baldi, PL; Bruera, G; Cannita, K; De Galitiis, F; Ficorella, C; Mancini, M; Marchetti, P; Ricevuto, E; Santomaggio, A; Tudini, M, 2010) |
| "Tetrathiomolybdate (TM) is an oral copper chelator under development as an anti-angiogenic agent." | 2.74 | A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer. ( Brewer, GJ; Gartner, EM; Griffith, KA; Henja, GF; Merajver, SD; Pan, Q; Zalupski, MM, 2009) |
| "Simvastatin 40 mg tablet was given once daily per oral everyday during the period of chemotherapy without a rest." | 2.74 | Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study. ( Ahn, JB; Byun, JH; Hong, YS; Im, SA; Jung, KH; Kang, WK; Kim, TW; Lee, J; Lee, N; Lim, HY; Oh, DY; Park, JO; Park, SH; Park, YS; Shin, DB; Shin, SJ, 2009) |
| "The incidence of liver metastasis in group A was 34% which was lower than 50% in group B." | 2.74 | Effect of multiple-phase regional intra-arterial infusion chemotherapy on patients with resectable pancreatic head adenocarcinoma. ( Fu, DL; Jin, C; Long, J; Ni, QX; Xu, J; Yang, F; Yao, L; Yu, XJ, 2009) |
| "The quality of life (QL) of advanced gastric cancer patients receiving irinotecan, folinic acid and 5-fluorouracil (5-FU) (IF arm) or cisplatin with 5-FU (CF arm) is presented." | 2.74 | Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial. ( Barone, C; Bugat, R; Curran, D; Dank, M; Goker, E; Peschel, C; Pozzo, C; Valvere, V; Wenczl, M; Yalcin, S; Zaluski, J, 2009) |
| " Common adverse events were diarrhea, rash, dry skin, asthenia, nausea, anorexia." | 2.74 | Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. ( Cobleigh, MA; Dickler, MN; Klein, PM; Miller, KD; Winer, EP, 2009) |
| "This study was designed to determine the efficacy and safety of biweekly oxaliplatin in combination with infusional 5-fluouracil (5-FU) and leucovorin in patients with advanced gastric cancer (AGC)." | 2.73 | Phase II study of oxaliplatin in combination with continuous infusion of 5-fluorouracil/leucovorin as first-line chemotherapy in patients with advanced gastric cancer. ( Chang, YF; Chao, TY; Chen, PM; Chiou, TJ; Chiu, CF; Chung, CY; Hwang, WS; Lin, SF, 2008) |
| " Oxaliplatin in combination with leucovorin and 5-FU should be considered a feasible chemotherapy regimen for patients with recurrent/metastatic biliary tract carcinoma." | 2.73 | Phase II trial of oxaliplatin combined with leucovorin and fluorouracil for recurrent/metastatic biliary tract carcinoma. ( Cho, JY; Jeung, HC; Lee, DK; Lee, SJ; Lim, JY; Mun, HS; Paik, YH; Yoon, DS, 2008) |
| "Our results show that the regimen of gemcitabine combined with capecitabine is effective and well tolerated in patients with unresectable relapsed or metastatic carcinoma of the biliary tract." | 2.73 | [Gemcitabine combined with capecitabine in the treatment for 41 patients with relapsed or metastatic biliary tract carcinoma]. ( Chen, X; Chen, ZS; Li, J; Ouyang, XN; Xie, FW; Yu, ZY, 2008) |
| "Irinotecan 180 mg/m2 was administered biweekly on D1, LV 200 mg/m2 by intravenous infusion in 2 hours before bolus intravenous injection of 5-Fu 400 mg/m2, then followed immediately by intravenous infusion of 5-Fu 2." | 2.73 | [Irinotecan plus fuorouracil/leucovorin (FOLFIRI) as a second line chemotherapy for refractory or metastatic colorectal cancer]. ( Bai, Y; Chu, YP; Jin, ML; Li, J; Liu, DQ; Shen, L; Wang, YH; Xu, JM; Zhang, XD, 2008) |
| " Ninety metastatic breast cancer patients were randomized to receive vinorelbine at one of the eight possible dosing times." | 2.73 | A randomized multicenter study of optimal circadian time of vinorelbine combined with chronomodulated 5-fluorouracil in pretreated metastatic breast cancer patients: EORTC trial 05971. ( Amoroso, D; Baron, B; Biville, F; Chollet, P; Coudert, B; Cvickovic, F; Fillet, G; Focan, C; Genet, D; Giacchetti, S; Gorlia, T; Lentz, MA; Lévi, F; Marreaud, S; Van Der Auwera, J; Zambelli, A, 2008) |
| " The suramin dosing nomogram used in phase I and II portions of the trial yielded the desired plasma level of 10-50 micromol/L from 4." | 2.73 | Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell carcinoma. ( Au, JJ; Bukowski, RM; Cooney, MM; Dreicer, R; Elson, P; Ganapathi, R; George, S; Mekhail, T; Rini, BI; Roman, S; Shen, T; Wientjes, GM, 2008) |
| "Full-dose reirradiation combined with chemotherapy has been shown to be feasible after salvage surgery with acceptable toxicity." | 2.73 | Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. ( Bardet, E; Benhamou, E; Bensadoun, RJ; Bourhis, J; Castaing, M; de Raucourt, D; Dolivet, G; Ferron, C; Géry, B; Grégoire, V; Hamoir, M; Janot, F; Julieron, M, 2008) |
| "Advanced pancreatic cancer, in addition to its high mortality, is characterized by one of the highest rates of venous thromboembolic events (VTE) as compared to other types of cancer." | 2.73 | Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy). ( Bramlage, P; Dörken, B; Hilbig, A; Kauschat-Brüning, D; Oettle, H; Opitz, B; Pelzer, U; Riess, H; Scholten, T; Stieler, J, 2008) |
| "Treatment of HER-2-negative metastatic breast cancer (MBC) patients after anthracycline exposure is controversial." | 2.73 | A multicentre phase II study to evaluate sequential docetaxel followed by capecitabine treatment in anthracycline-pretreated HER-2-negative patients with metastatic breast cancer. ( Bayo, J; Bernabé, R; Fernández, A; Fernández-Freire, A; Fuentes, J; Lomas, M; Moreno, A; Rodríguez, A; Ruiz, M; Salvador, J, 2008) |
| "Gemcitabine was administered at FDR of 10 mg/m(2) per min in escalating durations of infusion on days 1 and 8." | 2.73 | A phase I trial of fixed dose rate gemcitabine plus capecitabine in metastatic cancer patients. ( Leoni, V; Rocci, L; Santini, D; Tonini, G; Vincenzi, B; Virzí, V, 2007) |
| "Capecitabine was well tolerated, but is not effective in heavily pretreated patients with cisplatin-refractory or relapsed germ cell tumors." | 2.73 | An open-label, multicenter phase II trial of capecitabine in patients with cisplatin-refractory or relapsed germ cell tumors. ( Bokemeyer, C; Grünwald, V; Hartmann, JT; Honecker, F; Kollmannsberger, C; Mayer, F; Oechsle, K; Rick, O, 2007) |
| "Thirty-three patients with metastatic pancreatic cancer (22 men and 11 women) were treated and 31 were evaluable." | 2.73 | Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer. ( Dietrich, M; Goel, A; Grossbard, ML; Homel, P; Kozuch, P; Malamud, S; Mirzoyev, T; Rodriguez, T, 2007) |
| "Sixty-two patients with metastatic renal cell carcinoma participated in a Phase II study." | 2.73 | Immuno-chemotherapy in metastatic renal cell carcinoma: long-term results from the rambam and linn medical centers, Haifa, Israel. ( Best, LA; Gaitini, D; Gez, E; Kuten, A; Mashiach, T; Meretyk, S; Native, O; Rubinov, R; Stein, A, 2007) |
| "Metastatic breast cancer patients who experienced disease progression after at least one (taxane or anthracycline based) chemotherapy regimen and an expected survival of at least 3 months and ECOG performance status 0-2 were eligible." | 2.73 | A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer. ( Creaven, P; Levine, E; O'connor, T; Rustum, Y, 2008) |
| "The R0 secondary resection rate of metastases was greater in the FOLFOXIRI arm (6% v 15%; P = ." | 2.73 | Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor ( Allegrini, G; Andreuccetti, M; Barbara, C; Benedetti, G; Brunetti, I; Chiara, S; Cortesi, E; Crinò, L; Evangelista, W; Falcone, A; Fanchini, L; Fioretto, L; Granetto, C; Masi, G; Orlandini, C; Pfanner, E; Picone, V; Porcile, G; Ricci, S; Vitello, S, 2007) |
| "Capecitabine as third-line treatment showed a favourable toxicity profile, but exhibited low activity in patients with advanced renal cell carcinoma after failing immunotherapy." | 2.73 | Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy. ( Barbanti, G; de Rubertis, G; Francini, E; Francini, G; Manganelli, A; Marsili, S; Paolelli, L; Pascucci, A; Petrioli, R; Salvestrini, F; Sciandivasci, A, 2007) |
| "Thalidomide 100 mg was kept stable for all cohorts." | 2.73 | A phase I study of thalidomide, capecitabine and temozolomide in advanced cancer. ( Khan, MI; Kloecker, GH; Laber, DA; Salvador, C; Schonard, C; Taft, BS, 2007) |
| "Ninety patients with metastatic colorectal cancer were included in the study." | 2.73 | TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid. ( Berglund, A; Brünner, N; Byström, P; Christensen, IJ; Glimelius, B; Nielsen, HJ; Sørensen, NM, 2007) |
| "The management of metastatic breast cancer becomes increasingly intricate, requiring new drugs and combinations." | 2.73 | Results of a phase I trial of intravenous vinorelbine plus oral capecitabine as first-line chemotherapy of metastatic breast cancer. ( Biville, F; Chauffert, B; Coudert, B; Favier, L; Ferrant, E; Fumoleau, P; Garnier, J; Isambert, N; Mayer, F; Zanetta, S, 2008) |
| "Gemcitabine was given by intravenous administration over 30 min on day 1, week 1 and day 8, week 2." | 2.73 | A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma. ( Amato, RJ; Khan, M, 2008) |
| "This study assessed the clinical activity and safety of twice-weekly paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin (TP-HDFL) in patients with recurrent or metastatic esophageal squamous cell carcinoma." | 2.73 | Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma. ( Cheng, AL; Hsu, C; Hsu, CH; Hsu, WL; Lin, CC; Tsai, YC; Yang, CH; Yeh, KH, 2007) |
| "All patients had histologically proven squamous cell carcinoma of the esophagus." | 2.73 | A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma. ( Cho, EY; Hong, YS; Im, YH; Kang, WK; Kim, HS; Kim, K; Kim, MJ; Lee, HR; Lee, J; Park, K; Shim, YM, 2008) |
| "Sites of metastasis were as follows: liver (n = 10), lung (n = 8), skin (n = 1), and non-regional lymph nodes (n = 1)." | 2.73 | Phase II trial of 5-fluorouracil/leucovorin/gemcitabine/cisplatin as second-line treatment in patients with metastatic or recurrent colorectal carcinoma: a cancer therapeutics research group study. ( Chang, AY; Fong, FK; Hsin, KW; Lim, R; Lopes, G; Wong, J, 2007) |
| "Chemoradiotherapy of the last phase II study with intermittent capecitabine (1500 mg/m(2)/day, delivered on days 1-14 and 22-35) and irinotecan (4 x 60 mg/m(2)) concurrently to radiotherapy is a safe treatment with low toxicity and high efficacy." | 2.73 | Intensified irinotecan-based neoadjuvant chemoradiotherapy in rectal cancer: four consecutive designed studies to minimize acute toxicity and to optimize efficacy measured by pathologic complete response. ( Fietkau, R; Foitzik, T; Klar, E; Klautke, G; Küchenmeister, U; Ludwig, K; Prall, F; Semrau, S, 2007) |
| "on day 1 every 3 weeks until disease progression or unacceptable toxicities." | 2.73 | A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer. ( Chang, HM; Kang, HJ; Kang, YK; Kim, BS; Kim, TW; Lee, JS; Oh, ST; Ryu, MH; Sohn, HJ; Yook, JH, 2008) |
| "Individual FU dose adjustment based on pharmacokinetic monitoring resulted in significantly improved objective response rate, a trend to higher survival rate, and fewer grade 3/4 toxicities." | 2.73 | Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. ( Boisdron-Celle, M; Delva, R; Dorval, E; Gamelin, E; Jacob, J; Merrouche, Y; Morel, A; Pezet, D; Piot, G; Raoul, JL, 2008) |
| "Thalidomide was escalated individually to 600 mg po QD as tolerated." | 2.72 | The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer. ( Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; McCollum, AD; Michelini, A; Ryan, DP; Wu, B, 2006) |
| "Capecitabine was administered orally according to following schedule: 1/4 of dose at 8:00 a." | 2.72 | Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer. ( Gasparro, S; La Cesa, A; Santini, D; Schiavon, G; Tonini, G; Vincenzi, A; Vincenzi, B, 2006) |
| "The purpose of this study was to look at the pharmacokinetics of docetaxel, cisplatin-derived platinum and 5-fluorouracil (5-FU), when used in combination, to exclude potential clinically relevant pharmacokinetic interactions." | 2.72 | A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors. ( Cirillo, I; de Bruijn, P; de Jonge, MJ; Felici, A; Loos, WJ; Mathijssen, RH; Nooter, K; Verweij, J, 2006) |
| "Pharmacokinetics and non-hematological adverse events could be assessed in all patients included in the study." | 2.72 | Pharmacokinetics of oxaliplatin and non-hematological toxicity in metastatic gastrointestinal cancer patients treated with chronomodulated oxaliplatin, 5-FU and sodium folinate in a pilot investigation. ( Farker, K; Hippius, M; Höffken, K; Hoffmann, A; Merkel, U; Roskos, M; Wedding, U, 2006) |
| "The 18-year probability of any first breast cancer event was 73% and 59% (P < ." | 2.72 | Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. ( Grau, C; Jensen, AR; Nielsen, HM; Overgaard, J; Overgaard, M, 2006) |
| "Patients with untreated advanced colorectal cancer were enrolled to this single arm phase II multi-center cooperative group trial of bevacizumab combined with IFL." | 2.72 | A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. ( Benson, AB; Catalano, PJ; Giantonio, BJ; Levy, DE; Meropol, NJ; O'dwyer, PJ, 2006) |
| "Capecitabine/docetaxel dosing flexibility allows management of side-effects without compromising efficacy." | 2.72 | Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage? ( Barak-Wigler, N; Bexon, AS; Chan-Navarro, CA; Gorbounova, V; Harker, WG; Leonard, R; Maraninchi, D; McKendrick, JJ; O'Shaughnessy, J; Twelves, C; Vukelja, S, 2006) |
| "Overall, 77." | 2.72 | Capecitabine and mitomycin C is an effective combination for anthracycline- and taxane-resistant metastatic breast cancer. ( Burattini, L; La Cesa, A; Marcucci, F; Massacesi, C; Pilone, A; Rocchi, MB; Santini, D; Tonini, G; Zepponi, L, 2006) |
| "Capecitabine was administered to single-patient cohorts at escalating doses of 1500, 2000, and 2500 mg/m2/day in two equally divided doses for 14 of 21 days, beginning on day 1." | 2.71 | A pilot study of edrecolomab (Panorex, 17-1A antibody) and capecitabine in patients with advanced or metastatic adenocarcinoma. ( Fehn, K; Landau, L; Makower, D; Mani, S; Sparano, JA; Versola, M; Wadler, S; Wissel, P, 2003) |
| "The pharmacokinetics of ftorafur, 5-fluorouracil (5FU) and uracil were investigated in order to built a population pharmacokinetic model for the anticancer drug UFT, administered with leucovorin and vinorelbine." | 2.71 | Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancer. ( Bonneterre, J; Campone, M; Deporte-Fety, R; Fargeot, P; Fumoleau, P; Kerbrat, P; Urien, S, 2003) |
| "Only 1-year metastasis in the WCA group was 15." | 2.71 | [Clinical study on post-operative metastasis prevention of progressive stage of gastric cancer by weichang'an]. ( Shen, KP; Yang, JK; Zhen, J, 2003) |
| "Capecitabine was given orally at a dose of 2500 mg/m2 daily divided into two doses for 14 days, followed by a 7-day rest in the monotherapy as well as in the combination treatment." | 2.71 | Capecitabine monotherapy and in combination with immunotherapy in the treatment of metastatic renal cell carcinoma. ( Bartsch, R; Hussian, D; Kramer, G; Lintner, C; Locker, GJ; Mader, R; Marberger, M; Pluschnig, U; Rauchenwald, M; Steger, GG; Wenzel, C; Zielinski, CC, 2003) |
| "In patients with laryngeal cancer, radiotherapy with concurrent administration of cisplatin is superior to induction chemotherapy followed by radiotherapy or radiotherapy alone for laryngeal preservation and locoregional control." | 2.71 | Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. ( Chao, C; Cooper, J; Ensley, J; Forastiere, AA; Glisson, B; Goepfert, H; Leaf, A; Lee, DJ; Maor, M; Morrison, W; Pajak, TF; Peters, G; Ridge, JA; Trotti, A; Weber, R, 2003) |
| " The purpose of the current study was to determine whether dose intensification of parenteral hydroxyurea in combination with fluorouracil could enhance the response rates of the combination against refractory upper gastrointestinal malignancies." | 2.71 | Phase II clinical trial of parenteral hydroxyurea in combination with fluorouracil, interferon and filgrastim in the treatment of advanced pancreatic, gastric and neuroendocrine tumors. ( Haynes, H; Kaleya, R; Kaubisch, A; Rozenblit, A; Wadler, S, 2004) |
| "Weight gain was observed in 12 of 33 (36%) patients." | 2.71 | Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study. ( Androulakis, N; Aravantinos, G; Athanasiadis, A; Fountzilas, G; Georgoulias, V; Papakotoulas, P; Polyzos, A; Potamiannou, A; Rigatos, SK; Stathopoulos, GP; Syrigos, K; Tsiakopoulos, I; Ziras, N, 2004) |
| "The purpose of our study was to determine the maximum-tolerated dose, dose-limiting toxicity, safety profile, and pharmacokinetics of the polyamine synthesis inhibitor SAM486A given in combination with 5-fluorouracil/leucovorin (5-FU/LV) in cancer patients." | 2.71 | Phase I and pharmacokinetic study of the polyamine synthesis inhibitor SAM486A in combination with 5-fluorouracil/leucovorin in metastatic colorectal cancer. ( Bootle, D; Bridgewater, J; Choi, L; de Bruijn, P; Eskens, FA; Ledermann, JA; Mueller, C; Planting, AS; Sklenar, I; Sparreboom, A; van Zuylen, L; Verweij, J, 2004) |
| "This study was originally designed as a phase I/II study, with a dose escalation of docetaxel in combination with epirubicin 50 mg m(-2) and 5-fluorouracil (5-FU) 200 mg m(-2) day(-1)." | 2.71 | Phase II study of docetaxel in combination with epirubicin and protracted venous infusion 5-fluorouracil (ETF) in patients with recurrent or metastatic breast cancer. A Yorkshire breast cancer research group study. ( Bradley, C; Crawford, SM; Dent, J; Dodwell, D; Humphreys, AC; Joffe, JK; Perren, TJ; Rodwell, S, 2004) |
| "Capecitabine is an oral fluoropyrimidine converted to fluourouracil (FU) preferentially in tumor tissue." | 2.71 | Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma. ( Abbruzzese, JL; Carter, S; Hoff, PM; Lassere, Y; Pazdur, R; Polito, D; Samid, D, 2004) |
| "Distant metastases rate (DMR) was significantly reduced with CRT (14." | 2.71 | Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. ( Au, GK; Chan, RT; Cheng, AC; Choy, DD; Chua, DT; Kwok, CC; Kwong, DL; Kwong, PW; Law, MW; Sham, JS; Wan, KY; Wu, PM; Yau, CC, 2004) |
| "Gemcitabine was dose escalated, 50-300 mg/m(2) on day 1." | 2.71 | Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck. ( Argiris, A; Eng, C; Haraf, DJ; Kozloff, MF; Milano, MT; Mittal, BB; Pelzer, H; Stenson, KM; Vokes, EE; Witt, ME, 2004) |
| "Forty-seven patients with resectable metastases of colorectal cancer were prospectively enrolled onto this study." | 2.71 | Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study. ( André, T; Artru, P; de Gramont, A; Gayet, B; Goebel, FM; Hebbar, M; Louvet, C; Parc, R; Paye, F; Perez, N; Taïeb, J; Tournigand, C, 2005) |
| "Progression-free and freedom from metastases rates were 29." | 2.71 | Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy coo ( Bamberg, M; Baumann, M; Budach, V; Budach, W; Geismar, D; Grabenbauer, G; Herrmann, T; Hinkelbein, W; Jahnke, K; Lammert, I; Stueben, G; Stuschke, M; Wernecke, KD; Wust, P, 2005) |
| "Capecitabine is a highly active oral fluoropyrimidine that is an attractive alternative to 5-fluorouracil in colorectal cancer treatment." | 2.71 | A phase I clinical and pharmacokinetic study of capecitabine (Xeloda) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours. ( Bertheault-Cvitkovic, F; Bugat, R; Canal, P; Chatelut, E; Cornen, X; Delord, JP; Dieras, V; Guimbaud, R; Lochon, I; Lokiec, F; Mery-Mignard, D; Mouri, Z; Pierga, JY; Turpin, FL, 2005) |
| "In total, 203 renal carcinoma patients' status post radical tumour nephrectomy were stratified into three risk groups: patients with tumour extending into renal vein/vena cava or invading beyond Gerota's fascia (pT3b/c pN0 or pT4pN0), patients with locoregional lymph node infiltration (pN+), and patients after complete resection of tumour relapse or solitary metastasis (R0)." | 2.71 | Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). ( Atzpodien, J; Ecke, M; Fornara, P; Gertenbach, U; Heynemann, H; Jentsch, H; Maskow, A; Reitz, M; Schmitt, E; Wandert, T; Wieland, W; Wöltjen, HH, 2005) |
| " This study is a preliminary clinical investigation to determine if HA could be safely used in combination with 5-fluorouracil (5-FU) and doxorubicin (DOX)." | 2.71 | Phase I and pharmacokinetic evaluation of intravenous hyaluronic acid in combination with doxorubicin or 5-fluorouracil. ( Brown, TJ; Ellis, A; Fox, RM; Gibbs, P; Heldin, P; Li, L; Rosenthal, MA; Uren, S; Wong, S, 2005) |
| "Published data suggests that docetaxel combined with 5-fluorouracil (5-FU) may have synergistic activity in treating advanced gastric cancer." | 2.71 | Phase I dose-escalating study of docetaxel in combination with 5-day continuous infusion of 5-fluorouracil in patients with advanced gastric cancer. ( Bang, SM; Cho, EK; Chung, M; Lee, JH; Lee, WK; Park, SH; Shin, DB, 2005) |
| "Patients with either adenocarcinoma or squamous cell carcinoma of the esophagus could enroll; however, patients could not have received prior chemotherapy for metastatic disease." | 2.71 | A phase II trial of gemcitabine, 5-fluorouracil and leucovorin in advanced esophageal carcinoma. ( Ahuja, H; Bailey, H; Berlin, JD; Hansen, R; Jumonville, A; Kim, K; McFarland, T; Morgan-Meadows, S; Mulkerin, D; Saphner, T; Thomas, JP, 2005) |
| "In patients with metastatic colorectal cancer that have previously received treatment with 5-FU based chemotherapy, treatment with SIR-spheres has demonstrated encouraging activity." | 2.71 | A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy. ( Bailey, W; Dowling, R; Gibbs, P; Liechtenstein, M; Lim, L; Little, A; Shapiro, JD; Smith, D; Yip, D, 2005) |
| "Forty patients and 75 pharmacokinetic time-courses were available for analysis." | 2.71 | Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer. ( Lokiec, F; Rezaí, K; Urien, S, 2005) |
| " Studies of bimonthly regimens of high-dose leucovorin (LV) and 5-fluorouracil (5-FU) by continuous infusion combined with oxaliplatin (L-OHP) have shown encouraging response rates in patients not responding to a bimonthly LV/5-FU regimen." | 2.70 | Whole-body hyperthermia (41.8 degrees C) combined with bimonthly oxaliplatin, high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer: a phase II study. ( Atanackovic, D; Corovic, A; Gruber, Y; Hegewisch-Becker, S; Hossfeld, DK; Nierhaus, A; Pichlmeier, U, 2002) |
| "Eniluracil is a potent, irreversible inactivator of dihydropyrimidine dehydrogenase, the major catabolic enzyme for 5-fluorouracil (5-FU)." | 2.70 | Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study. ( Abbruzzese, JL; Benedetti, JK; George, CS; Giguere, JK; Macdonald, JS; Neubauer, MA; Pruitt, BT; Rothenberg, ML; Seay, TE; Tanaka, MS, 2002) |
| "Febrile neutropenia was observed in 10% of patients and 2." | 2.70 | Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a phase II study. ( Campos, B; Carrete, N; Constenla, M; Garcia-Arroyo, R; Lorenzo, I; Palacios, P, 2002) |
| "The authors present the results of a six-year clinicoimmunological study of a therapeutic effect of cytkins combined with 5-fluoruracyl in metastatic renal-cell carcinoma." | 2.70 | [Clinical and immunological studies of the therapeutical effect of cytokines combined with 5-fluorouracil in metastatic kidney cancer]. ( Babich, VM; Bazalitskaia, SV; Gruzov, MA; Klimenko, IA; Kushneruk, IuI; Romanenko, AM; Shcherbak, AIu; Vozianov, AF; Zak, KP; Zubko, VI, 2002) |
| "Irinotecan (CPT-11) is an active drug in the treatment of patients with advanced colorectal carcinoma." | 2.70 | Irinotecan and chronomodulated infusion of 5-fluorouracil and folinic acid in the treatment of patients with advanced colorectal carcinoma: a phase I study. ( Aschelter, AM; Comis, S; D'Attino, RM; Dogliotti, L; Garufi, C; Nisticó, C; Perrone, M; Pugliese, P; Tampellini, M; Terzoli, E, 2001) |
| "The aim of this study was to examine the efficacy and safety of both oxaliplatin as a single agent and oxaliplatin in combination with dailyx5 bolus 5-fluorouracil and folinic acid (5-FU/FA, Mayo clinic regimen) in the first-line treatment of metastatic colorectal cancer (CRC) patients." | 2.70 | A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients. ( Balbiani, L; Bella, S; Blajman, C; Cazap, E; Chacón, M; Cóppola, F; Giglio, R; Lastiri, F; Mickiewicz, E; Montiel, M; Perazzo, F; Pujol, F; Recondo, G; Richardet, E; Rodger, J; Schmilovich, A; Simon, J; Van Kooten, M; Vilanova, M; Wasserman, E; Zori Comba, A, 2001) |
| "Univariate analysis for distant metastasis revealed that T4 and N3 classifications, serum LDH level > 410 U/L (normal range, 180-460), parapharyngeal extension, and infiltration of the clivus were significantly associated with poor prognosis." | 2.70 | Examining prognostic factors and patterns of failure in nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy: impact on future clinical trials. ( Chan, KY; Cheng, JC; Cheng, SH; Chu, NM; Hsieh, CY; Huang, AT; Jian, JJ; Leu, SY; Tan, TD; Tsai, SY; Yen, KL, 2001) |
| "Distant metastases remain the main cause of treatment failure in NPC." | 2.70 | Neoadjuvant chemotherapy plus conventional radiotherapy or accelerated hyperfractionation in stage III and IV nasopharyngeal carcinoma--a phase II study. ( Allam, A; El-Badawi, S; El-Serafi, M; El-Weshi, A; Ibrahim, E; Khafaga, Y; Mosseri, V, 2001) |
| "Capecitabine is an oral, tumor-targeted fluoropyrimidine carbamate with high activity in metastatic breast carcinoma and in paclitaxel-pretreated metastatic breast carcinoma." | 2.70 | Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. ( Blum, JL; Buzdar, A; Dieras, V; Horton, J; Lo Russo, PM; Osterwalder, B; Rutman, O, 2001) |
| "Treatment with capecitabine resulted in clinically significant beneficial effects on tumor-related symptoms and yielded objective response activity in patients with metastatic or locally advanced pancreatic cancer." | 2.70 | Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. ( Cartwright, TH; Chen, YM; Cohn, A; Cox, JV; Schulz, JJ; Szatrowski, TP; Varkey, JA, 2002) |
| "Twenty-one patients with metastatic renal cell carcinoma (RCC) and a Cancer and Leukemia Group B performance status of 0 to 2 were enrolled." | 2.70 | A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma. ( Geoffroy, FJ; George, CM; Kollipara, P; Rini, BI; Stadler, WM; Vogelzang, NJ, 2002) |
| "Furthermore, presence of lung metastases, a primary rectal cancer and presence of lymph node metastases all predicted a better outcome in the multivariate setting." | 2.70 | Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. ( Aranda, E; Baron, B; Blijham, G; Cunningham, D; Di Costanzo, F; Glimelius, B; Hecker, H; Köhne, CH; Micheel, S; Palmer, M; Pignatti, F; Rougier, P; Scheithauer, W; Schöffski, P; Wils, J, 2002) |
| "The authors conducted a single-institution Phase I clinical trial to determine the maximum tolerated doses and to define the toxic effects of oral eniluracil and oral 5-fluorouracil (5-FU) combined with docetaxel in patients with metastatic breast carcinoma." | 2.70 | Phase I study of eniluracil and oral 5-fluorouracil in combination with docetaxel in the treatment of patients with metastatic breast carcinoma. ( Booser, DJ; Cristofanilli, M; Frye, DK; Hortobagyi, GN; Rivera, E; Rosales, MM; Valero, V, 2002) |
| "The overall incidence of distant metastases was 54% in the CDDP group." | 2.69 | Advanced nasopharyngeal carcinoma treated with chemotherapy and radiotherapy: distant metastasis and local recurrence. ( Hara, R; Isobe, K; Ito, H; Kawada, T; Kitahara, H; Kubo, A; Machida, N; Shigematsu, N; Takano, H; Uchida, Y; Uno, T; Yasuda, S, 1998) |
| "Patients with advanced gastric cancer unresponsive or progressing after PELF chemotherapy (5-fluorouracil, leucovorin, cisplatin and epidoxorubicin) received paclitaxel at the dose of 225 mg/m2 every 3 weeks, over 3 h infusion." | 2.69 | Phase II study of paclitaxel in pretreated advanced gastric cancer. ( Cardarelli, N; Cascinu, S; Catalano, G; Giordani, P; Graziano, F; Marcellini, M; Menichetti, ET, 1998) |
| " Because of the low incidence and reduced severity of toxicity, the dosage of chemotherapy was escalated to 5-FU, 1667 mg/m2, plus cisplatin, 33." | 2.69 | Outpatient weekly chemotherapy in patients with nasopharyngeal carcinoma and distant metastasis. ( Hsu, CY; Jan, JS; Lin, JC, 1998) |
| " Studies to assess the generation of progenitor cells in long-term bone marrow cultures were performed immediately preceding chemotherapy and at the end of six dosing cycles in 18 patients." | 2.69 | A randomized phase-II study of BB-10010 (macrophage inflammatory protein- 1alpha) in patients with advanced breast cancer receiving 5-fluorouracil, adriamycin, and cyclophosphamide chemotherapy. ( Clemons, MJ; Czaplewski, LG; DeTakats, P; Dexter, TM; Dougal, M; Dürig, J; Earl, H; Griffiths, A; Howell, A; Hunter, MG; Kiernan, J; Lord, BI; Marshall, E; Miles, D; Millar, A; Testa, NG; Towlson, K; Watanabe, K; Wood, LM, 1998) |
| " Five episodes of grade 3 or 4 stomatitis were observed and caused dosage modifications of MTX and 5-FU." | 2.69 | Biochemical modulation of 5-fluorouracil by methotrexate in patients with advanced gastric carcinoma. ( Barbieri, MR; Dominguez, ME; Lacava, JA; Langhi, MJ; Leone, BA; Machiavelli, MR; Ortiz, EH; Pérez, JE; Rodriguez, R; Romero Acuña, JM; Romero Acuña, LA; Romero, AO; Vallejo, CT, 1998) |
| "Metastatic breast cancer is commonly thought to be incurable." | 2.69 | The addition of paclitaxel to continuous infusion 5-fluorouracil is an active regimen for metastatic breast cancer. ( Coniglio, D; Elkordy, M; Fishman, R; Gilbert, C; Hussein, A; Matters, L; Peters, WP; Petros, W; Ross, M; Rubin, P; Vredenburgh, J, 1998) |
| "The potential for site of metastasis as a predictive variable for response to chemotherapy and survival was examined, in addition to other clinical parameters." | 2.69 | Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma. ( Assersohn, L; Benepal, T; Cunningham, D; Norman, A; Oates, J; Ross, PJ, 1999) |
| "Liver metastasis was the only significant variable in the best subset regression model that predicted good response to MAP (CR and good PR) (P = 0." | 2.69 | Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study. ( Hong, RL; Hsu, MM; Ko, JY; Sheen, TS; Ting, LL; Wang, CC, 1999) |
| " Dosage in subsequent cycles was adjusted according to toxicity." | 2.69 | A phase II trial of methotrexate, cisplatin, 5-fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma. ( Kantoff, PW; Loughlin, KR; Manola, J; Oh, WK; Richie, JP, 1999) |
| "In patients with metastatic renal cell carcinoma response rates of 7-26% have been achieved with immunotherapy." | 2.69 | Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party. ( De Mulder, PH; Groenewegen, G; Hoekman, K; Jansen, RL; Kruit, WH; Osanto, S; van Herpen, CM, 2000) |
| "This study was performed to investigate the activity and safety of high dose 5-fluorouracil (5-FU) given as a weekly 24-hour infusion in combination with folinic acid plus mitomycin C in patients with advanced gastric cancer." | 2.69 | Weekly 24-hour infusion of high-dose 5-fluorouracil plus folinic acid in combination with mitomycin C for the treatment of advanced gastric cancer. ( Benter, T; Dörken, B; Hohenberger, P; Köhne, CH; Kretzschmar, A; Reichardt, P; Thuss-Patience, PC, 2000) |
| "In conclusion, in a group of metastatic breast cancer patients, treated routinely by systemic therapies it was found, that the use of higher cut-off point for EGF-R positivity can improve the prediction of endocrine sensitivity." | 2.69 | Content of epidermal growth factor receptor in metastatic breast cancer: its role in endocrine sensitivity prediction. ( Branković-Magić, MV; Mitrovic, LB; Nesković-Konstantinović, ZB; Nikolić-Vukosavljević, DB; Spuzić, I, 2000) |
| "55 patients with advanced renal cell cancer were treated as follows: IL-2 and IFN-alpha according to the schedule originally described by Atzpodien, with PVI 5FU 200 mg m(-2)day(-1)during weeks 5-9." | 2.69 | Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study. ( Ahern, R; Allen, MJ; Bate, S; Eisen, T; Gore, ME; Johnston, S; Moore, J; Savage, P; Vaughan, M; Webb, A, 2000) |
| "To determine the dose-limiting toxicity of CPT-11 in combination with oxaliplatin, and the maximal tolerated dose (MTD) and the recommended dose (RD) of CPT-11 using an every two weeks schedule." | 2.69 | Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients. ( Cvitkovic, E; Di Palma, M; Goldwasser, F; Gross-Goupil, M; Marceau-Suissa, J; Misset, JL; Tigaud, JM; Wasserman, E; Yovine, A, 2000) |
| " However, in combination with radiation therapy, this regimen is tolerable when the primary goal is palliation of dysphagia near the end of life." | 2.68 | Split-course accelerated radiation therapy combined with carboplatin and 5-fluorouracil for palliation of metastatic or unresectable carcinoma of the esophagus. ( Turrisi, AT; Urba, SG, 1995) |
| "Advanced breast cancer remains a major clinical problem." | 2.68 | A phase II trial of mitoxantrone plus cyclophosphamide and 5-fluorouracil in modulation with levo-folinate for advanced breast cancer patients. ( Leonardi, V; Meli, M; Palmeri, S; Peralta, S; Rausa, L; Rini, GB; Russo, A, 1995) |
| "Forty-nine patients with metastatic breast cancer were enrolled; 41 were eligible." | 2.68 | Alternating chemotherapy regimens for patients with metastatic breast cancer. A pilot study based on tumor marker kinetics. Cancer and Leukemia Group B. ( Kennedy, BJ; Kiang, DT; Korzun, AH; Nowak, BS; Perry, MC; Schilling, A; Wood, W; Younger, J, 1995) |
| "Studies addressing the sequencing of radiation therapy and chemotherapy will necessarily be large because adverse effects from administering the two modalities simultaneously are not great." | 2.68 | Simultaneous adjuvant radiation therapy and chemotherapy in high-risk breast cancer--toxicity and dose modification: a Transtasman Radiation Oncology Group Multi-Institution study. ( Ackland, SP; Bonaventura, A; Christie, D; Dady, P; Denham, JW; Hamilton, CS; Lamb, DS; O'Brien, M; Spry, NA; Stewart, JF, 1995) |
| "Site of metastases included liver (n = 16), lung (n = 7), abdomen (n = 2), pelvic recurrences (n = 2), cutaneous (n = 1)." | 2.68 | Cytarabine and cisplatin as salvage therapy in patients with metastatic colorectal cancer who failed 5-fluorouracil + folinic acid regimen. French Northern Oncology Group. ( Adenis, A; Bonneterre, J; Carlier, D; Darloy, F; Demaille, A; Pion, JM, 1995) |
| "Thirty-five patients with metastatic colorectal cancer were treated; 15 (41%) had received previous therapy, 22 (63%) had W." | 2.68 | A phase I-II trial of five-day continuous intravenous infusion of 5-fluorouracil delivered at circadian rhythm modulated rate in patients with metastatic colorectal cancer. ( Adam, R; Bismuth, H; Caussanel, JP; Jasmin, C; Lévi, F; Metzger, G; Misset, JL; Smolensky, M; Soussan, A, 1995) |
| " 5FU was given as a 24-hour infusion at a dosage of 4 g/m2 and oral leucovorin at a dosage of 50 mg every 6 hours for four doses, starting with the infusion of 5FU." | 2.68 | Leucovorin and high-dose fluorouracil in metastatic prostate cancer. A phase II trial of the piedmont Oncology Association. ( Atkins, JN; Case, LD; Grote, T; McFarland, J; Muss, HB; Richards, F, 1996) |
| "2 per day) combined with a fixed dose of interferon-alpha 2b (5 million units) and allopurinol (300 mg." | 2.68 | 5-fluorouracil and allopurinol combined with recombinant interferon-alpha 2b in the treatment of patients with advanced prostate cancer: a phase I/II study. ( Amdur, RJ; Ernstoff, MS; Fukui, I; Glazier, DB; Harris, R; Heaney, JA; Schned, AR, 1996) |
| "Sixty-three patients developed distant metastases or local relapse, 30 in the CT + RT group and 33 in the RT group." | 2.68 | Radiotherapy and neoadjuvant chemotherapy for cervical carcinoma. A randomized multicenter study of sequential cisplatin and 5-fluorouracil and radiotherapy in advanced cervical carcinoma stage 3B and 4A. ( Bertelsen, K; Högberg, T; Koern, J; Onsrud, M; Simonsen, E; Sundfør, K; Tropé, CG; Westberg, R, 1996) |
| "To determine the most effective dose of leucovorin (folinic acid [FA]) within a weekly bolus fluorouracil (FU) schedule, we conducted a randomized multicenter trial to compare therapeutic effects and toxicity of high-dose FA versus low-dose FA combined with FU at equal doses in both treatment groups." | 2.68 | Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. ( Bernhard, G; Bernhard, H; Heike, M; Jäger, E; Klein, O; Knuth, A; Lautz, D; Meyer zum Büschenfelde, KH; Michaelis, J, 1996) |
| "24 patients with advanced breast cancer entered the study: 16 aged 65-70 yrs, 4 patients 70-75 yrs, and 4 > 75 yrs." | 2.68 | Phase II study of mitoxantrone, 5-fluorouracil, and levo-leucovorin (MLF) in elderly advanced breast cancer patients. ( Caroti, C; Gallo, L; Mammoliti, S; Merlini, L, 1996) |
| "Residual metastases were surgically removed in 13 patients (26%)." | 2.68 | Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. ( Adam, R; Bertheault-Cvitkovic, F; Bismuth, H; Brienza, S; Brummer, PD; Ithzaki, M; Jami, A; Kunstlinger, F; Lévi, F; Misset, JL, 1996) |
| "5-Fluorouracil was given at an initial daily dose of 250 mg/m2 administered continuously with the aid of an elastomer, non-electronic pump through a permanent central venous line for 21 days followed by a 7-day rest." | 2.68 | Low-dose continuous intravenous infusion of 5-fluorouracil for metastatic breast cancer. ( Cavalli, F; Goldhirsch, A; Marini, G; Pesce, G; Regazzoni, S, 1996) |
| "Distant metastases occurred in two high-risk patients and in eight patients with a locally advanced tumor." | 2.68 | Intraoperative radiation therapy in integrated treatment of rectal cancers. Results of phase II study. ( Bellantone, R; Bossola, M; Cellini, N; Crucitti, F; Doglietto, GB; Ippoliti, M; Merico, M; Nucera, P; Ratto, C; Sofo, L; Trodella, L; Valentini, V, 1996) |
| "In metastatic breast cancer patients who have had prior exposure to anthracyclines, single agents induce less than 15% and combination chemotherapy less than 20%-30% of objective responses." | 2.68 | Phase I/II study with a weekly 24-hour infusion of 5-fluorouracil plus high-dose folinic acid (HD-FU/FA) in intensively pretreated patients with metastatic breast cancer. ( Achterrath, W; Becher, R; Eberhardt, W; Harstrick, A; Hayungs, J; Klaassen, U; Losch, M; Seeber, S; Stahl, M; Vanhoefer, U; Wilke, H, 1996) |
| "5-fluorouracil was given at a dose of 1000 mg/m2 for 5 consecutive days and cisplatin was given on day 2 at a dose of 100 mg/m2." | 2.68 | The French experience with infusional 5-FU in gastric and pancreatic cancer. ( Ducreux, M; Rougier, P, 1996) |
| "These studies demonstrate that the present dose and schedule of AZT in combination with 5-FU + LV has significant activity in metastatic colorectal cancer and that the combination of 5-FU + LV with AZT increases the amount of DNA damage." | 2.68 | Maximum tolerable doses of intravenous zidovudine in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer patients. Clinical evidence of significant antitumor activity and enhancement of zidovudine-induced DNA single strand break ( Allegrini, G; Andreuccetti, M; Antonuzzo, A; Brunetti, I; Conte, PF; Danesi, R; Del Tacca, M; Falcone, A; Lencioni, M; Malvaldi, G; Pfanner, E, 1997) |
| "Renal cell carcinoma is relatively resistant to both chemotherapy and immunotherapy." | 2.68 | Treatment of renal cell carcinoma with 5-fluorouracil and alfa-interferon. ( Carpenter, C; Gebrosky, NP; Koukol, S; Lamm, DL; Nseyo, UO, 1997) |
| "Amonafide is a new imide derivative of naphthalic acid." | 2.68 | Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642). ( Berkowitz, I; Berry, D; Costanza, ME; Duggan, D; Henderson, IC; Kalra, J; Lyss, AP; Ratain, MJ; Shapiro, C; Wu, K, 1995) |
| "The EORTC Head and Neck Cancer Cooperative Group conducted a randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in chemotherapy naive patients with recurrent or metastatic squamous cell carcinoma of the head and neck." | 2.67 | Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head a ( Cappelaere, P; Clavel, M; Clerico, M; Cognetti, F; de Mulder, PH; Schornagel, JH; Tueni, EA; Vermorken, JB; Verweij, J; Wildiers, J, 1994) |
| "In advanced colorectal cancer the addition of folinic acid (FA) has been shown to lead to increased activity, at least in terms of response rate, in comparison with 5-fluorouracil (5FU) alone." | 2.67 | Double modulation of 5-fluorouracil in advanced colorectal cancer with low-dose interferon-alpha 2b and folinic acid. The "GISCAD" experience. Italian Group for the Study of Digestive Tract Cancer. ( Ambrosini, G; Barni, S; Duro, M; Fiorentini, G; Giaccon, G; Iirillo, A; Labianca, R; Oliani, C; Pancera, G; Piazza, E, 1994) |
| " There was an improvement in survival with increased 5-FU dosage (500 mg m-2) [relative hazard (RH) = 0." | 2.67 | Bolus/infusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma: are suboptimal dosages being used in the UK? ( Canney, PA; Cassidy, J; Jodrell, DI; Kaye, SB; Murray, LS; Reed, NS, 1994) |
| "Leukopenia was more frequent in the simultaneous than in the sequential arm (p = 0." | 2.67 | A randomized phase II study comparing sequential versus simultaneous chemo-radiotherapy in patients with unresectable locally advanced squamous cell cancer of the head and neck. ( Carlini, P; Cercato, MC; Cognetti, F; Del Vecchio, MR; Giannarelli, D; Impiombato, FA; Marzetti, F; Milella, M; Pinnarò, P, 1994) |
| "The response rate of metastatic renal cell cancer to cytotoxic therapy over the last 10 years has been 5." | 2.67 | Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group Study. ( Bueschen, A; Crawford, ED; Flanigan, RC; Kish, JA; Leimert, JT; Neefe, JR; Wolf, M, 1994) |
| "The purpose of this study was to determine the maximal tolerable dose (MTD) of epirubicin and ADR-529 given in combination with cyclophosphamide, 5-fluorouracil, and tamoxifen." | 2.67 | The cardioprotector ADR-529 and high-dose epirubicin given in combination with cyclophosphamide, 5-fluorouracil, and tamoxifen: a phase I study in metastatic breast cancer. ( Bastholt, L; Gjedde, SB; Jakobsen, P; Mirza, MR; Mouridsen, HT; Rose, C; Sørensen, B, 1994) |
| "Thirty-one patients with metastatic breast cancer treated on three successive high-dose chemotherapy and autologous bone marrow transplantation trials between January 1987 and March 1992 who achieved a complete response were evaluated." | 2.67 | Patterns of failure of complete responders following high-dose chemotherapy and autologous bone marrow transplantation for metastatic breast cancer: implications for the use of adjuvant radiation therapy. ( Halpern, H; Heimann, R; Mundt, AJ; Rubin, SJ; Sibley, GS; Weichselbaum, RR; Williams, S, 1994) |
| "The fraction of breast cancer cells undergoing DNA synthesis at any one time is relatively low, which is problematic because most chemotherapeutic agents are most effective against dividing cells." | 2.67 | Randomized trial of cyclophosphamide, methotrexate, and 5-fluorouracil with or without estrogenic recruitment in women with metastatic breast cancer. ( Foley, JF; Gesme, DH; Goldberg, RM; Hartmann, LC; Hatfield, AK; Ingle, JN; Jung, SH; Krook, JE; Mailliard, JA; Veeder, MH, 1994) |
| "Three had only bone metastases and were evaluable for toxicity and survival." | 2.67 | A phase II trial of 5-fluorouracil and cisplatinum in recurrent or metastatic nasopharyngeal carcinoma. ( Ang, PT; Au, E, 1994) |
| "Sixteen patients with metastatic colorectal cancer have been treated with a regimen involving an 120 h continuous infusion of rIL-2, 18 x 10(6) iu m-2 day followed by three injections of 5FU 600 mg m-2 at weekly intervals." | 2.67 | A phase-III study of recombinant interleukin 2 and 5-fluorouracil chemotherapy in patients with metastatic colorectal cancer. ( Franks, CR; Hamblin, TJ; Oskam, R; Palmer, P; Sadullah, S; Stevenson, J; Williamson, P, 1993) |
| "5-Fluorouracil (5-FU) has been previously associated with therapeutic benefit in hormone refractory prostate cancer." | 2.67 | A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer. An Illinois Cancer Center Study. ( Benson, AB; Blough, R; Braud, E; Johnson, P; Kilton, L; Kozlowski, J; Kuzel, TM; Shevrin, D; Tallman, MS; Vogelzang, NJ, 1993) |
| "Three patients with isolated liver metastases and one patient with local recurrence of rectal carcinoma received regional therapy with higher 5-FU doses." | 2.67 | Fluorouracil plus interferon + folinic acid in regional and systemic therapy in colorectal cancer. ( Preiss, J, 1992) |
| "In a prospective randomized multicentre trial 139 patients with metastatic colorectal carcinoma (70 men, 69 women; age 35-81 years) were given palliative treatment with fluorouracil (400 mg/m2 daily for 5 days) alone or combined with folic acid (100 mg/m2 before each dose of fluorouracil)." | 2.67 | [Fluorouracil as monotherapy or combined with folinic acid in the treatment of metastasizing colorectal carcinoma]. ( Aulbert, E; Burghardt, F; Hausamen, TU; Korsten, FW; Lindemann, W; Löffler, TM; Planker, M; Reis, HE; Schröder, M; Strohmeyer, G, 1992) |
| "Pancreatic cancer is the fourth-leading cause of cancer-related death." | 2.66 | Second-line treatment for metastatic pancreatic cancer. ( Kasi, A; Paluri, RK; Posey, JA; Young, C, 2020) |
| "Controversial questions in recurrent breast cancer include the magnitude of the survival benefit of combination chemotherapy and the best choice of first line chemotherapy." | 2.66 | Distant recurrence in breast cancer. Survival expectations and first choice of chemotherapy regimen. ( Brincker, H, 1988) |
| "5-Fluorouracil was infused 24 hours per day throughout the period of radiation at a dose of 300 mg/m2/day for a median of 42 days (range, 28-56 days)." | 2.66 | Concomitant 5-fluorouracil infusion and high-dose radiation for stage III non-small cell lung cancer. ( Chaffey, J; Lokich, J; Neptune, W, 1989) |
| "Responses in metastatic renal cell carcinoma appear confined to a favorable subset of patients." | 2.66 | Interferon alternating with chemotherapy for patients with metastatic renal cell carcinoma. ( Dexeus, FH; Finn, L; Logothetis, CJ; Sella, A, 1989) |
| "Concerning bone metastases there was no difference between the two schedules in response rate, nor in the median remission duration (CAP 11, FAC 10 months)." | 2.66 | Combination of cyclophosphamide, adriamycin and platinum (CAP) versus 5-fluorouracil, adriamycin and cyclophosphamide (FAC) as primary treatment in metastatic breast cancer: results of a prospective randomized study. ( Kolarić, K; Potrebica, V; Vukas, D, 1989) |
| " These results seem to emphasize that target cells of hormonotherapy are not target cells of chemotherapy and that this difference is persisting for long time under treatment, that others modalities of association between chemotherapy and hormonotherapy must be studied with the aim of reducing the kinetic's implication of chronic administration of TAM." | 2.66 | [Metastatic breast cancer. Modality of association of chemotherapy and hormonotherapy. Results of a controlled trial]. ( Asselain, B; Coutant, M; Dorval, T; Garcia-Giralt, E; Jouve, M; Magdelenat, H; Palangie, T; Pouillart, P, 1987) |
| "Thirty-six patients with metastatic breast cancer were admitted into the study." | 2.66 | Sequential administration of cyclophosphamide, methotrexate, 5-fluorouracil, and folinic acid as salvage treatment in metastatic breast cancer. ( Amoroso, D; Ardizzoni, A; Bertelli, G; Canobbio, L; Conte, PF; Cusimano, MP; Fusco, V; Gulisano, M; Lionetto, R; Pronzato, P, 1987) |
| "In rectosigmoid cancer the group on 5-FU included 26 patients who showed a response rate of 19% (5/26)." | 2.66 | Controlled phase III clinical study of 4-epi-doxorubicin + 5-fluorouracil versus 5-fluorouracil alone in metastatic gastric and rectosigmoid cancer. ( Kolarić, K; Potrebica, V; Stanovnik, M, 1986) |
| "Fifty-eight patients with disseminated breast cancer were randomly divided into 2 study groups." | 2.66 | [Evaluation of regimens for the simultaneous and sequential administration of cytostatics in the combined chemotherapy of disseminated forms of breast cancer]. ( Borisov, AI; Korman, DB; Maslova, IA; Pines, EV, 1985) |
| "Sixty-three patients with Stage IV breast carcinoma refractory to standard combination chemotherapy agents such as 5-fluorouracil (5-FU) were entered into a study to determine the efficacy of a multiple dose schedule of N-(phosphonacetyl)-L-aspartic acid (PALA) and whether the addition of PALA improves the therapeutic efficacy of 5-FU." | 2.66 | A comparative study of PALA, PALA plus 5-FU, and 5-FU in advanced breast cancer. ( Buzdar, AU; Hortobagyi, GN; Mann, GB; Valdivieso, M; Yap, HY, 1985) |
| "The symptoms of metastatic breast cancer may be effectively palliated with chemotherapeutic agents in most breast cancer patients." | 2.65 | Chemotherapy of breast cancer. A general overview. ( Henderson, IC, 1983) |
| "Patients with advanced cancer who had documented disease progression while receiving chemotherapy alone were subsequently treated with the same drug, by the same dose and route, combined with localized hyperthermia." | 2.65 | Clinical thermochemotherapy. A controlled trial in advanced cancer patients. ( Elliott, RS; Harrison, WH; Haskell, CM; Kaiser, LR; Morton, DL; Ramming, KR; Sarna, G; Silberman, AW; Storm, FK, 1984) |
| "Oral tegafur and I." | 2.65 | A comparative study of oral tegafur and intravenous 5-fluorouracil in patients with metastatic colorectal cancer. ( Bedikian, AY; Bodey, GP; Karlin, D; Korinek, J; Stroehlein, J, 1983) |
| "About 80 per cent of patients with breast cancer ultimately die of metastatic disease in the following twenty years." | 2.65 | [Breast cancer: chemotherapy preceding locoregional treatment with extension of the indications for conservative treatment]. ( Auclerc, G; Auclerc, MF; Baillet, F; Blondon, J; Facchini, T; Jacquillat, C; Lefranc, JP; Weil, M, 1984) |
| "A group of 243 patients with gastric cancer was subjected to a prospective randomized trial of adjuvant chemotherapy after curative gastrectomy." | 2.65 | Comparison of 5-fluorouracil with ftorafur in adjuvant chemotherapies with combined inductive and maintenance therapies for gastric cancer. ( Kajitani, T; Kuno, K; Nakajima, T; Takagi, K; Takahashi, T, 1984) |
| " Part II of the trial revealed that neither a higher dosage of ftorafur (2 g/m2/day X 5 days) nor the addition of vincristine to both regimens changed the previously obtained results significantly." | 2.65 | Comparison of ftorafur with 5-fluorouracil in combination chemotherapy of advanced gastrointestinal carcinoma. ( Arnold, H; Drings, P; Fritze, D; Geldmacher, J; Hartwich, G; Herrmann, R; Kempf, P; König, H; Meiser, RJ; Nedden, R; Pappas, A; Queisser, W; Schaefer, J; Schnitzler, G; Sievers, H; von Oldershausen, HF; Wahrendorf, J; Westerhausen, M; Witte, S, 1981) |
| "In patients without metastases median survival was 48 weeks in the treated group and 12 weeks in controls." | 2.65 | Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial. ( Cocking, JB; Cwynarski, MT; Diffey, BL; Fox, CA; Hanley, J; Jackson, GA; Mallinson, CN; Rake, MO; Wass, VJ, 1980) |
| "144 patients with disseminated breast cancer entered into a 4 arm randomized trial." | 2.65 | [Disseminated breast carcinoma. Study of activity of immunotherapy with BCG and duration of the phase of intensive chemotherapy. Results of a randomized trial (author's transl)]. ( Asselain, B; Garcia-Giralt, E; Jouve, M; Magdelenat, H; Palangie, T; Pouillart, P, 1981) |
| "Since in the treatment of advanced breast cancer chemotherapy and the various hormonal manipulations seem recently to have reached a plateau of effectiveness when used alone, it is widely assumed that the combination of both treatment modalities could improve therapeutic results." | 2.65 | [Simultaneous or sequential hormono/chemotherapy and a comparison of various polychemotherapies in the treatment of metastatic breast cancer]. ( Alberto, P; Beer, M; Brunner, KW; Cavalli, F; Jungi, WF; Martz, G; Mermillod, B; Obrecht, JP, 1982) |
| "Patients with advanced breast carcinoma and no prior chemotherapy were prospectively evaluated to assess the induction capabilities of cyclophosphamide, methotrexate and 5-fluorouracil (CMF), Adriamycin and vincristine (AV), and CMF plus prednisone (CMFP)." | 2.65 | Comparison of induction chemotherapies for metastatic breast cancer. An Eastern Cooperative Oncology Group Trial. ( Band, PR; DeWys, W; Gelman, R; Perlia, C; Rice, MA; Rosenthal, SN; Sears, M; Tormey, DC, 1982) |
| "A total of 156 patients with metastatic breast cancer were entered into a prospective multi-center trial in September 1975." | 2.65 | A randomized study of combination chemotherapy (VAC-FMC) with or without immunostimulation by Corynebacterium parvum in metastatic breast cancer. ( Abel, U; Becher, R; Bruntsch, U; Drings, P; Edler, L; Fritze, D; Gallmeier, WM; Jungi, WF; Kaufmann, M; Massner, B; Mayr, AC; Queisser, W; Senn, HJ, 1982) |
| "The age adjusted death rate for ovarian cancer has remained unchanged for the past 20 years." | 2.64 | Advances in the staging and treatment of ovarian cancer. ( Fisher, RI; Young, RC, 1977) |
| "A PR of hepatic metastases was noted in eight patients (35%) with a median and mean duration of response of 4." | 2.64 | Hepatic artery infusion of 5-FUDR after prior systemic 5-fluorouracil. ( Buroker, T; Correa, J; Fraile, R; Samson, M; Vaitkevicius, VK, 1976) |
| "However, since most patients with breast cancer present with local or regional disease but go on to die of disseminated cancer, major improvements in survival are most likely to occur by treating this neoplasm as a systemic disease through cobmining effective local therapy with systemic treatments." | 2.64 | Chemotherapy of disseminated breast cancer. Current status and prospects. ( Band, P; Bauer, M; Carbone, PP; Tormey, D, 1977) |
| "Fifty consecutive patients with colorectal cancer but no evidence of secondary deposits in the liver were included in an ongoing controlled clinical trial of adjuvant liver perfusion aimed at reducing the incidence of hepatic metastases." | 2.64 | Adjuvant liver perfusion in colorectal cancer: initial results of a clinical trial. ( Brooman, P; Rowling, JT; Taylor, I, 1977) |
| "Sixty-nine patients with advanced breast cancer treated with cytotoxic chemotherapy were randomized to receive concomitantly either norethisterone acetate (progestogen group) or a placebo (placebo group)." | 2.64 | Combined cytotoxic and progestogen therapy for advanced breast cancer. ( Begent, RH; Hayward, JL; Knight, RK; Rubens, RD; Sexton, SA, 1978) |
| "Forty-six adult patients with colorectal cancer were treated with cyclophosphamide and CCNU administered orally and 5-fluorouracil (5-FU) administered either orally or by continuous iv infusion (FCC-CIF), depending on the availability of hospital beds." | 2.64 | Chemotherapy for colorectal cancer with 5-fluorouracil, cyclophosphamide, and CCNU: comparison of oral and continuous iv administration of 5-fluorouracil. ( Bedikian, AY; Bodey, GP; Burgess, MA; Livingston, R; Staab, R; Valdivieso, M, 1978) |
| "Fifty-two untreated patients with colorectal cancer were randomized to receive 5-fluorouracil (5-FU) alternating either with methotrexate (MTX) or Baker's Antifol (BAF) with or without the immunostimulant, levamisole (Program I)." | 2.64 | Sequential chemoimmunotherapy of colorectal cancer: evaluation of methotrexate, Baker's Antifol and levamisole. ( Bedikian, AY; Bodey, GP; Burgess, MA; Mavligit, GM; Rodriguez, V; Valdivieso, M, 1978) |
| "Seventy patients with breast cancer (stage IIIb--IV) were randomized by an "envelope" method into 2 groups, each including 35 persons." | 2.64 | [Combined drug treatment of far-advanced forms of breast cancer]. ( Borisov, AI, 1978) |
| "originates in the stomach." | 2.64 | Gastric cancer: current status of treatment. ( Carter, SK; Comis, RL, 1977) |
| "route." | 2.64 | A double-blind comparison of intensive course 5-flourouracil by oral vs. intravenous route in the treatment of colorectal carcinoma. ( Bruckner, HW; Hahn, RG; Moertel, CG; Schutt, AJ, 1975) |
| " The present systematic review and meta-analysis evaluated the efficacy and safety data of bevacizumab combined with first-line fluoropyrimidine monochemotherapy for these complex patients." | 2.55 | Efficacy and Safety of Bevacizumab Combined With Fluoropyrimidine Monotherapy for Unfit or Older Patients With Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. ( Antonuzzo, L; Aprile, G; Barni, S; Maiello, E; Masi, G; Petrelli, F; Pinto, C; Porcu, L; Scartozzi, M; Torri, V, 2017) |
| "The management of metastatic colorectal cancer substantially improved over the last 10 years and median overall survival of patients might exceed 30 months." | 2.53 | Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancer. ( Lenz, HJ; Schirripa, M; Sunakawa, Y, 2016) |
| "Colorectal cancer is one of the most frequent solid tumors in the western world, with low survival rates in patients with metastatic disease." | 2.53 | Reconsidering the benefit of intermittent versus continuous treatment in the maintenance treatment setting of metastatic colorectal cancer. ( Bekaii-Saab, T; Stintzing, S; Sunakawa, Y, 2016) |
| " The risk of mortality, therapeutic efficacy, and adverse effect were meta-analyzed." | 2.53 | Efficacy and safety of addition of bevacizumab to FOLFIRI or irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer: A meta-analysis. ( Chen, K; Gong, Y; Shen, Y; Zhang, Q; Zhou, T, 2016) |
| " Herein, we critically discuss the current data on the efficacy and safety profile of bevacizumab in combination with fluoropyrimidine-based chemotherapy for first-line and maintenance treatment of metastatic CRC and briefly comment on existing controversies and future perspectives." | 2.52 | Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer. ( Grapsa, D; Saif, MW; Syrigos, K, 2015) |
| "More than half of radically resected gastric cancer patients relapse locally or with distant metastases, or receive the diagnosis of gastric cancer when tumor is disseminated; therefore, median survival rarely exceeds 12 mo, and 5-years survival is less than 10%." | 2.50 | Treatment of gastric cancer. ( Andreozzi, F; Ciardiello, F; De Vita, F; Fabozzi, A; Galizia, G; Gambardella, V; Laterza, MM; Lieto, E; Mabilia, A; Orditura, M; Savastano, B; Sforza, V; Ventriglia, J, 2014) |
| "The management of metastatic colorectal cancer remains a significant clinical challenge to oncologists worldwide." | 2.50 | Sequencing of treatment in metastatic colorectal cancer: where to fit the target. ( Mukherji, D; Shamseddine, A; Temraz, S, 2014) |
| "Despite advances in the treatment of gastric cancer, it remains the world's second highest cause of cancer death." | 2.50 | Treatment options in patients with metastatic gastric cancer: current status and future perspectives. ( Bilici, A, 2014) |
| "Capecitabine has become a standard treatment option for metastatic breast cancer, as a single agent or in combination." | 2.50 | Breast cancer, DPYD mutations and capecitabine-related ileitis: description of two cases and a review of the literature. ( Aftimos, PG; Errihani, H; Mokrim, M; Piccart-Gebhart, M, 2014) |
| "The treatment of metastatic colorectal cancer (mCRC) has evolved considerably in the last decade, currently allowing most mCRC patients to live more than two years." | 2.50 | Role of cetuximab in first-line treatment of metastatic colorectal cancer. ( Aguado, C; Díaz-Rubio, E; García-Paredes, B; Sastre, J; Sotelo, MJ, 2014) |
| "Capecitabine has previously been compared to 5-fluorouracil-either as a monotherapy or in combination with oxaliplatin, irinotecan, or biological drugs-and has been found to have comparable efficacy and safety profiles." | 2.50 | Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer? ( Aguado, C; Díaz-Rubio, E; García-Paredes, B; Sastre, J; Sotelo, MJ, 2014) |
| "To review the pharmacology, pharmacokinetics, efficacy, adverse effects, drug-drug interactions, dosage and administration, and formulary considerations for ado-trastuzumab emtansine." | 2.50 | Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate. ( Auten, JJ; Cicci, TA; Corrigan, PA; Lowe, DK, 2014) |
| "We report a case of recurrent colon cancer successfully treated by mFOLFOX6 and FOLFIRI, and maintaining a complete response(CR)over the long-term." | 2.49 | [A case of recurrent colon cancer involved in multiple organs maintaining complete response over the long-term after chemotherapy]. ( Hamada, T; Ohashi, S; Ohta, K; Taniguchi, E; Yamagami, Y; Yoshikawa, M, 2013) |
| " With a more capillary use of this new class of agents comes the recognition of diverse adverse events related to disturbance of critical biological pathways involved in physiological functions." | 2.49 | Molecularly targeted therapy: toxicity and quality of life considerations in advanced colorectal cancer. ( Cipriani, G; Fioretto, L; Marinozzi, C; Pino, MS; Ribecco, AS, 2013) |
| "Concerning penis cancer, the optimal protocols validated by a high level of evidence are missing." | 2.49 | [Chemotherapy in male external genital organs (testicular and penile cancer)]. ( Bastide, C; Bruyère, F; Deville, JL; Flechon, A; Guy, L; Karsenty, G, 2013) |
| "Capecitabine has substantial antitumor activity in the first-line treatment of patients with MBC in prospective, randomized, phase II/III clinical trials as monotherapy and in combination with biologic and novel agents." | 2.48 | Capecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancer. ( Dalivoust, P; Debled, M; Harbeck, N; Kaufmann, M; O'Shaughnessy, JA; Robert, NJ; Siedentopf, F, 2012) |
| "Studies that included patients with metastases at enrollment were excluded." | 2.48 | Effectiveness of 5-flurouracil-based neoadjuvant chemotherapy in locally-advanced gastric/gastroesophageal cancer: a meta-analysis. ( Cai, XH; Ge, L; Lei, C; Wang, HJ; Yin, D; Zhang, GQ; Zhu, JF, 2012) |
| "With regard to squamous cell carcinoma, treatment with 5-fluorouracil, methotrexate, interferon, and bleomycin are reviewed." | 2.47 | Intralesional agents in the management of cutaneous malignancy: a review. ( Good, LM; High, WA; Miller, MD, 2011) |
| "Patients with breast cancer that becomes resistant to taxanes and anthracyclines experience considerable morbidity and mortality." | 2.47 | Ixabepilone for the treatment of breast cancer. ( Alvarez, RH; Hortobagyi, GN; Valero, V, 2011) |
| "So far, the only curative treatment for gastric cancer is surgery." | 2.46 | Role of capecitabine and irinotecan combination therapy in advanced or metastatic gastric cancer. ( Farhat, FS; Ghosn, MG; Kattan, J, 2010) |
| "Median survival for pancreatic cancer patients has reached a plateau due to inherent and acquired resistance to these agents." | 2.46 | Challenges of drug resistance in the management of pancreatic cancer. ( Clynes, M; McDermott, R; O'Connor, R; Sheikh, R; Walsh, N, 2010) |
| "Lapatinib is an oral, small-molecule, dual kinase inhibitor that targets both HER2 and the EGF receptor." | 2.45 | Lapatinib in metastatic breast cancer. ( Berton-Rigaud, D; Bourbouloux, E; Campone, M; Frenel, JS; Sadot-Lebouvier, S; Zanetti, A, 2009) |
| "Around 16% to 20% of women with breast cancer have advanced, metastasized breast cancer." | 2.45 | Lapatinib for treatment of advanced or metastasized breast cancer: systematic review. ( Ferraz, MB; Puga, ME; Riera, R; Soárez, PC, 2009) |
| "Data on colorectal cancer in HIV-positive patients are limited." | 2.44 | FOLFOX-4 regimen with concomitant highly active antiretroviral therapy in metastatic colorectal cancer HIV-infected patients: a report of five cases and review of the literature. ( Bearz, A; Berretta, M; Berretta, S; Del Ben, C; Di Benedetto, F; Martellotta, F; Simonelli, C; Spina, M; Tirelli, U, 2008) |
| " In addition to demonstrated survival benefits, the convenient dosing schedule and lack of interactions should ensure the successful integration of this novel agent into clinical practice." | 2.44 | Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer. ( Krämer, I; Lipp, HP, 2007) |
| "The optimal management of locoregional esophageal cancer is controversial." | 2.44 | Combined-modality therapy for esophageal and gastroesophageal junction cancers. ( Gibson, MK; Yoon, HH, 2007) |
| " Following a pivotal trial demonstrating that capecitabine confers increased survival when used in combination with docetaxel, it is being investigated intensively in combined regimens using other standard chemotherapeutic agents, as well as with novel molecularly targeted therapies." | 2.44 | Capecitabine in combination with novel targeted agents in the management of metastatic breast cancer: underlying rationale and results of clinical trials. ( Tripathy, D, 2007) |
| "Gemcitabine has been a standard treatment for advanced pancreatic cancer since it was shown a decade ago to result in a superior clinical benefit response and survival compared with bolus 5-fluorouracil (5-FU)." | 2.44 | Pancreatic cancer--is the wall crumbling? ( Chua, YJ; Zalcberg, JR, 2008) |
| "Advances in the medical treatment of colorectal cancer patients have resulted in considerable improvements through the introduction of new cytotoxic drugs." | 2.44 | [Antibody treatment in colorectal cancer--what the surgeon needs to know]. ( Bueter, M; Fein, M; Gasser, M; Illert, B; Meyer, D; Reimer, P; Thalheimer, A; Thiede, A; Waaga-Gasser, AM, 2008) |
| "A patient with metastatic colorectal cancer should today be expected to have a median survival of 18-20 months compared to that of 11-14 months only a few years ago." | 2.43 | Chemotherapy for colorectal cancer. ( Goyle, S; Maraveyas, A, 2005) |
| "Colon cancer is a leading cause of cancer and cancer deaths in Western countries." | 2.43 | Adjuvant therapy for colon cancer. ( Cilley, J; Mulcahy, MF, 2006) |
| "Although a decrease in distant metastases has frequently been observed, an improvement in survival from induction has been difficult to demonstrate." | 2.43 | Does induction chemotherapy have a role in the management of locoregionally advanced squamous cell head and neck cancer? ( Adelstein, DJ; Leblanc, M, 2006) |
| "In patients with resectable pancreatic cancer, particularly in UICC-stage II neoadjuvant radiochemotherapy, this results in an improvement in survival: the median survival is between 15 and 30 months." | 2.42 | [Pancreatic cancer. The relative importance of neoadjuvant therapy]. ( Beger, HG; Gansauge, F; Poch, B; Schwarz, M, 2003) |
| "Selected patients with inflammatory breast cancer have the potential for long-term survival." | 2.42 | Ten-year outcome after combined modality therapy for inflammatory breast cancer. ( Bertsch, H; Fox, K; Glick, J; Harris, EE; Schultz, D; Solin, LJ, 2003) |
| "Risk of relapse of breast cancer depends largely on tumour features: size, grade and, particularly, lymph node status." | 2.42 | 21. The adjuvant treatment of breast cancer. ( Kelleher, M; Miles, D, 2003) |
| "The prognosis of pancreatic cancer is poor at any stage." | 2.42 | [Adjuvant treatment of pancreatic cancer]. ( Oettle, H, 2003) |
| "Systemic therapy for metastatic colorectal cancer is evolving rapidly after many years without significant change." | 2.42 | Systemic therapy for colorectal cancer: focus on newer chemotherapy and novel agents. ( O'Neil, BH, 2003) |
| "Untreated metastatic gastric cancer is associated with a median survival of only 3-4 months, but this can be increased to 8-10 months, associated with improved quality of life, with combination chemotherapy." | 2.42 | Systemic treatment of gastric cancer. ( Cunningham, D; Dickson, JL, 2004) |
| " In addition, studies show that dosing flexibility with capecitabine/docetaxel allows management of side effects without compromising efficacy." | 2.42 | Optimizing the management of HER2-negative metastatic breast cancer with capecitabine (Xeloda). ( Leonard, R; Miles, D; Reichardt, P; Twelves, C, 2004) |
| "Metastatic colorectal cancer has long been considered as a short-term, poor prognosis, chemoresistant disease." | 2.41 | Therapeutic advances in the management of metastatic colorectal cancer. ( Descos, L; Freyer, G; Kraft, D; Ligneau, B; Trillet-Lenoir, V, 2001) |
| "Many patients who develop metastases are offered systemic chemotherapy to try to extend survival and maintain or improve quality of life." | 2.41 | Chemotherapy for metastatic colorectal cancer. ( , 2002) |
| "Metastatic pancreatic cancer is one of the leading causes of cancer-related deaths in North America and Europe." | 2.41 | Metastatic pancreatic cancer. ( Kulke, MH, 2002) |
| "Gemcitabine has demonstrated a good efficacy in number of tumor types." | 2.41 | [Gemcitabine and breast cancer]. ( Besse, B; Spano, JP, 2002) |
| "Metastatic colorectal cancer is a major cause of cancer-related mortality." | 2.41 | Perspectives on the role of sequential or combination chemotherapy for first-line and salvage therapy in advanced colorectal cancer. ( Goldberg, RM; Hobday, TJ, 2002) |
| "Treatment of metastatic renal cell carcinoma (RCC) remains unsatisfactory." | 2.41 | Cytokine combinations: therapeutic use in patients with advanced renal cell carcinoma. ( Bukowski, RM, 2000) |
| "Metastatic gastric cancer is a relatively chemosensitive disease." | 2.41 | Developments in the treatment of gastric cancer in Europe. ( Köhne, CH; Wilke, HJ; Wils, JA, 2000) |
| "Capecitabine is an orally administered fluoropyrimidine which is selectively activated in tumour tissue to the active moiety fluorouracil and is cytotoxic through inhibition of DNA synthesis." | 2.41 | Capecitabine: a review of its use in the treatment of advanced or metastatic colorectal cancer. ( Goa, KL; McGavin, JK, 2001) |
| "Colorectal cancer is the second leading cause of cancer death and it is clear that patients with metastatic disease have better quality of life and survival when given treatment." | 2.41 | New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer. ( Holen, KD; Saltz, LB, 2001) |
| "Capecitabine is a synthetic oral fluoropyrimidine carbamate that is sequentially activated in a three-step process, which results in the preferential production of 5-fluorouracil in tumours, rather than in the normal surrounding tissue." | 2.41 | Capecitabine: fulfilling the promise of oral chemotherapy. ( Hwang, JJ; Marshall, JL, 2002) |
| "Pancreatic cancer is one of the deadliest malignancies and is fatal in more than 95% of affected individuals." | 2.41 | Management of locally advanced adenocarcinoma of the pancreas. ( Ryan, DP; Willett, CG, 2002) |
| " Raltitrexed, a thymidylate synthase inhibitor, offers similar antitumoral activity together with a tolerability in comparison to standard 5-fluorouracil based chemotherapy and its simple dosage schedule also contributes to better quality of life." | 2.40 | [Drug clinics. How I treat. II. Therapeutic approaches to metastatic colorectal cancer]. ( Bours, V; Fillet, G; Jerusalem, G, 1998) |
| "Irinotecan or CPT11 is a topoisomerase 1 inhibitor." | 2.40 | [Irinotecan monotherapy in the treatment of colorectal cancers: results of phase II trials]. ( Peeters, M; Van Cutsem, E, 1998) |
| "Irinotecan treated patients lived for significantly longer than those on 5FU: median time of survival was 10." | 2.40 | [Second-line irinotecan chemotherapy in the treatment of metastatic colorectal cancers: phase III trials]. ( Ducreux, M; Mitry, E; Rougier, P, 1998) |
| "Doxorubicin, the most active agent for breast cancer, was studied first." | 2.39 | Paclitaxel combination therapy in the treatment of metastatic breast cancer. ( Holmes, FA, 1996) |
| "The prognosis of metastatic renal cell cancer is unfavourable as neither chemo-, radiation- nor hormonal therapy achieve tumor remissions in more than 10% of the patients." | 2.38 | [Interferon-alpha therapy in hypernephroma]. ( Sagaster, KP, 1993) |
| "Several advances in the radiotherapy of pancreatic cancer have been made for the patient with resectable disease." | 2.38 | Radiotherapy in the treatment of pancreatic cancer. ( Bronn, DG; Dobelbower, RR, 1990) |
| "In the case of multi-site metastases, outside of trials, the decision to employ chemotherapy must be taken on an individual basis." | 2.38 | [Therapy of advanced colorectal cancer]. ( Schalhorn, A, 1991) |
| "After treatment of early breast carcinoma (stage I, II, and some III), the recurrent lesion can be classified as local, regional, distant, or combinations thereof." | 2.37 | Patterns of metastasis and natural courses of breast carcinoma. ( Lee, YT, 1985) |
| "Opinions regarding the best possible treatment of cancer of the breast are more controversial than ever." | 2.36 | [The present state of the art in diagnosis and therapy of cancer of the breast (author's transl)]. ( Becher, R, 1982) |
| "Fluorouracil has been used for a long time, remission rates reported range from 0% to 80%." | 2.36 | [Chemotherapy of gastrointestinal tumors (review of the literature)]. ( Mayr, AC, 1978) |
| "Hepatic metastasis is usually quite resistant to conventional systemic chemotherapy." | 2.36 | Nonsystemic treatment of metastatic tumors of the liver--a review. ( Lee, YT, 1978) |
| "This paper presents an overview of studies of therapy of head and neck squamous cell carcinoma in which chemotherapy was combined with other modalities." | 2.35 | Current concepts of chemotherapy combined with other modalities for head and neck cancer. ( DeWys, WD, 1975) |
| "A total of 83 patients with pancreatic cancer, including locally advanced and advanced pancreatic cancer, who had lost the opportunity for radical surgery and were admitted to Zhejiang Provincial People's Hospital between January 2015 and July 2021 were collected." | 1.72 | Conversion therapy, palliative chemotherapy and surgery, which of these is the best treatment for locally advanced and advanced pancreatic cancer? ( Chen, Z; Wang, M; Yang, L; Zhu, P, 2022) |
| " Treatment regimens, body surface area, dosage, number of treatment courses, and adverse events( AEs) were evaluated." | 1.72 | [Comparative Safety Assessment of Ramucirumab plus FOLFIRI and Bevacizumab plus FOLFIRI in Second- and Later-Line Treatment in Japanese Patients with Metastatic Colorectal Carcinoma]. ( Iwai, M; Kimura, M; Usami, E; Yoshimura, T, 2022) |
| "Colorectal cancer is one of the most common cancers in the world." | 1.62 | Topical aloe vera for the treatment of cetuximab-related acneiform rash in colorectal cancer: A case report. ( Akkuş, E; Gürbüz, M; Utkan, G, 2021) |
| "In patients with metastatic colorectal cancer (mCRC) receiving highly active first-line combination treatments, early tumor shrinkage (ETS) and depth of response (DoR) are associated with survival, but their influence on outcomes during maintenance therapy is unknown." | 1.62 | Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer. ( Antista, M; Antoniotti, C; Bergamo, F; Calareso, G; Clavarezza, M; Corallo, S; Cremolini, C; de Braud, F; Di Bartolomeo, M; Greco, FG; Lonardi, S; Manca, P; Morano, F; Murialdo, R; Pagani, F; Palermo, F; Pietrantonio, F; Prisciandaro, M; Racca, P; Raimondi, A; Randon, G; Rimassa, L; Smiroldo, V; Tampellini, M; Tomasello, G; Vaiani, M; Zaniboni, A, 2021) |
| " Although the survival benefits when combined with chemotherapy have been determined, there are no studies comparing the two agents with chemotherapy in the second-line treatment." | 1.62 | The effectiveness of cetuximab and panitumumab when combined with FOLFIRI in second-line treatment of KRAS wild type metastatic colorectal cancers. Single centre experience. ( Almuradova, E; Çakar, B; Doğanavşargil, B; Gürsoy, P; Harman, M; Karabulut, B; Karateke, M; Sezak, M, 2021) |
| "KRas is frequently mutated in pancreatic cancers." | 1.62 | GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals. ( Abrams, SL; Akula, SM; Candido, S; Cervello, M; Cocco, L; Duda, P; Falzone, L; Gizak, A; Libra, M; Martelli, AM; McCubrey, JA; Meher, AK; Montalto, G; Rakus, D; Ratti, S; Ruvolo, P; Steelman, LS, 2021) |
| "This study aimed to examine the efficacy of metabolically supported administration of chemotherapy combined with ketogenic diet, hyperthermia, and hyperbaric oxygen therapy (HBOT) in patients with metastatic pancreatic cancer." | 1.56 | Long-Term Survival Outcomes of Metabolically Supported Chemotherapy with Gemcitabine-Based or FOLFIRINOX Regimen Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy in Metastatic Pancreatic Cancer. ( Iyikesici, MS, 2020) |
| "We obtained 93 pancreatic cancer specimens (tumor and adjacent nontumor tissues) from patients who underwent surgery and gemcitabine chemotherapy and analyzed them by immunohistochemistry." | 1.56 | ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells. ( Brabletz, T; Bronze, MS; Cui, X; Ding, K; Edil, BH; Fernandez-Zapico, ME; Fung, KA; Houchen, CW; Li, M; Li, YP; Liu, M; Postier, RG; Stemmler, MP; Tian, X; Yang, J; Yang, Z; Zhan, H; Zhang, Y; Zhou, Z, 2020) |
| " Demographics, clinical and dosing characteristics, and treatment outcomes were collected." | 1.56 | Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States. ( Ahn, D; Barzi, A; Bekaii-Saab, T; Corvino, FA; Mamlouk, K; Miksad, R; Pulgar, S; Surinach, A; Torres, AZ; Valderrama, A; Wang, S, 2020) |
| "Fifty patients with metastatic colorectal cancer were prospectively followed-up during the first 4 cycles of fluoropyrimidine-based treatment to assess AEs." | 1.56 | Association of C677T and A1298C ( Chinchilla, R; Ramos-Esquivel, A; Valle, M, 2020) |
| "Objectives: Pancreatic cancer (PC) is a costly disease with a limited life-expectancy as it generally presents as an advanced, metastatic disease." | 1.56 | The economic burden of metastatic pancreatic cancer. ( Antico, G; Cole, A; Doleh, Y; Malangone-Monaco, E; Noxon, V; Pishvaian, MJ, 2020) |
| "Colon cancer is the 4th most common cancer causing death in both male and female equally, mainly caused due to the improper diet plans, consumption of the red meat and lack of exercise." | 1.51 | Can curcumin along with chemotherapeutic drug and lipid provide an effective treatment of metastatic colon cancer and alter multidrug resistance? ( Karthika, C; Sureshkumar, R, 2019) |
| "Treatment of B/U liver metastases from CRC with conversion chemotherapy using mFLOX regimen followed by surgical resection was associated with a high R0 resection rate and favorable survival outcomes." | 1.51 | Conversion Chemotherapy With a Modified FLOX Regimen for Borderline or Unresectable Liver Metastases From Colorectal Cancer: An Alternative for Limited-Resources Settings. ( Amor Divino, PH; Bonadio, RC; Capareli, FC; Hoff, PM; Kruger, JAP; Lima, KCA; Obando, JSM; Recchimuzzi, DZ; Saragiotto, DF, 2019) |
| "Studies of patients treated with bevacizumab and other vascular epithelial growth factor (VEGF) inhibitors have reported that hypertension adverse events (AEs) are associated with improved overall survival (OS) or progression-free survival (PFS)." | 1.51 | Effect of Early Adverse Events on Survival Outcomes of Patients with Metastatic Colorectal Cancer Treated with Ramucirumab. ( Hopkins, AM; Karapetis, CS; Lim, HH; Rowland, A; Sorich, MJ; Yuen, HY, 2019) |
| " Here, we investigated a safe and efficient dosing schedule of oxaliplatin in folinic acid, fluorouracil, and oxaliplatin (FOLFOX) regimen by monitoring total and free platinum concentrations in plasma." | 1.51 | Dose-escalation of oxaliplatin in hemodialysis patient treated with FOLFOX therapy: A case report. ( Cai, X; Fang, W; Gu, Y; Li, X; Wang, D; Wang, J; Wang, Y; Xu, L; Zhao, F, 2019) |
| "To investigate the efficacy of paclitaxel combined with a leucovorin and 5-fluorouracil regimen (PLF regimen; q2w) as neoadjuvant chemotherapy (NCT) for advanced gastric cancer." | 1.51 | Retrospective study on efficacy of a paclitaxel combined with a leucovorin and fluorouracil regimen for advanced gastric cancer. ( Chen, Q; Lin, X; Shi, C; Wang, X; Yang, B, 2019) |
| "Adult patients with R/M-HNSCC, who initiated systemic therapy between 1 September 2011 and 31 December 2014 and followed through 31 December 2015, were identified from iKnowMed electronic-health-records database (McKesson Specialty Health) supplemented with manual chart-abstraction." | 1.51 | Treatment patterns and outcomes among patients with recurrent/metastatic squamous cell carcinoma of the head and neck. ( Black-Shinn, J; Boyd, M; Chirovsky, D; Joo, S; Nadler, E, 2019) |
| " No statistical differences were observed in treatment-related adverse events, hospital admissions, or further treatment lines between age groups." | 1.51 | Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study. ( Antonuzzo, L; Aprile, G; Avallone, A; Bordonaro, R; Cinieri, S; Di Donato, S; Fanotto, V; Fornaro, L; Gerratana, L; Giampieri, R; Leone, F; Melisi, D; Nichetti, F; Pellegrino, A; Rimassa, L; Rosati, G; Santini, D; Scartozzi, M; Silvestris, N; Stragliotto, S; Tomasello, G; Vasile, E, 2019) |
| "Irinotecan (CPT-11) is a drug used against a wide range of tumor types." | 1.51 | Population pharmacokinetic model of irinotecan and its metabolites in patients with metastatic colorectal cancer. ( Aldaz, A; Insausti, A; Oyaga-Iriarte, E; Sayar, O, 2019) |
| " Severe adverse events were equivalent across age groups." | 1.51 | Patterns of Use, Safety, and Effectiveness of Targeted Therapies in First-Line Treatment of Metastatic Colorectal Cancer According to Age: The STROMBOLI Cohort Study. ( Bernard, MA; Coutureau, J; Droz, C; Duc, S; Forrier-Réglat, A; Gérard, S; Gouverneur, A; Grelaud, A; Jové, J; Lassalle, R; Noize, P; Ravaud, A; Rouyer, M; Smith, D, 2019) |
| "Here, we have analyzed STK17A in colorectal cancer and demonstrated decreased expression of STK17A in primary tumors, which is further reduced in metastatic lesions, indicating a potential role in regulating the metastatic cascade." | 1.51 | Serine Threonine Kinase 17A Maintains the Epithelial State in Colorectal Cancer Cells. ( Bilotta, AJ; Chen, X; Revetta, FL; Short, SP; Thompson, JJ; Washington, MK; Williams, CS, 2019) |
| "Hyperlipidemia is associated with metastasis in patients with gastric cancer (GC)." | 1.51 | 25-HC decreases the sensitivity of human gastric cancer cells to 5-fluorouracil and promotes cells invasion via the TLR2/NF-κB signaling pathway. ( Chen, W; Rao, C; Wang, S; Yao, Y; Zheng, G, 2019) |
| " Through univariate and multivariate logistic regression analyses, factors predicting the development of serious adverse events, fatal adverse events, and toxicity-related hospitalizations were determined." | 1.51 | Predictors of toxicity-related hospitalization in four randomized studies of 5-fluorouracil-based chemotherapy in metastatic colorectal cancer. ( Abdel-Rahman, O; Ahmed, O, 2019) |
| "Distant metastases (DM) are a leading cause of death for patients with oropharyngeal cancer (OPSCC)." | 1.51 | The addition of chemotherapy to radiotherapy did not reduce the rate of distant metastases in low-risk HPV-related oropharyngeal cancer in a real-world setting. ( Griffiths, RJ; Hall, SF; Liu, FF; O'Sullivan, B, 2019) |
| "Patients with recurrence or metastasis within 6 months after cisplatin administration were considered platinum-resistant and those with no recurrence or metastasis within 6 months were considered platinum-sensitive." | 1.51 | Clinical outcomes of platinum-based chemotherapy plus cetuximab for recurrent or metastatic squamous cell carcinoma of the head and neck: comparison between platinum-sensitive and platinum-resistant patients. ( Fushimi, C; Hanyu, K; Katsube, Y; Kondo, T; Miura, K; Okada, T; Okamoto, I; Sato, H; Shimizu, A; Tsukahara, K, 2019) |
| "Distant metastasis still remained a major concern in pCR patients following nCRT and TME." | 1.51 | Pathological complete response may underestimate distant metastasis in locally advanced rectal cancer following neoadjuvant chemoradiotherapy and radical surgery: Incidence, metastatic pattern, and risk factors. ( Chi, P; Huang, Y; Lin, H; Lu, X; Sun, Y; Wu, X; Zhang, Y, 2019) |
| "Survival benefits after synchronous metastasectomy have been reported for selected patients." | 1.51 | CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX. ( Büchler, MW; Hackert, T; Heckler, M; Heger, U; Klaiber, U; Mihaljevic, AL; Sun, H; Tanaka, M, 2019) |
| "Patients with rectal cancer who achieve complete clinical response after neoadjuvant chemoradiation have been managed by organ-preserving strategies and acceptable long-term outcomes." | 1.51 | Achieving a Complete Clinical Response After Neoadjuvant Chemoradiation That Does Not Require Surgical Resection: It May Take Longer Than You Think! ( Andrade, A; Araújo, SEA; Fernandez, LM; Gama-Rodrigues, J; Habr-Gama, A; Perez, RO; São Julião, GP; Vailati, BB, 2019) |
| "Sarcopenia was defined as SMI ≤38." | 1.51 | Sarcopenia supersedes subjective global assessment as a predictor of survival in colorectal cancer. ( Block, C; Gorsuch, K; Gupta, D; Hill, D; Vashi, PG; Wan, L, 2019) |
| "Our study included 90 cases of colorectal cancer liver metastasis resected after preoperative chemotherapy." | 1.51 | Sinusoidal Obstruction Syndrome and Postoperative Complications Resulting from Preoperative Chemotherapy for Colorectal Cancer Liver Metastasis. ( Akagi, Y; Akiba, J; Fujita, F; Fukahori, M; Goto, Y; Hisaka, T; Ishikawa, H; Kawahara, R; Kinugasa, T; Miwa, K; Mizobe, T; Naito, Y; Nakashima, O; Nomura, Y; Okuda, K; Sakai, H; Tanaka, H; Tanigawa, M; Yano, H; Yasunaga, M, 2019) |
| "Two cohorts of metastatic colorectal cancer (CRC) were analyzed: a nonrandomized exploratory cohort of 184 patients treated at a single institution from 2003 to 2010 and a confirmatory cohort of 200 patients from a multi-institutional randomized trial (NO16966)." | 1.48 | The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia. ( Ferrarotto, R; George, B; Hobbs, B; Hoff, PM; Kopetz, S; Loyer, EM; Machado, KK; Mazard, T; Overman, MJ; Qiao, W; Raghav, K; Saltz, LB; Vauthey, JN, 2018) |
| "BACKGROUND Triple negative breast cancer (TNBC) has a more aggressive recurrence." | 1.48 | Triple Negative Breast Cancer Depends on Sphingosine Kinase 1 (SphK1)/Sphingosine-1-Phosphate (S1P)/Sphingosine 1-Phosphate Receptor 3 (S1PR3)/Notch Signaling for Metastasis. ( Chang, W; Hu, B; Liang, Y; Wang, S; Zhang, Y, 2018) |
| "Successful treatment of colorectal cancer (CRC) is greatly impeded by metastasis and chemoresistance, particularly to 5-fluoruracil (5-Fu), one of the staples of clinical intervention in advanced CRC." | 1.48 | GDPD5, a target of miR-195-5p, is associated with metastasis and chemoresistance in colorectal cancer. ( Feng, C; Li, X; Liu, L; Lou, Y; Sun, Y; Wang, Y; Zhan, L; Zhang, L; Zhang, Y, 2018) |
| "Adjuvant chemotherapy is used for human breast cancer patients, even after curative surgery of primary tumor, to prevent tumor recurrence primarily as a form of metastasis." | 1.48 | Involvement of Prokineticin 2-expressing Neutrophil Infiltration in 5-Fluorouracil-induced Aggravation of Breast Cancer Metastasis to Lung. ( Baba, T; Matsugo, S; Mukaida, N; Muranaka, H; Sasaki, S; Takahashi, C; Tanabe, Y, 2018) |
| " Dosage was more often reduced in patients receiving FOLFOX based therapy." | 1.48 | Chemotherapy for metastatic colon cancer: No effect on survival when the dose is reduced due to side effects. ( Evert, M; Fest, P; Fichtner-Feigl, S; Gerken, M; Herr, W; Klinkhammer-Schalke, M; Munker, S; Ott, C; Reng, M; Schlitt, HJ; Schnoy, E; Stroszczynski, C; Teufel, A; Vogelhuber, M; Wiggermann, P, 2018) |
| "Since pancreatic cancer is becoming more common as a result of population aging, there is a need for diversification of chemotherapy." | 1.48 | Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer. ( Akao, J; Otsuka, N; Shimizu, K; Tahara, J; Takayama, Y; Tokushige, K, 2018) |
| "MH also influenced the anti-metastasis effects of 5-FU by decreasing migration ability, suppressing the expression of MMP-2, MMP-9 and increasing N-cadherin and E-cadherin." | 1.48 | Manuka honey synergistically enhances the chemopreventive effect of 5-fluorouracil on human colon cancer cells by inducing oxidative stress and apoptosis, altering metabolic phenotypes and suppressing metastasis ability. ( Afrin, S; Amici, A; Battino, M; Cianciosi, D; Forbes-Hernández, TY; Gasparrini, M; Giampieri, F; Quiles, JL, 2018) |
| "The use of circulating tumor cells (CTCs) as indicators of treatment response in metastatic colorectal cancer (mCRC) needs to be clarified." | 1.48 | Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients. ( de Miguel-Pérez, D; Delgado-Ramirez, M; Delgado-Ureña, M; Exposito-Hernandez, J; García-Puche, JL; Garrido-Navas, MC; Ilyine, H; Lorente, JA; Ortega, FG; Rodriguez-Martínez, A; Serrano, MJ, 2018) |
| "Esophageal squamous cell carcinoma (ESCC) is the second common cancer in Henan province and is well-known for aggressiveness and dismal prognosis." | 1.46 | All-trans retinoic acid suppresses the angiopoietin-Tie2 pathway and inhibits angiogenesis and metastasis in esophageal squamous cell carcinoma. ( Cui, H; Li, D; Li, N; Li, S; Lian, J; Lu, T; Lu, Y; Sang, L; Wang, Y; Yu, JJ; Zhang, L; Zheng, X, 2017) |
| "Right-sided colorectal cancer (RSCRC) were associated with reduced overall response rate (ORR) (4." | 1.46 | The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab. ( Antoniotti, C; Cascinu, S; Cremolini, C; Demurtas, L; Falcone, A; Gelsomino, F; Giampieri, R; Loretelli, C; Mandolesi, A; Masi, G; Meriggi, F; Pusceddu, V; Puzzoni, M; Scartozzi, M; Zaniboni, A; Ziranu, P, 2017) |
| "The economic burden of metastatic pancreatic cancer (mPC) is substantial while treatment options are limited." | 1.46 | Comparison of treatment patterns and economic outcomes among metastatic pancreatic cancer patients initiated on nab-paclitaxel plus gemcitabine versus FOLFIRINOX. ( Bonafede, M; Cai, Q; McBride, A; Parisi, M; Patel, M; Pelletier, C; Princic, N; Tran, O, 2017) |
| "Distant metastases was the predominant site of failure, seen in 5 patients (20%)." | 1.46 | Induction Methotrexate, Cisplatin, and 5-Fluorouracil Versus Cisplatin and 5-Fluorouracil Followed by Radiotherapy in Pediatric Nasopharyngeal Carcinoma: A Retrospective Analysis in a Tertiary Cancer Center. ( Abu-Hijlih, R; Al Mousa, A; Ismael, T; Mohamad, I; Mula-Hussain, L; Salem, A; Sultan, I, 2017) |
| "Of 216 stage IIIB cervical cancer patients, 114 of them had no LTI and 72 had LTI." | 1.46 | Comparing treatment outcomes of stage IIIB cervical cancer patients between those with and without lower third of vaginal invasion. ( Katanyoo, K, 2017) |
| "The aim of this retrospective study was to clarify the effectiveness of chemotherapy with gemcitabine combined with low-dose 5-fluorouracil and cisplatin (GFP) for advanced biliary carcinoma after hepatectomy." | 1.46 | Effect of Adjuvant Gemcitabine Combined with Low-dose 5-Fluorouracil and Cisplatin Chemotherapy for Advanced Biliary Carcinoma. ( Arakawa, Y; Ikemoto, T; Imura, S; Iwahashi, S; Morine, Y; Saito, YU; Shimada, M; Yamada, S, 2017) |
| "The most common sites of metastases were liver (63%) and peritoneum (22%)." | 1.46 | Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia: A Population-based Retrospective Study. ( Cheung, WY; Gill, S; Ho, MY; Kennecke, HF; Lim, HJ; Renouf, DJ, 2017) |
| "Patients with locally advanced rectal cancer (LARC) receiving neoadjuvant chemoradiation (nCRT) can have a complete pathologic response (pCR), and are given postoperative adjuvant chemotherapy (ACT)." | 1.46 | Is routine use of adjuvant chemotherapy for rectal cancer with complete pathological response justified? ( Church, JM; Gamaleldin, M; Gorgun, E; Kalady, M; Liska, D; Stocchi, L, 2017) |
| "Distinct metastasis accounts for the leading cause of mortality among patients with gastric cancer." | 1.46 | Traditional Chinese medicine Jianpi Bushen therapy suppresses the onset of pre-metastatic niche in a murine model of spontaneous lung metastasis. ( Wu, J; Xu, Q; Zhou, Y; Zhu, X, 2017) |
| "A historical cohort of 112 RAS mutated colorectal cancer patients treated with FOLFOX6 alone served as control group." | 1.46 | IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients. ( Barone, C; Basso, M; Berenato, R; Bossi, I; Capoluongo, E; Caporale, M; Danesi, R; de Braud, F; Del Re, M; Di Salvatore, M; Guarino, D; Martinetti, A; Mennitto, A; Mennitto, R; Orlandi, A; Pietrantonio, F; Rossi, E; Santonocito, C; Schinzari, G, 2017) |
| "AFP-PGC patients had more liver metastases than non-AFP-PGC patients (p < 0." | 1.46 | The efficacy of modified docetaxel-cisplatin-5-fluorouracil regimen as first-line treatment in patients with alpha-fetoprotein producing gastric carcinoma. ( Bozkaya, Y; Demirci, NS; Doğan, M; Erdem, GU; Yazıcı, O; Zengin, N, 2017) |
| "Currently, metastatic colorectal cancer is treated as a homogeneous disease and only RAS mutational status has been approved as a negative predictive factor in patients treated with cetuximab." | 1.46 | Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies. ( Bibeau, F; Del Rio, M; Emile, JF; Gongora, C; Martineau, P; Mollevi, C; Robert, J; Roger, P; Selves, J; Tubiana-Mathieu, N; Vie, N; Ychou, M, 2017) |
| "Metastatic and refractory gastric cancer (GC) are associated with a poor prognosis; therefore, the identification of prognostic factors and chemosensitivity markers is extremely important." | 1.43 | Nuclear PRMT1 expression is associated with poor prognosis and chemosensitivity in gastric cancer patients. ( Altan, B; Asao, T; Bai, T; Bao, P; Hara, K; Ide, M; Kimura, A; Kogure, N; Kuwano, H; Mochiki, E; Nishiyama, M; Ogata, K; Oyama, T; Suzuki, M; Toyomasu, Y; Yokobori, T, 2016) |
| "As an approach to improve treatment of breast cancer metastasis to the brain, we employed genetically engineered stem cells (GESTECs, HB1." | 1.43 | Synergistic effect of therapeutic stem cells expressing cytosine deaminase and interferon-beta via apoptotic pathway in the metastatic mouse model of breast cancer. ( Choi, KC; Kim, SU; Yi, BR, 2016) |
| "To (a) assess potential patient-specific factors related to adherence to mCRC chemotherapy regimens and (b) compare adherence with IV versus oral dosage forms." | 1.43 | Factors Associated with Adherence Rates for Oral and Intravenous Anticancer Therapy in Commercially Insured Patients with Metastatic Colon Cancer. ( Anderson, S; Seal, BS; Shermock, KM, 2016) |
| "At multivariate analysis liver metastases (p = 0." | 1.43 | First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors. ( Caparello, C; Catanese, S; Falcone, A; Fornaro, L; Lencioni, M; Musettini, G; Pasquini, G; Vasile, E; Vivaldi, C, 2016) |
| "The effect of individual dose adjustment of 5-fluorouracil (5-FU) based on pharmacokinetic monitoring on the outcome of FOLFOX for metastatic colorectal cancer was analyzed retrospectively." | 1.43 | [Individual Dose Adjustment of 5-Fluorouracil Based on Pharmacokinetic Monitoring May Improve the Outcome of FOLFOX for Metastatic Colorectal Cancer]. ( Kanda, J; Muneoka, K; Sakata, J; Sasaki, M; Shirai, Y; Wakabayashi, H; Wakai, T, 2016) |
| "The mean recurrence-free survival was 13." | 1.43 | [Adjuvant Systemic Chemotherapy with S-1/Oxaliplatin or mFOLFOX6 after Curative Resection of Distant Metastases in Patients with Colorectal Cancer]. ( Amada, E; Baba, S; Kameyama, N; Mitsuhashi, H; Miyata, R; Tomita, M, 2016) |
| "4% experienced grade 3/4 adverse events." | 1.43 | Effectiveness and safety of first-line bevacizumab plus FOLFIRI in elderly patients with metastatic colorectal cancer: Results of the ETNA observational cohort. ( Becouarn, Y; Fourrier-Réglat, A; Grelaud, A; Guimbaud, R; Jové, J; Moore, N; Noize, P; Ravaud, A; Robinson, P; Rouyer, M; Smith, D; Tubiana-Mathieu, N, 2016) |
| "Distant metastasis occurred in 86." | 1.43 | [Analysis of risk factors of distant metastasis in rectal cancer patients who received total mesorectal excision following neoadjuvant chemoradiotherapy]. ( Chi, P; Huang, S; Huang, Y; Lin, H; Lu, X; Sun, Y; Wang, X; Xu, Z; Ye, D, 2016) |
| "Patients who underwent metastasectomy or those with Eastern Cooperative Oncology Group performance status (ECOG-PS) ≤1 had longer PFS and OS independent of the type of chemotherapy regimen." | 1.43 | Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study. ( Artaç, M; Avcı, N; Çabuk, D; Coşkun, HŞ; Dane, F; Doruk, H; Faruk Aykan, N; Karaağaç, M; Karabulut, B; Karabulut, S; Korkmaz, L; Turhal, NS, 2016) |
| "Treatment with lenalidomide reduced tumor vessel density (p = 0." | 1.43 | Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity. ( Aglietta, M; Bertotti, A; Bussolino, F; Gammaitoni, L; Giraudo, E; Giraudo, L; Grignani, G; Leone, F; Leuci, V; Luraghi, P; Maione, F; Mesiano, G; Migliardi, G; Rotolo, R; Sangiolo, D; Sassi, F; Todorovic, M; Trusolino, L, 2016) |
| "The treatment of metastatic colorectal cancer (mCRC) has changed substantially in the last 2 decades, but to the authors' knowledge, the effect of age and comorbidities on chemotherapy use has not been well studied to date." | 1.43 | Chemotherapy use and adoption of new agents is affected by age and comorbidities in patients with metastatic colorectal cancer. ( Cohen, SJ; Dotan, E; Hall, MJ; Li, T; Vijayvergia, N; Wong, YN, 2016) |
| "Metastases were mostly in the lung (43%), lymph nodes (51%) and liver (46%)." | 1.43 | Oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) as second-line therapy for patients with advanced urothelial cancer. ( Chen, Q; Xue, H; Zhang, S, 2016) |
| "Acute kidney injury is an important issue in chemotherapy receiving patients an neutrophil gelatinase-associated lipocalin has been proposed as a novel marker." | 1.42 | Predictive role of neutrophil gelatinase-associated lipocalin in early diagnosis of platin-induced renal injury. ( Babacan, NA; Deveci, K; Kacan, T; Sancakdar, E; Seker, A; Seker, MM; Turesin, AK; Yilmaz, A, 2015) |
| " Most grade ≥ 3 adverse events (AEs) were reported during the initial cycles of treatment." | 1.42 | Aflibercept for metastatic colorectal cancer: safety data from the Spanish named patient program. ( Díaz de Corcuera, I; García de la Torre, M; Pérez Hoyos, MT; Salgado Fernández, M; Vidal Arbués, A, 2015) |
| " The remission rate, control rate and time to disease progression were compared among patients receiving cetuximab combined with different chemotherapy regimens in different periods." | 1.42 | [Clinical efficacy observation of cetuximab combined with chemotherapy in the treatment of metastatic colorectal carcinoma]. ( Bai, L; Han, C; Jiao, S; Li, J; Su, D; Wang, Y; Zhang, T, 2015) |
| "We present 2 patients with metastatic colorectal cancer who had progressed despite treatment with first-line FOLFOX and second-line FOLFIRI combination chemotherapy regimens." | 1.42 | Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy. ( El-Deiry, WS; Marks, EI; Scicchitano, A; Tan, C; Yang, Z; Zhang, J; Zhou, L, 2015) |
| "According to treatment, ORR, metastasectomies, PFS and OS were significantly favourable in triplet CT plus targeted agent compared to triplet, respectively: 80%, 40%, 13 months, not reached; 28%, 6%, 8 months, 11 months." | 1.40 | Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype. ( Bruera, G; Cannita, K; Ficorella, C; Giordano, AV; Ricevuto, E; Vicentini, R, 2014) |
| "Lapatinib was dissolved in water, and cholestyramine was continuously given twice a day." | 1.40 | Optimal tolerability and high efficacy of a modified schedule of lapatinib-capecitabine in advanced breast cancer patients. ( Gamucci, T; Mauri, M; Mentuccia, L; Moscetti, L; Pavese, I; Pizzuti, L; Sperduti, I; Vaccaro, A; Vici, P; Zampa, G, 2014) |
| "In the clinic, predicting metastasis and chemoresistance takes high priority, but has not been well established." | 1.40 | Predicting distant metastasis and chemoresistance using plasma miRNAs. ( Chen, J; Chen, Y; Hu, T; Wang, W; Zhang, Y, 2014) |
| "Ninety-two metastatic colorectal cancer patients treated with first-line 5-fluoropyrimidine (5-FU), leucovorin, and oxaliplatin (FOLFOX), capecitabine, and oxaliplatin (XELOX) and sixty-two patients receiving 5-FU, leucovorin, and irinotecan (FOLFIRI) were reviewed." | 1.40 | Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer. ( Cai, S; Li, W; Sun, M; Yu, Q; Zhang, W; Zhang, Z; Zhao, J; Zhu, D, 2014) |
| "The treatment of metastatic colon cancer (mCC) utilizes either combination therapies or sequential monotherapy followed by combination therapy in subsequent lines of treatment." | 1.40 | Retrospective comparison of CAPOX and FOLFOX dose intensity, toxicity, and clinical outcomes in the treatment of metastatic colon cancer. ( Ghosh, S; Loree, JM; Mulder, KE; Spratlin, JL, 2014) |
| "Survival, distant metastasis and local control rates are expressed as percentages at two years using the Kaplan-Meier method." | 1.40 | Sequential TPF chemotherapy followed by concurrent chemoradiotherapy in locally advanced head and neck cancer--a retrospective analysis of toxicity and outcomes. ( Correa, P; Grose, D; Haslett, K; James, A; Paterson, C; Rizwanullah, M; Sanders, IW, 2014) |
| "3%); alteration and complete recovery (31%) or sustained deterioration (45%), possibly due to inadequate chronotherapy dosing and/or timing." | 1.40 | The circadian rest-activity rhythm, a potential safety pharmacology endpoint of cancer chemotherapy. ( Beau, J; Innominato, PF; Iurisci, I; Karaboue, A; Lévi, F; Madrid, JA; Moreau, T; Ortiz-Tudela, E; Rol, MA, 2014) |
| "A 67-year-old man diagnosed with colorectal cancer in 2008 presented in April 2011 to Appalachian Regional Healthcare Cancer Center with obstructive jaundice and weight loss." | 1.40 | Safety and efficacy of FOLFOX followed by cetuximab for metastatic colorectal cancer with severe liver dysfunction. ( Craig, J; Elsoueidi, R; Mourad, H; Richa, EM, 2014) |
| "Patients with inoperable tumors due to metastasis at the time of diagnosis who were treated with oxaliplatin or irinotecan as the first-line treatment were included in this study." | 1.40 | Prognostic factors for metastatic colorectal cancer after first-line chemotherapy with FOLFOX-4 or FOLFIRI regimen. ( Choi, PR; Kim, JH; Kim, SE; Lee, GW; Moon, W; Park, MI; Park, SJ, 2014) |
| "Distant metastasis accounted for the predominant cause of death." | 1.40 | [Outcome and prognostic factors of 125 loco-regionally advanced head and neck squamous cell carcinoma treated with multi-modality treatment]. ( Guo, Y; Ji, Q; Qian, W; Wang, Y; Zhu, G, 2014) |
| "Cholangiocarcinoma is categorized into intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC)." | 1.40 | Efficacy of hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic pegylated interferon α-2b for advanced intrahepatic cholangiocarcinoma. ( Kasai, K; Kasai, Y; Kooka, Y; Miyamoto, Y; Oikawa, K; Oikawa, T; Sawara, K; Suzuki, A; Suzuki, Y; Takikawa, Y; Ushio, A, 2014) |
| "Adjuvant chemotherapy use in stage II colorectal cancer (CRC) is debated." | 1.40 | The role of adjuvant chemotherapy in stage II colorectal cancer patients. ( Chang, SC; Chang, YY; Chen, WS; Jiang, JK; Lan, YT; Lin, CC; Lin, HH; Lin, JK; Lin, TC; Wang, HS; Yang, SH, 2014) |
| "Colorectal cancer metastasis is a major cause of mortality worldwide, which may only be controlled with novel methods limiting tumor dissemination and chemoresistance." | 1.40 | Unbiased proteomic and transcript analyses reveal that stathmin-1 silencing inhibits colorectal cancer metastasis and sensitizes to 5-fluorouracil treatment. ( Chung, MC; Lim, TK; Tan, HT; Tan, XF; Wu, W, 2014) |
| "Existing treatments for metastatic breast cancer (mBC) are often effective but can cause adverse events (AEs)." | 1.40 | Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting. ( Brammer, M; Guardino, E; Guerin, A; Hurvitz, S; Lalla, D; Latremouille Viau, D; Wu, EQ; Zhou, ZY, 2014) |
| " The comparison revealed no significant differences in response rate, progression-free survival, overall survival, and the frequency of overall adverse events after the start of second-line chemotherapy, although the frequency of anemia(Bgrade 3, p=0." | 1.40 | [The efficacy and safety of FOLFIRI or combined FOLFIRI and bevacizumab treatment as second-line chemotherapy for metastatic colorectal cancer patients aged 75 years and older]. ( Baba, H; Chika, N; Haga, N; Ishibashi, K; Ishida, H; Kumagai, Y; Kumamoto, K; Okada, N; Sano, M; Tajima, Y, 2014) |
| "To estimate the incremental cost per life-year gained (LYG) of aflibercept in combination with FOLFIRI as second-line treatment in metastatic colorectal cancer (mCRC) patients previously treated with oxaliplatin." | 1.40 | [Cost-effectiveness analysis of aflibercept in combination with FOLFIRI in the treatment of patients with metastatic colorectal cancer]. ( Abad, A; Echave, M; Frías, C; Giménez, E; Joulain, F; Lamas, MJ; Naoshy, S; Oyagüez, I; Pericay, C; Rubio, M, 2014) |
| "Metastatic squamous cell carcinoma (SCCA) of the anal canal is a rare malignancy for which no standard treatment algorithm exists." | 1.40 | The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal. ( Chang, GJ; Crane, CH; Das, P; Eng, C; Ohinata, A; Pathak, P; Phillips, JK; Rodriguez-Bigas, M; Rogers, JE; Sethi, S; Vauthey, JN; Wolff, RA; Xing, Y; You, YN, 2014) |
| "Gastric samples from patients with gastric cancer were further analyzed for levels of a specifically downregulated lncRNA (termed as LEIGC)." | 1.40 | LEIGC long non-coding RNA acts as a tumor suppressor in gastric carcinoma by inhibiting the epithelial-to-mesenchymal transition. ( Chen, J; Chen, Z; Gao, S; Han, Y; Huang, J; Wu, D; Wu, P; Ye, J, 2014) |
| "Prognosis of metastatic breast cancer is poor with a 5-year survival rate of 21%." | 1.40 | Simultaneous 24 h-infusion of high-dose 5-fluorouracil and sodium-folinate as alternative to capecitabine in advanced breast cancer. ( Friedrich, M; Kummer, S; Terjung, A, 2014) |
| "Among them, 3 patients with bladder metastasis received intravesical chemotherapy of fluorouracil." | 1.40 | [Analysis of the treatment and prognosis for gestational trophoblastic neoplasia patients with urinary system and adrenal glands metastasis]. ( Feng, F; Ren, T; Wan, X; Wang, D; Xiang, Y; Yang, J, 2014) |
| "A 69- year-old man with metastatic rectal cancer received 4 courses XELOX therapy." | 1.40 | [A case of metastatic rectal cancer with fulminant hepatitis caused by XELOX therapy]. ( Egawa, T; Ito, Y; Kemmochi, T; Makino, H; Nagashima, A; Ohkubo, Y; Shimokawa, R; Suzuki, Y; Yamamuro, W; Yoneda, M, 2014) |
| " All patients were genotyped for MTHFR 1298A>C and 677C>T polymorphisms and analysed in both cohorts separately for the association between the MTHFR genotype and incidence of grade 3-4 overall toxicity and specific adverse events, as well as efficacy parameters." | 1.39 | MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer. ( Gelderblom, H; Guchelaar, HJ; Punt, CJ; van Huis-Tanja, LH, 2013) |
| "Borderline resectable pancreatic cancer remains an area that requires multi-disciplinary approach." | 1.39 | Advancements in the management of pancreatic cancer: 2013. ( Saif, MW, 2013) |
| " Food and Drug Administration approved cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer." | 1.39 | Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer. ( Chen, H; Cohen, MH; Fuchs, C; He, K; Keegan, P; Pazdur, R; Shord, S; Sickafuse, S; Zhao, H, 2013) |
| "Patients were eligible if they had intrahepatic cholangiocarcinoma with liver or extrahepatic metastasis and with no prior chemotherapy." | 1.39 | Retrospective analysis of survival benefits of chemotherapy for metastatic or non-resectable intrahepatic cholangiocarcinoma. ( Chauffert, B; Ghiringhelli, F; Wiazzane, N, 2013) |
| "The genome expression profiles of colorectal cancer tissues were examined using DNA microarray analysis, and differential gene expression was identified using a significance analysis of the microarray." | 1.39 | Establishment of a predictive genetic model for estimating chemotherapy sensitivity of colorectal cancer with synchronous liver metastasis. ( Chi, P; Huang, S; Huang, Y; Li, S; Lin, H; Lu, X; Pan, J; Shen, S; Xu, Z, 2013) |
| " Grade 3/4 adverse events were: neutropenia (54." | 1.39 | Safety and efficacy of modified FOLFOX6 plus high-dose bevacizumab in second-line or later treatment of patients with metastatic colorectal cancer. ( Maruyama, S; Takii, Y, 2013) |
| "A total of 250 White metastatic colorectal cancer patients homogenously treated with a first-line FOLFIRI regimen were genotyped for a panel of variants in five transporter genes." | 1.39 | Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment. ( Buonadonna, A; Cecchin, E; Corona, G; D'Andrea, M; De Mattia, E; Dreussi, E; Polesel, J; Toffoli, G; Zagonel, V, 2013) |
| "Chemoresistance of breast cancer is a worldwide problem for breast cancer and the resistance to chemotherapeutic agents frequently led to the subsequent recurrence and metastasis." | 1.39 | 53BP1 sensitizes breast cancer cells to 5-fluorouracil. ( Kong, X; Li, X; Wang, Y; Yan, S; Yang, Q, 2013) |
| "Elderly patients with metastatic colorectal cancer (mCRC) differ from the general population and are underrepresented in clinical trials." | 1.39 | Oxaliplapin and capecitabine (XELOX) based chemotherapy in the treatment of metastatic colorectal cancer: the right choice in elderly patients. ( Aprile, G; Bearz, A; Berretta, M; Borsatti, E; Canzonieri, V; Ferrari, L; Fiorica, F; Fisichella, R; Foltran, L; Lestuzzi, C; Lleshi, A; Lutrino, S; Nasti, G; Talamini, R; Tirelli, U; Urbani, M, 2013) |
| "The 3-year local recurrence and distant metastasis rates in the adjuvant chemotherapy group were 4." | 1.39 | [Value of postoperative adjuvant chemotherapy in locally advanced rectal cancer patients with ypT1-4N0 after neo-adjuvant chemoradiotherapy]. ( Chang, H; Chen, L; Du, XJ; Gao, YH; Liu, MZ; Peng, HH; Wen, BX; Xiao, L; You, KY; Zeng, ZF; Zhou, GQ, 2013) |
| "Liver and intrapelvic metastases were found upon examination 6 months after surgery during adjuvant chemotherapy with XELOX plus bevacizumab." | 1.39 | [A case in which chemotherapy-resistant sigmoid colon cancer was controlled effectively by radiotherapy and resection]. ( Kita, I; Mukubo, H; Nakanuma, S; Sato, N; Takanaka, T; Yasui, T, 2013) |
| "When treating colorectal cancer with chemotherapy, it is important to elucidate how the prognosis can be improved while maintaining the quality of life( QOL)." | 1.39 | [Protocol for the administration of modified FOLFOX6 (mFOLFOX6) in patients with unresectable/recurrent colorectal cancer]. ( Hagino, S; Iwata, K; Kiriyama, M; Kurata, T; Makita, N; Tsuneda, A, 2013) |
| " Another option is to use desensitization protocols that induce a temporary state of tolerance by gradually administering small quantities of the antineoplastic drug until the therapeutic dosage is reached." | 1.39 | Effectiveness of oxaliplatin desensitization protocols. ( Aguilella-Vizcaíno, MJ; Calleja-Hernández, MÁ; Cortés-Funes Castro, H; Cortijo-Cascajares, S; García-Escobar, I; Herreros-de-Tejada, A; Nacle-López, I, 2013) |
| "Periodontitis has been observed infrequently in bevacizumab-containing chemotherapy in clinical practice." | 1.39 | A retrospective analysis of periodontitis during bevacizumab treatment in metastatic colorectal cancer patients. ( Akiyoshi, K; Hamaguchi, T; Hosokawa, A; Iwasa, S; Kato, K; Nakajima, TE; Nishitani, H; Ogawa, K; Shimada, Y; Sugiyama, T; Ueno, T; Yamada, Y, 2013) |
| "Liver metastasis and peritonitis carcinomatosa were found in 20 (43 %) and 18 (39 %) of the 46 cases, respectively." | 1.39 | Modified DCF (mDCF) regimen seems to be as effective as original DCF in advanced gastric cancer (AGC). ( Aydogan, F; Aykan, F; Disci, R; Ekenel, M; Keskin, S; Kilic, L; Saglam, S; Sakar, B; Sen, F; Yıldız, I, 2013) |
| "The prognosis of unresectable biliary tract cancer has improved recently." | 1.39 | Improvement of prognosis for unresectable biliary tract cancer. ( Hirano, K; Isayama, H; Ito, Y; Kogure, H; Koike, K; Mizuno, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Toda, N; Yagioka, H; Yamamoto, N, 2013) |
| "Retinal vein thrombosis is a common vascular occlusive disorder of the retina responsible for varying degrees of vision impairment." | 1.38 | Retinal vein thrombosis in a patient with metastatic colon cancer receiving XELOX chemotherapy combined with bevacizumab pre-hepatic resection. ( Gilbar, P; Sorour, N, 2012) |
| "Eighty-nine patients (85%) had metastases confined to 1 organ." | 1.38 | Combined high-dose radiation therapy and systemic chemotherapy improves survival in patients with newly diagnosed metastatic nasopharyngeal cancer. ( Chen, Q; Han, L; Lin, S; Lu, JJ; Pan, J; Tham, IW, 2012) |
| " We investigated whether there might be a discrepancy between the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) and the Neurotoxicity Criteria of Debiopharm (DEB-NTC), the commonly used oxaliplatin-specific scales, in the evaluation of peripheral neurotoxicity." | 1.38 | Discrepancy between the NCI-CTCAE and DEB-NTC scales in the evaluation of oxaliplatin-related neurotoxicity in patients with metastatic colorectal cancer. ( Inoue, N; Ishibashi, K; Ishida, H; Kishino, T; Kumamoto, K; Okada, N; Sano, M, 2012) |
| "High TS, DPD, and positive lymph node metastasis (pN) were significantly poorer prognostic factors for DFS (TS: P < 0." | 1.38 | TS and DPD mRNA levels on formalin-fixed paraffin-embedded specimens as predictors for distant recurrence of rectal cancer treated with preoperative chemoradiotherapy. ( Inoue, Y; Kobayashi, M; Koike, Y; Kusunoki, M; Miki, C; Okugawa, Y; Saigusa, S; Tanaka, K; Toiyama, Y; Yokoe, T, 2012) |
| " Adverse effects ≥ grade 2 were observed in 32% of the patients and adverse effects ≥ grade 3 in 15%." | 1.38 | Safety and outcome of chemoradiotherapy in elderly patients with rectal cancer: results from two French tertiary centres. ( Bensadoun, RJ; Hamidou, H; Michel, P; Paillot, B; Roullet, B; Silvain, C; Tougeron, D; Tourani, JM, 2012) |
| "Ten patients had disease progression." | 1.38 | Chemotherapy with modified docetaxel, cisplatin, and 5-fluorouracil in patients with metastatic head and neck cancer. ( Bi, CP; Chang, TH; Chen, MK; Lai, GM; Lin, JT; Liu, MT; Wang, JW, 2012) |
| "Fifty seven metastatic colorectal cancer patients were prospectively included and 40 tumors were analyzed." | 1.38 | Absence of transcriptomic signature of response to chemotherapy in metastatic colorectal carcinoma patients. ( Brunet, R; Evrard, S; Kauffmann, A; Laroche-Clary, A; Laurand-Quancard, A; Le Morvan, V; Robert, J; Smith, D, 2012) |
| ", Salt Lake City, UT) that measures plasma 5-FU concentration and reports an AUC in mg · h/L has been developed to optimize therapy using pharmacokinetic (PK) dosing." | 1.38 | Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6. ( Grier, CE; Hamilton, SA; Haregewoin, A; Kaldate, RR; McLeod, HL, 2012) |
| "The vast majority of patients with pancreatic cancer present with locally advanced unresectable or metastatic disease, and in this setting only a palliative treatment can be offered." | 1.38 | Conventional chemotherapy of advanced pancreatic cancer. ( Colucci, G; Di Maio, M; Giuliani, F; Perrone, F, 2012) |
| "HER2-positive gastric cancer seems to confer poorer prognosis, particularly in patients without diffuse-type tumor, treated with modified FOLFOX-6." | 1.38 | The prognostic significance of HER2 positivity for advanced gastric cancer patients undergoing first-line modified FOLFOX-6 regimen. ( Bang, YJ; Cha, Y; Han, SW; Im, SA; Keam, B; Kim, JW; Kim, M; Kim, MA; Kim, TY; Kim, WH; Lee, KH; Oh, DY, 2012) |
| " We also observed bioavailability of ursolic acid in the serum and tissue of animals." | 1.38 | Ursolic acid inhibits growth and metastasis of human colorectal cancer in an orthotopic nude mouse model by targeting multiple cell signaling pathways: chemosensitization with capecitabine. ( Aggarwal, BB; Baladandayuthapani, V; Deorukhkar, A; Diagaradjane, P; Guha, S; Kannappan, R; Krishnan, S; Prasad, S; Reuter, S; Sung, B; Wei, C; Yadav, VR, 2012) |
| "After matching, only CEA and metastasectomy, but not CCRT, were independent prognostic factors." | 1.38 | Concurrent chemoradiotherapy followed by metastasectomy converts to survival benefit in stage IV rectum cancer. ( Chang, SC; Chen, WS; Jiang, JK; Lan, YT; Lee, LK; Lin, CC; Lin, JK; Lin, TC; Liu, JH; Teng, HW; Tzeng, CH; Wang, HS; Yang, SH; Yen, CC, 2012) |
| "Irinotecan was given as a combined regimen for median 6 cycles (range, 3-12) and as a single agent for median 3 cycles (range, 1-10)." | 1.38 | Second-line irinotecan after cisplatin, fluoropyrimidin and docetaxel for chemotherapy of metastatic gastric cancer. ( Akyol, M; Bayoglu, IV; Can, A; Demir, L; Dirican, A; Erten, C; Kucukzeybek, Y; Medeni, M; Somali, I; Tarhan, MO, 2012) |
| "Capecitabine seems to be an active and well-tolerated regimen, even in heavily pretreated, frail patients." | 1.38 | Efficacy and safety of capecitabine in heavily pretreated recurrent/metastatic head and neck squamous cell carcinoma. ( Ceruse, P; Fayette, J; Girodet, D; Péron, J; Poupart, M; Ramade, A; Zrounba, P, 2012) |
| " Recently, fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) demonstrated their superiority in first-line therapy." | 1.38 | Influcence of localization of primary tumor on effectiveness of 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: a retrospective study. ( Chauffert, B; Gentil, J; Ghiringhelli, F; Lorgis, V, 2012) |
| "Metastatic colorectal cancer is the second leading cause of cancer death in the United States." | 1.38 | Continuing single-agent bevacizumab as maintenance therapy after induction XELOX (or FOLFOX) plus bevacizumab in first-line treatment of metastatic colorectal cancer. ( de Braud, F; Díaz-Rubio, E; Pietrantonio, F, 2012) |
| "Temozolomide is an active agent in metastatic pancreatic endocrine carcinomas." | 1.37 | First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. ( Chen, DT; Choi, J; Coppola, D; Fine, RL; Helm, J; Kvols, L; Nasir, A; Strosberg, JR, 2011) |
| "Of the 58 patients with distant metastasis, DM6m had developed in 27 (46." | 1.37 | CA 19-9 level as indicator of early distant metastasis and therapeutic selection in resected pancreatic cancer. ( Han, SS; Hong, EK; Kim, DY; Kim, SH; Kim, TH; Lee, WJ; Moon, SH; Park, JW; Park, SJ; Woo, SM; Yoo, T, 2011) |
| "Patients with metastatic colorectal cancers have poor outcomes." | 1.37 | Changing management and survival in patients with stage IV colorectal cancer. ( Ng, S; O'bichere, A; Platell, C; Tebbutt, N, 2011) |
| "Multiorgan metastasis of drug-resistant 4T1 breast tumors was totally resistant to doxorubicin treatment." | 1.37 | Increased expression of P-glycoprotein is associated with doxorubicin chemoresistance in the metastatic 4T1 breast cancer model. ( Bao, L; Dash, S; Haque, A; Hazari, S; Jackson, K; Jetly, R; Moroz, K, 2011) |
| "Prognosis of metastatic gastric cancer is poor and median survival is between 3 and 5 months." | 1.37 | Comparison of cisplatin-5-fluorouracil-folinic acid versus modified docetaxel-cisplatin-5-fluorouracil regimens in the first-line treatment of metastatic gastric cancer. ( Abali, H; Aksoy, S; Budakoglu, B; Kos, FT; Odabaş, H; Oksuzoglu, B; Ozdemir, N; Uncu, D; Zengin, N, 2011) |
| "However, its role in colorectal cancer (CRC) pathobiology and clinical relevance remains unknown." | 1.37 | Overexpression of neurone glial-related cell adhesion molecule is an independent predictor of poor prognosis in advanced colorectal cancer. ( Chan, JY; Ong, CW; Salto-Tellez, M, 2011) |
| "Squamous cell cancer of the anal canal (anal cancer) is a rare disease but with worldwide increasing incidence." | 1.37 | Single-agent paclitaxel in advanced anal cancer after failure of cisplatin and 5-fluorouracil chemotherapy. ( Abbas, A; Fakih, M; Nehme, E, 2011) |
| "Approximately 30% of patients with breast cancer will develop metastatic breast disease." | 1.37 | Clinical roundtable monograph. Current treatment options for metastatic breast cancer: what now? ( O'Shaughnessy, JA; Perez, EA; Rugo, HS, 2011) |
| "Approximately 30% of patients with breast cancer will develop metastatic breast disease." | 1.37 | Current treatment options for metastatic breast cancer: what now? ( O'Shaughnessy, JA; Perez, EA; Rugo, HS, 2011) |
| "Patients with histologically proven gastric cancer and measurable metastatic disease received docetaxel 75 mg/m(2) as a 1-h intravenous infusion on day 1, and oral etoposide 50 mg/m(2) once daily on days 1-5, every 3 weeks until disease progression or unacceptable toxicities." | 1.36 | Docetaxel combined with oral etoposide as second-line treatment for advanced gastric carcinoma after failure of platinum- and fluoropyrimidine-based regimens. ( Alici, S; Benekli, M; Buyukberber, S; Camci, C; Coskun, U; Dane, F; Gumus, M; Kalender, ME; Kaya, AO; Ozturk, B; Sevinc, A; Uncu, D; Yaman, E; Yildiz, R, 2010) |
| "This patient with advanced breast cancer accompanied by distant metastasis responded to trastuzumab/docetaxel combination therapy." | 1.36 | [Efficacy of FEC and trastuzumab/docetaxel combination therapy for metastatic breast cancer]. ( Kanzaki, M; Maeda, M; Matsumoto, K; Miyoshi, S; Takano, Y; Teshima, S; Wakita, T; Yoshinouchi, S, 2010) |
| "The gastric cancer was complicated by malignant pericardial effusion and pleural effusion as well as metastasis to the peripheral lymph nodes and bones." | 1.36 | A case with cardiac tamponade as the first sign of primary gastric signet-ring cell carcinoma treated with combination therapy. ( Qin, YW; Xu, RL; Zhang, BL; Zheng, X, 2010) |
| "However, economic burden of colorectal cancer is considerable." | 1.36 | Clinical and economic evaluation of first-line therapy with FOLFIRI or modified FOLFOX6 for metastatic colorectal cancer. ( Ajima, H; Fujita, K; Ishida, H; Kawara, K; Miwa, K; Mizuno, K; Nakayama, H; Ogata, H; Sasaki, Y; Sunakawa, Y; Takahashi, H; Yamashita, K, 2010) |
| "(51)Cr-prelabelled colon cancer cells (simulating 'circulating tumor cells', CTCs) were added to human peripheral blood and exposed to staurosporine (ST) to increase carcinoembryonic antigen (CEA) expression." | 1.36 | Detection of circulating tumor cells is improved by drug-induced antigen up-regulation: preclinical and clinical studies. ( Aquino, A; Balduzzi, A; Bonmassar, E; Bonmassar, L; Caporaso, P; Cappelletti, D; Cardillo, A; Concolino, F; D'Atri, S; De Vecchis, L; Formica, V; Fossile, E; Graziani, G; Greiner, JW; Prete, SP; Roselli, M; Scoppola, A; Torino, F, 2010) |
| "For patients with advanced breast cancer, overall response rates were 41% for TN tumours and 31% for others (P = 0." | 1.35 | Platinum-based chemotherapy in triple-negative breast cancer. ( Arnedos, M; Ashley, S; Johnston, S; Nerurkar, A; Popat, S; Sirohi, B; Smith, IE; Walsh, G, 2008) |
| "Abdominal CT revealed metastases to para-aortic lymph node, so our diagnosis was unresectable sigmoid colon cancer." | 1.35 | [A case of sigmoid colon cancer with metastases of para-aortic lymph nodes treated with curative resection after irinotecan plus 5-fluorouracil and l-leucovorin combination chemotherapy]. ( Fukazawa, A; Hayashi, T; Konno, H; Kurachi, K; Nakajima, A; Nakamura, K; Nakamura, T; Suzuki, S, 2008) |
| "Liver metastases (n = 93) along with primary tumors (n = 48) were analyzed for K-Ras mutations (codons 12 and 13), p53 mutations (exons 4-9), p53 polymorphism (codon 72), thymidylate synthase (TS) polymorphism (28-bp repeats including G>C mutation), methylenetetrahydrofolate reductase polymorphism (677C>T, 1298A>C), thymidylate synthase (TS) activity, dihydropyrimidine dehydrogenase activity, folylpolyglutamate synthase activity, and p53 protein expression." | 1.35 | K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. ( Benchimol, D; Chazal, M; Delpero, JR; Etienne-Grimaldi, MC; Formento, JL; Formento, P; François, E; Francoual, M; Laurent-Puig, P; Letoublon, C; Milano, G; Pezet, D; Renée, N; Seitz, JF, 2008) |
| " Prospective trials are required to assess whether dosing adjustments based on neutropaenia may improve chemotherapy efficacy." | 1.35 | Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX. ( Inaba, Y; Matsuo, K; Muro, K; Najima, M; Sato, Y; Shitara, K; Takahari, D; Ura, T; Yamaura, H; Yokota, T, 2009) |
| "Depth of tumor invasion, lymph node metastasis, and differentiation were noted to be significantly correlated with the expression of this antigen in gastric carcinoma." | 1.35 | Serum 3'-sulfo-Lea indication of gastric cancer metastasis. ( Bao, WQ; Guo, L; Sheng, WQ; Wu, LH; Wu, XZ; Zhang, HL; Zheng, J, 2009) |
| " Grade 3 or 4 hematological toxicities were leukocytopenia in four patients, and neutropenia in 12 patients, while non-hematological toxicities such as nausea, anorexia and sensory neuropathy occurred in only one patient each adverse event." | 1.35 | The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer. ( Hattori, M; Honda, I; Kato, N; Kobayashi, D; Matsushita, H; Okochi, O; Tsuboi, K, 2009) |
| "Metastatic gastric cancer remains an incurable disease, with a relative 5-year survival rate of 7%-27%." | 1.35 | New perspectives in the treatment of advanced or metastatic gastric cancer. ( Ferrara, D; Manzione, L; Rosati, G, 2009) |
| "Seventy-six metastatic colorectal cancer patients receiving cetuximab plus FOLFIRI or FOLFOX-4 chemotherapy were enrolled." | 1.35 | Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer. ( Chang, YT; Chen, CW; Chu, KS; Lin, SR; Lu, CY; Tsai, HL; Wang, HM; Wang, JY; Yeh, YS; Yen, LC, 2009) |
| "In this study, we generated a dual cancer-specific targeting vector system by using PEGylation and the telomere reverse transcriptase (TERT) promoter and attempted to treat experimental metastases through systemic administration of the vectors." | 1.35 | Systemic administration of a PEGylated adenovirus vector with a cancer-specific promoter is effective in a mouse model of metastasis. ( Eto, Y; Mizuguchi, H; Morishige, T; Mukai, Y; Nakagawa, S; Okada, N; Okada, Y; Watanabe, H; Yao, X; Yoshioka, Y, 2009) |
| "Seven of the 45 had distant metastasis." | 1.35 | [Chemotherapy with MTX, 5-FU and CDGP for treatment of newly diagnosed head and neck cancer]. ( Enomoto, T; Enomoto, Y; Kitano, H; Morizane, R; Nakahara, K; Nosaka, A; Sakoda, T, 2009) |
| "To explore the potential markers of colorectal cancer metastasis and the influence of 5-FU on differentially expressed proteins by using proteomic technology, and to elucidate the mechanism of colorectal cancer metastasis." | 1.35 | [Proteomic research of biomarker of colorectal cancer metastasis]. ( Chen, HQ; Chu, ZX; Huang, L; Ma, YL; Peng, JY; Qin, HL; Shen, TY; Zhang, M; Zhang, P; Zhou, YK, 2009) |
| "The presence of ECE in breast cancer is positively related with tumor size and the number of positive lymph nodes." | 1.35 | [Clinical impact of extracapsular extension of axillary lymph node metastases in breast cancer]. ( Cao, WF; Cao, XC; Hao, XS; Ning, LS; Niu, Y; Song, YQ; Zhang, B; Zhao, HM, 2009) |
| "Adjuvant treatment of early breast cancer has changed considerably in recent years, and the majority of patients are currently treated with the most active single agents in this setting." | 1.35 | [Role of adjuvant chemotherapy in the choice of chemotherapeutic treatment of metastatic breast cancer]. ( Conti, F; Di Lauro, L; Foggi, P; Lopez, M; Vici, P; Viola, G, 2009) |
| "All 35 patients had metastatic pancreatic cancer (94% liver, 6% lung sites)." | 1.35 | The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. ( Andrade, R; Chabot, J; Desai, M; Fine, RL; Fogelman, DR; Guba, S; Schreibman, SM; Sherman, W; Strauss, J, 2008) |
| "Capecitabine was administered at a fixed dose of 2000 mg daily without interruptions." | 1.35 | Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors. ( Battistelli, S; Civitelli, S; Fiaschi, AI; Francini, E; Francini, G; Lorenzi, M; Marsili, S; Pascucci, A; Petrioli, R; Roviello, F; Tanzini, G, 2008) |
| "Treatment with the combination of (177)Lu-octreotate and capecitabine was feasible and safe considering acute and subacute side effects." | 1.35 | Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours. ( de Herder, WW; Kam, BL; Krenning, EP; Kwekkeboom, DJ; van Aken, MO; van Essen, M, 2008) |
| "Sixty-two patients with advanced gastric cancer previously treated were eligible for the study." | 1.35 | Treatment outcomes of oxaliplatin, 5-FU, and leucovorin as salvage therapy for patients with advanced or metastatic gastric cancer: a retrospective analysis. ( Choi, CW; Choi, IK; Choi, YS; Kim, BS; Kim, DS; Kim, JS; Kim, SJ; Kim, YH; Oh, SC; Park, KH; Seo, HY; Seo, JH; Shin, SW; Sung, HJ, 2009) |
| "4-year local-regional control, distant metastasis-free survival, disease-free survival and overall survival rates were 76." | 1.35 | Definitive chemoirradiation for resectable head and neck cancer: treatment outcome and prognostic significance of MRI findings. ( Chan, KY; Chen, YH; Cheng, JC; Cheng, SH; Jian, JJ; Tsai, SY; Yen, KC, 2008) |
| "The rate of distant metastases increased from 18." | 1.34 | Prognostic groups in 1,676 patients with T3 rectal cancer treated without preoperative radiotherapy. ( Eriksen, MT; Haffner, J; Wibe, A; Wiig, JN, 2007) |
| "Goblet cell appendiceal carcinoids represent rare tumors that exhibit histologic features of both adenocarcinomas and neuroendocrine tumors." | 1.34 | Goblet cell carcinoid tumors (adenocarcinoid) of the appendix. ( Baishnab, E; Caplin, ME; Standish, RA; Toumpanakis, C; Winslet, MC, 2007) |
| "Of the 223 patients, 32 had distant metastases but palliative gastrectomy (resected metastatic), 82 had recurrent disease after previous curative gastrectomy (recurrent), and 109 had distant metastases without gastrectomy (initially metastatic)." | 1.34 | Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis. ( Chang, HM; Kang, HJ; Kang, YK; Kim, TW; Kim, WK; Lee, JL; Lee, JS; Lee, SS; Ryu, MH, 2007) |
| "Liver metastases are the most common cause of death in gastric ECs, and their control is very important for improving the poor prognosis associated with the disease." | 1.34 | A successful treatment for metastatic liver tumors from endocrine carcinoma of the stomach. ( Fujiyama, Y; Nishimura, M, 2007) |
| "In order to develop a model of liver metastasis of human gastrointestinal cancer cells, we examined the potential of 10 human colon and stomach cancer cell lines (HT-29, WiDr, HCT-116, HCT-15, HCC-2998, MKN7, MKN28, MKN45, MKN74 and St-4) to form liver metastases in nude mice." | 1.34 | Development and characterization of a model of liver metastasis using human colon cancer HCT-116 cells. ( Ishizu, K; Makuuchi, H; Sadahiro, S; Sunose, N; Tsuruo, T; Yamazaki, K; Yamori, T, 2007) |
| "Here, we report a case of metastatic rectal cancer showing a complete response (CR) to cycle 4 in FOLFIRI regimen, while maintaining a CR status for over 11 months and good QOL, as a result of chemotherapy with 4 cycles of FOLFIRI followed by UFT." | 1.34 | [A case of metastatic rectal cancer showing a sustained complete response to chemotherapy with FOLFIRI followed by UFT]. ( Baba, K; Matsuda, M; Tashima, R; Yamashita, Y; Yokoyama, S, 2007) |
| "In this study we propose for the first time a limited sampling strategy to estimate the individual pharmacokinetic parameters of both irinotecan and SN-38 in patients treated with the irinotecan plus 5-fluorouracil (FOLFIRI) regimen." | 1.34 | A limited sampling strategy to estimate the pharmacokinetic parameters of irinotecan and its active metabolite, SN-38, in patients with metastatic digestive cancer receiving the FOLFIRI regimen. ( Abderrahim, AG; Bressolle, FM; Duffour, J; Pinguet, F; Poujol, S; Ychou, M, 2007) |
| "Liver metastasis is an important prognostic factor in colorectal cancer." | 1.34 | Benefit of FOLFOX to unresectable liver metastases secondary from colorectal carcinoma in an oncologic emergency. ( Higuchi, R; Koda, K; Kosugi, C; Sugimoto, M; Suzuki, M; Takenoue, T; Tezuka, T; Watayo, Y; Yagawa, Y; Yamamoto, S; Yamazaki, M; Yasuda, H, 2007) |
| "Twenty-six patients with non-metastatic rectal cancer >T1 on pathologic TNM staging who underwent primary laparoscopic surgery were considered for comparison." | 1.34 | Laparoscopic total mesorectal excision after neoadjuvant chemoradiotherapy. ( Bona, S; Elmore, U; Furlan, N; Romario, UF; Rosati, R, 2007) |
| "The 5-year distant metastasis-free survival rate, with and without adjuvant chemotherapy, was 97% and 96%, respectively." | 1.33 | Prognostic significance of parapharyngeal space venous plexus and marrow involvement: potential landmarks of dissemination for stage I-III nasopharyngeal carcinoma. ( Chan, KY; Cheng, SH; Chong, V; Chu, NM; Feng, AC; Hong, CF; Hsieh, CY; Huang, AT; Jian, JJ; Lin, CY; Lin, YC; Tan, TD; Tsai, SY; Yen, KL, 2005) |
| "With these fluorescent tools, tumors and metastasis in host organs can be externally imaged down to the single-cell level." | 1.33 | Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy. ( Hoffman, RM, 2005) |
| "However, long-term survival of cytokine-treated, advanced renal cell carcinoma (RCC) patients remains a rare event and, thus, emphasizes the need for further investigations toward more effective therapies." | 1.33 | Metastatic renal carcinoma long-term survivors treated with s.c. interferon-alpha and s.c. interleukin-2. ( Atzpodien, J; Reitz, M, 2005) |
| "The lymph node status of 73 resectable gastric cancer patients was analyzed preoperatively by computed tomography (CT), ultrasonography and magnetic resonance, and the OPRT activity of collected tumor tissue was measured." | 1.33 | Impact of orotate phosphoribosyl transferase activity as a predictor of lymph node metastasis in gastric cancer. ( Futagawa, S; Kitajima, M; Nishimura, K; Noguchi, H; Ochiai, T; Okada, T; Ouchi, M; Sugitani, M; Takahashi, Y; Tsuruoka, Y; Yamada, M, 2005) |
| "Endpoints were recurrence and distant metastasis rates, overall survival (OS) and disease-free survival (DFS) at 5 and 10 years." | 1.33 | Long-term survival after concomitant chemoradiotherapy prior to surgery in advanced cervical carcinoma. ( Buttarelli, M; Goncalves, A; Gonzague-Casabianca, L; Houvenaeghel, G; Lelievre, L; Moutardier, V; Resbeut, M, 2006) |
| "Carcinoid tumors are rare and often resistant to chemotherapy agents." | 1.33 | Oxaliplatin-based chemotherapy for the treatment of a metastatic carcinoid tumor. ( Ajani, JA; Tetzlaff, ED, 2005) |
| "To estimate the risk of venous thrombosis associated with pancreatic malignancies we followed a cohort of patients with pancreatic cancer (n = 202)." | 1.33 | High risk of venous thrombosis in patients with pancreatic cancer: a cohort study of 202 patients. ( Blom, JW; Osanto, S; Rosendaal, FR, 2006) |
| "Drug-induced immune thrombocytopenia (DITP) should be considered in patients who experience a sudden, isolated drop in platelet levels while being treated with chemotherapeutic agents, especially when adequate numbers of megakaryocytes are present in the bone marrow." | 1.33 | Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin. ( Aster, RH; Blank, J; Curtis, BR; Kaliszewski, J; Marques, MB; McFarland, JG; Nabelle, L; Saif, MW, 2006) |
| "Microsatellite instability is a recognised pathway of colorectal carcinogenesis responsible for about 15% of all sporadic colorectal cancers." | 1.33 | 5-fluorouracil (5FU) treatment does not influence invasion and metastasis in microsatellite unstable (MSI-H) colorectal cancer. ( Kaufman, A; Ramanathan, P; Robinson, BG; Schnitzler, M; Warusavitarne, J, 2006) |
| "(1) The prognosis for metastatic colorectal cancer is grim." | 1.33 | Bevacizumab: new drug. Metastatic colorectal cancer: good in theory, not in practice. ( , 2006) |
| "Bone metastases were the most frequent (83%)." | 1.33 | [Metastatic nasopharyngeal carcinoma: clinical study and therapeutic results of 95 cases]. ( Daoud, J; Drira, MM; Frikha, M; Ghorbel, A; Karray, H; Khanfir, A, 2006) |
| "CCL-51 breast cancer nodules suppressed the growth of uninjected metastatic tumor nodules in the lung." | 1.33 | Antitumor immune response induced by i.t. injection of vector-activated dendritic cells and chemotherapy suppresses metastatic breast cancer. ( Akbulut, H; Akbulut, KG; Deisseroth, A; Maynard, J; Tang, Y; Zhang, L, 2006) |
| "Under the diagnosis of multiple lung metastases, the patient was hospitalized and received intensive chemotherapy with docetaxel 40 mg/week (day 1), 5-fluorouracil 500 mg/day (days 1-5), cisplatin 10 mg/day (days 1-5)." | 1.33 | A case of early relapsed multiple lung metastases after esophagectomy successfully treated with S-1/cisplatin therapy after docetaxel/5-fluorouracil/cisplatin therapy. ( Honda, J; Miyoshi, T; Seike, J; Tangoku, A; Umemoto, A; Yoshida, T, 2006) |
| "The most common sites of distant recurrence are represented by lung, liver and bone while brain and breast metastases are rare." | 1.33 | Successful outcome after combined chemotherapeutic and surgical management in a case of esophageal cancer with breast and brain relapse. ( Cossu Rocca, P; Costantino, S; Fadda, GM; Farris, A; Pinna, MA; Piredda, G; Putzu, C; Sanna, G; Santeufemia, DA; Sarobba, MG, 2006) |
| "Capecitabine was interrupted, discontinued or given at an adjusted dose in 13 (15%) patients because of acute toxicity." | 1.33 | Concurrent capecitabine and upper abdominal radiation therapy is well tolerated. ( Abbruzzese, JL; Baschnagel, A; Crane, CH; Das, P; Delclos, ME; Evans, DB; Janjan, NA; Krishnan, S; Varadhachary, GR; Vauthey, JN; Wolff, RA, 2006) |
| "Breast cancer is a heterogeneous disease, so therapeutic predictive biological markers need to be identified." | 1.33 | Difference in Ki67 and thymidylate synthase expression in primary tumour compared with metastatic nodes in breast cancer patients. ( Aragona, F; Barresi, E; Cabibi, D; Calascibetta, A; Martorana, A; Rausa, L; Sanguedolce, R, 2006) |
| "Patients with unresectable distant metastasis are not suitable candidates for surgical resection and intraoperative radiation therapy, whereas those with resectable metastasis are potential candidates." | 1.32 | Indicators for surgical resection and intraoperative radiation therapy for pelvic recurrence of colorectal cancer. ( Hashiguchi, Y; Kato, S; Kazumoto, T; Nishimura, Y; Sakamoto, H; Sakura, M; Sekine, T; Tanaka, Y, 2003) |
| "First, the patient developed severe encephalopathy following a high-dose chemotherapy protocol commonly used in the treatment of metastatic breast carcinoma and second, the encephalopathy involved primarily deep gray matter structures rather than white matter." | 1.32 | Fatal chemotherapy-induced encephalopathy following high-dose therapy for metastatic breast cancer: a case report and review of the literature. ( Cossaart, N; Johnson, P; Preston, D; SantaCruz, KS; Skikne, BS, 2003) |
| "A remission of lymph node metastasis was accurately shown by rES in 17/19 cases (90%) and by CT in 10/12 cases (83%)." | 1.32 | [Preoperative diagnostic procedures in locally advanced rectal carcinoma (> or =T3 or N+). What does endoluminal ultrasound achieve at staging and restaging (after neoadjuvant radiochemotherapy) in contrast to computed tomography?]. ( Becker, H; Füzesi, L; Ghadimi, BM; Jakob, C; Langer, C; Liersch, T; Markus, PM; Müller, D; Siemer, A, 2003) |
| "Generalized metastases showed substantial progression." | 1.32 | Lung carcinoma with congenital plantar keratoderma as a variant of Clarke-Howel-Evans syndrome. ( Bonnekoh, B; Franke, I; Gollnick, H; Grundmann, JU; Weisshaar, E, 2003) |
| "Because of the resistance of pancreatic cancer against radiation and/or chemotherapy surgery is still the only possibility for cure." | 1.32 | [Operative management in the treatment of pancreatic cancer]. ( Büchler, MW; Fischer, L; Friess, H; Uhl, W; Z'graggen, K, 2003) |
| "Our results indicate that disseminated breast cancer cells in BM can survive first-line adjuvant chemotherapy." | 1.32 | Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy. ( Braun, S; Coith, C; Ebel, S; Hemsen, A; Jänicke, F; Kentenich, C; Oberhoff, C; Pantel, K; Riethdorf, S; Thurm, H; Wallwiener, D, 2003) |
| " However, only a few pharmacokinetic data of 5-FU during chronomodulated infusion are available but up to now not for oxaliplatin." | 1.32 | Pharmacokinetics of oxaliplatin during chronomodulated infusion in metastatic gastrointestinal cancer patients: a pilot investigation with preliminary results. ( Höffken, K; Hoffmann, A; Merkel, U; Roskos, M; Wedding, U, 2003) |
| " Oral administration of RDP58 significantly decreased the incidence of diarrhea and improved the survival rates of mice treated with toxic doses of CPT-11 or 5-fluorouracil." | 1.32 | Oral RDP58 allows CPT-11 dose intensification for enhanced tumor response by decreasing gastrointestinal toxicity. ( Belmar, N; Buelow, R; Fong, T; Huang, L; Zhao, J, 2004) |
| "Finally, RhoB inhibits melanoma metastasis to the lung in a mouse model." | 1.32 | Akt mediates Ras downregulation of RhoB, a suppressor of transformation, invasion, and metastasis. ( Cheng, J; Djeu, JY; Jiang, K; Sebti, S; Sun, J; Wei, S, 2004) |
| "We report a patient with metastatic colon cancer who developed a hypersensitivity reaction to oxaliplatin during the sixth cycle of combination chemotherapy with oxaliplatin, high-dose 5-fluorouracil and leucovorin." | 1.32 | Hypersensitivity reactions to oxaliplatin: a case report and the success of a continuous infusional desensitization schedule. ( Chang, MC; Chang, YF; Hsieh, RK; Huang, MJ; Lim, KH; Lin, HC; Lin, J; Su, YW, 2004) |
| "Locoregionally advanced, stage IV head and neck cancer has traditionally carried a poor prognosis." | 1.32 | Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. ( Brockstein, B; Fung, BB; Haraf, DJ; Kies, MS; Mittal, BB; Pelzer, H; Portugal, L; Rademaker, AW; Rosen, F; Stenson, KM; Vokes, EE; Weichselbaum, RW; Wenig, B; Witt, ME, 2004) |
| "Diarrhea was the major adverse effect of UFT/LV that made patients reduce dosage." | 1.31 | Oral uracil/ftorafur (UFT) plus leucovorin as first-line chemotherapy and salvage therapy with weekly high-dose 5-fluorouracil/leucovorin for the treatment of metastatic colorectal cancer. ( Chen, JS; Hsu, KC; Tang, R; Wang, JY; Yang, TS, 2002) |
| "Ovarian metastasis is frequent." | 1.31 | Adenocarcinoid of the appendix vermiformis: complete and persistent remission after chemotherapy (folfox) of a metastatic case. ( Blanchot, J; Boucher, E; Corbinais, S; Garin, L; Le Guilcher, P; Raoul, JL, 2002) |
| "5-Fluorouracil (5-FU) was given as a bolus (500-1000 mg/m2/day) during the first and last weeks of RT in 22 patients, whereas continuous 5-FU (225 mg/m2/day) was given to 3 patients." | 1.31 | Unresectable adenocarcinoma of the pancreas: patterns of failure and treatment results. ( Latona, C; Paulino, AC, 2000) |
| "Eight patients had synchronous distant metastases." | 1.31 | Preoperative radiation with concurrent 5-fluorouracil for locally advanced T4-primary rectal cancer. ( Grabenbauer, GG; Hohenberger, W; Papadopoulos, T; Rödel, C; Sauer, R; Schick, C, 2000) |
| "225 patients with squamous cell carcinoma of the oesophagus were prospectively studied." | 1.31 | Epithelial cells in bone marrow of oesophageal cancer patients: a significant prognostic factor in multivariate analysis. ( Busch, R; Roder, RJ; Rosenberg, R; Thorban, S, 2000) |
| "We discovered metastases in 6 patients (6%) after preoperative therapy." | 1.31 | [The importance of delay in patients with tumors exemplified by pretreatment of locally advanced rectal carcinoma]. ( Gretschel, S; Rau, B; Riess, H; Schlag, PM; Wust, P, 2000) |
| "Final diagnosis stated a multilocular metastasising gastric cancer with infiltration of bone, peritoneum and dura and signet-cell infiltration of the bone marrow." | 1.31 | [Hemorrhagic diathesis as initial symptom of stomach carcinoma]. ( Dempke, W; Kellner, O; Schmoll, HJ; von Poblozki, A; Wolf, HH, 2000) |
| "Capecitabine may inhibit the growth and metastasis of HCC." | 1.31 | [The expression of platelet-derived endothelial cell growth factor in liver cancer]. ( Fan, J; Tang, Z; Zhou, J, 2000) |
| "Its expression in esophageal cancer, however, has not been reported." | 1.31 | Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. ( Fujii, Y; Kato, J; Kudo, J; Kuwabara, Y; Mitani, M; Mitsui, A; Moriyama, S; Nishiwaki, T; Sato, A; Shinoda, N; Toyama, T, 2001) |
| "We found that the hazard function of metastasis in time presented two peaks of incidence at 20 and 60 months, respectively." | 1.31 | Angiogenesis sustains tumor dormancy in patients with breast cancer treated with adjuvant chemotherapy. ( Biganzoli, E; Bonoldi, E; Boracchi, P; Fanelli, M; Gasparini, G; Morabito, A, 2001) |
| "The 3-year metastasis-free survival rates were 49." | 1.31 | Evaluation of cytokeratin-19 mRNA as a tumor marker in the peripheral blood of nasopharyngeal carcinoma patients receiving concurrent chemoradiotherapy. ( Chen, KY; Jan, JS; Liang, WM; Lin, JC; Wang, WY; Wei, YH, 2002) |
| "Patients with advanced squamous cell head and neck cancer were treated with hyperfractionated radiation therapy (72 Gy at 1." | 1.31 | Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer With hyperfractionated radiation and concurrent chemotherapy. ( Adelstein, DJ; Carroll, MA; Esclamado, RM; Lavertu, P; Rybicki, LA; Saxton, JP; Strome, M; Wood, BG, 2002) |
| "The failure to reduce distant metastasis and improve survival may have related in part to the more advanced disease stage in our patients and the relatively low compliance rate of adjuvant chemotherapy." | 1.31 | Concomitant chemoirradiation for stage III-IV nasopharyngeal carcinoma in Chinese patients: results of a matched cohort analysis. ( Au, GK; Choy, D; Chua, DT; Sham, JS, 2002) |
| "Since metastases to the liver, left adrenal gland, and Douglas' pouch were detected in addition to ascites and bilateral hydronephrosis, the tumor was judged unresectable and systemic chemotherapy with TS-1 was begun." | 1.31 | [A case in which TS-1, an orally-administered 5-FU chemotherapeutic agent, showed marked effectiveness against scirrhous type gastric cancer with multiple organ metastases]. ( Araki, S; Asakura, R; Itou, A; Kobayashi, K; Naganuma, J; Teruya, M; Yanagida, O, 2002) |
| "Chemoradiotherapy combined with hyperthermia was administered to 35 patients with advanced esophageal carcinoma who either required preoperative treatment or had nonresectable disease." | 1.30 | Clinical results of treatment of advanced esophageal carcinoma with hyperthermia in combination with chemoradiotherapy. ( Fujimaki, M; Katoh, H; Sakamoto, T; Shimizu, T; Takemori, S; Tazawa, K; Yamashita, I, 1997) |
| "Capecitabine was also much safer, particularly much less toxic to the intestinal tract, than the other compounds, indicating higher therapeutic indices." | 1.30 | Antitumor activities of a novel fluoropyrimidine, N4-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine (capecitabine). ( Fukase, Y; Ishikawa, T; Ishitsuka, H; Sekiguchi, F; Yamamoto, T, 1998) |
| "However, the presence of metastases separate from the pituitary in the central nervous system or at a distance is necessary to designate pituitary tumors as carcinomas, i." | 1.30 | The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors. ( Besser, GM; Grossman, AB; Kaltsas, GA; Monson, JP; Mukherjee, JJ; Plowman, PN, 1998) |
| "Capecitabine (Xeloda) is a rationally designed oral, tumor-selective fluoropyrimidine carbamate aimed at preferential conversion to 5-fluorouracil (5-FU) within the tumor." | 1.30 | Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. ( Banken, L; Cassidy, J; Glynne-Jones, R; Goggin, T; Reigner, B; Roos, B; Schüller, J; Twelves, C; Utoh, M; Weidekamm, E, 1999) |
| "Lung metastasis in mice bearing subcutaneous tumors was significantly inhibited by HCFU at doses of 100-150 mg kg(-1) day(-1) without severe toxic side-effects, when orally administered three times per week either from week 4 or week 6 to 9 weeks after implantation." | 1.30 | Induction of apoptosis in metastatic foci from human gastric cancer xenografts in nude mice and reduction of circulating tumor cells in blood by 5-FU and 1-hexylcarbamoyl-5-fluorouracil. ( Abe, A; Inada, K; Nakanishi, H; Tatematsu, M; Tsukamoto, T; Yasui, K, 1999) |
| "Distant-metastases-free survival was influenced by the following factors: lymph-node involvement (NO: 82% vs N1 to N3: 68%, p = 0." | 1.30 | [Nasopharyngeal carcinoma: only irradiation or simultaneous radiochemotherapy?]. ( Grabenbauer, GG; Grüner, A; Iro, H; Martus, P; Rödel, C; Sauer, R; Weidenbecher, M, 1999) |
| "The recurrent tumors are suggested to be sensitive to the agents as follows: locally recurrent solid tumors, 5-FU; distantly recurrent solid tumors, 5-FU and CDDP; locally recurrent effusion, CDDP; distantly recurrent effusion, ADR." | 1.29 | Anticancer chemosensitivity changes between the original and recurrent tumors after successful chemotherapy selected according to the sensitivity assay. ( Araya, S; Hayashi, H; Imamura, M; Ishigami, S; Kawabata, K; Masai, Y; Nio, Y; Tamura, K; Tsubono, M, 1995) |
| "In patients with locally advanced cervical cancer, most of the treatment failures occur within the pelvis." | 1.29 | Concomitant chemoradiation prior to surgery in the treatment of advanced cervical carcinoma. ( Boubli, L; Cowen, D; Delpero, JR; Gamerre, M; Gouvernet, J; Houvenaeghel, G; Noirclerc, M; Perez, T; Resbeut, M; Viens, P, 1994) |
| " Increasing the dosage by boost technique above 50." | 1.29 | [Simultaneous radiochemotherapy in locoregional recurrent breast carcinoma after mastectomy. Results in patients with macroscopic residual tumor R2]. ( Renner, H; van Kampen, M, 1994) |
| "Pancreatic cancer is a disease with essentially no effective treatment." | 1.29 | A novel "patient-like" treatment model of human pancreatic cancer constructed using orthotopic transplantation of histologically intact human tumor tissue in nude mice. ( Furukawa, T; Hoffman, RM; Kitajima, M; Kubota, T; Watanabe, M, 1993) |
| " In CCR managed with EC, the independent factors of age, tumor classification, exact tumor location, true vocal cord motion, arytenoid cartilage motion, total dosage of drugs delivered, and number of courses received were tested for potential correlation with survival, local recurrence, nodal recurence, and distant metastasis." | 1.29 | Cisplatin-fluorouracil exclusive chemotherapy for T1-T3N0 glottic squamous cell carcinoma complete clinical responders: five-year results. ( Bassot, V; Brasnu, D; Khayat, D; Laccourreye, H; Laccourreye, O; Ménard, M, 1996) |
| "PKC activity was reduced in tumors derived from mice treated with either DXR or CGP 41251, but not from those derived from mice treated with the combination." | 1.29 | The antitumor activity of doxorubicin against drug-resistant murine carcinoma is enhanced by oral administration of a synthetic staurosporine analogue, CGP 41251. ( Beltran, P; Fan, D; Fidler, IJ; Killion, JJ; O'Brian, CA; Wilson, MR; Yoon, SS, 1995) |
| "Distant metastases occurred in 66 patients (54 percent); five-year rate was 72 percent." | 1.29 | Intraoperative electron and external beam irradiation with or without 5-fluorouracil and maximum surgical resection for previously unirradiated, locally recurrent colorectal cancer. ( Cha, S; Devine, R; Dozois, R; Fieck, JM; Gunderson, LL; Haddock, M; Martenson, JA; Nelson, H; O'Connell, MJ; Wolff, B, 1996) |
| "Pseudomyxoma peritonei is a rare disease caused by a perforated adenoma of the appendix." | 1.29 | Patterns of failure following treatment of pseudomyxoma peritonei of appendiceal origin. ( Sugarbaker, PH; Zoetmulder, FA, 1996) |
| "In 56 patients with a 3d stage gastric cancer regional intraarterial chemotherapy with 5-fluorouracil was used pre- and postoperatively." | 1.29 | [The combined treatment of locally disseminated stomach cancer with intra-arterial regional chemotherapy]. ( Makarkin, NA; Tikhonov, VI; Tuzikov, SA; Zyrianov, BN, 1996) |
| "Twenty-four patients with advanced cancer were treated with 5-Fluorouracil 600 mg/m2 intravenously and interferon-alfa-2b 3 MU subcutaneously both given weekly for 6 weeks followed by a 2-week hiatus." | 1.29 | Weekly 5-fluorouracil and interferon-alfa-2b in metastatic cancer. ( Casal, R; Quan, WD, 1996) |
| "The benefits from medical treatment in colorectal cancer are limited." | 1.28 | Reversal of resistance to doxifluridine and fluorouracil in metastatic colorectal cancer: the role of high-dose folinic acid. ( Bajetta, E; Colleoni, M; de Braud, F; Nelli, P; Nolè, F; Zilembo, N, 1992) |
| " In the present study the pharmacokinetic behavior of 5-FU was investigated in combination with interferon alfa (IFN-alpha-2b) and further after adding the second well-established biomodulating agent folinic acid (FA)." | 1.28 | Influence of interferon alfa-2b with or without folinic acid on pharmacokinetics of fluorouracil. ( Czejka, MJ; Fogl, U; Jäger, W; Micksche, M; Schernthaner, G; Schüller, J, 1992) |
| "Those with metastases in the liver or a lymphangitic pattern on chest x-ray were allowed either a single prior regimen for advanced disease or no therapy for metastatic disease if less than 1 year had elapsed since the completion of adjuvant chemotherapy." | 1.28 | Effective initial therapy of advanced breast cancer with fluorouracil and high-dose, continuous infusion calcium leucovorin. ( Akman, SA; Blevins, C; Doroshow, JH; Leong, LA; Margolin, KA; Morgan, RJ; Raschko, JW; Somlo, G, 1992) |
| "Fifty patients with advanced gastric cancer underwent chemotherapy in accordance with the FAMTX protocol." | 1.28 | [Initial results of combined surgical-medical therapy for metastatic cancer of the stomach]. ( Henne-Bruns, D; Kremer, B; Weh, HJ, 1990) |
| "with metastasis) of whom 3 had recurrent disease." | 1.28 | Cisplatin and 5-FU combined with radiotherapy and surgery in the treatment of squamous cell carcinoma of the esophagus. Palliative effects and tumor response. ( Albertsson, M; Hambraeus, G; Lillo-Gil, R; Mercke, C; Ranstam, J; Samuelsson, L; Tennvall, J; Willén, R, 1991) |
| " Considerable toxic side effects led to a dose reduction of cytostasan and adriamycine in 43 patients without clinical efficacy loss." | 1.28 | [Therapeutic results and toxic side effects of the cytostasan, adriamycin and vincristine combination as second line therapy in metastatic breast cancer]. ( Brockmann, B; Ebeling, K; Geschke, E; Schmidt, UM, 1991) |
| "Twenty-five patients with pretreated advanced colorectal carcinoma were subjected to second-line chemotherapy with sequential high-dose methotrexate and 5-fluorouracil." | 1.28 | Second-line chemotherapy of advanced colorectal cancer with sequential high-dose methotrexate and 5-fluorouracil. ( Airoma, G; Bianco, AR; Caponigro, F; Gridelli, C; Incoronato, P; Palmieri, G; Pepe, R, 1991) |
| "5-Fluorouracil (5-FU) was administered by arterial continuous infusion, Adriamycin (ADM) and mitomycin C (MMC) were given by bolus infusion in the hospital, and continuous arterial 5-FU infusion and ADM low-dose intermittent bolus infusion chemotherapy (AF therapy) were used for outpatients at home." | 1.28 | [Long-term arterial infusion chemotherapy in advanced and recurrent gastric cancer patients at home and an interesting autopsy case]. ( Saito, K; Sato, M; Takagane, A; Terashima, M, 1990) |
| "Neoadjuvant chemotherapy in Hodgkin's disease has improved survival time and tolerance to irradiation, allowing a lowering of the total doses used and the volumes irradiated." | 1.28 | [Radiotherapy with neoadjuvant chemotherapy]. ( Alapetite, C; Baillet, F; Dessard-Diana, B; Housset, M; Jacquillat, C; Michel-Langlet, P, 1989) |
| "Six patients developed distant metastases." | 1.28 | Cisplatin, fluorouracil with leucovorin calcium enhancement, and synchronous accelerated radiotherapy in the management of locally advanced head and neck cancer: a phase II study. ( Hartenstein, RC; Lissner, J; Wendt, TG; Wustrow, TP, 1989) |
| " In bioavailability studies of CF p." | 1.27 | Phase I-II trial of high-dose calcium leucovorin and 5-fluorouracil in advanced colorectal cancer. ( Campbell, J; Creaven, PJ; Herrera, L; Madajewicz, S; Mittelman, A; Perry, A; Petrelli, N; Rustum, YM, 1984) |
| "Chemotherapy results in metastatic breast cancer reached a plateau: Remission rate and duration are nearly equivalent for several regimens but not equitoxic." | 1.27 | [Vinblastine, 5-fluorouracil and prednisone (VFP) as "second-line" chemotherapy. Contribution to the problem of optimal therapy sequence in metastasizing breast carcinoma]. ( Hartlapp, JH; Illiger, HJ; Peiss, J; Vaupel, HA, 1983) |
| "Of 55 patients with esophageal squamous cell carcinoma, 30 with localized disease were treated with a combined modality for curative intent." | 1.27 | Combined modality therapy for esophageal squamous cell carcinoma. ( Asfaw, I; Franklin, R; Hoschner, J; Loh, J; Miller, P; Rosenberg, J; Steiger, Z; Vaishampayan, G, 1983) |
| "Spontaneous metastasis of highly metastatic variants, B16 melanoma BL-6 and colon adenocarcinoma 26 NL-22, was examined." | 1.27 | Spontaneous metastasis of highly metastatic variants of mouse tumors and the effect of drugs on the metastasis. ( Iida, H; Kawabata, H; Naganuma, K; Oh-Hara, T; Sakurai, Y; Tsukagoshi, S; Tsuruo, T; Yamori, T, 1984) |
| "Nevertheless, because breast cancer is one of the most responsive of the solid tumors to cytotoxic drugs, appropriately chosen chemotherapy can relieve symptoms and prolong survival." | 1.27 | Chemotherapy of advanced breast cancer. A general survey. ( Loeb, V; Lyss, AP, 1984) |
| "Distant metastases developed in 40% of patients." | 1.27 | Multimodal treatment of locoregionally advanced breast cancer. ( Blumenschein, GR; Buzdar, AU; Hortobagyi, GN; Montague, ED; Schell, F; Spanos, W; Yap, HY, 1983) |
| "Tumor metastasis was examined after iv inoculation of highly metastatic variants of mouse tumors." | 1.27 | Metastasis after intravenous inoculation of highly metastatic variants of mouse tumors and the effects of several antitumor drugs on the tumors. ( Hori, K; Kawabata, H; Naganuma, K; Sakurai, Y; Tsukagoshi, S; Tsuruo, T; Yamori, T, 1984) |
| "Ninety-one patients with malignant epithelial tumors of the nasopharynx seen in our department from 1970 to 1982 were evaluated." | 1.27 | Carcinoma of the nasopharynx. An analysis of 91 cases and a comparison of differing treatment approaches. ( Barzilay, J; Rahima, M; Rakowsky, E; Sidi, J, 1986) |
| "She died from general metastasis seven months after the radical mastectomy in spite of adjuvant immunochemotherapy." | 1.27 | [A case of bilateral metastatic breast carcinoma from gastric carcinoma]. ( Hanamura, N; Iida, F; Kasuga, Y; Katsuyama, T; Oota, H; Senga, O; Tsuchiya, S, 1986) |
| "Mitomycin C was given to 9 patients as a third-line regimen with resulting 5 NC for 2-4 months." | 1.27 | [Sequential treatment of progressive metastatic colorectal cancer with 5-fluorouracil/folinic acid, dipyramidole and mitomycin C]. ( Farroukh, R; Gerlach, D; Hoffmann, W; Kress, M; Migeod, F; Seeber, S, 1988) |
| "Twenty-three patients with advanced colorectal cancer were treated with folinic acid (200 mg/m2/day 1-5 IV bolus injection) and 5-fluorouracil (400 mg/m2/day 1-5 IV in 15 minutes) every 28 days." | 1.27 | High-dose folinic acid and 5-fluorouracil in advanced colorectal cancer. ( Bartolucci, R; Brugia, M; Buzzi, F; Di Costanzo, F; Padalino, D, 1988) |
| "Forty-four evaluable patients with breast carcinoma previously treated with combination chemotherapy consisting of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) were treated with a combination chemotherapy regimen consisting of doxorubicin (A) (20 mg/m2 on days 1, 8, 15, and 22, repeated every 28 days) and mitomycin (MIT) (10 mg/m2 on day 1, repeated every 28 days)." | 1.27 | Low-dose mitomycin and weekly low-dose doxorubicin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, and 5-fluorouracil. ( Colozza, M; Davis, S; Grignani, F; Tonato, M, 1988) |
| "A case of untreated bladder cancer with an unusual clinical course in a 48-year-old man is reported." | 1.27 | [An autopsy case of untreated bladder cancer]. ( Arai, Y; Ishida, A; Pak, K; Tomoyoshi, T, 1987) |
| "Patients with metastatic breast carcinoma and similar presentations should be considered for prophylactic therapy with allopurinol and hydration before chemotherapy." | 1.27 | Fatal acute tumor lysis syndrome with metastatic breast carcinoma. ( Coonley, CJ; Dyer, MC; Stark, ME, 1987) |
| "Dysgerminomas are highly sensitive not only to irradiation but also to chemotherapy." | 1.27 | [Chemotherapy of dysgerminoma]. ( Brökelmann, J; Hartlapp, JH, 1987) |
| "Among 30 patients with squamous cell carcinoma, five achieved complete response (CR) (17%) and 13 achieved partial response (PR) (43%)." | 1.27 | Cisplatin and 5-FU infusion chemotherapy in advanced, recurrent cancer of the head and neck: an Eastern Cooperative Oncology Group Pilot Study. ( DeConti, RC; Marsh, JC; Milner, LM; O'Donnell, MR; Rowland, KM; Showel, J; Spiers, AS; Stott, PB; Taylor, SG, 1986) |
| "Allopurinol has been shown to ameliorate the myelotoxicity of 5-fluorouracil (5-FU) given as an infusion." | 1.27 | Failure of allopurinol to provide clinically significant protection against the hematologic toxicity of a bolus 5-FU schedule. ( Ahmann, FR; Garewal, H, 1986) |
| "The dominant location of metastasis was the liver in 21 pts (48." | 1.27 | Chemotherapy of advanced gastric cancer: a study of 43 consecutive cases treated with fluorouracil, adriamycin and mitomycin C (FAM). ( Amadori, D; Amadori, M; Biserni, R; Bonaguri, C; Faedi, M; Gentilini, P; Ravaioli, A; Ridolfi, R, 1986) |
| " While the in vitro studies failed to reveal any synergism between 5-FU and MND, pharmacokinetic evaluation revealed that 5-FU clearance was significantly reduced (26." | 1.27 | 5-Fluorouracil-metronidazole combination therapy in metastatic colorectal cancer. Clinical, pharmacokinetic and in vitro cytotoxicity studies. ( Ayoub, J; Bardakji, Z; Besner, JG; Jolivet, J; Langelier, Y, 1986) |
| " Since toxicity is a prominent impediment, the possibility of therapeutic synergy may perhaps be explored at drastically reduced doses of PALA, combined with other modulating measures." | 1.27 | Weekly 5-fluorouracil combined with PALA: toxic and therapeutic effects in colorectal cancer. ( Camacho, FJ; Engstrom, PF; Green, MD; Greenwald, ES; Kaplan, BH; Muggia, FM; Wernz, JC, 1987) |
| "Treatment strategies for metastatic breast cancer are determined by various prognostic factors." | 1.27 | [Chemotherapy of metastasizing breast cancer]. ( Wascher, H, 1985) |
| " 5-FU infusions with allopurinol as used in this regimen appear to offer no therapeutic advantage over a conventional dosing schedule." | 1.27 | Phase II trial of high-dose continuous infusion 5-fluorouracil with allopurinol modulation in colon cancer. ( Ahmann, FR; Garewal, H; Greenberg, BR, 1986) |
| " In pharmacokinetic studies in five patients, both schedules produced prolonged plasma beta-half-lives of 5-FU (96-189 minutes)." | 1.27 | Phase I evaluation and pharmacokinetic study of weekly iv thymidine and 5-FU in patients with advanced colorectal carcinoma. ( Chun, H; Kemeny, N; Lynch, G; Martin, D; Young, C, 1985) |
| "Treatment of colorectal cancer beyond surgical resection has had only minimal success in the past." | 1.27 | Colorectal cancer: speculations on the role of intraperitoneal therapy. ( Muggia, FM, 1985) |
| " The therapy is to be used effectfully only then, when indication, dosage and control of the patients are performed critically and exactly." | 1.26 | [Chemotherapy of malignant solid tumors]. ( Knöll, P; Siering, H, 1980) |
| "Other nonneoplastic gastrointestinal disorders showed an 18% abnormal CSAp titer frequency, of which more than half bordered the upper limit of normalcy." | 1.26 | Colon-specific antigen-p (CSAp). I. Initial clinical evaluation as a marker for colorectal cancer. ( Goldenberg, DM; Nelson, MO; Pant, KD; Shochat, D, 1982) |
| "Seventeen patients with adenocystic carcinoma have received 34 adequate trials of chemotherapy at Princess Margaret Hospital since 1969." | 1.26 | Chemotherapy for adenocystic carcinoma. ( Sutherland, DJ; Tannock, IF, 1980) |
| "Patients with hepatic metastases have 5-FU TBCs about half that of those found in patients without hepatic involvement." | 1.26 | Clearance of continuously infused 5-fluorouracil in adults having lung or gastrointestinal carcinoma with or without hepatic metastases. ( Byfield, JE; Floyd, RA; Frankel, SS; Griffiths, JC; Hornbeck, CL, 1982) |
| "Patients without lymph node metastases were not treated." | 1.26 | [Ancillary chemotherapy with trofosfamid, methotrexate and fluoro-uracil in cancer of the breast (author's transl)]. ( Albrecht, M; Jepsen, G; Thomsen, K; Trams, G, 1981) |
| "Among 23 cases of lung metastases 48% had partial or complete remissions, among 16 cases of lymph node metastases 81%, and among 32 cases of bone metastases, 37." | 1.26 | [Combination chemotherapy in metastatic breast cancer]. ( Kuten, A; Lev, L; Mohaliver, J; Robinson, E, 1981) |
| " While earlier results suggested that adjuvant chemotherapy is especially effective in premenopausal women, newer studies and analyses indicate that appropriate dosage and consistent administration of chemotherapy are of decisive importance." | 1.26 | [Results of, and indications for adjuvant chemotherapy in breast cancer]. ( Brunner, KW; Goldhirsch, A; Joss, R; Sonntag, RW; Tschopp, L, 1981) |
| "A significant decrease in the number of metastases was observed in the triple drug therapy, administered for three cycles, BCNU only, and BCNU and adriamycin." | 1.26 | Triple drug chemotherapy in treatment of prostate adenocarcinoma Nb Pr A.I.-III. ( Drago, JR; Worgul, TJ, 1981) |
| "Breast cancer is the most common cause of cancer death in women in this country." | 1.26 | Modern approaches to the treatment of breast cancer. ( Knight, WA; McGuire, WL; Osborne, CK; Yochmowitz, MG, 1980) |
| " Radiation dosage must not be reduced." | 1.26 | [Five-years synchronized radiotherapy in treatment of carcinoma of the head and neck: clinical results, 1970--1974 (author's transl)]. ( Ammon, J; Schwab, W; zum Winkel, K, 1976) |
| "Gastrointestinal cancer has proved exceedingly resistant to chemotherapy efforts." | 1.26 | [Chemotherapy of gastrointestinal cancer (author's transl)]. ( Gropp, C; Havemann, K, 1978) |
| "A group of patients with metastatic breast cancer treated by a distinct drug regimen is analyzed with special respect to clinical and psychological problems." | 1.26 | [Experiences with drug therapy of advanced metastatic carcinoma of the breast (author's transl)]. ( Fernholz, HJ; Frik, W; Nüvemann, M, 1976) |
| " Maintenance therapy was carried out by the administration of these drugs at induction dosage alternated each week as a single 24 hourly intravenous infusion." | 1.26 | Intrahepatic arterial infusion of combination of mitomycin-C and 5-fluorouracil in treatment of primary and metastatic liver carcinoma. ( Das, B; Jaiswal, MS; Misra, NC; Singh, RV, 1977) |
| "A group of 24 patients with colorectal cancer and another group of 28 patients with 13 different primaries were treated." | 1.26 | Treatment of hepatic metastases by percutaneous hepatic arterial infusion. ( Minton, JP; Petrek, JA, 1979) |
| "Eighty-four previously untreated patients with metastatic adenocarcinoma of the large intestine received intravenous ftorafur at a dosage of 2." | 1.26 | Phase II evaluation of ftorafur in previously untreated colorectal cancer: a Southwest Oncology Group Study. ( Buroker, T; Groppe, C; Guy, G; Heilbrun, L; Hoogstraten, B; McCracken, J; Padilla, F; Quagliana, J; Vaitkevicius, VK, 1979) |
| "Thirteen cases of acute nonlymphocytic leukemia occurred among 5455 patients, as compared to 0." | 1.26 | Acute leukemia after alkylating-agent therapy of ovarian cancer. ( Fraumeni, JF; Hoover, R; Reimer, RR; Young, RC, 1977) |
| "Patients with breast cancer may show an increased requirement for thiamin particularly when treated with 5-fluorouracil, and a number of metabolic disturbances in which ascorbic acid may play a central role." | 1.26 | Nutrition and breast cancer. ( Dickerson, JW, 1979) |
| "Relief of pain was noted in two-thirds of the patients." | 1.26 | Intraarterial infusion chemotherapy (5-fluorouracil) in patients with inextirpable or locally recurrent rectal cancer. ( Hafström, L; Jönsson, PE; Landberg, T; Owman, T; Sundkvist, K, 1979) |
| "91 women with metastatic breast cancer, who received prior CTX-5FU or CTX-5FU-PRD, were treated in 3 consecutive clinical trials with either CTX-5FU-PRD-MTX-VCR, MTX-VCR, or MTX-VCR-PRD in order to elucidate whether the effectiveness of 5 drugs was due only to the newly added drugs (MTX-VCR +/- PRD) or whether the previously used drugs (CTX-5FU) were necessary as potentiating agents." | 1.26 | Potentiating role of previously administered agents in the combination chemotherapy of breast cancer. ( Nemoto, T; Rosner, D; Snyderman, M, 1979) |
| "Soft tissue metastases may be more responsive than bony lesions." | 1.26 | Chemotherapy trial with comp-F regimen in advanced adenocarcinoma of prostate. ( Bergreen, PW; Buell, GV; Saiers, JH; Saiki, JH, 1978) |
| "Of the 14 evaluable patients (11 with breast carcinoma and three with sarcoma), one patient with breast carcinoma achieved a partial remission and a second patient with breast carcinoma remained stable." | 1.26 | Amphotericin B and combination chemotherapy in the treatment of refractory metastatic breast carcinoma and sarcoma. ( Blumenschein, GR; Buzdar, AU; Krutchik, AN; Sinkovics, JG, 1978) |
| "Two young women with cancer of the pancreas are described." | 1.26 | Cancer of the pancreas in young adults. ( Butterfield, D; Hobbs, JB; Kune, GA; Sali, A, 1978) |
| "Tests for delayed hypersensitivity to homologous tumor antigen before treatment were positive in 83." | 1.26 | Delayed hypersensitivity reactions in patients with breast cancer. ( Boeva, M; Christov, I; Donchev, T; Markova, R, 1978) |
| "Hepatic hypoglycemia is discussed and the literature is reviewed." | 1.26 | Hypoglycemia secondary to metastases to the liver. A case report and review of the literature. ( Chawla, SK; LoPresti, PA; Sossi, AJ; Soterakis, J; Younus, S, 1977) |
| "Forty-three patients with metastatic breast cancer who had not received prior chemotherapy were divided into two groups on the basis of whether or not a bone marrow examination revealed tumor." | 1.26 | Bone marrow involvement in breast cancer: effect on response and tolerance to combination chemotherapy. ( Bull, JM; Ingle, JN; Simon, RM; Tormey, DC, 1977) |
| "40 patients with primary or metastatic liver malignancies have been treated with hepatic dearterialization, 19 of them in combination with regional infusion with 5-fluoroacil." | 1.26 | Results of liver dearterialization combined with regional infusion of 5-fluorouracil for liver cancer. ( Almersjö, O; Bengmark, S; Hafström, L; Leissner, KH, 1976) |
| "Seventy-two women with metastatic breast cancer were treated with multiple-agent chemotherapy." | 1.26 | Combination chemotherapy in the treatment of advanced breast cancer. ( Dao, TL; Nemoto, T; Rosner, D, 1976) |
| "Eighty-four patients with disseminated breast carcinoma were treated with the combination of hormonal therapy and combination chemotherapy from the time of diagnosis." | 1.26 | Multidisciplinary curative treatment for disseminated carcinoma of the breast. ( Dalcq, JM; Derriks, R; Laurent, C; Mannes, P; Moens, R, 1976) |
| "Most women with "early" breast cancer have distant metastases by the time the primary growth comes to diagnosis." | 1.26 | "Early" and "late" breast cancer: a unified concept for treatment. ( Edelstyn, GA; MacRae, KD, 1976) |
| "A fourth patient with previously treated epidermoid carcinoma of the anus presented with biopsy-proven pulmonary metastasis and was placed on the chemotherapeutic regimen alone." | 1.26 | Multi-modality therapy for epidermoid carcinoma of the anus. ( Newman, HK; Quan, SH, 1976) |
| "Seventeen patients with primary liver cancer were also treated with adriamycin." | 1.26 | Adriamycin in the treatment of cancer. ( Falkson, G; Falkson, HC; van der Merwe, AM; van Dyk, JJ, 1976) |
| "Metastases were from colon cancer in 13 and from other primary cancers in 6." | 1.25 | Hepatic artery ligation and postoperative chemotherapy for hepatic metastases: clinical and pathophysiological results. ( Hallauer, WC; Morton, DL; Mosher, MB; Passaro, E; Rangel, D; Silverstein, MJ; Sparks, FC, 1975) |
| "In evaluating response by sites of metastases, lymph nodes (30%), lung nodules (22%), and subcutaneous deposits (2/3) had the highest incidence of C." | 1.25 | An effective low-dose intermittent cyclophosphamide, methotrexate, and 5-fluorouracil treatment regimen for metastatic breast cancer. ( Catalano, RB; Creech, RH; Engstrom, PF; Mastrangelo, MJ, 1975) |
| "Although breast cancer presents as localized disease and is treated with local modalities, i." | 1.25 | Chemotherapy in the treatment strategy of breast cancer. ( Carbone, PP, 1975) |
| "Generally, metastases responded better than the advanced primaries from which they were derived, except for those from breast tumours." | 1.25 | The influence of site of metastasis on tumour growth and response to chemotherapy. ( Bross, ID; Slack, NH, 1975) |
| "Seventeen patients with metastatic breast carcinoma were treated with a combination of 5-fluorouracil, methotrexate, vincristine, cyclophosphamide and prednisone." | 1.25 | Nonbacterial pneumonitis with multidrug antineoplastic therapy in breast carcinoma. ( Blom, J; Stutz, FH; Tormey, DC, 1973) |
| "There was no clinical evidence of carcinoid syndrome." | 1.25 | 5-Hydroxyindole-secreting rectal carcinoid tumour. ( Cheetham, HD; Murray-Lyon, IM; Sandler, M; Watts, JA; Williams, R, 1972) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 870 (30.02) | 18.7374 |
| 1990's | 319 (11.01) | 18.2507 |
| 2000's | 731 (25.22) | 29.6817 |
| 2010's | 868 (29.95) | 24.3611 |
| 2020's | 110 (3.80) | 2.80 |
| Authors | Studies |
|---|---|
| Jiang, Y | 5 |
| Li, X | 9 |
| Hou, J | 2 |
| Huang, Y | 6 |
| Jia, Y | 3 |
| Zou, M | 2 |
| Zhang, J | 11 |
| Wang, X | 14 |
| Xu, W | 2 |
| Zhang, Y | 12 |
| Dai, H | 1 |
| Huang, M | 2 |
| Qian, J | 2 |
| Liu, J | 3 |
| Meng, C | 1 |
| Li, Y | 5 |
| Ming, G | 1 |
| Zhang, T | 6 |
| Wang, S | 5 |
| Shi, Y | 5 |
| Yao, Y | 2 |
| Ge, S | 1 |
| Ling, Y | 1 |
| Wang, M | 3 |
| Zhu, P | 1 |
| Chen, Z | 4 |
| Yang, L | 7 |
| Stahler, A | 2 |
| Heinemann, V | 22 |
| Schuster, V | 1 |
| Heinrich, K | 1 |
| Kurreck, A | 2 |
| Gießen-Jung, C | 1 |
| Fischer von Weikersthal, L | 5 |
| Kaiser, F | 2 |
| Decker, T | 6 |
| Held, S | 6 |
| Graeven, U | 9 |
| Schwaner, I | 2 |
| Denzlinger, C | 2 |
| Schenk, M | 2 |
| Neumann, J | 2 |
| Kirchner, T | 4 |
| Jung, A | 5 |
| Kumbrink, J | 2 |
| Stintzing, S | 18 |
| Modest, DP | 12 |
| Giuliani, J | 2 |
| Mantoan, B | 1 |
| Bonetti, A | 3 |
| Gupta, S | 2 |
| Biswas, G | 1 |
| Babu, S | 1 |
| Maksud, TM | 1 |
| Lakshmaiah, KC | 1 |
| Patel, JG | 1 |
| Raja, G | 1 |
| Boya, RR | 1 |
| Patil, P | 1 |
| Choudhury, K | 1 |
| Bondarde, SA | 1 |
| Neve, RS | 1 |
| Bhat, G | 1 |
| Mamillapalli, G | 1 |
| Patel, AA | 1 |
| Patel, P | 1 |
| Joshi, N | 1 |
| Bajaj, V | 1 |
| Khan, MA | 1 |
| Lee, YS | 1 |
| Lee, JC | 2 |
| Kim, JH | 13 |
| Kim, J | 2 |
| Hwang, JH | 2 |
| Phelip, JM | 3 |
| Desrame, J | 5 |
| Edeline, J | 1 |
| Barbier, E | 2 |
| Terrebonne, E | 2 |
| Michel, P | 5 |
| Perrier, H | 1 |
| Dahan, L | 6 |
| Bourgeois, V | 1 |
| Akouz, FK | 1 |
| Soularue, E | 1 |
| Ly, VL | 1 |
| Molin, Y | 1 |
| Lecomte, T | 11 |
| Ghiringhelli, F | 8 |
| Coriat, R | 5 |
| Louafi, S | 2 |
| Neuzillet, C | 1 |
| Manfredi, S | 2 |
| Malka, D | 4 |
| Claramunt García, R | 1 |
| Muñoz Cid, CL | 1 |
| Sánchez Ruiz, A | 2 |
| Marín Pozo, JF | 1 |
| Arai, H | 2 |
| Xiao, Y | 1 |
| Millstein, J | 2 |
| Wang, J | 10 |
| Battaglin, F | 3 |
| Kawanishi, N | 1 |
| Jayachandran, P | 1 |
| Soni, S | 2 |
| Zhang, W | 15 |
| Mancao, C | 2 |
| Salhia, B | 2 |
| Mumenthaler, SM | 2 |
| Parikh, AR | 1 |
| Lenz, HJ | 21 |
| Yu, HY | 1 |
| Lee, CY | 1 |
| Lin, LG | 1 |
| Chao, Y | 3 |
| Li, CP | 4 |
| Li, P | 2 |
| Pók-Udvari, A | 1 |
| Klauschen, F | 1 |
| Folprecht, G | 12 |
| Martinelli, E | 4 |
| Mazard, T | 4 |
| Tsuji, A | 7 |
| Esser, R | 2 |
| Cremolini, C | 21 |
| Falcone, A | 39 |
| Zheng, SH | 1 |
| Liu, SR | 1 |
| Wang, HB | 1 |
| Wei, YH | 3 |
| Li, H | 5 |
| Wang, GN | 1 |
| Huang, ZL | 1 |
| Ding, SR | 1 |
| Chen, C | 1 |
| Tao, YL | 2 |
| Li, XH | 2 |
| Glorieux, C | 1 |
| Huang, P | 1 |
| Wu, YF | 1 |
| Xia, YF | 2 |
| Lee, J | 11 |
| Koom, WS | 1 |
| Byun, HK | 1 |
| Yang, G | 1 |
| Kim, MS | 2 |
| Park, EJ | 1 |
| Ahn, JB | 5 |
| Beom, SH | 1 |
| Kim, HS | 7 |
| Shin, SJ | 7 |
| Kim, K | 6 |
| Chang, JS | 1 |
| Yoo, C | 2 |
| Takumoto, Y | 1 |
| Sasahara, Y | 1 |
| Narimatsu, H | 1 |
| Akazawa, M | 1 |
| Jo, H | 1 |
| Lee, MS | 2 |
| Lee, YP | 1 |
| Kim, H | 1 |
| Hong, JY | 2 |
| Park, SH | 9 |
| Park, JO | 8 |
| Park, YS | 12 |
| Lim, HY | 7 |
| Kang, WK | 7 |
| Kim, ST | 4 |
| Ducreux, M | 15 |
| Colombo, A | 1 |
| Rosati, G | 5 |
| Porretto, CM | 1 |
| Tiu, YC | 1 |
| Gong, L | 1 |
| Luo, J | 1 |
| Yang, Y | 5 |
| Tang, Y | 2 |
| Lee, WM | 1 |
| Guan, XY | 1 |
| Iwai, M | 1 |
| Kimura, M | 5 |
| Usami, E | 2 |
| Yoshimura, T | 2 |
| Raga, MG | 1 |
| Pérez, IP | 1 |
| Veiga, RC | 1 |
| Sosa, MM | 1 |
| Aguilera, MJS | 1 |
| Rodríguez, PL | 1 |
| Bonastre, MTT | 1 |
| Urtasun, JA | 1 |
| Abad, LP | 1 |
| Hernández, IB | 1 |
| Fukuda, K | 2 |
| Osumi, H | 3 |
| Yoshino, K | 1 |
| Nakayama, I | 3 |
| Fukuoka, S | 1 |
| Ogura, M | 3 |
| Wakatsuki, T | 4 |
| Ooki, A | 4 |
| Takahari, D | 6 |
| Chin, K | 4 |
| Yamaguchi, K | 10 |
| Shinozaki, E | 7 |
| O'Reilly, EM | 1 |
| Lyskjær, I | 1 |
| Kronborg, CS | 1 |
| Rasmussen, MH | 1 |
| Sørensen, BS | 1 |
| Demuth, C | 1 |
| Rosenkilde, M | 1 |
| Johansen, AFB | 1 |
| Knudsen, M | 1 |
| Vang, S | 1 |
| Krag, SRP | 1 |
| Spindler, KG | 1 |
| Andersen, CL | 1 |
| Karthika, C | 1 |
| Sureshkumar, R | 1 |
| Munemoto, Y | 3 |
| Nakamura, M | 5 |
| Takahashi, M | 4 |
| Kotaka, M | 3 |
| Kuroda, H | 1 |
| Kato, T | 10 |
| Minagawa, N | 1 |
| Noura, S | 1 |
| Fukunaga, M | 7 |
| Kuramochi, H | 4 |
| Touyama, T | 1 |
| Takahashi, T | 8 |
| Miwa, K | 3 |
| Satake, H | 2 |
| Kurosawa, S | 2 |
| Miura, T | 2 |
| Mishima, H | 9 |
| Sakamoto, J | 12 |
| Oba, K | 8 |
| Nagata, N | 6 |
| Khakoo, S | 1 |
| Chau, I | 3 |
| Pedley, I | 1 |
| Ellis, R | 1 |
| Steward, W | 1 |
| Harrison, M | 1 |
| Baijal, S | 1 |
| Tahir, S | 1 |
| Ross, P | 2 |
| Raouf, S | 2 |
| Ograbek, A | 1 |
| Cunningham, D | 22 |
| Bonadio, RC | 1 |
| Amor Divino, PH | 1 |
| Obando, JSM | 1 |
| Lima, KCA | 1 |
| Recchimuzzi, DZ | 1 |
| Kruger, JAP | 1 |
| Saragiotto, DF | 1 |
| Capareli, FC | 1 |
| Hoff, PM | 10 |
| Labriet, A | 2 |
| Lévesque, É | 3 |
| Cecchin, E | 6 |
| De Mattia, E | 3 |
| Villeneuve, L | 2 |
| Rouleau, M | 1 |
| Jonker, D | 3 |
| Couture, F | 5 |
| Simonyan, D | 2 |
| Allain, EP | 1 |
| Buonadonna, A | 10 |
| D'Andrea, M | 4 |
| Toffoli, G | 7 |
| Guillemette, C | 3 |
| Iyikesici, MS | 1 |
| Marmorino, F | 5 |
| Rossini, D | 3 |
| Lonardi, S | 21 |
| Moretto, R | 4 |
| Zucchelli, G | 2 |
| Aprile, G | 11 |
| Dell'Aquila, E | 3 |
| Ratti, M | 1 |
| Bergamo, F | 9 |
| Masi, G | 26 |
| Urbano, F | 2 |
| Ronzoni, M | 10 |
| Libertini, M | 1 |
| Borelli, B | 2 |
| Randon, G | 2 |
| Allegrini, G | 15 |
| Pella, N | 1 |
| Ricci, V | 4 |
| Boccaccino, A | 3 |
| Latiano, TP | 3 |
| Cordio, S | 2 |
| Passardi, A | 6 |
| Tamburini, E | 4 |
| Boni, L | 8 |
| Dho, SH | 1 |
| Cho, EH | 1 |
| Lee, JY | 4 |
| Lee, SY | 1 |
| Jung, SH | 3 |
| Kim, LK | 1 |
| Lim, JC | 1 |
| Ganesh, K | 1 |
| Wu, C | 2 |
| O'Rourke, KP | 1 |
| Szeglin, BC | 1 |
| Zheng, Y | 2 |
| Sauvé, CG | 1 |
| Adileh, M | 1 |
| Wasserman, I | 1 |
| Marco, MR | 1 |
| Kim, AS | 1 |
| Shady, M | 1 |
| Sanchez-Vega, F | 1 |
| Karthaus, WR | 1 |
| Won, HH | 1 |
| Choi, SH | 2 |
| Pelossof, R | 1 |
| Barlas, A | 1 |
| Ntiamoah, P | 1 |
| Pappou, E | 1 |
| Elghouayel, A | 1 |
| Strong, JS | 1 |
| Chen, CT | 1 |
| Harris, JW | 1 |
| Weiser, MR | 1 |
| Nash, GM | 1 |
| Guillem, JG | 1 |
| Wei, IH | 1 |
| Kolesnick, RN | 1 |
| Veeraraghavan, H | 1 |
| Ortiz, EJ | 1 |
| Petkovska, I | 1 |
| Cercek, A | 1 |
| Manova-Todorova, KO | 1 |
| Saltz, LB | 10 |
| Lavery, JA | 1 |
| DeMatteo, RP | 1 |
| Massagué, J | 1 |
| Paty, PB | 1 |
| Yaeger, R | 1 |
| Chen, X | 6 |
| Patil, S | 2 |
| Clevers, H | 1 |
| Berger, MF | 1 |
| Lowe, SW | 1 |
| Shia, J | 1 |
| Romesser, PB | 1 |
| Dow, LE | 1 |
| Garcia-Aguilar, J | 1 |
| Sawyers, CL | 1 |
| Smith, JJ | 1 |
| Legué, LM | 1 |
| van Erning, FN | 1 |
| Bernards, N | 1 |
| Lemmens, VEPP | 1 |
| de Hingh, IHJT | 2 |
| Creemers, GJ | 4 |
| Lim, HH | 1 |
| Hopkins, AM | 1 |
| Rowland, A | 1 |
| Yuen, HY | 1 |
| Karapetis, CS | 1 |
| Sorich, MJ | 1 |
| Wang, D | 4 |
| Xu, L | 1 |
| Fang, W | 2 |
| Cai, X | 2 |
| Wang, Y | 14 |
| Zhao, F | 1 |
| Gu, Y | 1 |
| Liu, M | 2 |
| Yang, J | 2 |
| Cui, X | 1 |
| Zhou, Z | 1 |
| Zhan, H | 1 |
| Ding, K | 1 |
| Tian, X | 1 |
| Yang, Z | 6 |
| Fung, KA | 1 |
| Edil, BH | 1 |
| Postier, RG | 1 |
| Bronze, MS | 1 |
| Fernandez-Zapico, ME | 1 |
| Stemmler, MP | 1 |
| Brabletz, T | 1 |
| Li, YP | 1 |
| Houchen, CW | 1 |
| Li, M | 3 |
| Bang, YJ | 9 |
| Lee, KH | 7 |
| Chiu, CF | 3 |
| Shan, YS | 2 |
| Kim, JS | 10 |
| Chen, JS | 6 |
| Shim, HJ | 1 |
| Rau, KM | 2 |
| Choi, HJ | 2 |
| Oh, DY | 10 |
| Belanger, B | 4 |
| Chen, LT | 5 |
| Iqbal, S | 4 |
| McDonough, S | 1 |
| Ilson, D | 1 |
| Burtness, B | 1 |
| Nangia, CS | 1 |
| Barzi, A | 3 |
| Schneider, CJ | 1 |
| Liu, JJ | 1 |
| Dotan, E | 2 |
| Guthrie, KA | 2 |
| Hochster, HS | 4 |
| Li, L | 6 |
| Yue, GGL | 1 |
| Fung, KP | 2 |
| Yu, J | 5 |
| Lau, CBS | 1 |
| Chiu, PWY | 1 |
| Hu, M | 1 |
| Zhou, X | 3 |
| Guan, K | 1 |
| Huang, L | 4 |
| Hendricks, A | 1 |
| Rosenstiel, P | 1 |
| Hinz, S | 1 |
| Burmeister, G | 1 |
| Röcken, C | 1 |
| Boersch, K | 1 |
| Schafmayer, C | 1 |
| Becker, T | 2 |
| Franke, A | 1 |
| Forster, M | 1 |
| Wan, X | 2 |
| Tan, C | 2 |
| Li, J | 13 |
| Peng, L | 3 |
| Holch, JW | 3 |
| Kiani, A | 3 |
| Heintges, T | 3 |
| Kahl, C | 3 |
| Kullmann, F | 6 |
| Scheithauer, W | 14 |
| Moehler, M | 6 |
| von Einem, JC | 3 |
| Michl, M | 2 |
| Tougeron, D | 3 |
| Sueur, B | 1 |
| Zaanan, A | 3 |
| de la Fouchardiére, C | 2 |
| Sefrioui, D | 1 |
| Aparicio, T | 11 |
| Des Guetz, G | 3 |
| Artru, P | 10 |
| Hautefeuille, V | 2 |
| Moulin, V | 1 |
| Locher, C | 6 |
| Touchefeu, Y | 1 |
| Lecaille, C | 4 |
| Goujon, G | 1 |
| Ferru, A | 1 |
| Evrard, C | 1 |
| Chautard, R | 1 |
| Gentilhomme, L | 1 |
| Vernerey, D | 1 |
| Taieb, J | 11 |
| André, T | 21 |
| Henriques, J | 1 |
| Cohen, R | 1 |
| Chiang, TY | 1 |
| Hsu, HC | 3 |
| Jane, SW | 1 |
| Chen, SC | 3 |
| Miksad, R | 1 |
| Surinach, A | 1 |
| Corvino, FA | 1 |
| Torres, AZ | 1 |
| Mamlouk, K | 2 |
| Pulgar, S | 1 |
| Valderrama, A | 1 |
| Bekaii-Saab, T | 5 |
| Ahn, D | 1 |
| Iveson, T | 3 |
| Carter, AM | 1 |
| Shiu, KK | 1 |
| Spooner, C | 1 |
| Stevens, D | 1 |
| Mullamitha, S | 2 |
| Dercle, L | 1 |
| Lu, L | 1 |
| Schwartz, LH | 1 |
| Qian, M | 1 |
| Tejpar, S | 5 |
| Eggleton, P | 1 |
| Zhao, B | 1 |
| Piessevaux, H | 1 |
| Xu, R | 2 |
| Wang, W | 4 |
| Zhu, B | 2 |
| Lin, X | 4 |
| Ma, D | 1 |
| Zhu, L | 1 |
| Zhao, Q | 1 |
| Nie, Y | 1 |
| Li, Q | 5 |
| Wang, N | 1 |
| Chen, Y | 5 |
| Peng, C | 1 |
| Fang, H | 1 |
| Shen, L | 7 |
| Clarke, SJ | 6 |
| Burge, M | 3 |
| Feeney, K | 1 |
| Gibbs, P | 10 |
| Jones, K | 1 |
| Marx, G | 1 |
| Molloy, MP | 1 |
| Price, T | 5 |
| Reece, WHH | 1 |
| Segelov, E | 2 |
| Tebbutt, NC | 5 |
| Bendell, JC | 7 |
| Sauri, T | 1 |
| Gracián, AC | 1 |
| Alvarez, R | 2 |
| López-López, C | 2 |
| García-Alfonso, P | 10 |
| Hussein, M | 1 |
| Miron, ML | 1 |
| Cervantes, A | 13 |
| Montagut, C | 4 |
| Vivas, CS | 1 |
| Bessudo, A | 1 |
| Plezia, P | 1 |
| Moons, V | 1 |
| Andel, J | 1 |
| Bennouna, J | 8 |
| van der Westhuizen, A | 1 |
| Samuel, L | 1 |
| Rossomanno, S | 1 |
| Boetsch, C | 1 |
| Lahr, A | 1 |
| Franjkovic, I | 1 |
| Heil, F | 1 |
| Lechner, K | 1 |
| Krieter, O | 1 |
| Hurwitz, H | 4 |
| Chen, L | 3 |
| Bi, S | 1 |
| Wei, Q | 1 |
| Zhao, Z | 5 |
| Wang, C | 3 |
| Xie, S | 1 |
| Chen, S | 1 |
| Hua, L | 1 |
| Feng, C | 3 |
| Mo, Q | 1 |
| Wei, M | 1 |
| Shen, Y | 2 |
| Lin, Z | 1 |
| Li, G | 3 |
| Xu, J | 10 |
| Guo, C | 1 |
| Huang, H | 3 |
| Rajan, SAP | 1 |
| Skardal, A | 1 |
| Hall, AR | 1 |
| Innominato, PF | 6 |
| Ballesta, A | 1 |
| Huang, Q | 1 |
| Focan, C | 9 |
| Chollet, P | 5 |
| Karaboué, A | 4 |
| Giacchetti, S | 7 |
| Bouchahda, M | 2 |
| Adam, R | 6 |
| Garufi, C | 6 |
| Lévi, FA | 1 |
| Jiang, T | 2 |
| Chen, H | 4 |
| Zheng, J | 2 |
| Du, B | 1 |
| Yang, B | 2 |
| Liu, Q | 3 |
| Zhong, D | 1 |
| Wang, H | 8 |
| Lin, M | 2 |
| Lai, J | 1 |
| Hou, P | 1 |
| Geissler, M | 2 |
| Martens, UM | 1 |
| Riera-Knorrenschild, J | 1 |
| Greeve, J | 1 |
| Florschütz, A | 1 |
| Wessendorf, S | 1 |
| Ettrich, T | 1 |
| Kanzler, S | 1 |
| Nörenberg, D | 1 |
| Seidensticker, M | 1 |
| Buechner-Steudel, P | 2 |
| Atzpodien, J | 8 |
| Seufferlein, T | 4 |
| Tannapfel, A | 4 |
| Reinacher-Schick, AC | 1 |
| Zhou, Y | 3 |
| Cheng, H | 1 |
| Tian, J | 1 |
| Yang, S | 1 |
| Paluri, RK | 1 |
| Kasi, A | 1 |
| Young, C | 2 |
| Posey, JA | 1 |
| Ma, L | 2 |
| Xu, Y | 3 |
| Liu, Y | 4 |
| Li, W | 5 |
| Cai, J | 1 |
| Wu, AA | 1 |
| Bever, KM | 1 |
| Ho, WJ | 1 |
| Fertig, EJ | 1 |
| Niu, N | 1 |
| Zheng, L | 3 |
| Parkinson, RM | 1 |
| Durham, JN | 1 |
| Onners, B | 1 |
| Ferguson, AK | 1 |
| Wilt, C | 1 |
| Ko, AH | 1 |
| Wang-Gillam, A | 3 |
| Laheru, DA | 1 |
| Anders, RA | 1 |
| Thompson, ED | 1 |
| Sugar, EA | 1 |
| Jaffee, EM | 1 |
| Le, DT | 2 |
| Nilsson, S | 1 |
| Stein, A | 2 |
| Rolfo, C | 1 |
| Kranich, AL | 1 |
| Mann, J | 1 |
| Papadimitriou, K | 1 |
| Theile, S | 1 |
| Amberg, S | 1 |
| Bokemeyer, C | 4 |
| Rinaldi, Y | 4 |
| Pointet, AL | 1 |
| Khemissa Akouz, F | 3 |
| Le Malicot, K | 4 |
| Wahiba, B | 1 |
| Gratet, A | 1 |
| Miglianico, L | 2 |
| Laharie, H | 1 |
| Bouhier Leporrier, K | 1 |
| Thirot Bidault, A | 1 |
| Texereau, P | 2 |
| Gouttebel, MC | 1 |
| Bachet, JB | 9 |
| Lepage, C | 4 |
| Raimondi, A | 2 |
| Di Maio, M | 4 |
| Morano, F | 2 |
| Corallo, S | 2 |
| Antoniotti, C | 10 |
| Rimassa, L | 4 |
| Sartore-Bianchi, A | 1 |
| Tampellini, M | 8 |
| Ritorto, G | 1 |
| Murialdo, R | 3 |
| Clavarezza, M | 3 |
| Zaniboni, A | 14 |
| Adamo, V | 1 |
| Tomasello, G | 12 |
| Petrelli, F | 4 |
| Antonuzzo, L | 4 |
| Giordano, M | 2 |
| Cinieri, S | 4 |
| Longarini, R | 2 |
| Niger, M | 1 |
| Antista, M | 2 |
| Peverelli, G | 1 |
| de Braud, F | 11 |
| Di Bartolomeo, M | 5 |
| Pietrantonio, F | 9 |
| Gürbüz, M | 1 |
| Akkuş, E | 1 |
| Utkan, G | 1 |
| Xiang, L | 2 |
| Ni, T | 1 |
| Jin, F | 2 |
| Deng, J | 1 |
| Shintaro, I | 1 |
| Hanna, DL | 2 |
| Nicolle, R | 1 |
| Blum, Y | 1 |
| Duconseil, P | 1 |
| Vanbrugghe, C | 1 |
| Brandone, N | 1 |
| Poizat, F | 2 |
| Roques, J | 1 |
| Bigonnet, M | 1 |
| Gayet, O | 1 |
| Rubis, M | 1 |
| Elarouci, N | 1 |
| Armenoult, L | 1 |
| Ayadi, M | 1 |
| de Reyniès, A | 1 |
| Giovannini, M | 1 |
| Grandval, P | 1 |
| Garcia, S | 1 |
| Canivet, C | 1 |
| Cros, J | 1 |
| Bournet, B | 1 |
| Buscail, L | 1 |
| Moutardier, V | 2 |
| Gilabert, M | 2 |
| Iovanna, J | 1 |
| Dusetti, N | 1 |
| Grothey, A | 10 |
| Amrane, K | 1 |
| le Pennec, R | 1 |
| Schick, U | 1 |
| Metges, JP | 1 |
| Abgral, R | 1 |
| Pishvaian, MJ | 2 |
| He, AR | 2 |
| Hwang, JJ | 2 |
| Smaglo, BG | 1 |
| Kim, SS | 1 |
| Weinberg, BA | 1 |
| Weiner, LM | 1 |
| Marshall, JL | 6 |
| Brody, JR | 1 |
| You, R | 1 |
| Liu, YP | 1 |
| Huang, PY | 3 |
| Zou, X | 1 |
| Sun, R | 1 |
| He, YX | 1 |
| Wu, YS | 1 |
| Shen, GP | 1 |
| Zhang, HD | 1 |
| Duan, CY | 1 |
| Tan, SH | 2 |
| Cao, JY | 1 |
| Li, JB | 1 |
| Xie, YL | 1 |
| Zhang, YN | 2 |
| Wang, ZQ | 2 |
| Yang, Q | 2 |
| Jiang, R | 1 |
| Zhang, MX | 1 |
| Hua, YJ | 1 |
| Tang, LQ | 1 |
| Zhuang, AH | 1 |
| Chen, QY | 1 |
| Guo, L | 2 |
| Mo, HY | 1 |
| Mai, HQ | 2 |
| Ling, L | 1 |
| Chua, MLK | 1 |
| Chen, MY | 1 |
| Chung, HH | 1 |
| Lee, CT | 1 |
| Hu, JM | 1 |
| Chou, YC | 1 |
| Lin, YW | 3 |
| Shih, YL | 1 |
| Ramos-Esquivel, A | 1 |
| Chinchilla, R | 1 |
| Valle, M | 1 |
| Fu, J | 1 |
| Yue, Q | 1 |
| Tsai, HL | 5 |
| Huang, CW | 4 |
| Wang, JH | 3 |
| Wu, CC | 3 |
| Sung, YC | 2 |
| Chen, TL | 1 |
| Wang, HM | 3 |
| Tang, HC | 2 |
| Chen, JB | 1 |
| Ke, TW | 1 |
| Tsai, CS | 2 |
| Huang, HY | 1 |
| Wang, JY | 10 |
| Hosokawa, A | 8 |
| Yamazaki, K | 13 |
| Matsuda, C | 3 |
| Ueda, S | 3 |
| Kusaba, H | 2 |
| Okamura, S | 1 |
| Tsuda, M | 4 |
| Tamura, T | 5 |
| Shinozaki, K | 2 |
| Tsushima, T | 2 |
| Tsuda, T | 1 |
| Shirakawa, T | 2 |
| Yamashita, H | 3 |
| Morita, S | 4 |
| Hironaka, S | 1 |
| Muro, K | 13 |
| Shi, X | 2 |
| Cheng, Y | 3 |
| Tan, W | 1 |
| Tan, Z | 1 |
| Malangone-Monaco, E | 1 |
| Doleh, Y | 1 |
| Cole, A | 1 |
| Noxon, V | 1 |
| Antico, G | 1 |
| Cui, J | 1 |
| Zhang, X | 7 |
| Qu, S | 1 |
| Wang, L | 3 |
| Santini, D | 9 |
| Cupini, S | 6 |
| Caponnetto, S | 1 |
| Bordonaro, R | 4 |
| Fea, E | 2 |
| Grande, R | 2 |
| Ueno, M | 3 |
| Nakamori, S | 2 |
| Sugimori, K | 1 |
| Kanai, M | 2 |
| Ikeda, M | 4 |
| Ozaka, M | 2 |
| Furukawa, M | 1 |
| Okusaka, T | 2 |
| Kawabe, K | 1 |
| Furuse, J | 1 |
| Komatsu, Y | 6 |
| Ishii, H | 1 |
| Sato, A | 5 |
| Shimizu, S | 2 |
| Chugh, P | 1 |
| Tang, R | 2 |
| Ioka, T | 1 |
| Macarulla, T | 5 |
| Blanc, JF | 3 |
| Mirakhur, B | 1 |
| de Jong, FA | 2 |
| Siveke, JT | 3 |
| Bang, YH | 1 |
| Hong, YS | 11 |
| Lee, JS | 13 |
| Lee, KW | 8 |
| Han, HS | 2 |
| Kim, SY | 6 |
| Kim, JW | 13 |
| Kim, HK | 3 |
| Eun, CK | 1 |
| Kim, TW | 21 |
| Kim, JE | 2 |
| Baboli, M | 1 |
| Winters, KV | 1 |
| Freed, M | 1 |
| Kim, SG | 1 |
| Manca, P | 1 |
| Smiroldo, V | 1 |
| Racca, P | 3 |
| Prisciandaro, M | 1 |
| Pagani, F | 1 |
| Palermo, F | 1 |
| Greco, FG | 1 |
| Vaiani, M | 1 |
| Calareso, G | 1 |
| Kamiimabeppu, D | 1 |
| Sato, T | 3 |
| Gürsoy, P | 1 |
| Çakar, B | 1 |
| Almuradova, E | 1 |
| Karateke, M | 1 |
| Doğanavşargil, B | 1 |
| Sezak, M | 1 |
| Harman, M | 1 |
| Karabulut, B | 2 |
| Guo, J | 1 |
| Yu, Z | 1 |
| Sun, D | 1 |
| Zou, Y | 1 |
| Huang, C | 1 |
| Gu, X | 1 |
| Zeng, X | 1 |
| Chen, B | 2 |
| Yu, W | 1 |
| Chen, M | 2 |
| Yamada, Y | 15 |
| Matsuhashi, N | 1 |
| Fujii, H | 1 |
| Makiyama, A | 3 |
| Iihara, H | 1 |
| Watanabe, D | 1 |
| Kiyama, S | 1 |
| Kobayashi, R | 1 |
| Suzuki, A | 2 |
| Yoshida, K | 4 |
| Patel, KK | 1 |
| Stein, S | 3 |
| Lacy, J | 3 |
| O'Hara, M | 1 |
| Huntington, SF | 1 |
| An, J | 1 |
| Seok, H | 1 |
| Ha, EM | 1 |
| Xuan, Y | 1 |
| Zhao, S | 1 |
| Xiao, X | 1 |
| Zheng, HC | 1 |
| Malvi, P | 1 |
| Janostiak, R | 1 |
| Nagarajan, A | 1 |
| Wajapeyee, N | 1 |
| Mahmood, RD | 1 |
| Shaw, D | 1 |
| Descamps, T | 1 |
| Zhou, C | 1 |
| Morgan, RD | 1 |
| Saunders, M | 1 |
| Mescallado, N | 1 |
| Backen, A | 1 |
| Morris, K | 2 |
| Little, RA | 1 |
| Cheung, S | 1 |
| Watson, Y | 1 |
| O'Connor, JPB | 1 |
| Jackson, A | 1 |
| Parker, GJM | 1 |
| Dive, C | 1 |
| Jayson, GC | 1 |
| De Dosso, S | 1 |
| Siebenhüner, AR | 1 |
| Winder, T | 3 |
| Meisel, A | 1 |
| Fritsch, R | 1 |
| Astaras, C | 1 |
| Szturz, P | 1 |
| Borner, M | 5 |
| Oziel-Taieb, S | 1 |
| Zemmour, C | 1 |
| Raoul, JL | 6 |
| Mineur, L | 6 |
| Charrier, N | 1 |
| Piana, G | 1 |
| Cavaglione, G | 1 |
| Niccoli, P | 1 |
| Busch, E | 1 |
| Werft, W | 1 |
| Bougatf, N | 1 |
| Hackert, T | 2 |
| Jäger, D | 1 |
| Springfeld, C | 1 |
| Berger, AK | 1 |
| Abrams, SL | 1 |
| Akula, SM | 1 |
| Meher, AK | 1 |
| Steelman, LS | 1 |
| Gizak, A | 1 |
| Duda, P | 1 |
| Rakus, D | 1 |
| Martelli, AM | 1 |
| Ratti, S | 1 |
| Cocco, L | 1 |
| Montalto, G | 1 |
| Cervello, M | 1 |
| Ruvolo, P | 1 |
| Libra, M | 1 |
| Falzone, L | 1 |
| Candido, S | 1 |
| McCubrey, JA | 1 |
| Mie, T | 1 |
| Sasaki, T | 3 |
| Takeda, T | 1 |
| Furukawa, T | 2 |
| Kasuga, A | 1 |
| Matsuyama, M | 1 |
| Sasahira, N | 2 |
| Chun, JW | 1 |
| Lee, SH | 3 |
| Park, N | 1 |
| Huh, G | 1 |
| Cho, IR | 1 |
| Paik, WH | 1 |
| Ryu, JK | 1 |
| Kim, YT | 1 |
| Hadoux, J | 1 |
| Afchain, P | 1 |
| Walter, T | 2 |
| Monterymard, C | 1 |
| Lorgis, V | 5 |
| Thuillier, F | 1 |
| Baudin, E | 1 |
| Scoazec, JY | 2 |
| Desgrippes, R | 1 |
| Rapposelli, IG | 1 |
| Casadei-Gardini, A | 1 |
| Vivaldi, C | 4 |
| Bartolini, G | 1 |
| Bernardini, L | 1 |
| Frassineti, GL | 3 |
| Massa, V | 1 |
| Cucchetti, A | 1 |
| Galot-Linaldi, J | 1 |
| Hernández-Sánchez, KM | 1 |
| Estrada-Muñiz, E | 1 |
| Vega, L | 1 |
| Teramachi, H | 1 |
| Poma, AM | 1 |
| Conca, V | 1 |
| Granetto, C | 6 |
| Frassoldati, A | 1 |
| Bertolini, AS | 1 |
| Germani, MM | 1 |
| Ugolini, C | 1 |
| Fontanini, G | 5 |
| Jin, L | 1 |
| Tanizawa, Y | 1 |
| Kristin, E | 1 |
| Endarti, D | 1 |
| Khoe, LC | 1 |
| Taroeno-Hariadi, KW | 1 |
| Trijayanti, C | 1 |
| Armansyah, A | 1 |
| Sastroasmoro, S | 1 |
| Raimondi, L | 1 |
| Rossi, L | 1 |
| Cimino, G | 1 |
| Gozzi, E | 1 |
| Gürler, F | 1 |
| İlhan, A | 1 |
| Güven, DC | 1 |
| Turhan, O | 1 |
| Kurt İnci, B | 1 |
| Sütçüoğlu, O | 1 |
| Yildiz, F | 1 |
| Arik, Z | 1 |
| Öksüzoğlu, B | 3 |
| Yalçin, Ş | 5 |
| Özdemir, N | 3 |
| Yazici, O | 3 |
| Özet, A | 1 |
| Williet, N | 1 |
| Bouché, O | 12 |
| Petorin, C | 1 |
| Rebischung, C | 2 |
| Turpin, A | 1 |
| Bignon, AL | 1 |
| Seitz, JF | 8 |
| François, E | 10 |
| Choi, IS | 4 |
| Kim, KH | 3 |
| Lee, JH | 12 |
| Suh, KJ | 3 |
| Park, JH | 3 |
| Kim, YJ | 5 |
| Denda, T | 7 |
| Takashima, A | 3 |
| Gamoh, M | 2 |
| Iwanaga, I | 1 |
| Ohori, H | 1 |
| Sakashita, A | 1 |
| Kobayashi, Y | 2 |
| Baba, H | 7 |
| Kotake, M | 2 |
| Ishioka, C | 2 |
| Yuki, S | 1 |
| Takahashi, S | 4 |
| Yamaguchi, T | 6 |
| Shimada, K | 3 |
| Chang, Y | 1 |
| Shen, C | 1 |
| Han, J | 1 |
| Zhao, H | 2 |
| Chang, R | 1 |
| Baron, MK | 1 |
| Nevala-Plagemann, C | 1 |
| Moser, JC | 1 |
| Haaland, B | 1 |
| Garrido-Laguna, I | 1 |
| Caron, B | 1 |
| Reimund, JM | 1 |
| Ben Abdelghani, M | 2 |
| Sondag, D | 1 |
| Noirclerc, M | 2 |
| Duclos, B | 2 |
| Kurtz, JE | 1 |
| Nguimpi-Tambou, M | 1 |
| Bayir Garbioglu, D | 1 |
| Demir, N | 1 |
| Ozel, C | 1 |
| Avci, H | 1 |
| Dincer, M | 1 |
| Siu, HWD | 1 |
| Tebbutt, N | 3 |
| Chantrill, L | 1 |
| Karapetis, C | 1 |
| Steer, C | 1 |
| Wilson, K | 4 |
| Espinoza, D | 1 |
| Bailey, L | 1 |
| Yip, S | 1 |
| Cuff, J | 1 |
| Pavlakis, N | 2 |
| Thavaneswaran, S | 1 |
| Briscoe, K | 1 |
| Srivastav, R | 1 |
| Shannon, J | 1 |
| Tie, J | 3 |
| Caird, S | 1 |
| Francesconi, A | 1 |
| Wuttke, M | 1 |
| Ladwa, R | 1 |
| Sjoquist, K | 1 |
| Botticelli, A | 1 |
| Cirillo, A | 1 |
| Strigari, L | 1 |
| Valentini, F | 1 |
| Cerbelli, B | 1 |
| Scagnoli, S | 1 |
| Cerbelli, E | 1 |
| Zizzari, IG | 1 |
| Rocca, CD | 1 |
| D'Amati, G | 1 |
| Polimeni, A | 1 |
| Nuti, M | 1 |
| Merlano, MC | 1 |
| Mezi, S | 2 |
| Marchetti, P | 3 |
| Dai, X | 2 |
| Liu, D | 1 |
| Qian, Y | 2 |
| Zhao, J | 3 |
| Wu, Y | 1 |
| Xiong, F | 1 |
| Chang, NA | 1 |
| Sun, YU | 1 |
| Hoffman, RM | 5 |
| Yoon, YS | 2 |
| Kim, CW | 4 |
| Roh, SA | 1 |
| Cho, DH | 1 |
| Kim, MB | 1 |
| Kim, JC | 5 |
| Tryfonidis, K | 2 |
| Marreaud, S | 2 |
| Khaled, H | 1 |
| De Valk, B | 1 |
| Vermorken, J | 1 |
| Welnicka-Jaskiewicz, M | 1 |
| Aalders, K | 1 |
| Bartlett, JMS | 1 |
| Biganzoli, L | 2 |
| Bogaerts, J | 1 |
| Cameron, D | 4 |
| Ahn, S | 1 |
| Kim, HW | 1 |
| Kim, YH | 4 |
| Paik, KH | 1 |
| Yang, YF | 1 |
| Wang, GY | 1 |
| He, JL | 1 |
| Wu, FP | 1 |
| Berger, MD | 5 |
| Yamauchi, S | 1 |
| Cao, S | 5 |
| Sunakawa, Y | 8 |
| Schirripa, M | 12 |
| Matsusaka, S | 7 |
| Yang, D | 8 |
| Groshen, S | 1 |
| Ning, Y | 6 |
| Okazaki, S | 4 |
| Miyamoto, Y | 6 |
| Suenaga, M | 9 |
| Loupakis, F | 19 |
| Li, N | 1 |
| Lu, Y | 2 |
| Li, D | 1 |
| Zheng, X | 3 |
| Lian, J | 1 |
| Li, S | 2 |
| Cui, H | 1 |
| Zhang, L | 8 |
| Sang, L | 1 |
| Yu, JJ | 1 |
| Lu, T | 1 |
| Gopez, RF | 1 |
| West, JD | 3 |
| Hanna, D | 1 |
| Dai, G | 1 |
| Ghidini, A | 1 |
| Guren, TK | 3 |
| Thomsen, M | 2 |
| Kure, EH | 5 |
| Sorbye, H | 4 |
| Glimelius, B | 12 |
| Pfeiffer, P | 9 |
| Österlund, P | 2 |
| Sigurdsson, F | 1 |
| Lothe, IMB | 1 |
| Dalsgaard, AM | 1 |
| Skovlund, E | 1 |
| Christoffersen, T | 1 |
| Tveit, KM | 7 |
| Yue, GG | 1 |
| Lee, JK | 1 |
| Wong, EC | 1 |
| Lau, CB | 1 |
| Chiu, PW | 1 |
| Leal, F | 1 |
| Ferreira, FP | 1 |
| Sasse, AD | 1 |
| Lim, KH | 3 |
| Lee, HY | 2 |
| Park, SB | 1 |
| Song, SY | 1 |
| Abrams, TA | 1 |
| Meyer, G | 1 |
| Meyerhardt, JA | 3 |
| Wolpin, BM | 1 |
| Schrag, D | 2 |
| Fuchs, CS | 8 |
| Gopez, R | 1 |
| Akihito, T | 1 |
| Ichikawa, W | 6 |
| DePaolo, RW | 2 |
| Crispin, A | 1 |
| Schalhorn, A | 6 |
| Giessen-Jung, C | 2 |
| Vehling-Kaiser, U | 7 |
| Stauch, M | 3 |
| Quietzsch, D | 2 |
| Kruger, S | 1 |
| Haas, M | 1 |
| von Einem, J | 1 |
| Salvatore, L | 10 |
| Zagonel, V | 7 |
| Valsuani, C | 1 |
| Di Donato, S | 5 |
| Demurtas, L | 1 |
| Puzzoni, M | 1 |
| Giampieri, R | 2 |
| Ziranu, P | 1 |
| Pusceddu, V | 1 |
| Mandolesi, A | 1 |
| Gelsomino, F | 1 |
| Loretelli, C | 1 |
| Meriggi, F | 1 |
| Cascinu, S | 8 |
| Scartozzi, M | 3 |
| Miaris, N | 1 |
| Sgouros, J | 2 |
| Gerolympou, M | 1 |
| Spyropoulos, B | 1 |
| Drakopoulos, D | 1 |
| Gkoura, S | 1 |
| Res, H | 1 |
| Samantas, E | 2 |
| De Stefano, A | 3 |
| Rosanova, M | 1 |
| Malapelle, U | 1 |
| Martini, M | 1 |
| De Falco, S | 1 |
| Attademo, L | 1 |
| Fiore, G | 1 |
| Cenci, T | 1 |
| Bellevicine, C | 1 |
| De Placido, S | 4 |
| Troncone, G | 1 |
| Carlomagno, C | 5 |
| Tao, Y | 1 |
| Aupérin, A | 1 |
| Graff, P | 1 |
| Lapeyre, M | 1 |
| Grégoire, V | 2 |
| Maingon, P | 1 |
| Geoffrois, L | 1 |
| Verrelle, P | 1 |
| Calais, G | 2 |
| Gery, B | 3 |
| Martin, L | 1 |
| Alfonsi, M | 1 |
| Deprez, P | 1 |
| Bardet, E | 2 |
| Pignon, T | 1 |
| Rives, M | 1 |
| Sire, C | 1 |
| Bourhis, J | 2 |
| Magnes, T | 1 |
| Melchardt, T | 1 |
| Hufnagl, C | 1 |
| Weiss, L | 1 |
| Mittermair, C | 1 |
| Neureiter, D | 2 |
| Klieser, E | 1 |
| Rinnerthaler, G | 1 |
| Roesch, S | 1 |
| Gaggl, A | 1 |
| Greil, R | 6 |
| Egle, A | 1 |
| Ye, R | 1 |
| Wu, X | 5 |
| Gao, L | 2 |
| Niu, B | 1 |
| Hamad, A | 1 |
| Singhi, AD | 1 |
| Bahary, N | 1 |
| McGrath, K | 1 |
| Amarin, R | 1 |
| Zeh, HJ | 1 |
| Zureikat, AH | 1 |
| McBride, A | 2 |
| Bonafede, M | 1 |
| Cai, Q | 1 |
| Princic, N | 1 |
| Tran, O | 1 |
| Pelletier, C | 1 |
| Parisi, M | 1 |
| Patel, M | 1 |
| Ito, Y | 6 |
| Ohue, M | 1 |
| Kanemitsu, Y | 2 |
| Kobatake, T | 1 |
| Ito, M | 1 |
| Moriya, Y | 1 |
| Saito, N | 1 |
| Ruff, P | 6 |
| Van Cutsem, E | 34 |
| Lakomy, R | 3 |
| Prausova, J | 7 |
| van Hazel, GA | 5 |
| Moiseyenko, VM | 5 |
| Soussan-Lazard, K | 2 |
| Dochy, E | 1 |
| Magherini, E | 3 |
| Papamichael, D | 3 |
| Al Mousa, A | 1 |
| Abu-Hijlih, R | 1 |
| Salem, A | 1 |
| Sultan, I | 1 |
| Mula-Hussain, L | 1 |
| Ismael, T | 1 |
| Mohamad, I | 1 |
| Ricard, I | 2 |
| Al-Batran, SE | 9 |
| Seipelt, G | 3 |
| Westphalen, CB | 1 |
| Ottaiano, A | 2 |
| Nasti, G | 3 |
| Cassata, A | 2 |
| Caraglia, M | 2 |
| Avallone, A | 4 |
| Ajani, JA | 6 |
| Abramov, M | 1 |
| Bondarenko, I | 4 |
| Shparyk, Y | 3 |
| Gorbunova, V | 3 |
| Hontsa, A | 1 |
| Otchenash, N | 1 |
| Alsina, M | 2 |
| Lazarev, S | 1 |
| Feliu, J | 2 |
| Elme, A | 1 |
| Esko, V | 1 |
| Abdalla, K | 1 |
| Verma, U | 1 |
| Benedetti, F | 1 |
| Aoyama, T | 2 |
| Mizuguchi, H | 2 |
| Makris, L | 1 |
| Marques, RP | 1 |
| Duarte, GS | 1 |
| Sterrantino, C | 1 |
| Pais, HL | 1 |
| Quintela, A | 1 |
| Martins, AP | 1 |
| Costa, J | 1 |
| Payette, E | 1 |
| Sarker, S | 1 |
| Chalchal, H | 1 |
| Erdem, GU | 2 |
| Bozkaya, Y | 2 |
| Ozdemir, NY | 1 |
| Demirci, NS | 2 |
| Zengin, N | 5 |
| Normanno, N | 2 |
| Esposito Abate, R | 1 |
| Lambiase, M | 2 |
| Forgione, L | 1 |
| Cardone, C | 2 |
| Iannaccone, A | 1 |
| Sacco, A | 1 |
| Rachiglio, AM | 1 |
| Rizzi, D | 2 |
| Pisconti, S | 2 |
| Biglietto, M | 2 |
| Troiani, T | 3 |
| Giuliani, F | 4 |
| Leo, S | 4 |
| Rinaldi, A | 1 |
| Maiello, E | 6 |
| Ciardiello, F | 9 |
| Katanyoo, K | 1 |
| Ungari, AQ | 1 |
| Pereira, LRL | 1 |
| Nunes, AA | 1 |
| Peria, FM | 1 |
| Maillard, E | 3 |
| Kirscher, S | 2 |
| Etienne, PL | 5 |
| Faroux, R | 5 |
| El Hajbi, F | 2 |
| Lavau-Denes, S | 2 |
| Baconnier, M | 2 |
| Oden-Gangloff, A | 2 |
| Genet, D | 5 |
| Paillaud, E | 2 |
| Retornaz, F | 2 |
| Bedenne, L | 5 |
| Morine, Y | 1 |
| Shimada, M | 1 |
| Ikemoto, T | 1 |
| Arakawa, Y | 1 |
| Iwahashi, S | 1 |
| Saito, YU | 1 |
| Yamada, S | 2 |
| Imura, S | 1 |
| Kajitani, T | 2 |
| Arita, S | 1 |
| Shimokawa, H | 1 |
| Oda, H | 1 |
| Baba, E | 5 |
| Esaki, T | 5 |
| Yeom, SS | 1 |
| Park, IJ | 2 |
| Jung, SW | 1 |
| Oh, SH | 1 |
| Lee, JL | 7 |
| Lim, SB | 3 |
| Kim, N | 1 |
| Yu, CS | 4 |
| Ina, K | 2 |
| Furuta, R | 1 |
| Denecke, T | 1 |
| Pratschke, J | 1 |
| Lang, H | 1 |
| Bemelmans, M | 1 |
| Rentsch, M | 1 |
| Seehofer, D | 1 |
| Bruns, CJ | 2 |
| Gebauer, B | 1 |
| Modest, HI | 1 |
| Neumann, UP | 1 |
| Meropol, NJ | 4 |
| Feng, Y | 1 |
| Grem, JL | 5 |
| Mulcahy, MF | 4 |
| Catalano, PJ | 2 |
| Kauh, JS | 1 |
| Hall, MJ | 2 |
| Saltzman, JN | 1 |
| George, TJ | 1 |
| Zangmeister, J | 1 |
| Chiorean, EG | 2 |
| Cheema, PS | 1 |
| O'Dwyer, PJ | 3 |
| Benson, AB | 7 |
| Manogue, C | 1 |
| Ledet, E | 1 |
| Guddati, AK | 1 |
| Lewis, B | 1 |
| Sartor, O | 1 |
| Fan, H | 1 |
| Song, G | 2 |
| Wang, F | 1 |
| Torén, W | 1 |
| Ansari, D | 1 |
| Andersson, B | 1 |
| Spelt, L | 1 |
| Andersson, R | 1 |
| Zeppola, T | 1 |
| Stellato, M | 1 |
| Chiara, S | 9 |
| Tonini, G | 14 |
| Tomcikova, D | 1 |
| Overman, MJ | 2 |
| Ferrarotto, R | 1 |
| Raghav, K | 1 |
| George, B | 1 |
| Qiao, W | 2 |
| Machado, KK | 1 |
| Vauthey, JN | 5 |
| Hobbs, B | 1 |
| Loyer, EM | 2 |
| Kopetz, S | 2 |
| Cotte, AK | 1 |
| Aires, V | 1 |
| Fredon, M | 1 |
| Limagne, E | 1 |
| Derangère, V | 1 |
| Thibaudin, M | 1 |
| Humblin, E | 1 |
| Scagliarini, A | 1 |
| de Barros, JP | 1 |
| Hillon, P | 1 |
| Delmas, D | 1 |
| Hofheinz, RD | 4 |
| Lorenzen, S | 4 |
| Trojan, J | 2 |
| Ocvirk, J | 2 |
| Ettrich, TJ | 1 |
| Schulz, H | 1 |
| Homann, N | 4 |
| Feustel, HP | 1 |
| Schatz, M | 1 |
| Kripp, M | 2 |
| Schulte, N | 1 |
| Tetyusheva, M | 1 |
| Heeger, S | 1 |
| Vlassak, S | 1 |
| Merx, K | 2 |
| Mescoli, C | 1 |
| Cardellino, GG | 1 |
| Coltelli, L | 1 |
| Corsi, DC | 2 |
| Lupi, C | 4 |
| Gemma, D | 1 |
| Di Fabio, F | 2 |
| Mancini, ML | 2 |
| Marcucci, L | 3 |
| Bonucci, M | 1 |
| Pastore, C | 1 |
| Ferrera, V | 1 |
| Fiorentini, C | 1 |
| Fabbri, A | 1 |
| Geredeli, C | 1 |
| Yasar, N | 1 |
| Liang, Y | 1 |
| Chang, W | 2 |
| Hu, B | 1 |
| Sun, Y | 4 |
| Zhan, L | 1 |
| Lou, Y | 1 |
| Liu, L | 2 |
| Sasaki, S | 1 |
| Baba, T | 1 |
| Muranaka, H | 1 |
| Tanabe, Y | 1 |
| Takahashi, C | 1 |
| Matsugo, S | 1 |
| Mukaida, N | 1 |
| Munker, S | 1 |
| Gerken, M | 1 |
| Fest, P | 1 |
| Ott, C | 1 |
| Schnoy, E | 1 |
| Fichtner-Feigl, S | 1 |
| Wiggermann, P | 1 |
| Vogelhuber, M | 2 |
| Herr, W | 1 |
| Stroszczynski, C | 1 |
| Schlitt, HJ | 1 |
| Evert, M | 1 |
| Reng, M | 1 |
| Klinkhammer-Schalke, M | 1 |
| Teufel, A | 1 |
| Liu, T | 3 |
| Lu, W | 1 |
| Zheng, F | 1 |
| Zhang, C | 1 |
| Long, Q | 1 |
| Qiu, H | 1 |
| Ge, Q | 1 |
| Yu, X | 1 |
| Chen, W | 2 |
| Zhang, H | 3 |
| Huang, W | 2 |
| Luo, M | 1 |
| Deng, W | 1 |
| Tahara, J | 1 |
| Shimizu, K | 1 |
| Otsuka, N | 1 |
| Akao, J | 1 |
| Takayama, Y | 1 |
| Tokushige, K | 1 |
| Choi, M | 1 |
| Kang, B | 1 |
| Kim, SH | 5 |
| Lee, JO | 4 |
| Bang, SM | 6 |
| Sánchez-Gundín, J | 1 |
| Fernández-Carballido, AM | 1 |
| Martínez-Valdivieso, L | 1 |
| Barreda-Hernández, D | 1 |
| Torres-Suárez, AI | 1 |
| Gharaibeh, M | 1 |
| Alberts, DS | 1 |
| Erstad, B | 1 |
| Slack, M | 1 |
| Alsaid, N | 1 |
| Bootman, JL | 1 |
| Abraham, I | 1 |
| Knödler, M | 1 |
| Körfer, J | 1 |
| Kunzmann, V | 1 |
| Daum, S | 1 |
| Schroll, S | 1 |
| Behringer, D | 1 |
| Stahl, M | 4 |
| Hacker, U | 1 |
| Ibach, S | 1 |
| Lindhofer, H | 1 |
| Lordick, F | 5 |
| Peeters, M | 8 |
| Rivera, F | 20 |
| Canon, JL | 3 |
| Pentheroudakis, G | 2 |
| Koukakis, R | 5 |
| Burdon, P | 1 |
| Siena, S | 5 |
| Aranda, E | 14 |
| Benavides, M | 6 |
| Guillén-Ponce, C | 3 |
| Safont, MJ | 4 |
| Alcaide, J | 1 |
| Gómez, A | 3 |
| López, R | 3 |
| Manzano, JL | 3 |
| Méndez Ureña, M | 2 |
| Sastre, J | 10 |
| Grávalos, C | 1 |
| García, T | 1 |
| Martín-Valadés, JI | 1 |
| Falcó, E | 5 |
| Navalón, M | 2 |
| González Flores, E | 1 |
| Ma García Tapiador, A | 1 |
| Ma López Muñoz, A | 1 |
| Barrajón, E | 2 |
| Reboredo, M | 5 |
| García Teijido, P | 1 |
| Viudez, A | 2 |
| Cárdenas, N | 1 |
| Díaz-Rubio, E | 16 |
| Afrin, S | 1 |
| Giampieri, F | 1 |
| Forbes-Hernández, TY | 1 |
| Gasparrini, M | 1 |
| Amici, A | 1 |
| Cianciosi, D | 1 |
| Quiles, JL | 1 |
| Battino, M | 1 |
| Graham, CN | 3 |
| Christodoulopoulou, A | 1 |
| Knox, HN | 2 |
| Sabatelli, L | 1 |
| Hechmati, G | 3 |
| Garawin, T | 1 |
| Strickler, JH | 1 |
| Oweira, H | 1 |
| Giryes, A | 1 |
| Mannhart, M | 1 |
| Decker, M | 1 |
| Abdel-Rahman, O | 4 |
| Laurent-Puig, P | 2 |
| Grisoni, ML | 1 |
| Liebaert, F | 1 |
| Montestruc, F | 2 |
| Gaston-Mathe, Y | 1 |
| Thiébaut, R | 1 |
| Qin, S | 1 |
| Pan, H | 2 |
| Bi, F | 2 |
| Lim, R | 5 |
| Zhang, S | 5 |
| Ba, Y | 2 |
| Bai, Y | 2 |
| Fan, N | 1 |
| Yeh, KH | 6 |
| Ma, B | 4 |
| Wei, V | 1 |
| Shi, D | 1 |
| Muñoz, A | 2 |
| Salgado, M | 3 |
| López-Ladrón, A | 2 |
| Ruiz de Mena, I | 1 |
| Durán, G | 2 |
| Shi, C | 1 |
| Chen, Q | 4 |
| Delgado-Ureña, M | 1 |
| Ortega, FG | 1 |
| de Miguel-Pérez, D | 1 |
| Rodriguez-Martínez, A | 1 |
| García-Puche, JL | 1 |
| Ilyine, H | 1 |
| Lorente, JA | 1 |
| Exposito-Hernandez, J | 1 |
| Garrido-Navas, MC | 1 |
| Delgado-Ramirez, M | 1 |
| Serrano, MJ | 1 |
| Semira, C | 1 |
| Wong, HL | 2 |
| Field, K | 1 |
| Lee, M | 2 |
| Lee, B | 2 |
| Nott, L | 1 |
| Shapiro, J | 1 |
| Wong, R | 4 |
| Tran, B | 2 |
| Richardson, G | 2 |
| Zimet, A | 2 |
| Lipton, L | 1 |
| Tamjid, B | 1 |
| Johns, J | 2 |
| Harold, M | 1 |
| Kusano, M | 1 |
| Okabayashi, K | 2 |
| Hirata, K | 2 |
| Tsuji, Y | 5 |
| Asahara, T | 1 |
| Ohashi, Y | 3 |
| Yoshikawa, T | 1 |
| Saji, S | 2 |
| Romera, A | 1 |
| Peredpaya, S | 1 |
| Mendonça Bariani, G | 1 |
| Abdalla, KC | 1 |
| Roca, E | 1 |
| Franke, F | 1 |
| Melo Cruz, F | 1 |
| Ramesh, A | 1 |
| Ostwal, V | 1 |
| Shah, P | 1 |
| Rahuman, SA | 1 |
| Paravisini, A | 1 |
| Huerga, C | 1 |
| Del Campo García, A | 1 |
| Millán, S | 1 |
| Jin, H | 1 |
| Seo, GS | 1 |
| Yoshino, T | 6 |
| Portnoy, DC | 2 |
| Obermannová, R | 3 |
| Bodoky, G | 8 |
| Garcia-Carbonero, R | 5 |
| Ciuleanu, T | 2 |
| Cohn, AL | 5 |
| O'Connor, J | 1 |
| Wijayawardana, SR | 1 |
| Hozak, RR | 1 |
| Nasroulah, F | 5 |
| Tabernero, J | 15 |
| Bendardaf, R | 4 |
| Sharif-Askari, FS | 2 |
| Sharif-Askari, NS | 2 |
| Syrjänen, K | 4 |
| Pyrhönen, S | 6 |
| Hiret, S | 1 |
| Bertaut, A | 2 |
| Deplanque, G | 2 |
| Borel, C | 1 |
| Conroy, T | 8 |
| Hebbar, M | 7 |
| Stanbury, T | 1 |
| Denis, MG | 1 |
| Adenis, A | 10 |
| Borg, C | 2 |
| Hubner, RA | 2 |
| Cubillo, A | 2 |
| Melisi, D | 2 |
| Von Hoff, DD | 2 |
| Becker, C | 1 |
| Nadler, E | 1 |
| Joo, S | 1 |
| Boyd, M | 1 |
| Black-Shinn, J | 1 |
| Chirovsky, D | 1 |
| Beck, JT | 1 |
| Nechaeva, M | 1 |
| Cubillo Gracian, A | 1 |
| Mangel, L | 1 |
| Elez Fernandez, E | 1 |
| Deming, DA | 1 |
| Ramanathan, RK | 4 |
| Torres, AH | 1 |
| Sullivan, D | 1 |
| Luo, Y | 1 |
| Berlin, JD | 5 |
| Jing, C | 1 |
| Du, Y | 1 |
| Cao, H | 1 |
| Liu, S | 1 |
| Wang, Z | 4 |
| Ma, R | 1 |
| Feng, J | 1 |
| Wu, J | 2 |
| Naseem, M | 2 |
| Salem, ME | 1 |
| Fanotto, V | 1 |
| Fornaro, L | 7 |
| Leone, F | 3 |
| Silvestris, N | 2 |
| Stragliotto, S | 1 |
| Nichetti, F | 1 |
| Pellegrino, A | 1 |
| Vasile, E | 5 |
| Gerratana, L | 1 |
| Yang, X | 1 |
| Gao, D | 1 |
| Miskimins, K | 1 |
| Qian, SY | 1 |
| Kearney, MR | 1 |
| Chen, EY | 1 |
| Vaccaro, GM | 1 |
| Strother, J | 1 |
| Burt, A | 1 |
| Todd, K | 1 |
| Donovan, J | 1 |
| Kampa-Schittenhelm, KM | 1 |
| Lopez, CD | 1 |
| Oyaga-Iriarte, E | 1 |
| Insausti, A | 1 |
| Sayar, O | 1 |
| Aldaz, A | 1 |
| Demonty, G | 2 |
| Douillard, JY | 16 |
| Gouverneur, A | 1 |
| Coutureau, J | 1 |
| Jové, J | 2 |
| Rouyer, M | 2 |
| Grelaud, A | 2 |
| Duc, S | 1 |
| Gérard, S | 1 |
| Smith, D | 5 |
| Ravaud, A | 4 |
| Droz, C | 1 |
| Bernard, MA | 1 |
| Lassalle, R | 1 |
| Forrier-Réglat, A | 1 |
| Noize, P | 2 |
| Short, SP | 1 |
| Thompson, JJ | 1 |
| Bilotta, AJ | 1 |
| Revetta, FL | 1 |
| Washington, MK | 2 |
| Williams, CS | 1 |
| Rao, C | 1 |
| Zheng, G | 1 |
| Ahmed, O | 1 |
| Hebart, H | 3 |
| Kiehl, M | 1 |
| Tomasek, J | 1 |
| Csoszi, T | 1 |
| Kafatos, G | 1 |
| Kuhn, A | 1 |
| Bjorklof, K | 1 |
| Buchler, T | 2 |
| Laccourreye, O | 2 |
| Marret, G | 1 |
| Rubin, F | 1 |
| Fabre, E | 1 |
| Badoual, C | 1 |
| Oudard, S | 1 |
| Bonfils, P | 1 |
| Lisan, Q | 1 |
| Yang, LY | 1 |
| Shan, YM | 1 |
| Zhou, EH | 1 |
| Chen, XP | 1 |
| Jiménez Gordo, AM | 1 |
| López Gómez, M | 1 |
| Hall, SF | 1 |
| Griffiths, RJ | 1 |
| O'Sullivan, B | 1 |
| Liu, FF | 1 |
| Chibaudel, B | 9 |
| Auby, D | 3 |
| Louvet, C | 20 |
| Tournigand, C | 13 |
| Lebrun-Ly, V | 1 |
| Dauba, J | 1 |
| Lledo, G | 7 |
| Garcia, ML | 2 |
| Dubreuil, O | 1 |
| Hamed, NB | 1 |
| Meurisse, A | 1 |
| Larsen, AK | 4 |
| Tijeras-Raballand, A | 1 |
| Bonnetain, F | 9 |
| De Gramont, A | 20 |
| Stern, PH | 1 |
| Lacas, B | 1 |
| Gasmi, M | 3 |
| Gargot, D | 3 |
| Lombard-Bohas, C | 2 |
| Azzedine, A | 1 |
| Denis, B | 1 |
| Geoffroy, P | 1 |
| Pignon, JP | 3 |
| Borget, I | 1 |
| Stavraka, C | 1 |
| Pouptsis, A | 1 |
| Okonta, L | 1 |
| DeSouza, K | 1 |
| Charlton, P | 1 |
| Kapiris, M | 1 |
| Marinaki, A | 1 |
| Karapanagiotou, E | 1 |
| Papadatos-Pastos, D | 1 |
| Mansi, J | 1 |
| Voiculescu, VM | 1 |
| Lisievici, CV | 1 |
| Lupu, M | 1 |
| Vajaitu, C | 1 |
| Draghici, CC | 1 |
| Popa, AV | 1 |
| Solomon, I | 1 |
| Sebe, TI | 1 |
| Constantin, MM | 1 |
| Caruntu, C | 1 |
| Sato, H | 2 |
| Tsukahara, K | 1 |
| Okamoto, I | 2 |
| Katsube, Y | 1 |
| Shimizu, A | 1 |
| Kondo, T | 2 |
| Hanyu, K | 1 |
| Fushimi, C | 1 |
| Okada, T | 3 |
| Miura, K | 1 |
| Lima, CMSR | 1 |
| Yu, K | 1 |
| McDonough, SL | 1 |
| Philip, PA | 1 |
| Hingorani, SR | 1 |
| Kortmansky, JS | 1 |
| Thumar, J | 1 |
| Shields, AF | 2 |
| Behl, D | 1 |
| Mehan, PT | 1 |
| Gaur, R | 1 |
| Seery, T | 1 |
| Santos, C | 1 |
| Azuara, D | 1 |
| Viéitez, JM | 2 |
| Páez, D | 2 |
| Élez, E | 2 |
| Valladares, M | 4 |
| Robles-Díaz, L | 1 |
| Bugés, C | 1 |
| Salud, A | 3 |
| Navarro, V | 1 |
| Capellá, G | 1 |
| Salazar, R | 2 |
| Tokunaga, R | 1 |
| Lo, JH | 1 |
| Puccini, A | 1 |
| Weisenberger, DJ | 1 |
| Liang, G | 1 |
| Lin, H | 3 |
| Lu, X | 3 |
| Chi, P | 3 |
| Delahunty, R | 1 |
| Mckendrick, J | 3 |
| Kosmider, S | 1 |
| Cooray, P | 1 |
| Ananda, S | 1 |
| Desai, J | 1 |
| Paralta Branco, F | 1 |
| Brito, CB | 1 |
| Luz, G | 1 |
| Teixeira, JA | 1 |
| Tanaka, M | 2 |
| Heckler, M | 1 |
| Mihaljevic, AL | 1 |
| Sun, H | 1 |
| Klaiber, U | 1 |
| Heger, U | 1 |
| Büchler, MW | 3 |
| Rovers, KP | 1 |
| Bakkers, C | 1 |
| Simkens, GAAM | 1 |
| Burger, JWA | 1 |
| Nienhuijs, SW | 1 |
| Creemers, GM | 1 |
| Thijs, AMJ | 1 |
| Brandt-Kerkhof, ARM | 1 |
| Madsen, EVE | 1 |
| Ayez, N | 1 |
| de Boer, NL | 1 |
| van Meerten, E | 2 |
| Tuynman, JB | 1 |
| Kusters, M | 1 |
| Sluiter, NR | 1 |
| Verheul, HMW | 1 |
| van der Vliet, HJ | 1 |
| Wiezer, MJ | 1 |
| Boerma, D | 1 |
| Wassenaar, ECE | 1 |
| Los, M | 2 |
| Hunting, CB | 1 |
| Aalbers, AGJ | 1 |
| Kok, NFM | 1 |
| Kuhlmann, KFD | 1 |
| Boot, H | 2 |
| Chalabi, M | 1 |
| Kruijff, S | 1 |
| Been, LB | 1 |
| van Ginkel, RJ | 1 |
| de Groot, DJA | 1 |
| Fehrmann, RSN | 1 |
| de Wilt, JHW | 1 |
| Bremers, AJA | 1 |
| de Reuver, PR | 1 |
| Radema, SA | 1 |
| Herbschleb, KH | 1 |
| van Grevenstein, WMU | 1 |
| Witkamp, AJ | 1 |
| Koopman, M | 5 |
| Haj Mohammad, N | 1 |
| van Duyn, EB | 1 |
| Mastboom, WJB | 1 |
| Mekenkamp, LJM | 1 |
| Nederend, J | 1 |
| Lahaye, MJ | 2 |
| Snaebjornsson, P | 1 |
| Verhoef, C | 1 |
| van Laarhoven, HWM | 1 |
| Zwinderman, AH | 1 |
| Bouma, JM | 1 |
| Kranenburg, O | 1 |
| van 't Erve, I | 1 |
| Fijneman, RJA | 1 |
| Dijkgraaf, MGW | 1 |
| Hemmer, PHJ | 1 |
| Punt, CJA | 2 |
| Tanis, PJ | 1 |
| Ou, FS | 1 |
| Venook, AP | 2 |
| Niedzwiecki, D | 2 |
| Goldberg, RM | 11 |
| Mayer, RJ | 8 |
| Bertagnolli, MM | 1 |
| Blanke, CD | 2 |
| Zemla, T | 1 |
| Qu, X | 1 |
| Wirapati, P | 1 |
| Innocenti, F | 3 |
| Kabbarah, O | 1 |
| Suzuki, T | 2 |
| Ota, Y | 2 |
| Ichimura, T | 1 |
| Yokoyama, T | 2 |
| Makino, H | 3 |
| Hirakata, A | 1 |
| Ueda, J | 1 |
| Takata, H | 1 |
| Okusa, M | 1 |
| Kawashima, M | 1 |
| Tsujino, T | 1 |
| Hosone, M | 1 |
| Matsushita, A | 1 |
| Nakamura, Y | 1 |
| Yoshida, H | 2 |
| Rambeau, A | 1 |
| Bastit, V | 1 |
| Thureau, S | 1 |
| Thariat, J | 1 |
| Moldovan, C | 1 |
| Roge, M | 1 |
| Babin, E | 1 |
| Di Fiore, F | 2 |
| Florescu, C | 1 |
| Clatot, F | 1 |
| Howells, LM | 1 |
| Iwuji, COO | 1 |
| Irving, GRB | 1 |
| Barber, S | 1 |
| Walter, H | 1 |
| Sidat, Z | 1 |
| Griffin-Teall, N | 1 |
| Singh, R | 1 |
| Foreman, N | 1 |
| Patel, SR | 1 |
| Morgan, B | 1 |
| Steward, WP | 1 |
| Gescher, A | 1 |
| Thomas, AL | 1 |
| Brown, K | 1 |
| Saade Lemus, P | 1 |
| Anderson, K | 1 |
| Smith, M | 1 |
| Bullock, A | 1 |
| Chen, J | 4 |
| Liang, W | 1 |
| Wan, N | 1 |
| Jiang, J | 2 |
| Habr-Gama, A | 2 |
| São Julião, GP | 1 |
| Fernandez, LM | 1 |
| Vailati, BB | 1 |
| Andrade, A | 1 |
| Araújo, SEA | 1 |
| Gama-Rodrigues, J | 1 |
| Perez, RO | 1 |
| Vashi, PG | 1 |
| Gorsuch, K | 1 |
| Wan, L | 1 |
| Hill, D | 1 |
| Block, C | 1 |
| Gupta, D | 2 |
| Ben Kridis, W | 1 |
| Marrekchi, G | 1 |
| Mzali, R | 1 |
| Daoud, J | 2 |
| Khanfir, A | 2 |
| Lin, W | 1 |
| Colomer, C | 1 |
| Margalef, P | 1 |
| Villanueva, A | 1 |
| Vert, A | 1 |
| Pecharroman, I | 1 |
| Solé, L | 1 |
| González-Farré, M | 1 |
| Alonso, J | 1 |
| Martinez-Iniesta, M | 1 |
| Bertran, J | 1 |
| Borràs, E | 1 |
| Iglesias, M | 1 |
| Sabidó, E | 1 |
| Bigas, A | 1 |
| Boulton, SJ | 1 |
| Espinosa, L | 1 |
| Hisaka, T | 1 |
| Ishikawa, H | 1 |
| Sakai, H | 1 |
| Kawahara, R | 1 |
| Goto, Y | 2 |
| Nomura, Y | 1 |
| Yasunaga, M | 1 |
| Kinugasa, T | 1 |
| Fujita, F | 1 |
| Mizobe, T | 1 |
| Fukahori, M | 1 |
| Nakashima, O | 1 |
| Tanigawa, M | 1 |
| Naito, Y | 1 |
| Akiba, J | 1 |
| Yano, H | 1 |
| Tanaka, H | 3 |
| Akagi, Y | 1 |
| Okuda, K | 1 |
| van Huis-Tanja, LH | 1 |
| Gelderblom, H | 5 |
| Punt, CJ | 11 |
| Guchelaar, HJ | 4 |
| Hamada, T | 1 |
| Taniguchi, E | 1 |
| Ohta, K | 1 |
| Yoshikawa, M | 1 |
| Yamagami, Y | 1 |
| Ohashi, S | 1 |
| Ciombor, KK | 1 |
| Berlin, J | 5 |
| Chan, E | 4 |
| Xynos, ID | 1 |
| Karadima, ML | 1 |
| Voutsas, IF | 1 |
| Amptoulach, S | 1 |
| Skopelitis, E | 1 |
| Kosmas, C | 2 |
| Gritzapis, AD | 1 |
| Tsavaris, N | 3 |
| Jouve, JL | 3 |
| Teillet, L | 2 |
| Subtil, F | 1 |
| Le Brun-Ly, V | 1 |
| Cretin, J | 2 |
| Breysacher, G | 3 |
| Charneau, J | 1 |
| Stefani, L | 2 |
| Ramdani, M | 2 |
| Mitry, E | 9 |
| Tonyali, O | 1 |
| Benekli, M | 2 |
| Berk, V | 2 |
| Coskun, U | 2 |
| Ozkan, M | 3 |
| Yildiz, R | 2 |
| Ucgul, E | 1 |
| Sevinc, A | 3 |
| Uncu, D | 3 |
| Demirci, U | 1 |
| Buyukberber, S | 3 |
| Saif, MW | 12 |
| Fang, YJ | 1 |
| Li, F | 1 |
| Ou, QJ | 1 |
| Chen, G | 1 |
| Ma, G | 1 |
| LaPresto, L | 1 |
| Cranmer, L | 1 |
| Morrison, L | 1 |
| Erickson, CP | 1 |
| Curiel-Lewandrowski, C | 1 |
| Lin, PC | 3 |
| Lin, HH | 2 |
| Lin, JK | 6 |
| Lin, CC | 6 |
| Yang, SH | 4 |
| Li, AF | 1 |
| Chen, WS | 5 |
| Chang, SC | 4 |
| Moreau, LC | 1 |
| Rajan, R | 1 |
| Thirlwell, MP | 2 |
| Alcindor, T | 2 |
| Engelen, SM | 1 |
| Maas, M | 1 |
| Leijtens, JW | 1 |
| van Berlo, CL | 1 |
| Jansen, RL | 3 |
| Breukink, SO | 1 |
| Dejong, CH | 1 |
| van de Velde, CJ | 1 |
| Beets-Tan, RG | 1 |
| Beets, GL | 1 |
| Cohen, MH | 6 |
| Shord, S | 1 |
| Fuchs, C | 1 |
| He, K | 1 |
| Sickafuse, S | 1 |
| Keegan, P | 2 |
| Pazdur, R | 10 |
| El-Arab, LR | 1 |
| Swellam, M | 1 |
| El Mahdy, MM | 1 |
| Rudek, MA | 1 |
| Connolly, RM | 1 |
| Hoskins, JM | 1 |
| Garrett-Mayer, E | 1 |
| Jeter, SC | 1 |
| Armstrong, DK | 1 |
| Fetting, JH | 1 |
| Stearns, V | 1 |
| Wright, LA | 1 |
| Zhao, M | 2 |
| Watkins, SP | 1 |
| McLeod, HL | 3 |
| Davidson, NE | 2 |
| Wolff, AC | 2 |
| Thuss-Patience, P | 1 |
| Haller, B | 1 |
| Schuster, T | 2 |
| Pauligk, C | 3 |
| Luley, K | 2 |
| Bichev, D | 1 |
| Schumacher, G | 1 |
| Kim, KP | 5 |
| Sym, SJ | 1 |
| Bae, KS | 1 |
| Chang, HM | 7 |
| Kang, YK | 8 |
| Shin, JG | 1 |
| Song, MQ | 1 |
| Lin, HZ | 1 |
| Hao, LH | 1 |
| Jiang, XJ | 1 |
| Li, ZY | 1 |
| Chen, YX | 1 |
| Bondar', GV | 2 |
| Basheev, VKh | 1 |
| Zolotukhin, SÉ | 1 |
| Sovpel', IV | 1 |
| Sovpel', OV | 1 |
| Kua, VF | 1 |
| Ismail, F | 1 |
| Chee Ee Phua, V | 1 |
| Aslan, NM | 1 |
| Bracarda, S | 1 |
| Sensi, E | 3 |
| Morvillo, M | 1 |
| Wu, XY | 1 |
| Huang, XE | 1 |
| You, SX | 1 |
| Lu, YY | 1 |
| Cao, J | 3 |
| Bennamoun, M | 3 |
| Mabro, M | 6 |
| Brusquant, D | 3 |
| Pruvot, FR | 2 |
| Wiazzane, N | 1 |
| Chauffert, B | 6 |
| Lindsay, CR | 1 |
| Roxburgh, P | 1 |
| Graham, J | 1 |
| Pan, J | 2 |
| Shen, S | 1 |
| Xu, Z | 2 |
| Huang, S | 3 |
| Pernot, S | 1 |
| Samalin, E | 4 |
| Dalban, C | 1 |
| Ychou, M | 16 |
| Turki, H | 1 |
| Lepère, C | 3 |
| Vaillant, JN | 2 |
| Landi, B | 2 |
| Rougier, P | 18 |
| Vermorken, JB | 4 |
| Stöhlmacher-Williams, J | 1 |
| Davidenko, I | 1 |
| Licitra, L | 2 |
| Winquist, E | 1 |
| Villanueva, C | 2 |
| Foa, P | 2 |
| Rottey, S | 2 |
| Skladowski, K | 1 |
| Tahara, M | 4 |
| Pai, VR | 1 |
| Faivre, S | 1 |
| Blajman, CR | 1 |
| Forastiere, AA | 2 |
| Stein, BN | 1 |
| Oliner, KS | 4 |
| Pan, Z | 1 |
| Bach, BA | 1 |
| Fu, Z | 1 |
| Yin, H | 1 |
| Chan, A | 3 |
| Conte, PF | 9 |
| Petruzelka, L | 2 |
| Tubiana-Mathieu, N | 6 |
| Ganju, V | 3 |
| Llombart, A | 2 |
| Espie, M | 3 |
| Majois, F | 2 |
| Gil, MG | 1 |
| Vaissiere, N | 2 |
| Villanova, G | 2 |
| Kaley, K | 3 |
| Brennan, M | 2 |
| Garcon, MC | 2 |
| Rodriguez, G | 3 |
| Lim, B | 1 |
| Scicchitano, A | 2 |
| Beachler, C | 1 |
| Gusani, N | 1 |
| Sarwani, N | 2 |
| Staveley-O'Carroll, K | 1 |
| Ashkenazi, A | 2 |
| Portera, C | 1 |
| El-Deiry, WS | 4 |
| Lamparella, NE | 1 |
| Saroya, BS | 1 |
| Sarwani, NE | 1 |
| Kim, HO | 1 |
| Kim, HJ | 5 |
| Lee, SJ | 5 |
| Oh, SJ | 1 |
| Ryu, JS | 1 |
| Moon, DH | 1 |
| Hansen, TF | 4 |
| Nielsen, BS | 1 |
| Jakobsen, A | 6 |
| Sørensen, FB | 2 |
| Crown, JP | 2 |
| Diéras, V | 8 |
| Staroslawska, E | 2 |
| Yardley, DA | 3 |
| Bachelot, T | 5 |
| Davidson, N | 3 |
| Wildiers, H | 1 |
| Fasching, PA | 1 |
| Capitain, O | 1 |
| Ramos, M | 1 |
| Cognetti, F | 6 |
| Fountzilas, G | 4 |
| Blasinska-Morawiec, M | 1 |
| Liedtke, C | 1 |
| Kreienberg, R | 2 |
| Miller, WH | 1 |
| Tassell, V | 1 |
| Huang, X | 2 |
| Paolini, J | 1 |
| Kern, KA | 2 |
| Romieu, G | 1 |
| Bohanes, P | 1 |
| Benhaim, L | 3 |
| Graziano, F | 7 |
| Ruzzo, A | 1 |
| Lucchesi, S | 1 |
| De Vita, F | 4 |
| Abe, H | 2 |
| Mafune, K | 1 |
| Minamimura, K | 1 |
| Abe, M | 2 |
| Umemura, A | 1 |
| Hirata, T | 1 |
| Boisen, MK | 1 |
| Johansen, JS | 2 |
| Dehlendorff, C | 1 |
| Larsen, JS | 1 |
| Østerlind, K | 1 |
| Hansen, J | 1 |
| Nielsen, SE | 2 |
| Tarpgaard, LS | 3 |
| Holländer, NH | 2 |
| Keldsen, N | 2 |
| Jensen, BB | 1 |
| Jensen, BV | 2 |
| Takii, Y | 1 |
| Maruyama, S | 2 |
| Mizunuma, N | 6 |
| Curigliano, G | 1 |
| Pivot, X | 4 |
| Cortés, J | 5 |
| Elias, A | 1 |
| Cesari, R | 1 |
| Khosravan, R | 1 |
| Collier, M | 2 |
| Cataruozolo, PE | 1 |
| Goldhirsch, A | 12 |
| Maindrault-Goebel, F | 3 |
| Bengrine-Lefevre, L | 2 |
| Tyc-Szczepaniak, D | 1 |
| Wyrwicz, L | 1 |
| Kepka, L | 1 |
| Michalski, W | 1 |
| Olszyna-Serementa, M | 1 |
| Palucki, J | 1 |
| Pietrzak, L | 1 |
| Rutkowski, A | 1 |
| Bujko, K | 1 |
| Rodriguez, T | 2 |
| Polesel, J | 1 |
| Corona, G | 3 |
| Dreussi, E | 1 |
| Zhao, Y | 1 |
| Bao, Q | 1 |
| Schwarz, B | 1 |
| Zhao, L | 2 |
| Mysliwietz, J | 1 |
| Ellwart, J | 1 |
| Renner, A | 1 |
| Hirner, H | 1 |
| Niess, H | 1 |
| Camaj, P | 1 |
| Angele, M | 1 |
| Gros, S | 1 |
| Izbicki, J | 1 |
| Jauch, KW | 1 |
| Nelson, PJ | 1 |
| Chen, WW | 1 |
| Huang, TC | 1 |
| Cheng, AL | 6 |
| Hsu, CH | 4 |
| Burkes, R | 3 |
| Barugel, M | 2 |
| Humblet, Y | 6 |
| Jassem, J | 6 |
| Kocákova, I | 4 |
| Błasińska-Morawiec, M | 2 |
| Šmakal, M | 2 |
| Rother, M | 2 |
| Williams, R | 5 |
| Rong, A | 1 |
| Wiezorek, J | 2 |
| Sidhu, R | 3 |
| Patterson, SD | 2 |
| Kong, X | 2 |
| Yan, S | 1 |
| Wainberg, ZA | 4 |
| Messersmith, WA | 1 |
| Peddi, PF | 1 |
| Kapp, AV | 1 |
| Royer-Joo, S | 1 |
| Portera, CC | 1 |
| Kozloff, MF | 3 |
| Berretta, M | 3 |
| Urbani, M | 1 |
| Bearz, A | 4 |
| Lutrino, S | 1 |
| Foltran, L | 1 |
| Ferrari, L | 1 |
| Talamini, R | 2 |
| Fiorica, F | 1 |
| Lleshi, A | 1 |
| Canzonieri, V | 1 |
| Lestuzzi, C | 1 |
| Borsatti, E | 1 |
| Fisichella, R | 1 |
| Tirelli, U | 3 |
| Ma, BB | 1 |
| Chan, SL | 1 |
| Ho, WM | 1 |
| Lau, W | 1 |
| Mo, F | 1 |
| Hui, EP | 1 |
| Chan, C | 1 |
| Poon, A | 2 |
| Dattatray, RD | 1 |
| Wong, SC | 1 |
| To, KF | 1 |
| King, AD | 1 |
| Ahuja, A | 1 |
| Chan, AT | 1 |
| Kjersem, JB | 2 |
| Ikdahl, T | 4 |
| Lingjaerde, OC | 1 |
| Guren, T | 2 |
| Fakih, M | 3 |
| Schwartzberg, L | 2 |
| Yee, L | 1 |
| Dreisbach, L | 1 |
| Hei, YJ | 1 |
| Galimi, F | 1 |
| Pan, Y | 3 |
| Haddad, V | 1 |
| Hsu, CP | 1 |
| Sabin, A | 1 |
| Saltz, L | 4 |
| Fukuchi, M | 2 |
| Ishibashi, K | 7 |
| Tajima, Y | 2 |
| Okada, N | 5 |
| Yokoyama, M | 1 |
| Chika, N | 3 |
| Hatano, S | 4 |
| Matsuzawa, T | 2 |
| Kumamoto, K | 5 |
| Kumagai, Y | 4 |
| Mochiki, E | 3 |
| Ishida, H | 8 |
| Giessen, C | 5 |
| Laubender, RP | 3 |
| Schulz, C | 4 |
| Porschen, R | 7 |
| Schmiegel, W | 7 |
| Reinacher-Schick, A | 5 |
| Hegewisch-Becker, S | 4 |
| Ribecco, AS | 1 |
| Pino, MS | 1 |
| Cipriani, G | 1 |
| Marinozzi, C | 1 |
| Fioretto, L | 2 |
| Michelucci, A | 1 |
| Pfanner, E | 8 |
| Brunetti, I | 7 |
| Simi, P | 1 |
| Ferry, DR | 2 |
| McKendrick, JJ | 3 |
| Chevalier, S | 2 |
| Allegra, CJ | 5 |
| Nicholson, S | 1 |
| Hall, E | 1 |
| Harland, SJ | 1 |
| Chester, JD | 1 |
| Pickering, L | 1 |
| Barber, J | 1 |
| Elliott, T | 1 |
| Thomson, A | 1 |
| Burnett, S | 1 |
| Cruickshank, C | 1 |
| Carrington, B | 1 |
| Waters, R | 1 |
| Bahl, A | 1 |
| Wu, Z | 2 |
| Su, Y | 1 |
| Zeng, RF | 1 |
| Gu, MF | 1 |
| Huang, SM | 1 |
| Unal, OU | 1 |
| Oztop, I | 1 |
| Unek, IT | 1 |
| Yilmaz, AU | 1 |
| Deville, JL | 1 |
| Flechon, A | 1 |
| Bruyère, F | 1 |
| Karsenty, G | 1 |
| Guy, L | 1 |
| Bastide, C | 1 |
| Rivera, E | 3 |
| Chang, JC | 2 |
| Semiglazov, V | 2 |
| Burdaeva, O | 1 |
| Kirby, MG | 1 |
| Spector, T | 1 |
| Swieboda-Sadlej, A | 2 |
| Barone, C | 7 |
| Kim, JG | 5 |
| Pericay, C | 6 |
| Pastorelli, D | 2 |
| Tarazi, J | 1 |
| Rosbrook, B | 1 |
| Bloom, J | 1 |
| Ricart, AD | 1 |
| Kim, S | 2 |
| Sobrero, AF | 2 |
| Lee, SU | 1 |
| Kim, DY | 2 |
| Baek, JY | 3 |
| Chang, HJ | 1 |
| Kim, MJ | 2 |
| Kim, TH | 2 |
| Park, JW | 2 |
| Oh, JH | 1 |
| von Weikersthal, LF | 4 |
| Kellokumpu-Lehtinen, PL | 2 |
| Tuunanen, T | 1 |
| Kautio, AL | 1 |
| Lehtinen, I | 1 |
| Tanner, M | 1 |
| Kuwabara, K | 2 |
| Ueda, A | 4 |
| Ogawa, K | 5 |
| Yoshita, H | 2 |
| Mihara, H | 2 |
| Ando, T | 3 |
| Kajiura, S | 3 |
| Fujinami, H | 2 |
| Nishikawa, J | 2 |
| Minemura, M | 2 |
| Terada, M | 1 |
| Kobayashi, T | 1 |
| Horikawa, N | 2 |
| Yabushita, K | 2 |
| Note, M | 1 |
| Sugiyama, T | 4 |
| Tzeng, CW | 1 |
| Tran Cao, HS | 1 |
| Lee, JE | 2 |
| Pisters, PW | 1 |
| Varadhachary, GR | 2 |
| Wolff, RA | 7 |
| Abbruzzese, JL | 6 |
| Crane, CH | 4 |
| Evans, DB | 2 |
| Abbott, DE | 1 |
| Aloia, TA | 1 |
| Fleming, JB | 1 |
| Katz, MH | 1 |
| Bruera, G | 3 |
| Cannita, K | 4 |
| Giordano, AV | 2 |
| Vicentini, R | 2 |
| Ficorella, C | 4 |
| Ricevuto, E | 4 |
| Uslu, R | 1 |
| Dane, F | 4 |
| Yilmaz, U | 2 |
| Buyukunal, E | 3 |
| Camci, C | 2 |
| Sencan, O | 1 |
| Kilickap, S | 2 |
| Ozdener, F | 1 |
| Cevik, D | 1 |
| Schwartzberg, LS | 4 |
| Wang, G | 1 |
| Somer, BG | 1 |
| Blakely, LJ | 1 |
| Wheeler, BM | 1 |
| Walker, MS | 2 |
| Stepanski, EJ | 2 |
| Houts, AC | 2 |
| Tatli, AM | 1 |
| Uysal, M | 2 |
| Goksu, SS | 1 |
| Gunduz, S | 1 |
| Arslan, D | 1 |
| Ozdogan, M | 1 |
| Gamucci, T | 4 |
| Moscetti, L | 2 |
| Mentuccia, L | 2 |
| Pizzuti, L | 1 |
| Mauri, M | 1 |
| Zampa, G | 1 |
| Pavese, I | 2 |
| Sperduti, I | 3 |
| Vaccaro, A | 1 |
| Vici, P | 4 |
| Hu, T | 1 |
| Correale, P | 3 |
| Botta, C | 1 |
| Rotundo, MS | 1 |
| Guglielmo, A | 1 |
| Conca, R | 2 |
| Licchetta, A | 1 |
| Pastina, P | 1 |
| Bestoso, E | 1 |
| Ciliberto, D | 1 |
| Cusi, MG | 1 |
| Fioravanti, A | 3 |
| Guidelli, GM | 1 |
| Bianco, MT | 1 |
| Misso, G | 1 |
| Martino, E | 1 |
| Tassone, P | 1 |
| Mini, E | 3 |
| Mantovani, G | 2 |
| Ridolfi, R | 4 |
| Pirtoli, L | 1 |
| Tagliaferri, P | 1 |
| Ueda, Y | 2 |
| You, KY | 1 |
| Peng, HH | 1 |
| Gao, YH | 1 |
| Zhou, GQ | 1 |
| Chang, H | 1 |
| Du, XJ | 1 |
| Xiao, L | 1 |
| Zeng, ZF | 1 |
| Wen, BX | 1 |
| Liu, MZ | 1 |
| Liao, Y | 1 |
| Fan, Y | 4 |
| Wan, Y | 1 |
| Zhu, D | 2 |
| Yu, Q | 1 |
| Zhang, Z | 2 |
| Sun, M | 1 |
| Cai, S | 2 |
| Zhang, B | 3 |
| Bae, S | 1 |
| Singh, K | 1 |
| Datta, PK | 1 |
| Kemmochi, T | 2 |
| Egawa, T | 2 |
| Mihara, K | 1 |
| Ohkubo, Y | 2 |
| Mori, T | 1 |
| Nagashima, A | 2 |
| Yamamuro, W | 2 |
| Babaya, A | 1 |
| Yamamoto, T | 3 |
| Oda, K | 1 |
| Nakata, K | 1 |
| Ohzato, H | 1 |
| Sato, N | 1 |
| Mukubo, H | 1 |
| Nakanuma, S | 1 |
| Yasui, T | 1 |
| Kita, I | 1 |
| Takanaka, T | 1 |
| Tsuneda, A | 1 |
| Kurata, T | 1 |
| Makita, N | 1 |
| Hagino, S | 1 |
| Iwata, K | 1 |
| Kiriyama, M | 1 |
| Janni, W | 1 |
| Sarosiek, T | 1 |
| Karaszewska, B | 1 |
| Pikiel, J | 1 |
| Potemski, P | 1 |
| Salat, C | 1 |
| Brain, E | 1 |
| Caglevic, C | 1 |
| Briggs, K | 1 |
| Desilvio, M | 1 |
| Marini, L | 1 |
| Papadimitriou, C | 1 |
| Loree, JM | 1 |
| Mulder, KE | 1 |
| Ghosh, S | 1 |
| Spratlin, JL | 1 |
| Seetharamu, N | 1 |
| Melamed, J | 1 |
| Miller, G | 1 |
| Rotterdam, H | 1 |
| Gonda, T | 1 |
| Villanueva, G | 1 |
| Halmos, B | 1 |
| Baroudi, O | 1 |
| Baroudi, T | 1 |
| Omrane, I | 1 |
| Moussa, A | 1 |
| Mezlini, A | 1 |
| Ayari, H | 1 |
| Guermazi, S | 1 |
| Bahloul, A | 1 |
| Bouzaienne, H | 1 |
| Uhrhammer, N | 1 |
| Bignon, YJ | 1 |
| El-Gaaied, AB | 1 |
| Bougatef, K | 1 |
| Bichard, D | 1 |
| Limat, S | 2 |
| Vincent, J | 2 |
| Berthou, J | 1 |
| Orry, D | 1 |
| Ortega-Deballon, P | 1 |
| Lakkis, Z | 1 |
| Facy, O | 1 |
| Heyd, B | 1 |
| Rat, P | 1 |
| Nerich, V | 1 |
| Ladoire, S | 2 |
| Sanders, IW | 1 |
| Haslett, K | 1 |
| Correa, P | 1 |
| Paterson, C | 1 |
| James, A | 1 |
| Rizwanullah, M | 1 |
| Grose, D | 1 |
| Engelmann, BE | 1 |
| Loft, A | 1 |
| Kjær, A | 1 |
| Nielsen, HJ | 4 |
| Gerds, TA | 1 |
| Benzon, EV | 1 |
| Brünner, N | 5 |
| Christensen, IJ | 5 |
| Hansson, SH | 1 |
| Kristensen, MH | 1 |
| Löfgren, J | 1 |
| Markova, E | 1 |
| Sloth, C | 1 |
| Højgaard, L | 1 |
| Song, P | 1 |
| Schrieber, S | 1 |
| Xu, Q | 2 |
| Blumenthal, G | 1 |
| Amiri Kordestani, L | 1 |
| Cortazar, P | 1 |
| Ibrahim, A | 3 |
| Justice, R | 3 |
| Tang, S | 2 |
| Booth, B | 2 |
| Mehrotra, N | 1 |
| Rahman, A | 1 |
| De Re, V | 1 |
| Caggiari, L | 1 |
| De Zorzi, M | 1 |
| Racanelli, V | 1 |
| D' Andrea, M | 1 |
| Yilmaz, M | 1 |
| Smorenburg, CH | 1 |
| de Groot, SM | 1 |
| van Leeuwen-Stok, AE | 1 |
| Hamaker, ME | 1 |
| Wymenga, AN | 1 |
| de Graaf, H | 1 |
| de Jongh, FE | 2 |
| Braun, JJ | 1 |
| Maartense, E | 1 |
| van Tinteren, H | 2 |
| Nortier, JWR | 1 |
| Seynaeve, C | 2 |
| Ortiz-Tudela, E | 1 |
| Iurisci, I | 1 |
| Beau, J | 1 |
| Moreau, T | 3 |
| Rol, MA | 1 |
| Madrid, JA | 1 |
| Lévi, F | 12 |
| Miger, J | 1 |
| Holmqvist, A | 1 |
| Sun, XF | 1 |
| Albertsson, M | 2 |
| Spindler, KL | 1 |
| Pallisgaard, N | 1 |
| Andersen, RF | 2 |
| Ploen, J | 1 |
| Terazawa, T | 1 |
| Nishitani, H | 3 |
| Kato, K | 11 |
| Hashimoto, H | 1 |
| Akiyoshi, K | 3 |
| Iwasa, S | 4 |
| Nakajima, TE | 3 |
| Hamaguchi, T | 8 |
| Shimada, Y | 10 |
| Hsieh, JS | 1 |
| Yeh, HT | 1 |
| Su, YC | 1 |
| Tai, CJ | 1 |
| Bai, LY | 1 |
| Su, WC | 1 |
| Chu, E | 5 |
| Haller, D | 2 |
| Cartwright, T | 4 |
| Twelves, C | 12 |
| Cassidy, J | 11 |
| Sun, W | 2 |
| McKenna, E | 3 |
| Lee, S | 4 |
| Schmoll, HJ | 12 |
| Herbertson, RA | 1 |
| Lee, FT | 1 |
| Gill, S | 3 |
| Chappell, B | 1 |
| Cavicchiolo, T | 1 |
| Saunder, T | 1 |
| O'Keefe, GJ | 1 |
| Lee, ST | 1 |
| Murphy, R | 2 |
| Hopkins, W | 1 |
| Scott, FE | 1 |
| Scott, AM | 2 |
| Miranda, MB | 1 |
| Hartmann, JT | 4 |
| Gencer, D | 1 |
| Hochhaus, A | 3 |
| Soares, HP | 1 |
| Bayraktar, S | 1 |
| Blaya, M | 1 |
| Lopes, G | 3 |
| Merchan, J | 1 |
| Macintyre, J | 1 |
| Mayo, C | 1 |
| Green, MR | 1 |
| Silva, O | 1 |
| Levi, J | 3 |
| Walker, G | 1 |
| Rocha-Lima, CM | 1 |
| Nakayama, G | 2 |
| Tanaka, C | 3 |
| Uehara, K | 1 |
| Mashita, N | 1 |
| Hayashi, N | 1 |
| Kobayashi, D | 2 |
| Kanda, M | 1 |
| Fujii, T | 2 |
| Sugimoto, H | 1 |
| Koike, M | 2 |
| Nomoto, S | 1 |
| Fujiwara, M | 2 |
| Ando, Y | 2 |
| Kodera, Y | 3 |
| Elsoueidi, R | 1 |
| Craig, J | 1 |
| Mourad, H | 1 |
| Richa, EM | 1 |
| Rambach, L | 1 |
| Orditura, M | 3 |
| Galizia, G | 3 |
| Sforza, V | 1 |
| Gambardella, V | 1 |
| Fabozzi, A | 1 |
| Laterza, MM | 1 |
| Andreozzi, F | 1 |
| Ventriglia, J | 1 |
| Savastano, B | 1 |
| Mabilia, A | 1 |
| Lieto, E | 2 |
| Dirican, A | 2 |
| Kucukzeybek, Y | 2 |
| Alacacioglu, A | 1 |
| Varol, U | 1 |
| Aksun, S | 1 |
| Bayoglu, IV | 3 |
| Demir, L | 2 |
| Coban, E | 1 |
| Sutcu, R | 1 |
| Tarhan, MO | 2 |
| Temraz, S | 1 |
| Mukherji, D | 1 |
| Shamseddine, A | 1 |
| Marks, E | 2 |
| Morganti, AG | 3 |
| Mignogna, S | 2 |
| Caravatta, L | 2 |
| Deodato, F | 2 |
| Macchia, G | 3 |
| Plantamura, NM | 1 |
| Massaccesi, M | 1 |
| Picardi, V | 2 |
| Cilla, S | 2 |
| Valentini, V | 4 |
| Gubanski, M | 1 |
| Lind, PA | 1 |
| Berruti, A | 4 |
| Fazio, N | 1 |
| Ferrero, A | 1 |
| Brizzi, MP | 2 |
| Volante, M | 1 |
| Nobili, E | 1 |
| Tozzi, L | 1 |
| Bodei, L | 1 |
| Torta, M | 1 |
| D'Avolio, A | 1 |
| Priola, AM | 1 |
| Birocco, N | 2 |
| Amoroso, V | 1 |
| Biasco, G | 2 |
| Papotti, M | 1 |
| Dogliotti, L | 3 |
| Hickey, R | 1 |
| Lewandowski, RJ | 1 |
| Gates, VL | 1 |
| Vouche, M | 1 |
| Habib, A | 1 |
| Kircher, S | 1 |
| Newman, S | 1 |
| Nimeiri, H | 1 |
| Salem, R | 1 |
| Boku, N | 10 |
| Mizusawa, J | 1 |
| Koizumi, W | 3 |
| Fukase, K | 1 |
| Goto, M | 2 |
| Nishina, T | 6 |
| Ohtsu, A | 6 |
| Chung, M | 3 |
| Cho, MS | 1 |
| Baek, SJ | 1 |
| Hur, H | 1 |
| Min, BS | 2 |
| Baik, SH | 1 |
| Kim, NK | 3 |
| Maurel, J | 4 |
| Ayoub, JP | 2 |
| Moore, MJ | 4 |
| Asmis, TR | 1 |
| Schwartz, JD | 1 |
| Ballal, S | 1 |
| Stec, R | 1 |
| Bodnar, L | 1 |
| Smoter, M | 1 |
| Korniluk, J | 1 |
| Kuchar, A | 1 |
| Młot, B | 1 |
| Szczylik, C | 2 |
| Iwamoto, S | 2 |
| Hazama, S | 3 |
| Miyake, Y | 2 |
| Bando, H | 4 |
| Sasaki, Y | 6 |
| Arai, T | 2 |
| Goto, A | 3 |
| Ura, T | 4 |
| Shirao, K | 5 |
| Primrose, J | 1 |
| Falk, S | 2 |
| Finch-Jones, M | 1 |
| Valle, J | 3 |
| O'Reilly, D | 1 |
| Siriwardena, A | 1 |
| Hornbuckle, J | 1 |
| Peterson, M | 1 |
| Rees, M | 1 |
| Hickish, T | 2 |
| Butler, R | 1 |
| Stanton, L | 1 |
| Dixon, E | 2 |
| Little, L | 1 |
| Bowers, M | 1 |
| Pugh, S | 1 |
| Garden, OJ | 1 |
| Maughan, T | 1 |
| Bridgewater, J | 4 |
| Tian, Y | 2 |
| Xu, F | 3 |
| Molina-Garrido, MJ | 1 |
| Mora-Rufete, A | 1 |
| Bilici, A | 1 |
| Mokrim, M | 1 |
| Aftimos, PG | 1 |
| Errihani, H | 1 |
| Piccart-Gebhart, M | 2 |
| Vamvakas, L | 5 |
| Matikas, A | 1 |
| Karampeazis, A | 1 |
| Hatzidaki, D | 1 |
| Kakolyris, S | 7 |
| Christophylakis, C | 1 |
| Boukovinas, I | 3 |
| Polyzos, A | 6 |
| Georgoulias, V | 13 |
| Souglakos, J | 7 |
| Choi, PR | 1 |
| Park, SJ | 5 |
| Park, MI | 2 |
| Moon, W | 1 |
| Kim, SE | 1 |
| Lee, GW | 1 |
| Bolonesi, RM | 1 |
| Rogers, JE | 2 |
| Shureiqi, I | 1 |
| Bozkurt, O | 1 |
| Kaplan, MA | 1 |
| Cetin, B | 1 |
| Ozaslan, E | 1 |
| Karaca, H | 2 |
| Inanc, M | 2 |
| Duran, AO | 2 |
| García-Girón, C | 4 |
| Alonso, V | 3 |
| Dueñas, R | 4 |
| Cirera, L | 2 |
| Bustos, IA | 1 |
| Sotelo, MJ | 2 |
| García-Paredes, B | 2 |
| Aguado, C | 2 |
| Miyamoto, S | 2 |
| Qian, W | 1 |
| Zhu, G | 1 |
| Ji, Q | 1 |
| Guo, Y | 2 |
| Kasai, K | 1 |
| Kooka, Y | 1 |
| Suzuki, Y | 2 |
| Oikawa, T | 1 |
| Ushio, A | 1 |
| Kasai, Y | 1 |
| Sawara, K | 1 |
| Oikawa, K | 1 |
| Takikawa, Y | 1 |
| McRee, AJ | 1 |
| Davies, JM | 2 |
| Sanoff, HG | 1 |
| Bernard, S | 1 |
| Dees, EC | 1 |
| Keller, K | 1 |
| Ivanova, A | 1 |
| O'Neil, BH | 2 |
| Scarabelli, L | 1 |
| Giovanardi, F | 1 |
| Gervasi, E | 1 |
| Prati, G | 1 |
| Pezzuolo, D | 1 |
| Scaltriti, L | 1 |
| Alonso-Espinaco, V | 1 |
| Cuatrecasas, M | 1 |
| Escudero, P | 2 |
| Marmol, M | 1 |
| Horndler, C | 1 |
| Ortego, J | 1 |
| Gallego, R | 1 |
| Codony-Servat, J | 1 |
| Garcia-Albeniz, X | 1 |
| Jares, P | 1 |
| Castells, A | 1 |
| Lozano, JJ | 1 |
| Rosell, R | 1 |
| Maillet, M | 1 |
| Dréanic, J | 1 |
| Dhooge, M | 1 |
| Mir, O | 2 |
| Brezault, C | 2 |
| Goldwasser, F | 3 |
| Chaussade, S | 2 |
| Ambros, T | 1 |
| Zeichner, SB | 2 |
| Zaravinos, J | 1 |
| Montero, AJ | 2 |
| Ahn, E | 1 |
| Aruna, M | 1 |
| Kronish, L | 1 |
| Mahtani, RL | 1 |
| Vogel, CL | 5 |
| Ide, M | 2 |
| Takada, T | 1 |
| Sutoh, T | 1 |
| Morita, H | 2 |
| Yajima, R | 1 |
| Yamaguchi, S | 1 |
| Tsutsumi, S | 1 |
| Asao, T | 3 |
| Oyama, T | 2 |
| Kuwano, H | 4 |
| Trouilloud, I | 1 |
| Markoutsaki, T | 1 |
| Gauthier, M | 1 |
| Dupont-Gossart, AC | 1 |
| Thirot-Bidault, A | 1 |
| Joubert, F | 1 |
| Fanica, D | 1 |
| Cihan, YB | 1 |
| Péron, J | 2 |
| Polivka, V | 1 |
| Chabaud, S | 1 |
| Poupart, M | 2 |
| Ceruse, P | 3 |
| Ramade, A | 2 |
| Girodet, D | 2 |
| Zrounba, P | 2 |
| Fayette, J | 2 |
| Chang, YY | 1 |
| Jiang, JK | 3 |
| Lan, YT | 2 |
| Wang, HS | 3 |
| Lin, TC | 4 |
| Wu, W | 1 |
| Tan, XF | 1 |
| Tan, HT | 1 |
| Lim, TK | 1 |
| Chung, MC | 1 |
| Landsman-Blumberg, PB | 1 |
| Carter, GC | 1 |
| Johnson, BH | 1 |
| Sedgley, R | 1 |
| Nicol, SJ | 1 |
| Shankaran, V | 1 |
| Corrigan, PA | 1 |
| Cicci, TA | 1 |
| Auten, JJ | 1 |
| Lowe, DK | 1 |
| Hurvitz, S | 1 |
| Guerin, A | 1 |
| Brammer, M | 1 |
| Guardino, E | 3 |
| Zhou, ZY | 1 |
| Latremouille Viau, D | 1 |
| Wu, EQ | 1 |
| Lalla, D | 1 |
| Williams, M | 1 |
| Singer, RA | 1 |
| Lerner, A | 1 |
| Ikeya, T | 1 |
| Shibutani, M | 1 |
| Maeda, K | 1 |
| Sugano, K | 2 |
| Nagahara, H | 1 |
| Ohtani, H | 2 |
| Hirakawa, K | 1 |
| Miyamae, Y | 1 |
| Takahashi, K | 1 |
| Igarashi, T | 1 |
| Tanaka, K | 5 |
| Takahashi, N | 1 |
| Hirai, K | 1 |
| Tsukagoshi, H | 1 |
| Ogawa, H | 1 |
| Yoshinari, D | 1 |
| Sunose, Y | 1 |
| Takeyoshi, I | 1 |
| Haga, N | 2 |
| Sano, M | 3 |
| Frías, C | 1 |
| Abad, A | 6 |
| Lamas, MJ | 1 |
| Echave, M | 1 |
| Oyagüez, I | 1 |
| Rubio, M | 1 |
| Giménez, E | 1 |
| Naoshy, S | 1 |
| Joulain, F | 2 |
| Iqbal, SU | 1 |
| Bellmunt, J | 1 |
| Suarez, C | 1 |
| Gallardo, E | 1 |
| Rodon, J | 1 |
| Pons, F | 1 |
| Bonfill, T | 1 |
| Beltran, M | 1 |
| Moya, I | 1 |
| Galtes, S | 1 |
| Albanell, J | 1 |
| Carles, J | 1 |
| Słomian, G | 1 |
| Świętochowska, E | 1 |
| Malinowska-Borowska, J | 1 |
| Kasperczyk, S | 1 |
| Rogalska, A | 1 |
| Nowak, P | 1 |
| Aoe, K | 1 |
| Takigawa, N | 1 |
| Hotta, K | 1 |
| Maeda, T | 1 |
| Kishino, D | 1 |
| Nogami, N | 1 |
| Tabata, M | 1 |
| Harita, S | 1 |
| Kubo, T | 2 |
| Hosokawa, S | 1 |
| Fujiwara, K | 1 |
| Gemba, K | 1 |
| Yasugi, M | 1 |
| Kozuki, T | 1 |
| Kato, Y | 1 |
| Katsui, K | 1 |
| Kanazawa, S | 1 |
| Ueoka, H | 1 |
| Tanimoto, M | 1 |
| Kiura, K | 1 |
| Liu, XF | 1 |
| Sun, JQ | 1 |
| Yin, C | 1 |
| Liu, TF | 1 |
| Yang, H | 3 |
| Chen, LH | 1 |
| Morris, VK | 1 |
| Parikh, N | 1 |
| Jiang, ZQ | 1 |
| Maru, D | 1 |
| Elvin, P | 1 |
| Gallick, G | 1 |
| Hjelmgren, J | 2 |
| de Liège, F | 1 |
| Lanier, J | 1 |
| Knox, H | 1 |
| Barber, B | 4 |
| Jackson, CG | 1 |
| Sharples, K | 1 |
| Thompson, PI | 2 |
| O'Donnell, A | 1 |
| Robinson, BA | 2 |
| Perez, DJ | 1 |
| Adams, J | 1 |
| Isaacs, R | 3 |
| Deva, S | 1 |
| Hinder, VA | 1 |
| Findlay, MP | 3 |
| Nagai, Y | 2 |
| Beppu, T | 1 |
| Sakamoto, Y | 2 |
| Hayashi, H | 3 |
| Nitta, H | 1 |
| Imai, K | 1 |
| Masuda, T | 1 |
| Okabe, H | 2 |
| Hirashima, K | 1 |
| Imamura, Y | 1 |
| Baba, Y | 1 |
| Chikamoto, A | 1 |
| Saura, C | 2 |
| Garcia-Saenz, JA | 2 |
| Xu, B | 6 |
| Harb, W | 1 |
| Moroose, R | 1 |
| Pluard, T | 1 |
| Kiger, C | 1 |
| Germa, C | 1 |
| Wang, K | 1 |
| Martin, M | 8 |
| Baselga, J | 4 |
| Kim, SB | 3 |
| Cortesi, E | 5 |
| Spadi, R | 2 |
| Amoroso, D | 4 |
| Boni, C | 4 |
| Sharma, MR | 1 |
| Gray, E | 1 |
| Sargent, DJ | 5 |
| Karrison, TG | 1 |
| Huang, WK | 1 |
| Kuo, YC | 1 |
| Tsang, NM | 1 |
| Shen, WC | 1 |
| Chou, WC | 1 |
| Yang, TS | 5 |
| Choo, SP | 3 |
| Ong, SJ | 1 |
| Ong, SY | 2 |
| Chong, SS | 1 |
| Teo, YY | 1 |
| Lee, CG | 1 |
| Eng, C | 4 |
| Chang, GJ | 3 |
| You, YN | 1 |
| Das, P | 3 |
| Rodriguez-Bigas, M | 1 |
| Xing, Y | 1 |
| Ohinata, A | 1 |
| Pathak, P | 1 |
| Sethi, S | 1 |
| Phillips, JK | 1 |
| Vahdat, L | 4 |
| Olivo, M | 1 |
| He, Y | 2 |
| Kaufman, PA | 1 |
| Awada, A | 3 |
| Fernandez-Plana, J | 1 |
| Quintero, G | 2 |
| Mendez, M | 2 |
| Saigi, E | 1 |
| Chung, IJ | 3 |
| Cho, SH | 2 |
| Kang, HJ | 7 |
| Shin, DB | 7 |
| Lee, JW | 1 |
| Jo, SJ | 1 |
| Malkhasyan, K | 1 |
| Halene, S | 1 |
| Arnold, D | 5 |
| Ten Tije, AJ | 2 |
| Vishwanath, RL | 1 |
| Bhargava, P | 1 |
| Palmieri, G | 3 |
| Buonerba, C | 1 |
| Ottaviano, M | 1 |
| Federico, P | 2 |
| Calabrese, F | 2 |
| Von Arx, C | 1 |
| De Maio, AP | 1 |
| Marino, M | 2 |
| Lalle, M | 2 |
| Montella, L | 2 |
| Merola, C | 2 |
| Milella, M | 3 |
| Bergaglio, M | 3 |
| Di Lorenzo, G | 2 |
| Damiano, V | 2 |
| Jackisch, C | 1 |
| Schoenegg, W | 1 |
| Reichert, D | 1 |
| Welslau, M | 2 |
| Selbach, J | 1 |
| Harich, HD | 1 |
| Tesch, H | 2 |
| Wohlfarth, T | 1 |
| Eustermann, H | 1 |
| Hinke, A | 5 |
| Han, Y | 1 |
| Ye, J | 1 |
| Wu, D | 1 |
| Wu, P | 1 |
| Gao, S | 3 |
| Huang, J | 1 |
| Terjung, A | 1 |
| Kummer, S | 1 |
| Friedrich, M | 1 |
| Park, P | 1 |
| Guo, W | 3 |
| Zhu, X | 5 |
| Soerensen, AV | 1 |
| Donskov, F | 1 |
| Kjellberg, J | 1 |
| Ibsen, R | 1 |
| Hermann, GG | 1 |
| Jensen, NV | 1 |
| Fode, K | 1 |
| Geertsen, PF | 1 |
| Ding, HH | 1 |
| Wu, WD | 1 |
| Ji, ZY | 1 |
| Jin, JH | 1 |
| Wang, JJ | 2 |
| Song, WF | 1 |
| Wang, LW | 2 |
| Ren, T | 1 |
| Feng, F | 1 |
| Xiang, Y | 1 |
| Xu, T | 1 |
| Zhou, M | 1 |
| Kong, S | 1 |
| Miao, R | 1 |
| Sheng, H | 1 |
| Derouet, MF | 1 |
| Liu, G | 2 |
| Darling, GE | 1 |
| Besiroglu, M | 1 |
| Menekse, S | 1 |
| Yapici, HS | 1 |
| Yazilitas, D | 1 |
| Bahceci, A | 1 |
| Hacibekiroglu, I | 2 |
| Aksoy, A | 1 |
| Tanriverdi, O | 1 |
| Arpaci, E | 1 |
| Ojima, H | 1 |
| Otsuji, T | 2 |
| Hyodo, I | 5 |
| Ohishi, T | 1 |
| Takeuchi, M | 3 |
| Sato, Y | 3 |
| Ohnuma, H | 1 |
| Hirakawa, M | 1 |
| Osuga, T | 1 |
| Okagawa, Y | 1 |
| Murase, K | 1 |
| Takada, K | 1 |
| Kawano, Y | 1 |
| Iyama, S | 1 |
| Hayashi, T | 3 |
| Miyanishi, K | 1 |
| Takimoto, R | 1 |
| Kobune, M | 1 |
| Okita, K | 1 |
| Mizuguchi, T | 1 |
| Furuhata, T | 1 |
| Kato, J | 2 |
| Carlsen, AL | 1 |
| Heegaard, NH | 1 |
| Ferrone, CR | 1 |
| Marchegiani, G | 1 |
| Hong, TS | 1 |
| Ryan, DP | 7 |
| Deshpande, V | 1 |
| McDonnell, EI | 1 |
| Sabbatino, F | 1 |
| Santos, DD | 1 |
| Allen, JN | 1 |
| Blaszkowsky, LS | 1 |
| Clark, JW | 5 |
| Faris, JE | 1 |
| Goyal, L | 1 |
| Kwak, EL | 2 |
| Murphy, JE | 1 |
| Ting, DT | 1 |
| Wo, JY | 1 |
| Zhu, AX | 3 |
| Warshaw, AL | 1 |
| Lillemoe, KD | 1 |
| Fernández-del Castillo, C | 1 |
| Wade, R | 1 |
| Duarte, A | 1 |
| Simmonds, M | 1 |
| Rodriguez-Lopez, R | 1 |
| Duffy, S | 1 |
| Woolacott, N | 1 |
| Spackman, E | 2 |
| Petrioli, R | 6 |
| Roviello, G | 2 |
| Fiaschi, AI | 5 |
| Laera, L | 2 |
| Marrelli, D | 2 |
| Roviello, F | 3 |
| Francini, E | 5 |
| Hwang, J | 2 |
| Heiskala, M | 1 |
| de La Bourdonnaye, G | 1 |
| Mita, M | 1 |
| Choi, DR | 1 |
| Yoon, SN | 1 |
| Kim, KY | 1 |
| Kim, BC | 1 |
| Choi, YK | 1 |
| Kim, JB | 1 |
| Han, B | 2 |
| Song, HH | 1 |
| Zang, DY | 4 |
| Nipp, RD | 1 |
| Hwang, IG | 3 |
| Jang, JS | 1 |
| Oh, SY | 3 |
| Rho, MH | 1 |
| Nam, EM | 1 |
| Lee, HR | 2 |
| Jun, HJ | 1 |
| Chi, KC | 1 |
| Joerger, M | 1 |
| Huitema, AD | 1 |
| Cats, A | 4 |
| Doodeman, VD | 1 |
| Smits, PH | 1 |
| Vainchtein, L | 1 |
| Rosing, H | 1 |
| Meijerman, I | 1 |
| Zueger, M | 1 |
| Meulendijks, D | 1 |
| Cerny, TD | 1 |
| Beijnen, JH | 1 |
| Schellens, JH | 1 |
| Linot, B | 1 |
| Boige, V | 3 |
| Legoux, JL | 2 |
| Lacave, R | 1 |
| Lefevre, M | 1 |
| Soussan, P | 1 |
| Antoine, M | 1 |
| Périé, S | 1 |
| Belloc, JB | 1 |
| Banal, A | 1 |
| Albert, S | 1 |
| Chabolle, F | 1 |
| Baril, P | 1 |
| Gatineau, M | 1 |
| Housset, M | 2 |
| Moukoko, R | 1 |
| Benetkiewicz, M | 1 |
| Lacau St Guily, J | 1 |
| Seker, MM | 1 |
| Deveci, K | 1 |
| Seker, A | 1 |
| Sancakdar, E | 1 |
| Yilmaz, A | 1 |
| Turesin, AK | 1 |
| Kacan, T | 1 |
| Babacan, NA | 1 |
| Goldstein, DA | 3 |
| Ayer, T | 1 |
| Howard, DH | 1 |
| Lipscomb, J | 1 |
| El-Rayes, BF | 2 |
| Flowers, CR | 2 |
| Rizvi, SM | 1 |
| Paré-Brunet, L | 1 |
| Sebio, A | 1 |
| Salazar, J | 1 |
| Berenguer-Llergo, A | 1 |
| Río, E | 1 |
| Barnadas, A | 1 |
| Baiget, M | 1 |
| Vitello, S | 3 |
| D'Amico, M | 2 |
| Abdallah, EA | 1 |
| Fanelli, MF | 1 |
| Buim, ME | 1 |
| Machado Netto, MC | 1 |
| Gasparini Junior, JL | 1 |
| Souza E Silva, V | 1 |
| Dettino, AL | 1 |
| Mingues, NB | 1 |
| Romero, JV | 1 |
| Ocea, LM | 1 |
| Rocha, BM | 1 |
| Alves, VS | 1 |
| Araújo, DV | 1 |
| Chinen, LT | 1 |
| Yoneda, M | 1 |
| Shimokawa, R | 1 |
| Nanni, O | 3 |
| Tassinari, D | 1 |
| Turci, D | 4 |
| Cavanna, L | 2 |
| Fontana, A | 1 |
| Ruscelli, S | 1 |
| Mucciarini, C | 1 |
| Lorusso, V | 6 |
| Ragazzini, A | 1 |
| Amadori, D | 11 |
| Maione, F | 2 |
| Oliaro-Bosso, S | 1 |
| Meda, C | 1 |
| Di Nicolantonio, F | 1 |
| Bussolino, F | 2 |
| Balliano, G | 1 |
| Viola, F | 1 |
| Giraudo, E | 2 |
| Argilés, G | 2 |
| Saunders, MP | 8 |
| Sobrero, A | 8 |
| Benson, A | 2 |
| Guillén Ponce, C | 1 |
| Macpherson, IR | 1 |
| Strumberg, D | 2 |
| Köhne, CH | 15 |
| Zalcberg, J | 2 |
| Wagner, A | 1 |
| Luigi Garosi, V | 1 |
| Grunert, J | 1 |
| Fakih, MG | 2 |
| Maglinte, GA | 1 |
| Bahhnassy, A | 1 |
| Mohanad, M | 1 |
| Shaarawy, S | 1 |
| Ismail, MF | 1 |
| El-Bastawisy, A | 1 |
| Ashmawy, AM | 1 |
| Zekri, AR | 1 |
| Kodaz, H | 1 |
| Erdogan, B | 1 |
| Turkmen, E | 1 |
| Esenkaya, A | 1 |
| Uzunoglu, S | 1 |
| Cicin, I | 1 |
| Yamazaki, T | 1 |
| Personeni, N | 1 |
| Verusio, C | 1 |
| Barni, S | 6 |
| Rubino, L | 1 |
| Bozzarelli, S | 1 |
| Villa, E | 4 |
| Carnaghi, C | 1 |
| Tronconi, MC | 1 |
| Gerardi, C | 1 |
| Galli, F | 1 |
| Floriani, I | 1 |
| Destro, A | 1 |
| Raschioni, C | 1 |
| Labianca, R | 5 |
| Santoro, A | 1 |
| Simkens, LH | 1 |
| May, A | 1 |
| Loosveld, OJ | 1 |
| Erdkamp, FL | 2 |
| Erjavec, Z | 1 |
| van der Torren, AM | 1 |
| Tol, J | 2 |
| Braun, HJ | 2 |
| Nieboer, P | 1 |
| van der Hoeven, JJ | 1 |
| Haasjes, JG | 1 |
| Wals, J | 1 |
| Derleyn, VA | 1 |
| Honkoop, AH | 1 |
| Mol, L | 2 |
| Ciuleanu, TE | 3 |
| Clingan, PR | 1 |
| Simms, L | 1 |
| Tamagawa, H | 2 |
| Hata, T | 2 |
| Morita, Y | 1 |
| Inukai, M | 1 |
| Kunieda, K | 1 |
| Kurachi, K | 3 |
| Ooshiro, M | 1 |
| Shimoyama, T | 1 |
| Qvortrup, C | 2 |
| Karlberg, M | 1 |
| Kersten, C | 1 |
| Vistisen, K | 1 |
| Lindh, B | 2 |
| Bjerregaard, JK | 1 |
| Terwey, JH | 2 |
| van Staveren, MC | 1 |
| Opdam, F | 1 |
| van Kuilenburg, AB | 1 |
| Maring, JG | 1 |
| Lin, CH | 2 |
| Yang, IP | 1 |
| Yeh, YS | 4 |
| Hsu, WH | 1 |
| Wu, JY | 1 |
| Kuo, CH | 1 |
| Tseng, FY | 1 |
| Roselló, S | 1 |
| Prenen, H | 2 |
| Laffranchi, B | 1 |
| Jego, V | 1 |
| von Richter, O | 1 |
| Lin, YC | 3 |
| Chen, YY | 1 |
| Lee, KD | 1 |
| Wang, CH | 2 |
| Chang, HK | 1 |
| Melichar, B | 2 |
| Kocak, I | 2 |
| Bortlicek, Z | 1 |
| Dusek, L | 1 |
| Kohoutek, M | 1 |
| Finek, J | 3 |
| Mohelnikova-Duchonova, B | 1 |
| Vyzula, R | 1 |
| Kawakami, H | 2 |
| Nishina, S | 1 |
| Sakiyama, T | 1 |
| Nonagase, Y | 1 |
| Okabe, T | 1 |
| Nakagawa, K | 3 |
| Salgado Fernández, M | 1 |
| Pérez Hoyos, MT | 1 |
| Díaz de Corcuera, I | 1 |
| Vidal Arbués, A | 1 |
| García de la Torre, M | 1 |
| Choueiri, MB | 1 |
| Shen, JP | 1 |
| Gross, AM | 1 |
| Huang, JK | 1 |
| Ideker, T | 1 |
| Fanta, P | 1 |
| Su, D | 1 |
| Han, C | 1 |
| Jiao, S | 1 |
| Bai, L | 1 |
| Giommoni, E | 1 |
| Latiano, T | 1 |
| Azzarello, D | 1 |
| Aieta, M | 1 |
| Pastina, I | 1 |
| Bertolini, A | 1 |
| Mogavero, S | 1 |
| Angelini, V | 1 |
| Pazzagli, M | 1 |
| Di Costanzo, F | 5 |
| Zhong, LP | 1 |
| Zhang, CP | 1 |
| Ren, GX | 1 |
| William, WN | 1 |
| Hong, CS | 1 |
| Sun, J | 2 |
| Zhu, HG | 1 |
| Tu, WY | 1 |
| Cai, YL | 1 |
| Yin, QM | 1 |
| Wang, LZ | 2 |
| Wang, ZH | 2 |
| Hu, YJ | 1 |
| Ji, T | 1 |
| Yang, WJ | 1 |
| Ye, WM | 1 |
| Wang, YA | 1 |
| Xu, LQ | 1 |
| Zhuang, Z | 1 |
| Lee, JJ | 3 |
| Myers, JN | 1 |
| Zhang, ZY | 1 |
| Chi, JY | 1 |
| Hsiao, YW | 1 |
| Li, CF | 1 |
| Lo, YC | 1 |
| Lin, ZY | 1 |
| Liu, YM | 1 |
| Han, X | 2 |
| Wang, SM | 2 |
| Chen, BK | 1 |
| Tsai, KK | 1 |
| Wang, JM | 1 |
| Weickhardt, AJ | 1 |
| Williams, DS | 1 |
| Lee, CK | 2 |
| Chionh, F | 1 |
| Simes, J | 1 |
| Murone, C | 1 |
| Parry, MM | 1 |
| Asadi, K | 1 |
| Nagtegaal, ID | 1 |
| Price, TJ | 3 |
| Mariadason, JM | 1 |
| Ho, MY | 1 |
| Kennecke, HF | 1 |
| Renouf, DJ | 2 |
| Cheung, WY | 1 |
| Lim, HJ | 1 |
| Li, T | 2 |
| Wang, B | 2 |
| Ragaz, J | 1 |
| Sun, S | 1 |
| Lv, F | 1 |
| Ni, C | 1 |
| Xie, J | 1 |
| Hu, X | 2 |
| Nagashima, K | 2 |
| Matsumoto, H | 1 |
| Ichikawa, Y | 2 |
| Yasui, H | 2 |
| Okita, NT | 1 |
| He, S | 1 |
| O'Connell, D | 1 |
| Oh, S | 1 |
| Varghese, B | 1 |
| Yip, J | 1 |
| Dolatshahi Pirooz, S | 1 |
| Li, GM | 1 |
| Ellen Martin, S | 1 |
| Machida, K | 1 |
| Liang, C | 1 |
| Hamfjord, J | 1 |
| Carlsson, G | 1 |
| Gustavsson, B | 5 |
| Indrebø, G | 1 |
| Lingjærde, O | 1 |
| Wettergren, Y | 1 |
| D'Haens, G | 4 |
| Carrato, A | 8 |
| Latini, L | 1 |
| Staines, H | 1 |
| Oum'Hamed, Z | 1 |
| Dressler, H | 1 |
| Studeny, M | 1 |
| Capdevila, J | 1 |
| Šišić, I | 1 |
| Pojskić, B | 1 |
| Mekić Abazović, A | 1 |
| Kovčin, V | 1 |
| Schneider, CC | 1 |
| Archid, R | 1 |
| Fischer, N | 1 |
| Bühler, S | 1 |
| Venturelli, S | 1 |
| Berger, A | 1 |
| Burkard, M | 1 |
| Kirschniak, A | 1 |
| Bachmann, R | 1 |
| Königsrainer, A | 1 |
| Glatzle, J | 1 |
| Zieker, D | 1 |
| Skoupá, J | 1 |
| Jandová, P | 1 |
| Cazzaniga, M | 1 |
| Hotko, Y | 2 |
| Strickland, AH | 2 |
| Wilson, G | 1 |
| Roman, L | 2 |
| He, P | 1 |
| Yu, H | 2 |
| Jung, AS | 1 |
| Lambrechts, D | 1 |
| Thienpont, B | 1 |
| Thuillier, V | 1 |
| Sagaert, X | 1 |
| Moisse, M | 1 |
| Peuteman, G | 1 |
| Zilocchi, C | 1 |
| Margherini, E | 1 |
| Chiron, M | 1 |
| Lerchenmüller, CA | 1 |
| Killing, B | 1 |
| Depenbusch, R | 1 |
| Steffens, CC | 1 |
| Lange, T | 1 |
| Dietrich, G | 1 |
| Stoehlmacher, J | 2 |
| Quidde, J | 1 |
| Trarbach, T | 2 |
| Validire, P | 1 |
| Hammel, P | 2 |
| Belgioia, L | 1 |
| Vagge, S | 1 |
| Agnese, D | 1 |
| Garelli, S | 1 |
| Fornarini, G | 1 |
| Gallo, F | 1 |
| Bacigalupo, A | 1 |
| Corvò, R | 1 |
| Soda, H | 1 |
| Maeda, H | 1 |
| Hasegawa, J | 1 |
| Kono, E | 1 |
| Altan, B | 1 |
| Yokobori, T | 1 |
| Toyomasu, Y | 1 |
| Kogure, N | 1 |
| Kimura, A | 2 |
| Hara, K | 1 |
| Bai, T | 1 |
| Bao, P | 1 |
| Suzuki, M | 2 |
| Ogata, K | 1 |
| Nishiyama, M | 1 |
| Honda, M | 1 |
| Oshiro, M | 1 |
| Kobayashi, M | 3 |
| Tokunaga, Y | 1 |
| Fujii, A | 1 |
| Loriot, MA | 1 |
| Lafargue, JP | 1 |
| Khemissa, F | 2 |
| Lim, SH | 2 |
| Han, SW | 5 |
| Grapsa, D | 1 |
| Syrigos, K | 5 |
| Azadeh, P | 1 |
| Mortazavi, N | 1 |
| Tahmasebi, A | 1 |
| Hosseini Kamal, F | 1 |
| Novin, K | 1 |
| Davis, EJ | 1 |
| Griffith, KA | 2 |
| Kim, EJ | 1 |
| Ruch, JM | 1 |
| McDonnell, KJ | 1 |
| Zalupski, MM | 4 |
| Polverari, RS | 1 |
| Ottone, A | 1 |
| Alabiso, I | 1 |
| Baratelli, C | 1 |
| Bitossi, R | 1 |
| Forti, L | 1 |
| Bertona, E | 1 |
| Mecca, C | 1 |
| Alabiso, O | 2 |
| Aglietta, M | 2 |
| Scagliotti, GV | 1 |
| Bartnik, CM | 1 |
| Neustadter, E | 1 |
| Cutler, MJ | 1 |
| Lowthers, EL | 1 |
| Richard, CL | 1 |
| Hajducek, DM | 1 |
| Spagnuolo, PA | 1 |
| Blay, J | 1 |
| Marks, EI | 1 |
| Zhou, L | 1 |
| Granata, V | 1 |
| Fusco, R | 1 |
| Catalano, O | 1 |
| Filice, S | 1 |
| Amato, DM | 1 |
| Izzo, F | 3 |
| Petrillo, A | 1 |
| Dean, A | 1 |
| Jameson, G | 1 |
| Schwartsmann, G | 1 |
| Braiteh, F | 2 |
| Moyo, V | 1 |
| Dhindsa, N | 1 |
| Bayever, E | 1 |
| Rollin, J | 1 |
| Payancé, A | 1 |
| Gouilleux-Gruart, V | 2 |
| Boisdron-Celle, M | 5 |
| Azzopardi, N | 2 |
| Morel, A | 4 |
| Gruel, Y | 1 |
| Paintaud, G | 2 |
| Gamelin, E | 8 |
| Watier, H | 2 |
| Driessen, CM | 1 |
| de Boer, JP | 1 |
| Rasch, CR | 1 |
| de Jong, MA | 1 |
| Verbist, BM | 1 |
| Melchers, WJ | 1 |
| Tesselaar, ME | 1 |
| van der Graaf, WT | 2 |
| Kaanders, JH | 1 |
| van Herpen, CM | 2 |
| Del Mastro, L | 2 |
| Levaggi, A | 1 |
| Michelotti, A | 1 |
| Cavazzini, G | 1 |
| Adami, F | 1 |
| Scotto, T | 1 |
| Piras, M | 1 |
| Danese, S | 1 |
| Garrone, O | 1 |
| Durando, A | 1 |
| Accortanzo, V | 1 |
| Bighin, C | 1 |
| Miglietta, L | 2 |
| Pastorino, S | 1 |
| Pronzato, P | 6 |
| Castiglione, F | 2 |
| Landucci, E | 2 |
| Conte, P | 7 |
| Bruzzi, P | 1 |
| Zhong, G | 1 |
| Li, HK | 1 |
| Shan, T | 1 |
| Zhang, N | 1 |
| Yi, BR | 1 |
| Kim, SU | 1 |
| Choi, KC | 1 |
| Lin, GN | 1 |
| Liu, PP | 1 |
| Liu, DY | 1 |
| Peng, JW | 1 |
| Xiao, JJ | 1 |
| Xia, ZJ | 1 |
| Hendlisz, A | 2 |
| Delaunoit, T | 2 |
| Varea, R | 1 |
| Chao, G | 1 |
| Wallin, J | 1 |
| Maindrault-Gœbel, F | 1 |
| Khalil, A | 1 |
| Dupuis, O | 1 |
| Arbaud, C | 1 |
| Wang, YW | 1 |
| Yeh, CG | 1 |
| Lu, CY | 4 |
| Cellini, F | 1 |
| Padula, GD | 1 |
| Buwenge, M | 1 |
| Di Lullo, L | 1 |
| Gambacorta, MA | 1 |
| Balducci, M | 2 |
| Mattiucci, GC | 1 |
| Autorino, R | 1 |
| Bustreo, S | 1 |
| Barbara, C | 4 |
| Feng, Q | 1 |
| Wei, Y | 1 |
| Ren, L | 1 |
| Zheng, P | 1 |
| Yu, Y | 1 |
| Ye, Q | 1 |
| Ding, J | 1 |
| Zhong, Y | 1 |
| Lin, Q | 2 |
| Qin, X | 1 |
| Xiong, BH | 1 |
| Sharma, NK | 1 |
| Ricke, J | 1 |
| Perez, D | 1 |
| Ferguson, T | 1 |
| Rodríguez, J | 3 |
| Kröning, H | 1 |
| Wolf, I | 1 |
| Walpole, E | 3 |
| Boucher, E | 5 |
| Tichler, T | 1 |
| Shacham-Shmueli, E | 2 |
| Powell, A | 1 |
| Eliadis, P | 1 |
| Price, D | 1 |
| Moeslein, F | 1 |
| Bower, G | 1 |
| Gebski, V | 1 |
| Van Buskirk, M | 1 |
| Cade, DN | 1 |
| Thurston, K | 1 |
| Iwasaki, K | 2 |
| Osaka, Y | 1 |
| Tachibana, S | 1 |
| Suda, T | 1 |
| Hoshino, S | 1 |
| Tsuchida, A | 1 |
| Nappi, A | 1 |
| Bordonaro, AR | 1 |
| Rachiglio, M | 1 |
| Modoni, G | 1 |
| Montesarchio, V | 1 |
| Febbraro, A | 1 |
| Colucci, G | 6 |
| Seal, BS | 1 |
| Anderson, S | 1 |
| Shermock, KM | 1 |
| Caparello, C | 1 |
| Musettini, G | 1 |
| Pasquini, G | 1 |
| Catanese, S | 1 |
| Lencioni, M | 4 |
| Shigeta, K | 1 |
| Hasegawa, H | 1 |
| Tsuruta, M | 1 |
| Ishii, Y | 1 |
| Endo, T | 1 |
| Ochiai, H | 2 |
| Kitagawa, Y | 1 |
| Muneoka, K | 1 |
| Shirai, Y | 1 |
| Sasaki, M | 2 |
| Sakata, J | 1 |
| Kanda, J | 1 |
| Wakabayashi, H | 1 |
| Wakai, T | 1 |
| Miyata, R | 1 |
| Kameyama, N | 1 |
| Tomita, M | 1 |
| Mitsuhashi, H | 1 |
| Baba, S | 2 |
| Amada, E | 1 |
| Dang, RP | 1 |
| LE, VH | 1 |
| Miles, BA | 1 |
| Teng, MS | 1 |
| Genden, EM | 1 |
| Bakst, RL | 1 |
| Gupta, V | 1 |
| Zhang, DY | 1 |
| Demicco, EG | 1 |
| Posner, MR | 1 |
| Misiukiewicz, KJ | 1 |
| Chong, DQ | 1 |
| Manalo, M | 1 |
| Imperial, M | 1 |
| Teo, P | 2 |
| Yong, G | 1 |
| Ng, M | 1 |
| Tan, IB | 1 |
| Chua, C | 1 |
| Fourrier-Réglat, A | 1 |
| Becouarn, Y | 4 |
| Guimbaud, R | 4 |
| Robinson, P | 1 |
| Moore, N | 1 |
| Lu, YM | 1 |
| Chien, TM | 1 |
| Chai, CY | 1 |
| Huang, CN | 1 |
| Thomas, A | 1 |
| Lopez Lopez, R | 1 |
| Roh, JK | 5 |
| Chistyakov, V | 1 |
| Höhler, T | 1 |
| Ackland, SP | 5 |
| Swinson, D | 1 |
| Kopp, M | 1 |
| Udovitsa, D | 1 |
| Hall, M | 1 |
| Vogel, A | 1 |
| Zalcberg, JR | 3 |
| Ye, D | 1 |
| Artaç, M | 1 |
| Coşkun, HŞ | 1 |
| Korkmaz, L | 1 |
| Karaağaç, M | 1 |
| Çabuk, D | 1 |
| Karabulut, S | 1 |
| Faruk Aykan, N | 1 |
| Doruk, H | 1 |
| Avcı, N | 1 |
| Turhal, NS | 1 |
| Leuci, V | 1 |
| Rotolo, R | 1 |
| Sassi, F | 1 |
| Migliardi, G | 1 |
| Todorovic, M | 1 |
| Gammaitoni, L | 1 |
| Mesiano, G | 1 |
| Giraudo, L | 1 |
| Luraghi, P | 1 |
| Grignani, G | 1 |
| Trusolino, L | 1 |
| Bertotti, A | 1 |
| Sangiolo, D | 1 |
| Sun, ZZ | 1 |
| Ning, K | 1 |
| Zhu, R | 1 |
| Liu, F | 2 |
| Tang, SC | 1 |
| Jiang, B | 1 |
| Hua, D | 1 |
| Nagase, M | 3 |
| Murata, K | 2 |
| Eguchi Nakajima, T | 1 |
| Moriwaki, T | 4 |
| Taira, K | 1 |
| Funai, S | 1 |
| Sugimoto, N | 1 |
| Okuno, T | 1 |
| Umeki, M | 1 |
| Kurimoto, T | 1 |
| Takayama, T | 2 |
| Yoshida, M | 4 |
| Shibata, Y | 1 |
| Suyama, K | 1 |
| Okabe, M | 1 |
| Suzuki, K | 2 |
| Seki, N | 1 |
| Kawakami, K | 2 |
| Sato, M | 2 |
| Fujikawa, K | 1 |
| Hirashima, T | 1 |
| Shimura, T | 3 |
| Taku, K | 3 |
| Tamura, F | 1 |
| Nakashima, K | 2 |
| Hara, H | 1 |
| Ando, M | 3 |
| Stremitzer, S | 1 |
| Parekh, A | 1 |
| Pilancı, KN | 1 |
| Saglam, S | 3 |
| Okyar, A | 1 |
| Yucel, S | 1 |
| Pala-Kara, Z | 1 |
| Ordu, C | 1 |
| Namal, E | 1 |
| Ciftci, R | 1 |
| Iner-Koksal, U | 1 |
| Kaytan-Saglam, E | 1 |
| Kochi, M | 2 |
| Takagane, A | 2 |
| Tani, S | 1 |
| Furushima, K | 1 |
| Koike, J | 1 |
| Yonemura, Y | 1 |
| Fujii, M | 3 |
| Nakajima, T | 4 |
| Hamidou, Z | 1 |
| Hug de Larauze, M | 1 |
| Garcia-Larnicol, ML | 1 |
| Wong, MH | 1 |
| Chan, DL | 1 |
| Lee, A | 1 |
| Li, BT | 1 |
| Lumba, S | 1 |
| Samra, J | 1 |
| Vijayvergia, N | 1 |
| Wong, YN | 1 |
| Cohen, SJ | 1 |
| Xue, H | 1 |
| Azzariti, A | 1 |
| Porcelli, L | 1 |
| Brunetti, O | 1 |
| Del Re, M | 2 |
| Longo, V | 1 |
| Nardulli, P | 1 |
| Signorile, M | 1 |
| Xu, JM | 4 |
| Calabrese, A | 1 |
| Quatrale, AE | 1 |
| Ørum-Madsen, MS | 1 |
| Nordgaard, C | 1 |
| Noer, J | 1 |
| Moreira, JM | 1 |
| Corvaisier, M | 1 |
| Bauzone, M | 1 |
| Corfiotti, F | 1 |
| Renaud, F | 1 |
| El Amrani, M | 1 |
| Monté, D | 2 |
| Truant, S | 2 |
| Leteurtre, E | 2 |
| Formstecher, P | 1 |
| Van Seuningen, I | 1 |
| Gespach, C | 2 |
| Huet, G | 2 |
| Garcia Alfonso, P | 1 |
| Portnoy, D | 1 |
| Cohn, A | 2 |
| Clingan, P | 2 |
| Rossius, L | 1 |
| Lerch, MM | 1 |
| Lerchenmüller, C | 1 |
| Jagenburg, A | 1 |
| Poston, G | 1 |
| Ronga, P | 1 |
| Beier, F | 3 |
| Paolicchi, E | 2 |
| De Gregorio, V | 1 |
| Crea, F | 2 |
| Danesi, R | 10 |
| Zhuang, RY | 1 |
| Yu, YY | 1 |
| Yu, S | 1 |
| Ji, Y | 2 |
| Sun, YH | 1 |
| Shen, KT | 1 |
| Shen, ZB | 1 |
| Liu, FL | 1 |
| Zhao, NQ | 1 |
| Liu, TS | 1 |
| Pinto, C | 2 |
| Porcu, L | 1 |
| Torri, V | 2 |
| Shitara, K | 3 |
| Yonesaka, K | 1 |
| Takano, T | 1 |
| Okuda, H | 1 |
| Sakai, K | 1 |
| Nishio, K | 2 |
| Tokunaga, S | 1 |
| Yamanaka, T | 2 |
| Moore, M | 3 |
| Asmis, T | 1 |
| Berry, S | 1 |
| Zbuk, K | 1 |
| Jeyakumar, A | 1 |
| Chan, T | 1 |
| Rao, S | 1 |
| Spratlin, J | 1 |
| Tang, PA | 1 |
| Rothenstein, J | 1 |
| Bendell, J | 1 |
| Kudrik, F | 1 |
| Kauh, J | 1 |
| Kambhampati, SR | 1 |
| Ramdas, N | 1 |
| Binder, P | 1 |
| Strevel, E | 1 |
| Cornelio, G | 1 |
| Dai, GH | 1 |
| Sharma, A | 1 |
| Zaatar, A | 1 |
| Guan, Z | 3 |
| Masood, N | 1 |
| Srimuninnimit, V | 1 |
| Yau, T | 1 |
| Doval, DC | 1 |
| Oh, ST | 5 |
| Shim, BY | 2 |
| Gorospe, C | 1 |
| Sirachainan, E | 1 |
| Hill, A | 1 |
| Suh, KW | 1 |
| Chatterjee, S | 1 |
| Zhang, XH | 1 |
| Hao, S | 1 |
| Gao, B | 1 |
| Tian, WG | 1 |
| Guo, LJ | 1 |
| Luo, DL | 1 |
| Sobhani, I | 1 |
| Boulat, O | 1 |
| Toledo, RA | 1 |
| Vega, E | 2 |
| Garralda, E | 1 |
| de la Varga, LU | 1 |
| Pascual, JR | 1 |
| Sánchez, G | 1 |
| Sarno, F | 1 |
| Prieto, SH | 1 |
| Perea, S | 1 |
| Lopéz-Casas, PP | 1 |
| López-Ríos, F | 1 |
| Hidalgo, M | 1 |
| Shim, YM | 3 |
| Choi, YS | 2 |
| Ahn, MJ | 2 |
| Park, K | 6 |
| Zo, JI | 1 |
| Sun, JM | 1 |
| Chen, K | 1 |
| Gong, Y | 2 |
| Zhang, Q | 1 |
| Zhou, T | 1 |
| Ma, CJ | 1 |
| Hu, HM | 1 |
| Wu, IC | 2 |
| Cheng, TL | 1 |
| Gamaleldin, M | 1 |
| Church, JM | 1 |
| Stocchi, L | 1 |
| Kalady, M | 1 |
| Liska, D | 1 |
| Gorgun, E | 1 |
| Kaneko, M | 2 |
| Yamada, T | 2 |
| Takemura, H | 1 |
| Minamoto, T | 1 |
| Zhao, X | 2 |
| Liu, X | 2 |
| Qiu, L | 1 |
| Park, M | 1 |
| Sundaramoorthy, P | 1 |
| Sim, JJ | 1 |
| Jeong, KY | 1 |
| Kim, HM | 1 |
| Pinter, T | 3 |
| Klippel, Z | 1 |
| Cesas, A | 1 |
| Croitoru, A | 1 |
| Decaestecker, J | 1 |
| Kurteva, G | 3 |
| Novotny, J | 1 |
| O'Reilly, S | 1 |
| Salek, T | 1 |
| Reiner, M | 1 |
| Morrow, PK | 1 |
| Choi, MR | 1 |
| Whittaker, S | 1 |
| Blanke, C | 2 |
| Guenther, S | 1 |
| von Hohnhorst, P | 1 |
| Lu, N | 1 |
| Di Salvatore, M | 1 |
| Orlandi, A | 1 |
| Berenato, R | 1 |
| Rossi, E | 2 |
| Caporale, M | 1 |
| Guarino, D | 1 |
| Martinetti, A | 1 |
| Basso, M | 1 |
| Mennitto, R | 1 |
| Santonocito, C | 1 |
| Mennitto, A | 1 |
| Schinzari, G | 1 |
| Bossi, I | 1 |
| Capoluongo, E | 1 |
| Kawada, J | 1 |
| Nishino, M | 1 |
| Hosoda, Y | 1 |
| Hoshino, H | 1 |
| Okano, M | 1 |
| Nagai, K | 1 |
| Okuyama, M | 1 |
| Kim, Y | 1 |
| Tsujinaka, T | 2 |
| Fujisaki, S | 1 |
| Takashina, M | 1 |
| Tomita, R | 1 |
| Sakurai, K | 1 |
| Schimanski, CC | 1 |
| Staib, F | 1 |
| Göhler, T | 1 |
| Heike, M | 3 |
| Neise, M | 1 |
| Rudi, J | 1 |
| Geer, T | 1 |
| Dingeldein, G | 1 |
| Lang, C | 1 |
| Ehscheidt, P | 1 |
| Flohr, T | 1 |
| Josten, KM | 1 |
| Karthaus, M | 1 |
| Schmittel, A | 2 |
| Wierecky, J | 1 |
| Boller, E | 1 |
| Indorf, M | 1 |
| Wörns, MA | 1 |
| Galle, PR | 2 |
| Hochster, H | 5 |
| Hart, LL | 4 |
| Firdaus, I | 2 |
| Mace, JR | 1 |
| McFarlane, JJ | 1 |
| Kozloff, M | 2 |
| Catenacci, D | 1 |
| Hsu, JJ | 1 |
| Hack, SP | 2 |
| Shames, DS | 1 |
| Phan, SC | 1 |
| Koeppen, H | 2 |
| Park, SR | 1 |
| Nam, BH | 2 |
| Oh, HS | 1 |
| Lee, MA | 3 |
| Park, YI | 1 |
| Song, EK | 1 |
| Lee, KT | 1 |
| Kang, JH | 2 |
| Itabashi, M | 1 |
| Nakajima, G | 1 |
| Hamano, M | 1 |
| Hirai, E | 1 |
| Yokomizo, H | 2 |
| Okuyama, R | 1 |
| Araida, T | 1 |
| Yoshimatsu, K | 2 |
| Kameoka, S | 1 |
| Hayashi, K | 1 |
| Doğan, M | 1 |
| Gore, I | 2 |
| Funke, R | 1 |
| Anderson, M | 1 |
| McCall, B | 1 |
| Stroh, M | 1 |
| Wakshull, E | 1 |
| Hegde, P | 1 |
| Ye, W | 1 |
| Chen, D | 3 |
| Chang, I | 1 |
| Rhee, I | 1 |
| Del Rio, M | 1 |
| Mollevi, C | 1 |
| Bibeau, F | 2 |
| Vie, N | 1 |
| Selves, J | 1 |
| Emile, JF | 1 |
| Roger, P | 1 |
| Gongora, C | 1 |
| Robert, J | 2 |
| Martineau, P | 1 |
| Kuga, Y | 1 |
| Kitamura, S | 1 |
| Mouri, T | 1 |
| Miwata, T | 1 |
| Sakimoto, H | 1 |
| Nishida, T | 1 |
| Guo, JH | 1 |
| Zhang, HY | 1 |
| Zhang, PJ | 1 |
| Li, XT | 1 |
| Wang, XD | 1 |
| Hwang, WS | 1 |
| Chao, TY | 1 |
| Lin, SF | 1 |
| Chung, CY | 1 |
| Chang, YF | 2 |
| Chen, PM | 5 |
| Chiou, TJ | 1 |
| Lim, JY | 1 |
| Jeung, HC | 4 |
| Mun, HS | 1 |
| Lee, DK | 1 |
| Paik, YH | 1 |
| Yoon, DS | 2 |
| Cho, JY | 2 |
| Greenberg, JA | 1 |
| Shibata, D | 1 |
| Herndon, JE | 1 |
| Steele, GD | 1 |
| Mayer, R | 1 |
| Bleday, R | 1 |
| Rothenberg, ML | 5 |
| Cox, JV | 3 |
| Butts, C | 2 |
| Navarro, M | 2 |
| Goel, R | 3 |
| Gollins, S | 2 |
| Siu, LL | 1 |
| Laguerre, S | 1 |
| Pestalozzi, BC | 3 |
| Francis, P | 1 |
| Quinaux, E | 2 |
| Dolci, S | 1 |
| Azambuja, E | 1 |
| Gelber, RD | 4 |
| Viale, G | 3 |
| Balil, A | 1 |
| Andersson, M | 2 |
| Nordenskjöld, B | 2 |
| Gnant, M | 1 |
| Gutierrez, J | 1 |
| Láng, I | 7 |
| Sirohi, B | 2 |
| Arnedos, M | 1 |
| Popat, S | 1 |
| Ashley, S | 4 |
| Nerurkar, A | 1 |
| Walsh, G | 2 |
| Johnston, S | 3 |
| Smith, IE | 6 |
| Di Benedetto, F | 2 |
| Simonelli, C | 3 |
| Martellotta, F | 2 |
| Del Ben, C | 1 |
| Berretta, S | 2 |
| Spina, M | 2 |
| Kweekel, DM | 1 |
| Van der Straaten, T | 2 |
| Antonini, NF | 2 |
| Müller, CI | 1 |
| Schulmann, K | 2 |
| Andre, N | 1 |
| Arkenau, H | 1 |
| Hahn, SA | 1 |
| Schmoll, SH | 1 |
| Estévez, LG | 1 |
| Batista, N | 1 |
| Sánchez-Rovira, P | 1 |
| Velasco, A | 1 |
| Provencio, M | 2 |
| León, A | 1 |
| Dómine, M | 1 |
| Cruz, J | 1 |
| Rodríguez, M | 1 |
| Senellart, H | 1 |
| Lechleider, RJ | 1 |
| Kaminskas, E | 1 |
| Jiang, X | 1 |
| Aziz, R | 1 |
| Bullock, J | 1 |
| Kasliwal, R | 1 |
| Harapanhalli, R | 1 |
| Pope, S | 1 |
| Sridhara, R | 2 |
| Leighton, J | 1 |
| Dagher, R | 1 |
| Nakamura, K | 2 |
| Nakamura, T | 3 |
| Fukazawa, A | 2 |
| Nakajima, A | 2 |
| Suzuki, S | 2 |
| Konno, H | 2 |
| Tannir, NM | 2 |
| Thall, PF | 1 |
| Ng, CS | 1 |
| Wooten, L | 1 |
| Siefker-Radtke, A | 1 |
| Mathew, P | 1 |
| Pagliaro, L | 1 |
| Wood, C | 1 |
| Jonasch, E | 2 |
| Nozawa, H | 3 |
| Muto, Y | 1 |
| Yu, ZY | 1 |
| Ouyang, XN | 1 |
| Chen, ZS | 1 |
| Xie, FW | 1 |
| Bunnell, C | 1 |
| Gralow, J | 1 |
| Klimovsky, J | 1 |
| Poulart, V | 2 |
| Peck, R | 4 |
| Thomas, E | 3 |
| Chang, PM | 1 |
| Teng, HW | 2 |
| Chang, SY | 1 |
| Chu, PY | 1 |
| Tsai, TL | 1 |
| Tai, SK | 1 |
| Wang, YF | 1 |
| Huang, JL | 1 |
| Yang, MH | 3 |
| Hofheinz, R | 2 |
| Rethwisch, V | 1 |
| Probst, S | 1 |
| Clemens, MR | 1 |
| Mahlberg, R | 1 |
| Fritz, M | 2 |
| Sievert, M | 1 |
| Atmaca, A | 2 |
| Jäger, E | 4 |
| Etienne-Grimaldi, MC | 2 |
| Formento, JL | 2 |
| Francoual, M | 2 |
| Formento, P | 2 |
| Renée, N | 2 |
| Chazal, M | 2 |
| Benchimol, D | 1 |
| Delpero, JR | 3 |
| Letoublon, C | 2 |
| Pezet, D | 5 |
| Milano, G | 6 |
| Kaufman, HL | 1 |
| Marshall, J | 3 |
| Singh, D | 1 |
| Garett, C | 1 |
| Cripps, C | 2 |
| von Mehren, M | 1 |
| Dalfen, R | 1 |
| Heim, WJ | 1 |
| Conry, RM | 1 |
| Urba, WJ | 1 |
| Yu, M | 1 |
| Caterini, J | 1 |
| Kim-Schulze, S | 1 |
| Debenedette, M | 1 |
| Salha, D | 1 |
| Vogel, T | 1 |
| Elias, I | 1 |
| Berinstein, NL | 1 |
| Bazarbashi, S | 1 |
| Abdelsalam, M | 1 |
| Amin, T | 1 |
| El-Bassiouni, M | 1 |
| Soudy, H | 1 |
| Elweshi, A | 1 |
| Alhusseiny, H | 1 |
| Rehman, K | 1 |
| Memon, M | 1 |
| Ajarim, D | 1 |
| Gartner, EM | 1 |
| Pan, Q | 1 |
| Brewer, GJ | 1 |
| Henja, GF | 1 |
| Merajver, SD | 1 |
| Martinez-Villacampa, M | 1 |
| Massutti, B | 2 |
| Marcuello, E | 5 |
| Constenla, M | 3 |
| Cámara, JC | 1 |
| Abali, H | 3 |
| Hayran, M | 1 |
| Yildirim, N | 1 |
| Budakoglu, B | 2 |
| Sherrill, B | 1 |
| Amonkar, MM | 1 |
| Walker, M | 1 |
| Geyer, C | 1 |
| Kanate, AS | 1 |
| Auber, ML | 1 |
| Higa, GM | 1 |
| Zhang, XD | 1 |
| Chu, YP | 1 |
| Wang, YH | 1 |
| Liu, DQ | 1 |
| Jin, ML | 1 |
| Andreetta, C | 1 |
| Puppin, C | 1 |
| Minisini, A | 1 |
| Valent, F | 1 |
| Pegolo, E | 1 |
| Damante, G | 1 |
| Di Loreto, C | 1 |
| Pizzolitto, S | 1 |
| Pandolfi, M | 1 |
| Fasola, G | 1 |
| Piga, A | 1 |
| Puglisi, F | 2 |
| Susnjar, S | 1 |
| Bosnjak, SM | 1 |
| Radulovic, S | 1 |
| Kabbinavar, FF | 1 |
| Wallace, JF | 1 |
| Holmgren, E | 3 |
| Yi, J | 1 |
| Cella, D | 1 |
| Yost, KJ | 1 |
| Hurwitz, HI | 4 |
| Coudert, B | 4 |
| Cvickovic, F | 1 |
| Zambelli, A | 1 |
| Fillet, G | 2 |
| Van Der Auwera, J | 1 |
| Lentz, MA | 1 |
| Baron, B | 3 |
| Gorlia, T | 1 |
| Biville, F | 3 |
| Matsumoto, S | 3 |
| Nishimura, T | 1 |
| Mori, Y | 1 |
| Nagayama, S | 1 |
| Kawamura, J | 1 |
| Nomura, A | 1 |
| Kitano, T | 1 |
| Ishiguro, H | 1 |
| Yanagihara, K | 2 |
| Teramukai, S | 1 |
| Sakai, Y | 1 |
| Chiba, T | 1 |
| Fukushima, M | 3 |
| Metro, G | 1 |
| Mottolese, M | 1 |
| Fabi, A | 1 |
| George, S | 1 |
| Dreicer, R | 1 |
| Au, JJ | 1 |
| Shen, T | 1 |
| Rini, BI | 2 |
| Roman, S | 1 |
| Cooney, MM | 1 |
| Mekhail, T | 1 |
| Elson, P | 1 |
| Wientjes, GM | 1 |
| Ganapathi, R | 1 |
| Bukowski, RM | 7 |
| Cianfrocca, M | 1 |
| Ryan, Q | 1 |
| Johnson, J | 1 |
| Ko, CW | 1 |
| Pluzanska, A | 2 |
| Utracka-Hutka, B | 1 |
| Zaluski, J | 4 |
| Glynne-Jones, R | 2 |
| Koralewski, P | 3 |
| Mainwaring, P | 2 |
| Wasan, H | 1 |
| Chan, RT | 3 |
| Tabah-Fisch, I | 2 |
| Núñez, MC | 1 |
| Díaz-Gavilán, M | 1 |
| Conejo-García, A | 1 |
| Cruz-López, O | 1 |
| Gallo, MA | 1 |
| Espinosa, A | 1 |
| Campos, JM | 2 |
| Arimoto, Y | 1 |
| Kanamiya, Y | 1 |
| Oba, H | 1 |
| Adachi, K | 1 |
| Shintani, M | 1 |
| Nakamura, R | 2 |
| Yui, S | 1 |
| Janot, F | 2 |
| de Raucourt, D | 1 |
| Benhamou, E | 1 |
| Ferron, C | 1 |
| Dolivet, G | 1 |
| Bensadoun, RJ | 2 |
| Hamoir, M | 1 |
| Julieron, M | 1 |
| Castaing, M | 1 |
| Bajetta, E | 5 |
| Buzzoni, R | 2 |
| Ferrario, E | 2 |
| Dotti, KF | 1 |
| Mariani, L | 3 |
| Bajetta, R | 1 |
| Gevorgyan, A | 1 |
| Venturino, P | 1 |
| Galassi, M | 1 |
| Huh, JW | 2 |
| Park, YA | 1 |
| Jung, EJ | 2 |
| Lee, KY | 1 |
| Kwon, JE | 1 |
| Sohn, SK | 4 |
| Lee, YC | 1 |
| Fisher, GA | 2 |
| Kuo, T | 1 |
| Ramsey, M | 1 |
| Schwartz, E | 1 |
| Rouse, RV | 1 |
| Cho, CD | 1 |
| Halsey, J | 1 |
| Sikic, BI | 2 |
| Fujita, K | 2 |
| Nagashima, F | 2 |
| Yamamoto, W | 1 |
| Endo, H | 1 |
| Yamashita, K | 3 |
| Mizuno, K | 2 |
| Matsunaga, M | 1 |
| Araki, K | 1 |
| Tanaka, R | 2 |
| Miya, T | 1 |
| Narabayashi, M | 1 |
| Akiyama, Y | 1 |
| Kawara, K | 2 |
| Vente, MA | 1 |
| Wondergem, M | 1 |
| van der Tweel, I | 1 |
| van den Bosch, MA | 1 |
| Zonnenberg, BA | 1 |
| Lam, MG | 1 |
| van Het Schip, AD | 1 |
| Nijsen, JF | 1 |
| Le Tourneau, C | 1 |
| Chen, EX | 1 |
| Vakhabova, JV | 1 |
| Semenov, NN | 1 |
| Dobrova, NV | 1 |
| Lichinitser, MR | 2 |
| Riess, H | 3 |
| Pelzer, U | 2 |
| Hilbig, A | 1 |
| Stieler, J | 2 |
| Opitz, B | 1 |
| Scholten, T | 1 |
| Kauschat-Brüning, D | 1 |
| Bramlage, P | 1 |
| Dörken, B | 4 |
| Oettle, H | 3 |
| Brown, TJ | 2 |
| Ng, R | 1 |
| Jennens, R | 1 |
| Cinc, E | 1 |
| Pho, M | 1 |
| Michael, M | 3 |
| Fox, RM | 3 |
| Bayo, J | 1 |
| Lomas, M | 1 |
| Salvador, J | 2 |
| Moreno, A | 1 |
| Ruiz, M | 1 |
| Rodríguez, A | 1 |
| Fuentes, J | 1 |
| Fernández-Freire, A | 1 |
| Bernabé, R | 1 |
| Fernández, A | 1 |
| Puthillath, A | 1 |
| Mashtare, T | 1 |
| Wilding, G | 1 |
| Khushalani, N | 1 |
| Steinbrenner, L | 1 |
| Ross, ME | 1 |
| Romano, K | 1 |
| Wisniewski, M | 1 |
| Makhson, A | 3 |
| Aparicio, J | 5 |
| Donea, S | 1 |
| Ludwig, H | 2 |
| Schuch, G | 1 |
| Stroh, C | 3 |
| Loos, AH | 2 |
| Zubel, A | 2 |
| Le, QA | 1 |
| Hay, JW | 1 |
| Oya, M | 1 |
| Muto, T | 1 |
| Konishi, F | 1 |
| Hatake, K | 4 |
| Cobb, P | 1 |
| Farella, A | 1 |
| Bucci, L | 1 |
| D'Armiento, FP | 1 |
| Pesce, G | 2 |
| Pepe, S | 2 |
| Cannella, L | 1 |
| Pacelli, R | 1 |
| Solla, R | 1 |
| D'Armiento, MR | 1 |
| Jung, KH | 1 |
| Im, SA | 6 |
| Lee, N | 2 |
| Byun, JH | 2 |
| Boehnke Michaud, L | 1 |
| Nolè, F | 6 |
| Crivellari, D | 2 |
| Mattioli, R | 2 |
| Pinotti, G | 2 |
| Verri, E | 1 |
| Fougeray, R | 1 |
| Brandely, M | 1 |
| Rodenburg, CJ | 2 |
| Schrama, JG | 1 |
| Vos, AH | 1 |
| van Groeningen, CJ | 1 |
| Sinnige, HA | 1 |
| Richel, DJ | 1 |
| Voest, EE | 2 |
| Dijkstra, JR | 1 |
| Vink-Börger, ME | 1 |
| van Krieken, JH | 1 |
| Dalesio, O | 2 |
| Matsuo, K | 2 |
| Yokota, T | 1 |
| Inaba, Y | 3 |
| Yamaura, H | 2 |
| Najima, M | 1 |
| Chae, YS | 3 |
| Moon, JH | 3 |
| Ryoo, HM | 3 |
| Bae, SH | 2 |
| Kum, Y | 1 |
| Jeon, SW | 1 |
| Kang, BM | 1 |
| Choi, GS | 3 |
| Jun, SH | 3 |
| Cao, Y | 2 |
| Liao, C | 1 |
| Tan, A | 1 |
| Mo, Z | 1 |
| Gao, F | 1 |
| Kim, HR | 2 |
| Wang, ML | 1 |
| Foo, KF | 1 |
| Qin, TJ | 1 |
| An, GL | 1 |
| Zhao, XH | 1 |
| Tian, F | 1 |
| Lian, JW | 1 |
| Pan, BR | 1 |
| Gu, SZ | 1 |
| Jin, C | 1 |
| Yao, L | 1 |
| Long, J | 1 |
| Fu, DL | 1 |
| Yu, XJ | 1 |
| Yang, F | 1 |
| Ni, QX | 1 |
| Mazzer, M | 1 |
| Moroso, S | 1 |
| Comella, P | 9 |
| Franco, L | 1 |
| Casaretti, R | 4 |
| de Portu, S | 2 |
| Menditto, E | 1 |
| Seymour, MT | 5 |
| Highley, MS | 1 |
| Griffiths, GO | 1 |
| Uscinska, BM | 1 |
| Huddart, RA | 1 |
| Barber, JB | 1 |
| Parmar, MK | 2 |
| Harper, PG | 1 |
| Giusti, RM | 1 |
| Gianni, M | 1 |
| Dentali, F | 1 |
| Lonn, E | 1 |
| Ch'ang, HJ | 1 |
| Huang, CL | 1 |
| Wang, HP | 1 |
| Shiah, HS | 1 |
| Chang, MC | 3 |
| Jan, CM | 1 |
| Tien, YW | 1 |
| Hwang, TL | 1 |
| Lin, JT | 2 |
| Whang-Peng, J | 2 |
| Shibata, SI | 1 |
| Doroshow, JH | 4 |
| Frankel, P | 1 |
| Synold, TW | 1 |
| Yen, Y | 1 |
| Gandara, DR | 1 |
| Chow, WA | 1 |
| Leong, LA | 2 |
| Lim, D | 1 |
| Margolin, KA | 2 |
| Morgan, RJ | 2 |
| Somlo, G | 2 |
| Newman, EM | 1 |
| Holubec, L | 1 |
| Svoboda, T | 1 |
| Sefrhansova, L | 1 |
| Pavlikova, I | 1 |
| Votavova, M | 1 |
| Sediva, M | 1 |
| Filip, S | 1 |
| Kozevnikova, R | 1 |
| Kormunda, S | 1 |
| Reed, SD | 1 |
| Anstrom, KJ | 1 |
| Schulman, KA | 1 |
| Hitre, E | 4 |
| Chang Chien, CR | 1 |
| Schlichting, M | 2 |
| Nippgen, J | 2 |
| Uzzan, B | 1 |
| Nicolas, P | 1 |
| Schischmanoff, O | 1 |
| Morere, JF | 2 |
| Prado, CM | 1 |
| Baracos, VE | 1 |
| McCargar, LJ | 1 |
| Reiman, T | 1 |
| Mourtzakis, M | 1 |
| Tonkin, K | 1 |
| Mackey, JR | 4 |
| Koski, S | 3 |
| Pituskin, E | 1 |
| Sawyer, MB | 1 |
| Van Laethem, JL | 3 |
| Husseini, F | 2 |
| Cals, L | 1 |
| Jackson, NA | 1 |
| Barrueco, J | 1 |
| Soufi-Mahjoubi, R | 1 |
| Mitchell, E | 1 |
| Meyerhardt, J | 1 |
| Teitelbaum, UR | 2 |
| Haller, DG | 7 |
| Bao, WQ | 1 |
| Sheng, WQ | 1 |
| Zhang, HL | 1 |
| Wu, LH | 1 |
| Wu, XZ | 1 |
| Dembinski, JL | 1 |
| Krauss, S | 3 |
| Lim, MC | 1 |
| Kim, JY | 1 |
| Yoo, CW | 1 |
| Park, SY | 1 |
| Bursi, S | 2 |
| Petrini, I | 1 |
| Brunetti, IM | 3 |
| Ricci, S | 5 |
| Antonuzzo, A | 3 |
| Andreuccetti, M | 6 |
| Muss, HB | 7 |
| Berry, DA | 3 |
| Cirrincione, CT | 2 |
| Theodoulou, M | 2 |
| Mauer, AM | 1 |
| Kornblith, AB | 1 |
| Partridge, AH | 1 |
| Dressler, LG | 1 |
| Cohen, HJ | 1 |
| Becker, HP | 1 |
| Kartcheske, PA | 1 |
| Wheeler, JD | 1 |
| Perez, EA | 6 |
| Gralow, JR | 1 |
| Burstein, HJ | 3 |
| Mahmood, AA | 1 |
| Magrinat, G | 2 |
| Parker, BA | 1 |
| Hart, RD | 2 |
| Grenier, D | 1 |
| Norton, L | 4 |
| Hudis, CA | 2 |
| Winer, EP | 5 |
| Pohlmann, PR | 1 |
| Mernaugh, RL | 1 |
| Goff, LW | 1 |
| Copur, MS | 1 |
| Norvell, M | 1 |
| Obermiller, A | 1 |
| Soga, N | 1 |
| Nishikawa, K | 1 |
| Hasegawa, Y | 2 |
| Kise, H | 1 |
| Arima, K | 1 |
| Sugimura, Y | 1 |
| Bathe, OF | 1 |
| Ernst, S | 1 |
| Sutherland, FR | 1 |
| Bigam, D | 1 |
| Holland, D | 1 |
| Porter, GA | 1 |
| Koppel, J | 1 |
| Dowden, S | 1 |
| Inaba, T | 1 |
| Kashiwaba, M | 1 |
| Takeda, Y | 1 |
| Komatsu, H | 1 |
| Tomisawa, Y | 1 |
| Takiyama, I | 1 |
| Wakabayashi, G | 1 |
| Matsushita, H | 1 |
| Tsuboi, K | 1 |
| Honda, I | 1 |
| Kato, N | 1 |
| Okochi, O | 1 |
| Hattori, M | 1 |
| Figer, A | 5 |
| Flesch, M | 4 |
| Buyse, M | 4 |
| Carola, E | 6 |
| Perez-Staub, N | 3 |
| Shiroiwa, T | 1 |
| Fukuda, T | 1 |
| Tsutani, K | 1 |
| Kim, TY | 6 |
| Ferrara, D | 1 |
| Manzione, L | 2 |
| Svoboda, M | 1 |
| Nemecek, R | 1 |
| Rehák, Z | 1 |
| Standara, M | 1 |
| Yen, LC | 2 |
| Chen, CW | 1 |
| Chang, YT | 1 |
| Chu, KS | 1 |
| Lin, SR | 3 |
| Curran, D | 2 |
| Pozzo, C | 2 |
| Dank, M | 1 |
| Valvere, V | 1 |
| Peschel, C | 3 |
| Wenczl, M | 2 |
| Goker, E | 2 |
| Bugat, R | 5 |
| Taha, FM | 1 |
| Zeeneldin, AA | 1 |
| Helal, AM | 1 |
| Gaber, AA | 1 |
| Sallam, YA | 1 |
| Ramadan, H | 1 |
| Moneer, MM | 1 |
| Dong, N | 2 |
| Jiang, W | 1 |
| Liu, Z | 2 |
| Xu, X | 1 |
| Bougnoux, P | 1 |
| Becquart, D | 1 |
| Morand, M | 1 |
| Cui, F | 1 |
| Chen, JZ | 2 |
| Wan, C | 1 |
| Luo, RC | 3 |
| Zheng, H | 2 |
| Zhou, JF | 1 |
| Bai, CM | 1 |
| Cheng, YJ | 1 |
| Jia, N | 1 |
| Shao, YJ | 1 |
| Kunnumakkara, AB | 1 |
| Diagaradjane, P | 2 |
| Anand, P | 1 |
| Harikumar, KB | 1 |
| Kuzhuvelil, HB | 1 |
| Deorukhkar, A | 2 |
| Gelovani, J | 1 |
| Guha, S | 2 |
| Krishnan, S | 4 |
| Aggarwal, BB | 2 |
| Ackland, S | 4 |
| Clarke, S | 4 |
| Perez-Carrión, R | 1 |
| Gapski, J | 1 |
| Langer, B | 4 |
| Young, S | 1 |
| Segal, NH | 1 |
| Kusama, M | 1 |
| Nomizu, T | 1 |
| Aogi, K | 1 |
| Yoshimoto, M | 2 |
| Horikoshi, N | 1 |
| Tabei, T | 1 |
| Noguchi, S | 3 |
| Miura, S | 1 |
| Yoshimura, N | 1 |
| Toyama, K | 1 |
| Shin, E | 1 |
| Yao, X | 2 |
| Yoshioka, Y | 1 |
| Morishige, T | 1 |
| Eto, Y | 1 |
| Watanabe, H | 1 |
| Okada, Y | 1 |
| Mukai, Y | 1 |
| Nakagawa, S | 1 |
| Jones, A | 1 |
| O'Brien, M | 2 |
| Sommer, H | 1 |
| Nowara, E | 1 |
| Welt, A | 2 |
| Pienkowski, T | 5 |
| Rolski, J | 1 |
| Pham, ML | 1 |
| Perraud, K | 1 |
| Trillet-Lenoir, V | 4 |
| Chua, W | 1 |
| Goldstein, D | 4 |
| Dhillon, H | 1 |
| Mitchell, P | 1 |
| Iacopetta, B | 1 |
| Orphanos, G | 1 |
| Alexopoulos, A | 1 |
| Malliou, S | 1 |
| Ioannidis, G | 1 |
| Ardavanis, A | 3 |
| Kandylis, C | 1 |
| Stavrakakis, J | 1 |
| Rigatos, G | 1 |
| Rocca, A | 1 |
| Maltoni, R | 2 |
| Massa, I | 1 |
| Aquilina, M | 1 |
| Ibrahim, T | 1 |
| Cecconetto, L | 1 |
| Sarti, S | 1 |
| Pietri, E | 1 |
| Oliva, C | 2 |
| Bergnolo, P | 1 |
| Inguì, M | 1 |
| Bianco, L | 1 |
| Pochettino, P | 1 |
| Cutin, SC | 1 |
| Boglione, A | 1 |
| Dal Canton, O | 1 |
| Garetto, F | 1 |
| Comandone, A | 1 |
| Todorović-Raković, N | 2 |
| Nesković-Konstantinović, Z | 3 |
| Nikolić-Vukosavljević, D | 3 |
| Muñoz-Martin, A | 1 |
| Mendez-Ureña, M | 1 |
| Quiben-Pereira, R | 1 |
| Gonzalez-Flores, E | 2 |
| Perez-Manga, G | 2 |
| Dy, GK | 2 |
| Hobday, TJ | 2 |
| Nelson, G | 1 |
| Windschitl, HE | 2 |
| O'Connell, MJ | 8 |
| Alberts, SR | 4 |
| Nikcevich, DA | 1 |
| Zhong, B | 1 |
| Tucker, S | 1 |
| Lu, C | 1 |
| Cheng, J | 2 |
| Cao, C | 1 |
| Sakoda, T | 1 |
| Morizane, R | 1 |
| Nakahara, K | 1 |
| Enomoto, Y | 1 |
| Nosaka, A | 1 |
| Enomoto, T | 1 |
| Kitano, H | 1 |
| Cathomas, R | 2 |
| Köberle, D | 2 |
| Ruhstaller, T | 3 |
| Mayer, G | 1 |
| Räss, A | 1 |
| Mey, U | 1 |
| von Moos, R | 2 |
| Sunela, KL | 1 |
| Koskinen, S | 1 |
| Li, YH | 2 |
| Luo, HY | 1 |
| Wang, FH | 2 |
| Qiu, MZ | 1 |
| Shi, YX | 1 |
| Xiang, XJ | 4 |
| Chen, XQ | 1 |
| He, YJ | 2 |
| Xu, RH | 2 |
| Lièvre, A | 1 |
| Assenat, E | 4 |
| Boyer-Gestin, C | 1 |
| Portales, F | 3 |
| Yoshimoto, N | 1 |
| Yamashita, T | 1 |
| Fujita, T | 1 |
| Tsunoda, N | 1 |
| Tsuzuki, N | 1 |
| Toyama, T | 2 |
| Kondo, N | 1 |
| Iwata, H | 1 |
| García-Castaño, A | 1 |
| Vega, N | 1 |
| Vega-Villegas, ME | 1 |
| Gutiérrez-Sanz, L | 1 |
| Kalender, ME | 1 |
| Gumus, M | 2 |
| Alici, S | 1 |
| Kaya, AO | 1 |
| Yaman, E | 1 |
| Ozturk, B | 1 |
| Jones, J | 1 |
| Takeda, A | 1 |
| Picot, J | 1 |
| von Keyserlingk, C | 1 |
| Clegg, A | 1 |
| Arts, J | 1 |
| King, P | 1 |
| Mariën, A | 1 |
| Floren, W | 1 |
| Beliën, A | 1 |
| Janssen, L | 1 |
| Pilatte, I | 1 |
| Roux, B | 1 |
| Decrane, L | 1 |
| Gilissen, R | 1 |
| Hickson, I | 1 |
| Vreys, V | 1 |
| Cox, E | 1 |
| Bol, K | 1 |
| Talloen, W | 1 |
| Goris, I | 1 |
| Andries, L | 1 |
| Du Jardin, M | 1 |
| Janicot, M | 1 |
| Page, M | 1 |
| van Emelen, K | 1 |
| Angibaud, P | 1 |
| Frenel, JS | 1 |
| Bourbouloux, E | 2 |
| Berton-Rigaud, D | 1 |
| Sadot-Lebouvier, S | 1 |
| Zanetti, A | 1 |
| Campone, M | 6 |
| Merola, G | 1 |
| Petillo, L | 1 |
| Ceribelli, A | 1 |
| Del Prete, S | 1 |
| Kawase, J | 1 |
| Ozawa, S | 1 |
| Kobayashi, K | 5 |
| Imaeda, Y | 2 |
| Umemoto, S | 2 |
| Ueda, M | 2 |
| Hillman, DW | 1 |
| Dentchev, T | 1 |
| Le-Lindqwister, NA | 1 |
| Geeraerts, LH | 1 |
| Fitch, TR | 2 |
| Liu, H | 1 |
| Graham, DL | 1 |
| Kahanic, SP | 1 |
| Gross, HM | 1 |
| Patel, TA | 1 |
| Palmieri, FM | 1 |
| Dueck, AC | 1 |
| Wagner, AD | 1 |
| Schmalenberg, H | 1 |
| Behrens, R | 1 |
| Fahlke, J | 1 |
| Wein, A | 2 |
| Behl, S | 1 |
| Kuss, O | 1 |
| Kleber, G | 1 |
| Fleig, WE | 1 |
| Zhang, P | 3 |
| Ma, YL | 1 |
| Peng, JY | 1 |
| Shen, TY | 1 |
| Chen, HQ | 1 |
| Zhou, YK | 1 |
| Chu, ZX | 1 |
| Zhang, M | 1 |
| Qin, HL | 1 |
| Ciruelos, EM | 1 |
| Cortés-Funes, H | 2 |
| Mayordomo, JI | 1 |
| Bermejo, B | 2 |
| Ojeda, B | 1 |
| García, E | 1 |
| Rodríguez, CA | 1 |
| Muñoz, M | 2 |
| Gómez, P | 1 |
| Manso, L | 2 |
| Andrés, R | 1 |
| Lluch, A | 4 |
| Mendiola, C | 2 |
| Kim, C | 1 |
| Ryu, MH | 6 |
| Ryoo, BY | 1 |
| Tsuchiya, T | 1 |
| Hiramatsu, K | 1 |
| Machiki, Y | 1 |
| Sakuragawa, T | 1 |
| Otsuji, H | 1 |
| Hara, T | 1 |
| Hosoya, J | 1 |
| Kojima, T | 4 |
| Uen, YH | 1 |
| Wu, DC | 1 |
| Yu, FJ | 1 |
| Bargagli, G | 1 |
| Lazzi, S | 1 |
| Pascucci, A | 3 |
| Bellan, C | 1 |
| Martellucci, I | 1 |
| Lorenzi, B | 1 |
| Francini, G | 6 |
| Cao, WF | 1 |
| Zhao, HM | 1 |
| Song, YQ | 1 |
| Ning, LS | 1 |
| Niu, Y | 1 |
| Hao, XS | 1 |
| Cao, XC | 1 |
| Valachis, A | 1 |
| Polyzos, NP | 1 |
| Patsopoulos, NA | 1 |
| Mavroudis, D | 9 |
| Mauri, D | 1 |
| Luber, B | 1 |
| Wöll, E | 1 |
| Endlicher, E | 1 |
| Röthling, N | 1 |
| Keller, G | 1 |
| Fend, F | 1 |
| Montagnani, F | 3 |
| Chiriatti, A | 2 |
| Turrisi, G | 1 |
| Fiorentini, G | 5 |
| Katamura, Y | 1 |
| Aikata, H | 1 |
| Kimura, Y | 2 |
| Kawaoka, T | 1 |
| Takaki, S | 1 |
| Waki, K | 1 |
| Hiramatsu, A | 1 |
| Kawakami, Y | 1 |
| Ishikawa, M | 1 |
| Hieda, M | 1 |
| Kakizawa, H | 1 |
| Chayama, K | 1 |
| Takamatsu, Y | 1 |
| Anan, K | 1 |
| Ohno, S | 1 |
| Nishimura, R | 1 |
| Yamamoto, Y | 5 |
| Masuda, N | 3 |
| Mitsuyama, S | 1 |
| Tamura, K | 3 |
| Kim, NS | 1 |
| Park, JY | 1 |
| Kang, BW | 1 |
| Garm Spindler, KL | 1 |
| Lindebjerg, J | 2 |
| Brandslund, I | 1 |
| Gore, ME | 2 |
| Griffin, CL | 1 |
| Hancock, B | 1 |
| Patel, PM | 1 |
| Pyle, L | 2 |
| Aitchison, M | 1 |
| James, N | 1 |
| Oliver, RT | 2 |
| Mardiak, J | 1 |
| Hussain, T | 1 |
| Sylvester, R | 1 |
| Royston, P | 1 |
| Mulders, PF | 1 |
| Riera, R | 1 |
| Soárez, PC | 1 |
| Puga, ME | 1 |
| Ferraz, MB | 1 |
| Roehrig, S | 1 |
| Albrecht, H | 1 |
| Konturek, PC | 1 |
| Reulbach, U | 1 |
| Männlein, G | 1 |
| Wolff, K | 1 |
| Ostermeier, N | 1 |
| Hohenberger, W | 2 |
| Hahn, EG | 1 |
| Boxberger, F | 1 |
| Lopez, M | 7 |
| Di Lauro, L | 4 |
| Viola, G | 1 |
| Conti, F | 1 |
| Foggi, P | 1 |
| Okines, AF | 1 |
| Dalla Chiesa, M | 1 |
| Buti, S | 2 |
| Rovere, RK | 1 |
| Brighenti, M | 1 |
| Lazzarelli, S | 2 |
| Donati, G | 1 |
| Passalacqua, R | 3 |
| Burris, HA | 2 |
| Jones, SF | 1 |
| Shipley, D | 1 |
| Meluch, AA | 1 |
| Greco, FA | 4 |
| Barton, JH | 1 |
| Hainsworth, JD | 6 |
| Zarate, R | 2 |
| Bandres, E | 2 |
| Patiño-Garcia, A | 1 |
| Ponz-Sarvise, M | 1 |
| Ramirez, N | 1 |
| Bitarte, N | 1 |
| Chopitea, A | 1 |
| Gacía-Foncillas, J | 1 |
| Yuuki, S | 1 |
| Fuse, N | 3 |
| Miyagishima, T | 1 |
| Kudo, M | 1 |
| Watanabe, M | 3 |
| Tateyama, M | 1 |
| Kunieda, Y | 1 |
| Wakahama, O | 1 |
| Sakata, Y | 1 |
| Asaka, M | 2 |
| Fontana, E | 2 |
| Merlano, M | 1 |
| Matsumoto, K | 1 |
| Yoshinouchi, S | 1 |
| Takano, Y | 1 |
| Kanzaki, M | 1 |
| Maeda, M | 1 |
| Miyoshi, S | 1 |
| Wakita, T | 1 |
| Teshima, S | 1 |
| Good, LM | 1 |
| Miller, MD | 1 |
| High, WA | 1 |
| Zhang, BL | 1 |
| Xu, RL | 1 |
| Qin, YW | 1 |
| Best, JH | 1 |
| Garrison, LP | 1 |
| Kotsori, AA | 1 |
| Noble, JL | 1 |
| Chung, EK | 1 |
| Posadas, EM | 1 |
| Kasza, K | 2 |
| Karrison, T | 1 |
| Manchen, E | 1 |
| Hahn, OM | 1 |
| Stadler, WM | 4 |
| Farhat, FS | 1 |
| Kattan, J | 3 |
| Ghosn, MG | 1 |
| Gorden, L | 1 |
| Saffroy, R | 1 |
| Hauteville, D | 1 |
| Guettier, C | 1 |
| Taguchi, T | 2 |
| Nakayama, T | 2 |
| Yoshidome, K | 2 |
| Akagi, K | 1 |
| Nishida, Y | 1 |
| Yoshikawa, Y | 1 |
| Ogino, N | 1 |
| Abe, C | 2 |
| Tsuyuki, S | 1 |
| Kawaguchisakita, N | 1 |
| Tsubota, Y | 1 |
| Ukikusa, M | 1 |
| Kohno, Y | 1 |
| Durando, X | 1 |
| Farges, MC | 1 |
| Buc, E | 1 |
| Abrial, C | 1 |
| Petorin-Lesens, C | 1 |
| Gillet, B | 1 |
| Vasson, MP | 1 |
| Thivat, E | 1 |
| Mantovani, LG | 1 |
| Ravaioli, A | 3 |
| Bollina, R | 1 |
| Cozzi, C | 1 |
| Grimaldi, AM | 1 |
| Testa, TE | 1 |
| Bianchessi, C | 1 |
| Carteni, G | 1 |
| Dessein, AF | 1 |
| Stechly, L | 1 |
| Jonckheere, N | 1 |
| Dumont, P | 1 |
| Figeac, M | 1 |
| Lecellier, CH | 1 |
| Lesuffleur, T | 1 |
| Dessein, R | 1 |
| Grard, G | 1 |
| Dejonghe, MJ | 1 |
| de Launoit, Y | 1 |
| Furuichi, Y | 1 |
| Prévost, G | 2 |
| Porchet, N | 1 |
| Doi, T | 5 |
| Hamamoto, Y | 3 |
| Takiuchi, H | 3 |
| Bergougnoux, L | 1 |
| Kockler, L | 1 |
| Martinez-Trufero, J | 1 |
| Isla, D | 1 |
| Adansa, JC | 1 |
| Irigoyen, A | 2 |
| Hitt, R | 2 |
| Gil-Arnaiz, I | 1 |
| Lambea, J | 1 |
| Lecumberri, MJ | 1 |
| Cruz, JJ | 2 |
| Hosoda, K | 1 |
| Aoki, M | 1 |
| Kido, H | 1 |
| Natsu, K | 1 |
| Tamura, H | 1 |
| Kojima, M | 1 |
| Amemiya, T | 1 |
| Kamoshida, T | 1 |
| Gebski, VJ | 1 |
| Cummins, MM | 1 |
| Zannino, D | 1 |
| Robinson, B | 2 |
| Broad, A | 1 |
| Forgeson, G | 1 |
| Stockler, MR | 1 |
| Chua, Y | 1 |
| Simes, RJ | 1 |
| Gallagher, DJ | 1 |
| Kemeny, N | 6 |
| Roth, A | 3 |
| Widmer, L | 1 |
| Uhlmann, C | 1 |
| Simcock, M | 1 |
| Lanz, D | 1 |
| Popescu, R | 1 |
| Paduch, R | 1 |
| Kandefer-Szerszeń, M | 1 |
| Piersiak, T | 1 |
| Sparano, JA | 3 |
| Vrdoljak, E | 5 |
| Rixe, O | 1 |
| Manikhas, A | 2 |
| Medina, C | 2 |
| Da Costa, SC | 1 |
| Ro, J | 3 |
| Rubio, G | 1 |
| Rondinon, M | 1 |
| Perez Manga, G | 2 |
| Chen, MH | 1 |
| Tzeng, CH | 3 |
| Wang, WS | 2 |
| Pownall, M | 1 |
| Goel, G | 1 |
| Jauhri, M | 1 |
| Negi, A | 1 |
| Aggarwal, S | 1 |
| Mallmann, P | 1 |
| Nitschmann, S | 1 |
| Koyama, M | 1 |
| Murata, A | 1 |
| Morohashi, H | 1 |
| Kimura, N | 1 |
| Gasa, F | 1 |
| Sato, J | 1 |
| Terui, K | 1 |
| Awatsu, A | 1 |
| Hakamada, K | 1 |
| Sellers, S | 1 |
| Diasio, RB | 1 |
| Boni, V | 1 |
| Villa, JC | 1 |
| Gomez, MA | 1 |
| Garcia-Foncillas, J | 2 |
| Ajima, H | 1 |
| Ogata, H | 1 |
| Nakayama, H | 1 |
| Takahashi, H | 1 |
| Urba, S | 1 |
| Foster, J | 1 |
| Worden, F | 1 |
| Brodowicz, T | 3 |
| Wrba, F | 1 |
| Beslija, S | 3 |
| Koza, I | 1 |
| Pápai, Z | 1 |
| Messinger, D | 3 |
| Faluhelyi, Z | 1 |
| Mrsic-Krmpotic, Z | 2 |
| Vrbanec, D | 1 |
| Zielinski, CC | 3 |
| Gazzaniga, P | 1 |
| Gradilone, A | 1 |
| Petracca, A | 1 |
| Nicolazzo, C | 1 |
| Raimondi, C | 1 |
| Iacovelli, R | 1 |
| Naso, G | 1 |
| Frederiksen, C | 1 |
| Berglund, A | 3 |
| Lorvidhaya, V | 3 |
| Chitapanarux, I | 3 |
| Phromratanapongse, P | 1 |
| Kamnerdsupaphon, P | 3 |
| Tharavichitkul, E | 2 |
| Lertsanguansinchai, P | 1 |
| Hsieh, CY | 3 |
| Sukthomya, V | 3 |
| Yukawa, N | 1 |
| Akaike, M | 1 |
| Shiozawa, M | 1 |
| Shiraishi, R | 1 |
| Matsukawa, H | 1 |
| Suzuki, H | 3 |
| Tamura, I | 1 |
| Ozawa, Y | 1 |
| Yamamoto, N | 2 |
| Rino, Y | 1 |
| Masuda, M | 1 |
| Imada, T | 1 |
| Anton, A | 5 |
| Casado, A | 1 |
| Lao, J | 1 |
| Paules, AB | 1 |
| Gayo, J | 1 |
| Konings, IR | 1 |
| Sleijfer, S | 1 |
| Mathijssen, RH | 2 |
| de Bruijn, P | 3 |
| Ghobadi Moghaddam-Helmantel, IM | 1 |
| van Dam, LM | 1 |
| Wiemer, EA | 1 |
| Verweij, J | 5 |
| Loos, WJ | 2 |
| Chiesa, MD | 1 |
| Re, GL | 1 |
| Lheshi, A | 1 |
| Simon, S | 1 |
| Caminiti, C | 1 |
| Mazza, G | 1 |
| Donini, M | 1 |
| Waddell, T | 1 |
| Soe, W | 1 |
| Allen, J | 2 |
| Bentley, D | 1 |
| Morris, J | 1 |
| Lloyd, A | 1 |
| Swindell, R | 2 |
| Taylor, MB | 1 |
| Penney, R | 1 |
| Michalaki, V | 1 |
| Fotiou, S | 1 |
| Gennatas, S | 1 |
| Gennatas, C | 1 |
| Won, YW | 1 |
| Park, YH | 3 |
| Do, IG | 1 |
| Ko, YH | 1 |
| Chua, TC | 1 |
| Marshall, MB | 1 |
| Esquivel, J | 1 |
| Cho, EY | 3 |
| Ahn, YC | 1 |
| Ahn, JS | 2 |
| Im, YH | 3 |
| Yuan, P | 2 |
| Ma, F | 2 |
| Cai, R | 1 |
| Kaufmann, M | 8 |
| Maass, N | 1 |
| Costa, SD | 1 |
| Schneeweiss, A | 1 |
| Loibl, S | 3 |
| Sütterlin, MW | 1 |
| Schrader, I | 1 |
| Gerber, B | 1 |
| Bauer, W | 1 |
| Wiest, W | 1 |
| Tomé, O | 1 |
| Distelrath, A | 1 |
| Hagen, V | 1 |
| Kleine-Tebbe, A | 1 |
| Ruckhaeberle, E | 1 |
| Mehta, K | 1 |
| von Minckwitz, G | 5 |
| Yook, JH | 3 |
| Kim, BS | 6 |
| Strosberg, JR | 1 |
| Fine, RL | 2 |
| Choi, J | 1 |
| Nasir, A | 1 |
| Coppola, D | 1 |
| Chen, DT | 1 |
| Helm, J | 1 |
| Kvols, L | 1 |
| Fusi, A | 1 |
| Tinhofer, I | 1 |
| Schneider, A | 1 |
| Keilholz, U | 2 |
| Kim, JA | 1 |
| Fornier, M | 1 |
| Schulman, KL | 1 |
| McKenna, EF | 1 |
| Licitra, S | 1 |
| Aliberti, C | 1 |
| Bruneton, D | 1 |
| Cassier, PA | 1 |
| Hervieu, V | 1 |
| Pilleul, F | 1 |
| Chayvialle, JA | 1 |
| Ling, W | 1 |
| Fan, J | 3 |
| Ma, Y | 2 |
| Snoeren, N | 1 |
| Bergman, AM | 1 |
| Verheul, HM | 1 |
| Tollenaar, RA | 1 |
| van der Sijp, JR | 1 |
| Schouten, SB | 1 |
| Rinkes, IH | 1 |
| van Hillegersberg, R | 1 |
| Grande, C | 1 |
| Méndez, JC | 1 |
| Jorge, M | 1 |
| Romero, C | 1 |
| de la Cámara, J | 1 |
| Candamio, S | 1 |
| Sheikh, R | 1 |
| Walsh, N | 1 |
| Clynes, M | 1 |
| O'Connor, R | 1 |
| McDermott, R | 1 |
| Yamamoto, D | 2 |
| Iwase, S | 1 |
| Kuroda, Y | 2 |
| Yamamoto, C | 1 |
| Kitamura, K | 1 |
| Odagiri, H | 1 |
| Nagumo, Y | 1 |
| Santomaggio, A | 1 |
| Baldi, PL | 2 |
| Tudini, M | 1 |
| De Galitiis, F | 2 |
| Mancini, M | 1 |
| Antonucci, A | 1 |
| Muñoz-Martin, AJ | 1 |
| Alvarez-Suarez, S | 1 |
| Jerez-Gilarranz, Y | 1 |
| Riesco-Martinez, M | 1 |
| Khosravi, P | 1 |
| Blum, JL | 4 |
| Kohles, J | 1 |
| Scotto, N | 2 |
| Hu, S | 2 |
| Odom, D | 1 |
| Kaye, JA | 1 |
| Glück, S | 3 |
| Mesia, R | 2 |
| Remenár, É | 1 |
| Erfán, J | 1 |
| Kawecki, A | 1 |
| Zabolotnyy, D | 1 |
| Benasso, M | 1 |
| Störkel, S | 1 |
| Senger, S | 1 |
| Pander, J | 1 |
| Wessels, JAM | 1 |
| Omrčen, T | 2 |
| Boban, M | 2 |
| Hrabar, A | 1 |
| Huang, MY | 1 |
| Huang, ML | 1 |
| Chen, MJ | 1 |
| Chen, CF | 1 |
| Tsai, PC | 1 |
| Chuang, SC | 1 |
| Hou, MF | 1 |
| Seidman, AD | 4 |
| Brufsky, A | 1 |
| Ansari, RH | 3 |
| Stein, RS | 2 |
| Stewart, JF | 2 |
| Russell, CA | 1 |
| Fein, LE | 2 |
| De La Cruz Vargas, JA | 1 |
| Cavalheiro, J | 1 |
| Gill, JF | 1 |
| Obasaju, CK | 1 |
| Orlando, M | 1 |
| Tai, DF | 1 |
| Bonmassar, L | 1 |
| Fossile, E | 1 |
| Scoppola, A | 1 |
| Graziani, G | 1 |
| Prete, SP | 1 |
| Formica, V | 2 |
| Cappelletti, D | 1 |
| De Vecchis, L | 1 |
| Cardillo, A | 1 |
| Concolino, F | 1 |
| D'Atri, S | 1 |
| Balduzzi, A | 2 |
| Torino, F | 2 |
| Caporaso, P | 1 |
| Greiner, JW | 1 |
| Bonmassar, E | 1 |
| Roselli, M | 3 |
| Aquino, A | 1 |
| Cereda, S | 2 |
| Reni, M | 3 |
| Rognone, A | 2 |
| Ghidini, M | 2 |
| Belli, C | 2 |
| Longoni, S | 2 |
| Fugazza, C | 2 |
| Brioschi, M | 1 |
| Nicoletti, R | 3 |
| Balzano, G | 3 |
| Passoni, P | 3 |
| Harris, CA | 1 |
| Ward, RL | 1 |
| Dobbins, TA | 1 |
| Drew, AK | 1 |
| Pearson, S | 1 |
| Song, X | 1 |
| Gregory, C | 1 |
| Wang, PF | 1 |
| Long, SR | 1 |
| Han, SS | 1 |
| Lee, WJ | 1 |
| Woo, SM | 1 |
| Yoo, T | 1 |
| Moon, SH | 1 |
| Hong, EK | 2 |
| Hassan, M | 1 |
| Osman, MM | 1 |
| Dubey, PK | 1 |
| Singodia, D | 1 |
| Verma, RK | 1 |
| Vyas, SP | 1 |
| Teke, Z | 1 |
| Nessar, G | 1 |
| Kiremitci, S | 1 |
| Aksoy, E | 1 |
| Elbir, OH | 1 |
| Choi, YL | 1 |
| Mishima, Y | 2 |
| Takagi, K | 2 |
| Terui, Y | 2 |
| Gordon, MA | 1 |
| El-Khouiery, A | 1 |
| Lurje, G | 2 |
| Labonte, M | 1 |
| Wilson, P | 2 |
| Sherrod, A | 1 |
| Ladner, RD | 2 |
| Galy, G | 1 |
| Labidi-Galy, SI | 1 |
| Perol, D | 2 |
| Ray-Coquard, I | 2 |
| Tredan, O | 1 |
| Biron, P | 3 |
| Latour, JF | 1 |
| Blay, JY | 1 |
| Guastalla, JP | 5 |
| Favier, B | 1 |
| Palmirotta, R | 1 |
| Del Monte, G | 1 |
| Savonarola, A | 1 |
| Ludovici, G | 1 |
| De Marchis, ML | 1 |
| Grenga, I | 1 |
| Schirru, M | 1 |
| Guadagni, F | 1 |
| Shah, MA | 1 |
| Jhawer, M | 1 |
| Ilson, DH | 2 |
| Lefkowitz, RA | 1 |
| Robinson, E | 3 |
| Capanu, M | 1 |
| Kelsen, DP | 2 |
| Jubb, AM | 1 |
| Miller, KD | 4 |
| Rugo, HS | 6 |
| Harris, AL | 2 |
| Reimann, JD | 2 |
| Cobleigh, MA | 3 |
| Schmidt, M | 1 |
| Langmuir, VK | 1 |
| Hillan, KJ | 1 |
| Chen, DS | 1 |
| Shioiri, M | 1 |
| Kojima, K | 1 |
| Yamamoto, S | 2 |
| Watanabe, Y | 1 |
| Mizutani, M | 1 |
| Kamimura, K | 1 |
| Platell, C | 1 |
| Ng, S | 1 |
| O'bichere, A | 1 |
| Papageorgis, P | 1 |
| Cheng, K | 1 |
| Ozturk, S | 1 |
| Lambert, AW | 1 |
| Abdolmaleky, HM | 1 |
| Zhou, JR | 1 |
| Thiagalingam, S | 1 |
| Sohal, D | 1 |
| Mykulowycz, K | 1 |
| Rosen, M | 1 |
| Soulen, MC | 1 |
| Caparro, M | 1 |
| Giantonio, B | 1 |
| Shaked, A | 1 |
| Reddy, R | 1 |
| Olthoff, K | 1 |
| Fridlyand, J | 1 |
| Kaiser, LD | 1 |
| Fyfe, G | 2 |
| Wong, NS | 1 |
| Fernando, NH | 1 |
| Nixon, AB | 1 |
| Cushman, S | 1 |
| Aklilu, M | 1 |
| Morse, MA | 2 |
| Blobe, GC | 1 |
| Ashton, J | 1 |
| Pang, H | 1 |
| Hrepic, D | 1 |
| Fridl-Vidas, V | 1 |
| Boskovic, L | 1 |
| Bao, L | 1 |
| Haque, A | 1 |
| Jackson, K | 1 |
| Hazari, S | 1 |
| Moroz, K | 1 |
| Jetly, R | 1 |
| Dash, S | 1 |
| Svensson, H | 2 |
| Hatschek, T | 2 |
| Johansson, H | 1 |
| Einbeigi, Z | 2 |
| Brandberg, Y | 2 |
| DI, Lj | 1 |
| Song, Gh | 1 |
| Che, L | 2 |
| Jiang, Hf | 1 |
| Zhu, Yl | 1 |
| Liang, X | 1 |
| Jia, J | 2 |
| Yang, Hb | 1 |
| Wang, Xl | 1 |
| Zhou, Xn | 1 |
| Ren, J | 2 |
| Nuzzo, F | 2 |
| Morabito, A | 4 |
| Gravina, A | 1 |
| Di Rella, F | 1 |
| Landi, G | 1 |
| Pacilio, C | 1 |
| Labonia, V | 1 |
| De Maio, E | 1 |
| Piccirillo, MC | 1 |
| D'Aiuto, G | 3 |
| Thomas, R | 3 |
| Rinaldo, M | 1 |
| Botti, G | 3 |
| Di Bonito, M | 2 |
| Gallo, C | 1 |
| Perrone, F | 2 |
| de Matteis, A | 2 |
| Machiels, JP | 2 |
| Besse, T | 1 |
| Dubin, F | 1 |
| Semiond, D | 1 |
| Sobočanec, S | 1 |
| Balog, T | 1 |
| Šariċ, A | 1 |
| Mačak-Šafranko, Ž | 1 |
| Štroser, M | 1 |
| Žarković, K | 1 |
| Žarković, N | 1 |
| Stojković, R | 1 |
| Ivanković, S | 1 |
| Marotti, T | 1 |
| Lal, LS | 1 |
| Atkinson, BJ | 1 |
| Byfield, SD | 1 |
| Miller, LA | 1 |
| Pagliaro, LC | 1 |
| Tsimafeyeu, I | 1 |
| Demidov, L | 1 |
| Kharkevich, G | 1 |
| Petenko, N | 1 |
| Galchenko, V | 1 |
| Sinelnikov, I | 1 |
| Naidzionak, U | 1 |
| Choi, IJ | 1 |
| Kim, CG | 1 |
| Oshima, A | 1 |
| Michalowski, A | 1 |
| Green, JE | 1 |
| Medley, L | 1 |
| Morel, AN | 1 |
| Farrugia, D | 1 |
| Reed, N | 1 |
| Hayward, N | 1 |
| Kirichek, O | 1 |
| Thakker, RV | 1 |
| Talbot, DC | 3 |
| Gajria, D | 1 |
| Feigin, K | 1 |
| Tan, LK | 1 |
| Geneus, S | 1 |
| Traina, TA | 1 |
| Cabebe, EC | 1 |
| Sohn, CH | 1 |
| Song, HS | 2 |
| Orlandi, P | 1 |
| Di Desidero, T | 1 |
| Canu, B | 1 |
| Frumento, P | 2 |
| Di Paolo, A | 5 |
| Bocci, G | 1 |
| Stemmler, HJ | 1 |
| diGioia, D | 1 |
| Freier, W | 3 |
| Tessen, HW | 1 |
| Gitsch, G | 1 |
| Jonat, W | 2 |
| Brugger, W | 1 |
| Kettner, E | 1 |
| Abenhardt, W | 2 |
| Hurtz, HJ | 1 |
| Rösel, S | 1 |
| Brudler, O | 1 |
| Zhi, J | 1 |
| Chen, E | 2 |
| Major, P | 2 |
| Burns, I | 1 |
| Rittweger, K | 1 |
| Abt, M | 1 |
| Backshall, A | 1 |
| Sharma, R | 2 |
| Keun, HC | 1 |
| Meguro, E | 1 |
| Shibata, H | 3 |
| Fukui, T | 1 |
| Hoshino, Y | 1 |
| Gilbar, P | 1 |
| Sorour, N | 1 |
| Yokoyama, H | 1 |
| Okuda, N | 1 |
| Watanabe, T | 2 |
| Iwata, N | 1 |
| Ohashi, N | 1 |
| Nakao, A | 2 |
| Starling, N | 2 |
| Vázquez-Mazón, F | 1 |
| Ramos, FJ | 1 |
| Iveson, TJ | 2 |
| Countouriotis, AM | 1 |
| Ruiz-Garcia, A | 1 |
| Wei, G | 1 |
| Tursi, JM | 3 |
| Hecht, JR | 4 |
| Germond, C | 1 |
| Berg, W | 2 |
| Chen, BL | 2 |
| Jalava, T | 2 |
| Lebwohl, D | 3 |
| Meinhardt, G | 2 |
| Laurent, D | 2 |
| Lin, E | 1 |
| Lloyd-Salvant, K | 1 |
| Pendergrass, K | 1 |
| Kerr, D | 1 |
| Frances, N | 2 |
| Claret, L | 1 |
| Bruno, R | 1 |
| Iliadis, A | 2 |
| Bertucci, F | 1 |
| Esterni, B | 1 |
| Madroszyk, A | 1 |
| Tarpin, C | 2 |
| Jacquemier, J | 1 |
| Extra, JM | 2 |
| Viens, P | 6 |
| Gonçalves, A | 2 |
| Nowacki, MP | 1 |
| Shchepotin, I | 1 |
| Celik, I | 2 |
| Gavoille, C | 1 |
| Guigay, J | 1 |
| Trigo, JM | 2 |
| Kerber, A | 1 |
| Bethe, U | 1 |
| Picard, M | 1 |
| Brummendorf, TH | 2 |
| Rankin, C | 1 |
| Gold, PJ | 1 |
| Ahmad, SA | 1 |
| El-Khoueiry, AB | 1 |
| Messino, MJ | 1 |
| Holcombe, RF | 1 |
| Desseigne, F | 4 |
| Gourgou-Bourgade, S | 2 |
| Khemissa-Akouz, F | 1 |
| Péré-Vergé, D | 1 |
| Delbaldo, C | 1 |
| Montoto-Grillot, C | 3 |
| Adler, M | 1 |
| Seraphin, J | 1 |
| Shibata, M | 1 |
| Nishina, Y | 1 |
| Gonda, K | 1 |
| Matsuo, S | 1 |
| Yajima, Y | 1 |
| Nakamura, I | 1 |
| Ohki, S | 1 |
| Takenoshita, S | 1 |
| Lin, S | 1 |
| Tham, IW | 1 |
| Han, L | 1 |
| Lu, JJ | 1 |
| Alvarez, RH | 1 |
| Valero, V | 4 |
| Hortobagyi, GN | 27 |
| Saridaki, Z | 1 |
| Malamos, N | 2 |
| Kourakos, P | 1 |
| Androulakis, N | 6 |
| Kalbakis, K | 5 |
| Kos, FT | 1 |
| Odabaş, H | 1 |
| Aksoy, S | 2 |
| Corey-Lisle, PK | 1 |
| Mukhopadhyay, P | 3 |
| Orsini, L | 1 |
| Safikhani, S | 1 |
| Bell, JA | 1 |
| Hortobagyi, G | 2 |
| Roche, H | 4 |
| Revicki, DA | 1 |
| Walter, B | 1 |
| Schrettenbrunner, I | 1 |
| Grassinger, J | 1 |
| Bross, K | 1 |
| Wilke, J | 1 |
| Suedhoff, T | 1 |
| Berand, A | 1 |
| Wieland, WF | 1 |
| Rogenhofer, S | 1 |
| Andreesen, R | 1 |
| Reichle, A | 1 |
| Norman, G | 1 |
| Rice, S | 1 |
| Stirk, L | 1 |
| Danso-Appiah, A | 1 |
| Suh, D | 1 |
| Palmer, S | 1 |
| Eastwood, A | 1 |
| Baraniskin, A | 1 |
| Munding, J | 1 |
| Meier, D | 1 |
| Arkenau, HT | 4 |
| Satoh, T | 5 |
| Okamoto, W | 1 |
| Shimamura, T | 1 |
| Werner Kraus, T | 1 |
| Bruch, HP | 1 |
| Noack, F | 1 |
| Altmannsberger, HM | 1 |
| Rezzonico, S | 1 |
| Slim, N | 1 |
| Cappio, S | 1 |
| Doglioni, C | 1 |
| Kitayama, J | 2 |
| Sunami, E | 2 |
| Saito, S | 2 |
| Kanazawa, T | 3 |
| Kazama, S | 2 |
| Yazawa, K | 2 |
| Kawai, K | 2 |
| Mori, K | 2 |
| Nagawa, H | 2 |
| Yoh, T | 1 |
| Yamamichi, K | 1 |
| Oishi, M | 1 |
| Iwaki, R | 1 |
| Motohiro, T | 1 |
| Chan, JY | 1 |
| Ong, CW | 1 |
| Salto-Tellez, M | 1 |
| Ankerst, DP | 1 |
| Moosmann, N | 3 |
| Kobunai, T | 1 |
| Matsuda, K | 1 |
| Ishihara, S | 1 |
| Nozawa, K | 1 |
| Iinuma, H | 1 |
| Ikeuchi, H | 1 |
| Bajard, A | 1 |
| Provencal, J | 1 |
| Coeffic, D | 2 |
| Agostini, C | 1 |
| Boisseau, M | 1 |
| Kaphan, R | 1 |
| Dramais, D | 1 |
| Oprea, C | 1 |
| Ferri-Dessens, RM | 1 |
| Ikeda, E | 1 |
| Kaneko, K | 2 |
| Minashi, K | 1 |
| Onozawa, M | 1 |
| Nihei, K | 1 |
| Yano, T | 1 |
| Florin, V | 1 |
| Desmedt, E | 1 |
| Vercambre-Darras, S | 1 |
| Mortier, L | 1 |
| Hass, HG | 2 |
| Dietzfelbinger, H | 2 |
| Oruzio, D | 1 |
| Klein, S | 1 |
| Zellmann, K | 1 |
| Schulze, M | 1 |
| Puchtler, G | 1 |
| Kappauf, H | 1 |
| Mittermüller, J | 1 |
| Haberl, C | 1 |
| Geh, JI | 1 |
| Ma, YT | 1 |
| Fedele, P | 1 |
| Marino, A | 1 |
| Orlando, L | 2 |
| Schiavone, P | 1 |
| Nacci, A | 1 |
| Sponziello, F | 1 |
| Rizzo, P | 1 |
| Calvani, N | 1 |
| Mazzoni, E | 1 |
| Cinefra, M | 1 |
| Kambe, M | 1 |
| Kikuchi, H | 1 |
| Gamo, M | 1 |
| Yoshioka, T | 2 |
| Kanamaru, R | 2 |
| Grimminger, PP | 1 |
| Shi, M | 1 |
| Barrett, C | 1 |
| Danenberg, KD | 3 |
| Brabender, J | 1 |
| Vigen, CL | 1 |
| Danenberg, PV | 2 |
| De Jesus-Acosta, A | 1 |
| Oliver, GR | 1 |
| Blackford, A | 1 |
| Kinsman, K | 1 |
| Flores, EI | 1 |
| Wilfong, LS | 1 |
| Donehower, RC | 1 |
| Cosgrove, D | 1 |
| Laheru, D | 2 |
| Chung, K | 1 |
| Diaz, LA | 2 |
| Lin, LS | 1 |
| DiCarlo, B | 1 |
| Dao, KM | 1 |
| Patel, R | 1 |
| Park, DJ | 1 |
| Wang, HJ | 2 |
| Elashoff, R | 1 |
| Ryba, N | 1 |
| Jacques, N | 1 |
| Vimond, N | 1 |
| Pierga, JY | 7 |
| Guichard, P | 1 |
| Galais, MP | 1 |
| Cvitkovic, F | 2 |
| Farace, F | 1 |
| Cao, B | 1 |
| Li, ST | 1 |
| Li, Z | 1 |
| Deng, WL | 1 |
| Brixi-Benmansour, H | 1 |
| Hentic, O | 1 |
| Cadiot, G | 1 |
| Inoue, N | 1 |
| Kishino, T | 1 |
| Dakik, HK | 1 |
| Moskovic, DJ | 1 |
| Carlson, PJ | 1 |
| Tamm, EP | 1 |
| Fogelman, DR | 2 |
| Leonard, R | 4 |
| Hennessy, BT | 1 |
| O'Shaughnessy, J | 6 |
| Kuniyoshi, R | 1 |
| Smaaland, R | 2 |
| Bjarnason, GA | 2 |
| Iacobelli, S | 2 |
| Tumolo, S | 3 |
| Carvalho, C | 1 |
| Teixeira, L | 1 |
| Shien, T | 1 |
| Doihara, H | 1 |
| Nishiyama, K | 2 |
| Masuda, H | 1 |
| Nogami, T | 1 |
| Ikeda, H | 1 |
| Taira, N | 1 |
| Mayerle, J | 1 |
| Bangerter, M | 1 |
| Sieber, M | 1 |
| Teschendorf, C | 1 |
| Freiberg-Richter, J | 1 |
| Aubele, P | 1 |
| Lu, J | 1 |
| Leaw, S | 1 |
| Hong, X | 2 |
| Shao, Z | 1 |
| Yun, T | 1 |
| Han, JY | 2 |
| Choi, HL | 1 |
| Kim, HY | 3 |
| Kim, HT | 1 |
| Farrar, WL | 1 |
| Pallis, AG | 1 |
| Varthalitis, I | 2 |
| Lortholary, A | 2 |
| Hardy-Bessard, AC | 1 |
| de Rauglaudre, G | 1 |
| Alexandre, J | 1 |
| Bourgeois, H | 1 |
| Jaubert, D | 1 |
| Paraiso, D | 1 |
| Largillier, R | 3 |
| Narang, AK | 1 |
| Miller, RC | 1 |
| Hsu, CC | 1 |
| Bhatia, S | 1 |
| Pawlik, TM | 1 |
| Hruban, RH | 1 |
| Zhou, J | 3 |
| Winter, JM | 1 |
| Haddock, MG | 2 |
| Donohue, JH | 1 |
| Schulick, RD | 1 |
| Wolfgang, CL | 1 |
| Cameron, JL | 1 |
| Herman, JM | 1 |
| Ternant, D | 1 |
| Piller, F | 1 |
| Vignault-Desvignes, C | 1 |
| Guan, ZZ | 1 |
| Feng, FY | 1 |
| Yu, SY | 1 |
| Liang, J | 1 |
| Qin, SK | 1 |
| He, J | 1 |
| Qi, C | 1 |
| Nemunaitis, J | 1 |
| Vukelja, SJ | 1 |
| Hagenstad, C | 1 |
| Campos, LT | 2 |
| Hermann, RC | 2 |
| Sportelli, P | 1 |
| Gardner, L | 1 |
| Richards, DA | 1 |
| Labonte, MJ | 2 |
| Wilson, PM | 1 |
| Gerger, A | 1 |
| Bohanes, PO | 1 |
| El-Khoueiry, R | 1 |
| El-Khoueiry, A | 2 |
| Mitchell, EP | 3 |
| Piperdi, B | 1 |
| Lacouture, ME | 1 |
| Shearer, H | 1 |
| Iannotti, N | 1 |
| Pillai, MV | 1 |
| Yassine, M | 1 |
| Horita, Y | 1 |
| Hirashima, Y | 1 |
| Saigusa, S | 1 |
| Toiyama, Y | 1 |
| Koike, Y | 1 |
| Okugawa, Y | 1 |
| Yokoe, T | 1 |
| Inoue, Y | 1 |
| Miki, C | 1 |
| Kusunoki, M | 1 |
| Thezenas, S | 3 |
| Viret, F | 1 |
| Kramar, A | 1 |
| Crapez-Lopez, E | 1 |
| Bleuse, JP | 2 |
| Poujol, S | 3 |
| Pinguet, F | 4 |
| Thirion, A | 1 |
| Isambert, N | 2 |
| Bonneterre, J | 4 |
| Fumoleau, P | 8 |
| Kondo, C | 1 |
| Kato, M | 1 |
| Komori, K | 1 |
| Ishiguro, S | 1 |
| Sano, T | 1 |
| Shimizu, Y | 1 |
| Rho, JK | 1 |
| Rha, SY | 4 |
| Chua, DT | 4 |
| Yiu, HH | 1 |
| Seetalarom, K | 1 |
| Ng, AW | 1 |
| Kurnianda, J | 1 |
| Shotelersuk, K | 1 |
| Krishnan, G | 1 |
| Hong, RL | 2 |
| Sze, WK | 1 |
| Ng, WT | 1 |
| Carlsson, L | 1 |
| Lidbrink, E | 1 |
| Linderholm, B | 1 |
| Loman, N | 1 |
| Malmberg, M | 1 |
| Rotstein, S | 1 |
| Söderberg, M | 1 |
| Sundquist, M | 1 |
| Walz, TM | 1 |
| Hellström, M | 1 |
| Aström, G | 1 |
| Carstensen, J | 2 |
| Fernö, M | 1 |
| Bergh, J | 2 |
| Roullet, B | 1 |
| Paillot, B | 2 |
| Hamidou, H | 1 |
| Tourani, JM | 1 |
| Silvain, C | 1 |
| Kornmann, M | 1 |
| Danenberg, K | 1 |
| Goeb, R | 1 |
| Staib, L | 1 |
| Kron, M | 1 |
| Henne-Bruns, D | 4 |
| Danenberg, P | 1 |
| Link, KH | 1 |
| Matsubara, J | 1 |
| Takagi, S | 1 |
| Yoshioka, A | 1 |
| Nakayama, N | 1 |
| Lai, GM | 1 |
| Chang, TH | 1 |
| Liu, MT | 1 |
| Bi, CP | 1 |
| Wang, JW | 2 |
| Chen, MK | 1 |
| Franko, J | 1 |
| Shi, Q | 1 |
| Goldman, CD | 1 |
| Pockaj, BA | 2 |
| Nelson, GD | 1 |
| Pitot, HC | 2 |
| Pelletier, E | 1 |
| Bhosle, M | 1 |
| Klingman, D | 1 |
| Jensen, NF | 1 |
| Smith, DH | 1 |
| Nygård, SB | 1 |
| Rømer, MU | 1 |
| Nielsen, KV | 1 |
| Hoesly, FJ | 1 |
| Baker, SG | 1 |
| Gunawardane, ND | 1 |
| Cotliar, JA | 1 |
| Abbas, A | 1 |
| Nehme, E | 1 |
| Takemoto, H | 1 |
| Kondo, K | 1 |
| Okuyama, Y | 1 |
| Tominaga, H | 1 |
| Katsumata, K | 2 |
| Kato, S | 4 |
| Ozeki, M | 1 |
| Yoshida, S | 2 |
| Fuchs, M | 1 |
| Hossain, AM | 1 |
| Stoffregen, C | 1 |
| Nicol, S | 1 |
| Pohl, A | 1 |
| Hu-Lieskoven, S | 1 |
| Kahn, M | 1 |
| Teo, JL | 1 |
| Shriki, J | 1 |
| Stebbing, J | 1 |
| Gómez-España, A | 4 |
| Massutí, B | 5 |
| Martínez de Prado, P | 2 |
| Gallén, M | 3 |
| González, E | 3 |
| Fernández-Martos, C | 5 |
| Losa, F | 2 |
| Arrivi, A | 3 |
| Lacasta, A | 2 |
| Llanos, M | 1 |
| Tabernero, JM | 2 |
| Gao, J | 1 |
| Xu, BQ | 1 |
| Tu, ZW | 1 |
| Liu, ZG | 1 |
| Zeng, MS | 1 |
| Ziras, N | 5 |
| Kentepozidis, N | 1 |
| Makrantonakis, P | 1 |
| Xynogalos, S | 1 |
| Christophyllakis, Ch | 1 |
| Kouroussis, Ch | 1 |
| Miles, D | 8 |
| Zielinski, C | 4 |
| Robert, N | 1 |
| Kim, SD | 1 |
| Shim, JW | 1 |
| Baek, SH | 1 |
| Zabel, BA | 1 |
| Bae, YS | 1 |
| Virzi, V | 3 |
| Vincenzi, B | 4 |
| Catalano, V | 3 |
| Bronte, G | 1 |
| Russo, A | 7 |
| Laroche-Clary, A | 1 |
| Kauffmann, A | 1 |
| Laurand-Quancard, A | 1 |
| Evrard, S | 1 |
| Brunet, R | 2 |
| Le Morvan, V | 1 |
| Sheng, W | 1 |
| Feng, XZ | 1 |
| Han, JQ | 1 |
| Dellapasqua, S | 4 |
| Bagnardi, V | 3 |
| Bertolini, F | 2 |
| Sandri, MT | 1 |
| Pastrello, D | 2 |
| Cancello, G | 2 |
| Montagna, E | 2 |
| Mancuso, P | 1 |
| Luini, A | 2 |
| Colleoni, M | 5 |
| Welch, S | 1 |
| Krzyzanowska, MK | 1 |
| Knox, J | 1 |
| Feld, R | 2 |
| MacKay, H | 1 |
| Petronis, J | 1 |
| Fujishima, H | 2 |
| Uchino, K | 1 |
| Mitsugi, K | 2 |
| Nakano, S | 2 |
| Akashi, K | 1 |
| O'Shaughnessy, JA | 4 |
| Machida, N | 3 |
| Yoshizaki, K | 1 |
| Onozawa, Y | 2 |
| Fukutomi, A | 1 |
| Trakultivakorn, H | 1 |
| Srisukho, S | 1 |
| Somwangprasert, A | 1 |
| Watcharachan, K | 1 |
| Kaldate, RR | 1 |
| Haregewoin, A | 1 |
| Grier, CE | 1 |
| Hamilton, SA | 1 |
| Assy, N | 1 |
| Basher, W | 1 |
| Chetver, L | 1 |
| Shnaider, J | 1 |
| Zidan, J | 1 |
| Ghosn, M | 2 |
| Saroufim, A | 1 |
| Chahine, G | 2 |
| Nasr, F | 2 |
| Farhat, F | 2 |
| Park, LC | 1 |
| Lee, HS | 1 |
| Shin, SH | 1 |
| Kwon, HC | 2 |
| Baek, JH | 2 |
| Choi, YJ | 1 |
| Kang, MJ | 2 |
| Kim, YS | 1 |
| Siedentopf, F | 1 |
| Dalivoust, P | 1 |
| Debled, M | 1 |
| Robert, NJ | 3 |
| Harbeck, N | 1 |
| Ishiguro, A | 1 |
| Takahata, T | 1 |
| Matsumoto, Y | 1 |
| Tanaka, S | 2 |
| Itoh, J | 1 |
| Kawasaki, H | 1 |
| Kudoh, Y | 1 |
| Kijima, H | 1 |
| Shimaya, S | 1 |
| Saijo, Y | 1 |
| Di, L | 1 |
| Jiang, H | 1 |
| Tan, WW | 1 |
| Allred, JB | 1 |
| Salim, M | 1 |
| Flynn, P | 1 |
| Fishkin, PA | 1 |
| Stella, PJ | 1 |
| Wiesenfeld, M | 1 |
| Bernath, AM | 1 |
| Kamal, AH | 1 |
| Camacho, F | 1 |
| Anderson, R | 1 |
| Wei, W | 2 |
| Balkrishnan, R | 1 |
| Kimmick, G | 1 |
| Gligorov, J | 1 |
| Lichinitser, M | 3 |
| Mitchell, L | 1 |
| Tjulandin, S | 2 |
| Tarver, K | 1 |
| Conibear, J | 1 |
| Zhao, HY | 2 |
| Hu, ZH | 2 |
| Lin, SX | 1 |
| Lin, TY | 1 |
| Liu, YW | 1 |
| Qiu, F | 2 |
| Yu, F | 2 |
| Zhan, ZY | 1 |
| Feng, M | 1 |
| Yan, J | 1 |
| Zhao, JG | 1 |
| Xiong, JP | 2 |
| Setton, J | 1 |
| Wolden, S | 1 |
| Caria, N | 1 |
| Tamura, S | 2 |
| Imano, M | 1 |
| Imamoto, H | 1 |
| Miki, H | 1 |
| Aoki, T | 2 |
| Peng, YF | 1 |
| Furukawa, H | 1 |
| Kim, M | 2 |
| Cha, Y | 2 |
| Keam, B | 1 |
| Kim, MA | 1 |
| Kim, WH | 1 |
| Luan, Y | 1 |
| Jing, F | 1 |
| Liu, N | 2 |
| Mou, J | 1 |
| Perri, G | 1 |
| Veronesi, P | 1 |
| Intra, M | 1 |
| Calleri, A | 1 |
| Rampinelli, C | 1 |
| Takao, S | 1 |
| Hirata, M | 1 |
| Okamoto, Y | 1 |
| Yamashita, S | 2 |
| Kawaguchi, Y | 1 |
| Takami, M | 1 |
| Furusawa, H | 1 |
| Miyata, Y | 1 |
| Mizutani, N | 1 |
| Hashigaki, S | 1 |
| Lechuga, MJ | 2 |
| Bleiberg, H | 9 |
| Vandebroek, A | 1 |
| Deleu, I | 1 |
| Vergauwe, P | 1 |
| Rezaei Kalantari, H | 1 |
| Paesmans, M | 1 |
| Efira, A | 1 |
| Luo, RZ | 1 |
| Cai, YC | 1 |
| Kwok, A | 1 |
| Patt, YZ | 1 |
| Bauer, KM | 1 |
| Lambert, PA | 1 |
| Hummon, AB | 1 |
| Inbar, MJ | 1 |
| Kahán, Z | 2 |
| Stemmer, SM | 2 |
| Kaufman, B | 3 |
| Zvirbule, Z | 2 |
| Steger, GG | 4 |
| Maestro, ML | 1 |
| Vidaurreta, M | 1 |
| Farid, M | 1 |
| Chowbay, B | 1 |
| Ramasamy, S | 1 |
| Koo, WH | 3 |
| Toh, HC | 1 |
| Trobaugh-Lotrario, AD | 1 |
| Katzenstein, HM | 2 |
| Krop, IE | 2 |
| LoRusso, P | 1 |
| Modi, S | 1 |
| Yardley, D | 1 |
| Lu, M | 1 |
| Zheng, M | 1 |
| Girish, S | 1 |
| Amler, L | 1 |
| Lee, EK | 1 |
| Revil, C | 1 |
| Ngoh, CA | 1 |
| Lister, J | 1 |
| Kwon, JM | 1 |
| Park, MH | 1 |
| Lee, NS | 1 |
| Bae, EJ | 1 |
| Gómez, H | 1 |
| Li, RK | 2 |
| Bosserman, L | 2 |
| Opatt, D | 1 |
| Karachaliou, N | 1 |
| Papadimitraki, E | 1 |
| Kontopodis, E | 1 |
| Bozionelou, V | 1 |
| Kalykaki, A | 1 |
| Dellas, K | 1 |
| Reese, T | 1 |
| Richter, M | 1 |
| Dunst, J | 2 |
| Srivastava, J | 1 |
| Siddiq, A | 1 |
| Emdad, L | 1 |
| Santhekadur, PK | 1 |
| Gredler, R | 1 |
| Shen, XN | 1 |
| Robertson, CL | 1 |
| Dumur, CI | 1 |
| Hylemon, PB | 1 |
| Mukhopadhyay, ND | 1 |
| Bhere, D | 1 |
| Shah, K | 1 |
| Ahmad, R | 1 |
| Giashuddin, S | 1 |
| Stafflinger, J | 1 |
| Subler, MA | 1 |
| Windle, JJ | 1 |
| Fisher, PB | 1 |
| Sarkar, D | 1 |
| Ku, GY | 1 |
| Haaland, BA | 1 |
| de Lima Lopes, G | 1 |
| Mochinaga, S | 1 |
| Okahashi, T | 1 |
| Koga, S | 1 |
| Nakano, Y | 1 |
| Yakabe, T | 1 |
| Sumi, K | 1 |
| Kitahara, K | 1 |
| Noshiro, H | 1 |
| Kimura, S | 1 |
| Fujito, H | 1 |
| Jiang, Z | 1 |
| Wang, T | 1 |
| Bian, L | 1 |
| Wu, S | 2 |
| Song, S | 2 |
| Dugué, PA | 1 |
| Pectasides, D | 1 |
| Papaxoinis, G | 1 |
| Kalogeras, KT | 1 |
| Eleftheraki, AG | 1 |
| Xanthakis, I | 1 |
| Makatsoris, T | 2 |
| Papakostas, P | 1 |
| Nikitas, N | 1 |
| Papandreou, CN | 1 |
| Timotheadou, E | 1 |
| Koutras, A | 2 |
| Bafaloukos, D | 1 |
| Klouvas, G | 1 |
| Economopoulos, T | 1 |
| Syrigos, KN | 1 |
| Regan, MM | 1 |
| Rotmensz, N | 2 |
| Mastropasqua, MG | 1 |
| Maiorano, E | 1 |
| Price, KN | 2 |
| Castiglione-Gertsch, M | 2 |
| Carloni, V | 1 |
| Mazzocca, A | 1 |
| Mello, T | 1 |
| Galli, A | 1 |
| Capaccioli, S | 1 |
| Suzuki, N | 1 |
| Tsukioka, Y | 1 |
| Fukuoka, J | 1 |
| Martin, LK | 1 |
| Kleiber, B | 1 |
| Ellison, EC | 1 |
| Bloomston, M | 1 |
| Zalupski, M | 1 |
| Bekaii-Saab, TS | 2 |
| Ouyang, T | 1 |
| Wang, TF | 1 |
| Xie, YT | 1 |
| Fan, ZQ | 1 |
| Fan, T | 1 |
| Lin, BY | 1 |
| Li, JF | 1 |
| Prasad, S | 1 |
| Yadav, VR | 1 |
| Sung, B | 1 |
| Reuter, S | 1 |
| Kannappan, R | 1 |
| Wei, C | 1 |
| Baladandayuthapani, V | 1 |
| Lee, LK | 1 |
| Yen, CC | 2 |
| Liu, JH | 2 |
| Reddy, S | 2 |
| Raffin, M | 1 |
| Kaklamani, V | 1 |
| Paquet, A | 1 |
| Weidler, J | 1 |
| Lie, Y | 1 |
| Sherwood, T | 1 |
| Bates, M | 1 |
| Haddad, M | 1 |
| Park, IH | 1 |
| Lee, KS | 3 |
| Gómez-Martin, C | 1 |
| Sánchez, A | 1 |
| Llorente, B | 1 |
| Pérez, B | 1 |
| Serrano, R | 1 |
| Muñoz, ML | 1 |
| Regueiro, P | 1 |
| Sanchez-Viñes, E | 1 |
| López, RL | 1 |
| Cortijo-Cascajares, S | 1 |
| Nacle-López, I | 1 |
| García-Escobar, I | 1 |
| Aguilella-Vizcaíno, MJ | 1 |
| Herreros-de-Tejada, A | 1 |
| Cortés-Funes Castro, H | 1 |
| Calleja-Hernández, MÁ | 1 |
| McCahill, LE | 1 |
| Yothers, G | 1 |
| Sharif, S | 1 |
| Petrelli, NJ | 2 |
| Lai, LL | 1 |
| Bechar, N | 1 |
| Giguere, JK | 2 |
| Dakhil, SR | 1 |
| Fehrenbacher, L | 5 |
| Lopa, SH | 1 |
| Wagman, LD | 1 |
| Wolmark, N | 2 |
| Garassino, MC | 1 |
| Kwak, JY | 1 |
| Jang, SJ | 1 |
| Shivapurkar, N | 1 |
| Mikhail, S | 1 |
| Navarro, R | 1 |
| Bai, W | 1 |
| Pishvaian, M | 1 |
| Wellstein, A | 1 |
| Erten, C | 1 |
| Somali, I | 1 |
| Can, A | 1 |
| Akyol, M | 1 |
| Medeni, M | 1 |
| Budai, B | 2 |
| Nagy, T | 1 |
| Koynov, KD | 1 |
| van Eyll, B | 1 |
| Pike, L | 1 |
| Fielding, A | 1 |
| Robertson, JD | 1 |
| Benjamin, L | 1 |
| Buthion, V | 1 |
| Iskedjian, M | 1 |
| Farah, B | 1 |
| Rioufol, C | 1 |
| Vidal-Trécan, G | 1 |
| Woloch, C | 1 |
| Marouani, H | 1 |
| Mercier, C | 1 |
| Gentil, J | 1 |
| Felekouras, E | 1 |
| Karatzas, T | 1 |
| Griniatsos, J | 1 |
| Dimitroulis, D | 1 |
| Polyzos, K | 1 |
| Kontzoglou, K | 1 |
| Mantas, D | 1 |
| Karavokyros, J | 1 |
| Nikiteas, N | 1 |
| Vafiadis, I | 1 |
| Ueno, T | 1 |
| Lieberman, R | 1 |
| Tezcan, H | 1 |
| Roach, N | 1 |
| Mun, Y | 1 |
| Fish, S | 1 |
| Flick, ED | 1 |
| Dalal, D | 1 |
| Verma, S | 4 |
| Gianni, L | 2 |
| Pegram, M | 1 |
| Fang, L | 1 |
| Lu, MW | 1 |
| Olsen, S | 1 |
| Blackwell, K | 1 |
| Gu, SY | 1 |
| Gan, Y | 1 |
| Wang, BY | 1 |
| Guo, HY | 1 |
| Wang, JL | 1 |
| Wang, LP | 1 |
| Zhao, XM | 1 |
| Hu, XC | 1 |
| Keskin, S | 1 |
| Yıldız, I | 1 |
| Sen, F | 1 |
| Aydogan, F | 1 |
| Kilic, L | 1 |
| Ekenel, M | 1 |
| Sakar, B | 2 |
| Disci, R | 1 |
| Aykan, F | 1 |
| Lyseng-Williamson, KA | 1 |
| Bisonni, R | 1 |
| Giordani, P | 3 |
| Alessandroni, P | 1 |
| Baldelli, AM | 1 |
| Casadei, V | 1 |
| Rossi, D | 1 |
| Fedeli, SL | 1 |
| D'Emidio, S | 1 |
| Giustini, L | 2 |
| Mackey, HM | 1 |
| Yauch, RL | 1 |
| Graham, RA | 1 |
| Bray, GL | 1 |
| Low, JA | 1 |
| King, TM | 1 |
| Hsu, CW | 1 |
| Sartorius, U | 1 |
| Griebsch, I | 1 |
| Avancha, K | 1 |
| Figueras, J | 1 |
| Lopez-Ben, S | 1 |
| Soriano, J | 1 |
| Hernandez-Yagüe, X | 1 |
| Albiol, M | 1 |
| Guardeño, R | 1 |
| Codina-Barreras, A | 1 |
| Queralt, B | 2 |
| Wei, JF | 1 |
| Meng, L | 1 |
| Gunderson, LL | 2 |
| Winter, KA | 1 |
| Pedersen, JE | 1 |
| Moughan, J | 1 |
| Thomas, CR | 1 |
| Rich, TA | 3 |
| Willett, CG | 2 |
| Chiba, A | 1 |
| Yoshida, A | 1 |
| Inaba, M | 1 |
| Matsuura, H | 1 |
| Ino, H | 1 |
| Suganuma, N | 1 |
| Inari, H | 1 |
| Kuroda, K | 1 |
| Mukaibashi, T | 1 |
| Matsuo, A | 1 |
| Kojima, I | 1 |
| Xue, C | 1 |
| Yu, QT | 1 |
| Pan, JJ | 1 |
| Liu, LZ | 1 |
| Song, XQ | 1 |
| Lin, SJ | 1 |
| Wu, JX | 1 |
| Zhang, JW | 1 |
| Liu, JL | 1 |
| Zhao, LP | 1 |
| Zhao, YY | 1 |
| Ma, YX | 1 |
| Bando, I | 1 |
| Asayama, M | 1 |
| Fujino, T | 1 |
| Zhang, K | 1 |
| Olszewski, AJ | 1 |
| Grossbard, ML | 4 |
| Chung, MS | 1 |
| Chalasani, SB | 1 |
| Malamud, S | 2 |
| Mirzoyev, T | 2 |
| Kozuch, PS | 1 |
| Bascoul-Mollevi, C | 1 |
| Bérille, J | 1 |
| Xu, BH | 1 |
| Ding, XY | 1 |
| Cai, RG | 1 |
| Njiaju, UO | 1 |
| Tevaarwerk, AJ | 1 |
| Chang, JE | 1 |
| Hansen, RM | 3 |
| Champeny, TL | 1 |
| Traynor, AM | 1 |
| Meadows, S | 1 |
| Van Ummersen, L | 1 |
| Powers, K | 1 |
| Stewart, JA | 1 |
| Nishi, T | 2 |
| Uemoto, J | 1 |
| Onodera, K | 1 |
| Warita, E | 1 |
| Yamanaka, Y | 1 |
| Xu, N | 2 |
| Jiao, SC | 1 |
| Liu, ZY | 1 |
| Valdiviezo, N | 1 |
| Sepúlveda, J | 1 |
| Ciruelos, E | 1 |
| Ghanem, I | 1 |
| Manneh, R | 1 |
| Dorta, M | 1 |
| Kang, EJ | 1 |
| Hermunen, K | 1 |
| Haglund, C | 1 |
| Amano, K | 1 |
| Ishiguro, T | 1 |
| Sobajima, J | 1 |
| Ohsawa, T | 1 |
| Tran, G | 1 |
| Kerr, A | 1 |
| Stokes, L | 1 |
| Todd, C | 1 |
| Zhu, J | 1 |
| Lian, P | 1 |
| Liang, L | 1 |
| Graves, CA | 1 |
| Camphausen, K | 1 |
| Wong, RP | 1 |
| Robertson, J | 1 |
| Stone, AM | 1 |
| Ryvo, L | 1 |
| Sirbu, D | 1 |
| Ge, L | 1 |
| Yin, D | 1 |
| Lei, C | 1 |
| Zhu, JF | 1 |
| Cai, XH | 1 |
| Zhang, GQ | 1 |
| Isayama, H | 1 |
| Nakai, Y | 1 |
| Takahara, N | 1 |
| Kogure, H | 1 |
| Mizuno, S | 1 |
| Yagioka, H | 1 |
| Hirano, K | 1 |
| Toda, N | 1 |
| Tada, M | 1 |
| Omata, M | 1 |
| Koike, K | 1 |
| Nagata, T | 1 |
| Nomura, M | 1 |
| Yoshino, H | 1 |
| Matsunami, N | 1 |
| Miyashita, M | 1 |
| Furuya, Y | 1 |
| Ishida, T | 1 |
| Wakita, K | 1 |
| Kii, T | 1 |
| Kawabe, S | 1 |
| Kuwakado, S | 1 |
| Asaishi, K | 1 |
| Miyamoto, T | 1 |
| Higuchi, K | 1 |
| Tawfik, H | 1 |
| Rostom, Y | 1 |
| Elghazaly, H | 1 |
| Okamura, R | 1 |
| Sata, R | 1 |
| Ichanté, JL | 1 |
| Staszewska-Skurczynska, M | 1 |
| Jonker, DJ | 1 |
| De la Cruz, JA | 1 |
| Williams, JA | 1 |
| Korytowsky, B | 1 |
| Christensen, JG | 1 |
| Chang, J | 1 |
| Ji, D | 1 |
| Peng, W | 1 |
| Bisagni, G | 1 |
| Musolino, A | 1 |
| Panebianco, M | 1 |
| Ardizzoni, A | 2 |
| Gori, S | 2 |
| Gnoni, R | 1 |
| Moretti, G | 1 |
| Bélanger, AS | 1 |
| Harvey, M | 1 |
| Kaminsky, MC | 1 |
| Keller, U | 1 |
| Goddemeier, T | 1 |
| Forssmann, U | 1 |
| Delord, JP | 3 |
| Freyer, G | 2 |
| Ligneau, B | 1 |
| Kraft, D | 1 |
| Descos, L | 1 |
| Norum, J | 1 |
| Balteskard, L | 1 |
| Edna, TH | 1 |
| Laino, R | 1 |
| Wählby, L | 1 |
| Rønning, G | 1 |
| London, WB | 1 |
| Douglass, EC | 1 |
| Reynolds, M | 1 |
| Plaschkes, J | 1 |
| Finegold, MJ | 1 |
| Bowman, LC | 1 |
| Gruber, Y | 1 |
| Corovic, A | 1 |
| Pichlmeier, U | 1 |
| Atanackovic, D | 1 |
| Nierhaus, A | 1 |
| Hossfeld, DK | 3 |
| Willey, A | 1 |
| Glusac, EJ | 1 |
| Bolognia, JL | 1 |
| Skillings, JR | 1 |
| Eisenberg, P | 2 |
| Harper, P | 2 |
| Vincent, MD | 1 |
| Lembersky, BC | 1 |
| Thompson, S | 1 |
| Maniero, A | 1 |
| Benner, SE | 1 |
| Carmichael, J | 1 |
| Popiela, T | 2 |
| Radstone, D | 1 |
| Oza, A | 2 |
| Skovsgaard, T | 1 |
| Munier, S | 2 |
| Martin, C | 3 |
| Hoffmann, R | 2 |
| Franzke, M | 1 |
| Stief, C | 1 |
| Wandert, T | 4 |
| Reitz, M | 5 |
| Nehls, O | 1 |
| Klump, B | 1 |
| Greschniok, A | 1 |
| Gregor, M | 1 |
| Kliche, KO | 1 |
| Kubsch, K | 1 |
| Raida, M | 1 |
| Masri-Zada, R | 1 |
| Höffken, K | 5 |
| Del Tacca, M | 5 |
| Messinese, S | 1 |
| Pozzessere, D | 1 |
| Marsili, S | 3 |
| Sabatino, M | 1 |
| Leonard, RC | 2 |
| Breddy, J | 1 |
| Chaturvedi, A | 1 |
| Hutcheon, A | 1 |
| Lepille, D | 1 |
| Marre, A | 1 |
| Mignot, L | 2 |
| Hua, A | 1 |
| Méry-Mignard, D | 2 |
| Benedetti, JK | 3 |
| Macdonald, JS | 4 |
| Seay, TE | 1 |
| Neubauer, MA | 1 |
| George, CS | 1 |
| Tanaka, MS | 1 |
| Pruitt, BT | 1 |
| Kornek, GV | 2 |
| Raderer, M | 2 |
| Schüll, B | 1 |
| Schmid, K | 1 |
| Längle, F | 1 |
| Huber, H | 1 |
| Cantore, M | 1 |
| Rabbi, C | 1 |
| Guadagni, S | 1 |
| Zamagni, D | 1 |
| Aitini, E | 1 |
| Garcia-Arroyo, R | 1 |
| Lorenzo, I | 1 |
| Carrete, N | 1 |
| Campos, B | 1 |
| Palacios, P | 1 |
| Kulke, MH | 4 |
| Hsu, KC | 1 |
| Hartung, G | 1 |
| Samel, S | 1 |
| Emig, M | 1 |
| Pilz, L | 1 |
| Willeke, F | 1 |
| Hehlmann, R | 1 |
| Queisser, W | 8 |
| Monnier, A | 1 |
| Namer, M | 5 |
| Fargeot, P | 5 |
| Assadourian, S | 1 |
| Leonard, P | 2 |
| James, R | 1 |
| Hochhauser, D | 1 |
| Ledermann, JA | 3 |
| Gambill, BD | 1 |
| Fishman, AD | 1 |
| Wadler, S | 4 |
| Besse, B | 1 |
| Spano, JP | 1 |
| Hedley, D | 1 |
| Pintilie, M | 1 |
| Maroun, J | 3 |
| Jolivet, J | 2 |
| Fields, A | 2 |
| Lee, IM | 1 |
| Calvo, E | 2 |
| Fernández-Hidalgo, O | 1 |
| Rebollo, J | 2 |
| Martín-Algarra, S | 1 |
| Martínez-Monge, R | 1 |
| de Irala, J | 1 |
| Brugarolas, A | 2 |
| Aschele, C | 5 |
| Debernardis, D | 4 |
| Bandelloni, R | 2 |
| Drudi, G | 1 |
| Gallo, L | 5 |
| Maley, F | 3 |
| Monfardini, S | 2 |
| Aapro, M | 2 |
| Misset, JL | 7 |
| Garin, L | 1 |
| Corbinais, S | 1 |
| Blanchot, J | 1 |
| Le Guilcher, P | 1 |
| Akbulut, H | 2 |
| Altuntas, F | 1 |
| Akbulut, KG | 2 |
| Ozturk, G | 1 |
| Cindoruk, M | 1 |
| Unal, E | 1 |
| Icli, F | 1 |
| Hashiguchi, Y | 1 |
| Sekine, T | 1 |
| Sakamoto, H | 1 |
| Nishimura, Y | 1 |
| Kazumoto, T | 1 |
| Sakura, M | 1 |
| Tanaka, Y | 2 |
| Hoffmann, T | 1 |
| Hildner, K | 1 |
| Siebler, J | 1 |
| Ahn, JH | 2 |
| Min, YJ | 1 |
| Kim, WK | 3 |
| Vozianov, AF | 1 |
| Zak, KP | 1 |
| Zubko, VI | 1 |
| Romanenko, AM | 1 |
| Klimenko, IA | 1 |
| Babich, VM | 1 |
| Kushneruk, IuI | 1 |
| Shcherbak, AIu | 1 |
| Bazalitskaia, SV | 1 |
| Gruzov, MA | 1 |
| Forni, F | 1 |
| Smaniotto, D | 1 |
| Trodella, L | 2 |
| Cellini, N | 2 |
| Loesch, DM | 1 |
| Asmar, L | 1 |
| Canfield, VA | 1 |
| Parker, GA | 1 |
| Hynes, HE | 1 |
| Ellis, PG | 1 |
| Ferri, WA | 1 |
| Nakagoe, T | 1 |
| Yamaguchi, E | 1 |
| Sawai, T | 1 |
| Tsuji, T | 2 |
| Shibasaki, S | 1 |
| Nanashima, A | 1 |
| Yamaguchi, H | 1 |
| Yasutake, T | 1 |
| Ayabe, H | 1 |
| Cossaart, N | 1 |
| SantaCruz, KS | 1 |
| Preston, D | 1 |
| Johnson, P | 2 |
| Skikne, BS | 1 |
| Grinev, MV | 1 |
| Tomioka, H | 1 |
| Sumi, T | 1 |
| Takagi, M | 1 |
| Kato, F | 1 |
| Koyanagi, Y | 1 |
| Beger, HG | 1 |
| Poch, B | 1 |
| Schwarz, M | 2 |
| Gansauge, F | 1 |
| Liersch, T | 1 |
| Langer, C | 1 |
| Jakob, C | 1 |
| Müller, D | 1 |
| Ghadimi, BM | 1 |
| Siemer, A | 1 |
| Markus, PM | 1 |
| Füzesi, L | 1 |
| Becker, H | 1 |
| Harris, EE | 1 |
| Schultz, D | 1 |
| Bertsch, H | 1 |
| Fox, K | 1 |
| Glick, J | 1 |
| Solin, LJ | 1 |
| Sohn, JH | 1 |
| Shin, HJ | 2 |
| Noh, SH | 2 |
| Min, JS | 1 |
| Jang, WI | 1 |
| Chung, HC | 4 |
| Bauduceau, O | 1 |
| Ceccaldi, B | 1 |
| Bernard, O | 1 |
| Dourhte, LM | 1 |
| Le Moulec, S | 1 |
| Hervé, R | 1 |
| Parnes, HL | 1 |
| Cirrincione, C | 1 |
| Aisner, J | 1 |
| Allen, SL | 1 |
| Abrams, J | 1 |
| Chuang, E | 1 |
| Cooper, MR | 6 |
| Perry, MC | 3 |
| Duggan, DB | 1 |
| Szatrowski, TP | 2 |
| Henderson, IC | 5 |
| Weiss, RB | 2 |
| Woolf, SH | 1 |
| Demakos, E | 1 |
| Holland, JF | 3 |
| Falkson, G | 19 |
| Robbins, A | 1 |
| Bothun, S | 1 |
| Kelleher, M | 1 |
| Makower, D | 1 |
| Fehn, K | 1 |
| Landau, L | 1 |
| Wissel, P | 1 |
| Versola, M | 1 |
| Mani, S | 2 |
| Becerra, CR | 1 |
| Frenkel, EP | 1 |
| Ashfaq, R | 1 |
| Gaynor, RB | 1 |
| Urien, S | 2 |
| Kerbrat, P | 1 |
| Deporte-Fety, R | 1 |
| Ilersich, AL | 1 |
| Oza, AM | 1 |
| Bigelow, RH | 1 |
| Garay, CA | 1 |
| Burger, BG | 1 |
| Le Bail, N | 2 |
| Grundmann, JU | 1 |
| Weisshaar, E | 1 |
| Franke, I | 1 |
| Bonnekoh, B | 1 |
| Gollnick, H | 1 |
| Gilles-Amar, V | 1 |
| Krulik, M | 4 |
| Fischer, L | 1 |
| Friess, H | 2 |
| Z'graggen, K | 1 |
| Uhl, W | 1 |
| Reina, JJ | 2 |
| Pica, JM | 1 |
| Rueda, A | 1 |
| Lorenzo, A | 1 |
| de la Puente, CG | 1 |
| Borrega, P | 1 |
| Moreno-Nogueira, JA | 1 |
| Thurm, H | 1 |
| Ebel, S | 1 |
| Kentenich, C | 1 |
| Hemsen, A | 1 |
| Riethdorf, S | 1 |
| Coith, C | 1 |
| Wallwiener, D | 1 |
| Braun, S | 1 |
| Oberhoff, C | 2 |
| Jänicke, F | 2 |
| Pantel, K | 1 |
| Chachoua, A | 1 |
| Speyer, J | 2 |
| Escalon, J | 1 |
| Zeleniuch-Jacquotte, A | 1 |
| Muggia, F | 2 |
| Merkel, U | 2 |
| Wedding, U | 2 |
| Roskos, M | 2 |
| Hoffmann, A | 2 |
| Reichardt, P | 5 |
| Thuss-Patience, PC | 3 |
| Kölbl, H | 1 |
| Kieback, DG | 1 |
| Kuhn, W | 1 |
| Schindler, AE | 1 |
| Mohrmann, S | 1 |
| Lück, HJ | 1 |
| Gonzalez, MA | 1 |
| Biswas, S | 1 |
| Clifton, L | 1 |
| Corrie, PG | 1 |
| Elomaa, I | 3 |
| Joensuu, H | 1 |
| Blomqvist, C | 4 |
| Kato, H | 1 |
| Hashimoto, M | 1 |
| Umehara, A | 1 |
| Fujimoto, T | 1 |
| Hwang, YH | 1 |
| Suh, CK | 1 |
| Park, SP | 1 |
| Yoshizawa, H | 1 |
| Tanaka, J | 1 |
| Kagamu, H | 1 |
| Maruyama, Y | 1 |
| Miyao, H | 1 |
| Ito, K | 3 |
| Iwashima, A | 1 |
| Suzuki, E | 1 |
| Gejyo, F | 1 |
| Kretzschmar, A | 4 |
| Schaller, G | 1 |
| Wils, J | 5 |
| Lorenz, M | 3 |
| Schöffski, P | 3 |
| Voigtmann, R | 2 |
| Lutz, M | 1 |
| Kleeberg, C | 1 |
| Ridwelski, K | 1 |
| Souchon, R | 1 |
| El-Serafi, M | 2 |
| Weiss, U | 1 |
| Burkhard, O | 1 |
| Rückle, H | 2 |
| Lichnitser, M | 1 |
| Langenbuch, T | 1 |
| Couvreur, ML | 1 |
| Pusztai, L | 1 |
| Zhen, JH | 1 |
| Arun, B | 1 |
| Whitehead, C | 1 |
| Thompson, WJ | 1 |
| Nealy, KM | 1 |
| Gibbs, A | 1 |
| Symmans, WF | 1 |
| Esteva, FJ | 1 |
| Booser, D | 1 |
| Murray, JL | 1 |
| Smith, TL | 7 |
| Nakazato, H | 1 |
| Koike, A | 1 |
| Takagi, H | 1 |
| Mai, M | 1 |
| DEMAREE, EW | 1 |
| MOORMAN, HD | 1 |
| BRENNAN, MJ | 1 |
| TALLEY, RW | 3 |
| DRAKE, EH | 2 |
| VAITKEVICIUS, VK | 7 |
| POZNANSKI, AK | 1 |
| BRUSH, BE | 1 |
| SULLIVAN, RD | 2 |
| NORCROSS, JW | 1 |
| WATKINS, E | 1 |
| ANSFIELD, FJ | 16 |
| CURRERI, AR | 6 |
| VONESSEN, CF | 1 |
| KLIGERMAN, MM | 1 |
| CALABRESI, P | 2 |
| ROSSMAN, RE | 1 |
| KNOX, JM | 1 |
| FREEMAN, RG | 1 |
| LANE, M | 1 |
| DALMAUCIRIA, M | 1 |
| KOOP, CE | 1 |
| MOERTEL, CG | 10 |
| REITEMEIER, RJ | 2 |
| HAHN, RG | 10 |
| HART, GD | 2 |
| KARNOFSKY, DA | 1 |
| JOHNSON, RO | 4 |
| CASTRO, R | 1 |
| GOLDENBERG, IS | 2 |
| HAYES, MA | 1 |
| GREENSPAN, EM | 2 |
| WATSON, EC | 1 |
| CAMMACK, KV | 1 |
| ROUSSELOT, LM | 1 |
| GROSSI, CE | 1 |
| SLATTERY, J | 1 |
| ROSSI, P | 1 |
| RUZICKA, FF | 1 |
| PRYTZ, B | 1 |
| LAWTON, RL | 3 |
| PACE, WG | 1 |
| KNOERNSCHILD, H | 1 |
| WILSON, WL | 1 |
| DELAGARZA, JG | 1 |
| SUHRLAND, LG | 1 |
| WEISBERGER, AS | 1 |
| Yang, JK | 1 |
| Zhen, J | 1 |
| Shen, KP | 1 |
| Giannakakis, T | 1 |
| Gouveris, P | 1 |
| Vadiaka, M | 1 |
| Dimitrakopoulos, A | 1 |
| Karadima, D | 1 |
| Rokana, S | 1 |
| Papalambros, E | 1 |
| Papastratis, G | 1 |
| Margaris, H | 1 |
| Tsipras, H | 1 |
| Araneo, M | 2 |
| Bruckner, HW | 6 |
| Frager, D | 2 |
| Homel, P | 3 |
| Marino, J | 2 |
| DeGregorio, P | 2 |
| Mortazabi, F | 1 |
| Firoozi, K | 1 |
| Jindal, K | 1 |
| Kozuch, P | 3 |
| Earle, CC | 4 |
| Enzinger, PC | 4 |
| Stuart, K | 1 |
| Catarius, KJ | 1 |
| Winkelmann, J | 1 |
| Belloc, J | 1 |
| Etienney, I | 1 |
| Montembault, S | 1 |
| Vayre, L | 1 |
| Ezenfis, J | 1 |
| Dominguez, S | 1 |
| Kanoh, K | 1 |
| Nomoto, K | 1 |
| Oka, M | 1 |
| Hinoda, Y | 1 |
| Wenzel, C | 1 |
| Locker, GJ | 1 |
| Bartsch, R | 1 |
| Pluschnig, U | 1 |
| Mader, R | 2 |
| Hussian, D | 1 |
| Kramer, G | 1 |
| Marberger, M | 1 |
| Lintner, C | 1 |
| Rauchenwald, M | 1 |
| Semiglazov, VF | 1 |
| Maksimov, SIa | 1 |
| Semiglazov, VV | 1 |
| Kosnikov, AG | 1 |
| Ward, S | 1 |
| Kaltenthaler, E | 1 |
| Cowan, J | 1 |
| Brewer, N | 1 |
| Begbie, S | 1 |
| Burns, WI | 1 |
| Jodrell, D | 1 |
| Levine, EL | 1 |
| Marschner, N | 2 |
| Tujakowski, J | 1 |
| Van Hazel, G | 2 |
| Wong, A | 3 |
| Goepfert, H | 4 |
| Maor, M | 1 |
| Pajak, TF | 1 |
| Weber, R | 1 |
| Morrison, W | 1 |
| Glisson, B | 1 |
| Trotti, A | 1 |
| Ridge, JA | 1 |
| Chao, C | 1 |
| Peters, G | 1 |
| Lee, DJ | 1 |
| Leaf, A | 1 |
| Ensley, J | 1 |
| Cooper, J | 1 |
| Fenández-Martos, C | 1 |
| Huarte, L | 1 |
| Balcells, M | 2 |
| Tang, ZY | 1 |
| Wu, ZQ | 1 |
| Xiao, YS | 1 |
| Shi, YH | 1 |
| Li, XM | 1 |
| Sun, QM | 1 |
| Liu, YK | 1 |
| Ye, SL | 1 |
| Isik, B | 1 |
| Altundag, K | 2 |
| Schmidt, WM | 1 |
| Kalipciyan, M | 1 |
| Dornstauder, E | 1 |
| Rizovski, B | 1 |
| Sedivy, R | 1 |
| Müller, MW | 1 |
| Mader, RM | 1 |
| Kaubisch, A | 1 |
| Kaleya, R | 1 |
| Haynes, H | 1 |
| Rozenblit, A | 1 |
| Lewis, NL | 1 |
| Salut, A | 1 |
| Diz, P | 1 |
| García López, MJ | 1 |
| España, P | 1 |
| de la Torre, A | 1 |
| Martínez del Prado, P | 1 |
| Duarte, I | 1 |
| Pujol, E | 1 |
| Arizcun, A | 1 |
| Artale, S | 1 |
| Frustaci, S | 2 |
| Carreca, I | 1 |
| Bonaglia, L | 1 |
| Marini, G | 5 |
| Iannelli, A | 1 |
| Cortinovis, D | 1 |
| Beretta, E | 1 |
| Lambiase, A | 1 |
| Wilke, H | 8 |
| Vanhoefer, U | 4 |
| Hirschfeld, S | 1 |
| Griebel, DJ | 1 |
| Williams, GA | 1 |
| Stathopoulos, GP | 1 |
| Rigatos, SK | 1 |
| Potamiannou, A | 1 |
| Tsiakopoulos, I | 1 |
| Aravantinos, G | 2 |
| Athanasiadis, A | 1 |
| Papakotoulas, P | 1 |
| Seidman, A | 1 |
| Kariya, K | 1 |
| Schwartz, RA | 1 |
| Jones, L | 1 |
| Hawkins, N | 1 |
| Westwood, M | 1 |
| Wright, K | 1 |
| Riemsma, R | 1 |
| Clippe, C | 1 |
| Orfeuvre, H | 1 |
| Lesimple, T | 2 |
| Culine, S | 2 |
| Audhuy, B | 2 |
| Serin, D | 1 |
| Curé, H | 4 |
| Vuillemin, E | 1 |
| Mouri, Z | 2 |
| Sørbye, H | 2 |
| Dahl, O | 2 |
| Wang, TL | 1 |
| Romans, K | 1 |
| Bardelli, A | 1 |
| Saha, S | 1 |
| Choti, M | 1 |
| Donehower, R | 1 |
| Parmigiani, G | 1 |
| Shih, IeM | 1 |
| Iacobuzio-Donahue, C | 1 |
| Kinzler, KW | 1 |
| Vogelstein, B | 1 |
| Lengauer, C | 1 |
| Velculescu, VE | 1 |
| Choi, EA | 1 |
| Lei, H | 1 |
| Maron, DJ | 1 |
| Mick, R | 2 |
| Barsoum, J | 1 |
| Yu, QC | 1 |
| Fraker, DL | 1 |
| Wilson, JM | 1 |
| Spitz, FR | 1 |
| Emura, T | 1 |
| Murakami, Y | 1 |
| Nakagawa, F | 1 |
| Kitazato, K | 1 |
| Dufour, P | 2 |
| Lokich, J | 3 |
| Madajewicz, S | 3 |
| Maroun, JA | 3 |
| Schoelmerich, J | 1 |
| Schilsky, RL | 5 |
| Neoptolemos, JP | 2 |
| Stocken, DD | 1 |
| Bassi, C | 1 |
| Dunn, JA | 1 |
| Hickey, H | 1 |
| Beger, H | 1 |
| Fernandez-Cruz, L | 1 |
| Dervenis, C | 1 |
| Lacaine, F | 1 |
| Falconi, M | 1 |
| Pederzoli, P | 1 |
| Pap, A | 1 |
| Spooner, D | 1 |
| Kerr, DJ | 2 |
| van Zuylen, L | 1 |
| Sparreboom, A | 1 |
| Eskens, FA | 2 |
| Sklenar, I | 1 |
| Planting, AS | 1 |
| Choi, L | 1 |
| Bootle, D | 1 |
| Mueller, C | 1 |
| Morant, R | 3 |
| Bernhard, J | 1 |
| Dietrich, D | 1 |
| Gillessen, S | 1 |
| Bonomo, M | 1 |
| Bauer, J | 2 |
| Cerny, T | 1 |
| Rochlitz, C | 1 |
| Wernli, M | 1 |
| Gschwend, A | 1 |
| Hanselmann, S | 1 |
| Hering, F | 1 |
| Schmid, HP | 1 |
| Machiavelli, MR | 2 |
| Salum, G | 1 |
| Pérez, JE | 4 |
| Ortiz, EH | 2 |
| Romero, AO | 2 |
| Bologna, F | 1 |
| Vallejo, CT | 2 |
| Lacava, JA | 2 |
| Dominguez, ME | 2 |
| Leone, BA | 5 |
| Razis, E | 1 |
| Kosmidis, P | 1 |
| Bakoyiannis, C | 1 |
| Janinis, J | 1 |
| Timotheadou, H | 1 |
| Christodoulou, C | 1 |
| Belmar, N | 1 |
| Buelow, R | 1 |
| Fong, T | 1 |
| Kikuchi, I | 1 |
| Miyanaga, O | 1 |
| Harada, M | 1 |
| Touboul, E | 1 |
| Moureau-Zabotto, L | 1 |
| Lerouge, D | 1 |
| Pène, F | 1 |
| Deniaud-Alexandre, E | 1 |
| Tiret, E | 1 |
| Sezeur, A | 1 |
| Houry, S | 1 |
| Gallot, D | 1 |
| Parc, R | 2 |
| Schlienger, M | 1 |
| Laugier, A | 1 |
| Humphreys, AC | 1 |
| Dent, J | 1 |
| Rodwell, S | 1 |
| Crawford, SM | 1 |
| Joffe, JK | 2 |
| Bradley, C | 1 |
| Dodwell, D | 1 |
| Perren, TJ | 1 |
| Kindler, HL | 1 |
| Nattam, S | 1 |
| Wade-Oliver, K | 1 |
| Vokes, EE | 4 |
| Wist, EA | 1 |
| Sommer, HH | 1 |
| Ostenstad, B | 2 |
| Risberg, T | 1 |
| Bremnes, Y | 1 |
| Mjaaland, I | 2 |
| Gallego, J | 1 |
| Yuste, AL | 1 |
| Marfa, X | 1 |
| Lassere, Y | 1 |
| Carter, S | 1 |
| Samid, D | 1 |
| Polito, D | 1 |
| Jiang, K | 1 |
| Djeu, JY | 1 |
| Wei, S | 1 |
| Sebti, S | 1 |
| Novotny, W | 1 |
| Hainsworth, J | 1 |
| Heim, W | 2 |
| Baron, A | 3 |
| Griffing, S | 1 |
| Ferrara, N | 1 |
| Rogers, B | 1 |
| Ross, R | 1 |
| Kabbinavar, F | 2 |
| Dickson, JL | 1 |
| Huang, MJ | 1 |
| Lin, HC | 2 |
| Su, YW | 1 |
| Lin, J | 1 |
| Hsieh, RK | 2 |
| Ross, K | 1 |
| Piacentino, V | 1 |
| Stepnowski, D | 1 |
| McClurken, JB | 1 |
| Furukawa, S | 1 |
| Dempsey, DT | 1 |
| Kwong, DL | 2 |
| Sham, JS | 3 |
| Au, GK | 4 |
| Kwong, PW | 1 |
| Cheng, AC | 1 |
| Wu, PM | 1 |
| Law, MW | 1 |
| Kwok, CC | 1 |
| Yau, CC | 1 |
| Wan, KY | 1 |
| Choy, DD | 1 |
| Askmalm, MS | 1 |
| Olsson, B | 1 |
| Rutqvist, LE | 1 |
| Skoog, L | 1 |
| Stål, O | 1 |
| Brockstein, B | 1 |
| Haraf, DJ | 2 |
| Rademaker, AW | 1 |
| Kies, MS | 1 |
| Stenson, KM | 2 |
| Rosen, F | 1 |
| Mittal, BB | 2 |
| Pelzer, H | 2 |
| Fung, BB | 1 |
| Witt, ME | 2 |
| Wenig, B | 1 |
| Portugal, L | 1 |
| Weichselbaum, RW | 1 |
| Hibi, K | 1 |
| Akiyama, S | 1 |
| Karvellas, CJ | 1 |
| Sawyer, M | 1 |
| Hamilton, M | 1 |
| Whitehead, RP | 1 |
| Ardalan, B | 1 |
| Williamson, S | 1 |
| Gaynor, ER | 1 |
| Balcerzak, SP | 1 |
| Morelli, MF | 1 |
| Porzio, G | 1 |
| Cianci, G | 1 |
| DI Rocco, ZC | 1 |
| Natoli, C | 1 |
| Tinari, N | 1 |
| Calista, F | 1 |
| Garcea, G | 1 |
| Polemonivi, N | 1 |
| O'Leary, E | 1 |
| Lloyd, TD | 1 |
| Dennison, AR | 1 |
| Berry, DP | 1 |
| Milano, MT | 1 |
| Argiris, A | 1 |
| Rouits, E | 1 |
| Dumont, A | 1 |
| Guérin, O | 1 |
| Ahn, SH | 1 |
| Kim, SM | 1 |
| Park, JM | 1 |
| Hecker, H | 2 |
| Kim, TM | 1 |
| Yu, SJ | 1 |
| Kim, DW | 1 |
| Joh, YH | 1 |
| Kwon, JH | 1 |
| Heo, DS | 2 |
| Casazza, S | 2 |
| Damjanovic, D | 1 |
| Thompson, P | 1 |
| Sun, L | 1 |
| Xue, Y | 1 |
| Fan, D | 2 |
| LaRocca, RV | 1 |
| Glisson, SD | 1 |
| Hargis, JB | 1 |
| Kosfeld, RE | 1 |
| Leaton, KE | 1 |
| Hicks, RM | 1 |
| Amin-Zimmerman, F | 1 |
| Gullu, I | 1 |
| Altundag, O | 1 |
| Ozyar, E | 2 |
| Cengiz, M | 2 |
| Akyol, F | 1 |
| Bar-Sela, G | 1 |
| Haim, N | 1 |
| Sharieff, W | 1 |
| Waters, JS | 1 |
| Moss, C | 1 |
| James, M | 1 |
| Hackett, S | 1 |
| A'hern, R | 1 |
| Gore, M | 1 |
| Eisen, T | 2 |
| Tonkin, KS | 1 |
| Koski, SL | 1 |
| Scarfe, AG | 1 |
| Smylie, MG | 1 |
| Joy, AA | 2 |
| Au, HJ | 1 |
| Bodnar, DM | 1 |
| Soulieres, D | 1 |
| Smith, SW | 1 |
| Brasiūnas, V | 1 |
| Brasiūniene, B | 1 |
| Juozaityte, E | 1 |
| Barauskas, G | 1 |
| Araake, M | 1 |
| Orita, H | 1 |
| Hess, D | 1 |
| Thürlimann, B | 1 |
| Pagani, O | 1 |
| Aebi, S | 1 |
| Rauch, D | 1 |
| Ballabeni, P | 1 |
| Rufener, B | 1 |
| Cerri, E | 2 |
| Saeki, T | 1 |
| Takashima, S | 2 |
| Maruyama, M | 1 |
| Koide, A | 1 |
| Ohbu, M | 1 |
| Hasegawa, K | 1 |
| Takashima, I | 1 |
| Ebuchi, M | 1 |
| Idelevich, E | 1 |
| Man, S | 1 |
| Lavrenkov, K | 1 |
| Gluzman, A | 1 |
| Geffen, DB | 1 |
| Shani, A | 1 |
| Schena, M | 1 |
| Dongiovanni, D | 1 |
| Numico, G | 1 |
| Colantonio, I | 1 |
| Bertetto, O | 2 |
| Borquez, D | 3 |
| Schleucher, R | 1 |
| Harstrick, A | 6 |
| Seeber, S | 11 |
| Etienne, MC | 1 |
| Magné, N | 1 |
| Bourgeon, A | 1 |
| Slee, PH | 1 |
| Nortier, JW | 1 |
| van Bochove, A | 1 |
| Ueno, H | 1 |
| Takezako, Y | 1 |
| Morizane, C | 1 |
| El-Mabhouh, A | 1 |
| Angelov, C | 1 |
| McEwan, A | 1 |
| Jia, G | 1 |
| Mercer, J | 1 |
| Paye, F | 1 |
| Perez, N | 1 |
| Gayet, B | 1 |
| Goebel, FM | 1 |
| Gambardella, A | 2 |
| Farris, A | 5 |
| Maiorino, L | 3 |
| Natale, D | 3 |
| Massidda, B | 4 |
| Tafuto, S | 3 |
| Reddy, GK | 2 |
| Gibson, AD | 1 |
| Price, N | 1 |
| Cheng, SH | 4 |
| Tsai, SY | 4 |
| Yen, KL | 2 |
| Jian, JJ | 4 |
| Feng, AC | 1 |
| Chan, KY | 4 |
| Hong, CF | 1 |
| Chu, NM | 3 |
| Lin, CY | 2 |
| Tan, TD | 3 |
| Chong, V | 1 |
| Huang, AT | 3 |
| Chap, LI | 1 |
| Holmes, FA | 7 |
| Marcom, PK | 1 |
| Dickler, M | 1 |
| Overmoyer, BA | 1 |
| Sing, AP | 1 |
| Langmuir, V | 1 |
| Carlini, LE | 1 |
| Bever, J | 1 |
| Andria, ML | 1 |
| Hill, T | 1 |
| Gold, P | 1 |
| Rogatko, A | 1 |
| Blanchard, RL | 1 |
| Gibson, MK | 2 |
| Holcroft, CA | 1 |
| Kvols, LK | 2 |
| Budach, V | 1 |
| Stuschke, M | 1 |
| Budach, W | 1 |
| Baumann, M | 1 |
| Geismar, D | 1 |
| Grabenbauer, G | 1 |
| Lammert, I | 1 |
| Jahnke, K | 1 |
| Stueben, G | 1 |
| Herrmann, T | 1 |
| Bamberg, M | 1 |
| Wust, P | 2 |
| Hinkelbein, W | 1 |
| Wernecke, KD | 1 |
| Nielsen, JN | 2 |
| Gyldenkerne, N | 1 |
| Lindeberg, J | 1 |
| Bertheault-Cvitkovic, F | 2 |
| Turpin, FL | 1 |
| Lokiec, F | 2 |
| Lochon, I | 1 |
| Chatelut, E | 1 |
| Canal, P | 1 |
| Cornen, X | 1 |
| Schmitt, E | 1 |
| Gertenbach, U | 1 |
| Fornara, P | 1 |
| Heynemann, H | 1 |
| Maskow, A | 1 |
| Ecke, M | 1 |
| Wöltjen, HH | 1 |
| Jentsch, H | 1 |
| Wieland, W | 1 |
| Dirix, L | 2 |
| Van Belle, S | 3 |
| Gonzalez Baron, M | 1 |
| Joosens, E | 1 |
| Gruia, G | 4 |
| Sibaud, D | 1 |
| Shiozaki, A | 1 |
| Yamagishi, H | 1 |
| Itoi, H | 1 |
| Fujiwara, H | 1 |
| Kikuchi, S | 1 |
| Okamoto, K | 1 |
| Ichikawa, D | 1 |
| Fuji, N | 1 |
| Ochiai, T | 2 |
| Sonoyama, T | 1 |
| Takatori, H | 1 |
| Natsugoe, S | 1 |
| Okumura, H | 1 |
| Matsumoto, M | 1 |
| Ishigami, S | 2 |
| Owaki, T | 1 |
| Aikou, T | 1 |
| Reid, TR | 1 |
| Freeman, S | 1 |
| Post, L | 1 |
| McCormick, F | 1 |
| Sze, DY | 1 |
| Seium, Y | 1 |
| Stupp, R | 1 |
| Gervaz, P | 1 |
| Mentha, G | 1 |
| Philippe, M | 1 |
| Allal, A | 2 |
| Trembleau, C | 1 |
| Roth, AD | 1 |
| Venook, A | 2 |
| Matano, E | 1 |
| Bianco, R | 1 |
| Infusino, S | 1 |
| Simeone, E | 1 |
| Diadema, MR | 1 |
| Castellano, P | 1 |
| Di Martino, N | 1 |
| Catalano, G | 4 |
| Bianco, AR | 2 |
| Kallinowski, B | 1 |
| Rosenthal, MA | 1 |
| Wong, S | 1 |
| Uren, S | 1 |
| Ellis, A | 1 |
| Heldin, P | 1 |
| Hambleton, J | 1 |
| Novotny, WF | 1 |
| Semiglazova, TIu | 1 |
| Filatova, LV | 1 |
| Gershanovich, ML | 2 |
| Kono, T | 2 |
| Ebisawa, Y | 1 |
| Tomita, I | 1 |
| Chisato, N | 1 |
| Kamiya, K | 1 |
| Asama, T | 1 |
| Ayabe, T | 1 |
| Ashida, T | 1 |
| Kohgo, Y | 1 |
| Kasai, S | 2 |
| Choi, EY | 1 |
| Cho, EK | 4 |
| Ki Lee, W | 1 |
| Kreutz, F | 1 |
| Longrée, L | 1 |
| Graas, MP | 1 |
| Focan-Henrard, D | 1 |
| Moeneclaey, N | 1 |
| David, A | 1 |
| Biquet, JF | 1 |
| Materne, R | 1 |
| Weerts, J | 1 |
| Delforge, M | 1 |
| Cannone, M | 1 |
| Dilhuydy, MS | 1 |
| Rueckert, S | 1 |
| Ruehl, I | 1 |
| Kahlert, S | 1 |
| Konecny, G | 2 |
| Untch, M | 2 |
| Demicheli, R | 3 |
| Miceli, R | 1 |
| Moliterni, A | 2 |
| Zambetti, M | 5 |
| Hrushesky, WJ | 2 |
| Retsky, MW | 1 |
| Valagussa, P | 11 |
| Bonadonna, G | 11 |
| Felici, A | 2 |
| Carlini, P | 2 |
| Ruggeri, EM | 2 |
| Pollera, CF | 1 |
| De Marco, S | 1 |
| Fariello, AM | 1 |
| Gelibter, A | 1 |
| Adami, E | 1 |
| Stollfuss, J | 1 |
| Hentrich, M | 1 |
| Zumschlinge, R | 1 |
| Thoedtmann, J | 1 |
| Hennig, M | 1 |
| Seroneit, T | 1 |
| Bredenkamp, R | 1 |
| Duyster, J | 1 |
| Alexandrescu, DT | 1 |
| Dutcher, JP | 1 |
| Wiernik, PH | 4 |
| Lee, WK | 1 |
| Kim, WS | 1 |
| Jung, CW | 1 |
| Leichman, CG | 3 |
| Wade Iii, JL | 1 |
| Bearden Iii, JD | 1 |
| Morgan-Meadows, S | 1 |
| Mulkerin, D | 1 |
| Bailey, H | 1 |
| Saphner, T | 2 |
| Jumonville, A | 1 |
| Hansen, R | 2 |
| Ahuja, H | 1 |
| McFarland, T | 1 |
| Thomas, JP | 2 |
| García Palomo, A | 1 |
| Alonso López, C | 1 |
| León Carbonero, A | 1 |
| Adróver Cebrián, E | 1 |
| Barceló Galíndez, R | 1 |
| Arroyo Yustos, M | 1 |
| Alvarez Gallego, J | 1 |
| Trudeau, M | 1 |
| Dranitsaris, G | 1 |
| Clemons, M | 1 |
| Adleff, V | 1 |
| Czeglédi, F | 1 |
| Horváth, Z | 1 |
| Gyergyay, F | 1 |
| Lövey, J | 1 |
| Kovács, T | 1 |
| Orosz, Z | 1 |
| Kásler, M | 1 |
| Kralovánszky, J | 1 |
| Sugitani, M | 1 |
| Nishimura, K | 1 |
| Noguchi, H | 1 |
| Ouchi, M | 1 |
| Yamada, M | 2 |
| Kitajima, M | 2 |
| Tsuruoka, Y | 1 |
| Takahashi, Y | 1 |
| Futagawa, S | 1 |
| Allen, WL | 1 |
| Johnston, PG | 2 |
| Barletta, E | 1 |
| Fiore, F | 2 |
| Daniele, B | 1 |
| D'Angelo, R | 1 |
| Ferrari, E | 1 |
| Formato, R | 1 |
| Tortoriello, A | 1 |
| Turitto, G | 1 |
| Bruni, GS | 1 |
| Pignata, S | 1 |
| Iaffaioli, RV | 1 |
| Leonard, GD | 1 |
| Wright, MA | 1 |
| Quinn, MG | 1 |
| Fioravanti, S | 1 |
| Harold, N | 1 |
| Schuler, B | 1 |
| Thomas, RR | 1 |
| Hillner, BE | 1 |
| Bontenbal, M | 1 |
| de Boer, AC | 1 |
| Janssen, JT | 1 |
| Leys, RB | 1 |
| Ruit, JB | 1 |
| Goey, SH | 1 |
| van der Velden, PC | 1 |
| Kerkhofs, LG | 1 |
| Schothorst, KL | 1 |
| Schmitz, PI | 1 |
| Bokma, HJ | 1 |
| Filippelli, G | 1 |
| Buzzi, F | 3 |
| Palmeri, S | 6 |
| De Lucia, L | 1 |
| Mancarella, S | 2 |
| De Cataldis, G | 1 |
| Houvenaeghel, G | 2 |
| Lelievre, L | 1 |
| Gonzague-Casabianca, L | 1 |
| Buttarelli, M | 1 |
| Resbeut, M | 2 |
| El-Helw, L | 1 |
| Coleman, RE | 1 |
| Lim, L | 1 |
| Yip, D | 1 |
| Shapiro, JD | 1 |
| Dowling, R | 1 |
| Little, A | 1 |
| Bailey, W | 1 |
| Liechtenstein, M | 1 |
| Tetzlaff, ED | 1 |
| Videnovic, A | 1 |
| Semenov, I | 1 |
| Chua-Adajar, R | 1 |
| Baddi, L | 1 |
| Blumenthal, DT | 1 |
| Beck, AC | 1 |
| Simuni, T | 1 |
| Futterer, S | 1 |
| Gradishar, W | 1 |
| Tellez, C | 1 |
| Raizer, JJ | 1 |
| Gasparini, G | 2 |
| Gattuso, D | 1 |
| Longo, R | 1 |
| Sarmiento, R | 1 |
| Vitale, S | 1 |
| Farrell, PJ | 1 |
| Rezaí, K | 1 |
| Woo, IS | 1 |
| Choi, MG | 1 |
| Chang, SK | 1 |
| Choi, SI | 1 |
| Lee, DS | 1 |
| Lutz, MP | 1 |
| Nolting, A | 1 |
| Pollert, P | 1 |
| Catania, C | 2 |
| Sanna, G | 2 |
| Imadalou, K | 1 |
| Munzone, E | 3 |
| Adamoli, L | 1 |
| Longerey, B | 1 |
| Blanchot, G | 1 |
| Innis, M | 1 |
| Sandiford, N | 1 |
| Shenoy, RK | 1 |
| Prussia, PR | 1 |
| Zbar, A | 1 |
| Casali, A | 1 |
| Tonachella, R | 1 |
| Tropea, F | 1 |
| Verri, C | 1 |
| Paoletti, G | 2 |
| Gionfra, T | 1 |
| Modugno, G | 1 |
| Gallo Curcio, C | 1 |
| Schmitz, R | 1 |
| Krakamp, B | 1 |
| Troidl, H | 1 |
| Pallis, A | 3 |
| Kouroussis, C | 3 |
| Agelaki, S | 4 |
| Xenidis, N | 1 |
| Milaki, G | 1 |
| Donadio, M | 2 |
| Ardine, M | 1 |
| Beano, A | 1 |
| Bottini, A | 2 |
| Mistrangelo, M | 1 |
| Bonardi, S | 1 |
| Generali, D | 1 |
| Polimeni, MA | 1 |
| Bretti, S | 1 |
| Blom, JW | 1 |
| Osanto, S | 2 |
| Rosendaal, FR | 1 |
| Vincent, JM | 1 |
| Maestu, I | 1 |
| Llorca, C | 1 |
| Busquier, I | 1 |
| Perez-Enguix, D | 1 |
| Levy, C | 2 |
| Valle, JW | 1 |
| Bhatnagar, P | 1 |
| Young, E | 1 |
| Levine, E | 2 |
| Seriakov, AP | 1 |
| Kopychev, IuE | 1 |
| Gorbunov, VA | 1 |
| Zav'ialov, MS | 1 |
| Kubyshkin, SI | 1 |
| Smolin, AV | 1 |
| Sukirko, VA | 1 |
| Iguchi, H | 2 |
| Kusuki, M | 1 |
| Nakamura, A | 1 |
| Kanazawa, A | 1 |
| Hachiya, K | 1 |
| Yamane, H | 1 |
| McCollum, AD | 1 |
| Wu, B | 1 |
| Michelini, A | 3 |
| Martinez, J | 1 |
| Chacon, M | 2 |
| Korbenfeld, E | 1 |
| Bella, S | 2 |
| Senna, S | 1 |
| Richardet, E | 2 |
| Coppola, F | 2 |
| Bas, C | 1 |
| Hidalgo, J | 1 |
| Escobar, E | 1 |
| Reale, M | 1 |
| Smilovich, AM | 1 |
| Wasserman, E | 3 |
| Bracco-Nolin, CH | 1 |
| Legat-Fagnoni, C | 1 |
| Chaigneau, L | 1 |
| Stein, U | 1 |
| Huchet, B | 1 |
| Woronoff-Lemsi, MC | 1 |
| Goyle, S | 1 |
| Maraveyas, A | 1 |
| Curtis, BR | 1 |
| Kaliszewski, J | 1 |
| Marques, MB | 1 |
| Nabelle, L | 1 |
| Blank, J | 1 |
| McFarland, JG | 1 |
| Aster, RH | 1 |
| Alliot, C | 1 |
| Schiavon, G | 2 |
| La Cesa, A | 2 |
| Gasparro, S | 1 |
| Vincenzi, A | 1 |
| Nistico, C | 2 |
| Bria, E | 1 |
| Agostara, B | 3 |
| Colella, E | 1 |
| Frontini, L | 1 |
| D'Ottavio, AM | 1 |
| Cuppone, F | 1 |
| Valenza, R | 3 |
| Terzoli, E | 3 |
| Ooyama, A | 1 |
| Toda, E | 1 |
| Sugimoto, Y | 1 |
| Oka, T | 1 |
| Shimizu, M | 2 |
| Hirayama, R | 2 |
| Varette, C | 3 |
| Cirillo, I | 1 |
| Nooter, K | 1 |
| de Jonge, MJ | 1 |
| Farker, K | 1 |
| Hippius, M | 1 |
| Rivory, L | 1 |
| Beale, P | 2 |
| Ong, S | 1 |
| Horvath, L | 1 |
| Warusavitarne, J | 1 |
| Ramanathan, P | 1 |
| Kaufman, A | 1 |
| Robinson, BG | 1 |
| Schnitzler, M | 1 |
| Lockhart, AC | 2 |
| Cropp, GF | 1 |
| Donnelly, E | 1 |
| Schumaker, RD | 1 |
| Schaaf, LJ | 1 |
| Hande, KR | 3 |
| Fleischer, AC | 1 |
| Hannah, AL | 1 |
| Lee, DH | 1 |
| Yoon, SM | 1 |
| Lee, HG | 1 |
| Yoon, SJ | 1 |
| Han, W | 1 |
| Han, MR | 1 |
| Kang, JJ | 1 |
| Bae, JY | 1 |
| Bae, YJ | 1 |
| Hwang, KT | 1 |
| Hwang, SE | 1 |
| Kim, SW | 1 |
| Noh, DY | 1 |
| Cilley, J | 1 |
| Nielsen, HM | 1 |
| Overgaard, M | 1 |
| Grau, C | 1 |
| Jensen, AR | 1 |
| Overgaard, J | 1 |
| Vincitore, M | 1 |
| Sheehan, S | 1 |
| Suto, K | 1 |
| Shirota, Y | 1 |
| Nihei, Z | 1 |
| Skibber, JM | 2 |
| Rodriguez-Bigas, MA | 1 |
| Feig, BW | 1 |
| Janjan, NA | 4 |
| Delclos, ME | 2 |
| Levy, LB | 1 |
| Ellis, LM | 1 |
| Gebbia, V | 11 |
| Verderame, F | 1 |
| Ferraù, F | 1 |
| Callari, A | 1 |
| Caruso, M | 1 |
| Tirrito, ML | 2 |
| Cicero, G | 1 |
| Borsellino, N | 2 |
| Tralongo, P | 1 |
| Liao, WJ | 1 |
| Adelstein, DJ | 3 |
| Leblanc, M | 1 |
| Colevas, AD | 1 |
| Murr, R | 1 |
| Kumekawa, Y | 1 |
| Ito, H | 2 |
| Kurahashi, T | 1 |
| Konishi, K | 2 |
| Katagiri, A | 1 |
| Kuwahara, M | 1 |
| Kubota, Y | 1 |
| Muramoto, T | 1 |
| Mizutani, Y | 1 |
| Imawari, M | 1 |
| Mrozek, E | 1 |
| Ramaswamy, B | 1 |
| Young, D | 1 |
| Rhoades, CA | 1 |
| Kendra, K | 1 |
| Moore, T | 1 |
| Hauger, M | 1 |
| Watson, H | 1 |
| Merriman, N | 1 |
| Nadella, P | 1 |
| Villalona-Calero, M | 1 |
| Shapiro, CL | 1 |
| Frikha, M | 1 |
| Ghorbel, A | 1 |
| Karray, H | 1 |
| Drira, MM | 1 |
| Pasetto, LM | 1 |
| Pessa, S | 1 |
| Errante, D | 1 |
| De Pangher, V | 1 |
| Giusto, M | 1 |
| Medici, M | 1 |
| Gaion, F | 1 |
| Sandri, P | 1 |
| Galligioni, E | 1 |
| Bonura, S | 1 |
| Boccalon, M | 1 |
| Biason, P | 1 |
| Endo, I | 1 |
| Fujii, Y | 2 |
| Miura, Y | 1 |
| Kubota, T | 2 |
| Togo, S | 1 |
| Shimada, H | 1 |
| Giantonio, BJ | 1 |
| Levy, DE | 1 |
| Artioli, F | 1 |
| Codignola, C | 1 |
| Lazzaro, A | 1 |
| Rizzi, A | 1 |
| Gamboni, A | 1 |
| Rota, L | 1 |
| Rodinò, C | 1 |
| Boni, F | 1 |
| Iop, A | 1 |
| Chao, TC | 2 |
| Hsiao, LT | 1 |
| Patiyil, S | 1 |
| Halabi, S | 1 |
| Rini, B | 1 |
| Ernstoff, MS | 2 |
| Davila, E | 1 |
| Picus, J | 1 |
| Barrier, R | 1 |
| Small, EJ | 1 |
| Gilliam, LK | 1 |
| Kohn, AD | 1 |
| Lalani, T | 1 |
| Swanson, PE | 1 |
| Vasko, V | 1 |
| Patel, A | 1 |
| Livingston, RB | 4 |
| Pickett, CA | 1 |
| Biedrzycki, BA | 1 |
| Maynard, J | 1 |
| Deisseroth, A | 1 |
| Putzu, C | 2 |
| De Rosa, V | 2 |
| Sandomenico, C | 1 |
| Di Seri, M | 1 |
| Spalletta, B | 1 |
| Caricato, M | 1 |
| Coppola, R | 1 |
| Seike, J | 1 |
| Yoshida, T | 1 |
| Honda, J | 1 |
| Miyoshi, T | 1 |
| Umemoto, A | 1 |
| Tangoku, A | 1 |
| Vukelja, S | 2 |
| Gorbounova, V | 2 |
| Chan-Navarro, CA | 1 |
| Maraninchi, D | 1 |
| Barak-Wigler, N | 1 |
| Harker, WG | 1 |
| Bexon, AS | 1 |
| Delozier, T | 3 |
| Yovine, A | 2 |
| Mousseau, M | 1 |
| Delva, R | 3 |
| Vannetzel, JM | 1 |
| Zazzi, ES | 1 |
| Brienza, S | 6 |
| Cvitkovic, E | 6 |
| Santeufemia, DA | 1 |
| Piredda, G | 1 |
| Fadda, GM | 1 |
| Cossu Rocca, P | 1 |
| Costantino, S | 1 |
| Sarobba, MG | 1 |
| Pinna, MA | 1 |
| Gibson, TB | 1 |
| Merritt, J | 1 |
| Robbins, J | 1 |
| Stewart, J | 1 |
| Schupp, J | 1 |
| Shiiki, S | 1 |
| Sonoo, H | 1 |
| Seki, M | 1 |
| Nomura, T | 1 |
| Hironou, M | 1 |
| Ookubo, S | 1 |
| Udagawa, K | 1 |
| Kurebayashi, J | 1 |
| Jouary, T | 1 |
| Kaiafa, A | 1 |
| Lipinski, P | 1 |
| Vergier, B | 1 |
| Lepreux, S | 1 |
| Delaunay, M | 1 |
| Taïeb, A | 1 |
| Massacesi, C | 2 |
| Marcucci, F | 1 |
| Pilone, A | 1 |
| Rocchi, MB | 1 |
| Zepponi, L | 1 |
| Burattini, L | 1 |
| Baschnagel, A | 1 |
| Calascibetta, A | 1 |
| Cabibi, D | 1 |
| Rausa, L | 6 |
| Aragona, F | 1 |
| Barresi, E | 1 |
| Martorana, A | 1 |
| Sanguedolce, R | 1 |
| Donadon, M | 1 |
| Charnsangavej, C | 1 |
| Abdalla, EK | 1 |
| Mariani, G | 2 |
| Fasolo, A | 1 |
| Marchiano, A | 1 |
| Rosa, DD | 1 |
| Ismael, GF | 1 |
| de Azambuja, E | 1 |
| Braga, S | 1 |
| Cardoso, F | 1 |
| Tiu, CM | 1 |
| Herrmann, E | 1 |
| Brinkmann, OA | 1 |
| Bode, ME | 1 |
| Bierer, S | 1 |
| Köpke, T | 1 |
| Bögemann, M | 1 |
| Hertle, L | 1 |
| Wülfing, C | 1 |
| Duffour, J | 3 |
| Gourgou, S | 1 |
| Debrigode, C | 1 |
| Chalbos, P | 1 |
| Bressole, F | 1 |
| Sledge, GW | 4 |
| Lee, SC | 1 |
| Heo, JS | 1 |
| Rocci, L | 1 |
| Leoni, V | 1 |
| Eriksen, MT | 1 |
| Wibe, A | 1 |
| Haffner, J | 1 |
| Wiig, JN | 1 |
| Toumpanakis, C | 1 |
| Standish, RA | 1 |
| Baishnab, E | 1 |
| Winslet, MC | 1 |
| Caplin, ME | 1 |
| Supko, JG | 1 |
| Eder, JP | 1 |
| Ogino, S | 1 |
| Stewart, CF | 1 |
| D'Amato, F | 1 |
| Dancey, J | 1 |
| Kinsella, K | 1 |
| Tyagi, P | 1 |
| Oechsle, K | 1 |
| Honecker, F | 1 |
| Kollmannsberger, C | 1 |
| Rick, O | 1 |
| Grünwald, V | 1 |
| Mayer, F | 2 |
| Goel, A | 1 |
| Dietrich, M | 1 |
| Sezgin, C | 1 |
| Kurt, E | 1 |
| Evrensel, T | 1 |
| Manavoglu, O | 1 |
| Lee, SS | 1 |
| Younes, F | 1 |
| Moukadem, W | 1 |
| Krämer, I | 1 |
| Lipp, HP | 1 |
| Gez, E | 1 |
| Rubinov, R | 1 |
| Gaitini, D | 1 |
| Meretyk, S | 1 |
| Best, LA | 1 |
| Mashiach, T | 1 |
| Native, O | 1 |
| Kuten, A | 2 |
| Kenny, L | 1 |
| Coombes, RC | 2 |
| Vigushin, DM | 1 |
| Al-Nahhas, A | 1 |
| Shousha, S | 1 |
| Aboagye, EO | 1 |
| Cho, BC | 1 |
| Huang, CY | 1 |
| Tsai, YC | 2 |
| Huang, KH | 1 |
| Pu, YS | 1 |
| Vardakis, N | 2 |
| Kourousis, C | 1 |
| Nishimura, M | 1 |
| Fujiyama, Y | 1 |
| Heuer, T | 1 |
| Nusch, A | 1 |
| Pandya, KJ | 3 |
| Hu, P | 2 |
| Osborne, CK | 3 |
| Tormey, DC | 14 |
| Zhang, CX | 1 |
| Fang, JW | 1 |
| Shen, P | 1 |
| Bao, YH | 1 |
| Mou, BH | 1 |
| Shi, MG | 1 |
| Zhong, XL | 1 |
| Xiong, PJ | 1 |
| Recchia, F | 2 |
| Saggio, G | 2 |
| Candeloro, G | 1 |
| Cesta, A | 1 |
| Amiconi, G | 1 |
| Blasio, AD | 1 |
| Necozione, S | 1 |
| Rea, S | 2 |
| O'connor, T | 1 |
| Rustum, Y | 4 |
| Creaven, P | 3 |
| Ikenaga, M | 1 |
| Ota, H | 1 |
| Tominaga, S | 1 |
| Ohnishi, T | 1 |
| Amano, M | 1 |
| Ikeda, K | 1 |
| Sekimoto, M | 1 |
| Monden, M | 1 |
| Yoon, HH | 1 |
| van Gameren, EC | 1 |
| Doorn, L | 1 |
| van der Gaast, A | 1 |
| Schreibman, SM | 1 |
| Desai, M | 1 |
| Sherman, W | 1 |
| Strauss, J | 1 |
| Guba, S | 1 |
| Andrade, R | 1 |
| Chabot, J | 1 |
| Elzagheid, A | 1 |
| Lamlum, H | 2 |
| Algars, A | 1 |
| Korkeila, E | 2 |
| Ristamäki, R | 2 |
| Collan, Y | 1 |
| Tripathy, D | 1 |
| Crinò, L | 1 |
| Benedetti, G | 1 |
| Evangelista, W | 1 |
| Fanchini, L | 1 |
| Picone, V | 1 |
| Porcile, G | 1 |
| Orlandini, C | 2 |
| Oh, SC | 2 |
| Sur, HY | 1 |
| Sung, HJ | 2 |
| Choi, IK | 2 |
| Park, SS | 1 |
| Seo, JH | 2 |
| Jeen, YT | 1 |
| Chun, HJ | 1 |
| Shin, SW | 2 |
| Mok, YJ | 1 |
| Chun, YJ | 1 |
| Posey, J | 1 |
| Tchekmedyian, S | 1 |
| Hu, E | 1 |
| Chan, D | 1 |
| Malik, I | 1 |
| Amado, RG | 1 |
| Kubicka, S | 2 |
| Chaves, M | 1 |
| Iyevleva, AG | 1 |
| Buslov, KG | 1 |
| Togo, AV | 1 |
| Matsko, DE | 1 |
| Filimonenko, VP | 1 |
| Imyanitov, EN | 1 |
| Shimizu, T | 2 |
| Ozaki, T | 1 |
| Fukuoka, M | 1 |
| Sultana, A | 1 |
| Smith, CT | 1 |
| Ghaneh, P | 1 |
| Paolelli, L | 1 |
| Sciandivasci, A | 1 |
| de Rubertis, G | 1 |
| Barbanti, G | 1 |
| Manganelli, A | 1 |
| Salvestrini, F | 1 |
| Labidi, SI | 1 |
| Gravis, G | 1 |
| Brun, V | 1 |
| Laber, DA | 1 |
| Khan, MI | 1 |
| Kloecker, GH | 1 |
| Schonard, C | 1 |
| Taft, BS | 1 |
| Salvador, C | 1 |
| Zampino, MG | 3 |
| Magni, E | 1 |
| Martignetti, A | 1 |
| Zorzino, L | 1 |
| Lorizzo, K | 1 |
| Santoro, L | 1 |
| Boselli, S | 1 |
| De Ruvo, N | 1 |
| Drigo, A | 1 |
| Zanet, E | 1 |
| Cho, YY | 1 |
| Ahn, BM | 1 |
| Kim, SN | 1 |
| Lee, IT | 1 |
| Haines, IE | 1 |
| Lerzo, G | 1 |
| Cai, C | 1 |
| Mullaney, B | 1 |
| Vallböhmer, D | 1 |
| Yang, DY | 1 |
| Shimizu, D | 1 |
| Sørensen, NM | 1 |
| Byström, P | 1 |
| Kan, N | 1 |
| Yoshikawa, K | 2 |
| Nio, Y | 2 |
| Iguchi, C | 1 |
| Kodama, H | 1 |
| Takeuchi, S | 1 |
| Muto, M | 1 |
| Majlis, A | 1 |
| Rodrigues, A | 1 |
| Fodor, M | 1 |
| Voznyi, E | 1 |
| Marabotti, C | 1 |
| Abrahantes, JC | 1 |
| Burzykowski, T | 1 |
| Chirivella, I | 1 |
| Hollis, D | 1 |
| Hantel, A | 1 |
| Fields, AL | 1 |
| Krook, JE | 4 |
| Green, EM | 1 |
| Morton, RF | 1 |
| Williamson, SK | 1 |
| Findlay, BP | 1 |
| Sticca, RP | 1 |
| Nam, E | 1 |
| Favier, L | 1 |
| Zanetta, S | 1 |
| Ferrant, E | 1 |
| Garnier, J | 1 |
| Amato, RJ | 3 |
| Khan, M | 1 |
| Zhong, LX | 1 |
| Tao, QS | 1 |
| Tang, XM | 1 |
| Maniadakis, N | 1 |
| Fragoulakis, V | 1 |
| Prezerakos, P | 1 |
| Yang, CH | 1 |
| Hsu, C | 1 |
| Hsu, WL | 1 |
| Senesse, P | 1 |
| Cany, L | 2 |
| Jacob, JH | 1 |
| Aloysius, MM | 1 |
| Zaitoun, AM | 1 |
| Beckingham, IJ | 1 |
| Neal, KR | 1 |
| Aithal, GP | 1 |
| Bessell, EM | 1 |
| Lobo, DN | 1 |
| Oestreicher, P | 1 |
| Ishizu, K | 1 |
| Sunose, N | 1 |
| Tsuruo, T | 3 |
| Sadahiro, S | 1 |
| Makuuchi, H | 1 |
| Yamori, T | 3 |
| Argyriou, AA | 1 |
| Polychronopoulos, P | 1 |
| Iconomou, G | 1 |
| Gerolymos, MK | 1 |
| Gourzis, P | 1 |
| Assimakopoulos, K | 1 |
| Kalofonos, HP | 1 |
| Chroni, E | 1 |
| Osako, T | 1 |
| Tokudome, N | 1 |
| Iwase, T | 1 |
| Jeong, WJ | 1 |
| Hah, JH | 1 |
| Kwon, TK | 1 |
| Wu, HG | 1 |
| Sung, MW | 1 |
| Kang, SH | 1 |
| Kim, JI | 1 |
| Goh, PG | 1 |
| Hwang, SW | 1 |
| Kwon, DS | 1 |
| Nam, KW | 1 |
| Kang, HM | 1 |
| Kang, YS | 1 |
| Moon, HS | 1 |
| Seong, JK | 1 |
| Lee, BS | 1 |
| Jeong, HY | 1 |
| Fürstenberger, G | 1 |
| Schmid, P | 1 |
| Duquesne, A | 1 |
| Ammann, M | 1 |
| Senn, HJ | 7 |
| Bosset, JF | 2 |
| Nguyen, F | 1 |
| Bosset, M | 1 |
| Servagi-Vernat, S | 1 |
| Sedrati, A | 1 |
| Tappenden, P | 1 |
| Jones, R | 2 |
| Paisley, S | 1 |
| Carroll, C | 1 |
| Ogreid, D | 1 |
| Wanderås, EH | 1 |
| Wentzel-Larsen, T | 1 |
| Cardot, JM | 1 |
| Château, Y | 1 |
| Song, TY | 1 |
| Yang, NC | 1 |
| Hu, ML | 1 |
| Tashima, R | 1 |
| Yokoyama, S | 1 |
| Yamashita, Y | 1 |
| Baba, K | 1 |
| Matsuda, M | 1 |
| Iida, S | 1 |
| Furukawa, K | 1 |
| Iwasaki, R | 1 |
| Noguchi, T | 1 |
| Tsuchiya, S | 3 |
| Sugisaki, Y | 1 |
| Naito, Z | 1 |
| Tajiri, T | 1 |
| Grothey, E | 1 |
| Moreno-Solórzano, I | 1 |
| Ibeas-Rollan, R | 1 |
| Monzó-Planella, M | 1 |
| Moreno-Solórzano, J | 1 |
| Martínez-Ródenas, F | 1 |
| Pou-Sanchis, E | 1 |
| Hernández-Borlan, R | 1 |
| Navarro-Vigo, M | 1 |
| Ortigosa-Rodríguez, S | 1 |
| Gel-Moreno, B | 1 |
| Chang, AY | 2 |
| Hsin, KW | 1 |
| Fong, FK | 1 |
| Wong, J | 1 |
| Barcelo, R | 1 |
| Colin, P | 1 |
| Thomas, ES | 2 |
| Gomez, HL | 1 |
| Chan, VF | 1 |
| Pivot, XB | 1 |
| Klimovsky, JV | 1 |
| de Mendoza, FH | 1 |
| Lerzo, GL | 1 |
| Peck, RA | 1 |
| Vahdat, LT | 2 |
| Roché, HH | 1 |
| Tejani, MA | 1 |
| Abderrahim, AG | 1 |
| Bressolle, FM | 1 |
| Verslype, C | 2 |
| Rakhit, A | 2 |
| Fettner, SH | 1 |
| Brennscheidt, U | 1 |
| Feyereislova, A | 1 |
| Sugimoto, M | 1 |
| Yasuda, H | 1 |
| Koda, K | 1 |
| Yamazaki, M | 1 |
| Tezuka, T | 1 |
| Takenoue, T | 1 |
| Kosugi, C | 1 |
| Higuchi, R | 1 |
| Watayo, Y | 1 |
| Yagawa, Y | 1 |
| Soulié, P | 2 |
| Casado, E | 1 |
| Valera, JS | 1 |
| Tortora, G | 1 |
| Kisker, O | 1 |
| Im, CK | 1 |
| Yoo, NC | 1 |
| Klautke, G | 1 |
| Küchenmeister, U | 1 |
| Foitzik, T | 1 |
| Ludwig, K | 1 |
| Semrau, S | 1 |
| Prall, F | 1 |
| Klar, E | 1 |
| Fietkau, R | 2 |
| Durand, M | 2 |
| Battista, C | 1 |
| Spaeth, D | 1 |
| Poiget, E | 1 |
| Monnot, F | 1 |
| Tanguy, ML | 1 |
| Tonusin, A | 1 |
| Rosati, R | 1 |
| Bona, S | 1 |
| Romario, UF | 1 |
| Elmore, U | 1 |
| Furlan, N | 1 |
| Civitelli, S | 1 |
| Tanzini, G | 1 |
| Battistelli, S | 1 |
| Lorenzi, M | 1 |
| Geboes, K | 1 |
| Kajiwara, T | 1 |
| Kataoka, J | 1 |
| Hori, S | 1 |
| Nasu, J | 1 |
| Imamine, S | 1 |
| Stuart, NS | 1 |
| McIllmurray, MB | 1 |
| Bishop, JL | 1 |
| Johnston, SR | 1 |
| Price, CG | 1 |
| O'Reilly, SM | 3 |
| Neave, F | 1 |
| Whipp, EC | 1 |
| Choi, CK | 1 |
| Tung, SY | 1 |
| Lui, L | 1 |
| Siu, S | 1 |
| Ho, JW | 1 |
| Law, WL | 1 |
| Do, YR | 1 |
| Hong, DS | 1 |
| Lee, KE | 1 |
| Jiang, WQ | 1 |
| Deng, YM | 1 |
| Hu, GQ | 1 |
| Xu, DM | 1 |
| van Essen, M | 1 |
| Krenning, EP | 1 |
| Kam, BL | 1 |
| de Herder, WW | 1 |
| van Aken, MO | 1 |
| Kwekkeboom, DJ | 1 |
| Casey, M | 1 |
| Press, M | 1 |
| Lindquist, D | 1 |
| Romieu, CG | 1 |
| Chan, S | 1 |
| Jagiello-Gruszfeld, A | 1 |
| Crown, J | 1 |
| Raats, JI | 1 |
| Skarlos, D | 1 |
| Newstat, B | 1 |
| Roychowdhury, D | 1 |
| Paoletti, P | 1 |
| Rubin, S | 1 |
| Geyer, CE | 1 |
| Sohn, HJ | 1 |
| De Rosa, F | 1 |
| Fettner, S | 1 |
| Wright, T | 1 |
| Bergsland, E | 1 |
| Rothenberg, M | 1 |
| Rosen, L | 1 |
| Englisch-Fritz, C | 1 |
| Leaw, J | 1 |
| Gu, W | 1 |
| Du, H | 1 |
| Yin, J | 1 |
| Chua, YJ | 1 |
| Seo, HY | 1 |
| Kim, DS | 1 |
| Park, KH | 1 |
| Kim, SJ | 1 |
| Choi, CW | 1 |
| Thalheimer, A | 1 |
| Illert, B | 1 |
| Reimer, P | 1 |
| Bueter, M | 1 |
| Thiede, A | 1 |
| Gasser, M | 1 |
| Fein, M | 1 |
| Waaga-Gasser, AM | 1 |
| Meyer, D | 1 |
| Sirzén, F | 3 |
| Efficace, F | 1 |
| Bjarnason, G | 1 |
| Coens, C | 1 |
| Bottomley, A | 1 |
| Walko, CM | 1 |
| Jacob, J | 1 |
| Merrouche, Y | 1 |
| Dorval, E | 1 |
| Piot, G | 2 |
| Allegra, C | 1 |
| Bertino, JR | 2 |
| Gustavsson, BG | 1 |
| O'Connell, M | 1 |
| Gilberg, F | 1 |
| Cartwright, TH | 2 |
| Paiva, CE | 1 |
| Michelin, OC | 1 |
| Bertoldi, I | 1 |
| Miracco, C | 1 |
| Mohammad, T | 1 |
| Basaran, M | 1 |
| Argon, A | 1 |
| Ustuner, Z | 1 |
| Ustaoglu, MA | 1 |
| Guney, N | 1 |
| Tenekeci, AN | 1 |
| Aykan, NF | 1 |
| Chen, YH | 1 |
| Yen, KC | 2 |
| Cheng, JC | 3 |
| Dickler, MN | 1 |
| Klein, PM | 1 |
| Kiribuchi, M | 1 |
| Gault, MH | 1 |
| Cohen, MW | 1 |
| Kahana, LM | 1 |
| Leelin, FT | 1 |
| Meakins, JF | 1 |
| Aronovitch, M | 1 |
| Stehlin, JS | 2 |
| Hills, WJ | 1 |
| Rufino, C | 1 |
| Thompson, JP | 1 |
| Dockerty, MB | 2 |
| Symmonds, RE | 1 |
| Hayles, AB | 1 |
| Ahmann, DL | 5 |
| Bisel, HF | 4 |
| Brindley, GV | 1 |
| Bonnet, JD | 1 |
| Hall, TC | 5 |
| Dederick, MM | 1 |
| Chalmers, TC | 1 |
| Krant, MJ | 1 |
| Shnider, BI | 2 |
| Lynch, JJ | 1 |
| Ross, C | 1 |
| Koons, CR | 1 |
| Owens, AH | 1 |
| Frei, E | 5 |
| Brindley, C | 1 |
| Miller, SP | 1 |
| Brenner, S | 1 |
| Hosley, HF | 1 |
| Olson, KB | 1 |
| Mackman, S | 6 |
| Manni, A | 2 |
| Trujillo, JE | 1 |
| Pearson, OH | 3 |
| Siering, H | 1 |
| Knöll, P | 1 |
| Hall, RR | 1 |
| Evans, RG | 1 |
| Pritchett, CJ | 1 |
| Price, DA | 1 |
| Pant, KD | 1 |
| Shochat, D | 1 |
| Nelson, MO | 1 |
| Goldenberg, DM | 2 |
| Tanigawa, N | 1 |
| Mizuno, Y | 1 |
| Hashimura, T | 1 |
| Honda, K | 1 |
| Satomura, K | 1 |
| Hikasa, Y | 1 |
| Niwa, O | 1 |
| Sugahara, T | 1 |
| Yoshida, O | 1 |
| Kern, DH | 1 |
| Kelsen, D | 1 |
| Klimenkov, AA | 1 |
| Barkanov, AI | 1 |
| Itin, AB | 1 |
| Yagoda, A | 3 |
| Braun, D | 2 |
| Perno, CF | 1 |
| Papaldo, P | 2 |
| Barduagni, M | 1 |
| Barduagni, A | 1 |
| Tannock, IF | 1 |
| Sutherland, DJ | 1 |
| Inuyama, Y | 1 |
| Horiuchi, M | 1 |
| Kohno, N | 1 |
| Mashino, S | 1 |
| Ozu, R | 1 |
| Asaoka, K | 1 |
| Budd, GT | 3 |
| Groppe, CW | 2 |
| Zia, ZF | 1 |
| Wang, YE | 1 |
| Balch, CM | 1 |
| Urist, MM | 1 |
| von der Maase, H | 1 |
| Magnusson, K | 1 |
| Sveinsson, T | 1 |
| Petrelli, N | 2 |
| Rustum, YM | 2 |
| Campbell, J | 1 |
| Herrera, L | 1 |
| Mittelman, A | 4 |
| Perry, A | 1 |
| Creaven, PJ | 1 |
| Cocconi, G | 2 |
| De Lisi, V | 1 |
| Mori, P | 1 |
| Malacarne, P | 1 |
| Giovanelli, E | 1 |
| Gough, IR | 2 |
| Furnival, CM | 1 |
| Storm, FK | 1 |
| Silberman, AW | 1 |
| Ramming, KR | 1 |
| Kaiser, LR | 1 |
| Harrison, WH | 1 |
| Elliott, RS | 1 |
| Haskell, CM | 2 |
| Sarna, G | 1 |
| Morton, DL | 5 |
| Buzdar, AU | 18 |
| Blumenschein, GR | 18 |
| Montague, ED | 2 |
| Yap, HY | 13 |
| Pinnamaneni, K | 1 |
| Marcus, CE | 1 |
| Illiger, HJ | 3 |
| Peiss, J | 1 |
| Vaupel, HA | 1 |
| Hartlapp, JH | 2 |
| Mouridsen, HT | 8 |
| Palshof, T | 3 |
| Mattheiem, W | 1 |
| Sylvester, RJ | 1 |
| Paridaens, RJ | 1 |
| Kolarić, K | 5 |
| Vukas, D | 2 |
| Cervek, J | 1 |
| Esparza, L | 3 |
| Hryniuk, W | 1 |
| Bush, H | 1 |
| Zekan, PJ | 1 |
| Capizzi, RL | 2 |
| Harding, RW | 1 |
| Hopkins, JO | 1 |
| Jackson, DV | 2 |
| Ramseur, WL | 1 |
| Richards, F | 6 |
| Spurr, CL | 5 |
| Xavier, AM | 1 |
| Kasimis, BS | 3 |
| Wu, SY | 1 |
| Kaneshiro, CA | 3 |
| Sternberg, CN | 1 |
| Magill, GB | 1 |
| Sordillo, PP | 1 |
| Cheng, EW | 1 |
| Faul, P | 1 |
| Altwein, JE | 1 |
| Pannuti, F | 1 |
| Iafelice, G | 1 |
| Martoni, A | 2 |
| Fruet, F | 1 |
| Angelelli, B | 2 |
| Casadei, M | 1 |
| Franklin, R | 1 |
| Steiger, Z | 2 |
| Vaishampayan, G | 1 |
| Asfaw, I | 2 |
| Rosenberg, J | 1 |
| Loh, J | 1 |
| Hoschner, J | 1 |
| Miller, P | 1 |
| Bedikian, AY | 4 |
| Stroehlein, J | 1 |
| Korinek, J | 1 |
| Karlin, D | 1 |
| Bodey, GP | 10 |
| Schutt, AJ | 4 |
| Rubin, J | 2 |
| Creagan, ET | 1 |
| Tanaka, T | 1 |
| Ishibashi, H | 1 |
| Iguchi, K | 1 |
| Hashimoto, I | 1 |
| Burk, K | 2 |
| Gropp, C | 3 |
| Rodeck, G | 1 |
| Beck, TM | 2 |
| Curtis, PW | 1 |
| Woodard, DA | 2 |
| Hart, NE | 2 |
| Smith, CE | 2 |
| Jacquillat, C | 2 |
| Baillet, F | 2 |
| Auclerc, G | 2 |
| Blondon, J | 1 |
| Auclerc, MF | 1 |
| Facchini, T | 1 |
| Lefranc, JP | 1 |
| Weil, M | 1 |
| Kuno, K | 1 |
| Naganuma, K | 2 |
| Kawabata, H | 2 |
| Oh-Hara, T | 1 |
| Iida, H | 1 |
| Tsukagoshi, S | 2 |
| Sakurai, Y | 2 |
| Shlemkevich, MP | 1 |
| Shiian, DN | 2 |
| Sternberg, A | 1 |
| Au, J | 1 |
| Kao, AK | 1 |
| Muggia, FM | 4 |
| Dubin, N | 2 |
| Lerner, WA | 1 |
| Stark, R | 1 |
| Wernz, JC | 3 |
| Speyer, JL | 3 |
| Blum, RH | 3 |
| Herrmann, R | 6 |
| Manegold, C | 2 |
| Schroeder, M | 1 |
| Tigges, FJ | 1 |
| Bartsch, H | 1 |
| Jungi, F | 3 |
| Fritze, D | 7 |
| Lyss, AP | 2 |
| Loeb, V | 1 |
| Goodnough, LT | 1 |
| Saito, H | 2 |
| Jones, PK | 1 |
| Casadei Giunchi, D | 1 |
| Cortesi, C | 1 |
| Maltoni, M | 1 |
| Kantarjian, HM | 1 |
| Montague, E | 2 |
| Martin, RG | 2 |
| Creech, RH | 3 |
| Catalano, RB | 3 |
| Dierks, KM | 1 |
| Shah, MK | 1 |
| Rabinovich, MG | 3 |
| Strauss, E | 3 |
| Arévalo, E | 1 |
| Larrad Jiménez, A | 1 |
| Ruiz-Tartas, A | 1 |
| Zapatero Gaviria, J | 1 |
| López Lazareno, N | 1 |
| Liberati, AM | 1 |
| Fatati, G | 1 |
| Biscottini, B | 1 |
| Ballatori, E | 1 |
| Falchi, R | 1 |
| Grignani, F | 2 |
| Brenner, HJ | 1 |
| Bibi, C | 1 |
| Chaitchik, S | 2 |
| Sulkes, A | 4 |
| Fuks, Z | 2 |
| Kotake, T | 1 |
| Usami, M | 1 |
| Miki, T | 1 |
| Kuroda, M | 1 |
| Obata, K | 1 |
| Osafune, M | 1 |
| Fujioka, H | 1 |
| Takasugi, Y | 1 |
| Spanos, W | 1 |
| Schell, F | 1 |
| Hirshaut, Y | 1 |
| Kesselheim, H | 1 |
| Moran, EM | 2 |
| Miller, JB | 2 |
| Forbes, KA | 2 |
| Poblet, MT | 1 |
| Williams, JL | 1 |
| Trishkina, EA | 1 |
| Pavlov, KA | 1 |
| Danova, LA | 1 |
| Labkovskiĭ, BM | 1 |
| Arndt, D | 2 |
| Higi, M | 2 |
| Heuser, L | 1 |
| Schmitt, G | 2 |
| Hori, K | 1 |
| Kovalenko, AV | 1 |
| Rossi, A | 5 |
| Veronesi, U | 4 |
| Dement'eva, IP | 1 |
| Ass, NIa | 1 |
| Lipovich, MM | 1 |
| Klein, HO | 3 |
| Wickramanayake, PD | 2 |
| Löffler, T | 1 |
| Mohr, R | 2 |
| Oerkermann, H | 2 |
| Schnitzler, G | 1 |
| Schaefer, J | 1 |
| Arnold, H | 2 |
| Drings, P | 7 |
| Geldmacher, J | 1 |
| Hartwich, G | 2 |
| Kempf, P | 1 |
| König, H | 1 |
| Meiser, RJ | 1 |
| Nedden, R | 2 |
| von Oldershausen, HF | 1 |
| Pappas, A | 1 |
| Sievers, H | 2 |
| Wahrendorf, J | 1 |
| Westerhausen, M | 2 |
| Witte, S | 1 |
| Conroy, JF | 3 |
| Roda, PI | 1 |
| Brodsky, I | 2 |
| Kahn, SB | 1 |
| Bulova, SI | 1 |
| Pequignot, E | 1 |
| Kinami, Y | 2 |
| Shinmura, K | 1 |
| Takada, M | 1 |
| Sakuma, H | 1 |
| Nagakawa, T | 1 |
| Miyazaki, I | 1 |
| Fujimoto, S | 1 |
| Miyazaki, M | 1 |
| Okui, K | 1 |
| Kunitomo, K | 1 |
| Kuwashima, T | 1 |
| Korematsu, H | 1 |
| Yoshikawa, H | 1 |
| Toyosaki, M | 1 |
| Komi, N | 1 |
| Bedwinek, JM | 1 |
| Ratkin, GA | 1 |
| Philpott, GW | 1 |
| Wallack, M | 1 |
| Perez, CA | 1 |
| Mughal, AW | 1 |
| Fritsche, HA | 1 |
| Schmidt, C | 1 |
| Kihara, K | 1 |
| Sakuramoto, T | 1 |
| Washizuka, M | 1 |
| Kawai, T | 1 |
| Ogawa, M | 2 |
| Madrigal Alonso, P | 1 |
| Alburquerque Carbuccia, H | 1 |
| Meguro, S | 1 |
| Kuraishi, Y | 1 |
| Ichiba, K | 1 |
| Yoda, T | 1 |
| Mikouchi, S | 1 |
| Mallinson, CN | 1 |
| Rake, MO | 2 |
| Cocking, JB | 1 |
| Fox, CA | 1 |
| Cwynarski, MT | 1 |
| Diffey, BL | 1 |
| Jackson, GA | 1 |
| Hanley, J | 1 |
| Wass, VJ | 1 |
| Payne, JE | 1 |
| Pheils, MT | 1 |
| Chapuis, PH | 1 |
| MacPherson, JG | 1 |
| Pouillart, P | 8 |
| Palangie, T | 11 |
| Jouve, M | 8 |
| Garcia-Giralt, E | 8 |
| Magdelenat, H | 2 |
| Asselain, B | 5 |
| Biran, S | 5 |
| Brufman, G | 4 |
| Cavalli, F | 4 |
| Alberto, P | 5 |
| Brunner, K | 1 |
| Martz, G | 6 |
| Fournier, DV | 1 |
| Staib, I | 1 |
| Wöllgens, P | 1 |
| Lochbühler, H | 1 |
| Christmann, D | 1 |
| Bühner, R | 1 |
| Pfuhl, PJ | 1 |
| Henningsen, B | 1 |
| Kuttig, H | 1 |
| Wysocki, S | 1 |
| Thüre, D | 1 |
| Köhler, C | 1 |
| Jungi, WF | 3 |
| Amgwerd, R | 1 |
| Hochuli, E | 1 |
| Deppe, G | 2 |
| Mourali, N | 1 |
| Tabbane, F | 1 |
| Muenz, LR | 1 |
| Bahi, J | 1 |
| Belhassen, S | 1 |
| Kamaraju, LS | 1 |
| Levine, PH | 1 |
| Canellos, GP | 4 |
| Hellman, S | 1 |
| Becher, R | 7 |
| Beer, M | 1 |
| Obrecht, JP | 1 |
| Mermillod, B | 1 |
| Brunner, KW | 5 |
| Gelman, R | 2 |
| Band, PR | 2 |
| Sears, M | 1 |
| Rosenthal, SN | 1 |
| DeWys, W | 1 |
| Perlia, C | 1 |
| Rice, MA | 2 |
| Green, SJ | 1 |
| Ingle, JN | 5 |
| Lee, RA | 2 |
| Edmonson, JH | 2 |
| Logothetis, CJ | 3 |
| von Eschenbach, AC | 1 |
| Samuels, ML | 3 |
| Trindade, A | 1 |
| Johnson, DE | 3 |
| Holzmann, K | 1 |
| Berken, A | 1 |
| Greenblatt, MN | 1 |
| Rosenthal, DS | 1 |
| Graham, G | 1 |
| Chlebowski, RT | 2 |
| Heber, D | 1 |
| Cantrell, JE | 2 |
| Lagarde, C | 1 |
| Schein, PS | 4 |
| Smith, FP | 1 |
| Falk, RE | 3 |
| Hardy, M | 1 |
| Makowka, L | 1 |
| Teodorczyk-Injeyan, J | 1 |
| Falk, JA | 1 |
| Massner, B | 3 |
| Bruntsch, U | 4 |
| Gallmeier, WM | 4 |
| Mayr, AC | 4 |
| Abel, U | 2 |
| Edler, L | 3 |
| Floyd, RA | 1 |
| Hornbeck, CL | 1 |
| Byfield, JE | 1 |
| Griffiths, JC | 1 |
| Frankel, SS | 1 |
| Finck, SJ | 1 |
| Gupta, RK | 1 |
| Giuliano, AE | 1 |
| Dieterle, F | 1 |
| Brock, J | 1 |
| Beyer, D | 1 |
| Gross, R | 1 |
| Albrecht, M | 1 |
| Jepsen, G | 1 |
| Trams, G | 1 |
| Thomsen, K | 1 |
| Falkson, HC | 9 |
| Ryan, RF | 2 |
| Litwin, MS | 3 |
| Krementz, ET | 3 |
| Fosså, SD | 3 |
| Gudmundsen, TE | 1 |
| Auvert, J | 2 |
| Lachand, AT | 2 |
| Botto, H | 1 |
| Abbou, C | 1 |
| Hannoun, M | 1 |
| Morin, P | 3 |
| Lev, L | 1 |
| Mohaliver, J | 1 |
| Joss, R | 1 |
| Sonntag, RW | 2 |
| Tschopp, L | 1 |
| Dymarskiĭ, LIu | 3 |
| Aleksandrova, GI | 1 |
| Sanchakova, AV | 1 |
| Wergowske, G | 1 |
| Drago, JR | 1 |
| Worgul, TJ | 1 |
| Schell, FC | 1 |
| Barnes, BC | 1 |
| Burgess, MA | 9 |
| Smalley, RV | 4 |
| Bartolucci, AA | 2 |
| Wilmanns, W | 2 |
| Hartenstein, R | 1 |
| Sauer, H | 1 |
| Binsack, T | 1 |
| Rubens, RD | 3 |
| Sexton, S | 1 |
| Tong, D | 1 |
| Winter, PJ | 1 |
| Knight, RK | 2 |
| Hayward, JL | 2 |
| Wils, JA | 2 |
| Park, RC | 1 |
| Blom, J | 4 |
| Disaia, PJ | 2 |
| Lagasse, LD | 1 |
| Blessing, JA | 1 |
| De Lena, M | 5 |
| Jirillo, A | 1 |
| Brambilla, C | 6 |
| Villa, S | 1 |
| Piver, MS | 3 |
| Lele, S | 1 |
| Barlow, JJ | 2 |
| Mukamel, E | 2 |
| Nissenkorn, I | 1 |
| Servadio, C | 2 |
| Knight, WA | 1 |
| Yochmowitz, MG | 1 |
| McGuire, WL | 2 |
| Aleksanjan, AZ | 1 |
| Zagrebin, VM | 1 |
| Sacharova, OV | 1 |
| Barberi-Heyob, M | 1 |
| Weber, B | 2 |
| Merlin, JL | 1 |
| Dittrich, C | 2 |
| de Bruijn, EA | 1 |
| Luporsi, E | 1 |
| Guillemin, F | 1 |
| Nestle-Krämling, C | 1 |
| Testa, A | 5 |
| Latteri, M | 1 |
| Bajardi, G | 2 |
| Mastrandrea, G | 2 |
| Cipolla, C | 1 |
| Pischedda, G | 1 |
| Curto, G | 1 |
| Cannata, G | 2 |
| Clavel, M | 2 |
| Cappelaere, P | 3 |
| de Mulder, PH | 4 |
| Schornagel, JH | 1 |
| Tueni, EA | 1 |
| Wildiers, J | 2 |
| Clerico, M | 1 |
| Urba, SG | 1 |
| Turrisi, AT | 1 |
| Schlumberger, M | 1 |
| Abdelmoumene, N | 1 |
| Delisle, MJ | 1 |
| Couette, JE | 1 |
| Simpson, WG | 1 |
| Heys, SD | 3 |
| Whiting, PH | 1 |
| Eremin, O | 3 |
| Broom, J | 1 |
| Kuitunen, T | 1 |
| Nyandoto, P | 1 |
| Kouri, M | 1 |
| Leonardi, V | 1 |
| Meli, M | 2 |
| Rini, GB | 1 |
| Peralta, S | 1 |
| Kirchner, H | 3 |
| Duensing, S | 1 |
| Lopez Hänninen, E | 1 |
| Franzke, A | 2 |
| Buer, J | 2 |
| Probst, M | 1 |
| Anton, P | 1 |
| Poliwoda, H | 1 |
| Joseph, G | 1 |
| Hamm, J | 1 |
| Seeger, J | 1 |
| Blumenreich, M | 1 |
| Hadley, T | 1 |
| Hendler, F | 1 |
| Woodcock, T | 1 |
| Romito, S | 1 |
| Pacilio, G | 1 |
| Giotta, F | 1 |
| Pezzella, G | 1 |
| Durini, E | 1 |
| Cariello, S | 1 |
| Benoit, G | 1 |
| Di Palma, M | 2 |
| Blanchet, P | 1 |
| Lecouturier, S | 2 |
| Yataghene, Y | 1 |
| Decroix, Y | 1 |
| Jardin, A | 1 |
| Berns, EM | 1 |
| Foekens, JA | 1 |
| van Staveren, IL | 1 |
| van Putten, WL | 1 |
| de Koning, HY | 1 |
| Portengen, H | 1 |
| Klijn, JG | 1 |
| Orsatti, M | 1 |
| Curotto, A | 1 |
| Canobbio, L | 2 |
| Guarneri, D | 2 |
| Scarpati, D | 1 |
| Venturini, M | 2 |
| Franzone, P | 1 |
| Giudici, S | 2 |
| Martorana, G | 1 |
| Boccardo, F | 1 |
| Zerillo, G | 2 |
| Restivo, G | 2 |
| Speciale, R | 2 |
| Cupido, G | 1 |
| Lo Bue, P | 1 |
| Ingria, F | 2 |
| Gallina, S | 1 |
| Spatafora, G | 2 |
| Jardines, L | 1 |
| Callans, LS | 1 |
| Torosian, MH | 1 |
| Piedbois, P | 1 |
| Lévy, E | 1 |
| Le Bourgeois, JP | 1 |
| Pein, F | 1 |
| Rainer, H | 1 |
| Oskam, R | 2 |
| de Peuter, RA | 1 |
| Palmer, PA | 1 |
| Franks, CR | 4 |
| Saarto, T | 1 |
| Tiusanen, K | 1 |
| Gröhn, P | 1 |
| Rissanen, P | 2 |
| Dorval, ED | 1 |
| Regimbeau, C | 1 |
| Picon, L | 1 |
| Bérard, H | 1 |
| Herzog, P | 1 |
| González-Barón, M | 1 |
| Espinosa, E | 1 |
| Chacón, I | 1 |
| Garrido, P | 1 |
| Colmenarejo, A | 1 |
| Ordóñez, A | 1 |
| Zamora, P | 1 |
| Ragnhammar, P | 1 |
| Blomgren, H | 1 |
| Edler, D | 1 |
| Lundell, G | 1 |
| Magnusson, I | 1 |
| Sonnenfeld, T | 1 |
| Zabudkin, AF | 1 |
| Bukhteev, SV | 1 |
| Sella, A | 2 |
| Kilbourn, RG | 1 |
| Gray, I | 1 |
| Finn, L | 2 |
| Zukiwski, AA | 1 |
| Ellerhorst, J | 1 |
| Cianci, C | 3 |
| Tsubono, M | 1 |
| Kawabata, K | 1 |
| Masai, Y | 1 |
| Araya, S | 1 |
| Imamura, M | 1 |
| Kiang, DT | 1 |
| Kennedy, BJ | 2 |
| Younger, J | 1 |
| Schilling, A | 1 |
| Korzun, AH | 2 |
| Nowak, BS | 1 |
| Wood, W | 1 |
| Giaccon, G | 1 |
| Ambrosini, G | 1 |
| Iirillo, A | 1 |
| Duro, M | 1 |
| Piazza, E | 1 |
| Oliani, C | 1 |
| Pancera, G | 2 |
| Denham, JW | 1 |
| Hamilton, CS | 1 |
| Christie, D | 1 |
| Bonaventura, A | 1 |
| Lamb, DS | 1 |
| Spry, NA | 1 |
| Dady, P | 1 |
| Fleming, TR | 2 |
| Laurie, JA | 2 |
| Tangen, CM | 1 |
| Ungerleider, JS | 1 |
| Emerson, WA | 1 |
| Glick, JH | 1 |
| Veeder, MH | 3 |
| Mailliard, JA | 5 |
| Carlier, D | 1 |
| Darloy, F | 1 |
| Pion, JM | 1 |
| Demaille, A | 1 |
| Castiglione, M | 1 |
| Coates, AS | 2 |
| Rudenstam, CM | 2 |
| Collins, J | 1 |
| Lindtner, J | 1 |
| Hacking, A | 1 |
| Jodrell, DI | 2 |
| Murray, LS | 1 |
| Reed, NS | 1 |
| Canney, PA | 1 |
| Kaye, SB | 4 |
| Pinnarò, P | 1 |
| Cercato, MC | 1 |
| Giannarelli, D | 1 |
| Del Vecchio, MR | 1 |
| Impiombato, FA | 1 |
| Marzetti, F | 1 |
| Repetto, L | 1 |
| Gardin, G | 4 |
| Lanfranco, C | 1 |
| Naso, C | 2 |
| Merlini, L | 3 |
| Venturino, A | 1 |
| Campora, E | 1 |
| Testore, F | 1 |
| Jakobsen, P | 2 |
| Sørensen, B | 2 |
| Bastholt, L | 2 |
| Mirza, MR | 2 |
| Gjedde, SB | 2 |
| Rose, C | 4 |
| Huan, SD | 2 |
| Aitken, SE | 2 |
| Stewart, DJ | 2 |
| Mahjoubi, M | 1 |
| Bellefqih, S | 1 |
| Oliveira, J | 1 |
| Bognel, C | 1 |
| Lasser, P | 1 |
| Elias, D | 1 |
| Swain, SM | 4 |
| Harris, LN | 1 |
| Hug, V | 4 |
| Clark, J | 1 |
| Johnston, D | 1 |
| Williams, SF | 1 |
| Myers, SE | 1 |
| Huffman, S | 1 |
| Bitran, JD | 2 |
| Cowen, D | 1 |
| Perez, T | 1 |
| Gouvernet, J | 1 |
| Gamerre, M | 1 |
| Boubli, L | 1 |
| Ono, K | 1 |
| Saijo, N | 1 |
| Kish, JA | 1 |
| Wolf, M | 2 |
| Crawford, ED | 2 |
| Leimert, JT | 1 |
| Bueschen, A | 1 |
| Neefe, JR | 1 |
| Flanigan, RC | 1 |
| Scholl, SM | 3 |
| Fourquet, A | 2 |
| Vilcoq, JR | 2 |
| Durand, JC | 2 |
| Dorval, T | 6 |
| Beuzeboc, P | 5 |
| Mundt, AJ | 1 |
| Sibley, GS | 1 |
| Williams, S | 1 |
| Rubin, SJ | 1 |
| Heimann, R | 1 |
| Halpern, H | 1 |
| Weichselbaum, RR | 2 |
| Renner, H | 1 |
| van Kampen, M | 1 |
| Carl, J | 1 |
| Brunsgaard, N | 1 |
| Kjaer, M | 1 |
| Nørgaard-Pedersen, B | 1 |
| Mammoliti, S | 2 |
| Caroti, C | 3 |
| Foley, JF | 1 |
| Hartmann, LC | 1 |
| Gesme, DH | 1 |
| Hatfield, AK | 1 |
| Au, E | 2 |
| Ang, PT | 3 |
| Catimel, G | 1 |
| Chauvin, F | 1 |
| Rebattu, P | 1 |
| Wagener, DJ | 3 |
| Burghouts, JT | 3 |
| Fickers, MM | 1 |
| de Graeff, A | 1 |
| Lalisang, FM | 1 |
| Wagner, JP | 1 |
| Mahe, MA | 1 |
| Romestaing, P | 1 |
| Rocher, FP | 1 |
| Berger, C | 1 |
| Gerard, JP | 1 |
| Weh, HJ | 5 |
| Wilke, HJ | 2 |
| Dierlamm, J | 1 |
| Klaassen, U | 6 |
| Siegmund, R | 1 |
| Kreuser, ED | 1 |
| Hilgenfeld, U | 1 |
| Steinke, B | 1 |
| Bertuccelli, M | 1 |
| Muttini, MP | 1 |
| Dargenio, F | 1 |
| Jones, AL | 1 |
| O'Brien, ME | 3 |
| Talbot, D | 1 |
| Ramage, F | 1 |
| Robertshaw, H | 1 |
| Rosso, R | 6 |
| Mazzei, T | 2 |
| Cartei, G | 1 |
| Cartei, F | 1 |
| Houston, SJ | 1 |
| Richards, MA | 1 |
| Bentley, AE | 1 |
| Smith, P | 1 |
| Demuynck, B | 2 |
| Beerblock, K | 1 |
| Soubrane, D | 1 |
| Marpeau, L | 1 |
| Pigné, A | 1 |
| Guillot, T | 1 |
| Hamblin, TJ | 1 |
| Sadullah, S | 1 |
| Williamson, P | 1 |
| Stevenson, J | 1 |
| Palmer, P | 1 |
| Sagaster, KP | 1 |
| Baldini, E | 1 |
| Rubagotti, A | 3 |
| Monzeglio, C | 1 |
| Brema, F | 1 |
| Pastorino, G | 1 |
| Gomez, EG | 1 |
| McAtee, N | 2 |
| Balis, F | 2 |
| Venzon, D | 1 |
| Kramer, B | 1 |
| Goldspiel, B | 1 |
| Begley, M | 1 |
| Jordan, E | 1 |
| Robson, ME | 1 |
| Binder, RA | 1 |
| Hamilton, JM | 2 |
| Steinberg, SM | 4 |
| Arbuck, SG | 2 |
| Beveridge, RA | 1 |
| Kales, AN | 1 |
| Miller, JA | 1 |
| Kuzel, TM | 1 |
| Tallman, MS | 1 |
| Shevrin, D | 1 |
| Braud, E | 1 |
| Kilton, L | 1 |
| Kozlowski, J | 1 |
| Vogelzang, NJ | 2 |
| Blough, R | 1 |
| Kurtz, JM | 1 |
| Pipard, G | 1 |
| Marti, MC | 1 |
| Miralbell, R | 1 |
| Popowski, Y | 1 |
| Egeli, R | 1 |
| Satou, T | 1 |
| Pavy, JJ | 1 |
| Hamers, HP | 1 |
| Horiot, JC | 1 |
| Fabri, MC | 1 |
| Eschwege, F | 1 |
| Schraub, S | 1 |
| Zirvi, KA | 1 |
| Najjar, TA | 1 |
| Slomiany, BL | 1 |
| Murphy, RF | 1 |
| Drake, J | 1 |
| Chisena, T | 1 |
| Cysyk, R | 1 |
| Rebmann, U | 1 |
| Möbus, V | 1 |
| Paula, J | 1 |
| Beck, T | 2 |
| Crombach, G | 1 |
| Hietanen, P | 1 |
| Nevasaari, K | 1 |
| Helle, L | 1 |
| Brockmann, WP | 1 |
| Wiegel, T | 1 |
| Sommer, K | 1 |
| Steiner, P | 1 |
| Hübener, KH | 1 |
| Bobbio-Pallavicini, E | 1 |
| Porta, C | 2 |
| Moroni, M | 2 |
| Spaghi, A | 1 |
| Casagranda, I | 1 |
| Nastasi, G | 2 |
| Poorter, RL | 1 |
| Bakker, PJ | 1 |
| Taat, CW | 1 |
| Veenhof, CH | 1 |
| Powles, TJ | 3 |
| Mohiuddin, M | 2 |
| Zeitzer, KL | 1 |
| Moylan, DJ | 1 |
| Yelovich, RM | 1 |
| Rose, L | 1 |
| Soussan, A | 1 |
| Caussanel, JP | 2 |
| Metzger, G | 2 |
| Jasmin, C | 1 |
| Bismuth, H | 2 |
| Smolensky, M | 1 |
| Pari, CP | 1 |
| Eberhardt, W | 2 |
| Diergarten, K | 1 |
| Atkins, JN | 2 |
| Case, LD | 2 |
| Grote, T | 1 |
| McFarland, J | 1 |
| Erlichman, C | 4 |
| Fine, S | 2 |
| Kerr, I | 1 |
| Hoffmann, W | 2 |
| Gorg, C | 1 |
| Preusser, P | 2 |
| Thuerlimann, B | 1 |
| Glazier, DB | 1 |
| Heaney, JA | 1 |
| Amdur, RJ | 1 |
| Schned, AR | 1 |
| Harris, R | 1 |
| Fukui, I | 1 |
| Remvikos, Y | 1 |
| Lemmens, J | 1 |
| Berteloot, P | 1 |
| Thomas, J | 1 |
| Paridaens, R | 1 |
| Bonnefoi, H | 1 |
| Allum, WH | 1 |
| Ebbs, S | 1 |
| Baum, M | 1 |
| Raymond, E | 2 |
| Livartowski, A | 1 |
| Scholl, S | 1 |
| Epis, O | 1 |
| Sundfør, K | 1 |
| Tropé, CG | 1 |
| Högberg, T | 1 |
| Onsrud, M | 1 |
| Koern, J | 1 |
| Simonsen, E | 1 |
| Bertelsen, K | 1 |
| Westberg, R | 1 |
| Vaughn, DJ | 2 |
| Treat, J | 2 |
| Estes, NC | 1 |
| Giri, S | 1 |
| Fabian, C | 1 |
| Shirasaka, T | 1 |
| Nakano, K | 1 |
| Takechi, T | 1 |
| Uchida, J | 1 |
| Fujioka, A | 1 |
| Oyama, K | 1 |
| Takeda, S | 1 |
| Unemi, N | 1 |
| Toulouse, C | 1 |
| Mauriac, L | 3 |
| Benhattar, J | 1 |
| Cerottini, JP | 1 |
| Saraga, E | 1 |
| Metthez, G | 1 |
| Givel, JC | 1 |
| Fisher, B | 4 |
| Dignam, J | 1 |
| Mamounas, EP | 1 |
| Costantino, JP | 1 |
| Wickerham, DL | 1 |
| Redmond, C | 2 |
| Dimitrov, NV | 1 |
| Bowman, DM | 1 |
| Glass, AG | 1 |
| Abramson, N | 1 |
| Sutherland, CM | 1 |
| Aron, BS | 1 |
| Margolese, RG | 1 |
| Gedouin, D | 1 |
| Desprez, P | 1 |
| Perron, JJ | 1 |
| Fleury, F | 1 |
| Leclech, G | 1 |
| Belpomme, D | 2 |
| Chenal, C | 1 |
| Blijham, G | 4 |
| Wagener, T | 1 |
| de Greve, J | 1 |
| Buset, M | 1 |
| Lacave, A | 1 |
| Dalmark, M | 1 |
| Selleslag, J | 1 |
| Collette, L | 1 |
| Sahmoud, T | 1 |
| Bernhard, H | 1 |
| Klein, O | 1 |
| Bernhard, G | 1 |
| Lautz, D | 1 |
| Michaelis, J | 1 |
| Meyer zum Büschenfelde, KH | 1 |
| Knuth, A | 2 |
| Brasnu, D | 1 |
| Bassot, V | 1 |
| Ménard, M | 1 |
| Khayat, D | 2 |
| Laccourreye, H | 1 |
| Colozza, M | 3 |
| Mosconi, AM | 2 |
| Anastasi, P | 1 |
| Basurto, C | 1 |
| Ludovini, V | 1 |
| De Angelis, V | 1 |
| Giansanti, M | 1 |
| Tonato, M | 3 |
| Contu, A | 2 |
| Ferrero, B | 1 |
| Santini, S | 1 |
| Gandolfo, GM | 1 |
| Vitelli, G | 1 |
| Frasca, AM | 1 |
| Ameglio, F | 1 |
| Rasi, G | 1 |
| Garaci, E | 1 |
| Ophir, R | 1 |
| Pecht, M | 1 |
| Keisari, Y | 1 |
| Rashid, G | 1 |
| Lourie, S | 1 |
| Meshorer, A | 1 |
| Ben-Efraim, S | 1 |
| Trainin, N | 1 |
| Burstein, Y | 1 |
| Werner, A | 1 |
| Bender, E | 1 |
| Mahaffey, W | 1 |
| McKeating, J | 1 |
| Marrangoni, A | 1 |
| Katoh, A | 1 |
| Azim, HA | 1 |
| Majello, E | 1 |
| Feo, M | 1 |
| Gebbia, N | 6 |
| Killion, JJ | 1 |
| Beltran, P | 1 |
| O'Brian, CA | 1 |
| Yoon, SS | 1 |
| Wilson, MR | 1 |
| Fidler, IJ | 1 |
| Dreyfus, B | 1 |
| Olivier, JP | 1 |
| Dumas, F | 1 |
| Olivares, R | 1 |
| Leszler, A | 1 |
| Bergerat, JP | 1 |
| Thill, L | 1 |
| Oberling, F | 1 |
| Antón-Torres, A | 1 |
| Massutí, T | 1 |
| Barneto, I | 1 |
| García-Conde, J | 1 |
| Barón, JM | 1 |
| Jami, A | 2 |
| Ithzaki, M | 1 |
| Brummer, PD | 1 |
| Kunstlinger, F | 2 |
| Regazzoni, S | 1 |
| Tan, EH | 1 |
| Astre, C | 2 |
| Rouanet, P | 1 |
| Fabre, JM | 1 |
| Saint-Aubert, B | 1 |
| Domergue, J | 1 |
| Ribard, D | 1 |
| Ciurana, AJ | 1 |
| Janbon, C | 1 |
| Pujol, H | 1 |
| Bellissant, E | 1 |
| Morvan, F | 1 |
| Tresca, P | 1 |
| Marty, M | 3 |
| Nelson, H | 1 |
| Martenson, JA | 1 |
| Cha, S | 1 |
| Haddock, M | 1 |
| Devine, R | 1 |
| Fieck, JM | 1 |
| Wolff, B | 1 |
| Dozois, R | 1 |
| Sofo, L | 1 |
| Ratto, C | 1 |
| Doglietto, GB | 1 |
| Ippoliti, M | 1 |
| Nucera, P | 1 |
| Merico, M | 1 |
| Bellantone, R | 1 |
| Bossola, M | 1 |
| Crucitti, F | 1 |
| Villalon, AH | 1 |
| De Guzman, LM | 1 |
| Samson, MC | 1 |
| Guancia, AA | 1 |
| Fernando, GY | 1 |
| Romana, IB | 1 |
| Zoetmulder, FA | 1 |
| Sugarbaker, PH | 3 |
| Volpi, A | 1 |
| Amaducci, L | 1 |
| Amadori, A | 1 |
| Giunchi, DC | 1 |
| Vio, A | 1 |
| Saragoni, A | 1 |
| Silvestrini, R | 2 |
| Johnson, DH | 3 |
| Paul, D | 2 |
| Achterrath, W | 3 |
| Losch, M | 1 |
| Hayungs, J | 1 |
| Geara, FB | 1 |
| Glisson, BS | 1 |
| Sanguineti, G | 1 |
| Tucker, SL | 1 |
| Garden, AS | 1 |
| Ang, KK | 1 |
| Lippman, SM | 1 |
| Clayman, GL | 1 |
| Peters, LJ | 1 |
| Hong, WK | 2 |
| Chan, AK | 1 |
| Wong, AO | 1 |
| Langevin, JM | 1 |
| Jenken, DA | 1 |
| Khoo, R | 1 |
| Heine, JA | 1 |
| Buie, WD | 1 |
| Johnson, DR | 1 |
| Ejlertsen, B | 1 |
| Pedersen, D | 1 |
| Bishop, JF | 3 |
| Dewar, J | 2 |
| Toner, GC | 1 |
| Tattersall, MH | 2 |
| Olver, IN | 2 |
| Kennedy, I | 2 |
| Gurney, H | 2 |
| Stephenson, J | 2 |
| Kardinal, CG | 2 |
| Suman, VJ | 1 |
| Schaefer, PL | 1 |
| Kirschling, RJ | 1 |
| Zyrianov, BN | 1 |
| Makarkin, NA | 1 |
| Tikhonov, VI | 1 |
| Tuzikov, SA | 1 |
| Ferrero, JM | 1 |
| Dufour, JF | 1 |
| Creisson, A | 1 |
| Teissier, E | 1 |
| Machiavello, JC | 1 |
| Lallement, M | 1 |
| Monticelli, J | 1 |
| Abbes, M | 1 |
| Chu, L | 1 |
| Sutton, LM | 1 |
| Peterson, BL | 1 |
| Havlin, KA | 1 |
| Dahrouge, S | 1 |
| Boisvert, D | 1 |
| Malvaldi, G | 1 |
| Otto, T | 1 |
| Krege, S | 1 |
| Otto, B | 1 |
| Goepel, M | 1 |
| Rübben, H | 1 |
| Lee, HD | 1 |
| Koo, JY | 1 |
| Suh, CO | 1 |
| Jung, WH | 1 |
| Oh, KK | 1 |
| Thiounn, N | 1 |
| Pages, F | 1 |
| Flam, T | 1 |
| Tartour, E | 1 |
| Mosseri, V | 2 |
| Zerbib, M | 1 |
| Deneux, L | 1 |
| Fridman, WH | 1 |
| Debré, B | 1 |
| Guldvog, I | 1 |
| Hagen, S | 1 |
| Trondsen, E | 1 |
| Harbitz, T | 1 |
| Nygaard, K | 1 |
| Nilsen, JB | 1 |
| Wist, E | 1 |
| Hannisdal, E | 2 |
| Nicholson, B | 1 |
| Shyr, Y | 1 |
| Garrett, M | 1 |
| Kemeny, NE | 1 |
| Tong, W | 1 |
| Harrison, J | 1 |
| Berkery, R | 1 |
| Minchella, I | 2 |
| De Pas, TM | 1 |
| Monti, S | 1 |
| Andreoni, G | 1 |
| Toner, G | 1 |
| Olver, I | 1 |
| Müller, C | 2 |
| Bascioni, R | 1 |
| Giorgi, F | 1 |
| Silva, RR | 1 |
| Acito, L | 1 |
| De Signoribus, G | 1 |
| Giuliodori, L | 1 |
| Testa, E | 1 |
| Ficarelli, R | 1 |
| Safi, MA | 1 |
| Cellerino, R | 1 |
| Sakamoto, T | 1 |
| Katoh, H | 1 |
| Yamashita, I | 1 |
| Takemori, S | 1 |
| Tazawa, K | 1 |
| Fujimaki, M | 1 |
| Gebrosky, NP | 1 |
| Koukol, S | 1 |
| Nseyo, UO | 1 |
| Carpenter, C | 1 |
| Lamm, DL | 1 |
| Guglielmi, A | 1 |
| Milandri, C | 1 |
| Vinci, M | 1 |
| Tixi, L | 1 |
| Ciferri, E | 1 |
| Verdi, E | 1 |
| Erkisi, M | 1 |
| Bilkay, BC | 1 |
| Seyrek, E | 1 |
| Hazar, B | 1 |
| Burgut, R | 1 |
| Molitor, JL | 2 |
| Moreau, S | 1 |
| Vignoud, J | 1 |
| Isobe, K | 1 |
| Shigematsu, N | 1 |
| Kawada, T | 1 |
| Yasuda, S | 1 |
| Hara, R | 1 |
| Takano, H | 1 |
| Uchida, Y | 1 |
| Uno, T | 1 |
| Kitahara, H | 1 |
| Kubo, A | 1 |
| Gelman, RS | 5 |
| Tormey, D | 3 |
| Cummings, FJ | 6 |
| Abeloff, MD | 4 |
| Bekradda, M | 2 |
| deBraud, F | 1 |
| De Pas, T | 1 |
| Biffi, R | 1 |
| Aapro, MS | 1 |
| Gerard, B | 1 |
| Van Daele, D | 1 |
| Gil, T | 1 |
| Di Leo, A | 1 |
| Fernez, B | 1 |
| Cardarelli, N | 1 |
| Marcellini, M | 1 |
| Menichetti, ET | 1 |
| O'Byrne, KJ | 1 |
| Koukourakis, MI | 1 |
| Salisbury, AJ | 1 |
| Varcoe, S | 1 |
| Taylor, M | 1 |
| Ganesan, TS | 1 |
| Chen, YM | 2 |
| Liu, JM | 1 |
| Wu, MF | 1 |
| Wu, HW | 1 |
| Lin, WC | 1 |
| Tsai, CM | 1 |
| Perng, RP | 1 |
| Ishikawa, T | 1 |
| Fukase, Y | 1 |
| Sekiguchi, F | 1 |
| Ishitsuka, H | 1 |
| Lin, JC | 3 |
| Jan, JS | 3 |
| Hsu, CY | 1 |
| Jerusalem, G | 1 |
| Bours, V | 1 |
| Clemons, MJ | 1 |
| Marshall, E | 1 |
| Dürig, J | 1 |
| Watanabe, K | 1 |
| Howell, A | 1 |
| Earl, H | 1 |
| Kiernan, J | 1 |
| Griffiths, A | 1 |
| Towlson, K | 1 |
| DeTakats, P | 1 |
| Testa, NG | 1 |
| Dougal, M | 1 |
| Hunter, MG | 1 |
| Wood, LM | 1 |
| Czaplewski, LG | 1 |
| Millar, A | 1 |
| Dexter, TM | 1 |
| Lord, BI | 1 |
| Markman, M | 1 |
| Haider, K | 1 |
| Kwasny, W | 1 |
| Lang, F | 1 |
| Krauss, G | 1 |
| Hejna, M | 1 |
| Weinländer, G | 1 |
| Depisch, D | 1 |
| Kuniyasu, T | 1 |
| Tabuchi, Y | 1 |
| Rodriguez, R | 1 |
| Barbieri, MR | 1 |
| Romero Acuña, LA | 1 |
| Langhi, MJ | 1 |
| Romero Acuña, JM | 1 |
| Blaszkowsky, L | 1 |
| James, RD | 1 |
| Hickish, TF | 1 |
| Heikkila, R | 1 |
| Johannesen, TB | 1 |
| Starkhammar, H | 2 |
| Topham, CA | 1 |
| Awad, L | 3 |
| Jacques, C | 1 |
| Herait, P | 2 |
| Nicolini, A | 1 |
| Carpi, A | 1 |
| Ferrari, P | 1 |
| Sagripanti, A | 1 |
| Anselmi, L | 1 |
| Dhingra, K | 1 |
| Frye, D | 4 |
| Newman, RA | 2 |
| Walters, R | 1 |
| Theriault, R | 1 |
| Fraschini, G | 3 |
| Smith, T | 2 |
| Buzdar, A | 3 |
| Costanza, ME | 2 |
| Berry, D | 1 |
| Ratain, MJ | 1 |
| Wu, K | 1 |
| Shapiro, C | 1 |
| Duggan, D | 1 |
| Kalra, J | 1 |
| Berkowitz, I | 1 |
| Kaltsas, GA | 1 |
| Mukherjee, JJ | 1 |
| Plowman, PN | 1 |
| Monson, JP | 1 |
| Grossman, AB | 1 |
| Besser, GM | 2 |
| Vredenburgh, J | 1 |
| Fishman, R | 1 |
| Coniglio, D | 1 |
| Matters, L | 1 |
| Elkordy, M | 1 |
| Ross, M | 1 |
| Hussein, A | 1 |
| Rubin, P | 1 |
| Gilbert, C | 1 |
| Petros, W | 1 |
| Peters, WP | 1 |
| Filez, L | 1 |
| Cote, C | 1 |
| Patiutko, IuI | 1 |
| Kotel'nikov, AG | 1 |
| Badalian, KhV | 1 |
| Sagaĭdak, IV | 1 |
| Gil-Delgado, M | 1 |
| de Gramond, A | 1 |
| Hudes, GR | 2 |
| Lipsitz, S | 1 |
| Grem, J | 1 |
| Morrisey, M | 1 |
| Weiner, L | 1 |
| Kugler, JW | 1 |
| Okuyama, T | 1 |
| Korenaga, D | 1 |
| Yao, T | 1 |
| Maekawa, S | 1 |
| Watanabe, A | 1 |
| Ikeda, T | 1 |
| Sugimachi, K | 1 |
| Ruffert, K | 1 |
| Penson, RT | 1 |
| Gallagher, CJ | 1 |
| Slevin, ML | 2 |
| Turpin, F | 1 |
| Closon, MH | 1 |
| Fernandez, R | 1 |
| Delgado, FM | 1 |
| Assersohn, L | 1 |
| Norman, A | 1 |
| Benepal, T | 1 |
| Ross, PJ | 1 |
| Oates, J | 1 |
| Blijham, GH | 1 |
| Lelli, G | 1 |
| Fortunato, S | 1 |
| Schröder, CP | 1 |
| de Vries, EG | 1 |
| Mulder, NH | 2 |
| Willemse, PH | 1 |
| Sleijfer, DT | 1 |
| Hospers, GA | 1 |
| Galli, C | 1 |
| Petrasch, S | 1 |
| Dörr, T | 1 |
| Kemmeries, G | 1 |
| Schüller, J | 2 |
| Goggin, T | 1 |
| Roos, B | 1 |
| Banken, L | 1 |
| Utoh, M | 1 |
| Weidekamm, E | 1 |
| Reigner, B | 1 |
| Kakisaka, A | 1 |
| Minami, M | 1 |
| Goto, J | 1 |
| Ohara, K | 2 |
| Isizaki, A | 1 |
| Kino, S | 1 |
| Abbruzzese, J | 1 |
| Khoo, VS | 1 |
| Cleary, K | 1 |
| Dubrow, R | 1 |
| Ajani, J | 1 |
| Goswitz, MS | 1 |
| Evetts, PA | 1 |
| Allen, PK | 1 |
| Lynch, PM | 1 |
| Joulia, JM | 1 |
| Bressolle, F | 1 |
| Maghfoor, I | 1 |
| Bewick, M | 1 |
| Chadderton, T | 1 |
| Conlon, M | 1 |
| Lafrenie, R | 1 |
| Morris, D | 1 |
| Stewart, D | 1 |
| Sheen, TS | 1 |
| Ko, JY | 1 |
| Hsu, MM | 1 |
| Wang, CC | 1 |
| Ting, LL | 1 |
| Han, S | 1 |
| Kim, YD | 1 |
| Oh, WK | 1 |
| Manola, J | 1 |
| Richie, JP | 1 |
| Loughlin, KR | 1 |
| Kantoff, PW | 1 |
| Wong, K | 1 |
| Antonelli, G | 1 |
| Tunesi, G | 2 |
| Baldo, C | 1 |
| Lionetto, R | 4 |
| Shineha, R | 1 |
| Ishibashi, S | 1 |
| Murakawa, Y | 1 |
| Shimodaira, H | 1 |
| Nakanishi, H | 1 |
| Abe, A | 1 |
| Inada, K | 1 |
| Tsukamoto, T | 1 |
| Yasui, K | 1 |
| Tatematsu, M | 1 |
| Ignoffo, RJ | 1 |
| Kucuk, O | 1 |
| Skeel, RT | 1 |
| Livingston, R | 2 |
| Crowley, J | 1 |
| Bensmaïne, MA | 1 |
| Ségal, V | 1 |
| Itzhaki, M | 1 |
| Grüner, A | 1 |
| Grabenbauer, GG | 3 |
| Rödel, C | 2 |
| Weidenbecher, M | 1 |
| Martus, P | 1 |
| Iro, H | 2 |
| Sauer, R | 3 |
| Abeloff, M | 1 |
| Schmitt, C | 2 |
| David, AK | 1 |
| Holroyde, CP | 1 |
| Armstead, B | 1 |
| Booser, DJ | 2 |
| Walters, RS | 1 |
| Bezwoda, WR | 2 |
| Kruit, WH | 1 |
| Hoekman, K | 1 |
| Groenewegen, G | 1 |
| Choy, D | 2 |
| Droller, MJ | 1 |
| Paulino, AC | 1 |
| Latona, C | 1 |
| Schick, C | 1 |
| Papadopoulos, T | 1 |
| Rühl, U | 1 |
| Bearman, SI | 1 |
| Juvekar, AS | 1 |
| Amonkar, AJ | 1 |
| D'cruz, AK | 1 |
| Saikaia, T | 1 |
| Pradhan, S | 1 |
| Marshall, ME | 1 |
| O'Rourke, M | 1 |
| Barnett, TC | 1 |
| Quan, WD | 1 |
| Casal, R | 1 |
| Sorio, R | 1 |
| Aita, P | 1 |
| Robieux, I | 1 |
| Colussi, AM | 1 |
| Stocco, F | 1 |
| Boiocchi, M | 1 |
| Rashidi, B | 1 |
| An, Z | 1 |
| Sun, FX | 1 |
| Moossa, AR | 1 |
| Thorban, S | 1 |
| Rosenberg, R | 1 |
| Busch, R | 1 |
| Roder, RJ | 1 |
| Pacini, P | 1 |
| Rinaldini, M | 1 |
| Algeri, R | 1 |
| Guarneri, A | 1 |
| Tucci, E | 1 |
| Barsanti, G | 1 |
| Neri, B | 1 |
| Bastiani, P | 1 |
| Marzano, S | 1 |
| Fallai, C | 1 |
| Jolain, B | 1 |
| Hohenberger, P | 1 |
| Benter, T | 1 |
| Luisi, A | 1 |
| Cipriani, S | 1 |
| Daidone, MG | 2 |
| Hakamies-Blomqvist, L | 1 |
| Luoma, M | 1 |
| Sjöström, J | 1 |
| Sjödin, M | 1 |
| Mouridsen, H | 1 |
| Ottosson-Lönn, S | 1 |
| Malmström, P | 1 |
| Chevlen, EM | 1 |
| O'Rourke, MA | 1 |
| Weaver, CH | 1 |
| Bell, WN | 2 |
| White, R | 1 |
| McGuirt, C | 1 |
| Levin, J | 2 |
| Hohneker, J | 1 |
| Oevermann, K | 1 |
| Schrader, A | 1 |
| Patzelt, T | 2 |
| Droz, JP | 2 |
| Mignard, D | 1 |
| Mormont, MC | 1 |
| Waterhouse, J | 1 |
| Bleuzen, P | 1 |
| Bogdan, A | 1 |
| Lellouch, J | 1 |
| Touitou, Y | 1 |
| Kleeberg, UR | 2 |
| Maillard, P | 1 |
| Perard, D | 1 |
| Vernillet, L | 1 |
| Besenval, M | 1 |
| Moiseenko, VM | 1 |
| Dalbot, DC | 1 |
| Gordon, RJ | 1 |
| Griffin, T | 1 |
| Osterwalder, B | 4 |
| Nesković-Konstantinović, ZB | 1 |
| Nikolić-Vukosavljević, DB | 1 |
| Branković-Magić, MV | 1 |
| Mitrovic, LB | 1 |
| Spuzić, I | 1 |
| Allen, MJ | 1 |
| Vaughan, M | 1 |
| Webb, A | 1 |
| Savage, P | 1 |
| Bate, S | 1 |
| Moore, J | 1 |
| Ahern, R | 1 |
| Rosen, LS | 1 |
| Locker, PK | 2 |
| Pirotta, N | 2 |
| Elfring, GL | 2 |
| Miller, LL | 2 |
| Sperone, P | 1 |
| Gorzegno, G | 1 |
| Brunelli, A | 1 |
| Botta, M | 1 |
| Alquati, P | 1 |
| Verderio, P | 1 |
| Potepan, P | 1 |
| Garbagnati, F | 1 |
| Breslin, T | 1 |
| Lenzi, R | 1 |
| Skibber, J | 1 |
| András, C | 1 |
| Csiki, Z | 1 |
| Gál, I | 1 |
| Takács, I | 1 |
| Antal, L | 1 |
| Szegedi, G | 1 |
| Bury, J | 1 |
| Beauduin, M | 1 |
| Herman, ML | 1 |
| Vindevoghel, A | 1 |
| Brohée, D | 1 |
| Lecomte, M | 1 |
| Stabuc, B | 1 |
| Markovic, A | 1 |
| Plesnicar, A | 1 |
| Cizej, TE | 1 |
| Gretschel, S | 1 |
| Rau, B | 1 |
| Schlag, PM | 1 |
| Nishino, H | 1 |
| Fujisawa, Y | 1 |
| Ishikawa, K | 1 |
| Miyata, M | 1 |
| Ichimura, K | 1 |
| Abe, K | 1 |
| Négrier, S | 1 |
| Caty, A | 1 |
| Escudier, B | 1 |
| Rossi, JF | 1 |
| Gomez, F | 1 |
| Bleeker, WA | 1 |
| Hermans, J | 1 |
| Otter, R | 1 |
| Plukker, JT | 1 |
| Gross-Goupil, M | 1 |
| Tigaud, JM | 1 |
| Marceau-Suissa, J | 1 |
| Gilles, V | 1 |
| Lotz, JP | 1 |
| Izrael, V | 1 |
| Eckel, F | 1 |
| Lersch, C | 1 |
| Lippl, F | 1 |
| Assmann, G | 1 |
| Schulte-Frohlinde, E | 1 |
| Behr, TM | 1 |
| Blumenthal, RD | 1 |
| Memtsoudis, S | 1 |
| Sharkey, RM | 1 |
| Gratz, S | 1 |
| Becker, W | 1 |
| Alakl, M | 1 |
| Habib, NA | 1 |
| Sarraf, CE | 1 |
| Mitry, RR | 1 |
| Havlík, R | 1 |
| Nicholls, J | 1 |
| Kelly, M | 1 |
| Vernon, CC | 1 |
| Gueret-Wardle, D | 1 |
| El-Masry, R | 1 |
| Salama, H | 1 |
| Ahmed, R | 1 |
| Michail, N | 1 |
| Edward, E | 1 |
| Jensen, SL | 2 |
| Breitbach, GP | 1 |
| Colajori, E | 1 |
| Delfino, C | 1 |
| Efremidis, A | 1 |
| Ezzat, A | 1 |
| Fittipaldo, A | 1 |
| Viaro, D | 1 |
| Laplanche, A | 1 |
| Alzieu, L | 1 |
| Berlie, J | 2 |
| Veyret, C | 1 |
| Luboinski, M | 1 |
| Lacour, J | 1 |
| Kulig, J | 1 |
| Kłek, S | 1 |
| Wachol, D | 1 |
| Bock, PR | 1 |
| Hanisch, J | 1 |
| Dempke, W | 1 |
| von Poblozki, A | 1 |
| Kellner, O | 1 |
| Wolf, HH | 1 |
| Amato, R | 1 |
| Tang, Z | 1 |
| Paradiso, A | 1 |
| Simone, G | 1 |
| Lena, MD | 1 |
| Leone, B | 1 |
| Vallejo, C | 2 |
| Lacava, J | 1 |
| Costa, A | 1 |
| D'Attino, RM | 1 |
| Aschelter, AM | 1 |
| Pugliese, P | 1 |
| Perrone, M | 1 |
| Comis, S | 3 |
| Kuwabara, Y | 1 |
| Mitani, M | 1 |
| Shinoda, N | 1 |
| Mitsui, A | 1 |
| Nishiwaki, T | 1 |
| Moriyama, S | 1 |
| Kudo, J | 1 |
| Biganzoli, E | 1 |
| Bonoldi, E | 1 |
| Fanelli, M | 1 |
| Boracchi, P | 2 |
| Mandalà, M | 1 |
| Peruzzotti, G | 1 |
| Marrocco, E | 1 |
| Antman, KH | 1 |
| Płuzańska, A | 1 |
| Jelic, S | 1 |
| Berzins, J | 1 |
| Nagykalnai, T | 1 |
| Wigler, N | 1 |
| Renard, J | 1 |
| Weil, C | 1 |
| Carnino, F | 1 |
| Vesentini, L | 1 |
| Zori Comba, A | 1 |
| Blajman, C | 1 |
| Vilanova, M | 1 |
| Van Kooten, M | 1 |
| Rodger, J | 1 |
| Giglio, R | 1 |
| Balbiani, L | 1 |
| Perazzo, F | 1 |
| Montiel, M | 1 |
| Pujol, F | 1 |
| Mickiewicz, E | 1 |
| Cazap, E | 1 |
| Recondo, G | 2 |
| Lastiri, F | 1 |
| Simon, J | 1 |
| Schmilovich, A | 1 |
| Chen, KY | 2 |
| Wang, WY | 2 |
| Liang, WM | 2 |
| Panucci, MG | 1 |
| Galli, L | 1 |
| Zerbi, A | 1 |
| Di Carlo, V | 1 |
| Leu, SY | 2 |
| Nobili, S | 1 |
| Gentile, AL | 1 |
| Dentico, P | 1 |
| Scicolone, S | 1 |
| Piana, E | 1 |
| Grumett, SA | 1 |
| Archer, VR | 1 |
| Midgley, R | 1 |
| Mulholland, P | 1 |
| Nicum, S | 1 |
| Blewitt, L | 1 |
| Chua, EJ | 1 |
| Soo, KC | 1 |
| Seow-Choen, F | 1 |
| Low, CH | 1 |
| Ng, BK | 1 |
| Hoe, M | 1 |
| Kasimir-Bauer, S | 1 |
| Mayer, S | 1 |
| Bojko, P | 1 |
| Neumann, R | 2 |
| Tucci, A | 1 |
| Pizza, C | 1 |
| Seymour, M | 1 |
| Caponigro, F | 2 |
| Budillon, A | 1 |
| Comella, G | 3 |
| De Filippis, S | 1 |
| Rosselli, M | 1 |
| Pompili, P | 1 |
| Piccinini, M | 1 |
| Frasci, G | 2 |
| Capasso, I | 2 |
| Cortino, GR | 2 |
| Christodoulakis, M | 1 |
| Stylianou, K | 1 |
| El-Weshi, A | 1 |
| Khafaga, Y | 1 |
| Allam, A | 1 |
| Ibrahim, E | 1 |
| El-Badawi, S | 1 |
| Leyland-Jones, B | 1 |
| Oshaughnessy, JA | 1 |
| Blum, J | 1 |
| Moiseyenko, V | 3 |
| Jones, SE | 4 |
| Bell, D | 1 |
| Burger, HU | 2 |
| Laws, S | 2 |
| Metzner, B | 1 |
| Ukena, D | 1 |
| Schott, H | 1 |
| Funke, PJ | 1 |
| Gramatzki, M | 1 |
| Jürgenson, S | 1 |
| Tominaga, T | 1 |
| Asano, T | 1 |
| Fujiwara, J | 1 |
| Danno, M | 1 |
| Barzdins, A | 1 |
| Robin, A | 1 |
| Lo Russo, PM | 1 |
| Horton, J | 3 |
| Rutman, O | 1 |
| Wong, NA | 1 |
| Brett, L | 1 |
| Stewart, M | 1 |
| Leitch, A | 1 |
| Longley, DB | 1 |
| Dunlop, MG | 1 |
| Lessells, AM | 1 |
| Granberg, D | 1 |
| Eriksson, B | 1 |
| Wilander, E | 1 |
| Grimfjärd, P | 1 |
| Fjällskog, ML | 1 |
| Oberg, K | 1 |
| Skogseid, B | 1 |
| McGavin, JK | 1 |
| Goa, KL | 1 |
| Varkey, JA | 1 |
| Schulz, JJ | 1 |
| Haensgen, G | 1 |
| Duffaud, F | 1 |
| Ries, P | 1 |
| Ville, E | 1 |
| Laugier, R | 1 |
| Liang, JT | 1 |
| Huang, KC | 1 |
| Cheng, YM | 1 |
| Chang, KJ | 1 |
| Rubulotta, R | 1 |
| Vallone, P | 1 |
| Kandilis, K | 1 |
| Sarra, E | 1 |
| Manziuk, LV | 2 |
| Artamonova, EV | 1 |
| Sholokhov, VN | 1 |
| Strygina, EA | 1 |
| Branković-Magić, M | 1 |
| Janković, R | 1 |
| George, CM | 1 |
| Geoffroy, FJ | 1 |
| Kollipara, P | 1 |
| Chevalier, V | 1 |
| Niezgodzki, G | 1 |
| Kwiatkowski, F | 1 |
| Perpoint, B | 1 |
| Chipponi, J | 1 |
| Saxton, JP | 1 |
| Lavertu, P | 1 |
| Rybicki, LA | 1 |
| Esclamado, RM | 1 |
| Wood, BG | 1 |
| Strome, M | 1 |
| Carroll, MA | 1 |
| Okamoto, T | 2 |
| Spielmann, M | 1 |
| Tubiana-Hulin, M | 1 |
| Mansouri, H | 1 |
| Bougnoux, Ph | 1 |
| Lotz, V | 1 |
| Eymard, JC | 1 |
| Palmer, M | 1 |
| Pignatti, F | 1 |
| Micheel, S | 1 |
| West, WH | 1 |
| Colwell, B | 1 |
| White, RL | 1 |
| Yates, BB | 1 |
| McGuirt, PV | 1 |
| Hargreaves, D | 1 |
| Nguyen-Van-Tam, J | 1 |
| Ng, T | 1 |
| Holen, KD | 1 |
| Matsumura, Y | 1 |
| Haruyama, K | 1 |
| Cufer, T | 1 |
| Beex, L | 1 |
| Lohrisch, C | 1 |
| Batter, V | 1 |
| Hamilton, A | 1 |
| Nooij, M | 1 |
| Piccart, M | 1 |
| Collichio, FA | 1 |
| Amamoo, MA | 1 |
| Fogleman, J | 1 |
| Griggs, J | 1 |
| Graham, M | 1 |
| Atahan, IL | 1 |
| Rhein, B | 1 |
| Koka, VN | 1 |
| Wibault, P | 1 |
| Domenge, C | 1 |
| Bessede, JP | 1 |
| Marandas, P | 1 |
| Schwaab, G | 1 |
| Luboinski, B | 1 |
| Gennari, A | 1 |
| Duan, Y | 1 |
| Alba Conejo, E | 1 |
| Melnychuk, D | 1 |
| Stemmler, J | 1 |
| Cristofanilli, M | 1 |
| Frye, DK | 1 |
| Rosales, MM | 1 |
| Elias, AD | 2 |
| Ibrahim, J | 1 |
| Richardson, P | 1 |
| Avigan, D | 1 |
| Joyce, R | 1 |
| Reich, E | 1 |
| McCauley, M | 1 |
| Wheeler, C | 2 |
| Hsieh, CI | 1 |
| Tsou, MH | 1 |
| Kourousis, Ch | 1 |
| Tsetis, D | 1 |
| Athanasiadis, N | 1 |
| Samonis, G | 1 |
| Yanagida, O | 1 |
| Teruya, M | 1 |
| Itou, A | 1 |
| Naganuma, J | 1 |
| Asakura, R | 1 |
| Araki, S | 1 |
| Podzamczer, D | 1 |
| Miralles, P | 1 |
| La Calle Md, Md | 1 |
| Zarco, C | 1 |
| Berenguer, J | 1 |
| López Aldeguer, J | 1 |
| Valencia, E | 1 |
| Rubio, R | 1 |
| Ribera, JM | 1 |
| Cervantes, G | 1 |
| Jones, S | 1 |
| Lui, WY | 1 |
| Croockewit, AJ | 1 |
| de Boer, JE | 1 |
| van Loenhout, JW | 1 |
| Koopmans, PP | 1 |
| Schreml, W | 3 |
| Barone, RM | 1 |
| Miki, Y | 1 |
| Kawatsu, T | 1 |
| Matsuda, H | 1 |
| Kahata, A | 1 |
| Miller, A | 2 |
| Just-Viera, JO | 1 |
| Silva, JE | 1 |
| DeWys, WD | 1 |
| Holoye, PY | 3 |
| Cuschieri, A | 1 |
| Swain, C | 1 |
| Forney, JP | 1 |
| Morrow, CP | 1 |
| Futoran, RJ | 1 |
| Prostman, TJ | 1 |
| Schwab, W | 2 |
| zum Winkel, K | 1 |
| Ammon, J | 3 |
| Nagasue, N | 1 |
| Inokuchi, K | 1 |
| Ogawa, Y | 1 |
| Iwaki, A | 1 |
| Lanzotti, VJ | 1 |
| Boyle, LE | 1 |
| Enck, RE | 1 |
| Sherman, DM | 1 |
| Weichselbaum, R | 1 |
| Order, SE | 1 |
| Cloud, L | 1 |
| Trey, C | 1 |
| Piro, AJ | 5 |
| Sundqvist, K | 1 |
| Hafström, LO | 2 |
| Jönsson, PE | 2 |
| Rydén, S | 1 |
| Forsberg, L | 2 |
| Lunderquist, A | 1 |
| Black, K | 1 |
| Hanna, SS | 1 |
| Jirsch, DW | 1 |
| Rider, WD | 1 |
| Usui, M | 1 |
| Lamy, P | 1 |
| Lamaze, R | 1 |
| Perevodchikova, NI | 2 |
| Garin, AM | 4 |
| Asserkritova, IV | 1 |
| Vaarik, GKh | 1 |
| Oberfield, RA | 4 |
| Cady, B | 2 |
| Pazianos, AG | 1 |
| Salzman, FA | 1 |
| Dunnick, NR | 1 |
| Jones, RB | 1 |
| Doppman, JL | 1 |
| Myers, CE | 2 |
| Lokich, JJ | 6 |
| Chawla, PL | 1 |
| Boecker, WR | 1 |
| Schmidt, CG | 4 |
| Pettavel, J | 2 |
| Morgenthaler, F | 2 |
| Fisher, RI | 1 |
| Young, RC | 4 |
| Buroker, T | 2 |
| Samson, M | 1 |
| Correa, J | 2 |
| Fraile, R | 1 |
| Schabel, FM | 1 |
| Lee, YT | 4 |
| Ensminger, WD | 1 |
| Rosowsky, A | 1 |
| Raso, V | 1 |
| Levin, DC | 1 |
| Glode, M | 1 |
| Come, S | 1 |
| Steele, G | 1 |
| Havemann, K | 1 |
| Engstrom, P | 1 |
| Lavin, PT | 2 |
| Carbone, PP | 6 |
| Elias, K | 1 |
| Cubilla, AL | 1 |
| Hajdu, SI | 2 |
| Holton, CP | 1 |
| Burrington, JD | 1 |
| Hatch, EI | 1 |
| Shiu, MH | 1 |
| Fortner, JG | 1 |
| Golden, GT | 1 |
| Rosenthal, JD | 1 |
| Shaw, A | 1 |
| Lo, TC | 1 |
| Wiley, AL | 1 |
| Brandenburg, JH | 1 |
| Davis, HL | 6 |
| Gollin, FF | 1 |
| Ramirez, G | 10 |
| Vermund, H | 1 |
| Taylor, SG | 6 |
| Pocock, SJ | 2 |
| Colsky, J | 1 |
| Kraybill, WG | 1 |
| Anderson, DD | 1 |
| Lindell, TD | 1 |
| Fletcher, WS | 3 |
| Ramming, KP | 2 |
| Sparks, FC | 4 |
| Eilber, FR | 2 |
| Holmes, EC | 1 |
| Umsawasdi, T | 2 |
| Chainuvati, T | 1 |
| Hitanant, S | 1 |
| Nilprabhassorn, P | 1 |
| Viranuvatti, V | 1 |
| Nüvemann, M | 1 |
| Fernholz, HJ | 1 |
| Frik, W | 1 |
| Zollinger, RM | 2 |
| Martin, EW | 1 |
| Carey, LC | 1 |
| Sparks, J | 1 |
| Minton, JP | 2 |
| Misra, NC | 1 |
| Jaiswal, MS | 1 |
| Singh, RV | 1 |
| Das, B | 1 |
| Kurihara, M | 1 |
| Shirakabe, H | 1 |
| Izumi, T | 1 |
| Miyasaka, K | 1 |
| Ariyama, J | 1 |
| Glass, A | 1 |
| Fisher, ER | 1 |
| Barton, B | 1 |
| Such, E | 1 |
| Carbone, P | 2 |
| Economou, S | 1 |
| Foster, R | 1 |
| Frelick, R | 1 |
| Lerner, H | 1 |
| Levitt, M | 1 |
| Margolese, R | 1 |
| MacFarlane, J | 1 |
| Plotkin, D | 1 |
| Volk, H | 2 |
| Bauer, M | 1 |
| Band, P | 1 |
| Ryan, R | 1 |
| Metman, EH | 1 |
| Oberfield, R | 1 |
| Glouse, M | 1 |
| Breuel, HP | 1 |
| Douwes, F | 1 |
| Bähre, M | 1 |
| San Luis, T | 1 |
| Emrich, D | 2 |
| Seligman, M | 1 |
| Weick, JK | 1 |
| Hewlett, JS | 1 |
| Greenstreet, RL | 1 |
| Mulder, JH | 1 |
| Smink, T | 1 |
| Van Putten, LM | 1 |
| Lindquist, SF | 1 |
| Hickey, AJ | 1 |
| Drane, JB | 1 |
| Bolton, PM | 1 |
| Clunie, GJ | 1 |
| Burnett, W | 1 |
| Oda, Y | 1 |
| Tokuriki, Y | 1 |
| Tsuda, E | 1 |
| Handa, H | 1 |
| Kieler, J | 1 |
| Corder, MP | 1 |
| Sheets, RF | 1 |
| Stone, WH | 1 |
| Flannery, EP | 1 |
| Justice, GR | 1 |
| Herbst, KD | 1 |
| Petrek, JA | 1 |
| Yonemoto, RH | 1 |
| Tan, MS | 1 |
| Byron, RL | 1 |
| Riihimaki, DU | 1 |
| Keating, J | 1 |
| Jacobs, W | 1 |
| Pipino, G | 2 |
| Germiniani, R | 2 |
| Lavorato, F | 1 |
| Obrecht, P | 2 |
| Maurice, P | 1 |
| deKernion, JB | 1 |
| Johnson, RJ | 1 |
| Carpenter, J | 2 |
| Bartolucci, A | 1 |
| Vogel, C | 1 |
| Pinedo, HM | 1 |
| Kenis, Y | 1 |
| Heal, JM | 1 |
| Rotte, K | 1 |
| Caffier, H | 1 |
| Blokhina, NG | 4 |
| Smolianskaia, AZ | 2 |
| Aledseev, VM | 1 |
| Sokolova, VD | 3 |
| Valdivieso, M | 8 |
| Bedikian, A | 1 |
| Rodriguez, V | 3 |
| Hersh, EM | 8 |
| Mavligit, GM | 5 |
| Diggs, CH | 1 |
| Smyth, AC | 1 |
| White, DR | 3 |
| Taylor, I | 2 |
| Brooman, P | 1 |
| Rowling, JT | 1 |
| Ettinger, DS | 1 |
| Buroker, TR | 3 |
| Kim, PN | 1 |
| Baker, LH | 4 |
| Ratanatharathron, V | 1 |
| Wojtaszak, B | 1 |
| Bull, JM | 2 |
| Li, SH | 1 |
| Perlin, E | 1 |
| Simon, R | 3 |
| Frederiksen, PL | 1 |
| Joergensen, ST | 1 |
| Roesdahl, K | 1 |
| Thomsen, J | 1 |
| Romanenko, NV | 1 |
| Korman, DB | 3 |
| Begent, RH | 1 |
| Sexton, SA | 1 |
| Staab, R | 1 |
| Chauvergne, J | 2 |
| Clavel, B | 1 |
| Guerrin, J | 1 |
| Gary-Bobo, J | 1 |
| Brulé, G | 1 |
| Klein, T | 1 |
| Pommatau, E | 1 |
| Carton, M | 1 |
| Stuart, JJ | 1 |
| Rhyne, L | 1 |
| Douglass, HO | 4 |
| Woll, J | 2 |
| Hestorff, R | 1 |
| Sardoff, L | 1 |
| Weiner, J | 1 |
| Bateman, JR | 2 |
| Borisov, AI | 2 |
| Harris, DT | 1 |
| Engstrom, PF | 3 |
| Grotzinger, PJ | 1 |
| Golbey, R | 1 |
| Padilla, F | 1 |
| Groppe, C | 1 |
| Guy, G | 1 |
| Quagliana, J | 1 |
| McCracken, J | 1 |
| Hoogstraten, B | 3 |
| Heilbrun, L | 1 |
| Stephens, EJ | 1 |
| Wood, HF | 1 |
| Mason, B | 1 |
| DeVita, VT | 3 |
| Berdov, BA | 1 |
| Aleksanian, AZ | 1 |
| Goldobenko, GV | 1 |
| Gapaniuk, ON | 1 |
| Sidorchenkov, VO | 1 |
| Tashima, CK | 6 |
| Krutchik, AN | 2 |
| Benjamin, RS | 3 |
| Gutterman, JU | 10 |
| Carter, SK | 4 |
| Comis, RL | 2 |
| Reimer, RR | 1 |
| Hoover, R | 1 |
| Fraumeni, JF | 1 |
| Dionne, LJ | 1 |
| Kibrite, A | 1 |
| Dickerson, JW | 1 |
| Swenerton, KD | 1 |
| Legha, SS | 3 |
| Gehan, EA | 3 |
| Khankhanian, N | 1 |
| Allegra, JC | 1 |
| Lippman, ME | 4 |
| Luporini, G | 2 |
| Mangiarotti, F | 1 |
| Fraschini, P | 1 |
| Tassi, GC | 1 |
| De Barbieri, A | 1 |
| Dietz, R | 2 |
| Tkocz, HJ | 1 |
| Tylén, U | 1 |
| Owman, T | 2 |
| Juraschek, F | 1 |
| Mennecier, P | 1 |
| Pallangie, T | 1 |
| Moustafa, T | 1 |
| Einhorn, L | 1 |
| Richman, SP | 2 |
| Sonoda, T | 1 |
| Solomon, A | 1 |
| Hafström, L | 8 |
| Landberg, T | 1 |
| Sundkvist, K | 1 |
| Kimball, JC | 1 |
| Cangir, A | 1 |
| Wheeler, WL | 1 |
| Freireich, EJ | 4 |
| Rosner, D | 5 |
| Snyderman, M | 1 |
| Nemoto, T | 6 |
| Estapé, J | 1 |
| Millá, A | 1 |
| Prats, M | 1 |
| Herranz, M | 1 |
| Visa, J | 1 |
| Kempgens, U | 1 |
| Russell, JA | 1 |
| Baker, JW | 1 |
| Dady, PJ | 1 |
| Ford, HT | 1 |
| Gazet, JC | 1 |
| McKinna, JC | 1 |
| Nash, AG | 1 |
| Khwaja, TA | 1 |
| Kolleg, MK | 1 |
| Nelson, RS | 1 |
| Nordman, EM | 1 |
| Mäntylä, M | 1 |
| Farndon, JR | 1 |
| Stephens, RL | 3 |
| Haas, C | 2 |
| Clark, G | 1 |
| Jochimsen, PR | 1 |
| Zike, WL | 1 |
| Shirazi, SS | 1 |
| Pearlman, NW | 1 |
| Buell, GV | 1 |
| Saiers, JH | 1 |
| Saiki, JH | 1 |
| Bergreen, PW | 1 |
| Betzler, M | 1 |
| Schlag, P | 1 |
| Herfarth, C | 1 |
| Krein, BM | 1 |
| Diaz, R | 1 |
| Dao, T | 1 |
| Sponzo, R | 1 |
| Cunningham, T | 1 |
| Tranum, B | 1 |
| Kennedy, A | 1 |
| Vaughn, CB | 2 |
| Samal, B | 1 |
| Thigpen, T | 1 |
| Rivkin, S | 1 |
| Smith, F | 1 |
| Palmer, RL | 1 |
| Costanzi, J | 1 |
| Tucker, WG | 2 |
| Wilson, H | 1 |
| Maloney, TR | 1 |
| Eckert, M | 1 |
| Gerassimidis, T | 1 |
| Schultess, F | 1 |
| Hammann, J | 1 |
| Beck, I | 1 |
| Kennealey, GT | 1 |
| Boston, B | 1 |
| Mitchell, MS | 2 |
| Knobf, MK | 1 |
| Bobrow, SN | 1 |
| Pezzimenti, JF | 1 |
| Lawrence, R | 1 |
| Bugarski, M | 1 |
| Vuletić, L | 1 |
| Boberić, J | 1 |
| Milosavljević, A | 1 |
| Dilparić, S | 1 |
| Tomin, R | 1 |
| Naumović, P | 1 |
| Möhlen, KH | 1 |
| Beller, FK | 1 |
| Block, GE | 1 |
| Ellis, RS | 1 |
| DeSombre, E | 1 |
| Jensen, E | 1 |
| DiBenedetto, J | 1 |
| Moayeri, H | 1 |
| Evans, JT | 1 |
| Richardson, RL | 1 |
| Shulman, SF | 1 |
| Oldham, RK | 1 |
| Ariel, IM | 3 |
| Padula, G | 1 |
| Heppner, GH | 1 |
| Dexter, DL | 1 |
| DeNucci, T | 1 |
| Miller, FR | 1 |
| Barkin, JS | 1 |
| Kalser, MH | 1 |
| Kaplan, R | 1 |
| Redlhammer, D | 1 |
| Heal, A | 1 |
| Sinkovics, JG | 1 |
| Mootz, W | 1 |
| Kune, GA | 1 |
| Hobbs, JB | 1 |
| Butterfield, D | 1 |
| Sali, A | 1 |
| Boeva, M | 1 |
| Donchev, T | 2 |
| Markova, R | 1 |
| Christov, I | 1 |
| Gatzemeier, U | 1 |
| Jüngst, G | 1 |
| Wagner, G | 1 |
| Cedermark, BJ | 1 |
| Didolkar, MS | 2 |
| Elias, EG | 4 |
| Matter, R | 1 |
| Lehane, DE | 1 |
| Ruffner, BW | 1 |
| Morrison, FS | 1 |
| Cardenas, JO | 1 |
| Gottlieb, JA | 3 |
| Waalkes, TP | 1 |
| Younus, S | 1 |
| Soterakis, J | 1 |
| Sossi, AJ | 1 |
| Chawla, SK | 1 |
| LoPresti, PA | 1 |
| Simon, RM | 1 |
| Fugmann, RA | 1 |
| Anderson, JC | 1 |
| Stolfi, RL | 1 |
| Martin, DS | 1 |
| Graze, PR | 1 |
| Korenman, SG | 1 |
| Ogaard, S | 1 |
| Jensen, TS | 1 |
| Shukla, HS | 1 |
| Hughes, LE | 1 |
| Davis, PW | 1 |
| Whitehead, RH | 1 |
| Leach, KG | 1 |
| MacGregor, AB | 2 |
| Ambus, U | 2 |
| Landi, S | 2 |
| Miller, AB | 1 |
| Samuel, ES | 1 |
| Kane, RD | 2 |
| Stocks, LH | 1 |
| Paulson, DF | 2 |
| Cerbonnet, G | 1 |
| Jacquillat, Cl | 1 |
| Malkasian, GD | 4 |
| Decker, DG | 4 |
| Jorgensen, EO | 2 |
| Krasnokuki, D | 1 |
| Hochman, A | 1 |
| Ferguson, DJ | 2 |
| Harper, PV | 2 |
| Tejada, F | 1 |
| Eisenberger, MA | 1 |
| Broder, LA | 1 |
| Brahm, M | 1 |
| Rahbek, I | 1 |
| Almersjö, O | 5 |
| Bengmark, S | 4 |
| Leissner, KH | 2 |
| Bergman, RB | 1 |
| Brown, I | 1 |
| Ward, HW | 1 |
| Riedler, L | 1 |
| Matthiessen, W | 1 |
| Pochhammer, KF | 1 |
| Murphy, S | 1 |
| Huguley, CM | 1 |
| Schwarzenberg, L | 2 |
| Mathé, G | 2 |
| Huguenin, P | 2 |
| Gautier, H | 1 |
| Laparre, C | 1 |
| Barndt, J | 1 |
| Collier, D | 1 |
| Soloway, MS | 1 |
| Baumgartner, G | 1 |
| Sears, ME | 1 |
| Klaasen, DJ | 1 |
| Dao, TL | 2 |
| Mickey, DD | 1 |
| Eagan, RT | 1 |
| Myers, RP | 1 |
| Mannes, P | 3 |
| Derriks, R | 3 |
| Moens, R | 3 |
| Laurent, C | 2 |
| Dalcq, JM | 1 |
| Edelstyn, GA | 4 |
| MacRae, KD | 2 |
| Ikram, H | 1 |
| Israel, L | 5 |
| Lozada, JA | 1 |
| Grillo-López, A | 1 |
| Vélez-Garciá, E | 1 |
| Fischerman, K | 1 |
| Petersen, CF | 1 |
| Christensen, KC | 1 |
| Efsen, F | 1 |
| Blumenshein, G | 1 |
| McBride, CM | 3 |
| Cohen, P | 1 |
| Fenichel, RL | 1 |
| Gregory, FJ | 1 |
| Alburn, HE | 1 |
| Cappellano, RS | 1 |
| Cintra, RA | 1 |
| Kushnir, IN | 1 |
| Sedransk, N | 2 |
| Segaloff, A | 1 |
| Kelley, RM | 1 |
| Haines, CR | 1 |
| Jugdutt, BI | 1 |
| Turner, FW | 1 |
| Mansell, PW | 1 |
| Reed, RJ | 2 |
| Gillespie, PJ | 1 |
| Alexander, JL | 1 |
| Mosher, MB | 1 |
| Hallauer, WC | 1 |
| Silverstein, MJ | 1 |
| Rangel, D | 1 |
| Passaro, E | 1 |
| Mastrangelo, MJ | 2 |
| Ingis, DA | 1 |
| Farmer, RG | 1 |
| Amiel, JL | 1 |
| Laparre, Ch | 1 |
| Parrot, R | 1 |
| Henderson, MD | 1 |
| Samson, MK | 1 |
| Mood, DW | 1 |
| Otis, PT | 1 |
| Armentrout, SA | 1 |
| Nevin, JE | 1 |
| Melnick, I | 1 |
| Baggerly, JT | 1 |
| Landes, R | 1 |
| Easley, CA | 1 |
| Ostuni, JA | 1 |
| Roginsky, MS | 1 |
| Lee, FJ | 1 |
| Vongtama, V | 1 |
| Greenwald, ES | 2 |
| Slack, NH | 4 |
| Bross, ID | 4 |
| Pajak, TL | 1 |
| Rees, GJ | 1 |
| Bugaighis, A | 1 |
| Anderson, G | 1 |
| Pitman, SW | 1 |
| Skarin, AT | 4 |
| Wirtanen, GW | 4 |
| Bryan, GT | 2 |
| Manalo, FB | 1 |
| Borden, EC | 1 |
| Davis, TE | 2 |
| Esmili, M | 1 |
| Mokka, RE | 1 |
| Larmi, TK | 1 |
| Huttunen, R | 1 |
| Kairaluoma, MI | 1 |
| Brusamolino, E | 1 |
| Brugnatelli, L | 1 |
| Tancini, G | 2 |
| Musumeci, R | 1 |
| Newman, HK | 1 |
| Quan, SH | 1 |
| van Dyk, JJ | 3 |
| van der Merwe, AM | 3 |
| Yamada, K | 1 |
| Holyoke, ED | 2 |
| Gold, GL | 2 |
| Chabner, BA | 3 |
| Nichols, M | 1 |
| Bergevin, PR | 1 |
| Vyas, AC | 1 |
| Hamilin, R | 1 |
| Falkson, CI | 3 |
| Ayash, L | 1 |
| Anderson, KC | 1 |
| Hunt, M | 1 |
| Schwartz, G | 1 |
| Tepler, I | 1 |
| Mazanet, R | 1 |
| Lynch, C | 1 |
| Pap, S | 1 |
| Pyrhönen, SO | 1 |
| Kouri, MO | 1 |
| Fiorentino, MV | 2 |
| Brandes, A | 1 |
| Weinerman, B | 1 |
| Shah, A | 1 |
| Cripps, IC | 1 |
| McCormick, R | 1 |
| Temple, W | 1 |
| Bogues, W | 1 |
| Pater, J | 1 |
| Gupta, P | 1 |
| Tandon, R | 1 |
| Falkson, CB | 1 |
| Zilembo, N | 1 |
| Nelli, P | 1 |
| Reid, I | 1 |
| Sharpe, I | 1 |
| Maxwell, W | 1 |
| McDevitt, J | 1 |
| Tanner, WA | 1 |
| Monson, JR | 1 |
| Kleeberg, U | 1 |
| Middeke, H | 1 |
| Korsten, FW | 2 |
| Trux, FA | 2 |
| Schmieder, A | 1 |
| Evers, C | 1 |
| Hidalgo, OF | 1 |
| Gonzalez, FG | 1 |
| Tangco, E | 1 |
| Herranz, P | 1 |
| Oguro, Y | 1 |
| Rischin, D | 1 |
| Laidlaw, CR | 1 |
| Jeal, P | 1 |
| Dipell, JF | 1 |
| Alberts, AS | 1 |
| Burger, W | 1 |
| Greeff, F | 1 |
| Schoeman, L | 1 |
| Friediger, D | 1 |
| Nel, J | 1 |
| Steyn, E | 1 |
| Schmid, EU | 1 |
| Nussbaum, B | 1 |
| Gundersen, S | 1 |
| Kvinnsland, S | 1 |
| Klepp, O | 1 |
| Lund, E | 1 |
| Høst, H | 1 |
| Platz, D | 2 |
| Braumann, D | 1 |
| Buggisch, P | 1 |
| Schmiegel, WH | 1 |
| Drescher, S | 1 |
| Müllerleile, U | 1 |
| Crone-Münzebrock, W | 2 |
| Hoffman, R | 1 |
| Hiddemann, W | 1 |
| Ruelfs, C | 1 |
| Ottensmeier, C | 1 |
| Musch, E | 1 |
| Koch, O | 1 |
| van de Loo, J | 1 |
| Preiss, J | 1 |
| Czejka, MJ | 1 |
| Schernthaner, G | 1 |
| Fogl, U | 1 |
| Jäger, W | 1 |
| Micksche, M | 1 |
| Negri, L | 1 |
| Correggia, F | 1 |
| Miozzo, S | 1 |
| Giacomasso, S | 1 |
| Cady, J | 1 |
| Delfau, S | 1 |
| Grangé, JD | 1 |
| Chazouillères, O | 1 |
| Zylberait, D | 1 |
| Park, KG | 1 |
| Murray, JB | 1 |
| Hayes, PD | 1 |
| Ashby, JA | 1 |
| Mizutani, J | 1 |
| Hiraoka, T | 1 |
| Yamashita, R | 1 |
| Miyauchi, Y | 1 |
| Löffler, TM | 1 |
| Reis, HE | 1 |
| Planker, M | 1 |
| Burghardt, F | 1 |
| Aulbert, E | 1 |
| Lindemann, W | 1 |
| Schröder, M | 2 |
| Hausamen, TU | 1 |
| Strohmeyer, G | 1 |
| Cimino, A | 1 |
| Pastorello, T | 1 |
| Ferrara, P | 1 |
| Cold, S | 1 |
| Akman, SA | 1 |
| Raschko, JW | 2 |
| Blevins, C | 1 |
| Ziegler, LD | 1 |
| Connelly, JH | 1 |
| Cunliffe, WJ | 1 |
| Tellez-Bernal, E | 1 |
| Belehradek, M | 1 |
| Leridant, AM | 1 |
| Vericel, R | 1 |
| Armand, JP | 1 |
| Kremer, B | 3 |
| Dobelbower, RR | 1 |
| Bronn, DG | 1 |
| Araújo, CM | 1 |
| Souhami, L | 1 |
| Gil, RA | 1 |
| Carvalho, R | 1 |
| Garcia, JA | 1 |
| Froimtchuk, MJ | 1 |
| Pinto, LH | 1 |
| Canary, PC | 1 |
| Mercke, C | 1 |
| Hambraeus, G | 1 |
| Tennvall, J | 1 |
| Lillo-Gil, R | 1 |
| Samuelsson, L | 1 |
| Willén, R | 1 |
| Ranstam, J | 1 |
| Winn, R | 1 |
| Bearden, J | 1 |
| Belt, RJ | 1 |
| Pilat, S | 1 |
| Hallinan, R | 1 |
| Levin, B | 2 |
| Inoshita, G | 1 |
| Yalavarthi, P | 1 |
| Murthy, S | 1 |
| Gibson, V | 1 |
| Sergi, JS | 1 |
| Bauer, L | 1 |
| Prestifilippo, J | 1 |
| Itzakhi, M | 1 |
| Descorps-Declère, A | 1 |
| Mitomi, T | 1 |
| Iijima, N | 1 |
| Aso, K | 1 |
| Amano, T | 1 |
| Murayama, N | 1 |
| Oka, H | 1 |
| Altendorf-Hofmann, A | 1 |
| Tzekova, V | 1 |
| Velikova, M | 1 |
| Koynov, K | 1 |
| Micheva, D | 1 |
| Merimsky, O | 1 |
| Inbar, M | 1 |
| Grunberg, SM | 1 |
| Clay, C | 1 |
| Spicer, DV | 1 |
| Baur, M | 1 |
| Schlappack, O | 1 |
| Havelec, L | 1 |
| Marosi, C | 1 |
| Brockmann, B | 1 |
| Geschke, E | 1 |
| Schmidt, UM | 1 |
| Ebeling, K | 1 |
| Campana, F | 1 |
| Goseki, N | 1 |
| Endo, M | 1 |
| Onodera, T | 1 |
| Kosaki, G | 1 |
| Topham, C | 1 |
| Glees, J | 1 |
| Rawson, NS | 1 |
| Woods, EM | 1 |
| Johnson, PW | 1 |
| Deasy, NP | 1 |
| Thuraisingham, RC | 1 |
| Wrigley, PF | 1 |
| Mennel, RG | 1 |
| Brooks, B | 1 |
| Westrick, MA | 1 |
| Allison, MA | 1 |
| Paulson, RS | 1 |
| Tilmann, K | 1 |
| Rea, B | 1 |
| Andrews, MB | 1 |
| Cruz, JM | 1 |
| Powell, BL | 1 |
| Albertini, M | 1 |
| Bonomi, P | 1 |
| Faber, LP | 1 |
| Ahlgren, JD | 1 |
| Trocki, O | 1 |
| Gullo, JJ | 1 |
| Goldberg, R | 1 |
| Muir, WA | 1 |
| Sisk, R | 1 |
| Schacter, L | 1 |
| Johnson, EA | 1 |
| Ueno, W | 1 |
| Woolley, PV | 1 |
| Gusarov, IuP | 1 |
| Gusarova, LT | 1 |
| Fedeli, A | 1 |
| Luzi Fedeli, S | 1 |
| Gridelli, C | 1 |
| Airoma, G | 1 |
| Pepe, R | 1 |
| Incoronato, P | 1 |
| Degner, RA | 1 |
| Kerley, SW | 1 |
| McGregor, DH | 1 |
| Dixon, AY | 1 |
| Walter, TA | 1 |
| Garbrecht, M | 2 |
| Crone-Muenzebrock, LS | 1 |
| Martino, S | 1 |
| Samal, BA | 1 |
| Redman, B | 1 |
| Flaherty, L | 1 |
| Kraut, M | 1 |
| Simon, M | 1 |
| Bowker, BL | 1 |
| Bayliss, EJ | 1 |
| Stewart, ME | 1 |
| Smyth, JF | 1 |
| Rodger, A | 1 |
| Duez, N | 1 |
| Natali, M | 1 |
| D'Aprile, M | 1 |
| Leggio, M | 1 |
| Carpano, S | 2 |
| Angelini, F | 1 |
| Carassai, A | 1 |
| Leichman, L | 2 |
| Spears, CP | 1 |
| Rosen, PJ | 1 |
| Jeffers, S | 1 |
| Waugh, W | 1 |
| Bastit, P | 1 |
| Horner, D | 1 |
| Metz, R | 1 |
| Fujioka, T | 1 |
| Hasegawa, M | 1 |
| Ishikura, K | 1 |
| Nomura, K | 1 |
| Tanji, S | 1 |
| Koike, H | 1 |
| Tomek, R | 1 |
| Lissoni, P | 1 |
| Paolorossi, F | 1 |
| Crispino, S | 1 |
| Archili, C | 1 |
| Gorbunova, VA | 1 |
| Trofimova, NB | 1 |
| Paccagnella, A | 1 |
| Pappagallo, GL | 1 |
| Segati, R | 1 |
| Zorat, P | 1 |
| Cavaniglia, G | 1 |
| Fosser, VP | 1 |
| De Besi, P | 1 |
| Fornasiero, A | 1 |
| Ghavamzadeh, A | 1 |
| Gribel', NV | 2 |
| Pashinskiĭ, VG | 2 |
| Terashima, M | 1 |
| Saito, K | 1 |
| Gray, R | 1 |
| Gilchrist, K | 1 |
| Grage, T | 1 |
| Wolter, J | 1 |
| Woll, JE | 1 |
| Rahima, M | 1 |
| Rakowsky, E | 1 |
| Barzilay, J | 1 |
| Sidi, J | 1 |
| Yahalom, J | 1 |
| Herskovic, A | 1 |
| Lattin, PB | 1 |
| Tapazoglou, E | 1 |
| Rosenberg, JC | 1 |
| Arbulu, A | 1 |
| Kinzie, J | 1 |
| Belsanti, V | 1 |
| Fiorucci, S | 1 |
| Gernini, I | 1 |
| Rambotti, P | 1 |
| Davis, S | 2 |
| Brincker, H | 1 |
| Hottenrott, C | 2 |
| Höfeler, H | 1 |
| Kloke, O | 2 |
| Kurschel, E | 2 |
| Schilcher, RB | 1 |
| Weinhardt, O | 2 |
| Wandl, U | 2 |
| da Silva e Sousa Júnior, AH | 1 |
| Nadalin, W | 1 |
| Gansl, R | 1 |
| da Silva, JH | 1 |
| Pinotti, HW | 1 |
| Flechtner, H | 2 |
| Heim, ME | 2 |
| Kabelitz, K | 1 |
| Kalman, J | 1 |
| Spigelman, M | 1 |
| Gorbaty, MI | 1 |
| Butwell, N | 1 |
| Storch, J | 1 |
| McKenna, A | 1 |
| Dessard-Diana, B | 1 |
| Michel-Langlet, P | 1 |
| Alapetite, C | 1 |
| Inglis, R | 1 |
| Kirkowa-Reimann, M | 1 |
| Chaffey, J | 1 |
| Neptune, W | 1 |
| Schwartz, EL | 1 |
| Goldman, M | 1 |
| Lyver, A | 1 |
| Rader, M | 1 |
| Zimmerman, M | 1 |
| Itri, L | 1 |
| Weinberg, V | 1 |
| Lupera, H | 1 |
| Lapleige, P | 1 |
| Theodore, C | 1 |
| Oliveri, D | 1 |
| Christiansen, NP | 1 |
| Quebbeman, E | 1 |
| Ausman, R | 1 |
| Frick, J | 1 |
| Ritch, P | 1 |
| Schulte, W | 1 |
| Beatty, P | 1 |
| Anderson, T | 1 |
| Marschke, RF | 2 |
| Schaid, DJ | 1 |
| Cullinan, SA | 2 |
| Pfeifle, DM | 1 |
| Votava, HJ | 1 |
| Ebbert, LP | 1 |
| Egan, EF | 1 |
| Drake, JC | 3 |
| Molinaro, P | 1 |
| Lafleur, F | 1 |
| Dexeus, FH | 1 |
| Marangolo, M | 3 |
| Pezzuoli, G | 1 |
| Marubini, E | 1 |
| Cunsolo, A | 1 |
| Garcea, D | 1 |
| Patel, HZ | 1 |
| Schoen, HD | 1 |
| Wendt, T | 1 |
| Saiga, T | 1 |
| Kashu, I | 1 |
| Tabuchi, K | 1 |
| Midorikawa, O | 1 |
| Potrebica, V | 2 |
| Swanson, JD | 1 |
| Sykes, E | 1 |
| Tsao, SY | 1 |
| Shiu, W | 1 |
| Leung, WT | 1 |
| Tsang, V | 1 |
| Yu, P | 1 |
| Lui, C | 1 |
| Leong, L | 2 |
| Margolin, K | 2 |
| Flanagan, B | 2 |
| Goldberg, D | 2 |
| Bertrand, M | 2 |
| Akman, S | 2 |
| Carr, B | 2 |
| Odujinrin, O | 2 |
| Newman, E | 1 |
| Wendt, TG | 1 |
| Hartenstein, RC | 1 |
| Wustrow, TP | 1 |
| Lissner, J | 1 |
| Fan, S | 1 |
| Liang, CL | 1 |
| Hsu, H | 1 |
| Fernández Hidalgo, O | 1 |
| González, F | 1 |
| Gil, A | 1 |
| Campbell, W | 1 |
| Lacave, AJ | 1 |
| Simoncini, E | 2 |
| Marpicati, P | 2 |
| Montini, E | 1 |
| Palazzi, M | 1 |
| Dhingra, HM | 1 |
| Chiuten, DF | 1 |
| Jeffries, D | 1 |
| Murphy, WK | 1 |
| Neidhart, JA | 1 |
| Lee, SM | 1 |
| Forbes, A | 1 |
| Paredes, J | 1 |
| Felder, TB | 1 |
| Dimery, IW | 1 |
| Choksi, AJ | 1 |
| Castellanos, AM | 1 |
| Robbins, KT | 1 |
| McCarthy, K | 1 |
| Atkinson, N | 1 |
| Conti, EM | 1 |
| Everson, LK | 1 |
| Klaassen, DJ | 2 |
| Schmid, H | 1 |
| Schmidt, R | 1 |
| Mouroux, J | 1 |
| Deixonne, B | 1 |
| Eledjam, JJ | 1 |
| Baumel, H | 1 |
| Follézou, JY | 1 |
| Feuilhade, F | 1 |
| Johnson, KG | 1 |
| Peterson, RF | 1 |
| Rivkin, SE | 1 |
| Neilan, B | 1 |
| Costanzi, JH | 1 |
| Morris, DM | 1 |
| Brown, SD | 1 |
| Miller, TP | 1 |
| Kasuga, Y | 1 |
| Senga, O | 1 |
| Hanamura, N | 1 |
| Iida, F | 1 |
| Oota, H | 1 |
| Katsuyama, T | 1 |
| Funovics, J | 1 |
| Knoflach, P | 1 |
| Grabner, G | 1 |
| Volling, P | 1 |
| Rauschning, W | 2 |
| Stennert, E | 1 |
| Nagel, G | 2 |
| Nagel, GA | 2 |
| Beyer, JH | 1 |
| Holtkamp, W | 1 |
| Kneba, M | 1 |
| Luig, H | 1 |
| Unger, C | 1 |
| Wander, HE | 1 |
| Valone, FH | 1 |
| Wittlinger, PS | 1 |
| Flam, MS | 1 |
| Drakes, T | 1 |
| Eisenberg, PD | 1 |
| Hannigan, J | 1 |
| Laufman, LR | 1 |
| Brenckman, WD | 1 |
| Stydnicki, KA | 1 |
| Morgan, ED | 1 |
| Knick, VB | 1 |
| Duch, DS | 1 |
| Mullin, R | 1 |
| Ferone, R | 1 |
| Scheulen, M | 1 |
| Niederle, N | 1 |
| Khan, H | 1 |
| Bergner, S | 1 |
| Fink, U | 1 |
| Schöber, C | 1 |
| Link, H | 1 |
| Freund, M | 1 |
| Hanauske, A | 1 |
| Meyer, HJ | 1 |
| Litchfield, T | 1 |
| Fiore, JJ | 1 |
| Zarrabi, MH | 1 |
| Danil'chenko, SA | 1 |
| Shlopov, VG | 1 |
| Serniak, PS | 1 |
| Geev, IuV | 1 |
| Common, H | 1 |
| Ricken, D | 1 |
| Henss, H | 1 |
| Fritsch, H | 4 |
| Cruciani, G | 2 |
| Tienghi, A | 2 |
| Molinari, AL | 1 |
| Rosti, G | 2 |
| Cantor, RJ | 1 |
| Biermann, W | 1 |
| Weiss, SM | 1 |
| Barbot, D | 1 |
| Rosato, FE | 1 |
| Keymling, M | 1 |
| Lübke, HJ | 1 |
| Wörner, W | 1 |
| Peek, U | 1 |
| Migeod, F | 1 |
| Gerlach, D | 1 |
| Kress, M | 1 |
| Farroukh, R | 1 |
| Theriault, RL | 1 |
| Kau, SW | 1 |
| Jabboury, K | 1 |
| Harding, MJ | 1 |
| Soukop, M | 1 |
| Ferguson, JC | 1 |
| Baumgart, J | 1 |
| Zhukovskaya, NV | 1 |
| Anisimov, VN | 1 |
| Choi, KE | 1 |
| Moran, WJ | 1 |
| Guarnieri, CM | 1 |
| Panje, WR | 1 |
| Bartolucci, R | 1 |
| Padalino, D | 1 |
| Brugia, M | 1 |
| Egan, GF | 1 |
| Hines, JD | 1 |
| Spiess, JL | 1 |
| Carter, SG | 1 |
| Trey, JE | 1 |
| Elhakim, T | 1 |
| Loehrer, PJ | 1 |
| Turner, S | 1 |
| Kubilis, P | 1 |
| Hui, S | 1 |
| Ansari, R | 1 |
| Stephens, D | 1 |
| Woodburn, R | 1 |
| Meyer, S | 1 |
| Kanno, A | 1 |
| Ito, T | 1 |
| Ban, K | 1 |
| Oshita, H | 1 |
| Fukata, D | 1 |
| Sakai, N | 1 |
| Kashizuka, T | 1 |
| Hatoh, T | 1 |
| Lotze, W | 1 |
| Richter, P | 1 |
| Sarembe, B | 1 |
| Coutant, M | 2 |
| Hayes, DF | 1 |
| Crowe, JP | 1 |
| Gordon, NH | 1 |
| Antunez, AR | 1 |
| Hubay, CA | 1 |
| Marshall, JS | 1 |
| Bertelli, G | 1 |
| Cusimano, MP | 1 |
| Fusco, V | 1 |
| Gulisano, M | 1 |
| Ames, FC | 1 |
| Derman, U | 2 |
| Serdengecti, S | 2 |
| Berkarda, B | 2 |
| Romero, A | 2 |
| Macchiavelli, M | 2 |
| Goldar, D | 1 |
| Alvarez, LA | 1 |
| Porzsolt, F | 1 |
| Buchelt, L | 1 |
| Meuret, G | 1 |
| Mende, S | 1 |
| Strigl, P | 1 |
| Redenbacher, M | 1 |
| Klumpp, D | 1 |
| Schmelz, M | 1 |
| Knöchelmann, R | 1 |
| Nicolin, A | 1 |
| Gentilini, P | 3 |
| Sismondi, P | 1 |
| Ginsberg, S | 1 |
| Wood, WC | 1 |
| Rotmensch, J | 1 |
| Senekjian, EK | 1 |
| Javaheri, G | 1 |
| Herbst, AL | 1 |
| Ahmann, FR | 3 |
| Moon, TE | 1 |
| Steinberg, S | 1 |
| Lippman, M | 1 |
| Pak, K | 1 |
| Ishida, A | 1 |
| Arai, Y | 1 |
| Tomoyoshi, T | 1 |
| Liu, TJ | 1 |
| Ginman, C | 1 |
| Graffman, S | 1 |
| Påhlman, L | 1 |
| Ståhle, E | 1 |
| Sholar, PW | 1 |
| Bagley, C | 1 |
| Loprinzi, CL | 1 |
| Rasmussen, P | 1 |
| Stanovnik, M | 1 |
| Athanassiades, P | 1 |
| Bacoyiannes, H | 1 |
| Kontoyiannes, D | 1 |
| Carpenter, JT | 1 |
| Raney, M | 2 |
| Weiner, RS | 1 |
| Keiling, R | 1 |
| Armand, PP | 1 |
| Hurteloup, P | 1 |
| Alama, A | 1 |
| Jacomuzzi, A | 1 |
| Johnson, JT | 1 |
| Myers, EN | 1 |
| Schramm, VL | 1 |
| Mayernik, DG | 1 |
| Nolan, TA | 1 |
| Sigler, BA | 1 |
| Wagner, RL | 1 |
| Taylor, RF | 1 |
| Harvey, JH | 1 |
| Wolter, JM | 1 |
| Tseng, A | 1 |
| Meyers, FJ | 1 |
| Silverberg, I | 1 |
| Boles, R | 1 |
| Fu, KK | 1 |
| Jacobs, CD | 1 |
| Stark, ME | 1 |
| Dyer, MC | 1 |
| Coonley, CJ | 1 |
| Brökelmann, J | 1 |
| Hesdorffer, CS | 1 |
| Dansey, RD | 1 |
| Murthy, AK | 2 |
| Showel, J | 2 |
| Caldarelli, DD | 2 |
| Hutchinson, JC | 2 |
| Holinger, LD | 2 |
| Witt, TR | 1 |
| Hoover, S | 1 |
| Dmitrieva, NV | 1 |
| Vyshinskaia, GV | 1 |
| Lichintser, MR | 1 |
| Spitzer, TR | 1 |
| Goldsmith, GH | 1 |
| Lazarus, HM | 1 |
| Kellermeyer, RW | 1 |
| Rowland, KM | 1 |
| Spiers, AS | 1 |
| DeConti, RC | 1 |
| O'Donnell, MR | 1 |
| Stott, PB | 1 |
| Milner, LM | 1 |
| Marsh, JC | 1 |
| Zweig, JI | 1 |
| Kabakow, B | 1 |
| Garewal, H | 2 |
| Pretorius, FJ | 1 |
| Bastian, G | 1 |
| Demarcq, C | 1 |
| Vedrenne, J | 1 |
| Fasano, M | 1 |
| Berthau, N | 1 |
| Khater, R | 1 |
| Frenay, M | 1 |
| Bourry, J | 1 |
| Faedi, M | 1 |
| Amadori, M | 1 |
| Biserni, R | 1 |
| Bonaguri, C | 1 |
| Niwayama, S | 1 |
| Masuyama, K | 1 |
| Berkarda, N | 1 |
| Zambruni, A | 1 |
| Gorni, F | 1 |
| Ragni, F | 1 |
| Bardakji, Z | 1 |
| Langelier, Y | 1 |
| Besner, JG | 1 |
| Ayoub, J | 1 |
| Cascinelli, N | 1 |
| Greco, M | 1 |
| Di Fronzo, G | 1 |
| Oriana, R | 1 |
| Merson, M | 1 |
| Galluzzo, D | 1 |
| Bufalino, R | 1 |
| Belli, F | 1 |
| Sacchini, V | 1 |
| Petru, E | 1 |
| Schmähl, D | 1 |
| Lane, WW | 1 |
| Camacho, FJ | 1 |
| Kaplan, BH | 1 |
| Green, MD | 2 |
| Balitskaia, EK | 1 |
| Shmal'ko, IuP | 1 |
| Malik, R | 1 |
| Roemeling, RV | 1 |
| Wood, PA | 1 |
| Langevin, TR | 1 |
| Lange, P | 1 |
| Farley, E | 1 |
| Asbury, RF | 1 |
| Boros, L | 1 |
| Brower, M | 1 |
| Chang, A | 1 |
| Bennett, J | 1 |
| Metter, GE | 1 |
| Roses, D | 1 |
| Sanger, J | 1 |
| Wascher, H | 1 |
| Page, JP | 1 |
| Levi, JA | 1 |
| Woods, RL | 1 |
| Tattersall, MN | 1 |
| Gianola, FJ | 1 |
| Wesley, R | 1 |
| Barofsky, I | 1 |
| Hoshino, A | 1 |
| Kamiya, O | 1 |
| Nagata, K | 1 |
| Kinoshita, T | 1 |
| Sugiura, I | 1 |
| Maslova, IA | 1 |
| Pines, EV | 1 |
| Showel, JL | 1 |
| Kramer, T | 1 |
| Kiel, K | 1 |
| de Riese, W | 1 |
| Löbenau, S | 1 |
| Lele, SB | 1 |
| Patsner, B | 1 |
| Emrich, LJ | 1 |
| Greenberg, BR | 1 |
| Fiorentini, GM | 1 |
| Lynch, G | 1 |
| Chun, H | 1 |
| Martin, D | 1 |
| Dias Wickramanayake, P | 1 |
| Pape, S | 1 |
| Meyer-Hofmann, H | 1 |
| MacFarlane, JR | 1 |
| McHattie, I | 1 |
| Hart, AJ | 1 |
| Mann, GB | 1 |
| Shepard, KV | 1 |
| Faintuch, J | 1 |
| Sweet, DL | 1 |
| Robin, E | 1 |
| Luce, JK | 1 |
| Massey, WH | 2 |
| Judkins, MP | 1 |
| Dennis, DL | 2 |
| Horsley, JS | 2 |
| Alrich, EM | 1 |
| Sears, HF | 1 |
| Wright, CB | 1 |
| Depierre, A | 3 |
| Le Bourgeois, J | 1 |
| Hughes, RR | 1 |
| Burdette, WJ | 1 |
| Humphrey, LJ | 2 |
| Tari, K | 1 |
| So, K | 1 |
| Nosaka, K | 1 |
| Gardner, B | 1 |
| Green, N | 1 |
| Beron, E | 1 |
| Melbye, RW | 1 |
| George, FW | 1 |
| Southwick, HW | 1 |
| Sievers, DB | 1 |
| Donovan, AJ | 1 |
| Holsti, LR | 2 |
| Bellet, RE | 1 |
| Dixon, LM | 1 |
| Dayal, Y | 1 |
| Binder, S | 1 |
| Nathanson, L | 1 |
| Battersby, C | 1 |
| Egerton, WS | 1 |
| Basso, A | 1 |
| Rosengren, K | 1 |
| Wedel, N | 1 |
| Czerwiński, W | 2 |
| Wilson, RE | 5 |
| Nordman, E | 3 |
| MacDonald, JA | 1 |
| Fain, WR | 1 |
| Conn, JH | 1 |
| Chavez, CM | 1 |
| Erez, S | 1 |
| Kaplan, AL | 1 |
| Wall, JA | 1 |
| Huys, J | 3 |
| Van Vaerenbergh, PM | 2 |
| Provan, JL | 1 |
| Stokes, JF | 1 |
| Edwards, D | 1 |
| Villasanta, U | 1 |
| Bloedorn, FG | 1 |
| Liebman, IM | 1 |
| Maguire, HC | 1 |
| Zimmermann, G | 1 |
| Boeckl, O | 1 |
| Donegan, WL | 3 |
| Harris, HS | 2 |
| Murray-Lyon, IM | 3 |
| Parsons, VA | 1 |
| Blendis, LM | 1 |
| Dawson, JL | 1 |
| Laws, JW | 1 |
| Sharoukhova, KS | 1 |
| Goncharova, MG | 1 |
| Murav'eva, NI | 1 |
| Smirnova, KD | 1 |
| Giesen, M | 1 |
| Palme, G | 1 |
| Copeland, EM | 2 |
| Macfayden, BV | 1 |
| Dudrick, SJ | 1 |
| Berenbaum, MC | 1 |
| Sheard, CE | 1 |
| Reittie, JR | 1 |
| Bundick, RV | 1 |
| Wise, L | 1 |
| Vikmanis, UE | 1 |
| Sviatukhina, OV | 1 |
| Lun'kova, EF | 1 |
| Koliadiuk, IV | 1 |
| Daniel'-Bek, KV | 1 |
| Vinogradov, AL | 1 |
| Rochlin, DB | 1 |
| Smart, CR | 1 |
| Wolberg, WH | 1 |
| Burrows, JH | 1 |
| Meyza, J | 3 |
| Ratner, LH | 1 |
| Weiner, MJ | 1 |
| Cohen, SM | 1 |
| Kaufman, S | 2 |
| Gorgun, B | 1 |
| Watne, AL | 1 |
| Bassilios, MI | 1 |
| Ramm, C | 1 |
| Jarmolych, J | 1 |
| Goffin, FB | 1 |
| Arsac, M | 1 |
| Bonnet, G | 1 |
| Mouzon, M | 1 |
| Bessot, M | 2 |
| Duprez, A | 2 |
| Watt, J | 1 |
| Costanzi, JJ | 2 |
| Coltman, CA | 2 |
| Kühböck, J | 6 |
| Pokorny, D | 1 |
| Steinbach, K | 1 |
| Eggerth, G | 1 |
| Earle, E | 1 |
| Butts, D | 1 |
| Hoaglin, LL | 1 |
| Freckman, HA | 3 |
| Karkos, J | 1 |
| Sanderson, TA | 1 |
| Man, B | 1 |
| Kraus, L | 1 |
| Pikielny, S | 1 |
| Wood, DC | 1 |
| Mauuary, G | 1 |
| Winsback, AM | 1 |
| Furnari, S | 1 |
| Pavone-Macaluso, M | 2 |
| Veroux, G | 1 |
| Mattea, E | 1 |
| Komatsu, K | 1 |
| Hiratsuka, H | 1 |
| Kamisasa, A | 1 |
| Nitze, HR | 1 |
| Ganzer, U | 1 |
| Vosteen, KH | 1 |
| Barclay, GA | 1 |
| al-Rais, SH | 1 |
| Smith, JP | 2 |
| Rutledge, FN | 1 |
| Moertel, C | 1 |
| Ricci, JA | 1 |
| Sanford, RG | 1 |
| Brown, RB | 1 |
| Silvernail, WI | 1 |
| Greeff, PJ | 1 |
| Mount, BM | 1 |
| Thelmo, WL | 1 |
| Husk, M | 1 |
| Linder, GT | 1 |
| Crook, JN | 1 |
| Cohn, I | 1 |
| Aasved, H | 1 |
| Seim, V | 1 |
| Faulkner, SL | 1 |
| Adkins, RB | 1 |
| Reynolds, VH | 2 |
| Heiss, WD | 2 |
| Kroiss, A | 2 |
| Profanter, W | 1 |
| Gailani, S | 1 |
| Leone, L | 1 |
| Ellis, H | 1 |
| Byland, W | 1 |
| Tsuchida, S | 1 |
| Sugawara, H | 1 |
| Harata, T | 1 |
| Yamaguchi, O | 1 |
| Arai, S | 1 |
| Prout, MN | 1 |
| McKenna, PJ | 1 |
| Cole, DR | 1 |
| Korbitz, BC | 2 |
| Andrews, JT | 1 |
| Cox, KR | 1 |
| Hare, WS | 1 |
| McConchie, IH | 1 |
| Stutz, FH | 2 |
| Weinberg, S | 1 |
| Jesse, RH | 2 |
| Lindberg, RD | 2 |
| van der Werf-Messing, B | 1 |
| Mulder, J | 1 |
| Catalona, WJ | 2 |
| Umhauer, I | 1 |
| Karim, F | 1 |
| Webb, MJ | 1 |
| Melchert, F | 1 |
| Glenn, EH | 1 |
| Cole, D | 1 |
| Wunderlich, HO | 1 |
| Holbrook, MA | 1 |
| Donaldson, GA | 1 |
| Welch, JP | 1 |
| Cichy, A | 1 |
| Jurga, L | 1 |
| Klvana, M | 1 |
| Fredlund, P | 1 |
| Vang, J | 1 |
| Wassif, SB | 1 |
| Markoff, N | 1 |
| Carr, DT | 1 |
| Childs, DS | 1 |
| Lee, RE | 1 |
| Hill, GJ | 1 |
| Larsen, RR | 1 |
| Jewell, WR | 2 |
| Chernomordikova, MF | 4 |
| Hermann, HJ | 1 |
| Janssen, B | 1 |
| Schmidt, L | 1 |
| Günther, W | 1 |
| Voznyĭ, EK | 1 |
| Moroz, LV | 2 |
| Karev, NI | 1 |
| Djalaly, A | 1 |
| Johnson, EC | 1 |
| Priestman, TJ | 1 |
| Hanham, IW | 1 |
| Kauppinen, C | 1 |
| Kummer, F | 1 |
| Kübböck, J | 1 |
| Poustka, F | 1 |
| Lapsa, RKh | 1 |
| Hirose, M | 1 |
| Takamatu, O | 1 |
| Tandon, RN | 1 |
| Bunnell, IL | 1 |
| Cooper, RG | 1 |
| Barb, U | 1 |
| Vielberg, H | 1 |
| Bevan, PG | 1 |
| Omura, GA | 1 |
| Roberts, GA | 1 |
| Tolia, BM | 1 |
| Whitmore, WF | 1 |
| Van Eden, EB | 2 |
| Goldstein, M | 1 |
| Otte, H | 1 |
| Gätera, G | 1 |
| Freyens, P | 1 |
| Berghe, GV | 1 |
| Greene, LF | 1 |
| Mulcahy, JJ | 1 |
| Warren, MM | 1 |
| Waddell, WR | 1 |
| Wallgren, A | 1 |
| Norin, T | 1 |
| Perlia, CP | 1 |
| Dana, M | 1 |
| Schick, M | 1 |
| Spigel, SC | 1 |
| Halden, A | 2 |
| Horn, Y | 2 |
| Walter, RM | 1 |
| Gordan, GS | 3 |
| Shonfeld, EM | 1 |
| Graham, JH | 1 |
| Helwig, EB | 1 |
| Hughes, J | 1 |
| Stoker, TA | 1 |
| Ellert, J | 1 |
| Vitvitskiĭ, KF | 1 |
| van Kaick, G | 1 |
| Moskwa, G | 3 |
| Castor, H | 2 |
| Chauvin, HF | 1 |
| Lee, JM | 1 |
| Lenhard, RE | 1 |
| Baker, RR | 1 |
| Creasey, WA | 1 |
| al-Sarraf, M | 1 |
| Reed, ML | 1 |
| Tully, TE | 1 |
| Shafer, RB | 1 |
| Solheim, OP | 1 |
| Steward, AM | 1 |
| Nixon, D | 1 |
| Zamcheck, N | 1 |
| Aisenberg, A | 1 |
| Marcrae, KD | 1 |
| Osieka, R | 1 |
| Dines, DE | 1 |
| von Kaick, G | 1 |
| Rozhold, J | 1 |
| Klucár, J | 1 |
| Witek, JT | 1 |
| Spencer, RP | 1 |
| Sickles, EA | 1 |
| Belliveau, RE | 1 |
| Mussey, E | 2 |
| Johnson, CE | 2 |
| Prout, GR | 1 |
| Ausman, RK | 1 |
| Klein, E | 1 |
| Stoll, HL | 1 |
| Miller, E | 1 |
| Milgrom, H | 1 |
| Helm, F | 1 |
| Burgess, G | 1 |
| Chahinian, P | 1 |
| Rutledge, F | 1 |
| Burns, BC | 1 |
| Soffar, S | 1 |
| Kaufman, JJ | 3 |
| Lichtenauer, P | 2 |
| Molina, C | 1 |
| Cheminat, JC | 1 |
| Passemard, N | 1 |
| Adam, J | 1 |
| Heynen, E | 1 |
| Tsuya, A | 1 |
| Kaneda, K | 1 |
| Okano, S | 1 |
| Goto, H | 1 |
| Blumenson, LE | 1 |
| Li, MC | 1 |
| Janelli, DE | 1 |
| Kelly, EJ | 1 |
| Kashiwabara, H | 1 |
| Kim, RH | 1 |
| Fracchia, AA | 1 |
| Farrow, JH | 1 |
| Adam, YG | 1 |
| Monroy, J | 1 |
| Knapper, WH | 1 |
| Karrer, K | 4 |
| Sighart, H | 1 |
| Wrbka, E | 1 |
| Johnston, GS | 1 |
| Jones, AE | 1 |
| Sandler, M | 1 |
| Cheetham, HD | 1 |
| Watts, JA | 1 |
| Nilsson, LA | 1 |
| Gulesserian, HP | 2 |
| Condon, RE | 1 |
| Zwaveling, A | 1 |
| Cohen, Y | 1 |
| Lichtig, C | 1 |
| Lleander, VC | 1 |
| Goldstein, G | 1 |
| Shingleton, WW | 1 |
| Pershin, MP | 1 |
| Chumakina, SI | 1 |
| Gunka, II | 1 |
| Pantophel, AM | 1 |
| Steklenev, NA | 1 |
| Zirin, MA | 1 |
| Grjaznova, IN | 1 |
| Shain, AA | 1 |
| Pecherskaja, BG | 1 |
| Saveliev, NP | 1 |
| Bashirova, NG | 1 |
| Kuzmin, VP | 1 |
| Budarina, EM | 1 |
| Svedencov, EP | 1 |
| Phateeva, KV | 1 |
| Iunusmetov, IR | 1 |
| Silitrin, NP | 1 |
| Shklovskii, GS | 1 |
| Balas, AN | 1 |
| Ushivceva, AE | 1 |
| Wessler, S | 1 |
| Avioli, LV | 1 |
| Vestfrid, MA | 1 |
| Castelleto, L | 1 |
| Giménez, PO | 1 |
| Nevinny, HB | 1 |
| Kitaoka, H | 1 |
| Matsui, K | 1 |
| Lahiri, SR | 2 |
| Boileau, G | 2 |
| Pugh, RP | 1 |
| Cassidy, FR | 1 |
| Marshall, GJ | 1 |
| Irwin, LE | 1 |
| Aliapoulios, MA | 2 |
| Moore, FD | 2 |
| Buchheim, E | 1 |
| Jones, HW | 1 |
| Droegemueller, W | 1 |
| Makowski, EL | 1 |
| Higashi, H | 1 |
| Heidelberger, C | 1 |
| Braun-Falco, O | 1 |
| Lukacs, I | 1 |
| Price, LA | 1 |
| Goldie, JH | 1 |
| Skibba, JL | 1 |
| Chevrel, B | 1 |
| Chevrel, JP | 1 |
| Ishida, M | 1 |
| Wieme, RJ | 1 |
| Van Hove, WZ | 1 |
| Van der Straeten, ME | 1 |
| Ohno, T | 1 |
| Harrison, LH | 1 |
| Cox, CE | 1 |
| Banks, KW | 1 |
| Boyce, WH | 1 |
| Bejdl, W | 1 |
| Berdjis, S | 1 |
| Sugimura, K | 1 |
| Alcini, E | 1 |
| Wiel Marin, A | 1 |
| Ronzoni, G | 1 |
| Pigliucci, GM | 1 |
| Fazio, M | 1 |
| Minetto, E | 1 |
| Cavallero, P | 1 |
| Sartoris, S | 1 |
| Van Way, CW | 1 |
| Rapoport, AH | 1 |
| Burleson, RL | 1 |
| Mansfield, CM | 1 |
| Kramer, S | 1 |
| Southard, ME | 1 |
| Hornowski, S | 1 |
| Llombart Bosch, M | 1 |
| Espinosa Cabañero, JA | 1 |
| Brix, M | 1 |
| Börjesson, B | 1 |
| Olsson, A | 1 |
| Szatkowska, R | 1 |
| Yamada, E | 1 |
| Miyaishi, S | 1 |
| Kuroyanagi, Y | 1 |
| Irikura, T | 1 |
| Mizuno, D | 1 |
| Deemarsky, LY | 2 |
| Gofman, AM | 1 |
| Faĭn, SN | 1 |
| Denck, H | 1 |
| Eras, P | 1 |
| Sherlock, P | 1 |
| Friedl, HP | 1 |
| Vansant, JH | 1 |
| Payne, RL | 1 |
| Wheeler, JR | 1 |
| Neubauer, HW | 1 |
| Milonov, BV | 1 |
| Kosarev, VA | 1 |
| Nikiforov, AM | 1 |
| Evseenko, LS | 1 |
| Orlova, RS | 1 |
| Genevrier, R | 1 |
| Gouletquer, J | 1 |
| Barrett, O | 2 |
| Cohen, A | 1 |
| Morere, P | 1 |
| Chauvet, MC | 1 |
| Vaudour, P | 1 |
| Maisse, P | 1 |
| Stain, JP | 1 |
| Lenail, C | 1 |
| Bernhardt, LC | 1 |
| Herter, FP | 1 |
| Mulcare, RJ | 1 |
| McCarthy, JG | 1 |
| Gump, FE | 1 |
| Ukai, M | 1 |
| Buckley, K | 1 |
| Wheeler, B | 1 |
| Abasov, IT | 1 |
| Nadzharov, AG | 1 |
| Bernard, E | 1 |
| Soots, ML | 1 |
| Gasparri, F | 1 |
| Periti, P | 1 |
| De Laurentiis, G | 1 |
| Firat, D | 1 |
| Olshin, S | 1 |
| Fleming, JW | 1 |
| Johnson, RH | 1 |
| Spratt, JS | 1 |
| Bourgeois, C | 1 |
| Plecha, FR | 1 |
| Danczkay, I | 1 |
| Clarkson, B | 1 |
| Ota, K | 1 |
| Ohkita, T | 1 |
| O'Connor, A | 1 |
| Zurek, WZ | 1 |
| Burt, FB | 1 |
| Horns, JW | 1 |
| Nance, FC | 1 |
| MacVaugh, H | 1 |
| Fitts, WT | 1 |
| Mendez, FL | 1 |
| Maurer, ER | 1 |
| Fry, HL | 1 |
| Samp, RJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Open, Multicenter Phase III Study With Capecitabine Plus Bevacizumab Versus Capecitabine Plus Irinotecan Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer[NCT01249638] | Phase 3 | 516 participants (Anticipated) | Interventional | 2010-12-31 | Recruiting | ||
| Randomised Phase II/III Study, Assessing the Safety and Efficacy of Modified Folfirinox Versus Gemcis in Locally Advanced, Unresectable and/or Metastatic Bile Duct Tumours[NCT02591030] | Phase 2/Phase 3 | 191 participants (Actual) | Interventional | 2015-12-15 | Completed | ||
| Targeted Therapy With or Without Dose Intensified Radiotherapy for Oligo-progressive Disease in Oncogene-addicted Lung Tumours[NCT03256981] | Phase 2/Phase 3 | 113 participants (Actual) | Interventional | 2017-11-27 | Active, not recruiting | ||
| Precision Radiation for OligoMetastatIc and MetaStatic DiseasE (PROMISE)-004: Consolidative Use of Radiotherapy to Block (CURB) Oligoprogression[NCT03808662] | Phase 2 | 107 participants (Actual) | Interventional | 2019-01-16 | Active, not recruiting | ||
| Stereotactic Radiotherapy for Oligo-Progressive Metastatic Cancer (The STOP Trial): A Randomized Phase II Trial[NCT02756793] | 90 participants (Actual) | Interventional | 2016-10-31 | Active, not recruiting | |||
| TRAP - Targeted Radiotherapy in Androgen-suppressed Prostate Cancer Patients.[NCT03644303] | 84 participants (Anticipated) | Interventional | 2018-08-13 | Recruiting | |||
| A Phase 2 Randomized Study Comparing the Efficacy and Safety of mFOLFOX6+Panitumumab Combination Therapy and 5-FU/LV+Panitumumab Combination Therapy in the Patients With Chemotherapy-Naive Unresectable Advanced Recurrent Colorectal Carcinoma of KRAS Wild-[NCT02337946] | Phase 2 | 164 participants (Actual) | Interventional | 2014-10-16 | Completed | ||
| An Observational Study of Avastin® (Bevacizumab) in Combination With Chemotherapy for Treatment of First-line Metastatic Colorectal Adenocarcinoma[NCT01506167] | 719 participants (Actual) | Observational | 2012-07-06 | Completed | |||
| Drug Response in Patient-derived Organoids Models of Advanced or Recurrent Ovarian Cancer, an Exploratory Research[NCT05290961] | 30 participants (Anticipated) | Observational [Patient Registry] | 2022-03-09 | Recruiting | |||
| A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy Wit[NCT01183780] | Phase 3 | 1,072 participants (Actual) | Interventional | 2010-12-02 | Completed | ||
| A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy[NCT01494506] | Phase 3 | 417 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| A Randomized, Multicenter Phase 3 Study to Compare the Efficacy of Panitumumab in Combination With Chemotherapy to the Efficacy of Chemotherapy Alone in Patients With Previously Treated Metastatic Colorectal Cancer[NCT00339183] | Phase 3 | 1,186 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| An Australian Translational Study to Evaluate the Prognostic Role of Inflammatory Markers in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab (Avastin™)[NCT01588990] | Phase 4 | 128 participants (Actual) | Interventional | 2012-06-26 | Completed | ||
| An Investigator Initiated Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor (KPT-330), An Oral Selective Inhibitor Of Nuclear Export (SINE), In Patients With Metastatic Colorectal Cancer[NCT02384850] | Phase 1 | 10 participants (Actual) | Interventional | 2015-03-31 | Terminated | ||
| Multicentre Randomization Clinic Trial of Systemic Chemotherapy Combined With Loco-regional Radiotherapy vs. Chemotherapy Alone for Initially Untreated Distant Metastatic Nasopharyngeal Carcinoma With Chemosensitivity[NCT02111460] | Phase 3 | 126 participants (Actual) | Interventional | 2013-10-31 | Active, not recruiting | ||
| Determination of the UGT1A1 Polymorphism as Guidance for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Treated With First-Line Bevacizumab and FOLFIRI (PURE FIST)[NCT02256800] | 213 participants (Actual) | Interventional | 2014-08-13 | Completed | |||
| Phase II Randomized Study of BAX2398 in Combination With 5-Fluorouracil and Calcium Levofolinate in Japanese Patients With Metastatic Pancreatic Cancer, Which Progressed or Recurred After Prior Gemcitabine-Based Therapy[NCT02697058] | Phase 2 | 84 participants (Actual) | Interventional | 2016-03-30 | Completed | ||
| Randomised Phase II Study in Metastatic Pancreatic Cancer Evaluating FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem in First-line[NCT02352337] | Phase 2 | 276 participants (Actual) | Interventional | 2014-12-23 | Completed | ||
| A Randomized Phase II Study of mFOLFOX vs. mFOLFIRI in Advanced or Recurrent Biliary Tract Cancer Refractory to First Line Gemcitabine Plus Cisplatin[NCT03464968] | Phase 2 | 120 participants (Actual) | Interventional | 2015-07-29 | Completed | ||
| A Randomized Phase II Study Of CMF Alone And In Combination With Anti c-erbB2 Antibody (Herceptin) In Women With c-erbB2 Positive Metastatic Breast Cancer[NCT00036868] | Phase 2 | 90 participants (Actual) | Interventional | 2002-02-28 | Active, not recruiting | ||
| FIRST-LINE FOLFOXIRI PLUS BEVACIZUMAB FOLLOWED BY REINTRODUCTION OF FOLFOXIRI PLUS BEVACIZUMAB AT PROGRESSION Versus FOLFOX PLUS BEVACIZUMAB FOLLOWED BY FOLFIRI PLUS BEVACIZUMAB AT PROGRESSION IN FIRST- AND SECOND-LINE TREATMENT OF UNRESECTABLE METASTATIC[NCT02339116] | Phase 3 | 654 participants (Anticipated) | Interventional | 2015-02-26 | Active, not recruiting | ||
| A Randomized, Multicenter, Phase III Trial Comparing Induction CT With Docetaxel, Cisplatin and 5-FU (TPF) Followed by Concurrent CT-RT to Concurrent CT Alone, in Nasopharyngeal Cancers Staged as T2b, T3, T4 and/or With Lymph Node Involvement (>N1)[NCT00828386] | Phase 3 | 83 participants (Actual) | Interventional | 2009-01-31 | Terminated (stopped due to Low accrual) | ||
| Multicenter Non-interventional Study to Investigate Safety, Tolerability and Efficacy of Nab-paclitaxel in Clinical Routine Treatment of First-line Pancreatic Cancer Patients[NCT02555813] | 317 participants (Actual) | Observational | 2015-05-08 | Completed | |||
| A Multinational, Randomized, Double-blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks Versus Placebo in Patients With Metastatic Colorectal Cancer (MCRC) Treated With Irinotecan / 5-FU Combination (FOLFIRI) After Failure of an Oxalipla[NCT00561470] | Phase 3 | 1,226 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| An Open-Label, Multicenter, Randomized, Phase 3 Study of S-1 and Cisplatin Compared With 5-FU and Cisplatin in Patients With Metastatic Diffuse Gastric Cancer Previously Untreated With Chemotherapy[NCT01285557] | Phase 3 | 361 participants (Actual) | Interventional | 2011-04-14 | Terminated (stopped due to Due to significant changes in investigational and clinical practice landscape of frontline advanced gastric cancer, which challenged viability of trial and increased use of modified chemotherapeutic triplets led to slow participant accrual in study.) | ||
| Surgery Outcome Treated by Neo-adjuvant Chemotherapy FOLFOXIRI Regimen in Colorectal Cancer With Liver-limited Synchronous Metastases[NCT05362825] | 89 participants (Anticipated) | Observational | 2022-02-18 | Recruiting | |||
| Incidence of The Bowel, Bladder, and Sexual Dysfunction Following Surgery for Colorectal Malignancy[NCT04134104] | 38 participants (Actual) | Observational [Patient Registry] | 2014-12-31 | Completed | |||
| Multicenter Randomized Trial Evaluating FOLFIRI Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment of Metastatic Colorectal Cancer.[NCT00433927] | Phase 3 | 568 participants (Anticipated) | Interventional | 2007-01-31 | Active, not recruiting | ||
| Efficacy and Safety of Crisaborole Ointment, a Phosphodiesterase 4 (PDE4) Inhibitor, for the Topical Treatment of Cetuximab-Related Skin Toxicity Among Metastatic Colorectal Cancer Patients：A Prospective, Single-arm, Phase II Clinical Trial[NCT06118047] | Phase 2 | 33 participants (Anticipated) | Interventional | 2023-08-01 | Recruiting | ||
| Induction Chemotherapy With Folfoxiri Plus Cetuximab and Maintenance With Cetuximab or Bevacizumab Therapy in Unresectable Kras Wild-type Metastatic Colorectal Cancer Patients[NCT02295930] | Phase 2 | 143 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| Effectiveness and Safety Evaluation of Microwave Ablation Combined With Chemotherapy in the Treatment of Pancreatic Cancer Oligohepatic Metastasis: A Prospective, Single-center, Single-arm, Phase II Clinical Study[NCT04677192] | Phase 2 | 50 participants (Anticipated) | Interventional | 2021-01-31 | Not yet recruiting | ||
| A Randomized, Multicenter, Phase 2 Study to Compare the Efficacy of Panitumumab in Combination With mFOLFOX6 to the Efficacy of Bevacizumab in Combination With mFOLFOX6 in Patients With Previously Untreated, KRAS Wild-Type, Unresectable, Metastatic Colore[NCT00819780] | Phase 2 | 285 participants (Actual) | Interventional | 2009-04-24 | Completed | ||
| Phase-II, Randomized, Multicentre Pilot Study to Evaluate the Safety and Efficacy of the Treatment With mFOLFOX-6 Plus Cetuximab Versus Initial Treatment With mFOLFOX-6 Plus Cetuximab (for 8 Cycles), Followed by Maintenance With Cetuximab Alone as First-l[NCT01161316] | Phase 2 | 194 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| A Multinational, Randomized, Double-Blind Study of Aflibercept Versus Placebo With Irinotecan/ 5-FU Combination (FOLFIRI) in Patients With Metastatic Colorectal Cancer (MCRC) After Failure of an Oxaliplatin Based Regimen[NCT01661270] | Phase 3 | 332 participants (Actual) | Interventional | 2012-07-31 | Completed | ||
| Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer: a Prospective Phase II Study[NCT06148402] | Phase 2 | 30 participants (Anticipated) | Interventional | 2024-01-31 | Recruiting | ||
| Phase II Study of Regorafenib as Single Agent for the Treatment of Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab[NCT02175654] | Phase 2 | 15 participants (Actual) | Interventional | 2014-06-30 | Terminated (stopped due to The trial was prematurely closed due to lack of accrual) | ||
| Open Label Randomized Bioequivalence Study to Evaluate the Pharmacokinetic and Safety Profile of Bevacizumab Biosimilar (BEVZ92) vs Bevacizumab (AVASTIN®), Both With FOLFOX or FOLFIRI, in First-line Treatment for mCRC Patients[NCT02069704] | Phase 1 | 142 participants (Actual) | Interventional | 2014-10-29 | Completed | ||
| Phase II, Multicentric Randomized Trial, Evaluating the Efficacy of Fluoropyrimidine-based Standard Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receivi[NCT01442649] | Phase 2 | 133 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| A Randomized, Multicenter, Phase 3 Study to Compare the Efficacy of Panitumumab in Combination With Oxaliplatin/ 5-fluorouracil/ Leucovorin to the Efficacy of Oxaliplatin/ 5-fluorouracil/ Leucovorin Alone in Patients With Previously Untreated Metastatic C[NCT00364013] | Phase 3 | 1,183 participants (Actual) | Interventional | 2006-08-01 | Completed | ||
| S1313, A Phase IB/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) Versus Modified FOLFIRINOX Alone in Patients With Good Performance Status Metastatic Pancreatic Adenocarcinoma[NCT01959139] | Phase 1/Phase 2 | 126 participants (Actual) | Interventional | 2014-01-23 | Active, not recruiting | ||
| Open Label Phase II Study of FOLFIRI + Panitumumab Using Ultra-selection Technology With Next Generation High Sensitivity Genotyping of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS G[NCT01704703] | Phase 2 | 72 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| Perioperative Systemic Therapy and Cytoreductive Surgery With HIPEC Versus Upfront Cytoreductive Surgery With HIPEC Alone for Isolated Resectable Colorectal Peritoneal Metastases: a Multicentre, Open-label, Parallel-group, Phase II-III, Randomised Superio[NCT02758951] | Phase 2/Phase 3 | 358 participants (Anticipated) | Interventional | 2017-06-01 | Recruiting | ||
| A Phase III Trial of Irinotecan / 5-FU / Leucovorin or Oxaliplatin / 5-FU/ Leucovorin With Bevacizumab, or Cetuximab (C225), or With the Combination of Bevacizumab and Cetuximab for Patients With Untreated Metastatic Adenocarcinoma of the Colon or Rectum[NCT00265850] | Phase 3 | 2,334 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| A Phase I/IIa Study Combining Curcumin (Curcumin C3-Complex, Sabinsa) With Standard Care FOLFOX Chemotherapy in Patients With Inoperable Colorectal Cancer.[NCT01490996] | Phase 1/Phase 2 | 41 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| Study Protocol - The Development of a Novel Patient Reported Outcomes Measure Committed to the Watch-and-wait Program for Rectal Cancer: An International Delphi Study Protocol[NCT05040646] | 80 participants (Actual) | Observational | 2021-11-01 | Completed | |||
| A Multicenter Randomized Dble-Blind Placebo Controlled Phase III Study of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin and 5-FU/LV Combination in First-Line Treatment of Patients With Metastatic Colorectal Carcinoma(MCRC)[NCT00272051] | Phase 3 | 620 participants | Interventional | 2002-07-31 | Completed | ||
| A Multicenter, Randomized Double-blind Placebo Controlled Phase III Study of the Efficacy of Xaliproden in Preventing the Neurotoxicity of Oxaliplatin in First-line Treatment of Patients With Metastatic Colorectal Cancer Treated With Oxaliplatin / 5-FU/LV[NCT00305188] | Phase 3 | 879 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| PACCE: A Randomized, Open-Label, Controlled, Clinical Trial of Chemotherapy and Bevacizumab With and Without Panitumumab in the First-Line Treatment of Subjects With Metastatic Colorectal Cancer[NCT00115765] | Phase 3 | 1,053 participants (Actual) | Interventional | 2005-06-01 | Completed | ||
| A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Pat[NCT00384176] | Phase 2/Phase 3 | 1,814 participants (Actual) | Interventional | 2006-08-30 | Completed | ||
| The Predictive Value of Cytokines on Response to Preoperative Chemoradiotherapy in Patients With Rectal Cancer[NCT02077296] | 34 participants (Actual) | Observational | 2014-03-31 | Completed | |||
| Randomized Study of Classic vs Simplified Leucovorin Calcium and Fluorouracil With or Without Irinotecan in Patients Aged At Least 75 Years With Advanced Colorectal Cancer[NCT00303771] | Phase 3 | 282 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| A Randomized Multicenter Phase II/III Study Comparing 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced Resectable Adenocarcinoma of the Esophagogastreal Junction or the Stomac[NCT01216644] | Phase 2/Phase 3 | 716 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| A Single Arm, Open Label, Exploratory Study of Pemetrexed and S-1 in Combination With Bevacizumab in Patients Who Have Progressed After Standard Second Line Therapy[NCT03843853] | Phase 2 | 0 participants (Actual) | Interventional | 2019-05-01 | Withdrawn (stopped due to cooperation terminated) | ||
| A Single Arm, Open Label, Exploratory Study of Pemetrexed and TAS-102 in Combination With Bevacizumab in Patients Who Have Progressed After Standard Second Line Therapy[NCT04683965] | Phase 2 | 27 participants (Anticipated) | Interventional | 2021-01-01 | Active, not recruiting | ||
| A Phase 3 Randomized Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)[NCT00460265] | Phase 3 | 658 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| A Randomized, Phase 3 Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Previously Treated Breast Cancer[NCT00435409] | Phase 3 | 442 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| XELOX III. Capecitabine (Xeloda) in Combination With Oxaliplatin (Eloxatin) as First-line Treatment of Patients With Advanced or Metastatic Colorectal Cancer. A Randomized Phase II Study[NCT00212615] | Phase 2/Phase 3 | 116 participants (Actual) | Interventional | 2004-02-29 | Completed | ||
| A Randomized Phase 2 Study Of SU011248 Versus Standard-Of-Care For Patients With Previously Treated, Advanced, Triple Receptor Negative (ER, PR, HER2) Breast Cancer[NCT00246571] | Phase 2 | 217 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| Palliative Radiotherapy Followed by Chemotherapy Against Palliative Surgery in Patients With Rectal Cancer With Unresectable Synchronous Distant Metastases[NCT01157806] | Phase 2 | 20 participants (Anticipated) | Interventional | 2010-01-31 | Recruiting | ||
| Clinical Study of Radiopeptide 177Lu-DOTATOC in Combination With Capecitabine and Temozolomide in Advanced, Non-resectable and Progressive Neuroendocrine Tumors With Somatostatin Receptor Overexpression[NCT04194125] | Phase 2 | 25 participants (Anticipated) | Interventional | 2019-02-01 | Recruiting | ||
| Development of a Prospective Clinicobiological Database in Metastatic Digestive Cancers[NCT03978078] | 200 participants (Anticipated) | Interventional | 2016-09-12 | Recruiting | |||
| Tempus CRC Surveillance Study: A Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients With Colorectal Cancer (CRC) Using Comprehensive Next-Generation Sequencing (NGS)Assays[NCT05234177] | 160 participants (Anticipated) | Observational | 2022-06-21 | Recruiting | |||
| A Phase II Clinical Trial Study on Apatinib and XELOX Combination Regimen in the First-line Treatment of End-stage Colorectal Cancer Patients[NCT02829385] | Phase 2 | 53 participants (Anticipated) | Interventional | 2016-06-30 | Recruiting | ||
| Predictive Impact of RAS Mutations in Circulating Tumor DNA for Efficacy of Anti-EGFR Reintroduction Treatment in Patients With Metastatic Colorectal Cancer[NCT03259009] | 73 participants (Anticipated) | Observational [Patient Registry] | 2017-10-01 | Not yet recruiting | |||
| The Oncopanel Pilot (TOP) Study[NCT02171286] | 432 participants (Actual) | Observational | 2014-10-31 | Completed | |||
| A Phase 1b/2 Study of AMG 655 in Combination With Modified FOLFOX6 and Bevacizumab for the First-Line Treatment of Subjects With Metastatic Colorectal Cancer[NCT00625651] | Phase 1/Phase 2 | 202 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| FOLFOXIRI Plus Bevacizumab as First-line Treatment for BRAF V600E Mutant Metastatic Colorectal Cancer: a Prospective Evaluation[NCT01437618] | 15 participants (Actual) | Observational | 2009-06-30 | Completed | |||
| Aromatase Inhibitors Plus Metronomic Capecitabine in Treatment of Patients With Recurrent or Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer[NCT04942899] | Phase 2 | 70 participants (Anticipated) | Interventional | 2023-08-30 | Not yet recruiting | ||
| Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled Study (CONCEPT Trial)[NCT04012918] | Phase 2 | 124 participants (Anticipated) | Interventional | 2018-08-30 | Recruiting | ||
| Phase I Trial of Oral Capecitabine Combined With 131I-huA33 in Patients With Metastatic Colorectal Cancer[NCT00291486] | Phase 1 | 19 participants (Actual) | Interventional | 2003-10-31 | Completed | ||
| "A Multicenter Phase II Study of Capecitabine and Docetaxel for Previously Treated Pancreatic Cancer Patients CapTere"[NCT00290693] | Phase 2 | 45 participants (Actual) | Interventional | 2004-07-31 | Completed | ||
| A Single-arm, Open Phase II Trial of CAPOX Combined With Bevacizumab Combined With Tirelizumab in First-line Treatment of PDL1 CPS < 5 Advanced Gastroesophageal Adenocarcinoma[NCT05299476] | Phase 2 | 30 participants (Anticipated) | Interventional | 2022-04-16 | Recruiting | ||
| NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Combination in Microsatellite Stable (MSS), MGMT Silenced Metastatic Colorectal Cancer (mCRC): the MAYA Study[NCT03832621] | Phase 2 | 135 participants (Actual) | Interventional | 2019-03-25 | Completed | ||
| Phase II Study of the Combination of Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Inoperable Well-Differentiated Neuroendocrine Tumors[NCT01203306] | Phase 2 | 42 participants (Anticipated) | Interventional | 2006-01-31 | Recruiting | ||
| UPCC 04219 Phase 2 Study of Capecitabine-Temozolomide(CapTem) With Yttrium-90 Radioembolization in the Treatment of Patients With Unresectable Metastatic Grade 2 Neuroendocrine Tumors[NCT04339036] | Phase 2 | 50 participants (Anticipated) | Interventional | 2021-10-07 | Recruiting | ||
| Randomized Phase III Study of 5-FU Continuous Infusion (5-FUci) Versus CPT-11 Plus CDDP (CP) Versus S-1 Alone (S-1) in Advanced Gastric Cancer (JCOG9912)[NCT00142350] | Phase 3 | 690 participants | Interventional | 2000-11-30 | Completed | ||
| A Multicenter Study of Prognosis and the Efficacy Comparison of Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Patients(Clinical Risk Score≥3) of Resectable Colorectal Liver Metastasis[NCT03031444] | Phase 2/Phase 3 | 135 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| Phase Ⅱ Clinical Study of RALOX or CAPOX Combined With Bevacizumab in the First-line Treatment of Advanced Colorectal Cancer[NCT03813641] | Phase 2 | 100 participants (Anticipated) | Interventional | 2019-01-28 | Recruiting | ||
| Double-blind, Phase II Study to Assess the Effectiveness of Lycopene vs Placebo to Reduce Skin Toxicity in Patients With Colorectal Carcinoma Treated With Panitumumab[NCT03167268] | Phase 2 | 28 participants (Actual) | Interventional | 2016-08-03 | Active, not recruiting | ||
| A Multicenter Phase II Study of the Capecitabine, Oxaliplatin and Bevacizumab as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer[NCT01024504] | Phase 2 | 46 participants (Anticipated) | Interventional | 2006-03-31 | Completed | ||
| A Sequential Phase I Study Of The Combination Of Everolimus (Rad001) With 5-Fu/Lv (De Gramont), Folfox6, And Folfox6/Panitumumab In Patients With Refractory Solid Malignancies[NCT00610948] | Phase 1 | 74 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| A Phase 1/2, Open-Label Study Of Neratinib (HKI-272) In Combination With Capecitabine In Subjects With Solid Tumors And ErbB-2 Positive Metastatic Or Locally Advanced Breast Cancer[NCT00741260] | Phase 1/Phase 2 | 105 participants (Actual) | Interventional | 2008-12-09 | Completed | ||
| Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Chemotherapy For Unresectable Locally Advanced Colon Cancer: An Open, Multi-centered, Randomize Controlled Phase 3 Trial.[NCT03970694] | Phase 3 | 49 participants (Actual) | Interventional | 2019-05-11 | Terminated (stopped due to Significant differences in conversion rate as well as R0 resection rate between the two groups.) | ||
| A PHASE III RANDOMIZED TRIAL OF FOLFOXIRI + BEVACIZUMAB VERSUS FOLFIRI + BEVACIZUMAB AS FIRST- LINE TREATMENT FOR METASTATIC COLORECTAL CANCER[NCT00719797] | Phase 3 | 509 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| A Prospective, Multicenter, Open-label, Phase II Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Canc[NCT04659382] | Phase 2 | 52 participants (Anticipated) | Interventional | 2020-10-07 | Recruiting | ||
| Evaluation of an Alternative Schedule for CRLX101 Alone in Combination With Bevacizumab and in Combination With mFOLFOX6 in Subjects With Advanced Solid Tumor Malignancies[NCT02648711] | Phase 1 | 41 participants (Actual) | Interventional | 2015-10-31 | Terminated (stopped due to Company decision) | ||
| Assessment of Histopathological Response to Combination Chemotherapy With Oxaliplatin, Irinotecan, Fluorouracil and Bevacizumab in Patients With Peritoneal Metastasis From Colorectal Cancer[NCT02591667] | Phase 2 | 30 participants (Anticipated) | Interventional | 2016-03-31 | Recruiting | ||
| Phase I Trial of Intraperitoneal Oxaliplatin in Combination With Intravenous FOLFIRI (5-fluorouracil, Leucovorin and Irinotecan) for Peritoneal Carcinomatosis From Colorectal and Appendiceal Cancer[NCT02833753] | Phase 1 | 14 participants (Actual) | Interventional | 2016-07-31 | Completed | ||
| Phase 1b Trial of 5-fluorouracil, Leucovorin, Irinotecan in Combination With Temozolomide (FLIRT) and Bevacizumab for the First-line Treatment of Patients With MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.[NCT04689347] | Phase 1 | 18 participants (Anticipated) | Interventional | 2021-01-01 | Recruiting | ||
| Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With RAS-mutated Metastatic Colorectal Cancer: a Dose-escalation, Phase I/II Trial[NCT03828799] | Phase 1/Phase 2 | 13 participants (Actual) | Interventional | 2019-05-17 | Active, not recruiting | ||
| A Randomized Phase III Study of SOX vs. COX in Patients With Advanced Colorectal Cancer[NCT00677443] | Phase 3 | 344 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Phase II Study of Irinotecan Plus Capecitabine as the First-line or Second-line Treatment for Advanced Colorectal Cancer Patients[NCT01322152] | Phase 2 | 52 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| The Utility of Circulating Tumour Cells and Plasma microRNA Detection to Predict the Response to Treatment in Patients With Esophageal Adenocarcinoma[NCT02812680] | 200 participants (Anticipated) | Observational | 2016-06-30 | Active, not recruiting | |||
| Open-label Phase 1b Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer Who Have Progressed Following Chemotherapy for Advanced or Metastatic Disease[NCT00719199] | Phase 1 | 21 participants (Actual) | Interventional | 2009-01-31 | Terminated (stopped due to Sponsor will discontinue further development of EMD 1201081) | ||
| Multicenter Phase III Randomized Study of FOLFIRI Plus Bevacizumab Following or Not by a Maintenance Therapy With Bevacizumab in Patients With Non-Pretreated Metastatic Colorectal Cancer[NCT00952029] | Phase 2/Phase 3 | 492 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| Study of Blood Components as Probable Prognostic and Predictive Markers of Response to Treatment in Advanced Colon and Rectal Cancers[NCT02979470] | 100 participants (Anticipated) | Observational [Patient Registry] | 2016-09-30 | Recruiting | |||
| SEQUENTIAL TREATMENT STRATEGY FOR METASTATIC COLORECTAL CANCER: A PHASE III PROSPECTIVE RANDOMIZED MULTICENTER STUDY OF CHEMOTHERAPY (CT) WITH OR WITHOUT BEVACIZUMAB AS FIRST-LINE THERAPY FOLLOWED BY TWO PHASE III RANDOMIZED STUDIES OF CT ALONE OR CT PLUS[NCT01878422] | Phase 3 | 350 participants (Anticipated) | Interventional | 2007-11-30 | Completed | ||
| Single-agent Capecitabine as Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase 3, Multicentre, Randomised Controlled Trial (CAN)[NCT02958111] | Phase 3 | 406 participants (Actual) | Interventional | 2017-01-31 | Active, not recruiting | ||
| Maintenance Treatment With Capecitabine and Bevacizumab Versus Observation After Induction Treatment With Chemotherapy and Bevacizumab as First-line Treatment in Patients With Advanced Colorectal Carcinoma[NCT00442637] | Phase 3 | 635 participants (Anticipated) | Interventional | 2007-01-31 | Active, not recruiting | ||
| Capecitabine Metronomic Chemotherapy Versus Conventional Chemotherapy as Maintenance Treatment in Metastatic Colorectal Cancer[NCT02893540] | Phase 2/Phase 3 | 250 participants (Anticipated) | Interventional | 2016-09-30 | Recruiting | ||
| Maintenance Treatment With Capecitabine Plus Cetuximab After First-line 5-Fluorouracil-based Chemotherapy Plus Cetuximab for Patients With RAS Wild-type Metastatic Colorectal Cancer: a Single Arm, Open-label, Multi-center Clinical Trial[NCT02717923] | Phase 2 | 50 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | ||
| Biological-guided Metronomic Chemotherapy as Maintenance Strategy in Responders After Induction Therapy in Metastatic Colorectal Cancer[NCT03158610] | Phase 2/Phase 3 | 20 participants (Actual) | Interventional | 2018-01-29 | Terminated (stopped due to Difficult to enrollment patient) | ||
| Apatinib Versus Bevacizumab in Combination With Second-line FOLFIRI in Patients With Metastatic Colorectal Cancer That Progressed During or After First-line Bevacizumab Plus an Oxaliplatin-based Regimen: A Randomised Phase 2 Trial[NCT03271255] | Phase 2 | 80 participants (Anticipated) | Interventional | 2018-05-23 | Recruiting | ||
| TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study.[NCT04392479] | Phase 3 | 202 participants (Anticipated) | Interventional | 2020-09-02 | Active, not recruiting | ||
| The Biomarkers Identification for Apatinib and Bevacizumab in the Second-line Therapy for Colorectal Cancer: A Randomised Controlled Trial[NCT03743428] | 40 participants (Anticipated) | Interventional | 2020-10-22 | Suspended (stopped due to Too slow speed for recruiting.) | |||
| Study Evaluating the Safety and Efficacy of FOLFOX Plus Apatinib or FOLFIRI Plus Apatinib as Second-line Therapy in Metastatic Colorectal Cancer[NCT03193814] | Phase 2 | 50 participants (Anticipated) | Interventional | 2019-12-01 | Not yet recruiting | ||
| Open-label, Efficacy and Safety Study of Bevacizumab (Avastin®) in Combination With XELOX (Oxaliplatin Plus Xeloda®) for the First-line Treatment of Patients With Metastatic Cancer of the Colon or Rectum - 'OBELIX'[NCT00577031] | Phase 4 | 205 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Phase II Study of Bevacizumab Plus Modified FOLFOX6 Regimen as the Salvage Treatment in Patients With Metastatic Breast Cancer[NCT01658033] | Phase 2 | 72 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| 5-Fluorouracil/Folinate/Oxaliplatin (Eloxatin) (FLOX Regimen), Given Continuously or Intermittently, in Combination With Cetuximab (Erbitux), in First-line Treatment of Metastatic Colorectal Cancer. A Phase III Multicenter Trial.[NCT00145314] | Phase 3 | 571 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| Randomized Three Arm Phase III Trial on Induction Treatment With a Fluoropyrimidine-, Oxaliplatin- and Bevacizumab-based Chemotherapy for 24 Weeks Followed by Maintenance Treatment With a Fluoropyrimidine and Bevacizumab vs. Bevacizumab Alone vs. no Maint[NCT00973609] | Phase 3 | 853 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| Randomized Phase II Study of Weekly ABI-007 Plus Gemcitabine or Simplified LV5FU2 as First-line Therapy in Patients With Metastatic Pancreatic Cancer[NCT01964534] | Phase 2 | 114 participants (Actual) | Interventional | 2013-12-12 | Active, not recruiting | ||
| Chemotherapy With FOLFIRI Plus Bevacizumab (AvastinR) in Patients With Metastatic Colorectal Cancer Bearing Genotype UGT1A1*1/UGT1A1*1 or UGT1A1*1/UGT1A1*1/UGT1A1*28: Prospective, Phase II, Multicenter Study[NCT00628810] | Phase 2 | 86 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer: a Phase I Study[NCT05277766] | Phase 1 | 45 participants (Anticipated) | Interventional | 2022-11-21 | Recruiting | ||
| Multicenter Phase I/IIa Study of NASOX (Nal-IRI + S-1 + Oxaliplatin) as First-line Treatment for Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma[NCT04662112] | Phase 1/Phase 2 | 40 participants (Actual) | Interventional | 2021-06-15 | Active, not recruiting | ||
| A Phase Ib/II Study of Ramucirumab (Cyramza®), Nal-IRI (ONIVYDE®) and Trifluridine/Tipiracil (Lonsurf®) in Second Line Metastatic Gastric Cancer (COOL Study).[NCT05927857] | Phase 1/Phase 2 | 45 participants (Anticipated) | Interventional | 2023-09-01 | Not yet recruiting | ||
| An Open-label, Randomized, Multicenter, Phase II Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers[NCT06135896] | Phase 2 | 98 participants (Anticipated) | Interventional | 2023-12-10 | Not yet recruiting | ||
| Randomized Phase II Trial of Fluorouracil and Folinic Acid With or Without Liposomal Irinotecan (ONIVYDE) for Patients With Metastatic Biliary Tract Cancer Which Progressed Following Gemcitabine Plus Cisplatin[NCT03524508] | Phase 2 | 178 participants (Actual) | Interventional | 2018-09-04 | Completed | ||
| Phase II Trial of TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma[NCT04923529] | Phase 2 | 28 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | ||
| Survival Rate and Treatment Cost in Patients With Pancreatic Cancer With the Advent of New Chemotherapeutic Agents in Korea: An Analysis Using NHIS Database and K-PaC Registry Focusing on the Newest One, Liposomal Irinotecan[NCT04984174] | 54,000 participants (Anticipated) | Observational | 2021-08-04 | Recruiting | |||
| Phase 2 Study to Improve Tolerance of Chemotherapy Involving Cetuximab and Multidrug FOLFIRI, With Pharmacokinetic and Pharmacogenetic Studies, in Patients With Metastatic Colorectal Cancer[NCT00559741] | Phase 2 | 80 participants (Anticipated) | Interventional | 2005-10-31 | Completed | ||
| A Randomised Study of TPF as Neoadjuvant Chemotherapy Followed by Concomitant Chemoradiotherapy (CRT) With Conventional Radiotherapy (RT) Versus Concomitant CRT With Accelerated RT in Patients With Locally Advanced Head and Neck Squamous Cell Cancer (HNSC[NCT00774319] | Phase 2 | 70 participants (Anticipated) | Interventional | 2008-12-31 | Recruiting | ||
| A Phase II Study of Efficacy and Safety of Induction Modified TPF (mTPF) Followed by Concurrent Chemoradiotherapy (CCRT) in Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LASCCHN)[NCT05527782] | Phase 2 | 40 participants (Anticipated) | Interventional | 2019-05-01 | Recruiting | ||
| Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) as First-line Treatment for Metastatic Colorectal Cancer[NCT01219920] | Phase 3 | 244 participants (Actual) | Interventional | 2001-11-30 | Completed | ||
| Randomised Comparative Study Of Folfox6m Plus Sir-Spheres® Microspheres Versus Folfox6m Alone As First Line Treatment In Patients With Nonresectable Liver Metastases From Primary Colorectal Carcinoma[NCT00724503] | 530 participants (Actual) | Interventional | 2006-08-31 | Completed | |||
| Assessment of Overall Survival of FOLFOX6m Plus SIR-Spheres Microspheres Versus FOLFOX6m Alone as First-line Treatment in Patients With Non-resectable Liver Metastases From Primary Colorectal Carcinoma in a Randomised Clinical Study[NCT01721954] | Phase 3 | 209 participants (Actual) | Interventional | 2013-05-01 | Completed | ||
| Randomized, Multinational, Study Of Aflibercept And Modified FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal Cancer[NCT00851084] | Phase 2 | 268 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| Essai De Phase III De Chimiotherapie Par FOLFOX 4 Ou Par Une Succession FOLFOX 7 - FOLFIRI Chez Des Patients Ayant Des Metastases Resecables D'Origine Colorectale - MIROX[NCT00268398] | Phase 3 | 284 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| The Molecular Mechanism of RAS Wild-type Metastatic Colorectal Cancer (mCRC) Resistance to Anti Epidermal Growth Factor Receptor (EGFR) Antibody[NCT04466267] | 40 participants (Actual) | Observational | 2017-03-01 | Completed | |||
| An Open-label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of 5 FU/FA and Oxaliplatin (Modified FOLFOX 6) in Combination With Ramucirumab or IMC-18F1 or Without Investigational Therapy as Second Line Therapy in Patients With M[NCT01111604] | Phase 2 | 158 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| Maintenance Treatment With S-1 Versus Observation After First-line Chemotherapy in Patients With Advanced Gastric Cancer: a Randomized Phase II Study[NCT03701373] | Phase 2 | 200 participants (Anticipated) | Interventional | 2016-01-01 | Recruiting | ||
| A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLF[NCT00911170] | Phase 3 | 847 participants (Actual) | Interventional | 2009-11-03 | Completed | ||
| Randomized, Double-Blind, Phase II Study of FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment for Patients With Metastatic Colorectal Cancer[NCT01418222] | Phase 2 | 194 participants (Actual) | Interventional | 2011-09-14 | Completed | ||
| A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer[NCT01399684] | Phase 2 | 127 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| An Adaptive, Randomized Phase II Trial to Determine Pathologic Complete Response With the Addition of Carboplatin With and Without Veliparib to Standard Chemotherapy in the Neoadjuvant Treatment of Triple-Negative Breast Cancer[NCT01818063] | Phase 2 | 9 participants (Actual) | Interventional | 2013-04-25 | Completed | ||
| A Multicenter, Randomised Phase II Trial on the Therapy of Advanced Gastric Cancer or Adenocarcinoma of the Esophagogastric Junction in Patients Older Than 65 Years With Specific Regard of Quality of Life and Pharmacogenetic Risk Profile[NCT00737373] | Phase 2 | 143 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| A Prospective Multicenter Study With 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) in Patients With Locally Advanced, Limited Metastatic or Extensive Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction[NCT00849615] | Phase 2 | 252 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| Pilot Phase II Study of Safety and Immunogenicity of an ALVAC-CEA/B7.1 Vaccine Administered With Chemotherapy, Alone or in Combination With Tetanus Toxoid, as Compared to Chemotherapy Alone, in Patients With Metastatic Colorectal Adenocarcinoma[NCT00027833] | Phase 2 | 0 participants | Interventional | 2001-12-31 | Active, not recruiting | ||
| A Phase III, Multicenter, Randomized, Active-Controlled Clinical Trial to Evaluate the Efficacy and Safety of rhuMAb VEGF (Bevacizumab) in Combination With Standard Chemotherapy in Subjects With Metastatic Colorectal Cancer[NCT00109070] | Phase 3 | 0 participants | Interventional | 2000-09-30 | Completed | ||
| A Phase II, Multicenter, Double-Blind, Randomized, Active-Controlled Clinical Trial to Evaluate the Efficacy and Safety of rhuMAb VEGF (Bevacizumab), a Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor, in Combination With 5-[NCT00109226] | Phase 2 | 0 participants | Interventional | 2000-08-31 | Completed | ||
| A Multicenter Randomized Trial, With Direct Individual Benefit, to Determine the Optimal Circadian Time of Vinorelbine Administration Combined With Chronomodulated Infusion of 5-Fluorouracil in Previously Treated Patients With Metastatic Breast Cancer[NCT00003730] | 80 participants (Anticipated) | Interventional | 1998-12-31 | Completed | |||
| A Study of ZD1839 (Iressa) in Combination With Oxaliplatin, 5-Fluorouracil (5-FU) and Leucovorin (LV) in Advanced Solid Malignancies (Phase I) and Advanced Colorectal Cancers (Phase II)[NCT00025142] | Phase 2 | 0 participants | Interventional | 2001-07-31 | Completed | ||
| Radioembolization With Yttrium-90 Microspheres for Intermediate or Advanced HCC (Hepatocellular Carcinoma) Not Eligible to Curative Approach. A Phase II-b Study.[NCT00910572] | Phase 2 | 60 participants (Anticipated) | Interventional | 2007-07-31 | Completed | ||
| Transarterial Radioembolization Versus Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma[NCT02729506] | Phase 4 | 150 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| Open, Randomized, Controlled, Multicenter Phase II Study Comparing 5-FU/FA Plus Oxaliplatin (FOLFOX-4) Plus Cetuximab Versus 5-FU/FA Plus Oxaliplatin (FOLFOX-4) as First-line Treatment for Epidermal Growth Factor Receptor-expressing Metastatic Colorectal [NCT00125034] | Phase 2 | 344 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| Cetuximab Added to Capecitabine, Oxaliplatin and Bevacizumab in Patients With Previously Untreated Advanced Colorectal Carcinoma, a Randomised Phase III Study[NCT00208546] | Phase 3 | 750 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Two Cycles Versus Four Cycles of Capecitabine Combined Oxaliplatin Concurrent Radiotherapy as First-line Therapy for Chinese Locally Advanced Esophageal Squamous Cell Carcinomas, an Open Randomised Phase III Cilinical Trial[NCT02604615] | Phase 3 | 60 participants (Anticipated) | Interventional | 2014-10-31 | Recruiting | ||
| A Phase II Study of Continuous 5-Fluorouracil (5-FU) in Recurrent Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urinary Tract[NCT00003175] | Phase 2 | 45 participants (Anticipated) | Interventional | 1997-12-31 | Completed | ||
| Role of Circulating Tumour DNA (ctDNA) Testing in Assessing for Alterations of Primary Anti-Epidermal Growth Factor Receptor (EGFR) Resistance in RAS/RAF Wild-type Metastatic Colorectal Cancer Patients[NCT05051592] | 40 participants (Anticipated) | Observational | 2021-03-26 | Recruiting | |||
| A Randomized Phase II Study to Evaluate the Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma[NCT02014831] | Phase 2 | 0 participants (Actual) | Interventional | 2016-02-29 | Withdrawn (stopped due to Industry decline to supply study drug) | ||
| Biomarker-Panel Enriched Maintenance Treatment With Cetuximab Monotherapy Versus Continuation After Induction Treatment With Chemotherapy + Cetuximab in Metastatic Colorectal Cancer (mCRC)[NCT02978313] | Phase 2/Phase 3 | 500 participants (Anticipated) | Interventional | 2016-11-30 | Not yet recruiting | ||
| Evaluation of Individual Peripheral Blood Circulating Tumor Cells Combined With Tumor Marker Detection of Efficacy of Chemotherapy in Patients With Advanced Colorectal Cancer: A Observational Clinical Trial[NCT02948985] | 100 participants (Anticipated) | Observational [Patient Registry] | 2017-01-31 | Not yet recruiting | |||
| Open, Randomized, Controlled, Multicenter Phase III Study Comparing 5FU/ FA Plus Irinotecan Plus Cetuximab Versus 5FU/FA Plus Irinotecan as First-line Treatment for Epidermal Growth Factor Receptor-expressing Metastatic Colorectal Cancer[NCT00154102] | Phase 3 | 1,221 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| Exploration of New Biologic Factors' Predictive Value , Especially Circulating VE-cadherin in Metastatic Colorectal Adenocarcinoma Patients Treated With Bevacizumab[NCT01405430] | 63 participants (Actual) | Interventional | 2010-05-31 | Completed | |||
| A Randomized, Placebo-controlled, Double-blind Multicenter Phase II Study to Investigate the Protectivity and Efficacy of Metformin Against Steatosis in Combination With FOLFIRI and Cetuximab in Subjects With First-line Palliative Treated, KRAS-Wild-Type,[NCT01523639] | Phase 2 | 8 participants (Actual) | Interventional | 2012-04-30 | Terminated (stopped due to Prematurely due to slow recruitment (07/08/2013). Newly defined study end=LPLV=05/11/2013. ABCSG guaranteed completed treatment period for ethical reasons.) | ||
| Patient Recorded Indexing Measurements[NCT05899205] | 300 participants (Anticipated) | Observational | 2021-06-01 | Recruiting | |||
| A Phase II Double Blind Randomized Trial Comparing Standard Dosing Based on Body Surface Area Versus Dosing Based on Personalized Lean Body Mass in Patients With Stage IIIB or IV Non-Small Cell Lung Cancer Receiving First Line Cisplatin Based Chemotherapy[NCT01624051] | Phase 2 | 144 participants (Anticipated) | Interventional | 2014-07-31 | Recruiting | ||
| A Randomized Trial of Adjuvant Chemotherapy With Standard Regimens, Cyclophosphamide, Methotrexate and Fluorouracil - (CMF) or Doxorubicin and Cyclophosphamide - (AC), Versus Capecitabine in Women 65 Years and Older With Node Positive or Node-Negative Bre[NCT00024102] | Phase 3 | 633 participants (Actual) | Interventional | 2001-09-30 | Completed | ||
| Phase 2 Study of Neoadjuvant 5-FU + Leucovorin + CPT-11 in Patients With Resectable Liver Metastases From Colorectal Adenocarcinoma[NCT00168155] | Phase 2 | 70 participants | Interventional | 2002-01-31 | Completed | ||
| Randomized, Placebo Controlled, Phase II Trial, on the Effect of an Oral Supplement,TK3 (Tryptophan and Thiamine) on the Quality of Life and Chemotherapy Tolerance in Cancer Patients With Advanced Disease.[NCT03341286] | Phase 2 | 140 participants (Anticipated) | Interventional | 2017-11-30 | Not yet recruiting | ||
| Maintenance Treatment With Capecitabine Versus Observation After First Line Chemotherapy in Patients With Metastatic Colorectal Cancer: a Randomized Phase II Study[NCT02027363] | Phase 2 | 245 participants (Anticipated) | Interventional | 2010-01-31 | Active, not recruiting | ||
| Phase II Trial Of Docetaxel With Capecitabine And Bevacizumab As First-Line Chemotherapy For Patients With Metastatic Breast Cancer[NCT00088998] | Phase 2 | 46 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| Efficacy and Tolerance of RADIOEMBOLIZATION for Patients With Unresectable Intrahepatic Cholangiocarcinoma With Tumor Progression After First-line Therapy[NCT01383746] | Phase 1/Phase 2 | 5 participants (Actual) | Interventional | 2011-10-31 | Terminated (stopped due to Not enough inclusion) | ||
| Multicenter Phase II Study of Apatinib in Patients With HER-2 Negative Advanced Breast Cancer With Chest Wall Metastasis[NCT02878057] | Phase 2 | 30 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
| A Randomized Controlled Trial of Interferon-alpha, Interleukin-2 and 5-Fluorouracil vs. Interferon-alpha Alone in Patients With Advanced Renal Cell Carcinoma[NCT00053820] | Phase 3 | 670 participants (Anticipated) | Interventional | 2002-07-31 | Completed | ||
| Phase II Study of Thalidomide in Combination With Capecitabine in Patients With Metastatic Breast Cancer[NCT00193102] | Phase 2 | 40 participants (Anticipated) | Interventional | 2001-04-30 | Terminated | ||
| Oxaliplatin, Irinotecan, and Capecitabine as a Combination Regimen for First-Line Treatment of Advanced or Metastatic Colorectal Cancer[NCT00217711] | Phase 1/Phase 2 | 23 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| Randomized Phase 3 Study of Xelox(Capecitabine Plus Oxaliplatin) Followed by Maintenance Capecitabine or Observation in Patients With Advanced Gastric Adenocarcinoma[NCT02289547] | Phase 3 | 184 participants (Anticipated) | Interventional | 2015-05-31 | Recruiting | ||
| A Phase Ⅱ Study on Low-expression and High-expression of ERCC1 in Recurrent or Metastastic Esophageal Cancer Patients Treated With Biweekly Paclitaxel and Cisplatin[NCT01444547] | Phase 2 | 92 participants (Anticipated) | Interventional | 2007-01-31 | Recruiting | ||
| Phase 2 Study of Temozolomide Plus Capecitabine in Patients With Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors[NCT03079440] | Phase 2 | 31 participants (Actual) | Interventional | 2017-05-15 | Completed | ||
| Randomized Phase III Study Post Radical Resection of Liver Metastasis of Colorectal Cancer: Bevacizumab in Combination With XELOX as Adjuvant Chemotherapy vs XELOX Alone[NCT00394992] | Phase 3 | 79 participants (Actual) | Interventional | 2006-12-31 | Terminated (stopped due to Data from the C08 study and Avant study) | ||
| Polymorphism Interaction to Predict Bevacizumab Efficacy in Advanced Breast Cancer Patients: an Exploratory Retrospective Analysis[NCT01935102] | 169 participants (Actual) | Observational | 2012-12-31 | Completed | |||
| Phase II Study of Oxaliplatin, Capecitabine, Cetuximab, and Bevacizumab in the Treatment of Metastatic Colorectal Cancer[NCT00290615] | Phase 2 | 30 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| Treatment With the Combination of Epirubicin and Paclitaxel Alone or Together With Capecitabine as First Line Treatment in Metastatic Breast Cancer. A Multicenter, Randomized Phase III Study[NCT01433614] | Phase 3 | 304 participants (Actual) | Interventional | 2002-12-31 | Completed | ||
| Phase III Multicenter Study of the Effects on Quality of Life of Three-weekly Versus Weekly First-line Chemotherapy for Metastatic or Locally Advanced Breast Cancer[NCT00540800] | Phase 3 | 139 participants (Actual) | Interventional | 2004-02-29 | Completed | ||
| Phase II Study With Lead-in Safety Cohort of Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases[NCT01934894] | Phase 2 | 11 participants (Actual) | Interventional | 2014-05-31 | Terminated (stopped due to Study was terminated due to lack of significant signal of efficacy) | ||
| Phase II Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma Patients[NCT01182142] | Phase 2 | 51 participants (Anticipated) | Interventional | 2007-09-30 | Completed | ||
| Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320] | Phase 2 | 200 participants (Actual) | Interventional | 2015-10-05 | Active, not recruiting | ||
| A Randomized, Double-blind, Placebo-controlled, Phase III Study of Oxaliplatin/5-fluorouracil/Leucovorin With PTK787/ZK 222584 or Placebo in Patients With Previously Treated Metastatic Adenocarcinoma of the Colon or Rectum[NCT00056446] | Phase 3 | 855 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| A Randomized, Double-blind, Placebo-controlled, Phase Lll Study in Patients With Metastatic Adenocarcinoma of the Colon or Rectum Who Are Receiving First-line Chemotherapy With Oxaliplatin/5-fluorouracil/Leucovorin With PTK787/ZK 222584 or Placebo[NCT00056459] | Phase 3 | 1,168 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| Randomized Phase 2 Study Comparing Pathological Responses on Colorectal Cancer Metastases After Preoperative Treatment Combining Bevacizumab With FOLFOX or FOLFIRI[NCT01858649] | Phase 2 | 60 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| Randomised Phase 2 Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors[NCT01858662] | Phase 2 | 4 participants (Actual) | Interventional | 2014-01-31 | Terminated (stopped due to due to poor recrutment) | ||
| Liquid Biopsy and Pancreas Cancer: Detection of AXL(+) Functional CTCs Using EPIDROP[NCT05346536] | 63 participants (Anticipated) | Interventional | 2022-06-16 | Recruiting | |||
| A Phase II Trial of Gemcitabine (NSC-613327) and Capecitabine (NSC-712807) in Patients With Unresectable or Metastatic Gallbladder or Cholangiocarcinoma[NCT00033540] | Phase 2 | 57 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
| Pre- and Postoperative Incidence and Prognostic Implication of Positive Peritoneal Lavage and Circulating Tumor DNA in Patients With Pancreatic Cancer[NCT05400681] | 200 participants (Anticipated) | Observational [Patient Registry] | 2020-08-01 | Recruiting | |||
| Therapeutic Efficacy and Safety of Concurrent FOLFIRINOX Plus HIFU for Locally Advanced/Borderline Resectable Pancreatic Cancer: A Prospective Single-center, Single-arm, Investigator-initiated, Open-labeled, Exploratory Clinical Trial[NCT05262452] | 60 participants (Anticipated) | Interventional | 2021-08-09 | Recruiting | |||
| Randomized Phase II/III Trial Comparing Folririnox Association [Oxaliplatin / Irinotecan / LV5FU2] Versus Gemcitabine in First Line of Chemotherapy in Metastatics Pancreas Cancers Patients[NCT00112658] | Phase 2/Phase 3 | 342 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| Evaluation of the Effect of Ocoxin-Viusid® Nutritional Supplement in the Life Quality in Patients Diagnosed With Advanced Pancreatic Adenocarcinoma. Phase II[NCT03717298] | Phase 2 | 30 participants (Actual) | Interventional | 2018-10-30 | Completed | ||
| 1911GCCC:Two Parallel, Single-arm, Open Label, Phase 2 Trials of Galeterone Alone or Galeterone Combined With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Standard Chemotherapy[NCT04098081] | Phase 2 | 58 participants (Anticipated) | Interventional | 2019-12-12 | Recruiting | ||
| Roux-en-Y Gastric Bypass Versus Loop Gastrojejunostomy for Malignant Gastric Outlet Obstruction[NCT05986890] | 16 participants (Anticipated) | Interventional | 2023-08-17 | Recruiting | |||
| Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis[NCT02869802] | 190 participants (Anticipated) | Observational | 2016-10-06 | Recruiting | |||
| Phase 2 Study of Neoadjuvant Modified FOLFIRINOX in Patients With Borderline Resectable Pancreas Adenocarcinoma[NCT02749136] | Phase 2 | 44 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
| Phase I Study of Low Kilovoltage Intraoperative Radiation for Patients With Resectable Pancreatic Adenocarcinoma[NCT02599662] | Phase 1 | 12 participants (Anticipated) | Interventional | 2015-01-31 | Recruiting | ||
| Pharmacotyping of Patient-derived Pancreatic Cancer Organoids From Endoscopic Ultrasound-guided Biopsy as a Tool for Predicting Oncological Response[NCT05196334] | 88 participants (Actual) | Observational | 2021-07-01 | Active, not recruiting | |||
| Postoperative and Long-term Survival in Relation to Life-expectancy After Pancreatic Surgery in Elderly Patients[NCT04893408] | 1,556 participants (Actual) | Observational | 2010-01-01 | Completed | |||
| Sintilimab Plus Chemotherapy and Radiotherapy for Patients With Inoperable Pancreatic Cancer: a Single-arm, Exploratory, Phase II Trial[NCT06050317] | Phase 2 | 25 participants (Anticipated) | Interventional | 2023-08-18 | Recruiting | ||
| A Phase III, Open Label, Multicentre Randomised Clinical Study Comparing Acelarin (NUC-1031) With Gemcitabine in Patients With Metastatic Pancreatic Carcinoma[NCT03610100] | Phase 2/Phase 3 | 328 participants (Anticipated) | Interventional | 2015-12-31 | Suspended (stopped due to Suspended to recruitment following TSC review on efficacy and toxicities) | ||
| An Open Single-center Phase II Clinical Study of Fruquintinib Combined With Chemotherapy in Patients With Liver Metastases From Pancreatic Cancer[NCT05168527] | Phase 2 | 30 participants (Anticipated) | Interventional | 2021-09-03 | Recruiting | ||
| Phase II Trial of Infusional 5 FLUOROURACIL, LEUCOVORIN, OXALIPLATIN AND IRINOTECAN (FOLFIRINOX) in First Line Treatment of Advanced Biliary Tract Cancers[NCT03291899] | Phase 2 | 32 participants (Anticipated) | Interventional | 2017-01-03 | Recruiting | ||
| Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer: The SMART Study[NCT04276857] | 27 participants (Anticipated) | Interventional | 2024-01-01 | Not yet recruiting | |||
| Phase II Study of Neoadjuvant Folfirinox Chemotherapy Followed by Pembrolizumab Followed by Surgery for Patients With Localized, Resectable Adenocarcinoma of the Pancreas[NCT05132504] | Phase 2 | 30 participants (Anticipated) | Interventional | 2022-08-31 | Recruiting | ||
| A Multicenter, Open-label, ExploRatory Platform Trial to EValuate ImmunOtherapy Combinations With Chemotherapy for the Treatment of Patients With PreviousLy UnTreated MetastatIc Pancreatic AdenOcarciNoma (REVOLUTION)[NCT04787991] | Phase 1 | 45 participants (Anticipated) | Interventional | 2021-08-09 | Active, not recruiting | ||
| A Phase II Trial of Flouro-Gem as a First Line Treatment of Metastatic Adenocarcinoma of the Pancreas (GEFLUPAN)[NCT04769414] | Phase 2 | 48 participants (Actual) | Interventional | 2021-02-20 | Completed | ||
| A Phase II Study of Induction Consolidation and Maintenance Approach for Patients With Advanced Pancreatic Cancer[NCT01488552] | Phase 1/Phase 2 | 60 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| An Open-label, Multi-center, Phase 1b Study to Investigate the Safety and Tolerability of SLC-0111 (WBI-5111) in Combination With Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma Subjects Positive for Carbonic Anhydrase IX[NCT03450018] | Phase 1/Phase 2 | 30 participants (Anticipated) | Interventional | 2019-01-10 | Recruiting | ||
| Clinical Efficacy of QingyiHuaji Optimized Formula Combined With Standard Chemotherapy in the Treatment of Advanced Pancreatic Cancer: a Prospective, Multicenter, Randomized Controlled Clinical Study[NCT05840341] | Phase 3 | 306 participants (Anticipated) | Interventional | 2023-05-01 | Recruiting | ||
| An Open-label, Single-centre, Single-arm Phase II Study of Capecitabine Combined With Oxaliplatin and Irinotecan (Xeloxiri) as First-line Treatment in Patients With Advanced Unresectable Pancreatic Adenocarcinoma[NCT01558869] | Phase 2 | 37 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| Randomized Phase II Trial Evaluating the Efficacy of a Sequential Treatment Gemcitabine Plus Nab-paclitaxel (Gembrax) Followed by Folfirinox Versus Folfirinox Alone in Patients Treated in First Metastatic Line Pancreatic Cancer[NCT05065801] | Phase 2 | 162 participants (Anticipated) | Interventional | 2022-01-30 | Recruiting | ||
| Phase II Study to Assess the Interest of a Sequential Treatment With Gemcitabine/Nab-paclitaxel (GEMBRAX) and Then FOLFIRINOX Followed by Stereotactic Magnetic Resonance-guided Adaptive Radiotherapy in Patients With Locally Advanced Pancreatic Cancer[NCT04570943] | Phase 2 | 103 participants (Anticipated) | Interventional | 2020-12-15 | Recruiting | ||
| A Phase III Randomized Study Evaluating Gemcitabine and Paclitaxel Versus Gemcitabine Alone After FOLFIRINOX Failure or Intolerance in Metastatic Pancreatic Ductal Adenocarcinoma[NCT03943667] | Phase 3 | 211 participants (Actual) | Interventional | 2019-05-23 | Completed | ||
| A Study of Preoperative FOLFIRINOX For Potentially Curable Pancreatic Cancer[NCT03167112] | Phase 2 | 20 participants (Anticipated) | Interventional | 2017-07-03 | Recruiting | ||
| PAXG Out in the Country[NCT04480268] | Phase 4 | 175 participants (Anticipated) | Interventional | 2020-07-08 | Recruiting | ||
| Phase II Randomized Study of First-Line Therapy Comprising Bevacizumab and Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil (FOLFIRI) Versus Bevacizumab and Irinotecan Hydrochloride and Capecitabine (XELIRI) in Patients With Unresectable Met[NCT00423696] | Phase 2 | 145 participants (Actual) | Interventional | 2006-03-23 | Completed | ||
| Study of First-Line Therapy Comprising Leucovorin Calcium, Fluorouracil, and Irinotecan (FOLFIRI) in Patients With Progressive Locally Advanced or Metastatic Duodenal-Pancreatic Endocrine Tumors[NCT00416767] | Phase 2 | 20 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| First Line Infusional 5-Fluorouracil, Folinic Acid and Oxaliplatin for Metastatic Colorectal Cancer or Loco-Regional Recurrency - Role of Chronomodulated Delivery Upon Survival - A Multicenter Randomized Phase III Trial[NCT00003287] | Phase 3 | 554 participants (Anticipated) | Interventional | 1998-03-31 | Completed | ||
| Phase II Study of an All-Oral Combination of Capecitabine (X) and Cyclophosphamide (C) in Patients With Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer[NCT00589901] | Phase 2 | 60 participants (Anticipated) | Interventional | 2006-08-31 | Recruiting | ||
| A Phase II Study of Weekly Paclitaxel and Capecitabine in Patients With Metastatic or Recurrent Esophageal Cancer[NCT00453323] | Phase 2 | 33 participants (Actual) | Interventional | 2006-06-30 | Active, not recruiting | ||
| A Multi-center, II Phase，Randomized Controlled Clinical Study of Capecitabine Metronomic Chemotherapy After Gemcitabine Plus Capecitabine Standard Adjuvant Therapy for Stage II/III Pancreatic Cancer[NCT03959150] | Phase 2/Phase 3 | 231 participants (Anticipated) | Interventional | 2020-01-05 | Recruiting | ||
| A Randomized Placebo-Controlled Study of Perifosine in Combination With Single Agent Chemotherapy for Metastatic Cancer Patients[NCT00398879] | Phase 2 | 381 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| A Phase III, Randomized, Open-label, Multicenter Study Comparing GW572016 and Capecitabine (XELODA) Versus Capecitabine in Women With Refractory Advanced or Metastatic Breast Cancer[NCT00078572] | Phase 3 | 408 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| A Phase 2, Open-label, Randomized Clinical Trial of Skin Toxicity Treatment in Subjects Receiving Second-line FOLFIRI or Irinotecan Only Chemotherapy Concomitantly With Panitumumab[NCT00332163] | Phase 2 | 95 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma: a Multicenter, Randomised, Phase 3 Study.[NCT02460419] | Phase 3 | 104 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| Intravital Microscopy (IVM) in Human Solid Tumors[NCT03823144] | 50 participants (Anticipated) | Interventional | 2019-02-28 | Recruiting | |||
| BEV-IP: Perioperative Chemotherapy With Bevacizumab in Patients Undergoing Cytoreduction and Intraperitoneal Chemoperfusion for Colorectal Carcinomatosis[NCT02399410] | Phase 2 | 60 participants (Actual) | Interventional | 2015-12-31 | Active, not recruiting | ||
| Intravital Microscopy (IVM) in Patients With Peritoneal Carcinomatosis (PC)[NCT03517852] | 30 participants (Actual) | Interventional | 2018-08-15 | Active, not recruiting | |||
| Circulating Tumor DNA (ctDNA) as a Assisted Diagnosis, Early Intervention and Prognostic Marker for Peritoneal Metastases From Colorectal Cancer: A Prospective, Open-label, Randomized Controlled Study[NCT04752930] | 138 participants (Anticipated) | Interventional | 2020-08-24 | Recruiting | |||
| A Randomized Phase III Trial of Three Different Regimens of CPT-11 Plus 5-Fluorouracil and Leucovorin Compared to 5-Fluorouracil and Leucovorin in Patients With Advanced Adenocarcinoma of the Colon and Rectum[NCT00003594] | Phase 3 | 1,691 participants (Actual) | Interventional | 1998-10-31 | Completed | ||
| A Phase II, Randomised Controlled Trial to Evaluate the Efficacy and Safety of Moisturising Creams With or Without Palm-oil-derived Vitamin E Concentrate in Addition to Urea-based Cream or Urea-based Cream Alone in Capecitabine-associated Palmar-Plantar E[NCT05939726] | 90 participants (Anticipated) | Interventional | 2023-05-16 | Recruiting | |||
| A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study of Enzastaurin With 5-FU/LV Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colorectal Cancer[NCT00612586] | Phase 2 | 117 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Randomized, Multicenter, Phase III Study, to Evaluate the Efficacy and Safety of Bevacizumab Alone or Combined With Capecitabine and Oxaliplatin as Support Therapy After Initial Chemotherapy Treatment With Capecitabine, Oxaliplatin and Bevacizumab in Meta[NCT00335595] | Phase 3 | 480 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| A Randomized Phase III Study of Irinotecan Plus 5-fluorouracil Plus Leucovorin and Bevacizumab (FOLFIRI+Avastin) Versus Irinotecan Plus Capecitabine and Bevacizumab (XELIRI+Avastin) as 1st Line Treatment of Locally Advanced or Metastatic Colorectal Cancer[NCT00469443] | Phase 3 | 330 participants (Anticipated) | Interventional | 2006-12-31 | Completed | ||
| A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer[NCT00483834] | Phase 2 | 50 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| Phase II Study of Capecitabine in Combination With Vinorelbine and Trastuzumab for the First- or Second-LineTreatment of HER2+ Metastatic Breast Cancer[NCT00093808] | Phase 2 | 47 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| A Single Arm Open-label, Phase II Study of Bevacizumab in Combination With Trastuzumab and Capecitabine as First-line Treatment of Patients With HER2-positive Locally Recurrent or Metastatic Breast Cancer[NCT00811135] | Phase 2 | 88 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| A Phase II Study Of Sunitinib In Combination With Irinotecan, L-leucovorin, And 5-Fluorouracil In Patients With Unresectable Or Metastatic Colorectal Cancer[NCT00668863] | Phase 2 | 71 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| Phase II Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients With Advanced Colorectal Cancer[NCT00159432] | Phase 2 | 63 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| A Phase II Clinical Trial of the Safety and Efficacy of Fruquintinib in Advanced Pancreatic Cancer Patients Who Failed Second-line Gemcitabine or 5-FU Based Chemotherapy[NCT05257122] | Phase 2 | 32 participants (Anticipated) | Interventional | 2022-02-28 | Not yet recruiting | ||
| Metastatic Breast Cancer in Brazil: Characterization of Patients and Treatments[NCT02662868] | 767 participants (Actual) | Observational | 2015-06-30 | Completed | |||
| A Prospective, Randomized, Multicenter, Open-label Comparison of Pre-surgical Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy Given for Twelve Weeks With a Quality of Life Assessment of Trastuzumab, Pertu[NCT03272477] | Phase 2 | 257 participants (Actual) | Interventional | 2017-10-05 | Active, not recruiting | ||
| A Randomized, Multicenter, Phase III Open-label Study of the Efficacy and Safety of Trastuzumab MCC-DM1 vs. Capecitabine + Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab-Based Ther[NCT00829166] | Phase 3 | 991 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| Trastuzumab Emtansine (T-DM1) Treatment in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy: a Multicenter, Single-arm, Phase II Study[NCT06125834] | Phase 2 | 36 participants (Anticipated) | Interventional | 2023-06-01 | Recruiting | ||
| Modified Folinic Acid-Fluorouracil-Oxaliplatin (FOLFOX) Followed by Capecitabine as First-line Chemotherapy for Elderly or Frail Patients With Metastatic or Recurrent Gastric Cancer[NCT02002195] | 47 participants (Anticipated) | Observational | 2013-11-30 | Recruiting | |||
| A Phase III Randomized Study of 5-Fluorouracil, Mitomycin-C, and Radiotherapy Versus 5-Fluorouracil, Cisplatin, and Radiotherapy in Carcinoma of the Anal Canal[NCT00003596] | Phase 3 | 682 participants (Actual) | Interventional | 1998-10-31 | Completed | ||
| A Dose-escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Aflibercept in Combination With Intravenous Irinotecan/5-fluorouracil/Isovorin (FOLFIRI) Administered Every 2 Weeks in Patients With Metastatic Colorectal Cancer[NCT00921661] | Phase 1 | 16 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| A Randomized Phase III 2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab for the First-line Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Locally Recurrent or Metastatic Breast Cancer[NCT00600340] | Phase 3 | 564 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Stereotactic Body Radiotherapy (SBRT) for the Treatment of OligoMetastasis in Breast Cancer Patients (STOMP): A Prospective Feasibility Trial[NCT03295916] | Early Phase 1 | 30 participants (Anticipated) | Interventional | 2018-01-01 | Recruiting | ||
| A Multicenter, Randomised, Double-Blind, Phase 3 Study Of Sunitinib In Metastatic Colorectal Cancer Patients Receiving Irinotecan, 5-Fluorouracil And Leucovorin (FOLFIRI) As First Line Treatment[NCT00457691] | Phase 3 | 768 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| A Randomized Phase II Study of Capecitabine and Cisplatin (XP) +/- Sorafenib (Nexavar®) in Patients With Advanced Gastric Cancer[NCT01187212] | Phase 2 | 195 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| A Phase II Trial of Eloxatin in Combination With 5-Fluorouracil and Leucovorin in Patients With Advanced Colorectal Carcinoma[NCT00004102] | Phase 2 | 0 participants | Interventional | 1999-01-31 | Completed | ||
| A Pilot Study of Additional Chinese Formula for Concurrent Chemoradiotherapy in Oral Cavity Cancer Patients[NCT05590650] | Phase 1 | 21 participants (Actual) | Interventional | 2018-07-07 | Completed | ||
| Phase I Study of Cabazitaxel - Platinum Fluorouracil Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck[NCT01379339] | Phase 1 | 40 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| Primary Surgery Vs Primary Chemoradiation for Oropharyngeal Cancer (Scope Trial) - A Phase II/III Integrated Design Randomized Control Trial[NCT05144100] | Phase 2/Phase 3 | 498 participants (Anticipated) | Interventional | 2021-12-01 | Not yet recruiting | ||
| PHASE III TRIAL TO PRESERVE THE LARYNX: INDUCTION CHEMOTHERAPY AND RADIATION THERAPY VERSUS CONCOMITANT CHEMOTHERAPY AND RADIATION THERAPY VERSUS RADIATION THERAPY[NCT00002496] | Phase 3 | 0 participants | Interventional | 1992-08-31 | Completed | ||
| Multicenter Phase II Trial of Oxaliplatin and Docetaxel for Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck[NCT00557206] | Phase 2 | 35 participants (Actual) | Interventional | 2005-04-30 | Terminated (stopped due to Funding was terminated) | ||
| Efficacy and Safety of Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinoma[NCT04059562] | Phase 2 | 28 participants (Anticipated) | Interventional | 2021-10-28 | Active, not recruiting | ||
| Phase 1 Study of Postoperative Capecitabine With Concurrent Radiation in Elderly With Stage II/III Rectal Cancer[NCT01268943] | Phase 1 | 18 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| Low-dose Versus Standard-dose Capecitabine Adjuvant Chemotherapy for Chinese Elderly Patients With Stage II/III Colorectal Cancer: A Randomized, Phase 3 Non-inferiority Study[NCT02316535] | Phase 3 | 710 participants (Anticipated) | Interventional | 2014-11-30 | Recruiting | ||
| Prospective Randomized Phase III Study of Concurrent Capecitabine and Radiotherapy With or Without Oxaliplatin as Adjuvant Treatment for Stage II and III Rectal Cancer[NCT00714077] | 570 participants (Anticipated) | Observational | 2008-04-30 | Recruiting | |||
| A Pilot Study Using Neoadjuvant Proton Beam Radiation Therapy and Chemotherapy for Marginally Resectable Carcinoma of the Pancreas[NCT00763516] | 8 participants (Actual) | Interventional | 2009-02-28 | Completed | |||
| Clinical Trial of Neoadjuvant Chemotherapy With S1 Plus Paclitaxel-albumin in Patients With Unresectable Locally Advanced Pancreatic Cancer[NCT03585062] | Phase 2 | 40 participants (Actual) | Interventional | 2017-11-20 | Terminated (stopped due to The paclitaxel-albumin halt production.) | ||
| Master Protocol for Metastatic Hormone-Resistant Prostatic Carcinoma - Phase II Trials - Protocol 5: Capecitabine[NCT00006023] | Phase 2 | 0 participants | Interventional | 2000-03-31 | Completed | ||
| Phase II Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian and Primary Peritoneal Carcinoma[NCT00868192] | Phase 2 | 38 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer Who Have Failed First-Line Therapy[NCT02045030] | Phase 2 | 14 participants (Actual) | Interventional | 2014-01-31 | Terminated (stopped due to Drug (Aflibercept) no longuer available for the study) | ||
| Medical and Economical Evaluation of Contrast-enhanced Ultrasound Imaging for the Early Estimate of Bevacizumab Effect on Colorectal Cancer Liver Metastases[NCT00489697] | 200 participants (Anticipated) | Interventional | 2007-01-31 | Completed | |||
| The Effects of Exercise Training on Tumor Vascularity and Response to Neoadjuvant Therapy in Operable Breast Cancer: A Phase I-II Study[NCT00405678] | Phase 1/Phase 2 | 23 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| Phase I Study Evaluating the Safety of Bevacizumab in Women With a History of Breast Cancer Suffering From Moderate to Severe Upper Extremity Lymphedema[NCT00318513] | Phase 1 | 35 participants | Interventional | Not yet recruiting | |||
| Effect of Short-duration Preoperative Neoadjuvant Therapy With FOLFOX Based Therapy on Morbidity After Liver Resection for Colorectal Cancer Metastases[NCT00537823] | Phase 2 | 9 participants (Actual) | Interventional | 2007-06-30 | Terminated (stopped due to Poor accrual.) | ||
| Angiogenesis Inhibitors and Hypertension: Clinical Aspects[NCT00511511] | 80 participants (Anticipated) | Observational | 2007-08-31 | Completed | |||
| MicroOrganoSphere Drug Screen to Lead Care (MODEL) Precision Oncology Pilot Trial in Colorectal Cancer (CRC)[NCT05189171] | 180 participants (Anticipated) | Observational | 2022-10-25 | Recruiting | |||
| A Pilot Study to Evaluate the Effects of Antiangiogenic Factor as an Adjunct Treatment After Photoangiolysis in Patients With Bilateral Recurrent Respiratory Papillomatosis of the Vocal Fold[NCT01020747] | Phase 1 | 20 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| A Phase II Safety and Tolerability Study of Avastin When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain[NCT00476827] | Phase 2 | 16 participants (Actual) | Interventional | 2007-05-31 | Terminated (stopped due to Slow accrual) | ||
| A Phase II Study to Assess Efficacy and Safety of Capecitabine and Irinotecan Plus Bevacizumab Followed by Capecitabine and Oxaliplatin Plus Bevacizumab or the Reverse Sequence in Patients With Metastatic Colorectal Cancer[NCT02119026] | Phase 2 | 120 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
| A Prospective, Phase II Trial of Intravenous Bevacizumab (Avastin) for the Prevention of Recurrent Malignant Ascites[NCT00908219] | Phase 2 | 0 participants (Actual) | Interventional | 2009-07-31 | Withdrawn (stopped due to Accrual closed by sponsor due to lack of accrual and study progress) | ||
| A Phase ll Study of Oxaliplatin, Capecitabine, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas[NCT00447330] | Phase 2 | 60 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| Preoperative Induction Chemotherapy in Combination With Bevacizumab Followed by Combined Chemoradiotherapy in Locally Advanced Rectal Cancer With High Risk of Recurrence- Phase II Pilot Study With Preoperative Administration of Capecitabine (Xeloda), Oxal[NCT01434147] | Phase 2 | 25 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II Study[NCT00462423] | Phase 2 | 50 participants (Actual) | Interventional | 2007-04-30 | Completed | ||
| Acute Kidney Injury in Cancer Patients Receiving Anti-Vascular Endothelial Growth Factor Monoclonal Antibody vs Immune Checkpoint Inhibitors: a Retrospective Real-world Study[NCT06119347] | 1,581 participants (Actual) | Observational | 2020-01-01 | Completed | |||
| A Phase II Randomised Controlled Study Assessing the Role of Dose Escalation Using [18F] FMISO PET CT in Head and Neck Cancer: The DE-HyART (Dose Escalation Using Hypoxia-adjusted Radiotherapy) Protocol[NCT06087614] | Phase 2 | 124 participants (Anticipated) | Interventional | 2023-10-31 | Recruiting | ||
| Phase I/II of Capecitabine and Vinorelbine in Elderly Patients (At Least 65 Years) With Metastatic Breast Cancer With or Without Bone Involvement[NCT00003902] | Phase 1/Phase 2 | 110 participants (Anticipated) | Interventional | 1999-03-31 | Completed | ||
| A Randomized Phase III Study to Investigate the Efficacy and Safety of Docetaxel + Capecitabine vs. Vinorelbine + Capecitabine Followed by Capecitabine Alone as 1st Therapy on Locally Advanced and Metastatic Breast Cancer Patients.[NCT01126138] | Phase 3 | 200 participants (Anticipated) | Interventional | 2010-07-31 | Recruiting | ||
| An Open Label, randomIzed Controlled Prospective Multicenter Two Arm Phase IV Trial to Determine Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab for Advanced (Inoperable or Metastatic) HER2-[NCT02248571] | Phase 4 | 85 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
| Multicentre Randomized Phase II Study of Neoadjuvant Trastuzumab Plus Docetaxel With and Without Bevacizumab and Trastuzumab Plus Docetaxel Plus Non-pegylated Liposome-encapsulated Doxorubicin (NPLD) With and Without Bevacizumab in HER2-positive Early Bre[NCT01367028] | Phase 2 | 100 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| A Phase II Single Arm Trial Evaluating the Efficacy and Safety of Eribulin in Combination With Bevacizumab for 2-Line Treatment of HER 2-Negative Metastatic Breast Cancer Progressing After 1-Line Therapy With Bevacizumab and Paclitaxel[NCT02175446] | Phase 2 | 61 participants (Anticipated) | Interventional | 2014-09-30 | Recruiting | ||
| Genetic Variants and the Efficacy or Severe Adverse Reactions of CPT-11 Based Regimens in mCRC[NCT01282658] | 200 participants (Anticipated) | Observational | 2010-11-30 | Recruiting | |||
| A Phase II Study of Oral Xeloda (Capecitabine) in Combination With Intravenous Irinotecan for Patients With Locally Advanced and/or Metastatic Colorectal Cancer[NCT00022698] | Phase 2 | 67 participants (Actual) | Interventional | 2001-05-31 | Completed | ||
| Phase III Trial of S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for First Line Treatment of Advanced Gastric Cancer[NCT01671449] | Phase 3 | 338 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| A Phase II Study of OSI-774 (Tarceva) in Combination With Oxaliplatin and Capecitabine in Previously Treated Patients With Stage IV Colorectal Cancer[NCT00123851] | Phase 2 | 32 participants | Interventional | 2003-03-31 | Completed | ||
| Phase II Trial of Fluorouracil (5-FU), Leucovorin (LV), Irinotecan (CPT-11) and Bevacizumab (Anti-VEGF) in Previously Untreated Patients With Advanced Colorectal Cancer[NCT00006786] | Phase 2 | 0 participants | Interventional | 2000-11-30 | Completed | ||
| A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma[NCT00042965] | Phase 2 | 60 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| A Phase I Study Of ZD1839 (Iressa) In Combination With Irinotecan, Leucovorin, And 5-Fluorouracil In Previously Untreated, Stage IV Colorectal Cancer[NCT00026364] | Phase 1 | 22 participants (Actual) | Interventional | 2001-11-30 | Completed | ||
| Ph 2 Trial of G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan & Oxaliplatin), Followed by G-FLIP-DM (G-FLIP + Low Doses Docetaxel & MitomycinC), When Used in Combination With Vitamin C, in Patients With Advanced Pancreatic Cancer[NCT01905150] | Phase 2 | 34 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| Phase I Study of Irinotecan Followed by Capecitabine in Patients With Advanced Breast Carcinoma[NCT00083148] | Phase 1 | 12 participants (Actual) | Interventional | 2002-11-30 | Completed | ||
| A Phase II Study Assessing Efficacy and Safety of TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated Metastatic Colorectal Cancer[NCT03517618] | Phase 2 | 41 participants (Actual) | Interventional | 2014-07-05 | Completed | ||
| mFOLFOXIRI Compared to mFOLFOX6 or CapeOx as Adjuvant Chemotherapy for Stage IIIB or Stage IIIC Colorectal Cancer: A Randomized Controlled Clinical Research[NCT05200299] | Phase 2 | 100 participants (Anticipated) | Interventional | 2022-02-01 | Recruiting | ||
| Phase II Trial of FOLFOXIRI Plus Panitumumab as First-Line Treatment for Kras and Braf Wild-Type Metastatic Colorectal Cancer[NCT01358812] | Phase 2 | 37 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| A Phase I-II Trial of Dovitinib Plus Docetaxel as Second-line Chemotherapy in Patients With Metastatic or Unresectable Gastric Cancer After Failure of First-line Chemotherapy[NCT01921673] | Phase 1/Phase 2 | 14 participants (Actual) | Interventional | 2013-08-31 | Completed | ||
| A Clinical Trial of the Safety and Efficacy of ABX-EGF in Combination With Irinotecan, Leucovorin, and 5-Fluorouracil in Subjects With Metastatic Colorectal Cancer[NCT00111761] | Phase 2 | 43 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| Phase II Study of Novel Epothilone (BMS-247550) in Patients With MBC Who Are Refractory to an Anthracycline, a Taxane, and Capecitabine[NCT00080262] | Phase 2 | 125 participants | Interventional | 2004-02-29 | Completed | ||
| Randomized Phase II Study Evaluating Three Chemotherapies: [Irinotecan + Oxaliplatin (Irinox)], [Irinotecan + LV5FU2] and [Oxaliplatin + LV5FU2] as First Intention Treatment in Subjects With Metastatic Colorectal Cancer[NCT00066274] | Phase 2 | 0 participants | Interventional | 2002-07-23 | Completed | ||
| A Phase III Trial of Novel Epothilone BMS-247550 Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Previously Treated With or Resistant to an Anthracycline and Who Are Taxane Resistant[NCT00080301] | Phase 3 | 752 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
| A RANDOMIZED, MULTI-CENTRE PHASE III TRIAL TO EVALUATE THE ROLE OF INTENSIFIED THERAPY WITH AUTOLOGOUS TRANSPLANTATION OF HEMATOPOIETIC STEM CELLS IN ADVANCED OR METASTATIC BREAST CANCER RESPONDING TO INDUCTION CHEMOTHERAPY[NCT00002870] | Phase 3 | 180 participants (Anticipated) | Interventional | 1994-12-31 | Completed | ||
| Vitro 3D Drug Sensitivity Detection of Micro Tumor (PTC) Combined With Tumor Whole Exon (WES) Sequencing Technology to Guide Postoperative Adjuvant Treatment Strategy and Prognosis of Colorectal Cancer[NCT05424692] | 200 participants (Anticipated) | Interventional | 2021-09-01 | Recruiting | |||
| Genistein Combined With FOLFOX or FOLFOX-Avastin for Treatment of Metastatic Colorectal Cancer: Phase I/II Pilot Study[NCT01985763] | Phase 1/Phase 2 | 13 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| FOcUs on Colorectal CAncer oUtcomes: Long-Term Study[NCT03965325] | 300 participants (Anticipated) | Observational | 2019-06-07 | Recruiting | |||
| [NCT02748772] | Phase 3 | 148 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| A Phase II, Multicenter, Open-Label Clinical Trial to Evaluate the Efficacy and Safety of OSI-774 in Patients With Advanced or Metastatic Breast Cancer and Disease Progression During or Following Chemotherapy[NCT00109265] | Phase 2 | 0 participants | Interventional | 2001-05-31 | Completed | ||
| An Open, Single-centre Non-randomized Phase II Clinical Trial on Intra-arterial Chemotherapy With Melphalan for the Treatment of Retinoblastoma (RTB) in Advanced Intraocular Stage[NCT01393769] | Phase 2 | 5 participants (Actual) | Interventional | 2009-11-30 | Terminated (stopped due to Only 5 subjects could be enrolled. Sample of 25 pat. not be achieved (rare disease).) | ||
| Evaluation of Dose-response, Pharmacodynamic and Pharmacokinetic Bioequivalence of Filgrastim in Healthy Male Volunteers After Single and Multiple-dose Subcutaneous Administration of the BK0023 Injectable Formulation vs. Neupogen®[NCT01933971] | Phase 1 | 102 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| A Pilot Trial of AC (Adriamycin, Cyclophosphamide) Chemotherapy With G-CSF (Granulocyte Colony-Stimulating Factor) Followed by Infusional Taxol (Paclitaxel) as Adjuvant Treatment for High Risk Stage II and Stage III Breast Cancer Patients[NCT00001384] | Phase 2 | 35 participants | Interventional | 1994-05-31 | Completed | ||
| A Phase II Study of Trastuzumab in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer[NCT01396707] | Phase 2 | 55 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| Phase II Trial of Neoadjuvant Chemotherapy for HPV-Associated Squamous Cell Carcinoma of the Oropharynx Followed by Reduced Dose Radiotherapy/Chemoradiotherapy for Responders or Standard Dose Chemoradiotherapy for Non-Responders[NCT01525927] | Phase 2 | 2 participants (Actual) | Interventional | 2010-08-31 | Terminated (stopped due to Principal Investigator left institution. IRB approval lapsed.) | ||
| A Randomised Phase-III Study Comparing Cytoreductive Surgery Plus Intraperitoneal Chemotherapy Versus Modern Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis.[NCT01524094] | Phase 3 | 49 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| A Phase I, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors[NCT02454062] | Phase 1 | 120 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
| A Prospective Clinical Trial of Improving the Treatment of Thoracic Esophageal Cancer[NCT01137123] | Phase 3 | 301 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| Impacts of Oral Supplement With L-Glutamine on the Radiation-induced Toxicity and Nutritional Status of Head and Neck Cancer Patients Under Radiotherapy[NCT03015077] | 59 participants (Actual) | Interventional | 2014-07-31 | Completed | |||
| The Effect of Prophylactic Swallowing Exercises on Head and Neck Cancer Patients[NCT01349309] | 26 participants (Actual) | Interventional | 2007-06-30 | Completed | |||
| Multiple Centre, Randomised, Controlled Trial of Hyperfractionated IMRT and Conventional Fraction IMRT for Patients With Loco-regionally Recurrent Nasopharyngeal Carcinoma.[NCT02456506] | 142 participants (Anticipated) | Interventional | 2015-06-30 | Active, not recruiting | |||
| An Open-label Randomized Clinical Trial to Compare the Toxicities and Efficacy of Pharmacokinetically-guided and BSA Fixed Dosing Strategy of Docetaxel and Paclitaxel in Chinese Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma, and Breast Cancer Patie[NCT01891123] | 300 participants (Anticipated) | Interventional | 2013-06-30 | Recruiting | |||
| Dose Escalation of Xeloda or 5FU Continuous Infusion in Combination With Taxotere and Concurrent Once Weekly, Hypofractionated Chest Radiotherapy for Advanced Non Small Cell Lung Cancer: A Phase I/II Study[NCT00256841] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2005-09-30 | Withdrawn (stopped due to Lack of funding) | ||
| A Prospective, Randomized, Open, Multi-center Phase III Clinical Study Comparing Efficacy and Safety of Sequential T-FEC and TX-XEC as Post-operative Adjuvant Chemotherapy Options for the Treatment of Triple-negative Breast Cancer[NCT01642771] | Phase 3 | 636 participants (Anticipated) | Interventional | 2012-06-30 | Active, not recruiting | ||
| Phase I Trial of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine[NCT00359606] | Phase 1 | 58 participants (Actual) | Interventional | 1999-04-30 | Completed | ||
| Phase 0 Trial of [F-18]-5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine[NCT01479348] | Early Phase 1 | 5 participants (Actual) | Interventional | 2011-11-01 | Terminated (stopped due to Slow, insufficient accrual.) | ||
| Evaluate Effectiveness and Security of Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen After 2nd-line or Over 2nd-line Therapy With Capecitabine Combine Regimen in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer[NCT03204734] | Phase 2 | 132 participants (Anticipated) | Interventional | 2016-01-01 | Recruiting | ||
| KCSP Trial of cONsolidation Chemotherapy for Locally Advanced Mid or Low Rectal Cancer After neoadjUvant Concurrent chemoraDiothErapy: A Multicenter, Randomized Controlled Trial (KONCLUDE Trial)[NCT02843191] | Phase 3 | 358 participants (Anticipated) | Interventional | 2016-12-31 | Recruiting | ||
| Combined Treatment of Adenoid Cystic Carcinoma With Cetuximab and IMRT Plus C12 Heavy Ion Boost - ACCEPT - (ACC, Erbitux, and Particle Therapy); Phase I/II Feasibility Study[NCT01192087] | Phase 1/Phase 2 | 49 participants (Anticipated) | Interventional | 2012-06-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
OS was defined as the time from the day of randomization (Day 0) until death by all causes. (NCT02337946)
Timeframe: Up to approximately 31 months
| Intervention | months (Median) |
|---|---|
| Group A | NA |
| Group B | NA |
Safety population was defined as all participants who received at least one dose of protocol treatment after randomization. (NCT02337946)
Timeframe: Up to 28 days after discontinuation of study drug or start of subsequent therapy (data cut off: 31 August 2017; Overall study completion date)
| Intervention | percentage of participants (Number) |
|---|---|
| Group A | 100 |
| Group B | 100 |
"Peripheral neuropathy was defined as events classified with a preferred term (PT) of peripheral neuropathy according to Standardized MedDRA Queries." (NCT02337946)
Timeframe: Up to 28 days after discontinuation of study drug or start of subsequent therapy (data cut off: 31 August 2017; Overall study completion date)
| Intervention | percentage of participants (Number) |
|---|---|
| Group A | 30.4 |
| Group B | 3.7 |
The PFS is the period from the date of randomization (Day 0) until the date of judgment of progression from the date of randomization, or until death by all causes, whichever comes first. The presence/absence of progressive disease (PD) was determined based on imaging, consideration of clinical PD, or survival research results. PD based on response evaluation criteria in solid tumors (RECIST) is at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (NCT02337946)
Timeframe: Up to approximately 31 months
| Intervention | months (Median) |
|---|---|
| Group A | 9.1 |
| Group B | 9.3 |
PFS rate was defined as the gross percentage of participants who survived with no evidence of progression from the day of randomization (Day 0) until 9 months after Day 0. The presence/absence of progressive disease (PD) was determined based on imaging, consideration of clinical PD, or survival research results. PD based on response evaluation criteria in solid tumors (RECIST) is at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (NCT02337946)
Timeframe: Up to 9 months after randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Group A | 46.4 |
| Group B | 47.4 |
RR was defined as the percentage of participants who had shown complete response (CR) or partial response (PR) as the best overall response in accordance with the RECIST 1.1 criteria after randomization. The best overall response was CR, followed by PR, stable disease (SD), progressive disease (PD), and not evaluable (NE). CR: disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to <10 mm. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters as the best overall response after randomization., SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). (NCT02337946)
Timeframe: Up to approximately 31 months
| Intervention | percentage of participants (Number) |
|---|---|
| Group A | 80.4 |
| Group B | 87.7 |
TTF was defined as the time from the day of randomization (Day 0) until the day of protocol treatment discontinuation determination, the day of PD decision during protocol treatment, or death from any cause, whichever came the earliest. (NCT02337946)
Timeframe: Up to approximately 31 months
| Intervention | months (Median) |
|---|---|
| Group A | 8.1 |
| Group B | 6.1 |
An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure. Grade refers to the severity of the AE. The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL). Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL. Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE. (NCT02337946)
Timeframe: Up to 28 days after discontinuation of study drug or start of subsequent therapy (data cut off: 31 August 2017; Overall study completion date)
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3, 4 and 5 | |
| Group A | 0 | 19.6 | 80.4 |
| Group B | 0 | 27.8 | 72.2 |
"Skin toxicity was defined as events classified with an system organ class of Skin and subcutaneous tissue disorders or a preferred term of paronychia." (NCT02337946)
Timeframe: Up to 28 days after discontinuation of study drug or start of subsequent therapy (data cut off: 31 August 2017; Overall study completion date)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Skin and subcutaneous tissue disorders | Paronychia | |
| Group A | 17.9 | 7.1 |
| Group B | 18.5 | 9.3 |
The EORTC QLQ-C30 (v. 3.0) is a self-administered, cancer-specific questionnaire with multidimensional scales assessing 15 domains (5 functional domains, 9 symptoms, and global health status). A linear transformation was applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For the functional domains and global health status scale, higher scores represent a better level of functioning. For symptom scales, higher scores represent a greater degree of symptoms. Maximum improvement is the best post-baseline change. (NCT01183780)
Timeframe: Baseline Up to 171 Weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Ramucirumab + FOLFIRI | 4.0 |
| Placebo + FOLFIRI | 6.6 |
The EQ-5D is a generic, multidimensional, health status instrument. The profile allows participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and mood using a 3-level scale (no problem, some problems, and major problems). These combinations of attributes were converted into a weighted health-state Index Score according to the United Kingdom (UK) population-based algorithm. The possible values for the Index Score ranged from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension). A negative change indicated a worsening of the participant's health status. (NCT01183780)
Timeframe: Baseline and 30-Day Follow-Up (FU) up to 171 Weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Ramucirumab + FOLFIRI | -0.097 |
| Placebo + FOLFIRI | -0.103 |
OS was defined as the time in months from the date of randomization to the date of death from any cause. For participants not known to have died as of the cut-off date, OS was censored at the last known date alive. (NCT01183780)
Timeframe: Randomization to Date of Death from Any Cause Up to 39.36 Months
| Intervention | months (Median) |
|---|---|
| Ramucirumab + FOLFIRI | 13.3 |
| Placebo + FOLFIRI | 11.7 |
The objective response rate is equal to the proportion of participants achieving a best overall response of partial response or complete response (PR + CR). Response was defined using RECIST, v. 1.1 criteria. CR was defined as the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm and normalization of tumor marker level of non-target lesions; PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions taking as reference the baseline sum diameter. (NCT01183780)
Timeframe: Randomization until Disease Progression Up to 38.01 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Ramucirumab + FOLFIRI | 13.4 |
| Placebo + FOLFIRI | 12.5 |
PFS was defined as the time from the date of randomization until the date of objectively determined progressive disease (PD) [according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v). 1.1] or death due to any cause, whichever was first. PD is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). Participants who died without a reported prior progression were considered to have progressed on the day of their death. Participants who did not progress or were lost to follow-up were censored at the day of their last radiographic tumor assessment. (NCT01183780)
Timeframe: Randomization to Measured PD or Date of Death from Any Cause Up to 38.01 Months
| Intervention | months (Median) |
|---|---|
| Ramucirumab + FOLFIRI | 5.7 |
| Placebo + FOLFIRI | 4.5 |
(NCT01183780)
Timeframe: Preinfusion and 1 hour postinfusion in Cycles 3, 5, 9, 13, and 17
| Intervention | micrograms/milliliter (ug/mL) (Geometric Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Cmin Dose 3 (n=248) | Cmin Dose 5 (n=154) | Cmin Dose 9 (n=27) | Cmin Dose 13 (n=11) | Cmin Dose 17 (n=5) | Cmax Dose 3 (n=88) | Cmax Dose 5 (n=51) | Cmax Dose 9 (n=18) | Cmax Dose 13 (n=12) | Cmax Dose 17 (n=7) | |
| Ramucirumab + FOLFIRI | 46.3 | 65.1 | 77.9 | 75.9 | 72.0 | 221.0 | 243.0 | 262.0 | 307.0 | 253.0 |
Blood samples were tested to determine if a participant reacted to ramucirumab by producing anti-ramucirumab antibodies. Samples were identified as treatment emergent anti-drug antibody (TE ADA) if the post-treatment sample had an increase of at least 4 fold in titer from pre-treatment values. If the pre-treatment value was not detected or was not present, a 1:20 post-treatment titer was required to indicate treatment emergence. The percentage of participants with TE ADA was calculated as: (the number of participants with TE ADA / total number of participants with at least 1 post-treatment immunogenicity sample analyzed)*100. (NCT01183780)
Timeframe: Cycles 1, 3, 5, and 30-Day FU
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Immunogenicity Any Time During Study (n=516, 512) | Immunogenicity Post-Treatment (n=477, 473) | |
| Placebo + FOLFIRI | 5.5 | 3.8 |
| Ramucirumab + FOLFIRI | 5.6 | 3.1 |
The objective response rate was a secondary efficacy endpoint of the study and was defined by the percentage of patients in the study population with a best overall response of Complete Response (CR) or Partial Response (PR) as assessed by the investigator. Best overall response was defined per RECIST (version 1.1) recorded from randomization until progression or end of study. RECIST (v 1.1) criteria does not require confirmation of response, but an additional, more stringent analysis was also conducted, with designation of CR (or PR) requiring confirmation of response at least 4 weeks following the initial assessment of CR (or PR). Stable disease (SD) required an assessment of SD at least 6 weeks after starting treatment. Subjects with insufficient data for response classification were classified as Not Evaluable for best overall response, and as a non-responder for objective response, in the ITT population. Treatment groups are as indicated for the primary outcome of OS. (NCT01494506)
Timeframe: Assessment every 6 weeks after initial response; Day 1 to data cut off of 14 Feb 2014; maximum time on study 25 months.
| Intervention | percentage with confirmed response (Number) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 3.31 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 0.67 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 7.69 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 0.84 |
"Overall survival was the primary efficacy endpoint of the study and was defined as the time from the date of patient randomization to the date of death or the date the patient was last known to be alive. OS was summarized by Kaplan-Meier methodology for each treatment group. Pairwise treatment group comparisons were carried out using unstratified log rank analyses on the ITT population. Hazard ratio estimates are from Cox regression analysis.~The comparison of Arm C is based only on patients who were randomized under the 3-arm version of the protocol. Consequently, the 5-FU+Leucovorin (Combo Therapy Comparison) group is a subset of all patients randomized to 5-FU+Leucovorin, which is the Mono Therapy Comparison control and contains patients randomized under both the 2-arm and 3-arm versions of the protocol." (NCT01494506)
Timeframe: From randomization to death; until the data cut off 14 Feb 2014. The maximum time in follow up was 25 months.
| Intervention | months (Median) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 4.9 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 4.2 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 6.1 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 4.2 |
"Composite measure based on patient-reported pain (per VAS), patient-reported pain medication, KPS, and weight. Clinical benefit is indicated by either:~(a) improvement in pain (less pain intensity with stable or decreased pain medication; or less pain medication with stable or decreased pain intensity) with stable or improved KPS; or (b) improvement in KPS with stable or improved pain.~With stable for KPS and pain, clinical benefit may be indicated with an observation of positive weight change.~Clinical benefit response (CBR) was classified weekly and a patient was considered a clinical benefit responder if clinical benefit was observed and maintained over a 4 week period." (NCT01494506)
Timeframe: Randomization to treatment discontinuation.The maximum time in follow up was 25 months
| Intervention | percentage of participants with CBR (Number) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 14 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 13 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 14 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 12 |
Tumor marker response (TMR) was evaluated by the change in CA19-9 serum levels. Response was defined as a decrease of 50% of CA19-9 in relation to the baseline level at least once during the treatment period. (NCT01494506)
Timeframe: Baseline to treatment discontinuation every 6 weeks; The maximum time in follow up was 25 months
| Intervention | percent of participants with TMR (Number) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 23.6 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 11.4 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 28.9 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 8.6 |
"Progression-free survival was defined as the time from the date of randomization to the date of disease progression, or death (any cause) on or prior to the clinical cutoff date, whichever occurred earlier. Participants who did not have disease progression or had not died were censored at the date of the last tumor assessment. Patients with two or more consecutive missing response assessments prior to a visit with documented progression (or death) were censored at the last date of tumor assessment when the patient was documented to be progression free. PFS was summarized using Kaplan-Meier methods.~The comparison of Arm C is based only on patients who were randomized under the 3-arm version of the protocol. Consequently, the 5-FU+Leucovorin (Combo Therapy Comparison) group is a subset of all patients randomized to 5-FU+Leucovorin, which is the Mono Therapy Comparison control and contains patients randomized under both the 2-arm and 3-arm versions of the protocol." (NCT01494506)
Timeframe: Randomization until disease progression or death from any cause; Until the data cut off of 14 Feb 2014. The maximum time in follow up was 25 months.
| Intervention | months (Median) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 2.7 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 1.6 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 3.1 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 1.5 |
Time from randomization to discontinuation of treatment for any reason, including disease progression, treatment toxicity or death. (NCT01494506)
Timeframe: Randomization to treatment discontinuation (any cause). The maximum time in follow up was 25 months
| Intervention | months (Median) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 1.7 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 1.4 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 2.3 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 1.4 |
This patient recorded outcome consists of 15 subscales in 3 independent domains: global health-related quality of life (HRQoL), functional scales (cognitive, emotional, physical, role and social functioning), and symptom scales (appetite loss, constipation, diarrhea, dyspnea, fatigue, insomnia, nausea and vomiting, and pain). For each subscale, patients were classified as improved, worsened or stable. Improvement is indicated by achievement of subscale score at least 10% improved from baseline and maintained for at least 6 weeks. Worsened is indicated by subscale score at least 10% worse than baseline. Stable is indicated by neither improvement nor worsened. Achievement of improvement prior to worsening was classified as improvement. (NCT01494506)
Timeframe: Baseline to treatment discontinuation every 6 weeks; The maximum time in follow up was 25 months
| Intervention | percent of patients in category (Number) | ||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Global Health Status: Improved | Global Health Status: Stable | Global Health Status: Worsened | Physical Functioning: Improved | Physical Functioning: Stable | Physical Functioning: Worsened | Role Functioning: Improved | Role Functioning: Stable | Role Functioning: Worsened | Emotional Functioning:Improved | Emotional Functioning:Stable | Emotional Functioning:Worsened | Cognitive Functioning:Improved | Cognitive Functioning:Stable | Cognitive Functioning:Worsened | Social Functioning:Improved | Social Functioning:Stable | Social Functioning:Worsened | Fatigue:Improved | Fatigue:Stable | Fatigue:Worsened | Nausea and Vomiting:Improved | Nausea and Vomiting:Stable | Nausea and Vomiting:Worsened | Pain:Improved | Pain:Stable | Pain:Worsened | Dyspnoea:Improved | Dyspnoea:Stable | Dyspnoea:Worsoned | Insomnia:Improved | Insomnia:Stable | Insomnia:Worsened | Appetite Loss:Improved | Appetite Loss:Stable | Appetite Loss:Worsened | Constipation:Improved | Constipation:Stable | Constipation:Worsened | Diarrhoea:Improved | Diarrhoea: Stable | Diarrhoea: Worsened | Financial Difficulties: Improved | Financial Difficulties: Stable | Financial Difficulties: Worsened | |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 11 | 41 | 48 | 11 | 37 | 52 | 10 | 39 | 52 | 8 | 59 | 33 | 6 | 42 | 52 | 11 | 43 | 46 | 11 | 30 | 59 | 6 | 42 | 52 | 10 | 37 | 53 | 6 | 69 | 24 | 4 | 49 | 47 | 6 | 42 | 52 | 4 | 63 | 34 | 4 | 58 | 39 | 1 | 67 | 31 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 12 | 44 | 44 | 11 | 40 | 49 | 11 | 37 | 53 | 9 | 58 | 33 | 7 | 44 | 49 | 11 | 47 | 42 | 12 | 33 | 54 | 4 | 46 | 51 | 11 | 40 | 49 | 5 | 68 | 25 | 5 | 49 | 46 | 5 | 46 | 49 | 4 | 67 | 30 | 4 | 58 | 39 | 0 | 74 | 26 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 17 | 38 | 45 | 10 | 41 | 49 | 15 | 32 | 52 | 20 | 46 | 34 | 11 | 48 | 41 | 13 | 34 | 54 | 14 | 20 | 66 | 13 | 32 | 55 | 27 | 34 | 39 | 7 | 51 | 42 | 18 | 34 | 48 | 11 | 45 | 44 | 13 | 56 | 31 | 6 | 39 | 55 | 8 | 51 | 41 |
| MM-398 Arm A (Mono Therapy Comparison) | 10 | 31 | 57 | 10 | 29 | 61 | 6 | 29 | 66 | 10 | 32 | 56 | 12 | 32 | 54 | 11 | 26 | 62 | 13 | 18 | 69 | 5 | 37 | 58 | 20 | 30 | 50 | 10 | 47 | 44 | 9 | 43 | 48 | 9 | 38 | 53 | 13 | 47 | 39 | 4 | 35 | 59 | 6 | 51 | 42 |
Plasma concentration-time data for MM-398 will be analyzed using population pharmacokinetic methods. (NCT01494506)
Timeframe: 6 weeks after first study drug administration
| Intervention | Total irinotecan = ug/L; SN38= ug/L (Geometric Mean) | |||
|---|---|---|---|---|
| Total Irinotecan-Cavg | Total Irinotecan-Cmax | Total SN38-Cavg | Total SN38-Cmax | |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 2120.00 | 28460.00 | 0.68 | 2.58 |
| MM-398 Arm A (Mono Therapy Comparison) | 2550.00 | 40550.00 | 0.82 | 3.93 |
"Calculated only for those participants with an objective response as the time from the first objective response (subsequently confirmed within no less than 4 weeks) to first observed disease progression per modified-RECIST criteria. Participants not meeting these criteria by the analysis data cutoff date were censored at their last evaluable disease assessment date.~Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions." (NCT00339183)
Timeframe: From randomization until the data cut-off date of 30 April 2009. Maximum follow-up time was 33 months
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS - Panitumumab Plus FOLFIRI | 7.6 |
| Wild-type KRAS - FOLFIRI Alone | 6.6 |
| Mutant KRAS - Panitumumab Plus FOLFIRI | 6.0 |
| Mutant KRAS - FOLFIRI Alone | 7.4 |
Overall survival was defined as the time from randomization to the date of death. Participants who had not died by the analysis data cutoff date had their time of death censored at their last contact date. (NCT00339183)
Timeframe: From randomization until the data cut-off date of 30 April 2009. Maximum follow-up time was 33 months
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS - Panitumumab Plus FOLFIRI | 14.5 |
| Wild-type KRAS - FOLFIRI Alone | 12.5 |
| Mutant KRAS - Panitumumab Plus FOLFIRI | 11.8 |
| Mutant KRAS - FOLFIRI Alone | 11.1 |
Participants were evaluated for tumor response per the modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria every 8 weeks until disease progression. Objective response was defined as the incidence of either a confirmed complete or partial response (CR or PR) while on study, as determined by blinded independent central review and confirmed no less than 4-weeks after the criteria for response are first met. CR: Disappearance of all target and non-target lesions and no new lesions. PR: At least a 30% decrease in the sum of the longest diameter of target lesions and no progression of non-target or no new lesions, or, disappearance of all target lesions and the persistence of ≥ 1 non-target lesion not qualifying for either CR or progressive disease. Participants without a post-baseline assessment were considered non-responders. (NCT00339183)
Timeframe: Every 8 weeks until disease progression up to the data cut-off date of 30 April 2009. Maximum time on follow-up was 33 months.
| Intervention | percentage of participants (Number) |
|---|---|
| Wild-type KRAS - Panitumumab Plus FOLFIRI | 35.35 |
| Wild-type KRAS - FOLFIRI Alone | 9.82 |
| Mutant KRAS - Panitumumab Plus FOLFIRI | 13.36 |
| Mutant KRAS - FOLFIRI Alone | 13.92 |
"Progression-free survival was defined as the time from randomization to first disease progression per modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria or death, based on independent central radiological assessment. Participants who were alive but did not meet criteria for progression by the data cutoff date were censored at their last evaluable disease assessment date.~Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions." (NCT00339183)
Timeframe: From randomization until the data cut-off date of 8 April 2008. Maximum follow-up time was 17 months.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS - Panitumumab Plus FOLFIRI | 5.9 |
| Wild-type KRAS - FOLFIRI Alone | 3.9 |
| Mutant KRAS - Panitumumab Plus FOLFIRI | 5.0 |
| Mutant KRAS - FOLFIRI Alone | 4.9 |
"Time to progression was defined as the time from the randomization date to the date of first observed disease progression per the modified RECIST criteria. Participants not meeting these criteria by the analysis data cutoff date were censored at their last evaluable disease assessment date.~Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions." (NCT00339183)
Timeframe: From randomization until the data cut-off date of 30 April 2009. Maximum follow-up time was 33 months
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS - Panitumumab Plus FOLFIRI | 7.3 |
| Wild-type KRAS - FOLFIRI Alone | 5.3 |
| Mutant KRAS - Panitumumab Plus FOLFIRI | 5.5 |
| Mutant KRAS - FOLFIRI Alone | 5.5 |
"A serious adverse event (SAE) is defined by regulatory authorities as one that • is fatal • is life threatening (places the subject at immediate risk of death) • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • is a congenital anomaly/birth defect • other significant medical hazard. The relationship of the adverse event to the study treatment was assessed by the Investigator by means of the question: Is there a reasonable possibility that the event may have been caused by the study treatment?" (NCT00339183)
Timeframe: From randomization until the data cut-off date of 30 April 2009. Maximum follow-up time was 33 months.
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Any adverse event | Serious adverse event | Leading to discontinuation of any study drug | Treatment-related adverse event (TRAE) | Serious treatment-related adverse event | TRAE leading to discontinuation of any study drug | |
| FOLFIRI Alone | 573 | 175 | 64 | 542 | 90 | 34 |
| Panitumumab Plus FOLFIRI | 584 | 232 | 123 | 577 | 124 | 97 |
NLR was calculated from the laboratory values as the ratio of Neutrophils to Lymphocytes. Longitudinal NLR was assessed by treating the NLR measurements taken over the time-course of treatment as a time-dependent covariate. OS was defined as the time from the start of initial treatment to the date of death, regardless of the cause of death. The association between longitudinal NLR (longitudinal NLR ≤5 vs NLR >5) and OS was reported as hazard ratio. (NCT01588990)
Timeframe: Baseline up to death or end of study (up to 4 years)
| Intervention | hazard ratio (Number) |
|---|---|
| Bevacizumab: Phase A and Phase B | 2.2 |
NLR was calculated from the laboratory values as the ratio of Neutrophils to Lymphocytes. Longitudinal NLR was assessed by treating the NLR measurements taken over the time-course of treatment as a time-dependent covariate. PFS was defined as time from the start of initial treatment to documentation of first disease progression or death from any cause, whichever occurred first. Disease progression was determined according to standard practice based on radiological, biochemical (CEA) or clinical factors. Determination of disease progression was to be unequivocal and was defined as: an unequivocal and clinically meaningful increase in size of known tumors, appearance of one or more new lesions, death due to disease without prior objective documentation of progression, elevated CEA accompanied by other radiological or clinical evidence of progression, or symptomatic deterioration. The association between longitudinal NLR (longitudinal NLR ≤5 vs N>5) and PFS was reported as hazard ratio. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)
| Intervention | hazard ratio (Number) |
|---|---|
| Bevacizumab: Phase A and Phase B | 1.3 |
NLR was calculated from the laboratory values as the ratio of Neutrophils to Lymphocytes. PFS was defined as the time from the start of initial treatment to documentation of first disease progression or death from any cause, whichever occurred first. Disease progression was determined according to standard practice based on radiological, biochemical (carcinoembryonic antigen [CEA]) or clinical factors. Determination of disease progression was to be unequivocal and was defined as any of the following: an unequivocal and clinically meaningful increase in the size of known tumors, the appearance of one or more new lesions, death due to disease without prior objective documentation of progression, elevated CEA accompanied by other radiological or clinical evidence of progression, or symptomatic deterioration. The association between NLR (NLR less than or equal to [≤] 5 vs greater than [>] 5) and PFS was reported as hazard ratio. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)
| Intervention | hazard ratio (Number) |
|---|---|
| Bevacizumab: Phase A and Phase B | 1.4 |
NLR was calculated from the laboratory values as the ratio of Neutrophils to Lymphocytes. OS was defined as the time from the start of initial treatment to the date of death, regardless of the cause of death. The association between NLR (NLR ≤ 5 vs > 5) and OS was reported as hazard ratio. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)
| Intervention | hazard ratio (Number) |
|---|---|
| Bevacizumab: Phase A and Phase B | 1.6 |
NLR was calculated from laboratory values as ratio of Neutrophils to Lymphocytes. NLR normalization was assessed by adding first post-baseline measurement of NLR to the primary model. This is equivalent to testing whether first change in NLR is significantly associated with outcome. PFS was defined as time from start of initial treatment to documentation of first disease progression or death from any cause. Disease progression was determined according to standard practice based on radiological, biochemical (CEA) or clinical factors. Determination of disease progression was defined as: an unequivocal and clinically meaningful increase in size of known tumors, appearance of ≥1 new lesions, death due to disease without prior objective documentation of progression, elevated CEA accompanied by other radiological or clinical evidence of progression, or symptomatic deterioration.The association between NLR normalization (first NLR post-baseline ≤5 vs >5) and PFS was reported as hazard ratio. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)
| Intervention | hazard ratio (Number) |
|---|---|
| Bevacizumab: Phase A and Phase B | 0.9 |
DDC was defined as PFS + PFS-B. In cases where a participant did not enter Phase B, then DDC was defined as PFS. PFS was defined as time from start of initial treatment to documentation of first disease progression or death from any cause, whichever occurred first. PFS-B was time from start of Phase B treatment to documentation of second disease progression or death from any cause, whichever occurred first. Disease progression was determined according to standard practice based on radiological, biochemical (CEA) or clinical factors. Determination of disease progression was to be unequivocal and was defined as any of the following: an unequivocal and clinically meaningful increase in the size of known tumors, appearance of one or more new lesions, death due to disease without prior objective documentation of progression, elevated CEA accompanied by other radiological or clinical evidence of progression, or symptomatic deterioration. Kaplan-Meier methodology was used to estimate DDC. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)
| Intervention | months (Median) |
|---|---|
| Bevacizumab: Phase A and Phase B | 14.0 |
Overall Survival in Phase B was defined as the time from the start of treatment in Phase B to death due to any cause. Kaplan-Meier methodology was used to estimate OS. (NCT01588990)
Timeframe: From the start of Phase B treatment death or end of study (up to 4 years)
| Intervention | months (Median) |
|---|---|
| Bevacizumab: Phase B | 14.9 |
OS was defined as the time from the start of initial treatment to the date of death, regardless of the cause of death. Kaplan-Meier methodology was used to estimate OS. (NCT01588990)
Timeframe: Baseline until death or end of study (up to 4 years)
| Intervention | months (Median) |
|---|---|
| Bevacizumab: Phase A and Phase B | 25.0 |
The results include percentage of participants who underwent potentially curative liver resection. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)
| Intervention | percentage of participants (Number) |
|---|---|
| Bevacizumab: Phase A and Phase B | 1.6 |
PFS until first progression was defined as the time from the start of initial treatment to documentation of first disease progression or death from any cause, whichever occurred first. Disease progression was determined according to standard practice based on radiological, biochemical (CEA) or clinical factors. Determination of disease progression was to be unequivocal and was defined as any of the following: an unequivocal and clinically meaningful increase in the size of known tumors, the appearance of one or more new lesions, death due to disease without prior objective documentation of progression, elevated CEA accompanied by other radiological or clinical evidence of progression, or symptomatic deterioration. Kaplan-Meier methodology was used to estimate PFS. (NCT01588990)
Timeframe: Baseline up to first disease progression, death or end of study (up to 4 years)
| Intervention | months (Median) |
|---|---|
| Bevacizumab: Phase A | 9.2 |
PFS in Phase B (PFS-B) was defined as the time from the start of Phase B treatment to documentation of second disease progression or death from any cause, whichever occurred first. Disease progression was determined according to standard practice based on radiological, biochemical (CEA) or clinical factors. Determination of disease progression was to be unequivocal and was defined as any of the following: an unequivocal and clinically meaningful increase in the size of known tumors, the appearance of one or more new lesions, death due to disease without prior objective documentation of progression, elevated CEA accompanied by other radiological or clinical evidence of progression, or symptomatic deterioration. Kaplan-Meier methodology was used to estimate PFS. (NCT01588990)
Timeframe: From the start of Phase B treatment to disease progression, death or end of study (up to 4 years)
| Intervention | months (Median) |
|---|---|
| Bevacizumab: Phase B | 6.7 |
Survival beyond first progression was defined as the time from the date of first disease progression to death due to any cause. Disease progression was determined according to standard practice based on radiological, biochemical (CEA) or clinical factors. Determination of disease progression was to be unequivocal and was defined as any of the following: an unequivocal and clinically meaningful increase in the size of known tumors, the appearance of one or more new lesions, death due to disease without prior objective documentation of progression, elevated CEA accompanied by other radiological or clinical evidence of progression, or symptomatic deterioration. Kaplan-Meier methodology was used to estimate survival beyond first disease progression. (NCT01588990)
Timeframe: Baseline until death or end of study (up to 4 years)
| Intervention | months (Median) |
|---|---|
| Bevacizumab: Phase A and Phase B | 12.6 |
TFS was defined as time from the start of initial treatment to documentation of first disease progression without entering Phase B, or second disease progression having entered Phase B. Disease progression was determined according to standard practice based on radiological, biochemical (CEA) or clinical factors. Determination of disease progression was to be unequivocal and was defined as any of the following: an unequivocal and clinically meaningful increase in the size of known tumors, the appearance of one or more new lesions, death due to disease without prior objective documentation of progression, elevated CEA accompanied by other radiological or clinical evidence of progression, or symptomatic deterioration. Kaplan-Meier methodology was used to estimate TFS. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)
| Intervention | months (Median) |
|---|---|
| Bevacizumab: Phase A and Phase B | 14.8 |
AQoL-8D provides a global utility score and consists of 8 separately scored dimensions including Independent Living, Life Satisfaction, Mental Health, Coping, Relationships, Self Worth, Pain, and Senses. Each of the 8 scales is calculated based on the answers to 3 questions. Each question is given an answer dependent utility score (0 [worst] to 1 [best]) and then these scores are combined using a multiplicative model to get the normalized scale score value, each scale ranging between 0.0 (representing death) and 1.0 (representing full health). (NCT01588990)
Timeframe: Baseline, every 8-9 weeks thereafter, EOT (30 days after disease progression [up to 4 years]), survival follow-up 12-weekly visits (up to 4 years) [Detailed time points are presented in the category titles]
| Intervention | units on a scale (Mean) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase B Baseline | Phase B Visit 2 (up to 4 years) | Phase B Visit 3 (up to 4 years) | Phase B Visit 4 (up to 4 years) | Phase B Visit 5 (up to 4 years) | Phase B Visit 6 (up to 4 years) | Phase B Visit 7 (up to 4 years) | Phase B Visit 8 (up to 4 years) | Phase B Visit 9 (up to 4 years) | Phase B Visit 10 (up to 4 years) | Phase B Visit 11 (up to 4 years) | Phase B Visit 12 (up to 4 years) | Phase B Visit 13 (up to 4 years) | Phase B Visit 14 (up to 4 years) | Phase B Visit 15 (up to 4 years) | Phase B Visit 16 (up to 4 years) | Phase B Visit 17 (up to 4 years) | Phase B Visit 18 (up to 4 years) | Phase B Visit 19 (up to 4 years) | Phase B Visit 20 (up to 4 years) | Phase B Visit 21 (up to 4 years) | Phase B Visit 22 (up to 4 years) | Phase B Visit 23 (up to 4 years) | Phase B Visit 24 (up to 4 years) | Phase B EOT Visit (up to 4 years) | Survival Follow-Up 1 (up to 4 years) | Survival Follow-Up 2 (up to 4 years) | Survival Follow-Up 3 (up to 4 years) | Survival Follow-Up 4 (up to 4 years) | Survival Follow-Up 6 (up to 4 years) | |
| Bevacizumab: Phase B | 0.736 | 0.773 | 0.813 | 0.878 | 0.808 | 0.809 | 0.825 | 0.910 | 0.819 | 0.856 | 0.730 | 0.960 | 0.965 | 0.958 | 0.967 | 0.942 | 0.927 | 0.931 | 0.866 | 0.887 | 0.940 | 0.919 | 0.937 | 0.950 | 0.708 | 0.788 | 0.791 | 0.989 | 0.981 | 0.875 |
AQoL-8D provides a global utility score and comprised of 35 questions from which 8 dimensions (Independent Living, Life Satisfaction, Mental Health, Coping, Relationships, Self Worth, Pain, and Senses) are derived. Each of the 8 scales is calculated based on the answers to 3 questions. Each question is given an answer dependent utility score (0 [worst] to 1 [best]) and then these scores are combined using a multiplicative model to get the normalized scale score value, each scale ranging between 0.0 (representing death) and 1.0 (representing full health). (NCT01588990)
Timeframe: Baseline, every 8-9 weeks thereafter, EOT (30 days after disease progression [up to 4 years]), survival follow-up 12-weekly visits (up to 4 years) [Detailed time points are presented in the category titles]
| Intervention | units on a scale (Mean) | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase A Baseline | Phase A Visit 2 (Weeks 8-9) | Phase A Visit 3 (Weeks 16-17) | Phase A Visit 4 (Weeks 24-25) | Phase A Visit 5 (Weeks 32-33) | Phase A Visit 6 (Weeks 40-41) | Phase A Visit 7 (Weeks 48-49) | Phase A Visit 8 (Weeks 56-57) | Phase A Visit 9 (Weeks 64-65) | Phase A Visit 10 (Weeks 72-73) | Phase A Visit 11 (Weeks 80-81) | Phase A Visit 12 (Weeks 88-89) | Phase A Visit 13 (Weeks 96-97) | Phase A Visit 14 (Weeks 104-105) | Phase A Visit 15 (Weeks 112-113) | Phase A Visit 16 (Weeks 120-121) | Phase A Visit 17 (Weeks 128-129) | Phase A Visit 18 (Weeks 136-137) | Phase A Visit 19 (Weeks 144-145) | Phase A Visit 20 (Weeks 152-153) | Phase A Visit 21 (Weeks 160-161) | Phase A Visit 22 (Weeks 168-169) | Phase A Visit 23 (Weeks 176-177) | Phase A EOT Visit (up to 4 years) | Survival Follow-Up 1 (up to 4 years) | Survival Follow-Up 2 (up to 4 years) | Survival Follow-Up 3 (up to 4 years) | Survival Follow-Up 4 (up to 4 years) | Survival Follow-Up 5 (up to 4 years) | Survival Follow-Up 6 (up to 4 years) | Survival Follow-Up 7 (up to 4 years) | |
| Bevacizumab: Phase A | 0.747 | 0.760 | 0.767 | 0.796 | 0.800 | 0.831 | 0.818 | 0.851 | 0.822 | 0.827 | 0.839 | 0.856 | 0.831 | 0.815 | 0.871 | 0.869 | 0.859 | 0.880 | 0.915 | 0.864 | 0.806 | 0.811 | 0.709 | 0.739 | 0.718 | 0.792 | 0.696 | 0.620 | 0.800 | 0.810 | 0.874 |
"EQ-5D is a standardized generic preference based health related quality of life instrument. It records how one's health is today and consists of a descriptive system. The descriptive system is comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each dimension on the EQ-5D involves a 3-point response scale which indicates the level of impairment (level 1 = no problem; level 2 = some or moderate problem[s] and level 3 = unable, or extreme problems). Level of problem reported in each EQ-5D dimension determines a unique health state which is converted into a weighted health state index by applying scores from EQ-5D preference weights elicited from general population samples. This generates a unique description of the subjects' health status, which is valued between 0 (representing death) and 1 (representing perfect health). Higher the score, the better the quality of life." (NCT01588990)
Timeframe: Baseline, every 8-9 weeks thereafter, end of treatment (EOT) (30 days after disease progression [up to 4 years]), survival follow-up 12-weekly visits (up to 4 years) [Detailed time points are presented in the category titles]
| Intervention | units on a scale (Mean) | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase A Baseline | Phase A Visit 2 (Weeks 8-9) | Phase A Visit 3 (Weeks 16-17) | Phase A Visit 4 (Weeks 24-25) | Phase A Visit 5 (Weeks 32-33) | Phase A Visit 6 (Weeks 40-41) | Phase A Visit 7 (Weeks 48-49) | Phase A Visit 8 (Weeks 56-57) | Phase A Visit 9 (Weeks 64-65) | Phase A Visit 10 (Weeks 72-73) | Phase A Visit 11 (Weeks 80-81) | Phase A Visit 12 (Weeks 88-89) | Phase A Visit 13 (Weeks 96-97) | Phase A Visit 14 (Weeks 104-105) | Phase A Visit 15 (Weeks 112-113) | Phase A Visit 16 (Weeks 120-121) | Phase A Visit 17 (Weeks 128-129) | Phase A Visit 18 (Weeks 136-137) | Phase A Visit 19 (Weeks 144-145) | Phase A Visit 20 (Weeks 152-153) | Phase A Visit 21 (Weeks 160-161) | Phase A Visit 22 (Weeks 168-169) | Phase A Visit 23 (Weeks 176-177) | Phase A EOT Visit (up to 4 years) | Survival Follow-Up 1 (up to 4 years) | Survival Follow-Up 2 (up to 4 years) | Survival Follow-Up 3 (up to 4 years) | Survival Follow-Up 4 (up to 4 years) | Survival Follow-Up 5 (up to 4 years) | Survival Follow-Up 6 (up to 4 years) | Survival Follow-Up 7 (up to 4 years) | |
| Bevacizumab: Phase A | 0.830 | 0.857 | 0.865 | 0.853 | 0.869 | 0.892 | 0.872 | 0.881 | 0.894 | 0.843 | 0.898 | 0.915 | 0.844 | 0.899 | 0.878 | 0.899 | 0.873 | 0.909 | 0.947 | 0.852 | 0.933 | 0.813 | 0.900 | 0.817 | 0.768 | 0.901 | 0.819 | 0.843 | 1.000 | 0.835 | 0.816 |
"EQ-5D is a standardized generic preference based health related quality of life instrument. It records how one's health is today and consists of a descriptive system. The descriptive system is comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each dimension on the EQ-5D involves a 3-point response scale which indicates the level of impairment (level 1 = no problem; level 2 = some or moderate problem[s] and level 3 = unable, or extreme problems). Level of problem reported in each EQ-5D dimension determines a unique health state which is converted into a weighted health state index by applying scores from EQ-5D preference weights elicited from general population samples. This generates a unique description of the subjects' health status, which is valued between 0 (representing death) and 1 (representing perfect health). Higher the score, the better the quality of life." (NCT01588990)
Timeframe: Baseline, every 8-9 weeks thereafter, EOT (30 days after disease progression [up to 4 years]), survival follow-up 12-weekly visits (up to 4 years) [Detailed time points are presented in the category titles]
| Intervention | units on a scale (Mean) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase B Baseline | Phase B Visit 2 (up to 4 years) | Phase B Visit 3 (up to 4 years) | Phase B Visit 4 (up to 4 years) | Phase B Visit 5 (up to 4 years) | Phase B Visit 6 (up to 4 years) | Phase B Visit 7 (up to 4 years) | Phase B Visit 8 (up to 4 years) | Phase B Visit 9 (up to 4 years) | Phase B Visit 10 (up to 4 years) | Phase B Visit 11 (up to 4 years) | Phase B Visit 12 (up to 4 years) | Phase B Visit 13 (up to 4 years) | Phase B Visit 14 (up to 4 years) | Phase B Visit 15 (up to 4 years) | Phase B Visit 16 (up to 4 years) | Phase B Visit 17 (up to 4 years) | Phase B Visit 18 (up to 4 years) | Phase B Visit 19 (up to 4 years) | Phase B Visit 20 (up to 4 years) | Phase B Visit 21 (up to 4 years) | Phase B Visit 22 (up to 4 years) | Phase B Visit 23 (up to 4 years) | Phase B Visit 24 (up to 4 years) | Phase B EOT Visit (up to 4 years) | Survival Follow-Up 1 (up to 4 years) | Survival Follow-Up 2 (up to 4 years) | Survival Follow-Up 3 (up to 4 years) | Survival Follow-Up 4 (up to 4 years) | Survival Follow-Up 6 (up to 4 years) | |
| Bevacizumab: Phase B | 0.814 | 0.859 | 0.894 | 0.897 | 0.866 | 0.837 | 0.876 | 0.874 | 0.908 | 0.811 | 0.806 | 0.844 | 1.000 | 1.000 | 0.844 | 0.833 | 0.844 | 0.833 | 0.827 | 0.816 | 0.844 | 0.844 | 0.827 | 0.844 | 0.809 | 0.740 | 0.772 | 0.827 | 0.827 | 1.000 |
FACT-C is one part of the FACIT Measurement System, which comprehensively assesses the health-related QoL of cancer participants and participants with other chronic illnesses. It is composed of 27 items of the general version of the FACT-C as a general core QoL measure and has a disease-specific subscale containing 9 colorectal cancer-specific items. It consists of total 36 items, summarized to 5 subscales: physical well-being (7 items), functional well-being (7 items), social/family well-being (7 items); all 3 subscales range from 0 to 28, emotional well-being (6 items) range from 0 to 24, colorectal cancer subscale (9 items) range from 0 to 36; higher subscale score=better QoL. All single-item measures range from 0='Not at all' to 4='Very much'. Total possible score range: 0 to 144. High scale score represents a better QoL. (NCT01588990)
Timeframe: Baseline, every 8-9 weeks thereafter, EOT (30 days after disease progression [up to 4 years]), survival follow-up 12-weekly visits (up to 4 years) [Detailed time points are presented in the category titles]
| Intervention | units on a scale (Mean) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase B Baseline | Phase B Visit 2 (up to 4 years) | Phase B Visit 3 (up to 4 years) | Phase B Visit 4 (up to 4 years) | Phase B Visit 5 (up to 4 years) | Phase B Visit 6 (up to 4 years) | Phase B Visit 7 (up to 4 years) | Phase B Visit 8 (up to 4 years) | Phase B Visit 9 (up to 4 years) | Phase B Visit 10 (up to 4 years) | Phase B Visit 11 (up to 4 years) | Phase B Visit 12 (up to 4 years) | Phase B Visit 13 (up to 4 years) | Phase B Visit 14 (up to 4 years) | Phase B Visit 15 (up to 4 years) | Phase B Visit 16 (up to 4 years) | Phase B Visit 17 (up to 4 years) | Phase B Visit 18 (up to 4 years) | Phase B Visit 19 (up to 4 years) | Phase B Visit 20 (up to 4 years) | Phase B Visit 21 (up to 4 years) | Phase B Visit 22 (up to 4 years) | Phase B Visit 23 (up to 4 years) | Phase B Visit 24 (up to 4 years) | Phase B EOT Visit (up to 4 years) | Survival Follow-Up 1 (up to 4 years) | Survival Follow-Up 2 (up to 4 years) | Survival Follow-Up 3 (up to 4 years) | Survival Follow-Up 4 (up to 4 years) | Survival Follow-Up 6 (up to 4 years) | |
| Bevacizumab: Phase B | 103.47 | 108.71 | 108.19 | 114.89 | 110.60 | 111.28 | 114.78 | 120.39 | 108.08 | 110.50 | 109.33 | 125.00 | 119.00 | 117.00 | 126.00 | 123.00 | 127.00 | 126.00 | 127.00 | 126.00 | 123.00 | 124.00 | 126.00 | 130.00 | 101.67 | 98.72 | 102.50 | 126.33 | 125.00 | 124.67 |
FACT-C is one part of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, which comprehensively assesses the health-related QoL of cancer participants and participants with other chronic illnesses. It is composed of 27 items of the general version of the FACT-C as a general core QoL measure and has a disease-specific subscale containing 9 colorectal cancer-specific items. It consists of total 36 items, summarized to 5 subscales: physical well-being (7 items), functional well-being (7 items), social/family well-being (7 items); all 3 subscales range from 0 to 28, emotional well-being (6 items) range from 0 to 24, colorectal cancer subscale (9 items) range from 0 to 36; higher subscale score=better QoL. All single-item measures range from 0='Not at all' to 4='Very much'. Total possible score range: 0 to 144. High scale score represents a better QoL. (NCT01588990)
Timeframe: Baseline, every 8-9 weeks thereafter, EOT (30 days after disease progression [up to 4 years]), survival follow-up 12-weekly visits (up to 4 years) [Detailed time points are presented in the category titles]
| Intervention | units on a scale (Mean) | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase A Baseline | Phase A Visit 2 (Weeks 8-9) | Phase A Visit 3 (Weeks 16-17) | Phase A Visit 4 (Weeks 24-25) | Phase A Visit 5 (Weeks 32-33) | Phase A Visit 6 (Weeks 40-41) | Phase A Visit 7 (Weeks 48-49) | Phase A Visit 8 (Weeks 56-57) | Phase A Visit 9 (Weeks 64-65) | Phase A Visit 10 (Weeks 72-73) | Phase A Visit 11 (Weeks 80-81) | Phase A Visit 12 (Weeks 88-89) | Phase A Visit 13 (Weeks 96-97) | Phase A Visit 14 (Weeks 104-105) | Phase A Visit 15 (Weeks 112-113) | Phase A Visit 16 (Weeks 120-121) | Phase A Visit 17 (Weeks 128-129) | Phase A Visit 18 (Weeks 136-137) | Phase A Visit 19 (Weeks 144-145) | Phase A Visit 20 (Weeks 152-153) | Phase A Visit 21 (Weeks 160-161) | Phase A Visit 22 (Weeks 168-169) | Phase A Visit 23 (Weeks 176-177) | Phase A EOT Visit (up to 4 years) | Survival Follow-Up 1 (up to 4 years) | Survival Follow-Up 2 (up to 4 years) | Survival Follow-Up 3 (up to 4 years) | Survival Follow-Up 4 (up to 4 years) | Survival Follow-Up 5 (up to 4 years) | Survival Follow-Up 6 (up to 4 years) | Survival Follow-Up 7 (up to 4 years) | |
| Bevacizumab: Phase A | 103.84 | 103.33 | 106.34 | 109.66 | 109.39 | 111.30 | 111.40 | 113.51 | 113.92 | 115.11 | 114.00 | 115.99 | 113.54 | 112.36 | 119.48 | 116.38 | 113.69 | 112.94 | 117.55 | 115.86 | 106.00 | 112.00 | 105.00 | 103.94 | 102.89 | 104.00 | 105.50 | 109.00 | 119.00 | 103.61 | 115.00 |
Percentage of participants with best overall response of confirmed complete response or partial response based on the investigator assessment of the response as per routine clinical practice was reported. The confirmation of response must be no less than 4 weeks after initial assessment. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Complete response | Partial response | |
| Bevacizumab: Phase A and Phase B | 3.1 | 8.6 |
Percentage of participants with best overall response of confirmed complete response or partial response based on the investigator assessment of the response as per routine clinical practice was reported. The confirmation of response must be no less than 4 weeks after initial assessment. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Complete response | Partial response | |
| Bevacizumab: Phase A | 3.1 | 8.6 |
Percentage of participants with best overall response of confirmed complete response or partial response based on the investigator assessment of the response as per routine clinical practice was reported. The confirmation of response must be no less than 4 weeks after initial assessment. (NCT01588990)
Timeframe: From the start of Phase B treatment to disease progression, death or end of study (up to 4 years)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Complete response | Partial response | |
| Bevacizumab: Phase B | 0 | 0 |
"Secondary objectives are to determine the efficacy and tolerability of selinexor in combination with mFOLFOX6 in patients with metastatic colorectal cancer by~- Overall survival (OS)~Overall survial is defined as length of time from start of treatment that patients are still alive. For this time-to-event variables the Kaplan-Meier method was intended to be used" (NCT02384850)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Selinexor 40 mg+ mFOLFOX6 | 0 |
| Selinexor 20mg + mFOLFOX6 | 2 |
"Secondary objectives are to determine the efficacy and tolerability of selinexor in combination with mFOLFOX6 in patients with metastatic colorectal cancer by~- Overall response rate (RR) (acc. to RECIST v1.1)~Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed byCT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR." (NCT02384850)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Selinexor 40 mg+ mFOLFOX6 | 0 |
| Selinexor 20mg + mFOLFOX6 | 1 |
"Secondary objectives are to determine the efficacy and tolerability of selinexor in combination with mFOLFOX6 in patients with metastatic colorectal cancer by~- Progression free survival (PFS) The disease status was measured by CT/MRI and evaluated according to RECIST 1.1 criteria every 8 weeks during treatment, at End of Treatment and every 3 weeks during Follow-up to determine time until patient has Progressive Disease (PD). PD is defined according to RECIST v1.1 at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression." (NCT02384850)
Timeframe: 2 years
| Intervention | months (Mean) |
|---|---|
| Selinexor 40 mg+ mFOLFOX6 | NA |
| Selinexor 20mg + mFOLFOX6 | NA |
"Secondary objectives are to determine the efficacy and tolerability of selinexor in combination with mFOLFOX6 in patients with metastatic colorectal cancer by~- Toxicity (acc. to NCI Common Terminology Criteria for Adverse Events (CTC AE) v4.03)" (NCT02384850)
Timeframe: treatment start to up to 30 days after last dose
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Patients with AEs of any CTCAE Grade | Patients with AEs of at least CTCAE Grade 3 | Patients with Selinexor related AEs of any Grade | Patients with Selinexor related AEs of at least Grade 3 | Patients with chemotherapy related AEs of any Grade | Patients with chemotherapy related AEs of at least Grade 3 | Patients with AEs leading to discontinuation | Patients with at least 1 SAE | Patients with at least 1 SAE related to Selinexor | Patients with at least 1 SAE related to chemotherapy | |
| Selinexor 20mg + mFOLFOX6 | 6 | 6 | 4 | 5 | 6 | 3 | 2 | 3 | 1 | 3 |
| Selinexor 40 mg+ mFOLFOX6 | 4 | 4 | 4 | 4 | 4 | 4 | 2 | 2 | 1 | 1 |
"Primary objective is the determination of the maximum tolerated dose (MTD) of selinexor in combination with mFOLFOX6 in patients with metastatic colorectal cancer.~Criteria to assess MTD was the experience of AEs > grade 3, discontinuation from study treatment due to adverse events or withdrawal of consent by the patients." (NCT02384850)
Timeframe: 28 days of treatment
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Discontinuation due to Adverse events | Discontinuation due to Withdrawal of Consent | Discontinuation due to Progressive Disease | |
| Selinexor 20mg + mFOLFOX6 | 2 | 2 | 2 |
| Selinexor 40 mg+ mFOLFOX6 | 2 | 2 | 0 |
"The overall ORR was the percentage of evaluable participants who achieved complete response [CR] or partial response [PR] according to RECIST criteria version 1.0.~CR reflected the disappearance of all tumor lesions (with no new tumors)~PR reflected a pre-defined reduction in tumor burden~Tumors were assessed by the IRC using Computerized Tomography (CT) scans or Magnetic Resonance Imaging (MRI) scans; and an observed response was confirmed by repeated imaging after 4 - 6 weeks." (NCT00561470)
Timeframe: From the date of the first randomization until the study data cut-off date, 06 May 2010 (approximately 30 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo/FOLFIRI | 11.1 |
| Aflibercept/FOLFIRI | 19.8 |
"Overall Survival was the time interval from the date of randomization to the date of death due to any cause. Once disease progression was documented, participants were followed every 2 months for survival status, until death or until the study cutoff date, whichever came first. The final data cutoff date for the analysis of OS was the date when 863 deaths had occurred (07 February 2011).~OS was estimated using the Kaplan-Meier method, and the Hazard Ratio was estimated using the Cox Proportional Hazard Model." (NCT00561470)
Timeframe: From the date of the first randomization until the study data cut-off date, 07 February 2011 (approximately three years)
| Intervention | months (Median) |
|---|---|
| Placebo/FOLFIRI | 12.06 |
| Aflibercept/FOLFIRI | 13.50 |
"PFS was the time interval from the date of randomization to the date of progression, or death from any cause if it occurs before tumor progression is documented. To evaluate disease progression, copies of all tumor imaging sets were systematically collected and assessed by the IRC.~PFS was analyzed using the Kaplan-Meier method, and the Hazard Ratio was estimated using the Cox Proportional Hazard Model.~The analysis for PFS was performed as planned when 561 deaths (OS events) had occurred." (NCT00561470)
Timeframe: From the date of the first randomization until the occurrence of 561 OS events, 06 May 2010 (approximately 30 months)
| Intervention | months (Median) |
|---|---|
| Placebo/FOLFIRI | 4.67 |
| Aflibercept/FOLFIRI | 6.90 |
Serum samples for immunogenicity assessment were analyzed using a bridging immunoassay to detect ADA. Positive samples in the ADA assay were further analyzed in the NAb assay using a validated, non-quantitative ligand binding assay. (NCT00561470)
Timeframe: Baseline, every other treatment cycle, 30 days and 90 days after the last infusion of aflibercept/placebo
| Intervention | participants (Number) | |
|---|---|---|
| At least one positive sample in the ADA assay | At least one positive sample in the NAb assay | |
| Aflibercept/FOLFIRI | 8 | 1 |
| Placebo/FOLFIRI | 18 | 2 |
"All AEs regardless of seriousness or relationship to study treatment, spanning from the first administration of study treatment until 30 days after the last administration of study treatment, were recorded, and followed until resolution or stabilization.~The number of participants with all treatment emergent adverse events (TEAE), serious adverse events (SAE), TEAE leading to death, and TEAE leading to permanent treatment discontinuation are reported." (NCT00561470)
Timeframe: From the date of the first randomization up to 30 days after the treatment discontinuation or until TEAE was resolved or stabilized
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Treatment-Emergent Adverse Event (TEAE) | Serious TEAE | TEAE leading to Death | TEAE causing permanent treatment discontinuation | |
| Aflibercept/FOLFIRI | 606 | 294 | 37 | 164 |
| Placebo/FOLFIRI | 592 | 198 | 29 | 73 |
Duration of response was defined as the time (in months) from date of first confirmed response (CR or PR) to date of first progressive disease (PD) or death. Per the RECIST criteria, definitions were as follows: CR was defined as the disappearance of all target or non-target lesions. Any pathological lymph nodes for target lesions or all lymph nodes for non-target lesions were non-pathological morphologically that was reduced in size in short axis to <10 mm. Analysis was performed by using Kaplan-Meier method. (NCT01285557)
Timeframe: From date of first study medication until cut-off date: 07 March 2014 (approximately 34.7 months)
| Intervention | months (Median) |
|---|---|
| S-1+Cisplatin | 5.1 |
| 5FU+Cisplatin | 4.2 |
An AE was any untoward medical condition that occurred in a participants while participating in a clinical study and does not necessarily had to have a causal relationship with the use of the study medication. TEAEs were defined as AEs that developed or worsened or became serious during on-treatment period (from first dose of study medication up to 30 days of last study medication [maximum duration: 35.7 months]). (NCT01285557)
Timeframe: From first dose of study medication up to 30 days of last study medication (maximum duration: 35.7 months)
| Intervention | Participants (Count of Participants) |
|---|---|
| S-1+Cisplatin | 157 |
| 5FU+Cisplatin | 78 |
ORR was defined as the percentage of participants with objective evidence of complete response (CR) or partial response (PR) based on the Investigator review of the images and application of Response Evaluation Criteria in Solid Tumors (RECIST) criteria. CR was defined as the disappearance of all target or non-target lesions. Any pathological lymph nodes for target lesions or all lymph nodes for non-target lesions were non-pathological morphologically that was reduced in size in short axis to less than (<) 10 millimeter (mm). PR was defined as target lesions with at least 30% decrease in the sum of diameters, taking baseline sum diameters as reference. (NCT01285557)
Timeframe: From date of first study medication until cut-off date: 07 March 2014 (approximately 34.7 months)
| Intervention | percentage of participants (Number) |
|---|---|
| S-1+Cisplatin | 34.7 |
| 5FU+Cisplatin | 19.8 |
OS was defined as the time from randomization to the date of death for the ITT population. Participants who did not die were censored at the date last known to be alive. Analysis was performed by using Kaplan-Meier method. (NCT01285557)
Timeframe: From the date of randomization until disease progression or death, cut-off date: 15 August 2014 (approximately 40 months)
| Intervention | months (Median) |
|---|---|
| S-1+Cisplatin | 7.5 |
| 5FU+Cisplatin | 6.6 |
PFS was defined as the time from date of randomization until date of radiological disease progression or death due to any cause. Disease Progression was defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, where any of the 3 criteria have been met: 1) at least 20% increase in the sum of diameters of the target lesions, taking as reference the smallest sum on study, including the baseline sum, 2) Progression in no-target lesion(s), 3) appearance of new lesion(s) Participants who were alive with no PD were censored at the date of the last tumor assessment. Participants who received new anticancer therapy before disease progression were censored at the date of the last evaluable tumor assessment before new anticancer therapy was initiated. Analysis was performed by using Kaplan-Meier method. (NCT01285557)
Timeframe: From date of randomization until disease progression or death, cut-off date: 07 March 2014 (approximately 34.7 months)
| Intervention | months (Median) |
|---|---|
| S-1+Cisplatin | 4.4 |
| 5FU+Cisplatin | 3.9 |
TTF was defined as the time from date of randomization until date of PD (clinical or radiologic), or permanent discontinuation of study treatment (S-1 or 5-FU), or death due to any cause. Participates who were still on study treatment at the time of the analysis were censored at the last date the participants was known to be on treatment. (NCT01285557)
Timeframe: From date of randomization until disease progression, cut-off date: 07 March 2014 (approximately 34.7 months)
| Intervention | months (Median) |
|---|---|
| S-1+Cisplatin | 4.2 |
| 5FU+Cisplatin | 3.8 |
TTR was defined as the time (in months) from the date of randomization to the date of first observation of response (PR or CR) (whichever status was recorded first). TTR was assessed based on investigator assessment utilizing RECIST 1.1. CR was defined as the disappearance of all target or non-target lesions. Any pathological lymph nodes for target lesions or all lymph nodes for non-target lesions were non-pathological morphologically that was reduced in size in short axis to <10 mm. PR was defined as target lesions with at least 30% decrease in the sum of diameters, taking baseline sum diameters as reference. Analysis was performed by using Kaplan-Meier method. (NCT01285557)
Timeframe: From date of first study medication until cut-off date: 07 March 2014 (approximately 34.7 months)
| Intervention | months (Median) |
|---|---|
| S-1+Cisplatin | 1.8 |
| 5FU+Cisplatin | 1.9 |
AE was defined as any untoward medical condition that occurs in a participants while participating in a clinical study and does not necessarily had to have a causal relationship with the use of the study medication. A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. TEAEs were defined as AEs that developed or worsened or became serious during on-treatment period (from first dose of study medication up to 30 days of last study medication [maximum duration: 35.7 months]). (NCT01285557)
Timeframe: From first dose of study medication up to 30 days of last study medication (maximum duration: 35.7 months)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| TEAE | TESAE | |
| 5FU+Cisplatin | 111 | 31 |
| S-1+Cisplatin | 214 | 63 |
For participants with a confirmed objective response, the time from first confirmed objective response to radiologic disease progression per modified RECIST 1.0 criteria or death. For participants who responded and have not progressed or died, duration of response was censored at their last evaluable disease assessment date. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus mFOLFOX6 | 10.0 |
| Bevacizumab Plus mFOLFOX6 | 9.0 |
Overall survival was defined as the time from randomization to the date of death, with participants alive or lost to follow-up at the analysis data cutoff date censored at their last contact date. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus mFOLFOX6 | NA |
| Bevacizumab Plus mFOLFOX6 | 25.4 |
Overall survival was defined as the time from randomization to the date of death, with participants alive or lost to follow-up at the analysis data cutoff date censored at their last contact date. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus mFOLFOX6 | NA |
| Bevacizumab Plus mFOLFOX6 | 29.0 |
Overall survival was defined as the time from randomization to the date of death, with participants alive or lost to follow-up at the analysis data cutoff date censored at their last contact date. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus mFOLFOX6 | NA |
| Bevacizumab Plus mFOLFOX6 | 29.0 |
Objective response was defined as having a confirmed complete response (CR) or partial response (PR) during first-line treatment, based on the investigator's review of scans using a modified-RECIST v1.0. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. Complete Response: Disappearance of all target and non-target lesions and no new lesions. Partial Response: At least a 30% decrease in the sum of the longest diameter (SLD) of target lesions and no progression of non-target lesions and no new lesions, or the disappearance of all target lesions with persistence of one or more non-target lesion(s) not qualifying for either CR or progressive disease and no new lesions. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | percentage of participants (Number) |
|---|---|
| Panitumumab Plus mFOLFOX6 | 57.75 |
| Bevacizumab Plus mFOLFOX6 | 53.52 |
"Objective response was defined as having a confirmed complete response (CR) or partial response (PR) during first-line treatment, based on the investigator's review of scans using a modified-RECIST v1.0. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met.~Complete Response: Disappearance of all target and non-target lesions and no new lesions. Partial Response: At least a 30% decrease in the sum of the longest diameter (SLD) of target lesions and no progression of non-target lesions and no new lesions, or the disappearance of all target lesions with persistence of one or more non-target lesion(s) not qualifying for either CR or progressive disease and no new lesions." (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | percentage of participants (Number) |
|---|---|
| Panitumumab Plus mFOLFOX6 | 63.64 |
| Bevacizumab Plus mFOLFOX6 | 60.49 |
Objective response was defined as having a confirmed complete response (CR) or partial response (PR) during first-line treatment, based on the investigator's review of scans using a modified-RECIST v1.0. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. Complete Response: Disappearance of all target and non-target lesions and no new lesions. Partial Response: At least a 30% decrease in the sum of the longest diameter (SLD) of target lesions and no progression of non-target lesions and no new lesions, or the disappearance of all target lesions with persistence of one or more non-target lesion(s) not qualifying for either CR or progressive disease and no new lesions. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | percentage of participants (Number) |
|---|---|
| Panitumumab Plus mFOLFOX6 | 63.64 |
| Bevacizumab Plus mFOLFOX6 | 61.54 |
PFS was defined as the time from the date of randomization to the date of first disease progression, or death within 60 days after the last evaluable tumor assessment or randomization date (whichever was later). Participants not meeting the criteria by the cutoff date were censored at the last evaluable tumor assessment date. Tumor response was evaluated by the investigator per modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 every 8 weeks until radiographic disease progression. Progression is defined as at least a 20% increase in the size of target lesions, unequivocal progression of existing non-target lesions, or any new lesions. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus mFOLFOX6 | 10.9 |
| Bevacizumab Plus mFOLFOX6 | 10.1 |
PFS was defined as the time from the date of randomization to the date of first disease progression, or death within 60 days after the last evaluable tumor assessment or randomization date (whichever was later). Participants not meeting the criteria by the cutoff date were censored at the last evaluable tumor assessment date. Tumor response was evaluated by the investigator per modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 every 8 weeks until radiographic disease progression. Progression is defined as at least a 20% increase in the size of target lesions, unequivocal progression of existing non-target lesions, or any new lesions. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus mFOLFOX6 | 13.1 |
| Bevacizumab Plus mFOLFOX6 | 9.7 |
PFS was defined as the time from the date of randomization to the date of first disease progression, or death within 60 days after the last evaluable tumor assessment or randomization date (whichever was later). Participants not meeting the criteria by the cutoff date were censored at the last evaluable tumor assessment date. Tumor response was evaluated by the investigator per modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 every 8 weeks until radiographic disease progression. Progression is defined as at least a 20% increase in the size of target lesions, unequivocal progression of existing non-target lesions, or any new lesions. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus mFOLFOX6 | 13.0 |
| Bevacizumab Plus mFOLFOX6 | 9.5 |
The resection rate was defined as the percentage of participants with a surgical procedure that resulted in partial reduction or complete eradication of all metastatic disease. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | percentage of participants (Number) |
|---|---|
| Panitumumab Plus mFOLFOX6 | 12.68 |
| Bevacizumab Plus mFOLFOX6 | 11.19 |
Time to progression (TTP) is defined as the time from randomization to the date of radiologic disease progression per modified RECIST 1.0 criteria. Participants not meeting criteria for disease progression by the analysis data cutoff date were censored at their last evaluable disease assessment date. Progression is defined as at least a 20% increase in the size of target lesions, unequivocal progression of existing non-target lesions, or any new lesions. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus mFOLFOX6 | 11.0 |
| Bevacizumab Plus mFOLFOX6 | 11.1 |
For participants with a confirmed objective response, the time from randomization to the date of first confirmed objective response. Assessments are based on the investigator's review of scans using a modified-RECIST v1.0. An objective response is defined as a best tumor response of complete or partial response. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus mFOLFOX6 | 1.8 |
| Bevacizumab Plus mFOLFOX6 | 1.9 |
Severity was graded using Common Terminology Criteria for Adverse Events (CTCAE) v3.0, with the exception of some dermatology/skin adverse events that were graded using CTCAE v3.0 with modifications. Fatal adverse events are classified as grade 5. Serious adverse events include any event that is fatal, life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, a congenital anomaly/birth defect, or other significant medical hazard. Treatment-related AEs were those that the investigator considered a reasonable possibility that might have been caused by study drug. (NCT00819780)
Timeframe: The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus mFOLFOX arm and 7.3 months for Bevacizumab Plus mFOLFOX6 arm.
| Intervention | participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any adverse event (AE) | AE with worst grade of 3 | AE with worst grade of 4 | AE with worst grade of 5 | Serious adverse event (SAE) | AE leading to discontinuation of study drug | Any treatment-related adverse event (TRAE) | Treatment-related AE with worst grade of 3 | Treatment-related AE with worst grade of 4 | Treatment-related AE with worst grade of 5 | Serious treatment-related adverse event | TRAE leading to discontinuation of study drug | |
| Bevacizumab Plus mFOLFOX6 | 139 | 78 | 28 | 9 | 53 | 37 | 136 | 77 | 25 | 2 | 28 | 29 |
| Panitumumab Plus mFOLFOX6 | 139 | 88 | 31 | 7 | 61 | 34 | 138 | 92 | 24 | 3 | 37 | 28 |
OS was defined as the time interval from the date of randomization to the date of death due to any cause. In the absence of confirmation of death, survival time was censored at the earliest between the last date of the participants was known to be alive and the study cut-off date. Analysis was performed by Kaplan-Meier method. (NCT01661270)
Timeframe: 31.6 months
| Intervention | months (Median) |
|---|---|
| Placebo | 11.93 |
| Aflibercept | 14.59 |
Objective response rate was defined as the proportion of participants with confirmed complete response (CR) or confirmed partial response (PR), as assessed by Investigators and the IRC according to RECIST 1.0 criteria, relative to the total number of participants in the relevant analysis population. Complete Response (CR): disappearance of all target and non-target lesions and no new lesions. Partial Response (PR): At least a 30% decrease in the size of target lesions with no progression of non-target lesions and no new lesions, or, the disappearance of all target lesions but persistence of 1 or more non-target lesions not qualifying for either CR or progressive disease (PD) and no new lesions. (NCT01661270)
Timeframe: 26.6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 3.7 |
| Aflibercept | 18.4 |
PFS was defined as the time interval from the date of randomization to the date of first observation of either tumor progression or death due to any cause. Tumor assessment was performed by Independent Review Committee (IRC) as per response evaluation criteria in solid tumors (RECIST) version 1.0. Progression was defined as at least 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study or absolute increase and at least 5 mm, progression of existing non-target lesions, or presence of new lesions. PFS was calculated by Kaplan-Meier estimates. (NCT01661270)
Timeframe: 26.7 months
| Intervention | months (Median) |
|---|---|
| Placebo | 5.59 |
| Aflibercept | 6.93 |
"To compare the pharmacokinetic (PK) profile of BEVZ92 and Avastin®, both administered in combination with FOLFOX (any) or FOLFIRI, by means of comparing the truncated AUC calculated from start of the first infusion until start of the second infusion (i.e. at Cycle 1; AUC0-336h)~For the PK similarity assessments, regulatory guidelines on bioequivalence were followed whereby two treatments are judged not to be different from one another if the 90% confidence interval (CI) of the ratio of a log-transformed exposure measure (AUC) falls completely within the range 80-125%." (NCT02069704)
Timeframe: AUC0-336 hrs: 0 to 336 hours after start of the first infusion
| Intervention | ng.h/mL (Geometric Least Squares Mean) |
|---|---|
| Bevacizumab Biosimilar (BEVZ92) | 16500000 |
| Avastin® (Bevacizumab, Ref. Product). | 16600000 |
"To compare the PK profile of BEVZ92 and Avastin®, both administered in combination with FOLFOX (any) or FOLFIRI, by means of comparing the truncated area under the concentration-versus-time curve calculated over a dosage interval at steady state (i.e. at Cycle 7; AUCss).~For the PK similarity assessments, regulatory guidelines on bioequivalence were followed whereby two treatments are judged not to be different from one another if the 90% CI of the ratio of a log-transformed exposure measure (AUC) falls completely within the range 80-125%." (NCT02069704)
Timeframe: AUCss: 0 to 336 hours after the administration of Cycle 7 infusion (Week 13).
| Intervention | ng.h/mL (Geometric Least Squares Mean) |
|---|---|
| Bevacizumab Biosimilar (BEVZ92) | 35900000 |
| Avastin® (Bevacizumab, Ref. Product). | 35700000 |
Secondary PK endpoints included the Cmax calculated at Cycle 1 (Cmax,sd ) (NCT02069704)
Timeframe: Cmax, sd: 0 to 336 hours after start of the first infusion.
| Intervention | ng/mL (Geometric Least Squares Mean) |
|---|---|
| Bevacizumab Biosimilar (BEVZ92) | 120000 |
| Avastin® (Bevacizumab, Ref. Product). | 123000 |
Secondary PK endpoints included the Cmax calculated at Cycle 7 (Cmax, ss ) (NCT02069704)
Timeframe: Cmax, ss: 0 to 336 hours post-dose after the administration of Cycle 7 infusion (Week 13)
| Intervention | ng/mL (Geometric Least Squares Mean) |
|---|---|
| Bevacizumab Biosimilar (BEVZ92) | 195000 |
| Avastin® (Bevacizumab, Ref. Product). | 200000 |
Secondary PK endpoints included the Ctrough calculated at Cycle 1 (Ctrough,sd ) (NCT02069704)
Timeframe: Ctrough, sd: 0 to 336 hours after start of the first infusion.
| Intervention | ng/mL (Geometric Least Squares Mean) |
|---|---|
| Bevacizumab Biosimilar (BEVZ92) | 344 |
| Avastin® (Bevacizumab, Ref. Product). | 349 |
Secondary PK endpoints included the Ctrough calculated at Cycle 7 (Ctrough,ss) (NCT02069704)
Timeframe: Ctrough, ss: 0 to 336 hours after the administration of the Cycle 7 infusion.
| Intervention | ng/mL (Geometric Least Squares Mean) |
|---|---|
| Bevacizumab Biosimilar (BEVZ92) | 69600 |
| Avastin® (Bevacizumab, Ref. Product). | 69300 |
Secondary PK endpoints included the t1/2 calculated at Cycle 7 (NCT02069704)
Timeframe: t1/2: 0 to 336 hours after the administration of the Cycle 7 infusion.
| Intervention | h (Geometric Least Squares Mean) |
|---|---|
| Bevacizumab Biosimilar (BEVZ92) | 294 |
| Avastin® (Bevacizumab, Ref. Product). | 289 |
Secondary PK endpoints included the Kel calculated at Cycle 7 (Ctrough,ss) (NCT02069704)
Timeframe: Kel: 0 to 336 hours after the administration of the Cycle 7 infusion.
| Intervention | l/h (Geometric Least Squares Mean) |
|---|---|
| Bevacizumab Biosimilar (BEVZ92) | 0.00236 |
| Avastin® (Bevacizumab, Ref. Product). | 0.00240 |
"Compare PFS between the randomized treatment arms. Progression-free survival (PFS) was defined as the time from the randomization date to the date of disease progression using RECIST v1.1, or death. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions plus 5 mm absolute increase, and/or unequivocal progression of known non-target lesion, and/or the appearance of new lesions." (NCT02069704)
Timeframe: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 weeks.
| Intervention | months (Median) |
|---|---|
| Bevacizumab Biosimilar (BEVZ92) | 10.8 |
| Avastin® (Bevacizumab, Ref. Product) | 11.1 |
Secondary PK endpoints included the Vd calculated at Cycle 7 (NCT02069704)
Timeframe: Vd: 0 to 336 hours after the administration of the Cycle 7 infusion.
| Intervention | L (Geometric Least Squares Mean) |
|---|---|
| Bevacizumab Biosimilar (BEVZ92) | 4.06 |
| Avastin® (Bevacizumab, Ref. Product). | 3.86 |
Immunogenicity profile by means of measurement of ADA developed de novo (seroconversion) after cycle 5, cycle 8, and 12 months after first drug administration (pre-dose). (NCT02069704)
Timeframe: At baseline, and on Day 1 (pre-dose) of Cycles: 1, 5 and 8, and 12 months after first drug administration
| Intervention | participants (Number) | |
|---|---|---|
| Seroconversion | No seroconversion | |
| Avastin® (Bevacizumab, Ref. Product) | 0 | 71 |
| Bevacizumab Biosimilar (BEVZ92) | 2 | 67 |
"To compare efficacy in terms of ORR between arms. Clinical and radiological tumor assessments were performed according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 using computed tomography (CT) or magnetic resonance imaging (MRI) scans.~Objective response (OR) is defined as a best overall response of partial response (PR) or complete response (CR) as defined by RECIST v1.1. All participants who did not meet the criteria for CR or PR by the end of the study were considered non-responders." (NCT02069704)
Timeframe: Every four weeks. Up to 48 weeks
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| ORR (CR+PR) | Stable disease | Progressive disease | unevaluable | |
| Avastin® (Bevacizumab, Ref. Product) | 40 | 25 | 2 | 4 |
| Bevacizumab Biosimilar (BEVZ92) | 35 | 27 | 4 | 5 |
Compare the safety profile by means of the frequency and severity of TEAEs and SAEs reported in each treatment arm. (NCT02069704)
Timeframe: From first study dose and up to 30 days after the end of study treatment for each patient, for an average of 11 months
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Any TEAE (any causality) | Any grade>=3 TEAE | Any TEAE leading to discontinuation | Any treatment-related TEAE | Any grade >=3 treatment-related TEAE | Any serious TEAE | Any bleeding event | |
| Avastin® (Bevacizumab, Ref. Product) | 71 | 49 | 6 | 70 | 70 | 21 | 19 |
| Bevacizumab Biosimilar (BEVZ92) | 66 | 44 | 13 | 63 | 63 | 19 | 14 |
Duration of response was calculated only for those participants with a confirmed CR or PR, as the time from the first CR or PR (subsequently confirmed within no less than 4 weeks) to first observed disease progression per modified RECIST criteria, based on a blinded central review. (NCT00364013)
Timeframe: Every 8 weeks until disease progression up to the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS - FOLFOX + Panitumumab | 11.1 |
| Wild-type KRAS - FOLFOX | 8.8 |
| Mutant KRAS - FOLFOX + Panitumumab | 7.4 |
| Mutant KRAS - FOLFOX | 8.0 |
The definition of overall survival is the time from randomization to death; participants who were alive at the analysis data cutoff were censored at their last contact date. (NCT00364013)
Timeframe: From randomization until the data cutoff date of 28 August 2009. Maximum time on follow-up was 153 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS - FOLFOX + Panitumumab | 23.9 |
| Wild-type KRAS - FOLFOX | 19.7 |
| Mutant KRAS - FOLFOX + Panitumumab | 15.5 |
| Mutant KRAS - FOLFOX | 19.3 |
Participants were evaluated for tumor response per the modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria every 8 weeks until disease progression. Objective response by central radiological assessment was defined as the incidence of either a confirmed complete or partial response (CR or PR) while on the first-line treatment, as determined by blinded independent central review and confirmed no less than 4-weeks after the criteria for response are first met. CR: Disappearance of all target and non-target lesions and no new lesions. PR: At least a 30% decrease in the sum of the longest diameter of target lesions and no progression of non-target or no new lesions, or, disappearance of all target lesions and the persistence of ≥ 1 non-target lesion not qualifying for either CR or progressive disease. Participants without a post-baseline assessment were considered non-responders. (NCT00364013)
Timeframe: Every 8 weeks until disease progression up to the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.
| Intervention | percentage of participants (Number) |
|---|---|
| Wild-type KRAS - FOLFOX + Panitumumab | 55.21 |
| Wild-type KRAS - FOLFOX | 47.68 |
| Mutant KRAS - FOLFOX + Panitumumab | 39.53 |
| Mutant KRAS - FOLFOX | 40.28 |
Progression-free survival (PFS), assessed by central radiological assessment, was defined as the time from randomization to disease progression per modified response evaluation criteria in solid tumors (RECIST) criteria or death. Participants who were alive but did not meet criteria for progression by the data cutoff date were censored at their last evaluable disease assessment date. Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions. (NCT00364013)
Timeframe: From randomization until the data cutoff date of 30 September 2008. Maximum follow-up time was 109 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS - FOLFOX + Panitumumab | 9.6 |
| Wild-type KRAS - FOLFOX | 8.0 |
| Mutant KRAS - FOLFOX + Panitumumab | 7.3 |
| Mutant KRAS - FOLFOX | 8.8 |
Time to progression was defined as time from randomization date to date of disease progression per the modified RECIST criteria. (NCT00364013)
Timeframe: From randomization until the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS - FOLFOX + Panitumumab | 10.8 |
| Wild-type KRAS - FOLFOX | 9.2 |
| Mutant KRAS - FOLFOX + Panitumumab | 7.5 |
| Mutant KRAS - FOLFOX | 9.0 |
"A serious adverse event (SAE) is defined as an AE that • is fatal • is life threatening • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • is a congenital anomaly/birth defect • other significant medical hazard. The relationship of the adverse event to the study treatment was assessed by the Investigator by means of the question: Is there a reasonable possibility that the event may have been caused by the study treatment?" (NCT00364013)
Timeframe: From randomization until the data cut-off date of 28 August 2009; Maximum time on follow-up was 153 weeks.
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Any adverse event | Serious adverse event | Leading to discontinuation of any study drug | Treatment-related adverse event (TRAE) | Serious treatment-related adverse event | TRAE leading to discontinuation of any study drug | |
| FOLFOX + Panitumumab | 583 | 262 | 136 | 581 | 162 | 117 |
| FOLFOX Alone | 579 | 198 | 84 | 565 | 89 | 63 |
"Objective tumor response rate (complete response, unconfirmed complete response, partial response, unconfirmed partial response) in patients with measurable disease were assessed in each arm and compared between arms using Chi-squared test.~Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions" (NCT01959139)
Timeframe: Up to 3 years
| Intervention | percent of participants (Number) |
|---|---|
| Phase II: mFOLFIRINOX | 45 |
| Phase II: mFOLFIRINOX + PEGPH20 | 33 |
"Assess safety of mFOLFIRINOX in combination with PEGPH20 and select the optimal dose of PEGPH20 for the Phase II portion.~MTD of PEGPH20 in combination with mFOLFORINOX was evaluated by testing decreasing doses of PEGPH20 from 3mcg/kg on Day 1 and Day 3/4, to 3mcg/kg on Day 1 only and to 1.6 mcg/kg on Day 1 only.~MTD reflects the highest dose that had a dose-limiting toxicity (DLT) rate of ≤ 17%. DLTs were defined as treatment regimen related: grade ≥ 3 non-hematologic toxicity; grade 4 absolute neutrophil count (ANC) anemia or thrombocytopenia; grade 4 ANC lasting > 7 days; grade ≥ 3 febrile neutropenia; grade ≥ 3 elevation of aspartate aminotransferase (AST)/alanine aminotransferase (ALT), total bilirubin, and creatinine; delay in starting the 2nd cycle of mFOLFIRINOX by > 2 weeks due to drug related toxicity.~DLT were graded using the NCI CTCAE version 4. Note: the third and lowest dose level was not reached." (NCT01959139)
Timeframe: 2 cycles of 14 days
| Intervention | ug/kg (Number) |
|---|---|
| Phase I: mFOLFIRINOX + PEGPH20, 3 ug/kg on Day 1 and Day 3/4 | 0 |
| Phase I: mFOLFIRINOX + PEGPH20, 3 ug/kg on Day 1 | 3 |
| All Phase 1 Participants | 3 |
"Time from date of registration to date of death due to any cause. Participants last known to be alive are censored at date of last contact.~Assessed using the logrank test." (NCT01959139)
Timeframe: From date of registration to date of death due to any cause, assessed up to 3 years
| Intervention | months (Median) |
|---|---|
| Phase II: mFOLFIRINOX | 14.4 |
| Phase II: mFOLFIRINOX + PEGPH20 | 7.7 |
Time from date of registration to date of first documentation of progression or symptomatic deterioration or death due to any cause. Participants last known to be alive without report of progression are censored at date of last contact. (NCT01959139)
Timeframe: From date of registration to date of death due to any cause, assessed up to 3 years
| Intervention | months (Median) |
|---|---|
| Phase II: mFOLFIRINOX | 6.2 |
| Phase II: mFOLFIRINOX + PEGPH20 | 4.3 |
"Adverse Events (AEs) are reported by CTCAE Version 4.0. Only adverse events that are possibly, probably or definitely related to study drug are reported.~Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living e.g. bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden.~Grade 4: Life-threatening consequences; urgent intervention indicated.~Grade 5: Death related to adverse event" (NCT01959139)
Timeframe: Duration of treatment and follow up until death or 3 years post registration
| Intervention | Participants (Number) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abdominal pain | Acute kidney injury | Alanine aminotransferase increased | Alkaline phosphatase increased | Anemia | Anorexia | Arthralgia | Ascites | Aspartate aminotransferase increased | Blood bilirubin increased | Creatinine increased | Dehydration | Depression | Diarrhea | Esophagitis | Fatigue | Febrile neutropenia | Gallbladder obstruction | Gastrointestinal disorders - Other, specify | General disorders and admin site conditions- Other | Generalized muscle weakness | Hyperglycemia | Hypertension | Hypokalemia | Hyponatremia | Hypophosphatemia | Hypotension | Infections and infestations - Other, specify | Infusion related reaction | Leukocytosis | Lung infection | Lymphocyte count decreased | Mucositis oral | Myalgia | Nausea | Neutrophil count decreased | Pain | Paresthesia | Peripheral motor neuropathy | Peripheral sensory neuropathy | Peritoneal infection | Platelet count decreased | Portal vein thrombosis | Pulmonary hypertension | Resp, thoracic and mediastinal disorders - Other | Sepsis | Skin infection | Small intestine infection | Spasticity | Thromboembolic event | Ventricular tachycardia | Vomiting | Weight loss | White blood cell decreased | |
| Phase I: mFOLFIRINOX + PEGPH20, 3 ug/kg on Day 1 and Day 3/4 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Phase I: mFOLFIRINOX + PEGPH20, 3 ug/kg on Day 1 Only | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Phase II: mFOLFIRINOX | 1 | 0 | 0 | 0 | 4 | 2 | 0 | 0 | 0 | 0 | 1 | 7 | 1 | 10 | 0 | 6 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 3 | 1 | 0 | 0 | 1 | 0 | 2 | 1 | 1 | 0 | 0 | 8 | 4 | 1 | 1 | 1 | 2 | 0 | 2 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 8 | 1 | 2 |
| Phase II: PEGPH20 + mFOLFIRINOX | 3 | 0 | 3 | 2 | 2 | 3 | 1 | 1 | 0 | 1 | 0 | 4 | 0 | 12 | 1 | 11 | 0 | 0 | 1 | 0 | 3 | 1 | 0 | 4 | 3 | 1 | 0 | 0 | 1 | 1 | 0 | 4 | 4 | 2 | 12 | 3 | 0 | 0 | 1 | 5 | 1 | 3 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 5 | 0 | 10 | 0 | 2 |
Survival time will be defined as the time from registration to death. Time to event distributions will be estimated using the Kaplan-Meier method. Overall Survival (OS) will be compared between Arm A and Arm B. (NCT00265850)
Timeframe: Up to 5 years post-treatment
| Intervention | months (Median) |
|---|---|
| Arm A: FOLFOX or FOLFIRI + Bevacizumab | 29.0 |
| Arm B: FOLFOX or FOLFIRI + Cetuximab | 30.0 |
PFS will be measured from study entry until first documented progression or death from any cause. Time to event distributions will be estimated using the Kaplan-Meier method. PFS will be compared between Arm A and Arm B. (NCT00265850)
Timeframe: Up to 5 years post-treatment
| Intervention | months (Median) |
|---|---|
| Arm A: FOLFOX or FOLFIRI + Bevacizumab | 10.6 |
| Arm B: FOLFOX or FOLFIRI + Cetuximab | 10.5 |
Best overall response of complete or partial response within irinotecan stratum (NCT00115765)
Timeframe: Overall Study
| Intervention | Participant (Number) |
|---|---|
| Irinotecan and Bevacizumab Plus Panitumumab | 49 |
| Irinotecan and Bevacizumab Without Panitumumab | 46 |
Best overall response of complete or partial response in participants treated with irinotecan and having a mutant Kirsten Rat Sarcoma Virus Oncogene (KRAS) (NCT00115765)
Timeframe: Overall Study
| Intervention | Participant (Number) |
|---|---|
| Irinotecan and Bevacizumab Plus Panitumumab | 14 |
| Irinotecan and Bevacizumab Without Panitumumab | 15 |
Best overall response of complete or partial response within oxaliplatin stratum (NCT00115765)
Timeframe: Overall study
| Intervention | Participant (Number) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 190 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 196 |
Best overall response of complete or partial response in participants treated with irinotecan and having a wild-type Kirsten Rat Sarcoma Virus Oncogene (KRAS) (NCT00115765)
Timeframe: Overall Study
| Intervention | Participant (Number) |
|---|---|
| Irinotecan and Bevacizumab Plus Panitumumab | 31 |
| Irinotecan and Bevacizumab Without Panitumumab | 28 |
Objective tumor response (complete or partial) rate through week 12 based on central review in the Irinotecan stratum (NCT00115765)
Timeframe: Overall Study
| Intervention | Participant (Number) |
|---|---|
| Irinotecan and Bevacizumab Plus Panitumumab | 29 |
| Irinotecan and Bevacizumab Without Panitumumab | 27 |
Incidence of mortality from any cause in groups treated with Irinotecan. Incidence is provided in lieu of the median time to death since the median or its measure of dispersion was not estimable for at least one treatment arm. (NCT00115765)
Timeframe: Overall study
| Intervention | Participant (Number) |
|---|---|
| Irinotecan and Bevacizumab Plus Panitumumab | 26 |
| Irinotecan and Bevacizumab Without Panitumumab | 18 |
Kaplan-Meier estimate of the median time from randomization to death from any cause in groups treated with Oxaliplatin and having a mutant Kirsten Rat Sarcoma Virus Oncogene (KRAS). Since the measure of dispersion could not be estimated for at least one treatment arm, participant incidence is provided in lieu of the median. (NCT00115765)
Timeframe: Overall Study
| Intervention | Participant (Number) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 47 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 45 |
Kaplan-Meier estimate of the median time from randomization to death from any cause in groups treated with Oxaliplatin (NCT00115765)
Timeframe: Overall study
| Intervention | Month (Median) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 19.4 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 24.5 |
Kaplan-Meier estimate of the median time from randomization to death from any cause in groups treated with Oxaliplatin and having a wild-type Kirsten Rat Sarcoma Virus Oncogene (KRAS). Since the measure of dispersion could not be estimated for at least one treatment arm, participant incidence is provided in lieu of the median (NCT00115765)
Timeframe: Overall Study
| Intervention | Participant (Number) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 71 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 46 |
Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression (NCT00115765)
Timeframe: Overall Study
| Intervention | Month (Median) |
|---|---|
| Irinotecan and Bevacizumab Plus Panitumumab | 10.1 |
| Irinotecan and Bevacizumab Without Panitumumab | 11.7 |
Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression in groups treated with oxaliplatin and having a mutant Kirsten Rat Sarcoma Virus Oncogene (KRAS) (NCT00115765)
Timeframe: Overall Study
| Intervention | Month (Median) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 10.4 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 11.0 |
Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression (NCT00115765)
Timeframe: Overall study
| Intervention | Month (Median) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 10.0 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 11.4 |
Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression in groups treated with oxaliplatin and having a wild-type Kirsten Rat Sarcoma Virus Oncogene (KRAS) (NCT00115765)
Timeframe: Overall Study
| Intervention | Month (Median) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 9.8 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 11.5 |
Kaplan-Meier estimate of the median time from randomization to disease progression or death due to disease progression within the irinotecan stratum (NCT00115765)
Timeframe: Overall Study
| Intervention | Month (Median) |
|---|---|
| Irinotecan and Bevacizumab Plus Panitumumab | 11.1 |
| Irinotecan and Bevacizumab Without Panitumumab | 11.9 |
Kaplan-Meier estimate of the median time from randomization to disease progression or death due to disease progression within the oxaliplatin stratum (NCT00115765)
Timeframe: Overall Study
| Intervention | Month (Median) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 10.8 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 11.4 |
Kaplan-Meier estimate of the median time from randomization to the date the decision was made to discontinue treatment for a reason other than a complete response to treatment within the irinotecan stratum (NCT00115765)
Timeframe: Overall Study
| Intervention | Month (Median) |
|---|---|
| Irinotecan and Bevacizumab Plus Panitumumab | 6.6 |
| Irinotecan and Bevacizumab Without Panitumumab | 6.0 |
Kaplan-Meier estimate of the median time from randomization to the date the decision was made to discontinue treatment for a reason other than a complete response to treatment within the oxaliplatin stratum. (NCT00115765)
Timeframe: Overall study
| Intervention | Month (Median) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 5.7 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 5.9 |
Duration of Response is calculated as the time from the first recording of CR/PR until the patient progresses, regardless of whether the patient was still taking study medication. Only confirmed responses are included in the calculation. For patients who had not progressed, the end date used in the calculation of duration of response is the data cut-off date of 15th November 2009. (NCT00384176)
Timeframe: Up until data cut-off date of 15/11/2007
| Intervention | Months (Median) |
|---|---|
| Cediranib 20 mg | 8.6 |
| Bevacizumab 5 mg/kg | 9.6 |
"Objective response rate is Complete Response (CR) + Partial Response (PR) as defined below:~CR = Disappearance of all target lesions. PR = At least a 30% decrease in the sum of longest diameters (LDs) of target lesions, taking as reference the baseline sum of LDs." (NCT00384176)
Timeframe: Up until data cut-off
| Intervention | Participants (Number) |
|---|---|
| Cediranib 20 mg | 328 |
| Bevacizumab 5 mg/kg | 337 |
Number of months from randomisation to the date of death from any cause (NCT00384176)
Timeframe: Randomisation until data cut-off
| Intervention | Months (Median) |
|---|---|
| Cediranib 20 mg | 22.8 |
| Bevacizumab 5 mg/kg | 21.3 |
Percentage change in tumour size from baseline to first RECIST assessment (Week 8) ((Week 8 - baseline)/baseline)*100 (NCT00384176)
Timeframe: Baseline to Week 8
| Intervention | Percentage change in tumour size (Mean) |
|---|---|
| Cediranib 20 mg | -23.2 |
| Bevacizumab 5 mg/kg | -22.1 |
Progression is defined as the number of months from randomisation until progressive disease based on RECIST (progression of target lesions, clear progression of existing non-target lesions or the appearance of one or more new lesions) or death in the absence of progression. (NCT00384176)
Timeframe: Baseline then at Weeks 8, 16, 24 and then every 12 weeks until progression
| Intervention | Months (Median) |
|---|---|
| Cediranib 20 mg | 9.9 |
| Bevacizumab 5 mg/kg | 10.3 |
Time to worsening of symptoms, as measured by the FACT colorectal symptom index (FCSI), will be defined as the time when a sustained clinically important deterioration in the total score from the FCSI has been recorded. (NCT00384176)
Timeframe: Baseline through to data cut-off
| Intervention | Days (Median) |
|---|---|
| Cediranib 20 mg | 170 |
| Bevacizumab 5 mg/kg | 245 |
Time from the first confirmed objective response of complete or partial response (that is subsequently confirmed at least 28 days later) to disease progression using a modified version of the RECIST v1.0 (see protocol Appendix H). (NCT00460265)
Timeframe: Every 6 weeks until disease progression, up to 56 months
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus Chemotherapy | 5.6 |
| Chemotherapy Alone | 5.7 |
An objective tumor response of complete or partial response per modified Response Evaluation Criteria in Solid Tumors (RECIST) v1.0 that was confirmed no less than 28 days after the criteria for response were first met. Complete response = disappearance of all target lesions and partial response = ≥30% reduction in lesion size. (NCT00460265)
Timeframe: Every 6 weeks until disease progression, up to 56 months
| Intervention | subjects (Number) |
|---|---|
| Panitumumab Plus Chemotherapy | 101 |
| Chemotherapy Alone | 73 |
Time from randomization to death (NCT00460265)
Timeframe: Upto 56 months
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus Chemotherapy | 11.1 |
| Chemotherapy Alone | 9.0 |
Time from randomization date to date of disease progression using a modified version of the RECIST v1.0 or death. (NCT00460265)
Timeframe: Every 6 weeks until disease progression or deaths, upto 56 months
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus Chemotherapy | 5.8 |
| Chemotherapy Alone | 4.6 |
Time from randomization date to date of disease progression using a modified version of the RECIST 1.0 (see protocol Appendix H) (NCT00460265)
Timeframe: Every 6 weeks until disease progression, up to 56 months
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus Chemotherapy | 6.8 |
| Chemotherapy Alone | 5.6 |
Time from randomization date to the first confirmed objective response of complete or partial response (that is subsequently confirmed at least 28 days later) using a modified version of the RECIST v1.0. (NCT00460265)
Timeframe: Every 6 weeks until disease progression, upto 56 months
| Intervention | months (Median) |
|---|---|
| Panitumumab Plus Chemotherapy | 1.4 |
| Chemotherapy Alone | 1.5 |
Time from the date of randomization to the date of death due to any cause. OS (in months) calculated as (date of death minus randomization date plus 1) divided by 30.4. For patients lacking survival data beyond the date of their last follow-up, the OS time was censored on the last date they were known to be alive. Patients lacking survival data beyond randomization had their OS times censored at randomization. (NCT00435409)
Timeframe: Baseline until death or up to 3 years from first dose
| Intervention | months (Median) |
|---|---|
| Sunitinib + Capecitabine | 16.5 |
| Capecitabine | 17.2 |
Time from the first documentation of objective tumor response (CR or PR) that was subsequently confirmed to the first documentation of disease progression (PD) or to death due to any cause, whichever occurred first. If tumor progression data included more than 1 date, the first date was used. DR (in months) was calculated as [the date response ended (date of PD or death) minus first CR or PR date that was subsequently confirmed plus 1)] divided by 30.4. (NCT00435409)
Timeframe: Baseline until response or disease progression (up to 3 years from first dose)
| Intervention | months (Median) | |
|---|---|---|
| Independent radiology assessment | Investigator's assessment | |
| Capecitabine | 8.8 | 7.6 |
| Sunitinib + Capecitabine | 9.0 | 5.7 |
Probability of survival 2 years and 3 years after the first dose of study treatment. (NCT00435409)
Timeframe: Year 1, Year 2, Year 3
| Intervention | probability of survival (Number) | ||
|---|---|---|---|
| Year 1 | Year 2 | Year 3 | |
| Capecitabine | 0.654 | 0.373 | 0.174 |
| Sunitinib + Capecitabine | 0.635 | 0.368 | 0.150 |
Proportion of participants with confirmed complete response (CR) or partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST); CR: disappearance of all target lesions, PR: greater than or equal to (>=) 30 percent (%) decrease in the sum of the longest dimensions (SLD) of the target lesions taking as a reference the baseline SLD. Confirmed responses = persist on repeat imaging study at least 4 weeks after initial documentation of response. Designation of best response of stable disease (SD) required the criteria to be met at least 5 weeks after randomization. (NCT00435409)
Timeframe: Baseline until response or disease progression (up to 3 years from first dose)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Independent radiology assessment | Investigator's assessment | |
| Capecitabine | 16.3 | 20.4 |
| Sunitinib + Capecitabine | 18.6 | 25.3 |
Defined as the time from the date of randomization to the date of the first documentation of objective tumor progression or death due to any cause, whichever occurs first. If tumor progression data include more than 1 date, the first date will be used. PFS (in months) will be calculated as (first event date minus randomization date plus 1) divided by 30.4. (NCT00435409)
Timeframe: Baseline until disease progression (up to 3 years from first dose)
| Intervention | months (Median) | |
|---|---|---|
| Independent radiology assessment | Investigator's assessment | |
| Capecitabine | 5.9 | 5.5 |
| Sunitinib + Capecitabine | 5.5 | 5.4 |
Time in months from the date of randomization to date of death due to any cause. OS was calculated as (date of death minus randomization date plus 1) divided by 30.4. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death). (NCT00246571)
Timeframe: Baseline until death (up to 3 years after first dose of study medication)
| Intervention | months (Median) |
|---|---|
| Sunitinib | 9.4 |
| Standard of Care | 10.5 |
Probability that the participants will survive at end of 1 year from the first dose of study treatment. Calculated using data collected from baseline until death (up to 3 years after first dose of study medication). Probability calculated from Kaplan-Meier estimate. (NCT00246571)
Timeframe: Baseline until death (up to 3 years after first dose of study medication)
| Intervention | ratio (Number) |
|---|---|
| Sunitinib | 0.376 |
| Standard of Care | 0.446 |
Blood samples were collected to enumerate the number of total CECs and sVEGFR1, sVEGFR2 and sVEGFR3 protein expression and/or cellular viability. (NCT00246571)
Timeframe: Days 1 and 15 of Cycles 1, 2 and 3, Day 1 of Cycles 4 and 5, and every odd cycle thereafter, and EOT/withdrawal
| Intervention | cells/mL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 (n=42, 48) | Cycle 1, Day 15 (n=28, 37) | Cycle 2, Day 1 (n=33, 35) | Cycle 2, Day 15 (n=7, 5) | Cycle 3, Day 1 (n=27, 25) | Cycle 3, Day 15 (n=4, 1) | Cycle 4, Day 1 (n=3, 5) | Cycle 5, Day 1 (n=2, 2) | EOT (n=18, 18) | |
| Standard of Care | 1176.92 | 1199.32 | 1048.31 | 852.96 | 509.75 | 231.80 | 976.79 | 2031.67 | 1087.94 |
| Sunitinib | 944.67 | 630 | 512.39 | 1310.86 | 390.09 | 923.85 | 169.24 | 145.68 | 477.83 |
Blood samples were collected to enumerate the number of total CTCs and insulin growth factor 1R positive (IGF-1R+) CTCs (NCT00246571)
Timeframe: Days 1 and 15 of Cycles 1, 2 and 3, Day 1 of Cycles 4 and 5, and every odd cycle thereafter, and EOT/withdrawal
| Intervention | cells/7.5 mL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 (n=33, 28) | Cycle 1, Day 15 (n=20, 16) | Cycle 2, Day 1 (n=19, 17) | Cycle 2, Day 15 (n=3, 7) | Cycle 3, Day 1 (n=8, 15) | Cycle 3, Day 15 (n=2, 4) | Cycle 4, Day 1 (n=2, 5) | Cycle 5, Day 1 (n=2, 3) | EOT (n=17,4) | |
| Standard of Care | 17.71 | 10.69 | 3.18 | 0.86 | 10.60 | 0 | 0.60 | 0.33 | 3 |
| Sunitinib | 119.76 | 183.60 | 189 | 33.33 | 36.50 | 40.50 | 61 | 19.50 | 55 |
(NCT00246571)
Timeframe: Predose Day 1, Cycles 1, 2, 3, 4, 5 and 7 and Day 15 of Cycles 1, 2, and 3
| Intervention | ng/mL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 (n=54) | Cycle 1, Day 15 (n=44) | Cycle 2, Day 1 (n=42) | Cycle 2, Day 15 (n=33) | Cycle 3, Day 1 (n=26) | Cycle 3, Day 15 (n=21) | Cycle 4, Day 1 (n=18) | Cycle 5, Day 1 (n=12) | Cycle 7, Day 1 (n=6) | |
| Sunitinib | 0.02 | 29.4 | 32.3 | 33.4 | 28.5 | 40.4 | 30.9 | 36.1 | 21.3 |
(NCT00246571)
Timeframe: Predose Day 1, Cycles 1, 2, 3, 4, 5 and 7 and Day 15 of Cycles 1, 2, and 3
| Intervention | ng/mL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 (n=54) | Cycle 1, Day 15 (n=44) | Cycle 2, Day 1 (n=42) | Cycle 2, Day 15 (n=33) | Cycle 3, Day 1 (n=26) | Cycle 3, Day 15 (n=21) | Cycle 4, Day 1 (n=18) | Cycle 5, Day 1 (n=12) | Cycle 7, Day 1 (n=6) | |
| Sunitinib | 0.14 | 94.9 | 94.4 | 91.6 | 78.6 | 105 | 82.2 | 84.2 | 63.6 |
Ctrough = plasma concentration of SU012662 prior to study drug administration, dose corrected using the following formula Intended Dose/Actual Dose, where Actual Dose: the dose the participant received over the last 10 consecutive days and Intended Dose: the starting dose per study protocol. (NCT00246571)
Timeframe: Predose Day 1, Cycles 1, 2, 3, 4, 5 and 7 and Day 15 of Cycles 1, 2, and 3
| Intervention | ng/mL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 (n=ND) | Cycle 1, Day 15 (n=44) | Cycle 2, Day 1 (n=42) | Cycle 2, Day 15 (n=33) | Cycle 3, Day 1 (n=26) | Cycle 3, Day 15 (n=21) | Cycle 4, Day 1 (n=18) | Cycle 5, Day 1 (n=12) | Cycle 7, Day 1 (n=6) | |
| Sunitinib | NA | 29.9 | 37.2 | 37.3 | 39.8 | 40.1 | 38.7 | 41.9 | 28.6 |
Ctrough = plasma concentration of sunitinib prior to study drug administration, dose corrected using the following formula Intended Dose/Actual Dose, where Actual Dose: the dose the participant received over the last 10 consecutive days and Intended Dose: the starting dose per study protocol. (NCT00246571)
Timeframe: Predose Day 1, Cycles 1, 2, 3, 4, 5 and 7 and Day 15 of Cycles 1, 2, and 3
| Intervention | ng/mL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 (n=ND) | Cycle 1, Day 15 (n=44) | Cycle 2, Day 1 (n=42) | Cycle 2, Day 15 (n=33) | Cycle 3, Day 1 (n=26) | Cycle 3, Day 15 (n=21) | Cycle 4, Day 1 (n=18) | Cycle 5, Day 1 (n=12) | Cycle 7, Day 1 (n=6) | |
| Sunitinib | NA | 67.5 | 73.4 | 69.8 | 69.3 | 65.3 | 68.7 | 58.4 | 64.0 |
Ctrough = plasma concentration of total drug (Sunitinib + SU012662) prior to study drug administration dose corrected using the following formula Intended Dose/Actual Dose, where Actual Dose: the dose the participant received over the last 10 consecutive days and Intended Dose: the starting dose per study protocol. (NCT00246571)
Timeframe: Predose Day 1, Cycles 1, 2, 3, 4, 5 and 7 and Day 15 of Cycles 1, 2, and 3
| Intervention | ng/mL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 (n=ND) | Cycle 1, Day 15 (n=44) | Cycle 2, Day 1 (n=42) | Cycle 2, Day 15 (n=33) | Cycle 3, Day 1 (n=26) | Cycle 3, Day 15 (n=21) | Cycle 4, Day 1 (n=18) | Cycle 5, Day 1 (n=12) | Cycle 7, Day 1 (n=6) | |
| Sunitinib | NA | 97.4 | 111 | 107 | 109 | 105 | 107 | 100 | 92.5 |
Time in months from the first documentation of objective tumor response (CR or PR) to objective tumor progression or death. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4. DR was calculated for the subgroup of participants with a confirmed objective tumor response. (NCT00246571)
Timeframe: Time from first response to disease progression up to 3 years from first dose
| Intervention | months (Median) | |
|---|---|---|
| Core radiology assessment (n=3,7) | Investigator's assessment (n=10,12) | |
| Standard of Care | NA | 4.6 |
| Sunitinib | 3.0 | 3.6 |
(NCT00246571)
Timeframe: Predose Day 1, Cycles 1, 2, 3, 4, 5 and 7 and Day 15 of Cycles 1, 2, and 3
| Intervention | ng/mL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, Day 1 (n=54) | Cycle 1, Day 15 (n=44) | Cycle 2, Day 1 (n=42) | Cycle 2, Day 15 (n=33) | Cycle 3, Day 1 (n=26) | Cycle 3, Day 15 (n=21) | Cycle 4, Day 1 (n=18) | Cycle 5, Day 1 (n=12) | Cycle 7, Day 1 (n=6) | |
| Sunitinib | 0.12 | 65.53 | 62.09 | 58.20 | 50.03 | 64.61 | 51.25 | 48.07 | 42.23 |
Plasma concentrations of sKIT were examined as a potential pharmacodynamic marker (NCT00246571)
Timeframe: Baseline (Cycle 1, Day 1), Day 1 (Cycles 2, 3, 4, 5 and 7), and EOT/withdrawal
| Intervention | pg/mL (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 (n=83, 64) | Cycle 2 Day 1 (n=66, 48) | Cycle 3 Day 1 (n=49, 35) | Cycle 4 Day 1 (n=33, 27) | Cycle 5 Day 1 (n=28, 19) | Cycle 7 Day 1 (n=9, 8) | End Of Treatment (n=49, 11) | |
| Standard of Care | 62232.81 | 65843.75 | 63582.86 | 62885.19 | 54811.05 | 56237.50 | 72854.55 |
| Sunitinib | 61862.65 | 44987.88 | 30855.10 | 25887.88 | 21696.07 | 18166.67 | 25004.08 |
Plasma concentrations of sPlGF were examined as a potential pharmacodynamic marker (NCT00246571)
Timeframe: Baseline (Cycle 1, Day 1), Day 1 (Cycles 2, 3, 4, 5 and 7), and EOT/withdrawal
| Intervention | pg/mL (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 (n=15, 11) | Cycle 2 Day 1 (n=11, 9) | Cycle 3 Day 1 (n=5, 4) | Cycle 4 Day 1 (n=2, 3) | Cycle 5 Day 1 (n=1, 3) | Cycle 7 Day 1 (n=1, 1) | End Of Treatment (n=5, 0) | |
| Standard of Care | 37.23 | 36.24 | 40.08 | 33.23 | 51.83 | 38.50 | 0 |
| Sunitinib | 36.96 | 168.05 | 72.16 | 144.60 | 118.30 | 176.60 | 87.54 |
Plasma concentrations of sVEGF-A were examined as a potential pharmacodynamic marker (NCT00246571)
Timeframe: Baseline (Cycle 1, Day 1), Day 1 (Cycles 2, 3, 4, 5, and 7), and EOT/withdrawal
| Intervention | pg/mL (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 (n=83, 66) | Cycle 2 Day 1 (n=67, 50) | Cycle 3 Day 1 (n=49, 37) | Cycle 4 Day 1 (n=33, 28) | Cycle 5 Day 1 (n=28, 20) | Cycle 7 Day 1 (n=9, 10) | End Of Treatment (n=49, 12) | |
| Standard of Care | 151.49 | 170.43 | 129.31 | 129.88 | 126.97 | 115.58 | 94.76 |
| Sunitinib | 152.28 | 455.17 | 265.56 | 274.94 | 324.09 | 241.78 | 294.66 |
Plasma concentrations of sVEGFR3 were examined as a potential pharmacodynamic marker (NCT00246571)
Timeframe: Baseline (Cycle 1, Day 1), Day 1 (Cycles 2, 3, 4, 5, and 7), and EOT/withdrawal
| Intervention | pg/mL (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 (n=83, 64) | Cycle 2 Day 1 (n=66, 48) | Cycle 3 Day 1 (n=48, 35) | Cycle 4 Day 1 (n=32, 27) | Cycle 5 Day 1 (n=28, 20) | Cycle 7 Day 1 (n=9, 9) | End Of Treatment (n=48, 10) | |
| Standard of Care | 25857.19 | 24515.83 | 29034.86 | 27929.63 | 32949 | 32004.44 | 29194 |
| Sunitinib | 24124.82 | 16299.70 | 14459.38 | 13702.81 | 16345.36 | 24795.56 | 26746.46 |
"Time in months from start of study treatment to first documentation of objective tumor progression (per RECIST) or death due to any cause. PFS was calculated as (first event date minus first randomization date plus 1) divided by 30.4. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD]), or from adverse event (AE) data (where the outcome was Death)." (NCT00246571)
Timeframe: Baseline, every 6 weeks until disease progression or death (up to 3 years from first dose)
| Intervention | Months (Median) | |
|---|---|---|
| Core radiology laboratory assessment | Investigator's assessment | |
| Standard of Care | 2.7 | 2.5 |
| Sunitinib | 2.0 | 1.7 |
Objective response based assessment of confirmed response (CR) or confirmed partial response (PR) according to RECIST. CR are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. PR are those with a greater than or equal to (≥) 30% decrease in the sum of the longest dimensions (SLD) of the target lesions taking as a reference the baseline SLD. (NCT00246571)
Timeframe: Baseline until response or disease progression (up to 3 years from first dose)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Core radiology laboratory assessment | Investigator's assessment | |
| Standard of Care | 6.7 | 11.5 |
| Sunitinib | 2.7 | 8.8 |
"Gamma camera imaging were performed on four occasions (1-4 hours, Day 1, Day 2 or 3, and Day 4 or 5) following completion of the initial infusion and 7+2 days post-therapy infusion in week 2, and again in week 3 or 4 and week 5 following the therapy infusion.~Dosimetry analysis was performed on the series of gamma camera whole-body planar images.~Tumor radioactivity content after the initial infusion was estimated from the geometric mean of anterior and posterior regions of interest counts. The counts for each organ were corrected for background using regions of interest drawn adjacent to each tumor. Resultant counts were converted to activity using a camera sensitivity factor calculated from a gamma camera standard of known activity which was scanned at the same time." (NCT00291486)
Timeframe: 5 weeks
| Intervention | Gy (Mean) |
|---|---|
| All Patients | 13.83 |
| Cohorts 2 and 3; 30 mCi 131I-huA33 | 13.15 |
| Cohorts 4 and 5: 40 mCi 131I-huA33 | 14.89 |
"Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE v3.0). DLT was defined as any of the following related events:~Any grade 2 or greater allergic reaction related to huA33. Any grade ≥ 3 non-haematological toxicity related to 131I-huA33 or capecitabine.~These toxicities included palmar plantar erythema, but skin rash thought to be related to huA33 protein was not a DLT as previous studies have shown no relation of this toxicity to dose of huA33 or radioiodine dose.~Capecitabine cardiotoxicity grade ≥ 3 - including vasospasm, acute coronary syndrome and arrhythmia, necessitated the cessation of study drug in the affected patient but were not considered DLT as these are recognized as idiosyncratic in nature and not known to be related to capecitabine dose.~Any grade ≥ 4 neutropenia ≥ 7 days in duration or any thrombocytopenia with a platelet count < 10 x 10^9/L." (NCT00291486)
Timeframe: 7 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 1 | 0 |
| Cohort 2 | 2 |
| Cohort 3 | 0 |
| Cohort 4 | 0 |
| Cohort 5 | 0 |
T1/2 biological is the clearance of the isotope from the whole body. Following the initial 131I-huA33 infusion, gamma camera scans were acquired over a 1 week period (1-4 hours, Day 1, Day 2 or 3, and Day 4 or 5). Whole body clearance, or biological half time, T1/2 biological, was calculated from the whole body anterior and posterior planar images. A region of interest (ROI) was calculated to encompass the whole body, and for each ROI at each time point, the mean counts per pixel per minute was normalised to imaging time point Day 1. (NCT00291486)
Timeframe: 1 week
| Intervention | hours (Mean) | ||
|---|---|---|---|
| Whole Body Clearance (T1/2 biologic) | Normal Organ Clearance in the Liver (T1/2 biological - liver) | Normal Organ Clearance in the kidney (T1/2 biological - kidney) | |
| Cohorts 1-5 | 219.56 | 62.29 | 104.89 |
"Blood samples for pharmacokinetics (PK) were drawn in week 0 immediately pre-initial 131I-huA33 infusion; then 5 minutes, 60 minutes and 2 hours post-initial 131I-huA33 infusion, Day 1, Day 2 or Day 3, Day 4 or Day 5. In week 1, PK samples were collected immediately pre-therapy 131I-huA33 infusion, 5 minutes, 24 ± 2 hours and approximately 7 days post-therapy 13II-huA33 infusion, then weekly until 4 weeks post therapy.~Pharmacokinetic calculations were performed on serum 131I-huA33 data using a curve fitting Program (WinNonLin version 5.2; Pharsight Co., Mountain View, CA)." (NCT00291486)
Timeframe: 5 weeks
| Intervention | ml/hr (Mean) | |
|---|---|---|
| Initial dose CL | Therapy dose CL | |
| Cohort 5; 1250 mg/m2/Day Capecitabine | 34.65 | 35.53 |
| Cohorts 1 and 2; 1500 mg/m2/Day Capecitabine | 34.88 | 26.88 |
| Cohorts 3 and 4; 1000 mg/m2/Day Capecitabine | 40.54 | 39.41 |
"Gamma camera imaging with anterior and posterior whole body scans using conjugate view methodology were performed on four occasions (1-4 hours, Day 1, Day 2 or 3, and Day 4 or 5) following completion of the intravenous initial infusion.~Dosimetric analysis was performed on the series of gamma camera whole-body planar images acquired in all patients following the first infusion.~Organ radioactivity content was estimated from the geometric mean of anterior and posterior regions of interest counts. The counts for each organ were corrected for background using regions of interest drawn adjacent to each organ where whole body thickness was comparable." (NCT00291486)
Timeframe: 1 week
| Intervention | cGy/MBq (Mean) | ||||
|---|---|---|---|---|---|
| Liver | Spleen | Kidney | Lung | Red Marrow | |
| Cohorts 1-5 | 0.12 | 0.18 | 0.14 | 0.09 | 0.056 |
"Blood samples for pharmacokinetics (PK) were drawn in week 0 immediately pre-initial 131I-huA33 infusion; then 5 minutes, 60 minutes and 2 hours post-initial 131I-huA33 infusion, Day 1, Day 2 or Day 3, Day 4 or Day 5. In week 1, PK samples were collected immediately pre-therapy 131I-huA33 infusion, 5 minutes, 24 ± 2 hours and approximately 7 days post-therapy 131I-huA33 infusion, then weekly until 4 weeks post therapy.~Pharmacokinetic calculations were performed on serum 131I-huA33 data using a curve fitting Program (WinNonLin version 5.2; Pharsight Co., Mountain View, CA)." (NCT00291486)
Timeframe: 5 weeks
| Intervention | mcg.hr/mL (Mean) | |
|---|---|---|
| AUC after initial 131I-huA33 infusion | AUC after therapy 131I-huA33 infusion | |
| Cohorts 1-5 | 130.43 | 592.46 |
"Blood samples for pharmacokinetics (PK) were drawn in week 0 immediately pre-initial 131I-huA33 infusion; then 5 minutes, 60 minutes and 2 hours post-initial 131I-huA33 infusion, Day 1, Day 2 or Day 3, Day 4 or Day 5. In week 1, PK samples were collected immediately pre-therapy 131I-huA33 infusion, 5 minutes, 24 ± 2 hours and approximately 7 days post-therapy 13II-huA33 infusion, then weekly until 4 weeks post therapy.~Pharmacokinetic calculations were performed on serum 131I-huA33 data using a curve fitting Program (WinNonLin version 5.2; Pharsight Co., Mountain View, CA)." (NCT00291486)
Timeframe: 5 weeks
| Intervention | mL/hr (Mean) | |
|---|---|---|
| CL after initial 131I-huA33 infusion | CL after therapy 131I-huA33 infusion | |
| Cohorts 1-5 | 36.72 | 32.60 |
"Blood samples for pharmacokinetics (PK) were drawn in week 0 immediately pre-initial 131I-huA33 infusion; then 5 minutes, 60 minutes and 2 hours post-initial 131I-huA33 infusion, Day 1, Day 2 or Day 3, Day 4 or Day 5. In week 1, PK samples were collected immediately pre-therapy 131I-huA33 infusion, 5 minutes, 24 ± 2 hours and approximately 7 days post-therapy 131I-huA33 infusion, then weekly until 4 weeks post therapy.~Pharmacokinetic calculations were performed on serum 131I-huA33 data using a curve fitting Program (WinNonLin version 5.2; Pharsight Co., Mountain View, CA)." (NCT00291486)
Timeframe: 5 weeks
| Intervention | mcg/mL (Mean) | |
|---|---|---|
| Cmax after initial 131I-huA33 infusion | Cmax after therapy 131I-huA33 infusion | |
| Cohorts 1-5 | 1.53 | 5.52 |
"Blood samples for pharmacokinetics (PK) were drawn in week 0 immediately pre-initial 131I-huA33 infusion; then 5 minutes, 60 minutes and 2 hours post-initial 131I-huA33 infusion, Day 1, Day 2 or Day 3, Day 4 or Day 5. In week 1, PK samples were collected immediately pre-therapy 131I-huA33 infusion, 5 minutes, 24 ± 2 hours and approximately 7 days post-therapy 131I-huA33 infusion, then weekly until 4 weeks post therapy.~Pharmacokinetic calculations were performed on serum 131I-huA33 data using a curve fitting Program (WinNonLin version 5.2; Pharsight Co., Mountain View, CA)." (NCT00291486)
Timeframe: 5 weeks
| Intervention | hours (Mean) | |||
|---|---|---|---|---|
| T½α after initial 131I-huA33 infusion | T½α after therapy 131I-huA33 infusion | T½β after initial 131I-huA33 infusion | T½β after therapy 131I-huA33 infusion | |
| Cohorts 1-5 | 15.78 | 28.63 | 100.24 | 152.60 |
"Blood samples for pharmacokinetics (PK) were drawn in week 0 immediately pre-initial 131I-huA33 infusion; then 5 minutes, 60 minutes and 2 hours post-initial 131I-huA33 infusion, Day 1, Day 2 or Day 3, Day 4 or Day 5. In week 1, PK samples were collected immediately pre-therapy 131I-huA33 infusion, 5 minutes, 24 ± 2 hours and approximately 7 days post-therapy 131I-huA33 infusion, then weekly until 4 weeks post therapy.~Pharmacokinetic calculations were performed on serum 131I-huA33 data using a curve fitting Program (WinNonLin version 5.2; Pharsight Co., Mountain View, CA)." (NCT00291486)
Timeframe: 5 weeks
| Intervention | mL (Mean) | |
|---|---|---|
| V1 after initial 131I-huA33 infusion | V1 after therapy 131I-huA33 infusion | |
| Cohorts 1-5 | 3204.26 | 3363.69 |
Serum samples for human anti-human antibody (HAHA) assessment were collected prior to each 131I-huA33 infusion, at weekly intervals during weeks 0-7, then alternate weeks until the end-of-study visit. Measurement of immune responses to huA33 in patients serum was performed using a BIAcore 2000 biosensor (Biacore AB, Uppsala, Sweden). (NCT00291486)
Timeframe: 13 weeks
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre-treatment72460703 | Pre-treatment72460704 | Pre-treatment72460705 | Pre-treatment72460706 | Pre-treatment72460702 | Week 172460703 | Week 172460704 | Week 172460705 | Week 172460706 | Week 172460702 | Week 272460703 | Week 272460704 | Week 272460705 | Week 272460706 | Week 272460702 | Week 372460703 | Week 372460704 | Week 372460705 | Week 372460706 | Week 372460702 | Week 472460703 | Week 472460704 | Week 472460702 | Week 472460705 | Week 472460706 | Week 572460703 | Week 572460704 | Week 572460705 | Week 572460702 | Week 572460706 | Week 672460703 | Week 672460704 | Week 672460706 | Week 672460702 | Week 672460705 | Week 872460702 | Week 872460703 | Week 872460704 | Week 872460705 | Week 872460706 | Week 10-1172460703 | Week 10-1172460704 | Week 10-1172460705 | Week 10-1172460706 | Week 10-1172460702 | Week 12-1372460703 | Week 12-1372460704 | Week 12-1372460705 | Week 12-1372460706 | Week 12-1372460702 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Negative HAHA | Positive HAHA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cohort 2 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cohort 4 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cohort 5 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cohort 2 | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cohort 3 | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cohort 4 | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cohort 5 | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cohort 4 | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cohort 3 | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cohort 4 | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cohort 3 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cohort 5 | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cohort 5 | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cohort 1 | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cohort 1 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cohort 2 | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cohort 2 | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cohort 3 | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cohort 5 | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cohort 1 | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of study participants experiencing toxicity (serious adverse events or adverse events). Study participants assessed for this outcome measure must have received at least one dose of protocol therapy. Toxicity assessed according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE). (NCT00290693)
Timeframe: Up to 1 year
| Intervention | participants (Number) |
|---|---|
| CapTere (Capecitabine + Docetaxel) | 38 |
Overall survival is measured from the time from date of initial protocol therapy to date of death. In the absence of confirmation of death, survival time will be censored to last date of follow-up. (NCT00290693)
Timeframe: Up to 1 year
| Intervention | months (Median) |
|---|---|
| CapTere (Capecitabine + Docetaxel) | 5.3 |
Progression-free survival (PFS) is measured the time from the start of protocol therapy to disease progression or death from any cause. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT00290693)
Timeframe: Up to 1 year
| Intervention | months (Median) |
|---|---|
| CapTere (Capecitabine + Docetaxel) | 3.7 |
Rate of participants achieving a 50% or more reduction in CA 19-9 levels after receiving protocol therapy. Baseline CA-19-9 will be compared to the lowest recorded value on patients receiving therapy on protocol. A 50% drop in CA 19-9 in patients with baseline levels above 100 U/ml will be recorded as a CA 19-9 response if the > 50% drop can be confirmed with at least one more CA 19-9 level thereafter with > 50% drop compared to baseline. (NCT00290693)
Timeframe: Up to 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| CapTere (Capecitabine + Docetaxel) | 35.48 |
Rate of participants achieving complete response (CR) or partial response (PR) to Captere therapy according to RECIST criteria v 1.0. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions. (NCT00290693)
Timeframe: Up to 1 year
| Intervention | participants (Number) | ||
|---|---|---|---|
| Partial Response (PR) >= 2 cycles | Stable Disease (SD), >= 2 cycles | Complete Response (CR), >= 2 cycles | |
| CapTere (Capecitabine + Docetaxel) | 6 | 25 | 0 |
The percentage of subjects with Complete Response, Partial Response, or Stable Disease at least 24 weeks per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.0: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. (NCT00741260)
Timeframe: From first dose date to progression or last tumor assessment, up to three years.
| Intervention | percentage of participants (Number) |
|---|---|
| Prior Lapatinib Subjects | 71.4 |
| Lapatinib Naive Subjects P1 | 72.1 |
| Lapatinib Naive Subjects Part 2 + Part 1 | 73.0 |
Duration of response was measured from the time at which response criteria were met for complete response (CR) or partial response (PR) (whichever status was recorded first) until the first date of recurrence or progressive disease (PD) or death per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.0: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions. (NCT00741260)
Timeframe: From start date of response to first PD/death, up to three years.
| Intervention | weeks (Median) |
|---|---|
| Prior Lapatinib Subjects | 48.3 |
| Lapatinib Naive Subjects P1 | 46.3 |
| Lapatinib Naive Subjects Part 2 + Part 1 | 46.3 |
MTD reflects the highest dose of capecitabine in combination with neratinib that did not cause a selected Grade 3 toxicity in >= 2 participants, which is any of 1) Grade 3 or 4 non-hematologic toxicity (Grade 3 asthenia was not considered a DLT unless lasting >3 days, 2) Grade 3 diarrhea lasting >2 days on optimal medical therapy or associated with fever or dehydration. 3) Grade 4 neutropenia lasting ≥ 3 days or Grade 4 febrile neutropenia, 4) Grade 4 thrombocytopenia lasting ≥3 days or associated with bleeding or requiring platelet transfusion, 5) Delayed recovery [to ≥ National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or baseline] from one of the above listed toxicities that were related to neratinib and/or capecitabine that delayed the initiation of the next dose by more than 3 weeks. (NCT00741260)
Timeframe: From first dose date to day 21.
| Intervention | mg/m^2 (Number) |
|---|---|
| Capecitabine in Combination With Neratinib | 1500 |
MTD reflects the highest dose of neratinib plus capeciteabine that did not cause a selected Grade 3 toxicity in >= 2 participants, which is any of 1) Grade 3 or 4 non-hematologic toxicity (Grade 3 asthenia was not considered a DLT unless lasting >3 days, 2) Grade 3 diarrhea lasting >2 days on optimal medical therapy or associated with fever or dehydration. 3) Grade 4 neutropenia lasting ≥ 3 days or Grade 4 febrile neutropenia, 4) Grade 4 thrombocytopenia lasting ≥3 days or associated with bleeding or requiring platelet transfusion, 5) Delayed recovery [to ≥ National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or baseline] from one of the above listed toxicities that were related to neratinib and/or capecitabine that delayed the initiation of the next dose by more than 3 weeks. (NCT00741260)
Timeframe: From first dose date to day 21.
| Intervention | mg (Number) |
|---|---|
| Neratinib in Combination With Capecitabine | 240 |
Number of participants reporting Adverse Events Causing Dose Limiting Toxicities (DLT). (NCT00741260)
Timeframe: From first dose date to day 21
| Intervention | Participants (Count of Participants) |
|---|---|
| N160 + C1500 | 0 |
| N160 + C2000 | 2 |
| N200 + C2000 | 2 |
| N240 + C1500 | 0 |
| N240 + C2000 | 2 |
| N + C MTD - No Prior Lap | 0 |
| N + C MTD - Prior Lap | 0 |
Number of Subjects with Complete or Partial Response per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v.1.0: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; and Non-PD for non-target lesions, and no new lesions. (NCT00741260)
Timeframe: From first dose date to progression or last tumor assessment, up to three years.
| Intervention | percentage of participants (Number) |
|---|---|
| Prior Lapatinib Subjects | 57.1 |
| Lapatinib Naive Subjects P1 | 63.9 |
| Lapatinib Naive Subjects Part 2 + Part 1 | 63.5 |
For participants with a best overall response of CR or PR, the duration of overall response was measured from the time that the criteria for CR or PR (whichever occurred first) was met until the first date that progressive disease was objectively documented or until the date of death due to underlying cancer, whichever occurred first. Data for participants who did not have an event or who were alive without an objectively documented progressive disease were censored at the date of last adequate tumor assessment. Median duration of overall response was estimated using the Kaplan-Meier method. (NCT00577031)
Timeframe: Baseline, every 3 weeks (every cycle) to disease progression or death up to 5 years
| Intervention | months (Median) |
|---|---|
| Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab | 8.52 |
For participants with a best overall response of CR, PR, or SD during first line treatment, the duration of stable response was measured from the time that the criteria for CR, PR, or SD (whichever occurred first) was met until the first date that progressive disease was objectively documented or until the date of death due to underlying cancer, whichever occurred first. Data for participants who did not have an event or who were alive without an objectively documented progressive disease were censored at the date of last adequate tumor assessment. Median duration of stable response was estimated using the Kaplan-Meier method. (NCT00577031)
Timeframe: Baseline, every 3 weeks (every cycle) to disease progression or death up to 5 years
| Intervention | months (Median) |
|---|---|
| Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab | 10.39 |
Overall survival was defined as the time from the date of the first day of treatment until the date of death from any cause. If a participant was not known to have died, survival was censored at the last date the participant was known to be alive. (NCT00577031)
Timeframe: Baseline, Day 1 of every cycle to end-of-treatment, every 3 months during longer-term follow-up, or to death due to any cause up to 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab | 50.76 |
Overall survival was defined as the time from the date of the first day of treatment until the date of death from any cause. If a participant was not known to have died, survival was censored at the last date the participant was known to be alive. Median overall survival was estimated using the Kaplan-Meier method. (NCT00577031)
Timeframe: Baseline, Day 1 of every cycle to end-of-treatment, every 3 months during longer-term follow-up, or to death due to any cause up to 5 years
| Intervention | months (Median) |
|---|---|
| Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab | 23.15 |
The percentage of participants with a best overall response of CR or PR according to RECIST. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis less than [<]10 millimeters [mm]). No new lesions. PR was defined as a greater than or equal to (≥) 30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. (NCT00577031)
Timeframe: Baseline, every 9 weeks (every 3 cycles) until end of treatment, disease progression, or withdrawal up to 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab | 58.79 |
CR and PR were defined using RECIST v1.0 criteria. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis <10 mm). No new lesions. PR was defined as a ≥30% decrease under baseline of the sum of diameters of all target lesions. Short axis was used in sum for target nodes, while longest diameter was used in sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. (NCT00577031)
Timeframe: Baseline, every 3 weeks (every cycle) to disease progression or death up to 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab | 54.64 |
CR and PR were defined using RECIST v1.0. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis <10 mm). No new lesions. PR was defined as a ≥30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. (NCT00577031)
Timeframe: Baseline, every 9 weeks (every 3 cycles) until end of treatment, disease progression, or withdrawal up to 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab | 49.24 |
Stable response defined as participants with a best overall response of CR, PR, or stable disease (SD), defined using RECIST v1.0 criteria. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis <10 mm). No new lesions. PR was defined as a ≥30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. SD defined as neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum longest diameter since the treatment started. (NCT00577031)
Timeframe: Baseline, every 3 weeks (every cycle) to disease progression or death up to 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab | 52.63 |
Treatment-failure was defined as discontinuation of treatment for any reason, including the following qualifying events: death due to any cause, adverse event, insufficient therapeutic response (progression of disease), failure to return (lost to follow-up), refusing treatment (participant non-compliance), being unwilling to cooperate and withdrawing consent (participant withdrew consent). (NCT00577031)
Timeframe: Baseline, every 3 weeks (every cycle) to disease progression or death up to 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab | 82.74 |
PFS was defined as the time period in months from the start of study treatment to the first observation of disease progression or death from any cause, whichever occurred first. Data for participants with no tumor assessments after baseline but who were still alive at the time of the clinical cutoff were censored at Day 1. Participants who underwent surgery after experiencing a sufficient shrinkage of the tumor, had any relapse, new occurrence of colorectal cancer, or who died were all considered as having had an event. Participants who underwent surgery without any such event were censored at the date of the last tumor assessment that documented that neither a relapse nor a new colorectal cancer had occurred. Median PFS was estimated using the Kaplan-Meier method. (NCT00577031)
Timeframe: Baseline and Day 1 of every cycle until disease progression or death up to 5 years
| Intervention | months (Median) |
|---|---|
| Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab | 9.70 |
PFS was defined as the time period in months from the start of study treatment to the first observation of disease progression or death from any cause, whichever occurred first. Data for participants with no tumor assessments after baseline but who were still alive at the time of the clinical cutoff were censored at Day 1. Participants who underwent surgery after experiencing a sufficient shrinkage of the tumor, had any relapse, new occurrence of colorectal cancer, or who died were all considered as having had an event. Participants who underwent surgery without any such event were censored at the date of the last tumor assessment that documented neither a relapse nor a new colorectal cancer had occurred. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20 percent (%) increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT00577031)
Timeframe: Baseline and Day 1 of every cycle until disease progression or death up to 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab | 50.25 |
Time to overall response (CR or PR) was calculated as the time between the date of start of treatment until first documented response (CR or PR defined per RECIST v1.0). Participants who did not achieve CR or PR were censored at the date of progression, death, or at last adequate tumor assessment date. Median time to CR or PR overall response was estimated using the Kaplan-Meier method. (NCT00577031)
Timeframe: Baseline, every 9 weeks (every 3 cycles) until end of treatment, disease progression, or withdrawal up to 5 years
| Intervention | months (Median) |
|---|---|
| Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab | 3.93 |
Time to treatment-failure was defined as the time from the first day of treatment to discontinuation of treatment for any reason, including: death due to any cause, adverse event, insufficient therapeutic response (progression of disease), failure to return (lost to follow-up), refusing treatment (participant non-compliance), being unwilling to cooperate and withdrawing consent (participant withdrew consent). For participants who did not experience a qualifying event, their data were censored at the earlier of either the date of last tumour assessment or the date of the last intake of study medication. Median time to treatment-failure was estimated using the Kaplan-Meier method. (NCT00577031)
Timeframe: Baseline, every 3 weeks (every cycle) to disease progression or death up to 5 years
| Intervention | months (Median) |
|---|---|
| Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab | 6.69 |
"Quality of life (QoL) assessments were used to derive pre-specified QoL scores according to the QoL manual EQ-5D-3 Level (3L) user guide for instrument version 4.0. The EQ-5D is a participant rated questionnaire to assess health-related quality of life in terms of a single index value. The visual analog scale (VAS) component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state. The overall health score absolute changes were calculated for each participant as follows: (score at the end of treatment minus score at baseline). EQ-5D health states were converted into EQ-5D-3L raw index value by applying the scoring algorithm based on the European EQ-net VAS set. The raw index was chosen instead of rescaled index, since the questionnaire was used in order to obtain a quality of life assessment. The raw index scores ranged from 0 (worst health state) to 100 (best health state)." (NCT00577031)
Timeframe: Baseline, every 9 weeks (every 3 cycles), at end-of-treatment up to 5 years
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Baseline | Last visit | Absolute change from baseline | |
| Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab | 80.24 | 74.94 | -5.30 |
The percentage of participants who underwent surgery during the study period with an evaluation of their disease status after surgery. The surgery during the study period was described by reason: curative, palliative, biopsy, other, or unknown. Residual disease status after surgery was described as: no residual disease due to radical surgery, presence of residual disease, unknown or not applicable. (NCT00577031)
Timeframe: At surgery, at least 6 to 8 weeks after last dose of bevacizumab up to 5 years
| Intervention | percentage of participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Curative, no residual disease | Curative, residual disease | Curative, unknown | Curative, not applicable | Palliative, no residual disease | Palliative, residual disease | Palliative, unknown | Palliative, not applicable | Biopsy, residual disease | Biopsy, not applicable | Unknown, unknown | Unknown, not applicable | Other, residual disease | Other, not applicable | |
| Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab | 55.77 | 13.46 | 3.85 | 7.69 | 3.85 | 7.69 | 3.85 | 1.92 | 1.92 | 1.92 | 1.92 | 3.85 | 1.92 | 3.85 |
"The percentage of participants with a best overall response of CR or PR according to RECIST. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis <10 mm). No new lesions. PR was defined as ≥30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.~The K-Ras and/or the B-Raf gene mutation status of participants was evaluated by the central laboratory using tumor samples. Wild-type participants did not have a mutation in either gene." (NCT00577031)
Timeframe: Baseline, every 9 weeks (every 3 cycles) until end of treatment, disease progression, or withdrawal up to 5 years
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Wild-type (n=18) | Gene mutation (n=15) | |
| Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab | 88.89 | 66.67 |
Tumour Response Rate per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT: Complete Response (CR) - Disappearance of all target lesions which is confirmed if determined by two observations not less than 4 weeks apart; Partial Response (PR) - >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT00724503)
Timeframe: Through study completion, up to 60 months
| Intervention | percentage of participants (Number) |
|---|---|
| B: FOLFOX + SIR-Spheres | 76.4 |
| A: FOLFOX Alone | 68.1 |
PFS defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as an increase in the sum of the longest diameters of ≥ 20% and an absolute increase in the sum of the longest diameters of ≥ 5 mm, or the appearance of a new lesion. (NCT00724503)
Timeframe: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months
| Intervention | Months (Median) |
|---|---|
| mFOLFOX6 Plus SIRT | 10.7 |
| mFOLFOX6 Alone | 10.2 |
OS defined as the time interval between the date of randomization and the date of death from any cause. (NCT01721954)
Timeframe: From date of randomization until the date of death from any cause assessed up 3 yrs 8 months
| Intervention | months (Median) |
|---|---|
| mFOLFOX6 Plus SIRT | 25.9 |
| mFOLFOX6 Alone | 25.0 |
PFS defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as an increase in the sum of the longest diameters of ≥ 20% and an absolute increase in the sum of the longest diameters of ≥ 5 mm, or the appearance of a new lesion. (NCT01721954)
Timeframe: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years 8 months.
| Intervention | months (Median) |
|---|---|
| mFOLFOX6 Plus SIRT | 11.8 |
| mFOLFOX6 Alone | 11.2 |
"Summary of overall objective response rate based on tumor assessment by the Independent Review Committee (IRC) as per Response Evaluation Criteria in Solid Tumours (RECIST) criteria. ORR was defined as the proportion of patients with confirmed Complete Response (CR) or confirmed Partial Response (PR) relative to the total number of patients in the analysis population.~Per RECIST v 1.0 target lesions evaluation and assessed by tumor imaging: Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): >=30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.~The study was not powered for comparison of ORR between the two arms (non-comparative, open-label study)." (NCT00851084)
Timeframe: From the date of the first randomization until the study data cut-off date, 14 April 2011 (approximately 26 months)
| Intervention | percentage of participants (Number) |
|---|---|
| mFOLFOX6 Only | 45.9 |
| mFOLFOX6 + Aflibercept | 49.1 |
"Overall survival was defined as the time from the date of randomization to the date of death due to any cause. In absence of confirmation of death, survival time was censored at the earliest between the last date the patient was known to be alive and the study cutoff date.~The study was not powered for comparison of OS between the two arms (non-comparative, open-label study)." (NCT00851084)
Timeframe: From the date of the first randomization until the study data cut-off date, 14 April 2011 (approximately 26 months)
| Intervention | months (Median) |
|---|---|
| mFOLFOX6 Only | 22.31 |
| mFOLFOX6 + Aflibercept | 19.45 |
"PFS was defined as the time from the date of randomization to the date of tumor progression or death from any cause, whichever occurred first. PFS was based on tumor assessment by the Independent Review Committee (IRC). PFS was estimated from Kaplan-Meier Curves.~The study was not powered for comparison of PFS between the two arms (non-comparative, open-label study).~Progression was defined using Response Evaluation Criteria In Solid Tumors (RECIST v1.0), as at least a 20 percent increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non target-lesions." (NCT00851084)
Timeframe: From the date of the first randomization until the study data cut-off date, 14 April 2011 (approximately 26 months)
| Intervention | Months (Median) |
|---|---|
| mFOLFOX6 Only | 8.77 |
| mFOLFOX6 + Aflibercept | 8.48 |
PFS rate at 12 months was defined as the percentage of patients alive without disease progression at 12 months after randomization. The primary efficacy analysis was based on assessment by the Independent Review Committee (IRC). The study was not powered for comparison of PFS rate at 12 months between the two arms (non-comparative, open-label study). Progression was defined using Response Evaluation Criteria In Solid Tumors (RECIST v1.0), as at least a 20 percent increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non target-lesions. (NCT00851084)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| mFOLFOX6 Only | 21.2 |
| mFOLFOX6 + Aflibercept | 25.8 |
The antidrug antibody (ADA) assay was evaluated for participants receiving aflibercept. (NCT00851084)
Timeframe: Any time post baseline and 90 days after the last infusion of aflibercept, according to baseline status
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| ADA Negative post-baseline | ADA Positive (drug specific) post-baseline | ADA Negative 90 days after last dose | ADA Positive 90 days after last dose | |
| Negative or Missing | 105 | 7 | 45 | 0 |
| Positive | 1 | 2 | 1 | 1 |
Summary of treatment-emergent adverse events in the safety population. The National Cancer Institute Common Terminology Criteria for Adverse Event (NCI-CTCAE), version 3.0 was used in this study to grade the severity of AEs. (NCT00851084)
Timeframe: From the date of the first randomization up to 30 days after the treatment discontinuation or until TEAE was resolved or stabilized
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Treatment Emergent Adverse Event (TEAE) | Grade 3-4 TEAE | Treatment emergent Serious Adverse Event (SAE) | TEAE leading to death | Premature treatment discontinuation | Permanent treatment discontinuation | |
| mFOLFOX6 + Aflibercept | 119 | 108 | 55 | 8 | 34 | 37 |
| mFOLFOX6 Only | 115 | 87 | 32 | 2 | NA | 26 |
DoR was measured from the time measurement criteria are first met for Complete Response or Partial Response or until the first date that the criteria for disease progression or death from any cause. whichever is first recorded. As defined according to RECIST v1.1, CR is the disappearance of all non-nodal target lesions, and PR is the short axes of any target lymph nodes reduced to < 10 mm and at least a 30% decrease in the sum of the diameters of target lesions including the short axes of any target lymph nodes.) (NCT01111604)
Timeframe: Criteria First Met for CR or PR until Disease Progression or Death from Any Cause (Up to 95 Weeks)
| Intervention | Weeks (Median) |
|---|---|
| mFOLFOX-6 | 35.6 |
| mFOLFOX-6 + Ramucirumab | NA |
| mFOLFOX-6 + Icrucumab | NA |
A sample will be considered positive for anti-Ramucirumab antibodies if it exhibits a post-baseline antibody level exceeding the normal anti-Ramucirumab antibody level seen in healthy untreated individuals. (NCT01111604)
Timeframe: 31 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| mFOLFOX-6 + Ramucirumab | 0 |
Overall survival is defined as the time from baseline to the date of death from any cause. If the participant is alive at the end of the follow-up period or is lost to follow-up, OS will be censored on the last date the participant is known to be alive. (NCT01111604)
Timeframe: Baseline Until Death from Any Cause (Up to 163 Weeks)
| Intervention | Weeks (Median) |
|---|---|
| mFOLFOX-6 | 53.6 |
| mFOLFOX-6 + Ramucirumab | 41.7 |
| mFOLFOX-6 + Icrucumab | 42.0 |
The ORR is the percentage of participants with Complete Response (CR, the disappearance of target lesions and any pathological lymph nodes [target or non-target] taking as reference the baseline sum of diameters in response to treatment) or Partial Response (PR, at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters in response to treatment) according to RECIST v1.1 from the start of the treatment until disease progression. (NCT01111604)
Timeframe: Baseline until Disease Progression (Up to 95 Weeks)
| Intervention | percentage of participants (Number) |
|---|---|
| mFOLFOX-6 | 14 |
| mFOLFOX-6 + Ramucirumab | 3.8 |
| mFOLFOX-6 + Icrucumab | 3.8 |
Maximum concentration (1 hour post end of infusion, Cmax) is the concentration measured in serum. (NCT01111604)
Timeframe: Cycle 5, 1 Hour Post End of Infusion
| Intervention | microgram/milliliter (µg/mL) (Geometric Mean) |
|---|---|
| mFOLFOX-6 + Ramucirumab | NA |
| mFOLFOX-6 + Icrucumab | 201 |
Trough (prior to infusion, Ctrough) concentrations measured in serum. (NCT01111604)
Timeframe: Cycle 5, Prior to Infusion
| Intervention | µg/mL (Geometric Mean) |
|---|---|
| mFOLFOX-6 + Ramucirumab | 53.6 |
| mFOLFOX-6 + Icrucumab | 146 |
PFS is defined as the time from baseline until the date of disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1), or death from any cause, whichever was first. Participants who die without a reported prior progression will be considered to have progressed on the day of their death. Participants who did not progress, are lost to follow-up, or have missed two or more scheduled tumor assessments will be censored at the day of their last radiographic tumor assessment, if there are no post-baseline tumor measurements for a randomized and treated participant, the participant will be censored at the date of randomization. If death or progressive disease (PD) occurs after 2 or more missing radiographic visits, censoring will occur at the date of the last radiographic visit prior to the last visit. (NCT01111604)
Timeframe: Baseline until Disease Progression or Death from Any Cause (Up to 95 Weeks)
| Intervention | Weeks (Median) |
|---|---|
| mFOLFOX-6 | 18.4 |
| mFOLFOX-6 + Ramucirumab | 21.4 |
| mFOLFOX-6 + Icrucumab | 15.9 |
A summary of serious AEs (SAEs) and all other non-serious AEs regardless of causality, is located in the Reported Adverse Events module. (NCT01111604)
Timeframe: Baseline up to 165 weeks
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Any TEAE | Any SAE | Any Grade ≥3 AE | Any AE leading to discontinuation (any drug) | |
| mFOLFOX-6 | 49 | 11 | 30 | 6 |
| mFOLFOX-6 + Icrucumab | 52 | 12 | 31 | 11 |
| mFOLFOX-6 + Ramucirumab | 52 | 18 | 37 | 18 |
Median time from randomization to date of death caclulated using the Kaplan-Meier method. Participants were censored on the date of last contact (i.e., the date the participant was last known to be alive) if they were not known to have died. (NCT00911170)
Timeframe: From randomization to the data cut-off date of 8 June 2012. Median time on study was 11.6 months and the maximum was 27.6 months.
| Intervention | months (Median) |
|---|---|
| Placebo | 24.6 |
| Pegfilgrastim | 21.8 |
The percentage of participants with a complete response (CR) or partial response (PR) defined by the RECIST v1.1 criteria at any time during the study. Response was be determined by the investigator's assessment of radiographic scans. CR: Disappearance of all non-nodal target lesions and the disappearance of all non-nodal non-target lesions, and no new lesions. All nodal lesions must have reduction of short axis to < 10 mm. PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters and no new lesions and/or unequivocal progression of existing non-target lesions, or, the disappearance of all non-nodal target lesions with persistence of one or more non-target lesion(s). (NCT00911170)
Timeframe: From randomization to the data cut-off date of 8 June 2012. Median time on study was 11.6 months and the maximum was 27.6 months.
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 56.7 |
| Pegfilgrastim | 58.1 |
Grade 3/4 febrile neutropenia (FN) is defined as: • A temperature ≥ 38.0°C (≥ 100.4°F) and absolute neutrophil count (ANC) < 1.0 × 10^9/L, where ANC was measured the same day or within ± 1 calendar day of a temperature ≥ 38.0°C (≥ 100.4°F), or • An ANC < 1.0 × 10^9/L in combination with: - documented sepsis or infection, OR - neutropenia-related hospitalization where ANC was measured the same day or within ± 1 calendar day. Participants monitored their oral temperatures and maintained diaries to record their temperature twice per day: once in the morning and once in the evening, as well as whenever they suspect they had fever throughout the first 4 cycles of chemotherapy treatment. (NCT00911170)
Timeframe: Approximately 2 months duration (Daily for 4 cycles of treatment; 2 weeks per cycle)
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 5.7 |
| Pegfilgrastim | 2.4 |
Grade 3/4 severe neutropenia is defined as neutropenia with absolute neutrophil count (ANC) <1.0 x 10^9/L. (NCT00911170)
Timeframe: Approximately 2 months duration (Daily for 4 cycles of treatment; 2 weeks per cycle)
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 17.0 |
| Pegfilgrastim | 3.6 |
"Grade 4 febrile neutropenia (FN) is defined as:~A temperature ≥ 38.0ºC (≥ 100.4ºF) and absolute neutrophil count (ANC) < 0.5 × 10^9/L, where ANC is measured the same day or within +/- 1 calendar day of a temperature ≥ 38.0ºC (≥ 100.4ºF), or~An ANC <0.5 × 10^9/L in combination with:~Documented sepsis or infection, OR~Neutropenia-related hospitalization where ANC is measured the same day or within +/- 1 calendar day." (NCT00911170)
Timeframe: Approximately 2 months duration (Daily for 4 cycles of treatment; 2 weeks per cycle)
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 3.5 |
| Pegfilgrastim | 2.4 |
Grade 4 severe neutropenia is defined as neutropenia with absolute neutrophil count (ANC) <0.5 x 10^9/L. (NCT00911170)
Timeframe: Approximately 2 months duration (Daily for 4 cycles of treatment; 2 weeks per cycle)
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 8.3 |
| Pegfilgrastim | 2.4 |
Time from randomization to date of radiological disease progression or death from any cause, whichever event occurs first, calculated using the Kaplan-Meier method. Participants without either event by the analysis data cutoff date were censored on the date of their last evaluable disease assessment. Disease progression based on the investigator's assessment of radiographic scans using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Clinical progression without radiological assessment was not be considered a disease progression in this analysis. Progression defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. (NCT00911170)
Timeframe: From randomization to the data cut-off date of 8 June 2012. Median time on study was 11.6 months and the maximum was 27.6 months.
| Intervention | months (Median) |
|---|---|
| Placebo | 10.1 |
| Pegfilgrastim | 9.7 |
Time from randomization to date of radiological disease progression calculated using the Kaplan-Meier method. Participants without progression were censored on the date of their last radiographic tumor assessment. Disease progression based on the investigator's assessment of scans using the RECIST v1.1. Clinical progression without radiological assessment was not considered a disease progression. Progression defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. (NCT00911170)
Timeframe: From randomization to the data cut-off date of 8 June 2012. Median time on study was 11.6 months and the maximum was 27.6 months.
| Intervention | months (Median) |
|---|---|
| Placebo | 11.1 |
| Pegfilgrastim | 10.8 |
A serious adverse event (SAE) is defined as an adverse event that - is fatal; - is life threatening (places the participant at immediate risk of death); - requires inpatient hospitalization or prolongation of existing hospitalization; - results in persistent or significant disability/incapacity; - is a congenital anomaly/birth defect; - other significant medical hazard. AEs were assessed for severity according to National Cancer Institute, Common Terminology Criteria for Adverse Events, Version 3.0, based on this general guideline: Grade 1 = Mild AE; Grade 2 = Moderate AE; Grade 3 = Severe AE; Grade 4 = Life-threatening or disabling AE; Grade 5 = Death related to AE. (NCT00911170)
Timeframe: Approximately 8 weeks (4 treatment cycles)
| Intervention | participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Any adverse event | Worst Grade of > 2 | Worst Grade of > 3 | Worst Grade of > 4 | Serious adverse events | Severe adverse events | Life-threatening adverse events | Fatal adverse events | Leading to discontinuation of IP | Leading to discontinuation from study treatment | |
| Pegfilgrastim | 344 | 240 | 115 | 31 | 68 | 106 | 27 | 10 | 3 | 8 |
| Placebo | 355 | 254 | 119 | 45 | 55 | 103 | 43 | 11 | 1 | 9 |
PCR is defined as the absence of any residual invasive cancer on hematoxylin and eosin (H&E) evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes. (NCT01818063)
Timeframe: 36 months following surgery
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm 1 (Paclitaxel, Carboplatin) | 3 |
| Arm 2 (Veliparib, Paclitaxel, Carboplatin) | 3 |
The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified World Health Organisation (WHO) criteria) as assessed by an IRC. (NCT00125034)
Timeframe: Evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 4 August 2006
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab Plus FOLFOX-4 | 45.6 |
| FOLFOX-4 Alone | 35.7 |
The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria) as assessed by an IRC. (NCT00125034)
Timeframe: Evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 1 Mar 2007
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab Plus FOLFOX-4 | 57.3 |
| FOLFOX-4 Alone | 34.0 |
The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria) as assessed by an IRC. (NCT00125034)
Timeframe: Evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 1 Mar 2007
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab Plus FOLFOX-4 | 33.8 |
| FOLFOX-4 Alone | 52.5 |
The disease control rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response + Stable Disease as best overall response according to radiological assessments as assessed by IRC (based on modified WHO criteria). (NCT00125034)
Timeframe: Evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 4 August 2006
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab Plus FOLFOX-4 | 85.2 |
| FOLFOX-4 Alone | 81.0 |
"Time from first assessment of Complete Response or Partial Response to disease progression or death (within 60 days of last tumor assessment).~Patients without event are censored on the date of last tumor assessment. Tumor assessments based on modified WHO criteria." (NCT00125034)
Timeframe: Time from first assessment of Complete Response or Partial Response to disease progression,death or last tumor assessment, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 01 Mar 2007
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus FOLFOX-4 | 9.0 |
| FOLFOX-4 Alone | 5.7 |
Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier. (NCT00125034)
Timeframe: Time from randomisation to death or last day known to be alive, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 30 Nov 2008
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus FOLFOX-4 | 18.3 |
| FOLFOX-4 Alone | 18.0 |
Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier. (NCT00125034)
Timeframe: Time from randomisation to death or last day known to be alive, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 30 November 2008
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus FOLFOX-4 | 13.4 |
| FOLFOX-4 Alone | 17.5 |
Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier. (NCT00125034)
Timeframe: Time from randomisation to death or last day known to be alive, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 30 November 2008
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus FOLFOX-4 | 22.8 |
| FOLFOX-4 Alone | 18.5 |
No residual tumor after on-study surgery for metastases. (NCT00125034)
Timeframe: Time from first dose up to 30 days after the last dose of study treatment, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 30 November 2008
| Intervention | participants (Number) |
|---|---|
| Cetuximab Plus FOLFOX-4 | 8 |
| FOLFOX-4 Alone | 4 |
"Duration from randomization until radiological progression as assessed by an IRC (based on modified WHO criteria) or death due to any cause.~Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment." (NCT00125034)
Timeframe: Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 01 Mar 2007
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus FOLFOX-4 | 7.2 |
| FOLFOX-4 Alone | 7.2 |
"Duration from randomization until radiological progression as assessed by an IRC (based on modified WHO criteria) or death due to any cause.~Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment." (NCT00125034)
Timeframe: Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 30 Nov 2008
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus FOLFOX-4 | 5.5 |
| FOLFOX-4 Alone | 8.6 |
"Duration from randomization until radiological progression as assessed by an IRC (based on modified WHO criteria) or death due to any cause.~Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment." (NCT00125034)
Timeframe: Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 30 Nov 2008
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus FOLFOX-4 | 8.3 |
| FOLFOX-4 Alone | 7.2 |
Please refer to Adverse Events section for further details (NCT00125034)
Timeframe: time from first dose up to 30 after last dose of study treatment, reported between day of first patient dose of study treatment, 27 Jul 2005, until cut-off date 30 Nov 2008
| Intervention | participants (Number) |
|---|---|
| Cetuximab Plus FOLFOX-4 | 170 |
| FOLFOX-4 Alone | 165 |
The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria). (NCT00154102)
Timeframe: evaluations were performed every 6 weeks until progression reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab Plus FOLFIRI | 46.9 |
| FOLFIRI Alone | 38.7 |
The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria). (NCT00154102)
Timeframe: evaluations were performed every 6 weeks until progression reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab Plus FOLFIRI | 31.3 |
| FOLFIRI Alone | 36.1 |
The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria). (NCT00154102)
Timeframe: evaluations were performed every 6 weeks until progression reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
| Intervention | percentage participants (Number) |
|---|---|
| Cetuximab Plus FOLFIRI | 57.3 |
| FOLFIRI Alone | 39.7 |
The disease control rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response + Stable Disease as best overall response according to radiological assessments (based on modified WHO criteria). (NCT00154102)
Timeframe: Evaluations were performed every 6 weeks until progression reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
| Intervention | percentage of participants (Number) |
|---|---|
| Cetuximab Plus FOLFIRI | 84.3 |
| FOLFIRI Alone | 85.5 |
"Time from first assessment of Complete Response or Partial Response to disease progression or death (within 60 days of last tumor assessment).~Patients without event are censored on the date of last tumor assessment. Tumor assessments based on modified WHO criteria." (NCT00154102)
Timeframe: Time from first assessment of complete response or partial response to disease progression, death or last tumor assessment reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus FOLFIRI | 9.6 |
| FOLFIRI Alone | 7.7 |
Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is later. (NCT00154102)
Timeframe: Time from randomisation to death or last day known to be alive reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 31 May 2009
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus FOLFIRI | 16.2 |
| FOLFIRI Alone | 16.7 |
Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is later. (NCT00154102)
Timeframe: Time from randomisation to death or last day known to be alive reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 31 May 2009
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus FOLFIRI | 23.5 |
| FOLFIRI Alone | 20.0 |
Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is later. (NCT00154102)
Timeframe: Time from randomisation to death or last day known to be alive, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 31 May 2009
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus FOLFIRI | 19.9 |
| FOLFIRI Alone | 18.6 |
Participants with no residual tumor after on-study surgery for metastases (NCT00154102)
Timeframe: time from first dose up to 30 days after last dose of study treatment reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 30 Nov 2007
| Intervention | Participants (Number) |
|---|---|
| Cetuximab Plus FOLFIRI | 29 |
| FOLFIRI Alone | 10 |
"Duration from randomization until radiological progression (based on modified World Health Organisation (WHO) criteria) or death due to any cause.~Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment." (NCT00154102)
Timeframe: Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus FOLFIRI | 8.9 |
| FOLFIRI Alone | 8.0 |
"Duration from randomization until radiological progression (based on modified WHO criteria) or death due to any cause.~Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment." (NCT00154102)
Timeframe: Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus FOLFIRI | 9.9 |
| FOLFIRI Alone | 8.4 |
"Duration from randomization until radiological progression (based on modified WHO criteria) or death due to any cause.~Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment." (NCT00154102)
Timeframe: Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
| Intervention | months (Median) |
|---|---|
| Cetuximab Plus FOLFIRI | 7.4 |
| FOLFIRI Alone | 7.7 |
Please refer to Adverse Events section for further details (NCT00154102)
Timeframe: time from first dose up to 30 days after last dose of study treatment reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 30 Nov 2007
| Intervention | participants (Number) |
|---|---|
| Cetuximab Plus FOLFIRI | 599 |
| FOLFIRI Alone | 597 |
Mean global health status scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a better QoL. (NCT00154102)
Timeframe: at baseline, at week 8, at week 16, at week 24, at week 32, and at week 40, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
| Intervention | scores on a scale (Least Squares Mean) | |||||
|---|---|---|---|---|---|---|
| At baseline | At week 8 | At week 16 | At week 24 | At week 32 | At week 40 | |
| Cetuximab Plus FOLFIRI | 58.88 | 59.02 | 60.77 | 61.83 | 59.68 | 63.43 |
| FOLFIRI Alone | 60.33 | 61.83 | 63.29 | 64.06 | 65.07 | 64.02 |
Mean social functioning scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a higher level of functioning. (NCT00154102)
Timeframe: at baseline, at week 8, at week 16, at week 24, at week 32, and at week 40, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006
| Intervention | scores on a scale (Least Squares Mean) | |||||
|---|---|---|---|---|---|---|
| At baseline | At week 8 | At week 16 | At week 24 | At week 32 | At week 40 | |
| Cetuximab Plus FOLFIRI | 75.21 | 74.14 | 73.72 | 76.31 | 74.04 | 76.58 |
| FOLFIRI Alone | 77.28 | 76.71 | 76.67 | 77.98 | 75.64 | 78.07 |
"The National Cancer Institute (NCI) Common Toxicity Criteria (CTC) Version 2.0 was used to evaluate toxicity.~Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life Threatening; Grade 5: Death." (NCT00024102)
Timeframe: Reported during protocol treatment after each cycle
| Intervention | participants (Number) |
|---|---|
| Standard Chemotherapy (CMF) | 92 |
| Standard Chemotherapy (AC) | 109 |
| Capecitabine | 101 |
Percentage of patients who were alive at 2.4 years. This rate was estimated using the Kaplan Meier method. (NCT00024102)
Timeframe: Time from registration to death (up to 15 years)
| Intervention | percentage of participants (Number) |
|---|---|
| Standard Chemotherapy | 93 |
| Capecitabine | 88 |
"Percentage of participants who were alive and relapse-free at time of analysis were counted as Alive without relapse at 2.4 years. Participants who had a first local recurrence, first distant metastasis or death from any cause were counted as relapse, first occurrence. These rates were estimated using the Kaplan Meier method" (NCT00024102)
Timeframe: randomization until date of first event, or date last known to be event free if no event was reported (up to 5 years)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Relapse, first occurrence | Alive without relapse | |
| Capecitabine | 20 | 80 |
| Standard Chemotherapy | 11 | 89 |
"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Progression Disease (PD), >=20% increase in the sum of the longest diameter of target lesions or appearance of new lesions; Stable Disease (SD), between PR and PD.~Disease control rate (DCR) = CR + PR + SD." (NCT02878057)
Timeframe: evaluation per 2 cycles (8 weeks), up to 55 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Advanced Breast Cancer | 20 |
all kind of adverse events, including hypertension, proteinuria, nausea, fatigue, and bilirubin increase. (NCT02878057)
Timeframe: evaluation per 2 cycles (8 weeks), up to 55 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Advanced Breast Cancer | 15 |
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Objective response rate = CR + PR. (NCT02878057)
Timeframe: evaluation per 2 cycles (8 weeks), up to 55 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Advanced Breast Cancer | 11 |
survival from first dose to death or last follow up (NCT02878057)
Timeframe: evaluation per 2 cycles (8 weeks), up to 55 months
| Intervention | months (Median) |
|---|---|
| Advanced Breast Cancer | 18 |
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT02878057)
Timeframe: evaluation per 2 cycles (8 weeks), up to 6 months;From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months
| Intervention | months (Median) |
|---|---|
| Advanced Breast Cancer | 4.9 |
Average months of survival of participants after receiving study drug. (NCT00290615)
Timeframe: From time of treatment until death from any cause, assesed up to 60 months.
| Intervention | months (Median) |
|---|---|
| Capecitabine, Oxaliplatin, Bevacizumab, Cetuximab | 18.8 |
"Disease assessment was performed and recorded according to the Response Evaluation Criteria in Solid Tumors (RECIST v.1.0) Guidelines.~Progressive disease is defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.~This is the average number of months participants survived without showing progressive disease." (NCT00290615)
Timeframe: From time of treatment until documented progression or death from any cause, whichever came first, assesed up to 60 months.
| Intervention | months (Median) |
|---|---|
| Capecitabine, Oxaliplatin, Bevacizumab, Cetuximab | 10.3 |
"Restaging scans occurred every 9 weeks from time of study drug initiation until disease progression.~Disease assessment was performed and recorded according to the Response Evaluation Criteria in Solid Tumors (RECIST v.1.0) Guidelines.~The definitions were:~Complete response (CR)- Disappearance of all target lesions Partial response (PD)- At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD Stable disease (SD)- Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started Progressive disease (PD) - At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions" (NCT00290615)
Timeframe: After all subjects were evaluated for restaging which occured every 9 weeks from drug initiation until disease progression, assesed up to 24 months.
| Intervention | percentage of participants with response (Number) |
|---|---|
| Capecitabine, Oxaliplatin, Bevacizumab, Cetuximab | 43 |
Number of participants with adverse events (NCT00290615)
Timeframe: After all participants went off study drug regimine.
| Intervention | participants with adverse event (Number) |
|---|---|
| Capecitabine, Oxaliplatin, Bevacizumab, Cetuximab | 30 |
The number of patients with Complete Response, Partial Response or Stable Disease extending beyond 6 months (CR+PR+SD ≥ 6 months), determined by RECIST v1.1. CR=disappearance of all target and non-target lesions; PR=at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter AND an absolute decrease of at least 5mm in at least one target lesion; SD=Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum of the longest diameter since the treatment started. (NCT01934894)
Timeframe: every 6 weeks thru cycle 8, and every 3 cycles thereafter until treatment discontinuation, projected 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Dose Level 1 (20 mg/m^2 Cabazitaxel + Lapatinib) | 2 |
| Dose Level 2 (25 mg/m^2 Cabazitaxel + Lapatinib) | 0 |
The number of patients with Complete and Partial Response (CR+PR) of CNS lesions assessed per modified RECIST Criteria for Evaluation of Intracranial Disease. CR=disappearance of all target and non-target lesions; PR=at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter AND an absolute decrease of at least 5mm in at least one target lesion. (NCT01934894)
Timeframe: every 6 weeks thru cycle 8, then every 9 weeks until treatment discontinuation, projected 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Dose Level 1 (20 mg/m^2 Cabazitaxel + Lapatinib) | 0 |
| Dose Level 2 (25 mg/m^2 Cabazitaxel + Lapatinib) | 0 |
The number of participants having Complete and Partial Responses (CR+PR) of extra-cranial lesions assessed per RECIST v1.1 Criteria. CR=disappearance of all target and non-target lesions; PR=at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter AND an absolute decrease of at least 5mm in at least one target lesion. (NCT01934894)
Timeframe: every 6 weeks for 8 cycles, then every 9 weeks until treatment discontinuation, up to 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Dose Level 1 (20 mg/m^2 Cabazitaxel + Lapatinib) | 0 |
| Dose Level 2 (25 mg/m^2 Cabazitaxel + Lapatinib) | 0 |
The maximum tolerated dose (MTD) of cabazitaxel and lapatinib will be determined as the highest dose at which ≤1 of 6 patients experiences a dose-limiting toxicity (DLT) assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0. A listing of DLTs are reported in the subsequent Primary Outcome Measure. (NCT01934894)
Timeframe: weekly for 3 weeks
| Intervention | mg/m^2 of cabazitaxel + lapatinib (Number) |
|---|---|
| Cabazitaxel and Lapatinib | NA |
During the safety lead-in, a standard 3+3 dose escalation design is used to determine the maximum tolerated dose (MTD) of cabazitaxel with lapatinib. The MTD would be determined by the highest dose at which ≤1 of 6 patients experiences a dose-limiting toxicity (DLT) during 1 cycle (21 days) of therapy. If 2 of 6 patients within a dose level experiences a DLT, that dose level would be defined as exceeding the MTD and the previous dose level would be evaluated. DLTs are assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0. (NCT01934894)
Timeframe: weekly for 3 weeks
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| febrile neutropenia | neutropenia | diarrhea | septic shock | |
| Dose Level 1 | 0 | 0 | 0 | 1 |
| Dose Level 2 | 1 | 1 | 2 | 0 |
Measured from time of registration to death, or last contact date (NCT00033540)
Timeframe: All patients will be followed until death or three years after registration, whichever is first.
| Intervention | months (Median) |
|---|---|
| Capecitabine + Gemcitabine | 7 |
Only eligible patients who received treatment were evaluable for response and survival outcomes. (NCT00033540)
Timeframe: 1-20 months
| Intervention | participants (Number) | |
|---|---|---|
| Eligible | Eligible and Analyzable | |
| Capecitabine + Gemcitabine | 54 | 52 |
To evaluate in a preliminary fashion relevant prognostic markers in gallbladder and cholangiocarcinoma which may have prognostic implications as predictors of survival. Overall survival measured from time of registration to death, or last contact date. (NCT00033540)
Timeframe: All patients will be followed until death or three years after registration, whichever is first.
| Intervention | months (Median) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TS 3' +/+ (N=14) | TS 3' +/- (N=6) | TS 3' -/- (N=2) | TS 5' Low functional significance (N=16) | TS 5' Intermediate functional significance (N=16) | MTHFR C677T - C/C (N=11) | MTHFR C677T - C/T (N=11) | MTHFR A1298C - A/A (N=11) | MTHFR A1298C - A/C (N=8) | MTHFR A1298C - C/C (N=3) | RRMI G/A - G/G (N=9) | RRMI G/A - G/A (N=10) | RRMI G/A - A/A (N=3) | CDA A79C - A/A (N=8) | CDA A79C - A/C (N=12) | CDA A79C - C/C (N=1) | |
| Capecitabine + Gemcitabine | 7 | 7 | 9 | 9 | 7 | 6 | 7 | 7 | 4 | 9 | 7 | 9 | 5 | 4 | 7 | NA |
Adverse Events (AEs) are reported by the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0. Any CTCAE 3.0 event of Grade 3 (severe), Grade 4 (life threatening) or Grade 5 (fatal) which were deemed to be related to protocol treatment are included. For each patient, worst grade of each event type is reported. (NCT00033540)
Timeframe: Patients were assessed for adverse events 3 weeks after starting treatment. Assessments for adverse events continued every 3 weeks for the duration of protocol treatment.
| Intervention | Participants (Number) | |||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALT, SGPT (serum glutamic pyruvic transaminase) | AST,SGOT (serum glutamic oxaloacetic transaminase) | Albumin, serum-low (hypoalbuminemia) | Alkaline phosphatase | Anorexia | Ascites (non-malignant) | Bilirubin (hyperbilirubinemia) | Constipation | Creatinine | Dehydration | Diarrhea | Dysphagia (difficulty swallowing) | Fatigue (asthenia, lethargy, malaise) | Hemoglobin | Hemolysis | Hemorrhage, GI - Esophagus | Infection w/Grade 3-4 neutrophils - Upper airway | Infection with normal ANC or Grade 1-2 neutrophils | Leukocytes (total WBC) | Mucositis/stomatitis (clinical exam) - Oral cavity | Mucositis/stomatitis (function/symp)-Oral cavity | Muscle weakness (not due to neuropathy) | Nausea | Neutrophils/granulocytes (ANC/AGC) | Pain - Abdomen NOS | Pain - Joint | Pain - Muscle | Pain - Tumor pain | Platelets | Potassium, serum-low (hypokalemia) | Rash: hand-foot skin reaction | Supraventricular nodal arrhythmia | Thrombosis/thrombus/embolism | Vomiting | |
| Gemcitabine and Capecitabine | 1 | 5 | 1 | 5 | 2 | 1 | 4 | 1 | 1 | 3 | 1 | 1 | 8 | 6 | 1 | 1 | 1 | 1 | 9 | 1 | 1 | 1 | 3 | 16 | 2 | 1 | 1 | 1 | 12 | 2 | 4 | 1 | 1 | 2 |
Complete Response (CR) is complete disappearance of all measurable and non-measurable disease. No new lesions, no disease related symptoms. Normalization of markers and other abnormal lab values. Partial Response (PR) is greater than or equal to 30% decrease under baseline of the sum of longest diameters of all target measurable lesions. No unequivocal progression of non-measurable disease. No new lesions. Confirmation of CR or PR means a repeat scan at least 4 weeks apart documented before progression or symptomatic deterioration. Progression is 20% increase in sum of longest diameters of target measurable lesions over smallest sum observed and/or unequivocal progression of non-measurable disease and/or appearance of new lesion/site or death due to disease without prior documentation of progression and without symptomatic deterioration. Symptomatic deterioration is global deterioration of health status requiring discontinuation of treatment without objective evidence of progression. (NCT00033540)
Timeframe: Patients assessed at least every six weeks while on protocol treatment
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Confirmed Partial Response | Unconfirmed Partial Response | Stable Disease | Progression | Symptomatic Deterioration | Early Death | Inadequate Assessment | |
| Capecitabine + Gemcitabine | 7 | 6 | 12 | 15 | 3 | 1 | 8 |
Best overall response rate is defined as the percentage of participants with a complete response (CR) or partial response (PR) while on study. Tumor response was assessed by CT scan or MRI of the abdomen, pelvis, and all other sites of disease. Disease assessments were performed by central review according to the modified RECIST criteria. CR: Disappearance of all target and non-target lesions and no new lesions. PR: Either the disappearance of all target lesions with persistence of one or more non-target lesion(s) not qualifying for either CR or PD (≥ 25% increase in lesion size) and no new lesions, or, at least a 30% decrease in the size of target lesions with no progression of existing non-target lesions, and no new lesions. (NCT00332163)
Timeframe: Response was assessed at Weeks 9 and 13 and then every 8 weeks for the Q2W regimen, or at Weeks 10, 14, 22 and then every 9 weeks for the Q3W regimen until the end of treatment; median treatment duration was 13 and 17 weeks in each group respectively.
| Intervention | percentage of participants (Number) |
|---|---|
| Pre-emptive Skin Treatment | 15 |
| Reactive Skin Treatment | 11 |
Overall Survival is defined as the time from the date of randomization to the date of death. Participants who did not die while on study or who were lost-to-follow-up were censored at their last contact date. Overall survival was analyzed using all data regardless of whether it was collected during second- or third-line treatment. (NCT00332163)
Timeframe: From randomization until the end of study; median time on study was 31 weeks and 41 weeks in each treatment group respectively with a maximum time on study of 97 weeks.
| Intervention | months (Median) |
|---|---|
| Pre-emptive Skin Treatment | 11.2 |
| Reactive Skin Treatment | 13.6 |
"The percentage of participants who developed at least 1 incidence of ≥ grade 2 skin toxicities of any type during the 6-week skin treatment period. Analysis of this endpoint was based on adverse event data associated with the Skin and Subcutaneous Tissue Disorders system organ class. Adverse events were graded according to the National Cancer Institute (NCI) CTCAE version 3.0." (NCT00332163)
Timeframe: 6 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Pre-emptive Skin Treatment | 40 |
| Reactive Skin Treatment | 62 |
(NCT00332163)
Timeframe: 6 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Pre-emptive Skin Treatment | 6 |
| Reactive Skin Treatment | 11 |
Skin toxicities were assessed by the study clinician and graded according to the modified Common Toxicity Criteria for Adverse Events (CTCAE) v.3.0 Dermatology Toxicity Grading criteria, on a scale from Grade 1 (mild) to 4 (life-threatening). The specific skin toxicities of interest were pruritus, acneiform dermatitis, skin desquamation (also described as skin exfoliation), exfoliative dermatitis, paronychia, nail disorder, skin fissures, skin laceration, pruritic rash, pustular rash, skin infection, skin ulceration, and local infection. (NCT00332163)
Timeframe: 6 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Pre-emptive Skin Treatment | 29 |
| Reactive Skin Treatment | 62 |
Defined as the time from the date of randomization to the first date of observed disease progression or death due to any cause (whichever comes first). Participants who were alive and had not progressed while on study were censored at the date of last progression-free tumor assessment. (NCT00332163)
Timeframe: From randomization until the end of study; median time on study was 31 weeks and 41 weeks in each treatment group respectively with a maximum time on study of 97 weeks.
| Intervention | months (Median) |
|---|---|
| Pre-emptive Skin Treatment | 4.7 |
| Reactive Skin Treatment | 4.1 |
Tumor response was assessed by CT scan or MRI of the abdomen, pelvis, and all other sites of disease. Disease assessments were performed by central review according to the modified response evaluation criteria in solid tumors (RECIST). Disease control rate is defined as the percentage of participants with a CR, PR or stable disease (SD) at the Week 9/10 assessment visit and a corresponding response (CR or PR) confirmed at the Week 13/14 assessment visit for the Q2W/Q3W regimens. SD: Neither sufficient shrinkage or increase in target lesions to qualify for PR or PD, with no progression of non-target lesions and no new lesions. (NCT00332163)
Timeframe: Week 9 with confirmed response at Week 13 for the FOLFIRI and panitumumab Q2W regimen or at Week 10 with confirmed response at Week 14 for the irinotecan and panitumumab Q3W regimen.
| Intervention | percentage of participants (Number) |
|---|---|
| Pre-emptive Skin Treatment | 63 |
| Reactive Skin Treatment | 64 |
Tumor response was assessed by computed tomography (CT) scan or magnetic resonance imaging (MRI) of the abdomen, pelvis, and all other sites of disease. Disease assessments were performed by central review according to the modified response evaluation criteria in solid tumors (RECIST). Response rate is defined as the percentage of participants with a complete response (CR) or partial response (PR) at the Week 9/10 assessment visit and a corresponding CR or PR confirmed at the Week 13/14 assessment visit for the Q2W/Q3W regimens. CR: Disappearance of all target and non-target lesions and no new lesions. PR: Either the disappearance of all target lesions with persistence of one or more non-target lesion(s) not qualifying for either CR or progressive disease (PD; ≥ 25% increase in lesion size) and no new lesions, or, at least a 30% decrease in the size of target lesions with no progression of existing non-target lesions, and no new lesions. (NCT00332163)
Timeframe: Week 9 with confirmed response at Week 13 for the FOLFIRI and panitumumab Q2W regimen or at Week 10 with confirmed response at Week 14 for the irinotecan and panitumumab Q3W regimen.
| Intervention | percentage of participants (Number) |
|---|---|
| Pre-emptive Skin Treatment | 6 |
| Reactive Skin Treatment | 6 |
Time to the first most severe grade ≥ 2 of all the specific skin-related toxicities of interest was defined as the time from the first dose of panitumumab to the date of the first occurrence of the most severe specific ≥ grade 2 skin toxicity of interest during the 6-week skin treatment period. Participants who did not experience any specific skin-related toxicity of grade ≥ 2 were censored at their last skin toxicity assessment during the 6-week skin toxicity assessment period. Skin toxicities were assessed by the study clinician and graded according to the modified CTCAE v.3.0 Dermatology Toxicity Grading criteria, on a scale from Grade 1 (mild) to 4 (life-threatening). The specific skin toxicities of interest were pruritus, acneiform dermatitis, skin desquamation (also described as skin exfoliation), exfoliative dermatitis, paronychia, nail disorder, skin fissures, skin laceration, pruritic rash, pustular rash, skin infection, skin ulceration, and local infection. (NCT00332163)
Timeframe: 6 weeks
| Intervention | weeks (Median) |
|---|---|
| Pre-emptive Skin Treatment | NA |
| Reactive Skin Treatment | 2.7 |
The time to the first occurrence of specific grade 2 or higher skin toxicities of interest was defined as the time from the first dose of panitumumab to the date of first occurrence of specific ≥ grade 2 skin toxicities of interest. Participants who did not experience specific skin-related toxicities were censored at their last skin toxicity assessment during the skin toxicity assessment period. Skin toxicities were assessed by the study clinician and graded according to the modified CTCAE v.3.0 Dermatology Toxicity Grading criteria, on a scale from Grade 1 (mild) to 4 (life-threatening). The specific skin toxicities of interest were pruritus, acneiform dermatitis, skin desquamation (also described as skin exfoliation), exfoliative dermatitis, paronychia, nail disorder, skin fissures, skin laceration, pruritic rash, pustular rash, skin infection, skin ulceration, and local infection. (NCT00332163)
Timeframe: 6 weeks
| Intervention | weeks (Median) |
|---|---|
| Pre-emptive Skin Treatment | NA |
| Reactive Skin Treatment | 2.1 |
"Time from the date of randomization to the date of observed disease progression or death due to disease progression. Participants who did not have documented disease progression were censored at the date of last tumor assessment; participants who died for reasons other than disease progression while on study were censored at the date of death. PD: At least a 20% increase in the size of target lesions, recorded since the treatment started, or at least a 25% increase in size of non-target lesions and the lesion(s) measure > 10 mm in one dimension, or the appearance of one or more new lesions.~Time to progression was analyzed using the Kaplan-Meier method. This analysis excludes any data collected during follow-up for participants who began third-line treatment." (NCT00332163)
Timeframe: From randomization until the end of study; median time on study was 31 weeks and 41 weeks in each treatment group respectively with a maximum time on study of 97 weeks.
| Intervention | months (Median) |
|---|---|
| Pre-emptive Skin Treatment | 4.9 |
| Reactive Skin Treatment | 4.1 |
Time-to-treatment failure is defined as the time from the date of randomization to the first date of any of the following events: discontinuation of study therapy due to any reason (except for complete response and curative surgery), progression of disease, or death due to any cause. Participants who did not discontinue, who were still alive, and who did not have disease progression were censored at the date of last contact. Time to treatment failure was analyzed using the Kaplan-Meier method. (NCT00332163)
Timeframe: From randomization until the end of study; median time on study was 31 weeks and 41 weeks in each treatment group respectively with a maximum time on study of 97 weeks.
| Intervention | months (Median) |
|---|---|
| Pre-emptive Skin Treatment | 3.1 |
| Reactive Skin Treatment | 4.2 |
Skin-related quality of life was assessed using the DLQI. The DLQI questionnaire asks participants to evaluate the degree that their skin condition has affected their quality of life in the last week. Participants answer 10 questions on a scale from 0 (not at all) to 3 (very much); The DLQI score is calculated by summing the scores for all questions, resulting in a maximum of 30 and a minimum of 0; higher scores indicate a more impaired quality of life. (NCT00332163)
Timeframe: Baseline and Weeks 2, 3, 4, 5, 6 and 7
| Intervention | units on a scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline (n=46, 44) | Change from Baseline to Week 2 (n=42, 41) | Change from Baseline to Week 3 (n=44, 42) | Change from Baseline to Week 4 (n=42, 42) | Change from Baseline to Week 5 (n=44, 42) | Change from Baseline to Week 6 (n=42, 38) | Change from Baseline to Week 7 (n=40, 40) | |
| Pre-emptive Skin Treatment | 0.3 | 0.7 | 1.3 | 1.7 | 1.3 | 1.6 | 2.0 |
| Reactive Skin Treatment | 0.1 | 1.6 | 4.2 | 3.8 | 2.7 | 2.3 | 2.6 |
The percentage of participants with a most severe grade of 2, 3 or 4 specific skin toxicity of interest reported during the 6-week skin treatment period. Skin toxicities were assessed by the study clinician and graded according to the modified CTCAE v.3.0 Dermatology Toxicity Grading criteria, on a scale from Grade 1 (mild) to 4 (life-threatening). The specific skin toxicities of interest were pruritus, acneiform dermatitis, skin desquamation (also described as skin exfoliation), exfoliative dermatitis, paronychia, nail disorder, skin fissures, skin laceration, pruritic rash, pustular rash, skin infection, skin ulceration, and local infection. (NCT00332163)
Timeframe: 6 weeks
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Grade 2 | Grade 3 | Grade 4 | |
| Pre-emptive Skin Treatment | 23 | 6 | 0 |
| Reactive Skin Treatment | 40 | 21 | 0 |
OS was the duration from enrollment to death due to any cause. For participants who are alive, OS is censored at the last contact. (NCT00612586)
Timeframe: Randomization up to 22.8 months
| Intervention | months (Median) |
|---|---|
| Enzastaurin + 5-FU/LV + Bev | NA |
| Placebo + 5FU/LV + Bev | NA |
OS was the duration from first line therapy to death due to any cause. For participants who are alive, OS is censored at the last contact. (NCT00612586)
Timeframe: Start of first line therapy (approximately 3 months prior to randomization) to date of death from any cause up to 27 months post randomization
| Intervention | months (Median) |
|---|---|
| Enzastaurin + 5-FU/LV + Bev | 20.0 |
| Placebo + 5FU/LV + Bev | NA |
PFS was defined as the time from first line therapy to the first observation of disease progression or death due to any cause. Progressive disease was determined using a modified version of RECIST Assessment and was defined as at least a 20% increase in sum of longest diameter of target lesions. Time to disease progression was censored at the date of death if death was due to other cause. (NCT00612586)
Timeframe: Start of first line therapy to measured progressive disease or death up to 24 months
| Intervention | months (Median) |
|---|---|
| Enzastaurin + 5-FU/LV + Bev | 8.9 |
| Placebo + 5FU/LV + Bev | 11.3 |
PFS was defined as the time from randomization to the first observation of disease progression or death due to any cause. Progressive disease was determined using a modified version of Response Evaluation Criteria in Solid Tumor (RECIST) Assessment and was defined as at least a 20% increase in sum of longest diameter of target lesions. Time to disease progression was censored at the date of death if death was due to other cause. (NCT00612586)
Timeframe: Randomization to measured progressive disease or death up to 17.2 months
| Intervention | months (Median) |
|---|---|
| Enzastaurin + 5-FU/LV + Bev | 5.8 |
| Placebo + 5FU/LV + Bev | 8.1 |
A summary of serious and all other non-serious AEs is located in the Reported Adverse Event module. (NCT00612586)
Timeframe: Randomization up to 17.2 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Serious AEs | Other Non-Serious AEs | |
| Enzastaurin + 5-FU/LV + Bev | 15 | 53 |
| Placebo + 5FU/LV +Bev | 11 | 52 |
A confirmed tumor response is defined to be either a Complete Response (CR) or Partial Response (PR) noted as the objective status on 2 consecutive evaluations at least 6 weeks apart. All patients meeting the eligibility criteria who have signed a consent form and initiated study medication will be evaluable for response. The proportion of confirmed tumor responses will be estimated by the number of tumor regressions that meet the RECIST criteria for a confirmed CR or PR divided by the total number of evaluable patients. A 95% confidence interval for the true confirmed response rate will be calculated using the properties of the binomial distribution. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT00093808)
Timeframe: Up to 5 years
| Intervention | proportion of patients (Number) |
|---|---|
| Capecitabine + Vinorelbine + Trastuzumab | 0.67 |
Duration of response is defined for all eligible patients who have achieved an objective response as the date at which the patient's objective status is first noted to be either a Complete Response (CR) or Partial Response (PR) to the date progression is documented. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions. (NCT00093808)
Timeframe: Up to 5 years
| Intervention | months (Median) |
|---|---|
| Capecitabine + Vinorelbine + Trastuzumab | 13.2 |
Overall survival: The overall survival or survival time is defined as the time from registration to death due to any cause. The distribution of overall survival will be estimated using the method of Kaplan-Meier method. (NCT00093808)
Timeframe: Up to 5 years
| Intervention | months (Median) |
|---|---|
| Capecitabine + Vinorelbine + Trastuzumab | 28.5 |
Time to progression is defined as the time from registration to disease progression. Patients who died without documentation of progression will be considered to have progressed on the date of their death. If a patient starts treatment and fails to return for any evaluations, that patient will be censored for progression of disease at day one post-registration. Otherwise, for patients that do not progress, censoring will occur at the last follow up date. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as at least a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions or unequivocal progression of existing non-target lesions. (NCT00093808)
Timeframe: Up to 5 years
| Intervention | months (Median) |
|---|---|
| Capecitabine + Vinorelbine + Trastuzumab | 11.3 |
DR was defined as the time from the first recorded response (CR/PR) to the date of first documented progression or death. CR: disappearance of all target lesions and non-target lesions and normalization of tumor marker level. PR: at least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD. Progression: at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. DR was estimated using Kaplan-Meier methods. (NCT00811135)
Timeframe: Screening until disease progression (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)
| Intervention | months (Median) |
|---|---|
| Trastuzumab + Bevacizumab + Capecitabine | 12.7 |
Disease progression was defined as at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. (NCT00811135)
Timeframe: Screening until disease progression (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)
| Intervention | participants (Number) |
|---|---|
| Trastuzumab + Bevacizumab + Capecitabine | 70 |
OS was defined as the time from enrollment to death from any cause where enrollment was defined as successfully passed screening visit, enrolled in the study and received first dose of study treatment. (NCT00811135)
Timeframe: Screening until death (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)
| Intervention | participants (Number) |
|---|---|
| Trastuzumab + Bevacizumab + Capecitabine | 40 |
Participants who had CR or PR were considered as responders. CR: disappearance of all target and non-target lesions and normalization of tumor marker level; PR: at least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD. (NCT00811135)
Timeframe: Screening until disease progression (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)
| Intervention | participants (Number) |
|---|---|
| Trastuzumab + Bevacizumab + Capecitabine | 66 |
TTP was defined as the time from enrollment to first documented disease progression (at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions). TTP was estimated using Kaplan-Meier methods. (NCT00811135)
Timeframe: Screening until disease progression (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)
| Intervention | participants (Number) |
|---|---|
| Trastuzumab + Bevacizumab + Capecitabine | 62 |
OS was defined as the time from enrollment to death from any cause where enrollment was defined as successfully passed screening visit, enrolled in the study and received first dose of study treatment. OS was estimated using Kaplan-Meier methods. (NCT00811135)
Timeframe: Screening until death (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)
| Intervention | months (Median) |
|---|---|
| Trastuzumab + Bevacizumab + Capecitabine | 31.8 |
Tumor response was assessed using the Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.0. BOR was defined as the best response recorded for a participant from the start of treatment until disease progression/recurrence. Percentage of participants with a BOR of confirmed CR or PR (responders) was reported. CR: disappearance of all target and non-target lesions and normalization of tumor marker level; PR: at least a 30 percent (%) decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD. Confirmed responses were those which were confirmed by a repeat assessment, performed 4 weeks after the criteria for response first met. (NCT00811135)
Timeframe: Screening until disease progression (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)
| Intervention | percentage of participants (Number) |
|---|---|
| Trastuzumab + Bevacizumab + Capecitabine | 75.0 |
PFS was defined as the time from enrollment to time of first documented disease progression or death due to any cause, whichever occurred first. Progression: at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. PFS was estimated using Kaplan-Meier methods. (NCT00811135)
Timeframe: Screening until disease progression (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)
| Intervention | months (Median) |
|---|---|
| Trastuzumab + Bevacizumab + Capecitabine | 14.2 |
TTP was defined as the time from enrollment to first documented disease progression (at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions). (NCT00811135)
Timeframe: Screening until disease progression (assessed at screening, every 6 weeks up to Week 36, thereafter every 9 weeks during treatment period, and then every 3 months during follow-up, up to approximately 4 years)
| Intervention | months (Median) |
|---|---|
| Trastuzumab + Bevacizumab + Capecitabine | 14.5 |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. (NCT00668863)
Timeframe: Cycle 1 Day 15
| Intervention | L/hour (Mean) |
|---|---|
| Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI | 32.9 |
CL is calculated as dose divided by AUC 0-∞ (NCT00668863)
Timeframe: Cycle 1 Day 15
| Intervention | L/hour (Mean) |
|---|---|
| Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI | 23.0 |
DR is defined as the time from the first objective documentation of complete or partial response that is subsequently confirmed to the first documentation of disease progression or to death due to any cause, whichever occurs first. The definition of censorship is the same as PFS. (NCT00668863)
Timeframe: Up to 11 cycles (1 cycle = 6 weeks)
| Intervention | weeks (Median) |
|---|---|
| Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI | 28.3 |
ORR is defined as the percentage of participants with best overall response of either a confirmed complete (CR) or partial response (PR) relative to the number of participants in FAS. Based on the response evaluation criteria in solid tumors (RECIST), CR is defined as the disappearance of all target lesions and PR is defined as a greater than or equal to 30% decrease in the sum of the longest dimensions of the target lesion. (NCT00668863)
Timeframe: Up to 11 cycles (1 cycle = 6 weeks)
| Intervention | percentage of participants (Median) |
|---|---|
| Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI | 36.6 |
Concentration at 22 hour post start of 5-FU infusion were to be used as Css if 5-FU concentrations suggested steady state at 22 hours time point. (NCT00668863)
Timeframe: Cycle 1 Day 15
| Intervention | ng/mL (Mean) |
|---|---|
| Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI | 650 |
"PFS is defined as the time from the date of enrollment to the date of the first documentation of objective tumor progression or death due to any cause, whichever occurs first.~PFS data was censored on the day following the date of the last tumor assessment documenting absence of progressive disease for patients who 1) were given anti-tumor treatment other than the study treatment prior to observing objective tumor progression; 2) were removed from the study prior to documentation of objective tumor progression; and 3) were ongoing at the time of the analysis." (NCT00668863)
Timeframe: Up to 11 cycles (1 cycle = 6 weeks)
| Intervention | weeks (Median) |
|---|---|
| Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI | 28.9 |
Terminal phase half-life of irinotecan was calculated as ln 2/ kel. (NCT00668863)
Timeframe: Cycle 1 Day 15
| Intervention | hours (Mean) |
|---|---|
| Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI | 5.36 |
Vss was calculated using following equation: CL x mean residence time (MRT), where MRT = the area under the first moment curve from zero time to infinity (AUMC 0-∞)/AUC 0-∞- (infusion time/2), AUMC 0-∞ = the area under the first moment curve from zero time to time t (AUMC t)+ ((t x Ct*)/ kel) + (Ct* / kel^2), AUMC t is calculated using the linear trapezoidal method. (NCT00668863)
Timeframe: Cycle 1 Day 15
| Intervention | L (Mean) |
|---|---|
| Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI | 160 |
AUC 0-24 was determined using the Linear/Log trapezoidal method. (NCT00668863)
Timeframe: Cycle 1 Day 15
| Intervention | ng.h/mL (Mean) | ||
|---|---|---|---|
| Sunitinib AUC 0-24 | SU012662 AUC 0-24 | Total (sunitinib + SU0122662) AUC 0-24 | |
| Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI | 1161 | 346 | 1507 |
"AUC last of irinotecan and its metabolite SN-38 were calculated using the Linear/Log trapezoidal method.~AUC∞ of irinotecan was calculated using following equation; AUC last+(C*t/kel), where Ct* is the estimated concentration at the time of the last quantifiable concentration, kel is terminal phase rate constant that is estimated as the absolute value of the slope of a linear regression during the terminal phase of the natural-logarithm (ln) transformed concentration-time profile." (NCT00668863)
Timeframe: Cycle 1 Day 15
| Intervention | ng.h/mL (Mean) | ||
|---|---|---|---|
| Irinotecan AUC last | Irinotecan AUC ∞ | SN-38 AUC last | |
| Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI | 13100 | 13800 | 274 |
Plasma concentrations were assessed at predose, 2, 4, 6, 8, and 24 hours postdose and Cmax and Ctrough of sunitinib, its metabolite SU012662, and the total (sunitinib + SU0122662) were determined. (NCT00668863)
Timeframe: Cycle 1 Day 15
| Intervention | ng/mL (Mean) | |||||
|---|---|---|---|---|---|---|
| Sunitinib Cmax | Sunitinib Ctrough | SU012662 Cmax | SU012662 Ctrough | Total (sunitinib + SU0122662) Cmax | Total (sunitinib + SU0122662) Ctrough | |
| Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI | 54.3 | 41.8 | 15.8 | 11.3 | 70.0 | 53.1 |
Plasma samples were assessed at prior to initiation of irinotecan (and l-leucovorin) infusion, 1, 2 (predose for 5-FU bolus), 4, 8, and 24 hours after initiation of irinotecan infusion, and Cmax of irinotecan and its metabolite SN-38 were determined. (NCT00668863)
Timeframe: Cycle 1 Day 15
| Intervention | ng/mL (Mean) | |
|---|---|---|
| Irinotecan Cmax | SN-38 Cmax | |
| Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI | 1963 | 25.1 |
Any untoward medical occurrence in a patient who received study drug was considered an adverse event (AE), without regard to possibility of causal relationship. Treatment-emergent adverse events (TEAE): those which occurred or worsened after baseline. An adverse event resulting in any of the following outcomes, or deemed to be significant for any other reason, was considered to be a serious adverse event (SAE): death; initial or prolonged inpatient hospitalization; a life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. (NCT00668863)
Timeframe: Up to 11 cycles (1 cycle = 6 weeks)
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Treatment emergent adverse events | Serious adverse events | CTCAE grade 3 or 4 adverse events | CTCAE grade 5 adverse events | |
| Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI | 71 | 32 | 70 | 1 |
(NCT00668863)
Timeframe: Cycle 1 Day 15
| Intervention | hours (Mean) | |
|---|---|---|
| Irinotecan tmax | SN-38 tmax | |
| Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI | 2 | 4 |
(NCT00668863)
Timeframe: Cycle 1 Day 15
| Intervention | hours (Mean) | ||
|---|---|---|---|
| Sunitinib Tmax | SU012662 Tmax | Total (sunitinib + SU0122662) Tmax | |
| Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI | 6 | 4 | 6 |
Progression-free survival was measured from the start of treatment until the time the subject is first recorded as having disease progression (progression = 20% increase in sum of longest diameters of target measurable lesions over smallest sum observed or baseline, progression of non-measurable disease in the opinion of treating physician, appearance of new lesion/site, death due to disease), or death due to any cause. If a subject has not progressed or died, progression-free survival was censored at the time of last follow-up or the start of another treatment, whichever came first. (NCT00159432)
Timeframe: Up to 6 years
| Intervention | Months (Median) |
|---|---|
| Oxaliplatin Followed by Bevacizumab, With Capecitabine | 15.8 |
Summary of grade 3 (per CTCAE v3.0) or higher toxicities which generally is described as a severe adverse reaction or symptom. (NCT00159432)
Timeframe: Baseline, every 2 weeks of each cycle, and at end of treatment, up to 18 months.
| Intervention | Participants (Number) |
|---|---|
| Oxaliplatin Followed by Bevacizumab, With Capecitabine | 51 |
Tumor response was assessed by an IRC according to modified RECIST. DOR was defined as the time from first documented OR to first documented PD or death from any cause, whichever occurred earlier. OR was defined as a CR or PR determined on 2 consecutive tumor assessments at least 4 weeks apart. For TLs, CR was defined as the disappearance of all TLs; PR was defined as >/=30% decrease in the SLD of TLs, taking as reference the baseline SLD; and PD was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. For non-TLs, CR was defined as the disappearance of all non-TLs; PR was defined as the persistence of 1 or more non-TLs; and PD was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. The 95% CI was computed using the method of Brookmeyer and Crowley. (NCT00829166)
Timeframe: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
| Intervention | Months (Median) |
|---|---|
| Trastuzumab Emtansine | 12.6 |
| Lapatinib + Capecitabine | 6.5 |
OS was defined as the time from the date of randomization to the date of death from any cause. The median duration of OS was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley. The results reported are from the final analysis. The final analysis is descriptive. (NCT00829166)
Timeframe: From the date of randomization through the data cut-off date of 31 Dec 2014 (up to 5 years, 11 months)
| Intervention | Months (Median) |
|---|---|
| Trastuzumab Emtansine | 29.9 |
| Lapatinib + Capecitabine | 25.9 |
OS was defined as the time from the date of randomization to the date of death from any cause. The median duration of OS was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley. The results are reported from second interim analysis, which deemed to be the confirmatory. (NCT00829166)
Timeframe: From the date of randomization through the data cut-off date of 31 Jul 2012 (up to 3 years, 5 months)
| Intervention | Months (Median) |
|---|---|
| Trastuzumab Emtansine | 30.9 |
| Lapatinib + Capecitabine | 25.1 |
The percentage of participants who died from any cause was reported. The results reported are from the final analysis. The final analysis is descriptive. (NCT00829166)
Timeframe: From the date of randomization through the data cut-off date of 31 Dec 2014 (up to 5 years, 11 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Trastuzumab Emtansine | 61.2 |
| Lapatinib + Capecitabine | 67.1 |
The percentage of participants who died from any cause was reported. The results are reported from second interim analysis, which deemed to be the confirmatory. (NCT00829166)
Timeframe: From the date of randomization through the data cut-off date of 31 Jul 2012 (up to 3 years, 5 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Trastuzumab Emtansine | 30.1 |
| Lapatinib + Capecitabine | 36.7 |
1 year survival was defined as the percentage of participants alive 1 year after starting treatment. The results reported are from the final analysis. (NCT00829166)
Timeframe: Year 1
| Intervention | percentage of participants (Number) |
|---|---|
| Trastuzumab Emtansine | 85.3 |
| Lapatinib + Capecitabine | 78.9 |
2 year survival was defined as the percentage of participants alive 2 years after starting treatment. The results reported are from the final analysis. (NCT00829166)
Timeframe: Year 2
| Intervention | percentage of participants (Number) |
|---|---|
| Trastuzumab Emtansine | 59.6 |
| Lapatinib + Capecitabine | 52.4 |
Tumor response was assessed by an IRC according to modified RECIST. Participants were considered as experienced clinical benefit if they had an OR or maintained stable disease (SD) for at least 6 months from randomization. OR: CR or PR determined on 2 consecutive tumor assessments >/=4 weeks apart. For TLs, CR: disappearance of all TLs; PR: >/=30% decrease in the SLD of TLs, taking as reference the baseline SLD; PD: >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or appearance of 1 or more new lesions; and SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. For non-TLs, CR: disappearance of all non-TLs; PR/SD: persistence of 1 or more non-TLs; and PD: appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. Participants without a post-baseline tumor assessment were considered non-responders. The 95% CI was computed using Blyth-Still Casella exact CI method. (NCT00829166)
Timeframe: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Trastuzumab Emtansine | 58.2 |
| Lapatinib + Capecitabine | 44.2 |
Tumor response was assessed by an IRC according to modified RECIST. OR was defined as the percentage of participants with a complete response (CR) or partial response (PR). All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as TLs and recorded at baseline. A sum of the longest diameter for all TLs was calculated as baseline SLD. For TLs, a CR was defined as the disappearance of all TLs and a PR was defined as >/= 30% decrease in the SLD of TLs, taking as reference the baseline SLD. For non-TLs, a CR was defined as the disappearance of all non-TLs and a PR was defined as the persistence of 1 or more non-TLs. Confirmation of response at a consecutive tumor assessment at least 4 weeks apart was required. Participants without a post-baseline tumor assessment were considered non-responders. The percentage of participants with CR or PR by IRC was reported. The 95% CI was computed using Blyth-Still Casella exact CI method. (NCT00829166)
Timeframe: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Trastuzumab Emtansine | 43.6 |
| Lapatinib + Capecitabine | 30.8 |
PD was assessed by an IRC using modified Response Evaluation Criteria in Solid Tumors (RECIST). All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as target lesions (TLs) and recorded at baseline. TLs should be selected on the basis of their size (those with the longest diameter) and their suitability for accurate repeated measurements either by imaging or clinically. A sum of the longest diameter for all TLs was calculated as baseline sum longest diameter (SLD). All other lesions (or sites of disease) should be identified as non-TLs and recorded at baseline. PD for TLs was defined as greater than or equal to (>/=) 20 percent (%) increase in SLD, taking as reference smallest SLD recorded since treatment started or appearance of 1 or more new lesions. PD for non-TLs was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. Percentage of Participants with PD by IRC or death from any cause was reported. (NCT00829166)
Timeframe: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Trastuzumab Emtansine | 53.5 |
| Lapatinib + Capecitabine | 61.3 |
PD was assessed by the investigator using modified RECIST. All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as TLs and recorded at baseline. A sum of the longest diameter for all TLs was calculated as baseline SLD. PD for TLs was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. PD for non-TLs was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. The percentage of participants who died or experienced PD by Investigator was reported. (NCT00829166)
Timeframe: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Trastuzumab Emtansine | 58.0 |
| Lapatinib + Capecitabine | 67.5 |
"Symptom progression was defined as the documentation of a >/= 5-point decrease from baseline in the scoring of responses as measured by the Functional Assessment of Cancer Therapy-for participants with Breast Cancer (FACT-B) questionnaire with the Trial Outcomes Index-Physical/Functional/Breast (TOI-PFB) subscale. The FACT-B TOI-PFB subscale contained 24 items from 3 subsections of the FACT-B questionnaire: Physical well-being, functional well-being, and additional concerns for breast cancer participants (breast cancer subscale [BCS]). All items in the questionnaire were rated by the participant on a 5-point scale ranging from 0 (not at all) to 4 (very much). The total score ranged from 0 to 96 with higher score indicating better perceived quality of life. The percentage of participants with symptom progression was reported." (NCT00829166)
Timeframe: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Trastuzumab Emtansine | 54.7 |
| Lapatinib + Capecitabine | 57.8 |
"Treatment failure was defined as discontinuation of treatment for any reason, including PD (per investigator review), treatment toxicity, or death from any cause. For Lapatinib + Capecitabine arm, a participant was considered as treatment failure only if both drugs were discontinued. For TLs, PD was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. For non-TLs, PD was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. Percentage of participants with treatment failure was reported." (NCT00829166)
Timeframe: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Trastuzumab Emtansine | 63.2 |
| Lapatinib + Capecitabine | 74.8 |
Tumor response was assessed by the investigator according to modified RECIST. All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as TLs and recorded at baseline. A sum of the longest diameter for all TLs was calculated as baseline SLD. PD for TLs was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. PD for non-TLs was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. PFS was defined as the time from randomization to first documented PD by Investigator or death from any cause (whichever occurred earlier). The median duration of PFS was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley. (NCT00829166)
Timeframe: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
| Intervention | Months (Median) |
|---|---|
| Trastuzumab Emtansine | 9.4 |
| Lapatinib + Capecitabine | 5.8 |
Tumor response was assessed by an IRC according to modified RECIST. All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as TLs (on the basis of their size and their suitability for accurate repeated measurements either by imaging or clinically) and recorded at baseline. A sum of the longest diameter for all TLs was calculated as baseline SLD. All other lesions were identified as non-TLs and recorded at baseline. PD for TLs: >/= 20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or appearance of 1 or more new lesions. PD for non-TLs: appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. PFS: time from randomization to first documented PD by IRC or death from any cause (whichever occurred earlier). The median duration of PFS was estimated using Kaplan-Meier method. The 95% confidence interval (CI) was computed using the method of Brookmeyer and Crowley. (NCT00829166)
Timeframe: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
| Intervention | Months (Median) |
|---|---|
| Trastuzumab Emtansine | 9.6 |
| Lapatinib + Capecitabine | 6.4 |
"Time to symptom progression was defined as the time from randomization to the first documentation of a >/= 5-point decrease from baseline in the scoring of responses as measured by the FACT-B questionnaire with the TOI-PFB subscale. The FACT-B TOI-PFB subscale contained 24 items from 3 subsections of the FACT-B questionnaire: Physical well-being, functional well-being, and additional concerns for breast cancer participants (BCS). All items in the questionnaire were rated by the participant on a 5-point scale ranging from 0 (not at all) to 4 (very much). The total score ranged from 0 to 96 with higher score indicating better perceived quality of life. The median time to symptom progression was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley." (NCT00829166)
Timeframe: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
| Intervention | Months (Median) |
|---|---|
| Trastuzumab Emtansine | 7.1 |
| Lapatinib + Capecitabine | 4.6 |
"Time to treatment failure was defined as the time from randomization to discontinuation of treatment for any reason, including PD (per investigator review), treatment toxicity, or death from any cause. For Lapatinib + Capecitabine arm, a participant was considered as treatment failure only if both drugs were discontinued with treatment failure date as the later of the 2 discontinuation dates. For TLs, PD was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. For non-TLs, PD was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. The median time to treatment failure was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley." (NCT00829166)
Timeframe: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
| Intervention | Months (Median) |
|---|---|
| Trastuzumab Emtansine | 7.9 |
| Lapatinib + Capecitabine | 5.8 |
Duration of response (DR) was defined as time from date of first occurrence of any response (complete response (CR) or partial response (PR)) until the occurrence of progression of disease or death. Patients with response who neither progressed nor died were censored at the date of their last tumor assessment. Median DR, associated stratified Hazard Ratio (HR). (NCT00600340)
Timeframe: Time from first occurrence of CR or PR until disease progression, death or study closure, whichever occurred first, assessed up to 3.4 years after occurrence of response.
| Intervention | months (Median) |
|---|---|
| Bevacizumab Plus Paclitaxel | 11.2 |
| Bevacizumab Plus Capecitabine | 10.3 |
Duration of response (DR) was defined as time from date of first occurrence of any response (complete response (CR) or partial response (PR)) until the occurrence of progression of disease or death. Patients with response who neither progressed nor died were censored at the date of their last tumor assessment. Median DR, associated stratified Hazard Ratio (HR). (NCT00600340)
Timeframe: Time from first occurrence of CR or PR until disease progression, death or study closure, whichever occurred first, assessed up to 3.4 years after occurrence of response.
| Intervention | months (Median) |
|---|---|
| Bevacizumab Plus Paclitaxel | 11.2 |
| Bevacizumab Plus Capecitabine | 10.3 |
Median observation time estimated with reverse Kaplan-Meier methods. Observation time (in months) is defined as time from randomization to the day the patient was last confirmed to be alive. In case of patient deaths the time was censored at the day of death. (NCT00600340)
Timeframe: Up to approximately 6 years
| Intervention | months (Median) |
|---|---|
| Bevacizumab Plus Paclitaxel | 54.3 |
| Bevacizumab Plus Capecitabine | 55.7 |
Overall survival (OS) defined as time from randomization to date of death from any cause. Patients without recorded death were censored at the date the patient was last known to be alive. OS was analyzed at two looks, one interim look and the final analysis. Due to group sequential testing, the overall significance level alpha = 0.025 was spent on both looks according to Lan-DeMets spending method with O'Brien-Fleming-type boundaries. Alpha spent at Interim after 50% of information was 0.0014. Alpha spent at final analysis after 99% of information was 0.0250. (NCT00600340)
Timeframe: Time from the date of randomization to the date of death or date last known to be alive, assessed up to approximately 6 years
| Intervention | months (Median) |
|---|---|
| Bevacizumab Plus Paclitaxel | 29.5 |
| Bevacizumab Plus Capecitabine | 26.0 |
Overall survival (OS) defined as time from randomization to date of death from any cause. Patients without recorded death were censored at the date the patient was last known to be alive. OS was analyzed at two looks, one interim look and the final analysis. Due to group sequential testing, the overall significance level alpha = 0.025 was spent on both looks according to Lan-DeMets spending method with O'Brien-Fleming-type boundaries. Alpha spent at Interim after 47% of information was 0.0010. Alpha spent at final analysis after 99% of information was 0.0250. (NCT00600340)
Timeframe: Time from the date of randomization to the date of death or date last known to be alive, assessed up to approximately 6 years
| Intervention | months (Median) |
|---|---|
| Bevacizumab Plus Paclitaxel | 30.2 |
| Bevacizumab Plus Capecitabine | 26.1 |
Progression Free Survival (PFS) is defined as time from randomization to date of documented progression or date of death due to any cause, whichever occurred first. Patients without recorded progression or death were censored at the last date they were known to have not progressed. Patients who were randomized and had no post-baseline tumor assessment were censored on the day of randomization. Median PFS, associated stratified Hazard Ratio (HR). (NCT00600340)
Timeframe: Time from the date of randomization to disease progression, death or censoring (whichever occurred first), assessed up to approximately 5 years.
| Intervention | months (Median) |
|---|---|
| Bevacizumab Plus Paclitaxel | 10.9 |
| Bevacizumab Plus Capecitabine | 8.1 |
Progression Free Survival (PFS) is defined as time from randomization to date of documented progression or date of death due to any cause, whichever occurred first. Patients without recorded progression or death were censored at the last date they were known to have not progressed. Patients who were randomized and had no post-baseline tumor assessment were censored on the day of randomization. Median PFS, associated stratified Hazard Ratio (HR). (NCT00600340)
Timeframe: Time from the date of randomization to disease progression, death or censoring (whichever occurred first), assessed up to approximately 5 years.
| Intervention | months (Median) |
|---|---|
| Bevacizumab Plus Paclitaxel | 10.9 |
| Bevacizumab Plus Capecitabine | 8.2 |
Time to treatment failure (TTF) was defined as time from first drug intake to progression, death or withdrawal from study treatment, whichever occurred first. Patients without an event were censored at the date of the last tumor assessment or last treatment administration, whichever occurred last. Median TTF, associated stratified Hazard Ratio (HR). (NCT00600340)
Timeframe: From first drug intake to progression, death or withdrawal from study treatment or study closure (whichever occurred first), assessed up to approximately 4.5 years
| Intervention | months (Median) |
|---|---|
| Bevacizumab Plus Paclitaxel | 8.4 |
| Bevacizumab Plus Capecitabine | 7.2 |
Time to treatment failure (TTF) was defined as time from first drug intake to progression, death or withdrawal from study treatment, whichever occurred first. Patients without an event were censored at the date of the last tumor assessment or last treatment administration, whichever occurred last. Median TTF, associated stratified Hazard Ratio (HR). (NCT00600340)
Timeframe: From first drug intake to progression, death or withdrawal from study treatment or study closure (whichever occurred first), assessed up to approximately 4.5 years
| Intervention | months (Median) |
|---|---|
| Bevacizumab Plus Paclitaxel | 8.3 |
| Bevacizumab Plus Capecitabine | 7.3 |
Objective response rate (ORR) is defined as the proportion of patients with complete response or partial response. Disease control rate (DCR) is defined as the proportion of patients with complete response, partial response and stable disease. The best overall response according to the RECIST criteria is the best response recorded from the start of the treatment until disease progression/recurrence or within 28 days of last intake of study medication in the Study Treatment Phase (NCT00600340)
Timeframe: Up to disease progression or up to 28 days after last intake of study medication, assessed up to approximately 5 years.
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Objective response | Disease control | |
| Bevacizumab Plus Capecitabine | 76 | 214 |
| Bevacizumab Plus Paclitaxel | 125 | 252 |
Objective response rate (ORR) is defined as the proportion of patients with complete response or partial response. Disease control rate (DCR) is defined as the proportion of patients with complete response, partial response and stable disease. The best overall response according to the RECIST criteria is the best response recorded from the start of the treatment until disease progression/recurrence or within 28 days of last intake of study medication in the Study Treatment Phase (NCT00600340)
Timeframe: Up to disease progression or up to 28 days after last intake of study medication, assessed up to approximately 5 years.
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Objective response | Disease control | |
| Bevacizumab Plus Capecitabine | 74 | 204 |
| Bevacizumab Plus Paclitaxel | 121 | 238 |
Time to response (TR) was defined as time from randomization until occurrence of response (complete response (CR) or partial response (PR)) according to RECIST criteria. Patients without response were censored after the longest time to response observed in any patient. Median TR, associated stratified Hazard Ratio (HR). Since the median TR was not observed, the number of subjects with a response at given timepoints were reported. (NCT00600340)
Timeframe: Time from randomization until occurrence of response, assessed up 1.7 years
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Month 3 | Month 6 | Month 9 | Month 12 | Month 15 | |
| Bevacizumab Plus Capecitabine | 57 | 69 | 74 | 75 | 75 |
| Bevacizumab Plus Paclitaxel | 83 | 111 | 121 | 123 | 123 |
Time to response (TR) was defined as time from randomization until occurrence of response (complete response (CR) or partial response (PR)) according to RECIST criteria. Patients without response were censored after the longest time to response observed in any patient. Median TR, associated stratified Hazard Ratio (HR). Since the median TR was not observed, the number of subjects with a response at given timepoints were reported. (NCT00600340)
Timeframe: Time from randomization until occurrence of response, assessed up 1.7 years
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Month 3 | Month 6 | Month 9 | Month 12 | Month 15 | |
| Bevacizumab Plus Capecitabine | 56 | 68 | 72 | 73 | 73 |
| Bevacizumab Plus Paclitaxel | 81 | 108 | 118 | 119 | 119 |
Objective response rate (ORR) is defined as the proportion of patients with complete response or partial response. Disease control rate (DCR) is defined as the proportion of patients with complete response, partial response and stable disease. The best overall response according to the RECIST criteria is the best response recorded from the start of the treatment until disease progression/recurrence or within 28 days of last intake of study medication in the Study Treatment Phase. Complete and partial response in this summary did not require a confirmation by a second tumor assessment. (NCT00600340)
Timeframe: Up to disease progression or up to 28 days after last intake of study medication, assessed up to approximately 5 years.
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Objective response | Disease control | |
| Bevacizumab Plus Capecitabine | 105 | 214 |
| Bevacizumab Plus Paclitaxel | 163 | 252 |
Objective response rate (ORR) is defined as the proportion of patients with complete response or partial response. Disease control rate (DCR) is defined as the proportion of patients with complete response, partial response and stable disease. The best overall response according to the RECIST criteria is the best response recorded from the start of the treatment until disease progression/recurrence or within 28 days of last intake of study medication in the Study Treatment Phase. Complete and partial response in this summary did not require a confirmation by a second tumor assessment (NCT00600340)
Timeframe: Up to disease progression or up to 28 days after last intake of study medication, assessed up to approximately 5 years.
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Objective response | Disease control | |
| Bevacizumab Plus Capecitabine | 100 | 204 |
| Bevacizumab Plus Paclitaxel | 157 | 238 |
DR was defined as the time from the first objective documentation of CR or PR that was subsequently confirmed to the first documentation of disease progression or to death due to any cause, whichever occurred first. (NCT00457691)
Timeframe: Day 28 of Cycle 1 up to 30 months
| Intervention | Weeks (Median) |
|---|---|
| FOLFIRI + Sunitinib | 30.1 |
| FOLFIRI + Placebo | 39.0 |
Objective disease response: participants with a confirmed complete response (CR) or partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST). CR was defined as the disappearance of all target lesions. PR was defined as a greater than or equal to 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. (NCT00457691)
Timeframe: Day 28 of Cycle 1 up to 30 months
| Intervention | Participants (Number) |
|---|---|
| FOLFIRI + Sunitinib | 124 |
| FOLFIRI + Placebo | 128 |
OS was defined as the time from randomization to the date of death due to any cause. OS data were censored on the day following the date of the last contact at which the patient was known to be alive. (NCT00457691)
Timeframe: Baseline up to 30 months
| Intervention | Weeks (Median) |
|---|---|
| FOLFIRI + Sunitinib | 87.9 |
| FOLFIRI + Placebo | 85.9 |
PFS defined as time from date of randomization to date of first documentation of objective tumour progression or death due to any cause, whichever occurred first. (NCT00457691)
Timeframe: First dose of study treatment up to 30 months
| Intervention | Weeks (Median) |
|---|---|
| FOLFIRI + Sunitinib | 33.6 |
| FOLFIRI + Placebo | 36.6 |
"EQ-5D: participant-rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problem); 3 indicates worst health state (eg, confined to bed). Scoring formula developed by EuroQol Group assigns a utility value for each domain. Score is transformed and results in total score range -1.11 to 1.000; higher score indicates better health state." (NCT00457691)
Timeframe: Day 1 of Cycles 1-3 and Day 1 of every odd-numbered cycle thereafter until EOT/withdrawal
| Intervention | Scores on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 5, Day 1 | Cycle 7, Day 1 | Cycle 9, Day 1 | Cycle 11, Day 1 | |
| FOLFIRI + Placebo | 0.04 | 0.04 | 0.03 | 0.05 | 0.05 | 0.09 |
| FOLFIRI + Sunitinib | 0.02 | 0.02 | 0.02 | 0.03 | 0.00 | 0.01 |
EQ-5D: participant-rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state. (NCT00457691)
Timeframe: Day 1 of Cycles 1-3 and Day 1 of every odd-numbered cycle thereafter until EOT/withdrawal
| Intervention | Scores on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 5, Day 1 | Cycle 7, Day 1 | Cycle 9, Day 1 | Cycle 11, Day 1 | |
| FOLFIRI + Placebo | 3.3 | 4.3 | 6.6 | 4.3 | 4.0 | 9.0 |
| FOLFIRI + Sunitinib | 1.0 | 1.7 | 1.8 | 3.8 | -0.9 | -1.6 |
Symptom Interference score is comprised of the sum 6 function items from MDASI core (general activity, walking, work, mood, relations with other people, and enjoyment of life). Participant asked to rate how much symptoms have interfered in past 24 hours; each item rated from 0 to 10, with 0=did not interfere and 10=interfered completely; lower scores indicated better outcome (range: 0 to 60). (NCT00457691)
Timeframe: Day 1 of Cycles 1-3 and Day 1 of every odd-numbered cycle thereafter until EOT/withdrawal
| Intervention | scores on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 5, Day 1 | Cycle 7, Day 1 | Cycle 9, Day 1 | Cycle 11, Day 1 | |
| FOLFIRI + Placebo | -1.3 | -1.7 | -1.2 | -0.2 | -1.7 | -1.0 |
| FOLFIRI + Sunitinib | 0.0 | -0.1 | 0.2 | -0.5 | 2.1 | 3.1 |
Symptom Intensity score is comprised of the sum of 13 MDASI core items (ie, pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, remembering things, lack of appetite, drowsiness, dry mouth, sadness, vomiting, numbness or tingling). Participant asked to rate severity of each symptom at their worst in past 24 hours; each item rated from 0 to 10, with 0=symptom not present and 10=as bad as you can imagine; lower scores indicated better outcome (range: 0 to 130). (NCT00457691)
Timeframe: Day 1 of Cycles 1-3 and Day 1 of every odd-numbered cycle thereafter until end of treatment (EOT)/withdrawal
| Intervention | Scores on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 5, Day 1 | Cycle 7, Day 1 | Cycle 9, Day 1 | Cycle 11, Day 1 | |
| FOLFIRI + Placebo | 0.4 | 0.9 | 1.8 | 2.7 | 1.2 | -2.7 |
| FOLFIRI + Sunitinib | 1.7 | 0.8 | 1.0 | 0.7 | 0.8 | 5.0 |
dose related toxicity is defined as follows:1. WBC damage >= grade 3; granular cell decrease >= grade 3; hemoglobin >= grade 2; platelet >= grade 2;SGPT/SGOT elevation >= grade 2; ALP >= grade 2; GGT >= grade 2; Tbil >= grade 2;renal function damage: BUN/Cr elevation >= grade 2;Non-gradular cell decreased fever >= grade 2;nausea/vomiting >= grade 2; fatigue >= grade 3; weight loss >= grade 3;gastritis >= grade 3; dairrea >= grade 3; abdominal pain >= grade 3; pancreatitis >= grade 2; upper gastrointestinal bleeding >= grade 2;other toxic reaction >= grade 3;KPS < 50 during the treatment (NCT01268943)
Timeframe: up to 9 weeks
| Intervention | event (Number) |
|---|---|
| 1000mg | 1 |
| 1200mg | 0 |
| 1400mg | 0 |
| 1500mg | 3 |
"Overall response rate = complete response + partial response~Complete response = disappearance of all target and non-target lesions and no evidence of new lesions documented by two disease assessments at least 4 weeks apart.~Partial response = at least a 30% decrease in the sum of the longest dimensions (LD) of all target measurable lesions taking as reference the baseline sum of LD. There can be non unequivocal progression of non-target lesions and no new lesions." (NCT00868192)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Pemetrexed and Bevacizumab | 41 |
OS = observed length of time from entry into the study to death or date of last contact (NCT00868192)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Pemetrexed and Bevacizumab | 79 |
OS = observed length of time from entry into the study to death or date of last contact (NCT00868192)
Timeframe: Median follow-up was 25.7 months (range 3.0-47.2 months)
| Intervention | months (Median) |
|---|---|
| Pemetrexed and Bevacizumab | 25.7 |
PFS = Period from study entry until disease progression, death, or date of last contact (NCT00868192)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Pemetrexed and Bevacizumab | 56 |
PFS = Period from study entry until disease progression, death, or date of last contact (NCT00868192)
Timeframe: Median follow-up was 25.7 months (range 3.0-47.2 months)
| Intervention | months (Median) |
|---|---|
| Pemetrexed and Bevacizumab | 7.9 |
A CA-125 response was defined as at least a 50% reduction in CA-125 levels from a pretreatment sample following guidelines described by the Gynecological Cancer Intergroup. (NCT00868192)
Timeframe: 6 months
| Intervention | participants (Number) | ||
|---|---|---|---|
| 50% CA-125 response | 75% CA-125 response | No CA-125 response | |
| Pemetrexed and Bevacizumab | 17 | 8 | 2 |
OS = observed length of time from entry into the study to death or date of last contact (NCT00868192)
Timeframe: Median follow-up was 25.7 months (range 3.0-47.2 months)
| Intervention | months (Median) | ||
|---|---|---|---|
| Platinum-free interval of <6 months | Platinum-free interval of 6-12 months | Platinum-free interval of >12 months | |
| Pemetrexed and Bevacizumab | 16.7 | 24.9 | 28.0 |
PFS = Period from study entry until disease progression, death, or date of last contact (NCT00868192)
Timeframe: Median follow-up was 25.7 months (range 3.0-47.2 months)
| Intervention | months (Median) | ||
|---|---|---|---|
| Platinum-free interval of <6 months | Platinum-free interval of 6-12 months | Platinum-free interval of >12 months | |
| Pemetrexed and Bevacizumab | 6.7 | 4.7 | 16.8 |
As measured by RECIST criteria (NCT00868192)
Timeframe: 6 months
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Complete response | Partial response | Stable disease | Progressive disease | |
| Pemetrexed and Bevacizumab | 0 | 14 | 18 | 2 |
Detailed serious adverse events and other adverse events are shown in the adverse event module of the results. (NCT00868192)
Timeframe: 6 months
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Grade 3/4 hematologic toxicity | Most common non-hematologic toxicity - fatigue | Grade 3 renal toxicity | Gastrointestinal toxicity | Subsequently developed hematologic malignancies | |
| Pemetrexed and Bevacizumab | 53 | 94 | 6 | 91 | 6 |
(NCT00537823)
Timeframe: 30 days following surgery
| Intervention | participants (Number) |
|---|---|
| Arm 1 - Wildtype | 0 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 |
-Compare total longest diameter from baseline to preoperative CT scan. (NCT00537823)
Timeframe: Completion of neoadjuvant therapy (approximately 8 weeks)
| Intervention | percentage of change of longest diameter (Median) |
|---|---|
| Arm 1 - Wildtype | -23.8 |
| Arm 2 K-Ras 12/13 Codon Mutation | -14.3 |
Number of participants whose tumor size decreased from baseline to completion of preoperative chemotherapy. (NCT00537823)
Timeframe: Upon completion of neoadjuvant chemotherapy (approximately 2 months)
| Intervention | participants (Number) |
|---|---|
| Arm 1 - Wildtype | 4 |
| Arm 2 K-Ras 12/13 Codon Mutation | 2 |
Fraction of patients with any complication grades IV and V (NCT00537823)
Timeframe: 30 days following surgery
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1 - Wildtype | 25 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 |
Fraction of patients with any grade of complication I-V (NCT00537823)
Timeframe: 30 days following surgery
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1 - Wildtype | 25 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 |
(NCT00537823)
Timeframe: Time of surgery (approximately 11-16 weeks)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Not reported on pathology report | Mild | Aborted surgery | None | |
| Arm 1 - Wildtype | 1 | 1 | 1 | 1 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 | 0 | 0 | 1 |
"NASH Scoring~Steatosis **<5% = 0~**5-33%=1~**>33-66%=2~**>66%=3~Lobular inflammation~**No foci=0~**<2 foci per x 200 field=1~**2-4 foci per x 200 field=2~**>4 foci per x 200 field=3~Hepatocellular ballooning **None=0 **Few balloon cells = 1 **Many cells/prominent ballooning=2" (NCT00537823)
Timeframe: Time of surgery (approximately 11-16 weeks)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Not reported on pathology report | Aborted surgery | Score 0 | |
| Arm 1 - Wildtype | 3 | 1 | 0 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 | 0 | 1 |
Liver only vs distant disease (NCT00537823)
Timeframe: Up to 5 years
| Intervention | participants (Number) | |
|---|---|---|
| Liver only | Distant disease | |
| Arm 1 - Wildtype | 0 | 1 |
| Arm 2 K-Ras 12/13 Codon Mutation | 0 | 0 |
Prior to each treatment,the area of reappearance of disease was measured and the % change from baseline was calculated. The change was then added to the % change from the previous treatment to generate a cumulative total % change of reappearance of RRP from baseline. The additive nature of this parameter resulted in % greater than 100% if the area of vocal fold affected by the RRP increased over the baseline measurement. (NCT01020747)
Timeframe: 6 months
| Intervention | total percentage change (Mean) |
|---|---|
| Bevacizumab Treated Vocal Fold | 85.3 |
| Untreated Vocal Fold | 225.3 |
"Duration of overall response was measured from the time that measurement criteria are met for complete response (CR) or partial response (PR) (whichever status was recorded first) until the onset of progression. Patients without progression at the last tumor assessment date during their study participation were censored at this last tumor assessment date (exception: availability of validated information about a later onset of progression or a longer progression free interval - in such a case the date of the follow-up assessment was either defined as the onset of progression or replaced the last tumor assessment date).~Missing onset of progression data because of refusal or because of death was replaced.~If several response evaluations for a patient showed progressive disease (PD), the time to PD was assessed by using the first of these measurements." (NCT02119026)
Timeframe: at the day of documented complete or partial response or at 28 days safety follow-up in cases without PD
| Intervention | days (Median) |
|---|---|
| A: XELIRI + BEV Followed by XELOX + BEV | 244.0 |
| B: XELOX + BEV Followed by XELIRI + BEV | 315 |
The primary variable was duration of disease control (DDC) and was defined as the sum of progression free survival intervals during first line and second line treatment (= time from the beginning of first line treatment until onset of progression during second line treatment). Patients without progression at the last tumor assessment date during their study participation were censored at this last tumor assessment date (exception: availability of validated information about a later onset of progression or a longer progression free interval - in such a case the date of the follow-up assessment was either defined as the onset of progression or replaced the last tumor assessment date). (NCT02119026)
Timeframe: screening, every 8 to 9 weeks until progression, at end of treatment (other than progression), every 3 months until progression, death or up to 24 months (whatever comes first)
| Intervention | days (Median) |
|---|---|
| A: XELIRI + BEV Followed by XELOX + BEV | 373.00 |
| B: XELOX + BEV Followed by XELIRI + BEV | 370.00 |
The first line PFS was defined as the progression free survival interval during first line treatment. Patients without progression at the last tumor assessment date during their study participation were censored at this last tumor assessment date (exception: availability of validated information about a later onset of progression or a longer progression free interval - in such a case the date of the follow-up assessment was either defined as the onset of progression or replaced the last tumor assessment date). Missing onset of progression data because of refusal or because of death was replaced. If several response evaluations for a patient showed progressive disease (PD), the time to PD was assessed by using the first of these measurements. (NCT02119026)
Timeframe: at progression of disease (PD) in first line therapy or at 28 days safety follow-up in cases without PD
| Intervention | days (Median) |
|---|---|
| A: XELIRI + BEV Followed by XELOX + BEV | 241 |
| B: XELOX + BEV Followed by XELIRI + BEV | 280 |
The rate of overall response was measured as the response rate from randomization until the day of documented complete response (CR) or partial response (PR) (whichever status is recorded first). (NCT02119026)
Timeframe: at the day of documented complete or partial response or at 28 days safety follow-up in cases without PD
| Intervention | Participants (Count of Participants) |
|---|---|
| A: XELIRI + BEV Followed by XELOX + BEV | 32 |
| B: XELOX + BEV Followed by XELIRI + BEV | 36 |
Overall survival was measured as the time from the randomization date to the date of death. Patients without death date were censored at the date of the last tumor assessment (exception: availability of validated information about a later exitus date or a prolonged survival - in such a case the date of the follow-up assessment was either defined as the exitus date or replaced the last tumor assessment date) or the date of refusal. (NCT02119026)
Timeframe: date of death or date of last tumor assessment (28d safety f-u) in patients without death
| Intervention | days (Median) |
|---|---|
| A: XELIRI + BEV Followed by XELOX + BEV | 593.0 |
| B: XELOX + BEV Followed by XELIRI + BEV | 643 |
"The second line PFS was defined as the progression free survival interval during second line treatment. Patients without progression at the last tumor assessment date during their study participation were censored at this last tumor assessment date (exception: availability of validated information about a later onset of progression or a longer progression free interval - in such a case the date of the follow-up assessment was either defined as the onset of progression or replaced the last tumor assessment date). Missing onset of progression data because of refusal or because of death was replaced.~If several response evaluations for a patient showed progressive disease (PD), the time to PD was assessed by using the first of these measurements." (NCT02119026)
Timeframe: at progression of disease (PD) in second line therapy or at 28 days safety follow-up in cases without PD
| Intervention | days (Median) |
|---|---|
| A: XELIRI + BEV Followed by XELOX + BEV | 129 |
| B: XELOX + BEV Followed by XELIRI + BEV | 155 |
Time to overall response was measured from the time of randomization until the day of documented complete response (CR) or partial response (PR) (whichever status is recorded first). Patients without response were censored at the date of the last tumor assessment, the date of death or the date of refusal. (NCT02119026)
Timeframe: at the day of documented complete or partial response or at 28 days safety follow-up in cases without PD
| Intervention | days (Median) |
|---|---|
| A: XELIRI + BEV Followed by XELOX + BEV | 185.0 |
| B: XELOX + BEV Followed by XELIRI + BEV | 178.0 |
Best response in first line was based on the tumor assessments (based on RECIST criteria) for target lesions and assessed by CT scans, MRI scans, X-ray, bone scan and clinical examination: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter (sum LD) of target lesions; Progressive Disease (PD), >= 20% increase in the sum of the LD of target lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. (NCT02119026)
Timeframe: Baseline, every 8-9 weeks, 28d Safety follow-up
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Progressive Disease (PD) | Stable Disease (SD) | Partial Response (PR) | Complete Response (CR) | |
| A: XELIRI + BEV Followed by XELOX + BEV | 4 | 21 | 26 | 2 |
| B: XELOX + BEV Followed by XELIRI + BEV | 1 | 23 | 30 | 0 |
Best response in second line was based on the tumor assessments (based on RECIST criteria) for target lesions and assessed by CT scans, MRI scans, X-ray, bone scan and clinical examination: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter (sum LD) of target lesions; Progressive Disease (PD), >= 20% increase in the sum of the LD of target lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. (NCT02119026)
Timeframe: Baseline, every 8-9 weeks, 28d Safety follow-up
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Progressive Disease (PD) | Stable Disease (SD) | Partial Response (PR) | Complete Response (CR) | Not available (NA) | |
| A: XELIRI + BEV Followed by XELOX + BEV | 7 | 11 | 6 | 0 | 8 |
| B: XELOX + BEV Followed by XELIRI + BEV | 8 | 13 | 2 | 0 | 1 |
Time in months from the start of study treatment to the date of first progression (PD) according to the RECIST criteria, or death due to any cause. PER RECIST, a PD is indicated when there is at least a 20% increase in the sum of the longest diameters from target lesions relative to the smallest sum recorded since treatment is initiated. Median PFS was estimated using a Kaplan-Meier curve, and is the time at which 50% of patients remain alive without disease progression. (NCT00447330)
Timeframe: 5 years from study start date
| Intervention | survival time in months (Median) |
|---|---|
| 1- Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avastin | 6.97 |
Time in months from the start of study treatment to date of death due to any cause. Median survival was estimated using a Kaplan-Meier curve and is the time point at which 50% of patients remain alive. (NCT00447330)
Timeframe: 5 years after study start date
| Intervention | survival time in months (Median) |
|---|---|
| 1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti | 10.51 |
The proportion of patients for whom the best overall response is complete response (CR) or partial response (PR). A CR occurs when all lesions disappear; whereas, a PR is indicated when there is at least a 30% decrease in the sum of the longest diameters (LD) of the target lesion. A PD (progressive disese) occurs when there is at least a 20% increase in the sum of the LD relative to the smallest sum LD recorded since treatment is initiated. Disease is considered stable if there is no response and no PD. All patients were assigned a best response for inclusion in this calculation in accordance with the protocol. (NCT00447330)
Timeframe: Every 9 weeks for up to 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| 1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti | 41.7 |
Number of subjects who experienced an adverse event (NCT00447330)
Timeframe: Every 21 days
| Intervention | participants (Number) |
|---|---|
| 1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti | 56 |
The objective response rate is defined as the percentage of patients showing complete or partial response. (NCT00462423)
Timeframe: The median duration of follow-up for surviving patients was 41.6 months.
| Intervention | Percentage of participants (Number) |
|---|---|
| Single Arm, Open Label | 36 |
The duration of overall survival was defined as the number of months between the start date of protocol treatment and the date of death (irrespective of cause), and was right-censored at the date of last contact for patients who were alive as of the data cutoff. (NCT00462423)
Timeframe: April 2007 through December 2010
| Intervention | months (Median) |
|---|---|
| Single Arm, Open Label | 16.8 |
Median time of progression-free survival from first treatment according to RECIST 1.0 (NCT00462423)
Timeframe: From start of treatment to disease progressin; median duration of follow-up for surviving patients was 41.6 months.
| Intervention | Months (Median) |
|---|---|
| Single Arm, Open Label | 7.63 |
Progression-free survival at 4 months from first treatment as determined by RECIST 1.0 (NCT00462423)
Timeframe: 4 months.
| Intervention | percentage of patients (Number) |
|---|---|
| Single Arm, Open Label | 75 |
The duration of overall complete response was assessed from the time that measurement criteria were met for complete response until the first date that recurrent or progressive disease was objectively documented. Participants without observed progressive disease after an objective complete response were censored at the date of the last tumor assessment. (NCT00022698)
Timeframe: Approximately 43 Months
| Intervention | months (Number) |
|---|---|
| Cohort 1, Initial Regimen: (Capecitabine + Irinotecan) | 12.45 |
| Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) | 12.68 |
Duration of overall response was assessed from the time that measurement criteria were first met for CR/PR (whichever is first recorded) until the first date that recurrent or progressive disease was documented. It was analyzed for responders only. Participants without observed progressive disease after an objective response were censored at the date of the last tumor assessment. (NCT00022698)
Timeframe: Approximately 43 Months
| Intervention | months (Median) |
|---|---|
| Cohort 1, Initial Regimen: (Capecitabine + Irinotecan) | 7.0 |
| Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) | 7.7 |
Overall Survival is defined as the time from start of treatment to the date of death. Participants who did not die were censored at the last date the participant was known to be alive. (NCT00022698)
Timeframe: Approximately 43 Months
| Intervention | months (Median) |
|---|---|
| Cohort 1, Initial Regimen: (Capecitabine + Irinotecan) | 22.9 |
| Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) | 20.5 |
Survival was measured as the time from start of treatment to the date of death or till one year whichever occurred first. (NCT00022698)
Timeframe: Up to Month 12
| Intervention | percentage of participants (Number) |
|---|---|
| Cohort 1, Initial Regimen: (Capecitabine + Irinotecan) | 67 |
| Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) | 71 |
Time to disease progression was assessed as the time from start of treatment to the time the participant was first recorded as having disease progression or died due to causes other than disease progression. If a participant never progressed while being followed, he/she was censored at the date of the last tumor assessment or the date of the last dose if no post-baseline tumor measurement was available. (NCT00022698)
Timeframe: Approximately 43 Months
| Intervention | months (Median) |
|---|---|
| Cohort 1, Initial Regimen: (Capecitabine + Irinotecan) | 6.1 |
| Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) | 7.6 |
The time to objective response is defined as the time from start of treatment to the date of first objective response. Participants who never responded during study were censored at the last tumor assessment or the date of last dose, whichever was later, or at the date of death if occurring prior to response. (NCT00022698)
Timeframe: Approximately 43 Months
| Intervention | months (Median) |
|---|---|
| Cohort 1, Initial Regimen: (Capecitabine + Irinotecan) | 5.5 |
| Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) | 4.3 |
Time to treatment failure was assessed as the time from start of treatment to the time the participant was withdrawn due to any of the reasons such as adverse events, progressive disease, insufficient therapeutic response, death, failure to return, or refused treatment, did not cooperate or withdrew consent. (NCT00022698)
Timeframe: Approximately 43 Months
| Intervention | months (Median) |
|---|---|
| Cohort 1, Initial Regimen: (Capecitabine + Irinotecan) | 5.8 |
| Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) | 7.3 |
An adverse event (AEs) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. A serious adverse event is defined as any event which was fatal (resulted in death), life-threatening (with immediate risk of death), resulted in a new or prolongation of a current hospitalization, resulted in persistent or significant disability or incapacity, was a congenital anomaly or birth defect, considered medically significant by the investigator, required intervention to prevent one or more of the outcomes listed above. (NCT00022698)
Timeframe: Approximately 43 Months
| Intervention | Number of participants (Number) | |||
|---|---|---|---|---|
| Any AEs | SAEs | Deaths During Study | Deaths During Follow-up | |
| Cohort 1, Initial Regimen: (Capecitabine + Irinotecan) | 15 | 10 | 0 | 13 |
| Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) | 52 | 25 | 3 | 23 |
| Total Participants (Cohort 1 + Cohort 2) | 67 | 35 | 3 | 36 |
Objective Response Rate (ORR) is defined as the percentage of participants with complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumors (RECIST 1.0). CR is defined as the disappearance of all target and non-target lesions and normalization of tumor marker level. PR is defined as a greater than or equal to (>/=) 30% decrease in the sum of the longest diameter (LD) of the target lesions, taking as reference the baseline sum of LD. Participants who did not have a post-baseline tumor measurement were considered non-responders in the assessment of ORR. (NCT00022698)
Timeframe: Approximately 43 Months
| Intervention | percentage of participants (Number) | |
|---|---|---|
| CR | PR | |
| Cohort 1, Initial Regimen:(Capecitabine + Irinotecan) | 7 | 40 |
| Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) | 2 | 42 |
The number of participants in Part 2 who died during the study. (NCT00111761)
Timeframe: From enrollment until last contact. Maximum follow-up was 16 months.
| Intervention | participants (Number) |
|---|---|
| Panitumumab With FOLFIRI | 6 |
Objective tumor response (complete or partial) in Part 2 of the study, based on Response Evaluation Criteria in Solid Tumors (RECIST), where complete response = disappearance of all target lesions, partial response = ≥30% reduction in lesion size, progressive disease = ≥20% increase in tumor size; otherwise stable disease. (NCT00111761)
Timeframe: Until disease progression (median 47 weeks)
| Intervention | Participants (Number) |
|---|---|
| Panitumumab With FOLFIRI | 8 |
The number of participants with grade 3 or grade 4 diarrhea in Part 1 of the study. Grading of diarrhea followed the grading scale in Version 2.0 of the National Cancer Institute Common Toxicity Criteria (NCI CTC). (NCT00111761)
Timeframe: Until disease progression (median 35 weeks) or 48 weeks, whichever occurred first
| Intervention | Participants (Number) |
|---|---|
| Panitumumab With IFL | 11 |
The number of participants with grade 3 or grade 4 diarrhea in Part 2 of the study. Grading of diarrhea followed the grading scale in Version 2.0 of the National Cancer Institute Common Toxicity Criteria (NCI CTC). (NCT00111761)
Timeframe: Until disease progression (median 47 weeks)
| Intervention | Participants (Number) |
|---|---|
| Panitumumab With FOLFIRI | 6 |
Objective tumor response (complete or partial) in Part 1 of the study, based on Response Evaluation Criteria in Solid Tumors (RECIST), where complete response = disappearance of all target lesions, partial response = ≥30% reduction in lesion size, progressive disease = ≥20% increase in tumor size; otherwise stable disease. (NCT00111761)
Timeframe: Until disease progression (median 35 weeks) or 48 weeks, whichever occurred first
| Intervention | Participants (Number) |
|---|---|
| Panitumumab With IFL | 9 |
Kaplan-Meier estimate of median time from enrollment to death or disease progression in Part 1 of the study. Participants who had not progressed and had not died were censored at their last disease assessment date. (NCT00111761)
Timeframe: From enrollment until disease progression or death. Maximum follow-up time was 25 months.
| Intervention | weeks (Median) |
|---|---|
| Panitumumab With IFL | 24.3 |
Kaplan-Meier estimate of median time from enrollment to death or disease progression in Part 2 of the study. Participants who had not progressed and had not died were censored at their last disease assessment date. (NCT00111761)
Timeframe: From enrollment until disease progression or death. Maximum follow-up time was 16 months.
| Intervention | weeks (Median) |
|---|---|
| Panitumumab With FOLFIRI | 41.1 |
Kaplan-Meier estimate of the median time from enrollment to death from any cause. Participants who did not die on study were censored at their last contact date. (NCT00111761)
Timeframe: From enrollment until death. Maximum follow-up time was 25 months.
| Intervention | weeks (Median) |
|---|---|
| Panitumumab With IFL | 73.1 |
Kaplan-Meier estimate of the median time from enrollment to death from any cause. Participants who did not die on study were censored at their last contact date. (NCT00111761)
Timeframe: From enrollment until death. Maximum follow-up time was 16 months.
| Intervention | weeks (Median) |
|---|---|
| Panitumumab With IFL | 73.1 |
Kaplan-Meier estimate of the median time from the first dose of study drug to disease progression or death if due to disease progression (whichever comes first) in Part 1 of the study. Participants who had not progressed or died for reasons other than disease progression were censored at their last disease assessment date. (NCT00111761)
Timeframe: From enrollment until disease progression or death. Maximum follow-up time was 25 months.
| Intervention | weeks (Median) |
|---|---|
| Panitumumab With IFL | 35.0 |
Kaplan-Meier estimate of median time from the first dose of study drug to first observed disease progression or death if the death was due to disease progression (whichever comes first) in Part 2 of the study. Participants who had not progressed or died for reasons other than disease progression were censored at their last disease assessment date. (NCT00111761)
Timeframe: From enrollment until death or diease progression. Maximum follow-up time was 16 months.
| Intervention | weeks (Median) |
|---|---|
| Panitumumab With FOLFIRI | 47.3 |
Median time to first observed objective tumor response (complete or partial) among responders in Part 1 of the study. (NCT00111761)
Timeframe: Until disease progression (median 35 weeks) or 48 weeks, whichever occurred first
| Intervention | weeks (Median) |
|---|---|
| Panitumumab With IFL | 5.9 |
Kaplan-Meier estimate of the median time from the date of first dose of panitumumab or chemotherapy to the date the decision was made to end treatment for any reason in Part 1 of the study. (NCT00111761)
Timeframe: Until disease progression (median 35 weeks) or 48 weeks, whichever occurred first
| Intervention | Weeks (Median) |
|---|---|
| Panitumumab With IFL | 24.3 |
"Computed for all patients with a best response of Partial or Complete per RECIST (a 4-item scale as described in previous outcome measure), calculated from the time when these criteria were first met until the first date of documented progression or death." (NCT00080301)
Timeframe: based on assessments every 6 weeks while on treatment until documented disease progression/unacceptable toxicity
| Intervention | months (Median) |
|---|---|
| Ixabepilone + Capecitabine | 6.4 |
| Capecitabine | 5.6 |
"Participants with best response of Complete or Partial according to Response Evaluation Criteria in Solid Tumors (RECIST) a 4-item scale wherein complete response=disappearance of all target lesions and partial response=30% decrease in the sum of the longest diameter of target lesions" (NCT00080301)
Timeframe: based on assessments every 6 weeks while on treatment until documented disease progression/unacceptable toxicity
| Intervention | percent (Mean) |
|---|---|
| Ixabepilone + Capecitabine | 34.7 |
| Capecitabine | 14.3 |
OS was defined as the time from randomization to death. Participants who did not die at the time of the analysis were censored at the latest follow-up date. Median OS with 95% CI was estimated using the Kaplan Meier product limit method. (NCT00080301)
Timeframe: from date of randomization until death
| Intervention | Months (Median) |
|---|---|
| Ixabepilone + Capecitabine | 12.9 |
| Capecitabine | 11.1 |
PFS defined as the time in months from randomization to date of progression. Patients who died without a reported prior progression were considered to have progressed on date of death; those who didn't progress or die were censored on date of last tumor assessment. Median PFS time with 95% CI estimated using the Kaplan Meier product limit method. (NCT00080301)
Timeframe: based on assessments every 6 weeks while on treatment until documented disease progression/unacceptable toxicity
| Intervention | Months (Median) |
|---|---|
| Ixabepilone + Capecitabine | 5.85 |
| Capecitabine | 4.17 |
Time to response was summarized using descriptive statistics and was defined as the time from first dose of study treatment until measurement criteria were first met for Partial Response or Complete Response. (NCT00080301)
Timeframe: based on assessments every 6 weeks while on treatment until documented disease progression/unacceptable toxicity
| Intervention | weeks (Median) |
|---|---|
| Ixabepilone + Capecitabine | 11.7 |
| Capecitabine | 12.0 |
Quality of life, as measured by the FBSI, an 8-item, participant-reported instrument to measure symptoms. Each item has 5 possible responses ranging from 0 (not at all) to 4 (very much). The scoring was conducted according to the Functional Assessment of Chronic Illness Therapy manual, Version 4; higher scores reflect fewer symptoms. (NCT00080301)
Timeframe: Baseline and prior to each 21-day cycle of treatment, and at first posttreatment follow-up assessment.
| Intervention | units on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Week 3 (n=282; n=273) | Week 6 (n=227; n=214) | Week 9 (n=194; n=184) | Week 12 (n=173; n=158) | Week 15 (n=148; n=145) | Week 18 (n=122; n=121) | Week 21 (n=116; n=101) | Week 24 (n=95; n=82) | |
| Capecitabine | 0.3 | 1.1 | 1.8 | 1.4 | 1.7 | 1.7 | 1.1 | 2.3 |
| Ixabepilone + Capecitabine | -0.4 | -0.2 | -0.6 | -1.3 | -0.7 | -1.0 | -0.7 | -0.8 |
Laboratory values, adverse events, and other symptoms were graded using the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTC) Version 3.0 (NCT00080301)
Timeframe: safety was assessed on a continual basis every cycle while on-treatment and every 4 weeks post treatment until toxicities resolved or were deemed irreversible.
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Deaths on-study or within 30 days of last dose | Treatment-related Serious Adverse Events (SAEs) | Treatment-related Adverse Events (AEs) | Treatment-related AEs leading to Discontinuation | |
| Capecitabine | 40 | 31 | 330 | 25 |
| Ixabepilone + Capecitabine | 33 | 91 | 357 | 137 |
Number of participants with an ORR - the portion of patients with a tumor size reduction of a predefined amount for a minimum time period (NCT01985763)
Timeframe: up to 50 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Genistein | 6 |
The number of participants with best overall response is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for PD the smallest measurements recorded since the treatment started). In general, the patient's best response assignment will depend on the achievement of both measurement and confirmation criteria. (NCT01985763)
Timeframe: up to 50 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Genistein | 8 |
Overall Survival - Number of months still living since baseline (NCT01985763)
Timeframe: up to 50 months
| Intervention | months (Median) |
|---|---|
| Genistein | 36.5 |
Percent change in tumor size after cycle 6. Each cycle is 21 days. (NCT01985763)
Timeframe: end of Cycle 6
| Intervention | Percent change (Median) |
|---|---|
| Genistein | -43.0 |
Patients monitored for progression. Progression-free survival (PFS) is the length of time during and after the treatment that a patient lives with the disease but it does not get worse. (NCT01985763)
Timeframe: up to 50 months
| Intervention | months (Median) |
|---|---|
| Genistein | 11.5 |
"Best Overall Response Rate (ORR) as measured by radiologic RECIST criteria. The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for PD the smallest measurements recorded since the treatment started). In general, the patient's best response assignment will depend on the achievement of both measurement and confirmation criteria.~SD - target lesion SD, non target lesions Non-PD, and no new lesions. PR - target lesion CR, non target lesions Incomplete response/SD and no new lesions; or target lesion PR, non target lesions Non-PD, and no new lesions.~PD - target lesions PD, non target lesions Any, can have new lesions; or target lesions Any, non target lesions PD, can have new lesions; or target lesions Any, non target lesions Any, have new lesions." (NCT01985763)
Timeframe: up to 50 months
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| PR | SD | PD | Not evaluable | |
| Genistein | 6 | 3 | 2 | 2 |
Number of adverse events to assess tolerability of genistein treatment. Evaluation of side effects conducted every 14 days before each chemotherapy/genistein cycle. (NCT01985763)
Timeframe: up to 6 months
| Intervention | events (Number) | |||
|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | |
| Genistein | 250 | 119 | 24 | 0 |
"Patients monitored for progression during the study period and 1 year following.~Progression-free survival (PFS) is the length of time during and after the treatment that a patient lives with the disease but it does not get worse." (NCT01985763)
Timeframe: 6 month and 12 month
| Intervention | percentage of participants (Number) | |
|---|---|---|
| 6 months | 12 months | |
| Genistein | 69 | 38 |
"Response Rate (RR) as measured by radiologic RECIST criteria. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm.~Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.~Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).~Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study." (NCT01985763)
Timeframe: end of Cycle 6
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| PR | SD | PD | Not evaluable | |
| Genistein | 8 | 1 | 2 | 2 |
Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01479348)
Timeframe: Date treatment consent signed to date off study, approximately 20 months and 12 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 2 |
[F-18]-5-fluoro-2'-deoxycytidine (FdCyd) was administered intravenously with administration of tetrahydrouridine (THU) and the frequency and severity of adverse events was observed. A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 0 is normal, Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe or medically significant but not immediately life-threatening, Grade 4 is life-threatening consequences, and Grade 5 is death related to adverse event. (NCT01479348)
Timeframe: Within 5 days after interventions
| Intervention | adverse events (Number) | |||||
|---|---|---|---|---|---|---|
| Day 1 Adverse Events | Day 2, Grade 2 Hypoalbuminemia | Day 2, Grade 3 Anemia | Day 3 Adverse Events | Day 4 Adverse Events | Day 5 Adverse Events | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 0 | 1 | 1 | 0 | 0 | 0 |
Radiation dosimetry was determined based on the first patients. This involved making region of interest measurements on the scan for each major organ and measuring the uptake. Using standard dosimetry software this is converted into mSv/MBq, a standard measure of dosimetry. The software is known as Organ Level INternal Dose Assessment/EXponential Modeling (OLINDA) and is commonly used to generate this kind of data. (NCT01479348)
Timeframe: 1 year
| Intervention | mSv/MBq (Mean) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adrenals | Brain | Breasts | Gallbladder wall | Lower large intestine wall | Small intestine | Stomach wall | Upper large intestine wall | Heart wall | Kidneys | Liver | Lungs | Muscle | Ovaries | Pancreas | Red marrow | Osteogenic cells | Skin | Spleen | Testes | Thymus | Thyroid | Urinary bladder wall | Uterus | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 1.83 | 8.17 | 1.03 | 4.05 | 2.52 | 2.13 | 1.90 | 2.04 | 1.10 | 5.26 | 6.02 | 1.82 | 1.16 | 1.57 | 1.63 | 1.14 | 1.71 | 8.65 | 1.69 | 1.03 | 1.12 | 8.23 | 7.96 | 1.63 |
Participants were scanned by positron emission tomography (PET) and lesions were measured at 4 time points after injection. (NCT01479348)
Timeframe: 9 minutes, 32 minutes, 56 minutes and 2 hours after injection
| Intervention | TBR ratio (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pt 1 L. Parotid adenosquam. cell ca at 9 min | Pt 1 L. Parotid adenosquam. cell ca at 32 min | Pt 1 L. Parotid adenosquam. cell ca at 56 min | Pt 1 L. Parotid adenosquam. cell ca at 2 hrs | Pt 2 R. Parapharyngeal Spindle Cell Ca at 9 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 32 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 56 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 2 hrs | Pt 3 Non-small Cell Lung Ca at 9 min | Pt 3 Non-small Cell Lung Ca at 32 min | Pt 3 Non-small Cell Lung Ca at 56 min | Pt 3 Non-small Cell Lung Ca at 2 hrs | Pt 4 Non-small Cell Lung Ca at 9 min | Pt 4 Non-small Cell Lung Ca at 32 min | Pt 4 Non-small Cell Lung Ca at 56 min | Pt 4 Non-small Cell Lung Ca at 2 hrs | Pt 5 Hepatocellular Ca at 9 min | Pt 5 Hepatocellular Ca at 32 min | Pt 5 Hepatocellular Ca at 56 min | Pt 5 Hepatocellular Ca at 2 hrs | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 1.4 | 1.5 | 1.5 | 1.6 | 1.9 | 1.7 | 1.7 | 1.6 | 1.4 | 1.4 | 1.5 | 1.7 | 2.4 | 2.1 | 1.6 | 2.0 | NA | NA | NA | NA |
247 reviews available for fluorouracil and Metastase
| Article | Year |
|---|---|
Pharmacoethnicity of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: a systematic review and meta-analysis.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Ethnicity; Fluorouracil; Ge | 2021 |
Triplet chemotherapy in combination with anti-EGFR agents for the treatment of metastatic colorectal cancer: Current evidence, advances, and future perspectives.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; C | 2022 |
Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Comparative Effectiveness Research; Deoxyc | 2022 |
Second-line treatment for metastatic pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabi | 2020 |
Treatment landscape of metastatic pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Clinical Tri | 2021 |
Metastatic Acinar Cell Carcinoma of the Pancreas: A Retrospective Cohort Study on Systemic Chemotherapy and Review of the Literature.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Acinar Cell; Deoxycytidine; | 2021 |
[FOLFIRI plus Ramucirumab Treatment for Metastatic Colorectal Cancer-Narrative Review of Real-World Evidence in Japan].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2021 |
Anti-PD-1 and Anti-PD-L1 in Head and Neck Cancer: A Network Meta-Analysis.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2021 |
Overall survival of patients with KRAS wild-type tumor treated with FOLFOX/FORFIRI±cetuximab as the first-line treatment for metastatic colorectal cancer: A meta-analysis.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neopla | 2017 |
[Cetuximab in association with an oxaliplatin-based chemotherapy as first-line treatment of metastatic colorectal cancer.]
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Fluorouracil; Human | 2017 |
FOLFOXIRI Regimen for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Sur | 2017 |
Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2017 |
Efficacy and safety of FOLFIRI and biotherapy versus FOLFIRI alone for metastatic colorectal cancer patients: A meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Therapy; Camptothecin; Colorectal Neoplas | 2017 |
New Trends in the Therapeutic Approach to Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Fluorouracil; Hum | 2018 |
Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives.
Topics: Chemotherapy, Adjuvant; Colorectal Neoplasms, Hereditary Nonpolyposis; DNA Mismatch Repair; Fluorour | 2018 |
Nowadays pancreatic cancer prognosis.
Topics: Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; C | 2019 |
Mediators of Inflammation in Topical Therapy of Skin Cancers.
Topics: Administration, Topical; Aminoquinolines; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineop | 2019 |
AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3.
Topics: AMP-Activated Protein Kinases; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarke | 2019 |
Efficacy and safety assessment of S-1-based regimens comparing to intravenous fluorouracil-based ones in Asian patients with metastatic colorectal carcinoma: A system review and meta-analysis.
Topics: Administration, Intravenous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian Peop | 2019 |
[A case of recurrent colon cancer involved in multiple organs maintaining complete response over the long-term after chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Female; Fluor | 2013 |
Molecularly targeted therapy: toxicity and quality of life considerations in advanced colorectal cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; M | 2013 |
[Chemotherapy in male external genital organs (testicular and penile cancer)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Chemotherapy, Adjuvant; Cisp | 2013 |
[A case of Stage IV sigmoid colon cancer cured with radical combined modality therapy].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Comb | 2013 |
Treatment of gastric cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy | 2014 |
Sequencing of treatment in metastatic colorectal cancer: where to fit the target.
Topics: Algorithms; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anti | 2014 |
Treatment options in patients with metastatic gastric cancer: current status and future perspectives.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cisplatin; Clinical Trials | 2014 |
Breast cancer, DPYD mutations and capecitabine-related ileitis: description of two cases and a review of the literature.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neopla | 2014 |
Role of cetuximab in first-line treatment of metastatic colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2014 |
Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer?
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combine | 2014 |
A retrospective study evaluating a fixed low dose capecitabine monotherapy in women with HER-2 negative metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deo | 2014 |
Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasm | 2014 |
A simple technique to estimate best- and worst-case survival in patients with metastatic colorectal cancer treated with chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Hu | 2014 |
Meta-analysis comparing the safety and efficacy of metastatic colorectal cancer treatment regimens, capecitabine plus irinotecan (CAPIRI) and 5-fluorouracil/leucovorin plus irinotecan (FOLFIRI).
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; De | 2015 |
The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Ana | 2015 |
Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal | 2015 |
Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bev | 2016 |
Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colore | 2016 |
XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chi-Square Distribution; Colorectal Ne | 2016 |
Reconsidering the benefit of intermittent versus continuous treatment in the maintenance treatment setting of metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Campt | 2016 |
Systematic Review and Meta-Analysis on the Role of Chemotherapy in Advanced and Metastatic Neuroendocrine Tumor (NET).
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Fluorouracil; Humans; Interfe | 2016 |
Efficacy and Safety of Bevacizumab Combined With Fluoropyrimidine Monotherapy for Unfit or Older Patients With Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasm | 2017 |
A network meta-analysis for toxicity of eight chemotherapy regimens in the treatment of metastatic/advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Do | 2016 |
Efficacy and safety of addition of bevacizumab to FOLFIRI or irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer: A meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Flu | 2016 |
FOLFOX-4 regimen with concomitant highly active antiretroviral therapy in metastatic colorectal cancer HIV-infected patients: a report of five cases and review of the literature.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highl | 2008 |
Is XELOX equivalent to FOLFOX or other continuous-infusion 5-fluorouracil chemotherapy in metastatic colorectal cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; F | 2008 |
HER-2-positive metastatic breast cancer: trastuzumab and beyond.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Application of epothilones in breast cancer therapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Epot | 2008 |
Design, synthesis and anticancer activity against the MCF-7 cell line of benzo-fused 1,4-dihetero seven- and six-membered tethered pyrimidines and purines.
Topics: Acetals; Antineoplastic Agents; Benzene Derivatives; Breast Neoplasms; Cell Line, Tumor; Cell Prolif | 2008 |
Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Colore | 2009 |
Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Colore | 2009 |
Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Colore | 2009 |
Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Colore | 2009 |
Molecularly targeted agents in the treatment of recurrent or metastatic squamous cell carcinomas of the head and neck.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2008 |
Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2008 |
The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabin | 2009 |
Capecitabine plus oxaliplatin vs fluorouracil plus oxaliplatin as first line treatment for metastatic colorectal caner - meta-analysis of six randomized trials.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neopl | 2010 |
The role of targeted therapy in the treatment of advanced colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 2009 |
Emerging role of capecitabine in gastric cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deox | 2009 |
Microsatellite instability: a predictive marker in metastatic colorectal cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Clinical Trials as | 2009 |
Evolving treatment of advanced colon cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2009 |
Secondary hepatic resection as a therapeutic goal in advanced colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2009 |
Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a North Central Cancer Treatment Group review of 3811 patients, N0144.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemother | 2009 |
Chemotherapy, which drugs and when.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; C | 2009 |
Lapatinib for the treatment of HER2-overexpressing breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabin | 2009 |
Lapatinib in metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2009 |
Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2010 |
A systematic review of FOLFOXIRI chemotherapy for the first-line treatment of metastatic colorectal cancer: improved efficacy at the cost of increased toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2011 |
Lapatinib for treatment of advanced or metastasized breast cancer: systematic review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Femal | 2009 |
Intralesional agents in the management of cutaneous malignancy: a review.
Topics: Aminolevulinic Acid; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bleomycin; Carci | 2011 |
Economic evaluation of capecitabine as adjuvant or metastatic therapy in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Cost Sa | 2010 |
Role of capecitabine and irinotecan combination therapy in advanced or metastatic gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Deoxycytidin | 2010 |
Metastatic colorectal cancer: from improved survival to potential cure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Catheter Ablation; | 2010 |
Ixabepilone plus capecitabine for breast cancer patients with an early metastatic relapse after adjuvant chemotherapy: two clinical trials.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidi | 2010 |
Differences in efficacy and safety between capecitabine and infusional 5-fluorouracil when combined with irinotecan for the treatment of metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; De | 2010 |
Capecitabine-based chemotherapy for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; De | 2011 |
Challenges of drug resistance in the management of pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; | 2010 |
The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis.
Topics: Anastrozole; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2011 |
Chemotherapy of metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neo | 2010 |
Metastatic pancreatic cancer: old drugs, new paradigms.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic | 2011 |
Ixabepilone for the treatment of breast cancer.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neopla | 2011 |
Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Capecitabine; Cisplatin; C | 2011 |
[A case of effective neoadjuvant chemoradiotherapy with capecitabine for locally advanced sigmoid colon cancer].
Topics: Adenocarcinoma; Capecitabine; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Humans; Male; | 2011 |
Evolution of systemic therapy for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2011 |
Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine | 2011 |
Predictive biomarkers with potential of converting conventional chemotherapy to targeted therapy in patients with metastatic colorectal cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Clinical Trials as Topic; Colorectal Neoplas | 2012 |
Pharmacogenomics and metastatic colorectal cancer: current knowledge and perspectives.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Campt | 2012 |
Capecitabine-induced hand-foot syndrome complicated by pseudomonal superinfection resulting in bacterial sepsis and death: case report and review of the literature.
Topics: Antimetabolites, Antineoplastic; Bacteremia; Breast Neoplasms; Capecitabine; Deoxycytidine; Fatal Ou | 2011 |
[A review of FOLFOXIRI chemotherapy for the 1st line treatment of metastatic colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2011 |
Combining capecitabine and bevacizumab in metastatic breast cancer: a comprehensive review.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brea | 2012 |
Capecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; | 2012 |
Definitive treatment of metastatic nasopharyngeal carcinoma: Report of 5 cases with review of literature.
Topics: Adult; Antineoplastic Agents; Carcinoma; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Femal | 2012 |
Chemotherapeutic approaches for newly diagnosed hepatoblastoma: past, present, and future strategies.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; C | 2012 |
Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2012 |
Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Circadian Clocks; Colorectal Ne | 2012 |
Cetuximab: a guide to its use in combination with FOLFIRI in the first-line treatment of metastatic colorectal cancer in the USA.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2012 |
Oxaliplatin-induced severe anaphylactic reactions in metastatic colorectal cancer: case series analysis.
Topics: Adult; Aged; Anaphylaxis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Col | 2012 |
Efficacy and toxicity of capecitabine-based chemotherapy in patients with metastatic or advanced breast cancer: results from ten randomized trials.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil | 2012 |
[Modified FOLFOX6(mFOLFOX6)in metastatic colorectal carcinoma patients with poor performance status].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Humans; | 2012 |
Clinical efficacy of including capecitabine in neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis of randomized controlled trials.
Topics: Anthracyclines; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Models, | 2013 |
Effectiveness of 5-flurouracil-based neoadjuvant chemotherapy in locally-advanced gastric/gastroesophageal cancer: a meta-analysis.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Disease-Free Survival; Esophageal Neoplasms; Fluorour | 2012 |
Therapeutic advances in the management of metastatic colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Colo | 2001 |
Chemotherapy for metastatic colorectal cancer.
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoplas | 2002 |
Metastatic pancreatic cancer.
Topics: Antineoplastic Agents; Autonomic Nerve Block; Celiac Plexus; Cholestasis; Clinical Trials as Topic; | 2002 |
The role of oxaliplatin in the treatment of advanced metastatic colorectal cancer: prospects and future directions.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neop | 2002 |
Advances in the treatment of metastatic colorectal cancer.
Topics: Administration, Oral; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cancer Vaccines; | 2001 |
[Gemcitabine and breast cancer].
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetaboli | 2002 |
Treatment for anthracycline-pretreated metastatic breast cancer.
Topics: Administration, Oral; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineo | 2002 |
Combination versus sequential single-agent therapy in metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetaboli | 2002 |
Single-agent capecitabine: a reference treatment for taxane-pretreated metastatic breast cancer?
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neo | 2002 |
Perspectives on the role of sequential or combination chemotherapy for first-line and salvage therapy in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2002 |
[Pancreatic cancer. The relative importance of neoadjuvant therapy].
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Case-Control Studies; Child; Ci | 2003 |
Ten-year outcome after combined modality therapy for inflammatory breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carci | 2003 |
Monotherapy options in the management of metastatic breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Fluo | 2003 |
21. The adjuvant treatment of breast cancer.
Topics: Acute Disease; Adult; Age Factors; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Ch | 2003 |
[Adjuvant treatment of pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2003 |
[Polymorphism in colorectal cancer].
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Fluorouracil; Genetic Predisposition to D | 2003 |
Systemic therapy for colorectal cancer: focus on newer chemotherapy and novel agents.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; | 2003 |
Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycyt | 2003 |
Development of new agents for the treatment of advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, Phase I | 2003 |
[Palliative therapy of colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Dise | 2003 |
New developments in systemic chemotherapy in advanced colorectal cancer.
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2003 |
Introduction. Single-agent or combination chemotherapy in metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe | 2003 |
Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda) for locally advanced and/or metastatic breast cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2004 |
[Radiation and concomitant chemotherapy after surgery for breast cancer].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; An | 2004 |
Systemic treatment of gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Combined Modali | 2004 |
Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Colorectal Neoplasms; | 2004 |
Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Colorectal Neoplasms; | 2004 |
Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Colorectal Neoplasms; | 2004 |
Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Colorectal Neoplasms; | 2004 |
Evidence-based update of chemotherapy options for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Campt | 2004 |
Current perspectives in the treatment of metastatic colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clini | 2004 |
Optimizing the management of HER2-negative metastatic breast cancer with capecitabine (Xeloda).
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 2004 |
Capecitabine plus docetaxel combination chemotherapy for metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as T | 2004 |
Critical evaluation of current treatments in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2005 |
Current status and future prospects of chemotherapy for metastatic gastric cancer: a review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Fluorouracil; Huma | 2005 |
Indications and effect on survival of standard chemotherapy in advanced colorectal cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neopl | 2005 |
Irinotecan-based regimens in the adjuvant therapy of colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2005 |
Interferon alpha for the treatment of advanced renal cancer.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Combined Modality T | 2005 |
Have we made progress in pharmacogenomics? The implementation of molecular markers in colon cancer.
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Biomarke | 2005 |
Chemotherapy for colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neop | 2005 |
Adjuvant therapy for colon cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 2006 |
Does induction chemotherapy have a role in the management of locoregionally advanced squamous cell head and neck cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Hu | 2006 |
Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; Head and Neck Neoplasms; H | 2006 |
Metastatic colorectal cancer: Therapeutic options.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2006 |
Bevacizumab in combination with 5-fluorouracil-based chemotherapy in the second-line treatment of metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2006 |
The role of angiogenesis inhibition in the treatment of breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2006 |
Bevacizumab in older patients and patients with poorer performance status.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2006 |
Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2006 |
Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, | 2007 |
A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Comb | 2008 |
Combined-modality therapy for esophageal and gastroesophageal junction cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Esophageal Neo | 2007 |
Capecitabine in combination with novel targeted agents in the management of metastatic breast cancer: underlying rationale and results of clinical trials.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2007 |
Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; | 2007 |
Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; | 2007 |
Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; | 2007 |
Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; | 2007 |
Presurgical chemotherapy in patients being considered for liver resection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorectal Neoplasms; Fluorouraci | 2007 |
[Preoperative treatments of rectal cancers].
Topics: Antimetabolites, Antineoplastic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as T | 2007 |
The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2007 |
The clinical efficacy of FOLFIRI and bevacizumab in combination as first-line therapy of metastatic colorectal cancer.
Topics: Age Factors; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combine | 2007 |
Safety of capecitabine use in patients with liver dysfunction.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Drug-Relate | 2007 |
The multidisciplinary management of gastrointestinal cancer. The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Com | 2007 |
Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans | 2008 |
Pancreatic cancer--is the wall crumbling?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Ad | 2008 |
Clinical studies with epothilones for the treatment of metastatic breast cancer.
Topics: Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progress | 2008 |
[Antibody treatment in colorectal cancer--what the surgeon needs to know].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, | 2008 |
Chemotherapy of esophageal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Doxorub | 1984 |
Chemotherapy of breast cancer: current views and results.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Tr | 1983 |
The importance of dose intensity in chemotherapy of metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dose-Response Re | 1984 |
The importance of dose intensity in chemotherapy of metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dose-Response Re | 1984 |
The importance of dose intensity in chemotherapy of metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dose-Response Re | 1984 |
The importance of dose intensity in chemotherapy of metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dose-Response Re | 1984 |
[Advanced prostatic cancer: therapeutic modalities].
Topics: Acid Phosphatase; Antineoplastic Agents; Bromocriptine; Castration; Combined Modality Therapy; Cypro | 1984 |
Adjuvant chemotherapy for early breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclopho | 1983 |
Chemotherapeutic treatment of endometrial carcinoma.
Topics: Antineoplastic Agents; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; | 1982 |
[The present state of the art in diagnosis and therapy of cancer of the breast (author's transl)].
Topics: Adult; Biopsy; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans; Lymph Node Excision | 1982 |
[Choice of treatment in rectal cancer. Consensus Conference, Chamber of Commerce and Industry, Paris, December 1-2, 1994].
Topics: Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Prot | 1995 |
Recurrent breast cancer: presentation, diagnosis, and treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bone Neoplasms; Breast | 1993 |
[Chemotherapy of metastasizing cancers of the colon and rectum].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colonic Neopla | 1993 |
Current approaches to metastatic colorectal cancer.
Topics: Adjuvants, Pharmaceutic; Clinical Trials as Topic; Colorectal Neoplasms; Drug Administration Schedul | 1994 |
[Interferon-alpha therapy in hypernephroma].
Topics: Carcinoma, Renal Cell; Combined Modality Therapy; Female; Fluorouracil; Humans; Interferon-alpha; In | 1993 |
Cancers of the large bowel and hepatobiliary tract.
Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as | 1996 |
Chronotherapy for gastrointestinal cancers.
Topics: Antineoplastic Agents; Chronotherapy; Clinical Trials as Topic; Colorectal Neoplasms; Drug Delivery | 1996 |
Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review.
Topics: Aminopterin; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antidotes; Antimetabolites, Antine | 1996 |
Paclitaxel combination therapy in the treatment of metastatic breast cancer.
Topics: Aminopterin; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 1996 |
Paclitaxel as first-line treatment for metastatic breast cancer. The Taxol Investigational Trials Group, Australia and New Zealand.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cyclophosphamide; Doxoru | 1997 |
Oxaliplatin plus 5-fluorouracil: clinical experience in patients with advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo | 1998 |
Oxaliplatin for the treatment of advanced colorectal cancer: future directions.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Col | 1998 |
[Drug clinics. How I treat. II. Therapeutic approaches to metastatic colorectal cancer].
Topics: Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic | 1998 |
Treatment of advanced and metastatic pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cis | 1998 |
[Ways of improving long-term results of treatment in resectable pancreatic cancer].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Combined Modality Therapy; Evaluation | 1998 |
[Irinotecan monotherapy in the treatment of colorectal cancers: results of phase II trials].
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Cam | 1998 |
[Second-line irinotecan chemotherapy in the treatment of metastatic colorectal cancers: phase III trials].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothec | 1998 |
[Irinotecan in combination for colon cancer].
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; C | 1998 |
Novel oral fluoropyrimidines in the treatment of metastatic colorectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 1999 |
New possibilities in chemotherapy for colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Color | 1999 |
Cytokine combinations: therapeutic use in patients with advanced renal cell carcinoma.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Ce | 2000 |
Current treatment options for advanced colorectal cancer.
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; H | 2000 |
Developments in the treatment of gastric cancer in Europe.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II a | 2000 |
Irinotecan-based combinations for the adjuvant treatment of stage III colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Clinical Trial | 2000 |
Irinotecan and high-dose fluorouracil/leucovorin for metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Prot | 2000 |
Randomized trials of high dose chemotherapy for breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Clinical Trials, Phas | 2001 |
Raltitrexed/5-fluorouracil-based combination chemotherapy regimens in anticancer therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo | 2001 |
Dose scheduling--Herceptin.
Topics: Abdominal Muscles; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplasti | 2001 |
New combinations with Herceptin in metastatic breast cancer.
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormo | 2001 |
Capecitabine: a review of its use in the treatment of advanced or metastatic colorectal cancer.
Topics: Absorption; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecit | 2001 |
Simultaneous radiochemotherapy in cervical cancer: recommendations for chemotherapy.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineop | 2001 |
Platinum compounds in the treatment of advanced breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineopl | 2001 |
New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neop | 2001 |
Role of epirubicin in advanced breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclo | 2000 |
Capecitabine: fulfilling the promise of oral chemotherapy.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2002 |
[Recommendations of GESIDA/Spanish National Plan of AIDS on diagnosis and treatment of Kaposi's sarcoma and cervical cancer in HIV-infected patients].
Topics: Acquired Immunodeficiency Syndrome; Algorithms; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2002 |
Gemcitabine/anthracycline combinations in metastatic breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, P | 2002 |
Management of locally advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, | 2002 |
[Oral fluoropyrimidines registered for the treatment of metastatic colorectal carcinoma: a possible gain].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neopl | 2002 |
Current concepts of chemotherapy combined with other modalities for head and neck cancer.
Topics: Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamide; Fluorouracil; Head; Head and Neck Neoplasms; | 1975 |
Progress report. Cytotoxic therapy for gastrointestinal carcinoma.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Bleomycin; Carcinoma, | 1976 |
[Chemotherapy of gastrointestinal tumors (review of the literature)].
Topics: Ancitabine; Carcinoma, Hepatocellular; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combination; Fl | 1978 |
Rationale for adjuvant chemotherapy.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carmustine; Cyclophosphamide; Cytarabine; Doxorubi | 1977 |
Nonsystemic treatment of metastatic tumors of the liver--a review.
Topics: Antineoplastic Agents; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; | 1978 |
Therapeutic approaches to hepatoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheterization; Drug Synergism; Drug Therapy, Com | 1975 |
Chemotherapy of solid tumors. Recent advances.
Topics: Adult; Alkylating Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Bronchogenic; Carcinom | 1976 |
[The state of hormone and chemotherapy in breast neoplasms].
Topics: Androgens; Brain Neoplasms; Breast Neoplasms; Castration; Cyclophosphamide; Doxorubicin; Drug Therap | 1978 |
The chemotherapy of advanced bladder carcinoma.
Topics: Antineoplastic Agents; Cyclophosphamide; Doxorubicin; Fluorouracil; Humans; Injections, Intra-Arteri | 1977 |
Chemotherapy of advanced soft-tissue sarcomas in adults.
Topics: Adult; Antineoplastic Agents; Bone Marrow; Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; | 1977 |
Management of gastrointestinal cancer.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Fluor | 1977 |
[Hormone and chemotherapy of breast carcinoma].
Topics: Androgens; Breast Neoplasms; Castration; Cyclophosphamide; Drug Therapy, Combination; Estrogens; Fem | 1977 |
A recent overview of chemotherapy for advanced stomach cancer in Japan.
Topics: Antineoplastic Agents; Carbazilquinone; Chromomycins; Drug Therapy, Combination; Fluorouracil; Human | 1978 |
[Basic trends in the combined treatment of locally spread rectal cancer].
Topics: Fluorouracil; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Postoperati | 1979 |
[Symposium on carcinoma of colon and rectum: 4. The role of adjuvant therapy with surgery in cancers of the colon and rectum].
Topics: Colonic Neoplasms; Fluorouracil; Humans; Immunosuppressive Agents; Neoplasm Metastasis; Nitrosourea | 1978 |
Biochemical markers in cancer of the breast.
Topics: Breast Neoplasms; Cadaverine; Carcinoembryonic Antigen; Chorionic Gonadotropin; Cyclophosphamide; Do | 1976 |
[Ligation of the hepatic artery in the treatment of liver tumors (review of the literature)].
Topics: Adult; Anti-Bacterial Agents; Fluorouracil; Hemangioma; Hepatic Artery; Humans; Ligation; Liver Cirr | 1975 |
Cytotoxic treatment of metastatic breast cancer. Which drugs and drug combinations to use?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; | 1992 |
The rationale for early postoperative intraperitoneal chemotherapy for gastric cancer.
Topics: Chemotherapy, Adjuvant; Cisplatin; Doxorubicin; Drug Evaluation; Fluorouracil; Humans; Infusions, Pa | 1991 |
Rationale for the intraperitoneal approach to surgical adjuvant chemotherapy of gastric cancer.
Topics: Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Fluorouracil; Humans; Infusions, Parent | 1991 |
Radiotherapy in the treatment of pancreatic cancer.
Topics: Combined Modality Therapy; Fluorouracil; Humans; Intraoperative Period; Neoplasm Metastasis; Neoplas | 1990 |
[5-Fluorouracil (5-FU)/leucovorin in comparison to other current chemotherapy protocols in metastasizing colorectal carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Fluorou | 1991 |
[Concomitant association of radiotherapy and chemotherapy in inflammatory breast cancer. Initial results of phase II trial].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 1991 |
Concurrent chemotherapy and thoracic irradiation in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lun | 1990 |
[Therapy of advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Flu | 1991 |
Biochemical modulation of 5-fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor | 1990 |
Treatment of metastatic breast cancer.
Topics: Breast Neoplasms; Cisplatin; Cyclophosphamide; Doxorubicin; Fluorouracil; Gonadotropin-Releasing Hor | 1990 |
Combined therapy in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclopho | 1985 |
[A case of an exogastric developing-type carcinoma of the stomach and a review of thirty nine cases reported in Japan].
Topics: Antigens, Neoplasm; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy P | 1988 |
Patterns of metastasis and natural courses of breast carcinoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bre | 1985 |
Genitourinary-tract problems of the aged male.
Topics: Adenocarcinoma; Age Factors; Aged; Cyclophosphamide; Cyproterone; Diethylstilbestrol; Fluorouracil; | 1974 |
Controversies in the management of potentially curable breast cancer.
Topics: Breast Neoplasms; Castration; Clinical Trials as Topic; England; Female; Fluorouracil; Humans; Lymph | 1974 |
[Chemotherapy of cancer of the rectum and the colon].
Topics: Antimetabolites; Colonic Neoplasms; Drug Synergism; Floxuridine; Fluorouracil; Humans; Injections, I | 1970 |
5-Fluorouracil in the treatment of gastrointestinal neoplasia.
Topics: Administration, Oral; Antineoplastic Agents; Floxuridine; Fluorouracil; Gastrointestinal Neoplasms; | 1973 |
Proceedings: Non-hormonal cytotoxic agents in the treatment of prostatic adenocarcinoma.
Topics: Acid Phosphatase; Adenocarcinoma; Aniline Compounds; Bone Neoplasms; Cyclophosphamide; Evaluation St | 1973 |
The use of cytotoxic drugs in the surgery of malignant disease.
Topics: Abdominal Neoplasms; Alkylating Agents; Animals; Antimetabolites; Antineoplastic Agents; Carcinoma, | 1968 |
[Carcinoid: problems of pathology, biochemistry and therapy].
Topics: Angiotensin II; Animals; Blood Pressure; Cyclophosphamide; Fluorouracil; Guinea Pigs; Histocytochemi | 1971 |
Newer concepts in chemotherapy of cancer.
Topics: Breast Neoplasms; Colonic Neoplasms; Dysgerminoma; Female; Fluorouracil; Humans; Injections, Intra-A | 1972 |
Management of cancer of the colon.
Topics: Colitis, Ulcerative; Colon; Colonic Diseases; Colonic Neoplasms; Diagnostic Errors; Fluorouracil; Hu | 1974 |
[Current status of cytostatic therapy].
Topics: Adrenal Cortex Hormones; Alkylating Agents; Antibiotics, Antineoplastic; Antineoplastic Agents; Cyta | 1974 |
Present experiences with hepatic dearterialization in liver neoplasm.
Topics: Adult; Aged; Alanine Transaminase; Alkaline Phosphatase; Animals; Aspartate Aminotransferases; Cathe | 1974 |
[Long-term therapy of liver diseases].
Topics: Aged; Anabolic Agents; Chronic Disease; Cortisone; Diet Therapy; Fatty Liver; Female; Fluorouracil; | 1972 |
Chemotherapy of squamous cell carcinoma of the cervix, vagina, and vulva.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Chemotherapy, Cancer, Regional Perfusion; Female; F | 1968 |
1168 trials available for fluorouracil and Metastase
| Article | Year |
|---|---|
Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorec | 2021 |
Fixed dose combination of capecitabine and cyclophosphamide in metastatic breast cancer: Results from THE ENCLOSE phase 2/3 randomized multicenter study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; De | 2021 |
Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytid | 2022 |
Germline polymorphisms in genes maintaining the replication fork predict the efficacy of oxaliplatin and irinotecan in patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; | 2022 |
[The TAILOR study establishes, in patients mCRC wt, the first line use of FOLFOX in combination with cetuximab].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; | 2022 |
SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2019 |
ACORN: Observational Study of Bevacizumab in Combination With First-Line Chemotherapy for Treatment of Metastatic Colorectal Cancer in the UK.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2019 |
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2019 |
Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asia | 2020 |
Randomized, Phase II Study Prospectively Evaluating Treatment of Metastatic Esophageal, Gastric, or Gastroesophageal Cancer by Gene Expression of
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; DNA-Binding Proteins | 2020 |
Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306).
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neo | 2020 |
The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomark | 2020 |
The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2020 |
Sex-dependent least toxic timing of irinotecan combined with chronomodulated chemotherapy for metastatic colorectal cancer: Randomized multicenter EORTC 05011 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel | 2020 |
Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panit
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2020 |
A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Combined Moda | 2020 |
Selinexor (KPT-330), an Oral Selective Inhibitor of Nuclear Export (SINE) Compound, in Combination with FOLFOX in Patients with Metastatic Colorectal Cancer (mCRC) - Final Results of the Phase I Trial SENTINEL.
Topics: Active Transport, Cell Nucleus; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neo | 2020 |
Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIR
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; | 2020 |
Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 2020 |
A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; BRCA1 P | 2020 |
Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Humans; Male | 2020 |
Determination of the UGT1A1 polymorphism as guidance for irinotecan dose escalation in metastatic colorectal cancer treated with first-line bevacizumab and FOLFIRI (PURE FIST).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2020 |
Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases: A post hoc analysis of the WJOG4407G phase III study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Antineoplastic C | 2020 |
Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy-a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; | 2020 |
nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug | 2020 |
Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineop | 2021 |
FOLFIRINEC: a randomized phase II trial of mFOLFIRINOX vs platinum-etoposide for metastatic neuroendocrine carcinoma of gastroenteropancreatic or unknown origin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Neuroendocrine; Etopos | 2021 |
Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; F | 2021 |
Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Leuco | 2021 |
A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Cisplatin; De | 2021 |
Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorec | 2021 |
MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Colorectal | 2021 |
Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B | 2017 |
Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Autophagy-Related Proteins; | 2017 |
Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neo | 2017 |
Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colonic Neoplasms; Disease-F | 2017 |
Feasibility of Modified FOLFOX in Elderly Patients Aged ≥80 Years with Metastatic Gastric Cancer or Colorectal Cancer.
Topics: Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2017 |
Prevalence and influence on outcome of HER2/neu, HER3 and NRG1 expression in patients with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasm | 2017 |
TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Dis | 2017 |
Very accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: Pooled analysis of two GORTEC randomized trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiothe | 2017 |
A phase II clinical study of combining FOLFIRI and bevacizumab plus erlotinib in 2nd-line chemotherapy for patients with metastatic colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2017 |
Postoperative Chemoradiotherapy After Local Resection for High-Risk T1 to T2 Low Rectal Cancer: Results of a Single-Arm, Multi-Institutional, Phase II Clinical Trial.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Colectomy | 2017 |
Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial.
Topics: Adenocarcinoma; Age Factors; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combin | 2018 |
Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306).
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tu | 2017 |
A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2017 |
RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial.
Topics: Alleles; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplas | 2018 |
Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2018 |
Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; C | 2018 |
Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG-ACRIN Cancer Research Group (E4203).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorec | 2018 |
Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal N | 2018 |
EVITA-a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuxi | 2018 |
Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2018 |
Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; | 2018 |
Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer.
Topics: Adult; Aged; Antibodies, Bispecific; Antineoplastic Combined Chemotherapy Protocols; CD3 Complex; Do | 2018 |
Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK cli
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2018 |
Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK cli
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2018 |
Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK cli
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2018 |
Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK cli
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2018 |
First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Diseas | 2018 |
A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy | 2018 |
Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tu | 2019 |
Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized Phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Campto | 2018 |
A randomized phase III study of hepatic arterial infusion chemotherapy with 5-fluorouracil and subsequent systemic chemotherapy versus systemic chemotherapy alone for colorectal cancer patients with curatively resected liver metastases (Japanese Foundatio
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 2018 |
Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial.
Topics: Adult; Aged; Antibodies; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy | 2018 |
Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2019 |
Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomark | 2019 |
Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreati | 2019 |
A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Beva | 2019 |
A Phase II Study Alternating Erlotinib With Second-line mFOLFOX6 or FOLFIRI for Metastatic Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2019 |
Efficacy of aflibercept with FOLFOX and maintenance with fluoropyrimidine as first‑line therapy for metastatic colorectal cancer: GERCOR VELVET phase II study.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pr | 2019 |
Quality of life and cost of strategies of two chemotherapy lines in metastatic colorectal cancer: results of the FFCD 2000-05 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2019 |
Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relations | 2019 |
Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2019 |
Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, random
Topics: Adult; Bevacizumab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Cytored | 2019 |
Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colorectal Neoplasms; | 2019 |
Curcumin Combined with FOLFOX Chemotherapy Is Safe and Tolerable in Patients with Metastatic Colorectal Cancer in a Randomized Phase IIa Trial.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Cu | 2019 |
Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; | 2013 |
Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brea | 2013 |
Metronomic chemotherapy in metastatic breast cancer: impact on VEGF.
Topics: Administration, Metronomic; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2012 |
Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxyc | 2013 |
Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2013 |
A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; | 2013 |
[Neoadjuvant chemotherapy and radiation therapy of resectable cancer recti of distal localization].
Topics: Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Surviv | 2013 |
Carboplatin/5-fluorouracil as an alternative to cisplatin/5- fluorouracil for metastatic and recurrent head and neck squamous cell carcinoma and nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Squamous C | 2013 |
FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO).
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; C | 2013 |
Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin | 2013 |
Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin | 2013 |
Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin | 2013 |
Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin | 2013 |
Randomized trial of simplified LV5FU2 versus FOLFOX7 followed by FOLFIRI (MIROX) in patients with initially resectable metastatic colorectal cancer: a GERCOR study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl | 2013 |
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Asia; Biomarkers, Tumo | 2013 |
Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
3'-Deoxy-3'-18F-fluorothymidine PET for the early prediction of response to leucovorin, 5-fluorouracil, and oxaliplatin therapy in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dideoxynucleoside | 2013 |
Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycy | 2013 |
Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimeta | 2013 |
Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Capecitabine; Chemotherapy, A | 2013 |
Palliative radiotherapy and chemotherapy instead of surgery in symptomatic rectal cancer with synchronous unresectable metastases: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Disease-Free Survival; Female; Fluorourac | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2013 |
A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
Intermittent versus continuous erlotinib with concomitant modified "XELOX" (q3W) in first-line treatment of metastatic colorectal cancer: correlation with serum amphiregulin and transforming growth factor alpha.
Topics: Adult; Aged; Amphiregulin; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal | 2013 |
Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Co | 2014 |
TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2013 |
FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2014 |
Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2014 |
Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2014 |
Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2014 |
Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2014 |
Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease P | 2013 |
Eniluracil plus 5-fluorouracil and leucovorin: treatment for metastatic breast cancer patients in whom capecitabine treatment rapidly failed.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycy | 2014 |
Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2014 |
Bi-weekly paclitaxel and capecitabine as a second- or third-line treatment for advanced breast cancer: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycy | 2013 |
Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III 'Stop and Go' study results--a Turkish Oncology Group Trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
Phase II trial of fulvestrant with metronomic capecitabine for postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca | 2014 |
Phase II trial of fulvestrant with metronomic capecitabine for postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca | 2014 |
Phase II trial of fulvestrant with metronomic capecitabine for postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca | 2014 |
Phase II trial of fulvestrant with metronomic capecitabine for postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca | 2014 |
Effectiveness and safety of intensive triplet chemotherapy plus bevacizumab, FIr-B/FOx, in young-elderly metastatic colorectal cancer patients.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2013 |
Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: the GOLFIG-2 multicentric open-label randomized phase
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2014 |
Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Cisp | 2016 |
Acceptable but limited efficacy of capecitabine-based doublets in the first-line treatment of metastatic triple-negative breast cancer: a pilot study.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Docetaxel; Drug Therapy, Combinatio | 2013 |
A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycy | 2014 |
Positron emission tomography/computed tomography and biomarkers for early treatment response evaluation in metastatic colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2014 |
Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; An | 2014 |
Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study.
Topics: Adipokines; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combin | 2014 |
A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplasti | 2014 |
Gemcitabine and capecitabine for heavily pre-treated metastatic colorectal cancer patients--a phase II and translational research study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2014 |
A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxyc | 2014 |
Epidemiology and natural history of central venous access device use and infusion pump function in the NO16966 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Catheterization, Central Venous; Cohor | 2014 |
Targeted chemoradiation in metastatic colorectal cancer: a phase I trial of 131I-huA33 with concurrent capecitabine.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antimetabolites, Antineoplasti | 2014 |
Mitomycin C and capecitabine in pretreated patients with metastatic gastric cancer: a multicenter phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycyti | 2014 |
A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxyc | 2014 |
The impact of dose/time modification in irinotecan- and oxaliplatin-based chemotherapies on outcomes in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2014 |
FOLFIRI-bevacizumab and concurrent low-dose radiotherapy in metastatic colorectal cancer: preliminary results of a phase I-II study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2014 |
Quality of life in patients with advanced gastric cancer sequentially treated with docetaxel and irinotecan with 5-fluorouracil and folinic acid (leucovin).
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Docetaxel; Female; Fluorouracil; Humans; Irinoteca | 2014 |
Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study.
Topics: Administration, Metronomic; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2014 |
Chemoradiation of hepatic malignancies: prospective, phase 1 study of full-dose capecitabine with escalating doses of yttrium-90 radioembolization.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Chemoradiotherapy; Cholangiocarcinoma; Deoxycytidine; | 2014 |
Determination of prognostic factors in Japanese patients with advanced gastric cancer using the data from a randomized controlled trial, Japan clinical oncology group 9912.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Fluorouracil; | 2014 |
An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2014 |
Mitomycin C and high-dose 5-fluorouracil with folinic acid as a therapeutic option for heavily pretreated patients with metastatic colorectal cancer: prospective phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; D | 2014 |
Multicenter phase II study of second-line cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type metastatic colorectal cancer: the FLIER study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2014 |
Phase I study of combination therapy with irinotecan, leucovorin, and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for advanced colorectal cancer in Japanese patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2014 |
Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2014 |
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2014 |
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2014 |
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2014 |
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2014 |
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2014 |
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2014 |
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2014 |
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2014 |
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2014 |
Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research G
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2014 |
Phase II study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohor | 2014 |
Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; De | 2014 |
Association between chemotherapy and plasma adipokines in patients with colorectal cancer.
Topics: Adipokines; Adipose Tissue; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colo | 2014 |
A phase II study of S-1 chemotherapy with concurrent thoracic radiotherapy in elderly patients with locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0801.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; | 2014 |
Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2014 |
Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.
Topics: Administration, Oral; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemot | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2014 |
Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Breast Neoplasms; Bridged-Ring Compounds; Capecitabi | 2014 |
Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2014 |
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administ | 2014 |
Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Camptothecin; Colorecta | 2015 |
Capecitabine plus gemcitabine in thymic epithelial tumors: final analysis of a Phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; G | 2014 |
Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal | 2014 |
A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv | 2015 |
A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2015 |
Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2015 |
Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine | 2015 |
Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic disease.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2015 |
A phase II study of capecitabine and oral leucovorin as a third-line chemotherapy in patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2015 |
Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; | 2015 |
Induction therapy with cetuximab plus docetaxel, cisplatin, and 5-fluorouracil (ETPF) in patients with resectable nonmetastatic stage III or IV squamous cell carcinoma of the oropharynx. A GERCOR phase II ECHO-07 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Doce | 2015 |
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2015 |
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2015 |
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2015 |
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2015 |
Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2015 |
Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 2015 |
FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2015 |
FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2015 |
Maintenance Therapy With Cetuximab Every Second Week in the First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-7.5 Study by the Nordic Colorectal Cancer Biomodulation Group.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Disease-Free | 2015 |
Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2015 |
Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2015 |
Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: an open-label, multi-center, non-comparative phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Br | 2015 |
Phase I trial of 5-FU, docetaxel, and nedaplatin (UDON) combination therapy for recurrent or metastatic esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Female | 2015 |
Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2015 |
Long-term results of a randomized phase III trial of TPF induction chemotherapy followed by surgery and radiation in locally advanced oral squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2015 |
Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biom | 2015 |
Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; | 2015 |
S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal N | 2015 |
A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Beva | 2015 |
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptoth | 2015 |
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptoth | 2015 |
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptoth | 2015 |
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptoth | 2015 |
Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2015 |
Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2015 |
Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2015 |
Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2015 |
Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2015 |
Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2015 |
Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2015 |
Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2015 |
Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2015 |
A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Clinical Protocols; Deoxycytid | 2015 |
Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuxi | 2015 |
Multicenter randomized phase II clinical trial of oxaliplatin reintroduction as a third- or later-line therapy for metastatic colorectal cancer-biweekly versus standard triweekly XELOX (The ORION Study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2016 |
High-Dose FOLFIRI plus Bevacizumab in the Treatment of Metastatic Colorectal Cancer Patients with Two Different UGT1A1 Genotypes: FFCD 0504 Study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; | 2015 |
A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capeci | 2015 |
A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2018 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Significant effect of VEGFA polymorphisms on the clinical outcome of metastatic colorectal cancer patients treated with FOLFIRI-cetuximab.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disea | 2015 |
Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-0
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease P | 2016 |
Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-0
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease P | 2016 |
Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-0
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease P | 2016 |
Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-0
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease P | 2016 |
5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epi | 2016 |
Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2016 |
PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2016 |
Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Fluoro | 2016 |
Low-dose radiotherapy and concurrent FOLFIRI-bevacizumab: a Phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemoradioth | 2016 |
FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2016 |
FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2016 |
FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2016 |
FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2016 |
SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Color | 2016 |
SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Color | 2016 |
SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Color | 2016 |
SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Color | 2016 |
SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Color | 2016 |
SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Color | 2016 |
SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Color | 2016 |
SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Color | 2016 |
SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Color | 2016 |
Phase I Study of Docetaxel, Cisplatin, and 5-Fluorouracil Chemoradiotherapy for Local or Metastatic Esophageal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Docetaxel | 2016 |
Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Class I Phosphatidylinositol 3-Kinases; C | 2016 |
Randomized phase II trial of TEGAFIRI (tegafur/uracil, oral leucovorin, irinotecan) compared with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) in patients with unresectable/recurrent colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2016 |
Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv | 2016 |
Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal N | 2016 |
Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo | 2016 |
Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2016 |
TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinogenesis; Cell Line, Tumor; Cell Movemen | 2016 |
Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2016 |
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; C | 2016 |
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; C | 2016 |
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; C | 2016 |
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; C | 2016 |
Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antibodies, Monoclonal; Antineoplastic Combined Chemotherap | 2016 |
Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2016 |
Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Co | 2017 |
Geriatric factors analyses from FFCD 2001-02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2017 |
Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; | 2017 |
A Randomized Phase II Study of Leucovorin/5-Fluorouracil with or without Oxaliplatin (LV5FU2 vs. FOLFOX) for Curatively-Resected, Node-Positive Esophageal Squamous Cell Carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2017 |
Maintenance treatment of Uracil and Tegafur (UFT) in responders following first-line fluorouracil-based chemotherapy in metastatic gastric cancer: a randomized phase II study.
Topics: Adult; Aged; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metast | 2017 |
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-V
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2017 |
Nimotuzumab Combined with Chemotherapy is a Promising Treatment for Locally Advanced and Metastatic Esophageal Cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidi | 2017 |
Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care.
Topics: Adenocarcinoma; Administration, Cutaneous; Administration, Oral; Adult; Aged; Aged, 80 and over; Ant | 2017 |
A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2017 |
Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Ag | 2017 |
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Mono | 2017 |
mFOLFOX6 Plus Panitumumab Versus 5-FU/LV Plus Panitumumab After Six Cycles of Frontline mFOLFOX6 Plus Panitumumab: A Randomized Phase II Study of Patients With Unresectable or Advanced/Recurrent, RAS Wild-type Colorectal Carcinoma (SAPPHIRE)-Study Design
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas | 2017 |
Phase II study of oxaliplatin in combination with continuous infusion of 5-fluorouracil/leucovorin as first-line chemotherapy in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Dr | 2008 |
Phase II trial of oxaliplatin combined with leucovorin and fluorouracil for recurrent/metastatic biliary tract carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Female; Fluoro | 2008 |
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capeci | 2008 |
Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup Phase III BIG 02-98 Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Central N | 2008 |
UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; De | 2008 |
Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; DNA, Neoplasm; Drug The | 2008 |
A Phase II study of capecitabine and vinorelbine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capec | 2008 |
Ixabepilone in combination with capecitabine and as monotherapy for treatment of advanced breast cancer refractory to previous chemotherapies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; | 2008 |
A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal | 2008 |
[Gemcitabine combined with capecitabine in the treatment for 41 patients with relapsed or metastatic biliary tract carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrah | 2008 |
Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridg | 2008 |
Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; | 2008 |
Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; | 2008 |
Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; | 2008 |
Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; | 2008 |
Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; B7-1 Antigen; Camptothecin; Carcinoembryonic A | 2008 |
Phase II trial of neoadjuvant cisplatin, 5-fluorouracil and interferon-alpha in operable squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Do | 2008 |
A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols | 2009 |
Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia | 2009 |
Capecitabine and cisplatin combination is an active and well-tolerated doublet in the treatment of metastatic breast carcinoma patients pretreated with anthracycline and taxanes.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Rin | 2008 |
Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disea | 2008 |
[Irinotecan plus fuorouracil/leucovorin (FOLFIRI) as a second line chemotherapy for refractory or metastatic colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Diseas | 2008 |
Severe skin toxicity observed with the combination of capecitabine and weekly paclitaxel in metastatic breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose- | 2008 |
Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
A randomized multicenter study of optimal circadian time of vinorelbine combined with chronomodulated 5-fluorouracil in pretreated metastatic breast cancer patients: EORTC trial 05971.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Circadian Rhythm; Fluoroura | 2008 |
Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug Administrat | 2008 |
FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca | 2008 |
Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Diseas | 2009 |
[Phase I study of CPT-11 and continuous 5-FU / l-leucovorin combination therapy(modified AIO regimen)in patients with metastatic colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined M | 2008 |
Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease Progression; Fem | 2008 |
Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cohort Stud | 2009 |
A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2008 |
Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Admin | 2008 |
Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy).
Topics: Adolescent; Adult; Animals; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Cisplati | 2008 |
A pilot human evaluation of a formulation of irinotecan and hyaluronic acid in 5-fluorouracil-refractory metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Carriers; F | 2009 |
A multicentre phase II study to evaluate sequential docetaxel followed by capecitabine treatment in anthracycline-pretreated HER-2-negative patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capec | 2008 |
A phase II study of first-line biweekly capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2009 |
Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Neo-adjuvant treatment of rectal cancer with capecitabine and oxaliplatin in combination with radiotherapy: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; D | 2009 |
Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2009 |
Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2009 |
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Effect of multiple-phase regional intra-arterial infusion chemotherapy on patients with resectable pancreatic head adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine | 2009 |
A phase II trial of continuous 5-fluorouracil in recurrent or metastatic transitional cell carcinoma of the urinary tract.
Topics: Aged; Antineoplastic Agents; Carcinoma, Transitional Cell; Female; Fluorouracil; Humans; Infusion Pu | 2009 |
FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2009 |
Phase II study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of 5-fluorouracil/leucovorin (GOFL) in advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Agents; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combi | 2009 |
Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Drug Therapy, Combination; Female; | 2009 |
A phase II trial of oral vinorelbine and capecitabine in anthracycline pretreated patients with metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; B | 2009 |
Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compo | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2009 |
Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study.
Topics: Administration, Oral; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2009 |
A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal | 2009 |
Adjuvant chemotherapy in older women with early-stage breast cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2009 |
Gemcitabine and capecitabine chemotherapy in Japanese patients with immunotherapy-resistant renal cell carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Dr | 2009 |
A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neopl | 2009 |
FOLFOX in patients with metastatic colorectal cancer and high alkaline phosphatase level: an exploratory cohort of the GERCOR OPTIMOX1 study.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols | 2009 |
Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Cost-Benefit Ana | 2009 |
Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2009 |
Prognostic value of serum vascular endothelial growth factor in Egyptian females with metastatic triple negative breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Disease Progression | 2009 |
Triweekly oxaliplatin plus oral capecitabine as first-line chemotherapy in elderly patients with advanced gastric cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capec | 2009 |
All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2009 |
[Clinical research of bevacizumab in combination with irinotecan, fluorouracil and leucovorin for advanced metastatic colorectal cancer].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2009 |
[Efficacy and safety of combination of irinotecan and capecitabine in patients with metastatic colorectal cancer after failure of chemotherapy with oxaliplatin].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal | 2009 |
Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Phase II study of 4-weekly capecitabine monotherapy in advanced/metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease | 2010 |
Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
Topics: Administration, Oral; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; B | 2010 |
A Phase II trial of the combination of vinorelbine and capecitabine as second-line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines.
Topics: Adult; Aged; Anemia; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasm | 2010 |
A phase IB dose-finding trial of liposomal doxorubicin in combination with capecitabine in patients with pretreated metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycy | 2010 |
Vinorelbine and fluorouracil plus leucovorin combination (ViFL) in patients with anthracycline and taxane-pretreated metastatic breast cancer: a phase II study.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carci | 2010 |
Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capeci | 2009 |
A phase II study of intra-arterial chemotherapy of 5-fluorouracil, cisplatin, and mitomycin C for advanced nonresectable gastric cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2009 |
A phase-II study of combination of pegylated interferon alfa-2a and capecitabine in locally advanced or metastatic renal cell cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Re | 2010 |
Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Ne | 2010 |
Lapatinib for the treatment of HER2-overexpressing breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabin | 2009 |
Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fl | 2010 |
North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Deoxy | 2009 |
Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial).
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capec | 2010 |
A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antin | 2011 |
Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2010 |
Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Oral combination chemotherapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: a phase II study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2010 |
Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2010 |
Palliative first-line treatment with weekly high-dose 5-fluorouracil as 24h-infusion and gemcitabine in metastatic pancreatic cancer (UICC IV).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumo | 2010 |
Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2011 |
Phase II study of capecitabine in combination with thalidomide in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycy | 2010 |
Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; | 2010 |
Modified-irinotecan/fluorouracil/levoleucovorin therapy as ambulatory treatment for metastatic colorectal cancer: results of phase I and II studies.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothec | 2010 |
Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin | 2010 |
A phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2011 |
Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2011 |
Study of low-dose capecitabine monotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant | 2010 |
Dietary methionine restriction with FOLFOX regimen as first line therapy of metastatic colorectal cancer: a feasibility study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diet; Disease Progressio | 2010 |
Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer.
Topics: Adult; Aged; Anorexia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com | 2010 |
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Coloni | 2011 |
Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment.
Topics: Adult; Aged; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Fluorouraci | 2010 |
Ixabepilone plus capecitabine for Chinese patients with metastatic breast cancer progressing after anthracycline and taxane treatment.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Ne | 2010 |
Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced/metastatic colorectal cancer: a phase I trial (SAKK 41/03).
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; De | 2010 |
Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capec | 2010 |
Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2010 |
A phase I dose-escalation study of edotecarin (J-107088) combined with infusional 5-fluorouracil and leucovorin in patients with advanced/metastatic solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Dose-Response Relationship, | 2010 |
A phase II trial evaluating weekly docetaxel and capecitabine in patients with metastatic or advanced, locally recurrent head and neck cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Case-Control Studies; Deo | 2010 |
Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
Molecular markers in circulating tumour cells from metastatic colorectal cancer patients.
Topics: AC133 Antigen; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Antigens, CD; Antineoplastic | 2010 |
Phase II study of capecitabine (Ro 09-1978) in patients who have failed first line treatment for locally advanced and/or metastatic cervical cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Disease Progression; Female; Fl | 2010 |
[Modified FOLFIRI (l-LV, 5-fluorouracil and irinotecan) therapy for Japanese patients with metastatic colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Colorectal Neoplas | 2010 |
Phase I study of oral vinorelbine and capecitabine in patients with metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2010 |
Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis study.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Mucoepidermoid; Carcinoma, Non-Small-Cell Lung; Es | 2011 |
Dose-finding trial of a combined regimen with bevacizumab, immunotherapy, and chemotherapy in patients with metastatic renal cell cancer: An Italian Oncology Group for Clinical Research (GOIRC) study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capeci | 2011 |
Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capeci | 2011 |
Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capeci | 2011 |
Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capeci | 2011 |
Trastuzumab plus capecitabine and docetaxel as first-line therapy for HER2-positive metastatic breast cancer: phase II results.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
A phase II study of combination chemotherapy with capecitabine and cisplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcin | 2011 |
Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineopl | 2010 |
First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: results of the MONICA trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Breast Neoplasms, | 2010 |
Phase I/II study of a combination of docetaxel, capecitabine, and cisplatin (DXP) as first-line chemotherapy in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; | 2011 |
Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Ci | 2011 |
A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2010 |
"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothera | 2011 |
Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2011 |
Phase II study of bevacizumab in combination with capecitabine as first-line treatment in elderly patients with metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Hu | 2011 |
Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorecta | 2011 |
Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca | 2011 |
Combination of oral vinorelbine and capecitabine in the treatment of metastatic breast cancer patients previously exposed to anthracyclines: a pilot study.
Topics: Administration, Oral; Adult; Aged; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic A | 2010 |
Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2011 |
Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2011 |
A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2011 |
Combination of capecitabine and mitomycin C as first-line treatment in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycy | 2011 |
Health-related quality of life as prognostic factor for response, progression-free survival, and survival in women with metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitab | 2012 |
[Randomized clinical case-control trial for the comparison of docetaxel plus thiotepa versus docetaxel plus capecitabine in patients with metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capec | 2011 |
Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycy | 2011 |
A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Cap | 2011 |
Phase II, multicenter, uncontrolled trial of single-agent capecitabine in patients with non-clear cell metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Papillary; Ca | 2012 |
A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cluster Analysis; Drug Re | 2011 |
Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Ma | 2011 |
Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2011 |
A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2012 |
A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Deoxyc | 2012 |
Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2011 |
Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cisplat | 2011 |
A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizuma | 2011 |
Phase II study of FOLFOX4 with "wait and go" strategy as first-line treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2011 |
Modified FOLFOX6 with oxaliplatin stop-and-go strategy and oral S-1 maintenance therapy in advanced colorectal cancer: CCOG-0704 study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 2011 |
A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2012 |
Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Che | 2011 |
Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Che | 2011 |
[Phase I / II study of XELOX plus bevacizumab in Japanese patients with metastatic colorectal cancer(JO19380)].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2011 |
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2011 |
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2011 |
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2011 |
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2011 |
Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2011 |
A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2011 |
Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disea | 2011 |
A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer.
Topics: Administration, Metronomic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy | 2012 |
Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Combine | 2012 |
Pioglitazone, etoricoxib, interferon-α, and metronomic capecitabine for metastatic renal cell carcinoma: final results of a prospective phase II trial.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antiviral Age | 2012 |
Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cohort St | 2012 |
A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin | 2012 |
Analysis for prognostic factors of 60-day mortality: evaluation of an irinotecan-based phase III trial performed in the first-line treatment of metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2011 |
Final results of ERASME-4: a randomized trial of first-line docetaxel plus either capecitabine or epirubicin for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycy | 2011 |
Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil.
Topics: Administration, Topical; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Antineopla | 2012 |
Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2011 |
Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer.
Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast | 2012 |
Phase I study of irinotecan by 24-h intravenous infusion in combination with 5-fluorouracil in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia | 2012 |
Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dise | 2011 |
Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2012 |
Yiqi zhuyu decoction combined with FOLFOX-4 as first-line therapy in metastatic colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease | 2011 |
Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Disease-Free Survival | 2011 |
Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-Fluorouracil-leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Clock | 2011 |
Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2011 |
A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2011 |
An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study.
Topics: Administration, Oral; Adult; Aged; Anorexia; Anthracyclines; Antineoplastic Combined Chemotherapy Pr | 2012 |
Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Deoxyc | 2011 |
A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Brea | 2012 |
A GINECO randomized phase II trial of two capecitabine and weekly paclitaxel schedules in metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; | 2012 |
Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma | 2011 |
Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2011 |
Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colore | 2011 |
The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2011 |
Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2012 |
Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2011 |
Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chromatogra | 2012 |
A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capec | 2012 |
Phase II trial of capecitabine plus cisplatin as first-line therapy in patients with metastatic nasopharyngeal cancer.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cispl | 2012 |
Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycy | 2012 |
Response prediction in metastasised colorectal cancer using intratumoural thymidylate synthase: results of a randomised multicentre trial.
Topics: Adult; Aged; Antineoplastic Agents; Biopsy; Colorectal Neoplasms; Female; Fluorouracil; Humans; Male | 2012 |
Phase II study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel as first-line therapy for advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Fluorour | 2011 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour | 2012 |
Multi-center phase II study of FLOX for advanced colorectal cancer patients in Japan: SWIFT 3 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Hu | 2011 |
A double-blind, randomized, placebo-controlled, phase 2 study of maintenance enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line therapy for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2012 |
Phase III aflibercept-chemotherapy combination trial shows benefit in previously treated metastatic colorectal cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor | 2011 |
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineop | 2012 |
Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2012 |
A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Deoxycy | 2012 |
[Efficacy of late accelerated hyperfractionated conformal radiotherapy combined with capecitabine for esophageal carcinoma].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Squamous Cell; Chemoradiotherapy; Deoxycyt | 2011 |
A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2012 |
Phase 2 study of modified irinotecan and bolus 5-fluorouracil/l-leucovorin in Japanese metastatic colorectal cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Fr | 2012 |
Capecitabine and weekly paclitaxel as first-line therapy in Thai patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycy | 2012 |
First-line treatment with capecitabine combined with irinotecan in patients with advanced colorectal carcinoma: a phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; | 2012 |
Sequential FOLFOX-6 and gemcitabine for locally advanced and/or metastatic pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabi | 2012 |
Phase II interventional study (N0337) of capecitabine in combination with vinorelbine and trastuzumab for first- or second-line treatment of HER2-positive metastatic breast cancer: a north central cancer treatment group trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brea | 2012 |
Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2012 |
A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; | 2012 |
Phase II study of docetaxel, cisplatin and 5-fluorouracil (DCF) for metastatic esophageal cancer (OGSG 0403).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neopla | 2012 |
Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity.
Topics: Administration, Metronomic; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemot | 2012 |
Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2012 |
First-line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothe | 2012 |
A phase II randomized study of combined infusional leucovorin sodium and 5- FU versus the leucovorin calcium followed by 5-FU both in combination with irinotecan or oxaliplatin in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Ant | 2012 |
A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2012 |
Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2012 |
Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2012 |
Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under C | 2012 |
A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineopl | 2012 |
Clinical and cost effectiveness of bevacizumab + FOLFIRI combination versus FOLFIRI alone as first-line treatment of metastatic colorectal cancer in South Korea.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2012 |
Maintenance of clinical efficacy after dose reduction of ixabepilone plus capecitabine in patients with anthracycline- and taxane-resistant metastatic breast cancer: a retrospective analysis of pooled data from 2 phase III randomized clinical trials.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cohort Studie | 2012 |
A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridg | 2012 |
Concurrent chemoradiation of metastases with capecitabine and oxaliplatin and 3D-CRT in patients with oligometastatic colorectal cancer: results of a phase I study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherap | 2012 |
Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2012 |
Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Circadian Clocks; Colorectal Ne | 2012 |
XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis.
Topics: Adult; Aged; Aged, 80 and over; Angiogenic Proteins; Antibodies, Monoclonal, Humanized; Antineoplast | 2012 |
VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineopla | 2012 |
Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brea | 2012 |
Incidence of hand-foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; | 2012 |
Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colo | 2012 |
Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2012 |
Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2012 |
Modified docetaxel-cisplatin in combination with capecitabine as first-line treatment in metastatic gastric cancer. a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; | 2012 |
Trastuzumab emtansine for HER2-positive advanced breast cancer.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antine | 2012 |
Trastuzumab emtansine for HER2-positive advanced breast cancer.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antine | 2012 |
Trastuzumab emtansine for HER2-positive advanced breast cancer.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antine | 2012 |
Trastuzumab emtansine for HER2-positive advanced breast cancer.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antine | 2012 |
Trastuzumab emtansine for HER2-positive advanced breast cancer.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antine | 2012 |
Trastuzumab emtansine for HER2-positive advanced breast cancer.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antine | 2012 |
Trastuzumab emtansine for HER2-positive advanced breast cancer.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antine | 2012 |
Trastuzumab emtansine for HER2-positive advanced breast cancer.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antine | 2012 |
Trastuzumab emtansine for HER2-positive advanced breast cancer.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antine | 2012 |
Trastuzumab emtansine for HER2-positive advanced breast cancer.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antine | 2012 |
Trastuzumab emtansine for HER2-positive advanced breast cancer.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antine | 2012 |
Trastuzumab emtansine for HER2-positive advanced breast cancer.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antine | 2012 |
Trastuzumab emtansine for HER2-positive advanced breast cancer.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antine | 2012 |
Trastuzumab emtansine for HER2-positive advanced breast cancer.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antine | 2012 |
Trastuzumab emtansine for HER2-positive advanced breast cancer.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antine | 2012 |
Trastuzumab emtansine for HER2-positive advanced breast cancer.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antine | 2012 |
Vinorelbine and capecitabine in anthracycline- and/or taxane-pretreated metastatic breast cancer: sequential or combinational?
Topics: Adolescent; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neop | 2013 |
A phase II study of modified FOLFOX as first-line chemotherapy for metastatic gastric cancer in elderly patients with associated diseases.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free S | 2013 |
A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2013 |
Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2013 |
Preoperative treatment with bevacizumab in combination with chemotherapy in patients with unresectable metastatic colorectal carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoradiotherapy; Cisplatin; | 2012 |
Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Disease-Free Surv | 2013 |
Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2012 |
A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer.
Topics: Administration, Intravenous; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2013 |
Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycyti | 2013 |
Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2013 |
Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Ci | 2013 |
Capecitabine and oxaliplatin in combination as first- or second-line therapy for metastatic breast cancer: a Wisconsin Oncology Network trial.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined | 2013 |
Pharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX-6 regimens: implications for health-care utilization in Australia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Capecitabine; Colorectal Neoplasms; Cost- | 2013 |
Phase II trial of first-line chemoradiotherapy with intensity-modulated radiation therapy followed by chemotherapy for synchronous unresectable distant metastases rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Capecitabine; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidi | 2013 |
Prognostic significance of serum levels of vascular endothelial growth factor and insulin-like growth factor-1 in advanced gastric cancer patients treated with FOLFOX chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Enzyme-Linked I | 2012 |
Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2013 |
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2013 |
Low dose capecitabine plus weekly paclitaxel in patients with metastatic breast cancer: a multicenter phase II study KBCSG-0609.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined | 2013 |
All-oral combination of vinorelbine and capecitabine as first-line treatment in HER2/Neu-negative metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2013 |
Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizu
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2013 |
Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2013 |
A phase II study of oxaliplatin in combination with leucovorin and fluorouracil as first-line chemotherapy in patients with metastatic squamous cell carcinoma of esophagus.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2013 |
The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens.
Topics: 3' Untranslated Regions; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2013 |
Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemo | 2013 |
Ralitrexed (Tomudex) or Nordic-FLv regimen in metastatic colorectal cancer: a randomized phase II study focusing on quality of life, patients' preferences and health economics.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Ne | 2002 |
Treatment of unresectable and metastatic hepatoblastoma: a pediatric oncology group phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Cisplatin; Dis | 2002 |
Whole-body hyperthermia (41.8 degrees C) combined with bimonthly oxaliplatin, high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2002 |
Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2002 |
Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2002 |
Thirteen-year, long-term efficacy of interferon 2alpha and interleukin 2-based home therapy in patients with advanced renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2002 |
Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2002 |
Chronomodulated chemotherapy in metastatic gastrointestinal cancer combining 5-FU and sodium folinate with oxaliplatin, irinotecan or gemcitabine: the Jena experience in 79 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Colorectal Ne | 2002 |
Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2002 |
Folinic acid, 5-fluorouracil and mitomycin C in metastatic breast cancer patients previously treated with at least two chemotherapy regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; | 2002 |
Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2002 |
Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; D | 2002 |
Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Col | 2002 |
Intra-arterial hepatic chemotherapy combined with continuous infusion of 5-fluorouracil in patients with metastatic cholangiocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangiocarcinoma; Cisplatin; Disease Progres | 2002 |
Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Disease Progress | 2002 |
Adding weekly irinotecan to high-dose 5-fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer--a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2002 |
Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 2002 |
Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia | 2002 |
The palliative benefit of irinotecan in 5-fluorouracil-refractory colorectal cancer: its prospective evaluation by a Multicenter Canadian Trial.
Topics: Adult; Aged; Camptothecin; Canada; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Admi | 2002 |
Irinotecan in 5-fluorouracil-refractory colorectal cancer.
Topics: Adult; Aged; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administrati | 2002 |
Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2002 |
Oral doxifluridine plus leucovorin in metastatic colorectal cancer: randomized phase II trial with intravenous 5-fluorouracil plus leucovorin.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Floxuridine; Fluorouraci | 2003 |
[Clinical and immunological studies of the therapeutical effect of cytokines combined with 5-fluorouracil in metastatic kidney cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Survival; Drug S | 2002 |
A phase II trial of weekly paclitaxel, 5-fluorouracil, and leucovorin as first-line treatment for metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brea | 2003 |
Infusional fluorouracil, etoposide, and cisplatin (FEP) in advanced and relapsed gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Fluoroura | 2003 |
[Metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycy | 2003 |
Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Pr | 2003 |
Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Cause of Deat | 2003 |
A pilot study of edrecolomab (Panorex, 17-1A antibody) and capecitabine in patients with advanced or metastatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigen | 2003 |
Increased toxicity and lack of efficacy of Rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: A phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; | 2003 |
Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2003 |
Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetaboli | 2003 |
Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2003 |
Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2003 |
A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogen | 2003 |
Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 2003 |
Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2003 |
Vinorelbine, epirubicin and fluorouracil as first-line therapy in metastatic breast cancer--a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration S | 2003 |
Phase I/II study of daily carboplatin, 5-fluorouracil and concurrent radiation therapy for locally advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell | 2003 |
Oxaliplatin and 5-fluorouracil for heavily pretreated metastatic breast cancer: a preliminary phase II study.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Drug Synergism; Female; Fluorouracil; Humans; Male; | 2003 |
Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastroint
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Sch | 2003 |
Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Co | 2003 |
Long-term effect of 5-fluorouracil enhanced by intermittent administration of polysaccharide K after curative resection of colon cancer. A randomized controlled trial for 7-year follow-up.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Administration, Oral; Aged; Antimetabolites, Antineoplastic; | 2004 |
[Clinical study on post-operative metastasis prevention of progressive stage of gastric cancer by weichang'an].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drugs, Chinese Herbal; Female; F | 2003 |
Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasm | 2003 |
Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Admin | 2003 |
A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 2003 |
Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Anti | 2003 |
Capecitabine monotherapy and in combination with immunotherapy in the treatment of metastatic renal cell carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Ther | 2003 |
[The modern organ- and function-sparing surgical treatment in oncology].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carci | 2003 |
Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; | 2003 |
Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2003 |
Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2003 |
Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2003 |
Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2003 |
Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2003 |
Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2003 |
Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2003 |
Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2003 |
Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2003 |
Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2003 |
Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2003 |
Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2003 |
Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2003 |
Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2003 |
Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2003 |
Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2003 |
Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Alopecia; Camptothecin; Chemotherapy, Adjuvant; Colorectal | 2003 |
Phase II clinical trial of parenteral hydroxyurea in combination with fluorouracil, interferon and filgrastim in the treatment of advanced pancreatic, gastric and neuroendocrine tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; F | 2004 |
A multicenter phase II study of irinotecan in patients with advanced colorectal cancer previously treated with 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Administrat | 2003 |
Randomized trial comparing the addition of oxaliplatin or irinotecan to high-dose leucovorin and 5-Fluorouracil intravenous bolus every two weeks in metastatic colorectal carcinoma: Southern Italy Cooperative Oncology Group 0103.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Admi | 2003 |
Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; | 2004 |
FDA drug approval summaries: oxaliplatin.
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Approval; Drug | 2004 |
Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; D | 2004 |
Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antimetabolites, Antineoplastic; Breast Neoplasms; B | 2004 |
Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antimetabolites, Antineoplastic; Breast Neoplasms; B | 2004 |
Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antimetabolites, Antineoplastic; Breast Neoplasms; B | 2004 |
Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antimetabolites, Antineoplastic; Breast Neoplasms; B | 2004 |
Nordic 5-fluorouracil/leucovorin bolus schedule combined with oxaliplatin (Nordic FLOX) as first-line treatment of metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2003 |
A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 2004 |
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
Topics: Administration, Oral; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2004 |
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
Topics: Administration, Oral; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2004 |
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
Topics: Administration, Oral; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2004 |
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
Topics: Administration, Oral; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2004 |
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
Topics: Administration, Oral; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2004 |
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
Topics: Administration, Oral; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2004 |
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
Topics: Administration, Oral; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2004 |
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
Topics: Administration, Oral; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2004 |
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
Topics: Administration, Oral; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2004 |
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Male; M | 2004 |
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Male; M | 2004 |
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Male; M | 2004 |
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Male; M | 2004 |
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Male; M | 2004 |
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Male; M | 2004 |
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Male; M | 2004 |
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Male; M | 2004 |
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Male; M | 2004 |
Phase I and pharmacokinetic study of the polyamine synthesis inhibitor SAM486A in combination with 5-fluorouracil/leucovorin in metastatic colorectal cancer.
Topics: Adult; Aged; Amidines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Coloni | 2004 |
Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma; Deoxycytidine; Drug Resistance, Neop | 2004 |
Double modulation of 5-fluorouracil by trimetrexate and leucovorin in patients with advanced colorectal carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Hu | 2004 |
Second line chemotherapy with 5 fluorouracil and vinorelbine in anthracycline and taxane pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance, Neop | 2004 |
[Radiation and concomitant chemotherapy after surgery for breast cancer].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; An | 2004 |
Phase I study of CPT-11 and bolus 5-FU/ l-leucovorin in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2004 |
Phase II study of docetaxel in combination with epirubicin and protracted venous infusion 5-fluorouracil (ETF) in patients with recurrent or metastatic breast cancer. A Yorkshire breast cancer research group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Respo | 2004 |
A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2004 |
Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Anthracyclines; Antimetabolites, Antineoplastic; Breast Neoplasms | 2004 |
Phase I study of the combination of oxaliplatin, irinotecan and continuous infusion 5-fluorouracil in digestive tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dos | 2004 |
Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dis | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcin | 2004 |
Mutation and accumulation of p53 related to results of adjuvant therapy of postmenopausal breast cancer patients.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C | 2004 |
Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Ne | 2004 |
Prolonged cytostatic tumor dormancy induced by serial exchange of chemotherapy in colorectal carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Cisplatin; Clinical | 2004 |
A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: a Southwest Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colorectal Neoplasms; Do | 2004 |
Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Admin | 2004 |
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Combined Modality Therapy; Deo | 2004 |
Capecitabine and vinorelbine in patients with metastatic breast cancer previously treated with anthracycline and taxane.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; D | 2004 |
Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic C | 2004 |
Abnoba-viscum (mistletoe extract) in metastatic colorectal carcinoma resistant to 5-fluorouracil and leucovorin-based chemotherapy.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Confidence Intervals | 2004 |
Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycyt | 2004 |
Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Ant | 2004 |
Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2004 |
Capecitabine and vinorelbine in elderly patients (> or =65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99).
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 2004 |
First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2004 |
First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2004 |
First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2004 |
First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2004 |
Capecitabine plus docetaxel combination chemotherapy for metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as T | 2004 |
Irinotecan combined with bolus 5-fluorouracil and folinic acid for metastatic colorectal cancer: is this really a dangerous treatment?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2004 |
Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2005 |
Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2005 |
A phase I dose-escalating study of docetaxel plus folinic acid and 5-fluorouracil in anthracycline-pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docet | 2004 |
A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat | 2005 |
Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Com | 2005 |
A tailored regimen including capecitabine and oxaliplatin for treating elderly patients with metastatic colorectal carcinoma Southern Italy Cooperative Oncology Group trial 0108.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2005 |
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2005 |
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2005 |
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2005 |
Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Duodenal Neoplas | 2005 |
Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy coo
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined | 2005 |
A phase I clinical and pharmacokinetic study of capecitabine (Xeloda) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area | 2005 |
Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Fluorourac | 2005 |
Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study.
Topics: Adult; Aged; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Mid | 2005 |
Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin.
Topics: Adenoviridae; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neop | 2005 |
Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dos | 2005 |
A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; D | 2005 |
Phase I and pharmacokinetic evaluation of intravenous hyaluronic acid in combination with doxorubicin or 5-fluorouracil.
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Doxoru | 2005 |
Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2005 |
Phase II study of irinotecan, leucovorin, 5-fluorouracil and tegafur/uracil for metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2005 |
Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2005 |
[Chronotherapy combining 5-fluorouracil, folinic acid and carboplatin as first line treatment in metastatic colorectal cancer. A phase 2 study].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chronob | 2005 |
Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2005 |
Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined M | 2005 |
Bi-weekly chemotherapy with cisplatin, epirubicin, folinic acid and 5-fluororacil continuous infusion plus g-csf in advanced gastric cancer: a multicentric phase II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2006 |
Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; F | 2005 |
Phase I dose-escalating study of docetaxel in combination with 5-day continuous infusion of 5-fluorouracil in patients with advanced gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Comb | 2005 |
Assessment of infusional 5-fluorouracil schedule and dose intensity: a Southwest Oncology Group and Eastern Cooperative Oncology Group study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; D | 2005 |
A phase II trial of gemcitabine, 5-fluorouracil and leucovorin in advanced esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2005 |
Phase II trial of fortnightly irinotecan (CPT-11) in the treatment of colorectal cancer patients resistant to previous fluoropyrimidine-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Color | 2005 |
Second-line intra-arterial chemotherapy in advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2006 |
Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Clinical Trials a | 2005 |
Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dis | 2005 |
Safety and efficacy of irinotecan plus high-dose leucovorin and intravenous bolus 5-fluorouracil for metastatic colorectal cancer: pooled analysis of two consecutive southern Italy cooperative oncology group trials.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptot | 2005 |
A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biopsy; Colorectal Neoplasms; Disease-Free Survival; D | 2005 |
Combined therapy with weekly irinotecan, infusional 5-fluorouracil and the selective COX-2 inhibitor rofecoxib is a safe and effective second-line treatment in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Flu | 2005 |
Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothe | 2005 |
Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2006 |
Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogeni | 2006 |
Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2005 |
FOLFOX alternated with FOLFIRI as first-line chemotherapy for metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2005 |
Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients?
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Comb | 2005 |
[Combined (chemo-radiation) treatment of patients with nasopharyngeal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2005 |
The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Col | 2006 |
Irinotecan, oxaliplatin plus bolus 5-fluorouracil and low dose folinic acid every 2 weeks: a feasibility study in metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia | 2006 |
Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemot | 2006 |
Weekly paclitaxel, 5-fluorouracil and folinic acid with granulocyte colony-stimulating factor support in metastatic breast cancer patients: a phase II study.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug | 2006 |
Phase II trial alternating FOLFOX-6 and FOLFIRI regimens in second-line therapy of patients with metastatic colorectal cancer (FIREFOX study).
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineo | 2006 |
A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cisplatin; Docetaxel; Dose- | 2006 |
Pharmacokinetics of oxaliplatin and non-hematological toxicity in metastatic gastrointestinal cancer patients treated with chronomodulated oxaliplatin, 5-FU and sodium folinate in a pilot investigation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Chronotherapy; Female | 2006 |
A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2006 |
Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Admin | 2006 |
A pilot trial of gemcitabine and vinorelbine plus capecitabine in locally advanced or metastatic nonsmall cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Car | 2006 |
Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Chemotherapy, Adjuv | 2006 |
Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2006 |
Raltitrexed plus levofolinic acid and bolus/continuous infusion 5-fluorouracil on a biweekly schedule for elderly patients with advanced colorectal carcinomas.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2006 |
[Efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2006 |
First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2006 |
Phase II study of weekly docetaxel and capecitabine in patients with metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Comb | 2006 |
The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2006 |
A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2006 |
Oxaliplatin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic gastric cancer (MGC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucovori | 2006 |
Sequential therapy with capecitabine followed by vinorelbine/cisplatin in patients with anthracycline/taxane-refractory metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Brea | 2006 |
A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycyti | 2006 |
Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2006 |
Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2007 |
Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcino | 2006 |
A phase II study of an oxaliplatin/vinorelbine/5-fluorouracil combination in patients with anthracycline-pretreated and taxane-pretreated metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Femal | 2006 |
Capecitabine and mitomycin C is an effective combination for anthracycline- and taxane-resistant metastatic breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deox | 2006 |
Capecitabine/Cyclophosphamide/Methotrexate for patients with metastatic breast cancer: a dose-finding, feasibility, and efficacy study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcino | 2006 |
Biweekly oxaliplatin plus 1-day infusional fluorouracil/leucovorin followed by metronomic chemotherapy with tegafur/uracil in pretreated metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; | 2007 |
Multicentre phase II study using increasing doses of irinotecan combined with a simplified LV5FU2 regimen in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camp | 2007 |
Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; | 2007 |
A phase I trial of fixed dose rate gemcitabine plus capecitabine in metastatic cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Admin | 2007 |
Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2007 |
An open-label, multicenter phase II trial of capecitabine in patients with cisplatin-refractory or relapsed germ cell tumors.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Blood Cell Count; Capecitabine; Cispl | 2007 |
Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agent | 2007 |
FOLFOX-6 combination as the first-line treatment of locally advanced and/or metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch | 2007 |
Immuno-chemotherapy in metastatic renal cell carcinoma: long-term results from the rambam and linn medical centers, Haifa, Israel.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cel | 2007 |
The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2008 |
Prognostic factors for metastatic urothelial carcinoma treated with cisplatin and 5-fluorouracil-based regimens.
Topics: Adult; Aged; Alkaline Phosphatase; Antineoplastic Agents; Cisplatin; Female; Fluorouracil; Humans; K | 2007 |
Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: a phase II trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camp | 2007 |
A randomised phase II study of irinotecan in combination with 5-FU/FA compared with irinotecan alone as second-line treatment of patients with metastatic colorectal carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2007 |
Phase III study of standard combination versus rotating regimen of induction chemotherapy in patients with hormone insensitive metastatic breast cancer: an Eastern Cooperative Oncology Group Intergroup Study (E3185).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Dru | 2007 |
Phase II study of epirubicin plus oxaliplatin and infusional 5-fluorouracil as first-line combination therapy in patients with metastatic or advanced gastric cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 2007 |
A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Camptothecin; Cyclin A; De | 2008 |
A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Comb | 2008 |
First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Pr | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2007 |
A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2007 |
A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogen | 2008 |
Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; | 2007 |
Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colore | 2007 |
Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Tri
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colore | 2007 |
Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Renal Cell; De | 2007 |
A phase I study of thalidomide, capecitabine and temozolomide in advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy | 2007 |
First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 2007 |
Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytid | 2007 |
TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoembryonic An | 2007 |
Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution | 2007 |
Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2007 |
Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasm | 2007 |
Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741.
Topics: Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Female; | 2007 |
A randomized trial of anemia correction with two different hemoglobin targets in the first-line chemotherapy of advanced gastric cancer.
Topics: Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Blood Cell Count; Endpoint Determination; Eryt | 2008 |
Results of a phase I trial of intravenous vinorelbine plus oral capecitabine as first-line chemotherapy of metastatic breast cancer.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Anti | 2008 |
A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2008 |
A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 2007 |
Economic analysis of a multicentre, randomised, phase III trial comparing FOLFOXIRI with FOLFIRI in patients with metastatic colorectal cancer in Greece.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost of Illness; | 2007 |
Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2007 |
A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2008 |
A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5 FU2 + irinotecan or LV5 FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2007 |
Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colonic Neoplasms; Electrophys | 2007 |
Preliminary results of pre-radiation neck dissection in head and neck cancer patients undergoing organ preservation treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Squamous Cell; Ch | 2007 |
Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2007 |
A clinical pharmacokinetic analysis of tegafur-uracil (UFT) plus leucovorin given in a new twice-daily oral administration schedule.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; | 2007 |
Two Doses of oxaliplatin with capecitabine (XELOX) in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo | 2007 |
Phase II trial of 5-fluorouracil/leucovorin/gemcitabine/cisplatin as second-line treatment in patients with metastatic or recurrent colorectal carcinoma: a cancer therapeutics research group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Deoxyc | 2007 |
FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Stud | 2007 |
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridg | 2007 |
A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecita | 2008 |
Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Comb | 2007 |
A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineop | 2008 |
Intensified irinotecan-based neoadjuvant chemoradiotherapy in rectal cancer: four consecutive designed studies to minimize acute toxicity and to optimize efficacy measured by pathologic complete response.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Capec | 2007 |
Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Comb | 2008 |
FOLFIRI chemotherapy for metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2007 |
Vinorelbine and infusional 5-fluorouracil in anthracycline and taxane pre-treated metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridg | 2008 |
Efficacy of combination chemotherapy with irinotecan (CPT-11) plus capecitabine in patients with metastatic or advanced colorectal carcinoma--a dual-centre phase II study: the MAC-6.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal | 2008 |
A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fl | 2008 |
Phase II study of capecitabine and cisplatin combination as first-line chemotherapy in Chinese patients with metastatic nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; De | 2008 |
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2008 |
A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Deoxycytidine; | 2008 |
Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cohort Studie | 2008 |
Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans | 2008 |
Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasm | 2008 |
Phase II clinical trial of advanced and metastatic gastric cancer based on continuous infusion of 5-fluorouracil combined with epirubicin and oxaliplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Epirubici | 2008 |
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2008 |
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2008 |
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2008 |
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2008 |
Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; F | 2008 |
Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; F | 2008 |
Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; F | 2008 |
Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; F | 2008 |
Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Body Surface Area; Colorec | 2008 |
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deox | 2008 |
Interferon-alpha plus capecitabine and thalidomide in patients with metastatic renal cell cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Car | 2008 |
Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Brea | 2009 |
A clinical pharmacologic study of chemotherapy and x-ray therapy in lung cancer.
Topics: Dactinomycin; Fluorouracil; Humans; Lung Neoplasms; Neoplasm Metastasis; Radiometry; Radiotherapy | 1967 |
Chemotherapy of breast cancer. A general overview.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; C | 1983 |
Metastatic colorectal carcinoma. A prospective randomized trial of Methyl-CCNU, 5-Fluorouracil (5-FU) and vincristine (MOF) versus MOF plus streptozotocin (MOF-Strep).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials | 1983 |
5-Fluorouracil, adriamycin and cyclophosphamide combined with high-dose medroxyprogesterone acetate in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox | 1983 |
Clinical trials with oral Futraful (INN: Tegafur) in cancer of the head and neck.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Adenoid Cystic; Car | 1981 |
Combined irradiation and three-drug chemotherapy in inoperable colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Cyclophosphamide; Drug | 1982 |
Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer. A prospective randomized study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 1983 |
Chemotherapy of breast cancer: current views and results.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Tr | 1983 |
High-dose intermittent iv 5-FU and melphalan in advanced colorectal carcinoma.
Topics: Adult; Aged; Clinical Trials as Topic; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug The | 1983 |
Clinical thermochemotherapy. A controlled trial in advanced cancer patients.
Topics: Adult; Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Fema | 1984 |
Combined modality approach in breast cancer with isolated or multiple metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined | 1984 |
Currently active protocols in the EORTC Breast Cancer Cooperative Group.
Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials | 1984 |
CAP (cyclophosphamide, adriamycin, platinum) vs CMFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisolone) combination chemotherapy in untreated metastatic breast cancer. A preliminary report of a controlled clinical study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical T | 1984 |
Mitoxantrone, cyclophosphamide, and 5-fluorouracil in the treatment of hormonally unresponsive metastatic breast cancer.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 1984 |
High-dose cyclophosphamide and 5-fluorouracil versus vincristine, doxorubicin, and cyclophosphamide in advanced carcinoma of the breast. A phase III study of the Piedmont Oncology Association (POA).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclopho | 1984 |
Combination chemotherapy with 5-fluorouracil, CCNU, and vincristine in metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neopl | 1984 |
MIFA III (mitomycin-C, 5-fluorouracil, and adriamycin) chemotherapy for advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Doxo | 1984 |
Breast cancer 1984: state of the art.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Tr | 1984 |
A new six-drug antiblastic regimen (R 14) at low doses (micropolychemotherapy) compared to CMF in the treatment of metastatic breast cancer: phase III study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 1984 |
A comparative study of oral tegafur and intravenous 5-fluorouracil in patients with metastatic colorectal cancer.
Topics: Administration, Oral; Colonic Neoplasms; Drug Evaluation; Female; Fluorouracil; Humans; Injections, | 1983 |
Adjuvant chemotherapy for early breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclopho | 1983 |
[Breast cancer: chemotherapy preceding locoregional treatment with extension of the indications for conservative treatment].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined | 1984 |
Comparison of 5-fluorouracil with ftorafur in adjuvant chemotherapies with combined inductive and maintenance therapies for gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluo | 1984 |
Multimodal treatment in operable breast cancer: five-year results of the CMF programme.
Topics: Adult; Aged; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination | 1981 |
Comparison of ftorafur with 5-fluorouracil in combination chemotherapy of advanced gastrointestinal carcinoma.
Topics: Adult; Carmustine; Drug Therapy, Combination; Female; Fluorouracil; Gastrointestinal Neoplasms; Huma | 1981 |
Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial.
Topics: Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorour | 1980 |
The effect of fluorouracil on survival in metastatic colorectal cancer fluorouracil response improves survival.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Fluorouracil; Humans; Neoplasm Metastasis; Prognosis; R | 1981 |
[Disseminated breast carcinoma. Study of activity of immunotherapy with BCG and duration of the phase of intensive chemotherapy. Results of a randomized trial (author's transl)].
Topics: Adult; Aged; BCG Vaccine; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; | 1981 |
Cyclic combination chemotherapy for metastatic breast cancer: comparison of two CMF schedules.
Topics: Adult; Aged; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Administration Sched | 1981 |
Hormono-chemotherapy versus hormonotherapy followed by chemotherapy in the treatment of disseminated breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Chlorambucil; Clinical Trials as Topic; Doxorubicin; Drug A | 1980 |
Adjuvant chemotherapy with chlorambucil and 5-fluorouracil in primary breast cancer (Cooperative Study Heidelberg).
Topics: Breast Neoplasms; Chlorambucil; Clinical Trials as Topic; Drug Therapy, Combination; Female; Fluorou | 1980 |
Divergent effect of adjuvant chemo-immunotherapy on recurrence rates in node-negative and node-positive breast cancer patients.
Topics: BCG Vaccine; Breast Neoplasms; Chlorambucil; Clinical Trials as Topic; Drug Therapy, Combination; Fe | 1980 |
Preliminary results of primary systemic chemotherapy in association with surgery or radiotherapy in rapidly progressing breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Dr | 1982 |
Occasional notes. The management of early breast cancer.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cast | 1982 |
[Simultaneous or sequential hormono/chemotherapy and a comparison of various polychemotherapies in the treatment of metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Castration; Chlorambucil; Clinical Trials as T | 1982 |
Comparison of induction chemotherapies for metastatic breast cancer. An Eastern Cooperative Oncology Group Trial.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Doxorubic | 1982 |
An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advances breast cancer undergoing oophorectomy: a later analysis.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Castration; Clinical Trials as Topic; Cyclophosphami | 1982 |
A randomized study of combination chemotherapy (VAC-FMC) with or without immunostimulation by Corynebacterium parvum in metastatic breast cancer.
Topics: Adjuvants, Immunologic; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; | 1982 |
Treatment of women with disseminated or recurrent advanced ovarian cancer with melphalan alone in combination with 5-fluorouracil and dactinomycin or with the combination of cytoxan, 5-fluorouracil and dactinomycin.
Topics: Cyclophosphamide; Dactinomycin; Drug Therapy, Combination; Erythrocyte Count; Female; Fluorouracil; | 1980 |
Combination chemotherapy of 5-fluorouracil, epidoxorubicin and mitomycin C in the palliative treatment of locally advanced and/or metastatic adenocarcinoma of the stomach.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Epir | 1994 |
Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head a
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcin | 1994 |
Split-course accelerated radiation therapy combined with carboplatin and 5-fluorouracil for palliation of metastatic or unresectable carcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, | 1995 |
Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d'Etude des Tumeurs a Calcitonine (GETC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Medullary; Combined Modality | 1995 |
Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Adminis | 1995 |
Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Adminis | 1995 |
Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Adminis | 1995 |
Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Adminis | 1995 |
A phase II trial of mitoxantrone plus cyclophosphamide and 5-fluorouracil in modulation with levo-folinate for advanced breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dos | 1995 |
Biochemotherapy of advanced metastatic renal-cell carcinoma: results of the combination of interleukin-2, alpha-interferon, 5-fluorouracil, vinblastine, and 13-cis-retinoic acid.
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Rena | 1995 |
Phase II trial of 5-fluorouracil, folinic acid, and N,N1,N11-triethylenethiophosphoramide (thiotepa) in patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration S | 1995 |
Laevofolinic acid, 5-fluorouracil, cyclophosphamide and escalating doses of epirubicin with granulocyte colony-stimulating factor support in locally advanced and/or metastatic breast carcinoma: a phase I-II study of the Southern Italy Oncology Group (GOIM
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Breast Neoplasms; Combi | 1995 |
Alternating chemo-radiotherapy in bladder cancer: a conservative approach.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Chemotherapy, Adjuvant; Ci | 1995 |
Chemotherapeutic treatment of recurrent and/or metastatic nasopharyngeal carcinoma: a retrospective analysis of 40 cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Carcinoma, Squamo | 1993 |
The use of mitoxantrone, 5-fluorouracil and high-dose leucovorin in the treatment of advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fluorouracil; | 1993 |
A phase III study of recombinant interleukin-2, 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in patients with unresectable or metastatic colorectal carcinoma.
Topics: Adult; Aged; Colorectal Neoplasms; Female; Fluorouracil; Humans; Interleukin-2; Leucovorin; Male; Mi | 1995 |
The prognosis of stage III breast cancer treated with postoperative radiotherapy and adriamycin-based chemotherapy with and without tamoxifen. Eight year follow-up results of a randomized trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 1995 |
[Treatment of acute chemically induced diarrhea by inhibition of enkephalinase. Results of a pilot study].
Topics: Acute Disease; Adenocarcinoma; Adult; Aged; Colorectal Neoplasms; Combined Modality Therapy; Diarrhe | 1995 |
Phase I/II trial of dipyridamole, 5-fluorouracil, leukovorin, and mitoxantrone in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Breast Neoplasms; | 1994 |
Treatment of advanced gastric cancer with the combination fluorouracil, leucovorin, etoposide, and cisplatin: a phase II study of the ONCOPAZ Cooperative Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Female; Fluorour | 1995 |
Different dose regimens of 5-fluorouracil and interferon-alpha in patients with metastatic colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Sc | 1995 |
Phase I study of interleukin-2 combined with interferon-alpha and 5-fluorouracil in patients with metastatic renal cell cancer.
Topics: Adult; Aged; Blood Cell Count; Carcinoma, Renal Cell; Drug Therapy, Combination; Female; Fluorouraci | 1994 |
Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine-based chemotherapy. A phase II study.
Topics: Adult; Aged; Colorectal Neoplasms; Female; Floxuridine; Fluorouracil; Humans; Male; Middle Aged; Neo | 1995 |
Alternating chemotherapy regimens for patients with metastatic breast cancer. A pilot study based on tumor marker kinetics. Cancer and Leukemia Group B.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cy | 1995 |
Double modulation of 5-fluorouracil in advanced colorectal cancer with low-dose interferon-alpha 2b and folinic acid. The "GISCAD" experience. Italian Group for the Study of Digestive Tract Cancer.
Topics: Adult; Aged; Colonic Neoplasms; Drug Administration Schedule; Drug Synergism; Female; Fluorouracil; | 1994 |
Simultaneous adjuvant radiation therapy and chemotherapy in high-risk breast cancer--toxicity and dose modification: a Transtasman Radiation Oncology Group Multi-Institution study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Australia; Breast Neoplasms; Cyclophosphamide | 1995 |
Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Female; F | 1995 |
Cytarabine and cisplatin as salvage therapy in patients with metastatic colorectal cancer who failed 5-fluorouracil + folinic acid regimen. French Northern Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Cytara | 1995 |
Effect of systemic adjuvant treatment on first sites of breast cancer relapse.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adju | 1994 |
Bolus/infusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma: are suboptimal dosages being used in the UK?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 1994 |
A randomized phase II study comparing sequential versus simultaneous chemo-radiotherapy in patients with unresectable locally advanced squamous cell cancer of the head and neck.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chi | 1994 |
Phase II study of weekly mitoxantrone, 5-fluorouracil, and leucovorin in metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedul | 1994 |
The pharmacokinetics of high-dose epirubicin and of the cardioprotector ADR-529 given together with cyclophosphamide, 5-fluorouracil, and tamoxifen in metastatic breast-cancer patients.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chroma | 1994 |
5-fluorouracil and high dose folinic acid in hormone-refractory metastatic prostate cancer: a phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Fluorouracil; Humans; Leucovorin; Ma | 1994 |
Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Femal | 1994 |
Simultaneous administration of CPT-11 and fluorouracil: alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 1994 |
Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group Study.
Topics: Carcinoma, Renal Cell; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Parent | 1994 |
The cardioprotector ADR-529 and high-dose epirubicin given in combination with cyclophosphamide, 5-fluorouracil, and tamoxifen: a phase I study in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Combi | 1994 |
Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc | 1994 |
Patterns of failure of complete responders following high-dose chemotherapy and autologous bone marrow transplantation for metastatic breast cancer: implications for the use of adjuvant radiation therapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms | 1994 |
Estimated treatment responses in metastatic colorectal carcinoma based on longitudinal carcinoembryonic antigen series.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colorectal Ne | 1993 |
Mitoxantrone, 5-fluorouracil and levo-leucovorin as salvage treatment in advanced breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fluorouracil; | 1994 |
Randomized trial of cyclophosphamide, methotrexate, and 5-fluorouracil with or without estrogenic recruitment in women with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 1994 |
A phase II trial of 5-fluorouracil and cisplatinum in recurrent or metastatic nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Follow | 1994 |
[Combination of 5-FU, high dose methotrexate, epirubicin and cisplatin (FEMTX-P protocol) in non surgical or locally recurrent metastatic gastric cancers].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Female; Fluorour | 1993 |
Continuous-infusion 5-fluorouracil in metastatic colorectal cancer patients pretreated with bolus 5-fluorouracil: clinical evidence of incomplete cross-resistance.
Topics: Colorectal Neoplasms; Drug Administration Schedule; Drug Resistance; Fluorouracil; Humans; Infusions | 1994 |
Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: an active new regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Epirubicin | 1994 |
Phase II trial of 5-fluorouracil and the natural l isomer of folinic acid in the treatment of advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Female; | 1994 |
The influence of adjuvant chemotherapy on outcome after relapse for patients with breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc | 1993 |
Folinic acid, 5-fluorouracil bolus and infusion and mitoxantrone with or without cyclophosphamide in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclo | 1993 |
A phase-III study of recombinant interleukin 2 and 5-fluorouracil chemotherapy in patients with metastatic colorectal cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capillary Permeabi | 1993 |
Stimulation of human breast cancer in vivo. Experimental findings and clinical results.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Cytarabine; Diet | 1993 |
A phase I clinical trial of a combination of mitoxantrone, 5-fluorouracil, and high-dose leucovorin given on a day 1 and day 8 schedule to patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration S | 1994 |
A phase II study of continuous infusion 5-fluorouracil and leucovorin with weekly cisplatin in metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Dose-Resp | 1993 |
Phase II study of fluorouracil, leucovorin, and interferon alfa-2a in metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati | 1993 |
A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer. An Illinois Cancer Center Study.
Topics: Aged; Fluorouracil; Hormones; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis | 1993 |
Determination of the optimal dose of 5-fluorouracil when combined with low dose D,L-leucovorin and irradiation in rectal cancer: results of three consecutive phase II studies. EORTC Radiotherapy Group.
Topics: Combined Modality Therapy; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Met | 1993 |
A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 1993 |
Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin, and fluorouracil in metastatic breast cancer: a randomized trial comparing weekly and every-4-week administration.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dru | 1993 |
[The chemoradiotherapy of advanced colorectal carcinoma--the results and toxicity in a pilot study with 44 patients].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo | 1993 |
Folinic acid does improve 5-fluorouracil activity in vivo. Results of a phase III study comparing 5-fluorouracil to 5-fluorouracil and folinic acid in advanced colon cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fema | 1993 |
MMM (mitomycin/mitoxantrone/methotrexate): an effective new regimen in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosp | 1993 |
Non-uniform dose/time fractionated radiation therapy and chemotherapy for non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small | 1995 |
A phase I-II trial of five-day continuous intravenous infusion of 5-fluorouracil delivered at circadian rhythm modulated rate in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Circadian Rhythm; Colorectal Neoplasms; Disease-Free S | 1995 |
Phase I/II study with paclitaxel in combination with weekly high-dose 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer: an interim analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration S | 1995 |
Leucovorin and high-dose fluorouracil in metastatic prostate cancer. A phase II trial of the piedmont Oncology Association.
Topics: Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Fluorouracil; Humans; Leucovori | 1996 |
A phase II trial of 5-fluorouracil and 1-leucovorin in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fe | 1996 |
5-fluorouracil and allopurinol combined with recombinant interferon-alpha 2b in the treatment of patients with advanced prostate cancer: a phase I/II study.
Topics: Aged; Allopurinol; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined C | 1996 |
Breast tumour response to primary chemotherapy predicts local and distant control as well as survival.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc | 1995 |
Mitoxantrone, 5-fluorouracil and leucovorin in metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Fe | 1995 |
Phase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infusional ECarboF): a very active and well-tolerated outpatient regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinom | 1996 |
A phase II study of 5-fluorouracil and high dose folinic acid in cisplatin-refractory metastatic bladder cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cispla | 1995 |
Protracted continuous infusion of 5-fluorouracil in combination with doxorubicin, vincristine, and oral cyclophosphamide in advanced breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1996 |
5-methyltetrahydrofolate or 5-formyltetrahydrofolic acid to modulate 5-fluorouracil's cytotoxic activity in vivo. A phase II study in patients with advanced colon cancer.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc | 1996 |
Radiotherapy and neoadjuvant chemotherapy for cervical carcinoma. A randomized multicenter study of sequential cisplatin and 5-fluorouracil and radiotherapy in advanced cervical carcinoma stage 3B and 4A.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 1996 |
Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of finding
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 1996 |
[Cancers of the base of the tongue and hypopharynx: results of a multicenter randomized trial of chemotherapy prior to locoregional treatment].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Female; Fluoro | 1996 |
Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: final results of a randomized European Organization for Research and Treatment of Cancer Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Europe; Female; Fluorour | 1996 |
Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 1996 |
Salvage chemotherapy in metastatic breast cancer: an experience with the combination of mitoxantrone, 5-fluorouracil, and L-leucovorin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fluorouracil; | 1996 |
Treatment of recurrent and/or metastatic squamous cell head and neck carcinoma with a combination of vinorelbine, cisplatin, and 5-fluorouracil: a multicenter phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1995 |
Sequential biochemotherapy for metastatic colorectal cancer using fluorouracil, folinic acid, thymopentin and interleukin-2: clinical and immunological effects.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 1995 |
Phase II study of mitoxantrone, 5-fluorouracil, and levo-leucovorin (MLF) in elderly advanced breast cancer patients.
Topics: Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fluoroura | 1996 |
A report of infusional 5-fluorouracil and subcutaneous alpha-2A-interferon in the treatment of advanced colorectal carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colorectal Neoplasms; Drug Ther | 1996 |
Treatment of metastatic breast cancer by navelbine, mitoxantrone and continuous infusion 5-fluorouracil (FMN regimen): results of a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration S | 1996 |
Subcutaneous low-dose interleukin-2 and intravenous 5-fluorouracil plus high-dose levofolinic acid as salvage treatment for metastatic colorectal carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Relationsh | 1996 |
5-Fluorouracil versus 5-fluorouracil plus alpha-interferon as treatment of metastatic colorectal carcinoma. A randomized study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colore | 1996 |
Outpatient weekly high-dose continuous-infusion 5-fluorouracil plus oral leucovorin in advanced colorectal cancer. A phase II trial. Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 1996 |
Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Topics: Adult; Aged; Ambulatory Care; Antibiotics, Antineoplastic; Antidotes; Antimetabolites, Antineoplasti | 1996 |
Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antidotes; Antineoplastic Combined Chemotherapy Protocols; | 1996 |
Low-dose continuous intravenous infusion of 5-fluorouracil for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Dose-Response Rel | 1996 |
5-Fluorouracil continuous infusion in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoembryonic Antigen; Colorectal N | 1996 |
A phase II study of 5-fluorouracil, leucovorin and cisplatin (FLP) for metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Humans | 1996 |
Efficacy and tolerance of vinorelbine and fluorouracil combination as first-line chemotherapy of advanced breast cancer: results of a phase II study using a sequential group method.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration S | 1996 |
Intraoperative radiation therapy in integrated treatment of rectal cancers. Results of phase II study.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Fluorouracil; Humans; Intraoperative Per | 1996 |
A comparative, randomized trial of UFT and 5-fluorouracil in combination with cyclophosphamide and doxorubicin in the treatment of advanced breast cancer patients at The Philippines General Hospital.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclo | 1997 |
Paclitaxel, 5-fluorouracil, and folinic acid in metastatic breast cancer: BRE-26, a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Fatigue; Female; Fluo | 1997 |
Phase I/II study with a weekly 24-hour infusion of 5-fluorouracil plus high-dose folinic acid (HD-FU/FA) in intensively pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relatio | 1996 |
Concurrent tamoxifen (TAM) + cyclophosphamide, epirubicin, and fluorouracil (CEF) versus TAM + delayed CEF after six months of endocrine therapy in metastatic breast cancer--a randomized trial from the Danish Breast Cancer Cooperative Group (DBCG).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Administrat | 1996 |
Paclitaxel as first-line treatment for metastatic breast cancer. The Taxol Investigational Trials Group, Australia and New Zealand.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cyclophosphamide; Doxoru | 1997 |
Mitoxantrone dose augmentation utilizing filgrastim support in combination with fixed-dose 5-fluorouracil and leucovorin in women with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relatio | 1997 |
The French experience with infusional 5-FU in gastric and pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bio | 1996 |
Maximum tolerable doses of intravenous zidovudine in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer patients. Clinical evidence of significant antitumor activity and enhancement of zidovudine-induced DNA single strand break
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; DNA Damage; DNA, | 1997 |
Phase II trial of doxorubicin, 5-fluorouracil, etoposide, and cisplatin in advanced or recurrent endometrial carcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineopla | 1997 |
[Therapy with mitomycin C, folic acid and 5-fluorouracil in treatment of metastatic, refractory urinary bladder carcinoma--phase II study].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Drug Resistance, | 1997 |
Breast conserving therapy in stage I & II breast cancer in Korea.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 1997 |
Randomized controlled trial of postoperative radiotherapy and short-term time-scheduled 5-fluorouracil against surgery alone in the treatment of Dukes B and C rectal cancer. Norwegian Adjuvant Rectal Cancer Project Group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Dis | 1997 |
Randomized controlled trial of postoperative radiotherapy and short-term time-scheduled 5-fluorouracil against surgery alone in the treatment of Dukes B and C rectal cancer. Norwegian Adjuvant Rectal Cancer Project Group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Dis | 1997 |
Randomized controlled trial of postoperative radiotherapy and short-term time-scheduled 5-fluorouracil against surgery alone in the treatment of Dukes B and C rectal cancer. Norwegian Adjuvant Rectal Cancer Project Group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Dis | 1997 |
Randomized controlled trial of postoperative radiotherapy and short-term time-scheduled 5-fluorouracil against surgery alone in the treatment of Dukes B and C rectal cancer. Norwegian Adjuvant Rectal Cancer Project Group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Dis | 1997 |
Paclitaxel/5-fluorouracil/leucovorin in metastatic breast cancer: a Vanderbilt Cancer Center phase II trial.
Topics: Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Admin | 1997 |
9-Aminocamptothecin by 72-hour continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Drug Resist | 1997 |
Phase I-II study of vinorelbine in combination with 5-fluorouracil and folinic acid as first-line chemotherapy in metastatic breast cancer: a regimen with a low subjective toxic burden.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fluorouracil; | 1997 |
A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5-fluorouracil/prednisone in previously untreated patients with advanced breast cancer: preliminary results. Taxol Investigational Trials Group, Australia/New Zealand.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1997 |
Infusional 5-fluorouracil/leucovorin plus paclitaxel and cisplatin in the first-line treatment of metastatic breast cancer: results of a phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Drug Administrat | 1997 |
Paclitaxel with mitoxantrone with or without 5-fluorouracil and high-dose leucovorin in the treatment of metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Fema | 1997 |
Mitoxantrone, fluorouracil, and L-folinic acid in anthracycline-pretreated metastatic breast cancer patients.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 1997 |
A phase I study of paclitaxel and 5-fluorouracil in advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Femal | 1997 |
Treatment of renal cell carcinoma with 5-fluorouracil and alfa-interferon.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Fluorourac | 1997 |
Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a multicentric phase II study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administr | 1998 |
Refractory breast cancer: a comparison of two different chemotherapy regimens.
Topics: Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Ant | 1997 |
[Oxaliplatin, folinic acid and 5-fluorouracil (folfox) in pretreated patients with metastatic advanced cancer. The GERCOD].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hum | 1997 |
Fluorouracil-based combinations in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast N | 1998 |
Advanced nasopharyngeal carcinoma treated with chemotherapy and radiotherapy: distant metastasis and local recurrence.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemother | 1998 |
Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosph | 1998 |
Synergistic activity of oxaliplatin and 5-fluorouracil in patients with metastatic colorectal cancer with progressive disease while on or after 5-fluorouracil.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Sche | 1998 |
Oxaliplatin combined to 5-fluorouracil and folinic acid: an effective therapy in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasm | 1998 |
Phase II study of paclitaxel in pretreated advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisp | 1998 |
Cyclophosphamide, methotrexate and infusional 5-fluorouracil (infusional CMF) in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Fem | 1998 |
Ifosfamide-based chemotherapy for previously treated lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcino | 1998 |
Outpatient weekly chemotherapy in patients with nasopharyngeal carcinoma and distant metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule | 1998 |
A randomized phase-II study of BB-10010 (macrophage inflammatory protein- 1alpha) in patients with advanced breast cancer receiving 5-fluorouracil, adriamycin, and cyclophosphamide chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Breast Neoplasms; Ce | 1998 |
A phase 2 study of weekly high-dose 5-fluorouracil and leucovorin plus biweekly plus biweekly alternating doxorubicin and cisplatin for advanced gastric cancer.
Topics: Antibiotics, Antineoplastic; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined Che | 1998 |
Effective treatment of advanced breast cancer with vinorelbine, 5-fluorouracil and l-leucovorin plus human granulocyte colony-stimulating factor.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fluorouracil; | 1998 |
Biochemical modulation of 5-fluorouracil by methotrexate in patients with advanced gastric carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Male; Met | 1998 |
Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Color | 1998 |
A multistep therapy with subcutaneous low dose recombinant interleukin-2, 5-fluorouracil and leucovorin prolongs the response of metastatic colorectal cancer patients: a pilot study.
Topics: Aged; Colonic Neoplasms; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Inte | 1998 |
Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Neopl | 1995 |
Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642).
Topics: Adenine; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophospha | 1995 |
The addition of paclitaxel to continuous infusion 5-fluorouracil is an active regimen for metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fluorouracil; Human | 1998 |
A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 1998 |
A phase II study of 5-fluorouracil, leucovorin, and interferon-alpha in the treatment of patients with metastatic or recurrent gastric carcinoma: an Eastern Cooperative Oncology Group study (E5292).
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; | 1999 |
[Primary chemotherapy of metastatic breast carcinoma with bendamustine hydrochloride, methotrexate and fluorouracil versus cyclophosphamide, methotrexate and fluorouracil].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Breast Neoplasms; Cyclop | 1998 |
Double modulation of 5-fluorouracil with interferon alpha-2a and high-dose leucovorin in advanced neuroendocrine tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Interfero | 1998 |
Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 1999 |
Treatment with a nonanthracycline regimen in advanced breast cancer: vinorelbine, cyclophosphamide, and 5-fluorouracil with folinic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; F | 1999 |
Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Ag | 1999 |
A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplas | 1999 |
Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplas | 1999 |
Epirubicin, folinic acid, fluorouracil, and etoposide in the treatment of advanced gastric cancer: phase II study of the Southern Italy Oncology Group (GOIM).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Etoposide; Female; Fluorour | 1999 |
Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B.
Topics: Adult; Amphotericin B; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ciprofloxac | 1999 |
Protracted continuous infusion of 5-fluorouracil and low-dose leucovorin in patients with metastatic colorectal cancer resistant to 5-fluorouracil bolus-based chemotherapy: a phase II study.
Topics: Adult; Aged; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Hu | 1999 |
[Irinotecan in the second-line therapy of metastatic colorectal carcinoma].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplas | 1999 |
[Peripheral 5-FU blood concentration after high-dose injection into the hepatic artery: potential preventive effect on extrahepatic metastatic foci].
Topics: Adult; Aged; Area Under Curve; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy; Hepatic Arte | 1999 |
Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Doxorubicin | 1999 |
A phase II trial of methotrexate, cisplatin, 5-fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin | 1999 |
Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cohort Studies; Colorectal Neoplasm | 1999 |
A new combination chemotherapy with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for advanced esophageal cancers.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Esophageal Neoplasms; Fluorouracil; | 1999 |
Phase II study of cisplatin and 5-fluorouracil in previously treated metastatic breast cancer: an Eastern Cooperative Oncology Group study (PA 185).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cispl | 1999 |
Oxaliplatin added to 5-fluorouracil-based therapy (5-FU +/- FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): results from the European compassionate-use program.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 1999 |
Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2000 |
A phase II trial of 5-fluorouracil, leucovorin, and interferon alpha 2A (IFN-alpha 2a) in metastatic pancreatic carcinoma: a Penn Cancer Clinical Trials Group (PCCTG) trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Interfero | 2000 |
Continuous-infusion high-dose leucovorin with 5-fluorouracil and cisplatin for relapsed metastatic breast cancer: a phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Female; Fluoroura | 2000 |
c-erb-B2 expression and response to treatment in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2000 |
Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Fluorouracil; Hu | 2000 |
A phase II study of ifosfamide, 5-fluorouracil and leucovorin in patients with recurrent nasopharyngeal carcinoma previously treated with platinum chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Follow-Up Studies; Huma | 2000 |
[Consolidation radiotherapy after high-dose chemotherapy and autologous bone marrow transplantation in patients with advanced breast cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2000 |
Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients.
Topics: Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplasti | 2000 |
FEC (5-fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. A multicentric randomised study. Final results.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophos | 2000 |
Medical care consumption in a phase III trial comparing irinotecan with infusional 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer after 5-FU failure.
Topics: Ambulatory Care; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; C | 1999 |
Weekly 24-hour infusion of high-dose 5-fluorouracil plus folinic acid in combination with mitomycin C for the treatment of advanced gastric cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Human | 2000 |
Cell proliferation and outcome following doxorubicin plus CMF regimens in node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Cell Division | 2000 |
Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian breast group.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Flu | 2000 |
Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 2000 |
Capecitabine in the treatment of metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Carcinoma, Renal Cell; Deoxy | 2000 |
Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups.
Topics: Adult; Aged; Antidiarrheals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Cam | 2000 |
Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Circadian Rhythm; Colorectal Neoplasms; | 2000 |
Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dis | 2000 |
Docetaxel in combination with 5-fluorouracil in patients with metastatic breast cancer previously treated with anthracycline-based chemotherapy: a phase I, dose-finding study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Fl | 2000 |
[A comparative randomized phase-II study of Xeloda (capecitabine) and paclitaxel in patients with breast cancer progressing after anthracycline antibiotics].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; | 2000 |
Content of epidermal growth factor receptor in metastatic breast cancer: its role in endocrine sensitivity prediction.
Topics: Adult; Aminoglutethimide; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Prot | 2000 |
Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Renal Cell; Disease- | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2000 |
Phase II study of vinorelbine with protracted fluorouracil infusion as a second- or third-line approach for advanced breast cancer patients previously treated with anthracyclines.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival | 2000 |
Five-day infusion fluorouracil plus vinorelbine in women with breast cancer previously treated with anthracyclines and paclitaxel.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug | 2000 |
Avoidance of colostomy placement in advanced colorectal cancer with twice weekly hypofractionated radiation plus continuous infusion 5-fluorouracil.
Topics: Colorectal Neoplasms; Colostomy; Contraindications; Dose Fractionation, Radiation; Drug Administrati | 2000 |
Adjuvant intraportal chemotherapy for Dukes B2 and C colorectal cancer also receiving systemic treatment: results of a multicenter randomized trial. Groupe Régional d'Etude du Cancer Colo-Rectal (Belgium).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2000 |
Double modulation of 5-fluorouracil by leucovorin and low-dose methotrexate in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel | 2000 |
Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Français d'Immunothérapie, Fédération Nationale des Centres de Lutte Contre le Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Sur | 2000 |
Value and cost of follow-up after adjuvant treatment of patients with Dukes' C colonic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Co | 2001 |
Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients.
Topics: Adult; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoco | 2000 |
Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; C | 2000 |
Phase II trial of cyclophosphamide, leucovorin, 5-fluorouracil 24-hour infusion and tamoxifen in pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Femal | 2000 |
Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2001 |
E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors.
Topics: Adenoviridae; Adenovirus E1B Proteins; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplast | 2001 |
Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosp | 2001 |
Double-blind pilot-study on the efficacy of enzyme therapy in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chymotrypsin; Colorectal Neo | 2000 |
Irinotecan and chronomodulated infusion of 5-fluorouracil and folinic acid in the treatment of patients with advanced colorectal carcinoma: a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chronotherapy; Colorectal | 2001 |
Vinorelbine, cisplatin and continuous infusion of 5-fluorouracil (ViFuP) in metastatic breast cancer patients: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Disease-Fr | 2001 |
Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dis | 2001 |
Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter G
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dis | 2001 |
A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Disease-Free Surviva | 2001 |
Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineopl | 2001 |
Examining prognostic factors and patterns of failure in nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy: impact on future clinical trials.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Disease-Fr | 2001 |
Oxaliplatin and protracted continuous 5-fluorouracil infusion in patients with pretreated advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progressi | 2001 |
Phase I study of a weekly schedule of oxaliplatin, high-dose leucovorin, and infusional fluorouracil in pretreated patients with advanced colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Dose-Response | 2001 |
Combined 5-fluorouracil infusion with fractionated epirubicin and cyclophosphamide in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dru | 2001 |
Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2001 |
Gemcitabine/cyclophosphamide/5-fluorouracil/folinic acid triplet combination in anthracycline- and taxane-refractory breast cancer patients: a Southern Italy Cooperative Oncology Group phase I/II study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 2001 |
Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracyclin
Topics: Adolescent; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neop | 2001 |
Neoadjuvant chemotherapy plus conventional radiotherapy or accelerated hyperfractionation in stage III and IV nasopharyngeal carcinoma--a phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squam | 2001 |
Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combi | 2001 |
IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial.
Topics: Adult; Aged; Carcinoma, Renal Cell; Female; Fluorouracil; Humans; Interferon-alpha; Interleukin-2; K | 2001 |
Postoperative chemoendocrine therapy for women with node-positive stage II breast cancer with combined cyclophosphamide, tamoxifen, and 1-hexylcarbamoyl-5-fluorouracil.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Ne | 2001 |
Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; | 2001 |
Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; | 2001 |
Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; | 2001 |
Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; | 2001 |
Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer.
Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Capecitabine; Consumer Product Safety; | 2002 |
P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoembryonic Antigen; Cell D | 2002 |
A phase I-II study on a gemcitabine-cyclophosphamide-fluorouracil/folinic acid triplet combination in anthracycline- and taxane-refractory breast cancer patients.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridg | 2002 |
Irinotecan (CPT-11) in combination with infusional 5-fluorouracil and leucovorin (de Gramont regimen) as first-line treatment in patients with advanced colorectal cancer: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2002 |
A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cisplatin; Deoxy | 2002 |
Phase II trial of chronomodulated infusion of high-dose fluorouracil and l-folinic acid in previously untreated patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chrono | 2002 |
Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis-X and sialyl Lewis-A epitope expression on tumour cells.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antig | 2002 |
Sequential or alternating administration of docetaxel (Taxotere) combined with FEC in metastatic breast cancer: a randomised phase II trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brea | 2002 |
Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients.
Topics: Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorour | 2002 |
Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 2002 |
Effect of a 3-hour interval between methotrexate and 5-fluorouracil in the treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati | 2002 |
An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 2002 |
Phase II study of low-dose infusional 5-fluorouracil and paclitaxel (Taxol) given every 2 weeks in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration S | 2002 |
[Laryngeal Preservation with Induction Chemotherapy. Experience of two GETTEC Centers, Between 1985 and 1995].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2002 |
[Capecitabine (xeloda) in the treatment of relapsed and metastatic breast cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; | 2002 |
Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines.
Topics: Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Ant | 2002 |
Phase I study of eniluracil and oral 5-fluorouracil in combination with docetaxel in the treatment of patients with metastatic breast carcinoma.
Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Ant | 2002 |
The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farbe
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma; Com | 2002 |
Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
[Chemotherapy of non-microcellular disseminated bronchial cancer (author's transl)].
Topics: Adenocarcinoma; Adult; Aged; Bleomycin; Bronchial Neoplasms; Carcinoma, Small Cell; Carcinoma, Squam | 1979 |
Adrenalectomy-oophorectomy and combined chemotherapy for carcinoma of the breast with metastases.
Topics: Adenocarcinoma; Adrenalectomy; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Castration; Cli | 1979 |
1.3 Bis-(2 chloroethyl)-1-nitrosourea and streptozotocin chemotherapy.
Topics: Adolescent; Adult; Aged; Bone Marrow; Carmustine; Child; Child, Preschool; Clinical Trials as Topic; | 1975 |
[Adriamycin, cyclophosphamide, and 5-fluorouracil in the treatment of metastasizing breast cancer (author's transl)].
Topics: Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination | 1976 |
Advances in the staging and treatment of ovarian cancer.
Topics: Alkylating Agents; Altretamine; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Cyclophos | 1977 |
Hepatic artery infusion of 5-FUDR after prior systemic 5-fluorouracil.
Topics: Adult; Aged; Colonic Neoplasms; Female; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Injection | 1976 |
Chemotherapy of gastric and pancreatic carcinoma: a controlled evaluation of combinations of 5-fluorouracil with nitrosoureas and "lactones".
Topics: Adenocarcinoma; Antineoplastic Agents; Drug Therapy, Combination; Fluorouracil; Humans; Lomustine; N | 1979 |
Combined radiation therapy and 5-fluorouracil for advanced squamous cell carcinoma of the oral cavity and oropharynx: a randomized study.
Topics: Carcinoma, Squamous Cell; Fluorouracil; Follow-Up Studies; Humans; Mouth Neoplasms; Neoplasm Metasta | 1976 |
Clinical studies of 5-fluorouracil + premarin in the treatment of breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Therapy, Combination; Estrogen | 1975 |
L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. An update of earlier findings and a comparison with those utilizing L-PAM plus 5-fluorouracil (5-FU).
Topics: Adenocarcinoma, Mucinous; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Clinical Trials | 1977 |
Chemotherapy of disseminated breast cancer. Current status and prospects.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Dr | 1977 |
Chemoimmunotherapy in disseminated melanoma and colorectal carcinoma.
Topics: Bacterial Vaccines; Colonic Neoplasms; Corynebacterium; Dacarbazine; Female; Fluorouracil; Humans; I | 1978 |
Randomized sequential hormonal therapy vs adrenalectomy for metastatic breast carcinoma.
Topics: Adrenalectomy; Adult; Breast Neoplasms; Castration; Clinical Trials as Topic; Cyclophosphamide; Diet | 1977 |
[Combination antimetabolite-alkylating agent-vinblastine in the treatment of advanced breast cancer].
Topics: Adult; Aged; Alkylating Agents; Antimetabolites; Breast Neoplasms; Clinical Trials as Topic; Cycloph | 1977 |
Combined chemo- and hormonal therapy in advanced breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Castration; Chlorambucil; Clinical Trials as Topic; Cycloph | 1977 |
Gastrointestinal cancer--colon (surgery-radiotherapy). The role of radiation therapy in the management of rectosigmoid cancer.
Topics: Clinical Trials as Topic; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Neoplasm Me | 1977 |
A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer: a Southeastern Cancer Study Group project.
Topics: Agranulocytosis; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; | 1977 |
Chemotherapy of advanced soft-tissue sarcomas in adults.
Topics: Adult; Antineoplastic Agents; Bone Marrow; Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; | 1977 |
Adjuvant chemotherapy in the primary management of breast cancer.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Survival; Clinica | 1977 |
Management of gastrointestinal cancer.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Fluor | 1977 |
Surgery and adjuvant chemotherapy in the treatment of operable breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Clinical Trials as Topic; Cycloph | 1977 |
Chemotherapy of metastatic breast cancer in postmenopausal women: a controlled trial of cyclophosphamide versus a five-drug combination of cyclophosphamide, vincristine, methotrexate, 5-fluorouracil and prednisone.
Topics: Aged; Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphami | 1977 |
Combination chemotherapy in advanced breast cancer.: a randomized trial comparing a three-vs a five-drug program.
Topics: Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Double-Blind Method; Drug Therapy, Com | 1977 |
Adjuvant liver perfusion in colorectal cancer: initial results of a clinical trial.
Topics: Aged; Clinical Trials as Topic; Colonic Neoplasms; England; Female; Fluorouracil; Follow-Up Studies; | 1977 |
Treatment of metastatic breast cancer with adriamycin-cyclophosphamide induction followed by alternating combination therapy.
Topics: Adult; Aged; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Therapy | 1977 |
Mitomycin-C alone and in combination with infused 5-fluorouracil to the treatment of disseminated gastrointestinal carcinomas.
Topics: Adenocarcinoma; Bone Marrow; Clinical Trials as Topic; Drug Therapy, Combination; Female; Fluorourac | 1978 |
A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy.
Topics: Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination | 1978 |
Activity of adriamycin in metastatic breast cancer resistant to a combination regimen with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prdnisone.
Topics: Adult; Aged; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Resista | 1978 |
[Survival of 5-fluorouracil-treated stomach cancer patients in the far-advanced stages].
Topics: Clinical Trials as Topic; Drug Evaluation; Fluorouracil; Gastrectomy; Humans; Kinetics; Neoplasm Met | 1978 |
Combined cytotoxic and progestogen therapy for advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Clinical Trials as Topic; Cycloph | 1978 |
Chemotherapy for colorectal cancer with 5-fluorouracil, cyclophosphamide, and CCNU: comparison of oral and continuous iv administration of 5-fluorouracil.
Topics: Administration, Oral; Adult; Clinical Trials as Topic; Colonic Neoplasms; Cyclophosphamide; Drug Eva | 1978 |
Chemotherapy of advanced breast cancer. Results of a controlled trial comparing two three-drug regimens.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Cycl | 1978 |
Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer: a randomized trial.
Topics: Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Do | 1978 |
Sequential chemoimmunotherapy of colorectal cancer: evaluation of methotrexate, Baker's Antifol and levamisole.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow; Clinical Trials as Topic; Colonic Neopl | 1978 |
Chemotherapy of advanced measurable colon and rectal carcinoma with oral 5-fluorouracil, alone or in combination with cyclophosphamide or 6-thioguanine, with intravenous 5-fluorouracil or beta-2'-deoxythioguanosine or with oral 3(4-methyl-cyclohexyl)-1(2-
Topics: Adenocarcinoma; Antineoplastic Agents; Bone Marrow; Clinical Trials as Topic; Colonic Neoplasms; Cyc | 1978 |
Cyclophosphamide (NSC 26271) versus the combination of adriamycin (NSC 123127), 5-fluorouracil (NSC 19893), and cyclophosphamide in the treatment of metastatic prostatic cancer: a randomized trial.
Topics: Adenocarcinoma; Aged; Bone Marrow; Clinical Trials as Topic; Cyclophosphamide; Digestive System; Dox | 1978 |
[Combined drug treatment of far-advanced forms of breast cancer].
Topics: Antineoplastic Agents; Breast Neoplasms; Castration; Clinical Trials as Topic; Cyclophosphamide; Dru | 1978 |
Low dose chemotherapy of metastatic breast cancer with cyclophosphamide, adriamycin, methotrexate, 5-fluorouracil (CAMF) versus sequential cyclophosphamide, methotrexate, 5-fluorouracil (CMF) and adriamycin.
Topics: Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Do | 1979 |
A randomized study of two different schedules of methyl CCNU, 5-FU and vincristine for metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Digestive System; D | 1979 |
Sequential combination chemotherapy in advanced breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination | 1978 |
Levamisole: as adjuvant to cyclic chemotherapy in breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Do | 1978 |
The dilemma regarding postoperative chemotherapy in primary carcinoma of the colon.
Topics: Antineoplastic Agents; BCG Vaccine; Breast Neoplasms; Carcinoma; Clinical Trials as Topic; Colonic N | 1979 |
5-Fluorouracil as adjuvant chemotherapy for large bowel cancer. Is it appropriate for routine community use?
Topics: BCG Vaccine; Clinical Trials as Topic; Fluorouracil; Humans; Intestinal Neoplasms; Neoplasm Metastas | 1979 |
Gastric cancer: current status of treatment.
Topics: Adenocarcinoma; Aged; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Ther | 1977 |
[Adriamycin-combination chemotherapy with or without immune stimulation by corynebacterium parvum in metastasizing carcinoma of the breast (author's transl)].
Topics: Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Hu | 1979 |
Response of metastatic breast cancer to combination chemotherapy according to site.
Topics: Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Hu | 1977 |
Pancreatic cancer treated with carmustine, fluorouracil, and spironolactone: a randomized study.
Topics: Adult; Carmustine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Middle Aged; Neopl | 1978 |
Cytotoxic perfusion for colorectal liver metastases.
Topics: Adult; Aged; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; Evaluation Studies as Topi | 1978 |
Combination chemotherapy for metastatic breast cancer: comparison of multiple drug therapy with 5-fluorouracil, cytoxan and prednisone with adriamycin or adrenalectomy.
Topics: Adrenalectomy; Aged; Bone Marrow; Breast Neoplasms; Cyclophosphamide; Digestive System; Doxorubicin; | 1978 |
Response of disseminated breast cancer to combined modality treatment with chemotherapy and levamisole with or without Bacillus Calmette-Guérin.
Topics: Adult; Aged; Antineoplastic Agents; BCG Vaccine; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Dr | 1978 |
Methyl-CCNU (NSC-95441) in advanced colorectal carcinoma after failure of 5-fluorouracil (NSC-19893) therapy.
Topics: Adenocarcinoma; Adult; Aged; Blood Platelet Disorders; Clinical Trials as Topic; Colonic Neoplasms; | 1976 |
Phase III comparison of the treatment of advanced gastrointestinal cancer with bolus weekly 5-FU vs. methyl-CCNU plus bolus weekly 5-FU. A Southwest Oncology Group study.
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Drug Therapy, Combination; Female; Fluorouracil; | 1976 |
Chemoimmunotherapy of advanced breast cancer: prolongation of remission and survival with BCG.
Topics: Adult; Aged; BCG Vaccine; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; | 1976 |
Fluorouracil, methyl-CCNU and vincristine in cancer of the colon.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Neopla | 1976 |
Distribution of 5-fluorouracil to body tissues compared after intraluminal, intravenous, and intramural administration in gastrointestinal cancer.
Topics: Aged; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Injections; Injections, Intravenous; | 1977 |
Combined treatment with BCG and chemotherapy for metastatic gastrointestinal cancer.
Topics: BCG Vaccine; Colonic Neoplasms; Evaluation Studies as Topic; Fluorouracil; Gastrointestinal Neoplasm | 1977 |
An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advanced breast cancer undergoing oophorectomy.
Topics: Adult; Age Factors; Breast Neoplasms; Castration; Cyclophosphamide; Drug Therapy, Combination; Evalu | 1977 |
5-fluorouracil versus CCNU in the treatment of metastatic prostatic cancer.
Topics: Drug Evaluation; Fluorouracil; Humans; Leukopenia; Lomustine; Male; Neoplasm Metastasis; Nitrosourea | 1977 |
[Cytostatic treatment of metastasizing breast cancer. A prospective controlled comparison between single drug and multiple drug chemotherapy].
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Evaluation; Drug Therapy, Comb | 1977 |
Doxorubicin in the treatment of advanced breast cancer; comparative studies of three combination chemotherapy regimes.
Topics: Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; F | 1976 |
Combination versus sequential five-drug chemotherapy in metastatic carcinoma of the breast.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Adminis | 1976 |
Combination chemotherapy for metastatic breast carcinoma. Prospective comparison of multiple drug therapy with L-phenylalanine mustard.
Topics: Adult; Aged; Antineoplastic Agents; Boston; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combin | 1976 |
Adriamycin (NSC-123127) versus 5-fluorouracil (NSC-19893) and cyclophosphamide (NSC-26271) in the treatment of metastatic prostate cancer.
Topics: Aged; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Humans; Male; Middle A | 1976 |
A double-blind comparison of intensive course 5-flourouracil by oral vs. intravenous route in the treatment of colorectal carcinoma.
Topics: Adenocarcinoma; Administration, Oral; Clinical Trials as Topic; Colonic Neoplasms; Evaluation Studie | 1975 |
Combined androgen and antimetabolite therapy of advanced female breast cancer. A report of the cooperative breast cancer group.
Topics: Administration, Oral; Breast Neoplasms; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Com | 1975 |
[Sequential chemotherapy based on the hypothesis of a circadian rhythm of tumor proliferation].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Circadian R | 1975 |
[Chemotherapy of metastasizing breast cancers. Indications and results].
Topics: Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Fema | 1975 |
Response and survival in advanced breast cancer after two non-cross-resistant combinations.
Topics: Antineoplastic Agents; Blood Cell Count; Blood Platelets; Bone Neoplasms; Breast Neoplasms; Cyclopho | 1976 |
Cyclophosphamide, doxorubicin and fluorouracil (CAF) plus depo-buserelin in the treatment of premenopausal women with metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Buserelin; Cyclophosphamide | 1992 |
Phase II study of epirubicin sequential methotrexate and 5-fluorouracil for advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diarrhea; Drug Admin | 1992 |
Systemic infusion versus bolus chemotherapy with 5-fluorouracil in measurable metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intra | 1992 |
Mitomycin C + high-dose medroxyprogesterone versus cyclophosphamide+doxorubicin plus fluorouracil as first-line treatment for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox | 1992 |
A phase 2 trial of recombinant interleukin-2 and 5-fluorouracil in patients with metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati | 1992 |
Sequential methotrexate and 5-fluorouracil (FU) vs. FU alone in metastatic colorectal cancer. Results of a randomized multicenter trial. The Association of Medical Oncology (AIO) of the German Cancer Society.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati | 1992 |
Carboplatin (CBDCA), 5-fluorouracil (5-FU) and mitoxantrone (DHAD): an effective and well tolerated regimen for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Drug Eva | 1992 |
A phase II trial of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisolone rapidly alternating with doxorubicin and vincristine (CMFP/AV) in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox | 1992 |
Severe complications of 5-fluorouracil and cisplatin with concomitant radiotherapy in inoperable non-metastatic squamous cell oesophageal cancer after intubation--early termination of a prospective randomised trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1992 |
Chemotherapy with or without high-dose medroxyprogesterone acetate in oestrogen-receptor-negative advanced breast cancer. Norwegian Breast Cancer Group.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosph | 1992 |
Alpha-interferon in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer: a phase I study.
Topics: Adenocarcinoma; Adult; Aged; Colorectal Neoplasms; Drug Evaluation; Drug Therapy, Combination; Fluor | 1992 |
Treatment of metastatic colorectal carcinoma with a combination of fluorouracil and recombinant interferon alfa-2b: preliminary data of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Fem | 1992 |
Fluorouracil continuous infusion plus alfa interferon plus oral folinic acid in advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Colorectal Neoplasms; Drug Administration Schedule; Drug Evaluati | 1992 |
Interleukin-2 followed by fluorouracil and folinic acid in refractory colorectal cancer--results of a clinical phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Evaluation; | 1992 |
Fluorouracil plus interferon + folinic acid in regional and systemic therapy in colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration | 1992 |
Recombinant interleukin-2 treatment in patients with metastatic colorectal cancer: effect on natural cytotoxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Cytotoxicity, Immunologic; Dru | 1992 |
[Fluorouracil as monotherapy or combined with folinic acid in the treatment of metastasizing colorectal carcinoma].
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Drug Therapy, Combination; Female; Fluorouraci | 1992 |
A randomized trial comparing radiation therapy versus concomitant radiation therapy and chemotherapy in carcinoma of the thoracic esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Co | 1991 |
A phase II trial of 5-fluorouracil and recombinant alpha-2a-interferon in previously untreated metastatic gastric carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Evaluation; Femal | 1992 |
A phase I trial of 5-fluorouracil, folinic acid, and alpha-2a-interferon in patients with metastatic colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 1992 |
A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Colo | 1992 |
Randomized, controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum (Kanagawa).
Topics: Adjuvants, Immunologic; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemothera | 1992 |
Antitumor effect of combination of cyclophosphamide, adriamycin and platinum (CAP) versus cyclophosphamide, adriamycin and 5-fluorouracil (CAF) in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosp | 1991 |
Treatment of advanced colorectal cancer by 5-fluorouracil-leucovorin combination with or without allopurinol: a prospective randomized study.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Colorec | 1991 |
[5-Fluorouracil (5-FU)/leucovorin in comparison to other current chemotherapy protocols in metastasizing colorectal carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Fluorou | 1991 |
[Concomitant association of radiotherapy and chemotherapy in inflammatory breast cancer. Initial results of phase II trial].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 1991 |
Randomised trial of epirubicin alone versus 5-fluorouracil, epirubicin and mitomycin C in locally advanced and metastatic carcinoma of the pancreas.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Fluorouracil; Fol | 1991 |
Phase II study of mitoxantrone, leucovorin, and infusional fluorouracil for treatment of metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dr | 1991 |
Mitoxantrone, fluorouracil, and high-dose leucovorin: an effective, well-tolerated regimen for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 1991 |
A phase I study of cisplatinum plus 5-fluorouracil in modulation with citrovorum factor in metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Colorectal Neopla | 1991 |
Cyclophosphamide plus epidoxorubicin and 5-fluorouracil with folinic acid as a novel treatment in metastatic breast cancer: preliminary results of a phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Eval | 1991 |
Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association.
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Administration | 1991 |
Continuous infusion 5-fluorouracil with escalating doses of intermittent cisplatin and etoposide. A phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Dose-Respo | 1991 |
Concurrent chemotherapy and thoracic irradiation in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lun | 1990 |
Protracted infusion of 5-FU with weekly low-dose cisplatin as second-line therapy in patients with metastatic colorectal cancer who have failed 5-FU monotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug A | 1991 |
Continuous infusion 5-fluorouracil with bolus adriamycin and mitomycin and low-dose cisplatin (FAMP) in the treatment of metastatic gastric carcinoma: an evaluation of efficacy and toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Female; Fluorou | 1991 |
Phase II study of deoxydoxorubicin in previously untreated metastatic breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 1990 |
Biological modification of protracted infusion of 5-fluorouracil with weekly leucovorin. A dose seeking clinical trial for patients with disseminated gastrointestinal cancers.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Clinical Trials as T | 1990 |
[Phase II trial as 2nd line chemotherapy with 5 fluorouracil and cisplatin (5FU-CDDP) for advanced breast cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Breast Neoplasms; Cisplatin | 1990 |
cis-platinum-based alternating non-cross-resistant chemotherapy as a first-line treatment in metastatic breast cancer. A phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox | 1990 |
Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An Eastern Cooperative Oncology Group trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Fluorour | 1990 |
Distant recurrence in breast cancer. Survival expectations and first choice of chemotherapy regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclopho | 1988 |
A controlled clinical trial including folinic acid at two distinct dose levels in combination with 5-fluorouracil (5FU) for the treatment of advanced colorectal cancer: experience of the Mayo Clinic and North Central Cancer Treatment Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Dose | 1988 |
[Can the occurrence of extrahepatic metastases in regional chemotherapy of the liver be prevented by adding systemic chemotherapy? A randomized multicenter study].
Topics: Adenocarcinoma; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Infusion Pumps | 1989 |
Dose escalation and split course of 4-epidoxorubicin in combination chemotherapy (FEM II) of advanced gastric carcinoma. A phase-II trail of the 'Chemotherapiegruppe Gastrointestinaler Tumoren (CGT)'.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Evaluat | 1989 |
Prevention of extrahepatic disease during intraarterial floxuridine of colorectal liver metastases by simultaneous systemic 5-fluorouracil treatment? A prospective multicenter study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Inju | 1989 |
Concomitant 5-fluorouracil infusion and high-dose radiation for stage III non-small cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Esophagit | 1989 |
Combination chemotherapy with etoposide and 5-fluorouracil in advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combinat | 1989 |
Continuous systemic 5-fluorouracil infusion in advanced colorectal cancer: results in 91 patients.
Topics: Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Colorectal Neoplasms; Female; Fluorouracil | 1989 |
Randomized clinical trial of CFP versus CMFP in women with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cl | 1989 |
Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 1989 |
A phase III randomized trial of epirubicin versus 5-fluorouracil in metastatic rectal/sigmoid adenocarcinoma.
Topics: Adenocarcinoma; Clinical Trials as Topic; Epirubicin; Fluorouracil; Humans; Neoplasm Metastasis; Ran | 1989 |
Interferon alternating with chemotherapy for patients with metastatic renal cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cisplatin; Clinical Trials as | 1989 |
Adjuvant chemotherapy with fluorouracil and CCNU in colon cancer. Results of a multicentric randomized study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neoplasms; C | 1989 |
[The results of a modified FAMeth chemotherapy protocol in metastatic stomach carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Clinical Trials as Topic; Combined Modali | 1989 |
Role of adjuvant chemotherapy in male breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical T | 1989 |
Salvage treatments in relapsing resectable breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cycloph | 1989 |
Combination of cyclophosphamide, adriamycin and platinum (CAP) versus 5-fluorouracil, adriamycin and cyclophosphamide (FAC) as primary treatment in metastatic breast cancer: results of a prospective randomized study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox | 1989 |
Prospective randomized trial of high-dose cisplatin and fluorouracil infusion with or without sodium diethyldithiocarbamate in recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cl | 1988 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclopho | 1988 |
Triazinate and platinum efficacy in combination with 5-fluorouracil and doxorubicin: results of a three-arm randomized trial in metastatic gastric cancer. Gastrointestinal Tumor Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Doxorubicin; Fl | 1988 |
5-Fluorouracil, adriamycin, cyclophosphamide (FAC) vs. 5-fluorouracil, epirubicin, cyclophosphamide (FEC) in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox | 1989 |
A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colonic Neoplasms; Drug Evaluat | 1985 |
Prospective randomized trial concerning hyper- and normoprolactinemia and the use of bromoergocryptine in patients with metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bromocriptine; Cyclophosphamide; D | 1986 |
[Randomized trial comparing mitoxantrone with adriamycin in advanced breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 1987 |
Combined therapy in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclopho | 1985 |
[Chemotherapy of advanced pancreatic cancer with 5-fluorouracil, doxorubicin and high-dose methotrexate].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dose-Response | 1988 |
5-Fluorouracil (FUra) and folinic acid (FA) therapy in patients with colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Drug | 1988 |
A northern California Oncology Group randomized trial of single agent 5-FU vs. high-dose folinic acid + 5-FU vs. methotrexate + 5-FU + folinic acid in patients with disseminated measurable large bowel cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neopl | 1988 |
Clinical experience with CF-FUra.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topi | 1988 |
5-Fluorouracil and 5-formyltetrahydrofolate in advanced malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Colorect | 1988 |
Folinic acid (CF)/5-fluorouracil (FUra) combinations in advanced gastrointestinal carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Evaluati | 1988 |
Effective salvage therapy for refractory disseminated breast cancer with 5-fluorouracil and high-dose continuous infusion folinic acid.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cl | 1988 |
Clinical experience with 5-FU/DDP +/- OHDW combination chemotherapy in patients with advanced colorectal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Colorectal Neop | 1988 |
Combined modality treatment of localized unresectable adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Clinical Trials as To | 1988 |
A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topi | 1988 |
A prospective randomized trial of fluorouracil versus fluorouracil plus cisplatin in the treatment of metastatic colorectal cancer: a Hoosier Oncology Group trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Co | 1988 |
Systemic therapy of colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Colonic Neoplas | 1988 |
[Intra-arterial chemotherapy in advanced ovarian cancer. 2. Technic, results, complications].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; | 1987 |
[Metastatic breast cancer. Modality of association of chemotherapy and hormonotherapy. Results of a controlled trial].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 1987 |
CAF in metastatic breast cancer: standard therapy or another effective regimen?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclopho | 1987 |
Recurrence patterns in a prospective study of patients with stage II breast cancer treated with endocrine-chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Breast Neoplasms; Clinical Trials as To | 1987 |
Sequential administration of cyclophosphamide, methotrexate, 5-fluorouracil, and folinic acid as salvage treatment in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 1987 |
Combined antiestrogen and cytotoxic therapy with pseudomonas vaccine immunotherapy for metastatic breast cancer. A prospective, randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bacterial Vaccines; Breast Neoplasms; C | 1987 |
A clinical trial of mitoxantrone (novantrone) versus doxorubicin (adriamycin) in combination chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Clini | 1987 |
Alternating versus sequential therapy in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 1987 |
Cytokinetic-based versus conventional chemotherapy in metastatic breast cancer: a randomized study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclopho | 1987 |
Responses to chemotherapy or chemohormonal therapy in advanced breast cancer patients treated previously with adjuvant chemotherapy. A subset analysis of CALGB Study 8081.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Dru | 1988 |
Prospective evaluation of carcinoembryonic antigen levels and alternating chemotherapeutic regimens in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoembryonic Antigen; Clinical | 1986 |
Controlled phase III clinical study of 4-epi-doxorubicin + 5-fluorouracil versus 5-fluorouracil alone in metastatic gastric and rectosigmoid cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Doxorubicin; | 1986 |
Combination chemotherapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cr | 1986 |
Etoposide (VP-16-213) and cis-dichlorodiammineplatinum (DDP) in advanced breast carcinoma resistant to previous chemotherapy.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; | 1986 |
Clinical trial of cisplatin and intensive course 5-fluorouracil for the treatment of advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Co | 1986 |
Ineffectiveness of levamisole in prolonging remission or survival of women treated with cyclophosphamide, doxorubicin, and 5-fluorouracil for good-risk metastatic breast carcinoma: a Southeastern Cancer Study Group Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Clinical Trials as | 1986 |
[French FAC vs FEC study in advanced breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Combined | 1986 |
Conventional versus cytokinetic polychemotherapy with estrogenic recruitment in metastatic breast cancer: results of a randomized cooperative trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle; Clinical | 1987 |
Adjuvant chemotherapy for high-risk squamous-cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Trials as Topic; | 1987 |
Pilot trial of prolonged continuous-infusion 5-fluorouracil and weekly cisplatin in advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical | 1987 |
Treatment of metastatic breast cancer in premenopausal women using CAF with or without oophorectomy: an Eastern Cooperative Oncology Group Study.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosph | 1987 |
Age as a prognostic factor in recurrent breast cancer.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined | 1986 |
A randomized study of intensive versus moderate chemotherapy programs in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox | 1987 |
Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox | 1987 |
Cyclophosphamide versus 5-fluorouracil, doxorubicin, and mitomycin C (FAM') in the treatment of hormone-resistant metastatic carcinoma of the prostate: a preliminary report of a randomized trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; | 1985 |
The Eastern Cooperative Oncology Group experience with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; | 1985 |
Adjuvant chemotherapy for breast cancer. Implications of clinical trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Tr | 1985 |
Randomized trial of combination chemotherapy in hormone-resistant metastatic prostate carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Do | 1985 |
Dose intensity in chemotherapy of metastatic breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cy | 1985 |
Comparison of CAF versus CMFP in metastatic breast cancer: analysis of prognostic factors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; C | 1985 |
Prospective randomized trial of intravenous v intraperitoneal 5-FU in patients with advanced primary colon or rectal cancer.
Topics: Adult; Catheters, Indwelling; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Colo | 1985 |
The effects of multiple combination chemotherapy with vincristine, cyclophosphamide (Endoxan), methotrexate, 5-fluorouracil, adriamycin and prednisolone (VEMFAH) for advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 1985 |
[Evaluation of regimens for the simultaneous and sequential administration of cytostatics in the combined chemotherapy of disseminated forms of breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Evaluation; Fema | 1985 |
Melphalan, 5-fluorouracil, and medroxyprogesterone acetate in metastatic endometrial carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Female; Fluorouracil; Humans | 1986 |
A comparative study of PALA, PALA plus 5-FU, and 5-FU in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Breast Neoplasms; Female | 1985 |
Controversies in the management of potentially curable breast cancer.
Topics: Breast Neoplasms; Castration; Clinical Trials as Topic; England; Female; Fluorouracil; Humans; Lymph | 1974 |
Combination therapy with 5-fluorouracil (5-FU; NSC-19893) and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) for disseminated gastrointestinal carcinoma.
Topics: Adult; Aged; Anemia, Aplastic; Blood Cell Count; Carcinoma; Clinical Trials as Topic; Colonic Neopla | 1972 |
Evaluation of 6,17 alpha-dimethyl-6-dehydroprogesterone for treatment of recurrent and metastatic gynecologic malignancy.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Drug | 1974 |
[Control studies on the cytostatic combination therapy in metastasizing breast carcinoma].
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Synergism; | 1973 |
Combined radiotherapy and chemotherapy for treatment of unresectable and or metastatic cancer.
Topics: Aged; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Female; Fluorouracil; Humans; Lu | 1974 |
Combination chemotherapy in disseminated solid tumours.
Topics: Clinical Trials as Topic; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Therapy, Combinat | 1974 |
Cancer of the gastrointestinal tract. Radiation therapy.
Topics: Adenocarcinoma; Clinical Trials as Topic; Fluorouracil; Humans; Neoplasm Metastasis; Neoplasm Recurr | 1974 |
Experience with furanidyl-fluorouracil in advanced tumours of the breast.
Topics: Adult; Aged; Breast Neoplasms; Clinical Trials as Topic; Drug Evaluation; Feeding and Eating Disorde | 1974 |
A pilot study for the evaluation of a new regime of combined therapy for the radical treatment of marginally operable rectal (or colo-rectal) cancer.
Topics: Adult; Aged; Clinical Trials as Topic; Colonic Neoplasms; Evaluation Studies as Topic; Female; Fluor | 1974 |
Radiotherapy plus 5-FU compared to radiotherapy alone for inoperable and unresectable bronchogenic carcinoma.
Topics: Adenocarcinoma; Carcinoma; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Clinical Trials as Top | 1972 |
A controlled evaluation of 5-fluorouracil utilizing a single injection technique.
Topics: Adenocarcinoma; Alopecia; Evaluation Studies as Topic; Fluorouracil; Gastrointestinal Diseases; Huma | 1974 |
Carcinoma of the bladder, 5-fluorouracil and the critical role of a placebo. A cooperative group report. I.
Topics: Adolescent; Adult; Aged; Carcinoma; Clinical Trials as Topic; Fluorouracil; Humans; Middle Aged; Neo | 1968 |
The effects of 5-fluorouracil (5-FU) ointment in the treatment of neoplastic dermatoses.
Topics: Clinical Trials as Topic; Fluorouracil; Humans; Neoplasm Metastasis; Ointments; Precancerous Conditi | 1970 |
Combination chemotherapy for 418 cases of advanced cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Bronchogenic; Carcinoma, Squamous Cel | 1971 |
Analysis of prognostic factors in patients with primary breast carcinoma.
Topics: Breast Neoplasms; Female; Fluorouracil; Humans; Mastectomy; Models, Biological; Neoplasm Metastasis; | 1971 |
1499 other studies available for fluorouracil and Metastase
| Article | Year |
|---|---|
Discovery of BC-01, a novel mutual prodrug (hybrid drug) of ubenimex and fluorouracil as anticancer agent.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; Fluorouracil; Leu | 2016 |
Excellent antitumor and antimetastatic activities based on novel coumarin/pyrazole oxime hybrids.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Coumarins; Epithelial-Mesenchymal Transition | 2019 |
Conversion therapy, palliative chemotherapy and surgery, which of these is the best treatment for locally advanced and advanced pancreatic cancer?
Topics: Age Factors; Aged; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Pr | 2022 |
Cost-effectiveness of maintenance therapy after first-line treatment in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colorectal Neoplasms; Cost-B | 2022 |
Bevacizumab and aflibercept in second-line metastatic colorectal cancer: 12 years of experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Female; Flu | 2022 |
Nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy: A real-world experience.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Iri | 2022 |
p130Cas Is Correlated with EREG Expression and a Prognostic Factor Depending on Colorectal Cancer Stage and Localization Reducing FOLFIRI Efficacy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Atlases as Topic; Breast Neoplasms; Camptothe | 2021 |
Treatment and Survival Outcomes Associated With Platinum Plus Low-Dose, Long-term Fluorouracil for Metastatic Nasopharyngeal Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Cohort Studie | 2021 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Second-line liposomal irinotecan plus fluorouracil and leucovorin in metastatic biliary tract cancer - Author's reply.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Fluorouracil; Humans; Irino | 2022 |
A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore | 2022 |
Measures to mitigate treatment-related toxicities in third-line metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor | 2021 |
GLIPR1 promotes proliferation, metastasis and 5-fluorouracil resistance in hepatocellular carcinoma by activating the PI3K/PDK1/ROCK1 pathway.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Epithelial-Mesenchymal Transition; | 2022 |
[Comparative Safety Assessment of Ramucirumab plus FOLFIRI and Bevacizumab plus FOLFIRI in Second- and Later-Line Treatment in Japanese Patients with Metastatic Colorectal Carcinoma].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2022 |
Cost-effectiveness of biweekly cetuximab plus chemotherapy in first-line treatment for RAS wild-type metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Cost- | 2022 |
Maintenance of angiogenesis inhibition with aflibercept after progression to bevacizumab in metastatic colorectal cancer: real life study in the Valencian community.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore | 2023 |
Single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2023 |
Flashback Foreword: Bevacizumab and FOLFOX4 for Colorectal Cancer and Bevacizumab Versus Placebo Plus Oxaliplatin-Based Chemotherapy in Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms | 2023 |
Correlation between early dynamics in circulating tumour DNA and outcome from FOLFIRI treatment in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2019 |
Can curcumin along with chemotherapeutic drug and lipid provide an effective treatment of metastatic colon cancer and alter multidrug resistance?
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Co | 2019 |
Conversion Chemotherapy With a Modified FLOX Regimen for Borderline or Unresectable Liver Metastases From Colorectal Cancer: An Alternative for Limited-Resources Settings.
Topics: Adult; Aged; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Middle Aged; N | 2019 |
Germline variability and tumor expression level of ribosomal protein gene RPL28 are associated with survival of metastatic colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2019 |
Long-Term Survival Outcomes of Metabolically Supported Chemotherapy with Gemcitabine-Based or FOLFIRINOX Regimen Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy in Metastatic Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreati | 2020 |
A novel therapeutic anti‑CD55 monoclonal antibody inhibits the proliferation and metastasis of colorectal cancer cells.
Topics: Antibodies, Monoclonal; CD55 Antigens; Cell Movement; Cell Proliferation; Colorectal Neoplasms; Comp | 2019 |
A rectal cancer organoid platform to study individual responses to chemoradiation.
Topics: Animals; Chemoradiotherapy; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Mice; Neoplasm Me | 2019 |
Addition of Bevacizumab to First-Line Palliative Chemotherapy in Patients with Metastatic Small Bowel Adenocarcinoma: A Population-Based Study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Fem | 2019 |
Effect of Early Adverse Events on Survival Outcomes of Patients with Metastatic Colorectal Cancer Treated with Ramucirumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Col | 2019 |
Dose-escalation of oxaliplatin in hemodialysis patient treated with FOLFOX therapy: A case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Colonic Neoplasms; Dose-Response Re | 2019 |
Combination of germline variations associated with survival of folinic acid, fluorouracil and irinotecan-treated metastatic colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Carboxylic Ester Hydrolases; Colorectal Neoplasms; Disease-Free Surv | 2019 |
ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cation Transport Proteins; Cell Line, Tumo | 2020 |
Combined use of
Topics: Andrographis; Animals; Antineoplastic Combined Chemotherapy Protocols; Caco-2 Cells; Cisplatin; Esop | 2019 |
Relaxin-FOLFOX-IL-12 triple combination therapy engages memory response and achieves long-term survival in colorectal cancer liver metastasis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Interle | 2020 |
Rapid response of stage IV colorectal cancer with APC/TP53/KRAS mutations to FOLFIRI and Bevacizumab combination chemotherapy: a case report of use of liquid biopsy.
Topics: Adenomatous Polyposis Coli Protein; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bev | 2020 |
Model-Based Cost-Effectiveness Analysis of Panitumumab Plus FOLFIRI for the Second-Line Treatment of Patients with Wild-Type Ras Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemot | 2020 |
Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorect | 2020 |
EGFRI-associated health-related quality of life by severity of skin toxicity in metastatic colorectal cancer patients receiving epidermal growth factor receptor inhibitor target therapy.
Topics: Acneiform Eruptions; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; | 2020 |
Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Disease-Fr | 2020 |
Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Pr | 2020 |
Radiomics Response Signature for Identification of Metastatic Colorectal Cancer Sensitive to Therapies Targeting EGFR Pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Cetu | 2020 |
Disease characteristics and treatment patterns of Chinese patients with metastatic colorectal cancer: a retrospective study using medical records from China.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizu | 2020 |
Ivermectin suppresses tumour growth and metastasis through degradation of PAK1 in oesophageal squamous cell carcinoma.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Down-Regulation; | 2020 |
Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumo | 2020 |
Multi-Domain Photopatterned 3D Tumor Constructs in a Micro-Physiological System for Analysis, Quantification, and Isolation of Infiltrating Cells.
Topics: Caco-2 Cells; Cell Separation; Colonic Neoplasms; Fluorouracil; HCT116 Cells; Humans; Hydrogels; Hyd | 2020 |
Cetuximab Maintenance Therapy in Patients with Unresectable Wild-Type RAS and BRAF Metastatic Colorectal Cancer: A Single-Institute Prospective Study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neopl | 2020 |
Roles of a TMPO-AS1/microRNA-200c/TMEFF2 ceRNA network in the malignant behaviors and 5-FU resistance of ovarian cancer cells.
Topics: Animals; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene Expr | 2020 |
Enalapril overcomes chemoresistance and potentiates antitumor efficacy of 5-FU in colorectal cancer by suppressing proliferation, angiogenesis, and NF-κB/STAT3-regulated proteins.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Movement; Cell Proliferation; Color | 2020 |
Topical aloe vera for the treatment of cetuximab-related acneiform rash in colorectal cancer: A case report.
Topics: Acneiform Eruptions; Adenocarcinoma; Administration, Topical; Aloe; Antineoplastic Agents; Antineopl | 2021 |
DJ‑1 is a new prognostic marker and predicts chemotherapy efficacy in colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2020 |
How we treat left-sided vs right-sided colon cancer.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizu | 2020 |
Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Bi | 2020 |
EGFR inhibition in colorectal cancer with liver metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; ErbB Receptors; Female; Fluoro | 2020 |
Complete Metabolic Response Assessed by FDG PET/CT to FOLFOXIRI-Bevacizumab in First-Line Treatment of BRAFV600E Mutated Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neo | 2020 |
NKX6.1 Represses Tumorigenesis, Metastasis, and Chemoresistance in Colorectal Cancer.
Topics: Animals; Biomarkers, Tumor; Carcinogenesis; Cell Line, Tumor; Cell Movement; Cell Transformation, Ne | 2020 |
Association of C677T and A1298C
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Ne | 2020 |
Functional loss of TAGLN inhibits tumor growth and increases chemosensitivity of non-small cell lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Epithe | 2020 |
3D printed intelligent scaffold prevents recurrence and distal metastasis of breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Chemoth | 2020 |
The economic burden of metastatic pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cost of Illne | 2020 |
Cost-effectiveness analysis of nab-paclitaxel plus gemcitabine versus folfirinox in the treatment of metastatic pancreatic cancer in china.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; China; Cost-Benefit Analysis; Deoxycytidin | 2021 |
Effectiveness of Combining Bevacizumab With First-Line Chemotherapy Regimens for Metastatic Colorectal Cancer in Real-World Practice.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B | 2021 |
Evaluation of metronomic chemotherapy response using diffusion and dynamic contrast-enhanced MRI.
Topics: Administration, Metronomic; Animals; Antimetabolites, Antineoplastic; Case-Control Studies; Contrast | 2020 |
Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Female; Flu | 2021 |
Early hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor inhibitors as second-line chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2021 |
The effectiveness of cetuximab and panitumumab when combined with FOLFIRI in second-line treatment of KRAS wild type metastatic colorectal cancers. Single centre experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemot | 2021 |
Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Hepatocellular; C | 2021 |
Cetuximab versus bevacizumab following prior FOLFOXIRI and bevacizumab in postmenopausal women with advanced KRAS and BRAF wild-type colorectal cancer: a retrospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Cetuximab; Col | 2021 |
Impact of Anti-angiogenic Agents on Chemotherapy Efficacy in Patients With Metastatic Colorectal Cancer: Second-line FOLFIRI Plus Bevacizumab or Aflibercept.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combi | 2021 |
Evaluation of the Cost-effectiveness of Doublet Therapy in Metastatic BRAF Variant Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carbamates; Cetuximab; Colorectal Neoplasms; Cost-Be | 2021 |
GABA-producing Lactobacillus plantarum inhibits metastatic properties and induces apoptosis of 5-FU-resistant colorectal cancer cells via GABA
Topics: Antineoplastic Agents; Apoptosis; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; gam | 2021 |
Inhibition of chaperone‑mediated autophagy reduces tumor growth and metastasis and promotes drug sensitivity in colorectal cancer.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Chaperone-Mediated Autophagy; Colorectal Neoplasms; | 2021 |
N-acylsphingosine amidohydrolase 1 promotes melanoma growth and metastasis by suppressing peroxisome biogenesis-induced ROS production.
Topics: Acid Ceramidase; Animals; Carcinogenesis; Cell Line, Tumor; Ceramides; E2F1 Transcription Factor; Fl | 2021 |
Effect of oxaliplatin plus 5-fluorouracil or capecitabine on circulating and imaging biomarkers in patients with metastatic colorectal cancer: a prospective biomarker study.
Topics: Aged; Biomarkers, Tumor; Capecitabine; Female; Fluorouracil; Humans; Male; Neoplasm Metastasis; Oxal | 2021 |
Efficacy of FOLFOX Chemotherapy in Metastatic Enteropancreatic Neuroendocrine Tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil | 2021 |
GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals.
Topics: Adenocarcinoma; Adenylate Kinase; Antineoplastic Agents; bcl-X Protein; Berberine; Biphenyl Compound | 2021 |
Comparison of Treatment Outcomes Between Gemcitabine With Nab-Paclitaxel and Modified FOLFIRINOX for First-Line Chemotherapy in Metastatic and Recurrent Pancreatic Cancer: Propensity Score Matching.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Anemia; Antineoplastic Combined Chemotherapy Protocols; De | 2021 |
Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; | 2021 |
Anacardic Acids from
Topics: Anacardiaceae; Anacardic Acids; Animals; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Carbop | 2021 |
Risk-benefit Analysis of FOLFIRI Plus Ramucirumab/Aflibercept as a Third-line Treatment in Metastatic Colorectal Cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camp | 2021 |
Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal N | 2021 |
Economic Evaluation of Adding Bevacizumab to Chemotherapy for Metastatic Colorectal Cancer (mCRC) Patients in Indonesia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Cos | 2021 |
Astonishing response to Cetuximab in metastatic nasopharyn- geal carcinoma: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Cisplatin; Fluorouracil; Humans; Male; Mi | 2021 |
Does docetaxel matter in metastatic gastric cancer? FOLFOX versus FLOT regimens as first-line treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophagogastric Junction; Female; F | 2022 |
Clinical Benefit of Therapeutic Drug Monitoring in Colorectal Cancer Patients Who Received Fluorouracil-Based Chemotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Cu | 2021 |
Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxyc | 2021 |
Survival and Predictive Factors of Chemotherapy With FOLFIRINOX as First-Line Therapy in Metastatic Pancreatic Cancer: A Retrospective Multicentric Analysis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H | 2021 |
Determination of therapeutic agents efficiencies of microsatellite instability high colon cancer cells in post-metastatic liver biochip modeling.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Screening Assays, Antitumor; | 2021 |
Anti-metastatic Efficacy of Traditional Chinese Medicine (TCM) Ginsenoside Conjugated to a VEFGR-3 Antibody on Human Gastric Cancer in an Orthotopic Mouse Model.
Topics: Animals; Antibodies; Antineoplastic Agents; Cell Line, Tumor; Drugs, Chinese Herbal; Female; Fluorou | 2017 |
Development and Applicability of Integrative Tumor Response Assays for Metastatic Colorectal Cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2017 |
Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: Using cumulative relative dose intensity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Ch | 2017 |
All-trans retinoic acid suppresses the angiopoietin-Tie2 pathway and inhibits angiogenesis and metastasis in esophageal squamous cell carcinoma.
Topics: Angiopoietin-1; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Mov | 2017 |
Timing of chemotherapy-induced neutropenia predicts prognosis in metastatic colon cancer patients: a retrospective study in mFOLFOX6 -treated patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Disease-Free Surviva | 2017 |
The adjuvant value of Andrographis paniculata in metastatic esophageal cancer treatment - from preclinical perspectives.
Topics: Adjuvants, Pharmaceutic; Andrographis; Animals; Antineoplastic Agents; Caco-2 Cells; Cell Line, Tumo | 2017 |
Patterns of Chemotherapy Use in a U.S.-Based Cohort of Patients with Metastatic Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Proto | 2017 |
Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials, Phas | 2017 |
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; | 2017 |
Posterior Reversible Encephalopathy Syndrome During Treatment with Aflibercept, 5-Fluorouracil, Leucovorin, and Irinotecan for Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Colorectal Neoplasms; Female; Fluoro | 2019 |
Discordance in RAS mutations between primary colon tumor and metastases: a real event or a matter of methodology?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Exons; Fluorouracil; Humans | 2017 |
The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab.
Topics: Adult; Aged; Cetuximab; Female; Fluorouracil; Genotype; Humans; Male; Middle Aged; Neoplasm Metastas | 2018 |
Neoadjuvant Treatment With Trastuzumab and FOLFOX Induces a Complete Pathologic Response in a Metastatic
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Combined Modality Therapy; Duodenal Neoplasm | 2017 |
Comparison of treatment patterns and economic outcomes among metastatic pancreatic cancer patients initiated on nab-paclitaxel plus gemcitabine versus FOLFIRINOX.
Topics: Aged; Albumins; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort St | 2017 |
Induction Methotrexate, Cisplatin, and 5-Fluorouracil Versus Cisplatin and 5-Fluorouracil Followed by Radiotherapy in Pediatric Nasopharyngeal Carcinoma: A Retrospective Analysis in a Tertiary Cancer Center.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Child; Cis | 2017 |
FOLFOXIRI in metastatic colorectal cancer: A criticism from its native land.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Sur | 2017 |
Appendix 6: Cancer of the pancreas: MCBS eUpdate published online 20 June 2017 (www.esmo.org/Guidelines/Gastrointestinal-Cancers).
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Leuc | 2017 |
Impact of travel distance on access to treatment and survival in patients with metastatic colorectal cancer prescribed bevacizumab plus chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitab | 2017 |
5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) as a third-line chemotherapy treatment in metastatic gastric cancer, after failure of fluoropyrimidine, platinum, anthracycline, and taxane.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-F | 2018 |
Comparing treatment outcomes of stage IIIB cervical cancer patients between those with and without lower third of vaginal invasion.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carbopla | 2017 |
Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brazil; Capecitabine; Colonic Neoplasms | 2017 |
Effect of Adjuvant Gemcitabine Combined with Low-dose 5-Fluorouracil and Cisplatin Chemotherapy for Advanced Biliary Carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Chemotherapy, Adjuvant; C | 2017 |
Anti-Epidermal Growth Factor Receptor Antibody Readministration in Chemorefractory Metastatic Colorectal Cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; C | 2017 |
Outcomes of patients with abdominoperineal resection (APR) and low anterior resection (LAR) who had very low rectal cancer.
Topics: Anal Canal; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Digestive System Surgi | 2017 |
Complete response of metastatic gastric cancer to chemoimmunotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Fluorouracil; | 2017 |
Extreme Prostate-Specific Antigen Response to Infusional 5-Flourouracil in Castrate-Resistant Prostate Cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Fluorouracil; Humans; Male; Neoplasm Metas | 2018 |
Thymidylate synthase: a predictive biomarker in resected colorectal liver metastases receiving 5-FU treatment.
Topics: Biomarkers, Tumor; Colorectal Neoplasms; Female; Fluorouracil; Gene Expression Regulation, Neoplasti | 2018 |
The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemica | 2018 |
Lysophosphatidylcholine acyltransferase 2-mediated lipid droplet production supports colorectal cancer chemoresistance.
Topics: 1-Acylglycerophosphocholine O-Acyltransferase; Animals; Caspases; CD8-Positive T-Lymphocytes; Cell D | 2018 |
Integrated Cancer Treatment in the Course of Metastatic Pancreatic Cancer: Complete Resolution in 2 Cases.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Comb | 2018 |
FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2018 |
Triple Negative Breast Cancer Depends on Sphingosine Kinase 1 (SphK1)/Sphingosine-1-Phosphate (S1P)/Sphingosine 1-Phosphate Receptor 3 (S1PR3)/Notch Signaling for Metastasis.
Topics: Animals; Cell Line, Tumor; Doxorubicin; Drug Synergism; Female; Fluorouracil; Heterografts; Humans; | 2018 |
GDPD5, a target of miR-195-5p, is associated with metastasis and chemoresistance in colorectal cancer.
Topics: Base Sequence; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene | 2018 |
Involvement of Prokineticin 2-expressing Neutrophil Infiltration in 5-Fluorouracil-induced Aggravation of Breast Cancer Metastasis to Lung.
Topics: Animals; Breast Neoplasms; Cell Proliferation; Chemokine CXCL1; Chemokine CXCL2; Cyclophosphamide; D | 2018 |
Chemotherapy for metastatic colon cancer: No effect on survival when the dose is reduced due to side effects.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2018 |
RBFOX3 Regulates the Chemosensitivity of Cancer Cells to 5-Fluorouracil via the PI3K/AKT, EMT and Cytochrome-C/Caspase Pathways.
Topics: Animals; Antigens, Nuclear; Apoptosis; Carcinoma, Hepatocellular; Caspases; Cell Line, Tumor; Cell M | 2018 |
Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemci | 2018 |
Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: A population-based outcomes study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Databases, Factual; Disease-Free Survival; Doc | 2018 |
Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer.
Topics: Adult; Albumins; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Cost-Benef | 2018 |
Manuka honey synergistically enhances the chemopreventive effect of 5-fluorouracil on human colon cancer cells by inducing oxidative stress and apoptosis, altering metabolic phenotypes and suppressing metastasis ability.
Topics: Apoptosis; Cell Movement; Cell Proliferation; Colonic Neoplasms; Drug Synergism; Fluorouracil; Gene | 2018 |
Impact of Time to Start Systemic Therapy on the Outcomes of Patients with Metastatic Colorectal Cancer Treated with First Line FOLFOX Chemotherapy; a Patient-Level Pooled Analysis of Two Clinical Trials.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevaciz | 2018 |
Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2018 |
Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2018 |
Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2018 |
Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2018 |
Retrospective study on efficacy of a paclitaxel combined with a leucovorin and fluorouracil regimen for advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluo | 2019 |
Impact of diabetes comorbidity on the efficacy and safety of FOLFOX first-line chemotherapy among patients with metastatic colorectal cancer: a pooled analysis of two phase-III studies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Colorecta | 2019 |
Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Colorectal Neoplasms; Female; Fluo | 2018 |
Chemotherapy and biologic use in the routine management of metastatic colorectal cancer in Australia: is clinical practice following the evidence?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemoth | 2019 |
A new chalcone derivative, 3-phenyl-1-(2,4,6-tris(methoxymethoxy)phenyl)prop-2-yn-1-one), inhibits phorbol ester-induced metastatic activity of colorectal cancer cells through upregulation of heme oxygenase-1.
Topics: Cell Movement; Cell Proliferation; Chalcone; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor | 2018 |
A population-based outcomes study of patients with metastatic gastric cancer receiving second-line chemotherapy: A nationwide health insurance database study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Patients with hMLH1 or/and hMSH2-deficient Metastatic Colorectal Cancer Are Associated with Reduced Levels of Vascular Endothelial Growth Factor-1 Expression and Higher Response Rate to Irinotecan-based Regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2018 |
Treatment patterns and outcomes among patients with recurrent/metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemot | 2019 |
MEK inhibitor enhanced the antitumor effect of oxaliplatin and 5‑fluorouracil in MEK1 Q56P‑mutant colorectal cancer cells.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Butadienes; Cell Line, Tumor; Cell Survival; C | 2019 |
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cap | 2019 |
[The inhibition of angiogenic pathway in second line treatment of metastatic colorectal cancer.]
Topics: Adenocarcinoma; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Campt | 2018 |
Dihomo-γ-linolenic acid inhibits xenograft tumor growth in mice bearing shRNA-transfected HCA-7 cells targeting delta-5-desaturase.
Topics: 8,11,14-Eicosatrienoic Acid; Animals; Antineoplastic Combined Chemotherapy Protocols; Cadherins; Cap | 2018 |
Population pharmacokinetic model of irinotecan and its metabolites in patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2019 |
Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinica | 2019 |
Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinica | 2019 |
Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinica | 2019 |
Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinica | 2019 |
Patterns of Use, Safety, and Effectiveness of Targeted Therapies in First-Line Treatment of Metastatic Colorectal Cancer According to Age: The STROMBOLI Cohort Study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Bevacizumab; Cetuximab; Cohort Studies; | 2019 |
Serine Threonine Kinase 17A Maintains the Epithelial State in Colorectal Cancer Cells.
Topics: Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Movement; Colorectal Neoplasms; Epithelial Cel | 2019 |
25-HC decreases the sensitivity of human gastric cancer cells to 5-fluorouracil and promotes cells invasion via the TLR2/NF-κB signaling pathway.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferatio | 2019 |
Predictors of toxicity-related hospitalization in four randomized studies of 5-fluorouracil-based chemotherapy in metastatic colorectal cancer.
Topics: Cohort Studies; Colorectal Neoplasms; Female; Fluorouracil; Hospitalization; Humans; Logistic Models | 2019 |
Prospective Observational Cohort Study to Describe the Use of Panitumumab in Combination with Chemotherapy in Real-World Clinical Practice for Patients with Wild-Type RAS mCRC.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; C | 2019 |
Ten-year outcome of curative "exclusive" chemotherapy in N0M0 squamous cell carcinoma of the larynx and pharynx with complete clinical response.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2019 |
Aurora kinase A induces chemotherapy resistance through revival of dormant cells in laryngeal squamous cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Aurora Kinase A; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell M | 2019 |
The addition of chemotherapy to radiotherapy did not reduce the rate of distant metastases in low-risk HPV-related oropharyngeal cancer in a real-world setting.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiothe | 2019 |
Dietary Methionine Restriction-Based Cancer Chemotherapy in Rodents.
Topics: Animals; Cell Cycle; Cell Line, Tumor; Cisplatin; Coculture Techniques; Diet; Doxorubicin; Ethionine | 2019 |
Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Breast Neoplasms, | 2019 |
Clinical outcomes of platinum-based chemotherapy plus cetuximab for recurrent or metastatic squamous cell carcinoma of the head and neck: comparison between platinum-sensitive and platinum-resistant patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Cohort Studies; D | 2019 |
Translating landmark trial-based evidence to the front lines of care for pancreatic cancer: the evolving trial-based and guideline-supported role for nanoliposomal topoisomerase inhibitors in metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Le | 2018 |
New guideline-sanctioned and emerging interventions for pancreatic cancer.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical | 2018 |
Identifying ideal candidates for nanoliposomal topoisomerase inhibitors in metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Le | 2018 |
A treatment landscape in evolution: new strategies, guidelines, and therapeutic advances for metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deo | 2018 |
Pathological complete response may underestimate distant metastasis in locally advanced rectal cancer following neoadjuvant chemoradiotherapy and radical surgery: Incidence, metastatic pattern, and risk factors.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain N | 2019 |
Utilisation of systemic therapy options in routine treatment of metastatic colorectal cancer in Australia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Australia; Bevacizum | 2020 |
Cytoplasmic E-Cadherin Expression Is Associated With Higher Tumour Level of VEGFA, Lower Response Rate to Irinotecan-based Treatment and Poorer Prognosis in Patients With Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomar | 2019 |
Central venous catheter misplaced in the epidural space.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Catheterization, Central Venous; Centra | 2019 |
CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Car | 2019 |
Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2019 |
Conversion Surgery for Metastatic Pancreatic Mucinous Carcinoma Responsive to Systemic Chemotherapy with Modified FOLFIRINOX: A Case Report.
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Endoscopic Ultrasound-Guid | 2019 |
Impact of locoregional irradiation in patients with upfront metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Cisplatin; Fema | 2019 |
Spontaneous regression of pancreatic cancer with liver metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Female; Fluorouracil; | 2019 |
Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase III as Topic; Cost | 2019 |
Achieving a Complete Clinical Response After Neoadjuvant Chemoradiation That Does Not Require Surgical Resection: It May Take Longer Than You Think!
Topics: Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Female; Fluorouracil; Humans; Ma | 2019 |
Sarcopenia supersedes subjective global assessment as a predictor of survival in colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2019 |
Prognostic factors in metastatic gastric carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combi | 2019 |
IPO5 promotes the proliferation and tumourigenicity of colorectal cancer cells by mediating RASAL2 nuclear transportation.
Topics: Active Transport, Cell Nucleus; Adult; Aged; Animals; beta Karyopherins; Carrier Proteins; Cell Line | 2019 |
IKKα Kinase Regulates the DNA Damage Response and Drives Chemo-resistance in Cancer.
Topics: Animals; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Fluorouracil; HCT116 Cells; Humans; I-ka | 2019 |
Sinusoidal Obstruction Syndrome and Postoperative Complications Resulting from Preoperative Chemotherapy for Colorectal Cancer Liver Metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Dise | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug- | 2019 |
MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer.
Topics: Aged; Biomarkers, Pharmacological; Capecitabine; Clinical Trials, Phase III as Topic; Colorectal Neo | 2013 |
Aflibercept.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Cl | 2013 |
Chemotherapy ± cetuximab modulates peripheral immune responses in metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2013 |
Advancements in the management of pancreatic cancer: 2013.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant | 2013 |
ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarke | 2013 |
A novel therapeutic combination approach for treating multiple vemurafenib-induced keratoacanthomas: systemic acitretin and intralesional fluorouracil.
Topics: Acitretin; Aged; Antineoplastic Agents; Drug Therapy, Combination; Fluorouracil; Humans; Indoles; In | 2013 |
Expression of ABCG2 associated with tumor response in metastatic colorectal cancer patients receiving first-line FOLFOX therapy--preliminary evidence.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette | 2013 |
Response to chemotherapy in metastatic colorectal cancer after exposure to oxaliplatin in the adjuvant setting.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2013 |
Modern multidisciplinary treatment of rectal cancer based on staging with magnetic resonance imaging leads to excellent local control, but distant control remains a challenge.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine | 2013 |
Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
Chemotherapy and resection for gastric cancer with synchronous liver metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations | 2013 |
Retrospective analysis of survival benefits of chemotherapy for metastatic or non-resectable intrahepatic cholangiocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; | 2013 |
How do we optimally use cetuximab in first-line treatment for metastatic colorectal cancer?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cet | 2013 |
Establishment of a predictive genetic model for estimating chemotherapy sensitivity of colorectal cancer with synchronous liver metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 2013 |
Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophagogastric Jun | 2014 |
A bioengineered metastatic pancreatic tumor model for mechanistic investigation of chemotherapeutic drugs.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bioengineering; Camp | 2013 |
Mitomycin-C and capecitabine (MIXE) as salvage treatment in patients with refractory metastatic colorectal cancer: a retrospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2013 |
FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2013 |
Contradictory KRAS mutation test results in a patient with metastatic colon cancer: a clinical dilemma in the era of personalized medicine.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2013 |
Visualising and quantifying angiogenesis in metastatic colorectal cancer : A comparison of methods and their predictive value for chemotherapy response.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cape | 2013 |
Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Hum | 2013 |
[Second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer after resection of the primary lesion].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2013 |
Safety and efficacy of modified FOLFOX6 plus high-dose bevacizumab in second-line or later treatment of patients with metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2013 |
Retrospective analysis on the efficacy of bevacizumab with FOLFOX as a first-line treatment in Japanese patients with metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic | 2014 |
Platinum-sensitivity in metastatic colorectal cancer: towards a definition.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease | 2013 |
A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Deoxycytidine; Dise | 2013 |
Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Camptothecin; Col | 2013 |
Stem cell-like side populations in esophageal cancer: a source of chemotherapy resistance and metastases.
Topics: Adenocarcinoma; Animals; Antimetabolites; Antineoplastic Agents; ATP Binding Cassette Transporter, S | 2014 |
Prognostic factors of metastatic or recurrent esophageal squamous cell carcinoma in patients receiving three-drug combination chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel | 2013 |
53BP1 sensitizes breast cancer cells to 5-fluorouracil.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Surv | 2013 |
Oxaliplapin and capecitabine (XELOX) based chemotherapy in the treatment of metastatic colorectal cancer: the right choice in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Ne | 2013 |
Oxaliplatin-based chemotherapy in patients aged 75 years or older with metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2013 |
Prognostic factors for 60-day mortality in first-line treatment of metastatic colorectal cancer (mCRC): individual patient analysis of four randomised, controlled trials by the AIO colorectal cancer study group.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under | 2013 |
Prognostic value of tumor volume for patients with nasopharyngeal carcinoma treated with concurrent chemotherapy and intensity-modulated radiotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplati | 2014 |
Two-week combination chemotherapy with gemcitabine, high-dose folinic acid and 5 fluorouracil (GEMFUFOL) as first-line treatment of metastatic biliary tract cancers.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2013 |
Comparison of two preoperative chemoradiotherapy regimens for locally advanced rectal cancer: capecitabine alone versus capecitabine plus irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2013 |
C-reactive protein is a negative independent factor in patients with stage IV colorectal cancer undergoing oxaliplatin-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
Non-randomized comparison between irinotecan plus mitomycin C and irinotecan alone in patients with advanced gastric cancer refractory to fluoropyrimidine and platinum.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2013 |
Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2014 |
Complete response of primary bladder adenocarcinoma with the FOLFOX4 regimen.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Immunoh | 2015 |
Optimal tolerability and high efficacy of a modified schedule of lapatinib-capecitabine in advanced breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca | 2014 |
Predicting distant metastasis and chemoresistance using plasma miRNAs.
Topics: Antineoplastic Agents; Case-Control Studies; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female | 2014 |
[Value of postoperative adjuvant chemotherapy in locally advanced rectal cancer patients with ypT1-4N0 after neo-adjuvant chemoradiotherapy].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2013 |
Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cass | 2014 |
Loss of Smad4 in colorectal cancer induces resistance to 5-fluorouracil through activating Akt pathway.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis Regulatory Proteins; Cell Cycle Proteins; Cell L | 2014 |
[Neoadjuvant chemotherapy with capecitabine plus oxaliplatin and bevacizumab for the treatment of patients with resectable metastatic colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo | 2013 |
[A case in which chemotherapy-resistant sigmoid colon cancer was controlled effectively by radiotherapy and resection].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cape | 2013 |
[Protocol for the administration of modified FOLFOX6 (mFOLFOX6) in patients with unresectable/recurrent colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2013 |
Retrospective comparison of CAPOX and FOLFOX dose intensity, toxicity, and clinical outcomes in the treatment of metastatic colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Deoxycytidine; Dose | 2014 |
Complete pathological response in a patient with metastatic esophageal cancer treated with a regimen of capecitabine, oxaliplatin and docetaxel: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Esophageal N | 2014 |
Thymidylate synthase polymorphism in sporadic colorectal and gastric cancer in Tunisian population: a predictive role in 5-fluorouracil based chemotherapy treatment.
Topics: 3' Untranslated Regions; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Case-Contr | 2014 |
Bevacizumab efficacy in metastatic colorectal cancer is dependent on primary tumor resection.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2014 |
Sequential TPF chemotherapy followed by concurrent chemoradiotherapy in locally advanced head and neck cancer--a retrospective analysis of toxicity and outcomes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Chemoradiotherapy; Cisplatin | 2014 |
Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Pr | 2014 |
The circadian rest-activity rhythm, a potential safety pharmacology endpoint of cancer chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Circad | 2014 |
Low-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dose-R | 2014 |
The feasibility of a short bevacizumab infusion in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2014 |
Safety and efficacy of FOLFOX followed by cetuximab for metastatic colorectal cancer with severe liver dysfunction.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; | 2014 |
Prognostic value of chemotherapy-induced hematological toxicity in metastatic colorectal cancer patients.
Topics: Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Databases, Factual; Female; Fluorou | 2014 |
Impact of pre-angiogenic factors on the treatment effect of bevacizumab in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Antibodies, Mono | 2014 |
Updates on first-line therapy for metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cam | 2014 |
Clinical significance of primary tumor resection in colorectal cancer patients with synchronous unresectable metastasis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asymptomatic Dis | 2014 |
Oral chemotherapy in elderly women with metastatic breast cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B | 2014 |
Prognostic factors for metastatic colorectal cancer after first-line chemotherapy with FOLFOX-4 or FOLFIRI regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2014 |
A case report--treatment of metastatic colorectal cancer in a patient on hemodialysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2014 |
Lack of prognostic value of mean corpuscular volume with capecitabine therapy in metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Car | 2014 |
[Bevacizumab-induced reversible posterior leukoencephalopathy syndrome in a patient with metastatic colorectal cancer].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Anticonvulsants; Antihypertensive Agents; A | 2014 |
[Outcome and prognostic factors of 125 loco-regionally advanced head and neck squamous cell carcinoma treated with multi-modality treatment].
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carc | 2014 |
Efficacy of hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic pegylated interferon α-2b for advanced intrahepatic cholangiocarcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antivi | 2014 |
Increased mean corpuscular volume of red blood cells in patients treated with capecitabine for advanced breast and colon cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colonic Neoplasms; Deoxycytid | 2013 |
RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colore | 2014 |
The predictive and prognostic value of the Glasgow Prognostic Score in metastatic colorectal carcinoma patients receiving bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2014 |
Effect of long interval between hyperthermochemoradiation therapy and surgery for rectal cancer on apoptosis, proliferation and tumor response.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Prolife | 2014 |
FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucovorin; Male | 2014 |
Relationship of body mass index with prognosis in breast cancer patients treated with adjuvant radiotherapy and chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2014 |
An effective and well-tolerated strategy in recurrent and/or metastatic head and neck cancer: successive lines of active chemotherapeutic agents.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineopla | 2014 |
The role of adjuvant chemotherapy in stage II colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2014 |
Unbiased proteomic and transcript analyses reveal that stathmin-1 silencing inhibits colorectal cancer metastasis and sensitizes to 5-fluorouracil treatment.
Topics: Antimetabolites, Antineoplastic; Cell Proliferation; Colorectal Neoplasms; Epithelial-Mesenchymal Tr | 2014 |
Metastatic colorectal cancer treatment patterns according to kirsten rat sarcoma viral oncogene homolog genotype in U.S. Community-based oncology practices.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2014 |
Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting.
Topics: Aged; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Costs and Cost Analysis; Deoxycytidine | 2014 |
Maintenance of the nutritional prognostic index predicts survival in patients with unresectable metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2015 |
[Retrospective analysis of the bevacizumab and CapeOX combination in untreated metastatic/recurrent colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2014 |
[The efficacy and safety of FOLFIRI or combined FOLFIRI and bevacizumab treatment as second-line chemotherapy for metastatic colorectal cancer patients aged 75 years and older].
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2014 |
[Cost-effectiveness analysis of aflibercept in combination with FOLFIRI in the treatment of patients with metastatic colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Ana | 2014 |
A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2014 |
Correlation between expression of thymidylate synthase and clinical outcome of advanced gastric cancer treated with capecitabine alone chemotherapy.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Female; Fluor | 2014 |
Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer.
Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Fluorouracil; Focal Adhesion Kinase 1; He | 2014 |
Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2014 |
Carcinoembryonic antigen half-life is an early predictor of therapeutic effects in induction chemotherapy for liver metastases from colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Ant | 2014 |
Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Cl | 2015 |
Concurrent chemoradiotherapy with or without induction chemotherapy versus chemotherapy alone in patients with locally advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; D | 2014 |
Potentially functional SNPs (pfSNPs) as novel genomic predictors of 5-FU response in metastatic colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2014 |
The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carb | 2014 |
Oxaliplatin-related acute disseminated intravascular coagulation syndrome in a patient with metastatic colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Disseminated Intravascular Coagul | 2015 |
Trastuzumab in advanced breast cancer--a decade of experience in Germany.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combi | 2014 |
LEIGC long non-coding RNA acts as a tumor suppressor in gastric carcinoma by inhibiting the epithelial-to-mesenchymal transition.
Topics: Adult; Aged; Aged, 80 and over; Animals; Base Sequence; Cell Line, Tumor; Cell Movement; Cell Prolif | 2014 |
Simultaneous 24 h-infusion of high-dose 5-fluorouracil and sodium-folinate as alternative to capecitabine in advanced breast cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast; Breas | 2014 |
Comparative survival effectiveness between pre-operative and postoperative chemoradiotherapy for locally advanced rectal cancer: a retrospective study in Phramongkutklao Hospital.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Combined Modalit | 2014 |
Health economic changes as a result of implementation of targeted therapy for metastatic renal cell carcinoma: national results from DARENCA study 2.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Angiogenesis Inhibitors; Antineoplastic Agents; Bev | 2015 |
[Analysis of the treatment and prognosis for gestational trophoblastic neoplasia patients with urinary system and adrenal glands metastasis].
Topics: Adrenal Gland Neoplasms; Adrenal Glands; Antineoplastic Combined Chemotherapy Protocols; China; Fema | 2014 |
Upregulation of CD147 promotes cell invasion, epithelial-to-mesenchymal transition and activates MAPK/ERK signaling pathway in colorectal cancer.
Topics: Basigin; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Epithelial-Mesenchymal T | 2014 |
MiR-145 expression accelerates esophageal adenocarcinoma progression by enhancing cell invasion and anoikis resistance.
Topics: Adenocarcinoma; Anoikis; Carcinoma, Squamous Cell; Cell Adhesion; Cell Line, Tumor; Cell Proliferati | 2014 |
XELOX plus bevacizumab vs. FOLFIRI plus bevacizumab treatment for first-line chemotherapy in metastatic colon cancer: a retrospective study of the Anatolian Society of Medical Oncology.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2014 |
Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2015 |
Should FOLFOXIRI plus bevacizumab Be the standard first-line therapy in metastatic colorectal cancer?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2015 |
Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogena | 2015 |
FOLFIRI+bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9--FFCD 0802).
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; | 2015 |
Predictive role of neutrophil gelatinase-associated lipocalin in early diagnosis of platin-induced renal injury.
Topics: Acute Kidney Injury; Acute-Phase Proteins; Adult; Aged; Antineoplastic Combined Chemotherapy Protoco | 2015 |
First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colo | 2015 |
A case of heterogeneous sensitivity to panitumumab in cetuximab-refractory colorectal adenocarcinoma metastases.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Campt | 2015 |
Genetic variations in the VEGF pathway as prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; G | 2015 |
Thymidylate synthase expression in circulating tumor cells: a new tool to predict 5-fluorouracil resistance in metastatic colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Resistan | 2015 |
[A case of metastatic rectal cancer with fulminant hepatitis caused by XELOX therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Hep | 2014 |
The cholesterol biosynthesis enzyme oxidosqualene cyclase is a new target to impair tumour angiogenesis and metastasis dissemination.
Topics: Animals; Apoptosis; Benzophenones; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferatio | 2015 |
Three-weekly oxaliplatin combined with gemcitabine and capecitabine in the first-line treatment of patients with advanced biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Ducts, Extrahep | 2015 |
Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neopla | 2015 |
Transforming growth factor-β, insulin-like growth factor I/insulin-like growth factor I receptor and vascular endothelial growth factor-A: prognostic and predictive markers in triple-negative and non-triple-negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Di | 2015 |
Comparative analysis of the efficacy and safety of oxaliplatin plus 5-fluorouracil/leucovorin (modified FOLFOX6) with advanced gastric cancer patients having a good or poor performance status.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Fema | 2015 |
[5-FU+CDDP(FP) +cetuximab in recurrence/metastasis head and neck cancer].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Cispla | 2015 |
Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cape | 2015 |
Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarke | 2015 |
Bevacizumab with FOLFIRI or XELIRI in the First-line Therapy of Metastatic Colorectal Carcinoma: Results from Czech Observational Registry.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2015 |
Aflibercept for metastatic colorectal cancer: safety data from the Spanish named patient program.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl | 2015 |
ERCC1 and TS Expression as Prognostic and Predictive Biomarkers in Metastatic Colon Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2015 |
[Clinical efficacy observation of cetuximab combined with chemotherapy in the treatment of metastatic colorectal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Ne | 2015 |
Targeting chemotherapy-induced PTX3 in tumor stroma to prevent the progression of drug-resistant cancers.
Topics: Animals; Antineoplastic Agents; Apoptosis; C-Reactive Protein; CCAAT-Enhancer-Binding Protein-delta; | 2015 |
Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia: A Population-based Retrospective Study.
Topics: Activities of Daily Living; Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplas | 2017 |
Truncating mutation in the autophagy gene UVRAG confers oncogenic properties and chemosensitivity in colorectal cancers.
Topics: Adult; Aged; Animals; Antimetabolites, Antineoplastic; Autophagy; Carcinogenesis; Cell Line, Tumor; | 2015 |
AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Clinical Trials, Pha | 2016 |
Considering Efficacy and Cost, Where Does Ramucirumab Fit in the Management of Metastatic Colorectal Cancer?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2015 |
Therapeutic efficacy and toxicity of bolus application of chemotherapy protocol in the treatment of metastatic colorectal cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; H | 2015 |
Metabolic alteration--Overcoming therapy resistance in gastric cancer via PGK-1 inhibition in a combined therapy with standard chemotherapeutics.
Topics: Adenocarcinoma; Adenoviridae; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug | 2015 |
[Cost-effectiveness Analysis of Panitumumab Plus mFOLFOX6 Compared to Bevacizumab Plus mFOLFOX6 for First-line Treatment of Patients with Wild-type RAS Metastatic Colorectal Cancer--Czech Republic Model Adaptation].
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neop | 2015 |
Intensified intensity-modulated radiotherapy in anal cancer with prevalent HPV p16 positivity.
Topics: Adult; Aged; Aged, 80 and over; Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradiotherapy; Cyclin- | 2015 |
Nuclear PRMT1 expression is associated with poor prognosis and chemosensitivity in gastric cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptosis; Biomarke | 2016 |
Cetuximab Plus Various Chemotherapy Regimens for Patients with KRAS Wild-Type Metastatic Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; | 2016 |
Circannual variation of efficacy outcomes in patients with newly diagnosed metastatic colorectal cancer and treated with first-line chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Circad | 2015 |
Chemotherapeutic agents attenuate CXCL12-mediated migration of colon cancer cells by selecting for CXCR4-negative cells and increasing peptidase CD26.
Topics: Animals; Camptothecin; Carcinogenesis; Cell Lineage; Cell Movement; Chemokine CXCL12; Colonic Neopla | 2015 |
Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Cell Line, Tumor; Colorec | 2015 |
Early Assessment of Colorectal Cancer Patients with Liver Metastases Treated with Antiangiogenic Drugs: The Role of Intravoxel Incoherent Motion in Diffusion-Weighted Imaging.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2015 |
Genetic variability of DNA repair mechanisms in chemotherapy treatment outcome of gastric cancer patients.
Topics: Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; DNA Repair; DNA-Binding Proteins; End | 2015 |
Synergistic effect of therapeutic stem cells expressing cytosine deaminase and interferon-beta via apoptotic pathway in the metastatic mouse model of breast cancer.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cytosine Deaminase; Drug Synergism; Female; | 2016 |
Prognostic significance of the pre-chemotherapy lymphocyte-to-monocyte ratio in patients with previously untreated metastatic colorectal cancer receiving FOLFOX chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati | 2016 |
Efficacy of continued cetuximab for unresectable metastatic colorectal cancer after disease progression during first-line cetuximab-based chemotherapy: a retrospective cohort study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Cohort Studies; Colorectal | 2016 |
Factors Associated with Adherence Rates for Oral and Intravenous Anticancer Therapy in Commercially Insured Patients with Metastatic Colon Cancer.
Topics: Administration, Intravenous; Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Combi | 2016 |
First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Female; F | 2016 |
[Individual Dose Adjustment of 5-Fluorouracil Based on Pharmacokinetic Monitoring May Improve the Outcome of FOLFOX for Metastatic Colorectal Cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; | 2016 |
[Adjuvant Systemic Chemotherapy with S-1/Oxaliplatin or mFOLFOX6 after Curative Resection of Distant Metastases in Patients with Colorectal Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dru | 2016 |
Clinical Outcomes in Patients with Recurrent or Metastatic Human Papilloma Virus-positive Head and Neck Cancer.
Topics: Bridged-Ring Compounds; Carcinoma, Squamous Cell; Disease-Free Survival; Fluorouracil; Follow-Up Stu | 2016 |
Safety and efficacy of aflibercept in combination with fluorouracil, leucovorin and irinotecan in the treatment of Asian patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2016 |
Effectiveness and safety of first-line bevacizumab plus FOLFIRI in elderly patients with metastatic colorectal cancer: Results of the ETNA observational cohort.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizu | 2016 |
Epidermal growth factor receptor inhibitor with fluorouracil, leucovorin, and irinotecan as an alternative treatment for advanced upper tract urothelial carcinoma: a case report.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorect | 2016 |
[Analysis of risk factors of distant metastasis in rectal cancer patients who received total mesorectal excision following neoadjuvant chemoradiotherapy].
Topics: Chemoradiotherapy; Digestive System Surgical Procedures; Fluorouracil; Humans; Neoadjuvant Therapy; | 2016 |
Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasm | 2016 |
Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Ce | 2016 |
B7-H3 upregulates BRCC3 expression, antagonizing DNA damage caused by 5-Fu.
Topics: B7 Antigens; Cell Line, Tumor; Colorectal Neoplasms; Deubiquitinating Enzymes; DNA Damage; DNA Repai | 2016 |
Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab.
Topics: Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Campt | 2016 |
Early Tumor Shrinkage and Depth of Response as Predictors of Favorable Treatment Outcomes in Patients with Metastatic Colorectal Cancer Treated with FOLFOX Plus Cetuximab (JACCRO CC-05).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Female | 2016 |
Chemotherapy use and adoption of new agents is affected by age and comorbidities in patients with metastatic colorectal cancer.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protoc | 2016 |
Oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) as second-line therapy for patients with advanced urothelial cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Sur | 2016 |
Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Angiopoietin-2; Antineoplastic Combined Chemotherapy Protocols | 2016 |
Regulation of cellular quiescence by YAP/TAZ and Cyclin E1 in colon cancer cells: Implication in chemoresistance and cancer relapse.
Topics: Adaptor Proteins, Signal Transducing; Aged; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; | 2016 |
FOLFIRI plus cetuximab in patients with liver-limited or non-liver-limited RAS wild-type metastatic colorectal cancer: A retrospective subgroup analysis of the CRYSTAL study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuxi | 2016 |
Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2016 |
Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX).
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2016 |
Paclitaxel/oxaliplatin/fluorouracil (TOF) regimen versus S-1/oxaliplatin (SOX) regimen for metastatic gastric cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Drug Combinations; F | 2017 |
Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated According to Uridine Diphosphate Glucuronosyltransferase 1A1 Genotyping in Patients With Metastatic Colorectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2017 |
Is routine use of adjuvant chemotherapy for rectal cancer with complete pathological response justified?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Disease-F | 2017 |
Prognostic and predictive significance of long interspersed nucleotide element-1 methylation in advanced-stage colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Caco-2 Cells; Cell Line, Tumor; Colorectal Neo | 2016 |
Synergistically Anti-metastatic Effect of 5-Flourouracil on Colorectal Cancer Cells via Calcium-mediated Focal Adhesion Kinase Proteolysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Calcium Compounds; Cell Death; Ce | 2017 |
Traditional Chinese medicine Jianpi Bushen therapy suppresses the onset of pre-metastatic niche in a murine model of spontaneous lung metastasis.
Topics: Animals; cdc42 GTP-Binding Protein; Cell Line, Tumor; Chemokine CXCL12; Disease Models, Animal; Drug | 2017 |
Quality of Life Analysis in Patients With RAS Wild-Type Metastatic Colorectal Cancer Treated With First-Line Cetuximab Plus Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuxi | 2017 |
IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cohort S | 2017 |
[Analysis of 5-Fluorouracil and Leucovorin Combined with Weekly Paclitaxel in Advanced Gastric Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Female; Fluorouracil; Humans; Leucovo | 2016 |
[CR of All Target Lesions in a Patient with Metastatic Esophageal Cancer and Generalized Weakness Treated with Systemic Chemotherapy after Nutritional Support].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcino | 2016 |
Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2017 |
The efficacy of modified docetaxel-cisplatin-5-fluorouracil regimen as first-line treatment in patients with alpha-fetoprotein producing gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Cis | 2017 |
Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2017 |
[A Case of Resected Advanced Esophageal Cancer That Responded to Combination Therapy Comprising Docetaxel, Cisplatin, and 5-Fluorouracil].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Fl | 2017 |
Hepatic artery infusion with raltitrexed or 5-fluorouracil for colorectal cancer liver metastasis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; He | 2017 |
Optimizing oxaliplatin-based therapy in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2008 |
Local excision of distal rectal cancer: an update of cancer and leukemia group B 8984.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2008 |
Platinum-based chemotherapy in triple-negative breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, | 2008 |
Docetaxel: new indication. Metastatic gastric cancer: keep using fluorouracil-based chemotherapy. No tangible progress.
Topics: Adenocarcinoma; Chemotherapy, Adjuvant; Drug Approval; Europe; Fluorouracil; Humans; Neoplasm Metast | 2008 |
[A case of sigmoid colon cancer with metastases of para-aortic lymph nodes treated with curative resection after irinotecan plus 5-fluorouracil and l-leucovorin combination chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Camptothecin; Female; Fluorouracil; Humans; I | 2008 |
Desensitization to oxaliplatin with two stages of premedication in a patient with metastatic rectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Desensitization, Immunologic; | 2008 |
Methotrexate and leucovorin double-modulated 5-fluorouracil combined with cisplatin (MPFL) in metastatic/recurrent head and neck cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcin | 2008 |
K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Female; Fluorouracil; Genes, ras; Humans; Leuc | 2008 |
Priorities and uncertainties of administering chemotherapy in a pregnant woman with newly diagnosed colorectal cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; H | 2009 |
Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Breast Neoplasms | 2009 |
Safety and efficacy of modified FOLFOX6 for treatment of metastatic or locally advanced colorectal cancer. A single-institution outcome study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2008 |
Efficacy and toxicity of fluorouracil, leucovorin plus oxaliplatin (FOLFOX4 and modified FOLFOX6) followed by fluorouracil, leucovorin plus irinotecan(FOLFIRI)for advanced or metastatic colorectal cancer--case studies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl | 2008 |
Complete remission of unresectable colon cancer after preoperative chemotherapy selected by adenosine triphosphate-based chemotherapy response assay.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capec | 2008 |
[Docetaxel-Cisplatin-5-Fu Combination Chemotherapy as a First-line Treatment in Patients with Metastatic or Recurred Gastric Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil; Humans; Neoplasm | 2007 |
Clinical study of combined use of tomudex (raltitrexed) and xeloda (capecitabine) as first-line treatment for patients with metastasizing colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dis | 2008 |
Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysi | 2009 |
Chemotherapy for small-bowel Adenocarcinoma at a single institution.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease P | 2009 |
Patient and practice impact of capecitabine compared to taxanes in first-/second-line chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2009 |
Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopla | 2009 |
Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2009 |
Complete peritonectomy and intraperitoneal chemotherapy for recurrent rectal cancer with peritoneal metastasis.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2009 |
Adjuvant chemoradiotherapy for high-risk pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Combined | 2009 |
Combined treatment of oxaliplatin and capecitabine in patients with metastatic esophageal squamous cell cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Deoxyc | 2009 |
The CAIRO and FOCUS studies: which lesson is to be learned?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2009 |
5 flourouracil-induced apical ballooning syndrome: a case report.
Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Coronary Disease; Female; Fluorouracil; | 2009 |
Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Body Composition; Body Mass Index; | 2009 |
Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Body Composition; Body Mass Index; | 2009 |
Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Body Composition; Body Mass Index; | 2009 |
Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Body Composition; Body Mass Index; | 2009 |
Lapatinib: new drug. For some women with metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Deoxycyt | 2009 |
Medical Oncology: Second-line XELOX or FOLFOX-4 for metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as To | 2009 |
Serum 3'-sulfo-Lea indication of gastric cancer metastasis.
Topics: Adult; Aged; Aged, 80 and over; Amino Acid Sequence; Biomarkers, Tumor; Cell Adhesion; Cell Movement | 2009 |
Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antigens, CD; Antimetabolites, Antineoplastic; Cell Line, Tumor; ErbB Recep | 2009 |
Metastasis at the site of a venous needle puncture in a patient with advanced cervical cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality The | 2009 |
Chemotherapy and immunotherapy in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2009 |
Chemotherapy and immunotherapy in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2009 |
Chemotherapy and immunotherapy in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2009 |
[Palliative chemotherapy for metastatic breast cancer with capecitabine].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2009 |
The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progressi | 2009 |
Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular | 2009 |
New perspectives in the treatment of advanced or metastatic gastric cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoplas | 2009 |
[Bevacizumab in combination with capecitabine and irinotecan (XELIRI) in treatment of metastatic colorectal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2009 |
Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Capecitabine; Cell Line, Tumor; Cell Proliferation; Color | 2009 |
Systemic administration of a PEGylated adenovirus vector with a cancer-specific promoter is effective in a mouse model of metastasis.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Combined Modality Therapy; Disease Models, Animal; Flu | 2009 |
Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; DNA-Binding Prote | 2009 |
Metastatic breast cancer survival according to HER2 and Topo2a gene status.
Topics: Adult; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pro | 2009 |
[Chemotherapy with MTX, 5-FU and CDGP for treatment of newly diagnosed head and neck cancer].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Comb | 2009 |
Heated (37 degrees C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colore | 2010 |
Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deo | 2010 |
Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2009 |
Docetaxel combined with oral etoposide as second-line treatment for advanced gastric carcinoma after failure of platinum- and fluoropyrimidine-based regimens.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2010 |
JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Colonic Neoplasms; Fluorouracil; Hist | 2009 |
Increase in E-selectin expression in umbilical vein endothelial cells by anticancer drugs and inhibition by cimetidine.
Topics: Actins; Antineoplastic Agents; Cimetidine; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; | 2009 |
[Proteomic research of biomarker of colorectal cancer metastasis].
Topics: Biomarkers, Tumor; Cell Line, Tumor; Colorectal Neoplasms; Fluorouracil; Humans; Neoplasm Metastasis | 2009 |
[A Case of gastric endocrine cell carcinoma successfully treated by FU plus irinotecan(CPT-11)adjuvant therapy against recurrent metastases].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 2009 |
Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
[Clinical impact of extracapsular extension of axillary lymph node metastases in breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Cisplatin; Combined Modali | 2009 |
Intra-arterial 5-fluorouracil/interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progressio | 2010 |
MGMT -535G>T polymorphism is associated with prognosis for patients with metastatic colorectal cancer treated with oxaliplatin-based chemotherapy.
Topics: Amino Acid Substitution; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cape | 2010 |
The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo | 2011 |
[Role of adjuvant chemotherapy in the choice of chemotherapeutic treatment of metastatic breast cancer].
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Br | 2009 |
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; | 2010 |
Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonate | 2011 |
[Efficacy of FEC and trastuzumab/docetaxel combination therapy for metastatic breast cancer].
Topics: Adenocarcinoma, Scirrhous; Adult; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, M | 2010 |
A case with cardiac tamponade as the first sign of primary gastric signet-ring cell carcinoma treated with combination therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Cardiac Tamponade; Drug | 2010 |
Moderate dose capecitabine in older patients with metastatic breast cancer: a standard option for first line treatment?
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytid | 2010 |
[More effective positioning of capecitabine for advanced and metastatic breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine | 2010 |
Cost analysis of capecitabine vs 5-fluorouracil-based treatment for metastatic colorectal cancer patients.
Topics: Age Factors; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Cost-Benefit Analy | 2010 |
Autocrine induction of invasive and metastatic phenotypes by the MIF-CXCR4 axis in drug-resistant human colon cancer cells.
Topics: Animals; Colonic Neoplasms; Doxorubicin; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Pr | 2010 |
[Investigation of FOLFIRI/FOLFOX (+/-bevacizumab) therapy for patients with metastatic colorectal cancer in our hospital].
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2010 |
The importance of release of proinflammatory cytokines, ROS, and NO in different stages of colon carcinoma growth and metastasis after treatment with cytotoxic drugs.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Coculture Techniques; | 2010 |
VEGF -460T → C polymorphism and its association with VEGF expression and outcome to FOLFOX-4 treatment in patients with colorectal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; Female; Fluo | 2011 |
NICE rejects drug for metastatic breast cancer because of cost and poor efficacy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cost-Benefit Analysi | 2010 |
[Adjuvant chemotherapy in older women with breast cancer. CALGB Study (The Cancer and Leukemia Group B Study)].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2010 |
[Bevacizumab in combination with mFOLFOX6 or FOLFIRI for previously treated metastatic colorectal cancer].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2010 |
Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Pr | 2011 |
Clinical and economic evaluation of first-line therapy with FOLFIRI or modified FOLFOX6 for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Costs and Cost A | 2010 |
Plasma TIMP-1 levels and treatment outcome in patients treated with XELOX for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colore | 2011 |
Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; | 2010 |
Multi-modality therapy for metastatic colorectal cancer-ready for prime time?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Appendicitis; Colectomy; Colonoscopy | 2010 |
Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcin
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; | 2010 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Da | 2011 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Da | 2011 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Da | 2011 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Da | 2011 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Da | 2011 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Da | 2011 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Da | 2011 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Da | 2011 |
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Da | 2011 |
Eradication of EGFR-positive circulating tumor cells and objective tumor response with lapatinib and capecitabine.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2010 |
Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neop | 2010 |
Evaluation of the combination 5-fluorouracil, dacarbazine, and epirubicin in patients with advanced well-differentiated neuroendocrine tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedu | 2010 |
A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2010 |
Efficacy of S-1 in patients with capecitabine-resistant breast cancer-Japan Breast Cancer Research Network (JBCRN) 04-1 trial.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Surv | 2010 |
Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antimetabolites, Antineoplastic; Antineoplastic Agent | 2010 |
Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neo | 2011 |
Detection of circulating tumor cells is improved by drug-induced antigen up-regulation: preclinical and clinical studies.
Topics: Aged; Aged, 80 and over; Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Biomarker | 2010 |
XELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2010 |
Treatment patterns and metastasectomy among mCRC patients receiving chemotherapy and biologics.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biologic | 2011 |
CA 19-9 level as indicator of early distant metastasis and therapeutic selection in resected pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols | 2011 |
Safety of 10 min infusion of bevacizumab in combination with 5FU-based chemotherapy in non-selected metastatic colorectal cancer patients.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabo | 2011 |
RGD modified albumin nanospheres for tumour vasculature targeting.
Topics: Animals; Antimetabolites, Antineoplastic; Cattle; Cells, Cultured; Drug Carriers; Drug Delivery Syst | 2011 |
Hepar lobatum carcinomatosum associated with metastatic rectal carcinoma: an unusual cause of liver dysmorphy.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Fluorouracil; Humans; Liver; Liver Neoplasms; Male; | 2011 |
Thymidylate synthase and thymidine phosphorylase as predictive markers of capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineopl | 2011 |
Circulating endothelial cells predict for response to bevacizumab-based chemotherapy in metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Hu | 2011 |
Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2011 |
Chemotherapy for metastatic breast cancer. Comparison of clinical practice and cost of drugs in two cohorts of patients: 1994-1998 and 2003-2006.
Topics: Adult; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; C | 2011 |
Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2011 |
Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2011 |
[Our experiences of XELOX + bevacizumab for two cases of metastatic sigmoid colon cancer].
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopla | 2010 |
Changing management and survival in patients with stage IV colorectal cancer.
Topics: Adenocarcinoma; Aged; Anastomosis, Surgical; Antineoplastic Agents; Australia; Camptothecin; Capecit | 2011 |
Smad4 inactivation promotes malignancy and drug resistance of colon cancer.
Topics: Cell Hypoxia; Cell Movement; Cell Transformation, Neoplastic; Colonic Neoplasms; Drug Resistance, Ne | 2011 |
Analysis of tumor burden versus progression-free survival for Phase II decision making.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, | 2011 |
Increased expression of P-glycoprotein is associated with doxorubicin chemoresistance in the metastatic 4T1 breast cancer model.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Line, T | 2011 |
Antitumor effect of Croatian propolis as a consequence of diverse sex-related dihydropyrimidine dehydrogenase (DPD) protein expression.
Topics: Animals; Antineoplastic Agents; Chromatography, High Pressure Liquid; Dihydrouracil Dehydrogenase (N | 2011 |
Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2011 |
Pharmacometabonomic profiling as a predictor of toxicity in patients with inoperable colorectal cancer treated with capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Pharmacological; Capeci | 2011 |
Retinal vein thrombosis in a patient with metastatic colon cancer receiving XELOX chemotherapy combined with bevacizumab pre-hepatic resection.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cape | 2012 |
Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as T | 2011 |
Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2011 |
[PSK decreased FOLFOX4-induced peripheral neuropathy and bone marrow suppression in patients with metastatic colorectal cancer].
Topics: Agaricales; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Co | 2011 |
Combined high-dose radiation therapy and systemic chemotherapy improves survival in patients with newly diagnosed metastatic nasopharyngeal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemothe | 2012 |
Comparison of cisplatin-5-fluorouracil-folinic acid versus modified docetaxel-cisplatin-5-fluorouracil regimens in the first-line treatment of metastatic gastric cancer.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fema | 2011 |
Prognostic value of reduced SMAD4 expression in patients with metastatic colorectal cancer under oxaliplatin-containing chemotherapy: a translational study of the AIO colorectal study group.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Capecitabine; Colorectal Neoplasms; Deoxycytidin | 2011 |
Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; | 2012 |
FOLFOX as adjuvant chemotherapy after curative resection of distant metastases in patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2011 |
Overexpression of neurone glial-related cell adhesion molecule is an independent predictor of poor prognosis in advanced colorectal cancer.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Cell Adhesion Molecules; Colorectal Neoplasms; Female; F | 2011 |
Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Comb | 2011 |
Efficacy of concurrent chemoradiotherapy as a palliative treatment in stage IVB esophageal cancer patients with dysphagia.
Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous C | 2011 |
TS and ERCC-1 mRNA expressions and clinical outcome in patients with metastatic colon cancer in CONFIRM-1 and -2 clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; D | 2012 |
A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antineoplastic Combined Chemot | 2012 |
Discrepancy between the NCI-CTCAE and DEB-NTC scales in the evaluation of oxaliplatin-related neurotoxicity in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Co | 2012 |
The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Do | 2012 |
Circulating endothelial progenitors and CXCR4-positive circulating endothelial cells are predictive markers for bevacizumab.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2011 |
Clinical efficacy of capecitabine and cyclophosphamide (XC) in patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; | 2011 |
An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2012 |
Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antineoplastic Agents; Chemoradiot | 2011 |
The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca | 2012 |
[FOLFOX as adjuvant chemotherapy after curative resection of distant metastatic lesions in patients with colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2011 |
TS and DPD mRNA levels on formalin-fixed paraffin-embedded specimens as predictors for distant recurrence of rectal cancer treated with preoperative chemoradiotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Dihydrouracil Dehydrogenase (NADP); | 2012 |
Prolonged survival of patients with metastatic colorectal cancer following first-line oxaliplatin-based chemotherapy with molecular targeting agents and curative surgery.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2011 |
Efficacy of oxaliplatin-based chemotherapy in curatively resected colorectal cancer with liver metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2011 |
C-myc as a predictive marker for chemotherapy in metastatic breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; | 2012 |
Safety and outcome of chemoradiotherapy in elderly patients with rectal cancer: results from two French tertiary centres.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiotherapy, Adjuvant; Deoxycyti | 2012 |
Chemotherapy with modified docetaxel, cisplatin, and 5-fluorouracil in patients with metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Docetax | 2012 |
Patterns of treatment with chemotherapy and monoclonal antibodies for metastatic colorectal cancer in Western Europe.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combin | 2012 |
Single-agent paclitaxel in advanced anal cancer after failure of cisplatin and 5-fluorouracil chemotherapy.
Topics: Adult; Antineoplastic Agents; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Disease Progressi | 2011 |
Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV stud
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort | 2012 |
[Development of oral drugs in the standard therapy for metastatic colorectal cancer patients].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, | 2011 |
Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy.
Topics: AC133 Antigen; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antigens, CD; Beva | 2013 |
Increased pretreatment levels of serum LDH and ALP as poor prognostic factors for nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Child | 2012 |
A WKYMVm-containing combination elicits potent anti-tumor activity in heterotopic cancer animal model.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Animals; Antineoplastic Agents; Apoptosis; Cancer Vaccines; | 2012 |
Absence of transcriptomic signature of response to chemotherapy in metastatic colorectal carcinoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Camptothec | 2012 |
Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2012 |
Clinical roundtable monograph. Current treatment options for metastatic breast cancer: what now?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineo | 2011 |
Current treatment options for metastatic breast cancer: what now?
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neopl | 2011 |
Feasibility of mFOLFOX6 as the adjuvant treatment after curative resection of metastases from colorectal cancer in Japanese patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2013 |
Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Co | 2012 |
Bevacizumab as a second- or later-line of treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2012 |
[A case of gastric cancer treated with modified docetaxel, cisplatin and 5-fluorouracil(mDCF)with ingestion inability].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxe | 2012 |
Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycy | 2012 |
Conventional chemotherapy of advanced pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clini | 2012 |
Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Disea | 2012 |
Dose-modified XELIRI chemotherapy for metastatic colorectal cancer--a retrospective study of 78 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; De | 2012 |
Evaluations of biomarkers associated with sensitivity to 5-fluorouracil and taxanes for recurrent/advanced breast cancer patients treated with capecitabine-based first-line chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; D | 2012 |
The prognostic significance of HER2 positivity for advanced gastric cancer patients undergoing first-line modified FOLFOX-6 regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Female; Fluorouracil; G | 2012 |
Design, synthesis, and activity evaluation of a new 5-fluorouracil prodrug containing an Asn-Gly-Arg(NO2)COOCH3 tripeptide.
Topics: Animals; Antimetabolites, Antineoplastic; CD13 Antigens; Cell Movement; Cells, Cultured; Collagen; D | 2012 |
Expression of ERCC1 predicts clinical outcome in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biomarkers, Tumor; Cisplatin; D | 2012 |
Comparative label-free LC-MS/MS analysis of colorectal adenocarcinoma and metastatic cells treated with 5-fluorouracil.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antioxidants; Cell Adhesion; Cell Line, Tumor; Chro | 2012 |
Astrocyte elevated gene-1 promotes hepatocarcinogenesis: novel insights from a mouse model.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Adhesion Molecules; Cell Transformat | 2012 |
Effects of reduced dose intensity of modified FOLFOX6 in patients with metastatic or recurrent colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Hu | 2011 |
A risk score based on histopathological features predicts higher risk of distant recurrence in premenopausal patients with lymph node-negative endocrine-responsive breast cancer.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 2012 |
Cell fusion promotes chemoresistance in metastatic colon carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Cattle; Cell Fusion; Colonic Neoplasms; Drug Resistance, N | 2013 |
Preventive effect of traditional Japanese medicine on neurotoxicity of FOLFOX for metastatic colorectal cancer: a multicenter retrospective study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2012 |
[Efficacy analysis of THP-containing regimens as neoadjuvant and adjuvant chemotherapy for primary breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br | 2012 |
Ursolic acid inhibits growth and metastasis of human colorectal cancer in an orthotopic nude mouse model by targeting multiple cell signaling pathways: chemosensitization with capecitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; | 2012 |
Concurrent chemoradiotherapy followed by metastasectomy converts to survival benefit in stage IV rectum cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2012 |
Targeting angiogenesis in metastatic breast cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2012 |
Effectiveness of oxaliplatin desensitization protocols.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cape | 2013 |
Challenge of primary tumor management in patients with stage IV colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colo | 2012 |
Oncologically safe distal resection margins in rectal cancer patients treated with chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2012 |
Decrease in blood miR-296 predicts chemotherapy resistance and poor clinical outcome in patients receiving systemic chemotherapy for metastatic colon cancer.
Topics: Capecitabine; Colonic Neoplasms; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Fluo | 2013 |
Second-line irinotecan after cisplatin, fluoropyrimidin and docetaxel for chemotherapy of metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin | 2012 |
Efficacy and safety of capecitabine in heavily pretreated recurrent/metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free | 2012 |
The use of high dose d,l-leucovorin in first-line bevacizumab+mFOLFIRI treatment of patients with metastatic colorectal cancer may enhance the antiangiogenic effect of bevacizumab.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Anti | 2013 |
Budget impact analysis of the use of oral and intravenous anti-cancer drugs for the treatment of HER2-positive metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Costs and | 2013 |
Optimize administration protocol of capecitabine plus docetaxel combination in metastatic breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Databases as Topic; | 2012 |
Influcence of localization of primary tumor on effectiveness of 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: a retrospective study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2012 |
A retrospective analysis of periodontitis during bevacizumab treatment in metastatic colorectal cancer patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
Food and Drug Administration approval of cetuximab and a new KRAS genetic test for metastatic colorectal cancer: major advance but just the tip of the biomarker iceberg.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2012 |
Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combin | 2012 |
Modified DCF (mDCF) regimen seems to be as effective as original DCF in advanced gastric cancer (AGC).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel | 2013 |
Continuing single-agent bevacizumab as maintenance therapy after induction XELOX (or FOLFOX) plus bevacizumab in first-line treatment of metastatic colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cape | 2012 |
A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer.
Topics: Albumins; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Cost-Benefit Analysis; Decision Mak | 2013 |
[Efficacy and toxicity of lapatinib plus capecitabine therapy in HER2-positive metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycy | 2012 |
Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.
Topics: Alleles; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; | 2013 |
UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; | 2012 |
Safety and efficacy of metronomic non-pegylated liposomal encapsulated doxorubicin in heavily pretreated advanced breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox | 2013 |
Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brid | 2013 |
CEA fluctuation during a single fluorouracil-based chemotherapy cycle for metastatic colorectal cancer.
Topics: Adult; Aged; Biomarkers, Tumor; Carcinoembryonic Antigen; Colorectal Neoplasms; Female; Fluorouracil | 2013 |
[Adjuvant chemotherapy comprising modified FOLFOX6 after curative resection of synchronous or metachronous metastasis from colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2012 |
Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRAS.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camp | 2013 |
Improvement of prognosis for unresectable biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biliary Tract Neoplasms; Deoxycytidine; Disea | 2013 |
Retrospective study as first-line chemotherapy combined anti-VEGF antibody with fluoropyrimidine for frail patients with unresectable or metastatic colorectal cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2013 |
[Oral combination chemotherapy with capecitabine and cyclophosphamide in combination with endocrine therapy and anti-HER2 therapy for advanced and metastatic breast cancer].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplasti | 2012 |
Potential of capecitabine as first-line therapy for metastatic breast cancer: dosing recommendations in patients with diminished renal function.
Topics: Administration, Oral; Aged; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials | 2002 |
Photoeruption in a patient treated with capecitabine (Xeloda) for metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil | 2002 |
Capecitabine named-patient programme for patients with advanced breast cancer. the UK experience.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deo | 2002 |
Oral uracil/ftorafur (UFT) plus leucovorin as first-line chemotherapy and salvage therapy with weekly high-dose 5-fluorouracil/leucovorin for the treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Colonic Neoplasms; Diarrhea; Dose-Response Relationship, Drug; D | 2002 |
First-line capecitabine is as effective as 5-fluorouracil/leucovorin in treating advanced colorectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials, Phase III as T | 2001 |
Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; B | 2002 |
Systemic chemotherapy for metastatic colorectal cancer: reasons to combine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2002 |
Adenocarcinoid of the appendix vermiformis: complete and persistent remission after chemotherapy (folfox) of a metastatic case.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Female; Fluor | 2002 |
[Chemotherapy protocol with taxol increase survival by 31 percent].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclopho | 2002 |
Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2002 |
Indicators for surgical resection and intraoperative radiation therapy for pelvic recurrence of colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2003 |
Weekly oxaliplatin, high-dose folinic acid and 24h-5-fluorouracil (FUFOX) as salvage therapy in metastatic colorectal cancer patients pretreated with irinotecan and folinic acid/5-fluorouracil regimens.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cam | 2002 |
Chemoradiation of unresectable pancreatic carcinoma: impact of pretreatment hemoglobin level on patterns of failure.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Fema | 2003 |
Distal intramural spread is an independent prognostic factor for distant metastasis and poor outcome in patients with rectal cancer: a multivariate analysis.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Fluoroura | 2003 |
Fatal chemotherapy-induced encephalopathy following high-dose therapy for metastatic breast cancer: a case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain; Brain Diseases; Breast Neoplas | 2003 |
[Cytoreductive surgery as an alternative to palliative operations in oncology (the model of treatment of stage IV colorectal cancer)].
Topics: Adenocarcinoma; Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Antineoplastic Combined Che | 2002 |
Correlation between clinicopathologic factors and kinetics of metabolic enzymes for 5-fluorouracil given to patients with colon carcinoma by two different dosage regimens.
Topics: Aged; Colonic Neoplasms; Dihydrouracil Dehydrogenase (NADP); Drug Administration Schedule; Fluoroura | 2003 |
[Preoperative diagnostic procedures in locally advanced rectal carcinoma (> or =T3 or N+). What does endoluminal ultrasound achieve at staging and restaging (after neoadjuvant radiochemotherapy) in contrast to computed tomography?].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2003 |
[Cylindroma of the trachea, a rate tumor with unusual evolution].
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineop | 2003 |
Lung carcinoma with congenital plantar keratoderma as a variant of Clarke-Howel-Evans syndrome.
Topics: Adult; Antineoplastic Agents; Cisplatin; Drug Therapy, Combination; Fatal Outcome; Fluorouracil; Hum | 2003 |
[Operative management in the treatment of pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Therapy, Co | 2003 |
Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy.
Topics: Adult; Aged; Anthracyclines; Antigens, Neoplasm; Bone Marrow Cells; Breast Neoplasms; Cell Adhesion; | 2003 |
Pharmacokinetics of oxaliplatin during chronomodulated infusion in metastatic gastrointestinal cancer patients: a pilot investigation with preliminary results.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Chron | 2003 |
Treatment of neuroendocrine tumours with infusional 5-fluorouracil, folinic acid and streptozocin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Fluorourac | 2003 |
Second-line chemotherapy with low-dose CPT-11 and cisplatin for colorectal cancer resistant to 5-FU-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cispla | 2003 |
Multifocal inflammatory leukoencephalopathy: use of thallium-201 SPECT and proton MRS.
Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Aspartic Acid; Axons; Biopsy; Brain; Brain | 2003 |
Bevacizumab, bleeding, thrombosis, and warfarin.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticoagulants; Antineoplastic Combined C | 2003 |
Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma.
Topics: Anthracyclines; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Deoxycytidine; Dr | 2003 |
5-Fluorouracil in metastatic mammary cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Fluorouracil; Humans; Middle | 1962 |
5-FLUOROURACIL TREATMENT OF LIVER METASTASES BY CONTINUOUS HEPATIC ARTERY INFUSION VIA COURNAND CATHETER: RESULTS AND SUITABILITY FOR INTENSIVE POSTSURGICAL ADJUVANT CHEMOTHERAPY.
Topics: Adenocarcinoma; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Fluorouracil; Gast | 1963 |
CHEMOTHERAPY OF METASTATIC LIVER CANCER BY PROLONGED HEPATIC-ARTERY INFUSION.
Topics: Alkaline Phosphatase; Bile Duct Neoplasms; Bilirubin; Chemotherapy, Cancer, Regional Perfusion; Colo | 1964 |
FURTHER CLINICAL COMPARISON BETWEEN 5-FLUOROURACIL (5-FU) AND 5-FLUORO-2' -DEOXYURIDINE (5-FUDR).
Topics: Brain Neoplasms; Breast Neoplasms; Diarrhea; Floxuridine; Fluorouracil; Geriatrics; Humans; Liver Ne | 1963 |
RADIATION AND 5-FLUOROURACIL: A CONTROLLED CLINICAL STUDY.
Topics: Biomedical Research; Fluorouracil; Humans; Neoplasm Metastasis; Neoplasms; Radiotherapy Dosage | 1963 |
CLINICOPATHOLOGIC CONFERENCE.
Topics: Black People; Bromides; Diagnosis, Differential; Drug Eruptions; Fluorouracil; Granuloma; Humans; Ke | 1964 |
[NEW ANTIBLASTIC AGENTS].
Topics: Antineoplastic Agents; Colonic Neoplasms; Ethoglucid; Fluorouracil; Neoplasm Metastasis; Neoplasms; | 1963 |
CURRENT MANAGEMENT OF NEPHROBLASTOMA AND NEUROBLASTOMA.
Topics: Antineoplastic Agents; Child; Dactinomycin; Fluorouracil; Infant; Infant, Newborn; Kidney Neoplasms; | 1964 |
FLUORINATED PYRIMIDINE THERAPY OF ADVANCED GASTROINTESTINAL CANCER.
Topics: Alopecia; Colonic Neoplasms; Drug Eruptions; Esophagitis; Fluorouracil; Gallbladder Neoplasms; Human | 1964 |
PALLIATIVE MANAGEMENT OF GASTROINTESTINAL CANCER.
Topics: Adenocarcinoma; Ascites; Deglutition Disorders; Fluorouracil; Humans; Neoplasm Metastasis; Neoplasms | 1964 |
NONSURGICAL TREATMENT OF PULMONARY CANCER.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adrenal Cortex Hormones; Alkylating Agents; Antineoplastic Agen | 1964 |
RESPONSE OF PRIMARY UNKNOWN CANCERS TO TREATMENT WITH 5-FLUOROURACIL (NSC-19893).
Topics: Adolescent; Biomedical Research; Child; Cyclophosphamide; Floxuridine; Fluorouracil; Geriatrics; Neo | 1964 |
HORMONAL THERAPY OF METASTATIC FEMALE BREAST CARCINOMA. IV. 17-BETA-AMINO-5-ALPHA-ANDROSTAN-11-BETA-OL.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma; Female; Fluorouracil; Humans; Neoplasm Metastasi | 1964 |
REGRESSION OF METASTATIC HEPATOMEGALY FROM MAMMARY CARCINOMA. CYTOTOXIC COMBINATION CHEMOTHERAPY WITH 5-FU.
Topics: Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Fluorouracil; Hepatomegaly; Humans; L | 1964 |
5-FLUOURACIL IN THE TREATMENT OF DISSEMINATED COLON AND RECTAL CARCINOMA.
Topics: Adenocarcinoma; Colonic Neoplasms; Fluorouracil; Geriatrics; Neoplasm Metastasis; Pharmacology; Rect | 1964 |
CLINICAL EXPERIENCE WITH PALLIATION OF METASTATIC ADENOCARCINOMA WITH 5-FLUOROURACIL CHEMOTHERAPY.
Topics: Adenocarcinoma; Bone Neoplasms; Breast Neoplasms; Colonic Neoplasms; Dextropropoxyphene; Fluorouraci | 1964 |
SELECTIVE CONCENTRATION OF ANTICANCER DRUGS IN THE LIVER: HEPATIC-ARTERY INFUSION AND INDUCED HEPATIC OUTFLOW BLOCK.
Topics: Animals; Antineoplastic Agents; Arteries; Biomedical Research; Chemotherapy, Cancer, Regional Perfus | 1965 |
CANCER CHEMOTHERAPY OF THE GASTROINTESTINAL TRACT WITH REFERENCE TO INTRA-ARTERIAL INFUSION AND IRRADIATION.
Topics: Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Cobalt Isotopes; Cyclophosphamide; | 1965 |
PELVIC PERFUSION AND CARCINOMA OF THE RECTUM.
Topics: Carcinoma; Chemotherapy, Cancer, Regional Perfusion; Equipment and Supplies; Fluorouracil; Humans; M | 1965 |
THE INDICATIONS FOR 5-FLUOROURACIL IN THE TREATMENT OF BREAST CANCER.
Topics: Breast Neoplasms; Drug Therapy; Fluorouracil; Geriatrics; Humans; Neoplasm Metastasis; Neoplasms | 1965 |
SYSTEMIC CHEMOTHERAPY FOR CNS METASTASES OF SOLID TUMORS.
Topics: Adenocarcinoma; Brain Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Therapy; Floxuridine; Fluo | 1965 |
INTRACAVITARY 5-FLUOROURACIL IN MALIGNANT EFFUSIONS.
Topics: Antimetabolites; Fluorouracil; Humans; Infusions, Parenteral; Neoplasm Metastasis; Neoplasms; Perica | 1965 |
Antitumor effect of a splenic injection of 5-fluorouracil on metastatic liver cancer in mice.
Topics: Animals; Antimetabolites, Antineoplastic; Disease Models, Animal; Fluorouracil; Injections; Interleu | 2004 |
Capecitabine inhibits postoperative recurrence and metastasis after liver cancer resection in nude mice with relation to the expression of platelet-derived endothelial cell growth factor.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Fl | 2003 |
Vinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: significance of the time between initiation of adjuvant therapy and of therapy for metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Admin | 2004 |
Gene expression profiling of colon cancer reveals a broad molecular repertoire in 5-fluorouracil resistance.
Topics: Antimetabolites, Antineoplastic; Colonic Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Ex | 2003 |
[Patient with stomach cancer with metastases. What is the value of chemotherapy?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoplasm Metastasis; Neoplasm | 2003 |
Trial of low-dose 5-fluorouracil/cisplatin therapy for advanced extramammary Paget's disease.
Topics: Aged; Antineoplastic Agents; Cisplatin; Fatal Outcome; Fluorouracil; Genital Neoplasms, Male; Humans | 2004 |
Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients.
Topics: Chromosomes, Human, Pair 18; Colorectal Neoplasms; DNA, Neoplasm; Drug Resistance, Neoplasm; Electro | 2004 |
Combined 5-fluorouracil/systemic interferon-beta gene therapy results in long-term survival in mice with established colorectal liver metastases.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Colorectal Neop | 2004 |
A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
Topics: Animals; Antimetabolites; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; C | 2004 |
A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
Topics: Animals; Antimetabolites; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; C | 2004 |
A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
Topics: Animals; Antimetabolites; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; C | 2004 |
A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
Topics: Animals; Antimetabolites; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; C | 2004 |
Oral RDP58 allows CPT-11 dose intensification for enhanced tumor response by decreasing gastrointestinal toxicity.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothera | 2004 |
[Radiotherapy of carcinomas of the anal canal. Tenon Hospital experience].
Topics: Aged; Anal Canal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Ch | 2003 |
Cytotoxic chemotherapy for metastatic renal cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Clinical Trials | 2004 |
Akt mediates Ras downregulation of RhoB, a suppressor of transformation, invasion, and metastasis.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Transformation, Neoplastic; Down-Regulation; Female; | 2004 |
Hypersensitivity reactions to oxaliplatin: a case report and the success of a continuous infusional desensitization schedule.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Desen | 2004 |
Use of LeVeen pleuroperitoneal shunt for refractory high-volume chylothorax.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chylothorax; | 2004 |
Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Com | 2004 |
Effect of capecitabine on mean corpuscular volume in patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deo | 2004 |
Two-stage liver resection and chemotherapy for bilobar colorectal liver metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality | 2004 |
Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Base | 2004 |
Deleted in colon cancer protein expression in colorectal cancer metastases: a major predictor of survival in patients with unresectable metastatic disease receiving palliative fluorouracil-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Adhesion Molecules; Colorectal Neo | 2004 |
Reversal of the malignant phenotype of gastric cancer cells by inhibition of RhoA expression and activity.
Topics: Agar; Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; | 2004 |
Compassionate-use oxaliplatin with bolus 5-fluorouracil/leucovorin in heavily pretreated patients with advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fema | 2004 |
Salvage ifosfamide-doxorubicin chemotherapy in patients with recurrent nasopharyngeal carcinoma pretreated with Cisplatin-based chemotherapy.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Bevacizumab in colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2004 |
Evaluation of clinical factors and treatment results in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Fem | 2004 |
Prognostic significance of thymidylate synthase in patients with metastatic colorectal cancer who receive protracted venous infusions of 5-fluorouracil.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; Female; Fluorouracil | 2004 |
[The 5-fluorouracil hepato-arterial infusion with oral UFT therapy for the hepatic and extra hepatic metastases of colorectal cancer].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dr | 2004 |
Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluor | 2004 |
Preclinical investigations of drug and radionuclide conjugates of bisphosphonates for the treatment of metastatic bone cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Bone Neoplasms; Diphosphonates; Female; Fluorouracil; Huma | 2004 |
The development of the FOLFOX regimens as a treatment standard of advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Ne | 2005 |
Evolution of FOLFOX regimens in the treatment of advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Co | 2005 |
The addition of bevacizumab to FOLFOX4 prolongs survival in relapsed colorectal cancer: interim data from the ECOG 3200 trial.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothera | 2005 |
Prognostic significance of parapharyngeal space venous plexus and marrow involvement: potential landmarks of dissemination for stage I-III nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Female; Fl | 2005 |
Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity.
Topics: Colorectal Neoplasms; Disease Progression; Drug Screening Assays, Antitumor; Female; Fluorouracil; H | 2005 |
Long-term administration of low-dose cisplatin plus 5-fluorouracil prolongs the postoperative survival of patients with esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2005 |
Predictive value of COX-2 for the effect of chemoradiotherapy on esophageal squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzothiazoles; Biopsy; Calibration; Carcinom | 2005 |
[Gemcitabine plus cisplatin therapy in breast cancer refractory to anthracyclines, docetaxel and capecitabine].
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cisp | 2005 |
Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Camptothecin; Cisplatin; Colonic Neoplasms; | 2005 |
A monoclonal antibody as an effective therapeutic agent in breast cancer: trastuzumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineop | 2005 |
Capecitabine-induced pancolitis.
Topics: Adult; Capecitabine; Colitis; Deoxycytidine; Fluorouracil; Humans; Male; Neoplasm Metastasis; Pancre | 2007 |
Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Disease-Free Survival; Female; Fluorouracil; Hemoglobins; Human | 2006 |
Metastatic renal carcinoma long-term survivors treated with s.c. interferon-alpha and s.c. interleukin-2.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Disease-Free Survival; Female; | 2005 |
Age does not impair the efficacy of immunochemotherapy in patients with metastatic renal carcinoma.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; | 2005 |
What is the best chemotherapy treatment option for anthracycline and taxane pretreated metastatic breast cancer?
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deox | 2005 |
Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil.
Topics: 3' Untranslated Regions; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers | 2005 |
Impact of orotate phosphoribosyl transferase activity as a predictor of lymph node metastasis in gastric cancer.
Topics: Aged; Antineoplastic Agents; Cell Proliferation; Female; Fluorouracil; Humans; Lymphatic Metastasis; | 2005 |
Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorecta | 2005 |
Long-term survival after concomitant chemoradiotherapy prior to surgery in advanced cervical carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2006 |
Reduced dose capecitabine is an effective and well-tolerated treatment in patients with metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Re | 2005 |
Oxaliplatin-based chemotherapy for the treatment of a metastatic carcinoid tumor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Fluorouracil; Humans; Infusions, In | 2005 |
Capecitabine-induced multifocal leukoencephalopathy: a report of five cases.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Brain; Breast Neoplasms; Capecitabine; Carcinoma; Deox | 2005 |
First-line treatment options for patients with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo | 2004 |
Can plasma Epstein-Barr virus DNA levels be used to monitor nasopharyngeal carcinoma progression?
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma; Case-Control Studies; Cisplat | 2005 |
Irinotecan, continuous 5-fluorouracil, and low dose of leucovorin (modified FOLFIRI) as first line of therapy in recurrent or metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2005 |
Carcinoma of the jejunum with multideposit peritoneal seeding, resection and intraperitoneal chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Infusions, Par | 2005 |
Treatment of advanced colorectal and gastric cancer with 5-fluorouracil and calcium n-methyltetrahydrofolate.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; F | 1989 |
Perfusion chemotherapy for colorectal liver metastases: a randomized study comparing FUDR against 5-FU/BCNU.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colorectal Neoplasms; Floxuridine; Fluor | 1989 |
Weekly cisplatin plus capecitabine in metastatic breast cancer patients heavily pretreated with both anthracycline and taxanes.
Topics: Anthracyclines; Antigen-Presenting Cells; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 2005 |
Perspectives in colorectal cancer - Sixth Annual Conference. Metastatic colorectal cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizum | 2005 |
High risk of venous thrombosis in patients with pancreatic cancer: a cohort study of 202 patients.
Topics: Antimetabolites, Antineoplastic; Cohort Studies; Female; Fibrinolytic Agents; Fluorouracil; Humans; | 2006 |
Irinotecan with bolus and infusional 5-flurouracil and folinic acid for patients with advanced or metastatic colorectal cancer previously treated with 5-flurouracil: a possible alternative to single-agent irinotecan in a 'real-life' setting.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem | 2005 |
Cetuximab: new drug. Metastatic colorectal cancer: an inappropriate evaluation.
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; C | 2005 |
Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials | 2005 |
Outcome of preoperative concurrent chemoradiotherapy and surgery for resectable lingual squamous cell carcinoma greater than 3 cm: the possibility of less extensive surgery.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2006 |
Economic impact of simplified de Gramont regimen in first-line therapy in metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Admin | 2006 |
Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Bone M | 2006 |
Capecitabine and mitomycin C in patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; F | 2006 |
Gene expression of ferredoxin reductase predicts outcome in patients with metastatic colorectal cancer treated by 5-fluorouracil plus leucovorin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; DNA Mutational An | 2006 |
5-fluorouracil (5FU) treatment does not influence invasion and metastasis in microsatellite unstable (MSI-H) colorectal cancer.
Topics: Animals; Cell Count; Cell Survival; Colorectal Neoplasms; Disease Models, Animal; Flow Cytometry; Fl | 2006 |
Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2006 |
Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1.
Topics: Adult; Aged; Drug Combinations; Drug Therapy, Combination; Female; Fluorouracil; Gene Expression; Hu | 2006 |
Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant | 2006 |
Bevacizumab: new drug. Metastatic colorectal cancer: good in theory, not in practice.
Topics: Antibodies, Monoclonal; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; | 2006 |
Late toxicity in complete response cases after definitive chemoradiotherapy for esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophagea | 2006 |
[Metastatic nasopharyngeal carcinoma: clinical study and therapeutic results of 95 cases].
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplasti | 2006 |
[Interferon-alpha+cisplatin+5-FU therapy for gemcitabine-refractory unresectable and recurrent pancreatic cancer].
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Admin | 2006 |
Capecitabine therapy for refractory metastatic thyroid carcinoma: a case series.
Topics: Adult; Antimetabolites, Antineoplastic; Capecitabine; Carcinoembryonic Antigen; Deoxycytidine; Dihyd | 2006 |
Case-based discussion for the management of metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Monitoring; | 2006 |
Antitumor immune response induced by i.t. injection of vector-activated dendritic cells and chemotherapy suppresses metastatic breast cancer.
Topics: Adenoviridae; Adenovirus E1A Proteins; Animals; Antineoplastic Agents; Breast Neoplasms; Cancer Vacc | 2006 |
Highlights from the 42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, June 2006.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2006 |
A case of early relapsed multiple lung metastases after esophagectomy successfully treated with S-1/cisplatin therapy after docetaxel/5-fluorouracil/cisplatin therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetaxel; Dru | 2006 |
Successful outcome after combined chemotherapeutic and surgical management in a case of esophageal cancer with breast and brain relapse.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carcinoma, Squamo | 2006 |
Do all patients with metastatic colorectal cancer need chemotherapy until disease progression?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease | 2006 |
Phase III multicenter randomized clinical trial to evaluate the safety and efficacy of CoFactor/5-fluorouracil/bevacizumab versus leucovorin/5-fluorouracil/bevacizumab as initial treatment for metastatic colorectal carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, | 2006 |
[Therapeutic efficacy of capecitabine on advanced and recurrent breast cancer with special reference to time to progression].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; C | 2006 |
Metastatic hidradenocarcinoma: efficacy of capecitabine.
Topics: Adenoma, Sweat Gland; Antimetabolites, Antineoplastic; Axilla; Capecitabine; Deoxycytidine; Diagnosi | 2006 |
Concurrent capecitabine and upper abdominal radiation therapy is well tolerated.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dose-Response Relationship, Radiation; | 2006 |
Difference in Ki67 and thymidylate synthase expression in primary tumour compared with metastatic nodes in breast cancer patients.
Topics: Antigens, Neoplasm; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Proliferation; Female; F | 2006 |
Portal thrombosis and steatosis after preoperative chemotherapy with FOLFIRI-bevacizumab for colorectal liver metastases.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2006 |
OPTIMOX1 in advanced colorectal cancer: lack of evidence for a stop-and-go strategy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Data Interpretation, Statistic | 2006 |
Histologic subtype of metastatic renal cell carcinoma predicts response to combined immunochemotherapy with interleukin 2, interferon alpha and 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Combined Modalit | 2007 |
Prognostic groups in 1,676 patients with T3 rectal cancer treated without preoperative radiotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2007 |
Goblet cell carcinoid tumors (adenocarcinoid) of the appendix.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Appendectomy; Appendiceal Neoplasms; Biomarke | 2007 |
Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: the NO16966 trial.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2006 |
Efficacy of lower dose capecitabine in patients with metastatic breast cancer and factors influencing therapeutic response and outcome.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; | 2007 |
Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; | 2007 |
Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2007 |
A successful treatment for metastatic liver tumors from endocrine carcinoma of the stomach.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Endocrine | 2007 |
Chemoimmunotherapy in the treatment of metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Antineop | 2007 |
The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Capecitab | 2008 |
Thymidylate synthase expression in primary colorectal tumours is correlated with its expression in metastases.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; Female; Fluorouracil; Huma | 2007 |
Size matters. What can we learn from a small randomized trial?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Data Interpretat | 2007 |
Elementary, my dear Watson.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Dermatoglyphics; Dose-R | 2007 |
Optimizing palliative treatment of metastatic colorectal cancer in the era of biologic therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal N | 2007 |
Measurement of DPD and TS transcripts aimed to predict clinical benefit from fluoropyrimidines: confirmation of the trend in Russian colorectal cancer series and caution regarding the gene referees.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Artifa | 2007 |
Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 2007 |
Medullary thyroid cancer treated by capecitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Carcinoma, Medullary; Cisplati | 2007 |
Cetuximab/targeted chemotherapy in an HIV-positive patient with metastatic colorectal cancer in the HAART era: a case report.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2007 |
Outpatient-basis chemotherapy of oxaliplatin, 5-fluorouracil, and leucovorin as first-line treatment for patients with metastatic or recurrent colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Femal | 2007 |
Questions about the role of palifermin in fluorouracil-based therapy for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Cryotherapy; Data Interpretati | 2007 |
DPD is a molecular determinant of capecitabine efficacy in colorectal cancer.
Topics: Aged; Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydr | 2007 |
[Evaluation of therapeutic regimens for taxane-resistant recurrent/metastatic breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2007 |
Feasibility of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) for Japanese patients with unresectable metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2007 |
Docetaxel, cisplatin, and fluorouracil in gastric cancer: does the punishment fit the crime?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase III as Topic; Doce | 2007 |
Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Colorectal N | 2007 |
Mismatch repair status is a predictive factor of tumour response to 5-fluorouracil and irinotecan chemotherapy in patients with advanced colorectal cancer.
Topics: Adaptor Proteins, Signal Transducing; Aged; Antineoplastic Combined Chemotherapy Protocols; Base Pai | 2007 |
The pathological response to neoadjuvant chemotherapy with FOLFOX-4 for colorectal liver metastases: a comparative study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; | 2007 |
Sequencing therapies: the role of targeted agents in metastatic colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials | 2007 |
Development and characterization of a model of liver metastasis using human colon cancer HCT-116 cells.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptot | 2007 |
Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplas | 2008 |
[Docetaxel-cisplatin-5-FU combination chemotherapy as a first-line treatment in patients with metastatic or recurred gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Fluoroura | 2007 |
Complete remission of a metastatic neuroendocrine tumor of the pancreas with capecitabine (Xeloda) monotherapy.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Chromogranin A; Deoxycytidine; Fluorouracil; Humans; | 2008 |
Antiproliferative and antimetastatic effects of the ethanolic extract of Phellinus igniarius (Linnearus: Fries) Quelet.
Topics: Animals; Antineoplastic Agents; Basidiomycota; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Mov | 2008 |
[A case of metastatic rectal cancer showing a sustained complete response to chemotherapy with FOLFIRI followed by UFT].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; L | 2007 |
[A case of elderly metastatic breast cancer with a complete response to treatment with capecitabine and cyclophosphamide].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Ch | 2007 |
A limited sampling strategy to estimate the pharmacokinetic parameters of irinotecan and its active metabolite, SN-38, in patients with metastatic digestive cancer receiving the FOLFIRI regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Body | 2007 |
Benefit of FOLFOX to unresectable liver metastases secondary from colorectal carcinoma in an oncologic emergency.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonoscopy; Colorecta | 2007 |
Laparoscopic total mesorectal excision after neoadjuvant chemoradiotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Dose Fractionation, Radiation; Female; Fluorouracil; F | 2007 |
Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxyc | 2008 |
[Clinical study of irinotecan plus infusional fluorouracil/l-leucovorin (FOLFIRI) in patients with fluoropyrimidine-resistant metastatic colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2007 |
Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Creatinine; Deoxycytidine; | 2008 |
Treatment outcomes of oxaliplatin, 5-FU, and leucovorin as salvage therapy for patients with advanced or metastatic gastric cancer: a retrospective analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucovori | 2009 |
Will we ever be ready for blood level-guided therapy?
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Body Surface Area; Colorectal Neoplasms; Drug Admin | 2008 |
Potential regional differences for the tolerability profiles of fluoropyrimidines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asia, Eastern; Cape | 2008 |
Pharmacoeconomic benefits of capecitabine-based chemotherapy in metastatic colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Color | 2008 |
Re: Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Color | 2008 |
Use of capecitabine in refractory metastatic medullary thyroid carcinoma.
Topics: Adult; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Medullary; Deoxycytidine; Fluoroura | 2008 |
Occurrence of autoimmunity in a long-term survivor with metastatic colon carcinoma treated with a new chemo-immunotherapy regimen.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Autoimmunity; Colonic Neopla | 2008 |
[Non-resectable metastases from colorectal cancers].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2008 |
XELOX followed by XELIRI or the reverse sequence in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal | 2007 |
Definitive chemoirradiation for resectable head and neck cancer: treatment outcome and prognostic significance of MRI findings.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Fema | 2008 |
[Retrograde infusion of anti-cancer drugs to ophthalmic artery for intraocular malignant tumors].
Topics: Eye Neoplasms; Female; Fluorouracil; Humans; Infant; Infusions, Parenteral; Lung Neoplasms; Male; Mi | 1966 |
Serum enzymes in patients with carcinoma of lung: lactic-acid dehydrogenase, phosphohexose isomerase, alkaline phosphatase and glutamic oxaloacetic transaminase.
Topics: Alkaline Phosphatase; Aspartate Aminotransferases; Clinical Enzyme Tests; Fluorouracil; Glucose-6-Ph | 1967 |
Disseminated melanoma. Biologic behavior and treatment.
Topics: Antineoplastic Agents; Chlorambucil; Cyclophosphamide; Dactinomycin; Fluorouracil; Humans; Hydrazine | 1967 |
Ovarian and parovarian tumors in infants and children.
Topics: Adenocarcinoma; Adolescent; Child; Child, Preschool; Dysgerminoma; Female; Fluorouracil; Histocytoch | 1967 |
An evaluation of 5-fluorouracil in the treatment of advanced breast cancer.
Topics: Aged; Breast Neoplasms; Evaluation Studies as Topic; Female; Fluorouracil; Humans; Menstruation; Mid | 1967 |
Bronchial adenoma and the carcinoid syndrome.
Topics: Adenocarcinoma; Adenoma; Adrenal Cortex Hormones; Bronchial Neoplasms; Carcinoid Tumor; Chlorpromazi | 1967 |
New adjuvant therapy for breast cancer-preliminary report.
Topics: Breast Neoplasms; Fluorouracil; Humans; Mastectomy; Neoplasm Metastasis | 1967 |
Sequential use of endocrine therapy and chemotherapy for metastatic breast cancer: effects on survival.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, C | 1980 |
[Chemotherapy of malignant solid tumors].
Topics: Bleomycin; Breast Neoplasms; Bronchial Neoplasms; Cyclophosphamide; Fluorouracil; Humans; Kidney Neo | 1980 |
Combination chemotherapy for advanced bladder cancer.
Topics: Bleomycin; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Humans; Methotrexate; Neoplasm Meta | 1982 |
Colon-specific antigen-p (CSAp). I. Initial clinical evaluation as a marker for colorectal cancer.
Topics: Adenocarcinoma; Adenoma; Antigens, Neoplasm; Carcinoembryonic Antigen; Colonic Neoplasms; Epitopes; | 1982 |
Multidisciplinary treatment for esophageal carcinoma.
Topics: Adult; Age Factors; Aged; Bleomycin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middl | 1983 |
Comparison of drug sensitivity among tumor cells within a tumor, between primary tumor and metastases, and between different metastases in the human tumor colony-forming assay.
Topics: Antineoplastic Agents; Bleomycin; Cell Division; Cell Survival; Cells, Cultured; Cisplatin; Doxorubi | 1984 |
[A method of radiation and combined treatment in inoperable cancer of the pancreas].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha | 1984 |
Chemotherapy for adenocystic carcinoma.
Topics: Alkylating Agents; Antineoplastic Agents; Carcinoma, Adenoid Cystic; Fluorouracil; Humans; Lung Neop | 1980 |
Adenoid cystic carcinoma of the salivary gland. Sustained complete response to chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenoid Cystic; Doxorubicin; Drug | 1983 |
5-Fluorouracil in malignant trophoblastic tumors. report of 350 cases.
Topics: Digestive System; Female; Fluorouracil; Hematopoiesis; Humans; Neoplasm Metastasis; Pregnancy; Troph | 1983 |
[Completely implantable infusion pump. A new therapeutic possibility for selected patients with liver tumors].
Topics: Carcinoma, Hepatocellular; Catheters, Indwelling; Colonic Neoplasms; Floxuridine; Fluorouracil; Hepa | 1983 |
Phase I-II trial of high-dose calcium leucovorin and 5-fluorouracil in advanced colorectal cancer.
Topics: Adult; Aged; Colonic Neoplasms; Drug Evaluation; Female; Fluorouracil; Humans; Leucovorin; Male; Mid | 1984 |
[Vinblastine, 5-fluorouracil and prednisone (VFP) as "second-line" chemotherapy. Contribution to the problem of optimal therapy sequence in metastasizing breast carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration S | 1983 |
Combined modality therapy for esophageal squamous cell carcinoma.
Topics: Abdomen; Adult; Aged; Carcinoma, Squamous Cell; Drug Therapy, Combination; Esophageal Neoplasms; Eso | 1983 |
Phase II study of ftorafur in previously untreated and treated patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Evaluation; Female; Fluorouracil; Humans; Male; | 1983 |
[Chemotherapy of gastric cancer patients with hepatic metastases].
Topics: Administration, Oral; Antibiotics, Antineoplastic; Fluorouracil; Humans; Liver Neoplasms; Mitomycin; | 1983 |
[Treatment of metastasizing prostatic carcinoma with DMF. Presentation of a prospective study].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Humans; M | 1983 |
Treatment of metastatic colorectal carcinoma with 5-FU, mitomycin, vincristine, and methotrexate.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Fem | 1984 |
Spontaneous metastasis of highly metastatic variants of mouse tumors and the effect of drugs on the metastasis.
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Doxorubicin; Fluorouracil; Lung Neoplasms; Lymphatic Met | 1984 |
[5-Fluorouracil treatment combined with ascorbic acid in patients with disseminated stomach cancer].
Topics: Adenocarcinoma; Adult; Aged; Ascorbic Acid; Carcinoma; Combined Modality Therapy; Female; Fluorourac | 1984 |
A combination of 5-fluorouracil and thymidine in advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Colonic Neoplasms; Drug Sy | 1984 |
Evaluation of a sequential 5-FU and hydroxyurea combination in advanced bowel cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colonic Neoplasms; | 1984 |
Sequential methotrexate and 5-FU in breast cancer resistant to the conventional application of these drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fluorouracil; Humans; Meth | 1984 |
Chemotherapy of advanced breast cancer. A general survey.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Mo | 1984 |
Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Coagulation Tests; Breast Neoplasms; Cy | 1984 |
A retrospective study of FAM regimen in 38 patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Humans; Midd | 1984 |
The management of locally advanced breast cancer: a combined modality approach.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Breast Neoplasms; Combined | 1984 |
Phase II study of mitolactol in chemotherapy-refractory metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 1984 |
[Sequential combination chemotherapy in metastatic cancer of the breast].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Fluorour | 1984 |
[Correlations between PRL and 17-beta-E in human breast cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Estradiol | 1984 |
5-Fluorouracil, vincristine and hydroxyurea combination chemotherapy in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil; Humans; Hyd | 1983 |
Combination chemotherapy with cyclophosphamide, mitoxantrone and 5-fluorouracil in patients with metastatic breast cancer.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclo | 1983 |
Adjuvant therapy for Dukes C adenocarcinoma of colon.
Topics: Abdomen; Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Middle | 1983 |
Induction chemotherapy with cisplatin and cyclophosphamide and maintenance chemotherapy with doxorubicin and 5-FU in advanced urinary bladder tumors.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Transitional Cell; Cisplatin; Cyclophosphamide; Doxor | 1983 |
Combination chemotherapy including adriamycin for advanced transitional cell carcinoma of the urinary tract.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Transitional Ce | 1983 |
Multimodal treatment of locoregionally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Breast Neoplasms; Cyclopho | 1983 |
Prolonged remissions of metastatic breast cancer achieved with a six-drug regimen of relatively low toxicity.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast | 1983 |
Treatment of hormone-resistant metastatic carcinoma of the prostate with 5-FU, doxorubicin, and mitomycin (FAM'): a preliminary report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Humans; Male; Middl | 1983 |
[Comparative evaluation of the results of mono- and polychemotherapy of disseminated forms of breast cancer using the CMFVP program and anthracycline antibiotics (carminomycin and adriamycin)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carubicin; Cyclophosphamide; Dauno | 1983 |
[Radiotherapy and combined modality treatment of advanced gastrointestinal tumors. Analysis of morbidity in 101 patients].
Topics: Aged; Combined Modality Therapy; Fluorouracil; Gastrointestinal Neoplasms; Humans; Hyperthermia, Ind | 1984 |
Metastasis after intravenous inoculation of highly metastatic variants of mouse tumors and the effects of several antitumor drugs on the tumors.
Topics: Adenocarcinoma; Age Factors; Animals; Antineoplastic Agents; Colonic Neoplasms; Doxorubicin; Fluorou | 1984 |
[Use of a combination of pyrogenal and drug preparations in the overall treatment of breast cancer].
Topics: Adult; Breast Neoplasms; Drug Evaluation; Drug Therapy, Combination; Female; Fluorouracil; Humans; M | 1980 |
[Combination chemotherapy including anablastine in disseminated breast cancer].
Topics: Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; Female; | 1981 |
High-dose therapy with ftorafur in gastrointestinal cancer.
Topics: Animals; Carcinoma, Ehrlich Tumor; Drug Therapy, Combination; Fluorouracil; Gastrointestinal Neoplas | 1981 |
Efficacy of dacarbazine imidazole carboxamide and mitomycin C combination therapy in patients with adenocarcinoma of the colon refractory to 5-fluorouracil therapy.
Topics: Adenocarcinoma; Colonic Neoplasms; Dacarbazine; Drug Resistance; Drug Therapy, Combination; Female; | 1981 |
[Effect of cancer chemotherapy for unresectable cancer of the pancreas].
Topics: Antineoplastic Agents; Drug Therapy, Combination; Female; Fluorouracil; Humans; Liver Neoplasms; Mal | 1982 |
[Antitumor treatment for synchronous hepatic metastasis from stomach cancer].
Topics: Adult; Aged; Antineoplastic Agents; Drug Therapy, Combination; Female; Fluorouracil; Humans; Liver N | 1982 |
[Clinical trial of UFT in recurrent or advanced cancer].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasm | 1982 |
Concurrent chemotherapy and radiotherapy for nonmetastatic, Stage IV breast cancer. A pilot study by the Southeastern Cancer Study Group.
Topics: Aged; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Therapy, C | 1983 |
Serial plasma carcinoembryonic antigen measurements during treatment of metastatic breast cancer.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Carcinoembryonic Antigen; Cyclophosphamide; Doxorubi | 1983 |
[Analysis of morbidity from simultaneous 5-fluorouracil therapy and radiation therapy in advanced gastrointestinal tumors. Report of results].
Topics: Colonic Neoplasms; Fluorouracil; Gastrointestinal Neoplasms; Humans; Neoplasm Metastasis; Radiothera | 1983 |
[Chemotherapy of metastatic urothelial carcinoma].
Topics: Adenocarcinoma; Aged; Carcinoma, Transitional Cell; Cisplatin; Doxorubicin; Drug Therapy, Combinatio | 1982 |
Adriamycin and VP16-213 combination treatment for breast cancer previously treated by the CMF regimen.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubic | 1982 |
Combination chemotherapy with 5-FU 1-(aminomethyl)-3-(2-chloroethyl)-3-nitrosourea (ACNU), and mitomycin (FUM) for carcinoma of the pancreas.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Therapy, Co | 1982 |
Doxorubicin, mitomycin, and 5-FU (DMF) in the treatment of hormone-resistant stage D prostate cancer: a preliminary report.
Topics: Adenocarcinoma; Bone Neoplasms; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Humans; Lung N | 1982 |
[Sequential methotrexate and fluorouracil in metastasizing colorectal carcinomas. Results of a phase II pilot study (author's transl)].
Topics: Adult; Aged; Colonic Neoplasms; Female; Fluorouracil; Humans; Life Expectancy; Male; Methotrexate; M | 1982 |
High-frequency low-dose multiple-drug chemotherapy in advanced metastatic breast cancer.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cycl | 1982 |
Hypogonadism in male patients with metastatic cancer prior to chemotherapy.
Topics: Body Weight; Fluorouracil; Follow-Up Studies; Humans; Hypogonadism; Luteinizing Hormone; Male; Middl | 1982 |
Phase II study of sequential methotrexate-5-FU therapy in advanced measurable colorectal cancer.
Topics: Colonic Neoplasms; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Fluorou | 1982 |
Sensitization to low dose 5-fluorouracil. Subsequent enhancement of its systemic antitumor effect in the rat.
Topics: Animals; Female; Fluorouracil; Male; Mammary Neoplasms, Experimental; Methotrexate; Neoplasm Metasta | 1982 |
Clearance of continuously infused 5-fluorouracil in adults having lung or gastrointestinal carcinoma with or without hepatic metastases.
Topics: Adult; Fluorouracil; Gastrointestinal Neoplasms; Humans; Lung Neoplasms; Male; Neoplasm Metastasis | 1982 |
Excretion of tumor-associated antigen(s) in the urine of patients with colon carcinoma.
Topics: Adult; Aged; Antigens, Neoplasm; Colonic Neoplasms; Complement Fixation Tests; Female; Fluorouracil; | 1982 |
[Chemotherapy schedule for the management of metastasizing gastric cancer. Methotrexate, adriamycin and 5-fluorouracil].
Topics: Adult; Aged; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Methotrexat | 1982 |
[Ancillary chemotherapy with trofosfamid, methotrexate and fluoro-uracil in cancer of the breast (author's transl)].
Topics: Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Lymphat | 1981 |
A five-drug combination in the treatment of metastatic breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Carmustine; Dacarbazine; Drug Therapy, Combination; Female; | 1981 |
A new concept in the management of Marjolin's ulcers.
Topics: Administration, Topical; Adult; Carcinoma, Squamous Cell; Cicatrix; Female; Fluorouracil; Humans; Ma | 1981 |
Single-drug chemotherapy with 5-FU and adriamycin in metastatic bladder cancer.
Topics: Adult; Aged; Doxorubicin; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Retrospective Stud | 1981 |
Combined chemotherapy in the management of metastatic bladder cancer.
Topics: Doxorubicin; Drug Evaluation; Drug Therapy, Combination; Fluorouracil; Humans; Mitomycins; Neoplasm | 1981 |
[Combination chemotherapy in metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; F | 1981 |
[Results of, and indications for adjuvant chemotherapy in breast cancer].
Topics: Adult; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; | 1981 |
[Use of "split" courses of combination chemotherapy in breast cancer].
Topics: Breast Neoplasms; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Female; Fluorouracil | 1981 |
Correlation of estrogen receptors and response to chemotherapy of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in advanced breast cancer.
Topics: Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Methotr | 1981 |
Triple drug chemotherapy in treatment of prostate adenocarcinoma Nb Pr A.I.-III.
Topics: Adenocarcinoma; Animals; Carmustine; Cyclophosphamide; Doxorubicin; Drug Combinations; Drug Therapy, | 1981 |
Combination chemoimmunotherapy with FAC-BCG for metastatic breast cancer: the impact of CMF maintenance chemotherapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; BCG Vaccine; Breast Neoplasms; Cyclophosph | 1981 |
Variations in responsiveness and survival of clinical subsets of patients with metastatic breast cancer to two chemotherapy combinations.
Topics: Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; F | 1980 |
[Chemotherapy of breast cancer].
Topics: Adult; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans; Mastectomy; Methotrexate; N | 1981 |
Combined chemotherapy and radiotherapy for locally advanced breast cancer.
Topics: Adult; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Therapy, | 1980 |
Moderately high-dosage methotrexate medication in metastatic breast cancer.
Topics: Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Hu | 1980 |
Mitomycin C in metastatic breast cancer resistant to hormone therapy and conventional chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Resistance | 1980 |
Melphalan, 5-fluorouracil, and medroxyprogesterone acetate in metastatic or recurrent endometrial carcinoma. Preliminary report.
Topics: Adenocarcinoma; Antineoplastic Agents; Drug Therapy, Combination; Female; Fluorouracil; Humans; Medr | 1980 |
Early combined hormonal and chemotherapy for metastatic carcinoma of prostate.
Topics: Aged; Castration; Cyclophosphamide; Diethylstilbestrol; Drug Therapy, Combination; Fluorouracil; Hum | 1980 |
Modern approaches to the treatment of breast cancer.
Topics: Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Menstru | 1980 |
Dose-response effect of adjuvant chemotherapy in breast cancer.
Topics: Aged; Breast Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Sche | 1981 |
[Clinical and morphological determination of the effectiveness of preoperative radiologic and combined radiologic-chemotherapeutic therapy in locally metastasized rectal cancer].
Topics: Adult; Aged; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Preoperative Care | 1980 |
Evaluation of plasma 5-fluorouracil nucleoside levels in patients with metastatic breast cancer: relationships with toxicities.
Topics: Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Female; Floxuridine; Fluorouracil; Humans; | 1995 |
[Use of G-CSF in dose-intensified chemotherapy of breast cancer with FEC (500/75/500 mg/m2 KO) in the adjuvant and metastatic situation].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosp | 1993 |
Acute phase proteins and recombinant IL-2 therapy: prediction of response and survival in patients with colorectal cancer.
Topics: Acute-Phase Proteins; Biomarkers, Tumor; Colorectal Neoplasms; Combined Modality Therapy; Fluorourac | 1995 |
[Treatment using concomitant radiochemotherapy of N+ M0 stage urothelial tumors of the bladder].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 1995 |
Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cy | 1995 |
[The use of endolymphatic chemotherapy in patients with metastatic stomach cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 1994 |
Anticancer chemosensitivity changes between the original and recurrent tumors after successful chemotherapy selected according to the sensitivity assay.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; DNA, Neoplasm; Dox | 1995 |
Renal cell cancer: is there long-term survival advantage from cytokine treatment?
Topics: Carcinoma, Renal Cell; Fluorouracil; Humans; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Neop | 1994 |
Can we increase survival in breast cancer with innovative applications of conventional drugs?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Drug Administration S | 1994 |
The results of modified use of chemotherapy for patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox | 1994 |
Mitoxantrone, vincristine, and 5-fluorouracil with leucovorin modulation as induction chemotherapy prior to high-dose intensification in metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, | 1993 |
Concomitant chemoradiation prior to surgery in the treatment of advanced cervical carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality | 1994 |
[Simultaneous radiochemotherapy in locoregional recurrent breast carcinoma after mastectomy. Results in patients with macroscopic residual tumor R2].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Combined M | 1994 |
FAC (fluorouracil, doxorubicin, cyclophosphamide) as second line chemotherapy in patients with metastatic breast cancer progressing under FEC (fluorouracil, epirubicin, cyclophosphamide) chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox | 1994 |
Radiation therapy in the conservative treatment of carcinoma of the anal canal.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brachytherapy; Carcinom | 1994 |
Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma. A multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 1994 |
A novel "patient-like" treatment model of human pancreatic cancer constructed using orthotopic transplantation of histologically intact human tumor tissue in nude mice.
Topics: Animals; Disease Models, Animal; Drug Screening Assays, Antitumor; Fluorouracil; Humans; Liver Neopl | 1993 |
Chemoradiotherapy versus radiotherapy alone for anal cancer: a retrospective comparison.
Topics: Adult; Aged; Aged, 80 and over; Anus Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Fol | 1993 |
[Importance of systemic administration of pyrimidine after thermochemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Fluorouracil; Gas | 1993 |
Sensitivity of human colon tumor metastases to anticancer drugs in athymic (nude) mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carmustine; Colonic Neoplasms; Doxorubicin; Female; | 1993 |
[Immunotherapy of renal cell carcinoma from an urological viewpoint].
Topics: Carcinoma, Renal Cell; Female; Fluorouracil; Humans; Immunotherapy, Active; Interferon-alpha; Interl | 1993 |
[Follow-up of tumor markers in evaluating the effectiveness of chemo- or hormone therapy in metastatic breast cancer].
Topics: Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Biomarkers | 1993 |
Intermittent continuous intravenous infusion of 5-fluorouracil; a useful approach in disseminated colorectal cancer?
Topics: Adult; Aged; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middl | 1993 |
Dose-intensive metastatic breast cancer chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Flu | 1996 |
Patterns of recurrence for advanced colon cancer modified by whole abdominal radiation and chemotherapy.
Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Colonic Neoplasms; Combined Modality Therap | 1996 |
Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell | 1996 |
Vinorelbine/5-FU combination in metastatic breast cancer chemotherapy. A retrospective study of 63 cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fluorouracil; | 1996 |
p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neo | 1996 |
Cisplatin-fluorouracil exclusive chemotherapy for T1-T3N0 glottic squamous cell carcinoma complete clinical responders: five-year results.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols | 1996 |
Thymic humoral factor-gamma 2 (THF-gamma 2) immunotherapy reduces the metastatic load and restores immunocompetence in 3LL tumor-bearing mice receiving anticancer chemotherapy.
Topics: Animals; Drug Synergism; Drug-Related Side Effects and Adverse Reactions; Erythrocytes; Female; Fluo | 1996 |
Inhibition of experimental liver metastasis by combined treatment with tamoxifen and interferon.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineopl | 1996 |
The antitumor activity of doxorubicin against drug-resistant murine carcinoma is enhanced by oral administration of a synthetic staurosporine analogue, CGP 41251.
Topics: Administration, Oral; Animals; Antibiotics, Antineoplastic; Cell Line; Doxorubicin; Drug Resistance, | 1995 |
Intraoperative electron and external beam irradiation with or without 5-fluorouracil and maximum surgical resection for previously unirradiated, locally recurrent colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Combined Modality Therapy; Female; | 1996 |
Patterns of failure following treatment of pseudomyxoma peritonei of appendiceal origin.
Topics: Abdomen; Adult; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Chemotherapy, | 1996 |
Cell proliferation as a predictor of response to chemotherapy in metastatic breast cancer: a prospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Cyclop | 1997 |
Induction chemotherapy followed by radiotherapy versus radiotherapy alone in patients with advanced nasopharyngeal carcinoma: results of a matched cohort study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 1997 |
"Sandwich" preoperative and postoperative combined chemotherapy and radiation in tethered and fixed rectal cancer: impact of treatment intensity on local control and survival.
Topics: Adenocarcinoma; Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Combined Mod | 1997 |
[The combined treatment of locally disseminated stomach cancer with intra-arterial regional chemotherapy].
Topics: Antimetabolites, Antineoplastic; Celiac Artery; Combined Modality Therapy; Evaluation Studies as Top | 1996 |
[A comparative study of 4 sequential first-line chemotherapy protocols in locally advanced breast cancer].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, | 1997 |
Continuous infusion 5-fluorouracil as first-line therapy for metastatic breast cancer.
Topics: Ambulatory Care; Antimetabolites, Antineoplastic; Breast Neoplasms; Disease Progression; Female; Flu | 1996 |
Retrospective comparative analysis of 5FU + low-dose folinic acid vs. 5FU + high-dose folinic acid in the treatment of metastatic colorectal cancer. The Ottawa experience.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 1997 |
IL-6 is a survival prognostic factor in renal cell carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers; Biopterins; C-Reactive Protein; Carcinoma, | 1997 |
Clinical results of treatment of advanced esophageal carcinoma with hyperthermia in combination with chemoradiotherapy.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplasti | 1997 |
Antitumor activities of a novel fluoropyrimidine, N4-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine (capecitabine).
Topics: Analysis of Variance; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; | 1998 |
Immunohistochemical evaluation of thymidylate synthase in gastric carcinoma using a new polyclonal antibody: the clinical role of thymidylate synthase as a prognostic indicator and its therapeutic usefulness.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies; Antimetabolites, Antineoplastic; Carcino | 1998 |
The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined C | 1998 |
The effectiveness of chemotherapy with cisplatin and 5-fluorouracil for recurrent small cell neuroendocrine carcinoma of the rectum: report of a case.
Topics: Adenoma, Villous; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Carcino | 1999 |
Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Colorectal Ne | 1999 |
Prognostic implications of response to preoperative infusional chemoradiation in locally advanced rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Flu | 1999 |
Plasma and salivary pharmacokinetics of 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer receiving 5-FU bolus plus continuous infusion with high-dose folinic acid.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil; | 1999 |
Colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 1999 |
Expression of C-erbB-2/HER-2 in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous blood stem cell support.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; | 1999 |
Reduced expression of p27Kip1 protein is associated with poor clinical outcome of breast cancer patients treated with systemic chemotherapy and is linked to cell proliferation and differentiation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br | 1999 |
Cancer's Trojan horse--tricking malignant cells to self-destruct.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Enzyme Activation; Escherichia coli; Female; Fluo | 1999 |
Induction of apoptosis in metastatic foci from human gastric cancer xenografts in nude mice and reduction of circulating tumor cells in blood by 5-FU and 1-hexylcarbamoyl-5-fluorouracil.
Topics: Animals; Antigens, Nuclear; Antineoplastic Agents; Apoptosis; Cell Division; Dose-Response Relations | 1999 |
Commentary on PBT-1 study of high-dose consolidation versus standard therapy in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cycloph | 1999 |
[Nasopharyngeal carcinoma: only irradiation or simultaneous radiochemotherapy?].
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 1999 |
Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cos | 1999 |
A phase II trial of methotrexate, cisplatin, 5-fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Fluor | 2000 |
Unresectable adenocarcinoma of the pancreas: patterns of failure and treatment results.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease Pro | 2000 |
Preoperative radiation with concurrent 5-fluorouracil for locally advanced T4-primary rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; | 2000 |
High-dose chemotherapy for breast cancer: we have not heard the final word.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Sur | 2000 |
Chemosensitivity of advanced larynx carcinoma cells in vitro and significance of multidrug resistance markers in these tumors.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; C | 1998 |
Treatment of stage D2 hormone refractory carcinoma of the prostate with 5-fluorouracil and Roferon-A: a Southwest Oncology Group study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Fluorouraci | 1996 |
Weekly 5-fluorouracil and interferon-alfa-2b in metastatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration | 1996 |
Antimetastatic intraoperative chemotherapy of human colon tumors in the livers of nude mice.
Topics: Animals; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; Female; Fluorou | 2000 |
Epithelial cells in bone marrow of oesophageal cancer patients: a significant prognostic factor in multivariate analysis.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Bone Marrow; Bon | 2000 |
[High-dose chemotherapy for metastatic breast cancer without certain advantages so far].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cycl | 2000 |
Moving beyond fluorouracil for colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Col | 2000 |
Retrospective evaluation of 5-fluorouracil-interferon-a aTreatment of advanced colorectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2000 |
[The importance of delay in patients with tumors exemplified by pretreatment of locally advanced rectal carcinoma].
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Endosonography; Fluorouracil; Humans; Le | 2000 |
[Chemotherapy for unresectable recurrent or metastatic squamous cell carcinomas of the head and neck].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2000 |
Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Colorectal Neoplasm | 2000 |
Cure of metastatic human colonic cancer in mice with radiolabeled monoclonal antibody fragments.
Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Bone Marrow Transplantation; Carci | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2001 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrh | 2001 |
Polyadenylic-polyuridylic acid plus locoregional radiotherapy versus chemotherapy with CMF in operable breast cancer: a 14 year follow-up analysis of a randomized trial of the Fédération Nationale des Centres de Lutte contre le Cancer (FNCLCC).
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasm | 2000 |
[Hemorrhagic diathesis as initial symptom of stomach carcinoma].
Topics: Algorithms; Anemia, Hemolytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplasti | 2000 |
Thalidomide for recurrent renal-cell cancer in a 40-year-old man.
Topics: Adenocarcinoma, Clear Cell; Adult; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Drug Therapy, Com | 2000 |
[The expression of platelet-derived endothelial cell growth factor in liver cancer].
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; En | 2000 |
Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Biomarkers, T | 2001 |
Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Esophageal Neo | 2001 |
Angiogenesis sustains tumor dormancy in patients with breast cancer treated with adjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br | 2001 |
Update of clinical trials with edrecolomab: a monoclonal antibody therapy for colorectal cancer.
Topics: Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody | 2001 |
Detection of Epstein-Barr virus DNA in the peripheral-blood cells of patients with nasopharyngeal carcinoma: relationship to distant metastasis and survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cisplatin; Combin | 2001 |
The role of mitomycin C in the treatment of patients with advanced colorectal cancer resistant to 5-fluorouracil-folinic acid chemotherapy.
Topics: Antibiotics, Antineoplastic; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; | 2001 |
Adjuvant postoperative 5-fluorouracil chemotherapy combined with pelvic radiation for rectal cancer: results from an Asian population.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Agranulocytosis; Antimetabolites, Antineoplastic; Ch | 2001 |
Survival of tumor cells in stem cell preparations and bone marrow of patients with high-risk or metastatic breast cancer after receiving dose-intensive or high-dose chemotherapy.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2001 |
Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu | 2001 |
Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cispla | 2001 |
Nuclear thymidylate synthase expression, p53 expression and 5FU response in colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Cell Differentiation; Cell Nucleus; Co | 2001 |
Experience in treatment of metastatic pulmonary carcinoid tumors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoi | 2001 |
[Adenocarcinomas of the distal esophagus and gastric cardia: what chemotherapy or chemoradiotherapy for recurrent or metastatic disease?].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cardia; Cisplatin; Combined Modality | 2001 |
Evaluation of cytokeratin-19 mRNA as a tumor marker in the peripheral blood of nasopharyngeal carcinoma patients receiving concurrent chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma; Cisplatin | 2002 |
[Combination therapy including mutamycin (mitomycin C) in the treatment of advanced colorectal and gastric cancer].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 2001 |
Clinical experience of capecitabine in metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Comb | 2002 |
Progesterone receptor status of breast cancer metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dis | 2002 |
Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer With hyperfractionated radiation and concurrent chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer With hyperfractionated radiation and concurrent chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer With hyperfractionated radiation and concurrent chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer With hyperfractionated radiation and concurrent chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2002 |
Capecitabine monotherapy in metastatic colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Hu | 2001 |
In regard to Cheng et al., examining prognostic factors of failure in nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy: impact on future clinical trials. IJROBP 2001;50:717-726.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemothe | 2002 |
Capecitabine as second-line treatment for metastatic cholangiocarcinoma: a report of two cases.
Topics: Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Cholangiocarcinoma; Deoxycytidine | 2002 |
Concomitant chemoirradiation for stage III-IV nasopharyngeal carcinoma in Chinese patients: results of a matched cohort analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Chemotherapy, Adj | 2002 |
Improvement of local control of T3 and T4 nasopharyngeal carcinoma by hyperfractionated radiotherapy and concomitant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2002 |
[A case in which TS-1, an orally-administered 5-FU chemotherapeutic agent, showed marked effectiveness against scirrhous type gastric cancer with multiple organ metastases].
Topics: Adenocarcinoma, Scirrhous; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocol | 2002 |
[Adjuvant therapy following curative surgery of colon cancer].
Topics: Antineoplastic Agents; BCG Vaccine; Colonic Neoplasms; Fluorouracil; Humans; Immunotherapy; Neoplasm | 1979 |
Treatment of carcinoma of the pancreas with radon seed implantation and intra-arterial infusion of 5-FUDR.
Topics: Adenocarcinoma; Adult; Aged; Fluorouracil; Humans; Infusions, Parenteral; Male; Middle Aged; Neoplas | 1975 |
[Topical chemotherapy for carcinoma of the skin (author's transl)].
Topics: Administration, Topical; Adolescent; Aged; Bleomycin; Bowen's Disease; Carcinoma, Basal Cell; Carcin | 1975 |
[Treatment of advanced cancer of the bladder].
Topics: Fluorouracil; Humans; Neoplasm Metastasis; Palliative Care; Time Factors; Urinary Bladder Neoplasms | 1975 |
Esophageal carcinoma. The value of staging in long-term survival.
Topics: Administration, Oral; Cyclophosphamide; Esophageal Neoplasms; Esophagus; Female; Fluorouracil; Follo | 1975 |
Bleomycin combination chemotherapy in the management of testicular neoplasia.
Topics: Abdominal Neoplasms; Adult; Bleomycin; Cyclophosphamide; Drug Therapy, Combination; Dysgerminoma; Fl | 1975 |
Hepatic artery ligation and prolonged cytotoxic therapy in advanced primary and secondary liver tumours.
Topics: Adult; Aged; Antineoplastic Agents; Bilirubin; Biopsy; Catheterization; Female; Fluorouracil; Hepati | 1975 |
Seven-drug polychemotherapy in the treatment of advanced and recurrent squamous carcinoma of the female genital tract.
Topics: Adult; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamide; Cytarabine; Dac | 1975 |
Letter: Chemotherapy after mastectomy.
Topics: Antineoplastic Agents; Breast Neoplasms; Chlorambucil; Cyclophosphamide; Drug Evaluation; Drug Thera | 1976 |
[Five-years synchronized radiotherapy in treatment of carcinoma of the head and neck: clinical results, 1970--1974 (author's transl)].
Topics: Antineoplastic Agents; Bleomycin; Fluorouracil; Head and Neck Neoplasms; Humans; Methods; Neoplasm M | 1976 |
Hepatic dearterialization for nonrespectable primary and secondary tumors of the liver.
Topics: Adult; Aged; alpha-Fetoproteins; Carcinoma, Hepatocellular; Female; Fluorouracil; Hemangiosarcoma; H | 1976 |
Combination chemotherapy in germinal cell tumors.
Topics: Adolescent; Adult; Antineoplastic Agents; Bleomycin; Choriocarcinoma; Cyclophosphamide; Drug Therapy | 1976 |
Mallory-Weiss lesion following cancer chemotherapy.
Topics: Drug Therapy, Combination; Fluorouracil; Humans; Lung Neoplasms; Male; Mallory-Weiss Syndrome; Methy | 1977 |
[Stomach neoplasms].
Topics: Aftercare; Eosinophilic Granuloma; Fluorouracil; Gastrectomy; Hodgkin Disease; Lymph Nodes; Mitomyci | 1978 |
Palliation of hepatic metastasis.
Topics: Female; Fluorouracil; Humans; Liver Neoplasms; Male; Neoplasm Metastasis; Palliative Care; Radiother | 1978 |
Treatment of liver cancer with regional intraarterial 5-FU infusion.
Topics: Adult; Aged; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle | 1978 |
Management of carcinoma of the extrahepatic bile ducts.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Bile Duct Neoplasms; Carcinoma, Squamous Cell; Child; Commo | 1978 |
[The influences of carcinostatic agents on the host immune response and lymphocytes-dynamics in mice].
Topics: Animals; Bleomycin; Fluorouracil; Immunosuppressive Agents; Lymphocytes; Mice; Neoplasm Metastasis; | 1979 |
[Effectiveness of ftorafur and hexamethylmelamine in advanced breast cancer].
Topics: Adult; Altretamine; Breast Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Humans; Leuko | 1978 |
Intraperitoneal contrast infusion for assessment of intraperitoneal fluid dynamics.
Topics: Adult; Antineoplastic Agents; Ascitic Fluid; Contrast Media; Female; Fluorouracil; Humans; Injection | 1979 |
[Hepatic metastases of cancers of the large intestine. Results of arterial chemotherapeutic treatment].
Topics: Female; Floxuridine; Fluorouracil; Humans; Injections, Intra-Arterial; Intestinal Neoplasms; Intesti | 1976 |
A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2'-deoxyuridine and 5-fluorouracil.
Topics: Adult; Aged; Drug Evaluation; Female; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusions, | 1978 |
[Chemotherapy of gastrointestinal cancer (author's transl)].
Topics: Carcinoid Tumor; Doxorubicin; Fluorouracil; Gastrointestinal Neoplasms; Humans; Liver Neoplasms; Neo | 1978 |
Letter: Osteoblastic repair of osteolytic tumor metastases following treatment.
Topics: Adult; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Cyclophospham | 1975 |
Islet cell carcinoma of the pancreas.
Topics: Adenoma, Islet Cell; Adolescent; Adult; Aged; Child; Cyclophosphamide; Dactinomycin; Female; Fluorou | 1975 |
A multiple chemotherapeutic approach to the management of hepatoblastoma. A preliminary report.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Child; Cyclophosphamide; Doxorubicin; Drug Therapy | 1975 |
Current status of regional arterial infusion chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Hepatocellular; Carotid Arteries; Catheterization; | 1975 |
[Determination of individual sensitivity of gastric cancer to 5-fluorouracil by tumor tissue respiratory and glycolytic indices].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenocarcinoma, Scirrhous; Carcinoma; Fluorouracil; Glycol | 1975 |
Current management of hepatic tumors.
Topics: Angiography; Biopsy, Needle; Blood Platelet Disorders; Carcinoma, Hepatocellular; Child; Child, Pres | 1975 |
Carcinoma of the rectum in adolescence.
Topics: Adenocarcinoma, Mucinous; Adolescent; Age Factors; Cyclophosphamide; Fluorouracil; Humans; Hydroneph | 1975 |
Islet cell carcinoma of the pancreas: effective therapy with 5-fluorouracil, streptozotocin, and tubercidin.
Topics: Adenoma, Islet Cell; Adult; Diazoxide; Doxorubicin; Drug Administration Schedule; Drug Therapy, Comb | 1976 |
Hepatic artery ligation and 5-fluorouracil infusion for metastatic colon carcinoma and primary hepatoma.
Topics: Adolescent; Adult; Aged; Carcinoma, Hepatocellular; Chemotherapy, Cancer, Regional Perfusion; Colect | 1976 |
Combination chemotherapy with 5--fluorouracil, amethopterin (methotrexate) and prednisolone (FAP protocol) in the therapy of cholangiocarcinoma.
Topics: Adenoma, Bile Duct; Drug Therapy, Combination; Fluorouracil; Humans; Liver Neoplasms; Male; Methotre | 1976 |
[Experiences with drug therapy of advanced metastatic carcinoma of the breast (author's transl)].
Topics: Adenocarcinoma; Adenocarcinoma, Scirrhous; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Car | 1976 |
Observations on the postoperative tumor growth behavior of certain islet cell tumors.
Topics: Adenoma, Islet Cell; Fasting; Fluorouracil; Gastrins; Humans; Liver Neoplasms; Neoplasm Metastasis; | 1976 |
Intrahepatic arterial infusion of combination of mitomycin-C and 5-fluorouracil in treatment of primary and metastatic liver carcinoma.
Topics: Adult; Carcinoma, Hepatocellular; Drug Synergism; Drug Therapy, Combination; Female; Fluorouracil; H | 1977 |
Futraful therapy on liver cancer.
Topics: Administration, Oral; Adult; Aged; Alkaline Phosphatase; Carcinoma, Hepatocellular; Drug Administrat | 1977 |
[Fluorinated pyrimidines administered by percutaneous arterial perfusion in primary or secondary cancers of the liver].
Topics: Carcinoma, Hepatocellular; Floxuridine; Fluorouracil; Humans; Infusions, Intra-Arterial; Liver Neopl | 1977 |
Case report: Liver scintigraphy in the follow-up of a patient on cytotoxic therapy.
Topics: Adenocarcinoma; Bronchial Neoplasms; Carcinoma, Small Cell; Cyclophosphamide; Fluorouracil; Humans; | 1976 |
Chemotherapy of metastatic gastrointestinal neoplasms with 5-fluorouracil and streptozotocin.
Topics: Adenocarcinoma; Adenoma, Bile Duct; Adenoma, Islet Cell; Adult; Aged; Bile Duct Neoplasms; Carcinoid | 1977 |
Schedule dependent effectiveness of CCNU and 5-fluorouracil in experimental chemotherapy.
Topics: Animals; Cell Survival; Drug Therapy, Combination; Fluorouracil; Hematopoietic Stem Cells; Lomustine | 1977 |
Effect of oral hygiene on stomatitis in patients receiving cancer chemotherapy.
Topics: Breast Neoplasms; Cyclophosphamide; Dental Plaque; Doxorubicin; Female; Fluorouracil; Humans; Inject | 1978 |
Trial of anticancer pellet in malignant brain tumours; 5 FU and urokinase embedded in silastic.
Topics: Animals; Brain Neoplasms; Carcinoma; Drug Implants; Endopeptidases; Fluorouracil; Glioma; Humans; Ne | 1979 |
Leucovorin in combination chemotherapy of breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Fluorouracil; Humans; Le | 1977 |
Treatment of hepatic metastases by percutaneous hepatic arterial infusion.
Topics: Antineoplastic Agents; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Gastroint | 1979 |
[Ftorafur concentration in the blood and urine of oncological patients].
Topics: Biopharmaceutics; Biotransformation; Breast Neoplasms; Dose-Response Relationship, Drug; Female; Flu | 1977 |
Chemoimmunotherapy of metastatic large bowel cancer: nonspecific stimulation with BCG and levamisole.
Topics: BCG Vaccine; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Levamisole; Lomusti | 1977 |
Iv methyl-CCNU and ftorafur with or without methanol-extracted residue of BCG for metastatic adenocarcinoma of the colon.
Topics: Adenocarcinoma; BCG Vaccine; Colonic Neoplasms; Fluorouracil; Humans; Injections, Intravenous; Leuko | 1977 |
[Use of ftorafur in disseminated breast cancer].
Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Capsules; Female; Fluorouracil; Humans; Middle | 1978 |
Phase II evaluation of ftorafur in previously untreated colorectal cancer: a Southwest Oncology Group Study.
Topics: Adenocarcinoma; Adult; Aged; Central Nervous System; Colonic Neoplasms; Drug Evaluation; Female; Flu | 1979 |
Chemotherapy of gastrointestinal cancer.
Topics: Adjuvants, Pharmaceutic; Antineoplastic Agents; Fluorouracil; Gastrointestinal Neoplasms; Humans; Ne | 1979 |
Chemoimmunotherapy with or without oophorectomy in premenopausal patients with advanced breast cancer.
Topics: BCG Vaccine; Breast Neoplasms; Castration; Cyclophosphamide; Doxorubicin; Drug Therapy; Female; Fluo | 1979 |
Acute leukemia after alkylating-agent therapy of ovarian cancer.
Topics: Acute Disease; Alkylating Agents; Altretamine; Chlorambucil; Cyclophosphamide; Female; Fluorouracil; | 1977 |
Nutrition and breast cancer.
Topics: Animals; Ascorbic Acid; Bone Neoplasms; Breast Neoplasms; Calcium; Dietary Fats; Feeding Behavior; F | 1979 |
Combined chemoimmunotherapy for advanced breast cancer: a comparison of BCG and levamisole.
Topics: Antineoplastic Agents; BCG Vaccine; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Administra | 1979 |
Prognostic factors in metastatic breast cancer treated with combination chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, C | 1979 |
Chemotherapy for sarcoma of the stomach.
Topics: Adult; Aged; Asparaginase; Cyclophosphamide; Dacarbazine; Dactinomycin; Doxorubicin; Drug Therapy, C | 1979 |
Chemotherapy for breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; F | 1979 |
[Importance of the analysis of the carcinoembryonic antigen in clinical oncology].
Topics: Carcinoembryonic Antigen; Colonic Neoplasms; Female; Fluorouracil; Gastrointestinal Neoplasms; Human | 1979 |
[The period of time between operation and irradiation of a mamma carcinoma and its cytostatic treatment (author's transl)].
Topics: Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; | 1979 |
Heparinized catheters for long-term intraarterial infusion of 5-fluorouracil in liver metastases.
Topics: Aged; Catheters, Indwelling; Female; Fluorouracil; Heparin; Humans; Infusions, Intra-Arterial; Liver | 1979 |
Sequential polychemotherapy for advanced prostatic carcinoma. A preliminary cooperative study on 30 patients.
Topics: Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Humans; Male; Neoplasm Metas | 1979 |
Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG.
Topics: Adult; Aged; Antineoplastic Agents; BCG Vaccine; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Dr | 1979 |
Treatment of advanced gastrointestinal cancer with 5-fluorouracil and mitomycin C.
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Gas | 1979 |
Effect of preoperative intralesional BCG and postoperative 5-FU chemotherapy in three adenocarcinoma lines in rats.
Topics: Adenocarcinoma; Animals; BCG Vaccine; Colonic Neoplasms; Female; Fluorouracil; Male; Mammary Neoplas | 1979 |
Intraarterial infusion chemotherapy (5-fluorouracil) in patients with inextirpable or locally recurrent rectal cancer.
Topics: Adult; Aged; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Neoplasm Me | 1979 |
Occurrence of testicular metastasis in a child with bilateral retinoblastoma.
Topics: Antineoplastic Agents; Child, Preschool; Cyclophosphamide; Dactinomycin; Doxorubicin; Drug Therapy, | 1979 |
Postoperative adjuvant chemotherapy with fluorouracil, doxorubicin, cyclophosphamide, and BCG vaccine. A follow-up report.
Topics: Antineoplastic Agents; BCG Vaccine; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, C | 1979 |
Potentiating role of previously administered agents in the combination chemotherapy of breast cancer.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Synergism; Drug Therapy, Comb | 1979 |
[Association of VCR-5FU-CYCLO-PDN in the treatment of disseminated carcinoma of the breast (author's transl)].
Topics: Breast Neoplasms; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Evaluation Studies a | 1979 |
Sequence for developing optimal combination chemotherapy of metastatic breast cancer.
Topics: Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Methotr | 1979 |
Adjuvant postoperative chemotherapy with 5-fluorouracil and methotrexate: effect of schedule of administration on metastasis of 13762 mammary adenocarcinoma.
Topics: Adenocarcinoma; Animals; BCG Vaccine; Drug Administration Schedule; Drug Therapy, Combination; Femal | 1977 |
[Practice in the treatment of rectal carcinoma. Recommendations of the Deutschen Gesellschaft für Chirurgie].
Topics: Anus Neoplasms; Female; Fluorouracil; Germany, West; Humans; Intestinal Polyps; Male; Neoplasm Metas | 1977 |
Chemotherapy for metastatic carcinoid tumors: experiences with 32 patients and a review of the literature.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoid Tumor; Cyclophosphamide; Doxorubicin; Drug Therapy, Co | 1977 |
Treatment of metastatic melanoma with combined 5-fluorouracil and procarbazine.
Topics: Adult; Aged; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Melanoma; Middle Aged; N | 1977 |
The carcinoid syndrome: methods of treatment and recent experience with hepatic artery ligation and infusion.
Topics: Female; Fluorouracil; Heart Failure; Hepatic Artery; Humans; Hydroxyindoleacetic Acid; Ileum; Intest | 1977 |
Chemo immunotherapy of advanced breast cancer with BCG.
Topics: Adult; Aged; Antineoplastic Agents; BCG Vaccine; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Dr | 1977 |
Recent trends in breast cancer treatment.
Topics: Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Hormones; Humans; Immunotherapy; Mastectom | 1978 |
Iatrogenic liver abscesses. A complication of hepatic artery ligation for tumor.
Topics: Arteriovenous Shunt, Surgical; Biliary Fistula; Bronchial Fistula; Female; Fluorouracil; Hepatic Art | 1978 |
Chemotherapy trial with comp-F regimen in advanced adenocarcinoma of prostate.
Topics: Adenocarcinoma; Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Fluorouracil; Hu | 1978 |
[Breast neoplasms. Staging, therapy and after care].
Topics: Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Immunot | 1978 |
Sequential 5-fluorouracil and hydroxyurea therapy for metastatic colorectal adenocarcinoma.
Topics: Adenocarcinoma; Colonic Neoplasms; Fluorouracil; Humans; Hydroxyurea; Neoplasm Metastasis; Rectal Ne | 1978 |
Adriamycin in combination for the treatment of breast cancer: a Southwest Oncology Group study.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Administra | 1978 |
[The primary appendix carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Appendiceal Neoplasms; Colostomy; Cyclophosphamide; Female; Fluorouraci | 1978 |
Combination chemotherapy for advanced breast cancer: two regimens containing adriamycin.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Cyclophosphamide; Digestive Syste | 1978 |
Treatment of hepatic metastases from breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; F | 1978 |
[Results of high-dosage attack treatment with cytostatics in mammary and ovarian cancer (author's transl)].
Topics: Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans; Methotrexat | 1978 |
Correlation of estrophilin content of primary mammary cancer to eventual endocrine treatment.
Topics: Adrenalectomy; Breast Neoplasms; Castration; Cyclophosphamide; Diethylstilbestrol; Drug Therapy, Com | 1978 |
Phase II study of melphalan in colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Evaluation; Female; Fluorouracil; Humans; Male; | 1978 |
Combination of constant-infusion 5-fluorouracil, methyl-CCNU, mitomycin C, and vincristine in advanced colorectal carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; H | 1978 |
Treatment of symptomatic metastatic cancer to the liver from primary colon and rectal cancer by the intraarterial administration of chemotherapy and radioactive isotopes.
Topics: Catheters, Indwelling; Colonic Neoplasms; Femoral Artery; Fluorouracil; Hepatic Artery; Humans; Infu | 1978 |
Heterogeneity in drug sensitivity among tumor cell subpopulations of a single mammary tumor.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line; Cyclophosphamide; Drug Resistance; Fluoro | 1978 |
The clinical results of 5-fluorouracil intrahepatic arterial infusion in 528 patients with metastatic cancer to the liver.
Topics: Diarrhea; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; | 1978 |
Initial levels of CEA and their rate of change in pancreatic carcinoma following surgery chemotherapy and radiation therapy.
Topics: Alkaline Phosphatase; Carcinoembryonic Antigen; Carcinoma; Cholestasis; Fluorouracil; Humans; Neopla | 1978 |
Amphotericin B and combination chemotherapy in the treatment of refractory metastatic breast carcinoma and sarcoma.
Topics: Adult; Aged; Amphotericin B; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Dacarbazine; | 1978 |
[Contribution to the radiation therapy of malignant tumors in the regions of the head and neck using the synchronization effects of fluorouracil (author's transl)].
Topics: Adult; Aged; Esophageal Neoplasms; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Laryngeal | 1978 |
Combination therapy with mitomycin C, 5-fluorouracil, and cytosine arabinoside for nonresectable malignant tumor in man.
Topics: Adult; Aged; Bone Marrow; Breast Neoplasms; Cytarabine; Drug Therapy, Combination; Female; Fluoroura | 1978 |
Cancer of the pancreas in young adults.
Topics: Adenocarcinoma; Adult; Biopsy, Needle; Female; Fluorouracil; Humans; Laparotomy; Liver Neoplasms; Ne | 1978 |
Delayed hypersensitivity reactions in patients with breast cancer.
Topics: Adult; Antigens, Neoplasm; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans; Hyperse | 1978 |
[Chemotherapy of inoperable endothoracic tumours (results of the Karrer and aco polycytostatic therapy) (author's transl)].
Topics: Adult; Aged; Bronchial Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; | 1979 |
Hypoglycemia secondary to metastases to the liver. A case report and review of the literature.
Topics: Aged; Cyclophosphamide; Fluorouracil; Humans; Hypoglycemia; Liver Neoplasms; Male; Neoplasm Metastas | 1977 |
Bone marrow involvement in breast cancer: effect on response and tolerance to combination chemotherapy.
Topics: Adult; Aged; Blood Cell Count; Blood Platelets; Bone Marrow Diseases; Breast Neoplasms; Cyclophospha | 1977 |
Comparison of adjuvant chemotherapeutic activity against primary and metastatic spontaneous murine tumors.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Doxorubicin; Drug Therapy, Combination; Female; Fluo | 1977 |
Systemic therapy for metastatic breast cancer.
Topics: BCG Vaccine; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Estrogens; Female; Fluor | 1977 |
Management of hepatic metastases.
Topics: Abdominal Neoplasms; Adult; Aged; Antineoplastic Agents; Carcinoma; Chemotherapy, Cancer, Regional P | 1977 |
[Combination cytostatic chemotherapy of advanced metastatic cancer of the prostate. A preliminary uncontrolled study].
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Bone Marrow Diseases; Cyclophosphamide; Dr | 1977 |
Multiple drug chemotherapy regimen for patients with hormonally-unresponsive carcinoma of the prostate: a preliminary report.
Topics: Administration, Oral; Antineoplastic Agents; Drug Administration Schedule; Drug Evaluation; Drug The | 1977 |
[Chemotherapy of breast cancers].
Topics: Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans; Methotrexate; Neoplasm Metastasis | 1977 |
Combination chemotherapy of advanced endometrial adenocarcinoma with adriamycin, cyclophosphamide, 5-fluorouracil, and medroxyprogesterone acetate.
Topics: Adenocarcinoma; Aged; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil | 1977 |
Chemotherapy of carcinoma of the cervix.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow; Carcinoma, Squamous Cel | 1977 |
Cyclic combination chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Hu | 1977 |
Selection of chemotherapy for metastatic mammary cancer by effect on cesium-131 uptake.
Topics: Antineoplastic Agents; Breast Neoplasms; Cesium; Cesium Radioisotopes; Cyclophosphamide; Diethylstil | 1977 |
Results of liver dearterialization combined with regional infusion of 5-fluorouracil for liver cancer.
Topics: Adult; Aged; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Parenteral; Ligation; Liver Ci | 1976 |
Editorial: Progress in the treatment of colorectal cancer.
Topics: Colonic Neoplasms; Fluorouracil; Humans; Neoplasm Metastasis; Postoperative Care; Rectal Neoplasms | 1976 |
Editorial: Adjuvant chemotherapy in colorectal cancer.
Topics: Carcinoembryonic Antigen; Colonic Neoplasms; Fluorouracil; Neoplasm Metastasis; Rectal Neoplasms | 1976 |
[Experiences in the treatment of 2 patients with xeroderma pigmentosum].
Topics: Adolescent; Adult; Brain Neoplasms; Female; Fluorouracil; Humans; Leiomyosarcoma; Male; Melanoma; Ne | 1976 |
[Polychemotherapy of the advanced and metastasizing carcinoma of the breast].
Topics: Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluoro | 1976 |
[Five-drug therapy in addition to hormonal treatment in advance breast cancer metastatic to the lung (author's transl)].
Topics: Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; F | 1976 |
[Combination chemotherapy in the treatment of polymetastic breast cancer. Comparison of therapeutic effects of 2 methods of sequential drug administration. Role of adriamycin in these combinations].
Topics: Adenocarcinoma; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Drug Tol | 1976 |
[Preliminary experiences in the treatment of metastatic mamma carcinoma by polychemotherapy-according to Cooper (author's transl)].
Topics: Breast Neoplasms; Cyclophosphamide; Drug Combinations; Drug Therapy, Combination; Female; Fluorourac | 1976 |
Doxorubicin hydrochloride, cyclophosphamide, and 5-fluorouracil combination in advanced prostate and transitional cell carcinoma.
Topics: Acid Phosphatase; Adenocarcinoma; Aged; Carcinoma, Transitional Cell; Cyclophosphamide; Doxorubicin; | 1976 |
[Cytostatic therapy of inoperable carcinomas].
Topics: Breast Neoplasms; Bronchial Neoplasms; Chlorambucil; Choriocarcinoma; Cyclophosphamide; Dactinomycin | 1976 |
Combination chemotherapy in the treatment of advanced breast cancer.
Topics: Adrenalectomy; Alopecia; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Co | 1976 |
Serial carcinoembryonic antigen assays in patients with metastatic carcinoma of prostate being treated with chemotherapy.
Topics: Acid Phosphatase; Adenocarcinoma; Carcinoembryonic Antigen; Drug Therapy, Combination; Fluorouracil; | 1976 |
Multidisciplinary curative treatment for disseminated carcinoma of the breast.
Topics: Androgens; Antineoplastic Agents; Breast Neoplasms; Castration; Cyclophosphamide; Diethylstilbestrol | 1976 |
"Early" and "late" breast cancer: a unified concept for treatment.
Topics: Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Fluorouracil; Hypophysectomy; Methotr | 1976 |
[Chemotherapy in primary and metastatic intrathoracic cancer].
Topics: Antineoplastic Agents; Breast Neoplasms; Bronchial Neoplasms; Cyclophosphamide; Doxorubicin; Drug Th | 1976 |
Acute cardiac pain and electrocardiographic changes following cytotoxic treatment for metastatic carcinoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Breast Neoplasms; Coronary Disease; Cyclophosphamide; | 1976 |
[Late results of the prophylactic treatment with 5-fluorouracil of cancer of the large intestine and rectum].
Topics: Adult; Aged; Female; Fluorouracil; Follow-Up Studies; Humans; Intestinal Neoplasms; Intestine, Large | 1976 |
The role of nonspecific immunotherapy in the treatment of breast cancer.
Topics: Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; | 1976 |
Concomitant androgen therapy in the management of advanced breast cancer by cyclical combined chemotherapy.
Topics: Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Hemoglobins; Humans; Methotrexate; Nandrol | 1976 |
Results of regional portal infusion of 5-fluorouracil in patients with primary and secondary liver cancer.
Topics: Adult; Aged; Breast Neoplasms; Colonic Neoplasms; Female; Fluorouracil; Hepatic Artery; Humans; Infu | 1976 |
Fluorouracil as an adjuvant to colorectal cancer surgery.
Topics: Colonic Neoplasms; Fluorouracil; Humans; Neoplasm Metastasis; Postoperative Care; Rectal Neoplasms | 1976 |
Combination chemotherapy for disseminated carcinoma of the breast.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Evaluation; Drug Therapy, Com | 1975 |
Survival among patients with liver metastases from cancer of the colon and rectum.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Alkaline Phosphatase; Bilirubin; Colonic Neoplasms; F | 1976 |
Immunotherapy of human solid tumors with Bacillus Calmette-Guérin: prolongation of disease-free interval and survival in malignant melanoma, breast, and colorectal cancer.
Topics: BCG Vaccine; Breast Neoplasms; Colonic Neoplasms; Dacarbazine; Doxorubicin; Female; Fluorouracil; Hu | 1976 |
[Treatment of osteosarcoma: an end to the present impasse?].
Topics: Cyclophosphamide; Doxorubicin; Fluorouracil; Humans; International Cooperation; Lung Neoplasms; Mito | 1976 |
Anti-tumour and anti-metastatic activity of 3-(P-Chlorophenyl)-2,3-Dihydro-3-Hydroxythiazolo (3,2-A)-Benzimidazole-2-acetic acid (WY-13,876).
Topics: Animals; Anthelmintics; Antilymphocyte Serum; Antineoplastic Agents; Benzimidazoles; Cyclophosphamid | 1976 |
[Continuous intra-arterial antiblastic chemotherapy in the treatment of rhinopharyngeal tumors invading the skull base. Association with radiotherapy].
Topics: Carcinoma, Squamous Cell; Fluorouracil; Humans; Injections, Intra-Arterial; Middle Aged; Neoplasm Me | 1975 |
Hepatic artery ligation in treatment of carcinoid syndrome.
Topics: Aged; Angiography; Cyclophosphamide; Female; Fluorouracil; Hepatic Artery; Humans; Hydroxyindoleacet | 1975 |
Chemotherapy of breast cancer.
Topics: Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Hu | 1975 |
Topical chemotherapy of lentigo maligna with 5-fluorouracil.
Topics: Aged; Evaluation Studies as Topic; Female; Fluorouracil; Follow-Up Studies; Humans; Immunity, Cellul | 1975 |
Changes in 87mSr concentractions in skeletal metastases in patients responding to cyclical combination chemotherapy for advanced breast cancer.
Topics: Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; | 1975 |
Hepatic artery ligation and postoperative chemotherapy for hepatic metastases: clinical and pathophysiological results.
Topics: Adult; Aged; Antineoplastic Agents; Biopsy; Carbon Dioxide; Colonic Neoplasms; Female; Fluorouracil; | 1975 |
An effective low-dose intermittent cyclophosphamide, methotrexate, and 5-fluorouracil treatment regimen for metastatic breast cancer.
Topics: Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; | 1975 |
Adriamycin plus vincristine compared to and combined with cyclophosphamide, methotrexate, and 5-fluorouracil for advanced breast cancer.
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy | 1975 |
Adenocarcinoma of the bile ducts. Relationship of anatomic location to clinical features.
Topics: Adenocarcinoma; Adult; Aged; Alkaline Phosphatase; Bile Duct Neoplasms; Bile Ducts; Bile Ducts, Intr | 1975 |
[Chemotherapeutic combinations of mutually potentializing drugs. 1-Application to the treatment of breast cancers].
Topics: Aged; Alopecia; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Synergism; Drug Ther | 1975 |
[Treatment of advanced prostatic cancer].
Topics: Adrenalectomy; Aged; Estrogens; Fluorouracil; Humans; Hypophysectomy; Male; Neoplasm Metastasis; Pro | 1975 |
5-fluorouracil with cytosine arabinoside in metastatic gastrointestinal cancer.
Topics: Adult; Aged; Cytarabine; Drug Therapy, Combination; Fluorouracil; Gastrointestinal Neoplasms; Humans | 1975 |
Response of patients with carcinoma of the breast to hormonal therapy and combination chemotherapy.
Topics: Adrenalectomy; Androgens; Breast Neoplasms; Castration; Cyclophosphamide; Estrogens; Female; Fluorou | 1975 |
Combination chemotherapy in metastatic carcinoma of the breast. Results with a three-drug combination.
Topics: Adenocarcinoma; Adult; Aged; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Ethylnit | 1975 |
Chemotherapy in the treatment strategy of breast cancer.
Topics: Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Hu | 1975 |
Arterial infusion of 5-FU as a therapeutic adjunct in the treatment of advanced carcinoma of bladder and prostate.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Female; Fluorou | 1975 |
Metastatic adrenal cortical carcinoma. Documented cure with combined chemotherapy.
Topics: Adolescent; Adrenal Gland Neoplasms; Carcinoma; Drug Therapy, Combination; Female; Fluorouracil; Hum | 1975 |
Sequential therapy for advanced ovarian adenocarcinoma: operation, chemotherapy, second-look laparotomy, and radiation therapy.
Topics: Adenocarcinoma; Chlorambucil; Cyclophosphamide; Dactinomycin; Female; Fluorouracil; Laparotomy; Melp | 1975 |
Letter: fluorouracil.
Topics: Fluorouracil; Humans; Neoplasm Metastasis; Skin | 1975 |
The influence of site of metastasis on tumour growth and response to chemotherapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Chlorambucil; Female; Fluorouracil; Genital Neoplasms, Fema | 1975 |
Comparison of 5-fluorouracil with 5-fluorouracil, cyclophosphamide, and methotrexate in metastatic colorectal carcinoma.
Topics: Colonic Neoplasms; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Female; Fluorouraci | 1975 |
Treatment of advanced bronchogenic carcinoma with adriamycin and 5-fluorouracil.
Topics: Alopecia; Carcinoma, Bronchogenic; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Hum | 1975 |
Combined 5-fluorouracil and hydroxyurea therapy for gastrointestinal cancer.
Topics: Administration, Oral; Ataxia; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Gastrointe | 1975 |
Further clinical studies with intrahepatic arterial infusion with 5-fluorouracil.
Topics: Fluorouracil; Hepatic Artery; Humans; Infusions, Parenteral; Liver Neoplasms; Neoplasm Metastasis | 1975 |
Evaluation of the ligation of the hepatic artery and regional arterial chemotherapy in the treatment of primary and secondary cancer of the liver.
Topics: Adolescent; Adult; Evaluation Studies as Topic; Female; Fluorouracil; Hepatic Artery; Humans; Ligati | 1975 |
Combination chemotherapy as an adjuvant treatment in operable breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Female; | 1976 |
Editorial: Major advance in breast-cancer therapy.
Topics: Breast Neoplasms; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Female; Fluorouracil | 1976 |
Multi-modality therapy for epidermoid carcinoma of the anus.
Topics: Anus Neoplasms; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Middle | 1976 |
Adriamycin in the treatment of cancer.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cyclophosphamide; Doxorubicin; Drug Therapy, Combi | 1976 |
Immunostimulation with intraperitoneally administered bacille Calmette Guérin for advanced malignant tumors of the gastrointestinal tract.
Topics: Adult; Aged; BCG Vaccine; Bile Duct Neoplasms; Carcinoma; Colonic Neoplasms; Cyclophosphamide; Femal | 1976 |
Intraluminal, lymph node, hepatic, and serum levels after intraluminal and intramural injection of 5-fluorouracil in the dog colon.
Topics: Animals; Carbon Radioisotopes; Colon; Colonic Neoplasms; Dogs; Fluorouracil; Injections; Injections, | 1976 |
Editorial: Large-bowel cancer-The current status of treatment.
Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi | 1976 |
Editorial: Large-bowel cancer-The current status of treatment.
Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi | 1976 |
Editorial: Large-bowel cancer-The current status of treatment.
Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi | 1976 |
Editorial: Large-bowel cancer-The current status of treatment.
Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi | 1976 |
Combination chemotherapy for advanced breast cancer: response and effect on survival.
Topics: Adult; Bone Neoplasms; Breast Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Humans; Li | 1976 |
Neurotoxicity from 5-fluorouracil (NSC-19893) administration reproduced by mitomycin C (NSC-26980).
Topics: Adenocarcinoma; Aged; Ataxia; Blood-Brain Barrier; Cerebellar Ataxia; Colonic Neoplasms; Fluorouraci | 1976 |
Results of regional portal infusion of 5-fluorouracil in patients with primary and secondary liver cancer.
Topics: Adult; Aged; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Parenteral; Ligation; Liver Ne | 1976 |
Clinical evaluation of ftorafur (pyrimidine-deoxyribose n1-2'-furanidyl-5-fluorouracil).
Topics: Adenocarcinoma; Adult; Aged; Carcinoma; Drug Evaluation; Female; Fluorouracil; Gastrointestinal Dise | 1976 |
Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Component Transfusion; Bone | 1992 |
Carboplatin plus 5-fluorouracil and leucovorin in previously treated patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca | 1992 |
Mitoxantrone for advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dose-Resp | 1992 |
Reversal of resistance to doxifluridine and fluorouracil in metastatic colorectal cancer: the role of high-dose folinic acid.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Resistance; | 1992 |
[Trend and problems of chemotherapy of stomach neoplasms with metastasis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Humans; Mitomycin; Neoplasm | 1992 |
Fifteen years' experience of combined hormone/chemotherapy in metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Comb | 1992 |
Influence of interferon alfa-2b with or without folinic acid on pharmacokinetics of fluorouracil.
Topics: Aged; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Interferon alpha-2; Interferon-alpha | 1992 |
[Chemotherapy and thymostimulin in the treatment of advanced-stage breast neoplasms].
Topics: Adjuvants, Immunologic; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cycl | 1992 |
High-dose folinic acid, 5-fluorouracil bolus and continuous infusion in metastatic colorectal cancer: a 3-day/3-week schedule. Group d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD)
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; F | 1992 |
Promotion of hepatic metastases by liver resection in the rat.
Topics: Animals; Fluorouracil; Liver; Liver Neoplasms; Liver Neoplasms, Experimental; Liver Regeneration; Mi | 1992 |
High-dose folinic acid and 5-fluorouracil plus cisplatin on a weekly schedule in the treatment of advanced cancer of the head and neck.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; | 1992 |
Effective initial therapy of advanced breast cancer with fluorouracil and high-dose, continuous infusion calcium leucovorin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration S | 1992 |
Lack of correlation between histologic findings and response to chemotherapy in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltr | 1991 |
Phase II study of cisplatin and continuous-infusion 5-fluorouracil and bleomycin for recurrent and metastatic head and neck squamous-cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1990 |
[Initial results of combined surgical-medical therapy for metastatic cancer of the stomach].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Fluorouracil; Gast | 1990 |
Cisplatin and 5-FU combined with radiotherapy and surgery in the treatment of squamous cell carcinoma of the esophagus. Palliative effects and tumor response.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 1991 |
[Simultaneous radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in advanced head and neck tumors].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F | 1991 |
Tolerance of extended (28 day) continuous infusion of 5-fluorouracil in advanced head and neck cancer.
Topics: Adult; Aged; Drug Eruptions; Drug Tolerance; Female; Fluorouracil; Head and Neck Neoplasms; Humans; | 1991 |
[Therapeutic results and toxic side effects of the cytostasan, adriamycin and vincristine combination as second line therapy in metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dos | 1991 |
Anti-tumor effect of L-methionine-deprived total parenteral nutrition with 5-fluorouracil administration on Yoshida sarcoma-bearing rats.
Topics: Animals; Body Weight; Cause of Death; Combined Modality Therapy; Disease Models, Animal; Evaluation | 1991 |
A less toxic regimen of 5-fluorouracil and high-dose folinic acid for advanced gastrointestinal adenocarcinomas.
Topics: Adenocarcinoma; Fluorouracil; Gastrointestinal Neoplasms; Leucovorin; Lymphatic Metastasis; Neoplasm | 1991 |
[The phagocytic activity and cytochemical indices of the neutrophils in patients with stomach cancer treated with 5-fluorouracil].
Topics: Adult; Aged; Female; Fluorouracil; Histocytochemistry; Humans; Male; Middle Aged; Neoplasm Metastasi | 1991 |
5-Fluorouracil dose intensity increase in 5-fluorouracil and leucovorin combination: results of a phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Relationship, Dr | 1991 |
Second-line chemotherapy of advanced colorectal cancer with sequential high-dose methotrexate and 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel | 1991 |
Metastatic basal cell carcinoma: report of a case presenting with respiratory failure.
Topics: Carcinoma, Basal Cell; Female; Fluorouracil; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Neopla | 1991 |
Treatment of metastatic gastric carcinoma with a modified FAMTX chemotherapy regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; | 1990 |
A phase II trial of mitomycin C and 5-fluorouracil as second-line therapy in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Evaluation; Fluo | 1990 |
An EORTC phase II study of sequential methotrexate-fluorouracil in locally advanced or metastatic gastric cancer. The EORTC Gastrointestinal Cancer Cooperative Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female; Fluorouracil; | 1990 |
[Fluorouracil and high-dose folinic acid in the treatment of advanced colorectal carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura | 1990 |
[Antitumor activity of UFT against murine renal cell carcinoma: a study on the suppression tumor metastases].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug Screening Assay | 1990 |
A study of the pineal hormone melatonin as a second line therapy in metastatic colorectal cancer resistant to fluorouracil plus folates.
Topics: Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Drug Resistance; Female; Fluorouracil; Fol | 1990 |
[Chemotherapy of disseminated forms of breast cancer using platinum derivatives].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Doxor | 1990 |
Response and toxicity of cisplatin and 120-h 5-fluorouracil infusion in pretreated and untreated patients with advanced epidermoid cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1990 |
Treatment of metastatic breast cancer with the combination of ifosfamide, epirubicin and 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Female; F | 1990 |
[The antitumor properties of honey].
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dr | 1990 |
[Long-term arterial infusion chemotherapy in advanced and recurrent gastric cancer patients at home and an interesting autopsy case].
Topics: Adult; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; D | 1990 |
Carcinoma of the nasopharynx. An analysis of 91 cases and a comparison of differing treatment approaches.
Topics: Actuarial Analysis; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomyc | 1986 |
[Treatment of metastatic breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Breast Neoplasms; Cyclophosphamide; Dacar | 1986 |
Nonoperative therapy for squamous-cell cancer of the esophagus.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin | 1987 |
5-Fluorouracil and isoprinosine in the treatment of advanced colorectal cancer. A limited phase I, II evaluation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Female; Fl | 1988 |
Ifosfamide, methotrexate, and 5-fluorouracil in advanced pretreated breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fluorouracil; | 1989 |
Epidermoid carcinoma of the anal canal. Results of treatment by combined chemotherapy and radiation therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 1989 |
Primary treatment of regional and disseminated pancreatic cancer with hexamethylmelamine, mitomycin C and 5-fluorouracil infusion.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Fluorouracil; Humans; Infusi | 1989 |
[Radiotherapy with neoadjuvant chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Doxorub | 1989 |
Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; Fluorouracil; Human | 1989 |
Phase II trial of combination chemotherapy with fluorouracil (F), doxorubicin (A), and cisplatin (P) (Fap) in hormonally resistant metastatic prostatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug E | 1989 |
Cis-diamminodichloroplatinum plus a 5-day continuous infusion of 5-fluorouracil in the treatment of locally recurrent and metastatic head and neck cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Head and Neck | 1989 |
[The effect of chemotherapy on survival time in advanced breast carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carmustine; Combined Mo | 1989 |
Increased contraenvironmental-pressure cell division capability: a decisive force in metastasis and invasion of mouse lung adenocarcinoma cell lines.
Topics: Adenocarcinoma; Animals; Cell Division; Cell Line; Clone Cells; Fluorouracil; Lung Neoplasms; Mice; | 1989 |
Bolus fluorouracil for metastatic colorectal carcinoma?
Topics: Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Neoplasm Metastasis; Progn | 1989 |
Metastatic sweat gland carcinoma: response to 5-fluorouracil infusion.
Topics: Aged; Carcinoma; Fluorouracil; Humans; Infusions, Parenteral; Male; Neoplasm Metastasis; Sweat Gland | 1989 |
A clinical study of 407 cases of nasopharyngeal carcinoma in Hong Kong.
Topics: Adult; Aged; Brachytherapy; Carcinoma; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; H | 1989 |
Refractory metastatic breast cancer: salvage therapy with fluorouracil and high-dose continuous infusion leucovorin calcium.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Female; Fluorouracil; Humans; Infu | 1989 |
Cisplatin, fluorouracil with leucovorin calcium enhancement, and synchronous accelerated radiotherapy in the management of locally advanced head and neck cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1989 |
Treatment of metastatic colorectal adenocarcinoma with fluorouracil and high-dose leucovorin: a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; F | 1989 |
120 hours simultaneous infusion of cisplatin and fluorouracil in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Female; Fl | 1989 |
5-Fluorouracil and dipyridamole in metastatic breast cancer: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dipyridamole; Drug To | 1989 |
Phase II pilot study with cisplatin, etoposide, and continuous-infusion 5-fluorouracil in metastatic non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Carcinoma, Non-Small-Cell Lung; Cisplat | 1987 |
Metastatic islet cell tumour with clinical manifestations of insulin and glucagon excess: successful treatment by hepatic artery embolization and chemotherapy.
Topics: Adenoma, Islet Cell; Combined Modality Therapy; Embolization, Therapeutic; Female; Fluorouracil; Glu | 1988 |
[Chemoprophylaxis of liver metastasis of colonic and rectal cancers].
Topics: Colonic Neoplasms; Fluorouracil; Humans; Liver Neoplasms; Neoplasm Metastasis; Portal Vein; Rectal N | 1986 |
A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors. A Southwest Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Cyclophosphamide; Doxo | 1987 |
Phase 1 and 2 studies of trimetrexate administered in combination with fluorouracil to patients with metastatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female; Fluorouracil; | 1988 |
The response to further chemotherapy in patients with carcinoma of the breast who progressed while receiving adjuvant therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltr | 1985 |
Phase II trial of 5-FU, vincristine, and mitomycin (FOMi) in metastatic bronchioloalveolar cell lung cancer: a Southwest Oncology Group Study.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Eval | 1985 |
[A case of bilateral metastatic breast carcinoma from gastric carcinoma].
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined | 1986 |
[Results of a phase II study with the new cytostatic drug carboplatin in combination with 5-fluorouracil in the primary treatment of advanced squamous cell cancers of the head and neck].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 1988 |
High-dose epirubicin + cyclophosphamide (HD-EC) in metastatic breast cancer: a dose-finding study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dos | 1988 |
An aggressive, sequential combination chemotherapy regimen in the treatment of metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose-Response Relati | 1986 |
[Pathomorphosis of bladder cancer after endolymphatic polychemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Cancer, | 1986 |
[Metastasizing primary duodenal cancer. Extended remission in a patient following chemotherapy].
Topics: Adenocarcinoma, Papillary; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality T | 1986 |
5-Fluorouracil, 4-epidoxorubicin, and mitomycin C (FEM) combination chemotherapy for advanced gastric carcinoma. A phase-II trial by the "chemotherapiegruppe gastrointestinaler tumoren (CGT)".
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; Drug E | 1987 |
Cyclophosphamide, methotrexate,5-fluorouracil, alternating with adriamycin and mitomycin C in metastatic breast cancer: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Doxorubici | 1987 |
[Chemotherapy and enteral nutrition in stomach cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; | 1988 |
[Inflammatory breast carcinoma--possibilities and results of surgical treatment and adjuvant chemotherapy, especially when done preoperatively].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Doxor | 1988 |
[Sequential treatment of progressive metastatic colorectal cancer with 5-fluorouracil/folinic acid, dipyramidole and mitomycin C].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dipyridamole; Dos | 1988 |
Sequential multiagent chemotherapy incorporating cisplatin, doxorubicin, and cyclophosphamide in the treatment of metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Doxor | 1988 |
Adjuvant chemotherapy with and without radiotherapy in stage II breast cancer.
Topics: Actuarial Analysis; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplat | 1988 |
A phase II study of sequential methotrexate and 5-fluorouracil in colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati | 1988 |
Carcinogenesis and aging. VIII. Effect of host age on tumour growth, metastatic potential, and chemotherapeutic sensitivity to 1.4-benzoquinone-guanylhydrazonethiosemicarbazone (ambazone) and 5-fluorouracil in mice and rats.
Topics: Adenocarcinoma; Aging; Animals; Antineoplastic Agents; Cell Division; Female; Fluorouracil; Leukemia | 1988 |
Cisplatin, fluorouracil, and high-dose leucovorin for recurrent or metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1988 |
High-dose folinic acid and 5-fluorouracil in advanced colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil; Gastr | 1988 |
The treatment of metastatic breast cancer with 5-fluorouracil and leucovorin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Drug | 1988 |
High-dose weekly oral leucovorin and 5-fluorouracil in previously untreated patients with advanced colorectal carcinoma: a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Evaluation; | 1988 |
[Concept of treatment of metastatic breast cancer outside university clinics: description of the method and evaluation of efficacy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cancer Care Facilities; Combined M | 1987 |
Evaluation of bolus cis-platinum and continuous 5-fluorouracil infusion for metastatic and recurrent squamous cell carcinoma of the cervix.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1988 |
The effect of prior adjuvant chemotherapy on survival in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dactinomycin; Do | 1988 |
Low-dose mitomycin and weekly low-dose doxorubicin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, and 5-fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Doxorubicin; Drug Evalu | 1988 |
Salvage treatment with intermediate-dose methotrexate and 5-fluorouracil in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fluorouracil; Humans; Meth | 1988 |
[An autopsy case of untreated bladder cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Doxorubicin | 1987 |
Dynamic hormonal chemotherapy in advanced metastatic breast carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Fluoroura | 1986 |
Sequential methotrexate--5-FU--leucovorin (MFL) in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration | 1986 |
Preliminary results of a phase II trial for the treatment of metastatic breast cancer with 5-fluorouracil and leucovorin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Evaluation; Fluorodeox | 1987 |
Mitoxantrone, cyclophosphamide, and fluorouracil in metastatic breast cancer unresponsive to hormonal therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Flu | 1987 |
Cisplatin, doxorubicin, and 5-fluorouracil chemotherapy for salivary gland malignancies: a pilot study of the Northern California Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 1987 |
Fatal acute tumor lysis syndrome with metastatic breast carcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Autopsy; Breast Neoplasms; Cyclophos | 1987 |
[Chemotherapy of dysgerminoma].
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Combined | 1987 |
Use of mitoxantrone-based combination chemotherapy regimens as first-line treatment for advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Administrat | 1987 |
Treatment of advanced head and neck cancer with concomitant radiation and chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Administr | 1987 |
[Rational combinations of hormonal and cytostatic agents in disseminated forms of breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Cyclophosphamide; D | 1987 |
Escalating doses of sequential methotrexate and 5-fluorouracil, doxorubicin, and vincristine for the treatment of metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; Fluorouracil; | 1987 |
Multiple drug intensification after cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF) induction in metastatic breast cancer: a Southeastern Cancer Study Group phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Flu | 1987 |
Cisplatin and 5-FU infusion chemotherapy in advanced, recurrent cancer of the head and neck: an Eastern Cooperative Oncology Group Pilot Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1986 |
Destruction of both extensive local recurrent and primary breast cancer with topical aqueous 5-FU: a clinical observation.
Topics: Administration, Topical; Breast Neoplasms; Female; Fluorouracil; Humans; Neoplasm Metastasis; Neopla | 1986 |
Failure of allopurinol to provide clinically significant protection against the hematologic toxicity of a bolus 5-FU schedule.
Topics: Adenocarcinoma; Adult; Allopurinol; Carcinoma, Squamous Cell; Colonic Neoplasms; Drug Administration | 1986 |
[Phase II trial of an ambulatory treatment with 5-fluorouracil administered by continuous perfusion combined with vindesine and cyclophosphamide].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Cancer, | 1986 |
Cisplatin plus 5-fluorouracil in the treatment of metastatic anal squamous cell carcinoma: a report of two cases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisp | 1986 |
Chemotherapy of advanced gastric cancer: a study of 43 consecutive cases treated with fluorouracil, adriamycin and mitomycin C (FAM).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Fluorouracil; Huma | 1986 |
[Combined chemotherapy in metastatic breast cancer: predictive value of dose levels and performance status].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dose-Response Re | 1986 |
Inhibition of experimental pulmonary metastasis in mice by beta-cyclodextrin-benzaldehyde.
Topics: Animals; Benzaldehydes; beta-Cyclodextrins; Cyclodextrins; Cytotoxicity, Immunologic; Dextrins; Fluo | 1986 |
Chemotherapy in colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neo | 1986 |
Treatment of advanced colorectal and gastric cancer with cisplatinum and 5-fluorouracil. A pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Female; F | 1986 |
5-Fluorouracil-metronidazole combination therapy in metastatic colorectal cancer. Clinical, pharmacokinetic and in vitro cytotoxicity studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Colonic Neoplasms; Femal | 1986 |
[Antimetastatic properties of aloe juice].
Topics: Aloe; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cyc | 1986 |
A reappraisal of oophorectomy in carcinoma of the breast.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Combined Modalit | 1987 |
On the relevance of "second-line" cytotoxic chemotherapy in patients with metastatic breast cancer resistant to standard combinations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Fluorour | 1986 |
Weekly 5-fluorouracil combined with PALA: toxic and therapeutic effects in colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Central Nervous System D | 1987 |
[Functional state of the sympatho-adrenal system at late stages of the tumor process after cyclophosphamide and 5-fluorouracil administration].
Topics: Adrenal Cortex; Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Fluoroura | 1987 |
High-dose intensity systemic therapy of metastatic bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Circadian Rhythm | 1987 |
5-Fluorouracil and high-dose folic acid treatment for metastatic colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diarrhea; Female; Fluorouracil; F | 1987 |
Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breast.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclo | 1985 |
[Chemotherapy of metastasizing breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dactinomycin; Fe | 1985 |
Improved control in advanced head and neck cancer with simultaneous radiation and cisplatin/5-FU chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Cisplatin; Female; Fluorouracil | 1985 |
[Experiences with polychemotherapy MAF (mitomycin C, adriablastine, 5-fluorouracil) in progressing metastasized prostate cancer].
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorourac | 1985 |
Sequential therapy with methotrexate and 5-fluorouracil in the treatment of advanced colorectal carcinoma.
Topics: Adult; Aged; Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Methotrexate; Middle Aged; Neopl | 1986 |
Phase II trial of high-dose continuous infusion 5-fluorouracil with allopurinol modulation in colon cancer.
Topics: Adult; Aged; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Ev | 1986 |
Modulated chemo-hormonotherapy in advanced breast cancer. A pilot study.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Female; Fluorouracil; Hormones; Humans; Methotrexate; | 1986 |
Phase I evaluation and pharmacokinetic study of weekly iv thymidine and 5-FU in patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration | 1985 |
[Chemotherapy protocol for metastasizing colorectal carcinoma. Methotrexate, 5-fluorouracil and cytarabine].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Cytarabine; Drug Adm | 1985 |
Chemotherapy before radiotherapy for T3 bladder cancer. A pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha | 1985 |
Treatment of metastatic colorectal carcinoma with cisplatin and 5-FU.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neop | 1985 |
Colorectal cancer: speculations on the role of intraperitoneal therapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Coloni | 1985 |
Adjuvant therapy in rectal cancer: a protocol proposal.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluorouracil; Humans; Inf | 1985 |
Cerebellar ataxia with weekly 5-fluorouracil administration.
Topics: Adenocarcinoma; Cerebellar Ataxia; Colonic Neoplasms; Female; Fluorouracil; Humans; Middle Aged; Neo | 1971 |
Hepatic artery infusion for metastatic malignancy using percutaneously placed catheters.
Topics: Adenoma, Islet Cell; Adult; Aged; Bile Duct Neoplasms; Breast Neoplasms; Carcinoid Tumor; Carcinoma, | 1971 |
Adrenalectomy for metastatic mammary cancer.
Topics: Adrenalectomy; Adult; Aged; Breast Neoplasms; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Me | 1971 |
[Experiences in the palliative chemotherapy of 228 cases of unmeasurable and 52 measurable intrapulmonary tumors].
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cyclophosphamide; Fluorouracil; Humans; Lung Neopla | 1971 |
Early diagnosis and management of premalignant lesions and early invasive cancers of the vulva.
Topics: Adult; Aged; Carcinoma; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoplasm Metas | 1971 |
Esophageal carcinoma.
Topics: Adult; Aged; Alkylating Agents; Carcinoma, Squamous Cell; Diagnosis, Differential; Esophageal Neopla | 1972 |
Prolonged intermittent arterial infusion for metastatic carcinoma of the liver.
Topics: Adult; Aged; Catheterization; Chemotherapy, Cancer, Regional Perfusion; Female; Fluorouracil; Hepati | 1972 |
[A case of the squamous cell carcinoma of the renal pelvis associated with staghorn calculus. Bleomycin treatment of the metastatic recurrence].
Topics: Antibiotics, Antineoplastic; Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamide; Fluorouracil; Hu | 1972 |
Current concepts in the treatment of advanced breast cancer.
Topics: Adrenalectomy; Adult; Androgens; Breast Neoplasms; Castration; Estrogens; Female; Fluorouracil; Huma | 1972 |
Carcinoma of pancreas--palliative radiotherapy.
Topics: Carcinoma; Cobalt Isotopes; Fluorouracil; Humans; Liver Neoplasms; Neoplasm Metastasis; Palliative C | 1973 |
Cancer of the tongue.
Topics: Bleomycin; Carcinoma, Squamous Cell; Dental Caries; Electrocoagulation; Fluorides, Topical; Fluorour | 1973 |
Palliative treatment of mammary cancer. Response of soft tissue, pleural and pulmonary disease.
Topics: Adrenalectomy; Adult; Age Factors; Aged; Breast Neoplasms; Castration; Cyclophosphamide; Dexamethaso | 1973 |
Alternative approaches to radiotherapy alone and radiotherapy as a part of a combined therapeutic approach for lung cancer.
Topics: Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Cyclophosphamide; Fluorouracil; Humans; Lung Neop | 1973 |
Letter: ICRF 159.
Topics: Animals; Antimetabolites; Cyclophosphamide; Doxorubicin; Drug Synergism; Fluorouracil; Leukemia L121 | 1974 |
Metastatic basal cell carcinoma: review, report of a case, and chemotherapy.
Topics: Aged; Antineoplastic Agents; Biopsy, Needle; Bleomycin; Carcinoma, Basal Cell; Cyclophosphamide; Dru | 1974 |
A carcinoid saga.
Topics: Anesthesia, General; Aprotinin; Carcinoid Tumor; Female; Fluorouracil; Hepatectomy; Humans; Hydroxyi | 1974 |
[Attack on liver cancer--what's the value of diagnosis and treatment?].
Topics: Adult; Aged; Colonic Neoplasms; Fluorouracil; Humans; Infusions, Parenteral; Liver Neoplasms; Middle | 1974 |
[Intra-arterial treatment of malignant neoplasms in children (author's transl)].
Topics: Adolescent; Carcinoma, Hepatocellular; Child; Female; Fluorouracil; Humans; Injections, Intra-Arteri | 1972 |
The treatment of hepatic metastases by long-term chemotherapeutic infusions.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Colonic Neoplasms; Evaluation Studies as Topic; Female; | 1970 |
A safe and effective method of administering 5-fluorouracil to adrenalectomized patients.
Topics: Adrenal Cortex Hormones; Adrenalectomy; Adult; Breast Neoplasms; Female; Fluorouracil; Humans; Infus | 1966 |
The value of radiotherapy in the treatment of carcinoma of the colon.
Topics: Abdominal Neoplasms; Colonic Neoplasms; Denmark; Female; Finland; Fluorouracil; Humans; Male; Neopla | 1966 |
Palliative treatment of metastatic carcinoma of the liver by hepatic artery infusion with 5-fluorouracil: report of a case.
Topics: Catheterization; Female; Fluorouracil; Hepatic Artery; Humans; Injections, Intra-Arterial; Liver Neo | 1967 |
Continuous arterial infusion chemotherapy. Experience with 44 cases.
Topics: Adenocarcinoma; Arteries; Brain Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Cath | 1967 |
Clinical staging of carcinoma of the uterine tube.
Topics: Adult; Aged; Barium; Carcinoma; Fallopian Tube Neoplasms; Female; Fluorouracil; Humans; Middle Aged; | 1967 |
The second look operation for carcinoma of the colon after administration of 5-fluorouracil.
Topics: Carcinoma; Colonic Neoplasms; Fluorouracil; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; | 1968 |
Palliative treatment of metastasized breast cancer with 5-fluoro-uracil in slow intravenous infusion.
Topics: Breast Neoplasms; Female; Fluorouracil; Humans; Infusions, Parenteral; Neoplasm Metastasis; Palliati | 1967 |
Hepatic artery infusion chemotherapy in hepatoma.
Topics: Aged; Alkaline Phosphatase; Angiography; Aorta; Brachial Artery; Carcinoma, Hepatocellular; Catheter | 1968 |
Operation, external irradiation, radioactive isotopes, and chemotherapy in treatment of metastatic ovarian malignancies.
Topics: Ascites; Carcinoma; Chlorambucil; Cyclophosphamide; Dactinomycin; Female; Fluorouracil; Follow-Up St | 1968 |
Maintenance of delayed hypersensitivity reactions in patients receiving cancer chemotherapy.
Topics: Cyclophosphamide; Female; Floxuridine; Fluorouracil; Humans; Hypersensitivity, Delayed; Immunity; Ma | 1968 |
[Therapy of advanced tumors with 5-fluoro-uracil].
Topics: Femoral Neoplasms; Fluorouracil; Humans; Injections, Intra-Arterial; Injections, Intravenous; Intest | 1969 |
Palliative treatment of metastasized breast cancer with 5-FU in slow intravenous infusion.
Topics: Adult; Breast Neoplasms; Female; Fluorouracil; Gastrointestinal Diseases; Hematologic Diseases; Huma | 1969 |
Metastatic colorectal carcinoma. Response to hepatic infusion. A review.
Topics: Adult; Aged; Colonic Neoplasms; Female; Fluorouracil; Humans; Infusions, Parenteral; Liver Neoplasms | 1970 |
Second-look operation for colon carcinoma after fluorouracil therapy.
Topics: Colectomy; Colonic Neoplasms; Fluorouracil; Humans; Lymphatic Metastasis; Neoplasm Metastasis; Palli | 1970 |
Treatment of secondary hepatic tumours by ligation of hepatic artery and infusion of cytotoxic drugs.
Topics: Adenocarcinoma; Aged; Angiography; Aortography; Carcinoid Tumor; Chemotherapy, Cancer, Regional Perf | 1970 |
[FSH and steroid hormone excretion in breast cancer during chemotherapy].
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Breast Neoplasms; Cyclophosphamide; Estrogens; Female; F | 1972 |
[Clinical results of synchronised radiotherapy on a theoretical and experimental basis (author's transl)].
Topics: Animals; Breast Neoplasms; Dose-Response Relationship, Radiation; Drosophila melanogaster; Ear Neopl | 1973 |
Intravenous hyperalimentation in cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Body Weight; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Ne | 1974 |
The growth of human tumours in immunosuppressed mice and their response to chemotherapy.
Topics: Animals; Chlorambucil; Cyclophosphamide; Dactinomycin; Disease Models, Animal; Female; Fluorouracil; | 1974 |
[Late results of observing patients with extensive breast cancer who have undergone chemotherapy by infusion].
Topics: Breast Neoplasms; Chemotherapy, Cancer, Regional Perfusion; Female; Fluorouracil; Follow-Up Studies; | 1974 |
[Chemotherapy in inoperable stomach cancer].
Topics: Adult; Drug Therapy, Combination; Female; Fluorouracil; Gamma Rays; Humans; Male; Moscow; Neoplasm M | 1974 |
An evaluation of 51 patients with hepatic artery infusion.
Topics: Antineoplastic Agents; Catheterization; Floxuridine; Fluorouracil; Gastrointestinal Neoplasms; Hepat | 1966 |
Determinants of human tumor sensitivity to fluorinated pyrimidine chemotherapy.
Topics: DNA, Neoplasm; Floxuridine; Fluorouracil; Humans; In Vitro Techniques; Ligases; Neoplasm Metastasis; | 1967 |
Infusion of fluorinated pyrimidines into hepatic artery for treatment of metastatic carcinoma of liver.
Topics: Adenocarcinoma; Catheterization; Floxuridine; Fluorouracil; Gastrointestinal Neoplasms; Hepatic Arte | 1967 |
Practical aspects of investigation and treatment of colorectal cancer.
Topics: Colonic Neoplasms; Female; Floxuridine; Fluorouracil; Humans; Infusions, Parenteral; Liver Function | 1972 |
Chemotherapy of colon and rectal cancer.
Topics: Administration, Oral; Antigens, Neoplasm; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasm | 1972 |
Regional infusion chemotherapy of hepatic metastases from carcinoma of the colon.
Topics: Age Factors; Aspartate Aminotransferases; Catheterization; Chemotherapy, Cancer, Regional Perfusion; | 1974 |
Infusion chemotherapy in hepatoma and metastatic liver tumors.
Topics: Adenocarcinoma; Adolescent; Aged; Carcinoma, Hepatocellular; Chemical and Drug Induced Liver Injury; | 1967 |
Cylindroma of the right maxillary antrum. Case report.
Topics: Adult; Carcinoma, Adenoid Cystic; Fluorouracil; Humans; Infusions, Parenteral; Male; Maxillary Neopl | 1967 |
Infusion of liver tumours.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Cancer, Regional Perfusion; Floxurid | 1968 |
[Cancer of the body of the pancreas with hepatic metastases].
Topics: Abdomen; Blindness; Catheterization; Cholangiography; Coma; Diagnosis, Differential; Fluorouracil; H | 1968 |
[Treatment of cancer of the liver by regional perfusion].
Topics: Adult; Aged; Angiography; Carcinoma, Hepatocellular; Catheterization; Colonic Neoplasms; Fluorouraci | 1968 |
Combination chemotherapy using cyclophosphamide, vincristine, methotrexate and 5-fluorouracil in solid tumors.
Topics: Adenocarcinoma; Adult; Carcinoma, Squamous Cell; Cyclophosphamide; Female; Fibrosarcoma; Fluorouraci | 1969 |
[Polychemotherapy of malignant tumors and hemoblastoses].
Topics: Adenocarcinoma; Adult; Aged; Alkylating Agents; Antineoplastic Agents; Bronchial Neoplasms; Carcinom | 1968 |
Metabolically active liver metastases treated by 5-fluorouracil hepatic artery infusion.
Topics: Adenoma, Islet Cell; Carcinoma, Squamous Cell; Female; Fluorouracil; Hepatic Artery; Hormones, Ectop | 1970 |
Hepatoma: long-term survival with disseminated tumor treated with 5-fluorouracil.
Topics: Carcinoma, Hepatocellular; Fluorouracil; Humans; Liver Neoplasms; Long-Term Care; Lung Neoplasms; Ma | 1970 |
Chemotherapy of breast cancer by regional intra-arterial infusion.
Topics: Adult; Aged; Antineoplastic Agents; Brachial Artery; Breast Neoplasms; Carotid Arteries; Cyclophosph | 1970 |
Experience with hepatic arterial infusions.
Topics: Adult; Aged; Bile Duct Neoplasms; Carcinoma, Hepatocellular; Female; Floxuridine; Fluorouracil; Gall | 1971 |
Catheterization of the umbilical vein and its use for hepatography.
Topics: Adenocarcinoma; Adult; Aged; Angiography; Breast Neoplasms; Catheterization; Diatrizoate; Female; Fl | 1971 |
Lactic dehydrogenase isoenzyme alterations in malignant disease of the liver.
Topics: Alkaline Phosphatase; Aspartate Aminotransferases; Bronchial Neoplasms; Carcinoma, Hepatocellular; C | 1971 |
[Study in man of recirculation and tissue uptake of 5-FU 6 H3].
Topics: Adenoma, Bile Duct; Antimetabolites; Carcinoma, Hepatocellular; Chemotherapy, Cancer, Regional Perfu | 1971 |
Cancer chemotherapy in urology.
Topics: Adenocarcinoma; Alkylating Agents; Antibiotics, Antineoplastic; Antimetabolites; Chlorambucil; Cobal | 1971 |
Widespread extracranial metastases of glioblastoma multiforme. Report of case and clinicopathological review of cases in literature.
Topics: Adolescent; Autopsy; Biopsy; Bone Neoplasms; Brain Neoplasms; Carotid Arteries; Cauda Equina; Cerebr | 1972 |
[Combined antineoplastic agents and surgery in treatment of cancer with multiple localizations: 22 cases].
Topics: Antineoplastic Agents; Cyclophosphamide; Drug Synergism; Female; Fluorouracil; Humans; Male; Methods | 1970 |
[Radiotherapy following synchronisation of the cell-division rhythm].
Topics: Animals; Carcinoma; Carcinoma, Squamous Cell; Cell Division; DNA; Fluorouracil; Humans; Mice; Neopla | 1972 |
Malignant insulinoma with hepatic secondaries treated with hepatic artery ligation.
Topics: Adenoma, Islet Cell; Aged; Fluorouracil; Hepatic Artery; Humans; Ligation; Liver Neoplasms; Male; Ne | 1973 |
The role of heparin in the chemotherapy of solid tumors: preliminary clinical trial in carcinoma of the lung.
Topics: Aged; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cyclophosphamide; Fibrinogen; Fluorouracil; H | 1972 |
Metastatic ovarian cancer.
Topics: Adenocarcinoma, Mucinous; Cyclophosphamide; Cystadenocarcinoma; Dactinomycin; Drug Combinations; Fem | 1973 |
Clinical management of advanced gastrointestinal cancer.
Topics: Adenocarcinoma; Alkylating Agents; Biliary Tract; Carcinoid Tumor; Carcinoma, Hepatocellular; Fluoro | 1973 |
Axillary metastases from unknown primary sites.
Topics: Adenocarcinoma, Mucinous; Adolescent; Adult; Aged; Axilla; Breast Neoplasms; Carcinoma, Squamous Cel | 1973 |
Long term survivor in metastatic colonic carcinoma to the brain.
Topics: Adenocarcinoma, Mucinous; Brain Neoplasms; Colonic Neoplasms; Fluorouracil; Humans; Male; Middle Age | 1973 |
Proceedings: Islets of Langerhans.
Topics: Adenoma, Islet Cell; Diarrhea; Fluorouracil; Follow-Up Studies; Gastrectomy; Gastrins; Glucagon; Hum | 1972 |
Experience with infusion and resection in cancer of the liver.
Topics: Adult; Aged; Breast Neoplasms; Carcinoma, Hepatocellular; Catheterization; Colonic Neoplasms; Female | 1974 |
A re-examination of the renal blastema graft model for Wilms tumor production.
Topics: Animals; Autopsy; Cell Differentiation; Cyclophosphamide; Dactinomycin; Disease Models, Animal; Drug | 1974 |
Heparin anticoagulation as adjuvant to chemotherapy in carcinoma of the lung.
Topics: Aged; Antineoplastic Agents; Blood Coagulation; Carcinoma; Carcinoma, Bronchogenic; Carcinoma, Small | 1974 |
Primary liver carcinoma.
Topics: Adolescent; Adrenal Gland Neoplasms; Adult; Aged; Biopsy; Bone Neoplasms; Carcinoma, Hepatocellular; | 1974 |
Chemotherapy in intraocular metastasis from carcinoma of the breast.
Topics: Breast Neoplasms; Cell Division; Cyclophosphamide; Diethylstilbestrol; DNA; Eye Neoplasms; Female; F | 1974 |
Chemotherapy for adenocarcinoma and alveolar cell carcinoma of the lung.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Female; Fluorouracil; Follow-Up Studies; | 1974 |
Metabolic studies of 5-fluorouracil. II. Influence of the route of administration on the dynamics of distribution in man.
Topics: Administration, Oral; Bile; Carbon Radioisotopes; Carcinoma, Hepatocellular; Chromatography, Thin La | 1974 |
[Combined cytostatic treatment of malignant brain tumors (author's transl)].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Astrocytoma; Blood-Brain Barrier; Brain Neoplasms; C | 1974 |
Phase II evaluation of BCNU and 5-FU in gastrointestinal carcinomas.
Topics: Adenocarcinoma; Administration, Oral; Carmustine; Colonic Neoplasms; Diarrhea; Fluorouracil; Hematoc | 1974 |
Prevention of recurrent cancer of the large bowel.
Topics: Animals; Antineoplastic Agents; Fluorouracil; Humans; Intestinal Neoplasms; Intestine, Large; Ligati | 1974 |
A second look at the second operation in colonic cancer after the administration of fluorouracil.
Topics: Biopsy; Colonic Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Lymphat | 1974 |
[Hormone therapy and chemotherapy of metastasizing breast cancer. Experiences of the Basle Oncology Center, 1969-72].
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma; Castration; Cyclophosphamide; Drug Therapy, Comb | 1974 |
Diagnosis, treatment and prognosis of renal cell carcinoma.
Topics: Adenocarcinoma; Angiography; Blood Sedimentation; Chromomycins; Female; Fluorouracil; Humans; Kidney | 1974 |
Systemic 5-fluorouracil in hepatic metastases from primary colon or rectal cancer.
Topics: Colonic Neoplasms; Fluorouracil; Humans; Injections, Intravenous; Liver Neoplasms; Neoplasm Metastas | 1972 |
Hepatic metastases from rectal and colon cancers. Treatment by infusion of 5-fluorouracil into umbilical vein.
Topics: Colonic Neoplasms; Fluorouracil; Humans; Injections, Intravenous; Liver Neoplasms; Neoplasm Metastas | 1972 |
Acute leukemia complicating metastatic breast cancer.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Chlorambucil; Cyclophosphamide; Female; Fluorouracil | 1973 |
Liver scanning for the detection of metastases following colo-rectal cancer surgery.
Topics: Adenocarcinoma; Adult; Celiac Artery; Colonic Neoplasms; Female; Fluorouracil; Gold Isotopes; Hepate | 1973 |
Combination chemotherapy in disseminated carcinoma of the breast.
Topics: Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Evaluation Stu | 1974 |
What's your diagnosis, doctor?
Topics: Adult; Female; Fluorouracil; Humans; Mastectomy; Neoplasm Metastasis; Thoracic Neoplasms; Tongue | 1973 |
Arterial infusion and radiation therapy in the treatment of advanced cancer of the nasal cavity and paranasal sinuses.
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Carotid Artery, External; Carotid Artery, Internal; Chemot | 1973 |
Letter: Metastatic kidney cancer treated with multiple drug therapy at the Rotterdam Radiotherapy Institute.
Topics: Cyclophosphamide; Drug Therapy, Combination; Fluorouracil; Humans; Kidney Neoplasms; Leucovorin; Met | 1974 |
Host-tumor interactions during 5-fluorouracil therapy for prostatic carcinoma.
Topics: Fluorouracil; Humans; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Male; Middle Aged; Neopl | 1974 |
Effects of chemotherapy for prostatic carcinoma on T lymphocyte levels.
Topics: Administration, Oral; Aged; Animals; Cyclophosphamide; Diethylstilbestrol; Erythrocytes; Fluorouraci | 1974 |
[Results of polycytostatic therapy in tumorous pleural effusion (author's transl)].
Topics: Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Me | 1974 |
Impressions on 5-fluorouracil in Bangladesh. Prolonged worthwhile survival in gastrointestinal malignancies.
Topics: Bangladesh; Drug Evaluation; Female; Fluorouracil; Follow-Up Studies; Gastrointestinal Hemorrhage; G | 1974 |
Cancer chemotherapy. I. Methods, agents and overall results in 400 patients.
Topics: Adenocarcinoma; Amides; Androgens; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamide; Estrogens; | 1972 |
Chemotherapy for recurrent carcinoma of the breast.
Topics: Adult; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Hepatic Artery; Humans; Injections, | 1972 |
[Features of regressive changes during chemotherapy of breast cancer metastases to the lungs].
Topics: Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans; Lung Neoplasms; Middle Aged; Neopl | 1972 |
[Principles, technic and clinical performance of synchronized radiotherapy].
Topics: Adenocarcinoma; Adult; Aged; Androstanols; Bone Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, S | 1972 |
[Preliminary results of the use of 5-fluoruracil to prevent recurrences and metastases following radical surgery for stomach cancer].
Topics: Adenocarcinoma; Female; Fluorouracil; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Metastasis; N | 1972 |
Treatment of the patient with adenocarcinoma of unknown origin.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Autopsy; Carmustine; Female; Fluorouracil; Human | 1972 |
Multiple arterial infusions with 5-fluorouracil.
Topics: Catheterization; Clinical Enzyme Tests; Female; Fluorouracil; Humans; Injections, Intra-Arterial; Li | 1972 |
Results of 27 cases with hepatic metastases treated by combination chemotherapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamide; Fluorouracil; Humans; | 1972 |
The value of megavolt therapy in carcinoma of the stomach.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma; Cardia; Cell Division; Cobalt Isotopes; Female; Fluorouracil | 1972 |
[Acid-base equilibrium under cytostatic therapy].
Topics: Acid-Base Equilibrium; Adolescent; Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Female; Flu | 1972 |
[Polychemotherapy of primary and secondary brain tumors].
Topics: Adult; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Cyclophosphamide; Female; Fluoro | 1972 |
[The reactivity of the RES in cancer of the gastrointestinal tract and during treatment with fluorofur].
Topics: Achlorhydria; Adult; Aged; Colonic Neoplasms; Esophageal Neoplasms; Female; Fluorouracil; Furans; Go | 1972 |
Five-drug combination chemotherapy for disseminated adenocarcinoma.
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamide; Drug | 1972 |
One shot administration of antineoplastic agents in massive doses via the celiac artery for inoperable cancer of the liver.
Topics: Angiography; Celiac Artery; Fluorouracil; Humans; Infusions, Parenteral; Injections, Intra-Arterial; | 1972 |
The treatment of metastatic carcinoma of the liver by the percutaneous selective hepatic artery infusion of 5-fluorouracil.
Topics: Adenocarcinoma; Fluorouracil; Hepatic Artery; Humans; Infusions, Parenteral; Injections, Intra-Arter | 1973 |
Nonbacterial pneumonitis with multidrug antineoplastic therapy in breast carcinoma.
Topics: Adenocarcinoma; Adrenalectomy; Adult; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Huma | 1973 |
[Iatrogenic diabetic coma. Contribution to adverse effects of cytostatic therapy].
Topics: Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Diabetic Coma; Female; Fluorouracil; Huma | 1973 |
Cytotoxic perfusion of the liver via the umbilical vein for liver metastases in carcinoma of the colon.
Topics: Aged; Blood Sedimentation; Cholestasis; Colonic Neoplasms; Diarrhea; Fluorouracil; Humans; Leukocyte | 1973 |
Combination therapy of solid tumors using 1,3-bis(2-chloroethyl)-1-nitrosourea (NCNU), vincristine, methotrexate, and 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Carmustine; Female; Fluorouracil; Gastrointes | 1973 |
Leiomyosarcoma of the renal pelvis.
Topics: Female; Fluorouracil; Humans; Kidney Neoplasms; Kidney Pelvis; Leiomyosarcoma; Middle Aged; Neoplasm | 1973 |
FIVB--a new combination of drugs in the treatment of cancer.
Topics: Adenocarcinoma; Aged; Amides; Breast Neoplasms; Colonic Neoplasms; Female; Fluorouracil; Humans; Imi | 1973 |
Combination chemotherapy in disseminated carcinoma of the breast.
Topics: Adult; Aged; Breast Neoplasms; Cyclophosphamide; Drug Synergism; Female; Fluorouracil; Humans; Metho | 1973 |
[Cytostatic therapy of metastazing rectal carcinoma].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Agents; Fluorouracil; Humans; Injections, Intra | 1973 |
[Intraportal chemotherapy for hepatic metastases].
Topics: Adult; Chemotherapy, Cancer, Regional Perfusion; Female; Fluorouracil; Humans; Injections, Intraveno | 1973 |
Primary transitional cell carcinoma of the prostate.
Topics: Aged; Alkaline Phosphatase; Blood Urea Nitrogen; Carcinoma, Transitional Cell; Diethylstilbestrol; F | 1973 |
Chemotherapy for carcinoma of the pancreas.
Topics: Adult; Aged; Autopsy; Biopsy; Carcinoma; Female; Fluorouracil; Humans; Laparotomy; Male; Middle Aged | 1973 |
Combined chemotherapy and radiation therapy in spindle and giant cell carcinoma of the thyroid gland. Report of a case.
Topics: Aged; Carcinoma; Cobalt Isotopes; Cyclophosphamide; Female; Fluorouracil; Humans; Neoplasm Metastasi | 1973 |
Thrombocytopenia from metastatic carcinoma of the breast. Effective managements of patients with this complication.
Topics: Adrenalectomy; Aged; Blood Cell Count; Blood Platelets; Bone Marrow; Bone Neoplasms; Breast Neoplasm | 1973 |
The problems of drug treatment of breast cancer.
Topics: Age Factors; Alkylating Agents; Androgens; Bone Neoplasms; Breast Neoplasms; Corticosterone; Drug Co | 1973 |
Radiotherapy for bronchogenic carcinoma: actual difficulties and plans for the future.
Topics: Adenocarcinoma; Brain Neoplasms; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Cyclophosphamide | 1973 |
The management of malignant pericardial effusions.
Topics: Angiography; Cardiac Tamponade; Fluorouracil; Gold; Heart Neoplasms; Humans; Lung; Mechlorethamine; | 1973 |
Survival with adrenal carcinoma.
Topics: Adrenal Gland Neoplasms; Female; Fluorouracil; Humans; Mitotane; Neoplasm Metastasis | 1973 |
Disseminated breast carcinoma. Treatment with combination chemotherapy.
Topics: Adenocarcinoma; Adult; Breast Neoplasms; Carcinoma; Cyclophosphamide; Drug Therapy, Combination; Fem | 1973 |
Combined high-dose delta1-testololactone with low-dose 5-fluorouracil in the treatment of metastatic breast cancer.
Topics: Blood Cell Count; Blood Platelets; Breast Neoplasms; Drug Therapy, Combination; Evaluation Studies a | 1973 |
Therapy of advanced gastrointestinal cancer with the nitrosoureas.
Topics: Adenocarcinoma; Antineoplastic Agents; Bone Marrow Diseases; Carmustine; Colonic Neoplasms; Cyclohex | 1973 |
[Cytostatic combination therapy in metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; F | 1973 |
Erythroplasia of Queyrat. A clinicopathologic and histochemical study.
Topics: Adult; Age Factors; Aged; Biopsy; Erythroplasia; Ethnicity; Female; Fluorouracil; Histocytochemistry | 1973 |
The treatment of jaundice due to liver metastases by quadruple chemotherapy.
Topics: Aged; Antineoplastic Agents; Cyclophosphamide; Fluorouracil; Humans; Jaundice; Liver Neoplasms; Meth | 1973 |
Timing of administration of 5-fluorouracil in combination with irradiation in the treatment of advanced adenocarcinoma. Comparison of methods used to assess radiological response to the treatment of pulmonary metastases.
Topics: Adenocarcinoma; Cobalt Radioisotopes; Fluorouracil; Humans; Lung Neoplasms; Male; Methods; Middle Ag | 1973 |
Leucopoietic effect of calusterone (7 beta, 17 alpha-dimethyltestosterone) in women with advanced breast cancer.
Topics: Administration, Oral; Breast Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Humans; Inj | 1973 |
[Postoperative chemotherapy as means of prophylaxis of recurrences and metastases of cancer of the rectum].
Topics: Aged; Female; Fluorouracil; Humans; Injections, Intravenous; Neoplasm Metastasis; Neoplastic Cells, | 1973 |
[Cooper's combination chemotherapy of metastasizing breast carcinoms].
Topics: Adult; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans; Male; Methotrexate; Middle | 1973 |
[Therapy of metastasizing solid tumors with cyclophosphamide, methotrexate, vincristine and 5-fluorouracil].
Topics: Adolescent; Adult; Aged; Cyclophosphamide; Female; Fluorouracil; Humans; Male; Methods; Methotrexate | 1973 |
Advanced cancer: New concepts of medical therapy.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Choriocarcinoma; Colonic Neopl | 1973 |
[Trial of combined intermittent chemotherapy in prostatic cancers. Estrogen resistant metastases].
Topics: Antibiotics, Antineoplastic; Bone Neoplasms; Drug Therapy, Combination; Estrogens; Fluorouracil; Fol | 1973 |
An evaluation of five drug combination chemotherapy in the management of recurrent carcinoma of the breast.
Topics: Administration, Oral; Adult; Aged; Blood Cell Count; Breast Neoplasms; Cyclophosphamide; Drug Therap | 1974 |
The administration of 5-fluorouracil by mouth.
Topics: Adenocarcinoma; Administration, Oral; Aged; Female; Fluorouracil; Gastrointestinal Neoplasms; Heart | 1974 |
Proceedings: Evaluation of combination vs. sequential cytotoxic chemotherapy in the treatment of advanced breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; | 1974 |
Serial liver scanning. Metastatic disease.
Topics: Adenocarcinoma; Adult; Colonic Neoplasms; Fluorouracil; Humans; Injections, Intra-Arterial; Injectio | 1974 |
Cyclical combination chemotherapy for advanced breast carcinoma.
Topics: Adrenalectomy; Adult; Alopecia; Bone Marrow; Bone Neoplasms; Breast Neoplasms; Castration; Cyclophos | 1974 |
[Fluorouracil for advanced breast cancer].
Topics: Breast Neoplasms; Cell Division; Fluorouracil; Humans; Neoplasm Metastasis | 1974 |
Carcinoembryonic antigen in breast cancer patients: serum levels and disease progress.
Topics: Adrenalectomy; Adult; Aged; Breast Neoplasms; Carcinoembryonic Antigen; Castration; Cyclophosphamide | 1974 |
Cyclical combination chemotherapy in advanced breast cancer.
Topics: Age Factors; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Hu | 1974 |
[Recent advances in the treatment of Ewing's sarcoma (author's transl)].
Topics: Adolescent; Adult; Cyclophosphamide; Dactinomycin; Doxorubicin; Drug Synergism; Female; Fluorouracil | 1974 |
[Combination chemotherapy with cyclophosphamide, methotrexate, 5-fluoro-uracil, and vincristine in solid metastasized tumours (author's transl)].
Topics: Adult; Aged; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Lung Neoplas | 1974 |
[Cytostatics in the regional chemotherapy of malignant tumors of the abdominal organs and of their liver metastases].
Topics: Abdominal Neoplasms; Chemotherapy, Cancer, Regional Perfusion; Female; Fluorouracil; Humans; Liver N | 1974 |
Scan evidence of decrease in size of intrahepatic tumors after chemotherapy. A case report.
Topics: Adult; Aged; Carcinoma, Transitional Cell; Cecal Neoplasms; Doxorubicin; Female; Fluorouracil; Human | 1974 |
Primary mediastinal choriocarcinoma in the male.
Topics: Adult; Choriocarcinoma; Cyclophosphamide; Cytodiagnosis; Drug Therapy, Combination; Fluorouracil; Hu | 1974 |
Cyclophosphamide. Evaluation in recurrent and progressive ovarian cancer.
Topics: Cyclophosphamide; Female; Fluorouracil; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Ova | 1967 |
Systemic chemotherapy for carcinoma of the cervix.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cyclophosphamide; Fema | 1967 |
Experimental studies of human bladder cancer: heterotransplantation to the hamster cheek pouch.
Topics: Animals; Antineoplastic Agents; Cheek; Cricetinae; Cyclophosphamide; Female; Fluorouracil; Humans; M | 1967 |
[Our experiences with polychemotherapy of malignant endothoracic tumors (103 cases)].
Topics: Adenocarcinoma; Adult; Androgens; Antineoplastic Agents; Azirines; Bronchial Neoplasms; Carcinoma; C | 1968 |
[Antineoplastic polychemotherapy in thoracic pathology].
Topics: Adrenalectomy; Aged; Antineoplastic Agents; Breast Neoplasms; Bronchial Neoplasms; Cortisone; Cyclop | 1968 |
[Effects of 5-FU (5-fluorouracil) in 4.3MeV Linac x-ray treatment of advanced cancer].
Topics: Adult; Aged; Breast Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fl | 1968 |
Therapeutic implications from a mathematical model characterizing the course of breast cancer.
Topics: Breast Neoplasms; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Mastectomy; | 1969 |
Metastatic carcinoma of the male breast treated with bilateral adrenalectomy and chemotherapy.
Topics: Adrenalectomy; Aged; Breast Neoplasms; Castration; Fluorouracil; Humans; Male; Methotrexate; Middle | 1970 |
Systemic chemotherapy for advanced breast cancer.
Topics: Adrenal Cortex Hormones; Adult; Aged; Androgens; Antineoplastic Agents; Breast Neoplasms; Chlorambuc | 1970 |
[Chemotherapy of inoperable bronchial carcinoma].
Topics: Age Factors; Aged; Antineoplastic Agents; Bronchial Neoplasms; Cyclophosphamide; Diagnosis, Differen | 1971 |
[Comparative evaluation of thiphosphamide, cyclophosphane, methotrexate and 5-fluorouracil in the treatment of breast cancer].
Topics: Adult; Aged; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans; Menopause; Menstruati | 1971 |
Sequential liver scanning.
Topics: Adult; Breast Neoplasms; Chloroquine; Colonic Neoplasms; Dactinomycin; Emetine; Estrogens; Female; F | 1969 |
Status of adjuvant therapy: results of The National Surgical Adjuvant Breast Project studies on oophorectomy, postoperative radiation therapy, and chemotherapy. Other comments concerning clinical trials.
Topics: Antineoplastic Agents; Breast Neoplasms; Castration; Female; Fluorouracil; Humans; Mastectomy; Neopl | 1971 |
Cancer of the breast. Endocrine ablation, hormone therapy and chemotherapy.
Topics: Adrenal Cortex Hormones; Adrenalectomy; Adult; Age Factors; Breast Neoplasms; Castration; Dyspnea; F | 1967 |
5-Fluorouracil (5-Fu; NSC-19893), 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388), vincristine (NSC-67574), and 1,3-bis(2-chloroethyl)-2-nitrosourea (BCNU; NSC-409962) given concomitantly in the treatment of solid tumors in man.
Topics: Adult; Aged; Alkylating Agents; Amides; Carmustine; Drug Combinations; Female; Fluorouracil; Humans; | 1972 |
5-Hydroxyindole-secreting rectal carcinoid tumour.
Topics: Adult; Carcinoid Tumor; Duodenal Ulcer; Female; Fluorouracil; Humans; Hydroxyindoleacetic Acid; Live | 1972 |
Evaluation of hepatic dearterialization in primary and secondary cancer of the liver.
Topics: Adult; Aged; Female; Fluorouracil; Hepatic Artery; Humans; Ligation; Liver; Liver Neoplasms; Lymphom | 1972 |
Hepatic artery ligation and cytotoxic infusion in treatment of liver metastases.
Topics: Aged; Alkaline Phosphatase; Female; Fluorouracil; Gallbladder Neoplasms; Hepatic Artery; Humans; Inj | 1972 |
[The treatment of metastatic breast cancer with 5-fluorouracil].
Topics: Breast Neoplasms; Female; Fluorouracil; Humans; Neoplasm Metastasis | 1972 |
The phase II study: some reflections, particularly concerning disseminated breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Carmustine; Cyclohexanes; Cyclophosphamide; Female; Fluorou | 1972 |
Combination chemotherapy in the treatment of metastatic hemangiopericytoma.
Topics: Administration, Oral; Cyclophosphamide; Dactinomycin; Fluorouracil; Hemangiopericytoma; Humans; Inje | 1972 |
Treatment of squamous cell carcinoma of the head and neck by chemotherapy.
Topics: Administration, Oral; Carcinoma, Squamous Cell; Fluorouracil; Head; Head and Neck Neoplasms; Humans; | 1972 |
Chemotherapy in the management of metastatic cancer of unknown primary site.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Carcinoma; Carcinoma, Squamous Cell; Chlorambucil; Cyclopho | 1972 |
Chemotherapy of breast carcinoma.
Topics: Adult; Amines; Breast Neoplasms; Chlorambucil; Cyclophosphamide; Female; Fluorouracil; Humans; Imida | 1972 |
Treatment with 5-fluorouracil in prophylaxis of relapses and metastases of stomach cancer.
Topics: Adenocarcinoma; Adult; Aged; Female; Fluorouracil; Gastrectomy; Humans; Injections, Intravenous; Mal | 1972 |
Calusterone in the therapy for advanced breast cancer.
Topics: Adenocarcinoma; Axilla; Bone Neoplasms; Breast Neoplasms; Castration; Drug Synergism; Female; Fluoro | 1972 |
Treatment of hepatic tumours by ligation of the hepatic artery and infusion of cytotoxic drugs.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Female; Fluorouracil; Hepatic Artery; Humans; | 1972 |
[Diffuse liver necrosis in treatment with 5-fluorouracil].
Topics: Adult; Chemical and Drug Induced Liver Injury; Fluorouracil; Humans; Liver; Male; Mesothelioma; Necr | 1972 |
Cyclophosphamide therapy in patients with advancing breast cancer following adrenalectomy and 5-fluorouracil.
Topics: Adrenal Insufficiency; Adrenalectomy; Adult; Aged; Alopecia; Breast Neoplasms; Cortisone; Cyclophosp | 1971 |
Complete regression of metastases following chemotherapy.
Topics: Aged; Cecal Neoplasms; Colectomy; Fluorouracil; Humans; Injections, Intravenous; Lung Neoplasms; Lym | 1971 |
[Continuous intra-arterial infusion of antineoplastic agents in cancerous peritonitis, with special reference to cancer].
Topics: Adult; Aged; Cytarabine; Female; Femoral Artery; Fluorouracil; Humans; Injections, Intra-Arterial; M | 1971 |
Topical chemotherapy of advanced cutaneous malignancy with 5-Fluorouracil creme.
Topics: Aged; Carcinoma; Carcinoma, Basal Cell; Carcinoma, Basosquamous; Carcinoma, Squamous Cell; Esthetics | 1971 |
Effective anti-cancer agents selected by suppression of cesium-131 uptake.
Topics: Adrenalectomy; Antineoplastic Agents; Breast Neoplasms; Cesium Isotopes; Cyclophosphamide; Estrogens | 1971 |
Treatment of metastatic colorectal carcinoma with 5-fluorouracil by mouth.
Topics: Administration, Oral; Aged; Bone Neoplasms; Colonic Neoplasms; Female; Fluorouracil; Humans; Liver C | 1971 |
5-fluorouracil given once weekly: comparison of intravenous and oral administration.
Topics: Adenocarcinoma; Administration, Oral; Biliary Tract Diseases; Breast Neoplasms; Female; Fluorouracil | 1971 |
Treatment of metastatic breast cancer with a combination of adrenalectomy and 5-fluorouracil. Progress report.
Topics: Adrenalectomy; Aged; Bone Neoplasms; Breast Neoplasms; Female; Fluorouracil; Follow-Up Studies; Huma | 1971 |
[Results of therapy of uterus sarcoma 1954-1968 under special consideration of combined radiotherapy and 5-fluorouracil treatment].
Topics: Adult; Aged; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Radiation-Sensitizing A | 1971 |
A primary melanocarcinoma of the cervix.
Topics: Adult; Cervix Uteri; Female; Fluorouracil; Humans; Imidazoles; Melanoma; Melphalan; Neoplasm Metasta | 1971 |
Five-drug therapy for advanced breast cancer: a phase I study.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans | 1971 |
Lack of effect of warfarin (NSC-59813) alone or in combination with 5-fluorouracil (NSC-19893) on primary and metastatic L1210 leukemia and adenocarcinoma 755.
Topics: Adenocarcinoma; Animals; Female; Fluorouracil; Leukemia L1210; Mice; Neoplasm Metastasis; Neoplasm T | 1971 |
[Hypernephroma metastases of the skin and therapeutic possiblities].
Topics: Adenocarcinoma; Aged; Fluorouracil; Humans; Kidney Neoplasms; Male; Neoplasm Metastasis; Nose Neopla | 1971 |
Multiple drug therapy for disseminated malignant tumours.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Child; Cyclophosphamide; Cytarabine; Dactinomy | 1971 |
Intrahepatic arterial infusion with 5-fluorouracil.
Topics: Chemotherapy, Cancer, Regional Perfusion; Fluorouracil; Hepatic Artery; Humans; Liver Neoplasms; Neo | 1971 |
Chemotherapy for metastatic colorectal liver carcinoma by intra-aortic infusion.
Topics: Antineoplastic Agents; Aorta, Abdominal; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms | 1971 |
[Gallbladder cancer].
Topics: Adenocarcinoma; Adenoma; Carcinoma; Cholelithiasis; Fluorouracil; Gallbladder Neoplasms; Humans; Mel | 1971 |
Cerebellar ataxia during 5-fluorouracil (NSC-19893) therapy.
Topics: Aged; Breast Neoplasms; Castration; Cerebellar Ataxia; Diagnosis, Differential; Female; Fluorouracil | 1971 |
Combination cancer chemotherapy by regional intra-arterial or intra-aortic infusion of 5-fluorouracil and mitomycin-C with or without irradiation.
Topics: Aorta; Cobalt Radioisotopes; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Hea | 1971 |
The influence of cytostatic treatment on serum LDH patterns of patients with bronchial carcinoma and its relation to tumor regression.
Topics: Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Fluorouracil; Humans; Isoenzymes; L-Lactate Dehyd | 1968 |
Bronchial artery infusion with anticancer agents in the treatment of osteosarcoma. Prevention of pulmonary metastasis and improvement of prognosis.
Topics: Adolescent; Adult; Angiography; Aortic Coarctation; Blood Cell Count; Bronchial Arteries; Catheteriz | 1971 |
Distant metastases from beta-naphthylamine induced vesical tumors in dogs.
Topics: Animals; Carcinogens; Carcinoma, Transitional Cell; Dogs; Female; Fluorouracil; Lung Neoplasms; Naph | 1969 |
Evaluation of adrenalectomy and hypophysectomy in the treatment of metastatic cancer of the breast.
Topics: Adrenalectomy; Breast Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Hypophysectomy; Ne | 1969 |
Combined 5-fluoro-uracil and procarbazin in the treatment of lung metastases from different carcinomas.
Topics: Adult; Aged; Benzoates; Fluorouracil; Humans; Lung Neoplasms; Neoplasm Metastasis; Neoplasms | 1969 |
[Therapy of the metastasising bronchial cancer].
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Bronchial Neoplasms; Cyclophosphamide; Fluorouracil; H | 1969 |
[Squamous cell carcinoma of the renal pelvis associated with gross hydrocalycosis due to a calculus: report of a case].
Topics: Calculi; Carcinoma, Squamous Cell; Cyclophosphamide; Female; Fluorouracil; Humans; Hydronephrosis; K | 1969 |
[Loco-regional intra-arterial therapy of liver neoplasms].
Topics: Adult; Aged; Catheterization; Female; Fluorouracil; Hepatic Artery; Humans; Liver Circulation; Liver | 1969 |
Esophageal metastases and dysphagia in patients with carcinoma of the breast.
Topics: Adrenalectomy; Adult; Aged; Breast Neoplasms; Cyclophosphamide; Deglutition Disorders; Dilatation; E | 1969 |
[Polychemotherapy of bronchial carcinoma].
Topics: Aged; Brain Neoplasms; Bronchial Neoplasms; Carcinoma, Bronchogenic; Cyclophosphamide; Fluorouracil; | 1970 |
A new method for treatment of carcinoma of the breast and colon with 5-fluorouracil.
Topics: Adult; Aged; Breast Neoplasms; Chemical Phenomena; Chemistry; Colonic Neoplasms; Female; Fluorouraci | 1970 |
Survival of patients treated with systemic fluorouracil for hepatic metastases.
Topics: Adult; Age Factors; Aged; Carcinoma; Colonic Neoplasms; Female; Fluorouracil; Follow-Up Studies; Hum | 1970 |
The influence of treatment on the survival of patients with hepatic metastases diagnosed by liver scanning.
Topics: Androgens; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamide; Fluorouracil; Hepatectomy; Humans; | 1970 |
Infusion chemotherapy for metastatic liver cancer.
Topics: Adolescent; Antineoplastic Agents; Catheterization; Female; Fluorouracil; Hepatic Artery; Humans; In | 1970 |
Preliminary experience with 5-fluorouracil ointment in the treatment of neoplasias and precancerous lesions of the skin.
Topics: Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Neoplasm Metast | 1970 |
Treatment of hepatic tumours.
Topics: Adenocarcinoma; Antineoplastic Agents; Female; Fluorouracil; Hepatic Artery; Humans; Laparotomy; Lei | 1970 |
[Treatment of metastases to the liver in the course of sigmoid and rectal cancer].
Topics: Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Male; Methods; Neoplasm Metastasis | 1970 |
One-shot infusion of non-surgically administered mitomycin C in the celiac artery for liver metastases. Clinical effects.
Topics: Adult; Aged; Angiography; Blood Cell Count; Blood Platelets; Celiac Artery; Colonic Neoplasms; Femal | 1970 |
Adverse effect of antitumor drugs on the prevention of metastasis in mice.
Topics: Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Cyclophosphamide; Fluorouracil; Male; Merc | 1970 |
Combination chemotherapy in the management of breast cancer metastases.
Topics: Adult; Aged; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Synergism; Fe | 1970 |
[Intra-portal infusion of 5-fluorouracil for metastasis of rectal cancer into the liver].
Topics: Adult; Aged; Chemotherapy, Cancer, Regional Perfusion; Fluorouracil; Humans; Liver Neoplasms; Middle | 1970 |
[Experimental results of the use of polychemotherapy in malignant tumors].
Topics: Amides; Amputation, Surgical; Animals; Antineoplastic Agents; Benzoates; Carcinoma; Cyclophosphamide | 1970 |
[Further proposals for chemotherapeutic prophylaxis of recurrence of bronchial carcinoma].
Topics: Antibiotics, Antineoplastic; Bronchial Neoplasms; Cyclophosphamide; Fluorouracil; Humans; Leukopenia | 1971 |
Hepatic coma secondary to metastatic liver disease.
Topics: Alkaline Phosphatase; Aspartate Aminotransferases; Breast Neoplasms; Colonic Neoplasms; Fluorouracil | 1971 |
The relation of tumour size to the results of chemotherapy in malignant tumours.
Topics: Amputation, Surgical; Animals; Antineoplastic Agents; Cyclophosphamide; Fluorouracil; Mercaptopurine | 1971 |
Clinical and roentgenologic picture of the alterations obtained in the treatment of breast cancer osseous metastases.
Topics: Adrenal Cortex Hormones; Androgens; Azirines; Benzoates; Bone Neoplasms; Breast Neoplasms; Cyclophos | 1971 |
Treatment of advanced cancer of the breast with 5-fluorouracil.
Topics: Adult; Aged; Breast Neoplasms; Castration; Cobalt Isotopes; Female; Fluorouracil; Humans; Mastectomy | 1971 |
[The possibilities of drug therapy in metastazing carcinoma of the large intestine].
Topics: Colonic Neoplasms; Fluorouracil; Humans; Neoplasm Metastasis; Rectal Neoplasms | 1967 |
[152. Testing of conservative forms of therapy on bladder cancer heterotransplants].
Topics: Animals; Antineoplastic Agents; Cricetinae; Fluorouracil; Humans; Mitomycins; Neoplasm Metastasis; N | 1967 |
[Experience with the treatment of patients with malignant tumors with 5-fluorouracil].
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Duodenal Neoplasms; Female; Fluorouracil; Humans; In | 1967 |
[On a method of treating patients with cancer of the stomach with 5-fluorouracil].
Topics: Aged; Duodenal Neoplasms; Female; Fluorouracil; Humans; Liver Neoplasms; Neoplasm Metastasis; Stomac | 1967 |
[Internal cancer therapy: cooperative clinical studies. Principles, organization and first results of the Swiss chemotherapy group].
Topics: Adenocarcinoma; Androgens; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Car | 1967 |
[Trial polychemotherapy of inoperable cancer (apropos of 71 cases)].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Azirines; Bronchial Neoplasms; Carcinoma, Squamo | 1968 |
Liver regeneration after major hepatectomy. Effect of chemotherapy on growth and function--case report.
Topics: Adenocarcinoma; Female; Fluorouracil; Gallbladder Neoplasms; Gold Isotopes; Hepatectomy; Humans; Liv | 1968 |
[Polychemotherapy of bronchopulmonary cancer].
Topics: Antineoplastic Agents; Azirines; Bronchial Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Cyclophos | 1968 |
Hepatic artery and celiac axis infusion for the treatment of upper abdominal malignant lesions.
Topics: Abdominal Neoplasms; Carcinoma; Celiac Artery; Fluorouracil; Gastrointestinal Neoplasms; Head and Ne | 1968 |
A radioisotopic method for determining optimum non-surgical therapy for advanced cancer. II. Clinical experience.
Topics: Adenocarcinoma; Breast Neoplasms; Diethylstilbestrol; Female; Fluorouracil; Fluoxymesterone; Gastroi | 1968 |
5-fluorouracil therapy for cancer of the stomaach.
Topics: Adenocarcinoma; Adult; Aged; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; S | 1968 |
[218 cases of prolonged polychemotherapy in advanced cancer (especially bronchopulmonary). Modalities and results].
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Bronchial Neop | 1968 |
Intracavity 5-fluorouracil for control of malignant effusions.
Topics: Exudates and Transudates; Fluorouracil; Humans; Neoplasm Metastasis | 1968 |
[A case of successful use of 5-fluorouracil and cyclophosphane in metastasis of cancer of the breast].
Topics: Adult; Brain Neoplasms; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Humans; Lung Neopl | 1968 |
[Perioperative antiblastic drug therapy with triethyleniminobenzoquinone and 5-fluorouracil in uterine neoplasms].
Topics: Antineoplastic Agents; Carcinoma; Female; Fluorouracil; Humans; Hysterectomy; Neoplasm Metastasis; N | 1968 |
Treatment of metastatic carcinoma of the female breast with combination of hormones and other chemotherapy.
Topics: Breast Neoplasms; Cyclophosphamide; Diethylstilbestrol; Female; Fluorouracil; Humans; Neoplasm Metas | 1968 |
Response to 5-fluorouracil of lung metastases from bladder and breast cancers.
Topics: Aged; Breast Neoplasms; Female; Fluorouracil; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastas | 1969 |
Combined intra-arterial infusion and radiotherapy for the treatment of advanced cancer of the head and neck.
Topics: Aged; Brain Neoplasms; Carcinoma, Squamous Cell; Esophageal Neoplasms; Fluorouracil; Follow-Up Studi | 1969 |
Prolonged continuous hepatic infusion. Results with fluorouracil for primary and metastatic cancer in the liver.
Topics: Adult; Catheterization; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; Female; Fluorou | 1969 |
Treatment of carcinoma of the bladder with combined radiotherapy, chemotherapy, and surgery.
Topics: Animals; Cricetinae; Female; Fluorouracil; Humans; Hydroxyurea; Male; Mitomycins; Neoplasm Metastasi | 1969 |
Fluorouracil toxicity following gastrointestinal surgery.
Topics: Adenocarcinoma; Colitis, Ulcerative; Colostomy; Fluorouracil; Humans; Intestinal Mucosa; Intestinal | 1965 |
[Cytostatic therapy of lung and pleural neoplasms].
Topics: Cyclophosphamide; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pleu | 1965 |
Kinetics of proliferation of cancer cells in neoplastic effusions in man.
Topics: Adenocarcinoma; Antineoplastic Agents; Autoradiography; Cell Division; DNA, Neoplasm; Exudates and T | 1965 |
Chemotherapy for liver cancer by protracted ambulatory infusion.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Colonic Neoplasms; Fluorouracil; Hepatic Artery; Humans | 1965 |
Heterotransplantation of bladder cancer in the hamster cheek pouch: in vivo testing of cancer chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Cheek; Cricetinae; Fluorouracil; Humans; Mitomycins; Neoplasm Metast | 1966 |
Metastatic tumor to the breast simulating bilateral primary inflammatory carcinoma.
Topics: Breast Neoplasms; Carcinoma; Diagnosis, Differential; Female; Fluorouracil; Humans; In Vitro Techniq | 1966 |
Chemotherapy for lung cancer by intra-aortic infusion.
Topics: Aorta; Carcinoma, Bronchogenic; Cyclophosphamide; Female; Fluorouracil; Humans; Injections, Intra-Ar | 1966 |
Breast cancer treated with fluorouracil. Survival studies in advanced stages.
Topics: Aged; Breast Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Injections, Intravenous; Ma | 1966 |